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This thesis is titled “From Despair to Hope” as these studies of HIV and AIDS 
were performed over a period when the prognosis for HIV-infected patients 
presenting with AIDS, evolved from one of rapid progression to death to one 
with a potential for decades of healthy life. The HIV pandemic reached South 
Africa later than its neighboring countries and developed rapidly in a country 
undergoing political upheaval. South Africa was totally unprepared for the 
onslaught of AIDS, which presented the greatest medical challenge in the 
country’s history. My research and academic work have been inexorably linked 
to the response to the onslaught of the HIV and TB epidemics in South Africa.  
 
There is an aphorism amongst epidemiologists that “to control an epidemic you 
must first know your epidemic”. The selected work (100 of 309 peer reviewed 
articles and book chapters) highlights my attempts to better understand both the 
South African HIV and HIV-associated tuberculosis epidemics and to disseminate 
scientific information that could influence and direct national and global 
opinions and policies.  
 
The Oxford dictionary provides a definition of “seminal” as having the properties 
of a seed; containing the possibility of future development.  However, history is 
lived forwards but written in retrospect. We know the end before we consider 
the beginning and we can never wholly recapture what it was like to know the 
beginning only. The seminal nature of this work must therefore be viewed within 
a rapidly changing historical and geographical context of what was known and 
not known at the time. Current readers already know the ending. Therefore, the 
studies where possible, are presented chronologically with some description of 
the contemporary knowledge status quo to illustrate this work’s 
contemporaneous relevance.  Thus I hope to enable the reader to better view the 
seminal nature and the extent to which the work played a part in the evolving 












My UCT career dates from 1986 when I exchanged the role of a general 
practitioner in Zambia for that of a medical registrar training post at Groote 
Schuur Hospital. During my training I was encouraged by senior physicians to 
publish case reports of unusual conditions among patients under my care.  In my 
Master of Medicine thesis I explored the role of chromium valency underlying 
mortality and morbidity associated with use of chromium containing traditional 
medicines. In retrospect, I realise that this study marked a progression from 
reporting “what” was happening to endeavoring to understand “why” this was 
happening.  It has been a desire to understand what is clinically observed that 
has motivated my subsequent research career. At the end of my clinical training, 
my mentor Professor Ralph Kirsch suggested that it was now time for me to 
acquire some experience in the laboratory.  
 
In 1991, I accepted a research fellowship at Stanford University, CA, USA and it 
was here that my close association with the HIV epidemic really started. I was 
fortunate to be able to discuss my work with scientific leaders in the field such as 
Luc Montaner and Bob Gallo, the co-discoverers of HIV.  These were desperate 
days for the San Francisco gay community, which was full of fear. However, this 
was accompanied by an incredible unity of purpose to confront and conquer this 
terrifying disease. It was here also that I had my first exposure to community 
activists, who while initially challenging to a medical scientist were subsequently 
to prove vital allies in the long fight against this scourge. I have a memory from 
that time of standing in the pulpit of the pink painted “Gay and Lesbian” church 
in the Castro section of San Francisco explaining intricacies of the studies we 
were recruiting. It was here also that I met people of extraordinary talent and 
courage; Elizabeth Glazer who while facing her own and her children’s mortality 
was to go on to found the Elizabeth Glazer Pediatric AIDS Foundation, and Randy 
Shilts, the AIDS correspondent for the San Francisco Herald, who had 
documented the San Francisco HIV epidemic, Randy presented me with a copy of 
his recently published book “And the Band Played On. Politics, People and the 
AIDS Epidemic” with the inscription dated May 1991 “ To Dr Robin Wood thanks 











of AIDS, February 17thand Elizabeth on December 3rd1994.  Death was a constant 
companion throughout these years. 
 
In 1993, I returned to UCT to take up a position of lecturer in the Department of 
Medicine and Consultant Physician at the New Somerset Hospital.  It was while at 
New Somerset Hospital that I headed the first HIV clinic in the Western Cape, 
developed the first South African HIV natural history cohort (Cape Town AIDS 
Cohort), introduced the first antiretroviral therapy (ART) within the public 
health sector, started the first community ART clinic in Gugulethu (Hannan 
Crusaid Centre), and initiated the first ART protocols to be used subsequently in 
the national roll-out in 2004. 
 
In 2004 I became director of the Desmond Tutu HIV Centre (DTHC), a research 
unit within the Department of Medicine situated in the Institute of Infectious 
Disease and Molecular Medicine.  With the wider availability of ART my research 
focus moved towards the interactions between HIV and tuberculosis, which in 
turn led to exploration of why tuberculosis control was failing. In order to better 
understand the population dynamics of TB in a South African township, I 
developed a community TB research site at Masiphumelele. Research at this site 
has incorporated mathematical modeling, molecular epidemiology and 
innovative interventions. The DTHC has maintained a prodigious scientific 
output over successive years by combining a community footprint of services 
with careful clinical and scientific observations.  
 
The selected publications are largely based on observations and analyses of 
clinical data from; the Cape Town AIDS Cohort at the New Somerset Hospital, the 
Hannan Crusaid Gugulethu ART programme, the Masiphumelele community and 
the Desmond Tutu HIV Centre clinical trials unit. I am indebted to the patients 
and staff who have supported my work over many years. My publications have 

















Book chapters = 11   
Articles published in peer reviewed journals = 299 
Articles awaiting publication = 10 
Articles accepted for publication = 309 
Article citations = 7,845‡. 
Hirsch H-index = 50, (50 articles with >50 citations each) 
Egghe G-index = 82, (81 articles with >812 or 6,734total citations) 
 
‡Google Scholar citations on 14th November 2011. 
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DETAILED SYNOPSIS OF THE CONTENTS OF THE WORK 
 
I.HIV BEFORE ANTIRETROVIRAL THERAPY 
 
The Beginning; AIDS studies in San Francisco [References 1-5]. 
 
As an introduction to my presented scientific work, I have chosen five papers 
from my time as an infectious disease fellow at Stanford University, which give 
some insight into the historical context, demonstrate the serendipity of scientific 
investigation and highlight the difficulty of identifying seminal works. Two 
papers illustrate an idea, which was the beginning of a great success story while 
the next three describe concepts that rapidly or eventually fizzled out. In the 
Journal of Acquired Immune Deficiency Syndrome [1] I reported early efforts to 
quantify HIV proviral DNA in different white cell populations. In the Journal of 
Clinical Microbiology, Jose Montoya and I went on to explore the relationship 
between quantity of provirus and immunological outcomes [2]. Together  these 
papers report some early steps in an endeavor, which was the beginning of a 
great success story.  Development of this nascent assay resulted in the licensure 
of a quantitative HIV viral load assay in 1999. Viral load was subsequently 
confirmed to be a predictor of HIV progression and is now in use by laboratories 
around the world. The ability to quantitate viral load has allowed identification 
of compounds with antiviral effect and viral load reduction is now an important 
component of antiretroviral drug development. However, a more negative 
measure of success has been the continuing legal battle over ownership and 
access to test royalties. The intellectual property dispute between Stanford 












The early nineties were a period of desperation as we had the tools to diagnose 
HIV infection and were able to measure the relentless progression of HIV disease 
but we had no effective treatments to stop that progression. The paper published 
in the Journal of Infectious Disease reflects the desperate search for treatments 
that could alleviate this progressively lethal disease [3]. The paper reports the 
results of an early strategy of giving long acting interleukin-2 (PEG IL-2), in order 
to reverse the immune deficiency known to accompany HIV disease progression. 
The treatment did temporarily increase CD4 cells but was very toxic. Two of my 
patients had serious neurological adverse events, which were fortunately 
reversible. I learned that IL-2 was also being used experimentally for the 
treatment of renal cell carcinoma at the National Cancer Institute (NCI). I 
therefore travelled across the USA to the NCI in Bethesda MA where we agreed 
to pool our experiences, which resulted in the collaborative publication in 
Journal of Neurology on the neurotoxicity of IL-2 [4]. The prospect of reversing 
immune suppression with IL-2 continued to have scientific appeal and studies of 
less toxic regimens of subcutaneous IL-2 continued. Unfortunately after 20 years 
several large studies have all failed to demonstrate any clinical benefit of 
immune based therapy with IL-2 strategy including the large STALWART (Study 
of Aldesleukin with and without Antiretroviral Therapy), SILCAT (Subcutaneous, 
Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ 
Counts under Active Antiretroviral Therapy) and ESPRIT (Evaluation of 
Subcutaneous Pro-leukin in A Randomized International Trial) studies. 
 
The final paper from this era describes a study that I initiated, incorporated the 
pro-viral assay described above but was completed after my return to South 
Africa.  The innovative but abortive strategy utilised a recombinant biologic 
chimeric protein combining domains of the CD4 molecule and Pseudomonas 
exotoxin A [5]. The concept was that the protein would bind to infected cells 
expressing gp120 and the exotoxin would kill the infected cell. Unfortunately 
binding of the chimeric protein to HIV-1 gp120 was probably impeded by the 












The Dark Ages [References 6-10] 
 
I was fortunate to return to South Africa with some training in HIV management 
but I found the medical response to the epidemic was characterized by 
ignorance, fear, prejudice and fatalism. Care was encouraged outside of the 
medical sphere; patients were turned away from emergency units and denied 
hospital admission. Official policy was for terminal care to be encouraged away 
from the health care system, at home. This time has accurately been described as 
the “Dark Ages” replicating the mediaeval responses to the great plagues. Sick 
patients with AIDS were frequently turned away from health facilities and access 
to effective medications for readily treatable oesophageal candidiasis, chronic 
painful herpetic ulcerations and fungal meningitis were severely restricted.  
 
Despite this environment, I continued the development of the first HIV clinic in 
the Western Cape at New Somerset Hospital with the resources and facilities 
available to me.  We used the available resources to minimize the mortality, 
alleviate the morbidity and restore dignity to these social pariahs. Patients 
travelled from all over Cape Town to attend the HIV clinic where they were 
treated with dignity and compassion.  
 
Medical need was swamping the resources of a single clinic and application of 
some rational triaging was outlined in a paper published in the journal AIDS in 
1995 [6].  
 
Until 1994 the “laying out” procedure for patients dying of AIDS in Cape 
provincial hospitals included sealing the body in double plastic bags and 
attaching “Danger of Infection” labels. The paper “HIV-infection: transmission 
hazards in life and death” was co-authored by the then professor of anatomical 
pathology and specifically targeted at the medical fraternity to highlight the 
rational observed risks rather than perceived risks of nosocomial HIV 












The following paper documented the profound impact of HIV-infection on 
quality of life of our patients [8]. It was first necessary to develop a validated tool 
for measuring quality of life of the South African population in indigenous 
languages. When administered to HIV-infected patients stigma was shown to 
affect all studied population groups with a particularly marked decline in quality 
of life across a broad spectrum of functional and well-being measurements 
immediately after receiving an HIV diagnosis. In contrast, subsequent HIV 
progression affected quality of life by progressive erosion of physical functioning 
[9].  
 
Monitoring of HIV disease progression was problematic as CD4 cell 
measurement was either not available or severely rationed.  The accuracy of 
clinical staging was refined and in combination with the more readily available 
and cheaper total lymphocyte count was shown to be highly predictive for 
subsequent prognosis [10].  
 
The Cape Town AIDS Cohort (References 11-21) 
 
The HIV clinic at New Somerset Hospital allowed the development of one of few 
African natural history cohorts, the Cape Town Aids Cohort (CTAC). Clinical 
observations and laboratory data were collated and entered into a prospective 
electronic data capture system from 1992. Retrospective data from 1985 to 1992 
was added by means of chart review. The spectrum of HIV-associated disease 
affecting USA and Europe had already been well described but there had been 
few descriptions from African cohorts. The change in HIV transmission in Cape 
Town from an earlier homosexual to later predominantly heterosexual epidemic 
was associated with changing clinical presentations in CTAC, which were 
described [11-13]. The associations between circulating HIV subtypes in patients 
infected by either homosexual or heterosexual transmission were also 
characterized for the first time [14].  These HIV-subtype analyses indicated that 
the HIV epidemic in South Africa had resulted from introduction of two major 












CTAC allowed further definition of the natural history of HIV and AIDS in Cape 
Town. Articles were published on the aetiology of severe abdominal pain [15], 
the first descriptions of AIDS related disseminated histoplasmosis [16], the 
prevalence of toxoplasmosis infection in different South African racial groupings 
[17], and the spectrum and prognosis of AIDS presentations [18, 19]. The rate of 
progression of HIV infection [20] and short-term risk of AIDS and death were 
published in high impact international journals [21]. Much of this CTAC HIV 
natural history data was incorporated into the Harvard Medical School Cost-
Effectiveness of Preventing AIDS Complications Model (CPAC) of HIV 
progression. The model had been initially developed for costing and efficacy 
projections for USA and has been the basis of ongoing collaboration with the 
Harvard team led by Kenneth Freedberg, to develop the CEPAC-International 
Model.   
 
II. ANTIRETROVIRAL THERAPY 
 
Feasibility of Antiretroviral Therapy in South Africa [References 22-28] 
 
The prognosis for HIV-infected individuals in developed world settings 
dramatically improved following the presentation of results of combination 
antiretroviral therapy (ART) at the 1996 International AIDS Society Conference 
in Vancouver, Canada. AIDS changed from an inevitable rapid progression to 
death to a chronic disease capable of long-term management albeit at a high 
financial cost. With the exception of Brazil, which passed federal law 9313 for 
universal access to ART in December 1996, ART was restricted to wealthy 
countries. Somewhat incredibly the global status quo of no ART in the continent 
with the highest need was justified by prejudicial statements about inability of 
Africans to tell the time and take therapy appropriately.  Therefore the national 
and international environment was not conducive for widespread use of ART. 
Furthermore, it was unclear when to initiate therapy, what drugs to use, how to 
monitor therapy and the costs and feasibility of large scale ART implementation. 
The first 3 papers were targeted at domestic policy makers arguing that an ART 











inevitable poor adherence of Africans would lead to ART resistance mayhem 
were addressed and demonstrated to be prejudicial and scientifically baseless 
[25]. Not surprisingly we showed that African patients were equally able as their 
western counterparts to take ART appropriately. The effectiveness of non-
nucleoside regimens for initial ART was explored in the investigator initiated 
CHARM [26] and 2NN [27] studies. Participation in these international studies 
gained access for CTAC patients to ART and allowed us to construct the 
sequential treatment regimens, which were to later be used in the national ART 
roll out programme. The final paper used CTAC ART data to estimate the cost 
effectiveness of different ART implementation strategies [28]. This analysis was 
performed with the Harvard Medical School GAP model as described above. 
 
Antiretroviral Scale Up [References 29-37] 
 
In 2002 in partnership with the UK charity CRUSAID, we were able to initiate the 
first public sector community ART clinic in the Cape Town township of 
Gugulethu. Lessons learned during the first 6 months of this project were 
published in 2003 [29] followed by results of ongoing rapid scale up [30]. 
Feasibility of community ART provision was established, together with 
experience of the necessary staffing levels. A new cadre of therapeutic 
counselors was developed which increased community involvement and has 
subsequently continued to be deployed with in the expanded Western Cape ART 
programme. Analysis of the costs of the programme ensued [31, 32]. An 
interesting comparison between the results of this public health approach in 
Cape Town and those of individualized management available within the Swiss 
national cohort demonstrated similar clinical and virologic outcomes despite 
very different use of resources [33]. In 2004 the national department of health 
eventually commenced ART provision in the public sector using ART regimens, 
which had been developed in the Gugulethu project.  
 
In collaboration with Ken Freedberg and Rochelle Walensky of Harvard Medical 
School, accumulated data from CTAC pre-ART and from our increasing cohorts 











scale up strategies on South African national mortality[34].  The need for patient 
management after treatment failure [35] and resources necessary to implement 
the recent changes in WHO guidelines were also modeled [36].  
 
The South African HIV burden was such that doctor-led treatment could not cope 
with the necessary expansion of ART. I was principal investigator of the NIH 
funded first randomized trial of -nurse versus doctor-monitored ART (CIPRA 
001) performed at Masiphumelele, which together with a parallel study in 
Soweto, Gauteng demonstrated that task-shifting from doctors to nurses was 
feasible strategy in South Africa [37]. The widespread provision of ART to our 
study population at Masiphumelele also enabled a second NIH CIPRA 003 study 
on the impact of ART provision on tuberculosis incidence and tuberculosis 
prevalence in a heavily burdened South African township (vide infra). 
 
Monitoring an Antiretroviral Programme [References 38- 47] 
 
ART access increased markedly in resource-poor countries with approximately 5 
million patients on ART by 2010. The expansion of treatment access outstripped 
the capacity of laboratory services to monitor CD4 cell counts and viral loads. In 
order to address this problem, data was presented on the utility of the total 
lymphocyte count to predict CD4 cell response to ART [38], the utility of CD4 cell 
count to predict viral load [39], and the value of viral load [40]. I also developed 
the novel intelligent dispensing of ART (iDART) pharmacy-based programme 
monitoring tool in conjunction with the University of Cape Town engineering 
department [41] which has been widely used for monitoring ART programmes in 
South Africa and has subsequently been incorporated into the Western Cape 
“iKapa” and the proposed National HIV-ART monitoring systems. Despite initial 
concerns that “viral mayhem” could result from widespread use of ART, there 
has been little monitoring of genotypic resistance developing in predominant HI 
subtype C virus within the South African national progamme. However, we were 
able to describe the development of genotypic resistance after first-line and 












The South African public health approach HIV management has been based on 
the wide availability of a restricted number of cheap ART drugs.  Conservation of 
ART [44] and substitution rates between regimens was described [45]. Much of 
the political opposition to the ART programme revolved around exaggeration of 
the toxicities of ART. However, we were able to demonstrate that ART generally 
improved quality of life and that in the minority with observed decline in quality 
of life, this was due in large part to HIV-related morbidities and not to drug 
toxicities [46]. 
 
While HIV prognosis is frequently described in patients receiving ART, the 
impact of ART provision at a population level is also determined by health 
seeking behavior and retention of patients in care. The carefully enumerated 
Masiphumelele community provided an almost unique opportunity to determine 
the population impact of an ART programme  [47, 48]. 
 
When to Start Antiretroviral Therapy [References 49-63] 
 
The threshold for starting ART has fluctuated widely since 1996 and has been 
likened to a swinging pendulum. In resource-rich countries, a “test and treat” 
policy followed observations of extremely high viral loads during asymptomatic 
HIV which was later replaced by a much more conservative approach following 
appreciation of long-term toxicities of the early ART regimens. Subsequent 
availability of less toxic ART together with the theoretical concept of treatment 
as prevention has led to a move towards early therapy again.  
 
The decision of when to start ART is complex as the chosen threshold can be 
defined by either clinical or immunologic parameters [49]. The projected 
benefits of ART in the South African population are related to the differential 
mortality and morbidity with and without ART [50-55]and the CD4 cell response 
on ART at different initiation strategies[56]. The affordability and provision of 
ART may be restricted by locally relevant costs and cost-effectiveness [57, 58].  
We are still awaiting the results of a controlled study of when to start (ongoing 











meantime, post hoc analyses from the SMART [59] and CIPRA 001 [60] studies 
that we conducted in Cape Town provide additional observational data 
informing when to start. Furthermore, reported data from the Gugulethu cohort 
demonstrated that generalized thresholds for initiating ART may need to be 
delayed or prioritized when co-infections are present [61-63].  
 
III. Tuberculosis studies 
 
Tuberculosis and HIV [References 64-78] 
 
While the presentation of homosexually transmitted HIV-1 subtype B infection 
presented with a similar spectrum of opportunistic infections to that reported in 
Europe and North America, tuberculosis proved to be by far the commonest co-
infection among heterosexually transmitted HIV subtype C. HIV infection 
changed the clinical presentations of tuberculosis and was described in the CTAC 
cohort [64-69]. The risk factors associated with development of tuberculosis 
were defined [70] and the impact on survival described [66].  
 
The high mortality of TB co-infected patients required high levels of clinical 
suspicion and the development of new TB diagnostic algorithms [71-74]. The 
attributable-risk of HIV for TB disease [75] was such that there was a 
fundamental change in the age specific notification rates in a typical township 
population [76]. The tuberculosis control programme in Masiphumelele with its 
diagnostic emphasis on positive sputum-smear was less relevant for HIV co-
infected patients and resulted in high prevalence of undiagnosed tuberculosis 
prevalence [77].  HIV-infection was shown to be radically changing the natural 
history of tuberculosis in the highly burdened Masiphumelele population [78]. 
 
Tuberculosis and ART [References 79-87] 
 
It was recognized that ART use was associated with a decreased tuberculosis 
incidence rate and we suggested, in a 2001 South African Medical Journal 











epidemic in South Africa [79]. Comparison between the ART and no ART CTAC 
cohorts allowed estimation of the magnitude of the decrease in incidence of 
tuberculosis, which was due to ART [80]. The therapeutic benefit was related to 
the clinical stage of disease and the CD4 cell count at ART initiation. However, 
immune restoration with ART was incomplete and patients remained at 
increased susceptibility to tuberculosis. Prolonged follow up of the Gugulethu 
ART cohort showed that ongoing tuberculosis incidence was largely determined 
by updated CD4 counts rather than solely on the initial CD4 value at ART 
commencement [81]. One of the concerns about simultaneous treatment with 
ART and tuberculosis treatment had been the development of immune 
restoration disease. Studies within the Gugulethu cohort allowed a distinction to 
be made between unmasking of prevalent TB and incident tuberculosis [82]. The 
need for integration of ART and TB control programmes was discussed  [83, 84]. 
We postulated that increased survival resulting from ART together with 
increased susceptibility for tuberculosis disease might have a paradoxical impact 
on the population incidence of tuberculosis. However, repeated randomised 
cross-sectional population based tuberculosis surveys in Masiphumelele as part 
of the CIPRA 3 study, demonstrated a profound decrease in untreated 
tuberculosis prevalence following ART scale up [85]. Subsequent deceases in 
tuberculosis notifications rates with increasing population ART use were also 
shown for the first time [86]. This section ends as it started ten years earlier with 
further discussion of the role of widespread ART for control of tuberculosis [87].  
 
Tuberculosis transmission [References 88-101] 
 
While it has been recognized that the burden of TB has been amplified by HIV 
epidemic, it has been unclear whether HIV has changed the transmission 
dynamics within South African communities. Infection rates can be more readily 
measured in children and we demonstrated high annual risk of TB infection 
throughout childhood in the Masiphumelele township population [88]. 
Subsequently we demonstrated high and continued TB infection rate throughout 
adolescence and HIV-uninfected young adults in Masiphumelele and greater 











geographically related to adult smear positive cases living in the household and 
on the residential plot but not related to the HIV-status of source case [91]. 
Knowledge of transmission probabilities in households allowed estimation of 
transmission probabilities and environmental conditions prevalent in township 
shacks [92].  
 
A court case brought against the minister of correctional services by a plaintiff 
who had contracted tuberculosis while a prisoner gave specific details of the 
conditions within the awaiting trial section of Pollsmoor prison. The detailed 
information afforded a unique opportunity to mathematically model the 
transmission probabilities and explore the necessary TB control measures that 
should be implemented [93]. 
 
Molecular epidemiology studies in Masiphumelele demonstrated multiple 
circulating strains, that there was no evidence that specific strains were strongly 
linked to HIV-status and that there was little nosocomial transmission among 
HIV-infected individuals on ART [94]. The interaction between HIV and TB was 
modeled mathematically for the first time in the Masiphumelele population [95].  
The significance of the magnitude clustering of strains within a population were 
explored [96], and the nature of the contact groups [97]. As tuberculosis and 
other respiratory diseases are dependent on person-to-person transmission of 
pathogens the first population-based social interaction study was performed 
[98]. Daily contacts were shown to be highest and most age-assorted among 
adolescents a group with the highest new tuberculosis burden. 
 
In 2009, approximately 30,000 cases of tuberculosis were notified in Cape Town 
of which 85% were HIV tested. In conjunction with actuarial HIV population 
estimates it was possible for the first time to calculate the age specific 
tuberculosis rates for HIV-infected and uninfected population of Cape Town [99]. 
The tuberculosis rates among young HIV-negative adults were similar to those 
recorded in the pre-chemotherapy era. Social mixing patterns, which play a role 
in the very high reported TB incidence rates, were described for the first time in 











HIV-infected and uninfected populations are an indication that the existing 
tuberculosis control programme is failing and new approached must be 
considered [101]. 
 
In late2011the WHO and Stop-TB initiative published an international roadmap 
for TB research, which highlighted for the first time an urgent priority for 
“identification of the biological, environmental, population-based and social 
drivers of transmission of Mycobacterium tuberculosis”. The development of the 
Masiphumelele cohort and many of the above-presented publications had 
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Most of the work to which I have referred in this document was carried out by 
myself. When not undertaken personally by myself, students under my 
supervision or in collaborations performed it with colleagues.  
The selected work presented is largely based on studies from three clinical 
cohorts, which I initiated and sustained. I designed and implemented the clinical 
and laboratory databases used for the individual analyses in these works and 
closely supervised the ongoing data collection systems and quality control. The 
important conceptual advances that have been achieved by the work I have 
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Safety and Efficacy of Polyethylene Glycol-Modified Interleukin-2 and 
Zidovudine in Human Immunodeficiency Virus Type 1 Infection: A Phase I/II 
Study 
Robin Wood, Jose G. Montoya, Smriti K. Kundu, 
David H. Schwartz, and Thomas C. Merigan* 
AIDS Clinical Trials Unit, Center for AIDS Research, Stanford 
University Medical Center, Stanford, California 
The safety and efficacy of combined therapy with polyethylene glycolated (PEG) interleukin 
(IL)-2 and zidovudine was assessed in 19 human immunodeficiency virus type 1 (HIV-^-sero- 
positive subjects in a phase I/II open-label dose-ranging study. During courses of three weekly 
infusions of PEG IL-2, dose-limiting side effects were seen at 5 X 106 lU/m2 and reversible 
encephalopathy in 1 subject at 3 X 106 lU/m2 . Significant increases were seen in CD4 cell counts 
(P < .01), NK cell activity (P < .05), and HIV-specific ytotoxicity (P < .01). Virologic monitor- 
ing (quantitative DNA polymerase chain reaction and p24 antigen assay) showed no evidence of 
increased HIV activation. Patients with CD4 cells ̂ OO/mm3 were entered into a chronic dosing 
phase. PEG IL-2 was given at 14-day intervals at doses of 106 lU/m2 for 8 weeks and 3 X 106 
lU/m2 for up to 16 weeks, resulting in mean CD4 cell count elevations of 1607o and 3307o, respec- 
tively. PEG IL-2 appears to warrant further investigation, especially in subjects with CD4 cell 
counts ̂ OO/mm3 , to determine whether increased lymphocyte numbers will translate into im- 
proved clinical outcome. 
Human immunodeficiency virus (HIV) infection is char- 
acterized by both a decline in circulating CD4 cells and the 
progression to an immunodeficient state, with decrease in 
cytotoxic lymphocyte responses against all major HIV pro- 
teins [1-5]. The risk of developing an opportunistic infection 
becomes significant when the CD4 lymphocyte count falls 
beneath 200/mm3 and continues to increase as the CD4 cell 
count further declines [6]. Conventional therapy for HIV 
infection is aimed at diminishing viral replication [7] and 
providing prophylaxis against opportunistic infections [8]. 
Advances in recombinant genetic technology have en- 
abled cloning of cDNA for human interleukin (IL)-2 into 
Escherichia coli to produce recombinant (r) IL-2 in therapeu- 
tic quantities [9]. Continuous infusions of rIL-2 together 
with zidovudine have been shown in HIV-infected individ- 
uals with CD4 cell counts ̂ 00/mm3 to increase HlV-speci- 
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fic and nonspecific cytotoxic responses, to elevate CD4 cell 
counts [10], and to decrease mononuclear cell HIV pro viral 
DNA [11]. 
Polyethylene glycol (PEG)-modified IL-2 (Chiron, Emery- 
ville, CA) is produced by covalently binding PEG, a polymer 
with a molecular mass of 6 kDa, to the primary amino group 
of rIL-2. PEG IL-2 is supplied as a sterile lyophilized powder 
that is dissolved in saline before infusion. The specific activ- 
ity as measured in a lymphocyte proliferation assay is about 
one-third that of nonmodified IL-2, and the biologic half-life 
is ~ 10 times that of nonmodified IL-2 with a median initial 
(a) half-life of 180 min and a final (0) half-life of 740 min 
[12,13]. One milligram of PEG IL-2 is approximately equiva- 
lent to 6 X 106 lU. The rationale of the present study was to 
investigate whether intermittent infusions of PEG IL-2 could 
reproduce the potentially beneficial immunologic, viral, and 
T lymphocyte changes seen with continuous-infusion IL-2 
[10] and to extend those observations to subjects with lower 
CD4 cell counts. The ability to deliver the drug by intermit- 
tent peripheral venous infusion rather than by continuous 
central venous infusion introduces the prospect of develop- 
ing a practical chronic dosing regimen. As the lymphocytes 
of an activated immune system may be at increased risk of 
HIV infection [14], the reverse transcriptase inhibitor zido- 
vudine was added to the regimen. 
Methods 
Trial design. We conducted an open-label dose-ranging 
study in two phases. Zidovudine, 500 mg/day in divided doses, 
was taken by all subjects for at least 8 weeks before initiation of 
and during the study. Seventeen subjects entered the first study 
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Table 1. Characteristics of HIV-infected patients at entry to study 
of PEG IL-2 and zidovudine treatment. 
CD4 cell count/mm3* 
After 
Age, CDC Before start of p24 
Subject years class therapy zidovudine antigen 
1 41.3 II 396 349 
2 40.5 II 508 504 
3 37.0 II 394 374 
4 41.9 II 635 683 
5 33.1 II 424 416 + 
6 30.0 II 388 495 
7 42.6 III 461 448 
8 46.5 IV-D 409 486 + 
9 45.9 II ? 200 
10 39.1 II ? 93 + 
11 48.3 II ? 53 
12 36.3 II ? 7 
13 29.8 IV-C-2 ? 67 
14 35.5 II ? 207 
15 44.4 IV-C-2 ? 272 
16 42.8 II ? 98 
17 40.0 IV-D ? 51 + 
18 41.3 II ? 385 
19 39.9 V-C-2 ? 297 
NOTE. CDC, Center for Disease Control. * Mean of 2*3 counts. 
phase, consisting of a series of 6-week cycles of three weekly 
infusions of PEG IL-2 followed by 3 weeks of zidovudine alone. 
Subjects received 1-3 courses consecutively, with a total of 41 
courses of PEG IL-2 being given. The initial dose of PEG IL-2 
was 3 X 106 lU/m2 , with dose escalation to establish the maxi- 
mum tolerated dose and subsequent decrease in dosage to 
106IU7m2 . 
In the second phase of the study, infusions were given at 14- 
day intervals for a 16-week chronic dosing regimen in which 5 
subjects with CD4 cell counts of 200-400/mm3 received eight 
infusions of 106 lU/m2 and 7 subjects with CD4 cell counts 
^OO/mm3 received four infusions at 106 lU/m2 and 5 subjects 
a further four infusions at 3 X 106 lU/m2 . Two subjects with 
CD4 cell counts ^OO/mm3 did not complete dosing at 3 X 106 
lU/m2 because they developed opportunistic infections and 
grade 3 hypotensive episodes. To confirm if the observed re- 
sponses could be maintained, 3 subjects in each group contin- 
ued dosing for a further 8 weeks. 
Subjects. Individual subject profiles are given in table 1. In- 
clusion criteria included a Karnofsky performance status of 
^0^, hematocrit ̂ 0^, neutrophil count > 1000/mm3 , plate- 
lets ^00,000/mm3 , creatinine ^.5 times the upper limit of 
normal, transaminases *c:1.5 times the upper limit of normal, 
and no active opportunistic infection. 
Toxicities. Clinical and laboratory toxicities were graded as 
grade 1, mild; grade 2, moderate, occasionally requiring treat- 
ment; grade 3, severe, requiring dose reduction or termination; 
or grade 4, life-threatening. 
Blood cell separation. Peripheral blood mononuclear cells 
(PBMC) were obtained from fresh citrated venous blood by Fi- 
coll-Paque (Pharmacia, Piscataway, NJ) centrifugation. Cells 
were removed from the interface, washed, and resuspended in 
RPMI 1640 (GIBCO, Grand Island, NY) with 1070 fetal calf 
serum (Irvine Scientific, Santa Ana, CA). 
Natural and lyphokine-activated killer cell assays. Briefly, 
K562 and Daudi tumor cells were labeled for 2 h with chro- 
mium 51 (Amersham, Arlington Heights, IL), washed twice 
with RPMI 1640, and coincubated with freshly isolated PBMC 
for 4 h in round-bottomed 96-well plates (Costar, Cambridge, 
MA) at 370C and 5% CO2. Assays were plated in quadruplicate 
at 105 labeled targets and PBMC effector-to-target (E:T) ratios 
of 50:1, 25:1, and 12.5:1 in a total volume of 200 jtL. Cells were 
harvested (Skatron, Sterling, VA) and measured with a gamma 
counter (Gamma 5500; Beckman Instruments, Palo Alto, CA). 
Specific lysis was calculated as (experimental release ? sponta- 
neous release)Z(maximum release ? spontaneous release) 
X 100. 
HIV-specific cytotoxicity assays. Epstein-Barr virus-immor- 
talized B cell lines were established and maintained as described 
[4]. These were then infected with recombinant vaccinia virus 
containing the bacterial {E. coli) jft-galactosidase gene (Vac- 
lacZ) or the HIV env, gag, and pol genes (vPE167Vac-^A?v, 
VV:gag7Vac-gtfg, vCF2\fVzLC-pol, respectively; AIDS Research 
and Reference Reagent Program, Division of AIDS, National 
Institutes of Health [NIH], Bethesda, MD). Infection of immor- 
talized B cells was done as described elsewhere [4]. These lym- 
phoblastoid cell lines were used as targets for HIV-specific cyto- 
toxic activities in a 6-h chromium 51 release assay. Autologous 
PBMC were used as effectors. E:T ratios used were 100:1, 50:1, 
25:1, and 12.5:1. Monoclonal antibody to major histocompati- 
bility complex (MHC) class I (PA2.6, a gift of A. M. Krensky, 
Stanford University Medical Center) was added at different con- 
centrations at the beginning of the incubation period to detect 
the inhibition of MHC-restricted cytotoxicity. Specific cytotoxic- 
ity was calculated as (experimental release ? spontaneous re- 
lease )7(maximum release ? spontaneous release) X 100. 
Proviral DNA quantification. This was a modification of the 
method described by Clark et al. [11]. Briefly, PBMC were fro- 
zen in RPMI 1640 with 10^ dimethyl sulfoxide and fetal calf 
serum and stored at ? 180oC. Each thawed cell aliquot was cen- 
trifuged at 12,500 g in a microfuge for 5 min. The cell pellet was 
digested by overnight incubation with proteinase K at 550C, 
followed by inactivation at 950C for 10 min. DNA was ex- 
tracted with phenol-chloroform-isoamyl alcohol (25:24:1), pre- 
cipitated with 100% ethanol plus 0.3 M sodium acetate, and 
redissolved in 55 ^L TE buffer (10 mM TRIS-HC1, pH 8.0, and 
0.5 mM EDTA). DNA concentration was determined by spec- 
trometer absorbance at 260 nm. At each time point, DNA was 
diluted in water to give 300,000, 100,000, and 30,000 cell equiv- 
alents at 6 pg of DNA/cell. Polymerase chain reaction (PCR) 
master mix, including primers SK39 and biotinylated SK38, was 
added to each sample, mineral oil was overlayered, and 40 cy- 
cles of amplification were done in a thermal cycler (model 480; 
Perkin-Elmer Cetus, Norwalk, CT). Samples were coamplified 
with a standard curve of dilutions of ACH2 cell DNA contain- 
ing one HIV genome per cell (AIDS Research and Reference 
 od al. 11019 3;167 ( arch) 
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Figure 1. Mean (+SE) changes 
in circulating CD4 cell number 
from baseline values in four 
groups of subjects receiving PEG 
IL-2 during acute and chronic 
dosing phases. A, 6 subjects with 
baseline CD4 cell counts (mean) 
of 470/mm3 , during acute dosing 
phase. Three courses of three 
weekly infusions of PEG IL-2 (3 
X 106 lU/m2) were given at times 
shown by horizontal bars. B, 5 
subjects with baseline CD4 
counts (mean) of 391 cells/mm3 ,
who received biweekly infusions 
of lOMU/m2 at weeks 1, 3, 5, 7, 
9, 11, 13, 15, 17, 19, 21, and 23. 
Data from weeks 16-24 are of 4 
subjects who continued mainte- 
nance for 24 weeks total. C, 3 
subjects with baseline CD4 cell 
count (mean) of 115/mm3 , dur- 
ing acute dosing phase. Sequen- 
tial courses of PEG IL-2 at 3, 5, 
and 1 X 106 lU/m2 were given at 
times shown by horizontal bars. 
D, 5 subjects with baseline CD4 
count (mean) of 144 cells/mm3 ,
who received biweekly infusions 
of PEG IL-2: 1 X 106 lU/m2 was 
given at weeks 1, 3, 5, and 7; 3 X 
106 lU/m2 was given at weeks 9, 
11, 13, 15, 17, 19, 21, and 23. 
Data from weeks 16-24 are of 3 
subjects who continued mainte- 
nance for 24 weeks total. 
Weeks on Acute Dosing Phase Weeks on Maintenance 
Reagent Program, Division of AIDS, NIH) and negative and 
positive controls. Avidin-coated 96-well microplates were used 
to capture PCR product, and a horseradish peroxidase-labeled 
SKI 9 probe with a substrate of o-phenylenediamine was used to 
give a colorimetric readout [15]. Optical density was measured 
at 490 nm and was linearly related to input copy number be- 
tween 10 and 3000 HIV copies, allowing calculation of sample 
HIV copy number by interpolation from the linear part of the 
standard curve. By using the CD4 cell percentage from the clini- 
cal flow cytometry laboratory, the HIV copy number was ex- 
pressed per 1000 CD4 cells. 
Serum p24 antigenemia. Serum p24 was measured with a 
commercial ELISA (Abbott, Abbott Park, IL) done and scored 
according to kit instructions. 
Lymphocyte subsets. Lymphocyte subsets were determined 
immediately before and 7 days after each PEG IL-2 infusion; 
blood was drawn between 8:00 and 11:00 a.m. to avoid diurnal 
fluctuations. Absolute white blood cell counts were done on a 
cell counter (Baker, Phillipsburg, NJ). Lymphocyte subsets were 
determined by a whole blood lysis technique using fluorescein 
isothiocyanate- and phycoerythrin-labeled monoclonal antibod- 
ies (CD3, CD4, CD8, CD56, and Leu-M3; Becton-Dickinson, 
Mountain View, CA) and analyzed on an EPICS Profile II 
(Coulter, Hialeah, FL). Baseline CD4 cell values were estab- 
lished as the mean of three or more time points while the subject 
was on zidovudine during the 8 weeks before the commence- 
ment of PEG IL-2. 
Statistics. For statistical analysis, CD4 cell numbers were 
expressed as logarithms (logjo), changes in CD4 cell numbers as 
logarithmic changes, and means of CD4 cell numbers as geomet- 
ric means. Analysis of variance (ANOVA) was used to compare 
the means of responses by different patient groups and dose 
regimens. Paired data were analyzed by two-tailed Student's t 
test. When trends from different dose levels appeared to be simi- 
lar, data were pooled to obtain sufficient points for statistical 
analysis. Differences were considered significant at P < .05. For 
graphic clarity, changes in CD4 cell numbers were shown as 
absolute numbers. 
Results 
Effects on circulating T lymphocyte subsets. No signifi- 
cant changes in CD4 or CDS cell counts were seen in the 5 
subjects starting on zidovudine during the first 8 weeks of 
study. Six subjects completed three courses of 3 X 106 lU/m2 
PEG IL-2 (figure 1 A). During each course, there was a mean 
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The peak response in each course followed the first or second 
of the three infusions, with no increased elevation following 
the third infusion. The CD8 cell responses paralleled the 
CD4 cell responses but showed greater variation with larger 
SEs. There was no significant change in CD4:CD8 ratio 
(data not shown); the changes in CD4 cell counts were attrib- 
utable to the rise in total T lymphocyte counts. Three sub- 
jects received courses at each of the three dose levels; the 
CD4 cell count elevations were highest at 3 and 5 X 106 
IU/m2 and lowest at 106 IU/m2 (figure 1C). Comparing the 
geometric mean of the three weekly CD4 cell counts while 
subjects were on PEG IL-2 with baseline values showed a 
10% increase in circulating CD4 cell count with 106 IU/m2, 
which, although statistically significant (geometric mean vs. 
baseline, P < .05), was of insufficient magnitude to be biolog- 
ically significant. Statistically significant (geometric mean vs. 
baseline, P < .01) increases of greater magnitude (76%), 
more likely to be of biologic significance, were seen at 3 and 
5 X 106 IU/m2. ANOVA of the CD4 cell responses at each 
dose level demonstrated a very significant difference (P < 
.01) between 1 and 3 or 5 X 106 IU/m2, but responses at 3 
and 5 X 106 IU/m2 were not significantly different. 
Subjects in each clinical group responded to 3 X 106 IU/ 
m2. Group A subjects, with CD4 cell counts >400/mm3, 
received 13 courses at 3 X 106 IU/m2, with a mean increase 
in geometric mean CD4 cell number from baseline of 95% (P 
< .01 ). Group B subjects, with CD4 cell counts of 200-400/ 
mm3, received 6 courses at 3 X 106 IU/m2, with a mean 
geometric increase of 37%. Group C subjects, with CD4 cell 
counts <200/mm3, received 5 courses, with a mean geomet- 
ric mean elevation of 74%. The results of groups B and C 
were combined for analysis and also reached statistical signifi- 
cance (P < .01). By ANOVA, the CD4 lymphocyte eleva- 
tions of the three clinical groups were not significantly dif- 
ferent. 
Because of apparent cumulative toxicity and diminishing 
responses following the second and third weekly infusions, 
an alternate weekly schedule was used for maintenance. 
Seven group C subjects with a mean CD4 cell count of 144/ 
mm3 achieved a 16% elevation in geometric mean at 106 IU/ 
m2 for 8 weeks, and 5 subjects continued for 8 weeks at 3 X 
106 IU/m2 with a 33% elevation (P < .01 comparing geomet- 
ric mean CD4 cell count while receiving PEG IL-2 with base- 
line values). Five group B subjects with a mean CD4 cell 
count of 391 achieved a 6% (P < .05) elevation of geometric 
mean for 16 weeks at 106 IU/m2. These elevations were 
maintained by 3 subjects at each dose level for a further 8 
weeks up to 24 weeks (figure 1B, D). 
Lymphokine-activated killer (LAK) and NK cell activity. 
Our subjects' initial NK cell activity was on average lower 
than that in normal controls. During the first 8-week period 
of zidovudine treatment, there was a significant decline (P < 
.05 comparing mean values of weeks before and after starting 
zidovudine) both in NK cell activity and in circulating NK 
cells (CD3-/CD56+). After each course of PEG IL-2 ther- 
apy, there was a rise in NK cell activity (figure 2A), which 
after the second and third courses was statistically significant 
(P < .05 comparing mean values of the week before and after 
each PEG IL-2 course). 
Infusions of PEG IL-2 at all dose levels studied (1, 3, and 5 
X 106 IU/m2) failed to produce any detectable LAK cell 
activity as defined by > 10% specific lysis of Daudi targets at 
an E:T ratio of 50:1. 
Study Weeks 
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Figure 2. In vitro cytotoxic activity. A, NK cell activity ofperiph- 
eral blood mononuclear cells (PBMC) of 8 subjects who started on 
zidovudine at beginning of study and completed three courses of 
PEG IL-2. Results are mean + SE of% K562 lysis at effector-to-tar- 
get (E:T) ratio of 50: 1. Fall in NK cell activity with zidovudine 
therapy and elevations after second and third courses were signifi- 
cant (P < .05). B, HIV major protein gene-specific cytotoxic activi- 
ties of PBMC before and after PEG IL-2 therapy. HIV env-, gag-, 
and pol-specific cytotoxicities were obtained by subtracting % spe- 
cific cytotoxicity of transformed B cells infected with vaccinia con- 
taining lacZ from that of transformed B cells infected with Vac-env, 
Vac-gag, and Vac-pol, respectively. Cytotoxicities of seven patients 
were measured before and after PEG IL-2 therapy. Three subjects 
received 106 IU/m2, and 4 subjects received 3 X 106 IU/m2. Each 
result is shown as mean + SE of % lysis of each group of patients at 
effector-to-target ratio of 50:1. HIV-specific cytotoxicities were sig- 
nificantly enhanced during 3 X 106 IU/m2 PEG IL-2 therapy (P < 
.01). 
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Table 2. Log,0 HIV provirus copies per 1000 CD4 cells of 7 sub- 
jects receiving three courses of 3 X 106 IU/m2 PEG IL-2. 
Table 4. Adverse events during PEG IL-2 therapy in HIV-in- 
fected subjects. 
Subject WeekO Week 4 Week 10 
NOTE. Week 0, before PEG IL-2 on zidovudine alone; week 4, after 
course 1; week 10, after course 2; week 16, after course 3. 
* PEG IL-2 dose, course 2, was 5 X 106 IU/m2 . 
HI V-specific ytotoxicity. HIV env- , gag- , and /^/-specific 
cytotoxicities increased after PEG IL-2 treatment. The en- 
hancements of cytotoxicities were statistically significant (P 
< .01) after 3 X 106 IU/m2 of PEG IL-2. The increase in 
cytotoxicities after 3 X 106 IU/m2 was higher than that after 
106 IU/m2 (figure 2B). These cytotoxicities were HLA-re- 
stricted (data not shown). 
PCR analvsis of HI V provirus. Quantitative PCR analysis 
data are shown in table 2. There was no increase in mean 
proviral HIV DNA demonstrable after two courses of PEG 
IL-2 (weeks 4, 10, and 16). 
Serum p24 antigenemia. Four subjects were p24-positive 
^30 pg/mL) at the start of the trial (table 3). There was no 
significant increase in titers, and no one became positive dur- 
ing the trial period. 
Toxicitv. No patient discontinued or decreased zidovu- 
dine dosage because of adverse drug-related events. Toxici- 
ties encountered during the acute and maintenance PEG IL- 
2 phases are listed in table 4. Dose-limiting toxicities 
included severe fatigue, hypotension, neutropenia, and cryp- 
tic brachial plexopathy manifested by shoulder pain with 
subsequent winging of the scapula. All hypotensive episodes, 
defined as a drop in diastolic blood pressure ̂ 0 mm Hg, 
Table 3. Serum p24 core antigen levels in 4 subjects receiving 
PEG IL-2 and zidovudine. 
5 80 21 32 35 37 32 
8 44 0 8 11 33 54 
10 ? 100 81 51 49 56 
17* ? 225 330 ? ? 251 
NOTE. Subjects were initially positive for serum p24 ^30 pg/mL). 
Values are shown in pg/mL. Before, prior to starting zidovudine; week 0, 
after 8 weeks of zidovudine but before receiving PEG IL-2; week 4, after 
course 1; week 10. after course 2; week 16, after course 3; After, 1 month 
after PEG IL-2. 
* Subject received only one course of PEG IL-2. 
NOTE. Data are no. of subjects out of 17 who entered acute dose-rang- 
ing phase (no. of subjects out of 13 who entered maintenance phase). Grade 
is maximum intensity of adverse event experienced. 
responded to bed rest and oral fluids (grade 2) or ̂ 00 mL 
of intravenous fluid (grade 3). The only grade 4 toxicity oc- 
curred in patient 7 (table 1), who became confused 60 h after 
the sixth PEG IL-2 infusion at 3 X 106 IU/m2 . Neurologic 
examination was compatible with a dominant parietal cortex 
lesion. There was rapid and full resolution of all neurologic 
signs and symptoms over the next 4 days. Lumbar puncture 
revealed a mild lymphocytic pleocytosis and a marginally 
elevated cerebrospinal fluid protein level. Magnetic reso- 
nance imaging (MR1) demonstrated multiple diffuse nonen- 
hancing white and gray matter lesions that enhanced with 
gadolinium contrast material and slowly resolved over the 
following 8 weeks. This evolution of MRI changes was 
thought to be consistent with a vasculitic process but has not 
been confirmed by histology in any patient to date. This 
patient received no further PEG IL-2, and the subsequent 
weekly dose was reduced to 106 IU/m2 for all subjects be- 
cause of this central nervous system (CNS) toxicity and simi- 
lar toxicity in two other PEG IL-2-treated cancer patients to 
be reported elsewhere. Two subjects (patients 10 and 11) 
developed cutaneous Kaposi's sarcoma during the 12-week 
Week 16 Symptom Grade 1 Grade 2 Grade 3 Grade 4 
1 0.81 1.03 0.95 0.58 
2 1.25 1.13 1.31 1.11 
3 1.04 1.00 1.50 1.20 
4 1.18 0.06 0.73 1.06 
5 1.04 0.95 0.48 0.96 
10 1.60 1.70 1.70* 1.70 
11 2.68 2.57 2.66* 2.57 
Mean 1.37 1.20 1.33 1.31 
Fever 16(7) 1(2) 
Myalgia 4 (3) 4 (6) 
Fatigue 3(2) ?(6) ?(1) 
Nasal stuffiness 6(1) 
Dizziness 1 ? (2) 
Hypotension ? 1(1) 2(1) 
Neutropenia ? 1 2 
Dry skin 4 (5) 3 
Rash/pruritis 2 (2) 3 
Flushing 5(2) 2(1) 
Facial edema 6(1) 1(4) 
Conjunctivitis 1 
General edema 2 (2) 1 
Stomatitis 2 (2) 1 
Jaw pain 1 1 
Laryngitis 1 
Cough 3(4) ?(1) 
Loss of appetite 1 (3) 
Nausea 6 (7) ? (2) 
Vomiting 1 
Loose Stool 4 (3) ? (3) 
Renal colic 1 
Headache 3(5) 2(1) 
Agitation 3(1) 1 
Encephalopathy ? ? ? 1 
Concentration problems 1 (2) 
Blurred vision 1(1) 
Paresthesias 1 (2) 
Brachial neuritis ? ? 1 
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interval between the two phases of this study. Subject 11 was 
removed from the study after diagnosis of cerebral toxoplas- 
mosis after the fourth maintenance infusion. The maximum 
weekly tolerated dose of PEG IL-2 during the acute dosing 
phase, defined as the maximal dose at which k337c of sub- 
jects had grade 3 or 4 toxicities, was 3 X 106 lU/m2 . 
Discussion 
IL-2 is a pivotal cytokine of the cellular immune response, 
with a very short plasma half-life. Studies of bolus infusions 
of rIL-2 in HIV disease have shown variable immune en- 
hancement [16-19]. A study of continuous-infusion rIL-2 in 
zidovudine-treated patients established an optimal daily 
dose at which there was an acceptable level of toxicity, asso- 
ciated with positive changes in immune parameters, includ- 
ing an increase in CD4 cell counts [10] and a decrease in 
mononuclear cell HIV proviral DNA [11]. 
PEG IL-2 is an analogue of IL-2 with a prolonged duration 
of action [ 19], which allows the drug to be given by intermit- 
tent peripheral venous infusion. Low-dose rIL-2 and PEG 
IL-2 have been given to HIV-infected patients by the subcuta- 
neous route with immune enhancement but no elevation of 
lymphocyte counts [20]. The T lymphocyte responses to in- 
travenous PEG IL-2 are complex. Peripheral T lymphocyte 
counts rapidly decline (data not shown) after intravenous 
infusion, reaching a nadir at 4 h, recovering to baseline val- 
ues at 24-48 h, and rising to supranormal levels at 7 days. 
Elevations in circulating CD4 cells were seen after PEG IL-2 
infusion in all patient groups defined by CD4 cell counts. 
The proportional elevation of CD4 cell counts (logjo changes 
or percentage rises) were similar in each group, although the 
absolute magnitude of these changes was baseline-depen- 
dent (i.e., was highest in group A and lowest in group C). 
Whether these new circulating cells represent an expanded T 
cell pool or a mobilization from the tissues to the circulation 
is not known at present. We did not assay soluble IL-2 recep- 
tors (sIL-2r), although Schwartz et al. [10] did show increas- 
ing sIL-2r levels peaking between 2 and 4 weeks of continu- 
ous rIL-2. The decreased CD4 lymphocyte response seen 
after the third weekly infusion may be modified by such an 
increase in sIL-2r. 
One major concern with the use of cytokines to stimulate 
the immune system is that a fertile ground may be produced 
in which HIV will proliferate. Zidovudine was added to the 
regimen to inhibit viral replication, and both serum p24 lev- 
els and HIV provirus were assayed as virus markers. There 
was no overall change in either of these two measures during 
the study period. The decreases in HIV provirus reported by 
Clark et al. [11] following continuous rIL-2 were noted after 
the first initiation of both zidovudine and rIL-2 and may 
have been due to the zidovudine component. 
Two subjects developed Kaposi's sarcoma between the 
two phases of this study. However, subject 8, who entered 
the study with cutaneous Kaposi's sarcoma, had partial reso- 
lution of his lesions over the course of the study. 
Both the low initial NK cell activity of HIV-infected sub- 
jects and the fall with commencement of zidovudine therapy 
have been reported by Schwartz et al. [10]. The significant 
fall in NK cell activity with zidovudine in our study was 
associated with a fall in circulating CD37CD56"' NK effec- 
tor cells (data not shown). The mechanism of this phenome- 
non is unknown, but as there was no associated decline in 
platelets, neutrophils, or red blood cells, it would seem un- 
likely that this was secondary to generalized zidovudine-in- 
duced marrow depression. The increase in both in vitro HIV- 
specific and NK cell activity following PEG IL-2 
administration is compatible with the known immunomodu- 
latory functions of IL-2 [21], but the clinical relevance of 
these changes remains to be determined. Our failure to dem- 
onstrate LAK cell activity 1 week after PEG IL-2 infusion is 
consistent with the findings of Schwartz et al. [10], who dem- 
onstrated LAK cell activity only once during IL-2 therapy, 
and Teppler et al. [20], who showed increased LAK cell activ- 
ity with an assay requiring a 5-day preincubation with rIL-2. 
The side effects of PEG IL-2 in our study were similar to 
those previously reported with the administration of IL-2 
[22]. The lowest dose, 106 lU/m2 , was well tolerated, allow- 
ing administration on an outpatient basis. Higher doses, ̂ 3 
X 106 lU/m2 , were associated with the risk of hypotension 
and necessitated observation of subjects for up to 12 h after 
infusion. Study of PEG IL-2 administration in animal mod- 
els has demonstrated that effectiveness and toxicity are both 
dose- and interval-dependent [23]. Our clinical impression 
was that toxicities were cumulative when dosing was weekly, 
and our most serious toxicities occurred after high-dose 
weekly infusions. There appeared to be no cumulative toxic- 
ity with biweekly dosing. 
Clinically significant CNS toxicities during IL-2 therapies 
are common, are often dose-limiting, and may progress after 
discontinuation of therapy [24, 25]. Two neurotoxicities de- 
veloped during the weekly dosing phase of our study. The 
etiology of cryptic brachial plexopathy is often uncertain, 
although there may be an association with viral infections, 
including HIV infection. However, the temporal association 
of symptoms with PEG IL-2 infusion in our patient and the 
recent report of 2 cases of brachial plexopathy related to IL-2 
therapy [26] would implicate PEG IL-2 as a probable caus- 
ative factor. Both reversible encephalopathy [27] and acute 
fatal leukoencephalopathy [28] have been associated with 
IL-2 therapy, but the MRI lesions associated with neurologic 
symptoms in patient 7 have not previously been reported 
with IL-2 therapy. These lesions are compatible with a dif- 
fuse vascular phenomenon rather than a demyelinating pro- 
cess. Two further cases of subacute CNS toxicity with MRI 
scan changes have occurred during intense high-dose PEG 
IL-2 therapy (6 X 106 lU/mVweek) for metastatic carcinoma 
(Yang JC, NIH personal communication). No further CNS 
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toxicity was observed during the maintenance phase of this 
study, in which the dosing interval was increased to alternate 
weekly infusions. Other side effects were not so limiting as to 
cause any patient to withdraw from the study. 
The dose-ranging phase of this study demonstrated the 
maximum tolerated dose, toxicity, and potentially beneficial 
effects of PEG IL-2 therapy, while the maintenance phase 
showed that a tolerable and effective chronic dosing regimen 
with PEG IL-2 is possible. The combination of augmented 
immune function and elevation of CD4 cell count opens the 
possibility of therapeutically reversing two key markers of 
HIV progression. However, the dose of PEG IL-2 required to 
produce sufficient elevation of these parameters to be of bio- 
logic relevance is close to the maximum weekly tolerated 
dose. Subjects with CD4 cell counts ̂ OO/mm3 , because of 
their increased risk of opportunistic infections, may have 
more to gain from the dose-related CD4 elevations and aug- 
mented immune function seen in this study. The number of 
subjects in this pilot study was small, and further studies will 
be required, with larger groups of patients and controls, to 
ascertain whether manipulation of CD4 cells and cytotoxic 
responses by PEG IL-2 can translate into clinical benefit. 
Acknowledgments 
We thank Barbara Carr for assistance in patient care and data 
collection, Lincoln E. Moses for his advice on statistical analy- 
sis, and Helin Dong for laboratory technical support. 
References 
1. Koenig S, Earl P, Powell D, et al. Group specific, major histocompatibil- 
ity complex class-1 restricted cytotoxic response to human immuno- 
deficiency virus-1 (HIV-1) envelope proteins by cloned peripheral 
blood T cells from an HIV-infected individual. Proc Natl Acad Sci 
USA 1988;85:8638-42. 
2. Walker BD, Chakrabarti S, Moss B, et al. HIV-specific cytotoxic T 
lymphocytes in seropositive individuals. Nature 1987;328:345-8. 
3. Walker BD, Flexner C, Paradis TJ, et al. HIV-1 reverse transcriptase is a 
target for cytotoxic T lymphocytes in infected individuals. Science 
1988;240:64-6. 
4. Kundu SK, Merigan TC. Inverse relationship of CD8+CD11+ suppres- 
sor T cells with human immunodeficiency virus (HlV)-specific cel- 
lular cytotoxicity and natural killer cell activity in HIV infection. 
Immunology 1991;74:567-71. 
5. Joly P, Guillon JM, Mayaud C, et al. Cell mediated suppression of 
HIV-specific cytotoxic T lymphocytes. J Immunol 1989; 143:2193- 
201. 
6. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of 
opportunistic pneumonias in HIV infection. Ann Intern Med 
1989;111:223-31. 
7. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothy- 
midine (AZT) in the treatment of patients with AIDS and AIDS-re- 
lated complex. A double-blind, placebo-controlled trial. N Engl J 
Med 1987;317:185-91. 
8. Centers for Disease Control. Guidelines for prophylaxis against Pneu- 
mocystis carinii pneumonia for persons infected with human immu- 
nodeficiency virus. MMWR 1989;38(suppl S-5):l-9. 
9. Taniguchi T, Matsui H, Fujita T, et al. Structure and expression of a 
cloned cDNA for human interleukin-2. Nature 1983;302:305-10. 
10. Schwartz DH, Skowron G, Merigan TC. Safety and effects of interleu- 
kin-2 plus zidovudine in asymptomatic individuals infected with hu- 
man immunodeficiency virus. J Acquir Immune Defic Syndr 
1991;4:11-23. 
11. Clark AGB, Holodny M, Schwartz DH, Katzenstein DA, Merigan TC. 
Decrease in HIV provirus in peripheral blood mononuclear cells dur- 
ing zidovudine and rIL-2 administration. J Acquir Immune Defic 
Syndr 1992;5:52-9. 
12. Katre NV, Knauf MJ, Laird WJ. Chemical modification of recombi- 
nant interleukin-2 by polyethylene glycol increases its potency in the 
murine Meth A sarcoma model. Proc Natl Acad Sci USA 
1987;84:1487-91. 
13. Knauf MJ, Bell DP, Hirtzer P, Luo ZP, Young JD, Katre NV. Relation- 
ship of effective molecular size to systemic clearance in rats of recom- 
binant interleukin-2 chemically modified with water soluble poly- 
mers. J Biol Chem 1988;263:15064-70. 
14. Gowda SD, Stein BS, Mohagheghpour N, Benike CJ, Engelman EG. 
Evidence that T cell activation is required for HIV-1 entry in CD4+ 
lymphocytes. J Immunol 1989;142:773-80. 
15. Holodny MD, Winters MA, Merigan TC. Detection and quantification 
of gene amplification products by a nonisotopic automated system. 
Biotechnology 1992;12:36-9. 
16. Lane HC, Siegel JP, Rook AH, et al. Use of interleukin-2 in patients 
with the acquired immunodeficiency syndrome. J Biol Response Mo- 
dif 1984;3:512-6. 
17. Kern P, Toy J, Deitrich M. Preliminary clinical observations with re- 
combinant interleukin-2 in patients with AIDS or LAS. Blut 
1985;50:1-6. 
18. Ernst M, Kern P, Flad HD, Ulmer AJ. Effects of systemic in vivo inter- 
leukin-2 (IL-2) reconstitution in patients with acquired immune defi- 
ciency syndrome (AIDS) and AIDS-related complex (ARC) on phe- 
notypes and functions of peripheral blood mononuclear cells. J Clin 
Immunol 1986;6:170-81. 
19. Volberding P, Moody DJ, Beardslee D, Bradley EC, Wofsy CB. Ther- 
apy of acquired immune deficiency syndrome with recombinant in- 
terleukin-2. AIDS Res Hum Retroviruses 1987;3:115-24. 
20. Teppler H, Cameron P, Kaplan G, Cohn ZA. Interleukin-2 in HIV 
infection. Safety and systemic effect of low dose intradermal adminis- 
tration [abstract]. Clin Res 1991;39:314A. 
21. Schwartz DH, Merigan TC. Interleukin-2 in the treatment of HIV dis- 
ease. Biotherapy 1990;2:119-30. 
22. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of 
high-dose IL-2 in the treatment of 652 cancer patients. Ann Surg 
1989;210:474-85. 
23. Zimmerman RJ, Aukerman SL, Katre NV, Winkelhake JL, Young JD. 
Schedule dependency of the antitumor and toxicity of polyethylene 
glycol-modified interleukin 2 in murine tumor models. Cancer Res 
1989;49:6521-8. 
24. Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric ef- 
fects of treatment with interleukin-2 and lymphokine-activated cells. 
Ann Intern Med 1987;107:293-300. 
25. Triozzi PL, Kinney P, Rinehart JJ. Central nervous system toxicity of 
biological response modifiers. Ann NY Acad Sci 1990;594:347-54. 
26. Loy FL, Hersovitz S, Berger AR, et al. Brachial plexopathy associated 
with interleukin-2 therapy. Neurology 1991;41(suppl 1):134. 
27. Margolin KA, Rayner MJ, Hawkins M, et al. Interleukin-2 and lym- 
phokine-activated killer cell therapy of solid tumors: analysis of toxic- 
ity and management guidelines. J Clin Oncol 1989;7:486-9. 
28. Vecht CJ, Keohane C, Menon RS, et al. Acute fatal leukoencephalopa- 
thy after interleukin-2 therapy. N Engl J Med 1990;323:1146-7. 
;  ( arch) I Therapy  -  
toxicity s ved during i tenance phase  is 
study, i   dosing rval s eased  nate 
weekly f sions. er e ts e  limiting   
se any patient raw o   study. 
dose-ranging phase  is study strated  
i um ated se, toxicity,  potentially eficial 
ts   -2 therapy, il   i tenance phase 
 t  able  tive onic dosing regi en 
  -2  possible. i ation  augmented 
e ction  ti    opens  
possibility  therapeutically reversing  key rkers  
I  progression. er,     -2 required  
produce fficient i   ese parameters   bio-
logic l ance    i um weekly ated 
se. Subjects   ts <200/ 3, se  
i  eased isk  opportunistic i tions, may e 
e gain o   related ti s  aug-
t  ne ction   is study. er  
subjects  is pilot study s ll,  ther dies l 
 required,  larger groups  patients  trols, 
tain er manipulation    cytotoxic 
responses by  -2  anslate  i al efit. 
cknowledgments 
e ank rbara rr r sistance  patient re  ta 
ll tion, i coln . ses r is vice  tistical analy-
sis,  lin Dong r laboratory nical support. 
ces 
I. Koenig . rl , el  .  l. Group specific. major histocompatibil-
ity complex s-I stricted cytotoxic response  an no-
deficiency us-I ( I -I) envelope proteins by  peripheral 
  o   I -i fected i idual. oc t!  i 
 ; : . 
. l er . krabarti . ss . l. I -specific cytotoxic 
lymphocytes  seropositive ividuals. re  
. l er . r e. radis ,  l. -I everse transcriptase  
target  cytotoxic lymphocytes  te  ividuals. ce 
; : . 
 du . erigan . erse relationship II+ suppres-
    an i unodeficiency us ( I )-specific 
 cytotoxicity  tural ll r l activity  I  tion. 
Immunology ; : - . 
. Joly . ill  . ayaud e.  l. ll i ted suppression  
HIV-specific cytotoxic  lymphocytes.  I1 ;1
 s r . Ognibene . choan .  l. ts  predictors  
opportunistic pneumonias  I  tion.  tern  
; III : . 
 hl . an . ieco . .  efficacy azidothy-
i e (AZT)   eat ent  patients    -re-
 complex. le-blind. placebo-controlled ial. Engl  
  
. ters r se trol. i elines  prophylaxis against eu-
mocys/is i i  pneumonia  persons te   an u-
nodeficiency us.  1989;38(suppl S-5): 1-9. 
. Taniguchi . tsui . Fujita .  l. ucture  expression  
  an rleukin-2. re ; : - . 
. artz . ron . erigan . Safety  cts   leu-
-2 plus ine  asymptomatic i i uals ted  -
 immunodeficiency us.  Acquir ne i  Syndr 
; : - . 
II. rk . Holodny . artz . tzenstein . erigan . 
ease  I  provirus  peripheral  clear  r-
ing ine  IL-2 inistration.  Acquir une i  
Syndr ; : - . 
. tre . J. ird . e ical ification  b i-
t rleukin-2 by polyethylene glycol eases  potency   
rine t  co a el. oc tl  i  
; : - . 
. f J. ll . tzer . . Young . tre . ti -
ship  tive lar   systemic ance  ts reco -
t rleukin-2 chemically ified  r l  poly-
rs.  i ern : . 
. a . i  . ohagheghpour . ike . Engel an . 
i ence t  l i ation  required r I  -I entry   
ly phocytes.  unol   . 
. Holodny . i ters . erigan . i   quantification 
 gene amplification products by nonisotopic t ated system. 
Biotechnology ; : . 
. e e. Siegel .  .  l.  interleukin-2  patients 
  acquired immunodeficiency syndrome.  i Response -
; : - . 
. n . Toy . rich . Preliminary i l vations  e-
i nt rleukin-2  patients    S. t 
; : . 
. nst . rn .  .  . fects  systemic   r-
in-2 (IL-2) stitution  patients  acquired e fi-
ciency syndrome ( I S)  -related co plex ( ) phe-
notypes  ctions  peripheral  clear .  i  
unol ; : . 
. Volberding . oody O . rdsle  . Bradley e. ofsy . r-
apy  acquired ne deficiency syndrome  binant -
leukin-2.    troviruses ; : - . 
 Teppler . eron . Kaplan .  . terleukin-2  I  
tion. Safety  systemic t l se radermal inis-
ation [abstract]. i   ; : . 
 rtz . erigan . terleukin-2   e t ent   is-
se. Biotherapy ; : - . 
 Rosenberg . tze . Yang e.  l. Experience     
high-dose -2   eatment  r patients. Surg 
; : . 
 erman . erman . tre . elhake , Young .
ule dependency   tit or  toxicity  polyethylene 
glycol-modified rleukin  rine r els. c r  
; : - . 
 . inow . Papa .  l.  neuropsychiatric -
ts  e t ent  rleukin-2  Iymphokine-activated l . 
 tern  ; : . 
 iozzi . Kinney . art . tral vous system toxicity  
biological response ifiers.    i . 
. Loy . sovitz . Berger .  l. achial plexopathy i ted 
 rleukin-2 therapy. Neurology 1991;41(suppll):134. 
argolin . Rayner . kins . l. terleukin-2  Iy -
phokine-activated ll r l therapy   ors: analysis toxic-
ity  management guidelines.   c l . 
 t . ne e.  .  l. te lleukoencephalopa-























































JOURNAL OF CLINICAL MICROBIOLOGY, OCt. 1993, p. 2692-2696 
0095-1137/93/102692-05$02.00/0 
Copyright © 1993, American Society for Microbiology 
Vol. 31, No. 10 
Peripheral Blood Mononuclear Cell Human Immunodeficiency 
Virus Type 1 Proviral DNA Quantification by Polymerase 
Chain Reaction: Relationship to Immunodeficiency 
and Drug Effect 
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Human immunodeficiency virus type 1 (HIV-l) proviral DNA from peripheral blood mononuclear cells 
(PBMCs) was quantitated in 61 HIV-l-seropositive individuals by a nonisotopic polymerase chain reaction 
assay_ Primers from the gag region (SK38, SK39) were used to determine the loglo HIV-l proviral copy number 
per 106 CD4+ T lymphocytes (peripheral blood proviral load). A standard curve was generated for each assay 
by using ACH-2 cell DNA. The peripheral blood proviral load was followed in 15 individuals in a longitudinal 
study and was measured in 45 individuals in a cross-sectional analysis. Three of four untreated patients who 
were followed for 14 months had stable PBMC proviral loads and CD4+ T lymphocyte counts; one untreated 
patient had a sustained increase in PBMC proviral load followed 5 months later by a significant decline in the 
CD4+ T lymphocyte count. Eleven previously untreated individuals were monitored for 1 year following 
initiation of zidovudine and/or 2' ,3' -dideoxyinosine therapy. The mean loglo number of proviral HIV-l copies 
per 106 CD4+ T cells decreased from 4.3 ± 0.4 at the baseline to 3.5 ± 0.6 after 2 to 4 months of therapy (P 
< 0.01). This initial 0.8 loglo fall in the PBMC proviral load after the initiation of therapy was followed by a 
rise in the PBMC proviral load by the sixth month of therapy. The PBMC proviral load in 45 subjects, both 
treated (n = 25) and untreated (n = 20), correlated inversely with the CD4+ T lymphocyte count (P < 0.01, 
R = 0.49). PBMC proviral DNA quantification by a nonisotopic polymerase chain reaction assay correlates 
with HIV-l disease progression and could be used to monitor the effect of antiretroviral therapy. 
Quantification of human immunodeficiency virus type 1 
(HIV-1) in peripheral blood by polymerase chain reaction 
(PCR) has been reported by using both RNA and DNA 
amplification (1, 5, 9-11, 13, 15, 17, 18, 21, 22, 24, 25, 27). 
Measurement of the HIV-1 proviral load may be useful in 
predicting the progression of disease and the response to 
currently available and experimental antiretroviral drugs (5, 
8, 12, 15, 16). By using quantitative PCR, the amount of 
HIV-1 proviral DNA in peripheral blood mononuclear cells 
(PBMCs) has been shown to increase significantly and 
transiently at the time of symptomatic primary infection (6) 
and to rise gradually and steadily as the disease progresses 
(3, 9, 18, 24, 27). 
PBMC proviral DNA amplification has also been used to 
assess the viral load response to therapy with immunomod-
ulators or nucleoside compounds (4, 8). Both Clark et al. (4) 
and Aoki et al. (2) reported significant decreases in the 
amount of PBMC proviral DNA in drug-naive patients 
commencing zidovudine with recombinant interleukin-2 and 
2' ,3'-dideoxyinosine (ddI) therapy, respectively. However, 
Donovan et al. (7) found no significant change in the amount 
of PBMC proviral DNA in six patients after 5 to 14 months 
of zidovudine therapy. 
Study of the peripheral blood proviral load (loglO HIV-1 
copy number per 106 CD4+ T lymphocytes), determined by 
• Corresponding author. 
t Present address: Division of Infectious Diseases (S-IS6), Stan-
ford University Medical Center, Stanford, CA 94305. 
:j: Present address: Infectious Diseases Section (III-ID), Veterans 
Affairs Medical Center, Palo Alto, CA 94304. 
2692 
a PBMC proviral DNA amplification assay developed and 
optimized in our laboratory, in 61 HIV-1-seropositive indi-
viduals is summarized here, as follows: a cross-sectional 
study of PBMC proviral load in 45 patients (25 patients on 
long-term therapy and 20 untreated patients) that correlated 
the PBMC proviral load with CD4 + T cell counts and the 
impact of long-term antiretroviral therapy, a longitudinal 
study of the PBMC proviral load in 4 untreated patients who 
were followed for 14 to 16 months, and a longitudinal study 
of the PBMC proviral load in 11 previously untreated indi-
viduals starting single or combination nucleoside therapy. 
MATERIALS AND METHODS 
Specimens from 61 ambulatory and asymptomatic patients 
participating in AIDS Clinical Trials Group clinical trials at 
the Center for AIDS Research at Stanford University Med-
ical Center in 1988 were available. All specimens were 
obtained from the patients with informed consent, and the 
study was approved by the institutional review board of the 
Stanford University Medical Center. 
Citrated blood was obtained by peripheral venipuncture, 
and PBMCs were separated by Ficoll-Hypaque density 
gradient centrifugation. Cells were stored at -180°C. DNAs 
extracted from the PBMCs of seronegative individuals were 
used as negative controls in each assay. Cells were digested 
overnight at 55°C in proteinase K buffer, and proteinase K 
was inactivated by heating the samples at 95°C. DNA was 
extracted with phenol-chloroform (23), dissolved in 55 IJ.I of 
TE buffer (10 mM Tris-HCI [pH 8.0], 0.5 mM EDT A), and 
quantitated by measuring the A 26o • DNA equivalent to 
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FIG. 1. Serial CD4+ T lymphocyte counts (0) and IOglO HIV-l proviral copy number per 106 CD4+ T lymphocytes (&) in four 
asymptomatic individuals (A to D) who were followed for 16 months. 
proviral load in the combination therapy group at baseline 
(4.17 ± 0.3 HIV-1 copies per 104 CD4+ T lymphocytes [SD)) 
decreased to 2.96 ± 0.5 HIV-1 copies per 104 CD4+ T 
lymphocytes (SD) at 2 to 4 months after the initiation of 
therapy (P < 0.05). Their mean CD4 cell count at the 
baseline of 360 ± 34 cells per mm3 (SD) increased to 458 ± 
52 cells per mm3 (SD). In both the monotherapy and com-
bination therapy groups, the increases in CD4 cell counts 
after therapy did not achieve statistical significance, as 
shown in Table 1. 
DISCUSSION 
Quantification of HIV -1 proviral DNA in PBMCs provides 
a direct measure of the number of infected cells in the 
peripheral circulation. The peripheral blood HIV-1 proviral 
load measured by the assay described here was stable over 
time in untreated individuals without progressive disease, 
correlated with the stage of disease as defined by the CD4 + 
T lymphocyte count, and decreased following the initiation 
of therapy with nucleoside compounds in drug-naive pa-
tients. 
To evaluate the stability of the signal over time, the PBMC 
proviral load was measured in four untreated individuals for 
a period of 14 to 16 months. These samples had been stored 
in dimethyl sulfoxide since 1988 and were analyzed in 1992. 
The 10glO HIV-1 copy number per 106 CD4+ T lymphocytes 
and CD4 + T lymphocyte counts were stable over time in 
three patients; however, in one patient a significant decline 
in the CD4 + T cell lymphocyte count was preceded by a 
1-loglo rise in the PBMC proviral load. It appears that 
changes in the proportion of infected cells detected by this 
technique precede the subsequent deterioration of the im-
mune system seen in HIV-1-infected individuals. A similar 
finding has been reported very recently by Connor et al. (5). 
Several studies have shown a correlation between pro-
gressive disease and increasing copies of HIV -1 proviral 
DNA quantitated by PCR in sorted CD4+ T cells (15, 24), 
PBMCs (3), or PBMCs corrected for the percentage of CD4 + 
T cells in peripheral blood (9, 18, 19, 27). In the present 
study, the PBMC proviral load (expressed as 10glO HIV-1 
copy number per 106 CD4+ T cells) increased with decreas-
ing CD4 + T cell count. However, a wide spectrum of PBMC 
proviral loads (up to a 100-fold range) was observed among 
patients with similar CD4 + T lymphocyte counts. Further 
studies correlating the PBMC proviral load and clinical 
status in HIV-1-infected individuals are needed to determine 
whether PBMC proviral load qualifies as a better surrogate 
marker than CD4 + T cell count of disease progression. 
An important goal in the quantification of viral load in 
patients infected with HIV-1 is direct measurement of the 
impact of antiviral therapy. Although two studies have 
shown no significant change in the viral load in peripheral 
blood measured by proviral DNA amplification while pa-
tients have been on zidovudine (7, 19), in both of those 
investigations baseline measurements preceding the initia-
tion of drug therapy were not obtained. In the study reported 
here, there was a modest but significant decrease in PBMC 
proviral load when baseline values were compared with 
those obtained 2 to 4 months after the initiation of therapy in 
drug-naive individuals. These findings are consistent with 
reports by Aoki et al. (2) and a previous study conducted in 
our laboratory (4) in which changes in PBMC proviral load 
were assessed in patients starting ddI and zidovudine ther-
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Quantification and Comparison of HIV -1 Proviral Load 
in Peripheral Blood Mononuclear Cells and Isolated 
CD4 + T Cells 
Robin Wood, Helin Dong, David A. Katzenstein, and Thomas C. Merigan 
AIDS Clinical Trials Unit, Center j(lr AIDS Research. Stwtford Unil'ersity Medical Center, 
Stanford. Calij(lrnia, U.S .A . 
Summary: HIV proviral load was determined by quantitative DNA polymerase 
chain reaction (PCR) in peripheral blood mononuclear cell s (PBMC) and lym-
phocyte subsets isolated by cell sorter. Provirus measured in PBMC. when 
expressed as HIV copy number per million CD4 ' cells. resulted in values 
which approximated those obtained from sorted CD4 + T lymphocytes. A cross 
sectional analysis of HIV proviral load in CD4 -+ T cells from 25 previously 
untreated and 30 zidovudine-treated seropositive patients with CD4 + T-cell 
counts between 25 and 802/mm~ demonstrated HIV copy numbers ranging 
from I copy per 10.000 cells in early disease to I copy per 10 cells in advanced 
disease. HIV proviral load can be rapidly assayed by PCR to give a reproduc-
ible value which varies over a I.OOO-foid range and is positively correlated with 
cell infectivity as measured by a quantitative micrococulture assay. A less 
technically demanding assay using PBMC as substrate can give similar re sults 
to those obtained with sorted CD4 + T cells, Key Words: HIV provirus-
Quantitative PCR-CD4 + T cells-PBMC. 
Assays to quantitate HIV DNA by gene amplifi-
cation have utilized both sorted CD4 + T cells and 
peripheral blood mononuclear cells (PBMC) as sub-
strates. As polymerase chain reaction (PCR)-based 
assays become more widely used in clinical trials. 
choices must be made concerning the most appro-
priate clinical samples to collect. store. and pro-
cess. In this study. HIV proviral DNA from FACS-
purified CD4 + T cells was assayed at different 
stages of disease . In addition. the values obtained 
from sorted CD4 + T cells were compared with viral 
load measured by a cell coculture assay and a sim-
pler PCR assay using lysed PBMC as substrate, 
Address correspondence and reprint requests to Dr. Robin 
Wood at Center for AIDS Research . Division of Infectiolls Dis-
eases. Stanford Universit y Medical Center. Stanford . CA 94305 . 
U.S.A. 
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MATERIALS AND METHODS 
Written . informed consent was obtained from all patients par-
ticipating in this study who were volunteers sc reening for clinical 
trials between October. 1991 and March. 1992 . 
Cell Preparation and Storage 
PBMCs were isolated from citrated blood by Ficoll-Hypaque 
ce ntrifugation. Res idual red cells were lysed with a solution of 
0.H4'7r ammonium chloride. 0.1 '7r potassium bicarbonate. 0.2'7r 
sodium azide . (J.()()2'7r EDT A and the remaining cells washed 
twice in phosphate-buffered saline. One million cell pellets of 
PBMC were stored at - 7(fC. For FACS so rting, .5 x 10" PBMC 
were labe led with fluorescein-conjuga ted (FITCl anti-CD3 and 
phycoerythrin-conjugated (PE) anti-CD4 a ntibodies <Becton-
Dickinson, Mounta in View . CA. U .S. A.) according to manufac-
turer's instructions . washed and fixed in O . .5'7r paraformalde-
hyde . CD4 ' ICD3 ' cells were isolated b y a FACStarPLUS ce ll 
sorter <Becton-Dickinson. CAl. 
DNA PCR 
The quantitative peR assay used was a modification of the 
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described. were digested in 50 fl.1 of 0 .01 % proteinase K buffer 
overnight at 55°C and then denatured at 95°C for 5 min . Fifty 
microliters of PCR reagent mixture was added to give final con-
centrations of 75 mM KCI. 3.75 mM MgCI,. 15 mM Tris· HCI. 
0.01 % gelatin. 250 fl.M of each deoxynucleoside triphosphate . 50 
pmol each of HIV 1:111: primers SK31! and biotinylated SK39 (Pro· 
tein and Nucleic Acid Facility. Beckman Center. Stanford Uni-
versity) together with 0.6 fl.g of human placental DNA and 2.5 
units AmpliTaq DNA polymerase (Perkin-Elmer Cetus) in each 
digested sample. These IOO-fl.1 reaction mixtures were amplified 
in a GeneAmp PCR System %00 (Perkin-Elmer Cetus) for thirty 
cycles with the following parameters; 95°C x 10 s . 55°C x 30 s. 
n oc x 30 s. PCR product was quantitated by a nonisotopi<.: 
method in which hybridization with an enzyme-linked probe al-
lowed a colorimetric optical density readout. Ten microliters of 
denatured PCR product were added to avidin-coated 96-well mi-
croplates together with 65 fl.1 of hybridization solution containing 
I pmol of horseradish peroxidase (HRPHabeled SK 19 HIV 1:111:-
specific probe and incubated at 42°C for I h . Plates were washed 
and 150 fl.1 of HRP substrate containing ii-phenylenediamine was 
added to each well. The reaction was stopped with 100 fl.1 of I N 
H,SO. and optical density of each well was measured at 490 nm. 
All the experiments were performed in duplicate or triplicate to 
confirm results . The HIV copy number of any sample was cal-
culated by comparison of the resulting optical density with that 
of a coamplified half log", dilution series of ACH2 (AIDS Re-
search and Reference Reagent Program. National Institutes of 
Health. Bethesda. MD. U.S.A.) DNA. A linear relationship was 
obtained between the log", of the optical density and input HIV 
DNA loglll copy number within the range 10 to I .O()() copies . 
Micrococulture Assay 
The micrococulture assay was performed according to the 
AIDS Clinical Trials Group standardi zed protocol (2). Briefly. 
five 5-fold dilutions of patient PBMCs were made from a starting 
concentration of 1.0 x IOh cells/ml. Each dilution was cocultured 
in duplicate in 24-well microculture plate with 1.0 x 10' phyto-
hemagglutinin (PH A)-stimulated normal PBMCs. At 7 days half 
the medium was removed and replaced with fresh medium con-
taining .5 x 10' PH A-stimulated PBMCs. Cultures were termi-
nated on day 14 when a microculture well was scored a, positive 
if > 30 pg/ml of p24 antigen was present. Two consecutive neg-
ative wells defined an end point and split end points were scored 
as intermediate titers. tor comparison with HIV provirus copy 
number. the limiting dilution titer was corrected for the CD4 
percentage. 
RESULTS 
To explore the effect of varying the sample size 
within our assay. PBMC constructs with a fixed 
HIV copy number (ACH2 cells) were prepared and 
triplicate samples of 10.000. 30.000, and 100,000 
cells were analyzed in the assay. For each of the 
constructs the optical density of the product was 
linearly related to the sample size (data not shown) 
demonstrating the ability to measure HIV copies in 
samples between 10,000 and 100,000 cells. The abil-
Jllllmlli o( Acc/llifl'd /lIImlllll' DI~f;cil'IIc\' SVIIf/romf'.\. \'01. fl. No . 3 . 1Y93 
ity to combine a standard curve which was linear 
over a 100-fold range (10-103 copies) together with 
the adjustment of sample size between 10,000 and 
100,000 cells enabled us to measure HIV copy num-
bers/million cells in any given subject over a 1,000-
fold range (102_105 HIV copies/million cells). 
The HIV log copy number/million CD4 + T cells 
of 55 patients was plotted against their peripheral 
blood CD4 T cell counts at the time of venesection 
(Fig. I) . There was a significant correlation (p = 
< 0.001) between increasing CD4 T-cell HIV load 
and decreasing CD4 + T-cell counts. 
The HIV log copy number/million CD4 + T cells 
of 25 patients was plotted against the cell infectivity 
titer as determined by micrococulture assay (Fig. 
2A), three other patients' PBMCs failed to grow in 
culture. There was a significant correlation (p = 
< 0.01) between CD4 T-cell HIV load and culturable 
cell virus. 
HIV log copy numbers from aliquots of lysed 
PBMC were compared with log copy numbers de-
rived from analysis of aliquots of isolated CD3 + / 
CD4 t cells (Fig . 2B). When the PBMC log copy 
number was corrected for the CD4 T-cell percent-
age 1+ logw (100/CD4%)], similar results were ob-
tained by both methods (mean difference 0.18). 
DISCUSSION 
The calculation of provirus copy number/million 
CD4 ' cells from assays performed on PBMC Iy-
sates is based on two assumptions, tirstly, that the 
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FIG, 1. The relationship between 10glo of HIV copies/million 
CD4 ' cells of 55 patients and their CD4 T-cell counts at time 
of assay. The best fit regression line coefficient (R) was 0.61 
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FIG. 2. A: The relationship between 10glO of HIV copies/ 
million CD4 ' cells of 55 patients and the cell infectivity titer/ 
million CD4' cells. The best fit regression line coefficient (R) 
was 0.55 (p < 0.01) . A . untreated ; O. ZDV treated. B: A com-
parison of log,o HIV copy number of 19 patients by both 
FACS-isolated CD4 ' T cells (abscissa) and with values from 
PBMC. but expressed per 106 CD4 ' T cells (ordinate) is 
shown. The results from both methods are closely related 
with an unforced R value of 0.904 (p < 0.01) an intercept of 0 
and a slope of 1. 
phocyte provirus and, secondly, that the CD4 + 
T-cell percentage in the peripheral circulation rep-
resents the CD4 " T-cell percentage in isolated 
PBMC. Several authors have reported CD4 + T 
cells to be the major reservoir for HIV (3-5). An 
analysis of HIV proviral signal in lymphocyte sub-
sets (CD3 ' ICD4 + , CD3 t ICD8 t , CD45 t ICD20' . 
and CD45 + /CD 14 ' cells) demonstrated 93% of sig-
nal to be in the CD3 . /C D4 " cell popUlation (data 
not shown). Differing CD4 percentages in Ficoll-
Hypaque and whole blood lysate samples have been 
reported in one study (6). Comparison in 10 subjects 
of CD4 + T-cell percentages in both whole blood 
and isolated PBMC from the same venesection re-
sulted in a mean error of 3.8o/r· and a maximum error 
of 11 % . This error is likely to be greater in those 
subjects with lower CD4" T-cell percentage . 
Levels of HIV provirus of I in 1,000 to I in 10,000 
CD4 + cells in early disease are consistent with pre-
vious studies (3,7-9). In advanced di sease, the pres-
ence of provirus DNA at levels of 1 in 10 CD4 " 
cells is less certain. Studies utilizing in situ RNA 
hybridization (10) and DNA PCR (I \) have demon-
strated very low HIV expression and low provirus 
in PBMC of AIDS-related complex (ARC) and 
AIDS patients. whereas several other studies have 
demonstrated proviral loads comparable to those 
found in this study, i.e ., I in 100 CD4 + cells (3,7,9) 
and as high as I in 10 (8) . Increase in viral load with 
disease progression has been previously demon-
strated (8,9). The cross-sectional study of HIV-
infected patients demonstrated that although there 
was a range of HIV DNA copy number at any given 
CD4 count. there was a statistically significant cor-
relation between proviral copies/million CD4 j. cells 
and a decreasing CD4 I T-cell count. The compar-
ison of proviral copy number with infectivity titer 
demonstrated a positive association, although the 
number of culturable cells was between 10- and 100-
fold less than the number of DNA copies. Explana-
tions for this finding. include multiple proviral cop-
ies per cell. defective HIV DNA. nonintegration of 
HIV DNA, and latent nonexpressing provirus de-
spite IL-2 stimulation in culture. 
Quantitative PCR assays require accurate mea-
surement of input substrate, which can be achieved 
by DNA extraction and quantitication by spectros-
copy or by counting input cell number. Quantifica-
tion of cell number avoids a lengthy ON A extrac-
tion. but if frozen specimens are to be utilized. they 
must be enumerated before storage. Our CD4' 
T-cell assay utilized immunostaining and immediate 
cell sorting of fresh patient samples; the ability to 
perform such an assay is limited to relatively few 
centers. The assay of PBMC Iysates gave similar 
results when CD4 + T cells were enumerated at the 
time of venesection. This PBMC assay should allow 
the prospective collection of samples in large clini-
cal trials to determine the short- and long-term ef-
fect of antiviral drugs on HIV provirus in CD4 " 
cells. 
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Multiple cerebral lesions complicating 
therapy with interleukin-2 
B. Illowsky Karp, MD; J. C. Yang, MD; M. Khorsand, MD; R. Wood, MD; and T. C. Merigan, MD 
Article abstract-We reviewed the records and radiologic studies of eight patients who developed new focal neurologic 
abnormalities while receiving interleukin-2 (IL2bbased immunotherapy for malignancy or HIV infection. Initial confusion 
and delirium in the patients evolved into coma, ataxia, hemiparesis, seizures, and cortical syndromes including aphasia, 
apraxia, and cortical blindness. Imaging studies showed multiple white and gray matter lesions with a predilection for the 
occipital poles, centrum semiovale, and cerebellum. After cessation of IL2 treatment, seven patients improved to normal or 
near-normal neurologic function paralleled by resolution of the lesions on scans. One patient improved only minimally. 
Possible etiologies for the lesions include an IL2-induced cerebral vasculopathy, a direct toxic effect of IL2, or immunolog- 
ically mediated damage. 
NEUROLOGY 1996;47:417-424 
Interleukin-2 (IL2) is a lymphokine effective against 
advanced metastatic malignancies in some pa- 
tients,'." which may also act against the human im- 
munodeficiency ~ i r u s . ~ , ~  IL2 is used alone, in a long- 
acting preparation conjugated to polyethylene glycol 
(PEG-ILB), in combination with activated lympho- 
cytes as part of adoptive immunotherapy, or with 
other cytokines such as alpha-interferon (alpha-IFN) 
or granulocyte-macrophage colony stimulating factor 
Systemic side effects of IL2 such as fever, chills, 
malaise, nausea, vomiting, and diarrhea are com- 
mon. Fluid extravasation from a capillary leak syn- 
drome may lead to hypotension, multiorgan failure, 
and arrhythmias. 1.7 The most common neurologic 
side effect of IL2 therapy is a reversible encephalop- 
athy characterized by confusion, lethargy, and poor 
concentration.R-10 
(GM-CSF).l" 
It can progress to delirium with psychotic features 
or to coma. Over the past several years, there have 
been a few case reports of focal neurologic deficits in 
patients receiving IL2. Aphasia, hemiparesis, sei- 
zures, visual distortions, and ataxia have occurred as 
well as brachial plexopathy and carpal tunnel syn- 
drome.11-17 Vecht e t  a1.I6 reported an  acute fatal de- 
myelinating leukoencephalopathy in a patient re- 
ceiving IL2. 
As therapy with IL2 has become more widespread, 
neurologic illness has become a n  important cause of 
morbidity and a treatment-limiting complication. We 
describe eight patients who developed neurologic def- 
icits and lesions on brain imaging during IL2-based 
treatment of malignancy or HIV infection. 
Methods. From 1985-1994, over 1,500 patients received 
IL2-based therapy for malignancy at  our institution, in- 
From the National Institute of Neurological Disorders and Stroke (Dr. Illowsky Karp), the National Cancer Institute (Dr. Yang), National Institutes of 
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cluding five who developed neurologic illness with abnor- 
malities on magnetic resonance imaging (MRI) during or 
shortly after treatment. No patient had metastases to the 
nervous system or a history of neurologic disease or stroke 
prior to receiving IL2. The medical records and imaging 
studies were reviewed. Three additional patients (cases 4, 
7 ,  and 8) receiving IL2 for HIV infection or malignancy at 
other institutions with similar neurologic symptoms, 
courses, and imaging studies were also studied. 
Case reports. Patient 1. A 53-year-old man with renal 
cell carcinoma underwent nephrectomy and radiotherapy 
before referral for IL2. His immunotherapy included 
alpha-IFN and IL2. Five days after the start of treatment, 
the patient became progressively confused and lethargic 
and lapsed into coma. He had intermittent left focal sei- 
zures, which stopped spontaneously within 24 hours. Peri- 
toneal dialysis was begun on the 10th hospital day for 
renal failure. Two days after beginning dialysis, the pa- 
tient was alert but disoriented with hallucinations. The 
symptoms improved over the next week. On the 22nd hos- 
pital day, left focal seizures recurred and were followed by 
a generalized seizure. He was started on phenytoin. 
Following the seizure, he had a left spastic hemiparesis. 
Cerebrospinal fluid (CSF) was normal except for a slight 
elevation in protein to 56 mg/dL. An electroencephalogram 
(EEG) showed diffuse background slowing with right tem- 
poral lobe periodic epileptiform discharges. A CT of the 
head showed nonenhancing white matter lucencies extend- 
ing from occipital areas forward into the centrum semi- 
ovale. White matter hyperintensities, which were espe- 
cially prominent occipitally, were seen on MRI. 
He improved rapidly and was fully awake 48 hours 
after the seizure. A repeat MRI 3 weeks later was un- 
changed, and an EEG was improved. On discharge from 
the hospital on the 38th hospital day, the patient had 
persistent reflex asymmetry but an otherwise normal neu- 
rologic examination. MRI 1 month after discharge showed 
resolution of the white matter abnormalities. 
Patient 2. A 41-year-old man with renal cell carcinoma 
started IL2 2 months after a radical nephrectomy. He re- 
ceived seven doses of IL2, then three weekly doses of PEG- 
IL2. During the second week of PEG-IL2 treatment, he 
developed right proximal arm weakness, sensory loss, and 
shoulder pain with winging of the scapula. Deep tendon 
reflexes were normal. MRI of the cervical spine showed 
bony degeneration and bulging disks a t  C-5 through C-7. 
MRI of the head showed a few small areas of high signal in 
the cerebral white matter. 
A second cycle of therapy began 1 month later. He re- 
ceived five doses of IL2 followed by PEG-IL2 for 3 weeks. 
Two days after the last PEG-IL2 dose, he became delirious 
and was treated with haloperidol. On examination, the 
patient was lethargic but able to state his name and open 
his eyes on command. There was no visual fixation or 
response to visual threat. The pupils were small and reac- 
tive to light. A right gaze preference was present. Both legs 
moved spontaneously, but the right arm was immobile and 
hyperreflexic. The left arm withdrew to noxious stimuli 
only. Plantar responses were extensor. The patient had a 
generalized tonic-clonic seizure, which was treated with 
phenytoin. 
At the time of neurologic deterioration, the white blood 
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cell (WBC) count was 23,000/mm3 with 46% eosinophils. 
Coagulation studies, serum sodium, magnesium, calcium, 
and liver function tests were normal. There was mild renal 
insufficiency. CK was markedly elevated at 1,024 U/L. A 
nonenhanced CT of the head showed no lesions. MRI 
showed new cortical, subcortical, and cerebellar lesions, 
including bilateral occipital lesions that did not enhance 
with gadolinium (figure 1A). The CSF had 3 white blood 
cells and 44 red blood cells/mm". CSF protein, glucose, and 
cultures were normal. An EEG done 4 days after the sei- 
zure showed diffuse slowing without epileptiform activity. 
The patient remained intubated and pharmacologically 
paralyzed for 5 days after the seizure. When paralysis and 
sedation were discontinued, he gradually awoke. He was 
able to read and identify objects and colors, but complained 
of difficulty locating objects visually. The right arm re- 
mained weak and atrophic. MRI of the head 1 week later 
showed persistence of the brain lesions, which now en- 
hanced with gadolinium (figure 1B). 
Two months later, his mental status and vision were 
completely normal. The right arm weakness had improved. 
An MRI 5 months after admission showed only those small 
white matter lesions that had been present prior to the 
second cycle of IL2. 
Patient 3. A 63-year-old woman with renal cell carci- 
noma of the sternum tolerated an initial course of IL2 
followed after 1 week by PEG-IL2. A second, higher dose of 
PEG-IL2 was given 1 week later. Forty-eight hours after 
the second PEG-IL2 administration, she became confused, 
agitated, incontinent, and progressively somnolent. Her 
speech was dysarthric. Strength, tone, and deep tendon 
reflexes were decreased in the left arm and leg. Snout, 
root, and bilateral grasp reflexes were present. The left toe 
was upgoing. CSF analysis was normal. An MRI of the 
head showed possible bilateral occipital hyperintensities 
that had not been present on a baseline scan before admis- 
sion. 
The patient deteriorated. By the next day she was ob- 
tunded and unable to follow any commands and had inter- 
mittent decorticate posturing of her right arm. A repeat 
MRI showed multifocal white matter and cortical hyperin- 
tensities including definite bilateral occipital lesions (fig- 
ure 2A). An EEG showed generalized slowing. Because the 
first two patients had seizures in a similar clinical setting, 
this patient was given phenytoin prophylactically. 
At the time of neurologic deterioration, she had mild 
respiratory insufficiency, hypotension, and oliguria. Her 
WBC count was 29,00O/mm" with 50% eosinophils. Her 
serum CK rose to 694. The prothrombin time was slightly 
prolonged a t  18.6; other coagulation studies were normal. 
The patient continued to worsen. By the fifth day after 
the last IL2 infusion, she could open her eyes spontane- 
ously but did not focus visually, follow objects, or respond 
consistently to visual threat. Her pupils were equal and 
reactive. She appeared unaware of her surroundings and 
did not follow commands. There was no spontaneous move- 
ments of her arms or legs, and the left side did not with- 
draw to pain. 
Over the next several weeks, the left spastic hemipare- 
sis persisted. Noxious stimuli to the right side of the body 
elicited flexor posturing. Myoclonic jerks were intermit- 
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Figure 1. (A) T,-weighted MRI of patient 2 showing multiple cortical lesions. The lesions did not enhance with gado- 
linium. (B) TI-weighted MRI with gadolinium obtained 1 week after that i n  A showing new enhancement of lesions. 
showed multiple well-circumscribed lucencies throughout 
the cerebral hemispheres (figure 2B). 
There was only slight improvement over the second 
month of hospitalization. Although she became responsive 
to her surroundings and was able to speak, she had irrita- 
bility and marked deficits in attention and concentration. 
She was able to recognize her family and some objects. All 
limbs were spastic and hyperreflexic, and she had no 
movement of her right hand. Bilateral grasps persisted. 
She was transferred to a rehabilitation facility 7 weeks 
after receiving her final dose of IL2. 
Patient 4. A 43-year-old HIV-seropositive man on azido- 
thymidine began weekly doses of PEG-IL2. Approximately 
60 hours after the sixth infusion, he became confused and 
unsteady. The following day he complained of mild bifron- 
tal headache and was unable to feed or clothe himself 
properly. On examination, he was alert and oriented to 
person and place, but not date. His answers were slow, and 
he was unable to follow multi-step commands or do even 
simple arithmetic. Left-right confusion and perseveration 
were present. He could neither write clearly nor copy fig- 
ures. 
Cranial nerve examination was normal as was sensa- 
tion to pinprick, light touch, vibration, and position. He 
had agraphesthesia and astereognosis. Strength was nor- 
mal. Rapid alternating movements were performed poorly, 
and he was unable to walk with a tandem gait. Babinski 
responses were present bilaterally. 
Laboratory studies included a WBC count of 18,700/ 
mm3 with 41% eosinophils. CD4 count was 450 cells/kL. 
LDH was elevated a t  2,286 IU/L, and AST a t  139 IU/L. 
Renal function was normal. The CSF contained nine RBCs/ 
mm3 and five WBCs/mm". The CSF protein was 57 mg/dL. 
Two CTs were unrevealing. MRI 3 days after admission 
showed diffuse, nonenhancing white and gray matter le- 
sions. An EEG showed left temporal slowing with bursts of 
frontal intermittent rhythmic delta activity. The patient 
improved rapidly and was neurologically normal at dis- 
charge on the fifth hospital day. 
Patient 5. A 28-year-old woman with metastatic malig- 
nant melanoma received IL2 after failing to respond to 
conventional chemotherapy. After her seventh dose of IL2, 
she developed renal and respiratory insufficiency, hypoten- 
sion, and peripheral edema. She required a brief period of 
respirator support. After extubation, the patient was con- 
fused. Although awake and alert, she was oriented to per- 
son only. She had little spontaneous speech, mild word- 
finding difficulty, poor repetition of words, and 
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Figure 2. (A) T,-weighted MRI of patient 3 showing multiple cortical and subcortical lesions. (B) CT obtained 3 weeks 
after A. The lesions appear as multiple cortical and subcortical lucencies. 
perseveration. The deep tendon reflexes were brisk, and 
plantar responses were extensor. A head CT was normal. 
However, MRI showed a hyperintense lesion in the left 
parietal lobe. The CSF was normal. The patient's symp- 
toms cleared completely over 5 days. The lesion was 
smaller but still visible on scans performed up to 10 
months later. 
Patient 6. A 56-year-old man with metastatic renal cell 
carcinoma was referred for immunotherapy after a radical 
nephrectomy. He completed the first course of eight doses 
of IL2 without difficulty. One week later, he was lethargic 
and had recurrent episodes of vertigo lasting about 15 
minutes. He complained of unsteadiness while walking 
and a loss of grip strength in the left hand. The symptoms 
cleared for 2 days, then recurred along with blurred vision. 
A left homonymous hemianopia and bilateral limb ataxia 
were found on examination. 
At the time the neurologic symptoms developed, renal 
function was normal, but the alkaline phosphatase and 
AST were slightly increased. The peripheral WBC count 
was 13,000/mm3 with 2% eosinophils. The CSF contained 3 
WBC/mm" and was otherwise normal. A head CT was 
normal, but an MRI showed multiple hyperintense lesions 
on the T,-weighted scan. Lesions involved both gray and 
white matter and were found in the occipital cortex, left 
thalamus, and cerebellar hemispheres. They did not en- 
hance. 
The patient improved over 8 days. MRI 1 week after the 
initial scan showed the earlier lesions, but additionally 
found that the right occipital lesion enhanced with gado- 
linium. All lesions were smaller on a scan obtained 6 
weeks later. 
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Patient 7. A 48-year-old man with metastatic renal cell 
carcinoma became confused and lethargic after two infu- 
sions of IL2 and GM-CSF. His neurologic examination was 
otherwise normal, as was MRI. Further immunotherapy 
was stopped because his white blood cell count had risen to 
95,70O/mrn:' with 55% eosinophils. Hydrocortisone and hy- 
droxyurea were given to decrease the white blood cell 
count. At the time neurologic symptoms began, his renal 
function was normal; LDH and alkaline phosphatase were 
elevated to twice normal levels. 
One day later, the patient deteriorated. He complained 
of dizziness and a headache and was disoriented with cog- 
nitive difficulties, hallucinations, expressive aphasia, and 
right-hand weakness. An EEG showed generalized and 
right frontal slowing. The CSF was normal. A second MRI 
showed nonenhancing, white matter hyperintensities in 
both frontal lobes, occipital poles, right parietal lobe, and 
right parietotemporal junction. MR angiography was nor- 
mal. A third MRI 1 day later showed the previous white 
matter lesions and new signal abnormalities in the gray 
matter of the medial frontal lobes bilaterally. The patient 
gradually improved. By 6 weeks after admission he noticed 
only a slight impairment of fine motor movements when 
playing piano. 
Patient 8. A 52-year-old man who underwent nephrec- 
tomy for renal cell carcinoma in 1986 had a recurrence of' 
disease in 1994. He received IL2 and GM-CSF for 4 days. 
The second week of therapy was interrupted by severe 
diarrhea. The doses of both drugs were halved when treat- 
ment was restarted, and that of GM-CSF was reduced 
further when the absolute eosinophil count reached 
20,000. During the third week of treatment, the patient 
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Table Patient demographics and drug doses 
Patient SedAge Diagnosis DruglDose''' Time of Symptom Onset 
--__ 
3 F/63 RCC 3 days after second PEG-IL2 dose 
1 MI53 RCC H-L IL2 4.5 mU/m2 X 11 doses 22 days after start of treatment 
alpha-IFN 3 mU X 11 doses 
2 M/4 1 RCC First course: 3 days after start of second PEG-IL2 course 
IL2: 720,000 IUkg X 7 doses 
PEG-IL2: 3 mU/m2 X 1 dose 
PEG-IL2: 6 mU/m' X 3 doses 
Second course: 
IL2: 720,000 IUkg X 7 doses 
PEG-IL2: 3 mU/mz X 1 dose 
PEG-IL2: 6 mU/m2 X 1 dose 
IL2: 720,000 IUkg X 7 doses 
PEG-IL2: 3 mU/m2 X 1 dose 
PEG-IL2: 6 mU/m2 X 1 dose 
4 M/43 HIV PEG-IL2: 3 mU/m" X 6 doses 3 days after sixth PEG-IL2 dose 
5 F/28 Melanoma IL2: 720,000 IUkg X 7 doses 6 days after seventh IL2 dose 
6 M/56 RCC IL2: 720,000 IUkg X 8 doses 8 days after first course IL2 completed 
7 M/48 RCC IL2: 1.5 mU/mz X 8 doses 6 days after eighth IL2 dose 
GM-CSF: 5 Fg/mz 
8 M/5 3 RCC IL2: 1.5 mU/m2 X 6 doses 2 days into second week of treatment 
GM-CSF: 5 pgln? 
* H-L IL2: Hoffman-LaRoche; other patients received the ChirodCetus preparation 
RCC = renal cell carcinoma. 
became confused and restless. He was able to follow only 
simple commands and had poor attention with persevera- 
tion. A right homonymous hemianopia was present as well 
as right-sided neglect and ocular apraxia. There was right 
facial and arm weakness, hyperreflexia, and bilateral 
Babinski signs. 
At the time of neurologic deterioration, the white blood 
cell count was 41,000/mm3 with 50% eosinophils. The 
platelet count was 505,0OO/t~L, and serum viscosity was 
increased to 4.3 (normal, 1.4 to 1.8). Serum protein electro- 
phoresis was normal. Fibrinogen level was normal and 
fibrin split products were absent. CSF was normal. CT and 
MRI scans showed nonenhancing lesions in the left cere- 
bellum and left frontal deep white matter. Repeat MRI 
several days later showed new nonenhancing lesions in 
both gray and white matter involving the thalamus, cere- 
bellum, and occipital lobes. A third MRI the next day 
showed gadolinium enhancement in the left cerebellar, oc- 
cipital, and posterior frontal lesions. 
The patient gradually improved. Six weeks later, exam- 
ination showed slight right arm weakness but was other- 
wise normal. 
Results. The patients included six men and two women 
ranging in age from 28 to 63 years (mean age, 48 years). 
Six patients received IL2 for renal cell carcinoma, one for 
melanoma, and one for HIV infection (table). IL2 was the 
sole immunotherapeutic agent in five patients, three of 
whom received the long-acting preparation, PEG-IL2. One 
patient received alpha-IFN and two patients received GM- 
CSF in addition to IL2. 
Neurologic symptoms did not begin immediately with 
the start of IL2 treatment. Five patients became symptom- 
atic 3 to 8 days after completing a course of therapy, the 
other three during a course of treatment. 
In each patient, the first sign of deterioration was a 
change in mental status with confusion, disorientation, 
and agitation. Three patients had hallucinations. Two pa- 
tients became obtunded and one comatose. Two patients 
had seizures. Speech difficulties, including aphasia, dysar- 
thria, and mutism, were present in four patients. Two 
patients had cortical blindness, and two had a homony- 
mous hemianopia. Corticospinal tract involvement was 
manifest in seven of the eight patients who had weakness, 
spasticity, hyperreflexia, or Babinski signs. Three patients 
had perseveration, and one had primitive reflexes, includ- 
ing snout, bilateral grasp, and rooting reflexes. Four pa- 
tients had limb or gait ataxia. Two patients had hemisen- 
sory deficits. One patient had left-right confusion, 
agraphesthesia, and astereognosis. 
All patients had abnormal brain imaging. Multiple le- 
sions were present in both gray and white matter in corti- 
cal and subcortical territories except for one patient who 
had an isolated left cortical parietal lesion. The lesions 
were not apparent or hypodense on CT (see figure 2B). On 
MRI, the lesions were either not visible or hypointense on 
TI-weighted images, and hyperintense on T,-weighted im- 
ages. In one patient, the lesion enhanced with gadolinium 
on the first MRI scan obtained. In three other patients, 
lesions that did not enhance on the initial MRI scans did 
show enhancement on scans obtained 5 to 7 days later (see 
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figure 1). MR angiography, performed in only one patient, 
was normal. 
Seventy-five percent of the patients had occipital lobe 
involvement, which was often bilateral. Half had parietal 
lesions and half frontal lesions. The cerebellum was in- 
volved in 33% of patients and the thalamus in 25%. No 
patient had brainstem lesions. 
EEGs, recorded in five patients, showed generalized 
slowing. Additional focal slowing was noted in two pa- 
tients. One patient had periodic localizing epileptiform dis- 
charges, and one patient had frontal intermittent rhythmic 
delta activity. CSF analysis was usually normal. Two pa- 
tients had a slight increase in CSF protein. Three patients 
had a mild lymphocytic pleocytosis. 
At the time of neurologic compromise, one patient had 
renal failure and several others had mild renal or hepatic 
dysfunction. Two patients had hypotension, which im- 
proved with intravenous fluid infusion. Routine coagula- 
tion studies were usually normal. The serum viscosity was 
elevated in the single patient in whom it was measured. 
All patients except one had an IL2-induced eosinophilia. 
Eosinophilia was mild in one patient whose absolute eosin- 
ophil count was 700/mm", but was marked in the others 
whose absolute eosinophil counts ranged from 1,372/mm3 
to 57,OOO/mm:'. 
No patient received additional IL2 after the develop- 
ment of neurologic symptoms. While patients did not re- 
ceive specific treatment for their neurologic symptoms, all 
received supportive care. Several required medication for 
agitation or  seizures. Seven patients had complete or 
nearly complete recovery of neurologic function. Improve- 
ment usually began within a week of the onset of neuro- 
logic symptoms. One patient, however, had only minimal 
recovery. This patient remained severely encephalopathic 
with a spastic quadriparesis. 
Discussion. The patients presented here devel- 
oped neurologic illness during or shortly after treat- 
ment with IL2 with corresponding cortical and sub- 
cortical lesions on imaging studies. The initial 
behavioral changes were often similar to the more 
common IL2-induced encephalopathy, but focal signs 
rapidly evolved reflecting the areas of the brain af- 
fected. 
There was no evidence to suggest an  infectious or 
malignant cause for the neurologic illness. Patients 
with nervous system metastases were excluded from 
the IL2 trials, and CSF cytology and cultures were 
negative. Metabolic disturbances, including hypona- 
tremia, hepatic failure, renal insufficiency, or hyp- 
oxia, were present in some of our patients, but they 
are not likely to have caused the neurologic syn- 
drome as they were often mild and transient. One 
patient had renal failure severe enough to require 
dialysis, but the others had only oliguria or a slight 
increase in BUN and creatinine. The disturbance in 
three patients was limited to transaminase eleva- 
tion. No single abnormality was uniformly present in 
all patients, and none is known to cause focal symp- 
toms with multiple cortical and subcortical lesions. 
Two of the patients were co-treated with GM-CSF 
and one with alpha-IFN. The other five patients re- 
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ceived IL2 alone. Three of the patients received IL2 
conjugated to polyethylene glycol (PEG), which de- 
creases the clearance rate 15-f0ld.'~ The neurologic 
illness, however, cannot be due to GM-CSF, alpha- 
IFN, or the PEG moiety, since nonconjugated IL2 
alone caused a similar picture and GM-CSF has no 
known neurologic complications. This neurologic tox- 
icity occurred in 2 of 92 patients treated with PEG- 
IL2 a t  the National Cancer Institute. While PEG-ILS 
may prolong exposure to high levels of IL2, in the 
absence of a prospective study it is not clear that  
neurologic complications are more frequent in pa- 
tients receiving PEG-IL2 than in those receiving un- 
conjugated IL2. 
Patients with hypereosinophilia may develop pe- 
ripheral neuropathy, cerebral infarction, or dementia 
with white matter lesions on MRI.19-22 While we can- 
not dismiss the possibility that hypereosinophilia 
contributed to the development of neurologic symp- 
toms, marked eosinophilia was not present in all of 
our patients, and there are no previous reports of 
this constellation of signs and reversible lesions in 
patients with idiopathic hypereosinophilia. 
There are a few reports of similar neurologic il l-  
ness associated with IL2. Aphasia, hemiparesis, sei- 
zures, visual distortions, and ataxia occurred in a 
few patients receiving IL2I2 or PEG-IL2" for meta- 
static renal cell carcinoma reported by Philip et al. 
and Bukowski et al. Meyers and Yung2" described a 
melanoma patient who developed a cerebellar syn- 
drome and dementia 3 months after completing 
treatment with IL2 who had multiple white matter 
lesions on a later MRI scan.23 The melanoma patient 
of Somers e t  al.I5 developed a spastic quadriparesis 
following IL2 with subcortical and cortical hyperin- 
tensities on MRI. The neurologic symptoms and the 
lesions gradually resolved. Bernard et al. described 
two IL2 patients with brief episodes of focal neuro- 
logic deficits. Brain imaging was normal in both. 
Vecht et al.I6 reported a melanoma patient who de- 
veloped a rapidly fatal encephalopathy with blind- 
ness, ataxia, and bilateral Babinski signs during an  
initial course of IL2. A CT was normal; MRI was not 
reported. At autopsy, the gray matter was normal 
but the white matter contained multiple small foci of 
perivascular demyelination. Because of the patho- 
logic resemblance to acute perivenous encephalomy- 
elitis, they postulated that the lesions were autoim- 
munologically mediated. 
IL2 penetrates the blood-brain barrier. The CSF 
IL2 concentration averages 50% of serum leveL2-' 
Specific cerebral IL2 binding sites are present in rat  
brain with highest density in the hippocampus. Sim- 
ilar receptors are likely present in human 
IL2 can alter adrenergic, dopaminergic, and cholin- 
ergic neurotransmission.' La.L7.30 ' Direct neuromodula- 
tory effects mediated by endogenous IL2 receptors 
may underlie the acute delirium frequently associ- 
ated with IL2 the rap^,^^;^^ but are unlikely to have 
caused structural lesions. 
IL2 can both promote the proliferation and matu- 
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ration of oligodendrocyte~~l and damage m ~ e l i n . ~ ~ * ~ ~  
Demyelination was the primary pathology in the 
case of fatal IL2 encephalopathy reported by Vecht 
et a1.I6 There was, however, no clear evidence of my- 
elin breakdown in our patients. The lesions affected 
both gray and white matter, and the CSF protein, 
which is often elevated in demyelinating diseases, 
was normal in six of the eight patients. 
IL2 causes a systemic capillary leak syndrome.34 
Although Elison et al.32 reported increased cerebral 
vascular permeability in cats, others have not found 
blood-brain barrier disruption with IL2 i n f u ~ i o n . ~ ~ , ~ ~  
The absence of gadolinium enhancement at  the time 
of disease onset in our patients argues against blood- 
brain barrier dysfunction as a precipitating factor in 
the illness. 
The brain lesions in our patients were not typical 
of arterial strokes. Multiple arterial territories were 
affected simultaneously and lesions resolved quickly. 
The subacute evolution of lesions, absence of hemor- 
rhage, and lack of an embolic source make it unlikely 
that the lesions were caused by emboli. 
IL2 induces IL1 and tumor necrosis factor (TNF) 
which affect endothelial cell function and coagula- 
t i ~ n . ~ , ~ ~ , " , " ~  TNF alone can damage axons and myelin 
in vitro and can cause a transient aphasia and focal 
neurologic deficits in  patient^.'^^:'^.^^ IL2 may, there- 
fore, cause neurologic dysfunction by inducing other 
cytokines. 
IL2 can prolong the prothrombin time (PT) and 
partial thromboplastin time (PTT) and decrease co- 
agulation  factor^,^^.^' but the PT and PTT were usu- 
ally normal in our patients. More extensive monitor- 
ing of coagulation at one of our institutions showed 
an increase in von Willebrand's factor, but no abnor- 
malities in protein C, protein S, antithrombin 111, 
fibrinogen, PT, or PTT in patients receiving IL2. 
The pattern of illness and distribution of lesions 
associated with IL2 are similar to  those complicating 
cyclosporine therapy and occasionally seen with che- 
motherapy, alpha-IFN, hypertensive encephalopa- 
thy, and e c l a m p ~ i a . ~ ~ - ~ ~  The etiology of neurologic dis- 
ease in these circumstances is unknown, but has 
been attributed to direct toxic effects of medications, 
cortical venous thrombosis, or a local vasculopathy 
with fluid extravasation. Cytokine activation is also 
likely in all these circumstances. 
In summary, we describe eight patients who de- 
veloped cortical and subcortical neurologic signs and 
cerebral lesions during treatment with IL2-based im- 
munotherapy. The etiology of this illness is not 
known, but the similarity to  neurologic complications 
of cyclosporine, chemotherapy, and other immuno- 
therapy suggests a common pathogenesis. 
The occurrence of new neurologic signs and le- 
sions in patients receiving IL2 should not be pre- 
sumed to  be progression of the underlying disease. 
Since the neurologic illness associated with IL2 may 
be completely reversible, further IL2 infusion should 
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Is H IV/AI DS a primary-care disease? 
Appropriate levels of outpatient care 
for patients with H IV/AI DS 
Aaron S. Metrikin*t, Merrick Zwarenstein*, Malcolm H. Steinbergt, 
Estelle Van Der Vyver+, Gary Maartens§~ and Robin Wood§ 
Introduction 
Objective: To estimate the proportion of outpatient visits that could be managed at a 
primary-care level, by World Health Organization (WHO) clinical staging. 
Design: Prospective, descriptive study. Six medical doctors in a tertiary hospital 
HIV ambulatory clinic recorded clinical diagnoses, WHO clinical staging and their 
recommendation regarding the appropriate level of care for each outpatient seen. 
Setting and study population: All HIV-infected patients attending a public-sector, 
urban, South African, referral and teaching hospital HIV outpatient clinic between 
September and November 1992. 
Participants: There were 238 visits by 148 patients during the study period. 
Results: Of 238 visits, 165 (69.3%) were deemed suitable for treatment at the 
primary-care level. After allowing for contradictory responses, at least 141 visits 
(59.2%) could be appropriately treated at the primary-care level. Although all six 
doctors assessed more than half of their visits as suitable for primary care, there 
were significant differences among them. In total, 83 visits (34.8%) needed a medical 
specialist, and 45 (18.9%) required tertiary-care facilities. Of all the visits, 58 (24.9%), 
51 (21.9%), 60 (25.8%) and 64 (27.4%) were classified as WHO stages 1, 2, 3 and 
4, respectively. For these stages, 55 (94.8%), 38 (74.5%), 42 (70.0%) and 26 (40.5%) 
visits, respectively, were suitable for treatment at a primary-care facility. 
Conclusions: Many of the outpatient visits to this outpatient specialist clinic could 
have been safely cared for at a primary-care level. As the severity of the disease 
increases, there is a decrease in the proportion of patients that can be treated at a 
primary-care level. 
AIDS 1995, 9:619-623 
Keywords: AIDS, primary care, ambulatory care, referral, 
appropriateness, severity, staging 
As the number of HIV-infected individuals in South 
Africa continues to rise, referral hospitals, which are 
presently the major site at which treatment occurs, will 
accumulate more HIV-infected patients [1]. Recent re-
search estimates that by 2005 up to 75% of the South 
African health-care budget could be consumed by HIV-
infected individuals if the current approach to HIV treat-
ment is maintained [2]. However, a number of studies in 
South Africa have shown that referral hospitals provide 
unnecessarily and ineffectively sophisticated care for a 
large proportion of their in- and outpatients, many of 
whom could have been safely treated in primary-care 
facilities. One study concluded that 30% of all inpatient 
days in referral hospital internal medicine beds could 
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have been appropriately managed in a less sophisticated 
facility [3]. 
This study gathers clinician's opinions on the level of 
health care appropriate to the needs of their HIV-
infected outpatients attending the Somerset Hospital. At 
the time of the study, this was the only centre provid-
ing HIV care in the city of Cape Town (population, 2 
million [4]). 
This study limits its focus to clinical conditions, rather 
than to patient's feelings, or their social and personal 
circumstances. Counselling and other social and psy-
chological support systems have long been community 
oriented, and are, in our setting, more often based in 
communities or in primary-care clinics than are specialist 
clinical services. The reluctance to decentralize clinical 
functions has been the main obstacle to basing more HIV 
care in the community and in primary-care facilities. 
The purpose of this study is to contribute to the integra-
tion of care for HIV disease within the overall restruc-
turing of health services towards the primary health-care 
approach [5,6], and to contribute to the planning of 
health care for the HIV epidemic. 
Our objectives were (1) to determine the proportion of 
outpatient visits that could have been safely cared for at a 
primary-care level, according to the clinical staging de-
scribed by the World Health Organization (WHO), and 
(2) to describe outpatient visits in terms of the elements 
of clinical care provided: diagnosis, tests, and specialist 
services. 
Methods 
The study population consisted of all HIV -infected pa-
tients attending the city's only HIV clinic, the Somerset 
teaching and referral hospital, between September and 
November 1992. At the time of the study all public-sec-
tor patients and many of those with private medical in-
surance were referred there on diagnosis. The HIV clinic 
operates 1 day each week. At their first visit, patients 
from a single queue are sequentially allocated to doc-
tors as they become available, in an essentially random 
manner. Thereafter they remain under the care of that 
doctor. 
For every consultation, the six medical doctors in the 
clinic (two internal medicine specialists and three general 
practitioners with specific HIV expertise and one general 
practitioner new to HIV clinical management) recorded 
information on clinical diagnosis, WHO clinical HIV 
stage [7], management, follow-up and appropriate level 
of care. 
Three complementary questions (Table 1) were an-
swered as to level of care. The first question asks the clin-
ician to judge whether the patient could have received 
appropriate care for that visit if it had taken place at the 
primary-care level, with a suitably trained primary-care 
practitioner. 
Table 1. Level of care by practitioner. 
n(%) 
Observer 'Yes' or 'probably' Total 
Patient visits that could have been appropriately managed 
at a primary-care centre by a su itably trained primary 
health-care practitioner: 
1 26 (56.5) 





Total 165 (69.4) 







238 (1 00) 
Patient visits that needed specialist skills or knowledge: 
1 19 (41.3) 46 (19.3) 
2 14 (34.1) 41 (17.2) 
3 34 (52.3) 65 (27.3) 
4 6(31.5) 19( 7.9) 
5 9(16.4) 55(23.1) 
6 1 (8.3) 12 ( 5.1) 
Total 83 (34.8) 238 (1 00) 
95% CI (29-41) 
Patient visits that required tertiary-care facilities: 
1 9 (19.5) 46 (19.3) 
2 12 (29.2) 41 (17.2) 
3 6 (9.2) 65 (27.3) 
4 8 (42.1) 19 (7.9) 
5 9 (16.3) 55 (23.1) 
6 1 (8.3) 12(5.1) 
Total 45 (18.9) 238 (1 00) 
95% CI (14-24) 
CI, confidence interval. 
'Appropriate' care was defined as care that is as good as 
the care provided by the tertiary hospital clinician for 
the patient at that visit. The primary-care level in South 
Africa would be a small clinic, not attached to a hospital, 
and with no laboratory or radiology facilities on site. 
A limited drug list would, for example, include cotri-
moxazole and non-systemic antifungal agents, but would 
exclude zidovudine. It would be staffed by nurses, with 
training in diagnosis and treatment of common condi-
tions, with regular visits from a general practitioner. A 
larger health centre may have a full-time medical gen-
eral practitioner on the staff, a wider drug list, and basic 
radiology and laboratory facilities. 
A 'suitably trained' primary-care practitioner was de-
fined as a clinical nurse, or a non-specialist medical doc-
tor working in a primary-care facility who has under-
gone appropriate short training courses in HIV manage-
ment. This was described as including 5 days of clinical 










at Somerset Hospital, with a regular refresher course of 
similar length and method. 
The second and third questions asked whether the clini-
cian believed that the level of clinical skill and the techni-
cal facilities (diagnostic and therapeutic) required for the 
patient at that visit could only be provided in a tertiary 
setting. 
These questions could be answered 'yes', 'probably', 'un-
likely' or 'no'. Apart from a standard description of the 
definitions of levels of care, no attempt was made to 
ensure a consensus among the doctors on the appropriate 
level of care for different clinical conditions. 
Statistical analysis 
The data were coded, and analysed using SAS [8]. The 
X2 test or Fisher's exact test was used where appropriate 
and 95% confidence intervals were calculated. 
Results 
Over the study period, a total of 148 patients had 238 
consultations. 
level of Care 
Of all visits, 69.4% (range, 52-80%) were considered 
suitable for primary care (Table 1); 102 (42.9%) visits 
had a definite positive answer to this question, while 63 
(26.5%) visits were rated as 'probably'. There were sig-
nificant differences between practitioners (Fisher's exact 
test, 11.02; P=0.047). 
Specific needs 
One-third of all visits needed a medically trained spe-
cialist, and one-fifth required tertiary hospital facilities 
(Table 1). There were significant differences between the 
clinicians' opinions on these proportions (P=O.OOl and 
P=O.Ol, respectively). 
Although 165 (69.3%) visits were rated as suitable for 
primary care by the first question, 21 (12.7%) were 
deemed to need specialist care, nine (5.4%) to need ter-
tiary facilities and three (1.8%) to need both. These con-
tradictions amount to 20.0% of the visits suitable for pri-
mary care and 13.8 % of all visits. Of the 73 visits which 
were classified as not being suitable for the primary-care 
level, 31 (42.4%) needed both tertiary facilities and spe-
cialist skills, 28 (38.3%) needed specialist skills only, and 
five (6.8%) needed tertiary facilities only. There were 
nine (12.3%) contradictions (i.e., needed neither a spe-
cialist nor tertiary facilities). Taking these contradictory 
responses into account, at least 141 (59.2%) visits could 
be appropriately treated at the primary-care level. 
Stage of disease and level of care 
As the severity of the disease increases, there is a signif-
icant decrease (Mantel-Haenszel X2 test for trend, 40.0; 
P< 0.0001) in the proportion of patients that can be 
treated at a primary-care level (Table 2). Of the WHO 
stage 4 visits, 59.5% could not have been adequately 
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managed at a primary health-care level ('definitely not', 
36.5% and 'unlikely', 23%). lfthe 14 contradictory re-
sponses are included, then only 18.7% of stage 4 visits 
could have been cared for at a primary-care level. 
Table 2. Level of care by World Health Organization (WHO) stage 
of patients. 
'Yes' or 'probably' 
WHO stage n (%) 95% CI 
Total 
n(%) 
Patient visits that could have been appropriately managed 
at a primary-care centre by a suitably trained 
primary health-care practitioner: 
1 55 (94.8) 84-99 
2 38 (74.5) 59-86 
3 42 (70~0) 59-82 
4 (AIDS) 26 (40.5) 28-53 





233* (1 00.0) 
Patient visits that needed specialist skills or knowledge: 
1 5 (8.6) 3-18 58 (24.9) 
2 16(31.3) 18-44 51(21.9) 
3 18 (30.0) 18-42 60 (25.7) 
4 (AIDS) 42 (65.6) 54-77 64 (27.5) 
Total 81 (34.7) 29-41 233* (1 00.0) 
Patient visits that required tertiary-care facilities: 
1 5 (8.6) 3-18 58 (24.89) 
2 10 (19.6) 9-32 51 (21.89) 
3 8 (13.3) 6-24 60 (25.75) 
4 (AIDS) 22 (34.4) 23-46 64 (27.47) 
Total 45 (19.3) 14-24 233* (1 00.00) 
*Total is less than 238 because five visits were not staged. 
CI, confidence interval. 
As the severity of the disease increases, there are signifi-
cant increases in the proportions of patients who needed 
to be seen by a specialist (X2 =40; P< 0.0001), and who 
required tertiary-care facilities (X2 =40; P =0.001) (Table 
2). 
Diagnosis 
There were 349 diagnoses: an average of 1.4 diagnoses 
per visit. Mucocutaneous disorders were the most com-
mon problems encountered (Table 3), most of which 
(75.5%) could be cared for at a primary-care level. 
Of the 14 visits with a diagnosis of oral candidiasis which 
were rated as not suitable for primary health care, 10 
had other diagnoses [lymphoma, pancytopaenia, Kaposi's 
sarcoma (two), atypical mycobacteriosis, wasting syn-
drome, peripheral neuropathy, oesophageal candidiasis, 
pulmonary tuberculosis and anaemia]. 
The total number of investigations requested during the 
period of study was 214, or 0.9 tests per visit. More 
than half of all visits (128; 53.9%) had no laboratory 
tests ordered. Patients deemed appropriate for treatment 
at a primary-care level needed 0.65 tests per visit, most 
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Table 3. Common diagnoses·. 
No. (%) suitable for 
Diagnosis primary care 95% CI Total 
Mucocutaneous disorderst 34(75.5) 59-87 45 
Asymptomatic follow-up 25(86.1) 68-96 29 
Oral candidiasis 10(41.6) 22-61 24 
Pulmonary tuberculosis 11(64.6) 42-87 17 
Kaposi's sarcoma 8(50.0) 26-75 16 
Persistent glandular 
lymphadenopathy 9 (81.8) 48-98 11 
Urinary tract infection 6(85.7) 45-99 7 
Unexplained cough 2(28.6) 4-68 7 
Total 105(67.3) 6-75 156 
·Other diagnoses each <2% prevalence. tSebhorraeic dermatitis, 
prurigo, fungal skin and nail infections, recurrent oral ulcerations, 
angular cheillitis, Herpes Zoster, scabies, molluscum contagiosum. 
CI, confidence intervals. 
count and a chest radiograph. Common microbiology 
tests included syphilis serology, hepatitis B tests and pus 
and sputum microscopy and culture. 
Follow-up 
Routine follow-up of an asymptomatic patient consti-
tuted a relatively high percentage of all consultations 
(12%) and diagnoses (8.3%). Over 85% of these could 
be moved to primary care. 
Discussion 
All doctors independently assessed that more than half of 
their patients' visits could be managed by trained clini-
cians at a primary-care level. Further studies are needed 
in other centres to confirm the generalizability of this 
finding. 
The differences between practitioners for the first ques-
tion (on the level of care) and the contradictory answers 
are not large enough to change the conclusion of the 
study. Variation between otherwise similar physicians in 
decision making and consequent clinical practice is well 
known [9]. 
Instead of using subjective opinions, objective criteria 
could have been developed to assign patients to a spec-
ified level of care [3]. However, the complexity of de-
ciding on an appropriate level of care for a given patient 
will always entail subjective judgment [10], and given 
that the regular clinician makes frequent decisions about 
patients' therapy, he or she is ideally positioned to assess 
the appropriate level of care for their patient. 
In contrast to other studies (H. Schneider, personal com-
munication, 1993), which used retrospective record re-
views to assess the level of care needed for adult medical 
outpatients, data for this study were collected prospec-
tively at the time of consultation. This ensured that in-
formation was fresh in the minds of the practitioners. 
The WHO staging clinical system for HIV disease [7] 
proved useful in distinguishing subgroups of patients 
more likely to need tertiary care. The higher percentage 
of stage 4 (AIDS) patients that required a specialist com-
pared with the percentage that required tertiary facilities 
(Table 2) may indicate that it is the skill and experience 
of the specialist rather than sophisticated diagnostic or 
therapeutic faCilities which are needed in the late stages 
of the disease. 
Although diagnosis of skin conditions in the early stages 
requires skill and experience, the study results suggest 
that a suitably trained clinician could have managed these 
problems adequately, using a limited range of medica-
tions. 
Chronic unexplained cough, oral candidiasis and Ka-
posi's sarcoma were associated with a higher percent-
age of visits, which could not be adequately treated at 
a primary-care level. An unexplained cough often re-
quires radiological and laboratory support for diagnostic 
work-up and exclusion of treatable opportunistic infec-
tions like Pneumocystis carinii pneumonia (PCP) and tu-
berculosis. 
Pulmonary tuberculosis often, but not always, requires 
tertiary levels of expertise for diagnosis, early treatment 
and stabilization, but could be treated at a primary-care 
level thereafter. Oral candidiasis, provided it is not ac-
companied by other more severe and complicated diag-
noses, is usually easy to diagnose and treat at lower levels 
of care. Kaposi's sarcoma requires specialist referral, for 
diagnosis and care. 
South African public-sector referral and teaching hospi-
tals are already having to cope with restricted funding 
and an increasing patient population, especially in urban 
areas [11]. The emergence of HIV infection will over-
whelm health care as it is currently organized. 
This study has highlighted the urgent need for HIV in-
fection to be seen in the context of the primary health-
care approach. The results of this study suggest that all 
stage 1 visits, routine follow-up visits in other stages and 
selected symptomatic visits should be dealt with at the 
primary-care level. Clinics could be staffed by appro-
priately trained nurses, with larger health centres run 
by nurse and doctor teams, provided the clinicians re-
ceive appropriate training in managing HIV-related ill-
ness using clinical guidelines, and receive specialist sup-
port. These facilities need not have laboratories or radi-
ological facilities. Specialist centres could then be more 
appropriately used caring for referred patients with com-
plicated illness, developing the clinical guidelines and 
providing training, telephone, visit, and referral support 
to peripheral clinics and health centres; 
Pilot programmes and evaluations are needed to assess 
the impact of decentralization on cost and quality of 
care, including patient perceptions. This would 'assist in 
decisions on policy and wider implementation of this 
system, which, in high prevalence areas, may well offer 
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CME 
HIV infection: transmission 
hazards in life and death 
Inconsistencies in the 
application of universal 
precautions could lead to 
unnecessary exposure to 
and infection by HIV. 
Increasing numbers of South Africans 
are becoming infected with the human 
immunodeficiency virus (HIV). The 
national HIV seroprevalence rate in 
women attending antenatal clinics in 
November 1994 was 7.5% and an 
estimated 1 in 40 of the general 
population may be infected. The 
epidemic is rapidly approaching the 
scale seen in other southern African 
countries, where HIV infection is the 
major cause of mortality in young adults 
and where more than 50% of 
hospitalised patients have HIV-related 
diseases. As the epidemic develops, 
significant numbers of patients will die 
as a result of HIV infection. This poses 
further hazards. Undertakers, 
embalmers, nursing staff, mortuary 
attendants and pathologists are 
increasingly called upon to handle HIV-
infected cadavers. Undertakers and 
nurses perform procedures such as 
'laying out a body', which are 
associated with minimal exposure to 
virus-infected tissues and body fluids. 
Anatomical pathologists and mortuary 
attendants perform highly invasive 
procedures such as autopsies, 
laparotomies, skin suturing, bone 
cutting and drilling with mechanical 
devices, As part of the process of body 
preservation, embalmers may be 
required to remove abdominal and 
cranial contents and inject 
preservatives into the vasculature under 
pressure. 
There is a potential for transmission of 
HIV infection associated with each of 
these procedures and appropriate 
infection control measures should be 
utilised, The aim of this article is to 
review some of the available scientiflc 
data in order to allow a rational. 
assessment of transmission risk from 
living and dead patients. 
Current control policies 
Fear of acquiring HIV infection, as well 
as the social stigma of AIDS, has led to 
the shunning of many HIV-infected 
individuals by health care workers 
(HeWs) and the general public. These 










fears have not been limited to the 
living, but have led to undignified 
and extreme precautions for 
handling the dead. The belief that 
HIV-positive patients are easily 
identifiable has resulted in 
extraordinary precautions being 
taken with known HIV-positive 
individuals, while precautions for 
the unrecognised cases are 
ignored. Until 1994, the 'laying 
out' procedure for patients who 
died in Cape provincial hospitals 
included sealing known HIV-
infected cadavers in double 
plastic bags and attaching 
'Danger of Infection' labels. No 
added precautions were taken for 
cadavers of unknown HIV 
serological status. 
Anatomical pathologists have also 
been reluctant to perform 
postmortem examinations on 
known HIV-infected patients. 
When postmortems are 
performed on these cadavers, 
they are limited in nature and 
special precautions are taken. 
However, no added precautions 
are taken when the HIV 
serological status is unknown. 
Patients known to be HIV-infected 
represent the 'tip of the iceberg' 
of the infected population. In the 
Western Cape, the region with the 
lowest HIV prevalence in South 
Africa, a prospective hospital 
Sampling and 
investigation of body 
fluids is an Integral part 
of modern medicine and 
exposes HeWs to the risk 
of nosocomial HIV 
infection, 
study found that 33% of newly 
diagnosed tuberculosis patients 
were HIV seropositive. The 
present inconsistent application 
of infection control measures 
results in a false sense of 
security, while doing little to 
decrease the real risks. The 
epidemic is now well established 
in this country with significant 
numbers of all population groups 
infected. 
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Assessment of HIV 
infection risk 
Data on human transmission risk 
have been derived from in vitro 
virological studies and 
epidemiological observations. 
Virological studies have utilised 
HIV-l culture techniques and very 
sensitive polymerase chain 
reaction technologies. These 
studies have demonstrated cell-
associated virus, cell-free virus, 
viral RNA and pro-viral DNA in 
many human tissues and body 
fluids. They confirm that 
postmortem tissues and body 
fluids have the potential for HIV 
transmission. Epidemiological 
studies~ in contrast, have 
generally demonstrated little 
transmission outside the 
conventional risk behaviours. 
Community-acquired 
HIV infection 
The main risk factors for acquiring 
H1V infection were recognised in 
the early stages of the AIDS 
pandemic and included sexual 
contact with an infected 
individual, parenteral exposure to 
infected blood and vertical 
transmission from an infected 
mother to her infant. The isolation 
of HIV from body fluids other than 
blood and semen raised concerns 
that 'casual' contact with patients 
might lead to il'1fection. 
Subsequent long-term 
epidemiological studies of 
families and household contacts 
of AIDS patients showed no 
'casual' transmission of HIV, 
despite many years of exposure yl 
They have established that the 
infection is extraordinarily difficult 
to transmit outside the 












Sampling and investigation of 
body fluids is an integral part of 
modern medicine and exposes 
HeWs to the risk of nosocomial 
HIV infection. Potential infection 
risks include: contact with blood 
on intact skin; contact with blood 
or body ftuids on broken skin; 
contact of body fluids with the 
mucosa of eyes, mouth or nose; 
penetrating injuries caused by 
scalpel blades, needles, etc. and 
inhalation of aerosols from 
mechanical devices such as bone 
saws. 
• Exposure of intact skin to 
infected blood does not appear 
to be a significant risk for 
acquiring HIV infection.4 
• Non-parenteral exposure of 
non-intact skin to infected 
blood has been reported to 
result in infection on rare 
occasions. 
• There is an estimated 
transmission risk of 1 in 
2 500 following mucosal 
exposure. 
• The most significant infection 
risk is associated with needle-
stick injuries. The HIV 
seroconversion rate following 
hollow-needle penetration is 
approximately 1 in 250 
exposures, Absolute risks are 
dependent on the quantity of 
blood transferred and the titre 
of virus in the HIV-infected 
blood. HIV is present in the 
blood in high titre at the time 
of seroconversion, declines 
rapidly and remains at low 
levels until finally rising with 
the onset of AIDS. 
• Transmission by aerosol has 
not been documented. 
• Exposure to body fluids other 
than blood poses a lower 
infectious risk as viral titres 
are usually lower than those 
found in blood. 
Postmortem HIV 
viability 
HIV has repeatedly been isolated 
from cadaveric blood and 
tissues,s.7 although viral titres 
decline after death. Cell co-culture 
assays have shown that the 
tissue infectious titre of whole 
blood taken from H IV-infected 
patients decreased by 










of 5 patients studied over a 4-day 
period.' Even though HIV may be 
present in a decreased titre in 
cadaver tissues, body fluids 
should be considered potentially 
infectious and refrigeration does 
not seem to decrease recovery of 
the virus. Epidemiological 
evidence of any postmortem HIV 
transmission is scanty. Despite 
the performance of many 
thousands of autopsies on HIV-
positive cadavers, there have 
been no reports of pathologists 
seroconverting as a result of an 
injury acquired in a mortuary. 
Three mortuary technicians, 
however, have been reported to 
have acquired possible 





Control measures should be 
based on scientific principles, 
should not engender unnecessary 
fear and prejudice against HIV-
infected patients and should not 
be seen in isolation from other 
common infectious diseases such 
as hepatitis B and tuberculosis. 
The HIV epidemic in South Africa 
now affects significant numbers 
of all age, sex and racial groups, 
necessitating the universal 
application of precautions. 
Infection control measures should 
be applied to everybody and not 
limited to those known to be HIV-
positive. An alternative strategy 
would be to institute universal HIV 
testing before performing higher-
HIV TRANSMISSION 
risk procedures. The level of 
precaution should be related to 
the exposure to blood and 
tissues. 
For minimal risk activities such as 
'laying out' bodies disposable 
gloves and aprons should be 
worn, especially when blood 
contamination is present. 
Antiseptics should be used for 
neutral ising contaminating body 
fluid leaks, and the body should 
be covered with a shroud. The 
transmission risk is low and 
probably comparable with that of 
household contacts of AIDS 
patients. 










an autopsy have increased 
potential for HIV transmission. 
Besides the use of gloves, 
protective clothing and eye 
protection and suitable extraction 
venting of postmortem rooms, 
adequate skill and training are 
required. Protective measures 
should, however, not impede 
dexterity. Mechanical devices 
such as bone drills should cause 
minimal aerosol production. 
Protection against inhalational 
exposures is more problematic. 
While there is no epidemiological 
If professionals are called 
upon to perform 
procedures they perceIve 
as risky, failure to 
address theIr concerns 
will prove counter-
productive. 
evidence that this is a route of 
transmission, fUll protection 
would require a close-fitting face 
mask or plastic visor with down-
draft air flow. 
Added infection control 
precautions may add significantly 
to the cost of pathology services. 
It has been estimated that a 
postmortem on an HIY-positive 
cadaver in the UK cost R6 000, 
approximately 50% more than the 
cost of a conventional procedure,s 
If universal application is 
unaffordable, an alternative 
strategy would be the HIV testing 
of all cadavers which are 
subjected to postmortem 
examination. 
Embalming is not a common 
procedure but has attendant 
transmission risks of at least 
similar magnitude to a 
postmortem. Infection control 
measures should be of a similar 
nature to those of a postmortem 
examination and should be 
applied universally. Such 
procedures, moreover, should 
only be performed by suitably 
trained individuals. In the USA 
and Europe, appropriate training 
of embalmers and mortuary 
attendants Is ensured by a 
nationally recognised training 
programme, with subsequent 
registration. There is no such 
recognised training programme in 
South Africa. 
Available epidemiological 
evidence Indicates that 
postmortem transmission of HIV 
is very rare.' The risk of 
transmission Is highest when the 
intact skin barrier Is broached by 
a needle or scalpel. Infection 
control measures are applied 
inconsistently. Many of those at 
most risk have no recognised 
training and there are no 
professional bodies to ensure the 
maintenance of minimum 
standards. 
There have been no systematic 
postmortem studies in South 
Africa and we are dependent on 
data from Zaire' and the Ivory 
CoasPo to characterise AIDS 
manifestations in our 
communities. If professionals are 
called upon to perform 
procedures they perceive as risky, 
failure to address their concerns 
will prove counter-productive. The 
actual transmission risks in South 
Africa can only be assessed If 
ongoing surveillance data are 
collected throughout the country. 
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Such data are required before 
individuals exposed to 
occupational infection can be 
reassured that the risk of 
transmission is insignificant. 
Nevertheless, the occupational 
risks appear to be low. 
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In the South African population 1 In 40 
people .re HIV·lnfected .nd the 
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Tl1e application of InfectIon control 
me,.UrN only to known HIV· 










sense of security, while doing little to 
reduce HIV transmission. 
Virological studies confirm that HIV 
remains viable In cadaver tissues and 
blood and these are potential sources 
of infection. 
Epidemiological evidence Indicates that 
exposure to HIV-Infected blood Is the 
major risk factor for nosocomial HIV 
transmission. 
The rlsk"for acquiring HIV Infection from 
blood Is approximately .1 In 2 500 for 
mucosal exposure and 1 In 250 for 
hollow needle stick InJuries. 
Rational HIV Infection control measures 
should also be adequate for other 
common Infectious diseases and they 
must be universally applied by suitably 
trained IndIviduals. 
IN 'N NEUTEDOP 
In die Suld·Afrlkaanse bevo/k/ng Is .1 ult 
40 mense met HIY geiitfekteer en die 
proporsle Is Bsnslenllk hoer In 
gehospltsllseerde paslente. 
Ole toepasslng van 
Infekslebeheermaatreels slegs vir 
bekende HIV-seroposltlewe Indlvldue 
gee 'n va's gavoel van vell/gheld terwyl 
dlt min doen om dIe HIV-transmiule te 
vermlnder. 
Vlrologlese studies bevestlg dat HIV 
lewensvatbaar bly In kadawerweefsels 
en -bloed en dlt Is potens/e/e bronne 
van Infeks/e. 
Epldemlologlese bewyse dul daarop dat 
biootstelllng san HIV-geiitfekteerde 
bloed die belangrlkste rlslkofaktor vir 
nosokomla/e HIV-transmlssle Is. 
Ole kanse om HIY-Infeksle van bloed op 
te doen Is omtrsnt :1 In 2 500 vir 
mukosa/e biootstelllng en 1 In 250 vir 
hoinaaid prlkbeserlngs. 
Redellke Infsks/ebeheermaatreels vir 
HIV behoort oak voldosnde te wees vir 
snder algemene aan.teekllke sleldel 
en hulle moet unlverseel deur toed-
oP6elelde Indlvldue tosgepas te word. 
HIV TRANSMISSION 
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The impact of human immunodeficiency virus (HIV) 
infection on quality of life in a multiracial South 
African population 
E. A. O'Keete* and R. Wood 
Department of Medicine, Somerset Hospital, University of Cape Town, South Africa 
We set out to document quality of life in South 
African HIV subjects, using the Medical Outcomes 
Survey (MOS) SF-36 instrument, and to determine 
whether this was affected by race, gender or clinical 
stage of disease. A cross-sectional survey of 134 
HIV outpatients (42 White, 49 Mixed race, 43 Black) 
and 114 healthy non-medical hospital personnel (36 
White, 37 Mixed race, 42 Black) was carried out at 
a referral centre for HIV patients in the Western 
Cape region of South Africa. Scores on eight scales 
measuring different aspects of quality of life were 
calculated. Black female controls scored signifi- 
cantly lower on all scales (p<0.05) except physical 
function. HIV-lnfected subjects of Mixed race (both 
genders) reported poorer physical function (p<0.05) 
but no other scale was affected by race. HIV subjects 
scored significantly lower than controls on all scales 
(p<0.01); the majority of the decline in function 
occurred early in disease by WHO stages 1 and 2. 
We conclude that HIV-infection impacts early on all 
aspects of quality of life and that this impact is 
largely independent of racial origin. 
Key words: Human immunodeficiency virus (HIV); 
Medical Outcomes Survey (MOS) Instrument SF-36; 
race; quality of life; WHO Clinical disease stage. 
Introduction 
Random testing of patients attending antenatal clinics 
in South Africa in 1994 revealed an overall seropre- 
valence for Human Immunodeficiency Virus (WV) 
infection of 8% (ranging from just over 1% in the 
Western Cape region to nearly 15% in Kwazulu/Natal) 
and is expected to rise to 20% by the year 2000.1 The 
Cape Town population is comprised of Blacks (mainly 
of Xhosa origin), Whites (English and Afrikaans) and 
* To whom correspondence should be addressed at 
Department of Medicine, Somerset Hospital, Pnvate Bag, 
Greenpoint 8051, South Africa. Tel: 27 21 402 6911; Fax: 
27 21 402 6000. 
persons of Mixed race (English or Afrikaans peaking). 
Homosexually transmitted HIV-infection was first 
reported in Cape Town in 1982 in White and Mixed 
race males, but heterosexually acquired infection is 
now predominant and the majority of infected 
persons are Black or of Mixed race. Cape Town is 
thus ideally situated to study the potential effects of 
race on HIV disease presentation. 
HIV-related quality of life is an important issue 
both for the infected individual and for society as a 
whole. Impairment of quality of life has been shown 
in Western AIDS patients. However, there iS little 
data concering quality of life at earlier stages of 
HIV-infection or race-related differences in quality of 
life2'34'5 and no data for African HIV subjects. Given 
South Africa's political history, one might expect to 
find differences in quality of life between the 
population groups. However, there are problems 
associated with assessment of quality of life in Africa 
as comprehensive instruments are not available in 
the local languages and their content may not be 
appropriate in the different cultural setting. The 
Medical Outcomes Survey (MOS) instrument, MOS 
SF-36,6 was selected for this study of quality of life 
in the Cape Town WV population because it has been 
widely used internationally.7 Translations into the 
other local languages, Afrikaans and Xhosa, had to 
be made and validated. 
Methods 
Setting 
The HV Clinic at Somerset Hospital, Cape Town is 
a well established referral centre for WV-infected 
patients from the Western Cape region of South 
Africa. Whites, Blacks and people of Mixed race at 
all clinical stages of HIV disease are seen at the clinic. 
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E. A. O'Keefe t al. 
Patients are routinely counselled at the time of 
diagnosis. All HIV outpatient visits are recorded on 
a computer database which is updated weekly. 
Instrument 
The MOS 36-item Short-Form Health Survey (SF-36) 
assesses eight health concepts: (1) limitations in 
physical activities because of health problems; (2) 
limitations in social activities because of physical or 
emotional problems; (3) limitations in usual role 
activities because of physical health problems; (4) 
bodily pain; (5) general mental health (psychological 
distress and well-being); (6) limitations in usual role 
activities because of emotional problems; (7) vitality 
(energy and fatigue) and (8) general health percep- 
tions.6 The survey can be administered by a trained 
interviewer or completed by the subject himself. 
Translations into Afrikaans and Xhosa were made 
and validated as described below. 
Study design 
The study comprised three parts: 
1. Establishment of normal values for the South African 
population: The SF-36 was administered to healthy 
non-medical hospital personnel (domestic workers, 
porters and administrative staff) from the three racial 
groups of both sexes, between the ages of 20-40. 
2. Validation of the translated instruments: The validity 
of each of the translated instruments was examined 
by a test-retest procedure to ensure reproducibility, 
and by patient interview to show concurrent validity. 
Reproducibility: HIV-subjects completed the 
translated SF-36 during a clinic visit. A second 
identical questionnaire was given to tiem to 
complete and return 7 days later. The responses 
on the two questionnaires were compared and Kc 
statistics calculated. 
Concurrent validity: A trained research nurse 
interviewed the patients and completed an 
additional questionnaire based on their responses. 
This was compared with the patient-completed 
questionnaire and K statistics calculated. 
3. Cross-sectional survey: The SF-36 was administered 
to eligible patients attending the HtV clinic between 
April 1993-May 1994. Clinical stage according to 
WHO criteria8 and CD4 lymphocyte counts were 
recorded. Where possible, the patients completed the 
questionnaire themselves, if not, it was administered 
by the research nurse. 
Exclusion criteria were acute or terminal illness, 
impaired mental status, first clinic visit and prison 
residence. Patients on secondary prophylaxis for 
opportunistic infections were included in the study. 
The HIV clinic database was used retrospecfively to 
identify all eligible patients visiting the clinic during 
the study period. Those who completed the survey 
('responders') were compared with those who did 
not ('non-responders') to confinm that a representative 
sample of the clinic population had been surveyed. 
Statistical analysis 
Scores for each MOS scale were derived from the 
subjects responses on the SF-36 and transformed to 
a 0-100 scale, with a higher score representing better 
function. The reliability and concurrent validity of 
the translated instruments were assessed by calcu- 
lating weighted K statistics9 for individual questions 
and median differences between overall scores for 
each scale. 
One-way ANOVA was used to examine the effect 
on MOS score of race/gender (six groups) in control 
subjects and of race/gender, WHO clinical stage and 
CD4 count in HIV subjects. In the HIV subjects, the 
effect of race/gender was examined within each 
disease stage and with all subjects grouped together 
to increase statistical power. Similarly, the effect of 
clinical stage was assessed within each race/gender 
group and with all races and genders together. WHO 
stages 1 and 2 were combined for analysis to increase 
the statistical power. CD4 counts were grouped into 
>400, 200-400 and <200. 
'Responders' and 'non-responders' were compared 
using the x2 test to determine if there were differences 
in the proportions sampled with regard to gender, 
race and clinical stage of disease. 
Results 
Control data 
One hundred and fourteen healthy subjects were 
surveyed. Forty-nine per cent completed the ques- 
tionnaire in English, 32% in Afrikaans and 19% in 
Xhosa. The mean scores for each MOS scale are shown 
for the different racial groups and genders in Table 1. 
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Quality of life in HIV in South Africa 
ANOVA showed that the race/gender groups were 
not uniform in their performance on any scale except 
vitality. Black females scored significantly lower on 
all scales except physical function, where Mixed race 
males recorded the lowest scores. When black females 
were excluded, the groups were found not to differ 
significantly except for poorer physical function in 
Mixed race males. 
Validation data for the translated questionnaires 
Reproducibility: Thirty subjects (16 Afrikaans, 14 
Xhosa) completed two translations of the SF-36 a 
week apart. The overall scores for each scale were 
compared and the median differences are shown in 
Table 2. The median weighted x for individual 
questions in the Afrikaans version was 0.60 (range= 
0.15-1.0), and in Xhosa 0.53 (range=0-1.0). Kappa 
values for questions referring to vitality were poor 
in both translations (Afrikaans mean=0.32, Xhosa 
mean=0.43), as were some of the questions referring 
to mental health and general health. 
Concurrent validity: Interview data from 45 subjects 
(25 Afrikaans, 20 Xhosa) was compared with their 
independent responses on the SF-36. The overall scores 
for each scale were compared and the median differ- 
ences are shown in Table 2. The median weighted K 
for individual questions on the Afrikaans version was 
0.73 (range 0.04-0.98), and 0.57 (range 0.17-90) on 
the Xhosa. The questions used to calculate the vitality 
score performed poorly with a mean K of 0.40 for the 
Afrikaans translation and 0.41 for the Xhosa. 
Patient data 
One hundred and thirty-four HIV patients were 
surveyed (53 WHO stage 1 and 2, 51 stage 3 and 30 
stage 4). Twenty-six per cent of patients visiting the 
clinic were not eligible to be included in the survey 
Table 1. Mean MOS scores (95%CI) for control subjects by race and gender 
White M White F Mixed M Mixed F Black M Black F 
(n=21) (n=15) (n=19) (n=18) (m21) (m'21) 
PHYS 89 (78-99) 94 (82-100) 64 (53-75) 81 (70-92) 88 (78-98) 73 (62-83) 
ROLE 88 (77-99) 90 (77-100) 80 (69-92) 97 (85-100) 86 (75-97) 68 (57-79) 
PAIN 85 (73-96) 86 (72-99) 79 (68-91) 80 (67-92) 75 (64-86) 55 (43-66) 
GEN 75 (67-83) 76 (67-86) 78 (70-87) 74 (6543) 67 (59-75) 61 (53-69) 
VIT 68 (60-76) 57 (48-66) 74 (66-82) 65 (57-73) 72 (65-80) 66 (58-74) 
SOC 87 (77-96) 76 (65-88) 81 (71-92) 81 (71-92) 84 (74-93) 63 (53-72) 
EMOT 77 (62-92) 73 (55-90) 83 (68-99) 90 (74-100) 77 (62-92) 52 (37-66) 
MENT 78 (71-85) 70 (61-79) 83 (75-91) 75 (6743) 80 (73-87) 65 (57-72) 
PHYS=physical health, ROLE=role-physical, GEN=general health, VIT=vitality, SOC=social functioning, 
EMOT=role-emotional, MENT=mental health 
Table 2. The median differences between MOS scores on each scale in test-retest studies 
Afrikaans Afrikaans Xhosa Xhosa 
reliability validity reliability validity 
PHYS 5 0 5 2.5 
ROLE 0 0 0 0 
PAIN 8.5 0 11.5 1 
GEN 11.5 5 8 5 
VIT 10 7.5 12.5 12.5 
SOC 0 0 0 12 
EMOT 0 0 0 0 
MENT 8 8 12 12 
PHYS=physical health, ROLE=role-physical, GEN=general health, VIT=vitality, SOC=social functioning, EMOT=role-emotional, MENT=mental health 
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Table 3. Mean MOS scores (95% Cl) related to CD4 lymphocyte count 
Control CD4>400 CD4 200-400 CD4<200 
(n =114) (n =32) (n =44) (n =58) 
PHYS 81 (76-86) 67 (57-76) 71 (63-79) 70 (63-77) 
ROLE 84 (78-91) 59 (47-72) 54 (43-65) 46 (37-55) 
PAIN 76 (70-81) 60 (50-71) 56 (47-65) 60 (52-67) 
GEN 72 (68-76) 44 (37-52) 51 (44-57) 43 (37-49) 
VIT 68 (64-72) 52 (45-60) 53 (47-59) 48 (42-54) 
SOC 79 (74-84) 64 (54-73) 63 (55-71) 59 (52-66) 
EMOT 75 (68-82) 54 (40-67) 47 (35-58) 49 (39-59) 
MENT 75 (72-79) 58 (51-65) 61 (55-67) 61 (56-86) 
PHYS=physical health, ROLE=role-physical, GEN=general health, VIT=vitality, SOC=social functioning, 
EMOT=role-emotional, MENT=mental health 
Of the remainder, no differences were found with 
respect to gender, race and clinical stage of disease 
between 'responders' and 'non-responders', thus, the 
134 patients surveyed were representative of all 
eligible patients attending the HIV clinic during the 
study period. 
Forty-three per cent of questionnaires were com- 
pleted in English, 34% in Afrikaans and 23% in Xhosa. 
Only five questionnaires (0.4%) were completed by 
the research nurse. The patient group comprised 42 
Whites (3 female), 49 Mixed race (14 female), 43 Blacks 
(28 female). Mean CD4 lymphocyte counts in WHO 
stages 1, 2, 3 and 4 were 367, 382, 257 and 93 respec- 
tively. The mean age was 32.5 and this did not differ 
significantly between the six race/gender groups; age 
was therefore not considered further in the analysis. 
Physical function was the only MOS scale to be 
affected by race/gender in HIV-infected subjects; 
mixed race males and females had lower scores 
(p<0.05). The mean scores (?95%CI) for each scale 
related to WHO stage are shown in Figures 1 and 2. 
HIV subjects scored significantly lower than controls 
on all scales (p<0.001). The majority of the overall 
decline in function had occurred by WHO stage 1 
and 2 (50% on pain, 51% role-emotional, 55% social 
function, 60% role-physical, 62% vitality, 74% general 
health and 88% mental health). Physical parameters 
showed a trend towards a linear decline with disease 
progression, but this did not reach significance. MOS 
scores on the other scales did not decline significantly 
with advancing disease. Similar findings were 
evident when MOS scores were related to CD4 lym- 
phocyte count (Table 3). 
Twenty-five per cent and 26% of stage 1 and 2 
subjects scored zero on the role-physical and role- 
emotional scales, respectively. There were few zero 
scores on the other scales. 
Figure 1. The relationship between mean MOS scores 
(+ 95%CI) on physical function, role-physical, pain and 
general health scales and WHO clinical stage of disease 
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Discussion 
The instrument 
Quality of life is a broad concept that indudes not 
only functional status and well-being, but also 
involves other aspects not directly related to health, 
such as income, freedom and environment. Increas- 
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Quality of life in HIV in Southt Africa 
Figure 2. The relationship between mean MOS scores 
(+95%CI) on vitality, role-emotional, mental health 
and social functioning scales and WHO clinical 
stage of disease 
V100r ROLME - EMOTIONAL 
~70 
30 






N0 WHO 13 WaO me44 WmOL WH WH2 D3 VO4 
ingly, health is being evaluated not only in terms of 
life expectancy but also quality of life remaining. 
Furthermore, functional status may be a strong 
independent predictor of survival in H[V-infection.5 
An instrument designed to measur  quality of life 
in one country may not be appropriate for use in 
another as concepts of health may vary across cultures 
and these cultural differences can adversely affect 
the instruments validity. However, the SF-36 was able 
to differentiate between healthy and HIV-infected 
individuals on all scales and appeared to be a satis- 
factory measure of quality of life in the South African 
HIV population. 
Translating an instrument can also cause problems 
as it may be interpreted differently in the new 
language. Validation studies of the Afrikaans and 
Xhosa translations of the SF-36 demonstrated good 
overall reliability and concurrent validity on most 
scales. However, the x statistics relating to questions 
on the vitality scale, in particular, were not acceptable. 
This was probably due to the complexity of these 
questions in a relatively uneducated population. 
Further work is being carried out on the translations 
according to international guidelines.10 
Control data 
Previous MOS data have shown that men tend to 
report slightly better health than women on all 
measures except health perceptions and Non-whites 
report poorer health perceptions, social functioning 
and more pain. In addition, education and income 
influence MOS scores."1 Thus, the lower scores 
reported by Black females in our study are in line 
with previously reported data for females and Non- 
whites, but could also be attributable to poorer 
socioeconomic status which was not directly control- 
led for in the study. There are obviously limitations 
to using a small, fairly select control population, but 
it was beyond the scope of this study to match 
patients and controls for socioeconomic factors. 
However, socioeconomic status and race are still 
interdependent in South Africa and the majority of 
patients seen at the hospital are of lower socio- 
economic class and would be comparable with the 
controls selected. A possible confounding factor is 
that controls were not tested for HIV; this might be 
particularly relevant in Black females who currently 
have the highest incidence of HIV in Cape Town. 
However, given its political history, quality of life 
issues in South Africa might be expected to differ 
between racial groups and Black females probably 
have poorer quality of life. There was no obvious 
explanation for the reported poorer physical function 
of Mixed race males, but this was consistent in both 
control and HIV subjects. 
Patient data 
We have shown that all aspects of quality of life are 
affected in 'asymptomatic' H[V-infection. This early 
impact was maximal on emotional and psychological 
factors, whereas physical function showed a more 
linear decline with disease progression. One might 
expect quality of life to deteriorate as a person 
becomes more symptomatic, and quality of life in 
HIV-infection has been shown to be related to clinical 
stage of disease in some studies.4'5 Wu showed that, 
compared with AIDS-related complex, asymptomatic 
HIV patients reported better overall health, physical 
function, role function and less pain,3 and Burgess12 
demonstrated deterioration in measures of physical 
health with disease progression. Our data also 
suggest that physical function declines with advancing 
disease and the lack of significance may be due to a 
type 2 error. Furthernore, all subjects who were acutely 
ill were exduded from the survey and since most of 
them were clinically Wi O stage 3 or 4 our results 
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represent a conservative estimate of the decline in 
function with advancing disease. Possible declines in 
the physical and emotional aspects of role function 
with disease progression might have been missed due 
to the relative insensitivity of the SF-36 at the lower 
end of these scales. This has been noted with previous 
MOS instruments in HIV patients2"2 and additional 
items to improve sensitivity in the lower ranges of 
the role functioning scales would be beneficial. 
The majority of literature on the psychiatric aspects 
of HV disease comes from the USA and Europe, and 
concerns homosexual and bisexual men; it therefore 
may not apply to the largely heterosexual HIV popu- 
lation in South Africa. Several studies have shown 
an increase in psychiatric morbidity in early symp- 
tomatic H[V disease.13 HIV-infection clearly had an 
early impact on psychological well-being in the Cape 
Town HIV population with little further deterioration 
demonstrable on progression to AIDS. However, this 
study did not address the nature of psychological 
disturbances present and these may well be different 
at different stages of disease.13 
Race and gender appeared to have little effect on 
quality of life once HIV-infection was present with a 
significant difference between groups being detected 
only on one of the eight scales measured. Despite 
the differences in the control population, Black 
females with HV-infection scored comparably with 
the other race/gender groups. It is possible that the 
overwhelming effect of HIV-infection on quality of 
life might have masked an effect of race or gender 
and that a statistical difference could have been found 
with larger numbers, but it seems unlikely that this 
would be of clinical importance. 
Using a comprehensive instrument, we have 
shown that HV-infection impacts early on all aspects 
of quality of life and that race-related differences in 
quality of life do not appear to be important in the 
South African HIV population. With the emphasis in 
the South African Health Service now being placed 
on primary care, it is important not to neglect the 
needs of patients with early HV disease who have 
considerable morbidity, especially psychologically, 
and to make provision to support them at a primary 
care level. 
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Quality of Life in HIV Infection 
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HIV infection gives' rise to incurable, debilitating disease in young persons and treatments capable of 
prolonging survival are often associated with toxicity. Quality of Life (QOL) assessment is therefore 
important in the evaluation of clinical interventions in HIV-infected patients. It also has a role in 
determining the needs of individuals and directing healthcare resources. A wide range of QOL 
instruments is available and choice of instrument should be guided by the information required. As would 
be expected, poorer QOL is correlated with the presence of disease-related symptoms and advancing 
WHO clinical stage of disease. Psychological dysfunction, however, is evident from the time of diagnosis 
and should not be overlooked. 
Key words: AIDS; CMV; functional status; HIV; MOS; Quality of Life (QOL); well-being; zidovu~ine 
E. A. O'Keefe, Dept. of Medicine, Somerset Hospital, Private Bag, Greenpoint 8051, South Africa (fax: 
+ 2721 402 6000) 
With no prospect of a cure for human immunodeficiency virus 
(HIV) infection in the near future, current management of 
HIV -infected persons is directed towards prolonging survival 
and maintaining Quality of Life (QOL). HIV infection, unlike 
most other chronic medical conditions, affects young other-
wise healthy adults causing slowly progressive disease. Many 
HIV-infected persons remain asymptomatic for years (mean 
time to AIDS 10 years). With advancing disease, however, 
constitutional symptoms (fever, night sweats, weight loss), 
diarrhoea, dyspnoea, cognitive and neurological impairment 
become more prevalent. Psychological dysfunction, on the 
other hand, is prominent from the time of diagnosis, as not 
only do patierits have to come to terms with the fact that they 
have an incurable disease, but they also have to contend with 
the stigma attached to the diagnosis (I). 
Care must be taken in interpreting QOL data from HIV-
infected persons as they are a sociodemographically diverse 
group. QOL measures designed for use in Western HIV 
populations may not be appropriate for use in other parts of 
the world, as concepts of health vary across cultures. 
Furthermore, translation of an instrument can cause problems 
as it may be interpreted differently in the new language. 
Instruments should therefore be validated in the HIV popu-
lation under study. For these reasons, there has been a lack of 
QOL data from HIV patients in non-industrialized countries. 
This review discusses the role of QOL assessment in HIV 
infection and QOL data reported from cross-sectional, 
longitudinal and interventional studies in HIV -infected 
persons. 
ROLE OF QOL ASSESSMENT IN HIV INFECTION 
Clinical trials 
Health status has become an increasingly impottant 
outcome measure in HIV -related clinical trials, especially 
where 'asymptomatic' persons are studied who have a 
relatively low incidence of hard endpoints, such as disease 
progression or death. Toxicity may be poorly tolerated by 
patients who are relatively well. Therapies that can be of 
benefit in prolonging life in HIV -infected persons are often 
associated with unpleasant side effects and may increase 
longevity at the expense of QOL. Thus, QOL measures can 
give information which will help determine not only the 
acceptability of the treatment to the patient but also the 
optimal effective dose of a medication. 
In a placebo-controlled trial of high-dose zidovudine in 
early 'symptomatic' HIV infection, zidovudine delayed 
progression of disease but QOL data documented impairment 
in all dimensions of well-being (2). Subsequently a lower 
dose of zidovudine was shown to be associated with at least as 
good survival and less toxic side effects (3). 
Individual assessment 
In the individual HI V-infected patient QOL measures can 
be used to determine specific areas of dysfunction which may 
be amenable to treatment. QOL data from clinical interven-
tions can also be used to help patients make informed 
decisions about their treatment. This is of particular relevance 
with regard to a condition like cytomegalovirus retinitis, 
which causes blindness if untreated, but effective therapy 
until recently required life-long intravenous administration of 
medications with adverse side-effect profiles. A questionnaire 
has been developed that measures visual function, treatment 
impact and QOL in patients with CMV retinitis to address this 
problem (4). 
Healthcare planning 
QOL data may assist in healthcare planning by providing 
information that identifies groups of HIV patients at particular 










timeously targeted at these groups. For instance, psychologi-
cal stress is well documented in 'asymptomatic' HIV disease 
(1) and early psychosocial intervention has been shown to 
improve QOL (5), thus it is appropriate to provide counselling 
and social support for HIV -infected persons from the time of 
diagnosis. 
In resource-poor countries it is important to ensure that the 
limited funds available for heaHhcare are directed to the areas 
of greatest need where there is potential for benefit. Assess-
ment of functional status following treatment of AIDS-related 
illnesses, such as cryptococcal meningitis, will document 
whether patients are returned to a functional lifestyle. A 
decision may then be made to provide treatment for these 
conditions rather than for those where the functional outcome 
is less good. 
INSTRUMENTS FOR MEASURING QOL IN HIV 
There are many different concepts related to QOL and it is 
important to define what aspects of health status need to be 
assessed in a specific situation (6). Several standardized, 
generic measures of health status have been developed for use 
in chronic medical conditions and some of these have been 
validated in the HIV population, e.g. the Medical Outcome 
Survey instruments MOS SF-36 and MOS-20 (7,8). How-
ever, these instruments were not designed for use in this 
population and may be insensitive to some aspects of QOL 
that are of particular importance to HIV -infected persons. A 
Medical Outcome Survey instrument has been developed for 
use in HIV patients (MOS-HIV) by inclusion of questions 
relating to energy level, cognitive function and health distress 
(9) and a number of other instruments have been structured 
specifically for use in the HIV population. The single-item, 
observer-dependant Karnofsky Performance Scale has been 
widely used in HIV -related clinical trials to assess physical 
dependance but gives no information on well-being (10). 
Standardized non-QOL measures, e.g. the Hospital Anxiety 
and Depression Rating scale, can be used for the assessment 
of specific areas of function. The ideal instrument for use in 
HIV clinical trials should be short, self-administered, measure 
the desired aspects of QOL, be sensitive to small changes in 
function and have been validated in the HIV population under 
study. 
CROSS-SECTIONAL DATA ON QOL IN 
HlV INFECTION 
Studies of QOL in HIV populations must take into account the 
diverse nature of the persons affected as findings in one group 
may not necessarily be applicable to another. The strongest 
predictors of poorer QOL iQ. HI V-infected persons have been 
found to be the presence of disease-related symptoms (8, 9) 
and advancing WHO clinical stage of disease (1 I, 12). Minor 
differences in health status have been found in HIV -infected 
persons of different racial origin, gender and age (8, 11). 
QOL in HIV 31 
Intravenous drug abuse and lower education level have been 
associated with lower reported function in all areas (8), 
Constitutional and neurological symptoms have the greatest 
overall negative impact on health status, chronic diarrhoea 
has a serious adverse effect on role function- by disrupting 
ability to work or perform normal daily activities and 
dyspnoea interferes more with physical than role function 
(8,13). 
HIV -infected individuals report impairment in all aspects 
of health-related QOL when compared with healthy persons 
from the same population (11). Poorer function was evident 
even in persons with early 'asymptomatic' HIV disease, but 
was more marked in areas relating to psychological function 
whereas physical function declined in a more linear fashion 
with disease progression, Generalized scales that measure 
psychological distress show little change in psychological 
function, with advancing disease, but more specialized 
instruments may show that the nature of the stresses change. 
For instance, at the time of diagnosis, anxiety, guilt and denial 
may be prominent, whereas, with the onset of symptomatic 
disease, adjustment disorders and depression are more 
common. 
'Asymptomatic' HIV patients generally report better QOL 
than outpatients with other chronic conditions, although they 
experience more psychological distress. Patients with early 
'symptomatic' HIV disease had similar QOL profiles to those 
with hypertension except for poorer mental health and more 
health distress (9). 
LONGITUDINAL DATA ON QOL IN HIV INFECTION 
Knowledge of the natural history of QOL in HIV infection is 
important in understanding the significance of QOL data 
related to clinical interventions. The progressive nature of the 
disease must be taken into account as stabilization of 
declining function with a particular intervention may 
represent a significantly better outcome than would have 
been expected in the natural course of the disease, 
There is a paucity of longitudinal QOL data in HIV 
infection. A prospective study of QOL in the Cape Town HIV 
population, using the MOS SF-36, documented a significant 
decline in physical function, general health and physical 
component score (14) in symptomatic patients (including 
those with AIDS) at 1 year of follow-up (Table I). Lubeck and 
Fries were able to demonstrate deterioration in disability, 
general health, energy and symptoms even in 'asymptomatic' 
HIV patients at a mean of 9 months follow-up using the 
AIDS-HAQ (12). Neither study showed any changes in 
mental health scores with time. Prospective studies of health 
status in advanced HIV patients are likely to underestimate 
deterioration due to the high mortality of this group, as 
follow-up data will only be available for the 'sUTvivors' who 
are likdy to be healthier. 
It has been suggested that QOL is an independent predictor 
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Table I. Mean MOS scores in symptomatic HIV patients (WHO 
clinical stages 3 and 4) at baseline and 1 year follow-up 
Baseline One year p value'" 
Physical function 75 64 P < 0.05 
Role-physical 55 50 NS 
General health 49 42 P < 0.05 
Pain 57 52 NS 
Vitality 55 49 NS 
Social function 58 61 NS 
Role---emotional 53 52 NS 
Mental health 64 63 NS 
PCS 43 38 P < 0.05 
MCS 42 43 NS 
pes = physical component score, MCS = mental component 
score. 
"'Paired I-test (two-tailed), 
that the risk of death was greater in HIV patients who needed 
assistance with activities necessary for independent living 
than in those with no functional dependencies (15). However, 
in the Cape Town HIV outpatient population, MOS scores did 
not predict survival. Instruments specifically documenting 
functional dependence may be better able to predict survival 
than generic measures of functional status and well~being. 
CONCLUSIONS 
QOL assessment in HIV ~infected persons is important as an 
outcome measure in clinical trials, in determining specific 
needs of individuals or groups that might be amenable to 
therapy and in directing the appropriate use of healthcare 
resources. Instruments need to be adapted and validated for 
use in the different HIV populations and there is an urgent 
need for the development of QOL instruments referrable to 
Third World countries. 
A knowledge of the natural history of QOL in HIV 
infection is necessary to be able to interpret QOL data 
associated with clinical interventions. The deterioration in 
physical aspects of QOL associated with advancing HIV 
infection is largely attributable to disease~related symptoms, 
but psychological stress is apparent even in early 'asympto~ 
matic' disease. 
In the context of the vast scale of the HIV epidemic and the 
dwindling resources available for healthcare and social 
support in many countries, it is important to be able to 
identify areas where intervention can improve function and 
keep HIV -infected persons independent for as long as 
possible. QOL assessment will contribute significantly to 
our ability to do this. 
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Summary
C D 4 + T-lymphocyte (CD4) counts are a standard
laboratory marker of disease progression in HIV
infection, but expense precludes their use in large
parts of the world. Total lymphocyte counts (TLC),
in contrast, are widely available. We compared CD4
and TLC counts as predictors of developing AIDS
or death in 831 HIV-positive out-patients (582 males
and 249 females with both homosexual (males, n —
316) and heterosexual (n = 515) transmission pat-
terns. The first CD4 count <200/j i l and first TLC
< 1250/uJ predicted similar (p = 0.52) survival, irre-
spective of clinical stage. For each clinical stage, a
significant difference in progression to AIDS and
mortality was predicted by TLC above or below
1250/uJ (p<0.03). Survival and progression to
AIDS occurred at similar rates in patients with a
TLC < 1250/uJ or a CD4 count < 200/uJ (p>0.1) ,
and patients with a TLC > 1250/uJ or a CD4 count
>200/uJ (p>0.5) . A TLC < 1250/uJ preceded the
development of Pneumocystis carinii pneumonia or
cerebral toxoplasmosis in 76% of patients. In this
longitudinal study, TLC and CD4 counts were equal
predictors of disease progression. A TLC < 1250/uJ
could be considered an indication for commencing
cotrimoxazole prophylaxis.
Introduction
HIV infection can be monitored by laboratory1'2 and
clinical3'4 markers of disease progression. The CD4 +
T-lymphocyte (CD4) count is considered the best
laboratory marker of progression of HIV infection,1
but lacks uniform reproducibility,5 is a crude pre-
dictor of HIV disease progression when taken by
itself,6 and, because of expense, has limited availabil-
ity in both resource-poor and developed countries.7
In the absence of C D 4 + T-lymphocyte counts,
the use of total lymphocyte counts (TLC) has been
advocated to predict CD4 count8 and to stage HIV
disease.4'9 The use of the TLC as predictor of CD4 +
T-lymphocyte count is limited by the presence of
C D 4 + T-lymphophenia in up to 30% of non-
lymphopenic patients.8 However, a low TLC was
found to predict progression to clinical AIDS.2'10 This
longitudinal study compared total lymphocyte count
with CD4 count as predictor of developing AIDS
and death in lymphopenic and non-lymphopenic
HIV-positive patients.
Methods
Computer-based medical records of Somerset and
Groote Schuur Hospital HIV clinics, two principal
Western Cape HIV out-patient clinics, were analysed.
Patients had been staged clinically (retrospectively
from 1984 to 1991, prospectively from 1992
onwards) at each visit according to the WHO clinical
staging system,9 in which stage 4 is equivalent to
the 1987 Centres for Diseases Control (CDC) defini-
tion of AIDS.11 Paired CD4 and TLC values (n =
1965) were available in 831 patients. CD4 counts
were determined by flow cytometry and total
Address correspondence to Dr R. Wood, Department of Medicine, University of Cape Town Medical School, Anzio Road,
Observatory 7925, Cape Town, South Africa
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lymphocyte counts by automated blood cell counter.
Lymphopenia was defined as a TLC <1250/jil.
Survival was expressed as the Kaplan-Meier estim-
ate of cumulative probability of survival, and was
calculated in months from the index visit (first visit
at which CD4 or TLC occurred in the defined range)
to the date of death (not censored) or last visit
(censored). Similarly, AIDS-free survival was calcu-
lated from the index visit to the date of initial AIDS
diagnosis/death (not censored) or last visit (censored).
Survival curves were created for various degrees
of lymphopenia (increments of 250 lymphocytes)
and compared for closest fit to the curves of a CD4
count below 200 and 50/uJ. Optimal match of the
survival curve of a CD4 count <200/u,l was
achieved by a TLC <1250/uI Probability of AIDS-
free and overall survival was therefore determined
for each clinical stage and a TLC above or below
1250/|il or a CD4 count above or below 200/uJ.
Statgraphics version 6.0 was used to create Kaplan-
Meier plots and the log-rank test used to establish
statistical difference between survival curves.
Results
Patients of the two HIV clinics represented both
homosexual (n = 316) and heterosexual (n = 515)
transmission pattern, male (n = 582) and female {n =
249) sex, and the three local population groups
(Whites n = 280, Blacks n = 339, and mixed-race
n = 212). Intravenous drug abuse and haemophilia
did not occur as risk factors for HIV infection in
our patients.
A CD4 count <200/uJ occurred in 81% (547/675)
of total lymphocyte counts <1250/u,l, and a CD4
count >200/uJ was present in 80% (1032/1290) of
TLC >1250/uJ. A total lymphocyte count <1250/uJ
was 68% sensitive and 89% specific for a CD4 count
<200/uJ. ATLC >1250/|iloraCD4count >200/uJ
predicted the absence of clinical AIDS in 90% and
94% of patients, respectively. Survival of patients of
any clinical stage whose total lymphocyte count had
declined below 1250/|il was similar to the survival
of patients with a first CD4 count below 200/jil
(Figure 1). Survival of patients (n=132) with a first
TLC below 750/uJ was not statistically different (p =
0.37) from patients (n = 146) who had a CD4 count
below 50/|il (45% at 1 year and 20% at 2 years). In
lymphopenic patients (TLC<1250/uJ) as well as
patients with a CD4 count <200/jil, clinical stage
was a major determinant of mortality (Figure 2a,b).
Progression to AIDS and death occurred at signific-
antly (p<0.03) higher rates in lymphopenic patients
than in non-lymphopenic (TLC>1250/(jJ) patients
(Table 1). Mortality and progression to AIDS were
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Figure 1. Overall survival for HIV-positive patients from
the first CD4 count <200/uJ or first total lymphocyte
count <1250/uJ, regardless of WHO clinical stage.
of similar clinical stage and a TLC <1250/jxl or a
CD4 count <200/|il (Figure 2a-d), nor between
patients with a TLC > 1 250/JJ.I and patients with a
CD4 count >200/uJ (p>0.1, data not shown).
Pneumocystis carinii pneumonia (PCP) was diag-
nosed in 51 patients and cerebral toxoplasmosis in
eight. In the 12 months preceding the onset of PCP
or toxoplasmosis, a TLC <1250/u,l was present in
76% of these patients.
Discussion
The CD4+ T-lymphocyte count is considered the
best laboratory marker of progression of HIV infec-
tion,1 and serial CD4 count determinations are com-
monly used to monitor the degree of HIV-induced
immunosuppression. Low CD4 counts are indicative
of decreased cellular immunity, and are associated
with increased risk of developing AIDS or death. In
the absence of CD4 counts, the use of total lympho-
cyte counts has been advocated to predict CD4
count and to stage HIV disease.4'8'9 The usefulness
of the total lymphocyte count is best evaluated by
direct comparison with CD4 count as predictor of
end-points such as AIDS and death. This study found
CD4 and TLC to be equal predictors of progression
of HIV infection. The routine use of total lymphocyte
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Figure 2. Overall survival and AIDS-free survival for patients with CD4 counts <200/jxl and total lymphocyte counts
<1250/fil. p values represent log-rank comparison of survival curves.
Table 1 One-year Kaplan-Meier estimate of progression to clinical AIDS (WHO stage 1-3) and death (WHO stage A),
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reduce the costs associated with managing HIV
infection.
The WHO staging system incorporates the use of
TLC <1000/ 1000-2000 and > 2000/u.l to replace
CD4 counts <200, 200-500 and >500/uJ in its
laboratory axis.9 In Rwandan HIV-positive women,
few of whom had severe lymphopenia, a TLC above
or below 2000/uJ had no prognostic value.12 Our
results suggest that a TLC of 1250 rather than 10OO/jul
should be the equivalent of a CD4 count of 200/uJ,
and that the presence of a TLC above or below
1250/jul is associated with a significant difference in
rates of progression of HIV infection.
In two previous studies, patients of various WHO
clinical and/or laboratory stages were rearranged into
four 'modified stages', and survival was determined
for each 'modified stage'.412 In our patients, TLC
(and CD4 counts) added independent, prognostically
meaningful information to the WHO clinical stage
(Table 1). The stratification of patients by WHO
clinical stage and absence or presence of lymphop-
enia is easily performed and practical for the manage-
ment of HIV infection in resource-poor countries.
In advanced HIV infection, the total lymphocyte
count declines as a result of progressive depletion
of CD4 + T-lymphocytes, CD8 + T-lymphocytes and
B-lymphocytes.13 CD8 + T-lymphopenia was found
to be an independent predictor of mortality,14 and
the decrease in B-cells may further contribute to the
immunodeficient state associated with advanced HIV
infection. In our patients, severe lymphopenia (TLC
<750/uJ) predicted poor survival regardless of clin-
ical stage, and might reflect a high susceptibility to
opportunistic infections. In one study, systemic
Mycobacterium avium complex infection was
restricted to patients with severe lymphopenia (mean
540/u.l).15
Cotrimoxazole is effective prophylaxis against
toxoplasmosis, PCP and bacterial infections, and is
recommended for all patients with CD4 counts
<200/ui16 Although PCP is less common in Africa,
toxoplasmosis and bacterial infections are major
causes of mortality.17 As lymphopenia preceded the
development of PCP or toxoplasmosis in 76% of our
patients, a TLC < 1250/(4,1 could be considered a
criterion for instituting cotrimoxazole prophylaxis.
A TLC > 1250/uJ was only 4% less sensitive than
a CD4 count >200/jil as a predictor of the absence
of clinical AIDS. Using lymphopenia rather than
CD4 T-lymphopenia as a criterion for commencing
cotrimoxazole prophylaxis may thus select a slightly
smaller group of patients at risk for developing PCP.
Although we have shown the total lymphocyte count
to be equal to the CD4 count for overall prognosis,
its usefulness in individual patients as a criterion
for commencing prophylaxis needs to be studied
prospectively.
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mv has infected more than 10 million people in sub·Saharan Africa with prevalence rates of up to 30% 
reported from some countries. Adult transmission of HIV in Africa is mainly heterosexual and over half 
of new infections are in women, About 40% of infants born to HIV -positive mothers are themselves 
infected. Diarrhoea occurs in 90% of African AlDS patients and 'slim disease' (prolonged diarrhoea and 
wasting usually due to coccidian parasites) is pathognomic of AIDS in Central Africa. Dual infection 
with HIV and tuberculosis is a major problem. African AIDS patients appear to succumb to virulent 
pathogens, especially Mycobacterium tuberculosis, before they become sufficiently immunosuppressed to 
develop the opportunistic infections typically associated with advanced HIV disease in -developed 
countries. 
Key words: Africa; AIDS; coccidian parasites; diarrhoea; HIV; opportunistic infections; 'slim disease'; 
tuberculosis; wasting 
Elizabeth Anne O'Keefe, M.D., Dept of Medicine, Somerset Hospita~ Private Bag, Greenpoinl, 8051, 
South Africa (fox: + 27 21 402 6000) 
In 1994 the World Health Organization (WHO) estimated 
that the human immunodeficiency virus (HIV) had infected 
more than 16 million adults worldwide and that this figure 
would increase to 30-40 million by the end of the century, of 
whom 90% would be in developing countries (1). Sub-
Saharan Africa has b:een the site of nearly two-thirds of all 
HIV infections to date. 
The HIV epidemic in Africa has important differences from 
that in the USA and Europe. This review highlights some of 
these differences and focuses on the particular clinical 
problems encountered in sub-Saharan Africa. 
EPIDEMIOWGY OF HIV-l AND HIV-2 
The origin of HIV-1 is unproven, but it is closely related to 
other retroviruses present in tropical Africa, the simian 
immunodeficiency viruses which are endemic in African 
primates and HIV-2, which is highly prevalent in West 
Africa. HIV -1 has been present in Central Africa for more 
than 30 years (2-5) and has spread more recently to West and 
Southern Mrica. Central Africa still has the highest 
prevalence of infection, with rates of up to 20-30% in 
women attending antenatal clinics, 50% in people attending 
sexual1y transmitted disease clinics and 80% in female 
prostitutes (6). 
In South Africa HIV -1 seroprevalence is increasing 
rapidly: antenatal surveys in 1992 and 1994 showed a rise 
in the number of women infected nationally from 0.7% to 8% 
(7). As in other African countries, the distribution of infection 
is not uniform tending to be lower in rural and higher in urban 
areas. 
HIV -2 has been present in West Africa for at least 20 years 
and is still largely localized to this region (8, 9). It appears to 
be less easily transmitted and less virulent than HIV-l (10). 
Transmission of HIV amongst adults in Africa is mainly 
through unprotected heterosexual intercourse. The rapid 
spread of infection has been attributed to several factors, 
including the number of sexual contacts, multiplicity of 
sexual partners, availability of prostitution and necessity for 
men to work away from home for prolonged periods of time. 
Cultural factors, such as the importance of African women 
demonstrating their fertility, have undoubtedly played a role. 
Furthermore, the high prevalence of other sexually trans-
mitted diseases, particularly those that cause genital ulcera-
tion, might increase .the efficacy of transmission of the virus 
(11-13). The only country where homosexual transmission 
has played a significant role is South Africa and the epidemic 
there, especially in Cape Town, has features of both the North 
American and African epidemics. 
In sub-Saharan Africa, over half of new HIV infections are 
occurring in women of childbearing age (14). Published rates 
of mother-to-child transmission of HIV-l vary from 13 to 
45%, but rates of around 40% are typical in Mrica (15). This 
could result in 3-4 million HIV-infected children in sub-
Saharan Mrica by the end of the decade (6). 
GASTROINTESTINAL DISEASE 
Diarrhoea and ~slim disease' 
Diarrhoea occurs in nearly 90% of patients with advanced 
HIV infection in Central Africa compared with 30--60% in 
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Table I. Geographical differences in prevalence of enteric pathogens in HIV patients with diarrhoea 
Pathogen USA (23) Zambia (24, 25) Zaire (19) Uganda (26) 
Cryptosporidium 17% 25% 22% 48% 
Microsporidium 28% 33% NA NA 
Isospora 2% 25% 7% 13% 
Cytomegalovirus 17% 0% NA 0% 
MAl 10% 3% NA 1% 
USA (23). Endoscopy with biopsy, EM, stool microscopy, culture and parasitology. 
Zambia (24, 25). Small-oowel biopsy with EM, stool parasitology and m culture. 
Zaire (19). Stool microscopy, culture and parasitology. 
Uganda (26). Endoscopy 1: biopsy, stool micro~copy, culture and parasitology. 
NA. Appropriate investigations to detect pathogen not undertaken. 
South Africa, with only 30% of AIDS patients in Cape Town 
reporting three or more episodes of diarrhoea in the last year 
(17). Furthermore, prolonged diarrhoea associated with 
extreme wasting ('slim disease') (18) is present in up to 
73% of AIDS patients in Zaire (19) compared with only 11 % 
of a similar African population in Johannesburg, South Africa 
(20). 
Several factors may contribute to the increased prevalence 
of diarr boea in Central African HIV patients, amongst them 
are poor sanitation, contaminated food and water supplies, 
higher mean ambient temperature, unhealthy methods of food 
preservation and dose proximity to livestock. The lower 
prevalence of diarrhoea in South Africa may be partly 
attributable to the fact that the studies reported were 
conducted in urban areas where basic toilets and water are 
usually provided, but HIV -related diarrhoea does not appear 
to be a major problem in rural areas of the country either. 
The spectrum of gastrointestinal pathogens encountered in 
Africa is similar to that found in developed countries (Table J) 
but coccidian parasites (cryptosporidium, microsporidium 
and isospora) are responsible for the majority of cases of 
prolonged HIV-related diarrhoea and disease· due to myco-
bacterium avium intracellulare (MAl) and cytomegalovirus 
(CMV) is much less prevalent: this may be as a result of 
African AIDS patients dying of more virulent infections, 
particularly tuberculosis, before they are sufficiently immu-
nosuppressed to develop these late-stage infections (21). 
Shigellae and Campylobacter are commonly isolated from 
stools but, if treated, do not cause prolonged diarrhoea. 
Amoebiasis and strongyloidosis do not appear to be more 
common in HIV -infected persons and although there have 
been occasional reports of invasive amoebiasis, there is no 
evidence that strongyloidosis is more severe in HIV -infected 
persons (22). 
Tuberculosis was initially thought to be the major factor in 
the pathogenesis of 'slim disease' (27), but cryptosporidia, 
microsporidia and isospora have DOW been found in up to 77% 
of cases (19,24,26). Microsporidian infections are particu-
larly difficult to diagnose, often requiring facilities not 
available in African hospitals, and have now been shown to 
be responsible for many cases of prolonged diarrhoea that 
were previously considered to be pathogen negative. M. 
tuberculosis is occasionally found in stools of patients with 
AIDS-related diarrhoea but appears to have originated from 
pulmonary infections in the majority of cases (25,28). 
African patients with AIDS-related diarrhoea have evi-
dence of more marked villous atrophy and crypt hyperplasia 
than their European counterparts. This is associated with 
immune activation, which is probably multifactorial in origin, 
but may be related to small-bowel parasitic infections in Some 
cases (24). The higher prevalence of protein-calorie malnu-
trition in Africans would also predispose to the development 
of more severe enteropathy. 
Abdominal pain 
Abdominal pain is common at all stages of HIV infection 
(17). In early HIY infection the underlying pathology is 
similar to that in the non-HIV population, but with advancing 
immunosuppression opportunistic infections and tumours 
become dominant. The aetiology of abdominal pain in 
AIDS is thus related to the predominant opportunistic 
infections in the community and differs between Europe 
and Mrica (Table II) with the majority of cases in South 
African black and coloured patients being du~ to disseminated 
TB (29). 
Wasting 
The AIDS epidemic has hit sub-Saharan Mrica at a time of 
economic crisis associated with drought, crop failure and 
Table II. Main causative disorders of abdominal pain in AIDS 






Bacterial GI infections 
GI non-Hodgkin's lymphoma 
Acute pancreatitis 
MAl enteritis 
South Africa (29) 









NB. More than one diagnosis in some patients. 
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Fig. 1. The inteFaction between malnutrition and HIV infection. 
devastating wars. Malnutrition is therefore prevalent, espe-
cially in poor rural communities. Weight loss occurs in 
60-90% of AIDS patients in developed countries and is 
almost universal in Africa. Malnutrition and HIV are 
inextricably linked (Fig. 1). There is evidence that wasting 
in AIDS is associated with decreased survival (31), but few 
data suggest that it is possible to reverse the weight loss and 
improve the prognosis (32). Recent studies indicate that 
reduced energy intake at the time of secondary infection is the 
prime factor rather than increased total energy exp nditure 
(33). Clearly, the high prevalence of diarrhoea and premorbid 
protein-calorie malnutrition in Africa add to the risk of 
significant wasting. 
TUBERCULOSIS 
The World Health Organization estimates that there are 
between 3 and 5 million persons dually infected with M. 
tuberculosis and HIV, 70% of whom live in sub-Saharan 
Africa (34). Pulmonary and extra-pulmonary tuberculosis are 
the commonest 'opportunistic' infections encountered in 
African AIDS patients in contrast to Pneumocystis carinii 
pneumonia (PCP) in the USA and Europe (35-38) (Table 
III). Reactivation of latent tuberculosis due to immunosup-
pression is probably responsible for the majority of cases of 
AIDS in Africa 149 
HIV -related tuberculosis in Africa. The vast scale of the 
problem is emphasized by the high prevalence (60-70%) of 
latent tuberculosis in adult Africans (41,42). Even in 
countries with relatively low HIV seroprevalence up to a 
third of tuberculosis cases are in HIV -infected persons (Table 
IV). Thus, tuberculosis is a 'sentinel' marker for HIV in 
Africa (43). 
Tuberculosis is not always an easy diagnosis to make, as it 
is mimicked by other HIV -related diseases. Furthennore, the 
radiographic appearances of pulmonary tuberculosis in HIV-
infected persons are often atypical and may even appear 
normal in the severely immunosuppressed as they are unable 
to mount the typical fibrocavitary response (50). Extrapul-
monary disease is common in Africa, frequently involving 
lymph nodes, pleura and pericardium, and dissemination is 
frequently seen in those with advanced disease. 
The effect of tuberculosis on HIV progression is uncertain. 
Activation of the cellular immune system and cytokine 
production has been shown to increase mv replication in 
vitro, and there is limited data to indicate that morbidity and 
mortality are increased in African mY-infected patients who 
develop tuberculosis (45,51). 
The cornerstone of tuberculosis control remains early case 
identification and effective chemotherapy. Discussion of the 
different regimes used in Africa is beyond the scope of this 
article, but neither primary nor secondary prophylaxis is 
commonly used because of the concern that non-compliance 
will increase resistance to available drugs. In contrast to the 
North American experience, resistance to rifampicin a~d 
isoniazid does not appear to be specifically associated with 
HIV infection. 
NON-TUBERCUWUS PULMONARY INFECTION 
Pneumocystis carini': pneumonia appears to be less common 
in African patients but there is considerable variation in 
reporting with a prevalence of up to 22% in Zimbabwean 
HIV patients and less than 10% in other Central African 
countries (52). The prevalence in the Cape Town homosexual 
HIV population is similar to that reported from the USA 
Table III. Frequency of opportunistic infections in AIDS patients in South Africa (Cape Town), Central Africa (Kinshasa, Zaire) and the 
USA (New York) 
South Africa Central Africa (39) USA (40) 
Opportunistic infection (n = 314) (n = 64) (n = 1822) 
Extrapulmonary TB 29% 41% 5% 
Pneumocystis pneumonia 23% 2% 67% 
Kaposi's sarcoma 18% 16% 15% 
Oesophageal candidiasis 16% 31% 17% 
Herpes simplex < 1 month 12% NA 1% 
Wasting syndrome 12% 13% 3% 
Cryptococcal meningitis 7% 19% 5% 
Atypical mycobacteria 4%t NA 8%# 
Cerebral toxoplasmosis 3% 11% 10% 
tMycobacteria other than tuberculosis #Mycobacterium avium intracellulare. 
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Table IV. Relationship between the prevalence of mv and tuberculosis in sub-Saharan Africa 
mv prevalence of % TB cases 
Country general population HIV infected Year of study 
Uganda (44) 28%t 76%# 1992 
Zambia (45,46) 25%t 60% 1988-1990 
Malawi (47±) 23%t 75%# 1990-1994 
Ivory Coast (48,49) 2,4%'" 31% 1987-1990 
South Africa (7) l.3%t 330/"// 1994-1995 
(Cape Town) 
tAntenatal survey, #Hospitalized patients, *Random adult sample, :tA. D. Harries, personal communication, University of Malawi. 
(Table III). The explanation for the lower prevalence in 
Central Mrican patients is not clear as the organism is 
ubiqitous in Africa and antibiotic prophylaxis is not widely 
available. Furthermore, PCP often occurs relatively early in 
AIDS, in contrast to MAl and CMV. 
Pneumococcal pneumonia occurs with increased frequency 
in African HIV patients and is a significant cause of morbidity 
and mortality (53). Pulmonary cryptococcosis is seen in HlV 
infection in Central Africa and, if not treated, may 
disseminate to cause cryptococcal meningitis (54). Nocardio-
sis also occurs and may be confused with tuberculosis because 
of similar clinical and radiological features (52). 
OTHER INFECTIONS 
Bac;teraemia due to non-typhoid Salmonella organisms is 
very common in African HIV patients and may cause 
extraintestinal sepsis eg osteomyelitis. It is associated with a 
high mortality rate (55, 56). 
In contrast to North America, MAl has been infrequently 
isolated from African AIDS patients despite its presence in 
the environment. Even in the multiracial Cape Town AIDS 
population, MAl was grown in only 15% of positive 
mycobacterial blood cultures (57). As discussed above, the 
low prevalence of MAl may be due to African AIDS patients 
dying earlier from more virulent organisms, but there is also 
the possibility that previous exposure to M. tuberculosis 
confers some protection against infection with MAl (22). 
Cytomegalovirus, although prevalent in the community, 
rarely causes significant retinitis or enteritis in Africans (21), 
but does cause disease in homosexual AIDS patients in Cape 
Town (29). 
NEUROLOGICAL DISEASE 
There are very few data on HIV -related neurological disease 
in Africa and data that have been reported come from small 
postmortem series. Clinical studies are hampered by the lack 
of investigational facilities and the poor resources available 
for treatment. Dramatic increases in cryptococcal meningitis 
have been documented since 1981 (58, 59). Focal cerebral 
lesions in Central African HIV patients are reported to be 
about equally attributable to lymphoma, toxoplasmosis, 
tuberculosis and cryptococcosis (60,61) but, in the Cape 
Town experience, the majority of such lesions are attribu-
table to tuberculosis, often presenting in patients with 
disseminated disease already on anti-tuberculous therapy. 
HlV-RELATED TUMOURS 
Kaposi's sarcoma (KS) is endemic in Central Africa, but 
HIV-related KS behaves more aggressively. Epidemiological 
evidence has pointed to an infectious aetiology and recently 
herpes virus (HHV-8) DNA has been found in affected ceils 
but, as yet, its causative role has not been proven- (62). 
Involvement of the gastrointestinal tract with KS may cause 
bleeding and/or obstruction and infiltration of the lungs may 
lead to progressive respiratory failure. 
High-grade non-Hodgkin's lymphomas are associated with 
mv infection in developed countries. but there is a scarcity of 
data from Africa, which rna y be attributed to limited resources 
for investigation and a low postmortem rate. Childhood 
Burkitt's lymphoma in Africa does not appear to be 
associated with HN infection (63). 
CONCLUSIONS 
While the HIV epidemic has begun to plateau in developed 
countries, the incidence of new infections continues to rise in 
sub-Saharan Africa. The epidemic in Africa differs in that it 
affects young heterosexual adults rather than specific 
subgroups. The high prevalence of sexually transmitted 
diseases. together with social-. and cultuial factors, has 
contributed to the rapid 'spread 'of the epidemic in Africa. 
Many women of childbearing age have become infected and 
with a vertical transmission rate of about 40% large numbers 
of HIV-infected children and orphans are inevitable. 
Although the spectrum of HIV disease in Africa is similar 
to that in industrialized countries, infections with pathogenic 
organisms, particularly M. tuberculosis, predominate and 
opportunistic infections occur less commonly. This is 
attributable to the high prevalence of virulent organisms, 
poor access to healthcare and inadequate resources for 
diagnosis and treatment in Africa. The main burden of 
disease is related to the gastrointestinal tract and lungs. 










the maJonty of cases of prolonged diarrhoea and 'slim 
disease'. Tuberculosis (pulmonary and extrapulmonary) is the 
most frequent HIV -related illness and. is a 'marker' for HIV 
infection in Africa. 
The impact of the HIV epidemic in sub-Saharan Africa is 
not confined to those who are infected. Displacement of 
limited healthcare resources by HIV -infected persons has 
adverse consequences for those with other unrelated illnesses 
and for primary healthcare, especially amongst children. 
Furthermore, the struggling economies of the region have 
been affected by the loss of many HlV -infected professionals 
and skilled workers. The challenge presented by the human 
immunodeficiency virus in Africa is daunting, but while 
efforts to slow the spread of the epidemic through education 
have had limited success, progress has been made in defining 
the problems associated with HIV infection and this will 
allow the resources available to be directed against achievable 
goals. 
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CD4 Decline and Incidence of Opportunistic Infections
in Cape Town, South Africa: Implications
for Prophylaxis and Treatment
Charles B. Holmes, MD, MPH,*!" Robin Wood, FCP, MMed, DTM&H,§ Motasim Badri, PhD,§
Sophia Zilber, MS,! Bingxia Wang, MS,"¶ Gary Maartens, FCP, MMed, DTM&H,|| Hui Zheng, PhD,!"
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Objectives: To determine the rate of CD4 decline and the incidence
of opportunistic infections (OIs) among antiretroviral therapyYnaive
South African HIV-infected patients and inform timing of OI
prophylaxis.
Methods: We used mixed-effect models to estimate CD4 cell
decline by CD4 cell count strata in HIV-infected patients in the Cape
Town AIDS Cohort between 1984 and 2000. Stratum-specific OI
incidence per 100 person-years of observation was determined using
incidence density analysis.
Results: Nine hundred seventy-four patients with 2 or more CD4
cell counts were included. CD4 counts declined by 47.1 cells/KL per
year in the stratum with more than 500 cells/KL, 30.6 cells/KL
per year in the stratum with 351 to 500 cells/KL, and 20.5 cells/KL
per year in the stratum with 201 to 350 cells/KL. Tuberculosis and
oral candidiasis were the only OIs that occurred frequently in the
stratum with more than 200 CD4 cells/KL. Rates of chronic diarrhea,
wasting syndrome, tuberculosis, and oral and esophageal candidiasis
increased in the stratum with less than 200 cells/KL, and rates of all
OIs were highest in the stratum with 50 cells/KL or less.
Conclusions: CD4 cell count declines were dependent on CD4 strata
and can inform timing of clinic visits and treatment initiation in
South Africa. Incidence rates of OIs suggest that targeted OI
prophylaxis could prevent substantial HIV-related morbidity in
South Africa.
Key Words: HIV, opportunistic infections, CD4 cell count, South
Africa, prophylaxis
(J Acquir Immune Defic Syndr 2006;42:464Y469)
Despite the apparent similarity in disease survival fromHIV seroconversion to AIDS in sub-Saharan Africa and
industrialized countries,1,2 differences in laboratory and
clinical markers of progression have not been fully defined.
Such differences could have important implications for
clinical care and policy in sub-Saharan Africa, yet the
research and data necessary to formulate HIV guidelines in
the region are lagging far behind that used to create HIV
policies in the United States and Europe.3Y6
Reports from the United States and Europe suggest that
in HIV-infected patients not receiving combination antire-
troviral therapy (ART), CD4 cell counts decline from 36 to
77 cells/KL per year, with greater absolute declines associ-
ated with higher levels of HIV RNA and higher baseline CD4
cell counts.7,8 This information has been used extensively in
Western countries by clinicians making clinical decisions
about individual patients and by policymakers in the
development of guidelines for the outpatient management
of HIV-infected patients.5 However, it is not yet known
whether differences in viral subtypes, human leukocyte
antigen types, or other cofactors in sub-Saharan Africa affect
the rates of decline, although 2 small studies have suggested
slower declines.9,10
In addition, the relationship between CD4 cell counts
and the risk for specific opportunistic infections (OIs) is
poorly understood in sub-Saharan Africa. With high back-
ground rates of tuberculosis (TB) and other infectious
diseases in the general population, it is important to determine
when HIV-infected patients are at greatest risk so that
preventive measures and ART can be properly targeted.
However, there are limited numbers of large cohorts of HIV-
infected patients in sub-Saharan Africa and few that have
been followed systematically for long periods.
Our objectives were to estimate the CD4 count declines
over time and determine the incidence of OIs in an
established cohort of HIV-infected patients in Cape Town,
South Africa, in the absence of combination ART and to
examine the implications of these findings for the clinical
management of HIV disease in the region.
METHODS
Clinical Cohort
We analyzed data from patients enrolled in an
observational cohort from 2 public sector clinics affiliated
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with the University of Cape Town (Groote Schuur and New
Somerset Hospitals), which provided adult HIV care in Cape
Town, South Africa. The cohort has been described in detail
elsewhere.11Y14 Two thousand eighty-six patients were
confirmed to be HIV-infected and enrolled in the cohort
between 1984 and the end of 2000. The clinics mainly served
indigent communities, with a predominance of heterosexually
transmitted infection since 1991.11
Demographic information collected on the first visit
included date of birth, sex, marital status, race/ethnic
background, occupation, number of dependents, sexual pre-
ference, and HIV risk factors. HIV diagnosis was confirmed
on 2 separate blood specimens by enzyme-linked immuno-
sorbent assay and/or Western blot. Clinical information
collected on the first visit and each subsequent visit included
weight, diagnosis of OIs and other HIV-related complica-
tions, prophylaxis, and other medications dispensed. After
1992, clinical events meeting World Health Organization
(WHO) staging criteria were recorded, and a WHO clinical
stage was assigned, whereas patients with visits before 1992
were staged retrospectively.15 Laboratory data were collected
approximately every 6 months and included CD4 cell count,
blood count with differential, lymphocyte count, hemoglobin
level, platelet count, and erythrocyte sedimentation rate.
Some patients with a diagnosis of AIDS or with CD4 cell
counts of less than 200 cells/KL received cotrimoxazole
prophylaxis after 1993.16 In addition, zidovudine mono-
therapy was used, although infrequently.
The diagnosis of pulmonary and extrapulmonary TB
included both definite TB (culture of Mycobacterium
tuberculosis or an autopsy diagnosis) and probable TB (a
positive smear or a histologic diagnosis together with a
clinical response to short-course TB therapy). Diagnosis of
other diseases, including chronic diarrhea, cytomegalovirus
(CMV) retinitis, cryptococcal meningitis, herpes simplex
virus (HSV), esophageal candidiasis, oral candidiasis,
Pneumocystis jiroveci pneumonia (PCP), prolonged fever,
toxoplasmosis, and wasting syndrome were made if definitive
diagnosis was available or on standard presumptive grounds
as defined by the Centers for Disease Control and Preven-
tion.17 For this analysis, severe bacterial disease included all
WHO stage III bacterial diseases, including pneumonia,
bacteremia, pyomyositis, bone and joint infection, menin-
gitis, and empyema, and non-typhi Salmonella bacteremia, a
WHO stage IV diagnosis. When OIs were diagnosed,
standard therapy was available for all OIs with the exception
of CMV infection, for which access to antiviral therapy was
limited. In the event of death, the date was recorded in
hospital records or obtained from close contacts of the
patient. If a patient did not attend clinic after a 6-month
interval, research staff searched regional death records.
Statistical Analysis
CD4 Cell Count Changes
CD4 cell count changes were examined for the
following clinically relevant CD4 count strata: more than
500 cells/KL, 351 to 500 cells/KL, and 201 to 350 cells/KL.
Mixed-effect models were used to estimate mean CD4 cell
count change and standard deviation for each CD4 stratum
over a 12-month period.18 The model used CD4 decline as the
outcome variable, and covariates included time, baseline CD4
cell count, age, sex, and zidovudine monotherapy. To address
the issue of differential loss to follow-up between groups
(informative dropout), we fit a Cox proportional hazards
model using time to dropout as the outcome and CD4 cell
count as a time-dependent variable.
Incidence Density of OIs
Patients with 2 or more CD4 cell counts were included
in the OI incidence analysis. We used linear interpolation
between consecutive CD4 cell counts to estimate the time
spent in each CD4 stratum until the occurrence of the OI of
interest. The time spent in each CD4 stratum was summed,
yielding person-years of observation for each CD4 stratum. In
the case for which cotrimoxazole could have a substantial
preventative effect (toxoplasmosis, PCP, bacterial disease,
chronic diarrhea, prolonged fever, and wasting syndrome),
follow-up time was censored at the time of cotrimoxazole
initiation. OIs that occurred on the first visit were considered
prevalent infections and were not included in the main
analysis, and no further follow-up time was attributed to that
individual for that particular OI. Follow-up was also censored
on the date that patients were recruited away from the natural
history cohort and into clinical trials.
We defined the incidence rate of each OI as the number
of new cases of a specific infection occurring in a specific
CD4 stratum divided by the person-year for that CD4 stratum.
Poisson regression was used to examine whether OI incidence
rates differed by CD4 stratum and whether incidence rates
differed among specific OIs. The analysis was also performed
separately for men and women and for different racial/ethnic
groups. We also compared the demographic and clinical
characteristics of those included in the analyses with those
excluded because they had fewer than 2 CD4 cell counts.
RESULTS
Cohort Description
Of the 2086 patients in the cohort, 1766 had 2 or more
visits, and 974 of these had 2 or more CD4 cell count mea-
surements and were included in the study. Characteristics of
the study cohort are shown in Table 1. Those excluded from
the study were not significantly different in age, sex, race,
sexual preference, or mean baseline CD4 cell count, although
they did have significantly shorter mean follow-up time than
those included in the study (18.7 months vs 28.5 months;
P G 0.0001). The mean initial CD4 cell count for patients in-
cluded in the studywas 307.3 cells/KL (median, 262.0 cells/KL),
and on enrollment, 42.1% of patients had WHO stage I HIV
disease and 15.0% had stage IV HIV disease. One hundred
twenty-five patients received zidovudine monotherapy for
some time during the study period.
During follow-up, 306 deaths (31.4% of the study
population) were identified from hospital records and
regional death records, and 27 patients were recruited from
the cohort to clinical trials. Three hundred ninety-eight
patients (40.9% of study population) were lost to follow-up
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over the 16-year study period, an average rate of 2.6% per
year. Loss to follow-up did not differ significantly by race,
although a higher proportion of men were lost to follow-up
(47.7%) compared with women (37.0%) (P G 0.0001), and
those lost to follow-up were slightly younger (31.0 years)
than those not lost to follow-up (34.5 years) (P G 0.0001). In a
Cox proportional hazards analysis, CD4 cell count was not
significantly related to dropout (P = 0.75 in the age- and sex-
adjusted analysis, P = 0.68 in the unadjusted analysis).
CD4 Cell Count Decline
CD4 counts declined at the highest absolute rates (up to
47.1 cells per year) in those with more than 500 cells/KL and
declined at lower absolute rates in the lower strata (Table 2).
Multivariate analysis showed that baseline CD4 cell count had
a significant direct association with CD4 decline (P G 0.0001),
whereas age group (P = 0.83), sex (P = 0.19), race (P = 0.15),
and zidovudine monotherapy use (P = 0.25) did not.
Incidence of OIs
OIs diagnosed on the first visit were considered prevalent
OIs, and most common prevalent OIs included bacterial
infections (3.0%), extrapulmonary TB (7.4%), pulmonary TB
(11.4%), and oral candidiasis (15.7%). Incidence rate trends of
selected OIs are shown graphically in Figure 1; the number of
cases and incidence rates (with standard deviation) for each OI
by CD4 cell count stratum is shown in Table 3.
Incidence rates were significantly higher (P G 0.0001)
at lower CD4 cell counts for all OIs, with the highest rates
in the stratum of 50 cells/KL or less. In the CD4 stratum
with 50 cells/KL or less, the combined incidence of
pulmonary and extrapulmonary TB exceeded 20.0 per 100
person-years. Rates of chronic diarrhea, esophageal candidi-
asis, wasting syndrome, severe bacterial infection, and oral
candidiasis were over 10.0 per 100 person-years, and PCP,
cryptococcal meningitis, prolonged fever, HSV, and CMV
each had rates exceeding 6.0 per 100 person-years. From 51 to
200 CD4 cells/KL, the highest incidence rates were for TB,
chronic diarrhea, wasting syndrome, and oral and esophageal
candidiasis. TB and oral candidiasis occurred commonly with
CD4 cell counts of more than 200 cells/KL and were the only
OIs to occur in cell counts of more than 500 cells/KL (not
shown), with rates of 0.5 per 100 person-years and 4.1 per
100 person-years.
In a subanalysis of OIs by sex and racial/ethnic groups,
there was a significantly higher rate of PCP with 50 CD4
cells/KL or less (P G 0.001) in men (14.1/100 person-years)
compared with women (1.4/100 person-years) and a trend
toward higher rates in whites that was not statistically
significant. There were no other significant differences in OI
incidence by race.
DISCUSSION
We determined both CD4 cell count declines and
incidence rates of OIs in a large, established cohort of HIV-
infected patients in Cape Town, South Africa. Yearly CD4
cell count declines ranged from 47.1 cells/KL in the stratum
with more than 500 CD4 cells/KL to 20.5 cells/KL in the
stratum with 200 to 350 cells/KL stratum. The incidence of all
OIs increased significantly at lower CD4 cell count strata. TB
and oral candidiasis were diagnosed across all strata and were
the only OIs in the analysis to occur commonly in patients
with CD4 cell counts of more than 200 cells/KL. The most
frequently diagnosed OIs with cell count of lesser than
TABLE 2. CD4 Cell Count Declines by CD4 Count Stratum
CD4 Cell Count Stratum
(cells/KL)





*Adjusted for age and sex.
CI indicates confidence interval.
TABLE 1. Demographic and Clinical Characteristics of
HIV-1Y Infected Patients in the Cape Town Cohort
Characteristics






Mixed race 226 (24.5)
White 220 (23.8)
Risk behavior
Injection drug use 1 (0.3)
Blood transfusion 8 (2.1)








Duration of follow-up (mo) 28.5 T 23.3 [0.1Y170.5]
CD4 cell counts per person 3 {2Y5} [2Y17]
Baseline CD4 307.3 T 227.5 [1Y1351]
262.0 {133Y427}











Values are given as n (%), mean T SD, median {IQR}, and [range].
N = 974 (subject to missing data). Percentages were calculated for complete data.
IQR indicates interquartile range.
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200 cells/KL included TB, oral and esophageal candidiasis,
chronic diarrhea, and wasting syndrome.
These results come from one of the largest cohorts in the
region, which also has the advantage of being an ethnically and
sex-diverse group of HIV-infected patients not concentrated in
a specific occupation. Although the range of CD4 cell count
declines we report overlaps with ranges reported elsewhere in
the United States and Europe, mean declines in South Africa
(not stratified by viral load) seem generally lower.7,8,19 In the
United StatesYbased Multicenter AIDS Cohort Study, the
range of reported CD4 cell count declines ranged from
36 cells/KL (viral load, e500 copies/mL) to 77 cells/KL per
year (viral load, 930,000 copies/mL), although the mean
starting CD4 cell count of 527 cells/KL was higher than that
in this cohort.7 Studies fromZambia and Tanzania also reported
lower estimated CD4 cell count declines from 15.0 to
26.9 cells/KL per year in HIV-seroprevalent patients, but
were limited by small sample size.9,10 The findings in the
present study suggest that methodologic and sample size
considerations may have accounted for some of these earlier
reports of substantially slower declines from sub-Saharan
Africa, although stratification by viral load is necessary
before drawing further conclusions.9,10
The approach we took to estimation of OI incidence
density has been used in both the United States and Europe
and yields clear information about when OIs occur during the
natural history of HIV infection.19,20 Although use of this
methodology makes it difficult to compare our results directly
with other African studies, several trends were consistent
between our studies and others. First, the distribution of TB
incidence across all CD4 strata in this study was also seen at
TB diagnosis in studies from South Africa and Kenya.21,22
Likewise, the finding that cryptococcal disease, CMV, and
toxoplasmosis occurred almost exclusively in the stratum
FIGURE 1. Trends in the incidence of OIs by CD4 cell count strata.
TABLE 3. Incidence of OIs Among HIV-Infected Patients in Cape Town, South Africa
OI
e50 cells/KL 51Y200 cells/KL 201Y350 cells/KL 9350 cells/KL P (for
Trend)Cases IR (95% CI) Cases IR (95% CI) Cases IR (95% CI) Cases IR (95% CI)
Oral candidiasis 64 42.7 (32.2Y53.2) 122 24.7 (20.3Y29.1) 69 15.2 (11.6Y18.8) 50 6.9 (5.0Y8.8) G0.0001
Chronic diarrhea 24 24.3 (14.6Y34.0) 24 5.9 (3.6Y8.3) 9 2.2 (0.8Y3.6) 0 0.0 G0.0001
Esophageal candidiasis 38 17.7 (12.1Y23.4) 27 4.1 (2.5Y5.6) 6 1.1 (0.2Y1.9) 3 0.7 (0.0, 1.5) G0.0001
Wasting syndrome 12 15.6 (6.8Y24.5) 10 2.8 (1.1Y4.5) 1 0.2 (j0.2Y0.7) 0 0.0 G0.0001
Severe bacterial 31 13.9 (9.0Y18.8) 3 0.5 (0.0Y1.0) 2 0.4 (0.0Y0.9) 0 0.0 G0.0001
Pulmonary TB 31 13.9 (9.0Y18.7) 52 8.5 (6.2Y10.8) 30 5.7 (3.7Y7.8) 10 1.3 (0.5Y2.0) G0.0001
Extrapulmonary TB 26 11.8 (7.3Y16.3) 36 5.7 (3.8Y7.6) 12 2.2 (1.0Y3.4) 5 0.6 (0.1Y1.2) G0.0001
PCP 17 8.1 (4.2Y11.9) 4 0.6 (0.0Y1.2) 2 0.3 (0.0Y0.9) 0 0.0 G0.0001
HSV 17 7.3 (3.8Y10.7) 12 1.8 (0.8Y2.8) 7 1.3 (0.3Y2.2) 3 0.4 (0.0Y0.8) G0.0001
CMV 16 6.8 (3.5Y10.1) 2 0.3 (0.0Y0.7) 0 0.0 1 0.1 (0.0Y0.4) G0.0001
Cryptococcal meningitis 15 6.3 (3.1Y9.5) 6 0.9 (0.2Y1.6) 1 0.2 (0.0Y0.5) 0 0.0 G0.0001
Prolonged fever 5 6.2 (0.8Y11.7) 2 0.6 (j0.2Y1.4) 0 0.0 0 0.0 G0.0001
Toxoplasmosis 3 1.2 (0Y2.6) 0 0.0 0 0.0 0 0.0 V
IR indicates incidence rate per 100 person-years; CI, confidence interval.
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with 50 CD4 cells/KL or less was consistent with the low
median CD4 cell counts reported for these diseases in South
Africa and elsewhere in sub-Saharan Africa.21,23,24 Although
we found relatively high rates of PCP with CD4 counts of
50 cells/KL or less, there was a nonsignificant trend toward
a lower rate in blacks.21,25 It is also possible that delays in
PCP diagnosis, while ruling out TB and treating empirically
for bacterial disease, may have underestimated the incidence
rate with CD4 counts of more than 50 cells/KL.
The results of this study suggest that targeted prophy-
laxis could have a large impact on reducing OIs, the reduction
of which may be a key to reducing long-term mortality in
HIV-infected patients.26,27 Although the data on efficacy of
primary prophylaxis of TB are mixed, current WHO guide-
lines recommend isoniazid preventive therapy in countries
with good TB treatment programs in place.28Y31 We found
that the risk for TB in South Africa is highest when CD4 cell
counts decline to 500 cells/KL or less, which suggests that
this CD4 count may be the appropriate threshold if isoniazid
is used for primary prophylaxis in this setting. Recent data
also suggest a possible role for secondary prophylaxis in
patients initiating ART with a clinical history of TB.32
Additionally, existing provisional WHO guidelines on
cotrimoxazole preventive therapy suggest it should be
targeted to HIV-infected persons with stage II or higher
HIV disease, those with a CD4 cell count of 500 cells/KL or
less, and pregnant women who are in their second or third
trimester. These recommendations were based in part on 2
randomized controlled trials of daily double-strength (800/
160 mg) cotrimoxazole from Côte d’Ivoire.4,33 A cohort from
Cape Town that overlapped in part with our study population
found benefit of single-strength cotrimoxazole only in those
with CD4 cell counts 200 cells/KL or less (or TLC e 1250)
and/or WHO stage III or IV disease.16 The present analysis
included patients before cotrimoxazole prophylaxis was used
and censors follow-up time after its introduction for the
incidence of OIs potentially preventable by cotrimoxazole
(bacterial infection, PCP, toxoplasmosis, chronic diarrhea,
prolonged fever, and wasting syndrome). We found that
cotrimoxazole-preventable infections occurred rarely in
patients with CD4 counts of more than 200 cells/KL, and
thus, this does not suggest a role for cotrimoxazole
prophylaxis in this region above 200 cells/KL.
The high rate of cryptococcal disease in the stratum
with 50 cells/KL or less and the high case-fatality rate of this
infection in other cohorts would seemingly make it a prime
target for prevention if prophylaxis was effective and
available.21,23,24 Although no trials of fungal prophylaxis
have been reported from sub-Saharan Africa, 2 recent
randomized controlled trials from Thailand resulted in a
significant decrease in systemic mycoses, of which most were
cryptococcal disease.34,35 Fungal prophylaxis may be appro-
priate for consideration in South Africa both before wide-
spread availability of ART and as an adjunct when ART is
initiated at very low CD4 cell counts.
This study has several limitations. About half of the
patients initially enrolled in the Cape Town cohort had less
than 2 CD4 cell counts during their follow-up and, therefore,
could not be included in the main study. Although these
patients had shorter follow-up time, they were not different
with regard to their demographics or baseline CD4 cell counts
than those included. Conversely, the patients who were
recruited away from the cohort to clinical trials may have
been healthier, although this number was small. Although
loss to follow-up in this study was similar to that in the United
StatesYbased Multicenter AIDS Cohort Study, differential
losses to follow-up are a concern in longitudinal studies.36Y38
However, we did not find evidence of informative dropout
based on severity of disease, as measured by CD4 cell count.
In addition, HIV RNA testing was not widely available in
Cape Town during the period of this analysis. Therefore, we
were unable to report mean CD4 cell count declines stratified
by viral load. Lastly, we did not have information on patients’
history of OIs before study enrollment. If significant numbers
of patients had prior OIs (eg. TB), they would have been at
higher risk for recurrence, and we would have overestimated
the incidence of those particular OIs.
In conclusion, we report stratum-specific CD4 cell
count declines that can be used to inform the development of
algorithms for clinical management of HIV in South Africa.
We found that rates of OIs in Cape Town increased
significantly at lower CD4 cell count strata. Those OIs with
the highest incidence at lower CD4 cell counts included TB,
bacterial infections, chronic diarrhea, oral and esophageal
candidiasis, wasting syndrome, and cryptococcal disease.
These results suggest a large potential health gain from
maximization of preventive therapies, especially early
isoniazid preventive therapy, and cotrimoxazole in patients
with 200 CD4 cells/KL or less and prophylaxis against
cryptococcal disease with 50 CD4 cells/KL or less. Further
work is needed to better quantify the benefits of these
interventions in South Africa and to expand the availability of
effective therapies.
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Introduction
WHO estimated in June, 2005, that 4·7 million people 
living in sub-Saharan Africa were in urgent need of 
antiretroviral treatment (ART).1 Several initiatives to 
achieve large-scale delivery of ART to people infected with 
HIV in resource-limited countries have been launched. 
Despite formidable logistical challenges, the number of 
individuals receiving treatment is steadily increasing.2 
UNAIDS/WHO estimated that 250 000–350 000 deaths 
were averted in 2005 in low-income and middle-income 
countries as a result of widened access to HIV treatment.2 
Community-based and hospital-based studies from South 
Africa have shown that ART is a reasonably cost-e! ective 
public-health intervention.3–5 However, there are limited 
data on which to base recommendations for when ART 
should be started in these settings.
Clinical stage of disease, CD4-cell count, and viral load 
are all well established predictors of prognosis in HIV-
infected people.6–12 Treatment in high-income countries is 
largely based on the presence of symptoms and on CD4-
cell count; additionally, viral load may be used to stratify 
risk in asymptomatic patients with CD4-cell counts of 
200 cells per µL or more.13–15 Guidelines for the treatment 
of individuals in low-income countries are based on WHO 
stage of disease and CD4-cell count.16 These guidelines 
are now being revised,17 but the scarcity of relevant data 
from resource-poor settings is a hindrance to this process. 
Thus while acknowledging the limitations of such an 
approach, some have attempted to model rates of disease 
progression in resource-poor settings with use of data 
from European cohorts.18
Historically, guidelines have been based on fi ndings of 
studies that have assessed long-term risk of disease 
progression. However, fi ndings of the CASCADE 
collaborative analysis of observational data from 
20 cohorts in Europe and Australia underscore the 
importance of short-term risk assessment of disease 
progression for informing decisions on when to start 
ART.19 No such data exist for individuals living in 
resource-poor settings. Furthermore, in most guidelines 
from developed countries, recommendations about when 
to initiate ART are mainly on the basis of aversion of the 
risk of AIDS. However, risk of death should also be 
considered. We therefore undertook this analysis of data 
from the Cape Town AIDS Cohort (CTAC) study to fi nd 
out the short-term risk of AIDS, death, and combined 
risk of AIDS and death according to current CD4-cell 
count and WHO stage of disease in patients who had 
either no access to ART or who received zidovudine 
monotherapy. 
Short-term risk of AIDS or death in people infected with 
HIV-1 before antiretroviral therapy in South Africa: 
a longitudinal study
Motasim Badri, Stephen D Lawn, Robin Wood
Summary
Background In sub-Saharan Africa, data for short-term risk of AIDS or death, which might inform decisions about 
when to start antiretroviral therapy (ART), are scarce. Our aim was to investigate these risks in patients who had no 
access to ART or who were given zidovudine alone.
Methods 6-month risks (%) of death, AIDS, and combined risk of AIDS and death (AIDS/death) were calculated 
according to CD4-cell count category of less than 200 cells per !L, 200–350 cells per !L, or greater than 350 cells per !L, 
stratifi ed by WHO clinical stages 1 and 2 combined, 3, or 4 in untreated patients (n=1399) seeking care in tertiary 
public-sector HIV clinics before widespread availability of ART in Cape Town, South Africa. 
Findings Risk of death for WHO stages 1 and 2 was 3·5% for those with less than 200 cells per ! L, 2·8% for 
200–350 cells per !L, and 1·2% for greater than 350 cells per !L. The corresponding rates for WHO stage 3 were 
10·8%, 4·3%, and 4·9% and for stage 4, 22·2%, 10·3%, and 13·8%. 52% (90) of deaths took place in patients without 
AIDS. 6-month risk of AIDS for WHO stages 1 and 2 was 3·5% for those with less than 200 cells per !L, 1·6% for 
200–350 cells per !L, and zero for greater than 350 cells per !L. The corresponding rates for those with WHO stage 3 
disease were 17·4%, 7·0%, and 2·2%.
Interpretation In this study, risk of AIDS in patients with a CD4-cell count of less than 200 cells per !L or greater than 
350 cells per !L was similar to that previously reported from European cohorts, but was 1·9 times greater for those 
with CD4-cell counts of between 200 and 350 cells per !L. The high death rate before development of AIDS and a 
high risk of AIDS in those with CD4-cell counts of 200–350 cells per !L indicate that delay in initiation of ART is 
associated with increased morbidity and mortality. These fi ndings might help to amend criteria for start of ART in 
resource-limited settings. 





Desmond Tutu HIV Centre, 
Institute of Infectious Disease 
and Molecular Medicine, 
Faculty of Health Sciences, 
University of Cape Town, 
Observatory 7925, Cape Town, 
South Africa (M Badri PhD, 
S D Lawn MD, R Wood FCP); and 
Clinical Research Unit, 
Department of Infectious and 
Tropical Diseases, London 
School of Hygiene and Tropical 
















www.thelancet.com   Vol 368   October 7, 2006   1255
Methods
Participants 
Details of the CTAC study methods have been described 
elsewhere.20,21 The cohort consisted of people with HIV 
infection living in urban areas who had been referred from 
a wide range of primary health-care facilities between 1992 
and 2005 to tertiary public-sector HIV clinics in Cape 
Town. Individuals were eligible for inclusion in this study 
if they were not receiving ART (except for zidovudine 
monotherapy) and if a current CD4-cell count was available 
at the start of any 6-month period of assessment. Protocols 
of the CTAC study were approved by the University of 
Cape Town clinical research ethics committee.
Procedures
The analyses undertaken in this study were based on the 
methods described in the CASCADE study, with minor 
modifi cations.19 In separate analyses, we calculated 
6-month risk of death, progression to AIDS, and 
progression to a combined endpoint of a new AIDS-
defi ning disease or death (AIDS/death). In the analysis 
with death as the endpoint, all eligible patients were 
included. In the other two analyses, patients already 
diagnosed with AIDS, as defi ned by WHO clinical staging 
criteria,22 were excluded. Death was identifi ed from 
patients’ records and hospital or municipality death 
registry.
In three analyses, we divided duration of event-free 
follow-up into nine strata defi ned by three categories of 
CD4-cell count (<200 cells per "L, 200–350 cells per "L, 
and >350 cells per " L), and stratifi ed further by three 
WHO clinical stages (stage 1 and 2 combined, stage 3, 
and stage 4). In every stratum, we recorded the duration 
of event-free follow-up from the date the patient fi rst 
entered the respective stratum until the date of 
progression to another stratum, loss to follow-up, or until 
death or diagnosis of AIDS were recorded. To limit the 
analysis to 6 months, event-free follow-up in each stratum 
was censored after 6 months from date of entry into the 
respective stratum. Thus any event-free follow-up or 
endpoint for which CD4-cell count had not been 
measured in the preceding 6 months was not included in 
the analysis. However, a patient could contribute further 
event-free follow-up if they became eligible again at any 
later follow-up point. The time spent in each CD4 stratum 
was summed, yielding total patient-years of follow-up for 
each.
Statistical analysis
We calculated rates for all endpoints by dividing the 
number of endpoints by the patient-years of follow-up in 
the respective stratum.
Patients with appreciably di! erent CD4-cell counts in 
each CD4-cell count and WHO stage stratum were used 
as the basis for calculations of rates and estimates of 
6-month risk of AIDS, death, and AIDS or death. This 
method was used because every stratum had to be of 
su#  cient size for rates to be calculated with reasonable 
precision, and these estimates were not adjusted for the 
potential confounding e! ect of other variables. Thus we 
fi tted univariate and multivariate Poisson regression 
models to explore the potential confounding e! ects of 
age, sex, socioeconomic status (as defi ned by Cape 
Metropolitan Council suburbs composite index20,21), and 
ART monotherapy on risk of AIDS, death, and AIDS or 
death, using a separate model for each. We considered 
for inclusion in the fi nal model fi tted to generate the 
6-month-risk prediction, variables that were signifi cantly 
associated with the likelihood of AIDS, death, or AIDS or 
death. To improve the fi t of the model, we used the square 
root value of CD4-cell count instead of the absolute value. 
We fi tted a separate model for each WHO clinical stage. 
Incidence rates and predicted 6-month-risk (%) rates are 
presented. 
In all models fi tted, only CD4-cell count and WHO 
clinical stage were independently associated with risk 
of the three endpoints studied. Therefore, only these 
two variables were considered in the further 
analyses. For any CD4-cell count, the rate for each 
endpoint was calculated by WHO clinical stage as: 
rate=exponential($+[%&{CD4-cell count}]), where $ is the 
slope and %  is the coe#  cient of the CD4-cell count 
calculated in the Poisson regression models. Based on 
the assumption that the rate was constant for 6 months, 
the 6-month risk (%) was calculated as (1 – exp [–0·5 rate]).12 
The predicted rate for each of these endpoints can be 
calculated using the formulae shown in table 1.
Role of the funding source
The sponsor of the study had no role in the study design, 
data collection, data analysis, data interpretation, or writing 
of this report. The corresponding author had full access to 
all the data in the study and had fi nal responsibility for the 
decision to submit for publication.
Results 
Of all patients recruited into CTAC between 1992 and 
2005, 1399 fulfi lled the eligibility criteria for inclusion in 
our analysis. Table 2 shows baseline demographic and 
WHO clinical 
stage
AIDS 1 or 2 exp(0·11–0·259![CD4–cell count]))
3 exp(0·309–0·152![CD4–cell count])
AIDS or death 1 or 2 exp(–0·44–0·138![CD4–cell count])
3 exp(0·385–0·116![CD4–cell count])




Table !: Formulae for calculation of the rate of AIDS, AIDS/death, 
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clinical characteristics. The study included young adults 
with a wide spectrum of baseline CD4-cell counts and 
WHO clinical stages, only a few of whom received 
zidovudine monotherapy. Median follow-up was 
16·6 months (IQR, 8·7–29·3 months). A median of fi ve 
measurements of CD4-cell count (IQR, 2–11) were 
available per patient.
Overall, incidence of death was 0·1 (95% CI 0·1–0·2) 
per patient-year. 14% (n=24) of deaths occurred in patients 
with WHO stage 1 or 2 disease, 38% (66) in those with 
WHO stage 3 disease, and 48% (82) in those with stage 4 
disease. Thus 52% (52) of patients who died had not been 
diagnosed with AIDS. Both the rate and 6-month risk of 
death were signifi cantly higher in patients with advanced 
immunodefi ciency and symptomatic disease than in those 
in higher CD4-cell-count categories and earlier WHO 
clinical stages (table 3). In patients with stage 3 or 4 disease, 
the rate and risk of death did not di! er between those with 
CD4-cell counts of 200–350 cells per "L and those with 
more than 350 cells per "L. 
In 1009 patient-years of follow-up, 111 new AIDS events 
were identifi ed in patients without previously diagnosed 
AIDS, yielding an incidence rate of 0·11 events per 
patient-year (95% CI 0·09–0·13, table 4). The risk of 
progression to AIDS was greater for patients with low 
CD4-cell counts than for those with high counts, and was 
also much greater for those with WHO stage 3 disease 
than for those with stage 1 or 2 disease (table 4). The 
6-month risk of AIDS ranged from zero in patients with 
a CD4-cell count of more than 350 cells per "L and WHO 
stage 1 or 2 disease to almost 20% in patients with CD4-
cell counts of less than 200 cells per "L and WHO stage 3 
disease. The pattern for the rate of progression to AIDS 
across the CD4-cell count and WHO stage strata was 
similar to that for risk of death (table 4). 
Overall, 179 AIDS or death events took place in the 
964 patient-years of follow-up (incidence rate=0·19, 95% CI 
0·16–0·22 per patient-year). The combined rate of AIDS/
death ranged from 0·02 per patient-year for patients with 
the highest CD4-cell count and lowest stage, to 0·54 per 
patient-year in those with the lowest CD4-cell count and 
stage 3 disease (table 4). The 6-month risk ranged from 
just greater than 1 to nearly 24 for the same CD4-cell count 
and stage strata. Both rate and 6-month risk of death 
increased with more advanced immune suppression and 
clinical disease (table 4).
The fi gures 1 and 2 show that both WHO clinical 
stage and CD4-cell count were strong predictors of the 
6-month risk of AIDS, death, and AIDS/death according 
to our regression models. The risk of all endpoints rose 
steeply as CD4-cell counts fell from 200 cells per " L 
(fi gure 2). However, the risk for each of the endpoints 
also increased as the CD4-cell count decreased from 
350 cells per "L to 200 cells per "L. In particular, the 
risk of AIDS and AIDS/death increased appreciably in 
those with WHO stage 3 disease in this CD4-cell count 
range. Also, for any specifi c CD4-cell count, risk of 
death in people with stage 3 disease was about double 
that for those with stage 1 or 2 disease and risk of death 
in people with WHO stage 4 disease was about double 
that of those with WHO stage 3 disease (fi gure 2). 
Discussion
We have derived short-term estimates of the risk of 
death, AIDS, and combined risk of AIDS or death 
according to CD4-cell count and WHO clinical stage. 
The short-term risk of death in individuals without a 
previous AIDS diagnosis was alarmingly high. The 
Number 
Male 852 (61%) 
Female 547 (39%)
Age, (years)* 32 (27–37)
Socioeconomic status 
High status 913 (65%)
Low status 486 (35%)
Monotherapy ART use 55 (4%)






1 and 2 757 (54%)
3 461 (33%)
4 181 (13%)
ART=antiretroviral therapy. Data are number (%), unless otherwise indicated. 
*Median (IQR).
Table ": Baseline demographic and clinical characteristics of the 
cohort studied (n=1399 patients)
Patient years Number of 
events
Rate, deaths per patient-
years (95% CI)
6-month risk of death, 
% (95% CI)
WHO stage 1 or 2
<200 cells per µL 98·2 7 0·07 (0·03–0·15) 3·50 (1·43–7·09)
200–350 cells per µL 158·1 9 0·06 (0·03–0·11) 2·81 (1·29–5·26)
>350 cells per µL 347·1 8 0·02 (0·01–0·05) 1·15 (0·50–2·25)
WHO stage 3
<200 cells per µL 221·1 47 0·21 (0·16–0·28) 10·08 (7·52–13·19)
200–350 cells per µL 113·8 10 0·09 (0·04–0·16) 4·30 (2·08–7·75)
>350 cells per µL 89·7 9 0·10 (0·05–0·19) 4·89 (2·26–9·06)
WHO stage 4
<200 cells per µL 145·5 73 0·50 (0·39–0·63) 22·19 (17·91–27·13)
200–350 cells per µL 22·9 5 0·22 (0·07–0·51) 10·34 (3·47–22·40)
>350 cells per µL 13·5 4 0·30 (0·08–0·79) 13·78 (4·11–32·56)
Total
<200 cells per µL 464·8 127 0·27 (0·23–0·33) 12·77 (10·86–15·21)
200–350 cells per µL 294·9 24 0·08 (0·50–0·12) 3·99 (2·57–5·87)
>350 cells per µL 450·4 21 0·05 (0·03–0·07) 2·30 (1·49–3·44)
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rates of clinical events in people with CD4-cell counts of 
between 200 and 350 cells per "L was higher than those 
reported in high-income countries.
Whereas previous studies have used laboratory or 
clinical markers to measure HIV disease progression in 
sub-Saharan Africa,23–30 we focused on assessment of 
short-term risk of AIDS or death using CD4-cell count 
and WHO clinical stage. This distinction is important 
because health-care providers use these criteria when 
deciding when to start ART. The fi ndings of this study 
highlight the importance of assessment of not only 
short-term risk of AIDS, but also short-term risk of 
death when considering initiation of ART in resource-
limited settings, where delayed access to treatment 
might account for up to two-thirds of early deaths in 
patients accessing ART programmes.31,32 Our data are 
important to the continuing e! orts to formulate and 
refi ne operational guidelines for scaling up access to 
treatment in resource-limited countries.
In previous analyses we have shown that WHO clinical 
stage could be used to identify patients who will benefi t 
most from ART programmes, and that this measure 
could provide prognostic information independent of 
CD4-cell count.20,21 Present WHO guidelines for initiation 
of ART in resource-limited settings largely recommend 
use of WHO clinical stage, but also that of CD4-cell counts 
where available, especially for asymptomatic patients.16 
This study shows that combined use of data for WHO 
clinical stage and CD4-cell count can be used to accurately 
assess short-term risk of AIDS and death. Although the 
cost of routine laboratory testing remains one of the major 
barriers for increased access to treatment in sub-Saharan 
Africa,33 these data nevertheless support moves to expand 
the use of measurement of CD4-cell count.
This study is strengthened by the use of three important 
endpoints. Consideration of risk of death and combined 
risk of AIDS or death when the need for treatment is 
assessed is especially important in this setting, since the 
6-month risk of death is high, amounting to 15% in our 
cohort.21 52% of deaths occurred in individuals without a 
previous AIDS diagnosis, indicating that WHO stage 3 
disease is associated with a high mortality risk in this 
setting. Analysis of clinical progression that relies on 
AIDS diagnosis alone might have underestimated the 
6-month risk of disease progression by misclassifying 
some patients as non-progressors for whom recording of 
an AIDS event was delayed until the next scheduled visit. 
Misclassifi cation might well happen in AIDS-defi ning 
illnesses such as extrapulmonary tuberculosis, in which 
laboratory confi rmation of diagnoses might be delayed. 
The patterns of average estimates of short-term AIDS 
risk by CD4-cell-count categories in this study are in 
agreement with fi ndings from the CASCADE collaborative 
analysis of European and Australian cohorts.19 Comparison 
Current CD4-cell count























Figure !: Predicted 6-month risk of AIDS, death, and AIDS or death in the 
whole group
AIDS AIDS or death





6-month risk of 
AIDS, % (95% CI)





6-month risk of 
AIDS or death, 
% (95% CI)
Stage 1 or 2
<200 97·1 7 0·07 (0·03–0·15) 3·5 (1·4–7·2) 97·1 14 0·14 (0·08–0·24) 7·0 (3·9–11·4)
200–350 157·3 5 0·03 (0·01–0·07) 1·6 (0·5–3·7) 157 13 0·08 (0·04–0·14) 4·1 (2·2–6·8)
>350 347·1 0 0 0 347·1 8 0·02 (0·01–0·05) 1·2 (0·5–2·3)
Stage 3
<200 206·9 79 0·38 (0·30–0·48) 17·4 (14·0–21·2) 204·4 110 0·54 (0·44–0·65) 23·6 (19·9–27·7)
200–350 110·7 16 0·14 (0·08–0·23) 7·0 (4·0–11·1) 110·5 24 0·22 (0·14–0·32) 10·3 (6·7–14·9)
>350 89·7 4 0·04 (0·01–0·11) 2·2 (0·6–5·5) 48·4 10 0·21 (0·10–0·38) 9·8 (4·9–17·4)
Total
<200 304·0 86 0·28 (0·23–0·35) 13·2 (10·9–16·1) 301·5 124 0·41 (0·34–0·49) 18·6 (15·6–21·7)
200–350 268·0 21 0·08 (0·05–0·12) 3·8 (2·5–5·8) 267·5 37 0·14 (0·09–0·19) 6·7 (4·8–9·1)
>350 436·9 4 0·01 (0·003–0·02) 0·5 (0·2–1·0) 395·6 18 0·05 (0·03–0·07) 2·3 (14·5–3·4)
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of the average predicted 6-month risk of AIDS in the two 
cohorts (adjusted for factors associated with risk of AIDS 
and calculated for individual CD4-cell counts) show that 
the risk estimates were strikingly similar. The unadjusted 
average 6-month estimates of the risk of AIDS of 13·2% 
and 0·46% calculated in our study are in accord with that 
of 14·9% and 0·54% that could be calculated in the 
CASCADE study for patients with low and high CD4-cell 
counts, respectively.19 However, in those with a CD4-cell 
count of 200–350 cells per "L, the risk estimate for AIDS 
in our cohort was 1·9 times greater than that calculated in 
the CASCADE study. This di! erence suggests that in this 
setting, those with CD4-cell counts of 200–350 cells per µL 
have a higher risk of morbidity than do similar patients 
living in high income countries. This fi nding might be 
due to di! erences in the spectrum of HIV-associated 
disease between resource-limited and high-income 
countries, or di! erences in disease progression. This 
fi nding might have implications for guidelines for when 
to initiate ART in resource-limited settings.
This study has some limitations. Information for cause-
specifi c mortality was not available and, therefore, we were 
unable to identify whether all deaths reported in this study 
were HIV-related. We included patients who received 
zidovudine monotherapy, but these patients were only a 
small proportion of the study population, and the results 
were unchanged when they were excluded from the 
analysis. Informative censoring—ie, a greater number of 
censored observations at an earlier time in one group 
compared with another, or a greater proportion of censored 
survival times in patients with a particular range of the 
explanatory variables) is a well-known issue in longitudinal 
studies.34 To take this issue into account, we examined 
whether our approach might have violated this assumption, 
by plotting survival times against the explanatory variables 
included in the Poisson regression models, fi tted to 
construct the formulae used for calculating the predicted 
6-month risk estimates of the various endpoints. We 
showed no discernible pattern suggestive of violation of 
this assumption. This fi nding might, as was suggested in 
the CASCADE study, be attributable to our approach, 
“censored patients from an observation period and not 
from the entire analysis”.19 Underestimation of CD4-cell 
count-specifi c and WHO stage-specifi c rates is therefore 
unlikely.
Risk of AIDS estimates calculated in this study are likely 
to be generalisable to people infected with HIV from other 
sub-Saharan African countries in view of the similar 
spectrum of AIDS-defi ning illnesses. However, estimates 
and determinants of risk of death might di! er, for example, 
because of other co-morbid diseases, such as malaria, that 
are absent in this setting, and because of di! ering 
standards of health care.
The di! erence between the rates of clinical events in our 
low-income setting and those in high-income countries 
suggests that delayed initiation of ART in resource-limited 
settings is associated with increased HIV-associated 
morbidity and mortality. These data might be useful for 
refi ning criteria for initiation of ART in resource-limited 
settings.
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Figure ": Risk of death according to WHO clinical stage (A), risk of AIDS 
according to WHO clinical stage (B), and risk of AIDS or death according to 
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The changing pattern of transmission and clinical 
presentation of HIV infection in the Western Cape 
region of South Africa (1984-1995) 
R Wood, EA O'KeeCe, G Maartens 
The clinical spectrum of HIV infection in South Africa has not been well dncumented. This study, 
at a major HIV referral clinic in Cape Town, describes the changes in clinical presentation of a 
large adult urban HIV population (n=1 288) over an ll-year period. From 1984-1991, data were 
obtained by retrospective chart review and from 1992-1995 were collected prospectively. The 
attendunce of lurge numbers of patients from each of the three main population groups allows a 
unique opportunity to compare disease frequency in these groups. During the study period, the 
change in predominant HIV transmission pattern from homosexual to heterosexual resuhed in 
significant changes in patient demography and HIV presentation. The relative incidence of 
Pneumocystis carinii pneumonia (PCP) declined (p < 0.01), while pulmonary and extrapulmon-
ary tuberculons increased (p < 0.01). Wasting syndrome and HIV encephalopathy were noted to 
occur less frequently in black patients (p < 0.05 and p < 0.01, respectively). The presentation of 
AIDS in Cape Town differed significantly in each of the main population groups and from both 
Western and African reported series. Kaposi's sarcoma, PCP, oesophageal candidiasis and herpes 
simplex infections were diagnosed more frequently than previously described in South African 
reports. A knowledge of the local presentation of HIV infection is necessary for the development 
of appropriate prophylaxis and treatment regimens. 
Introduction 
South Mrica is at present experiencing a rapid growth of 
the human immunodeficiency virus (lIIV) epidemic. By 
November 1994, the national antenatal HIV seropreva-
lence was estimated to be 7.6%, while the prevalence in 
the Western Cape was 1.2%.1 HIV infection was first 
recognised in the Western Cape region of South Africa in 
1984, and in the following years the epidemic was largely 
homosexually transmitted (pattern I). By 1990 the local 
epidemic had changed to predominantly heterosexual 
(pattern 2) transmission. Genetic sequence analysis of 
HIV-l isolates from patients infected by each transmis-
sion pattern, indicates that these are two' largely 
independent epidemics? To date, there has been limited 
information describing the clinical presentations of HIV 
in South Africa,3 and no reports of the changes 
associated with differing race or transmission pattern. 
In 1984, following the identification of the first AIDS 
cases in Cape Town, a multidisciplinary HIV clinic was 
started at the New Somerset Hospital (NSH); subse-
quently a second clinic was opened at Groote Schuur 
Hospital, Cape Town. The clinic population included 
patients from each of the three main population groups 
of the Western Cape. 
This study describes the changing demographic profile 
and clinical presentation of a large diverse urban adult 
HIV population over the ll-year period from 1984 to 
1995. 
Materials and methods 
The study population consisted of all adult HIV 
seropositive patients presenting to NSH and Groote 
Schuur Hospital HIV clinics of the University of Cape 
R Wood, EA O'Keefe, G Maartens, Department of Medicine, University of Cape Town 
Medical SchooL 
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Town between July 1984 and November 1995. HIV 
diagnosis was confirmed on two separate blood speci-
mens by positive screening enzyme immunoassay (EIA) 
and a combination of enzyme-linked immunosorbent 
assays (ELISA) and Western blot. 
Retrospective clinical chart reviews were performed on 
patient records prior to January 1992. Demographic 
details, HIV risk behaviours, laboratory results and 
clinical data were extracted and entered into a computer 
database (Epi Info 6.0 I Centers for Disease Control, 
Atlanta, USA, and World Health Organization (WHO), 
Geneva, Switzerland). From January 1992, data were 
<;ollected prospectively. Comparisons of disease fre-
quency were made using the chi-squared test. 
HIV -related manifestations were classified using the 
proposed WHO clinical HIV staging system' WHO 
stage IV equates with AIDS and stage III with AIDS-
related complex. CD4 + T-cell counts were measured 
approximately six monthly.;. by flow cytometry. Patients 
with less than 200 CD4 T-cells/~L were routinely 
commenced on cotrimoxazole prophylaxis. 
Results 
During the study period, a total of 8868 outpatient visits 
were made by I 288 patients. AIDS (WHO stage IV) was 
diagnosed in 342 individuals and 244 deaths were 
recorded. The mean age of females at presentation was 
28.9 years which was significantly lower (p < 0.01) than 
the mean male age of 33.9 years. The changing 
demographic characteristics of patients presenting be-
tween July 1984 to December 1989 and January 1990 to 
November 1995 are shown in Figure 1. A comparison of 
AIDS defining diagnoses pre and post January 1990 
(Figure 2) demonstrated a significant increase (p < 0.01) 
in extrapulmonary tuberculosis from 5% (1984-1989) to 
28% (1990-1995). Similary, pulmonary tuberculosis 
significantly increased from 4% to 18% (p < 0.01), data 
not shown in Figure 2. Disseminated non-tuberculous 
mycobacterial infections were diagnosed in 17 patients of 
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Figure 1: The demographic characteristics of the IllY 
outpatient population from 1984 to 1989 in-
volving mainly white male homosexuals (pat-
tern 1) and from 1990 to 1995 showing a mar-
ked increased in heterosexual transmission 
(pattern 2) with involvement of each of the 
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pcp KS HIVenceph Expulm Oes candida 
tuberculosis 
The 5 most common AIDS defining condi-
tions diagnosed between 1984-1989 and 1990-
1995 demonstrating a significant decline in 
PCP (p < 0.01) and increase in extrapnlmon-
ary tubercnlosis (p < 0.01). 
PCP = pneumocystis carinil pneumonia, 
KS = Kaposi's sarcoma, mv enceph = IllY 
encephalopathy, Expulm tuberculosis = ex-
trapulmonary tuberculosis, Oes candida 
oesophageal candidiasis 
which two were due to Mycobacterium avium-intracellu-
lare (MAl). Pneumocystis carinii pneumonia (PCP) 
showed a decline (p < 0.0 I) in incidence from 41 % to 
12%. Cytomegalovirus infection of the retina and 
intestinal mucosa occurred only with advanced HIV 
disease as manifested by a low CD4 + T-cell count « 50 
cells/fiLl. Unexplained diarrhoea lasting longer than one 
month was recorded in only 4% of WHO stage III 
patients. 
The frequency with which AIDS diagnoses occurred in 
each of the three main patient population groups of the 
Western Cape is shown in Figure 3. Extrapulmonary 
tuberculosis was diagnosed significantly more frequently 
in black than coloured and white patients (p <0.01). 
PCP, Kaposi's sarcoma, HIV encephalopathy and 
cytomegaloviral (CMV) disease were seen more fre-
quently in white patients (p < 0.01). Oesophageal candi-
diasis also occurred more frequently in the white 
population (p < 0.05). 
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Figure 3: The total number of AIDS diagnoses (both 
AIDS defining and subsequent diagnoses) in 
each of the 3 main population groups of the 
Western Cape. PCP, KS, IllY encephalo-
pathy and CMV disease occurred more fre-
quently in the white population (p < 0.01) 
while extra-pnlmonary tuberculosis was diag-
nosed more frequently in the black compared 
to other population groups (p < 0.01) 
Discussion 
During the study period a change in predominant 
pattern of HlV transmission was paralleled by changes 
in HIV presentation. The Western Cape has the highest 
incidence rate of pulmonary tuberculosis (702/100 000 
per ann urns) on the continent of Africa and this has 
greatly influenced the local presentation of HIV disease. 
Pulmonary tuberculosis, which is not included in the 
WHO stage IV definition of AIDS, has increased 
together with extrapulmonary tuberculosis, which has 
become the commonest AIDS diagnosis. The strong 
interaction between tuberculosis and HIV was demon-
strated by a prospective study of NSH inpatients with 
newly diagnosed tuberculosis and prior unknown HIV 
status, who had a 33 % HIV seroprevalence.' The low 
incidence of disseminated atypical mycobacterial infec-
tion amongst our AIDS patients (17 of 342) is in contrast 
to the experience of developed countries, where up to 
40% of AIDS patients develop MAl infection.' The low 
incidence of MAl may result from the high exposure of 
our patient population to M. tuberculosis which may 
protect against subsequent MAl infection. A reciprocal 
relationship between tuberculosis and MAl has been 
shown within the USA where regions with the highest 
rates of tuberculosis reported the lowest rates of MAl 
infections. 8 
The high incidence of PCP and Kaposi's sarcoma seen in 
homosexual white males pre-1990 was similar to that 
seen in homosexual males in the USA'" The decline in 
PCP after 1990 may reflect the increasing use of primary 
PCP prophylaxis but is more likely to be related to a 
lower incidence of PCP in the black and mixed race 
patients. Although initial reports indicated that PCP was 
extremely rare in Africa, it has been increasingly 
diagnosed in African patients.IO,11 Cotrimoxazole acts 
as a prophylaxis against PCP, bacterial infections and 
toxoplasmosisl2 and may be responsible for the low 
incidence of cerebral toxoplasmosis despite evidence of 
latent toxoplasmosis in 31 % of clinic attendees (unpub-
lished data). 
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and cultural factors have to be taken into account; 
however, this should not be a factor when more marked 
signs of dementia are present. The low incidence of HIV 
encephalopathy in black patients therefore requires 
further careful prospective study to confirm this finding. 
The low incidence of wasting syndrome (weight loss + 
fever or diarrhoea) is similar to reports from other areas 
of South Africa 13.14 but is in contrast to studies from 
Central Africa where 'slim disease' (weight loss + 
diarrhoea) is the commonest presentation of AIDS.15 
Although diarrhoeal disease causes significant morbidit~ 
in both early and advanced HIV disease in Cape Town, I 
prolonged unexplained diarrhoea was not common. The 
low rate of unexplained diarrhoea may be related to a 
lower prevalence of coccidial infections in our popula-
tion.6 
Significant changes have occurred in the spectrum of 
clinical HIV presentation in Cape Town associated with 
the increase in heterosexnally transmitted infection. The 
frequency of opportunistic infections differ from both 
Central Africa and developed countries but is dominated 
by the high prevalence of latent tuberculosis in the 
community. In each local population group, PCP, 
Kaposi's sarcoma, oesophageal candidiasis and herpes 
simplex infections were diagnosed more fre'Juently than 
previously noted in South African reports. I .14 
A knowledge of the spectrum of clinical HIV presenta-
tions in South Africa is necessary for the rational 
allocation of resources and the formulation of appro-
priate prophylaxis and treatment regimens. 
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Introduction
It is estimated that 14 million adults in sub-Saharan
Africa are HIV-infected [1], with the major route of
transmission being heterosexual contact. In South
Africa, unlike the rest of sub-Saharan Africa, HIV-1
was initially spread by homosexual contact [2,3]. The
first two South African cases of AIDS, recorded in
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Objectives: To determine HIV-1 env and gag subtypes in male homosexual and
heterosexual populations in Cape Town, South Africa.
Design: DNA was isolated from blood originating from 61 patients attending local
clinics. Samples were divided according to presumed mode of transmission: male
homosexual (n = 26), heterosexual/vertical (n = 32), blood transfusion (n = 1) and
unknown (n = 2).
Methods: Proviral HIV-1 DNA was subtyped by heteroduplex mobility assay (HMA)
based on the 700 base-pair V3–V5 region of the env gene (n = 47) or by sequence
analysis of the p17 region of the gag gene (n = 33), or both. For HMA, reference
plasmids were constructed containing the V1–V5 env region sequences (1.2–kb)
representative of local subtypes. Subtype designation of reference subtypes was
confirmed by sequence analysis of the V3-loop region. 
Results: Analysis of the partial gag sequences and HMA of the V3–V5 env region
identified three subtypes: B, C and D. A fourth env subtype, subtype E, was also
identified by HMA. Subtypes were found to segregate according to mode of
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homosexual group and subtype C viruses found in 81% (26 out of 32) of the
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1982, were male homosexuals [4], and until 1987 HIV-
1 was diagnosed almost exclusively in men [2,3]. In
1988, an increasing number of HIV-infected women
were reported, signalling the start of a second epidemic,
and by 1992 the numbers of new cases in women were
was roughly equivalent to those in men [2,3]. Results
of a 1995 annual antenatal survey of 13 741 specimens
showed that 10.44% of pregnant women were infected
[5]. At this time it was estimated that there were just
over 1.8 million HIV-positive persons in South Africa
of a total population of over 41 million. 
The rapid evolution of HIV-1 is well documented and
at least 10 subtypes have been defined in the env region
[subtypes A–I (M group) and subtype O (O group)]
[6,7]. Subtypes A and D are predominant in Central
and East Africa [8] and subtype C in Zambia and
Malawi [6]. Subtype C was the first HIV genotype
from South Africa to be identified [9] and was subse-
quently shown to be the major virus subtype in the
heterosexual population of this country [10]. Subtype B
viruses, commonly found in Europe and America, are
not often detected in Africa. Investigations into genetic
heterogeneity are important in the development and
application of vaccines whose efficacy could be influ-
enced by virus variation [11]. It is also possible to use
genetic variation to monitor the spread of HIV-1 into
new population groups such as in Thailand where dis-
tinct subtypes were associated with the independent
introduction of HIV-1 into the injecting drug user
population (subtype B) and heterosexual population
(subtype E) [12].
A preliminary study has been performed investigating
subtypes from different risk groups in South Africa [10].
In this study, we investigated the genetic heterogeneity
of HIV-1 in 61 individuals presumed to be infected by 
different modes of transmission. Results showed that
distinct subtypes of HIV-1 were associated with the 
heterosexual and male homosexual populations.
Materials and methods
Patient data
EDTA-treated blood originated from two sources: the
HIV/AIDS clinic (Somerset Hospital; ZA001–ZA078;
n = 54) and the diagnostic virology laboratory (Groote
Schuur Hospital; ZA201–ZA207; n = 7). Somerset
Hospital has the major HIV/AIDS adult referral clinic
in the Cape Town region and services mainly govern-
ment hospitals. The clinical and demographic data of
the 58 patients infected by heterosexual/vertical trans-
mission and male homo-/bisexual transmission is
shown in Table 1. None of the infants listed in Table 1
were born to women in this study. In addition, blood
was obtained from a white woman, aged 28 years,
infected by a blood transfusion (94ZA008); a mixed-
race man, aged 42 years, infected by unknown mode of
transmission (94ZA074); and a mixed-race man, age
unknown, infected by unknown mode of transmission
(94ZA078). Travel history and travel history of sexual
partner were recorded.
Polymerase chain reaction, cloning and
sequencing
DNA was extracted directly from EDTA-treated blood
[13]. A ± 500 base-pair region of the gag gene 
was amplified using outer primers SK28 [14] 
and SK431 [15], and inner primers LTR236 
(5￿-CGCAGGACTCGGCTTGC) and gag778 
(5￿-CCCATGC[A/G]TT[T/C]GTTCTAGGTG)
which were designed for the study. Forty cycles of
amplification were performed using Taq polymerase
(Boehringer Mannheim, Mannheim, Germany) and
recommended buffer conditions. The DNA was dena-
tured at 94°C for 30 sec, primers annealed at 45°C for
30 sec and DNA elongated at 72°C for 60 sec.
A 1.2 kb and 700 base-pair fragment of the env gene
was amplified in a nested polymerase chain reaction
(PCR) using primers ED3/14 and ED5/12 or ED5/12
and ES7/8 [National Institutes for Health (NIH) AIDS
Research and Reference Reagent Program, Rockville,
Maryland, USA], respectively, as previously described
[16]. The 1.2 kb fragment was cloned into pMOS-blue
vector (Amersham International, Little Chalfont,
Buckinghamshire, UK) for sequencing, whereas the
700 base-pair fragment was used for heteroduplex
mobility assay (HMA). For sequencing of 360 bases
including the V3 loop, ES7 and ED33 (NIH AIDS
Research and Reference Reagent Program) were used
as the forward and reverse primers, respectively.
The ± 500 base-pair gag fragments (n = 33) and the 1.2
kb env fragments (n = 5) were cloned by (i) blunt-end
ligation into SmaI restriction site of pUC18
(Boehringer) or the Srf I restriction site of pCR Script
(Stratagene, La Jolla, California, USA); or (ii) by 
TA, overhang cloning into pMos-blue T-vector
(Amersham), as recommended by the manufacturers.
Ligated DNA was transformed into Escherischia coli and 
white colonies containing putative clones screened 
for inserts by PstI/EcoRI double digestion (env clones)
or probing with digoxigenin labelled probe gag 1 
(5￿-GAAGGAGAGAGATGGGTGCG; gag clones).
DNA from positive clones was purified and both
strands were sequenced by standard dideoxy chain ter-
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Table 1. Patient clinical and demographic data by heterosexual/vertical and homo-/bisexual modes of transmission.
Age Year of first CD4 count
Sample Race Sex (years) serodiagnosis (x106/l)
Heterosexual transmission
93ZA006 White Male 30 1993 342
93ZA010 Black Female 41 1993 530
93ZA020 Mixed race Female 33 1992 5
93ZA023 Black Male 48 1992 169
93ZA024 Black Male 41 1993 200
93ZA025 Mixed race Female 24 1992 375
93ZA029 Black Female 29 1993 172
93ZA030 Black Male 58 1991 0
93ZA031 Black Male 31 1991 154
93ZA032 Black Female 34 1993 72
93ZA035 Mixed race Male 52 1993 140
93ZA036 Black Male 42 1992 625
93ZA037 Mixed race Male 32 1993 418
93ZA040 Black Female 34 1990 269
93ZA042 Mixed race Male 27 1991 54
93ZA043 Mixed race Female 32 1993 443
93ZA046 Black Female 21 1993 404
93ZA047 Black Male 24 1993 373
93ZA048 Black Male 40 1993 111
93ZA049 Black Female 20 1992 517
94ZA058 White Female 37 1991 357
94ZA061 Black Male 33 1994 138
94ZA063 Mixed race Male 24 1994 ND
94ZA067 Black Female 30 1989 ND
94ZA200 Black Male Unknown 1994 ND
94ZA201 Mixed race Female 38 1993 ND
94ZA202 Black Female 44 1992 ND
94ZA205 Black Male 21 1992 ND
94ZA206 White Female Unknown 1993 ND
Vertical transmission
94ZA203 Black Female 0.7 1993 ND
94ZA204 Black Male 0.1 1993 ND
94ZA207 Black Unknown 1 1993 ND
Homosexual transmission
93ZA001 White Male 37 1988 504
93ZA002 White Male 35 1991 52
93ZA003 White Male 32 1990 84
93ZA004 White Male 30 1984 564
93ZA005 Mixed race Male 42 1991 231
93ZA007 White Male 41 1987 0
93ZA009 Mixed race Male 31 1991 499
93ZA011 Mixed race Male 25 1991 481
93ZA012 Mixed race Male 26 1990 550
93ZA017 White Male 25 1989 8
93ZA019 White Male 40 1987 534
93ZA021 Mixed race Male 44 1991 245
93ZA022 White Male 49 1993 69
93ZA033 White Male 36 1990 374
93ZA034 White Male 42 1991 21
93ZA041 Mixed race Male 30 1993 54
93ZA044 White Male 48 1991 208
93ZA045 Mixed race Male 26 1992 397
94ZA050 Mixed race Male 39 1993 32
94ZA051 White Male 29 1993 18
94ZA059 Mixed race Male 55 1994 77
94ZA073 White Male 47 1989 23
94ZA076 White Male Unknown 1994 ND
94ZA077 Mixed race Male Unknown 1988 ND
Bisexual transmission
93ZA038 White Male 38 1990 0
94ZA072 White Male 56 1986 45
ND, not determined.
Heteroduplex mobility assay
HMA was performed on the 700 base-pair V3–V5
region of the env gene as previously described [16]. For
subtype designation, unknown samples were initially
compared with reference plasmids A–F in an HMA kit










Program, after which South African reference plasmids
(two B, two C and one D) could be constructed.
Subsequent unknown samples were compared with the
South African reference plasmids and one subtype A
reference plasmid from the NIH AIDS Research and
Reference Reagent Program. The heteroduplexes were
separated by electrophoresis on a 190￿160￿1.5mm3
(Hoefer SE600) 5% polyacrylamide gel at 200 V for 5 h.
The DNA was visualized by ethidium bromide staining.
Sequence analysis
The sequences were named by year of isolation, coun-
try of origin, patient identification number and mode
of transmission. Sequences were aligned using
CLUSTAL V [17], with a final manual adjustment.
Phylogenetic analysis was performed using the distance
matrix neighbour-joining method in TREECON for
Windows 1.0 [18]. The neighbour-joining trees were
constructed using 1000 bootstrap replicates with the
simian immunodeficiency virus SIVCPZ-Gab sequence as
outgroup, ignoring insertions/deletions, and using the
Kimura 2-parameter correction for multiple substitu-
tions [19]. The gag sequence set was also analysed using
PAUP 3.1.1 [20] by use of the simple heuristic tree
generation algorithm with gaps counted as ‘missing’
and tree-breaking and resection, with the SIVCPZ-Gab
sequence as outgroup. All the 900 equally parsimonious
shortest trees found were used to generate a strict 50%
majority rule consensus tree.
Results
Two methods were used to subtype a total of 61 sam-
ples from Cape Town: sequence analysis of the p17
region of the gag gene, and HMA of the V3–V5 region
of the env gene.
Phylogenetic analysis of 33 partial gag sequences identi-
fied three subtypes: B, C and D (Fig. 1a). Nine out of
10 individuals from the male homo-/bisexual group
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Fig. 1. Neighbour-joining phylogenetic trees resulting from 1000 bootstrap replicates on (a) partial gag sequences (441 base-
pairs) and (b) V3 region sequences (360 base-pairs). The trees were rooted on the SIVCPZ-Gab sequence (not shown). Horizontal
distances are proportional to sequence distances between species; vertical distances are arbitrary. Numbers along the horizon-
tal branches represent bootstrap scores in percentages: only values of 85% and higher are shown. Samples are named accord-
ing to year of isolation, country of origin (ZA, South Africa), patient identification number and mode of transmission: ho, homo-
sexual; he, heterosexual; bt, blood transfusion. Country of origin of reference strains are as follows: (a) DJ, Djibouti; ZAM19,
Zambia; NDK, Zaire; ELI, Zaire; MN, United States of America (USA); SF2, USA; MAL, Zaïre; U455, Uganda. (b) MA, Malawi;
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were infected with subtype B and one with subtype D.
Of the 22 people infected by heterosexual/vertical
transmission, 19 were infected with subtype C and
three with subtype B. The individual infected by blood
transfusion was infected with a subtype B virus. The
consensus PAUP tree showed very similar topology to
the neighbour-joining tree in all major branches, with
small differences confined to the terminal branches (not
shown). All sequences had intact open reading frames
and varied in length from 380 to 420 bases. The aver-
age intrasubtype DNA difference for subtypes B and C
were 7.6 and 6.7%, respectively, and ranged from 4.6
to 10.9% and from 1.0 to 10.6%, respectively. 
Forty-seven samples were subtyped on the basis of the
env region using HMA. Reference plasmids were con-
structed containing env sequences representative of local
strains, as the subtype designation of certain samples was
ambiguous using the NIH AIDS Research and
Reference Reagent Program reference plasmids. Three
subtype B, two subtype C and one subtype D reference
plasmids were constructed and their subtype desig-
nation confirmed by sequence analysis of 360 bases of
the V3-loop region of the env gene (Fig. 1b). The
tetrapeptide crown of the V3 loop was GPGR in all
three of the subtype B viruses. The two subtype C
viruses and one subtype D virus had a GPGQ tetrapep-
tide crown motif. Four different subtypes were identi-
fied by HMA: B, C, D and E. Of the 23 patients in the
male homo-/bisexual group, 22 were infected with sub-
type B and one with a subtype D virus. Of the 21
patients in the heterosexual group, 17 were infected
with subtype C, two with subtype B, one with a sub-
type D, and one with a subtype E virus. Three addi-
tional subtype B viruses were identified, two transmitted
by unknown route and one by blood transfusion.
Nineteen samples subtyped by HMA based on the 
env gene were also subtyped by sequence analysis of 
the partial gag gene. There was no discrepancy in 
subtype designation among this group. The results of
subtyping by sequencing and HMA are summarized in
Table 2.
All patients were residing in Cape Town at the time of
the study. The following homosexual men reported
having had sexual contact with men while travelling in
foreign countries in the 5 years prior to sampling:
ZA004, ZA005 (United States); ZA003, ZA005,
ZA007, ZA019 (Europe); ZA022, ZA033 (Australia);
and ZA050 (Thailand). All these individuals were
infected with subtype B viruses. Heterosexual men
who reported having had sexual contact while in near-
by Southern African countries within 5 years of sam-
pling included ZA020, ZA030 (Zambia); ZA024
(Namibia); ZA031 (Zimbabwe); and ZA200 (Malawi).
All these individuals were infected with subtype C
viruses. 
Discussion
There have been two patterns of infection in South
Africa on two time scales: in the early 1980s the epi-
demic affected mainly the male homosexual population
and by the late 1980s this had shifted to a predominant-
ly heterosexual epidemic [2,3]. In this study, four sub-
types were identified: 32 subtype B, 26 subtype C, two
subtype D viruses and one env subtype E virus. It
would be of interest to sequence the subtype E virus in
the gag and env regions to determine whether the strain
is an env E–gag A recombinant such as has been found
in Thailand and the Central African Republic [6]. The
subtypes segregated according to mode of transmission
with 96% (25 out of 26) of the male homo-/bisexual
group infected with subtype B viruses and 81% (26 out
of 32) of the heterosexual/vertical group infected with
subtype C viruses. There is a significant association
between subtype and mode of transmission (P<0.001),
which suggests two independent epidemics and that the
origin of the second epidemic was largely independent
of the first wave of infections. Many of the homosexual
men in this study reported having had sexual contact
while travelling abroad. In addition, a study performed
in 1983 on 32 HIV-positive homosexual men reported
that the majority reported having had sexual contact
with men in the United States or Europe [21]. Thus
both epidemiological and molecular data suggest that
the initial epidemic in South Africa was, at least in part,
a result of the introduction of HIV-1 into South Africa
from other continents. In addition, a subtype D virus,
commonly found in Central Africa [6], was identified
in a male homosexual patient from our study.
Table 2. HIV-1 subtype designation according to presumed mode of transmission.
Heterosexual/vertical Homo-/bisexual Unknown Blood transfusion
Region used 
for subtyping B C D E B D B B
env 1 7 1 1 16 – 2 –
gag 2 9 – – 3 – – –
env and gag 1 10 – – 6 1 – 1
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The heterosexual epidemic is a relatively recent epi-
demic, as the first cases in women were reported in the
mid-1980s [2,3]. The intrasubtype DNA distance for
subtype C viruses was greater than expected for a
clonal HIV-1 epidemic and it is probable that there
was multiple introduction of the same subtype into the
heterosexual community. This is supported by epi-
demiological data whereby some of the patients in this
study reported having had sexual contact in Zambia,
Malawi and Zimbabwe, where this subtype is found
[6,22]. The origin of this second epidemic is therefore
probably due to regional spread. Since there are close
socioeconomic ties between South Africa and its
neighbouring countries, there is a constant traffic of
people facilitating the spread of HIV-1 to South
Africa.
The global spread of subtypes is a dynamic process and
the association between subtype and mode of transmis-
sion has been observed in several regions where there
are relatively new epidemics including Thailand,
Russia, China, and now South Africa [10,12,23,24]. It
is possible that certain subtypes have different pheno-
typic properties resulting in a selective advantage in
alternative routes of transmission. A recent study in
Thailand showed that subtype E viruses may be associ-
ated with higher risk of heterosexual transmission than
subtype B viruses [25]. Langerhans’ cells are thought to
be the primary target cells in heterosexual transmission
and it was shown that subtype E, and probably C,
replicate more efficiently in these cells than subtype B
[26]. In the last few years there has been rapid spread of
subtype C viruses throughout the world [23,24,27,28]
and this subtype may have a selective advantage in het-
erosexual transmission. Subtype D viruses were previ-
ously reported in five out of 11 South African male
homosexual patients diagnosed in the early to mid-
1980s [29]. However, in our own study, out of 26 male
homosexual patients diagnosed in the late-1980s to
early-1990s only one was infected with a subtype D
virus. Further work needs to be done to determine
whether virus genotype affects the transmissibility and
pathogenicity of HIV-1, and studies to further explore
this may be possible in South Africa. 
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Summary
Survival with HIV infection is shorter in sub-Saharan diagnosis in 36/90 heterosexuals and 5/58 homo-
sexuals (p<0.0001). Survival after AIDS was longerAfrica than in developed countries. The pattern of
HIV transmission in our region has changed from in heterosexuals (p=0.0015), but AIDS occurred
earlier as shown by their higher CD4+ count athomosexual to heterosexual, with viral subtypes sim-
ilar to those in North America/Europe and Central AIDS onset (median 98/ml vs. 40/ml; p=0.036).
Survival was similar in the two groups after firstAfrica, respectively. We compared survival for the
two transmission patterns after AIDS, and after CD4+ count <200/ml and <50/ml. Race, socio-
economic status and morbidity are markedly differ-the first CD4+ lymphocyte counts <200/ml and
<50/ml, for adults presenting 1988–1993. Anti- ent in the two transmission groups. AIDS occurs
with less severe immune suppression in hetero-retroviral therapy was excluded. There were 180
homosexuals (63% White, 56% employed) and 314 sexuals, with correspondingly longer survival.
Survival after defined CD4+ counts, however, isheterosexuals (67% Black, 34% employed).
Extrapulmonary tuberculosis was the AIDS-defining remarkably similar.
Introduction
The prognosis of HIV infection in sub-Saharan Africa progression to AIDS twice as rapid as that in cohorts
from industrialized countries.4has been reported to be worse than in industria-
lized countries.1,2 This may be due to death from The transmission pattern of HIV in our area has
changed from an initial homosexual/bisexual epidemicendemic non-opportunistic infections (particularly
Mycobacterium tuberculosis, the salmonellae, and (pattern 1) to a heterosexual epidemic (pattern 2).
Our pattern 1 patients have viral subtype B (the sameStreptococcus pneumoniae) prior to the onset of
severe immunosuppression.1 This seems plausible as in North America/Europe), whilst pattern 2 patients
have subtype C, which occurs in sub-Saharan Africa,5given the overburdened and poorly-funded health-
care facilities in most countries in this region. Death indicating that the two epidemics are independent.
Health-care facilities in South Africa are better thanprior to the onset of severe immunosuppression
may also explain the observed scarcity of many elsewhere in sub-Saharan Africa,6 which enables us
to diagnose and treat most opportunistic infections,opportunistic infections in HIV-infected patients in
Africa.1,3 and monitor serial CD4+ lymphocyte counts.
However, anti-retroviral therapy is not generally avail-Alternatively, the poorer prognosis in Africa may
be due to more rapid disease progression as a result able in the state health sector. We are thus in a
unique position to compare the outcome of the twoof more virulent HIV subtypes, genetic predisposition,
or the presence of co-factors. Supporting this hypo- transmission patterns in an HIV-infected population
unexposed to anti-retroviral therapy.thesis, the Nairobi sex-worker cohort study reported
Address correspondence to: Dr G. Maartens, Department of Medicine, Medical School, Anzio Road, Observatory 7925,
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Methods
Somerset and Groote Schuur hospital HIV clinics are
both affiliated to the University of Cape Town. The
same treatment protocol is used at both clinics, and
medical personnel are partly shared. Patients were
referred from primary care, often following screening
for insurance or blood donation, or from hospitals
in the Western Cape region. There was no private
specialist HIV care available. Adult patients attending
for their initial visits between 1988–1993 were
studied. All patients had HIV-1 infection confirmed
by ELISA and Western blot or three different ELISAs
on specimens drawn on two occasions. Data were
acquired by retrospective chart review prior to Figure 1. The proportion of new pattern 1 and 2 patients
December 1991, and prospectively thereafter. attending the HIV clinics in Cape Town from 1988 to 1993.
Follow-up continued until April 1995. CD4+
lymphocyte counts were performed 3- to 6-monthly
Table 1 Demographic databy flow cytometry. Demographic data, including
sexual preferences and employment status, were
Pattern 1 Pattern 2collected. Patients who were taking anti-retroviral
therapy were excluded. Cotrimoxazole primary pro- Race
phylaxis was routinely prescribed from 1991 for White 114 (63.3%) 11 (3.5%)
patients with CD4+ counts <200/ml. Primary pro- ‘Mixed’ 65 (36.1%) 93 (29.5%)
phylaxis for fungal or mycobacterial infections was Black 1 (0.6%) 210 (67%)
not used. Age (years) 33.1±8.95 30.22±8.94
Males 180 (100%) 147 (46.8%)Date of death was obtained from hospital records
Employed* 101 (56.1%) 50 (34%)or from deaths reported to the clinics by relatives or
friends. In addition, regional death records were
*Employment status applies only to males.searched if patients failed to attend for more than
6 months.
Statistical analysis was done using the software were no intravenous drug users. Employment status
packages EpiInfo version 6 (Centers for Disease was assessed only for males. Because being unem-
Control), SAS and Statgraphics version 6 (Statistical ployed at the time of presentation may reflect disabil-
Graphics). Survival from the first AIDS diagnosis ity due to HIV, we also evaluated prior employment
(1987 Centers for Disease Control case definition)7 status. The proportion of males who had ever worked
and the first recorded CD4+ lymphocyte counts was 70.6% in pattern 1 compared with 47.5% in<200/ml and <50/ml were assessed by Kaplan- pattern 2 ( p<0.0001). In those patients who had
Meier analysis. Patients were right censored if their ever worked, unskilled or semi-skilled labour was
last clinic attendance was before 2 years follow-up. performed by 18% of pattern 1 patients compared
The survival curves for patterns 1 and 2 were with 73.5% of pattern 2 patients ( p<0.0001).
compared using log rank tests. Yates’ correction was Nine patients in each transmission pattern died
applied to x2 tests. prior to the onset of AIDS ( p=0.308). The degree
of immunosuppression in each group was similar as
assessed by CD4+ lymphocyte count at first visit
(357±244 pattern 1; 312±221 pattern 2; p>0.05)Results and the proportion with AIDS at first visit (13%
pattern 1; 17% pattern 2; p=0.18). The mean timeThe transmission pattern changed from predominant
homosexual transmission to heterosexual transmis- to developing AIDS was also similar (12.3 months
pattern 1; 11.3 months pattern 2; p>0.05). Medicalsion during the study period (Figure 1). There were
662 patients whose first clinic visit was between care was similar, as assessed by the number of clinic
visits per year prior to developing AIDS (6.3 visits1988 and 1993. Anti-retroviral therapy was taken at
some stage by 112 patients, and sexual preference pattern 1; 5.5 visits pattern 2; p>0.05)
AIDS was diagnosed on entry or subsequentlywas not recorded in 56, leaving 494 evaluable
patients (36% pattern 1, 64% pattern 2). occurred in 148 patients (58 pattern 1, 90 pattern
2). The commonest AIDS-defining conditions areDemographic data is shown in Table 1. Pattern 2
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Table 2 Most frequent AIDS-defining diagnoses in the following AIDS diagnosis (evaluable in 130
two transmission patterns patients)(Figure 2).
Survival from the first recorded CD4+ lymphocyte
AIDS-defining Pattern 2 Pattern 1 Odds ratio count <200/ml (n=190) and <50/ml (n=82) was
condition (n=90) (n=58) (95% CI) similar for both patterns (Figure 3). Survival from the
first CD4+ lymphocyte count <200/ml was similarExtrapulmonary 36 (40%) 5 (9%) 7.07
for male and female pattern 2 patients ( p=0.33).TB (2.47–24.56)
Controlling for age by Cox proportional hazard inPneumocystis 6 (7%) 11 (19%) 0.31
males with CD4+ lymphocyte count <200/mlcarinii (0.09–0.98)
showed no significant difference in survival (riskKaposi’s 8 (9%) 8 (14%) 0.61
sarcoma (0.19–2.0) ratio for death in pattern 1 patients 1.857, 95% CI
Candidosis 10 (11%) 5 (9%) 1.33 0.975–3.537; p=0.06). In this group, survival was
(0.39–5.22) shorter for pattern 1 compared with male pattern 2
Herpes simplex 7 (8%) 6 (10%) 0.73 patients <33 years ( p=0.018) but similar for males
(0.2–2.8) 33 years or older ( p=0.55) (a cutpoint of 33 years
Wasting 5 (6%) 7 (12%) 0.43 was chosen because it gave approximately equal
syndrome (0.1–1.67) numbers in the sexual preference groups). We also
controlled for the time when AIDS or the first CD4+TB, tuberculosis.
count <200/ml or <50/ml was found, as the quality
of care may have changed over time. This did not
occurred more frequently in pattern 1 patients ( p= alter the findings that pattern 2 patients survived
0.043) whilst extrapulmonary tuberculosis occurred longer after AIDS and that survival was similar after
more frequently in pattern 2 patients ( p<0.0001). first CD4+ count <200/ml or <50/ml.
CD4+ lymphocyte counts at the time of AIDS-
defining diagnosis were available in 53 patients.
These were lower in pattern 1 patients (median Discussion40/ml; interquartile range 16–126) compared with
pattern 2 patients (median 98/ml; interquartile range The major finding of our study was that survival,
when assessed from CD4+ counts <200/ml and47–194; p=0.036, Mann-Whitney U test). Pattern
2 patients survived significantly longer ( p=0.0015) <50/ml, was similar for both major transmission
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(a)
(b)
Figure 3. Cumulative survival following CD4+ lymphocyte counts a <200/ml and b <50/ml. Survival was similar for
pattern 1 and 2 patients (a p=0.206; b p=0.91).
patterns. This was not due to age differences, which fined to late HIV disease, the fact that there were no
excess deaths in pattern 2 patients before AIDSare important prognostically,8 between the two
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progression is similar for both transmission patterns. enables us to investigate and treat most HIV-related
infections. This is illustrated by the similar survivalThe longer survival of pattern 2 AIDS patients is
reflected in their higher frequency of extrapulmonary of our AIDS patients to those in Europe9 and New
York.21 Our patients with severe immune suppressiontuberculosis. This presents with higher CD4+
lymphocyte counts than most other AIDS-defining (a CD4+ lymphocyte count <50/ml) have a median
survival similar to that reported from the USA.22 It isconditions, and is associated with longer survival.9
The CDCs expanded definition of AIDS10 has been noteworthy that this similar survival in late HIV
disease was achieved without anti-retroviral therapy.criticized by one centre, which found that the revised
definition led to a threefold increase in patients
defined as having AIDS, and their survival was more
than twice as long.11 The use of a CD4+ lymphocyte Acknowledgements<200/ml to define AIDS is problematic, because of
This study would not have been possible withoutconsiderable differences in results from different
the meticulous observations of the late Dr Franklaboratories.12 These problems apply to industrialized
Spracklen, former head of the Somerset Hospital HIVcountries—resource-poor countries are generally
clinic. The South African Medical Research Council,unable to afford CD4+ lymphocyte determinations.
particularly Dr Aaron Metrikin, assisted with theIn addition, the inclusion of pulmonary tuberculosis
establishment of the database. Carl Lombard, Centreas an AIDS-defining condition is not applicable to
for Epidemiolical Research in South Africa, Medicalareas where tuberculosis is endemic.13 Therefore we
Research Council, provided statistical assistance. Weused the 1987 CDC case definition of AIDS.7
thank Professor A.D. Harries for critically reviewingIn sub-Saharan Africa, the reason for the scarcity
the manuscript.of certain major opportunistic infections is thought
to be due to death before the development of severe
immunosuppression.1,3 In our pattern 2 patients,
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Disseminated histoplasmosis in AIDS patients in South 
Africa: a report of three cases and review 
R Wood, T Jackson 
Histoplasmosis has not been previously reported in South African AIDS patients. Three cases of 
disseminated Histoplasma capsulaturn infection are described in HIV-infected individuals living in 
Cape Town who did not belong to previously recognised risk groups for exposure to H. 
capsulatum. The clinical presentations were predominated by systemic symptoms with the 
diagnosis being confumed by tissue histology and fungal culture. Histoplasmosis is amenable to 
treatment, associated with prolonged survival and should be included in the differential diagnosis 
of HIV-infected patients in South Africa with fever, wasting, hepatomegaly, pulmonary infiltrates 
or mucocutaneous lesions. 
Introduction 
Histoplasma capsulatum infection in immune competent 
individuals typically causes a mild primary pulmonary 
infection which rarely disseminates.! In South Africa H. 
capsulatum infection has been considered a rare disease, 
affecting predominantly spelaeologists exposed to bat 
infested caves2-' with occasional case reports of 
disseminated disease in other groups.6-' In recognised 
endemic areas, of the USA, the immune snppression 
associated with HIV infection increases the risk of 
dissemination, resulting in H. capsulalum infection in up 
to 27% of AIDS patients,!O In contrast, disseminated H. 
capsulaturn infection in AIDS has been very rarely 
reported in African patients!!-!4 and not previously 
reported in South Africa. We describe three cases of 
disseminated histoplasmosis occurring in HIV-infected 
individuals living in Cape Town. 
Patients and methods 
Case 1 
A 39-year-old white male presented with a history of 
fever and weight loss. Four months prior to admission he 
had been treated for an acute respiratory illness, while 
working in a recently reopened underground diamond 
mine in the Free State. Following this illness he lost 
approximately 30 kilograms of weight and noted 
increasing dyspnoea on effort. On examination the 
patient was wasted, dyspnoeic at rest with a tempera-
ture of 40°C and pulse rate of llOJmin. A diffuse papular 
erythematous rash involving the face, trunk and limbs 
was present but there was no significant lymphadeno-
pathy and no mouth lesions. Examination of the 
cardiovascular system and abdomen was normal. 
Auscultation of the chest revealed normal vesicular 
breath sounds. Central nervous system examination was 
completely normal. 
Results of laboratory investigations were: haemoglobin 
9.2 g/dl, leucocyte count 2.88xlO' JL, neutrophils 98%, 
lymphocytes 2%, CD4 count 8xl06/L, CD8 count 
23x106/L, sodium 125 mmol/L, potassium 4,0 mmolJL, 
urea 3.4 mmolJL, creatinine 45 f1Il1.ol/L, AST 125 IU/L, 
ALP 280 IU/L, bilirubin Il f1Il1.oIJL, HIV-I serology 
positive and serum cryptococcal antigen negative. 
R Wood, Department of Medicine, University of Cape Town. 
T Jackson, South African Institute for Medical Research, Cape Town. 
Correspondence to: Dr Robin Wood, Department of Medicine, Somerset Hospital, Green 
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Chest radiograph showed a diffuse interstitial infiltrate 
involving both lung fields. A skin biopsy demonstrated a 
perivascular neutrophil infiltrate with narrow-budding 
encapsulated yeasts compatible with H. capsula turn seen 
lying free within the dermis and within macrophages 
(Grocot! silver stain). Mucicarmine staining for Crypto-
coccus neoforrnans polysaccharide was negative. Treat-
ment was commenced with oral fluconazole (200 mg/ 
day) with rapid resolution of the rash and respiratory 
symptoms. Two months after starting therapy, the 
patient was no longer dyspnoeic, the chest radiograph 
infiltrates had cleared and his weight had increased by 20 
kilograms. The patient remained well and in full 
employment on maintenance fluconazole (100 mg/day) 
at 12 months' follow-up. 
Case 2 
A 30-year-old HIV positive white male chef presented 
with a 'respiratory illness characterised by fever, non 
productive cough, arterial oxygen desaturation on 
exercise and a normal chest radiograph. The patient 
had not travelled outside the Western Cape and gave no 
history of exposure to caves, mines or bat guano. A 
presumptive diagnosis of Pneumocystis carinii pneumo-
nia was made and treatment commenced with high dose 
cotrimoxazole with rapid resolution of respiratory 
symptoms. A generalised erythematous papular rash 
developed 21 days later. On examination the patient was 
not dyspnoeic, temperature was 39°C and pulse rate was 
lO5/min. A diffuse papular erythematous rash involving 
the face, trunk and limbs was present but there was no 
significant lymphadenopathy and no mucocutaneous 
ulceration. Examination of the abdomen revealed 
moderate hepatosplenomegaly. Respiratory' and ner-
vous system examination was normal. 
Results of laboratory investigations were: haemoglobin 
9.6 g/dL, leucocyte count 4.93x109 L, neutrophils 53%, 
lymphocytes 31 %, monocytes 13% and atypical lym-
phocytes 2.6%, CD4 count l2x106L, CD8 count 
l283x106L, sodium 132 mmol/L, potassium 3.9 mmol/ 
L, urea 3.0 mmolJL, creatinine 66 ~mol/L, AST 66 lU/L, 
ALP 49 IU /L, bilirubin I 0 ~mol/L, HIV -1 serology 
positive and serum cryptococcal antigen negative. 
Chest radiograph was normal. A skin biopsy demon-
strated small encapsulated budding yeasts, and culture of 
biopsy tissue grew the dimorphic fungus H. capsulaturn. 
Treatment was started with oral fluconazole (200 mg/ 
day) but new skin lesions continued to develop. 










which was continued for six weeks with eventual 
resolution of skin lesions and maintenance therapy with 
itraconazole (100 mg/day) was continued. The patient 
returned to full time employment and was asymptomatic 
at three months' follow-up. 
Case 3 
A 52-year-old HIV posItIve black male screen printer 
presented with a four-month history of weight loss, non 
productive cough and decreasing effort tolerance. He 
had been born in the Eastern Cape and lived most of his 
life in Cape Town, except for a short residence in 
Gabarone, Botswana. There had been no exposure to 
mines or caves. On examination he was pyrexial at 
40.2"C, mildly obtunded with oral candidiasis and shotty 
lymphadenopathy. Sparse pigmentation papules were 
present on the limbs but no oral ulceration. Respiratory, 
cardiac and abdominal systems were normal. 
Result oflaboratory investigations were: HIV-l serology 
positive, haemoglobin 12.2 g/dL, leucocyte count 
2.2xl09/L, neutrophils 77%, lymphocytes 12%6' eosino-
phils 2%, platelets 103xl09/L, CD4 count 2xlO /L, CD8 
count 249xl06/L, so<;lium 135 mmol/L, potassium 5.3 
mmol/L, urea 5.0 mmol/L, creatinine 124 J.I1Ilol/L, AST 
200 IU/L, ALP 64 IU/L, bilirubin 12 ~mol/L and INR 
1.0; cerebral spinal fluid analysis: protein 4.4, glucose 
3.3, red cells 3/hpf, lymphocytes 4/hpf, Gram stain 
negative, fungal culture negative, cryptococcal antigen 
negative; serum cryptococcal antigen negative and 
histoplasma precipitin test negative. 
Chest radiograph was normal. A liver biopsy showed 
portal tract histiocytes containing numerous intracellular 
budding yeasts. Fungal culture of hepatic tissue grew H. 
capsulaturn. Pyrexia settled rapidly after starting intra-
venous amphotericin B and subsequent maintenance 
therapy with fluconazole (100 mg/day). 
Discussion 
The high rate of dissemination of histoplasmosis in HIV-
infected individuals has resulted in increased recognition 
of this infection in areas where it was not previously 
thought to be endemic. In West Africa, a large HIV post-
mortem study demonstrated H. capsula tum infection in 
2% of autopsies l3 and disseminated histoplasmosis was 
diagnosed in three of 100 AIDS patients who had been 
long term residents in Central Africa. II HIV -associated 
histoplasmosis reported in non-endemic areas may result 
from reactivation of latent disease in individuals with 
prior travel to endemic regions,J6 or from new acquisi-
tion of disease in areas not grevi9usly recognised as 
endemic for histoplasmosis.'7. In the 1950s a limited 
histoplasmin survey performed in SQuth Africa identified 
cutaneous reactivity, in fungal but not general labora-
tory workers and in individuals exposed to caves in the 
Transvaal but not in the Cape Province. 2 More recently, 
a single cave in the Cape Province has been recognised 
as the source of three outbreaks of acute pulmonary 
infection in cavers4 .' The full extent of environmental 
exposure in South Africa, however, has not been 
assessed because population-based histoplasmin surveys 
have never been performed, acute histoplasmosis is 
frequently unrecognised and serological tests lack 
sensitivity and specificity for reliable diagnosis or 
seroprevalence studies. While the source of infection 
can not be established with certainty in Case I, 
circumstantial evidence points to occupational under-
ground exposure. The mine workings had been disused 
for a prolonged period during which they may have 
become contaminated with bat guano, a recognised 
South Afr J Epidemiol Infect 1997; Vol 12 (3) 
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sOUrce of histoplasmosis infection in caves of the region2 
An initial pneumonic illness three weeks after starting 
work in a previously disused mine is consistent with 
acute pulmonary H. capsula/urn. The subsequent weight 
loss, fever, skin rash and chest radiological findings are 
typical of patients with AIDS and acute disseminated 
histoplasmosis.l 9 Neither of the other two patients had 
travelled to an endemic area or reported exposure to 
underground caves, fungal laboratories, bats or bird 
guano. The source of H. capsula tum in these cases is 
unknown but as neither belonged to previously recog-
nised risk groups, this may indicate that environmental 
exposure to this organism is more widespread than 
previously recognised. 
The predominance of systemic symptoms seen in all 
three cases is similar to the clinical findings of a series of 
70 histoplasmosis patients, in which fever was present in 
100%~ significant weight loss in 84% and anaemia in 
72%. 0 The clinical features of histoplasmosis in AIDS 
patients are protean and disease may involve many 
organs induding the liver, spleen, lungs, skin or 
gastrointestinal tract. IO-22 Infection almost invariably 
occurs in HIV-infected individuals with very low CD4 T-
cell counts." A fungal aetiology was sought in our 
patients, because of severe immune suppression and 
systemic symptoms, together with a prominent papular 
skin eruption in Cases I and 2 and hepatomegaly in Case 
3. The diagnosis can be established by demonstration of 
the organism in culture, on direct microscopy of bone 
marrow or by demonstration of the yeast forms in tissue 
sections. The tissue forms of H. capsula tum are narrow-
based encapSUlated budding yeasts, 1-5 )! in size, which 
can be seen both free in the extracellular tissues and 
intracellularly within macrophages. Other fungi such as 
Blastomyces dermatitidis, Torulopsis glabrata and Peni-
cillium rnarneffei may rarely mimic the extracellular 
tissue forms of H. capsulaturn. The usefulness of biopsy 
has been demonstrated in a study of Brazilian AIDS 
patients with histoplasmosis, in whom the histology of 
mucocutaneous lesions led to confirmation of diagnosis 
in 68% of patients21 In contrast, failure to biopsy skin 
lesions, presumed to be a drug-related eruption, resulted 
in the misdiagnosis and death of a patient with AIDS 
and disseminat d histoplasmosis.22 
Continuous life-long suppressive antifungal therapy is 
required for AIDS patients with disseminated histoplas-
mosis, because of a high relapse rate. to Favourable 
initial clinical responses have been reported in 85% of 
AIDS patients treated with amphotericin B, but relapses 
occur in up to 20% of those receiving maintenance 
therapy with this drug23 Satisfactory initial responses 
have also been reported using oral triazole therapy with 
intraconazole and fluconazole24 and treatment with 
amphotericin B is now reserved for life-threatening 
histoplasmosis. Itraconazole has been the most fre-
quently used triazole, although both itraconazole and 
fluconazole are effective for maintenance thera:!ily and 
have been associated with prolonged survival."· 
Histoplasmosis should be included in the differential 
diagnosis of HIV -infected patients in South Africa with 
severe immune suppression and fever, wasting, hepato-
megaly, pulmonary infiltrates or mucocutaneous lesions. 
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CORRESPONDENCE 
Toxoplasma gondii infection in HIV-
infected individuals in South Africa 
In a review of opportunistic infections in Africa, Jentsch 
stated that no studies have addressed toxoplasmosis in 
HIV-infected individuals in South Africa, I Clinical data, 
however, describing this and other opportunistic infec-
tions in Cape Town AIDS patients have recently been 
published in this journal? Toxoplasmic encephalitis was 
reported in 3% of all AIDS patients in the Cape Town 
series and was the cause of 12% of neurological AIDS 
presentations, Toxoplasmosis was associated with 
advanced immune. suppression, as manifested by a 
mean CD4 T-cell :coun! of 86 x 106/L at time of 
diagnosis' and therefore was less frequently the initial 
AIDS defining condition. Preliminary data describing 
toxoplasma sero-status of South African HIV -infected 
patients have also been presented locally.' The serolo-
gical status of individuals attending Somerset Hospital 
HIV clinic, Cape Town, has been collected prospectively 
since 1994 and is summarised in Table L Toxoplasma 
sero-testing using the Toxostat™ ELISA assay for IgG 
(graded 1 + to 3 +) and the Toxocap-M™ capture assay 
Table 1: Toxoplasma gondii serostatus of 480 conse-
cutive mv -infected individuals presenting to 
Somerset Hospital HIV clinic, Cape Town, The 
seroprevalence for eacb of the main population 
groups of the Western Cape is shown together 
with 95% confidence intervals, Toxoplasma 
IgG seropositivity was significantly higber in 
black patients (p < 0.01) compared to otber 
population groups. 
HIV patients Black Coloured Wbite 
Number tested 327 91 61 
IgG positive 140 23 9 
IgG positive % 43% 26% 15% 
95% conf 
intervals 37-48 17-35 6-24 
for IgM was perfonued as per manufacturer's instruc-
tions (BioWhittaker Inc. Walkersville, MD, USA) by the 
South African Institute for Medical Research. No sera 
testing positive for IgM was confinued by subsequent 
testing with an indirect immunofluorescent assay. 
Positive IgG serology was present in 36% of the total 
population and was significantly higher in black patients 
(p < 0.01) compared to the other racial groups. There 
was no significant differences of prevalence between 
males and females. Forty one percent of all positive IgG 
sera were reported at high titre (3 + ). These data indicate 
that prior exposure to Toxoplasma gondii is commonest 
in the South African population group in which HIV 
infection is most prevalent4 It has been estimated that 
approximately 30% of African AIDS patients who are 
seropositive for toxoplasma will ultimately develop 
toxoplasmic encephalitis' with the risk being highest in 
those patients with high titre6 The incidence of cerebral 
toxoplasmosis may therefore be expected to increase, as 
the South African HIV epidemic matures and an 
increasing proportion of patients have advanced im-
mune suppression Clinical experience in the developed 
world has shown that the combination of multiple 
intracerebral ring enhancing lesions on computer 
tomography and a positive IgG toxoplasma serology 
has an 80% positive predictive value for the diagnosis of 
cerebral toxoplasmosis? The main differential diagnosis 
for multiple ring enhancing lesions in the USA is 
multifocallymphoma, whereas in South Africa, cerebral 
tuberculomata must also be considered. The specificity 
of such a clinical algorithm for focal neurological lesions 
applied in South Africa may, however, be lower due to 
the high prevalence of both toxoplasmosis and tubercu-
losis. The high toxoplasma seroprevalence in black HIV-
infected patients also reinforces the need for co-
trimoxazole prophylaxis, despite the lower incidence of 
pneumocystis carinii penumonia in this population,2 as 
this antimicrobial gives protection against toxoplasmic 
encephalitis.8 
Dr Robin Wood 
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Human Immunodeficiency Virus-Related Abdominal Pain in South Africa
Aetiology, Diagnosis, and Survival
E. A. O’KEEFE, R. WOOD, A. VAN ZYL & A. K. CARIEM
Dept. of Medicine and Dept. of Radiology, University of Cape Town, Somerset Hospital, Greenpoint,
Gastrointestinal Clinic, University of Cape Town, Groote Schuur Hospital, Observatory, South Africa
O’Keefe EA, Wood R, Van Zyl A, Cariem AK. Human immunodeficiency virus-related abdominal pain
in South Africa. Aetiology, diagnosis, and survival. Scand J Gastroenterol 1998;33:212–217.
Background: Abdominal pain in acquired immunodeficiency syndrome (AIDS) patients is often a marker
of an underlying opportunistic pathologic condition. There are no data on HIV-related abdominal pain in
Africa. Methods: Forty-four consecutive Cape Town patients with advanced human immunodeficiency
virus (HIV) infection (CD4 200) and abdominal pain were studied prospectively to determine aetiology
and survival. Results: A probable cause of pain was identified in 37 (84%): disseminated Mycobacterium
tuberculosis infection in 11, cryptosporidiosis in 6, cytomegalovirus infection in 6, and atypical myco-
bacterial infection in 2. Gastrointestinal lymphoma and pancreatitis were not seen. Fever, hepatomegaly,
respiratory symptoms, abnormal chest radiograph, and adenopathy, ascites, or abscesses on ultrasound had
predictive diagnostic value for disseminatedM. tuberculosis. Fifty-one per cent of abdominal pain patients
survived 6 months, compared with 73% of all AIDS patients (P 0.001). Conclusions: The aetiology of
HIV-related abdominal pain in Cape Town reflects the high local prevalence of tuberculosis. Clinical and
ultrasound features facilitate diagnosis. Abdominal pain is associated with poor survival.
Key words: Abdominal pain; abdominal ultrasound; acquired immunodeficiency syndrome; Africa;
atypical mycobacterial infection; cryptosporidiosis; cytomegalovirus; human immunodeficiency virus;
survival; tuberculosis
Dr. E. A. O’Keefe, Dept. of Medicine, Somerset Hospital, Private Bag, Greenpoint 8051, South Africa
(fax: 27 21 402 6000)
Gastrointestinal symptoms occur in up to 60% of acquired
immunodeficiency syndrome (AIDS) patients in developed
countries and 90% in Africa (1). Abdominal pain is a common
problem at all stages of human immunodeficiency virus (HIV)
disease; previous retrospective series in industrialized coun-
tries have documented a prevalence of between 12% and 15%
in AIDS patients (2, 3), whereas 45% of AIDS outpatients in
Cape Town, South Africa, reported having had abdominal
pain in the preceding month (4).
There are few data on the aetiology of HIV-related
abdominal pain in industrialized countries and none from
Africa. Abdominal pain in early HIV disease may have an
aetiology to similar that in HIV-seronegative persons,
whereas in advanced disease it is often a marker of underlying
opportunistic infection or malignancy. Gastrointestinal lym-
phoma, cytomegalovirus (CMV) colitis and Mycobacterium
avium intracellulare (MAI) enteritis were the most commonly
implicated causes of abdominal pain in Italian AIDS patients
(2). Thuluvath et al. (5) found that the predominant site of
pain had predictive diagnostic value, with the commonest
cause of right upper quadrant pain being sclerosing cholangi-
tis and diarrhoea frequently being associated with more
diffuse abdominal pain.
Tuberculosis is highly prevalent in Africa and particularly
in the Western Cape region of South Africa, where the
incidence is over 700 per 100,000 (6). In Cape Town, as in
Central Africa, extrapulmonary tuberculosis is the common-
est AIDS-defining illness, and atypical mycobacterial and
CMV infections have been reported less commonly than in
developed countries (7). The aetiology of abdominal pain in
South African AIDS patients might be expected to reflect this
different spectrum of opportunistic conditions.
We set out to determine prospectively the prevalence of
conditions associated with abdominal pain in a multiracial
group of patients with advanced HIV disease (CD4 200) in
Cape Town, South Africa, and to determine whether an
underlying diagnosis of disseminated M. tuberculosis infec-
tion could be predicted by simple measures such as clinical
presentation, chest radiograph appearance, and abdominal
ultrasound findings. The prognostic significance of abdominal
pain in advanced HIV infection was studied by comparing




Somerset Hospital, Cape Town, is a well-established
referral centre for HIV-infected patients from the Western





































































racial (white, black, and mixed race), and subjects at all
clinical stages of HIV disease are seen. The clinic is staffed by
two full-time physicians (E. O’Keefe, R. Wood), who are also
responsible for HIV inpatient care. Outpatient visit data have
been recorded on a computer database (Epi Info 6.02) since
1984 and are updated weekly.
Subjects
HIV-infected subjects (in- and out-patients) presenting to
Somerset Hospital with new onset of abdominal pain 1 week
or more in duration and a CD4 count 200 were studied
prospectively from November 1994 to September 1996. Most
of these patients were taking prophylaxis against Pneumo-
cystis carinii pneumonia, but antituberculous prophylaxis was
not routinely prescribed. Antiretroviral therapy was not
available within the state health system.
The site of abdominal pain, the presence of other symptoms
(fever, weight loss, diarrhoea, hepatomegaly, and respiratory
symptoms), full blood count, CD4 count, erythrocyte sedi-
mentation rate (ESR), and liver profile were recorded. Chest
radiograph and abdominal ultrasound examination were
undertaken in most patients. In the presence of diarrhoea,
stool samples were examined for evidence of bacterial or
parasitic infection. Upper gastrointestinal endoscopy, sig-
moidoscopy, and liver biopsy were performed when indi-
cated. Postmortem examinations were obtained, when
possible, in patients who died without an established reason
for their abdominal pain.
Diagnostic criteria
Disseminated M. tuberculosis infection was defined by
positive mycobacterial blood or bone marrow cultures, posi-
tive mycobacterial cultures from two or more other sites, or
postmortem evidence. Atypical mycobacterial infection was
diagnosed by mycobacterial blood culture and niacin slope. A
diagnosis of gastrointestinal CMV disease was made by
demonstration of typical histologic findings in endoscopic
biopsy specimens (four of six) or compatible gastrointestinal
symptoms in the presence of CMV retinitis with no other
identifiable cause. Cryptosporidiosis was diagnosed by
visualization of oocysts in stool, duodenal aspirate, or biopsy.
The presence of HIV cholangitis was confirmed by endo-
scopic retrograde cholangiopancreatography (ERCP). Oeso-
phageal ulcers were considered to be HIV-related only when
endoscopic biopsy specimens were negative for CMV, herpes
simplex, and other known pathogens.
Data analysis
Data were entered onto a computer database (Epi Info
6.02). The association between the predominant site of
abdominal pain, weight loss, fever, diarrhoea, respiratory
symptoms, hepatomegaly, and abdominal ultrasound findings
and the presence or absence of disseminated M. tuberculosis
infection was examined using two-tailed chi-squared analysis.
Student’s t test was used to determine whether there was a
relationship between haemoglobin or ESR levels and dis-
seminated M. tuberculosis infection. The sensitivity and
specificity of abdominal ultrasound findings for predicting
disseminated M. tuberculosis were calculated. Numbers were
not large enough to examine these relationships for other
conditions.
Cumulative survival was calculated for all subjects with
HIV-related abdominal pain and for the subgroups with and
without disseminated M. tuberculosis, using the Kaplan–
Meier method. This was compared with the survival of all
AIDS patients (from the time of AIDS-defining illness)
attending the Somerset Hospital HIV clinic during the same
time period as the study.
RESULTS
The demographics of the 44 patients studied are shown in
Table I. The mean age of the patients was 32.9 (range, 18.4 to
53.3 years). The mean CD4 count was 55 (interquartile range,
11–86); there was no significant difference between the CD4
counts of those with disseminated tuberculosis and those
without: 69 (34–93) and 48 (8–58), respectively. Forty
subjects (91%) fulfilled the WHO clinical criteria for AIDS
(8). No patient underwent surgery during the study period.
A probable cause of the abdominal pain was established in
37 of the 44 patients (84%), with more than 1 cause in 10
(23%) (Table II). Disseminated M. tuberculosis infection was
the commonest condition, occurring significantly more often
in non-white persons (P 0.05). A further three patients were
suspected of having disseminated M. tuberculosis, but the
Table I. Demographic features of the study population (n = 44)
Male Female Homosexual
Black, n 10 15 0
Mixed race, n 7 3 4
White, n 9 0 9
Table II. Conditions associated with abdominal pain in advanced
human immunodeficiency virus (HIV) infection (CD4 200) in




Disseminated tuberculosis 14 (32%) 9 5 0
Cytomegalovirus infection 6 (14%) 1 1 4
Cryptosporidiosis 6 (14%) 4 0 2
HIV cholangitis 3 (7%) 1 0 2
Bacterial enteritis 3 (7%) 3 0 0
Helminths 2 (5%) 2 0 0
Atypical mycobacteria 2 (5%) 0 0 2
HIV-related ulcers 2 (5%) 1 0 1
Acalculous cholecystitis 1 (2%) 1 0 0
Microsporidiosis 1 (2%) 1 0 0
Isosporiasis 1 (2%) 1 0 0
* More than 1 condition in 10 subjects.





































































criteria for diagnosis were not fulfilled; two others developed
abdominal pain while taking antituberculous therapy (these
five subjects were not included in the disseminated tubercu-
losis group for statistical analysis). In contrast, atypical
mycobacterial infection was rare and documented in only
two cases, both white homosexual men.
Gastrointestinal CMV disease (oesophagitis, gastritis, and
duodenitis) was thought to be the cause of abdominal pain in
six subjects, four of whom were white. Of the six patients
presenting with abdominal pain and cryptosporidiosis, five
had co-existing conditions that might have contributed to the
pain; three had ERCP evidence of HIV cholangitis, and 2 had
bacterial gastrointestinal infections. One case each of micro-
sporidiosis and isosporiasis were found in association with
generalized abdominal pain.
A pathologic condition of the oesophagus was responsible
for some cases of abdominal pain. Oesophageal ulceration
was documented at endoscopy in five subjects and on barium
swallow in a further two. There was histologic evidence of
CMV disease in two cases and oesophageal tuberculosis in
one. Oesophageal biopsies in the other two subjects showed
non-specific inflammation, and the symptoms resolved with
steroids (HIV-related ulcers).
Thirteen subjects had generalized abdominal pain, 10 pain
in more than one area, 6 epigastric pain, 10 right upper
quadrant pain, and 5 pain at other sites. There was a trend for
generalized abdominal pain to be present more often in those
with disseminated M. tuberculosis (P = 0.07), but otherwise
the site of pain was not predictive of the underlying disorder.
Thirty-nine patients (89%) had lost weight, 34 (77%) had
fever, 31 (70%) diarrhoea, 28 (64%) hepatomegaly, and 20
(45%) respiratory symptoms. The presence of fever, respira-
tory symptoms, and hepatomegaly were significantly asso-
ciated with disseminated M. tuberculosis infection (all,
P 0.05). Haemoglobin and ESR levels did not differentiate
between patients with and without disseminated M. tubercu-
losis infection. Liver profiles were often abnormal but not
predictive of the underlying disorder.
Chest radiographs taken within 1 month of entry to the
study were available for evaluation in 34 subjects (10 with
confirmed or suspected disseminated M. tuberculosis and 24
with other conditions). Only one patient with disseminatedM.
tuberculosis had a normal radiograph; pleural effusions,
atypical infiltrates, reticulonodular pattern, or adenopathy
was present in the others. Fifteen (63%) of the patients
without disseminated tuberculosis had entirely normal radio-
graphs, two had old fibrocystic changes only, and five (33%)
had atypical infiltrates. Pleural effusions, reticulonodular
pattern, and adenopathy were seen only in the presence of
disseminated M. tuberculosis infection.
Ultrasound examination of the abdomen was performed in
35 patients (80%) and was normal in 7 (20%). The main
features encountered were liver abnormalities (increased
echogenicity or hepatomegaly), abscesses (splenic in four of
five cases), adenopathy, ascites, and abnormalities of the
gallbladder and biliary system (thickened gallbladder wall,
stones, and dilation of the ducts). Splenic size was not
recorded prospectively. The presence of intra-abdominal
adenopathy, abscesses, or ascites was significantly associated
with (P 0.05) and highly specific for disseminated M.
tuberculosis infection (Table III). When the three patients
with suspected disseminated M. tuberculosis were included
with the proven cases, the specificities of adenopathy and
ascites increased to 95%, and abscesses to 100%. Adenopathy
and ascites on ultrasound were otherwise seen only in atypical
mycobacterial infection.
Stool samples from 18 subjects were sent for microscopy
and culture, with identification of possible pathogens in 7
(Trichuris trichiura in 3, Campylobacter jejuni in 1, Shigella
sonnei in 1, Cryptosporidium parvum in 2, Isospora belli in 1,
and M. tuberculosis in 1). Upper intestinal endoscopy with
biopsies in 17 patients yielded a diagnosis in 12 (71%):
conditions found were CMV-related disease, crypto-
sporidiosis, microsporidiosis, oesophageal candidiasis, dis-
seminated M. tuberculosis, HIV-related oesophageal ulcers,
and gastritis. ERCP was performed in five subjects with
evidence of dilated bile ducts on ultrasound. HIV cholangitis
was confirmed in three, whereas one procedure failed, and the
other showed a normal biliary tree. Hepatic biopsy (two
cases) and sigmoidoscopy (five cases) did not increase
diagnostic yield. Seven postmortem examinations were
performed; five showed disseminated mycobacterial infection
(fourM. tuberculosis and one atypical), one cryptosporidiosis
and cryptococcosis involving the small bowel, and one was
non-diagnostic.
Twenty-nine subjects died during the follow-up period,
with a median time to death of 101 days (interquartile range,
56–210 days). Six patients died within 1 month of entering the
study; five had disseminated mycobacterial infection, and one
disseminated CMV disease. The median follow-up time of the
survivors was 168 days (81–262 days). Cumulative survival
of the abdominal pain cohort was 51% (standard error of the
mean (sx) 8%) at 6 months, compared with 73% (sx 3%)
for Cape Town AIDS patients (P 0.001) (Fig. 1). There was
no significant difference between the cumulative survival at 6
Table III. Abdominal ultrasound findings in patients with abdominal
pain in advanced human immunodeficiency virus infection
(CD4 200) in the presence (TB) or absence (non-TB) of










Hepatic abnormalities 9 10 75% 57%
Adenopathy 8 2 67% 91%
Abscesses 4 1 33% 96%
Ascites 5 2 42% 91%
Bile duct dilatation 1 7 NA NA
Gallstones 1 1 NA NA
Cholecystitis 0 1 NA NA





































































months of those with disseminatedM. tuberculosis (58%) and
those with other conditions (50%).
DISCUSSION
This study has shown that the aetiology of HIV-related
abdominal pain in South Africa differs considerably from that
reported in industrialized countries. To our knowledge, this is
the first prospective study of an unselected group of patients
with abdominal pain in advanced HIV infection, and it is
certainly the first such study to be reported from Africa.
Previous data have largely been derived from small surgical
series and retrospective data analysis.
The study was designed to capture all known patients with
advanced HIV infection presenting to Somerset Hospital,
Cape Town, with abdominal pain. Most presented to the HIV
physicians, but patients with symptomatic HIV disease pre-
senting to the surgeons are usually managed with the physi-
cians and should, therefore, have been identified. Whereas the
increasingly high prevalence of HIV infection in the local
African community (around 10%) makes it likely that some
unidentified seropositive subjects will have been missed, we
believe that the study findings are representative of the Cape
Town HIV population and are probably generalizable to HIV-
infected persons in the rest of South Africa and other non-
industrialized countries.
In contrast to previous series, no patient underwent surgery
during the study period. This can be partly attributed to the
fact that suspected tuberculous peritonitis was managed by
the physicians and not referred to the surgeons. However,
there was no evidence of bowel perforation and obstruction
among the study patients even at postmortem, suggesting that
these conditions occur less commonly in the Cape Town HIV
population. It is unlikely that sick patients were underrepre-
sented in the series, as Somerset Hospital is a regional HIV
referral centre, and mortality during the study period was
high.
In non-industrialized countries it is important to have
simple cost-effective management strategies for common
problems like HIV-related abdominal pain. Epidemiologic
data are very important in this setting, both to document the
local prevalence of conditions and to identify clinical markers
for the different disease processes.
Abdominal tuberculosis was the commonest cause of
abdominal pain in non-white persons with advanced HIV
infection in Cape Town, reflecting the high prevalence of
tuberculosis in these communities. Abdominal involvement
has been found to be universal in HIV-infected persons with
disseminated M. tuberculosis infection (9). Unfortunately,
postmortem data in this study were limited, owing to logistic
and religious difficulties in obtaining permission to perform
examinations on non-white subjects, but tuberculous perito-
nitis was demonstrated in all four cases of disseminated M.
tuberculosis for which postmortem data were available. It is
important to recognize that disseminated tuberculosis may
present with an acute abdomen, since optimal management is
immediate antituberculous therapy, to which there is usually
an excellent response, and surgery should be reserved for
complications (10).
It was not possible to show a clear relationship between the
predominant site of pain and the underlying aetiology for two
main reasons. First, about a quarter of the patients studied had
multiple pathologic conditions, making it difficult to deter-
mine the relative contribution of each to the symptoms, and,
secondly, the numbers with any particular condition other
than disseminated tuberculosis were small. Interestingly,
most of the subjects with disseminated M. tuberculosis did
not have co-existing conditions and usually presented with
generalized abdominal pain, possibly related to tuberculous
peritonitis.
The presence of fever, hepatomegaly, respiratory symp-
toms, or an abnormal chest radiograph in an HIV patient with
abdominal pain was predictive of a diagnosis of disseminated
M. tuberculosis. Computerized tomography of the abdomen
has been shown to be of diagnostic value in abdominal
tuberculosis, with adenopathy being the commonest finding
(11, 12), but abdominal ultrasound examination, which is
widely available and non-invasive, can provide the same
information in most cases. We have shown that adenopathy,
ascites, or abscesses are strongly associated with dissemi-
nated tuberculosis and would suggest that these findings
together with the clinical presentation are sufficient to justify
empiric antituberculous therapy pending appropriate myco-
bacterial culture results.
Abdominal pain related to atypical mycobacterial infection
was diagnosed in two white homosexual men only, consistent
with the previously reported low prevalence of atypical
mycobacterial infection in African AIDS patients (7, 13). An
Fig. 1. Cumulative survival rates of subjects with abdominal pain in
advanced human immunodeficiency virus infection (n = 44) and
Cape Town acquired immunodeficiency syndrome (AIDS) patients
(n = 332). Data were complete ( ) in 29 patients with abdominal
pain and 194 with AIDS and censored ( ) in 15 and 138,
respectively.





































































inverse relationship between the prevalence of M. tubercu-
losis and atypical mycobacterial infection has been noted
(14), and it is possible that previous exposure to M. tubercu-
losis or bacillus Calmette–Guérin vaccination has a protective
effect. However, HIV-infected Africans who have emigrated
to the West have been found to develop atypical mycobacter-
ial infections with the same frequency as locals, suggesting
that environmental factors are also involved (15).
CMV disease of the gastrointestinal tract was relatively
common in the Cape Town HIV population. Earlier reports
suggested that CMV disease was uncommon in African AIDS
patients (16), but it is being increasingly recognized in non-
white persons, which is in keeping with preliminary findings
of a high seroprevalence for CMV in Africans in Cape Town.
Cryptosporidium parvum has been isolated from 25–50%
of patients with prolonged diarrhoea and wasting in Central
Africa (‘slim disease’) (17, 18). Chronic diarrhoea is less of a
problem in South African AIDS patients (4), but when it
occurs, is often related to cryptosporidiosis. Cryptosporidiosis
has previously been reported to cause diffuse abdominal pain
(2, 5), but more localized pain would suggest the presence of
additional pathologic conditions, such as secondary cholan-
gitis or other infections, as was found in five of the six patients
in this series. Similarly, Isospora belli and microsporidial
infection might be responsible for diffuse abdominal pain, as
was found in the two cases reported in this study.
Although the relatively small size of this series might
explain the failure to show gastrointestinal lymphoma as a
cause of abdominal pain in South African HIV patients, there
have been no cases of HIV-related gastrointestinal lymphoma
recorded in Cape Town since the start of HIV data collection
in 1984; it would therefore appear to be as uncommon in
South Africa as it has been reported to be in India (19).
None of the patients studied in Cape Town were receiving
dideoxyinosine (ddI), but it is still surprising that pancreatitis
was not identified as a cause of abdominal pain, as it has been
shown to occur more frequently in HIV-infected persons,
even in the absence of ddI (20).
The occurrence of abdominal pain in AIDS patients has
previously been shown to carry a poor prognosis (2). The 6-
month survival of our patient cohort was significantly
decreased as compared with Cape Town AIDS patients in
general. There are two possible explanations for this increased
mortality. First, the abdominal pain is due to a condition such
as intestinal perforation, which carries a high mortality in
itself, and secondly, the abdominal pain may be associated
with advanced immunocompromise. The latter explanation
seems more likely, as no acute surgical emergencies were
identified in our series, and the patients who died within a
month of entering the study all had evidence of disseminated
opportunistic infection. M. tuberculosis infection in HIV-
infected patients is generally expected to respond well to
antituberculous therapy, but inability to localize the disease
may be associated with a poor prognosis.
In conclusion, the commonest cause of abdominal pain in
advanced HIV infection in Cape Town was tuberculosis,
reflecting its high local prevalence. Cryptosporidial and CMV
infection were relatively common, but atypical mycobacterial
infection was rare and only seen in white homosexuals.
Gastrointestinal lymphoma and pancreatitis, which are lead-
ing causes of AIDS-related abdominal pain in the West, were
not found in Cape Town.
Abdominal ultrasound examination and upper gastrointest-
inal endoscopy were found to be valuable diagnostic tools.
The symptom complex of abdominal pain in association with
fever, hepatomegaly, respiratory symptoms, or an abnormal
chest radiograph was found to be highly suggestive of
tuberculosis, and the presence of adenopathy, ascites, or
intra-abdominal abscesses on ultrasound should be considered
sufficient justification for initiating antituberculous therapy
pending appropriate mycobacterial culture results. The
occurrence of abdominal pain in advanced HIV infection
usually implies underlying disseminated opportunistic infec-
tion and carries a poor prognosis.
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AIDS IN AFRICA - SURVIVAL
ACCORDING TO AIDS-DEFINING
ILLNESS
Frank A Post, Motasim Badri, Robin Wood, Gary Maartens
Objective. Evaluation of prognostic significance of the type
of AIDS-defining illness (ADD and performance status in a
cohort of AIDS patients.
Design, setting, subjects, outcome measures. A retrospective
analysis of 280 patients with AIDS, as defined by the
proposed World Health Organisation (WHO) clinical
staging system, who attended two Cape Town-based HIV
clinics between 1984 and 1997. Patients were stratified
according to the type of initial AD!. Survival associated
with each opportunistic event was determined by Kaplan-
Meier analysis. Cox proportional hazard analysis was used
to determine relative risk for death associated with three
strata of AD!.
Results. Median survival associated with various initial
ADIs varied from less than 3 months (encephalopathy and
wasting), to over 2 years (extrapulmonary tuberculosis and
herpes simplex virus infection). This effect of AD! on
outcome was most striking in patients with relatively
preserved CD4 counts (CD4 > SO/pl). A performance status
score 4 predicted 50% mortality at 1 month, irrespective of
co-morbidity.
Conclusion. The type of ADI is an important determinant of
survival, particularly in patients with preserved CD4
counts. The stratification of patients by type of ADl and
performance status may be useful in the management of
patients with adv~cedHIV infection in resource-limited
environments.
s AIr Med I 2001; 91, 583-586.
The disease burden caused by HN infection has been
overwhelming health care facilities in many African countries.'
It has been suggested that African patients with HIV infection
have an increased rate of progression from asymptomatic HIV
infection to AIDS compared with patients in the developed
world, and this difference has been related to limited access to
Infectious DiseJlses Unit, University ofCape Tcnun Lung Institute, Cape Town
Frank A Post, FeP (SA), MMed
Motasim Badri, MSc (Med)
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medical care. l However, a recent longitudinal cohort study
from Uganda' showed the rate of progression to AIDS in HN-
positive patients to be comparable to figures previously
reported from the Western world. Survival of South African
AIDS patients, provided with adequate medical care, has been
shown to be similar to that of European and American patients
with AIDS.'
Laboratory markers that reflect the degree of immune
compromise in HN infection, such as CD4+ T-Iyrnphocyte
(CD4) count' and quantitative HN viral load: are frequently
unavailable in Africa. In this setting, prognostic information
may be obtained from clinical staging as proposed by the
World Health Organisation (WHO) clinical staging system and
the totallymphocyte count.'··7
AIDS includes a variety of opportunistic diseases that may
occur across a spectrum of immune dysfunction.· The
prognosis for patients with AIDS varies accordingly and is
influenced significantly by the type of AIDS-defining illness
(ADI).'-'·'o Prognostic stratification based on ADI and
performance status can be performed in the outpatient clinic
and does not require sophisticated laboratory facilities. It is
therefore widely applicable in resource-poor settings, and
potentially useful to guide resource allocation and patient
management. This study evaluated outcome of the commonest
AIDs-defining events and poor performance status in a cohort
of South African HN-positive patients.
METHODS
All patients with an AIDS diagnosis (as defined by the
proposed WHO clinical staging system," which is similar to the
Centers for Diseases Control 1987 definition of AIDS")
attending the HIV outpatient clinics of the University of Cape
Town medical school (at Somerset and Groote Schuur
hospitals) were selected from computer-based medical records.
From 1984 to 1997, patients with HIV infection were regularly
followed up at these clinics at 6-monthly intervals during the
asymptomatic phase of their illness, more frequently as
opportunistic infections occurred. At each visit, patients were
staged according to the WHO clinical staging system,
retrospectively until 1992, prospectively thereafter,' and CD4
counts were regularly performed. Tertiary care diagnostic
facilities such as bronchoscopy, liver and bone marrow
biopsies, microbiology and computed tomography (CT)
scanning, were available to confirm the presence of AIDS-
related illnesses. These clinics mainly served the
underprivileged communities, where heterosexually acquired
HIV infection had been increasingly prevalent. However, before
1991 the majority of clinic attendees had been white male
homosexuals.3
Patients with AIDS or CD4 counts below 200/j.l1 routinely
received co-trimoxazole prophylaxis since 1996, and standard
treatment for tuberculosis (TB), herpes simplex infection (HSV),
July 2001, Vo!. 91, No. 7 SAMJ
oesophageal candidiasis, Pneumocystis carinii pneumonia (PCP)
and cryptococcal meningitis was available. Antiretroviral
therapy was not routinely available for patients with AIDS, and
48 patients who had received such therapy were excluded from
analysis.
Date of death was obtained from hospital records or from
deaths reported to the clinics by relatives or friends. In
addition, regional death records were searched if patients failed
to attend for more than 6 months. Status of patients discharged
from the clinic for terminal care was obtained from the Red
Cross Home-Based Care Society.
Survival was analysed from the first presentation at either
clinic according to type of ADI, for diseases that occurred in at
least 10 patients. If two or more ADIs occurred simultaneously,
patients were placed in the group according to the event with
the worst outcome. Survival of patients with AIDS was also
analysed according to CD4 count « 50,51 - 200, > 200/j.l1), and
for patients with performance status 4 (in bed> 50% of normal
day time during the last month). CD4 counts performed within
3 months (before or following) onset of AIDS-related illnesses
were used for analysis.
Survival was calculated in months from the index visit (first
visit at which the condition occurred) to the date of death or
last visit (censored), using Epi-info (version 6). Kaplan-Meier
survival curves were created using the software package
Statistica (version 6), and evaluated for statistical difference by
log-rank test. Relative hazards of death and 95% confidence
intervals (CIs) were calculated using the univariate Cox
proportional hazard model and Fisher's exact test.
RESULTS
From May 1984 to April 1997, 1 735 patients with HIV infection
were seen during 11 493 visits. By April 1997, 280 patients had
developed AIDS, and 160 of this number had died. Of the 120
patients alive at the end of the study, 45 had been lost to
follow-up after a median clinic attendance of 8.7 months (range
1 - 63 months). Median follow-up for patients with AIDS who
were still alive at the end of the study period was 10.2 months
(range 1 - 65 months), and 9.7 months (0 - 114) for those who
had died. The median number of clinic visits for patients with
AIDS was 5 (range 1 - 47), the mean age of patients was 33
years (range 17 - 75 years), and both homosexual (N = 109) and
heterosexual (N = 171) transmission patterns, male (N = 199)
and female (N = 81) gender, and the three major population
groups (76 whites, 75 coloureds and 129 blacks) were
represented. Intravenous drug abuse and haemophilia did not
occur as risk factors for HIV infection in our patients. Both
patients who were diagnosed HN-positive on presentation at
either clinic with an AD! (N = 143) and patients who developed
AIDS during follow-up from WHO clinical stages 1 - 3 (N =
137) were represented in this cohort. The total number of ADls
diagnosed in our cohort was 430 (average per patient 1.54); the
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Early 56 42 30 28 20 16 10 10
lnter-
mediate 53 40 31 25 16 11 9 5 4
Late 13 5 4 2 2 I 0 0 0
eight diseases mentioned in Table I occurred 317 times (261 as
initial ADI).
The overall median survival time from the onset of AIDS was
11.5 months. Initial ADIs were stratified into early, intermediate
and late events, according to median survival rates (Table I).
There was no statistical difference for the survival curves of
individual diseases within each stratum (P = 0.90, 0.43, and
0.98 respectively). Kaplan-Meier survival for each of the three
strata of opportunistic diseases is depicted in Fig. 1.
Performance status score 4 predicted 50% I-month mortality,
irrespective of co-morbidity.
Survival of AIDS patients was related to both CD4 count and
AD!. The relative risk of death for patients with early,
intermediate and late diseases within defined strata of CD4
counts is shown in Table IT. The influence of ADI on mortality
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DISCUSSION
This study, undertaken in a resource-limited environment,
showed that the type of ADI was a major predictor of outcome,
and that the opportunistic disease could be used as a
prognostic adjunct to the CD4 count. Stratification of patients
according to ADI and performance status is easily performed,
and therefore widely applicable in resource-poor settings. The
prognostic information provided by these clinical parameters
can be used for counselling and management of HIV-infected
patients.
Extrapulmonary TB and HSV infection (lasting more than 1
month) as initial AIDS diagnoses were associated with the most
favourable outcome and survival was comparable to reported
figures from the developed world"·IO Extrapulmonary TB was
the initial AIDS diagnosis in one-third of our patients, and was
Fig. 1. Survival for the eight commonest AIDS-defining illnesses
could be stratified mto one of three patterns: early diseases include
extrapulmonary TB and HSV, intermediate diseases KS, oesophageal
candldzasls, PCP and cryptococcal meningitis, late diseases
encephalopathy and wastin$. Survival was significantly different for
early (solzd lme), mtermedzate (dotted line) and late events
(intermittent line) (P < 0.00001).
associated with a relatively preserved CD4 count. Our
diagnostic facilities allowed for early detection and treatment
of extrapulmonary TB, which may explain the more favourable
overall prognosis for patients with AIDS in Cape Town
compared with Uganda.'.>
Survival in our patients following cryptococcal meningitis
was similar (7 v. 9 months) to survival of patients with
cryptococcosis in a large European study, ID and predicted
outcome for Kaposi's sarcoma (KS) was similar to that in an
American cohort (12 v. 12.3 months)." The comparability of
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lnitial AIDS-defining illnesses werestratified into early, intermediate and late events according to median survival rates (> 12, 6 . 12, < 6 months). N reflects the number of patients in
each stratum, and median SurvlvallS expressed m months from diagnosis.
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Table n. Relative hazards for death associated with class of AIDs-defining illness and defined CD4 count strata. Values for intermediate
(Kaposi's sarcoma, oesophageal candidiasis, PCP and cryptococcal meningitis) and late diseases (encephalopathy and wasting) are expressed
relative to the risk of early diseases (extrapulmonary TB and herpes simplex) in the same CD4 count stratum. Figures in brackets represent 95%
confidence intervals










10.50 (1.60 - 88.90)
3.18 (1.98 - 4.70)
1.39 (0.50 - 3.56)
Late
21.00 (1.83 - 240.50)
4.33 (1.88 - 30.90)
2.90 (1.60 - 5.(0)
African and Western AIDS survival figures supports the notion
that access to care is an important determinant of the survival
of African AIDS patients.!
Reports from sub-Saharan Africa suggest that wasting
syndrome is cornmon,'~ and post-mortem studies have
revealed that TB is highly prevalent in cachectic African AIDS
patients.!' HIV-positive patients who presented to our clinics
with a wasting illness were thoroughly investigated for TB by
means of sputum smears and culture, histology of lymph node,
liver or bone marrow, and blood culture. The resulting high
frequency with which TB was diagnosed, and the relatively
low prevalence of diarrhoeal illnesses in South African HIV-
positive patients,'S may account for the small number of
patients with unexplained HIV-wasting syndrome in this study.
The type of ADI;'!O prior HIV or AlDS-related morbidity,"
totallymphocyte count'.6 and performance status!7 all provide
useful prognostic information in patients with advanced HIV
infection. This study has grouped opportunistic illnesses into
three categories, as cases were recruited from a single site and
hence numbers for individual diseases were small. Although
the survival difference for the three groups was marked, and
the outcome for each group is consistent with our clinical
observations, we cannot exclude the possibility that these
diHerences occurred by chance because of post hoc
classification. Our stratification would therefore need to be
validated prospectively in an African setting.
.Prognostic stratification of HIV-infected patients is
particularly relevant in resource-poor countries in order to
avoid irrational spending of scarce health care resources.
Expensive investigations or therapy could then be limited to
patients with favourable prognostic criteria. Survival figures of
patients with performance status 4 or diseases such as HIV
wasting syndrome or encephalopathy, on the other hand,
supports the institution of home-based terminal care for these
riI'I patients.
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The spectrum and prognosis of AIDS-
defining illnesses in Cape Town




Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine,
and Department of Clinical Pharmacology, Faculty of Health Sciences, University of Cape Town
Objectives. To describe the incidence, spectrum and prognosis of AIDS-defining illnesses (ADI) in patients without access to
antiretroviral therapy (ART). 
Design. Prospective cohort study.
Subjects. 1 215 HIV-infected patients attending adult HIV clinics affiliated to the University of Cape Town in the New Somerset
and Groote Schuur Hospitals from 1992 to 2000. 
Main outcome measures. Incidence rate (IR) of ADIs and survival after the development of ADI.
Results. During follow-up, 430 ADIs occurred (IR = 21.3 cases per 100 patient-years (PYs)). IR varied according to CD4 count, with
38.8, 17.0 and 8.52 cases/100 PYs in patients with CD4 counts < 200 cells/µl, 200 - 350 cells/µl and > 350 cells/µl, respectively.
Tuberculosis (TB) was the commonest ADI, followed by candidiasis of the oesophagus/trachea/bronchi. IRs for chronic herpes
simplex ulcers, HIV wasting, Pneumocystis carinii pneumonia and Kaposi's sarcoma were > 1.00 cases/100 PYs. TB was diagnosed
in all CD4 strata, and was the only illness to occur commonly above 200 cells/µl. The median CD4 counts within 6 months of
diagnosis of ADI ranged from 138 cells/µl for TB to 17 cells/µl for cryptococcosis. Overall, median time to death from date of
diagnosis was 18 months, and ranged from 24.1 months for patients diagnosed with TB to 6 months for those diagnosed with
cytomegalovirus. 
Conclusions. HIV-infected patients with no access to ART in Cape Town are at high risk of AIDS-defining illnesses. This study
provides useful data for designing therapeutic interventions for preventing these infections.
HIV infection is characterised by progressive immune
suppression, which eventually results in the development of
opportunistic diseases.1-3 The spectrum of these infections
varies across the world, and is partially determined by the
organisms that are prevalent in the community.
The spectrum of severe HIV-related diseases in sub-Saharan
Africa is characterised by an abundance of virulent pathogens
such as Mycobacterium tuberculosis, Streptococcus
pneumoniae and Salmonella spp.4,5 Pneumocystis carinii
pneumonia (PCP) is uncommon, and avirulent organisms such
as cytomegalovirus (CMV) and M. avium complex are seldom
found.4,5 Tuberculosis (TB), bacterial infections and malaria are
the leading causes of HIV-related morbidity across sub-Saharan
Africa. In studies reporting CD4 count, the range of cell counts
at the time of diagnosis of severe HIV-related diseases is wide.4,5
While the spectrum of severe HIV-related diseases in
industrialised countries is well described, few published studies
exist describing the incidence and prognosis of HIV-related
diseases in Africa, and the level of immune suppression at
which these diseases occur. Most existing studies are of cross-
sectional design, and is difficult to compare them owing to
differences in referral patterns, study population, criteria for
HIV testing, diagnostic methods, and the disease reported.6
Sound incidence data on severe HIV-related events are
important for designing preventive or curative therapeutic
intervention.
The objectives of this analysis were to estimate the incidence of
AIDS-defining illness (stratified by CD4 count and WHO clinical
stage) and survival after the development of AIDS-defining
illness, and to describe the distribution of the CD4 count within
6 months of the onset of AIDS-defining illnesses in HIV-
infected patients with no access to antiretroviral therapy (ART). 
The analysis was based on the Cape Town AIDS Cohort (CTAC),
which comprises patients from the wide socio-demographic
METHODS
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spectrum of the Western Cape. CTAC is based on patients
attending public sector HIV health care services at New
Somerset Hospital (NSH) and Groote Schuur Hospital (GSH),
which are affiliated to the University of Cape Town. For the
purpose of this analysis, patients presenting with an AIDS-
defining illness at their initial clinic visit or receiving any form
of ART were excluded. 
Data on the CTAC patients were collected prospectively from
1992. Routine demographic, clinical and laboratory data were
collected using a standard computerised format. Patients
presented to the clinic approximately 3 - 6-monthly or more
frequently if clinically indicated. At each visit, patients were
examined for manifestations of HIV/AIDS-related illness and
staged using the World Health Organization (WHO) criteria.7 HIV
diagnosis was confirmed by enzyme-linked immunosorbent
assay (ELISA) and confirmed with Western blot (or subsequently
a second ELISA) on two different blood specimens. The CD4
count was measured approximately bi-annually, using flow
cytometry (Beckman Coulter®, Miami, Fla, USA). Vital status
data were acquired from the inpatient records, via notification
by family or the patient's general practitioner, or by reviewing
local death registries. The analysis was carried using Epi Info
(version 6.0; CDC, Atlanta, Ga, USA) and STATISTICA (release 6.6,
Tulsa, Oklahoma, USA).
AIDS-FREE SURVIVAL AND RISK OF DEATH FROM
ONSET OF AIDS
The Kaplan-Meier method was used to plot AIDS-free survival
curves by WHO stage and CD4 count from the initial clinic visit
date to the date of onset of an AIDS-defining illness. The same
method was used to measure risk of death from the onset of
AIDS. The analysis was further stratified by specific illness. CD4
count was measured ± 6 months from the initial clinic visit, if
not available at the date of the initial clinic visit. CD4 count was
categorised as < 200, 200 - 350 and > 350 cells/µl.
INCIDENCE OF AIDS-DEFINING ILLNESSES
The incidence rate (IR) for each diagnosis was calculated by
dividing the number of new diagnoses of the AIDS-defining
illness that occurred after entry into the cohort by the total
number of the person-years (PYs) of the cohort. The analysis
was further stratified by baseline CD4 count. The time spent in
each CD4 count stratum was summed, yielding PYs by CD4
count stratum, and the incidence rate of each AIDS-defining
illness was calculated as the number of new cases occurring
while in a given CD4 count stratum, divided by the total number
of PYs of observation in that CD4 count stratum. For each AIDS-
defining illness the distribution of CD4 counts (within ± 6
months of the diagnosis of the condition) was examined. All-
cause mortality was estimated for each AIDS-defining illness
using the Kaplan-Meier method. Follow-up was continued until
death, date last seen in the clinic or end-point of the study (31
December 2000). In this analysis, all sites of TB diagnosis
(pulmonary, extrapulmonary or disseminated) were included in
one group. 
STUDY SAMPLE
The study included 1 215 patients who did not use ART during
follow-up and had no AIDS-defining illness before the initial
clinic visit. The baseline characteristics of these patients are
described in Table I. The cohort consists mostly of young
indigent patients with a wide clinical and immune suppression
spectrum. Approximately 50% of these patients received
prophylactic cotrimoxazole at some point of their follow-up.
AIDS-FREE SURVIVAL
Median time to occurrence of an AIDS-defining illness varied
according to baseline CD4 count (ranging from 63 months for
patients with CD4 count > 350 cells/µl to 18 months in those
with CD4 count < 200 cells/µl) and WHO stage (ranging from
56 months for patients with WHO stage I to 18 months in those
with WHO stage III) (Fig. 1). 
INCIDENCE OF AIDS-DEFINING ILLNESSES
During a median 1.66 years of follow-up, 430 AIDS-defining
illnesses occurred (IR = 21.3 cases per 100 PYs, 95% confidence
interval (CI) 19.6 - 23.2) (Table II). Of these illnesses, 255
occurred in patients with CD4 count < 200 cells/µl (IR = 38.8
cases per 100 PYs, 95% CI 35.0 - 42.6), 108 illnesses in patients
with CD4 count 200 - 350 cells/µl (IR = 17.0 cases per 100 PYs,
95% CI 14.2 - 20.2), and 59 in patients with CD4 count > 350
cells/µl (IR = 8.52 cases per 100 PYs, 95% CI 6.6 - 10.9). Eight
illnesses occurred in 30.1 PYs of follow-up in patients with
unknown CD4 count (IR = 26.7, 95% CI 12.3 - 45.9 cases per
100 PYs). Incidence ranged from 10.6 cases per 100 PYs for TB
to 0.05 cases per 100 PYs for endemic mycosis.
Age (mean ± SD) (yrs) 31.3 (± 8.89)
CD4 count
< 200 cells/µl 415 (34.2%)
200 - 350 cells/µl 319 (26.3%)
> 350 cells/µl 446 (36.7%)
Not done 35 (2.8%)
Median (interquartile range) 276.5 (143.5 - 437.0)
WHO stage
Stage I 547 (45%)
Stage II 210 (17.3%)
Stage III 458 (37.7%)







SD = standard deviation.
TABLE I. BASELINE CHARACTERISTICS OF THE COHORT
RESULTS
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CD4 COUNT AT DIAGNOSIS OF
AIDS-DEFINING ILLNESSES
At (or ± 6 months of) the date of
diagnosis, median CD4 counts ranged
from 138 cells/µl for TB cases to 17




Overall, median time to death from date
of diagnosis was 18 months. Median
survival ranged from 24.1 months for
patients diagnosed with TB to 6 months
for those diagnosed with CMV (Table III).
This study reported high rates of AIDS-
defining illnesses among HIV-infected
patients living in Cape Town with no
access to highly active antiretroviral
therapy (HAART). The IR of these illnesses
was high at low CD4 cell strata,
particularly in the < 200 cells/µl stratum.
TB was the commonest illness, followed
by candidiasis of the oesophagus/
trachea/bronchi or lungs. Herpes simplex
virus (HSV) infection, wasting, Pneumo-
cystis carinii pneunomia (PCP) and
Kaposi's sarcoma had an IR > 1.00 cases
per 100 PYs. Disseminated mycosis,
progressive multifocal leukoencephalo-
pathy and lymphoma were rare. TB was
diagnosed in all CD4 strata, and was the
only illness to occur commonly above
200 cells/µl. This study is one of only a
few that have assessed the incidence of
the AIDS-defining illnesses in Africa,
stratified both by CD4 count and WHO
clinical stage. However, the pre-
ponderance of TB and the level of
immune suppression at which it occurs,
and the overall spectrum of illnesses, is
consistent with other reports from the
region.5,8-10 Of note is the fact that most
of the illnesses diagnosed in this cohort
are preventable or are amenable to
treatment. The incidence estimates and
time to AIDS according to baseline CD4
count and WHO stage, and survival
following the onset of each AIDS-
Median AIDS-free survival (months) 
CD4 > 350 CD4 200 - 350 CD4 < 200 Stage 1 Stage 2 Stage 3
63 41 18 56 39 18
Overall < 200 cells/µl 200 - 350 cells/µl > 350 cells/µl 
Illness (2014.8 PYs) (657.5 PYs) (635.1 PYs) (692.1 PYs) N/A
No. Incidence No. Incidence No. Incidence No. Incidence
1 Tuberculosis 214 10.6 111 16.88 62 9.76 39 5.64 2
2 Candidiasis of O/T/B/L 57 2.83 40 6.08 13 2.05 2 0.29 2
3 HSV 27 1.34 19 2.89 7 1.10 1 0.14 0
4 Wasting 27 1.34 15 2.28 6 0.94 6 0.87 0
5 PCP 24 1.19 15 2.28 6 0.94 3 0.43 0
6 Kaposi's sarcoma 23 1.14 17 2.59 2 0.31 3 0.43 1
7 Cryptococcosis 13 0.65 9 1.37 2 0.31 1 0.14 1
8 Encephalopathy 11 0.55 5 0.76 4 0.63 1 0.14 1
9 Cryptosporidiosis 10 0.50 8 1.22 0 0 1 0.14 1
10 Disseminated atypical 
mycobacteria 8 0.40 5 0.76 3 0.47 0 0 0
11 CMV 6 0.30 4 0.61 1 0.16 1 0.14 0
12 Lymphoma 4 0.20 4 0.61 0 0 0 0 0
13 Toxoplasmosis 3 0.15 3 0.46 0 0 0 0 0
14 PML 2 0.10 0 0 2 0.31 0 0 0
15 Mycosis 1 0.05 1 0.15 0 0 0 0 0
Total 430 21.34 256 38.94 108 17.01 58 8.38 8
Incidence = per 100 PY; Candidiasis of O/T/B/L = candidiasis of the oesophagus, trachea, bronchi or lungs;  
PML = progressive multifocal leukoencephalopathy.
TABLE II. INCIDENCE OF AIDS-DEFINING ILLNESSES IN 1 215 HIV-INFECTED PATIENTS WITH NO ACCESS TO HAART
(1992 - 2000) BY CD4 COUNT STRATA
Fig. 1. Kaplan-Meier probabilities of AIDS-free survival according to baseline CD4
count category and WHO stage.
DISCUSSION
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defining illness calculated in this study, are useful data for
designing and assessing the outcome of therapeutic
interventions for preventing and treating these infections.
Survival after AIDS in Africa may be shorter than in
industrialised countries. This may be due to high prevalence of
virulent pathogens in the environment and lack of access to
health care. In a recent review, Holmes et al.5 observed that in
sub-Saharan Africa, TB and bacterial infections are the major
cause of morbidity and mortality among hospitalised patients.
Bacteraemia, particularly caused by non-typhoid salmonellae
and S. pneumoniae, and associated with cryptosporidia and
Isospora belli, are the most frequently isolated pathogens. Non-
typhoid salmonellae and Shigella species are also commonly
isolated when stool cultures are performed. Cerebral
toxoplasmosis, and meningitis due to Cryptococcus
neoformans, tuberculosis and bacterial pathogens, are the most
frequent neurological infections. Infections with atypical
mycobacteria,  Pneumocystis carinii and CMV are rare.5 They
also found that, compared with industrialised countries, death
occurs at a higher range of CD4 counts, although still in the
range consistent with advanced disease. 
The findings of this study have important implications for
health care management of HIV-infected patients. Very few
infections preventable by cotrimoxazole occurred at CD4 counts
> 200 cells/µl. This suggests a limited beneficial effect for
prophylactic cotrimoxazole in patients with CD4 counts at this
level. The high incidence of TB across the different CD4 count
strata indicates that preventive therapy with isoniazid should
be considered early in the course of HIV disease.
This study had the following limitations. Cause of death was
not ascertained, and therefore all-cause mortality was reported.
As such, we are unable to exclude non-HIV-related causes of
death. Median follow-up of 19.9 months is relatively short and
reflects the difficulty of maintaining long follow-up in this
setting. It is therefore possible that the actual incidence rate of
the various infections reported among this cohort might have
been underestimated.
In conclusion, in HIV-infected patients without access to HAART
in Cape Town, the overall risk of AIDS-defining illnesses is high
and increases with lower CD4 counts and more advanced WHO
clinical stage. Early prevention and treatment of these
infections will result in large health benefits. Guidelines for
therapeutic interventions for prevention of AIDS-defining
illness, including ART, in this region should be tailored
according to the spectrum and epidemiology of these
infections.
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Condition All TB WAS KS HSV PCP CRYPS CAND Enc Lymph CRYPO ATYP CMV
Median 18.1 24.1 22.2 17.8 17 14 13.9 9.5 8.6 7.6 6.5 6.4 6.1
survival
TABLE III. KAPLAN-MEIER PROBABILITIES OF SURVIVAL FOLLOWING DIAGNOSIS.
This study was funded by an academic research grant from
Secure the Future, Bristol-Myers and Squibb, and partially
funded by CIPRA-SA (National Institutes of Health, USA). The
authors acknowledge invaluable assistance in data acquisition
from Desmond Tutu HIV Research Centre staff, Dr R Kirsten
(medical superintendent), M Goliath, R Solomons and J Preez
of Somerset Hospital, and M Hassan and J Daniels of the Cape
Town Metropolitan Council. 
TB = all forms of TB; ENC = HIV encephalopathy; PCP = Pneumocystis
carinii pneumonia; TOXO = toxoplasmosis; HSV = herpes simplex virus; KS
= Kaposi's sarcoma; WAS = HIV wasting syndrome; CRYS =
cryptosporidiosis with diarrhoea > 1 month; CAND = candidiasis of the
oesophagus, trachea, bronchi or lungs; ATYP = disseminated atypical
mycobacteriosis; CMV = cytomegalovirus; LYM = lymphoma; CRYB =
extrapulmonary cryptococcosis.
Fig. 2. CD4 count distribution at (or ± 6 months of) the date of
diagnosis.











Fig. 2. Pattern ofadherence to therapy at 12 and 48 weeks of
treatment (Orrell C, Wood R. IAS Abstract, Buenos Aires, 2001).
Fig. 1. Adherence with protease inhibitor therapy (Paterson et al.,
Abstract 1-172, ICAAC, 1998).
high levels of adherence are achievable by South African
patients. Adherence of a black cohort of patients to a variety of
antiretroviral regimens (Fig. 2) was as good as or better than
that attained in many other First-World countries (personal
communication with C Orrell, who will present these data at
lAS, Buenos Aires, in July).
The reasons for poor adherence can be complex, and often go
beyond the doctor-patient relationship.' There are four key
aspects of treatment adherence: the patient, the social milieu,
the treatment regimen, and the programme support offered.
Certain personality traits will make some patients more




70 - 80% 80 - 90% 90 - 95% > 95%
Percentage of tablets taken (as per tablet count)
<70%
< 70% 70 - 80% 80 - 90% 90 - 95%






I---- I---- I---- f--
f- I---- f- c--





























CLl 'lOANS SOCIETY AIDS REVIEW
90
ADHERENCE TO ANTIRETROVIRAL
THERAPY - ACHIEVABLE IN THE
SOUTH AFRICAN CONTEXT?
'Patients will fail to take antiretroviral drugs consistently in
countries of lower income' is a claim in the Harvard Consensus
Statement on Antiretroviral Therapy for AIDS in Poor
Countries' and reflects the perception of many in the
developed world. Approximately one in every five sexually
active adults in South Africa is currently infected with HIV.2~
The majority of these individuals will go on to develop AIDS
and consequently die of the illness. Following the Durban 2000
AIDS Conference there has been increasing pressure from
international organisations and activist groups for the
pharmaceutical industry to reduce antiretroviral costs to the
Third World. Drug prices have now decreased to such an
extent that triple therapy has become an affordable and cost-
effective option for an increased proportion of our population.
An aspect that has received scant attention during the fight for
cheaper therapy is precisely how these therapies will be
delivered to larger segments of the public.
Triple therapy results in markedly decreased mortality for
patients with advanced infection. It also reduces the number of
opportunistic infections and hospitalisations.J.4 Data from both
South Africa and Brazil also demonstrate a reduction in
tuberculosis infections in those taking antiretroviral treatment'
(and personal communication with D Wilson, who will present
data from a South African-treated cohort of patients at lAS,
Buenos Aires, in July 2001). Despite these demonstrable
advantages, therapy itself can be problematic. High pill
burdens, complex regimens and adverse events make
adherence to any antiretroviral regimLn a challenging prospect
for many.
The goal of antiretroviral therapy is to improve health by
reduction of viral load to undetectable levels. This suppression
allows recovery of immune function, reflected by an increase in
CD4+ T cells, and stops disease progression. ear-perfect
adherence is required to maintain viral load suppression, as is
shown in Fig. 1....
Poor adherence usually results in decreased viral
Suppression and may be associated with the development of
drug-resistant virus. Resistant viral strains may be further
transmitted to others.
Data from two major HIV drug trial sites demonstrate that
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ClINICIANS SOCIETY AIDS REVIEW
ANTIRETROVIRAL THERAPY IN
SOUTH AFRICA - CAN WE DO IT?
As antiretroviral (ARV) drug prices plummeted in the last few
months the question of accessibility for t~e public HIV-infected
sector in South Africa became less 'can we afford it?' and much
more 'can we do it?'. Approximately 4.8 million South Africans
are currently infected with HIV, and the majority of them will
go on to develop AIDS and consequently die of the illness'
unless we can introduce ARV medications that are now
increasingly available to the private sector to the public sector
as well.
The logistical challenge of providing treatment on the scale
required in South Africa, with other problems such as a relative
paucity of resources, lack of expertise among treaters and the
need to reach urban and rural populations; will demand
innovative and radical thinking.
The World Health Organisation (WHO) recommends that,
owing to the high cost of antiretroviral drugs, the complexity
of the regimens and the need for careful monitoring, the
following essential services and facilities must be in place
before considering the introduction of antiretroviral therapy
(ART) into any setting:
• Assured access to voluntary counselling and testing.
• Institution <:>f follow-up counselling services for ART to
ensure continued psychosocial support and to enhance
adherence to treatment.
• Capacity to recognise and appropriately manage common
HIV-related illnesses and opportunistic infections (OIs).
• Reliable laboratory monitoring services, including routine
haematological and biochemical tests for the detection of
drug toxicity as well as access to facilities for monitoring the
immunological and virological parameters of HIV infection.
• Assurance of an adequate supply of quality drugs, including
drugs for treatment of OIs and other HIV-related illnesses.
• Identification of sufficient resources to pay for treatments on
a long-term basis.
• Information and training on safe and effective use of ART
drugs for health professionals in a position to prescribe ART.
• Establishment of reliable regulatory mechanisms against
misuse and misappropriation of drugs.
POLITICAL WILL
Before launching into any ideas of 'how to' a few words must
be said about 'want to'. A nation-wide community-based ARV
programme cannot exist without political will and support.
Many issues such as the procurement of the cheapest therapies,
provision of adequate resources and maintenance of
international links with funding bodies and other organisations
are all largely dependent on political backing. Countries such
as Botswana and Uganda and some regions in South Africa
have shown what can be achieved when political will exists.
Botswana is exploring country-wide access to ART, Uganda has
some early access projects, and the Western Cape has achieved
80% mother-to-child transmission (MTCT) prevention coverage
of all pregnant women in the province and has an ART pilot
project run by 'Medicine Sans Frontier' in Khayelitsha, with
plans for more.'
COMMUNITY 'BUY-IN'
Recent media reports have begun to create the awareness of
need in our HIV-infected population and there is growing
dissatisfaction with the obvious and wide disparity between
therapy in the First versus the Third World. MTCT prevention
programmes have done much to sensitise whole communities
to the HIV problem and lift some of the veils of secrecy and
denial.
PARALLELS WITH TUBERCULOSIS CONTROL
The national tuberculosis programme necessitates the delivery
and monitoring for a period of 6 months of a cocktail of drugs,
including relatively hepatotoxic agents, to large numbers of
patients. This is achieved by utilising scheduled therapy
dispensed at primary health care clinics without routine
laboratory safety monitoring, and an adherence strategy based
on directly observed therapy (DOT).'"
The logistics of the tuberculosis programme and a proposed
HIV treatment programme are compared in Table I, and this
comparison will serve as a discussion framework for this
article.
Numbers
Following the recognition of long-term toxicities of ARV drugs,
particularly protease inhibitors, international guidelines have
become more conservative with respect to commencement of
ART. Unlike tuberculosis, where a diagnosis of disease is ImJ
followed by irrunediate treatment, there is a need to be more
circumspect with respect to initiation of ART for HN infection.
In developing countries where resources for treatment are
more constrained than in the First World, we may need to limit
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Table I . Comparison of TB and proposed ARV programmes
Tuberculosis programme Proposed HIV programme










AFB = acid-fast bacilli











Approx. 200 000 per annum
Lifelong
Passive case finding
Clinical ± CD4 < 200/pl
Treating family unit/partners




Clinical ± CD4 ± viral load
Primary health care
ART initially to those symptomatic HIV-infected patients with
AIDS who will derive maximal benefit from therapy.
Case identification
Patients will be identified as suitable for ART by passive case
finding from voluntary counselling and testing sites Mc),
prevention of MTCT programmes, symptomatic HIV-infected
patients presenting to primary health clinics, or patients co-
infected with HIV and tuberculosis presenting to TB clinics.
The diagnosis of AIDS is a clinical definition based on such
manifestations as extrapulmonary TB, Pneumocystis carinii
pneumonia, wasting syndrome, toxoplasmosis and
cryptococcosis. When resources become more widely available,
treatment could be expanded to include patients with WHO
clinical stage 3 disease such as oral candidiasis or hairy
leukoplakia, a CD4 T-cell count < 200/pl, or a totallymphocyte
count < 1 250 cells/plo This strategy would reduce the health
care burden that these patients currently impose on in- and
outpatient health resources.
Treatment modalities
The TB programme has been successfully run from primary
health clinics on a large scale utilising two basic schedules that
are simple and have recognised adverse effects. The scheduled
approach simplifies management, training and drug supplies,
ensures uniformity of medical care, and allows management by
nurse practitioners and/or clinical assistants - a cadre of the
health care profession much utilised in Africa.' Adherence data
from Cape Town have shown that high levels of ART
adherence can be achieved in patients from poor communities,
and that regimens with twice rather than 3 times daily dosing
and with drugs presented in blister packs were associated with
better adherence. In addition, in designing schedules
compatibility with pregnancy and/or tuberculosis medication
will need to be considered. Other simple interventions such as
provision of weekly pill boxes may also assist adherence.
March 2002, Vo!. 92, No. 3 SAMJ
Drug supply
Since an ART programme will involve high-cost drugs in high
volume, there will need to be a secure delivery system. Should
drugs be manufactured locally they will need to be shown to
be biologically as well as chemically equivalent to imported
ones. Finally, since the ARV drugs will be required for a long
time and missed doses may result in viral resistance, there
should be a reliable supply.
Adherence support
Compliance or adherence is a major obstacle to overcome in all
ARV programmes worldwide. The Harvard Consensus
Statement on antiretroviral therapy for AIDS in poor countries
claims that 'patients will fail to take antiretroviral drugs
consistently in countries of lower income',6 and this reflects the
perception of many in the First World. However, data from the
HIV drug trial units in Cape Town and Johannesburg, and the
MSF programme in Khayelitsha, demonstrate that adherence
can be as good as or better than that attained in many First-
World countries.7 Aside from the treatment regimen itself,
adherence is also very dependent on the individual support the
ARV programme offers.' We have trained a group of HIV-
infected peer counsellors in all aspects of ART including
mechanisms of action, side-effect profiles, the rationale of
treatment, and the need for good adherence. It is proposed that
these therapeutic counsellors (TCs) act as a buffer between
clinic staff and patients.The TC will help in the assessment of
treatment readiness in the potential candidate and will run
treatment readiness programmes in the patient's own
language. Patients and TCs would set up alliances which
would enable quicker reporting of serious side-effects and
more careful surveillance of individual patients. In addition the
use of cell phone technology to enhance communication is
being investigated. In a study carried out in a corrective facility
in the USA it has been shown that adherence to ART was much
improved when therapy was delivered with DOT." However,
s
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while long-term DOT is practical in a corrective facility, the
impact of lifelong ART on quality of life in patients leading
busy normal lives needs to be assessed carefully.
HIV often affects more than one family member and
adherence is also improved when family support is availablelO
Wherever possible treatment schedules should be similar for
infected adults and children within the same family to assist
with sid~effectand adherence issues.
Monitoring
This aspect of ARV provision can be costly and has been cited
as a reason for stalling implementation of ART on a wider
scale. Monitoring includes measures of both safety and efficacy.
Safety monitoring. As far as possible the schedules chosen
should comprise drugs that have few side-effects, and side-
effects should be clinically monitorable or easily checked in the
side-room, e.g. haemoglobin. Drugs that cause silent metabolic
or hepatic inflammation, for example, may need to be avoided,
while those to which patients manifest hypersensitivity with a
rash or flu-W<e symptoms are easier to monitor on a large scale.
The patient, TC and clinic staff must be well trained to pick up
drug side-effects for the particqlar scheduleS being used and to
differentiate them from opportunistic infections.
Efficacy monitoring. The First-World model has been that of
quantitative viral load measurement with the goal of viral
suppression. Advances in technology may result in
significantly lower costs of viral quantification in the near
future; however, in resource-constrained settings there will be a
need to explore cheaper monitoring. surrogates such as CD4
count, totallymphocyte count, or combinations of clinical and
simple laboratory tests.
Clinical setting
If the goal of getting .the large numbers of South Africans in
need onto ART is to be realised, the programme cannot be run
from large tertiary urban centers only, but will need an
extensive primary clinic network. In the Western Cape, where
the majority of the population live in the greater metropole
area, strategic use of a few key existing primary health care
facilities where training could be concentrated could
incorporate a large proportion of the HIV-infected population.
In other regions, where communities are more rural and
distances greater, a wider network of primary health clinics
will need to be utilised to ensure extensive coverage similar to
that seen in the TB control programme.
Sustainability
In order to ensure sustainability of drug supply and resources
for ART programmes, both international and national
mobilisation of funding will be needed. International initiatives
such as the Global Fund are one such option. It is also probable
that for reasons of sustainability cheaper generic alternatives
will need to be considered. Sustainability also requires that
where possible the programme be integrated into the existing
health infrastructure with adaptations to local needs. This will
demand sufficient capacity building and training to ensure
ongoing expertise.
CONCLUSION
Most importantly, for an ART programme to give hope to the
4.8 million HIV-infected citizens in South Africa, it will require
bold political vision in terms of national AIDS policy and
thinking. It will not be possible to introduce full-scale
programmes across the country immediately. Yet there is
tremendous urgency to begin. Where infrastructure already
allows we should move forward immediately and have a
systematic well-planned approach to extending the ART
programme to include as much of the HIV-infected population
as possible in the least possible time.
Linda-Gail Bek'ker
Robin Wood
Infectious Disease and HIV Research Units
University of Cape Town
1. Lovelife, Henry J Kaiser Foundation. The Impending CDlastrophe. A Resource Book on lhe
Emerging HIVIA/DS Epidemic in Soulh Africo. Cape Town: Abt Associates. 2000.
.www.lovelife.org.ca
2. Abdullah MF, Young T, Bitalo L, Coetzee N, Mey.,. JE. Public health lessons from a pilot
programme to reduce mother-to-child transmission of I-ITV in Khayelitsha. 5 Afr Med / 2001;
9J, 579-583.
3. Walley ID, Khan MA, Newell IN,.Khan MH. Effectiveness of the direct observation
component of 0015 for tuberculosis: a randomized controlled trial in Pakistan. LAncet 2001;
357, 664-669.
4. Laing RO, McGoldric.k KM. Tuberculosis drug issues: prices, fixed.-dose combination
products and second-lioe drugs. loll I Tuber< Lung Vis 2000; 4 (Dec), 12 suppl2: Sl94-207.
5. Adeloye A. Surgical services and training in the context of national health care policy: the
Malawi experience. J Trap Med Hyg 1993; %: 215-221-
6. Individual members of the faculty of Harvard University. Consensus statement on
antiretroviral treatment for AIDS in poor countries, Apri12001. http://aids.harvard.edu
7. Orrell C, Badri M, Wood R Data on antiretroviral adherence in Cape TO\\'I\, South Africa. 1st
1AS Conference on HI\' pathogenesis and treatment, Buenos Aires, Argentina, 8-11 July 2001.
www.aids2001ias.org
8. Davidson H, Smimoff M, Klein SI. et al. Patient satisfaction with care at directly observed.
programmes for tubeIculosis in New York City. Am J Public Heolth 1999; 8'/,1567-1570.
9. Hschl M, Rodriguez A, Scerpella E, et al. Impact of directly observed therapy on outcomes in
HlV clinical trials. 7th CooIerence on RelrOviruses and Opportunistic Infections, Chicago, ill.:
2000 (abstract 71).
10. Akkslip S, Rasmithat S. Maher 0, et al. Direct observation of tuberculosis treatment by
supervised family members in Yasothom Province, Thailand. 1nl JTuber< Lung Vis 1999; 3:
106],]065.
11. Alrica Uve Database. http,UwblnOO18.worldbankon;/afr/afr.nsI
.-   
> 
il  l -t r  O  is r ti l i   rr ti  f ilit , t  
i t f lif l    lit  f lif  i  ti ts l ffi  
 l li s s t   s  refu ly. 
 t  t   t   il  r  
 i  l  i r   il  rt i  il l .to 
r  i l  t t l  l   i il   
i  lt   il  it i  t     i t 
it  e-eff    i es. 
 
            
    t l        
l .        i acy. 
         
      t   
          
  l i .     l  
          
         
  -lik          l . 
             
 l    tj  les     
     
         
         
       
         
         
    ,     
 l l        
   
  
     t        
            
          
   rk      
          
           
  t i      
        
    i      
i t  ,        
ill     t  . r  i   il   
t  i    t l . 
 
 r r t   s st i ilit   r  l    
f   r , t  i t r ti l  ti l 
ilis ti  f f i  ill   I t r ti l i iti ti  
s  s t  l al  r   s  t , It is l  r l  
t t f r r s s f s st i ilit  r ri  lt  
ill  t   i  st i ilit  ls  re ir s t t 
her  ssi l  t  r r   i t r t  i t  t  isti  
lt  i fr str t r  it  t ti s t  l c l eeds. is ill 
 s f  acit  il i   tr i i  t  s r  
i  ertise. 
I  
 i t       i    t  
.   i     ri , it ill  
 liti l     ti     
  ill    t    
    iately.    
   i .    
         
       
         
      . 
  
  
      
    
I  .    .   atasl1O .  k;oUTC<   t  
i  NI l  i i  i  t  jriCJJ.  : t ss i t s. . 
\\ww.1 li  
. ll  .  , it l  . t  . yers . li  lt  l  fr   il t 
r r  t  r  t r-tO< il  tr i i  f HN i  lit .  fr  / ; 
1: . 
. 'N ll  J .  . il I .  . ff ti  f t  ir t r ti  
  OOTS      i l i  . D   
  
. i  , ric  .    , -- .   
r t   ·lin  r . lilt / c  Di  ;  ( ).  l:C 51 - , 
. l  . r i l s r i s  tr i i  i  t  t t f ti l lt  r  li : t  
 , /     96, . 
. I i i l r  f t  f r lt  f rvard. i r it .  t t t  
tir tr ir l tr t t f r I  i  r tri , ri . tt :/ ai . r r .  
, rr ll . Sa ri .  . t   tir tr ir lac! r  i   own. t  fri . st 
l  f r   I-flV t i   tr t t,  ir s, r ti , &-  l  . 
\\'WW . .id i s. r  
.  ,    5J,  I    it    ir l  d 
r r  f r t r l i  i  '  r  Gt ,  / li  alt  ; <), - , 
, FLSC l . ri  . r il  . t I. I t f ir tl  s r  t r   t  i  
I  li i l tri l . t  nf r   trovir   rt i ti  I f ti , i . ill, 
 (abstr   
. sli  , s it t 5. r D. t I, ire t r ti  f t r l sis tr t t  
s r is  f il  r  i  t  r i . il , Inl / c  Di  ; , 
1061·1 . 










~ . ORIGINAL ARTICLESL-----.----.
Table VI. Logistics regression report
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Days (in hospital) 0.005
Blunt (l = blunt) 0.054
Age -0.019
Hospital (l =JH) -0.463
Helicopter (l = helicopter) -1.300

















EXPLORING THE COSTS OF A
LIMITED PUBLIC SECTOR
ANTIRETROVIRAL TREATMENT
PROGRAMME IN SOUTH AFRICA
Andrew Boulle, Christopher Kenyon, ]olene Skordis, Robin
Wood
highly significant variable, only the patient's age is possibly
significant (P = 0.076). Not surprisingly, the older the patient
the less likely the TRISS methodology is to predict the
probability of survival or death correctly.
CONCLUSION
Helicopters clearly deserve a place in the emergency care of
trauma victims. However, this is only one link in the chain that
will ultimately lead to either death or survival. For it to be
successful, it must link reliable, efficient emergency medical
services (road-based) and effective trauma' centres that are
staffed appropriately with a committed team of health care
professionals. If used appropriately there appears to be little
doubt that these expensive machines can play an important
role in preventing certain unnecessary deaths while reducing
costs for both individuals and health care facilities""
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Bar;kground. The role of antiretroviral treatment for adults in
the pubic sector in South Africa is debated with little
consideration of programme choices that could impact on the
cost-effectiveness of the intervention. This study seeks to
explore the impact of these programme choices at an
individual level, as well as explore the total cost of a rationed
national public sector antiretroviral treatment programme.
Methods. Eight Scenarios were modelled of limited national
treatment programmes over the next 5 years, reflecting
different programme design choices. The individual cost-
effectiveness of these scenarios were compared. The total
costs of the most cost-effective scenario were calculated, and
the potential for savings in other areas of health care
utilisation was explored.
Results. The direct programme costs per life-year saved
varied between scenarios from R5 923 to R11 829. All the
costs of the most cost-effective scerJario could potentially be
offset depending on assumptions of health care access and
utilisation. The total programme costs for the most cost-
effective scerJario in 2007 with 107 000 people on treatment
are around R409 million.
Conclusion. Specific policy choices could almost double the
number of people who could benefit from an investment in a
limited national antiretroviral treatment programme. Such a
programme is affordable within current resource constraints.
The consideration of antiretroviral treatment calls for a
unique public health approach to the rationing of health
services in the public sector.
S Afr Med J 2002; 92: 811-817.
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Table I. Description of modelled scenarios and sensitivify analysis scenarios
The cost per life-year gained is presented at 5 years for the following eight inteIVention options:
(A) Baseline (generic medication, baseline testing and visit costs)
(B) Optional (higher proportion of doctor visits, and additional viral load testing)
(C) Patent medicine pricing scenario
(D) Second-line treatment offered to 50% of those with virological failure on first-line treatment at generic medicine prices
(E) Second-line treatment offered to 75% with virological failure on first-line treatment at generic medicine prices
(F) Patent medicine pricing and optional testing and consultation schedule (B & C combined)
(G) Patent medicine pricing, optional testing and consultation schedule, and 50% of those failing first line offered second-line treatment
(B, C & D combined)
(H) Second-line treatment offered to 50% of those with virological failure on first-line treatment at generic medicine prices, with optional
testing and consultation parameters (B & D combined)
In addition, sensitivity analyses are produced for the following seven changes in assumptions:
SI. (A) with no discount over time for medicines
52. (A) with a 15% per annum discount over time for medicines for 3 years, followed by 7.5% annually
53. (A) with no additional costs for each consultation compared to current services
54. (A) with 2.5 times the current consultation costs for each consultation
SS. (A) with increased mean survival on first-line treatment to 3.6 years (from 2.68)
56. (D) with increased mean survival on first line to 3.6 years and 7.41 years for consecutive regimens
57. (A) with no provision for visits to the new services for people who are not on ARVs, and
58. (D) with no discount over time for medicines
Whereas the role for antiretroviral therapy (ART) for HIV has
been an issue for scientific and public debate in South Africa, a
number of middle-income and poor countries have already
initiated treatment programmes in spite of resource constraints
(Brazil, Chile, Thailand, Nigeria, Senegal, Cote D'Ivoire). The
recent publication by the World Health Organisation! of
guidelines for the scaling up of antiretroviral treatment
programmes is indicative of both a convergence of clinical
thinking and the increasing pressure on health care systems to
provide antiretroviral interventions.
In addition to the survival and quality of life benefits for
individual patients,'.3 many authors have pointed to the
synergies between antiretroviral treatment programmes and
preventive strategies.<-7 Others have compellingly described the
role extended HIV survival could have in reducing the burden
on society and preserving our human and social
infrastructure.·"
The following model costs a rationed national antiretroviral
treatment programme for adult South Africans that could
conceivably begin in 2002. From the perspective of the public
health system, we explore the relative cost-effectiveness of a
number of ART-related policy options and the overall resource




The approach to costing ART provision is based on an
October 2002, Vol. 92, o. 10· SAMJ
emerging service model in which:
• Specific HIV/ AIDS services are required to develop the
relationships between patients and clinicians, to ensure
continuity of care, and to provide a mechanism through
which patients can be evaluated for potential enroIlment
onto an ART programme.
• Consequent on meeting predetermined eligibility criteria,
which are a combination of clinical and (possibly) soc~al
assessment; patients are considered eligible for ART around
the time that they become AIDS symptomatic.
• After commencing treatment, patients are managed through
the HIV/ AIDS service, but still attend regular services for
other routine and acute care.
Numbers on treatment
A spreadsheet model vvith eight scenarios (Table 1) was used to
anticipate the numbers of people on antiretroviral treatment
over the next 10 years. In the model, the number of new
patients receiving treatment was gradually increased over 5
years. The cumulative number of people surviving on
treatment in the model by the middle of 2007 varied between
scenarios from 106 911 to 117621, depending on survival
assumptions and whether or not second-line treatment was
offered to a proportion of those failing the first-line regimen
(Fig. 1).
Those on treatment were stratified into a number of
subgroups, reflecting those on a first-line regimen, those on a
second-line regimen, and those failing treatment. The first 6
months of a new regimen were distinguished from the
remaining time on the regimen. The model was run for a
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0 D: 50% accessing second line 3179 10586 27930 61420.~
c E: 75% accessing second line 3204 10677 28249 62254
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medicines, the price of the
combination tablet was included.
Future price changes are another
important variable in anticipating
medicine costs. The model
presented assumes an annual price
reduction in real terms of 10% per
year for the first 3 years and 5%
annually thereafter. Sensitivity
analysis explores the impact of no
reduction in price and a 15% initial
reduction (for the first 3 years)
followed by 7.5% per annum.
Fig. 1. Numbers on treatment btJ category of treatment in modelled scenarios.
Laboratory monitoring
further 5 years with constant assumptions in order to explore
the medium-tenn impact of deferring costs. By 2007 the
numbers of people accessing treatment in the model could
represent 10% of those becoming AIDS-symptomatic that year
(compared with estimates of adult deaths in the subsequent 2
years lO). The combined impact on new infections of extended
survival, reduced viral load and altered behaviour for those on
treatment was assumed to be neutral compared with a no-
treatment scenario. Additional or averted new infections are
likely to have little impact on the total direct treatment costs in
the timeframe of this analysis.
Direct programme costs
Medicines
The biggest cost-driver of ART is undoubtedly the medicine
costs. In this model, the limited number of medicines selected
is sufficient for a single regimen or for two independent
regimens, while still sufficiently restricted to limit costs in both
the generic and patent pricing scenarios. It is assumed that all
rationally selected starting regimens have equivalent treatment
outcomes.1!
The estimated proportion of patients likely to switch from
any single medicine due to intolerance is based on the
experience to date in Khayelitsha12 validated by HIV clinicians.
In cases of single-medicine changes, the first 6 months of
treatment are apportioned to the starting medicine, while the
remaining time on the regimen is apportioned to the medicine
to which the patient changes. In effect virological failure and
intolerance are modelled separately, with the crude assumption
that 6 months is the average time at which a medicine is
changed for reasons of intolerance. It was necessary to include
intolerance-driven individual medicine switches within first-
and second-line regimens as they impact significantly on
overall medicine costs in the baseline scenario (where generic
pricing is utilised). Where a combination tablet could
Based on the WHO
recommendations,' the model incorporates two testing
scenarios. The first provides for all tests (including a h\ice-
yearly CD4 count and a CD4 count before enrolment) except
for viral load testing. The second is an optional scenario in
which viral load tests and CD4 counts are conducted three
times a year.13
Visit costs for the antiretroviral treatment programme
Allowing that consultation costs (including additional staff
training) may be higher than for standard primary care
consultations, a factor of 1.5 is applied to the average cost of a
primary care consultation in the Western Cape metropole
(where there are doctor- and nurse-driven services). This factor
is varied between 1 and 2.5 in the sensitivity analysis.
The visit schedule applied is that used in the current Medicin
Sans Frontieres treatment protocol' to estimate the additional
visits required as a result of ART. Again two scenarios are
built; one in which a proportion of the visits are at a lower cost
structure as the visit is principally to ensure adherence and
dispense medicines, and another where the majority of the
visits are with a doctor.
Provision is also made for visits to HIV/ AIDS services by a
proportion of HIV-infected people in WHO clinical stage 3.
This proportion is set equal to the proportion of patients
accessing treatment when becoming AIDS-symptomatic. The
model assumes an average of 3 visits per year for those not on
antiretrovirals but attending the HIV/ AIDS services as a
prelude to possible enrolment in an ART programme. These
visits are costed at the existing clinic consultation costs, and
fonn a substantial component of the workload.
Anticipating the individual benefits of treatment
The survival benefits of ART are not yet fully described.
Published data at 3 years since the initiation of therapy,
however, suggest a remarkable reduction in the anticipated
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mortality.2.3 UNAIDS currently recommend that a survival
benefit of 5 - 7 years be used for HIV modelling in rich
countries. I ' Early indications suggest that a rationed programme
in South Africa is likely to have comparable benefits to rich
countries, taking into account baseline immunological
characteristics at the onset of treatment. I5.J6 The model below
uses a median survival from initiating treatment of 4.5 years if
two regimens are offered (weibull distribution, mean of 6.06
years of which the benefit is 4.46 years). The model assumes that
treatment is failing for a period at the end of treatment of
equivalent duration to WHO stage 4. It is further assumed that,
of the survival benefit, 60% is derived from the first regimen,
and the remainder from an alternative regimen. For the
scenarios in which second-line treatment is included, it is
assumed that not everyone in whom a first regimen fails will be
offered a second regimen, either because they have exhausted
their affordable treatment options through intolerance-driven
individual medicine changes, or because they do not meet
additional eligibility criteria for second-line treatment.
The life-years gained derive directly from the survival
benefit assumptions, and are calculated as life-years gained per
year on treatment while treatment is not failing (Fig. 2).
Benefits on broader health care utilisation
Although antiretroviral treatment does not prevent the
eventual morbidity and associated health care utilisation that
occurs in the terminal stages of HIV infection, this utilisatiQn is
deferred by the duration of the survival benefit. Within the
realistic timeframes of any planning exercise of this nature, this
deferment could result in a real benefit to the health care
system. The key contributors to the cost saving are the
principal cost drivers of hospital inpatient days, ambulatory
consultations and tuberculosis treatment. To discounting was
applied to deferred costs.
The estimates used (Table Il) are similar to those used in
other HIV costing studies."·I'
o E
0%, 50%, or 75%
,-------------,- - - - - - - - - -
Second line non-failing, mean 1.78 years: Failing'treatment, mean 1.6 years
~__~B~ ~ £ _
1 - 10% First line non-failing, mean 2.68 years
A
HIV infection until stage 4: Mean 7.5 - 9.1 years : Si;;ge 4-:-Mea;:; 1-:-47- 1.8 years
, Failing treatment, mean 1.6 years
Life years saved per non-failing year on treatment
Fig. 2. Survival and effectiveness assumptions.
First line: (B+G-A)/B ~ 1 Second line: (D+E-G)/D ~ 1
~lI:lU
Table n. Cost and utilisation assumptions
Utilisation Cost
Units Stage 4 ARVFL ARVSL Failing Units Min. Max.
on-ARV HIV-related clinical costs
Hospitalisation (I) Inpatient days 18.8 2.8 3.8 18.8 Inpatient day R530 R530
Clinic consultations (2) Extra consults 11 2 2 11 Visit cost R73 R73
Tuberculosis (3) Annual risk 36% 4% 4% 36% Treatment cost R1560 R1560
ARV-related costs
ARV medicine costs (4) ARV utilisation 100% 100% 50% Annual cost R4612 R15288
ARV laboratory costs (5) Extra tests Yes Yes 0 Annual cost R457 R2206
ARV visit costs (6) Visits 12 12 3 Annual cost R821 R986
(I & 2) Utilisation assumptions the same as used in the studv by Abt and associates)' with a reduction in length of stay from 10 days to 8 days for stage 4 based on more recent
inpatient studies. Clinic visits are calculated at the current price per consultation in primary health care services in Cape Town, and reflect excess visits as a result of HN. Utilisation
while on ARVs is premised on an 80% reduction in hospitalisation and clinic visits compared "....ith stage 4.
(3) Taken from cohort data in Cape Town," with additional assumption of relative risk of tuberculosis between stages 4 and 3 of 2, and relative prevalence between stages 3 and 4 of 2.
Cost per completed treatment from Western Cape Department of Health, reflecting only a proportion (60%) of the DOTS-related costs so as not to doubl~ount the tuberculosis-related
PHc, medicine and hospitalisation costs.
(4) Starting regimen in generic scenarios is Triomune (o4T, 3TC, l\,'VP, S295/year), with 57% still on Triomune by 6 months due to intolerance-driven individual medicine switches.
Second-line regimen for generic scenarios is All, DDI and INV/RTV. The same regimen is the cheapest patented regimen as well (used here as individual drugs) unless DOl and D4T
are combined. Medicine costs calculated for on average half of the time after treatment has started failing. It is hoped that LPV/RTV could replace INV/RTV wilb little impact on costs
if preferential pricing is obtained. .
(5) Range of tests depending on individual medicines include FBC, diff., creatinine, ALT, cholesterol, glucose and amylase. Twice-yearly CD4 counts (R83 per test) are included
additionally in pragmatic scenarios. Thrice-yearly viral loads 0050 per test) and CD4 counts are included only in the 'optional' scenarios.
(6) 80% of visits in the 'optional' scenarios, and 60% in the remaining scenarios, are \,'ith a doctor. The non-doctor visits are with a nurse and I or counsellor, and are principally to
support adherence and dispense medicines. Doctor visits are calculated at the current price per consultation in primary health care services in Cape Town, with an additional cost of
50% varied to an additional 150% in sensitivity analysis. Non-<loctor visits are costed at 75% of the reference costs.
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~: . ORIGINAL ARTICLES
RESULTS
Direct treatment costs
The direct costs of treatment for the baseline (A and D)
scenarios were stratified by regimen and by the first 6 months
on each regimen (Fig. 3). The first 6 months of treatment are
disproportionately expensive compared with the subsequent
annual costs, especially with respect to laboratory and
consultation costs. The differential between first-line and
second-line medicine prices when accessing generic medicines
is clearly evident. The costs per treatment year (after the first 6
months) vary .between scenarios and regimens from R5 890 (A:
first-line) to R15 288 (G: second-line). Medicine costs dominate
expenditure across all scenarios and regimens.
Cost per life-year gained
The use of generic versus patented medicines is the single most
important factor impacting on the costs per life-year gained at
5 years (Table ill). The cost per life-year gained is 48 - 53%






A4.000 - I--- -
C:J - I--- r---A2.000 r l
AO
First line, initial Rrstline Second line Second line
6 months annually initial 6 months annually
o Consuttations A93' AB21 A767 R821
• Laboratory A7B9 A40'7 R724 A473
o Medicines Al.649 R4,612 A4.704 AB.933
Total A3.3GB AS.Boo R6.195 Al0.227
Changing costs for baseline (A) scenario based on regimen








Generic Generic Patient Patient, Optional
Pra9matic (A) Optional (B) Pragmatic (C) (F)
o Consultations f-_A_82_'_-+-_A_986__+-_A_B2_'_-+__A986_----j
• Laboratory A457 A2,19O R457 R2,19O
o MedK:ines A4,612 A4.612 AB,668 AB.668
Total AS.Boo A7.7aB A9,946 All.843
Differential costs between scenarios, for the first-line regimen
following the initial 6 months of treatment, 2002 prices
Fig. 3. Direct costs at an individual level for antiretroviral
interventions.
testing and switching most of the consultations to doctors
increased costs by a further 45%. Combining patented
medicines with optional laboratory monitoring and
consultation schedules yielded a 99% increase in the cost per
life-year saved (F).
In those scenarios where second-line treatment is included at
generic prices (D and E), the marginal cost per life-year saved
when adding this treatment is 36 - 39% higher than the baseline
cost (A: first-line only).
5ensitivity analysis reinforced the pivotal role of assumed
changes in future medicine pricing (51 and 52: 23% increase in
the baseline cost per life-year saved over 5 years if no price
reductions). It also demonstrated the relatively small impact of
changing assumptions on the services required before
enrolment (57), the cost-structure for consultations (53 and 54),
or the duration of the survival benefit on treatment (55 and 56).
Total costs and potential resource savings as a result
of deferred treatment
In the most cost-effective scenario, the total direct costs of a
programme of this size are estimated to be R409 million in the
year 2006 - 2007. Taking into account the deferred
hospitalisation and consultation costs for those on ART, there is
a considerable impact on resource utilisation. When quantified
financially over 5 years, this covers the cost of antiretroviral
treatment 035% of direct programme costs averted). At 10
years some of the deferred costs have re-entered the system,
reflected by a reduction in cumulative savings as a percentage
of the direct intervention costs over this period (90% of
intervention costs) .
DISCUSSION
This exercise illustrates how policy choices impact on the
benefits of a rationed ART programme and how those benefits
are distributed. It is immediately apparent that accessing
cheaper medicines could significantly extend the impact of
such an intervention. We used generic pricing in our baseline
scenario based on the sincere belief that it is a realistic policy
option which has been successfully applied in a number of
countries (generics of zidovudine and lamivudine have
recently been registered by the Medicines Control Council,
although they are still inaccessible due to patent restrictions). It
is sometimes argued that medicine costs are over-emphasised.
This analysis supports a strong emphasis on medicine costs.
While the cost of monitoring patients on ART has fallen over
the past year, some investigations (viral load testing in this
analysis) remain prohibitively expensive for the benefit they
add, and should not necessarily be an automatic component of
a public sector programme until their costs are reduced.
The marginal cost per life-year saved when adding second-
line treatment to the baseline scenario was considerably higher
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Table m. Cost-effectiveness and sensitivity analyses
% change % change
from Marginal from first
Cost/life-year baseline cost/life-year line
A: Baseline R5923
B:Optional R8595 45
C: Patent pricing R9089 53
D: 50% second-line access R6082 3 R8215 39 (l)
E : 75% second-line access R6136 4 R8042 36 (2)
F: B & C combined Rll 761 99
G: B, C & D combined R1l829 lOO R12736 8 (3)
H: B & D combined R8775 48 Rll 202 23 (4)
Sensitivity analysis
51: A with no medicine discount R7266 23
52: A with medicine discounts 50% higher R5 388 -9
53: A with no additional cost for consultations R5571 ---{j
54: A with visit cost factor 2.5 R6627 12
55: A with first-line survival 4 years R5675 --4
56: D with combined survival of 6.5 years R5797 -2 R8184 44 (5)
57: A with no non-ARV visit costs R5398 -9
58: D with no medicine discounts R7528 27 Rll 048 52 (6)
(l & 2) compared to A, (3) compared to F, (4) compared to 5, (5) compared to SS, (6) compared to 51.
(39%) than the cost without this option. This increase is
partially masked by the reductions in medicine prices over
time, as those accessing second-line treatment are doing so a
few years into the programme. One sensitivity analysis (58)
demonstrates that the marginal increase could be as high as
52% without the effect of the medicine price reductions.
Although clinicians baulk at limiting ART to a single tier of
therapy, the option of spreading a smaller ben fit to a greater
number of patients needs serious consideration, bearing in
mind the additional health system implications of enrolling
additional new patients. We are not necessarily advocating
that only one tier of therapy be considered. A gradual .
implementation of ART would have relatively few people on
second-line treatment by 5 years, with the total programme
costs not being considerably more expensive than the baseline
programme cost presented. It is also likely that the differential
cost between first- and second-line treatment will reduce over
time as a greater number of antiretrovirals are produced by
generic manufacturers. If the price differential remains large
and financial resource constraints are considered the limiting
factor to more widespread treatment, and if maximal diffusion
of treatment is a policy goal, then an examination of the
marginal costs of second-line treatment will remain important.
Even yvithout offsets, the total costs of a programme of this
size are a small fraction of anticipated health sector
expenditure on HIV/ AIDS. Although many may find the size
of this programme unpalatably small, a programme that is
approaching 100 000 people on treatment within 5 years would
be a significant achievement.
October 2002, Vol. 92, 0.16 SAM]
This study has a number of limitations. Importantly, in the
absence of an existing policy to provide antiretrovirals as
treatment for adults in the public sector, it was necessary to
piece together assumptions from many different sources. Some
assumptions should be treated with great caution, in particular
those anticipating health service utilisation in the absence of
antiretroviral treatment.
Although estimates of health care utilisation that derive from
cohort studies may not apply to the whole population due to
unequal access, it is likely that those who do access the ART
programme would have been able to access clinical services
had they not received the intervention. Given the huge excess
demand for services, it is unlikely that averted utilisation will
result in financial savings in any but the least-affected
provinces, resulting instead in better quality of care for those
who would otherwise be unable to access services. The re-
entry into the system of deferred utilisation only partially
erodes these gains even at 10 years, and should not deter
health planners from comprehensively responding to the
immediate crisis.
It has been demonstrated that with the correct policy choices,
the cost of providing an ART intervention could be
considerably cheaper per year of treatment than has been
quoted by many of the studies that have deemed ART to be
unaffordable. 17•19.2ll It has been further demonstrated that the
averted costs could result in savings that make the intervention
cost-saving, or at least significantly more cost-effective than an
examination of the direct costs yields. This is only from the
perspective of the health sector without consideration of
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possible synergistic prevention gains. Even with the averted
costs factored in, when the modelled intervention is scaled up
to cover much greater percentages of those in need, it demands
extraordinary expenditures. How can a cost-saving
intervention be unaffordable?
The public health system is implicitly rationing services
through reduced access to care, and the extent of this is likely
to increase. A modelled ART programme that assumes more
extensive access than is implicitly provided for non-ART
services at present, ,vill appear unaffordable even if it is cost-
saving at an individual level.
CONCLUSIONS
There are very clear policy choices, political and clinical, which
for the same expenditure could double the number of people
benefitting from a rationed ART programme. A programme
that utilises generic medicines, is pragmatic with respect to
laboratory monitoring and consultations, and maximises the
diffusion of benefits, is the most cost-effective, and is
considerably cheaper than many previous estimates suggest.
Whereas we should strive to provide treatment to as many of
those in need as possible through the future mobilisation of
additional resources and campaigning for price reductions in
medicines and laboratory tests, a rationed treatment
programme is currently affordable ""rithin existing resource
constraints, and would have enormous benefits. We should not
make our provision of this intervention consequent on raising
additional resources, and the decision to proceed could in fact
aid our attempts to mobilise external financial resources. The
public good reswting from the broader impact on prevention
and morale, which is arguably one of the major benefits of
introducing a rationed programme now, could be substantially
realised with relatively small numbers on treatment.
The present and anticipated HIV burden on the public health
care system is such that rationing is inevitable, with the
prospect of planning for a new intervention such as ART
requiring us to be explicit about our inability to meet demand.
This paper serves to highlight the need for a revised public
health discourse around rationing to deal with the unique
challenges faced in providing antiretroviral interventions
where they are most needed.
antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-
129.
:J. Hogg RS, Yip B, Chan KJ. et al. Rates of disease progression by baseline CD:l cell count and
viral load after initiating triple-<!rug therapy. JAMA 2001; 286, 256&-2577.
4. Berkman A. Confronting global AIDS: prevention and treatment. Am ] Public Health 2001; 91:
1348-1349.
5. Farmer p. leandre F, Mukherjee JS, et al. Community-based approaches to HIV treatment in
resource-poor settings. l.Jmcet 2001; 358: 404-409.
6. Moatti Jp. N'[)oye I, Hammer SM, Hale P, Kazatchkine MD. Antiretroivral treatnle,nt for HIV-
infected adults and children in developing countries: some evidence in favour of expanded
diffusion. State of the Art: AIDS and Economics 2002; July, 96-116.
7. Kenyon C, Heywood M, Conway S. Mainstreaming HIV/ AIDS: Progress and challenges. In:
Ntuli A, ed. South African Health Revie-..o 2001: 161-183.
8. Bradshaw D, johnson L, Schneider H, Bourne D, Dorrington R. O.-phans of the HIV/AlDS
Epidemic: The Time to Act is Now. Tygerberg: Medical Research Council, 2002.
9. Medicin Sans Frontieres. Affordable Antiretrouirals in South Africa: Protocol. Cape Tov.rn: MSF.
2001.
10. ASSA2000lite Aids and Demographic Model of the Actuarial Society of South Africa,
http://www.ossa.org.... (I)ownloadOO on 13 Sept 2001).
11. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of
triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15: 1369-
1377.
12- Reuter H, Kasper T, PooIe, C, Skefile V, Goemaere E. Frequency, type, severity, and duration
of adverse drug events on highly-active antiretroviral therapy (HAART) in a resource-poor
setting. 14th International AIDS Conference, 2002.
13. Southen African HlV Clinicians Society. OinicaJ Guidelines' Antiretroviral Therapy in
Adults. June 2002 version. Southem African /aumal of HIV Medicine 2002; July, 22-29.
14. lmproved methods and assumptions for estimation of the HN/ AIDS epidemiC and its
impact R&..--ommendations of the AIDS Reference Group on Estimates, Modelling and
Projections. AIDS 2002; 16, WI·14.
15. Medidns Sans Frontieres. Providing Antiretrcruiraf Therapy at Primary Care Clinics in Resource
Poor Settings. Cape Tmvn: MSF. 2002.
16. Orrell C, Sekker lG, Wood R Adherence to antiretroviral therapy - achievable in the South
African context? S Afr M~d /2001; 91: 483-484.
17. Abt Associates. HlV facts, figures and the future. in, Ntuli A, 00. South African H"'lth Review,
Durbano Health Systems Trust, 2000.
18. KarstaOOt AS, Lee TCM, Kinghom AW, Schneider H. Care of HlV-infectOO adults at
Barag....anath Hospital, Soweto: Part Il. Management and costs of inpatients. 5 Afr Med J
1996; 86, 1490-1493.
19. Z\..i K, Soderlund ,Schneider H. Cheaper antiretrovirals to treat AIDS in South Africa.
They are at their most cost effective in preventing mother to child transmission. BMI 2000;
320: 1551-1552-
20. Wood E, Braitstein P, Montaner JS, et al. Extent to which low-level use of antiretroviral
treatment could curb the AIDS epidemic in sub-Saharan Africa. lAncet 2000; 355: 2095-2100.
21. Badri M, Wtlson D, Wood R. Effect of highly active antiretroviral therapy on incidence of
tuberculosis in South Africa: a cohort study. lArIat 2002; 359: 2059-2064.
Accepted 6 September 2002.
The assistance of Fareed Abdullah, Steve Andrews, Motassim
Badri, Susan Cleary, Emmanuelle Davaiud, Rob Dorrington, Eric
Goemaere, Leigh Johnson, Anthony Kinghom, Gary Maartens and
Doug Wilson in sharing data and providing input is acknowledged
with gratitude.
References
1. World Health Organisation. Scaling Up Antiretroviral Therapy il1 Resource Limited Settings:
Guidelines for a Public Health Approach. Geneva: WHO, 2002-
2. Egger M, May M. Chene G, et aL. Prognosis of HIV-l-infected. patients starting highly active
    
        
          
           
      
   
        
            
         
        
   ",'        
     
 
   de        
          
        
         
       
         
       
           
          
        
       
    wit    
     .    
         
          
       .  
  ul        
           
        
   SlIl     
          
          
          
          . 
           
         
      
     
        
   rn      
    rn     
          
  
 
        n (}U   5 ll : 
        . 
     .    f    -l ted     
        uz d   
 
,.   i    1<], '" .1        4    
    le-d   l    S-  
    aJ J      J  t    
3  
.  P     5   J     r    
  i    Q..l.-409. 
.  P, D  1.    .  O  .r t  tme   
             
           
        I        
J      i!iIl  & iew  J.  
S            ",h "5   I I  
       :     
     ll iretrwi       w   
 
             
1I a za D nloaded    (  
  j  a    j           
bi     l-   L'li cl  l    
 
. r    l   J     .    wati  
            
     2 
   I    Clinic l :    
    rn  Jo rn   N ll    -  
 I         mv   ic   
 ecom endati    UN f        
    1-  
 ici     tiretrov l    o     
   ow : 1  
   B  L            
    rti I 200 ; ,  
   I       I : J   ed.   ,   
     
IS  staed     rn      I ·inlected   
a~    t   11        I   I 
  ~1493. 
 \-\'i   N  Sch i          . 
             8   
 . 
   i    5   i     100v-Ie    fu t i 
         um     
 S   I         t iraJ     
       umc.e     










Adherence is not a barrier to successful antiretroviral
therapy in South Africa
Catherine Orrell, David R. Bangsberga, Motasim Badri and Robin Wood
Objective: to determine adherence of an indigent African HIV-infected cohort initiat-
ing antiretroviral therapy (ART); to identify predictors of incomplete adherence
(, 95%) and virologic failure (. 400 HIV RNA copies/ml).
Design: Prospective monitoring of adherence in a poor HIV-positive cohort, attending
a public sector hospital and receiving ART through phase III studies.
Methods: Adherence to ART was determined over 48 weeks by counting tablet-
returns. Logistic regression models including age, WHO HIV stage, home language,
socio-economic status, complexity and type of regimen were fitted to determine
predictors of incomplete adherence and virologic failure at 48 weeks.
Results: 289 patients were recruited between January 1996 and May 2001. Median
(mean) adherence of the cohort was 93.5% (87.2%). Three times daily dosing [risk
ratio (RR), 3.07; 95% confidence interval (CI), 1.40–6.74], speaking English (RR, 0.41;
95% CI, 0.21–0.80) and age (RR, 0.97; 95% CI, 0.94–0.99) were independent
predictors of incomplete adherence. Socio-economic status, sex and HIV stage did not
predict adherence. Independent predictors of virologic failure included baseline viral
load (RR, 2.57; 95% CI, 1.57–4.22) and three times daily dosing (RR, 2.64; 95% CI,
1.23–5.66), incomplete adherence (RR, 1.92; 95% CI, 1.10–3.57), age (RR, 0.96;
95% CI, 0.92–0.99) and dual nucleoside therapy (RR, 2.69; 95% CI, 1.17–6.15).
Conclusion: The proportion of individuals achieving viral suppression matched results
from the developing world. Speaking the same language as site staff and simplified
dosing frequency were beneficial. Socio-economic status had no impact on adherence
and should not be used as a limitation to ARTaccess. & 2003 Lippincott Williams & Wilkins
AIDS 2003, 17:1369–1375
Keywords: antiretroviral therapy, Africa, adherence, viral load, socio-economic
status
Introduction
The majority of HIV infected individuals live in sub-
Saharan Africa. Over 4.7 million people are infected in
South Africa alone, approximately one in every five
adults [1,2]. South Africa is a middle-income, develop-
ing country and until recently, treatment with antire-
troviral therapy (ART) on a large scale was considered
financially impossible. In 2001, however, the local
pricing of triple ART decreased by approximately 75%,
and it is now available for less than $1000 per year. A
recent out of court settlement between the government
and pharmaceutical industry has further encouraged
reduced antiretroviral pricing, which will expand access
to South Africans receiving health care in the public
sector.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
From the Diana, Princess of Wales HIV Research Unit, Somerset Hospital, University of Cape Town, South Africa, and the
aEpidemiology and Prevention Interventions Centre, Division of Infectious Diseases and the Positive Health Program, UCSF, San
Francisco, California, USA.
Correspondence to C. Orrell, Diana, Princess of Wales HIV Research Unit, PO Box 50309, V & A Waterfront, Cape Town,
South Africa, 8005.
Note: Presented in part at the International AIDS Society Conference, Buenos Aires, July 2001 [abstract 696] and at the XIV
International Conference on AIDS, Barcelona, July 2002 [abstract WePeB5816].
Received: 16 August 2003; revised: 20 December 2003; accepted: 22 January 2003.
DOI: 10.1097/01.aids.0000060398.18106.f6










Expectation of poor adherence is a major concern in
expanding therapy to South Africans, many of whom
live in severe poverty [3,4]. A spokesman for USAID
encapsulated these assumptions with his statement: ‘Ask
Africans to take their drugs at a certain time of day,
and they do not know what you are talking about’ [5].
This is concerning because adherence to therapy is a
strong predictor of viral load suppression, immune
recovery, disease progression, and death [6–13]. There
is also the widely held belief that non-adherence to
therapy among sub-Saharan Africans will lead to rapid
development and spread of HIV drug resistance [3]. In
contrast to current expectations of non-adherence,
Laurent et al. reported high levels of adherence in
Senegal [14.] As yet there are no published studies of
objectively measured adherence in resource-limited
settings comprising the majority of HIV infected
patients.
We set out to measure pill count adherence and
virologic suppression in a cohort of semi-urban South
Africans living in extreme poverty.
Methods
Eligibility and recruitment
Participants were recruited from the Cape Town AIDS
Cohort (CTAC), a group of HIV-positive individuals
presenting to University of Cape Town HIV clinics
which serve largely indigent populations. Patients were
referred to the clinic study site between January 1996
and May 2001 by a broad spectrum of health care
workers in the public sector of the wider Cape Town
area. All participants were antiretroviral naive and
provided written consent to participate in multi-centre
phase III clinical trials of combination ART. These
studies were approved by the University of Cape Town
Research Ethics Committee. Inclusion and exclusion
criterion were trial determined. All antiretroviral naive
patients who commenced ART on any established
study by December 2000 were eligible for adherence
monitoring.
ART, routine medical care from the site doctors and
nursing staff, and trial-related laboratory monitoring
were free. The routine public service hospital system,
which requires payment from the patients proportional
to their income, was accessed for treatment of inter-
current problems, opportunistic infections or non-trial
medication.
A single group education session (usually in English) is
held prior to the consenting process and inclusion onto
a study. There is no dedicated adherence counseling
service, structured adherence support or formal adher-
ence intervention as part of treatment. Patients access
the site for 1–2 h every 2 or 3 months. There are no
off-site visits by health care staff.
Demographic and socio-economic data
collection
The socio-economic status of participants was assessed
using the Cape Metropolitan Council per-suburb com-
posite index which is based on household income
(percentage of households earning less than US $1500
per annum), education level (percentage of adults with
less than 8 years of schooling), unemployment status
(unemployed adults who are actively seeking work as a
percentage of all adults), welfare status (percentage of
household heads who are single women with three or
more children) and overcrowding status (percentage of
households with more than 1.5 people per habitable
room). The composite index is the sum of these five
percentages (maximum 500%) and tends to range from
4 to . 70. A score of . 28.5 correlates well (r, 0.7)
with extremely poor conditions of living (shack or
informal dwellings with outside tap or public sector
housing blocks). An index of 10–28.5 indicates a
moderate standard of living (low-cost housing, basic
amenities), and an index of , 10 indicates a high
standard of living (brick house, full amenities) [15]. For
analysis purposes a cut-off of 28.5 was used as the break
between poor and reasonable socio-economic circum-
stances.
Other demographic variables recorded include: age at
commencement of therapy, language spoken at home
(to question the impact of English-based education
processes on adherence), sex, World Health Organisa-
tion (WHO) HIV stage, as well as viral load and CD4
cell count at baseline.
Antiretroviral treatment
Patients were assigned to one of six multi-center phase
III studies. Patients in two studies in 1996 were given
dual therapy with an additional third concurrent,
placebo-controlled and double-blinded drug (placebo
versus a non-nuceoside reverse transcriptase inhibitor
regimen). In the other four studies patients were given
triple therapy regimens.
Adherence monitoring
Adherence to therapy was assessed using clinic-based
pill counts and pharmacy refill data over a period of 48
weeks. All ART was dispensed from the single study
site. Patients were provided with more medication than
required, i.e. tablets were usually dispensed in multiples
of 30, whereas visits were booked in multiples of 28
days. Patients were instructed to return all medication
bottles and unused pills at each study visit, but were
not told that the returns were to be counted. All tablets
of each antiretroviral medication were counted prior to
dispensing and upon return. Adherence to therapy was
calculated using the formula: (sum of tablets dis-
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.










pensed – sum of tablets returned) / (total tablets pre-
scribed over the 48-week study interval).
Patients who did not complete at least 30 days of ART
were excluded from the analysis. Patients who com-
pleted at least 30 days of therapy, but who failed to
bring any tablet returns over the study period have
been included in the analysis and assigned a 0%
adherence value. For those who withdrew from the
study before 48 weeks, the last data available has been
brought forward to be included in the 48-week data
analysis.
Statistical analysis
Chi-squared test was used to compare categorical data
and the student’s t test was used for continuous
variables. Associations were examined at the P , 0.05
level of significance. Logistic regression models were
fitted to determine variables predictive of adherence
and virologic failure. Only variables which were
predictive on univariate analysis (P, 0.05) were in-
cluded in the multivariate modeling.
Factors used in the univariate model for predicting
adherence less than 95% included age (modeled as a
continuous variable), language spoken at home (Eng-
lish), three times daily medication dosing, socio-
economic status (low), WHO HIV clinical stage (stage
3 or 4), sex (female), and baseline CD4 cell count and
viral load.
The univariate models for virologic failure (. 400 HIV
RNA copies/ml at 48 weeks) included the baseline
viral load, age, daily dosing schedule, adherence and
antiretroviral regimen type. Viral load at baseline, age,
three times a day regimens, medication-related food
restrictions, taking more than 10 tablets a day, adher-
ence , 95% and dual nucleoside therapy were modeled
as baseline risk factors.
Results
Recruitment and retention
A total of 289 patients was eligible for adherence
monitoring. Eleven patients (3.8%) were excluded from
the analysis because they withdrew consent (six pa-
tients) or discontinued therapy due to toxicity (five
patients) within 4 weeks of treatment initiation. An
additional 36 patients (12.4%) withdrew from the study
after the first 4 weeks and were included in the
analysis.
Patient and regimen characteristics
The mean age of the cohort at commencement of
ART was 33.4 years (SD, 8.7) and 43% of the cohort
was female. Forty-two per cent of the cohort was
drawn from poor socio-economic conditions areas
(approximately US $1500 per annum per household).
A further 20% came from moderate income areas
(approximately US $5500 per annum per household).
Only 20% of the cohort spoke English as their home
language. The majority of the cohort spoke Xhosa, the
local African language (48%), or Afrikaans (28%).
Demographic and clinical characteristics of the cohort
are presented in Table 1.
Regimens containing protease inhibitors were used by
120 (41.5%) patients. Ninety-four (32.5%) patients
received non-nucleoside based regimens, 30 (10.4%)
took triple nucleoside regimens and 45 (15.6%) of the
patients, who commenced treatment in 1996, received
dual nucleoside reverse transcriptase inhibitor therapy.
Fifty-five percent of the cohort took more than 10
tablets a day and 41% had dietary restrictions related to
antiretroviral medication.
Treatment discontinuation
Forty-seven patients (16.2%) discontinued therapy
within 48 weeks. Those who discontinued were
significantly younger, and had increased viral loads at
baseline, with lower CD4 cell counts. Socio-economic
status, sex, language spoken at home and WHO stage
of HIV illness were not associated with discontinua-
tion.
Treatment adherence and viral suppression
The median adherence of the cohort up to 48 weeks
was 93.5% (mean, 87.2%; n, 278). This includes eight
patients who did not return any tablets after continuing
therapy beyond 4 weeks and who were assigned 0%
adherence. Sixty-three percent of the patients main-
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Table 1. Baseline characteristics of the cohort (n, 289): patients
who completed 48 weeks of therapy were compared with those
who withdrew before 48 weeks. Chi-squared analysis for categorical
data and t tests for continuous data show that there was no significant
difference in the groups with regards to sex, socio-economic status,
HIV stage and home language. The group withdrew were signifi-
cantly younger, and had increased viral loads with decreased CD4






Total number of patients 242 47
Mean age [years (SD)] 34.1 (8.4) 31 (8.6) P, 0.05a
Female 105 (43.4) 19 (40.4) P ¼ 0.7
Home language
(English)
47 (19.4) 10 (21.2) P ¼ 0.8
WHO stage (3 or 4) 119 (49.2) 18 (38.3) P ¼ 0.2
Low socio-economic
status
103 (43.6) 17 (36.2) P ¼ 0.4
Mean CD4 cell count
(SD)
268 (165.2) 197 (147.8) P, 0.01a
Mean log10 viral load
(SD)
5.49 (0.67) 5.71 (0.75) P, 0.05
at test for age, viral load, CD4 cell count), 2 test for the remaining
variables.










tained adherence of > 90% to the prescribed tablets.
There was no significant difference in adherence to
protease regimens compared to non-nucleoside based
regimens. The proportion of subjects in each adherence
category is illustrated in Fig. 1.
Dosing interval, age and speaking English at home
were independently associated with incomplete adher-
ence (Table 2). Medication-related food restrictions
(RR, 1.01; 95% CI, 0.63–1.63), taking 10 or more
tablets a day (RR, 1.23; 95% CI, 0.77–1.98), low
socio-economic status (RR, 1.42; 95% CI, 0.88–2.29)
and HIV stage 3 or 4 (RR, 0.90; 95% CI, 0.56–1.45)
were not significantly associated with adherence in
univariate models and therefore were not included in
the multivariate model.
Adherence, modeled as a continuous variable, was
significantly associated with reduction in viral load at
48 weeks (r, 0.2923; P ¼ 0.001). Of those who
reached 48 weeks of therapy (n, 242), 66.1% had a viral
load of , 400 HIV RNA copies/ml. This included
70.9% of those on triple therapy and 41.0% of those on
dual therapy. For those who were > 95% adherent at
48 weeks, 73.4% had a viral load of , 400 copies/ml
compared with only 61.0% of those whose adherence
was , 95% (P ¼ 0.018).
Independent predictors of virologic failure included
baseline viral load, three times daily dosing, adherence
, 95%, age and dual nucleoside therapy. Taking 10 or
more tablets a day (RR, 1.11; 95% CI, 0.57–2.17) and
medication-related food restrictions (RR, 1.95; 95%
CI, 0.95–4.03) were not independently associated with
virologic failure at 48 weeks (Table 3).
Discussion
We found that indigent patients recruited from the
greater Cape Town area, receiving free therapy on
clinical trials, took 93.5% of their medication as meas-
ured by clinic-based pill count and, of those on triple
therapy, 70.9% maintained a viral load of , 400 copies
at 1 year in the absence of formal adherence inter-
vention. This data is consistent with the high levels of
self-reported adherence and viral suppression in poor
patients receiving ART in Senegal [14]. This level of
adherence and viral suppression is similar to or better
than that reported in most observational and clinical
trial cohorts in developed countries where objective
measures of adherence indicate that patients take 70%
of their HIV antiretroviral medications (range 53–93%)
and rate of viral load suppression is 50% (range 37–
72%) on similar regimens [6–10,16–18].
Living in poor socio-economic circumstances, as de-
fined by the Cape Metropolitan Council index, did not
impact on adherence to therapy [15]. In contrast to our
study, most patients receiving ART in sub-Saharan
Africa directly purchase their medications and pay for
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% of category achieving virologic success


































Fig. 1. Proportion of patients in each adherence category at 48 weeks (n, 242). Each full column represents the percentage of
the cohort (n, 278) in each adherence category. The actual numbers per category are given below the graph. The 11 people with
no tablet returns are recorded as 0% adherence. The dark shaded area within each column reflects the proportion of patients in
that adherence category who achieved an undetectable viral load at 48 weeks. The actual percentage that achieved virologic
success is recorded below the graph.










the cost of monitoring which can be a significant
barrier to sustained treatment adherence [19]. Our
results suggest that poor patients in sub-Saharan Africa
can have successful treatment outcomes when the
financial barriers to treatment are removed.
Three times daily therapy was the strongest predictor
for both poor adherence and virologic failure in the
multivariate analyses. Food restrictions on medication
taking and absolute tablet count did not impact on
adherence in this cohort and only predicted poor
virologic outcomes at a univariate level. Several other
studies have also shown that the best improvement in
adherence comes with the reduction of dosing fre-
quency from three to two times a day, but have also
shown a negative effect of increasing tablet burden on
adherence, which this study did not [20,21].
Increasing age was found to correlate with a higher
likelihood of remaining on therapy for 48 weeks, as
well as improved adherence and virological outcomes.
This has been noted in recent literature and is particu-
larly relevant given the rapid increase in HIV seropre-
valence in young (19–25-year-old) South Africans
[18,22,23].
The home language of each patient was collected as a
demographic factor on the hypothesis that patients
speaking the same language as the site staff would have
an adherence advantage compared to those who were
being educated in a second language. People who
spoke English, did appear have an adherence benefit.
This was unrelated to socio-economic status.
Adherence above 95% to treatment regimens predited
virological success. Other factors which impacted on
virologic outcome included baseline viral load and
regimen type. We noted decreased virologic success
with dual nucleoside therapy. Increased viral load at
baseline reduced the likelihood of successful viral
suppression after 1 year. These factors have been noted
to impact similarly elsewhere [18,24].
In this study, clinical stage of HIV at commencement
of therapy did not predict adherence, whereas this has
been previously reported as a significant predictor
[3,20]. Individuals with or without AIDS had the same
adherence. Patients in this cohort, in view of their poor
socio-economic circumstances and the lack of availabil-
ity of ART in the South African public sector, may
have similar adherence because of the global recogni-
tion of the lack of other options for therapy.
In this edition of AIDS, Liechty and Bangsberg [25]
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Table 2. Three times daily dosing predicted adherence < 95% in both the univariate and
multivariate analyses. Increasing age and speaking English as a home language were
protective against poor adherence in both analyses. Socio-economic index, sex, number of
tablets per day, medication-related food restrictions and stage of HIV disease did not impact
on adherence.
Univariate analysis Multivariate analysis
Variables RR 95% CI RR 95% CI
Age 0.97 0.94–0.99 0.97 0.94–0.99
Home language (English) 0.45 0.25–0.84 0.41 0.21–0.80
Dosing (three times a day) 2.07 1.11–3.84 3.07 1.40–6.74
RR, Risk ratio; CI, confidence interval.
Table 3. In the univariate analysis baseline viral load, three times daily dosing, dual
nucleoside regimens, taking more than 10 tablets a day and medication-related food
restrictions predicted virological failure (> 400 HIV RNA copies/ml) at 48 weeks. Increas-
ing age and adherence . 95% were protective against failure. In the multivariate model
baseline viral load, three times daily dosing and adherence , 95% predicted virological
failure. Increasing age remained protective.
Univariate analysis Multivariate analysis
Variables RR 95% CI RR 95% CI
Age 0.98 0.97–0.99 0.96 0.92–0.99
Baseline viral load (log10) 2.71 1.74–4.25 2.57 1.57–4.22
Dosing (three times a day) 5.58 2.96–10.52 2.64 1.23–5.66
Adherence (, 95%) 2.13 1.22–3.57 1.92 1.10–3.57
Antiretroviral therapy (two NRTI) 3.94 1.96–7.89 2.69 1.17–6.15
Tablets (. 10 a day) 1.85 1.08–3.16 1.11 0.57–2.17
Food restrictions 3.57 1.97–6.49 1.95 0.95–4.03
RR, Risk ratio; CI, confidence interval. NRTI, Nucleoside reverse transcriptase inhibitor.










argue that the anticipated need to deliver ART as
directly observed therapy in developing countries may
be premature [3,5,26]. Our results which indicate that
poor patients in sub-Saharan Africa can achieve high
rates of adherence and viral suppression in the absence
of formal adherence intervention support this view.
We used clinic-based pill counts as the primary
adherence measure. Whilst there are other measures of
adherence that may more accurately reflect pill-taking
behavior than clinic-based pill counts [7,8,27–30], this
was the only practical and objective method that gave
consistent, comparable data across different ART trials.
Patients were generally not informed that returns were
counted, although this information was not purpose-
fully withheld. Tablet counts are widely used as a
marker for adherence [8,11,22,28,29,31]. Pill consump-
tion, however, is not directly measured and therefore
the data may represent the upper boundary of actual
patient adherence. Patients may not bring in all their
medications or some may empty (pill dump) their
bottles prior to a clinic visit [22,30]. While these
possibilities cannot be excluded, the high rate of viral
suppression combined with the significant association
between adherence and viral load data suggest the
tablet counts in this study correlated with actual
adherence. Other investigators have also found a close
association between similar clinic-based refill data, as a
proxy for adherence, and HIV viral load as well as HIV
clinical outcomes, including AIDS and death [12,13,
16,32,33].
The decision to enter patients onto therapy in this
study was made on clinical and immunologic criteria;
however it is possible that there may have been a
selection bias towards patients likely to have better
adherence than the general population. ART is not
widely available in Cape Town, and, out of large
numbers of people with HIV, this cohort was moti-
vated enough to warrant referral from their primary
care clinic to a secondary hospital. Subjects on trial also
received information and encouragement on a regular
basis from medical staff and counselors. This may have
enhanced adherence and limit more general applica-
bility.
Most subjects completed 48 weeks of therapy. Subjects
who actively withdrew from therapy with in the 48
weeks of the study, tended to do so early in therapy.
These patients were generally younger and, although
they were not clinically more advanced in terms of
disease staging, they tended to have more advanced
immunologic and virologic disease. This may have
resulted in increased adverse events leading to with-
drawal through removal of consent, toxicity, or an
HIV-related event. Other demographic factors, such as
sex, language and socio-economic status, did not differ
between those that withdrew and the rest of the
cohort, confirming how difficult it is to predict patient
behavior [8,9,34,35].
This study demonstrates that the high levels of adher-
ence required to implement successful ART were
achieved in an African cohort without formal adher-
ence intervention. Factors impacting on adherence and
virologic outcomes elsewhere were similarly reflected
in this cohort. Clinical and virologic benefits were
maintained after 1 year. Most importantly, low socio-
economic status was not a barrier to success. Individuals
with HIV disease, who could potentially benefit from
ART, should not be denied access based on otherwise
unsubstantiated expectations of poor adherence.
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Evaluation of nevirapine and/or hydroxyurea with
nucleoside reverse transcriptase inhibitors in treatment-
naive HIV-1-infected subjects
Daniel H. Blanckenberga, Robin Woodb, Andrzej Horbanc,
Marek Beniowskid, Anna Boron-Kaczmarskae, Hanna Trochaf,
Waldemar Halotag, Reinhold E. Schmidth, G. Fatkenheueri,
Heiko Jessenj and Joep M. A. Langea, for the CHARM Study Group
Objective: To examine the effect of adding nevirapine (NVP) and/or hydroxyurea
(HU) to a triple nucleoside analogue reverse transcriptase inhibitor (NRTI) regimen in
terms of efficacy and tolerability.
Methods: HIV-1-infected, treatment-naive adults were randomized, using a factorial
design, to add NVP and/or HU to the triple NRTI backbone of zidovudine plus
lamivudine plus abacavir. Primary endpoint was treatment failure, defined as having
plasma HIV RNA levels . 50 copies/ml after week 24, or discontinuation of rando-
mized treatment. Follow-up was 72 weeks
Results: For the 229 subjects, median plasma HIV-1 RNA was 4.61 log10 copies/ml
and median CD4 cell count was 269 3 106 cells/l. NVP users reached plasma HIV-1
RNA , 50 copies/ml more rapidly than subjects using no NVP (log-rank test;
P ¼ 0.011). In the as-treated analysis, 21.6% of subjects using NVP versus 48.8%
using no NVP reached the primary endpoint (P ¼ 0.013). In the intent-to-treat analysis,
83.3% of subjects using HU versus 73.0% using no HU experienced treatment failure
(P ¼ 0.060), while no difference was observed in the as-treated analysis (34.5 versus
36.7%). Differences in the intent-to-treat analysis were accounted for by toxicity:
52.6% of subjects using HU experienced toxicity leading to discontinuation of
randomized treatment versus 28.7% of subjects using no HU.
Conclusion: The use of NVP in addition to a triple NRTI regimen improved both short-
and long-term antiretroviral efficacy. The use of HU significantly contributed to
treatment failure because of toxicity. & 2004 Lippincott Williams & Wilkins
AIDS 2004, 18:631–640
Keywords: HIV, triple therapy, abacavir, nevirapine, hydroxyurea, nucleoside
analogue reverse transcriptase inhibitor
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Ambulanz, Köln and jPraxis Heiko Jessen, Berlin, Germany.
Correspondence to Dr J. M. A. Lange, Academic Medical Center, room T0-120, Meibergdreef 9, 1105 AZ Amsterdam, the
Netherlands.
Received: 30 July 2003; revised: 11 September 2003; accepted: 22 September 2003.
DOI: 10.1097/01.aids.0000111410.02002.6e











Highly active antiretroviral therapy (HAART), consist-
ing of a combination of two nucleoside reverse
transcriptase inhibitors (NRTI) and one protease in-
hibitor, has been shown to reduce the occurrence of
opportunistic infections and death significantly, translat-
ing into clinical benefit for those patients who have
access to therapy [1]. In addition, protease inhibitor-
containing HAART has been shown to suppress viral
replication in a two-thirds of treated patients for up to
3 years [2]. A combination of two NRTI and the non-
nucleoside reverse transcriptase inhibitor (NNRTI)
efavirenz has been shown to provide better and more
durable suppression of viral replication than a protease
inhibitor plus two NRTI in treatment-naive chroni-
cally HIV-infected patients through 144 weeks of
follow-up [3]. Also, in the Atlantic study [4], the
combination of nevirapine (NVP) and two NRTI as
first-line therapy for chronic HIV-1 infection displayed
similar potent antiviral activity compared with a pro-
tease inhibitor-containing or triple NRTI-containing
regimen for up to 48 weeks. Guidelines for the initial
treatment of chronically HIV-1-infected patients as
such have been updated to include the combination of
two NRTI plus one NNRTI [5,6].
Recently, the use of the triple NRTI regimen, zidovu-
dine (ZDV) plus lamivudine (3TC) plus abacavir
(ABC), in antiretroviral treatment-naive patients has
been shown to be at least as effective as the protease
inhibitor-containing triple drug regimen ZDV/3TC/
indinavir in terms of achieving plasma HIV-1 RNA
, 400 copies/ml at 48 weeks [7]. However, when an
assay with a lower limit of quantification (LLQ) of
50 copies/ml was used, the protease inhibitor-contain-
ing regimen proved superior in terms of suppression of
viral replication below this limit in patients with a pre-
treatment plasma HIV RNA level . 100 000 copies/
ml.
Although the current stated goal of antiretroviral
therapy is complete inhibition of viral replication [6], it
is becoming increasingly clear this goal cannot be met
by standard triple drug regimens. Ongoing residual viral
replication was shown to occur, albeit at low levels, in
peripheral blood of a group of highly selected patients
who had a long-term response to therapy (plasma
HIV-1 RNA , 50 copies/ml, conventional assay),
when an experimental ultrasensitive assay with a LLQ
of 5 copies/ml [8] or 3 copies/ml [9] was used.
Also, on a cellular level, evidence exists of incomplete
suppression of viral replication during successful triple
drug therapy, such as the continued expression of viral
RNA in lymphoid tissue [10], sequence evolution in
the viral envelope gene [11], unintegrated circular
forms of HIV-1 DNA associated with peripheral blood
mononuclear cells [12], and the selection of drug
resistance-associated mutations [13].
It was previously shown that implementation of the
five-drug triple class regimen ZDV/3TC/ABC/NVP/
indinavir led to an accelerated initial decline (over 12
weeks) in plasma HIV RNA level in nine treatment-
naive subjects compared with that achieved with a
standard triple drug regimen [14]. After 144 weeks of
therapy with the same multidrug regimen, improved
suppression of viral replication compared with standard
therapy was still observed [15].
Around 1998, the use of hydroxyurea (HU) gained
popularity, after preliminary studies had shown that the
addition of HU to didanosine (ddI) monotherapy
resulted in a significant and prolonged suppression of
viral replication, both in naive and in ZDV-pretreated
patients [16–18]. Randomized, controlled studies fol-
lowed. In one study [19], the addition of HU to ddI
resulted in a significantly higher decrease in plasma
HIV-1 RNA compared with ddI monotherapy at 24
weeks, while in another [20], HU was shown to
improve the antiviral activity of the dual NRTI
combination ddI plus stavudine (d4T) over a 12 week
period.
The use of HU has also been studied in the context of
triple combination drug therapy [21,22]. In the 3D
study [21], 147 patients were randomized 2 : 1 to add
HU (600 mg twice daily) or placebo to efavirenz plus
ddI plus d4T. At 48 weeks, there was no difference in
efficacy among treatment-naive patients. In addition,
31 patients who added HU experienced significant
adverse events compared with 19 in the placebo group.
In the ACTG 5025 study [22], subjects who had been
successfully treated with ZDV/3TC/indinavir for at
least 6 months were randomized to continue this
treatment or to switch to d4T/ddI/indinavir with or
without HU 600 mg twice daily. No virological or
immunological differences were found, but there was a
higher incidence of toxicities with HU, including two
deaths caused by pancreatitis. In both studies [21,22],
the use of HU was discontinued prematurely by the
Drug Safety and Monitoring Board because of in-
creased toxicity. When the CHARM study was de-
signed, data on the efficacy and toxicity of HU when
used as a component of triple antiretroviral combina-
tion drug therapy was scarce.
It is known that the main side effect of HU is bone
marrow toxicity. However, this toxicity is dose depen-
dent. At the low doses commonly used for HIV
infection (1–1.2 g daily), bone marrow toxicity (anae-
mia and neutropenia) occurs in 5–7% of patients
[19,20,23]. Most is a grade I–II toxicity, not requiring
dosage adjustment or discontinuation of treatment.
Grade III–IV toxicity is rare. Other toxicities that have
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been described include alopecia, gastrointestinal disor-
ders (nausea and vomiting) and transient elevation of
liver enzymes [24].
The observation that HU enhances the in vitro anti-
HIV activity of a thymidine analogue (d4T) and
cytidine analogue (3TC) NRTI by increasing their
intracellular phosphorylation [25,26] provides a ratio-
nale for combining HU with these drugs. However,
there is no in vivo proof that this is the mechanism.
The clinical benefit of adjunctive HU therapy in
combination with other nucleosides remains an impor-
tant research question. In addition, given the unique
features of HU, such as ease of administration, limited
drug interactions and low cost, its possible role in
simplified treatment regimens that target populations in
developing countries is particularly appealing.
The aim of the study was to investigate the effect of
adding NVP and/or HU to the triple NRTI regimen
ZDV/3TC/ABC in terms of efficacy and tolerability.
In addition, the study examined the effect of adjuvant
prednisolone during the first 2 weeks of therapy on the
development of hypersensitivity reactions associated
with ABC and NVP. Results of this additional analysis
have been published elsewhere [27].
Methods
Study participants
The main eligibility criteria for inclusion in this study
were documented HIV-1 infection by a licensed
HIV-1 antibody enzyme-linked immunosorbent assay
(ELISA), no previous exposure to antiretroviral drug
therapy (prior NRTI exposure for less than 2 weeks
was permitted), plasma HIV-1 RNA at least 5000
copies/ml within 4–12 weeks of study drug adminis-
tration and a negative serum pregnancy test (human
beta-chorionic gonadotrophin) at screening for women
of child-bearing potential. There was no entry criterion
for CD4 cell count. Patients were excluded they were
known to have experienced clinically relevant pancrea-
titis or neuropathy during the 6 month period preced-
ing screening; if they had hepatic dysfunction evident
by grade III or IV hyperbilirubinaemia (ACTG toxicity
grading scale) or aspartate transaminase . 5 times the
upper limit of normal (local laboratory limits); if they
had renal failure requiring dialysis; or if any of the
following laboratory parameters were present during
the 4 week period prior to study drug administration: a
haemoglobin concentration , 10.0 g/dl (6.3 mmol/l)
for men and , 9.0 g/dl (5.7 mmol/l) for women,
neutrophil count , 1 3 109 cells/l, thrombocyte count
, 75 3 109 cells/l and a serum pancreatic amylase
. 1.5 times the upper limit of normal. Subjects were
also excluded if they were pregnant or breastfeeding;
had received radiation therapy or cytotoxic chemother-
apeutic agents within 30 days of study drug administra-
tion (or had an anticipated need for such treatment),
with the exception of localized treatment for Kaposi’s
sarcoma; had received treatment with immunomodu-
lating agents such as systemic corticosteroids, inter-
leukins or interferons within 30 days of study drug
administration; abused alcohol; or had a severe HIV-
related or non-HIV-related disease incompatible with
study treatment, as judged by the investigator.
Study design
This 72-week open-label, randomized, multicentre
study was conducted at 21 sites in South Africa,
Canada, western and eastern Europe. The institutional
review boards and independent ethics committee at
each site approved the study and all patients gave
written informed consent before initiating the study.
The study had a factorial design. All patients who
entered the study received ZDV, 3TC and ABC.
When possible, ZDV and 3TC were given as the
combination tablet Combivir
1
. In this factorial design,
subjects were first allocated to the addition or not of
NVP. Second, subjects were randomized to the addi-
tion or not of HU. Finally, there was a third randomi-
zation to the addition or not of prednisolone during
the first 2 weeks of the study, with the intention to
prevent hypersensitivity reactions associated with NVP
and ABC. Study dosages were ZDV 300 mg twice
daily, 3TC 150 mg twice daily, ABC 300 mg twice
daily, HU 500 mg twice daily, NVP 200 mg once daily
during the first 14 days of treatment, followed by
200 mg twice daily from day 15 onwards, and predni-
solone 40 mg once daily during the first 14 days only.
Subjects were to continue their randomized treatment
until 72 weeks follow-up unless they met protocol-
defined criteria for premature treatment discontinua-
tion, such as treatment failure, pregnancy, withdrawal
of written consent or experienced treatment-related
adverse events sufficiently severe to discontinue rando-
mized treatment prematurely.
Study monitoring
Study visits were scheduled for week 4 (screening
visit), week 2, week 0 (baseline visit and start of study
medication), and weeks 2 (dose escalation of NVP and
discontinuation of prednisolone), 4, 6, 12, 24, 36, 48,
60 and 72. At week 4, subjects signed informed
consent and were screened to see whether they met all
entry criteria. If not previously recorded, seropositive
status for HIV-1 infection was confirmed by a licensed
HIV-1 antibody ELISA test. A serum pregnancy test
was performed where applicable and was repeated at
weeks 12, 24, 36 and 48. Current medical conditions,
HIV-associated conditions, classification according to
the Center for Disease Control (CDC), weight, the use
of concurrent medications and/or blood products were
recorded, and haematology, clinical chemistry, lympho-
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cyte subsets (using flow cytometry), quantitative HIV-1
RNA measurement [Roche Amplicor version 1.5
(Roche Molecular Systems, Branchburg, New Jersey,
USA) with a LLQ of 50 copies/ml] were measured at
each study visit. A plasma sample was also collected. All
laboratory assays were performed at the local laboratory
with the exception of HIV-1 RNA and sample storage,
which were carried out at a central laboratory. At week
2, demography, risk factors or mode of transmission
and height were recorded and serology for hepatitis B
and C was done. Safety assessments were based on
evaluations of medical history, vital signs, haematology,
clinical chemistry, urinalysis and clinical adverse experi-
ences. The last were evaluated using the ACTG
toxicity grading tables for grading severity of adult
adverse experiences. Clinical Research Associates mon-
itored the different study sites for consistency of data
and laboratory tests performed at the local laboratories.
An independent Data and Safety Monitoring Board
reviewed safety and efficacy data once all subjects
completed 24 weeks follow-up.
Outcome measurements
A factorial study design was chosen to allow for indepen-
dent consideration of the effect of adding HU and NVP
on treatment outcome. To test whether this assumption
was valid, an interaction factor (NVP 3 HU) was
calculated to examine the appropriateness of pooling data
for analyses. Comparisons in both the efficacy and safety
analyses were based on study groups, categorized as
follows: NVP use/non-use and HU use/non-use, as
opposed to the different treatment arms in the study.
The primary efficacy analysis was a comparison of the
different study groups with respect to the proportion of
subjects with treatment failure at week 72. The popu-
lation considered for the primary analysis was the inten-
tion-to-treat population and included all randomized
subjects, categorizing those subjects who withdrew from
the study for any reason as treatment failures. Treatment
failure was defined as having a plasma HIV RNA level
> 50 copies/ml after week 24 or discontinuation of
randomized treatment. Missing plasma HIV-1 RNA
measurements were considered to be . 50 copies/ml,
unless the measurement preceding and following the
missing measurement were both, 50 copies/ml.
In the secondary efficacy analysis, a comparison was
made between the different study groups with respect
to the proportion of subjects with treatment failure in
the as-treated population, consisting only of those
subjects still on randomized treatment at week 72.
Additionally, the log10 copies/ml reduction in plasma
HIV RNA from baseline was calculated by using an
uncensored method, where plasma HIV RNA levels
< 50 copies/ml (LLQ of the assay) were set at 50 co-
pies/ml. Also included in the secondary efficacy ana-
lyses were the time to reach a plasma HIV RNA level
< 50 copies/ml and the time to first virological failure,
both in the intention-to-treat population. For the latter
analysis, only subjects who had reached a plasma HIV
RNA level < 50 copies/ml on or before week 24 were
included. Logistic regression analysis was performed in
the intention-to-treat population to determine the
influence of NVP use, HU use, gender, age, baseline
CD4 cell count and baseline plasma HIV RNA level
on treatment outcome at week 72.
The change in CD4 cell count from baseline was
calculated by study group in the intention-to-treat
population. For the purpose of the drug safety analysis,
all serious adverse events and additional grade III
(severe) and grade IV (life-threatening) adverse events
considered to be possibly, probably or almost certainly
attributable to the use of the study medication were
tabulated by study group. In addition, all grades of
treatment-emergent laboratory toxicity, as measured by
the ACTG toxicity scale, were summarized by study
group. When an event occurred more than once in the
same subject, only the highest toxicity grade measured
was included in the analysis. A summary was made, by
study group, of all adverse events that led to a
discontinuation or change in randomized treatment.
Statistical analysis
All nalyses were carried out according to a predefined
data analysis plan using SAS statistical package version
8.2 (SAS Institute, Cary, North Carolina, USA). The
study had 80% power to detect a difference in the
proportions of subjects with treatment failure of 0.15 to
0.20 with a significance level of 0.05 between the
treatment groups. Differences in proportions were
analysed by the chi-squared test. In the logistic regres-
sion analysis, variables that were statistically significant
in the univariate analysis were used in the multivariate
analysis. To test the factorial design assumption of
independence of the treatment groups, the interaction
between NVP and HU use was tested in a multivariate
model, which included NVP use, HU use and their
interaction. For analysis of the time to reach plasma
HIV RNA , 50 copies/ml and to first virological
failure, Kaplan–Meier estimates were produced and
tested by a log rank test. The change in CD4 cell count
from baseline was analysed by using a ‘proc mixed’
procedure, which accommodates repeated measure-
ments and estimates mean values by a least square
analysis. Treatment group and time were used as
covariates in an unstructured matrix.
Results
Baseline characteristics
A total of 229 subjects were enrolled in the study
between August 1999 and June 2000. Baseline char-
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acteristics are shown in Table 1 and study design in
Fig. 1. The two different study groups were balanced
with respect to demographic and baseline character-
istics.
Subject disposition at week 72
Seven subjects never received randomized, assigned
treatment. Thirty-eight subjects prematurely discontin-
ued the study after having received assigned treatment
(Fig. 1). Reasons included patient request (n ¼ 18), lost
to follow-up (n ¼ 18) and other reasons (n ¼ 2). A
total of eight deaths occurred during the study. Four of
these deaths were AIDS related (one each of crypto-
coccal meningitis, tuberculous meningitis, extensive
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Table 1. Summary of demographic and baseline characteristics by study group.
NVParm Hu arm
Characteristics Without NVP NVP Without HU HU
No. 114 115 115 114
Mean age [years (SD)] 34.4 (10.1) 35.3 (9.3) 35.1 (9.7) 34.5 (9.7)
Sex (% male) 67 75 67 72
Mean weight [kg (SD)] 67.6 (12.0) 67.8 (12.9) 67.9 (13.2) 67.5 (11.8)
Median CD4 cell count
[3 106 cell/l (IQR)]
254 (121–400) 273 (146–383) 256 (146–383) 272 (92–400)
Median HIV-1 RNA
[log10 copies/ml (IQR)]
4.73 (4.38–5.38) 4.56 (4.33–5.21) 4.63 (4.31–5.23) 4.61 (4.36–5.37)
Mean BMI [kg/m2 (SD)] 23.0 (3.5) 23.3 (3.6) 23.4 (3.7) 22.8 (3.4)
CDC class (%)
A 49 55 49 54
B 32 27 29 30
C 19 18 22 16
Risk group (%)
Homosexual/bisexual 31 34 30 34
Heterosexual 51 45 50 46
Intravenous drug use 14 17 16 15
Blood – – – –
Other 1 0 1 0
Unknown 3 4 3 5
Region (%)a
Western Europe 35 40 38 37
Eastern Europe 27 24 24 27
South Africa 38 36 38 36
NVP, nevirapine; HU, hydroxyurea; BMI, body mass index; IQR, interquartile range; CDC, Centers for Disease
Control and Prevention.aOne patient was included in Canada.
Discontinued before start:       –       1         1          1(†)           –             1               2 1
Discontinued after start
• patient request       4        2         2           3            3              2               1 1
• lost to follow-up       –       2         2           3            3              2               3 3
• death       –       1         –          1            1              1               3 –
• other       –       1         –          –           –             –              –                1
On study at week 72:      23      26        24          18           22             19            21 24































Fig. 1. Patient disposition at week 72. ZDV, zidovudine; 3TC, lamivudine; ABC, abacavir; NVP, nevirapine; HU, hydroxyurea;
PRED, prednisolone.










Kaposi sarcoma and wasting syndrome). The other
deaths were unrelated to HIV disease: one subject died
of metastatic carcinoma (aetiology unknown), one
committed suicide, one died of mesentery infarction
and one of aplastic anaemia. It is possible that the
aplastic anaemia was related to ZDV and HU use.
After 72 weeks, 177 patients were still in the study, of
whom 78 (44%) were still on randomized treatment
(Fig. 1).
Efficacy analysis
No significant interaction was found between NVP use
and HU use on treatment outcome, odds ratio 1.36
[95% confidence interval (CI), 0.37–4.99], validating
the assumption of independence of effects and allowing
for pooling of data (Table 2).
Primary efficacy endpoint
The population considered was the intention-to-treat
population (n ¼ 229). Treatment failure in the NVP
group was 74.8% (95% CI, 65.8–82.4) in those taking
NVP versus 81.6% (95% CI, 73.2–88.2) for those not
taking NVP (P ¼ 0.213); in the HU group, it was
83.3% (95% CI, 75.2–89.7) in those taking HU versus
73.0% (95% CI, 64.0–80.5) in those not taking HU
(P ¼ 0.060) (Table 3).
Secondary efficacy endpoints
In the as-treated population (n ¼ 78), in the NVP
group, 21.6% (95% CI, 9.8–38.2) of subjects adding
NVP versus 48.8% (95% CI, 32.9–64.9) of subjects not
adding NVP experienced treatment failure (P ¼ 0.013),
while in the HU group there was no significant
difference in treatment failure rate between subjects
(P ¼ 0.841).
Overall, subjects experienced a median reduction of
2.78 log10 copies/ml HIV-1 RNA from baseline at
week 72, while no significant differences were seen
between subjects in the different treatment groups. In
the NVP group, the proportion of subjects reaching
plasma HIV-1 RNA , 50 copies/ml increased more
rapidly over time in NVP users than in non-users (log
rank test; P ¼ 0.011; Fig. 2, while in the HU group no
significant difference was observed between subjects.
Kaplan–Meier estimates showed no significant differ-
ences between the groups with respect to the time to
first virological failure (NVP use versus non-use: log-
rank P ¼ 0.238; HU use versus non-use: log-rank
P ¼ 0.493). In the univariate logistic regression analysis,
none of the parameters tested significantly increased the
odds ratio of experiencing treatment failure (Table 2).
However, a trend was observed for HU use: odds ratio
1.85 (95% CI, 0.97–3.51).
The change from baseline in absolute CD4 cell count
in time by study group is shown in Fig. 3. There were
no treatment effects observed in the NVP group. In
the HU group, subjects taking no HU experienced a
significantly higher increase in absolute CD4 cell count
than did non-users (P , 0.001). However, no signifi-
cant differences in CD4 cell percentage increase over
time was seen between subjects in either treatment
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Table 2. Univariate analysis for treatment failure.
OR Interaction
NVP 0.67 (0.36–1.26) 0.57 (0.25–1.31)
HU 1.85 (0.97–3.51) 1.59 (0.60–4.20)
Interaction NVP3 HU 1.36 (0.37–4.99)
Sex (female) 0.98 (0.50–1.95)
Age (years) 1.02 (0.98–1.05)
Baseline CD4 (3 106 cell/l) 1.03 (0.88–1.20)
Baseline HIV-1 RNA (log10 copies/ml) 1.15 (0.72–1.81)
OR, odds ratio; CI, confidence interval; NVP, nevirapine; HU, hydroxyurea.
Table 3. Percentage of patients with treatment failure at week 72.
Intention-to-treat population As-treated population
Study group No.
Failure [%
(95% CI) P value No.
Failure [%
(95% CI) P value
NVP arm
Without NVP 114 81.6 (73.2–88.2) 41 48.8 (32.9–64.9)
NVP 115 74.8 (65.8–82.4) 0.213 37 21.6 (9.8–38.2) 0.013
HU arm
Without HU 115 73.0 (64.0–80.9) 49 36.7 (23.4–51.7)
HU 114 83.3 (75.2–89.7) 0.060 29 34.5 (17.9–54.3) 0.841
CI, confidence interval; NVP, nevirapine; HU, hydroxyurea.










group. Disease progression, defined as deterioration in
CDC class or death, occurred in 14% of subjects
(intention-to-treat). No differences were observed be-
tween the different treatment groups.
Safety analysis
One or more serious adverse event, or additional grade
III and IV adverse event that was considered treatment
emergent, was observed in 59 subjects (51.3%) taking
NVP versus 37 subjects (32.5%) not taking NVP in the
NVP arm (P ¼ 0.003), and 54 subjects (47.4%) taking
HU versus 42 subjects (36.5%) not taking HU in the
HU arm (P ¼ 0.096) (Table 4). In the NVP arm, the
following events were reported more frequently in
NVP users than in non-users: rash (5.2% versus 1.8%),
liver toxicities (11.3% versus 1.8%), hypersensitivity
reaction to ABC and/or NVP (16.5% versus 5.3%) and
gastrointestinal events (13.9% versus 7.9%). In the HU
arm, gastrointestinal events (14.9% versus 7.0%), anae-
mia (16.7% versus 2.6%), neutropenia (17.5% versus
9.6%) and pancytopenia (1.8% versus 0%) were re-
ported more frequently in users than in non-users. One
or more adverse events that led to discontinuation of
randomized treatment occurred in 60 subjects (52.6%)
adding HU versus 33 subjects (28.7%) not adding HU
in the HU arm (P , 0.001), and in 55 subjects (47.8%)
adding NVP versus 38 subjects (33.3%) not adding
NVP in the NVP arm (P ¼ 0.026). In September
2001, the Drug Safety and Monitoring Board unan-
imously recommended that HU be discontinued be-
cause of the unacceptably high proportion of subjects
experiencing adverse events that led to a change or
discontinuation of randomized treatment. The propor-
tion of subjects with laboratory abnormalities (all
grades) was similar between the different treatment
groups (data not shown), with the exception of
gamma-glutamyl transaminase toxicity, which occurred
significantly more frequent in NVP users (P ¼ 0.04).
Discussion
This randomized trial is the first that has allowed
independent consideration of the effect of adding NVP
and/or HU to a triple NRTI drug regimen in terms of
antiviral efficacy and tolerability; this was achieved by
the factorial design.
In the NVP group, subjects who added NVP experi-
enced an accelerated decay in plasma HIV-1 RNA. In
Fig. 3, it can be seen that the proportion of subjects
reaching ‘undetectability’ of HIV-1 RNA over time
increased more rapidly in NVP users, suggesting that
the addition of NVP increased the potency of the triple
NRTI regimen. The as-treated analysis, which is a
reflection of virological efficacy, confirms this observa-
tion. The addition of NVP failed to improve treatment
outcome in the intention-to-treat population. This was
because a significant proportion of subjects who added
NVP experienced one or more adverse events that
necessitated a change in randomized treatment. By















Fig. 2. Kaplan–Meier curve showing the proportion of sub-
jects reaching plasma HIV-1 RNA < 50 copies/ml over time
for the nevirapine arm. —, patients not using nevirapine;



































Fig. 3. Change from baseline in CD4 cell count over time
summarized by study group. NVP, patients not using nevir-
apine; NVP+, patients using nevirapine; HU, patients not
using hydroxyurea; HU+, patients using hydroxyurea.










definition, these subjects were considered treatment
failures.
Hypersensitivity reactions to ABC and/or NVP were
reported more frequently in subjects allocated to the
use of NVP (n ¼ 19; non-users reported 7). As clinical
symptoms of NVP- and ABC-associated hypersensitiv-
ity reactions overlap, a clear distinction between the
two cannot reliably be made. Furthermore, none of the
study arms consisted of the use of NVP without ABC,
making adequate comparisons between NVP- and
ABC-associated hypersensitivity reactions impossible.
Therefore, these events were treated as a composite
endpoint. In addition, the outcome of ABC hypersen-
sitivity reactions can be fatal if the reaction is not
recognized and treatment with ABC discontinued. It is
possible that the open-label design of the study may
have introduced a bias in reporting the occurrence of
hypersensitivity reactions.
More subjects allocated to the use of HU experienced
treatment failure at week 72 (intention-to-treat popu-
lation), although the difference between subjects did
not reach significance. The observed difference
between subjects resulted from the more frequent
occurrence of adverse events in subjects using HU. In
the as-treated population, treatment failure was the
same in those that did and did not use HU, suggesting
that HU use did not improve the antiviral efficacy of
the triple NRTI regimen.
The main toxicity encountered in clinical practice with
HU is bone marrow suppression, which can lead to
neutropenia, anaemia and/or thrombocytopenia [24].
In the HU group, anaemia and neutropenia of severe
or life-threatening intensity were reported in 20 and 21
subjects who were allocated to HU versus 3 and 12
subjects not taking the drug, respectively. The myelo-
suppressive effect of HU has been shown to be
enhanced if HU is used in association with other
haematotoxic drugs such as ZDV or cotrimoxazole
[17]. We are able to confirm this observation.
In our study, 85 (74.6%) of the 114 subjects originally
allocated to the use of HU discontinued the drug by
week 72. These numbers are comparable with those
reported in the long-term follow-up of subjects in the
ddH study [28], where 75% of the 72 patients originally
randomized to HU in combination with d4T/ddI and
80% of the 30 patients who elected to add HU after
week 12 discontinued the drug 24 months after the
start of the trial. In the as-treated population, we have
observed a treatment failure rate in the order of 35% in
subjects taking HU. Once again, these results are very
similar to those reported in the ddH study [28], where
9/18 (50%) of subjects still taking ddI/d4T/HU and 5/
15 (33%) taking ddI/d4T had plasma HIV-1 RNA
levels . 200 copies/ml after 72 weeks of follow-up.
HU enhances the antiviral activity of adenosine analo-
gues, mainly that of ddI, by decreasing the intracellular
dATP pool, which is the natural competitor of ddI at
the DNA elongation process [17,25]. The benefits
obtainable with the association of HU with other
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Table 4. All serious and additional grade III and IV adverse events, summarized by study group.
No. in NVP arm No. in HU arm
Without NVP NVP Without HU HU
Adverse event AE 3/4 SAE AE 3/4 SAE AE 3/4 SAE AE 3/4 SAE
Rash 0 2 3 3 1 5 2 0
Hypersensitivity reactiona 0 6 0 19 0 14 0 11
Gastrointestinal events 1 8 10 6 3 5 8 9
Pancytopenia 1 0 0 1 0 0 1 1
Anaemia 1 17 1 2 1 1 1 18
Neutropenia 11 1 18 1 11 0 18 2
Constitutional events 2 4 6 4 6 5 2 3
Urogenital events 0 3 1 1 0 4 1 0
Liver toxicities 2 0 13 0 8 0 7 0
Neurological events 2 6 3 7 4 7 1 6
Cryptococcal disease 0 1 0 1 0 2 0 0
Other skin event 0 2 0 2 0 2 0 2
ENT disease 0 2 0 0 0 0 0 2
Respiratory events 0 2 0 2 0 3 0 1
Sepsis/bacteraemia 0 0 0 2 0 1 0 1
Other 0 2 0 4 0 2 0 4
Patients with one or more events 37 59 42 54
P valueb 0.003 0.096
NVP, nevirapine; HU, hydroxyurea, AE 3 /4, grade III and IV adverse event; SAE, serious adverse event; ENT, ear nose throat.
aTo abacavir and/or NVP.
bP value for comparison of with and without drug in trial arm.










NRTI are smaller as the reduction of paired dNTP
levels is less effective than for dATP competitive
inhibitors [29,30]. This is one possible explanation why
addition of HU to the triple NRTI regimen ZDV/
3TC/ABC did not improve the antiviral efficacy of the
regimen.
In a systematic overview of results from clinical trials
involving triple drug therapy [31], the overall estimated
percentages of patients with plasma HIV-1 RNA
, 50 copies/ml at 48 weeks by drug class were 46%
for a regimen containing a protease inhibitor, 51% for
one containing a NNRTI, and 45% for triple NRTI.
The overall failure rates in our study were much
higher, especially for a treatment-naive population.
The primary endpoint of the study was a composite of
failure of virological suppression and discontinuation of
randomized treatment for any reason. This explains the
high failure rate in the intention-to-treat population. In
addition, approximately 35% of subjects in the NVP
and HU groups failed in the as-treated population. It is
possible that this was caused by adherence problems.
Although adherence was measured in the study, insuffi-
cient data were collected for analysis.
From an immunological viewpoint, a significant in-
crease in the CD4 cell count in subjects was observed
over time in both treatment groups. Subjects who used
HU experienced a slower rate of increase in absolute
CD4 cell numbers, with no difference in increase in
CD4 cell percentage compared with non-users. This
observation is similar to reports from a previous study
in which HU was shown to decrease lymphocyte
counts by means of its cytostatic effect [20].
The present study has some limitations. It had an
open-label design so a reporting bias for adverse events
could have been introduced. In addition, we have only
limited data on adherence. Therefore, the question of
whether the high failure rate observed in the as-treated
population was the result of poor adherence to therapy
remains unanswered.
In conclusion, our findings suggest that the addition of
NVP to the triple NRTI regimen ZDV/3TC/ABC
resulted in an accelerated decay in plasma viraemia and
enhancement of the antiviral efficacy of the regimen.
However, the higher incidence of hypersensitivity
reactions in subjects who added NVP is an argument
for the sequential introduction of ABC and NVP when
these two agents are used in combination. The addition
of HU significantly contributed to treatment failure
and was poorly tolerated because of toxicity. It is
regrettable that HU has proven to be that toxic, as the
low cost of the drug makes it an ideal candidate for use
in resource-poor settings, where effective antiretroviral
therapy remains beyond the reach of most HIV-
infected persons because of its cost.
Sponsorship: This study was supported by Boehringer
Ingelheim Pharmaceuticals Inc. and GlaxoSmithKline.
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efavirenz. The difference between nevirapine twice daily and
efavirenz was 5·9% (95% CI –0·9 to 12·8). There were no
significant differences among the study groups in the
proportions with plasma HIV-1 RNA concentrations below 
50 copies per mL at week 48 (p=0·193) or the increases in
CD4-positive cells (p=0·800). Nevirapine plus efavirenz was
associated with the highest frequency of clinical adverse
events, and nevirapine once daily with significantly more
hepatobiliary laboratory toxicities than efavirenz. Of 
25 observed deaths, two were attributed to nevirapine.
Interpretation Antiretr viral therapy with nevirapine or
efavirenz showed similar efficacy, so triple-drug regimens
with either NNRTI are valid for first-line treatment. There are,
however, differences in safety profiles. Combination of
nevirapine and efavirenz did not improve efficacy but caused
more adverse events.
Lancet 2004; 363: 1253–63
See Commentary page 1248
Introduction
Several randomised clinical trials in antiretroviral-therapy-
naive patients have shown that a regimen based on a non-
nucleoside reverse-transcriptase inhibitor (NNRTI) is at
least as effective as a regimen that includes a protease
inhibitor.1–3 During the past few years, the use of NNRTI-
based antiretroviral therapy as the first regimen of choice
has become increasingly popular. Among the reasons for
this change are the lower pill burden of such a regimen
and the perceived toxicity associated with protease-
inhibitor-based regimens. Furthermore, NNRTI-based
antiretroviral therapy does not necessitate any restrictions
on food intake. These factors can contribute to better
adherence to therapy by the patient, which is crucial for a
sustained effect of treatment.4–6
The two most used NNRTI drugs are nevirapine and
efavirenz. No large randomised comparison between these
two drugs has yet been undertaken. Several large cohort-
studies have suggested that efavirenz is more effective
than nevirapine.7–9 However, interpretation of cohort
studies might be hampered by the possible biases that are
inherent in this design.
We report the results of the 2NN Study, a large
randomised trial in patients with chronic HIV-1 infection
who had not previously received antiretroviral therapy,
comparing the efficacy and safety of treatment with two
nucleoside-analogue reverse-transcriptase inhibitors
(NRTI) and either nevirapine once daily, nevirapine twice
daily, efavirenz, or the combination of nevirapine and
efavirenz. The study addressed several questions. First, it
compared the standard dose of nevirapine (twice daily)
with efavirenz. Second, it compared the standard twice-
daily regimen of nevirapine with a once-daily dose. The
Summary
Background The 2NN Study was a randomised comparison
of the non-nucleoside reverse-transcriptase inhibitors (NNRTI)
nevirapine and efavirenz.
Methods In this multicentre, open-label, randomised trial,
1216 antiretroviral-therapy-naive patients were assigned
nevirapine 400 mg once daily, nevirapine 200 mg twice daily,
efavirenz 600 mg once daily, or nevirapine (400 mg) and
efavirenz (800 mg) once daily, plus stavudine and lamivudine,
for 48 weeks. The primary endpoint was the proportion of
patients with treatment failure (less than 1 log10 decline in
plasma HIV-1 RNA in the first 12 weeks or two consecutive
measurements of more than 50 copies per mL from week 24
onwards, disease progression [new Centers for Disease
Control and Prevention grade C event or death], or change of
allocated treatment). Analyses were by intention to treat.
Findings Treatment failure occurred in 96 (43·6%) of 220
patients assigned nevirapine once daily, 169 (43·7%) of 387
assigned nevirapine twice daily, 151 (37·8%) of 400 assigned
efavirenz, and 111 (53·1%) of 209 assigned nevirapine plus
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use of once-daily dosing helps to simplify treatment.
Although once-daily dosing is used widely, no large
formal comparison with nevirapine twice daily has been
done. Third, the study assessed the relative merit of
combining the two NNRTI drugs. This combination has
never been investigated in a clinical setting, and in-vitro
data on the combination are inconclusive.10,11
Methods
Participants
Study participants were recruited during regular visits to
HIV treatment centres in North and South America,
Australia, Europe, South Africa, and Thailand. Eligible
patients were antiretroviral-therapy naive, chronically
infected with HIV-1, and aged at least 16 years, and had a
plasma concentration of HIV-1 RNA of more than 
5000 copies per mL. There was no inclusion criterion for
the number of CD4-positive T lymphocytes or disease
stage. Reasons for exclusion were: pregnancy or lactation;
haemoglobin concentration less than 6·3 mmol/L in men
or 5·7 mmol/L in women; neutrophil count less than 
1109/L; platelet count less than 75109/L; serum
amylase more than 2·0 times the upper limit of normal in
combination with serum lipase more than 1·5 times the
upper limit of normal; aspartate aminotransferase more
than 5·0 times the upper limit of normal; or bilirubin
more than 2·5 times the upper limit of normal; history of
clinical pancreatitis or neuropathy within the previous 
6 months; renal failure necessitating dialysis; radio-
therapy, cytotoxic, or immunomodulating treatment
within the month preceding the start of study or the
expected need for it; infection with HIV-2; or likely non-
adherence as judged by the investigator.
The study was approved by the ethics review bodies in
the participating countries, and all patients gave written
informed consent.
Design and interventions
All patients received stavudine 40 mg twice daily (30 mg
twice daily if weight was less than 60 kg) and lamivudine
150 mg twice daily. They also received nevirapine 400 mg
once daily, nevirapine 200 mg twice daily, efavirenz
600 mg once daily, or a combination of nevirapine
400 mg once daily and efavirenz 800 mg once daily. The
higher dose of efavirenz when it is used in combination is
recommended because efavirenz concentrations are
lowered when the drug is used in normal dosing in the
presence of nevirapine.12 Nevirapine was given as 200 mg
once daily for the first 2 weeks.
At the central study coordination centre (International
Antiviral Therapy Evaluation Center, Amsterdam), a
treatment allocation sequence was generated by use of the
minimisation variables CD4-positive T-cell count (350
vs >350 cells per µL) and study region. Treatment
allocation was stratified by baseline plasma HIV-1 RNA
concentration (30 000 copies per mL vs >30 000 copies
per mL).
The study started with three comparison groups, an
estimated sample size of 450, and a treatment allocation
ratio of 1:1:1 for nevirapine once daily, efavirenz, and
nevirapine plus efavirenz. The group assigned nevirapine
twice daily was added 5 months later because another
study had found that the efficacy of nevirapine was related
to the minimum concentration13 and raised the issue of
whether once-daily nevirapine resulted in a high enough
minimum concentration.
The focus of the trial shifted to the comparisons of
nevirapine twice daily versus efavirenz (testing for
equivalence) and of nevirapine once daily versus twice
daily (testing for superiority). For these comparisons, the
treatment allocation probabilities were recalculated to
arrive at the end of the inclusion period at a 1:2:2:1
allocation ratio for nevirapine once daily, nevirapine twice
daily, efavirenz, and nevirapine plus efavirenz, and an
estimated sample size of 1200 patients. The decision to
add the fourth treatment group was taken without
knowledge of outcomes for patients already enrolled. For
828 (68%) of the total 1216 patients, treatment allocation
could have been to one of four study groups. Treatment
allocation was done at the central study coordination
centre, concealed from the investigator before enrolment,
and implemented by sending a fax to the study site.
Generation and implementation of the allocation
sequence were fully separated. There was no masking
after treatment allocation.
By protocol, patients were not allowed to change any
component of their allocated treatment for more than 5%
of the follow-up time. The only exception was a change of
stavudine or lamivudine for reason of toxicity, provided
that two NRTI drugs were used at all times. Women who
became pregnant while taking efavirenz were switched to
nevirapine and could remain in the study, but they were
judged to have had a change of allocated treatment. The
use of prophylactic medication for opportunistic
infections was at the discretion of the treating physician.
Follow-up and assessments
Participants were assessed at study weeks –6 (screening),
0 (start of treatment), 2, 4, 8, 12, 24, 36, and 48. At these
visits, we measured plasma HIV-1 RNA concentration,
counted CD4-positive T cells, and recorded clinical and
laboratory adverse events. Further monitoring of plasma
HIV-1 RNA concentration was done at day 3, week 1,
and week 18. Plasma samples for measurement of HIV-1
RNA concentration were frozen at –70°C and transported
to a central laboratory (LabCorp, Research Triangle Park,
NC, USA), where the RNA concentration was measured
with an Ultrasensitive Roche Amplicor 1.5 (Roche
Diagnostics, NJ, USA) with a lower limit of quantification
of 50 copies per mL. All other laboratory tests were done
at local or regional laboratories by standard techniques or
enzymatic assays. The Virtual Central Laboratory (VCL,
Zeist, Netherlands) selected these laboratories, assured
the quality, and normalised all results. The toxicity
grading scale of the AIDS Clinical Trial Group was used
for the reporting of clinical and laboratory adverse
events.14
Outcome measures
The primary efficacy outcome was the proportion of
patients with treatment failure, defined as a composite
endpoint with three components: virology (a decline of
less than 1 log10 in plasma HIV-1 RNA concentration
within the first 12 weeks or two consecutive
measurements 50 copies per mL from week 24 onwards;
a single plasma HIV-1 RNA concentration 50 copies per
mL at week 48 constituted a failure); disease progression
(Centers for Disease Control and Prevention grade C
event from 8 weeks onwards diagnosed according to
published guidelines,15 or death); and therapy change
(non-allowable change of allocated treatment). Secondary
endpoints were the proportion of patients with virological
failure (never having a plasma HIV-1 RNA concentration
<50 copies per mL, or two consecutive measurements
50 copies per mL after having had a concentration
below the cut-off); the proportion of patients with plasma
HIV-1 RNA concentrations below 50 copies/mL at each
study week; the change in CD4-positive cells between the
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start of treatment and week 48; and the frequencies of
clinical and laboratory adverse events. Matters that were
reported as clinical adverse events but reflected only
asymptomatic laboratory abnormalities were excluded
from the clinical-adverse-events listing but incorporated
in the listing of laboratory abnormalities. Laboratory
abnormalities were classified as hepatic or non-hepatic.
Since hepatic abnormalities were expected, this approach
allowed us to examine the overall frequency of laboratory
toxicities among the study groups apart from those
associated with the liver. Hepatic laboratory abnormalities
included an increase in aspartate or alanine amino-
transferase and a high bilirubin concentration that was
associated with an increase in these enzymes. Isolated
rises in -glutamyl transferase were excluded because they
reflect only enzyme induction caused by the use of
nevirapine, efavirenz, or both. If an event occurred more
than once in the same patient, that with the highest
toxicity grade was included. All the analyses compared the
treatment groups at week 48.
Statistical analyses
Categorical variables were tested with a 2 or Fisher’s
exact test, as appropriate. Continuous variables were
tested with a Kruskal-Wallis test. Missing data on plasma
HIV-1 RNA concentration were taken to be above 
50 copies per mL. Patients who withdrew prematurely
were therefore classified as failures because two
measurements of plasma HIV-1 RNA concentration were
missing and taken to be above 50 copies per mL. Risk
factors for treatment failure were assessed by logistic
regression.
All analyses were done for the intention-to-treat
population, including all randomised patients (n=1216).
In the safety analyses, only adverse events that occurred
while the patient was taking the allocated treatment were
included. A two-sided p value of less than 0·05 was
deemed significant in comparisons of all four study groups
(reported as “overall”).
All outcome measurements were analysed by
randomisation period (before or after addition of the
fourth study group). The data for both periods were
pooled only when the outcome was not modified by the
randomisation period (non-significant interaction term in
models excluding the group assigned nevirapine twice
daily).
At the time that the fourth treatment group was added,
four pairwise comparisons were defined: nevirapine once
daily versus nevirapine twice daily; nevirapine twice daily
versus efavirenz; efavirenz versus nevirapine plus
efavirenz; and nevirapine once daily versus nevirapine plus
efavirenz. This last analysis was chosen because
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220 assigned
       nevirapine
       once daily
208 started
       treatment
       as allocated
182 (83%)
       completed
       week 48
 12 did not
      start
      treatment
    1 died
    4 patient's
       request
    5 lost to
       follow-up
    2 other
 26 withdrew
    6 died
    6 patient's
       request
  11 lost to
       follow-up
    3 other
387 assigned
       nevirapine
       twice daily
378 started
       treatment
       as allocated
322 (83%)
       completed
       week 48
   9 did not
      start
      treatment
    6 patient's
       request
    2 lost to
       follow-up
    1 other
 56 withdrew
    9 died
    9 patient's
       request
  22 lost to
       follow-up
  16 other
400 assigned
       efavirenz
381 started
       treatment
       as allocated
337 (84%)
       completed
       week 48
 19 did not
      start
      treatment
    1 died
    9 patient's
       request
    5 lost to
       follow-up
    4 other
 44 withdrew
    6 died
    8 patient's
       request
  21 lost to
       follow-up
    9 other
209 assigned
       nevirapine
       and efavirenz
199 started
       treatment
       as allocated
175 (84%)
       completed
       week 48
 10 did not
      start
      treatment
    5 patient's
       request
    4 lost to
       follow-up
    1 other
 24 withdrew
    2 died
  10 patient's
       request
    7 lost to
       follow-up
    5 other
1432 patients
         screened
1216 randomised
 216 not eligible
Figure 1: Trial profile
All patients received stavudine and lamivudine (see Methods). The reasons for exclusion were not recorded.










nevirapine was dosed once daily in the group assigned
nevirapine plus efavirenz. On the basis of these four
comparisons, the definition of significance was adjusted to
p<0·0125 (Bonferroni’s method). This significance
definition was used for all pairwise comparisons, except
for the primary outcome comparing nevirapine twice daily
versus efavirenz. For that comparison we assessed
equivalence of the two groups, with a null hypothesis of at
least 10% more treatment failures with nevirapine twice
daily than with efavirenz. Equivalence was assumed if the
limits of the conventional 95% CI of this difference were
within 10% of zero. The number of patients in the
comparison (n=787) provided adequate power for
assessment of equivalence within the 10% limits of the
percentage of treatment failures if the two treatments were
equivalent (assumed failure rate 35%, =0·05, =0·2). A
sensitivity analysis assessed equivalence in the same way
with the exclusion of patients who never started allocated
treatment. Data were analysed with SAS statistical
software (version 8.02).
Two interim analyses were done. The first, at week 8,
included the first 400 patients who were assigned
nevirapine once daily, efavirenz, or nevirapine plus
efavirenz. The purpose of this analysis was to assess viral
decay within the first 2 weeks of treatment, to reassure the
Data Safety and Monitoring Board that the novel
combination of nevirapine and efavirenz did not
underperform with respect to viral suppression. The
second interim analysis was for all patients at week 24, to
assess efficacy and safety of the four treatments. Results
were shared only between the trial statistician and the
Data Safety and Monitoring Board. The Board did not
recommend discontinuation or modification of the trial at
any stage.
Role of funding sources
The study was investigator initiated and financially
supported by Boehringer-Ingelheim. The sponsor had a
non-binding input on issues of study design and analyses,
which did not lead to any significant influence on the
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Nevirapine once daily (n=220) Nevirapine twice daily (n=387) Efavirenz (n=400) Nevirapine plus efavirenz (n=209)
Demographic and anthropometric characteristics
M/F 139 (63·2%)/81 (36·8%) 236 (61·0%)/151 (39·0%) 254 (63·5)/146 (36·5%) 143 (68·4)/66 (31·6%)
Age, years* 34·4 (28·4–40·3) 33·9 (29·7–41·0) 34·7 (30·1–39·7) 33·2 (29·0–39·0)
Body-mass index, kg/m2* 19·2 (17·4–21·2) 19·7 (17·7–22·4) 19·3 (17·3–21·8) 19·2 (17·2–21·4)
Geographical region
Asia/Australia (n=223) 52 (23·6%) 52 (13·4%) 76 (19·0%) 43 (20·6%)
Europe (n=249) 50 (22·7%) 72 (18·6%) 78 (19·5%) 49 (23·4%)
South Africa (n=430) 72 (32·7%) 146 (37·7%) 141 (35·2%) 71 (34·0%)
South America (n=249) 40 (18·2%) 89 (23·0%) 84 (21·0%) 36 (17·2%)
North America (n=65) 6 (2·7%) 28 (7·2%) 21 (5·3%) 10 (4·8%)
HIV risk behaviour
Heterosexual 124 (56·4%) 236 (61·0%) 224 (56·0%) 111 (53·1%)
Homosexual 58 (26·4%) 102 (26·4%) 117 (29·3%) 73 (34·9%)
Intravenous drug use 11 (5·0%) 13 (3·4%) 21 (5·3%) 10 (4·8%)
Other, unknown 27 (12·2%) 36 (9·2%) 38 (9·5%) 15 (7·2%)
CDC class C 44 (20·0%) 86 (22·2%) 84 (21·0%) 39 (18·7%)
CD4-positive cells
Median count, cells per 	L* 200 (95–340) 170 (60–310) 190 (80–350) 190 (80–330)
Number <50 per 	L 35 (15·9%) 79 (20·4%) 70 (17·5%) 28 (13·4%)
Number 50–200 per 	L 76 (34·5%) 138 (35·7%) 144 (36·0%) 80 (38·3%)
Number >200 per 	L 109 (49·5%) 170 (43·9%) 186 (46·5%) 101 (48·3%)
HIV-1 RNA
Median log10 copies 4·7 (4·4–5·4) 4·7 (4·4–5·5) 4·7 (4·4–5·5) 4·7 (4·4–5·5)
per mL*
Number <100 000 152 (69·1%) 264 (68·2%) 263 (65·8%) 139 (66·5%)
Number >100 000 68 (30·9%) 123 (31·8%) 137 (34·3%) 70 (33·5%)
Coinfection
Hepatitis B virus† 15 (6·8%) 17 (4·4%) 16 (4·0%) 16 (7·7%)
Hepatitis C virus‡ 22 (10·0%) 35 (9·0%) 40 (10·0%) 19 (9·1%)
CDC=Centers for Disease Control and Prevention. Data are number of patients unless indicated otherwise.*Median (IQR). †Presence of HBsAg at screening.
‡Presence of antibodies to hepatitis C virus.
Table 1: Baseline characteristics of all randomised patients (n=1216)
Before protocol change After protocol change
Nevirapine once Efavirenz Nevirapine plus p Nevirapine once Efavirenz Nevirapine plus p
daily (n=131) (n=131) efavirenz (n=126) daily (n=89) (n=269) efavirenz (n=83)
Treatment failure 61 (46·6%; 45 (34·4%; 65 (51·6%; 0·016 35 (39·3%; 106 (39·4%; 46 (55·4%; 0·0289 
(%; 95% CI) 37·8–55·5) 26·3–43·2) 42·5–60·6) 29·1–50·3) 33·5–45·5) 44·1–66·3)
Component of treatment failure
Virological 16 (12·2%) 19 (14·5%) 18 (14·3%) 0·838 9 (10·1%) 42 (15·6%) 16 (19·3%) 0·235
Progression 5 (3·8%) 2 (1·5%) 3 (2·4%) 0·529 2 (2·3%) 8 (3·0%) 2 (2·4%) 0·918
Change of assigned treatment 40 (30·5%) 24 (18·3%) 44 (34·9%) 0·009 24 (27·0%) 56 (20·8%) 28 (33·7%) 0·048
HIV-1 RNA <50 copies per mL 91 (69·5%; 97 (74·1%; 78 (61·9%; 0·107 63 (70·8%; 183 (68·0%; 53 (63·9%; 0·618
(%; 95% CI) 60·8–77·2) 65·7–81·3) 52·8–70·4) 60·2–80·0) 62·1–73·6) 52·6–74·1)
Median (IQR) CD4-cell increase, 160 150 145 0·676 185 170 180 0·558
cells per 	L (105–230) (90–230) (70–240) (100–320) (70–260) (100–290)
Data are number of pateints unless otherwise stated.
Table 2: Outcome of efficacy analyses before and after protocol change in randomisation










resulting design and analyses. The sponsor was allowed to
provide comments on the report in progress but had no
influence on reporting of the data or the decision to
publish. All investigators and the sponsor had full access
to the data after official closure of the database.
Results
Of 1432 patients screened, 1216 underwent randomi-
sation between February, 2000, and June, 2001. 5 months
after the start of enrolment, a group to receive nevirapine
twice daily was opened for treatment allocation as
described above. 50 patients, who potentially knew their
treatment allocation, never started their study drugs. In
total, 1166 patients started follow-up, of whom 981 (81%
of those randomised) reached week 48 (figure 1). The
baseline characteristics of all randomised patients were
similar among the study groups (table 1).
Table 2 summarises the results from the efficacy
analyses separately for the periods before and after the
randomisation change. In both periods, the proportion of
patients with treatment failure differed significantly
among the treatment groups and was highest in the group
assigned nevirapine plus efavirenz. In both randomisation
periods, the main reason for treatment failure was change
of allocated treatment, which occurred in a higher
proportion of the nevirapine plus efavirenz group than of
the other groups. In the logistic regression analysis to
assess the effect of randomisation period on the risk of
treatment failure, there was no evidence for such an effect
(odds ratio 1·01, p=0·868), nor significant evidence that
treatment differences varied by randomisation period
(interaction term p=0·326). Furthermore, there were no
significant effects of randomisation period on the
proportion of patients with plasma HIV-1 RNA
concentrations below 50 copies per mL at week 48 or the
increase in CD4-positive T cells (interaction p=0·513 and
0·892, respectively). Subsequently, the data were pooled
for all efficacy analyses, despite numerical differences
between the randomisation periods.
The results of the primary analysis and the
contributions of the three components to the composite
endpoint for all patients are summarised in table 3. The
proportion of patients with treatment failure at week 48
was 43·6% (95% CI 37·0 to 50·5) for nevirapine once
daily, 43·7% (38·7 to 48·8) for nevirapine twice daily,
37·8% (33·0 to 42·7) for efavirenz, and 53·1% (46·1 to
60·0) for nevirapine plus efavirenz (overall p=0·004). The
difference of 5·9% (95% CI –0·9 to 12·8) between the
groups assigned nevirapine twice daily or efavirenz was
not significant (p=0·091), but equivalence within the 10%
limits could not be demonstrated.
The sensitivity analysis testing for equivalence of
nevirapine twice daily and efavirenz in the population
after exclusion of patients who never started treatment
showed similar results to the primary analysis (7·7% 
[95% CI 0·8 to 14·6], p=0·03). In the population of
concurrently randomised patients (including only those
randomised after the protocol change) the difference was
4·3% (–3·4 to 11·9, p=0·276).
There was no significant difference between patients
assigned nevirapine once daily and those assigned
nevirapine twice daily (0·1%, p=0·994). Patients assigned
nevirapine plus efavirenz had a significantly higher
probability of treatment failure than those assigned
efavirenz (15·3%, p=0·0003) but no significant difference
from those assigned nevirapine once daily (9·5%, p=0·05).
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A: Nevirapine B: Nevirapine C: Efavirenz D: Nevirapine p*
once daily twice daily (n=400) plus efavirenz 
(n=220) (n=387) (n=209) Overall A vs B B vs C A vs D C vs D
Treatment failure on or before 96 (43·6%; 169 (43·7%; 151 (37·8%; 111 (53·1%; 0·004 0·994 0·091 0·050 0·0003
week 48 (%; 95% CI) 37·0–50·5) 38·7–48·8) 33·0–42·7) 46·1–60·0)
Components of failure
Virological 25 (11·4%) 73 (18·9%) 61 (15·3%) 34 (16·3%) 0·108 0·016 0·178 0·140 0·742
Progression 7 (3·2%) 11 (2·8%) 10 (2·5%) 5 (2·4%) 0·949 0·813 0·766 0·620 0·935
Change of treatment 64 (29·1%) 85 (22·0%) 80 (20·0%) 72 (34·4%) 0·0002 0·050 0·499 0·233 <0·0001
Permanent change of NNRTI 37 61 51 51
Temporary discontinuation of NNRTI 13 13 8 6
Additional antiretroviral drugs 2 1 1 2
Non-allowable change of NRTI 0 1 1 3
Never started ART 12 9 19 10
Plasma HIV-1 RNA concentration <50 154 (70·0%; 253 (65·4%; 280 (70·0%; 131 (62·7%; 0·193 0·244 0·165 0·109 0·067
copies per mL at 48 weeks (%; 95% CI)† 63·5–76·0) 60·4–70·1) 65·2–74·5) 55·7–69·3)
ART=antiretroviral therapy. *For significance: overall (four groups) p<0·05, pairwise comparisons p<0·0125. †Intention-to-treat population.
Table 3: Number of patients with treatment failure, components of treatment failure, and number of patients with plasma HIV-1 RNA
concentration <50 copies per mL
Nevirapine Nevirapine Efavirenz Nevirapine plus Nevirapine twice daily vs 
once daily twice daily efavirenz efavirenz (95% CI)
Treatment failure
Asia/Australia 23 (44·2%) 17 (32·7%) 15 (19·7%) 24 (55·8%)
South Africa 33 (45·8%) 73 (50·0%) 54 (38·3%) 35 (49·3%) 5·9 (–0·9 to 12·8)*
South America 15 (37·5%) 35 (39·3%) 33 (39·3%) 14 (38·9%)
Europe/USA/Canada 25 (44·6%) 44 (44·0%) 49 (49·5%) 38 (64·4%)
Asia/Australia 23 (44·2%) 17 (32·7%) 15 (19·7%) 24 (55·8%) 13·0 (–2·6 to 28·5)
Other 73 (43·5%) 152 (45·4%) 136 (42·0%) 87 (52·4%) 3·4 (–4·2 to 11·0)
Virological failure
Asia/Australia 11 (21·2%) 13 (25·0%) 13 (17·1%) 9 (20·9%)
South Africa 31 (43·1%) 65 (44·5%) 49 (34·8%) 31 (43·7%)
South America 9 (22·5%) 26 (29·2%) 25 (29·8%) 9 (25·0%)
Europe/USA/Canada 26 (46·4%) 37 (37·0%) 42 (42·4%) 31 (52·5%)
Percentages are for the total of patients per group per region.*For overall trial, all four regions.
Table 4: Numbers of patients with treatment failure or virological failure by region










The main reason for treatment failure in each of the
study groups was change of allocated treatment (table 3).
The only difference significant at p=0·0125 was that
between efavirenz and nevirapine plus efavirenz (14·4%,
p<0·0001). The change of allocated treatment in all
groups was predominantly a permanent change in the
NNRTI component.
The response to treatment differed among the
geographical regions (interaction between region and
treatment group p=0·035). In Asia and Australia (90% of
the patients in this region were enrolled at one centre in
Bangkok, Thailand), the proportion of treatment failure in
the efavirenz group was much lower and the differences
between the nevirapine groups larger than in the other
regions (table 4, figure 2). There were no significant
differences between the regions other than Asia and
Australia (interaction term p=0·328). Despite this
modifying effect of region, testing for equivalence of
nevirapine twice daily and efavirenz within the 10% limits
gave similar results to the primary analysis: equivalence
could not be established in either Asia and Australia or the
other regions combined (table 4). However, this analysis
lacks power and should be interpreted cautiously.
For virological failure, there was no significant
interaction between outcome and region (interaction term
p=0·629; table 4, figure 2), but region remained signif-
icant with Asia and Australia having virological failure
rates below 25% and Europe, the USA, and Canada
having rates approaching 50%.
The proportion of patients reaching a plasma HIV-1
RNA concentration of less than 50 copies per mL at week
48 is summarised in table 2 for each randomisation period
and in figure 3 for all patients. The mean values at week
48 were 70·0% (95% CI 63·5 to 76·0) for nevirapine once
daily, 65·4% (60·4 to 70·1) for nevirapine twice daily,
70·0% (65·2 to 74·5) for efavirenz, and 62·7% (55·7 to
69·3) for nevirapine plus efavirenz. Overall, there were no
significant differences in any of the four pairwise
comparisons.
The treatment groups had similar median increases in
CD4-positive T cells over 48 weeks (overall p=0·8). The
median increase was 170 cells per 	L for nevirapine once
daily, 160 cells per 	L for the groups assigned nevirapine
twice daily and efavirenz, and 150 cells per 	L for
nevirapine plus efavirenz (figure 4). Age, sex, disease
stage, baseline CD4-positive cell count, and mode of
HIV-1 transmission were not associated with treatment
failure.
Patients with a baseline plasma HIV-1 RNA concen-
tration of more than 100 000 copies per mL were 
1·63 times (95% CI 1·28 to 2·07) more likely than those
with baseline concentrations below this value to
experience treatment failure. The difference in treatment
failure rate between patients with high and low baseline
plasma HIV-1 RNA concentrations was 19·9% for
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Figure 2: Proportion of patients with treatment failure or
virological failure by region
Error bars=95% CI.



















Figure 3: Proportion of patients with plasma HIV-1 RNA
concentrations below 50 copies per mL
Error bars=95% CI.
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Number of patients with counts
Nevirapine
once daily
208 189/186/181 179 180 174
Nevirapine
twice daily
376 349/329/337 323 313 313




198 185/174/177 175 164 168
Figure 4: CD4-positive T-cell response over 48 weeks
Dotted line represents the baseline value. Error bars=IQR.










nevirapine once daily, 15·8% for nevirapine twice daily,
5·9% for efavirenz, and 8·2% for nevirapine plus efavirenz
(overall p=0·004). However, the adverse effect of high
baseline plasma HIV-1 RNA concentration on the
probability of treatment failure was similar for all
treatment groups (interaction term p=0·368; figure 5). If
the groups assigned nevirapine only were combined, the
difference in treatment failure within this stratum was
17·3%. Again, the adverse effect of a high baseline plasma 
HIV-1 RNA concentration on treatment failure did not
differ between the combined
nevirapine group and the efavirenz
group (interaction term p=0·105). The
same effect of high baseline plasma
HIV-1 RNA concentration was seen
for virological failure (interaction term
p=0·571; figure 5).
In total, 25 patients died during the
study, two before taking any study
medication. Seven (3·2%) patients
assigned nevirapine once daily died,
compared with nine (2·3%) assigned
nevirapine twice daily, seven (1·8%)
assigned efavirenz, and two (1·0%)
assigned nevirapine plus efavirenz.
One patient assigned nevirapine
twice daily, without evidence of
hepatitis B or C virus coinfection,
developed fulminant hepatitis, attrib-
uted to the use of nevirapine, as well as
pancreatitis and renal failure 32 days
after the start of treatment; this patient
died a week later. Another patient
assigned nevirapine twice daily devel-
oped Stevens-Johnson syndrome,
attributed to the use of nevirapine, 
39 days after the start of treatment;
although recovering, she was admitted
to hospital for assessment of blephar-
itis. While in hospital she developed
septicaemia due to a meticillin-
resistant Staphylococcus aureus infection
and died after 8 days. One patient
assigned nevirapine once daily died of
lactic acidosis that was attributed to
the use of stavudine.
11 deaths were related to HIV-1 dis-
ease: three were due to Pneumocystis
carinii pneumonia, one each to
generalised cytomegalovirus infection,
tuberculous meningitis, Mycobacterium
avium infection, generalised histoplasma infection, and
Kaposi’s sarcoma, and three to end-stage HIV-1 disease.
The other 11 deaths were not related to study medication
or HIV-1 disease (murder, renal failure, brainstem
glioma, suicide of a patient who had not started study
medication, congestive heart failure, myocardial infection
[two], endocarditis, empyema, and unknown reason
[two]).
For all reported safety analyses, the change in
randomisation did not modify the outcome analysed.
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Figure 5: Proportion of patients with treatment failure or virological failure by baseline
plasma HIV-1 RNA concentration
Overall=all patients randomised. Low baseline=patients with baseline plasma HIV-1 RNA 
100 000 copies/mL. High baseline=patients with baseline plasma HIV-1 RNA concentration
>100 000 copies/mL. Error bars=95% CI.
A: Nevirapine B: Nevirapine C: Efavirenz D: Nevirapine p*
once daily twice daily (n=400) plus efavirenz 
(n=220) (n=387) (n=209) Overall A vs B B vs C A vs D C vs D
Reasons for temporary or permanent discontinuation of study drugs
Adverse events or HIV event 53 (24·1%) 83 (21·5%) 63 (15·8%) 63 (30·1%) 0·0005 0·453 0·040 0·158 <0·0001
Patient’s request 5 (2·3%) 8 (2·1%) 15 (3·8%) 16 (7·7%) 0·004 0·877 0·161 0·01 0·037
Physician’s decision 14 (6·4%) 26 (6·7%) 11 (2·3%) 20 (9·6%) 0·005† 0·866 0·009 0·219 <0·0001
Other 27 (12·3%) 32 (8·3%) 36 (9·0%) 27 (12·9%) 0·175 0·109 0·715 0·840 0·132
Adverse events leading to temporary or permanent discontinuation of study drugs
Rash 27 (12·3%) 25 (6·5%) 15 (3·8%) 29 (13·9%)
CNS/psychiatric 11 (5·0%) 22 (5·7%) 27 (6·7%) 16 (7·7%)
Clinical hepatitis 4 (1·8%) 6 (1·6%) 1 (0·3%) 2 (1·0%)
Peripheral neuropathy 6 (2·7%) 12 (3·1%) 9 (2·3%) 8 (3·8%)
Hepatic laboratory abnormality 13 (5·9%) 9 (2·3%) 1 (0·3%) 6 (2·9%)
Vomiting 1 (0·5%) 5 (1·3%) 5 (1·3%) 4 (1·9%)
Data are number of patients. CNS=central nervous system.*For significance: overall (four groups) p<0·05, pairwise comparisons p<0·0125. †Fisher’s exact test for
overall significance and subsequent pairwise comparisons.
Table 5: Reasons for temporary or permanent discontinuation of study drugs









wnTherefore, all safety analyses are reported for the pooled
data. The reasons for temporary or permanent
discontinuation of one of the study drugs are summarised
in table 5. The reasons are not mutually exclusive. The
commonest reason for discontinuation was adverse
events. The rate of adverse events differed significantly by
study group. However, of the predefined comparisons,
only the difference between efavirenz and nevirapine plus
efavirenz was significant at p=0·0125 (14·3%, p<0·0001).
The difference between nevirapine once daily and
efavirenz also reached statistical significance 
(8·3%, p=0·011).
Although the randomisation period did not statistically
modify the proportion of patients who temporarily or
permanently discontinued study drugs because of an
adverse event or HIV event (interaction p=0·106),
patients assigned efavirenz were more likely to discontinue
study drugs for this reason before the randomisation
change than afterwards. However, this difference did not
result in a significantly different proportion of patients in
the efavirenz group having treatment failure because of
change of allocated treatment (table 2).
15·0% of patients in the group assigned nevirapine once
daily had at least one grade 3 or 4 clinical adverse event,
compared with 20·4% of those assigned nevirapine twice
daily, 18·0% of those assigned efavirenz, and 24·4% of
those assigned nevirapine plus efavirenz (table 6; overall
p=0·077). There were no statistically significant
differences between the single NNRTI groups. The
difference in frequency between the group assigned
nevirapine plus efavirenz and the nevirapine once daily
group was significant (p=0·014), but that between the
group assigned nevirapine plus efavirenz and the efavirenz
group was not (p=0·062). The grade 3 or 4 adverse events
that were reported in more than 1% of the patients are
listed in table 6.
The proportion of patients with at least one grade 3 or 4
liver-associated laboratory toxicity was 13·6% for
nevirapine once daily, 8·3% for nevirapine twice daily,
4·5% for efavirenz, and 9·1% for nevirapine plus efavirenz
(table 6; overall p=0·001). None of the predefined
pairwise comparisons was significant, but the frequency
was significantly higher for nevirapine once daily than for
efavirenz (p<0·0001). Of the patients with grade 3 or 4
liver-associated laboratory toxicity, the proportions
coinfected with hepatitis B or hepatitis C virus were
13·8% and 20·7% in the nevirapine once daily group,
6·7% and 20·0% in the nevirapine twice daily group,
5·6% and 11·1% in the efavirenz group, and 16·7% and
22·2% in the nevirapine plus efavirenz group. In the total
study po ulation, the rates of hepatitis B and C
coinfection were 7·7% and 9·1%.
There were no significant differences between the
groups in the incidence of non-hepatobiliary laboratory
toxicities, overall or by randomisation period.
Discussion
For each randomisation period separately, and overall, we
found a significant difference in the proportion of patients
with treatment failure at week 48, which was driven by the
higher risk of failure in the group assigned nevirapine plus
efavirenz. Although, overall, treatment failure was
numerically lower in the efavirenz group than in the
nevirapine-only groups, our findings show no evidence
that efavirenz is superior to nevirapine twice daily in terms
of treatment failure. However, we could not show
equivalence within the 10% limits of these treatment
groups even though the study was adequately powered for
such an analysis. The performance of nevirapine twice
daily compared favourably with that of other drugs that
have been formally compared with efavirenz. In previous
studies, efavirenz was found to have better efficacy than
indinavir,1 nelfinavir,16 or protease-inhibitor-based regi-
mens in general.17 Nevirapine once or twice daily showed
similar rates of treatment failure in our study, which
accords with findings by others in small studies.18,19 The
simultaneous use of nevirapine and efavirenz resulted in a
higher probability of treatment failure, mainly due to
increased rates of change of allocated treatment because
of an adverse event.
There were no significant differences between the study
groups in the proportion of patients with virological
failure, the proportion with plasma HIV-1 RNA
concentrations below 50 copies per mL at week 48, or the
increase in CD4-positive T cells during the study. The
difference in treatment failure rates between patients with
baseline plasma HIV-1 RNA concentrations above and
below 100 000 copies per mL was largest for the
ARTICLES
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A: Nevirapine B: Nevirapine C: Efavirenz D: Nevirapine p*
once daily twice daily (n=400) plus efavirenz 
(n=220) (n=387) (n=209) Overall A vs B B vs C A vs D C vs D
Clinical adverse events
Hepatobiliary 4 (1·8%) 10 (2·6%) 2 (0·5%) 2 (1·0%) 0·082† 0·546 0·017 0·686 0·610
Clinical hepatitis 3 (1·4%) 8 (2·1%) 1 (0·3%) 2 (1·0%)
Cutaneous 9 (4·1%) 14 (3·6%) 15 (3·8%) 12 (5·7%) 0·619 0·769 0·922 0·428 0·257
Rash 9 (4·1%) 13 (3·4%) 8 (2·0%) 11 (5·3%)
CNS/psychiatric 3 (1·4%) 14 (3·6%) 22 (5·5%) 16 (7·7%) 0·001 0·106 0·337 0·002 0·296
Insomnia/abnormal dreams 0 0 6 (1·5%) 5 (2·4%)
Anxiety 0 0 4 (1·0%) 3 (1·4%)
Depression 0 1 (0·3%) 6 (1·5%) 1 (0·5%)
Diarrhoea 1 (0·5%) 3 (0·8%) 4 (1·0%) 4 (1·9%)
Vomiting 3 (1·4%) 4 (1·0%) 4 (1·0%) 3 (1·4%)
Pyrexia 2 (0·9%) 8 (2·1%) 3 (0·8%) 2 (1·0%)
Total number of patients‡ 33 (15·0%) 79 (20·4%) 72 (18·0%) 51 (24·4%) 0·077 0·098 0·390 0·014 0·062
Laboratory toxicities
Hepatobiliary 30 (13·6%) 32 (8·3%) 18 (4·5%) 19 (9·1%) 0·001 0·036 0·030 0·139 0·024
Non hepatobiliary 20 (9·1%) 53 (13·7%) 41 (10·3%) 22 (10·5%) 0·276 0·094 0·133 0·617 0·915
Neutropenia 6 (2·7%) 17 (3·9%) 9 (2·3%) 13 (6·2%)
Amylase increased 4 (1·8%) 13 (3·6%) 15 (3·8%) 3 (1·4%)
Triglycerides increased 3 (1·4%) 5 (1·3%) 5 (1·3%) 1 (0·5%)
Alkaline phosphatase 2 (0·9%) 5 (1·3%) 3 (0·8%) 4 (1·9%)
*For significance: overall (four groups) p<0·05, pairwise comparisons p<0·0125. †Fisher’s exact test for overall significance and subsequent pairwise comparisons.
‡Number with at least one grade 3 or 4 clinical adverse event.
Table 6: Numbers of patients with at least one grade 3 or 4 clinical adverse event and laboratory toxicities










nevirapine-only groups, but a detrimental effect of high
baseline plasma HIV-1 RNA concentration was observed
for all regimens. A higher probability of treatment or
virological failure in patients with such a high baseline
viral load has been described previously for nevirapine,20,21
but not for efavirenz.1
The observed regional differences in treatment failure
might be attributable to physicians’ management of
patients within the study (210 of the 223 patients in Asia
and Australia region were from a single treatment centre
in Bangkok). Another reason might be population
differences in frequencies of drug-related adverse events,
since in Asia and Australia 26% of patients temporarily or
permanently discontinued study treatment because of
adverse events, whereas in other regions this proportion
was between 18% and 23%. However, distinction
between these two hypotheses is difficult, and they are not
mutually exclusive. The high rate of discontinuation in
Asia and Australia might also be the cause of the
difference in temporary or permanent discontinuation of
study drug in the efavirenz group in the comparison of
both randomisation periods. In the period before
randomisation change there was over-representation of
patients from Asia and Australia.
Owing to the randomisation change and the regional
differences, the presented overall efficacy estimates should
be interpreted with caution. However, we believe that the
main conclusions of the study are robust. The
contributions of the reasons for treatment failure are
similar in the two randomisation periods. Furthermore, the
difference in treatment failure in both periods is driven by
the poor performance of nevirapine plus efavirenz. The
secondary efficacy endpoints are also similar in the two
periods. With respect to the effect of region on treatment
failure, the conclusions about the comparisons of
nevirapine twice daily versus efavirenz, and nevirapine
once daily versus nevirapine twice daily, as well as the poor
performance of the nevirapine plus efavirenz group can be
drawn for the region Asia and Australia alone as well as for
the other regions combined. Thus, the results of this study
can be seen as qualitatively generalisable in terms of the
direction of effects observed, but not numerically
generalisable in terms of the size of the efficacy estimates.
Our findings contrast with those of cohort studies in
antiretroviral-therapy-naive patients. In the Italian ICoNA
cohort, patients who started treatment with two NRTIs
and nevirapine had a relative hazard of virological failure
of 2·15 (95% CI 0·9 to 5·1) compared with those starting
treatment with two NRTIs and efavirenz.7 Although this
estimate did not achieve conventional statistical
significance, the increased risk is large. In a cohort of 
888 patients, Matthews and colleagues found a hazard
ratio for therapy failure at 24 weeks of 2·03 (1·26 to 3·18)
for patients starting nevirapine-based antiretroviral
therapy compared with those starting an efavirenz-based
therapy.9 In a study by Keiser and co-workers,8 including
more than 1000 patients, efavirenz was superior to
nevirapine in terms of time to virological failure, decrease
in plasma HIV-1 RNA concentration, and the proportion
of patients with undetectable plasma HIV-1 RNA.
The only data from a randomised trial were reported by
Núñez and colleagues.22 In this small trial, 64 therapy-
naive patients started a regimen of stavudine and
didanosine with either nevirapine or efavirenz; 64% of the
nevirapine group and 74% of the efavirenz group had
plasma HIV-1 RNA concentrations below 50 copies per
mL after 48 weeks in an intention-to-treat analysis
(p=0·43). However, the study had power only of 14% to
find a significant difference in this variable.
The disparities between results from cohort studies and
the 2NN Study might be partly explained by differences
in study design. Since there is no randomisation in cohort
studies, selection bias could have been introduced if the
choice between nevirapine and efavirenz were influenced
by patients and physicians. Physicians’ preconceived
ideas about efficacy and safety of certain therapy
regimens will have a role in decisions on a therapy
regimen for a particular patient and on management.
Knowledge and experience of physicians is clearly
associated with the adaptation of new treatment
strategies.23 Although these biases can be kept to a
minimum by the use of multivariate models,24 the
possibility of residual confounding in cohort studies
remains. However, differences in management of patients
in an open-label clinical trial such as the 2NN, even when
within the boundaries of the study protocol, could also
lead to biased estimates. The magnitude of such bias in
clinical trials is difficult to establish but it should not be
ignored, especially when the chosen composite endpoint
includes a component that is easily influenced by
management of patients.
The two nevirapine-attributed deaths were caused by
known complications of the drug. Strict adherence to
guidelines on management of rashes could minimise the
risk of Stevens-Johnson syndrome.25,26 However, monitor-
ing of plasma aminotransferase concentrations might not
prevent the occurrence of fulminant hepatitis.27,28
The reported frequency of clinical and laboratory
adverse events in patients taking nevirapine or efavirenz
varies widely. We reported all grade 3 or 4 events
irrespective of the relation of the event to the study drugs,
to minimise ascertainment bias in the reporting of events,
although the open-label design of the study cannot fully
prevent the occurrence of such bias. The frequencies of
grade 3 or 4 rash in the nevirapine once daily and twice
daily groups (4·1% and 3·4%) were at the lower end of
the range reported in other studies. In the ATLANTIC
study, 7% of patients assigned stavudine, didanosine, and
nevirapine developed a grade 3 or 4 rash.2 In the INCAS
study, severe rash (grade 4) was seen in 4% of patients
allocated zidovudine plus nevirapine with or without
didanosine.29 Pollard and co-workers reported a grade 3
or 4 rash in 6·6% of the patients included in clinical
trials.30
Grade 3 or 4 adverse events related to the central
nervous system were seen only in study groups assigned
efavirenz, apart from one patient assigned nevirapine
twice daily who had depression. Staszewski and colleagues
reported that 58% of patients allocated zidovudine,
lamivudine, and efavirenz had some kind of central
nervous system symptom, although none of the events was
reported to be severe.1
The frequencies of hepatic laboratory abnormalities and
clinical hepatotoxicity were similar to those reported
previously. Patients assigned nevirapine once daily had a
higher frequency of hepatic laboratory abnormalities than
those assigned this drug twice daily. Peak plasma
concentrations of nevirapine are greater with once daily
than with twice daily dosing, but the total exposure to the
drug is nearly identical.31 Previous studies have not
confirmed a relation between nevirapine concentration
and toxicity.31,32
The occurrence of liver-associated laboratory toxicities
is known to be increased in patients coinfected with
hepatitis B or hepatitis C virus.33,34 The proportions of
patients with hepatic coinfection who developed liver-
associated laboratory toxicity differed between the groups,
but the numbers of patients were too small to allow
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definitive conclusions about the effect of hepatic
coinfection on the risk of such effects. Factors other than
hepatic coinfection could be in play.
Apart from the drawback of the change in random-
isation, the 2NN study has the limitation of an open-label
design, which might have influenced decisions to change
therapy. Such influences could affect the result for the
composite endpoint, which was driven by the change-of-
treatment component. However, the study was based in
centres that had extensive experience with antiretroviral
therapies. Inappropriate treatment changes are unlikely to
have occurred on a scale large enough to render the study
results not reproducible. Virological and immunological
endpoints based on laboratory results are less influenced
by the open-label design. These endpoints support the
findings of the composite endpoint in that there were no
significant differences among the single NNRTI groups of
the 2NN Study.
The follow-up of 48 weeks in this study does not differ
from that in many other HIV trials but is shorter than in
cohort studies. There is a possibility that the difference
between nevirapine twice daily and efavirenz will grow
larger over time and that the efficacy of efavirenz is more
sustainable than that of nevirapine twice daily.35 Further
follow-up of 2NN patients is planned. The overall drop-
out rate of less than 20% is similar for all study groups,
and similar to other large HIV clinical trials.
We conclude that the 2NN Study showed no significant
differences in treatment failure between regimens with a
single NNRTI in the treatment of antiretroviral-therapy-
naive HIV-1-infected patients. Although nevirapine twice
daily and efavirenz were not equivalent within the 10%
limit, the two regimens are valid options for first-line
therapy. However, the use of nevirapine was associated
with two deaths in the study. The safety profiles of the
drugs differ and should be taken into account when
regimens are being chosen. Nevirapine once daily had a
similar antiretroviral efficacy to nevirapine twice daily and
seems therefore suitable for treatment simplification. The
regimen of nevirapine plus efavirenz did not have
additional efficacy and caused more adverse events than
each drug separately. This regimen is therefore less
desirable than the other treatment options presented in
this study.
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A B S T R A C T
Background
Little information exists on the impact of highly active antiretroviral therapy (HAART) on
health-care provision in South Africa despite increasing scale-up of access to HAART and
gradual reduction in HAART prices.
Methods and Findings
Use and cost of services for 265 HIV-infected adults without AIDS (World Health Organization
[WHO] stage 1, 2, or 3) and 27 with AIDS (WHO stage 4) receiving HAART between 1995 and
2000 in Cape Town were compared with HIV infected controls matched for baseline WHO
stage, CD4 count, age, and socioeconomic status, who did not receive antiretroviral therapy
(ART; No-ART group). Costs of service provision (January 2004 prices, US$1¼7.6 Rand) included
local unit costs, and two scenarios for HAART prices for WHO recommended first-line regimens:
scenario 1 used current South African public-sector ART drug prices of $730 per patient-year
(PPY), whereas scenario 2 was based on the anticipated public-sector price for locally
manufactured drug of $181 PPY. All analyses are presented in terms of patients without AIDS
and patients with AIDS.
For patients without AIDS, the mean number of inpatient days PPY was 1.08 (95% confidence
interval [CI]: 0.97–1.19) for the HAART group versus 3.73 (95% CI: 3.55–3.97) for the No-ART
group, and 8.71 (95% CI: 8.40–9.03) versus 4.35 (95% CI: 4.12–5.61) respectively for mean
number of outpatient visits PPY. Average service provision PPY was $950 for the No-ART group
versus $1,342 and $793 PPY for the HAART group for scenario 1 and 2 respectively, whereas the
incremental cost per life-year gained (LYG) was $1,622 for scenario 1 and $675 for scenario 2.
For patients with AIDS, mean inpatients days PPY was 2.04 (95% CI: 1.63–2.52) for the HAART
versus 15.36 (95% CI: 13.97–16.85) for the No-ART group. Mean outpatient visits PPY was 7.62
(95% CI: 6.81–8.49) compared with 6.60 (95% CI: 5.69–7.62) respectively. Average service
provision PPY was $3,520 for the No-ART group versus $1,513 and $964 for the HAART group
for scenario 1 and 2 respectively, whereas the incremental cost per LYG was cost saving for
both scenarios. In a sensitivity analysis based on the lower (25%) and upper (75%) interquartile
range survival percentiles, the incremental cost per LYG ranged from $1,557 to $1,772 for the
group without AIDS and from cost saving to $111 for patients with AIDS.
Conclusion
HAART is a cost-effective intervention in South Africa, and cost saving when HAART prices
are further reduced. Our estimates, however, were based on direct costs, and as such the actual
cost saving might have been underestimated if indirect costs were also included.
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South Africa is experiencing an HIV epidemic with
enormous social and economic consequences. Recent esti-
mates suggest that between 4.5 and 6.2 million of the 43
million South Africans are infected with HIV-1 [1]. There
were 370,000 AIDS deaths during 2003 [1], and the cumulative
projected AIDS mortality for 2010 is 4–7 million in absence
of a highly active antiretroviral therapy (HAART) programme
[2]. The largest impact of HIV on the public health sector lies
in the hospital sector [3]. In the year 2000, HIV-related
admissions amounted to 24% of all public hospital admis-
sions [4] and 12.5% of the total public health budget [5]. Cost
of inpatient and ambulatory health care of both private and
public health-care sectors is expected to rise rapidly [5].
The cost-effectiveness of HAART, in terms of reducing
HIV-related morbidity and mortality, has been documented
in industrialized countries [6–12]. The introduction of
combination HAART into routine clinical care in these
countries has been associated with a shift from inpatient to
outpatient-based hospital care [11–17]. Until recently the
prevailing assumption was that the public sector of the South
African health-care system was unable to afford the intro-
duction of antiretroviral therapy (ART) in routine clinical
care. However, the government of South Africa recently
announced its commitment towards creating the necessary
conditions for introducing ART into the public health sector
[18]. In addition, the price of HAART for resource-poor
countries decreased markedly since the year 2000 [19,20]. The
South African Department of Health has recently awarded
contracts for the supply of ART drugs to public health
facilities countrywide to international pharmaceutical com-
panies [21]. This tender is expected to reduce HAART price
to $181 per patient-year (PPY).
The aim of this study was to compare use and cost of HIV-
1–related service provision between patients receiving
HAART and a comparison group not receiving ART, and
assess the cost effectiveness of HAART.
Methods
Study Population
This study was based on the Cape Town AIDS Cohort
(CTAC); a prospective cohort study which has been described
previously [22,23]. In brief, patients of this cohort were
accrued from the HIV clinics affiliated to the University of
Cape Town, who were referred from a wide range of primary
HIV health-care providers. During the study period 1st
January 1995 to 31st December 2000, HAART was not
available in the publicly funded South African health-care
sector. All patients in this study accessed HAART through the
participation in the international HAART multicentre phase
III clinical trials, as approved by the Research Ethics
Committee of the University of Cape Town.
For the purpose of this study, all patients who participated
in the clinical trials and received at least three ART drugs—a
non-nucleoside reverse transcriptase inhibitor or protease
inhibitor together with two nucleoside analogues or three
nucleoside analogues—were included as the treated arm of
the study (HAART group). Patients were excluded from the
clinical trials if they were active injecting-drug users, were
diagnosed with an acute opportunistic infection at the time
of recruitment, were reported to have significant laboratory
abnormalities, or if they were treated with immune-modulat-
ing or systemic chemotherapeutic agents. Lactating or
pregnant women were also excluded. The trial visit schedule
was usually at weeks 2, 4, and 8 and then every two to three
months thereafter.
Patients who did not participate in these clinical trials and
never had access to ART throughout the study period (No-
ART group) but received other HIV-related care were the
sample from which a ‘‘comparator’’ group was identified for
the HAART group.
At each clinic visit, all patients were routinely examined for
HIV related manifestations and staged using the World
Health Organization (WHO) clinical HIV staging system
[24]. HIV-1 infection was diagnosed by enzyme-linked
immunosorbent assay (ELISA) tests and confirmed by West-
ern blot or a second enzyme-linked immunosorbent assay
test. Viral load (which was available only for the HAART
group) was determined by reverse transcriptase-polymerase
chain reaction (Amplicor; Roche Molecular Systems, Branch-
burg, New Jersey, United States) and CD4þ count, measured
by flow cytometry (Beckman Coulter, Miami, Florida, United
States).
Analysis
This analysis calculated the use and cost of HIV service
provision and compared the clinical outcome, in terms of
disease progression or life year gained (LYG) by clinical stage
of HIV infection, between patients receiving HAART and a
matched comparison group who did not receive ART (No-
ART group). Patients were classified as either being non-AIDS
(WHO stages 1, 2, or 3) or AIDS (WHO stage 4) patients.
Several strategies were employed to ensure that the two
groups studied were clinically, immunologically, and socio-
economically similar and matched for the same variables used
to recruit the HAART group into the clinical trials. Logistic
regression models were fitted to identify factors associated
with receiving HAART in this cohort using SAS GENMODE
procedure with logit link function and binomial error
distribution [25]. HAART patients were individually matched
with randomly selected No-ART patients on the basis of
variables independently associated with the likelihood of
receiving HAART. The socioeconomic status of each patient
was classified into ‘‘low’’ or ‘‘high’’, using a composite index
developed by the Cape Metropolitan Council [26]. A
subgroup logistic regression analysis was performed for the
HAART group, to examine whether the likelihood of
hospitalisation differed by HAART class.
To examine for residual confounding, the matched case–
control data were analysed using a conditional logistic
regression model, stratified by matching variables. The model
was fitted using the SAS PHREG procedure with discrete
logistic model. All data analyses were performed in SAS
version 8.02. v2 was used to compare categorical variables,
and the non-parametric median test was used to compare
continuous non-normally distributed variables. All p-values
quoted are two sided, with a p-value , 0.05 considered as
significant.
Use and Cost of Services
Information on inpatient and outpatient care was obtained
from the computerized hospital information systems supple-
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mented by case notes. The mean number of inpatient days
and outpatient visits PPY were calculated for the non-AIDS
(WHO stage 1, 2, and 3) and AIDS (WHO stage 4) WHO
clinical stages for both HAART and No-ART groups. A
patient-year was defined as 365.25 days of follow up and
methods used for calculating the mean use of services were
similar to those used in other studies [12,16,17,27]. The
denominator consisted of the total duration of follow up for
all patients seen during the study period and numerators
were calculated by summing the use of each service. Mean and
95% confidence intervals (CI) of inpatient and outpatient
service use PPY by WHO stage were calculated for the two
groups using the binomial distribution, and were compared
between the two groups by calculating the odds ratio (OR) of
the use of inpatient and outpatient services, using the No-
ART group as a reference group.
The costs of hospital HIV service provision were calculated
from a public health-care system perspective [28–30]. Unit
costs were obtained from a detailed costing study of HIV
inpatient and outpatient care conducted in the year 2000
[31], and were adjusted for inflation to financial year 2004
prices using the South African Consumer Price Index [32].
Prices were converted from South African Rand to US dollars
using the average exchange rate for 2004 (US dollars ¼ 7.6
Rand) [33]. The unit cost was $215 for an inpatient day and
$33 for an outpatient visit and included costs for tests
including CD4 counts, procedures, and non-ART drug costs.
The non-ART drugs included all drugs other than ART
dispensed to the patients during the course of care, including
treatment and prophylaxis for opportunistic infections. Mean
inpatient days and outpatient visits PPY were multiplied by
their respective unit costs to estimate the PPY cost of service
provision.
ART prices used in this study are those currently available
to the public health-care sector (Ministry of Health, Provin-
cial Administration of the Western Cape). HAART drug-price
scenarios presented were (1) present public sector prices,
which amounted to $730 per annum, and (2) anticipated
public sector price for locally manufactured drugs, which
amounted to $181 per annum, for the WHO-recommended
regimen for resource-limited settings [34].
To estimate the total cost of service provision PPY for
HAART patients for the two scenarios, average ART drug
costs PPY were added to the average inpatient and outpatient
PPY costs. In sensitivity analysis, minimum and maximum
ART drug PPY costs for the two scenarios were also added to
the lower and upper limit of the 95% CI: inpatient and
outpatient PPY cost of care to provide a range of costs. Viral
load was not measured for the No-ART group because it was
not available in publicly funded institutions during the study
period and, therefore, PPY cost of viral-load investigation of
$79 (D. Roditti, personal communication) was only added to
the annual cost of service provision for the HAART group.
Cost of LYG by WHO Stage of HIV Infection
Progression times were calculated from date of entry into
non-AIDS (WHO stage 1, 2, or 3) to date of progression to
AIDS (WHO stage 4) or death, and from initial diagnosis of
AIDS (WHO stage 4) to death for AIDS patients. Patients not
known to have progressed during follow-up were censored at
either the most recent visit to the clinic or when lost to
follow-up. Median progression times were estimated using
the product-limit Kaplan-Meier survival method, and these
were compared for the HAART and No-ART groups using
log-rank test. Due to the small number of individuals who
progressed during the follow-up period, median and inter-
quartile ranges (IQR) for time to progression to AIDS or
death were extrapolated from the product-limit time to
failure estimates using the maximum likelihood least squares
method. The progression-free times for non-AIDS and AIDS
patients for each group were multiplied by the average PPY
cost of service provision, and the additional life years gained
of non-AIDS and AIDS groups was calculated as the
incremental cost per LYG, based on the difference in the
estimated median progression times of the two groups [27].
Because discounting health benefits remains controversial
[35], only non-discounted estimates are presented. However,
given the relatively short time in each WHO stage, it is
unlikely that an analysis with a non-zero discount rate would
yield qualitatively different results than those presented here.
Sensitivity Analysis
Robustness of results was assessed in a sensitivity analysis;
accounting for variances associated with treatment effects
and total cost of service provision. IQRs between the lower
(25%) and upper (75%) progression-free times percentiles of
the non-AIDS and AIDS patients were multiplied by the
average and 95% CI of the cost of service provision, and the
incremental cost per LYG was calculated.
Results
Study Sample
Of the 1,630 patients in the cohort, 292 patients (265 non-
AIDS and 27 with AIDS) received HAART through partic-
ipation in the clinical trials. The rest of the patients (n ¼
1,328; 1,093 non-AIDS and 235 with AIDS) did not have access
to ART during the study period and comprised the
population from which the No-ART comparator group for
the 292 patients who received HAART was identified.
Baseline CD4 count, WHO stage, age, and socioeconomic
status were independently associated with the likelihood of
receiving HAART (Table 1), but gender was not, and
therefore this variable was not considered in further analyses.
Matching was therefore based on WHO stage, CD4 count
(,200, 200–350, and .350 cells/ll), age (less than the median
age or equal to the median age or greater of the non-AIDS
and AIDS groups respectively) and socioeconomic status (low
or high socioeconomic status).
HAART drug classes were not independently associated
with increased risk of hospitalisation (Table 2) and were
therefore analysed as one category. The characteristics of the
final study population of the 292 patients who received
HAART and the 292 matched No-ART patients are described
in Table 3.
The Non-AIDS Population (WHO Stage 1, 2, or 3)
The matched non-AIDS group included 265 patients both
in the HAART and No-ART group. Approximately one-third
of the patients in the two groups had a baseline CD4 count
,200 cell/ll and (49.4%) were of low socioeconomic status.
Median age at inclusion into study did not differ in the two
groups; 32 y, [IQR: 28–39 y] in the HAART group versus 32 y
[IQR: 28–40 y] in the No-ART group (median test p ¼ 0.48).
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wnAlthough not matched for, gender distribution did not differstatistically in the two groups (v2 ¼ 0.07, p ¼ 0.79; Table 3).
Median progression time was significantly longer in the
HAART group compared with the No-ART group at 4.1 and
3.0 y respectively (log-rank test v2¼ 36.6, p , 0.001; Figure 1).
Use and Cost of Services and Cost per LYG
Patients on HAART had 1.08 (95% CI: 0.97–1.19) mean
inpatient days, significantly fewer than the 3.75 d (95% CI:
3.55–3.97) of the No-ART group; v2¼ 147, OR¼ 0.29, 95% CI:
0.23–0.36, p , 0.001; but had significantly more outpatient
visits of 8.71 (95% CI: 8.40–9.03) compared with 4.35 (95% CI:
4.12–5.61); v2¼ 145, OR¼ 2.00, 95% CI: 1.78–2.25, p , 0.0001
(Table 4). The average PPY inpatient cost in the HAART
group was significantly less than that for the No-ART group,
while the average costs of outpatient visits PPY for the No-
ART group were less than those for the HAART group (Table
4).
Based on the two HAART price scenarios, the average cost
of service provision PPY for the HAART group ranged from a
minimum of $760 to $1,377 PPY, with scenario 2 having the
lowest service provision cost (Table 4). The incremental cost
per LYG for median progression time was $1,622 (95% CI:
1,607–1,627) for scenario 1 and $675 (95% CI: 659–679) for
scenario 2 (Table 5). When a sensitivity analysis was
performed based on the IQR of the progression times, the
incremental cost per LYG varied between $1,578 (95% CI:
1,557–1,581) and $1,759 (95% CI: 1,748–1,772) for the 25th
and 75th percentiles respectively (Table 5).
The AIDS Population (WHO Stage 4)
The AIDS population included 27 patients in each group.
The majority of patients in the two groups presented with a
CD4 count ,200 cell/ll (77%), and 40.74% were of low
socioeconomic status. Median age did not differ in the two
groups; 35 y (IQR: 32–41) in the HAART group versus 37 y
(IQR: 33–50) in the No-ART group (median test p ¼ 0.27).
Gender distribution, with 63% and 70.4% males in the
HAART and No-ART groups respectively, was not signifi-
cantly different in the two groups (v2 ¼ 0.33, p ¼ 0.56) (see
Table 3). Median progression time was significantly longer in
the HAART group compared with the No-ART group; at 3.1
and 1.4 y respectively (log-rank v2¼ 5.28, p ¼ 0.02; Figure 2).
Use and Cost of Services and Cost per LYG
Patients on HAART had significantly fewer mean PPY
inpatient days at 2.04 d (95% CI: 1.63–2.52) compared with
15.36 d (95% CI: 13.97–16.85) for the No-ART group (v2 ¼
1,019, OR ¼ 0.13, 95 CI: 0.11–0.15, p , 0.0001). Mean
outpatient visits PPY in the two groups did differ signifi-
cantly; at 7.62 (95% CI: 6.81–8.49) for the HAART group
compared with 6.60 (95% CI: 5.69–7.62) for the No-ART
Table 1. Univariate and Multivariate Logistic Regression Analyses of Factors Associated with the Likelihood of Receiving HAART
Characteristic Subcategory Univariate Analysis Multivariable Analysis
OR 95% CI: p-Value OR 95% CI: p-Value
CD4 count (cells/ll) ,200 1.00 0.73–1.38 0.98 1.14 0.82–1.60 0.44
200–350 2.05 1.49–2.84 ,0.001 2.14 1.54–2.99 ,0.001
.350 1 1
WHO stage Non-AIDS 2.10 1.39–3.21 0.001 2.24 1.43–3.49 ,0.001
AIDS 1 1
Age ,32 0.68 0.53–0.88 0.004 0.70 0.54–0.92 0.01
32 1 1
Socioeconomic status Low status 0.44 0.34–0.56 ,0.001 0.43 0.33–0.56 ,0.001
High 1 1




Table 2. Logistic Regression Analysis of Factors Associated with Hospitalisation among the Treated Group
Variable Subcategory Univariate Analysis Multivariate Analysis
RR 95% CI p-Value RR 95% CI p-Value
CD4 count (cells/ll) ,200 2.04 1.02–4.10 0.04 1.77 0.86–3.64 0.12
200–350 1.31 0.64–2.66 0.46 1.22 0.59–2.52 0.59
.350 1 1
Viral load (log10 copies/ll) 0.70 0.46–1.06 0.09 0.77 0.50–1.19 0.24
HAART drug class NNRTI (n ¼ 154, 52.7%) 1.23 0.71–2.14 0.13 1.16 0.67–2.04 0.59
TNRTI (n ¼ 21, 7.2%) 0.53 0.15–1.93 0.34 0.59 0.16–2.16 0.42
PI (n ¼ 117, 40.1%) 1 1
NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; RR, risk ratio; TNRTI, triple nucleoside reverse transcriptase inhibitor.
DOI: 10.1371/journal.pmed.0030004.g002
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group; v2 ¼ 7.3, OR ¼ 1.15, 95% CI: 1.04–1.28, p ¼ 0.007,
though not as substantially as for the non-AIDS group (see
Table 4). The average inpatient cost PPY in the HAART
group was significantly less than that for the No-ART group,
but the average costs of outpatient visits PPY in the groups
were not significantly (see Table 4).
Based on the two HAART price scenarios, the average cost
of service provision PPY for the HAART group ranged from a
minimum of $850 to $1,645 PPY, with the lowest care cost
observed for scenario 2 (see Table 4). For patients diagnosed
with AIDS, the incremental cost per LYG for the median
progression time was cost saving for both HAART price
scenarios (Table 5). When a sensitivity analysis was performed
based on the IQR of the progression times, the incremental
cost per LYG varied between $71 (95% CI: 43–111) and cost
saving for the 25th and 75th progression-free time percentiles
respectively (Table 5).
Discussion
This study, employing methods used in similar studies from
industrialized countries [27], provides a unique contempora-
neous comparison of the use, cost, and outcome of hospital
service provision for a group of HIV-infected patients in
Cape Town receiving HAART compared with an immuno-
logically, clinically, and socioeconomically similar group of
patients who did not receive ART. Use of HAART was
associated with decreased disease progression, AIDS, and
death. The HAART group used fewer inpatient services than
the No-ART group, and the magnitude of these changes did
not differ by HAART regimens used in this study. The
Table 3. Baseline Demographic and Clinical Characteristics of the Matched Non-AIDS and AIDS Groups
Variable Subcategory Non-AIDS AIDS
HAART (n ¼ 265) No-ART (n ¼ 27) HAART(n ¼ 265) No-ART (n ¼ 27)
n (%) n (%) n (%) n (%)
CD4 count ,200 cells/ll 81 (30.6) 81 (30.6) 21 (77.7) 21 (77.7)
200–350 cells/llL 110 (41.5) 110 (41.5) 1 (3.8) 1 (3.8)
.350 cells/lL 74 (27.9) 74 (27.9) 5 (18.5) 5 (18.5)
Median age (IQR) 32 (28–39) 32 (28–40) 35 (32–41) 37 (33–50)
Socio-economic status Low status 131 (49.4) 131 (49.4) 11 (40.74) 11 (40.74)
High status 134 (50.6) 134 (50.6) 16 (59.26) 16 (59.26)
Gender Male 142 (53.60) 145 (54.7) 17 (63) 19 (70.4)
Female 123 (46.4) 120 (45.3) 10 (37) 8 (29.6)
IQR, interquartile range.
DOI: 10.1371/journal.pmed.0030004.g003
Figure 1. Progression of HIV-Infected Individuals from Non-AIDS Stages (WHO Stage 1, 2, or 3) for Patients on HAART and Not on ART
The solid line indicates patients on HAART, and the dotted line indicates patients not on ART.
DOI: 10.1371/journal.pmed.0030004.g001
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wnreduction in use of inpatient services, which has beenobserved in similar studies in industrialized countries [10–15], was most likely due to a reduction in morbidity and
mortality [6,12]. The use of services increased for both groups
with increased severity of HIV infection, resulting in an
increased cost of service provision. The increased use of
inpatient services for patients with AIDS is most likely related
to AIDS-related events or their terminal phase of their illness
[36–41]. In Zimbabwe, medical insurance claims of privately
insured HIV-infected patients in the last few months of their
lives were 700% higher than that of uninfected patients in the
same age group [42].
To date, very few cost-effectiveness studies have been
performed on HAART in a South African setting [43]. The
incremental cost per LYG ranged from being cost saving to
$1,772. The cut-off point for what constitutes a cost-effective
intervention per outcome measure varies from society to
another. For instance, the cost-effective cut-off point in the
United States is currently considered to be $50,000 per
outcome measure and £30,000 in the United Kingdom [30].
To date such a consensus on what would constitute a realistic
threshold for South Africa has not yet emerged, but a cut-off
of twice the per capita gross domestic product (GDP) has
been suggested as a reasonable cut-off point for developing
countries [44]. For the year 2004, the per capita gross
domestic product in South Africa was $3,480, and therefore
this threshold would amount to $6,960 [45]. The cost per LYG
of two HAART cost scenarios for the non-AIDS and AIDS
patients showed that introducing HAART in this hospital
setting would be a very cost-effective intervention. However,
it is clear that the cost-effectiveness ratios were very sensitive
to the price of HAART. If prices of the awarded tender could
be achieved, the introduction of HAART will be a very cost-
effective intervention in Cape Town and probably in similar
settings in sub-Saharan Africa, because HIV accounts for
between 40% and 70% of the public sector inpatient service
provision in the region [3,36–40].
Concern has been expressed that increased access to
Table 4. Mean Number of Inpatient Days, Outpatient Visits, and Associated Costa PPY
Variable Non-AIDS AIDS
HAART No-ART HAART No-ART





Average inpatient days cost (95% CI) $232 (209–256) $806 (763–854) $439 (351–542) $3,302 (3,004–3,623)





Average outpatient visits cost (95% CI) $287 (277–298) $144 (136–185) $251 (225–280) $218 (188–252)
Average total cost PPY (95% CI) $950 (899–1,039) $3,520 (3,192–3,875)
Scenario 1 (current public sector price ¼ $730) $1,342 (1,309–1,377) $1,513 (1,399–1,645)
Scenario 2 (anticipated tender price ¼ 181) $793 (760–828) $964 (850–1,096)
aOdds ratio (OR) uses the No-ART group as baseline risk.
DOI: 10.1371/journal.pmed.0030004.g004
Table 5. Incremental Cost-Effectiveness Ratio (US$) for Current ART Rollout Prices (US$730 Per Annum—Scenario 1) and Anticipated
Tender Prices (US$181 Per Annum—Scenario 2), Comparing HAART and No-ART Groups for Non-AIDS and AIDS Groups at 25th, 50th
(Median). and 75th Progression-Free Times Percentiles
Survival Quartile Group Survival Time (d) ICER (95% CI)
Scenario 1a Scenario 2b
25% Non-AIDS HAART (1391) $1,578 (1,557–1,581) $698 (676–701)
No-ART (523)
AIDS HAART (739) $71 (43–111) Cost-saving
No-ART (309)
Median 50% Non-AIDS HAART (2,641) $1,622 (1,607–1,627) $675 (659–679)
No-ART (1,111)
AIDS HAART (1,120) Cost-saving Cost-saving
No-ART (510)
75% Non-AIDS HAART (3,891) $1,759 (1,748–1,772) $608 (597–621)
No-ART (2,035)




ICER, incremental cost-effectiveness ratio.
DOI: 10.1371/journal.pmed.0030004.g005
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HAART in sub-Saharan Africa will result in the widespread
viral resistance due to poor adherence [46]. Studies
performed in a number of sub-Saharan African countries,
however, have shown that the proportion of individuals
maintaining viral suppression is comparable to that reported
from developed countries [47–49].
This study did have a number of limitations. Because
HAART was not used in routine clinical practice, we had to
compare a group of patients enrolled in clinical trials with a
control group that was not part of the trials. Individuals who
take part in clinical trials have to fulfil certain entry criteria,
as well as to conform to well-defined protocols and cheduled
attendances. It is therefore difficult to exclude the possibility
that a selection bias might have resulted from the inclusion/
exclusion criteria of these clinical trials. However, the No-
ART control group was selected on the basis of clinical,
socioeconomic, and immunologic characteristics similar to
those individuals recruited into the HAART trials conducted
in this study. The frequency of inpatient and outpatient
services utilization of the HAART and No-ART patients in
this study is similar to that reported by UK and Canadian
observational studies [12,27]. However, in this study, the
sample is relatively small for the AIDS group.
This study was focused on hospital services provided at the
level of a teaching hospital. Therefore the costs incurred
through primary, community, or secondary hospital care
were not included, but this reflected the configuration of
services available to the majority of HIV-infected people in
Cape Town at the time of the study. Similarly, the costs
included were direct costs only and did not incorporate the
indirect or intangible costs, such as loss of productivity or
quality of life associated with this illness, because currently no
such data exist in South Africa. Some studies from the United
Kingdom have demonstrated that from a public sector
perspective, indirect costs can comprise between 58% and
124% of direct treatment costs for HAART or between 45%
and 102% from a societal perspective [30]. If these costs were
all included, it is likely that the cost-effectiveness ratio would
even be more favourable. Our estimates did not incorporate
the costs of providing the infrastructure required to support
appropriate HAART provision in rollout programmes.
However the rollout programmes were designed to start
from settings where infrastructure currently exists, which
would predominantly be urban. Recent reports estimated
that if the public sector included HAART as part of a package
of HIV treatment and care in the year 2003, the cost would be
1.2% of the South African GNP, which is unlikely to push
health-care expenditure beyond prudent levels [50,51].
The recent commitment towards scale-up of HAART in
South Africa as part of HIV treatment and care has been an
important and positive development. The urgent need to
introduce HAART as part of routine HIV treatment and care
was recently re-iterated in a World Bank report, which
indicated that if this is not done soon, failure to do so would
have devastating effects on this and future generations of
South Africans [52].
Although the primary rationale for wider access to HAART
is humanitarian, a national HAART programme targeting
patients with symptomatic HIV disease, using low-cost
HAART prices would also significantly decrease hospital
services utilization by HIV-infected patients, resulting in
either health expenditure saving by cost deferral or freeing
substantial resources for health care of non-HIV patients.
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Background The number of cases of AIDS continues to increase
worldwide; the disease is a major threat to humanity, with Africa facing
the very worst problems. In South Africa alone there were 370,000 AIDS
deaths in 2003. AIDS is caused by a type of retrovirus—the human
immunodeficiency virus (HIV). Highly active antiretroviral treatment
(HAART) is a treatment that uses a combination of three or more
antiretroviral drugs that attack different parts of the virus. HAART is
expensive, making it difficult for poor countries to provide treatment for
all those who need it. Prices are falling, however, and South Africa is one
country where efforts are now being made to improve access to
treatment.
Why Was This Study Done? The cost-effectiveness of HAART has been
studied in developed countries, but developing countries also need to
know how much it is going to cost their health services if they introduce
HAART, and whether there will be financial savings because of switching
to a more effective treatment.
What Did the Researchers Do and Find? During the study period
(January 1995 to 31st December 2000), HAART was not available in the
publicly funded South African health-care sector. The study, funded by
the drug manufacturer Bristol-Myers Squibb, took place in HIV clinics
affiliated to the University of Cape Town. The researchers compared the
cost of services for 292 patients who were given HAART with the costs
for a comparison group (with the same number of patients) who were
not given any antiretroviral drugs. Twenty-seven patients in each group
had AIDS; the others were HIV-infected but did not have AIDS. The
researchers calculated costs per patient year (PPY) and per life-year
gained (LYG), i.e., the total cost divided by the number of extra years the
treated patients lived. Calculations were done separately for patients
with AIDS and those without AIDS. Patients on HAART required fewer
hospital admissions. Depending on how long the patient survived and
the price of antiretrovirals drug it cost less to treat the HAART patients
with AIDS. For this group, the cost saving ranged from $219 to $2,116 (in
U.S. dollars). For patients without AIDS, the cost of treatment (ranging
from $597 to $1,772) was, by the South African standard of cost of living,
affordable. However, it is expected that South Africa will soon be able to
manufacture antiretroviral drugs locally and more cheaply. This would
increase the amount saved by introducing HAART.
What Does This Mean? HAART seems to be a more cost-effective way
for South African hospitals to treat HIV infection than by simply waiting
for patients to come to hospital and then dealing with their symptoms.
However, it should be noted that, when a person is infected with HIV
and becomes ill or dies from AIDS, it is not only hospitals that face costs.
The patient, their family, and the country suffer financially. Effective
treatment might also lower these ‘‘indirect’’ costs, but this was not an
issue examined in this research.
Where Can I Find More Information Online? For a comprehensive
source of information on HIV/AIDS:
http://www.thebody.com
The site also includes a useful section on HAART:
ht t p : / / w ww . t heb ody . c om/ Fo r u m s / AI D S/ I nfe ct i on s/ Ar c hi v e/
NewMedications/Q12178.html.
For information about the global AIDS situation and the position in
different countries:
http://www.unaids.int.
PLoS Medicine | www.plosmedicine.org January 2006 | Volume 3 | Issue 1 | e40009










June 2003, Vol. 93, No. 6  SAMJ
ORIGINAL ARTICLES
Combination antiretroviral therapy (ART) has substantially
improved the prognosis of HIV-infected individuals, resulting
in a precipitous drop in AIDS-related mortality in affluent
countries.1-3 In contrast, in the most heavily burdened
developing countries of the world, the response to the
epidemic has focused on prevention. Prevention strategies have
not been successful and the combination of large numbers of
HIV-infected individuals compounded by unequal access to
medical resources, has resulted in an ever-widening life
expectancy gap between wealthy and developing countries.4 In
response to this crisis, the World Health Organisation (WHO)
has called for expanded access to ART in resource-poor
countries.5 ART programmes have been successfully
incorporated into highly divergent medical environments.
Brazil, a middle-income developing country, has incorporated
ART into its public health system 6 and a successful ART
programme has been implemented in rural Haiti, the poorest
country in the Western hemisphere.7
Antiretroviral therapy in a community clinic — early lessons
from a pilot project
Linda-Gail Bekker, Catherine Orrell, Larissa Reader, Kwezi Matoti, Karen Cohen, Rob Martell, Fareed Abdullah, Robin Wood
Objectives. To report on operational and clinical problems
encountered during the first 6 months of a community-based
antiretroviral therapy (ART) programme.
Methods. ART was implemented in a primary care setting
utilising an easily replicable service-delivery model based on
a medical officer and nurse. Therapeutic counsellors,
themselves HIV-infected, provided counselling and adherence
support. Drug and monitoring costs were charitably funded
and provincial health authorities supplied the medical
infrastructure. The HIV Research Unit, University of Cape
Town, supplied training and additional clinical support. Local
HIV primary care clinics provided patient referrals.
Standardised ART regimens were used with strict entry
criteria (AIDS or CD4 count < 200 cells/µl). 
Results. Demand for the service was high. Referred patients
had advanced disease (AIDS 57%, median CD4 count 96/µl)
and high pre-treatment mortality (83/100 person-years).
Mycobacterial disease was a major contributor to this
mortality (40%). Scheduled clinic visit hours were six times
higher during recruitment than maintenance. Attributable
costs were: drugs 61%, staff 27%, viral load and CD4 cell
counts 10% and safety monitoring 2%. Viral load after 16
weeks of therapy was < 400 copies/ml in the first 16 patients.
Conclusions. ART can be successfully implemented within a
primary care setting. Drug purchases and staff salaries drive
programme costing. The service model is capable of
managing 250 - 300 patients on chronic ART, but staffing
needs to be increased during recruitment. Attention must be
given to the diagnosis of  tuberculosis during screening and
early ART. Incorporating therapeutic counsellors into the
programme increased community involvement and utilised a
valuable and previously untapped resource. 
S Afr Med J 2003; 93: 458-462.
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In South Africa, AIDS is now the major cause of death
among young adults.8 While ART is available to thousands of
South Africans in the private medical sector,9 there is little or no
ART access in the public sector, despite demands for such
therapy from the HIV-infected community.10 It has been argued
that ‘where HIV is the leading cause of death, a basic minimum
package that does not include antiretrovirals is not worthy of
the name’.7
In this paper we report on the initial medical, ethical and
logistic challenges of initiating a community-based ART pilot
project in a district where there is an existing network of HIV
primary health care (PHC) clinics. The project was called
Usapho Lwethu (My Family), since treatment was offered to
individuals and their partners and children wherever
appropriate. An easily replicable service delivery model was
chosen based on a team consisting of a medical officer, nurse
and therapeutic counsellors. In order to minimise operational
complexity, standardised ART regimens were used11,12 which
complied with international5 and national treatment
guidelines.13 To facilitate expansion of this or similar service
delivery models for ART elsewhere in South Africa, there is
urgent need to report and share knowledge of the operational
challenges that need to be overcome. 10
Methods
The ART clinic was situated in the Guguletu Community
Health Centre in the Nyanga district of Cape Town, which has
a population of 325 436 (projected figure from 1996 census
data). There are 10 primary care HIV clinics within the district,
which served as the patient referral base. Each clinic had
trained staff able to provide voluntary testing and counselling
services together with prophylaxis and outpatient management
of common HIV opportunistic infections. Patients requiring
inpatient care were referred to a local 200-bed secondary
hospital. 
Funding for antiretroviral medication, viral load
measurements and CD4 cell counts, sufficient for 150 patients,
was provided by UK-based charities. The local Community
Health Service Organisation and AIDS Directorate of the
Western Cape provided clinic space and medical support
services, together with dedicated clinic staff, consisting of a
medical officer and nurse. Training, clinical support, protocol
development and programme evaluation were provided by the
HIV Research Unit of the University of Cape Town. 
In August 2002, medical staff of the referring PHC clinics
were invited to workshops, where eligibility criteria and
patient referral mechanisms were discussed. Referring doctors
were requested to select suitable drug-naïve candidates from
their regular clinic attendees and to fax contact details and a
medical summary to the programme nurse. The medical
criteria for ART eligibility were either a prior AIDS diagnosis
or a CD4 cell count less than 200 cells/µl.5
Branded medications registered with the Medicines Control
Council of South Africa were used in standard doses. ART
consisted of two schedules, an initial non-nucleoside reverse
transcriptase (NNRTI)-based regimen of stavudine (d4T),
lamivudine  (3TC) and efavirenz (nevirapine was substituted
for efavirenz in women of child-bearing potential), with a
second protease inhibitor (PI)-based regimen of zidovudine
(AZT), didanosine (ddI) and Kaletra. Medication was sourced
from a single pharmaceutical supplier with a rapid delivery
turnaround time, to minimise on-site drug stocks. Drugs were
packaged for each named patient and supplied in 4 x 30 day
packs and stored in a secure locked section of the main clinic
pharmacy.
During September 2002, the first patients were recruited into
the programme, with a schedule of visits as follows: –4 weeks,
–2 weeks, treatment initiation, +4 weeks, +8 weeks, +16 weeks
and then at 16-week intervals. The early schedule of visits was
truncated for women in the latter stages of pregnancy, to
maximise therapeutic benefit to mother and baby. At the
screening visit (week –4), potential candidates were allocated a
therapeutic counsellor, whose responsibility was to provide
ongoing counselling support, to reinforce the need for high
levels of adherence, to maintain communication between
clients and the clinic staff and to visit clients in their homes.
The therapeutic counsellors were HIV-infected individuals,
many on ART themselves, who had been trained in drug
adherence and ART toxicity recognition by a non-governmental
organisation, Sizophila. The therapeutic counsellor/patient ratio
was 1:20. At this initial visit, a treatment readiness assessment
questionnaire was completed and 4 weeks of co-trimoxazole
were dispensed, with pill counts performed after 14 and 28
days to assess adherence. All patients had a checklist
completed, which screened for symptoms and signs of
tuberculosis (TB) infection. At the week –2 visit, blood was
taken for quantitative viral load and CD4 cell count. These tests
were repeated at 16-week intervals thereafter. Drug safety
monitoring of liver function test (LFT) and full blood count
(FBC) were also performed at weeks –2, +8 and 16-weekly
thereafter, with an additional LFT performed at week +2 in
those receiving nevirapine to screen for potential
hepatotoxicity. The final decision to commence or defer
initiation of ART was made at a combined meeting of medical
and therapeutic counsellors during the third week (week –1),
when information on clinical status, blood tests, treatment-
readiness and adherence data were available. Following this
meeting, drugs were ordered for those commencing ART. The
cohort pre-ART period was defined as the cumulative number
of days between the screening visit and the date of either
commencement of ART or permanent deferral. The ART
exposure period was defined as the cumulative number of
days from ART commencement to the censoring date of 
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28 February 2003. Resource utilisation data including
scheduled and non-scheduled visits and staff allocated time
were prospectively collected in a clinic register. Clinical,
laboratory and adherence data were kept in an electronic
database. 
Results
The number of eligible patients referred and their subsequent
status within the programme are outlined in Fig. 1. The mean
age of those screened was 34 years (range 7 - 55 years); 78%
were female. The population had advanced HIV infection, with
95% having symptomatic disease (WHO clinical stages 3 and 4)
and 57% having AIDS (WHO clinical stage 4). The median CD4
count was 96 cells/µl (range 3 - 452 cells/µl), and the median
viral load was 4.91 logs (range 2.611 ≥ 500.000). 
Eight patients were permanently deferred; 4 because of
failure or inability to attend clinic visits, 1 because of advanced
debilitating HIV disease and multidrug-resistant pulmonary
tuberculosis, 2 because of asymptomatic HIV and CD4 cell
counts above entry criteria at screening, and 1 because he
denied being HIV-infected. One patient was withdrawn after
therapy commenced because of failure to attend clinic visits.
Viral load data at 16 weeks were available for the first 16
patients, all of which were < 400 copies/ml. The first child
born to a mother on the programme was HIV PCR-negative at
3 months. 
Five deaths occurred between screening and the
commencement of ART or treatment deferral. The total pre-
ART period for the cohort was 2 186 days, which translated to
a pre-treatment crude mortality rate of 83/100 patient years.
Two of the five patients had active Mycobacterium tuberculosis
infection. Four deaths occurred on ART, none of which was
directly related to ART. The period of ART exposure up to the
censoring date totalled 4 271 days.
The proportional costs of drugs, staffing, quantitative viral
load with CD4 cell counts and laboratory safety monitoring are
shown in Fig. 2. Programme costs were dominated by drug
procurement and personnel costs. Of the personnel costs, the
medical officer contributed 39.3%, the nurse 16%, Sizophila
counsellors 15.7% and specialist medical support and training
29%.
Patient referrals reached 150 after 8 weeks of the programme.
Initiation of the 150 patients onto ART was scheduled over 9
months, with a mean of 15 patients starting therapy per month.
In the first 6 months there were 421 scheduled and 20
unscheduled visits. Duration of scheduled visits varied
between 15 minutes for a week-8 visit and 45 minutes for a
treatment-initiation visit. The number of scheduled clinic hours
per week was not evenly distributed and the projected weekly
scheduled visit hours required for the programme are shown in
Fig. 3. 
Discussion
This ART pilot project is a unique collaboration between
funding organisations from a developed country, local and
Fig. 1. Numbers of patients referred, screened and started on the
antiretroviral therapy (ART) programme, together with their status
within the programme and clinical and virological outcomes at week
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Fig. 2. The first 6 months’financial costs of the programme
introducing ART to an HIV primary care service. The attributable
proportion of costs for the following components are shown: drug
acquisition; staffing — medical, nursing and counsellors; monitoring











regional public sector health authorities and a local academic
institution. The programme was designed to identify the
attributable resources needed when adding an ART
programme to an existing primary care HIV service using an
easily reproducible service model. 
Public debate around treatment access, together with the
large numbers of HIV-infected individuals with advanced
disease, has created a backlog of demand for access to ART.
The programme was initially limited by funding sources to
treatment of 150 individuals. Recruitment to the programme
was completed by 8 weeks, confirming a high demand for ART
in our patient population. Many patients are desperate to
access therapy and perceive that they may not survive a delay
of several weeks. The clinic nurse highlighted this therapeu ic
urgency when she reported her distress at ‘watching patients’
faces, informed of the waiting time before they access
antiretroviral therapy’. 
Initiation of ART was staggered over 9 months, which still
resulted in staffing time requirements peaking at
approximately six times the level required for subsequent long-
term management of these patients. The high clinic time
requirement resulted from the combined effects of the
recruitment rate, increased frequency of protocol-required
visits and increased time per visits during the early weeks of
ART initiation. The team of medical officer, nurse and
therapeutic counsellors allocated to the clinic would be
sufficient to supply 20 hours per week of scheduled clinic
visits, enough for a daily clinic of 4 hours’ duration. This
scheduled clinic time could service 250 - 300 patients on stable
ART; however, it is insufficient for the recruitment and
initiation phase of the ART programme. In any new
programme this increased staffing requirement will coincide
with the need for staff training in ART. Our training personnel
were able to provide the extra staffing capacity during the
recruitment phase. There will be a need for programmes to
allocate increased logistical support to ART clinics during the
initial ‘set-up’ phase.    
Patients on the programme had a functional status sufficient
to be able to attend an outpatient clinic; however, the pre-
treatment crude mortality rate was 83/100 patient years. The
on-treatment mortality showed significant decline; the
mortality rate has not been presented at this stage because the
drug exposure period is subject to a major confounder of ‘right
censoring’ and these data will be reported later. TB was a
significant contributor to mortality and the exclusion of active
TB presents a particular challenge to those initiating ART in
high TB-prevalence populations such as South Africa.14,15
Present treatment guidelines5,13 give an upper threshold of
200 CD4 cells/µl for initiating therapy, but there is no lower
limit. This introduces the dilemma of whether patients are ever
too sick to join a programme. While the sickest patients have
much to gain, they utilise programme resources
disproportionately and a high death rate can impact negatively
on community perceptions of the programme and affect staff
morale adversely. The non-medical therapeutic counsellors
required specific counselling support around this issue. In an
analysis of 12 574 individuals on ART, the CD4 count and
clinical stage at the time of initiation of treatment were the
dominant prognostic factors.16 In a cohort with very advanced
HIV disease and low CD4 counts such as ours, between 11%
and 15% would be predicted to develop further AIDS-related
complications during the first year of therapy, with the
majority of these events occurring within the first 6 months.16
Despite this high predicted complication rate, European and
North American experience indicates that only 1.5 - 3.1% of
advanced patients with 50 - 100 CD4 cells/µl die in the first
year of ART.16 These data support initiation of therapy at low
CD4 counts, which can still result in a reasonable prognosis if
the initial complications around the time of starting therapy
can be managed. Staff of the clinic and referral hospital
therefore need a high level of expertise in the recognition and
management of medical complications occurring during early
ART, particularly if very ill patients are to be entered into a
programme.   
Drug procurement accounted for 61% of the attributable cost
of adding ART to the existing primary care HIV management
programme. Although retail costs of ART have declined in
South Africa in recent years, they remain a major obstacle to
wider implementation in the public sector. In the next few
months the programme is expected to access UNAIDS
preferential pricing which will reduce the cost of the initial
regimen to approximately 50% of current retail pricing.
Availability of generic formulations could reduce the cost of
our initial schedule by an additional 50%, to approximately
R350 per month.12,17 Medical specialist support contributed 29%
of initial staffing costs; however, this component will also
decrease as training requirements decline and an increasing
461
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Fig. 3. Number of hours of scheduled visits per week required for 150
patients initiating HAART over a 9-month period. There is an initial
staffing requirement, which peaks at approximately six times the
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proportion of patients are stabilised on ART. Viral load and
CD4 cell measurement contributed 10% of total attributable
expenditure. Until recently these high-technology assays were
considered to be too expensive for ‘low-cost programmes’ and
the use of low-technology substitutes such as total lymphocyte
counts was proposed.5 The recent marked cost reduction of
these assays in South Africa makes low-technology substitution
less attractive.
The preliminary viral response data are very encouraging
and demonstrate that an ART programme can be initiated
successfully within an existing primary care facility. The ART
delivery model chosen was well suited for those districts with
an existing HIV primary care infrastructure. Expansion to other
sites will be dependent not only on funding for antiretrovirals,
but also on the allocation of sufficient resources for the
development of a training and support infrastructure,
particularly during the early recruitment phase of the
programme. There are significant ethical issues concerning the
selection of patients into an ART programme where resources
are very limited. While there is a need for clear, transparent
and strictly maintained criteria for ART access, 10 both the
inclusion and exclusion of very sick patients was very
challenging and stressful for the clinic team. Therapeutic
counsellors gave valuable input to the programme from
persons in the local community living with HIV and AIDS. The
incorporation of HIV-infected individuals as ‘treatment
buddies’ and to give counselling support meant that a
previously untapped resource of expertise and talent was
utilised. 
This programme was sponsored by CRUSAID and the
Hannan Trust, UK. 
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Initiating highly active antiretroviral therapy in sub-
Saharan Africa: an assessment of the revised World
Health Organization scaling-up guidelines
Motasim Badri, Linda-Gail Bekker, Catherine Orrell, Jennifer Pitt,
François Cilliers and Robin Wood
Objectives: To assess the utility of the 2003 revised World Health Organization
(WHO) criteria [initiating highly active antiretroviral therapy (HAART) in stage IV, in
stage III plus CD4 cell count , 350 3 106 cells/l, or in stage I or II plus CD4 cell count
, 200 3 106 cells/l] relative to other scenarios of HAART initiation.
Methods: Progression to AIDS and death in 292 patients taking HAART and 974 not
taking HAART in a South African institution in 1992–2001, stratifying patients by
baseline CD4 cell count and WHO stage.
Results: HAARTwas associated with decreased AIDS [adjusted rate ratio [ARR], 0.16;
95% confidence interval (CI), 0.08–0.31) and death (ARR, 0.10; 95% CI, 0.06–0.18).
Benefit of HAART was significant across all WHO stages plus CD4 cell counts. The
greatest number of deaths averted was in stages IV [74.0/100 patient-years (PY); 95%
CI, 50.2–84.5) and III (32.8/100 PY; 95% CI, 22.4–40.9). AIDS cases averted in stage
III (22.0/100 PY; 95% CI, 6.1–26.9) were higher than in stage I and II with CD4 cell
count , 200 3 106 cells/l (8.9/100 PY 95% CI, 5.6–13.3). Treatment initiation for
symptomatic disease resulted in greater benefits than using any CD4 cell thresholds.
Application of WHO criteria increased the treatment-eligible proportion from 44.5%
to 56.7% (P , 0.05) but did not prevent more death (P. 0.05) than treating sympto-
matic disease.
Conclusion: Implementation of the revised WHO guidelines in sub-Saharan Africa
may result in a significantly increased number of individuals eligible for treatment but
would not be as effective a strategy for preventing death as treating symptomatic
disease. & 2004 Lippincott Williams & Wilkins
AIDS 2004, 18:1159–1168
Keywords: HAART, AIDS, mortality, sub-Saharan Africa, WHO guidelines
Introduction
Antiretroviral therapy has significantly improved the
prognosis of individuals with HIV-1 disease in the devel-
oped world [1–9]. Therapy has evolved from treatment
with a single nucleoside to highly active antiretroviral
therapy (HAART), which is presently the standard of
care. The potency of HAART has been shown by
comparison with dual nucleoside therapy in the
ACTG 320 study [10] and other trials [11–13], together
with a temporal association with sustained decreases in
AIDS-related morbidity and mortality [1–9]. However,
placebo-controlled studies of HAART have not been
conducted for underlying ethical considerations.
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The initial ‘hit early hit hard’ strategy has been
moderated following increased recognition of long-
term adverse events associated with HAART to one of
defering treatment to a later stage of HIV immune
suppression [14]. In recent years, there has been some
convergence of the European and North American
treatment guidelines, but precise CD4 cell count and
viral load thresholds for therapy initiation still vary and
undergo regular revision [15–17]. Benefits of HAART
demonstrated in the developed world may differ for
populations in sub-Saharan Africa because of the vary-
ing spectrum of opportunistic infections and the level
of immune suppression at which they occur [18].
However, determination of the accurate threshold for
HAART initiation is of particular economic relevance
to large-scale programmes as it defines the proportion
of the HIV-infected population eligible for treatment.
The World Health Organization (WHO) has set a
target of treating three million individuals in the
developing world with HAART by 2005 [19]. The
2002 WHO guidelines for scaling up antiretroviral
therapy in resource-limited settings recommended in-
itiation of HAART for those with AIDS and WHO
stages I, II or III with CD4 cell counts , 200 3 106
cells/l [20]. The 2003 guidelines revision recom-
mended extending treatment to those with WHO stage
III disease with CD4 cell counts of 200–350 3 106
cells/l [21]. In sub-Saharan Africa, frequent manifesta-
tions of WHO stage III disease include pulmonary
tuberculosis, oral hairy leukoplakia and mucosal candi-
diasis [22–27], which have been independently asso-
ciated with progressive immune suppression [24–33]
and occur in more than 30% of African patients at a
CD4 cell count . 200 3 106 cells/l [22,23,27]. In
addition, laboratory capacity may not be routinely
available in primary health-care sites in resource-limited
settings. Therefore, it would be relevant to explore
low-cost strategies based on clinical parameters
to identify and refer eligible patients to HAART
programmes.
The present study is a comparative stratified analysis to
assess the utility of the revised WHO criteria relative to
other possible scenarios of HAART initiation, compar-
ing the rates of disease progression to AIDS and death
in a group of indigent patients accessing HAART and
a group attending the same institution in Cape Town,
South Africa who did not have access to HAART.
Methods
Setting and patients
The setting and methods of enrolment into the
prospective Cape Town AIDS Cohort (CTAC) have
been described previously [34]. In brief, the study site
was a specialized HIV clinic at New Somerset Hospital,
a major public health-care provider for HIV-infected
patients in Cape Town. Antiretroviral therapy was not
provided by the public health services during the study
period. Patients presenting to the HIV clinic between
1995 and 2001 had limited access to HAART by
participation in clinical trials. Informed consent was
obtained from all participants, and studies were ap-
proved by the University of Cape Town Research
Ethics Committee. Study inclusion criteria were age
. 16 years but specific entry CD4 cell counts and viral
loads differed between studies [34]. Exclusion criteria
included clinically significant laboratory abnormalities,
acute opportunistic disease, substance abuse, pregnancy,
lactation or recent use of systemic chemotherapeutic
agents or immune-modulating agents. All patients
treated with HAART received at least three antiretro-
viral drugs: a non-nucleoside reverse transcriptase in-
hibitor or protease inhibitor together with two
nucleoside analogues or three nucleoside analogues.
Patients were followed every 2–3 months or more
frequently if deemed clinically necessary. A prospective
log of medication dispensed at each attendance was
maintained. Adherence was monitored by clinic-based
tablet refills. Viral load was determined by reverse
transcriptase polymerase chain reaction (Amplicor;
Roche Molecular Systems, Branchburg, New Jersey,
USA).
A comparison group (no-HAART group) who did not
access HAART was identified. This group included all
patients who presented to the HIV clinic between
1992 and 2000 and did not participate in the clinical
trials or access HAART privately. Patients in the no-
HAART cohort were followed-up approximately 3–6
monthly or when clinically indicated. Viral load was
not available in publicly funded health-care facilities
and, therefore, was not measured in this group.
For both groups, HIV-1 infection was confirmed by
enzyme-linked immunosorbent assay or Western blot
on two different blood specimens. CD4 cell counts
were measured by flow cytometry (Beckman Coulter,
Miami, Florida, USA). At each attendance, clinical
information was recorded, and HIV disease staged using
the WHO staging criteria [35]. Socioeconomic status
of each patient was defined using the Cape Metropoli-
tan Council suburbs composite index, which has been
described previously [34].
Statistical analysis
The primary end-points in this study were AIDS and
death. Time to these events was defined, respectively,
as time from the initial clinic visit (or from starting
treatment for the HAART group) to the date of first
AIDS-defining illness, and/or date of death, date of last
known clinic visit or end of study period. Death events
were identified from patients’ records and hospital or
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municipality death registry. Patients switching from the
no-HAART group to the HAART group contributed
survival time to the no-HAART group from their
initial clinic visit till the date of initiating HAART, and
subsequently to the HAART group until the date of
onset of AIDS (or death), the last follow-up visit or
study end-point.
The Kaplan–Meier technique and the generalized log-
rank test were used to plot and compare AIDS-free and
death-free survival probabilities curves of the two
groups. Because the WHO guidelines utilize a combi-
nation of clinical stage plus CD4 cell count for
treatment initiation [21], analyses were further stratified
by baseline CD4 cell count, WHO stage and a
combination of WHO stage III with CD4 cell count
, 200, 200–350 or . 350 3 106 cells/l.
Cumulative incidence rate of AIDS and death was
defined as the number of events occurring in each
group per 100 patient-years (PY) of follow-up. Patients
presenting with prior AIDS-defining illness were ex-
cluded from the calculation of incidence rate of AIDS.
The analyses were further stratified by baseline CD4
cell count and WHO stage. In addition, relative hazards
from Cox multivariate proportional hazards regression
models, described below, were used to calculate num-
ber of AIDS or death events averted by HAART.
Binomial distribution was used to calculate the 95%
confidence (CI) for incidence rates and number of
AIDS and death averted. The chi-square test was used
to compare differences in proportions. All calculated P
values were two sided.
Cox proportional hazard regression analysis was used to
identify variables associated with the likelihood of
AIDS or death using SAS software version 8.2 (SAS,
Cary, North Carolina, USA). A number of baseline
prognostic variables were examined in analysis, includ-
ing CD4 cell count, WHO stage, prophylactic cotri-
moxazole, age, socioeconomic status, gender, and year
of initial care. The assumption of proportional hazards
was examined by plotting the log [log (survival
function)] estimates against log time. Interaction terms
were not included in the final models as they were not
significant and did not impact on the fit of the models.
The relative utility of the 2003 revised WHO treat-
ment guidelines was assessed by comparing the pro-
jected number of patients eligible for HAART and the
resulting number of deaths averted applying five differ-
ent scenarios of initiating HAART in the 974 no-
HAART group: scenario I the revised WHO treatment
guidelines (treating patients with stage IV irrespective
of CD4 cell count enumeration, with stage III plus
CD4 cell count , 350 3 106 cells/l, with stage I or II
plus CD4 cell count , 2003 106 cells/l); scenario II
the previous WHO treatment guidelines (treating pa-
tients with stage IV irrespective of CD4 cell count
enumeration, with WHO stages I–III with CD4 cell
count cell count , 200 3 106 cells/l); scenario III
treating symptomatic patients (WHO stages III and
IV); scenario IV treating patients with AIDS only;
scenario V treating patients with CD4 cell count
, 200 3 106 cells/l only.
Results
As of December 2001, 292 patients had received
HAART who met our inclusion criteria and consti-
tuted the treated arm of this study. The no-HAART
group comprised 981 patients. Of these, seven patients
did not have clinical or laboratory data and were,
therefore, excluded from the analysis. Baseline demo-
graphic and clinical characteristics of the two groups
are shown in Table 1. Age, gender, ethnicity and
WHO stage did not differ in the two groups. More
patients in the HAART group had a higher socio-
economic status. Prophylactic cotrimoxazole was used
more frequently in the no-HAART group than in the
HAART group. The HAART group had lower CD4
cell counts than did the no-HAART group. Mean
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Table 1. Baseline demographic and clinical characteristics of the




[No. (%)] P valuea
No. in group 292 974
Age (years) 0.19
, 33) 145 (49.7) 441 (45.3)
> 33 147 (50.3) 533 (54.7)
Gender 0.35
Male 159 (54.5) 502 (51.5)
Female 132 (45.5) 472 (48.5)
Population group 0.97
Black 170 (58.2) 573 (58.8)
Mixed race 67 (23) 224 (23)
White 55 (18.8) 177 (18.)
Socioeconomic status , 0.0001
High 149 (51) 346 (35.5)
Low 143 (49) 628 (64.5)
Year of initial care , 0.0001**
1992–1996 0 588 (60.4)
1997–2000 292 (100) 386 (39.6)
Cotrimoxazole , 0.0001
Yes 98 (33.6) 506 (52)
No 194 (66.) 468 (48)
WHO stage 0.09
I and II 157 (53.8) 541 (55.5)
III 108 (37) 307 (31.5)
IV 27 (9.2) 126 (13)
CD4 cell count (3 106 cells/l) , 0.0001
, 200 102 (34.9) 447 (45.9)
200–350 111 (38) 229 (23.5)
. 350 79 (27.1) 298 (30.6)
HAART, highly active antiretroviral therapy; WHO, World Health
Organization.
*By chi-square test; **by Fisher exact test.










follow-up was longer in the HAART group (17.4
months) than in the no-HAART group (14.4 months)
(P ¼0.0005). The 415 baseline stage III diagnoses in
this cohort consisted of 154 (37%) with pulmonary
tuberculosis [median CD4 cell count 168 3 106 cells/l;
interquartile range (IQR), 68–279], 206 (50%) with
oral candidiasis or hairy leukoplakia (median CD4 cell
count 166 3 106 cells/l; IQR, 61–276) and 55 (13%)
with other stage III diagnoses (severe bacterial infec-
tions, weight loss . 10% of body weight, unexplained
prolonged fever, unexplained chronic diarrhoea) (med-
ian CD4 cell count 201 3 106 cells/l; IQR 74–301).
In patients without prior AIDS, 10 new AIDS-defining
illnesses occurred in the HAART group (2.8/100 PY)
compared with 125 (12.9/100 PY) in the no-HAART
group [unadjusted rate ratio (ARR), 0.22; 95% CI,
0.11–0.41; P , 0.0001]. Overall, AIDS-free survival
proportion in the Kaplan–Meier analysis was signifi-
cantly higher in the HAART compared with the no-
HAART group (P, 0.0001), and remained significant
when the analysis was stratified by baseline WHO
stage, CD4 cell count or the different combinations of
CD4 cell count and WHO stage (Fig. 1). After
adjusting simultaneously for baseline differences in a
Cox multivariate analysis, HAART conferred an in-
dependent protective benefit against risk of AIDS
(ARR, 0.16; 95% CI, 0.08–0.31; P , 0.0001). Other
variables associated with risk of AIDS were baseline
WHO stage plus CD4 cell count (Table 2).
An analysis was carried out to calculate and compare
the incidence of AIDS in the two groups, and to
calculate the adjusted number of AIDS cases averted by
HAART, stratifying patients by CD4 cell count,
WHO stage, and the different combinations of WHO
stages plus CD4 cell counts. Overall, adjusted number
of AIDS cases averted was 10.8/100 PY (95% CI, 7.5–
14.0), and this increased by advancing clinical stage of
disease or immune suppression, with the largest number
of adjusted cases averted in patients with WHO stage
III (22.0/100 PY; 95% CI, 6.1–26.9) and CD4 cell
count , 2003 106 cells/l (15.4/100 PY; 95% CI,
8.6–21.3) (Table 3).
A similar trend was observed when the analysis was
carried out using death as an end-point. During the
follow-up period, 15 deaths occurred in the HAART
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.






































































































































Patients with CD4 cells  200
Fig. 1. Kaplan–Meier probabilities of AIDS-free survival for the group taking highly active antiretroviral therapy (solid line)
and those not taking such therapy (dotted line). Stages are World Health Organization staging; CD4 cell counts given as
3 106 cells/l.










group (3.6/100 PY) compared with 302 (26.4/100 PY)
in the no-HAART group (ARR, 0.13; 95% CI, 0.08–
0.23; P , 0.0001). Survival proportion was consistently
significantly better in the HAART group than in the
no-HAART group in the WHO stratified Kaplan–
Meier analyses (Fig. 2). HAART was independently
associated with significant reduction in death (ARR,
0.10; 95% CI, 0.06–0.18; P , 0.0001). Prophylactic
cotrimoxazole, baseline CD4 cell count and WHO
stage were also independently associated with risk of
death (Table 2). The overall adjusted number of deaths
averted was 23.8/100 PY (95% CI, 19.6–27.4) and, as
in the AIDS analysis, also increased by advancing clin-
ical stage of disease or immune suppression (Table 4).
In the analysis carried out to compare the relative
impact of applying the WHO revised criteria and the
other three scenarios defined above, the percentage of
patients eligible for treatment from the total 974 no-
HAART patients applying the revised WHO guide-
lines (56.7; 95% CI, 53.5–59.8) was significantly higher
(P , 0.05) than that calculated for symptomatic WHO
stage III or IV patients (44.5; 95% CI, 41.3–47.6),
AIDS patients (12.9; 95% CI, 10.9–15.2) or patients
with , 200 3 106 cells/l CD4 cell counts (45.9; 95%
CI, 42.7–49.1) (Table 5). However, the number of
deaths averted per 100 PY using the WHO revised
criteria (30.0/100 PY; 95% CI, 23.1–35.9) was not
statistically different from that calculated applying other
scenarios, except for patients with AIDS (cases averted
74.0/100 PY; 95% CI, 50.2–84.5). There was no
significant advantage in terms of number of AIDS cases
averted in treating symptomatic patients in comparison
with treating patients meeting the revised WHO
criteria (Table 3).
Discussion
This study is unique in that it compares the outcome
of HIV disease in a group of patients receiving
HAART with a comparison group without access to
treatment, controlling for measurable confounding fac-
tors. Our findings address the identification of those at
greatest need of immediate access to HAART in sub-
Saharan Africa and are of practical relevance for the
cost-effective use of scarce medical resources. HAART
substantially reduced both progression to AIDS and
deaths across all WHO stages plus CD4 cell counts.
The magnitude of therapeutic benefit increased with
advancing HIV disease progression. WHO clinical stage
was a stronger predictor than CD4 cell count for both
risk of AIDS and death.
Our comparative analysis of HAART initiation strate-
gies demonstrated that a treatment threshold of clinical
stage IV only would identify the lowest number
(12.9%) of patients eligible for treatment but achieve
the highest deaths/100 PY averted (74.0%). These
patients would represent an appropriate target popu-
lation for HAART where resources are severely con-
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Table 2. Coxproportional hazards regression models for predictors of AIDS and death.










Yes 0.23 (0.12–0.44) 0.16 (0.08–0.31) 0.14 (0.08–0.23) 0.10 (0.06–0.18)
No 1 1 1 1
Cotrimoxazole
Yes 0.65 (0.47–0.97) 0.96 (0.66–1.39) 1.00 (0.80–1.25) 0.67 (0.53–0.85)
No 1 1 1 1
WHO stage
I and II 0.22 (0.15–0.32) 0.23 (0.16–0.35) 0.14 (0.11–0.20) 0.15 (0.11–0.21)
III 1 1 0.45 (0.34–0.59) 0.48 (0.36–0.64)
IV – – 1 1
CD4 cell count (3 106 cells/l)
, 200 2.52 (1.61–3.95) 1.82 (1.13–2.91) 2.44 (1.80–3.30) 1.86 (1.36–2.55)
200–350 0.98 (0.57–1.71) 0.98 (0.56–1.72) 1.34 (0.94–1.91) 1.56 (1.09–2.26)
. 350 1 1 1 1
Initial year of care
1992–1996 1.16 (0.81–1.65) 0.69 (0.47–1.01) 1.57 (1.24–1.99) 0.85 (0.66–1.09)
1997–2000 1 1 1 1
Age (years)
, 33 0.88 (0.63–1.24) 0.96 (0.67–1.36) 0.78 (0.63–0.97) 0.84 (0.67–1.05)
> 33 1 1 1 1
Socioeconomic status
High 1.02 (0.72–1.45) 1.17 (0.81–1.69) 1.09 (0.87–1.36) 0.95 (0.75–1.20)
Low 1 1 1 1
HAART, highly active antiretroviral therapy; WHO, World Health Organization.










strained. Targeting those with symptomatic HIV dis-
ease (WHO stages III and IV) would have resulted in a
significantly lower number of individuals eligible for
treatment (44.5%) than with implementation of the
revised WHO criteria (56.7%) but would have resulted
in comparable numbers of deaths/100 PY averted [40.8
(95% CI, 32.0–48.5) and 30.0 (95% CI, 23.1–35.9),
respectively]. Implementation of therapy at a threshold
of CD4 cell count , 200 3 106 cells/l would also
result in a significantly lower eligible proportion
(45.9%) but would result in less deaths averted per
100 PY (29.6; 95% CI, 21.7–36.0) than treatment of
symptomatic disease.
The decision of when to initiate HAART is multi-
faceted and depends on many factors, including avail-
able resources, the untreated prognosis, benefits of
therapy, drug toxicity, and the need for long-term
adherence. North American and European HIV treat-
ment guidelines recommend initiating HAART for all
patients with symptomatic disease, together with var-
ious CD4 cell count and viral load thresholds for
asymptomatic individuals [15–17]. The WHO guide-
lines for scaling-up antiretroviral therapy in resource-
poor settings included a CD4 cell count threshold of
200 3 106 cells/l for asymptomatic patients but ex-
cluded stage III disease with . 200 3 106 cells/l,
which was revised in 2003 to exclude stage III with a
CD4 cell count . 350 3 106 cells/l. In our cohort,
43% of stage III disease occurred at CD4 cell counts
. 2003 106 cells/l. Individuals with stage III disease,
regardless of their CD4 cell counts, had more AIDS
events and deaths than those with stage I or II disease
with a CD4 cell count of , 2003 106 cells/l. Oral
candidiasis and oral hairy leukoplakia were the com-
monest stage III diagnoses (50%), with pulmonary
tuberculosis (37%) and other stage III conditions (13%)
occurring less frequently. CD4 cell counts did not
differ significantly between these conditions, and com-
parable survival of patients with these conditions has
been previously reported in our cohort [27]. Applica-
tion of the initial WHO guidelines would have
excluded 43% [20], and the revised WHO guidelines
21% [21], of stage III patients who would benefit from
HAART. However, when CD4 cell count , 200 3
106 cells/l is not used for access to HAART, and only
symptomatic patients are treated, 41% of the patients
with CD4 cell count , 200 3 106 cells/l who may
benefit from HAART would be excluded.
Several points should be considered in interpretation of
our analysis. The observational design of our study is a
limitation but, because of the undoubted benefits of
HAART, a randomized placebo-controlled trial would
not be a feasible alternative. In this none-randomized
cohort study, there were some recognized but unavoid-
able confounders. The HAART group was largely self-
selected and this may have resulted in a selection bias;






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































however, each group had a broad spectrum of immune
suppression and clinical disease, which allowed for
stratification of outcomes, and controlling for well-
established prognostic indicators of disease progression.
The median follow-up time was lower in those not
receiving HAART, but this could not explain the
higher event frequency noted in this group. The study
population was attending a public sector health facility
































































Patients with CD4 cells 200
P  0.0001































































Patients with stage 3 and CD4 cells 350
P  0.0001
0 6 12 18 24 30 36 42 48
Months
Fig. 2. Kaplan–Meier probabilities of survival of the group taking highly active antiretroviral therapy (solid line) and those not
taking such therapy (dotted line). Stages are World Health Organization staging; CD4 cell counts given as 3 106 cells/l.
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(95% CI) P value
Adjusteda No. cases
averted (95%CI)
Overall 292 15 422.5 3.6 (1.9–5.8) 974 302 1,142.6 26.4 (23.9–29.1) 0.10 (0.06–0.18) , 0.0001 23.8 (19.6–27.4)
WHO stage
I and II 157 – 226.0 – 541 89 704.0 12.6 (10.3–15.3) – –
III 108 9 153.9 5.9 (2.7–10.8) 307 133 340.1 39.1 (33.9–44.5) 0.16 (0.08–0.34) , 0.0001 32.8 (22.4–40.9)
IV 27 6 42.6 14.1 (5.3–27.9) 126 80 98.5 81.2 (71.7–88.0) 0.10 (0.04–0.30) , 0.0001 74.0 (50.2–84.5)
CD4 cell count (3 106 cells/l)
, 200 102 14 156.9 8.9 (4.96–14.5) 447 177 502.7 35.2 (31.0–39.5) 0.16 (0.09–0.30) , 0.0001 29.6 (21.7–36.0)
200–350 111 – 158.0 – 229 73 300.7 24.3 (19.5–29.5) – –
. 350 79 1 107.6 0.9 (0.02–5.1) 298 52 339.2 15.3 (11.7–19.6) 0.03 (0.004–0.26) 0.0012 14.8 (8.7–19.5)
WHO stage plus CD4 cell count (3 106 cells/l)
Stage I and II plus CD4 cell , 200 24 – 34.6 – 186 38 247.1 15.4 (11.1–20.5) – –
Stage I and II plus CD4 cell 200–
350
72 – 110.5 – 139 32 209.3 15.3 (10.7–20.9) – –
Stage I and II plus CD4 cell . 350 61 – 80.9 – 216 19 247.6 7.7 (4.7–11.7) – –
Stage III plus CD4 cell, 200 57 8 87.4 9.2 (4.1–17.3) 175 83 190.9 43.5 (36.3–50.8) 0.24 (0.11–0.56) 33.1 (16.0–45.2)
Stage III plus CD4 cell 200–350 38 – 46.2 – 67 26 74.3 35.0 (24.4–47.1) – –
Stage III plus CD4 cell. 350 13 1 20.3 4.9 (0.1–24.9) 65 24 74.9 32.0 (21.7–43.8) 0.15 (0.01–0.61) 0.012 27.2 (8.5–43.4)
Stage IV plus CD4 cell , 200 21 6 34.8 17.2 (6.6–33.7) 86 56 64.7 86.6 (75.3–93.5) 0.11 (0.04–0.34) , 0.0001 77.0 (49.7–89.8)
Stage IV plus CD4 cell 200–350 1 – 1.3 – 23 15 17.2 87.2 (63.6–98.5) – –
Stage IV plus CD4 cell . 350 5 – 6.5 – 17 9 16.6 54.2 (27.8–77.0) – –
HAART, highly active antiretroviral therapy; WHO, World Health Organization; PY, person-years; CI, confidence interval.






























and may not be representative of the total South
African HIV-infected population; however, it would
resemble those who are most likely to access HAART
in a national treatment programme. We did not adjust
our results for viral load, as it was not available for the
no-HAART group. However, while baseline CD4 cell
count and clinical stage were predictive of on-HAART
progression in a large multicentre analysis, only viral
loads . 105 copies/ml were associated with increased
progression rate [8]. Survival of our untreated cohort
was not dissimilar from that of the US Multi-Center
AIDS Cohort Study [36], and better than elsewhere in
Africa [22,23,37,38], probably because of the availability
of rifampicin-based tuberculosis therapy, cotrimoxazole
prophylaxis and treatment of common opportunistic
infections. Death rates in our on-HAART group were
comparable to those reported by Egger et al. [8];
however, cause-specific mortality was not available,
and, therefore, it was not possible to ascertain whether
all deaths reported in both cohorts studied were HIV
related. The clinical benefits of HAART in this
indigent African population appear to be of similar
magnitude to those in developed world settings. Low
socioeconomic status is not a predictor of poor adher-
ence to HAART [39], and indigent African patients
have been shown to be able to adhere to therapy and
achieve high rates of viral suppression [39–49]. The
low number of individuals accessing HAART in
resource-poor settings is a consequence of economic
factors, particularly the prohibitive cost of drugs, rather
than any medical rationale.
We have quantified the impact of HAART initiated at
various thresholds and shown a graded response: great-
est in those with AIDS and lowest in asymptomatic
disease with preserved CD4 cell counts. The combina-
tion of the number of AIDS and deaths averted by
varying strategies and the proportion of individuals
eligible for treatment at different initiation thresholds
are useful data for HAART programme planning and
cost-effectiveness modelling. Where medical resources
are limited, it is appropriate to treat first those who
would benefit most from HAART. The superiority of
WHO clinical stage over CD4 cell count for identify-
ing those who will benefit most from HAART allows
therapy to be targeted to symptomatic individuals who
are already likely to be seeking care within the health
system. Where resources are less constrained, CD4 cell
counts can be utilized to identify asymptomatic patients
at high risk of progression to AIDS and death, who
may also benefit from HAART. Implementation of the
2003 revised WHO guidelines in sub-Saharan Africa
could result in a significantly larger number of eligible
individuals but with lower impact on mortality than an
alternative strategy based on clinical parameters.
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In 2003 the World Health Organization (WHO) and the United 
Nations AIDS Organization (UNAIDS) launched a strategy 
to extend antiretoviral treatment (ART) to 3 million people 
living with HIV/AIDS in low- and middle-income countries 
by the end of 2005.1 As a result of this strategy there are now 
over 500 000 people on ART in sub-Saharan Africa, where the 
burden of disease is greatest. This reflects a 3-fold increase in 
the number of people receiving treatment in the region during 
the 12 months up to June 2005.2 With this dramatic expansion 
in services, concerns have been raised that expanding access 
to ART in resource-poor settings will lead to ‘antiretroviral 
anarchy’ characterised by poor adherence to therapy, 
widespread viral resistance to medications and ultimately poor 
clinical outcomes.3 
To date, a number of programmes have demonstrated the 
feasibility of providing ART services on a relatively small 
scale,4-10 and have shown that in these instances clinical and 
virological outcomes in these programmes parallel outcomes 
in Europe and North America.11,12 A recent article by Severe 
et al.13 makes an important contribution to the published 
literature on the scale-up of access to ART in resource-limited 
settings. The results of the first 1 000 patients treated in Port-
au-Prince, Haiti, with limited infrastructure and staff are 
remarkable compared with those from First-World settings. 
After 1 year of therapy, 87% of adults and 98% of children 
were still alive. An editorial in the same journal14 called for 
accelerated enrolment in both urban and rural settings. But 
despite the rapid expansion of ART services in sub-Saharan 
Africa, there are few documented experiences of how the 
expansion of ART services over time may affect their quality. 
As ART programmes increase the numbers of patients served, 
there are parallel increases in the burden on staff, affecting 
each category of health care provider. The increased burden 
on health providers associated with scale-up may result in 
reduced time, on average, spent in the care of each patient in 
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Background. Despite rapid expansion of antiretroviral therapy 
(ART) in sub-Saharan Africa there are few longitudinal data 
describing programme performance during rapid scale-up. 
Methods. We compared mortality, viral suppression and 
programme retention in 3 consecutive years of a public sector 
community-based ART clinic in a South African township. 
Data were collected prospectively from establishment of 
services in October 2002 to the censoring date in September 
2005. Viral load and CD4 counts were monitored at 4-monthly 
intervals. Community-based counsellors provided adherence 
and programme support.
Results. During the study period 1 139 ART-naïve patients 
received ART (161, 280 and 698 in the 1st, 2nd and 3rd years 
respectively). The median CD4 cell counts were 84 cells/μl 
(interquartile range (IQR) 42 - 139), 89 cells/μl (IQR 490 
- 149), and 110 cells/μl (IQR 55 - 172), and the proportions 
of patients with World Health Organization (WHO) clinical 
stages 3 and 4 were 90%, 79% and 76% in each sequential year 
respectively. The number of counsellors increased from 6 to 28 
and the median number of clients allocated to each counsellor 
increased from 13 to 33. The overall loss to follow-up was 2.9%. 
At the date of censoring, the Kaplan-Meier estimates of the 
proportion of patients still on the programme were 82%, 86% 
and 91%, and the proportion who were virally suppressed  
(< 400 copies/ml) were 100%, 92% and 98% for the 2002, 2003 
and 2004 cohorts respectively.
 Conclusions. While further operational research is required 
into optimal models of care in different populations across 
sub-Saharan Africa, these results demonstrate that a single 
community-based public sector ART clinic can extend care to 
over 1 000 patients in an urban setting without compromising 
programme performance.
S Afr Med J 2006; 96: 315-320.
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the service. Similar phenomena, with increases in patient load 
associated with reductions in programmatic success, have 
been documented in a number of other primary care services, 
including the diagnosis and management of tuberculosis and 
sexually transmitted infections.15-17 In this light it is possible 
that the good programmatic outcomes – including high rates 
of virological suppression and retention in services along with 
low mortality – that have been achieved by small, focused ART 
services, may be difficult to maintain as programmes grow in 
size. 
The question of how programmatic outcomes in 
antiretroviral services are influenced by rapid increases in 
patient load has significant implications for the scale-up of 
HIV care and treatment services in sub-Saharan Africa. While 
there is a wide range of different approaches to delivering ART 
services, there are few insights into the service delivery models 
that can best maintain optimal patient care and programmatic 
outcomes. For example, if programmes with large patient 
loads have difficulty maintaining the high levels of viral 
suppression and patient retention and low levels of mortality 
that can be achieved with smaller services, then multiple small-
scale services may be preferable to fewer, larger services for 
delivering ART to a specific population. Insights into these 
questions of programme expansion and optimal patient load 
are urgently required to inform health systems and policies for 
ART scale-up in resource-limited settings.
In this light, we reviewed changing patterns in virological 
outcomes, patient survival and programme retention among 
patients attending a public sector community-based ART 
programme in a South African township. The programme 
was established in September 2002 and rapidly expanded its 
services, enrolling 1 139 patients by October 2005.
Methods
Setting
Guguletu Clinic is situated in the urban Nyanga district of 
Cape Town, which has an estimated population of 350 000 
and is served by 10 primary care HIV clinics18 that comprised 
the patient referral base. The district is socially deprived 
with an estimated 57% unemployment rate and with 81% 
of households living in informal dwellings,19 a tuberculosis 
notification rate of 1 026/100 000,20 and an antenatal HIV-1 
seroprevalence rate of 28%, which is among the highest in the 
province.21 The Usapho Lwethu (Our Family) ART programme 
is a dedicated ART clinic based at the Guguletu Community 
Health Centre, Cape Town.22 A pilot programme was started 
in 2002 with funding support from an international donor, 
and the expansion of services in subsequent years has been 
supported by a grant from the Global Fund to Fight AIDS, 
Tuberculosis and Malaria. 
ART programme
Enrolment into the programme follows the National Ministry 
of Health ART guidelines,23 which are based on the 2002 
WHO recommendations for scaling up ART in resource-poor 
settings.24 The medical criteria for adult ART eligibility include 
those with a prior AIDS diagnosis or a blood CD4 cell count  
< 200 cells/μl, and for children, paediatric stage III disease or a 
CD4 cell percentage < 20%.
Following referral from a primary care clinic, the standard 
schedule of visits was as follows: screening visit (week 0), 
screening blood tests (week 2), treatment initiation (week 4) 
and treatment follow-up (weeks 8, 12, and 20, and 16-weekly 
thereafter). At the screening visit, a treatment-readiness 
evaluation was completed and a 4-week supply of co-
trimoxazole was dispensed to patients with less than 200 
CD4 cells/μl, with pill counts at 14 and 28 days to assess 
adherence. Dapsone was used as an alternative for those 
with co-trimoxazole intolerance. Patients were assessed by 
a doctor for symptomatic HIV-associated disease. First-line 
ART comprised stavudine, lamivudine plus a non-nucleoside 
reverse transcriptase inhibitor (efavirenz or nevirapine). The 
second-line regimen comprised lopinavir/ritonavir, zidovudine 
and didanosine. A secure supply of medication was maintained 
by the local health authority throughout the study period and 
all treatment was supplied free of charge. In addition to the 
scheduled clinic appointments, patients had open access to the 
clinic for medical problems. 
Therapeutic counsellors
At the screening visit patients were allocated to a community-
based ‘therapeutic counsellor’ living in the Guguletu area. 
These community-based counsellors, the majority of whom 
are living with HIV/AIDS, provide ongoing counselling 
support, addressing psychosocial issues and reinforcing the 
need for high levels of treatment adherence. Counsellors were 
responsible for treatment-readiness group information sessions 
carried out twice weekly in a local community hall, clinic-
based adherence reinforcement sessions and home visiting.
Laboratory monitoring
Plasma HIV load and blood CD4 cell count were performed 
at week 2 and 4-monthly after commencing ART. Toxicity 
monitoring comprised a full blood count and liver function 
tests performed at week 2, and subsequently at 4-monthly 
intervals. All laboratory tests were performed on site by a 
single laboratory technician in a self-contained laboratory 
located in a modified shipping container. Plasma HIV-1 
load was measured using the Versant HIV-1 RNA 3.0 assay 
performed on a 340 bDNA analyser (Bayer Diagnostics, 
Tarrytown, NY, USA) with a lower limit of detection of 50 
RNA copies/ml. Blood CD4 cell counts were measured using 
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flow cytometry (Becton Dickenson FACSCount, New Jersey, 
USA). Internal quality assurance (QA) and interlab QA were 
performed for the viral load and CD4 measurements and 
full blood counts and CD4 measurements were subject to 
additional external QA.
Data sources
Structured clinical records were maintained on all patients 
screened on entry to the ART programme and this information 
together with laboratory results was regularly transferred 
to an electronic database. The Research Ethics Committee 
of the University of Cape Town approved the use of patient 
information from this service for programme evaluation, and 
as part of this, all enrolled patients gave written informed 
consent for anonymous clinical data to be recorded and 
analysed. 
Statistical analysis
Data were analysed using Stata version 9.0 (College Station, 
Texas, USA). Three annual cohorts were defined as patients 
initiating ART during the 12 months from 1 September 2002 
(the 2002/2003 cohort), 2003 (the 2003/2004 cohort) and 2004 
(the 2004/2005 cohort). The demographic profile and baseline 
immunological and virological characteristics of the cohorts 
were compared using Wilcoxon’s rank-sum and chi-square 
tests for medians and proportions, respectively; trends across 
annual cohorts were assessed using Cuzick’s non-parametric 
trend test for medians and Cochrane-Armitage tests for 
proportions. The retention of patients in the programme was 
compared across annual cohorts using Kaplan-Meier analyses 
with log-rank tests. All statistical tests are 2-sided at a = 0.05.
Results
Programme entry
During the first 3 years of the service, 1 510 patients were 
referred to the programme for ART, of whom 1 139 were 
commenced on treatment. Of the 371 not starting ART, 155 
(42%) did not meet entry qualifications or received therapy 
elsewhere, 146 (39%) were awaiting treatment initiation at the 
censoring date and 70 (19%) died before starting ART.  The pre-
ART death rate was 34.6/100 patient-years (confidence interval 
(CI): 27 - 43) and did not vary significantly between the annual 
cohorts. Recruitment increased steadily during the study 
period (October 2002 - September 2005), with greater numbers 
of children and pregnant women entering the programme in 
the second and third years (Table I). There was a significant 
trend for individuals recruited into the programme to have less 
advanced HIV in the second and third years as demonstrated 
by higher median CD4 c unt, lower log10 mean viral load 
and a lower proportion with an AIDS diagnosis (Table I). 
The proportion of pregnant women entering the programme 
who had AIDS was low (5%) compared with non-pregnant 
adults (30%). The CD4 count of children at programme entry 
(median 540 cells/μl, interquartile range (IQR) 244 - 906) was 
significantly higher than that of adults (101 cells/μl, IQR  
244 - 906). As further treatment sites were initiated elsewhere in 
South Africa, an increasing number of patients were transferred 
in and out of the programme on ART. 
Staffing and physical infrastructure
The programme commenced with a staff of 1 doctor, 1 nurse 
and 8 counsellors. At the end of the study period staffing 
Table I. Baseline characteristics of 1 139 patients starting ART between October 2002 and  
September 2005
2002/3 2003/4 2004/5 p-value
Number starting ART 161 280 698
Median age (yrs) 33 32 32   0.19
Age range (yrs) 7 - 58 1 - 54 1 - 64
Female (N (%)) 114 (74.5) 193 (75.7) 479 (65.4)   0.002
Pregnant at entry (N) 1 39 80   0.06
Children < 14 years (N) 1 3 69 < 0.001
Median CD4 (cells/μl (IQR)) 84 (42 - 139) 89 (49 - 149) 110 (55 - 172) < 0.001
Median log10 viral c/ml (IQR) 4.98 (4.58 - 5.33) 4.87 (4.50 - 5.23) 4.72 (4.25 - 5.14) < 0.001
WHO stage 4 (N (%)) 68 (44.4) 64 (25.1) 157 (21.5) < 0.001
WHO stage 3 (N (%)) 69 (45.1) 140 (54.9) 397 (54.2)
WHO stages 1 and 2 (N (%)) 16 (10.5) 51 (20.0) 178 (24.3)
Transfers in/out (N) 0/1 0/39 32/80
Died on treatment (N) 21 22 35
Lost to follow-up (N) 8 17 8
IQR = interquartile range.
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had increased to 4 doctors, 3 nurses, 1 pharmacist and 
28 counsellors (Fig. 1). There was a high turnover of the 
professional staff employed by the local provincial authority, 
with frequent use of temporary staff to provide services. In 
contrast, there was very low turnover of counsellors, who 
constitute approximately 80% of all staff employed by the 
programme. The number of clients allocated to each counsellor 
increased over time, with a median of 13, 19, and 33 patients 
per counsellor during 2002/3, 2003/4 and 2004/5, respectively. 
In terms of infrastructure, the ART service started in a single 
clinic room within the local health facility. Increasing patient 
numbers necessitated a move to an on-site prefabricated cabin 
in 2004 and to a self-contained building within the clinic 
grounds in 2005.
Programme retention
One hundred and one patients were lost to the programme, 
and 78 patients (7%) died after starting ART, with 63% of 
deaths occurring in the first 90 days of ART. 
Thirty-three patients (3%) were lost to follow-up during the 
study period. The Kaplan-Meier estimate of proportion lost to 
programme at 1 year did not differ significantly between the 3 
annual cohorts (Fig. 2).
Virological outcomes
The median proportions of viral loads < 400 copies/ml and  
< 50 copies/ml at all monitoring time points were 95% and 
82%. At the censoring date, the 2002/3, 2003/4 and 2004/5 
cohorts had 100%, 92% and 98% of viral loads < 400 copies/ml 
and 88%, 67% and 85% < 50 copies/ml respectively (Fig. 3, A 
and B). During the study period 21 patients had 2 consecutive 
viral loads > 1 000 copies/ml (6, 11 and 5 in each sequential 
annual period) and 17 patients were changed from first- to 
second-line regimen (6, 8 and 3 in each of the sequential annual 
periods). 
Discussion
This is one of longest-running public-sector community-based 
ART programmes in sub-Saharan Africa, allowing a unique 
assessment of trends during a period of increasing recruitment 
Fig. 1. The cumulative number of patients recruited onto the 
antiretroviral programme together with number of doctors, nurses and 






















































Fig. 2. The cumulative proportion of individuals remaining on ART 
for each of the 3 annual cohorts (Kaplan-Meier analysis). The survival 
proportions of the cohorts do not differ significantly (log-rank test).   
Fig. 2.

























































Fig. 3. A: The proportion of individuals in each annual cohort with < 400 
HIV copies per ml of plasma at each 4-month monitoring time point.   
B: The proportion of individuals in each annual cohort with < 50 HIV 
copies per ml of plasma at each 4-month monitoring time point.
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to more than 1 000 patients at a single clinic.  On-treatment 
virological suppression rates were excellent, were sustained 
over the 3-year period and compare very favourably with 
other published treatment programme outcomes in Africa,4-10 
Europe and North America.25 These results show that key 
programmatic outcomes can be maintained during a period of 
rapid expansion of services.
While the experience of this programme in rapidly 
expanding services is encouraging, these results should be 
interpreted with the following caveats. Recruitment to the 
programme was restricted to individuals living within a 
demarcated urban catchment area. While this geographical 
proximity may be similar to that of other peri-urban townships 
where large populations access health care, this model 
may not be generalisable to rural and other settings where 
populations are more dispersed. Furthermore the median 
pre-ART period of follow-up was similar for each of the 
yearly cohorts and therefore pre-ART mortality rates could be 
compared.  However, the median on-ART follow-up varied 
and was shorter for the later cohorts. Therefore, while the 
short-term results were comparable, the long-term results seen 
in the 2003/4 cohort may not necessarily be achieved by those 
accessing therapy later.    
The low proportion of males together with the advanced 
clinical stage of non-pregnant adults accessing this programme 
is of concern, as this may be an indication that ART coverage 
is still inadequate at a population level. Patients generally 
accessed the programme when their disease was advanced, 
which is reflected by high mortality in the pre-ART and early 
treatment phase. The high mortality and morbidity of those 
who present with very advanced illness disproportionately 
utilises medical resources around the time of ART initiation.26 
Clinic recruitment could be increased if the programme were 
accessed earlier. There was a trend towards an increase in 
median CD4 cell count over the study periods, which was more 
marked in the third year. It would be encouraging if earlier 
presentation represented a decrease in the backlog of advanced 
HIV infection in the population; however the increase in 
median CD4 cell count was not paralleled by a decrease in pre-
ART mortality, which remained unacceptably high.  The higher 
median CD4 cell count was largely explained by an increase in 
non-traditional recruitment of pregnant women and children. 
Pregnant women were referred after accessing voluntary 
counselling together with CD4 cell count testing at the local 
maternal-obstetric service and had markedly less symptomatic 
HIV disease. The increasing number of children reflected an 
increase in collaboration with paediatric HIV services resulting 
in increased referrals from hospital-based specialist units to 
community care, and children had significantly higher baseline 
CD4 cell counts than adults. 
To date, physical infrastructure has not been identified as 
a key barrier to implementation of ART access in the context 
of small-scale services.27 However our experience has been 
that physical space is a critical constraint in the expansion of 
this programme, as the clinic had to be relocated twice in 3 
years, including the development of an off-site location for 
pre-treatment counselling. In addition, the positioning of a 
dedicated laboratory in a shipping container on site enabled 
an efficient monitoring service, avoiding the need for sample 
courier services and expediting access of results to medical 
staff. The on-site laboratory was economically viable when 
monitoring > 1 000 patients on ART (data not shown) and 
could be used for similar large single clinics or geographically 
clustered clinics in both urban and rural settings serving  
1 000 - 10 000 patients. An increasing number of patients were 
transferred from and to other treatment centres during year 3. 
As ART programmes mature there will be an increasing need 
for tracking systems, which can enable efficient transfer of 
patients between treatment centres.
Although programme acceptability was not specifically 
measured as part of routine clinical services, the low rate 
of loss to follow-up observed may reflect levels of client 
satisfaction. Shortage of human resources, in particular 
nurses, has been identified as a major operational constraint 
to treatment access.27 The specific model of care reported in 
this study was a dedicated ART community clinic, relying 
on a high ratio of lay counsellors to clients. The community-
based counsellors supplied continuity and served as the major 
conduit for ongoing interaction between the programme and 
clients. The allocation of a personal ‘therapeutic counsellor’ 
to each client on entry into the programme facilitated the 
high levels of treatment adherence (contributing to virological 
suppression rates) and retention in the programme. In contrast 
to the health professionals, they are readily accessible and 
their utilisation results in employment opportunities for 
individuals living with HIV/AIDS in a community with high 
unemployment.
In summary, this analysis of a community-based, public-
sector ART service demonstrates that a single urban public 
clinic can supply and monitor ART to more than 1 000 patients, 
without compromising programme performance during rapid 
scale-up. This finding bodes well for the expansion of ART 
services in resource-limited settings
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Performance of a trained traditional bonesetter in primary 
fracture care
John E Onuminya 
Background. In developing nations traditional bonesetters 
(TBSs) play a significant role in primary fracture care. 
However, despite high patronage the TBS remains an untrained 
quack whose practice is often associated with high morbidity. 
This study evaluated the performance of a trained TBS in 
primary fracture care. 
Methods. Between 2002 and 2004 a prospective study was 
undertaken comparing the performance of a trained TBS with 
that of an untrained TBS at two separate locations. The two 
centres selected were both popular in traditional bone setting. 
A 1-day instructional course was given to the TBS at Afuje 
study centre, while the TBS at Ogua control centre received no 
instruction. The outcome of treatment of tibial shaft fractures 
at the two centres was evaluated and compared to assess the 
success of the course.
Results. There was a considerable decrease in the rate of 
gangrenous limbs, infection, non-union and malunion at the 
trained TBS centre compared with the untrained TBS centre 
(2.5% v. 10%, 5% v. 12.5%, 7.5% v. 15%, and 20.0% v. 30%, 
respectively). The observed difference between the trained and 
untrained TBSs was statistically significant (p < 0.05).   
Conclusion. It appears that training TBSs can reduce 
morbidity rates following TBS treatment.
S Afr Med J 2006; 96: 320-322.
In most developing nations traditional bonesetters (TBSs) still 
play a significant role in primary fracture care.1-12 They are 
highly patronised by local people. Over 70.0% of the rural 
population relies on the TBS for fracture treatment. While 
many fractures do heal properly with traditional treatment, 
bonesetters often do not appreciate the dangers of the 
complications arising from their practices.2-10
It is generally believed that TBSs are not trainable, but I 
have observed that some are willing to learn new methods 
of treatment to improve their services.1 At least they could be 
trained as plaster technicians and be incorporated into primary 
health care services. I therefore conducted a 2-year prospective 
study to evaluate the performance of a trained TBS in primary 
fracture care in a developing country.  
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Methods 
In the period between January 2002 and December 2004 I 
evaluated the performance of a trained TBS at Afuje TBS centre, 
a 75-bed facility for the traditional treatment of fractures. 
The centre is located in the rural area of Owan East Local 
Government Area (LGA), Edo North Senatorial district of 
Nigeria, where most people are subsistence farmers. The 
TBS centre is situated in a remote area, where there is no 
orthodox orthopaedic practice. The chief TBS has three sons 
who help him to set bones. Two of the sons are university 
undergraduates. The centre enjoys the services of a trained 
nurse and a general practitioner, and uses an X-ray facility 
situated about 5 km away for diagnosis and follow-up. The 
general practitioner, who is in private practice, often co-
operates with the TBS and does osteoclasis and open reduction 
without fixation for cases of malunion and delayed union as 
requested by the TBS. After the skin wounds have healed, 
the patients are sent back to the TBS centre for subsequent 
treatment of the fracture.  Most cases of fresh fractures in the 
non-specialist private clinics are directed to the TBS centres 
for treatment. Fracture victims find the TBS method attractive 
because it obviates the use of implants, which most of the local 
people dislike.  The nurse at the TBS centre visits the centre 
often to sell analgesics, antibiotics and haematinics. She is 
occasionally requested to immunise patients against tetanus. 
The Afuje TBS centre, a well-organised ‘tradorthopaedic’ clinic, 
was used as the study centre (A).
Another popular TBS centre in a similar rural setting at Ogua 
in Esan West LGA was used as the control for the study (centre 
B). The two selected centres used similar conservative methods 
of treating fractures and were both reputable traditional bone 
setting practitioners with good patronage within and outside 
their LGAs. The co-operation of the TBSs at the centres was 
won with the assistance of my photographer, who at various 
times had personally had fractures treated at these centres.
I was able to give a 1-day instructional course to the TBS 
at the Afuje study centre (A) on safe conservative treatment 
of fractures with regard to diagnosis, patient selection, basic 
principles of fracture treatment, prevention of complications 
including transmission of HIV infection, referral services and 
outcome of treatment.  Centre B received no instruction.
A 2-year prospective study of the outcome of fracture 
treatment at the two centres was conducted soon after the 
course between 2002 and 2004 in order to assess the success 
of the course.  The outcome of the treatment of tibial shaft 
fractures at the centres was assessed. The chi-square method 
was used to test for significance of the outcome of the study.
Results
Between January 2002 and December 2004 I studied the 
outcome of 40 tibial shaft fractures treated in centre A.  There 
were 40 similar tibial shaft fractures in centre B.  In both centres 
the male-to-female ratio was 3:1; the ages of the patients 
ranged from 20 years to 65 years with a median age of 30 years, 
and the distribution of the pattern of fractures between the 
groups was fairly similar. 
The outcome of the treatment of tibial shaft fractures is 
shown in Table I.
There was no death in either of the centres.  The median 
duration of stay in centre A was 4 months (range 2 - 12 months) 
for patients with tibial shaft fractures.  In centre B the median 
duration of stay was 8 months (range 2 - 18 months).  The rate 
of voluntary discharge was 25% (10 patients) from centre A 
and 50% (20 patients) from centre B. Voluntary discharge was 
usually due to dissatisfaction with the outcome of treatment, 
such as non-union, delayed union, infection or gangrene.  In 
both centres the TBS no longer used the same blade for more 
than one patient for scarification.  Each patient bought his or 
her own personal blade for this purpose. 
Most of the patients studied had received their initial 
treatment in an orthodox hospital before discharging 
themselves and seeking treatment from the TBS. In most cases 
this decision was due to pressure from senior members of the 
victim’s family.
Discussion
The instruction received by the TBS on safe application of a 
splint in tibial shaft fracture appeared to result in a marked 
decrease in iatrogenic limb gangrene in centre A, where 
there was 1 case of extremity gangrene compared with 4 
cases in centre B (control).  TBSs often use splits made from 
split bamboo or strips of wood tightly bound around the 
limb,1 which may not be removed when pain increases after 
immobilisation.  A compartment syndrome with its permanent 
sequelae and gangrene may result.  For gangrene, amputation 
is the only possible treatment.  Death may result from 
complications such as tetanus and septicaemia.6
These problems are due to a lack of awareness of the dangers 
of tight splints among TBSs.  The TBS has traditionally been 
considered secretive, and it was difficult to teach them how 
Table I. Outcome of the treatment of tibial shaft fractures 
at Afuje (A) and Ogua (B) TBS centres
              No. (%)
Outcome Centre A Centre B 
Acceptable union  19 (47.5) 5 (12.5)
Malunion  8 (20.0) 12 (30.0)
Non-union 3 (7.5) 6 (15.0)
Delayed union 7 (17.5) 8 (20.0)
Post-traumatic osteomyelitis  2 (5.0) 5 (12.5)
Limb gangrene  1 (2.5) 4 (10.0)
   Total  40 (100) 40 (100)
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complications could be prevented.3,6 However, with the co-
operation of the modern TBS it was possible to arrange 1-day 
instructional courses on the safe fracture treatment.  This has 
resulted in a considerable decrease in the rate of gangrenous 
limbs, infection, non-union and malunion.  There has been 
a significant increase in the rate of acceptable union among 
patients treated by the trained TBS compared with the 
untrained TBS (p < 0.05).    
The morbidity associated with fracture treatment in an 
untrained TBS centre is high, and the median period of 8 
months’ stay in such centres is distressing in terms of man-
hours and productivity lost.  Training reduced the median 
period of stay to 4 months for tibial shaft fractures in study 
centre A.
If voluntary discharge from an untrained TBS centre implies 
a dismal outcome of treatment, the rate of treatment failure at 
such centres is very high at 50%. This suggests that people’s 
confidence in the TBS is misplaced.  Training reduced the rate 
of voluntary discharge by half.  Voluntary discharge of fracture 
victims in a developing nation from one treatment facility 
to another is a complex phenomenon. Voluntary discharge 
from an orthodox hospital to a TBS has, for example, been 
blamed on an external locus of control in decision-making 
and not failure of the orthodox hospitals.11 The high rate of 
return to orthodox care suggests that people’s confidence in 
the TBS is highly misplaced and their internal locus of control 
in decision-making is reawakened by TBS failure.5,11,12  Over 
80% of the patients who had been treated by an untrained 
TBS had complications.2-15  This is not surprising as their 
treatment consists of the application of herbs and wrapping of 
the fractured limbs in short traditional splints and cloth14 after 
inadequate reduction and stabilisation, and rehabilitation.
Conclusions
It was been established that the modern TBS is willing to 
co-operate with the orthodox orthopaedic practitioner,1,16 
and the results of this study showed that training improves 
performance of the TBS.  I recommend that the TBS should 
be trained as a traditional orthopaedic attendant (TOA) for 
effective primary fracture care in developing countries.
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Although the provision of antiretroviral therapy (ART) through 
the South African public health care sector has expanded 
rapidly since its inception in 2003, it has been estimated that 
less than one-quarter of those in need of antiretrovirals (ARVs) 
were on treatment by the end of 2005.1 Furthermore, the 
numbers of people requiring ART will continue to rise for the 
foreseeable future, as those currently too well to need ART join 
those continuing in the programme. 
The South African government is committed to providing 
ARVs to all who need them.2 Given the size of the epidemic, 
and the limited resources available for public health care, it 
is crucial that the most efficient models of ART provision are 
utilised in order to achieve this goal. Unfortunately, there is 
little existing information on the cost and cost-effectiveness of 
different models of ART care. This is particularly true of those 
primary and community care-based models most relevant 
to lower- and middle-income countries with generalised 
epidemics.3-5 Early cost analyses of ART provision, conducted 
in North America and Europe, focused largely on the cost of 
hospital, rather than clinic-based, care.6 However, one recent 
study7 of Swiss clinics compared hospital-based with general 
practice-based ART provision. The authors found that although 
hospital-based care was more expensive, this was almost 
entirely because of differences in ARV prescribing patterns and 
that non-medication costs did not differ significantly between 
the study arms. 
Two costing studies of middle-income countries that do 
not have generalised epidemics have been performed, viz. in 
Thailand, looking at hospital-based clinics,8 and in Mexico.9 
The latter study covered 11 major clinics nationwide, but the 
analysis abstracted away the variation due to differences in 
site of care provision via clinic fixed-effects. This made any 
consideration of cost differentials due to different models of 
care impossible. 
Almost nothing is currently known about the overall cost 
of providing ARV services through the public health care 
sector in Africa. A study from KwaZulu-Natal found that 
running a voluntary counselling and testing (VCT) clinic cost 
between $161 and $53 per client in 2002/03, falling as the 
number of clients seen rose.10 The only existing cost study of 
ART provision in South Africa of which the authors are aware, 
found that a dedicated, primary care ART clinic in Khayelitsha 
in the Western Cape cost R145.15 ($22.56) per visit in 2002/03, 
excluding patient-specific items such as medicines and 
laboratory tests.11 
A more recent, predominantly qualitative, comparison of 
different models of ART care provision in the Western Cape12 
noted the significant variations in staff costs across clinics 
depending on whether they operated at hospitals or primary 
health care facilities, and on the mix of clinical staff. 
This study aimed to provide information on the operating 
costs of a doctor- and adherence counsellor-intensive clinic 
based in the Western Cape. The objectives of the analysis were 
first to measure the cost components of a dedicated ART clinic 
Cost of a dedicated ART clinic 
Guy Harling, Linda-Gail Bekker, Robin Wood
Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular 
Medicine, University of Cape Town 
Guy Harling, MA, MPH
Linda-Gail Bekker, MB ChB, FCP, PhD
Robin Wood, BScBM, MMed, FCP
Background. The provision of antiretroviral therapy (ART) is 
being rolled out across South Africa. Little evidence exists on 
the cost of running clinics for ART provision. 
Objectives. To determine the cost per patient-month enrolled 
in an ART programme and per patient-visit for a dedicated, 
public-sector ART clinic in a South African peri-urban setting 
in 2004/05 and 2005/06, as the clinic moved from a temporary 
to a permanent site. 
Methods. A retrospective costing study was performed from a 
programme perspective. Two years of expenditure data for the 
clinic were collected from primary sources. Costs per patient 
visit and per patient-month were calculated in Rand and 
converted to 2004 US$ (R6.4347 = US$1). 
Results. The total cost of running the site, excluding patient-
specific items (medicines and medical tests), was $174 072 in 
2004/05 and $421 872 in 2005/06. Cost per patient-month fell 
from $40.29 to $36.47, a 9% decrease; cost per patient-visit fell 
from $54.79 to $41.62, a 24% decrease. In 2005/06, 68% of all 
expenditure was on medical and pharmacy staff (versus 62% 
in 2004/05), 23% was on the employment of peer adherence 
counsellors (versus 35%), and the remaining 9% was on capital 
costs and supplies (versus 3%). 
Conclusions. The increase in scale of operation for the 
provision of ART at this clinic allowed economies of scale to 
be reaped. Staff costs, both medical and support, comprised 
the large majority of total clinic costs, such that the erection 
of a dedicated building for the clinic had little impact on the 
economic cost of care. 
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in South Africa, and second to determine how the importance 
of these components varied as the clinic grew in size. It is 
hoped that this will contribute to a fuller understanding of the 
likely evolution of the cost of providing ART as the national 
treatment programme expands. 
Methods 
Site description 
The site studied, the Hannan Crusaid Treatment Centre 
(HCTC), is a dedicated ART clinic based at the Gugulethu Day 
Hospital in Nyanga, a peri-urban settlement close to Cape 
Town. Operating since September 2002 it was initially a joint 
project between the Desmond Tutu HIV Centre (DTHC), which 
is a not-for-profit HIV research organisation; the UK-based 
charity Crusaid; and the provincial government of the Western 
Cape (PGWC). It has subsequently been fully integrated into 
the provincial ART roll-out programme. The HCTC acts as the 
primary care provider to all individuals enrolled at the centre, 
providing ART and non-ART-related care. The work of the 
HCTC has been described previously.13 
This study was conducted retrospectively covering the 2 
financial years 2004/05 and 2005/06, from March 2004 to 
February 2006. At the beginning of the observation period the 
clinic was run from a temporary structure with 70 m2 of floor 
space, in the grounds of the Gugulethu Day Hospital. In March 
2005 the clinic relocated to a purpose-built clinic, 369 m2 in size, 
on the same site. A wide range of medical and non-medical 
equipment was purchased for this new clinic. 
All medical staff are employed by the PGWC. In March 2004 
the staff consisted of 1 principal medical officer (PMO) and 1 
professional nurse (PN). Two years later this had expanded 
to include 3 PMOs, 2 senior medical officers, 2 PNs, a staff 
nurse, a principal pharmacist and 2 assistant pharmacists. A 
unit manager was also employed during some of the period in 
question. 
The Sizophila adherence counsellor programme is a peer-
counselling project that has been an integral part of the HCTC 
ART programme since its inception. Counsellors are employed 
from the local community and are all openly living with HIV. 
Each counsellor is responsible for up to 50 patients, providing 
pre-treatment counselling, group education on living on ART, 
home visits to monitor adherence and ongoing treatment 
support. This support is intensified if ART adherence declines. 
The project is co-ordinated by a nurse employed by the DTHC 
and during the period of study utilised a cellphone-based 
reporting system for relaying messages and reporting ART pill 
counts from home visits. 
Data collection and analysis 
The cost analysis was performed retrospectively from a 
programme perspective. The cost of the buildings and their 
contents were sourced from receipts for the relevant items 
provided by the DTHC and PGWC. Costs were apportioned 
across all years of useful lifetime: the temporary building 
was assumed to have a lifetime of 10 years, the purpose-
built building 30, the fixtures and fittings 5, and electronic 
equipment 3. All costs were discounted at 3%, in line with 
international standards.14 
The monthly cost of employing medical staff was taken 
from PGWC wage rates in February 2006. The costing of the 
Sizophila was complicated by the programme being managed 
from the DTHC by the nurse co-ordinator. The cost of running 
her office at the DTHC was included in proportion to her time 
spent on Sizophila. The cost of developing, implementing 
and running the cellphone-based reporting system was also 
included. 
The quantity of medical supplies, such as needles, gloves 
and thermometers, and of cleaning products used in 2005/06 
by the centre, was estimated by the nurse in charge of ordering 
such items. The cost of these items was calculated from the 
PGWC medical depot catalogue. A cost per visit for those 
supplies was calculated and that cost attributed to 2004/05 
visits. 
Stationery for patient records was provided by the DTHC. 
This cost was calculated from receipts for all items except 
paper forms, for which costs were based on the number of 
sheets of paper used per visit multiplied by the cost of the 
paper and of photocopying. 
All costs were standardised to average 2004 prices using 
South Africa’s consumer price index.15 Costs were then 
converted into US dollars using the average exchange rate for 
2004 at the rate of US$1 to R6.4347.16 Total costs were calculated 
by summing all categories. The total number of visits for each 
financial year, both scheduled and unscheduled, was taken 
from clinic records. The total number of patient-months was 
calculated by measuring the number of days each patient 
who enrolled at the HCTC before 1 March 2006 spent in the 
programme in each financial year, and dividing the total by 28. 
Results 
The total cost of running the HCTC rose by 142% from $174 072 
in 2004/05 to $421 872 in 2005/06 (Table I). The total number 
of patient visits made in the 2005/06 financial year was 10 137, 
an increase of 219% over 2004/05, although the total number of 
patient-months on treatment rose by only 167%, from 4 321 to 
11 569. 
The move from a temporary structure to a purpose-built 
building meant that the annual economic cost of the centre’s 
building and equipment rose more than eightfold from 
$3 075 to $29 221, far faster than the rate of increase in patient 
numbers. However, even in 2005/06 physical assets accounted 
for only 6.2% of total costs. 
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In contrast, the cost of the counselling programme rose more 
slowly than patient growth, increasing by 60% between the 
2 years. As a result, the proportion of clinic costs due to this 
programme fell from 34.9% in 2004/05 to 23.0% in 2005/06. 
The largest cost component at the clinic was that of clinical 
and managerial staff, which rose from $287 829 to $693 785 
over the period of observation. This accounted for 61.9% of 
all costs in 2004/05, rising to 68.2% in 2005/06. More than 
three-fifths (62.0%) of this cost in the more recent year was due 
to doctors’ salaries, with the remainder being split between 
nurses (14.3%), pharmacists (17.5%) and a unit manager (6.1%). 
The cost per patient visit fell by 24.0% between the 2 years 
of observation, from $54.79 to $41.62 (Fig. 1). Although the 
proportion of costs attributable to physical assets rose, it 
had little impact on the overall cost per patient-month. More 
noticeable was the fall in the proportion attributable to the 
adherence counsellor programme. The cost per patient-month 
changed little between 2004/05 and 2005/06, falling from 
$40.29 to $36.47 (Fig. 2). 
Discussion 
The reduction in cost per patient visit seen at this clinic over 
the period of observation, as services were rapidly scaled-up, 
suggests that there are significant potential returns to clinic 
scale in the provision of ARVs. Evidence that the clinic’s 
clinical outcomes were not affected by this scale-up,13 suggests 
that the reduction in cost per patient seen is not due to a 
reduced standard of care. The smaller reduction in cost per 
18
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Fig. 2. Cost per patient-month (US$) at the Hannan Crusaid Treatment 
Centre.
Table I. Cost components at the Hannan Crusaid Treatment Centre (2004 US$)
                    2004/05                         2005/06 
Physical assets 
Building         2 636    22 993 
Fixtures and fittings          439      2 991 
Electronic hardware              -      3 236 
Medical staff  
Doctors’ salaries       82 427                 178 540 
Nurses’ salaries       22 903    41 196 
Pharmacists’ salaries        2 489                   50 423 
Office manager’s salary               -                   17 670 
Sizophila Counselling Programme 
Management and administration     15 152    15 788 
Counsellor salaries                     36 447   72 102 
Cellphone-based reporting system       9 115      9 412 
Supplies and overheads 
Medical supplies         1 086     3 466 
Stationery            998     2 763 
Overheads            381     1 484 
Total cost*                     174 072                421 872 
Number of patient-visits        3 177   10 137 
Cost per visit         54.79     41.62 
Number of patient-months on treatment      4 321     1 569 
Cost per patient-month on treatment       40.29     36.47 
*Figures do not sum precisely because of rounding.
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patient-month can be attributed to the rise in the proportion 
of patients who were newly enrolled at the clinic, since clinic 
visits are more frequent in the first 6 months of care than 
thereafter. 
The cost of running the HCTC was largely driven by staff 
salaries. This is in line with evidence from other South African 
studies that medical staff costs make up the majority of non-
patient-specific expenditures at ARV clinics.11 Unlike most 
other ARV clinics in South Africa, the HCTC is a heavily 
doctor-based programme,12 which has the effect of raising the 
overall cost per visit well above that seen at another peri-urban 
clinic in the Western Cape.11 The expansion in spending on staff 
salaries at the HCTC in this study period was proportional 
to the expansion in patient-months on treatment, but was 
slower than the rise in visits made, suggesting that some slight 
economies of scale may be achievable for medical staff. 
An unusual aspect of the HCTC programme is the heavy use 
made of community-based adherence counsellors. The number 
of counsellors, even on a per-patient basis, is far higher than 
in comparable clinics across the Western Cape.12 In March 2004 
the counselling programme had been growing rapidly since its 
inception 18 months previously. It continued to expand, at a 
reduced rate, throughout the period of study. 
Economies of scale in respect of training and administration 
were seen as the programme grew. This suggests that an 
intensive counselling intervention, such as the Sizophila 
model, is likely to be most efficient in large clinics, or when 
administration is shared between multiple sites. 
The limitations of this study arise largely from the limited 
scope of enquiry made. No attempt was made to consider 
the effect of scale on demand for patient-specific items at the 
clinic, although it is likely that they remained approximately 
level on a per-visit basis. More importantly, no attempt was 
made to quantify what change, if any, was seen in the cost of 
care at other levels of care within the health care system; lower 
expenditure on primary care might have led to more secondary 
or tertiary care visits. 
The HCTC ARV programme is a human resource-intensive 
one, employing more doctors and more counsellors per 
patient than other models of ARV care.12 Nevertheless, 
significant economies of scale were reaped from expanding 
the programme between 2004 and 2006, particularly from the 
adherence counsellor component, without affecting clinical 
performance. Increased clinic scale appears to offer cost 
benefits in the South African ART roll-out. 
Guy Harling receives support from the City Bridge Foundation. 
Robin Wood receives part support from NIH CIPRA grant 
1U19AI53217-01 and from NIH RO1 grant (A1058736-01A1). 
The authors declare no competing interests. 
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EPIDEMIOLOGY AND SOCIAL SCIENCE
The Evolving Cost of HIV in South Africa
Changes in Health Care Cost With Duration on Antiretroviral
Therapy for Public Sector Patients
Guy Harling, MA, MPH and Robin Wood, FCP(SA)
Summary: A retrospective costing study of 212 patients enrolled in
a nongovernmental organization–supported public sector antiretro-
viral treatment (ART) program near Cape Town, South Africa was
performed from a health care system perspective. g-Regression was
used to analyze total costs in 3 periods: Pre-ART (median length =
30 days), first 48 weeks on ART (Year One), and 49 to 112 weeks on
ART (Year Two). Average cost per patient Pre-ARTwas $404. Average
cost per patient-year of observation was $2502 in Year One and
$1372 in Year Two. The proportion of costs attributable to hospital
care fell from 70% Pre-ART to 24% by Year Two; the proportion
attributable to ART rose from 31% in Year One to 55% in Year Two. In
multivariate analysis, Pre-ART and Year One costs were significantly
lower for asymptomatic patients compared with those with AIDS.
Costs were significantly higher for those who died Pre-ART or in
Year One. In Year Two, only week 48 CD4 cell count and being male
were significantly associated with lower costs. This analysis suggests
that the total cost of treatment for patients on ART falls by almost half
after 1 year, largely attributable to a reduction in hospital costs.
Key Words: cost, health care, highly active antiretroviral therapy,
hospitalization, South Africa
(J Acquir Immune Defic Syndr 2007;45:348–354)
In nations with generalized HIV epidemics, the burden ofHIV-positive individuals on the public health care system
is considerable, often accounting for more than half of all
inpatient care provided.1,2 Provision of combination antiret-
roviral therapy (ART) in these settings is likely to have
a significant impact on the annual, and particularly lifetime,
cost of care, as it did when introduced to high-income
countries.3–5 Most comprehensive studies of health care costs
to date have been conducted in North America and Europe.6
Evidence from Africa is important, because the cost of
providing ART to all who need it is likely to dwarf existing
total health care expenditures on the continent; the cost of
antiretroviral medicines alone is several times most African
nations’ current annual health care expenditures per capita.5
Given the variation in care delivery methods observed
worldwide, it is not clear whether evidence from studies in
non-African settings are comparable to those conducted on the
continent. For example, antiretroviral medicines have typically
comprised most of all treatment costs in high- and middle-
income countries,3,7–10 but existing South African studies have
found them to contribute only a third of all costs.11
Evidence on the total cost of public health care for
individuals on ART in Africa is limited.11 In South Africa, one
study calculated the program cost of running a clinic to
provide ART to health care workers in KwaZulu-Natal to be
between $1054 and $1382 per patient per year.12 Three cost-
effectiveness studies, 2 of hospital-based ART programs and 1
of a primary care ART clinic, also produced estimates of cost
per patient-year.13–15 All 3 showed that annual costs for those
on ART were lower than for those not on ART, although
lifetime costs were higher. In stratified analyses, those with
low CD41 T-cell count or a history of AIDS had higher health
care costs. One of these studies considered factors associated
with hospitalization; however, in multivariate analysis, this
study found neither CD4 cell count nor HIV RNA viral load
level to predict use of services.13 A costing study of theWestern
Cape provided a total cost per patient in a public sector clinic
and total provincial expenditure requirements but not annual
health care costs per patient.16
The only other study the authors are aware of that
considered predictors of health care costs on ARToutside a high-
income setting was conducted in Mexico and found that patient
health status measured by Centers for Disease Control and
Prevention (CDC) stage, patient education level, and the specialty
of the attending physician was associated with total cost.10
The first objective of this study was to determine the
total annual cost to the health care system of a patient access-
ing a public sector ART clinic in South Africa according to
time on ART, World Health Organization (WHO) stage, and
CD4 cell count. The second objective was to analyze which of
these factors were associated with significantly higher health
care expenditures before treatment and in the first and second
years on ART. It is hoped that this provides data for cost-
effectiveness analyses and aids administrators in planning the
provision of ART services.
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This study followed all eligible patients enrolled at the
Hannan Crusaid Treatment Center (HCTC) between Septem-
ber 1, 2002 and December 31, 2003. The HCTC is a dedicated
ART clinic based at the Gugulethu Day Hospital in Nyanga
district, a periurban settlement close to Cape Town. During
the period of study, it was jointly run by the Desmond Tutu
HIV Center (a not-for-profit HIV research organization), the
UK-based charity Crusaid, and the Provincial Government of
the Western Cape (PGWC). Eligibility criteria for the clinic
at the time of the study included a CD4 cell count of
,200 cells/mL or a history of an AIDS-defining illness. The
HCTC acts as the primary care provider to all individuals
enrolled at the center, providing ART and non–ART-related
care. Its work has previously been described.17
Patients are referred by local primary care providers.
They are screened at the HCTC and seen a second time 14 days
later, before commencing ART. Patients attend scheduled
visits at weeks 0, 4, 8, and 16 after commencement and every
16 weeks thereafter. Patients may make unlimited unscheduled
visits to the HCTC as required. First-line ART comprises
stavudine, lamivudine, and efavirenz unless the patient is
pregnant or a woman of child-bearing age not taking birth
control medication; in such cases, zidovudine and nevirapine
replace stavudine and efavirenz. The second-line regimen
comprises lopinavir/ritonavir (Kaletra"), zidovudine, and
didanosine. HIV RNA load, CD4 cell counts, and alanine
transaminase tests are conducted before treatment and every
16 weeks during ART. Other safety tests are performed accord-
ing to the provincial ART protocol and vary according to the
treatment regimen.18
Subjects were followed from enrollment at the HCTC
until their final scheduled 4-month visit in 2004, a maximum
of 112 weeks after ART commencement. Patients were right-
censored for death, loss to follow-up (LTFU), or transfer to
another ART site. The baseline characteristics of this study
population have previously been described.19 Ethical approval
for this study was gained from the University of Cape Town
Research Ethics Committee, and all patients gave informed
consent.
Data Collection
Costs were calculated from a public health care provider
perspective. Data on patient-specific service utilization were
collected prospectively from files at the HCTC and retrospec-
tively from computer- and paper-based medical records at
hospitals to which subjects were referred. The costs of
antiretroviral medicines were taken from the 2004 national
public sector tender, and those of other medicines were taken
from provincial hospital tender prices. Medical test prices were
taken from public sector tariffs charged by the National Health
Laboratory Service and medical procedure costs from cost
recovery charges made to private patients attending public
hospitals.20
Non–patient-specific costs at the HCTC for the financial
year 2005 to 2006 were calculated per patient-month in the
program. Methods and results for this have been detailed
previously.21 Non–patient-specific costs for hospital visits
were calculated from financial year 2004 to 2005 expenditure
data, excluding all patient-specific line items,22 on a per
patient-day-equivalent basis using step-down accounting
methods. Each inpatient day was weighted as 3.77 outpatient
visits.15 The cost of providing tuberculosis directly observed
therapy (DOTS) was based on data collected in the same health
district in 2000, calculated on a per-day-on-DOTS basis.23
Unit costs for key inputs are shown in Table 1.
All costs were standardized to average 2004 prices using
South Africa’s consumer price index.24 They were then
converted into US dollars using the average exchange rate for
2004 of US $1 to R 6.4347.25 Observation time was separated
into 3 periods: between enrollment and ART commencement
(Pre-ART), the first 48 weeks on ART (Year One), and any
time after 48 weeks (Year Two). Costs were calculated per
eligible patient enrolled in the program and per patient-year of
observation (PYO; 365.26 days) in each period.
Multivariate Analysis
A multivariate regression model was used to determine
which clinical factors were associated with demand for health
care in each period. Utilization, and therefore cost, data are
frequently noted to be right-skewed in distribution, with
a large number of individuals consuming few resources and
a few subjects using many. In this situation, ordinary least
squares regression is not appropriate, because the data are not
normally distributed and do not have constant variance.26
To take these features into account, a g-distribution with a log
link was used.27 The ability of this model to account for
the nonnormal distribution was evaluated using deviance
residuals.28
Explanatory variables used included age, gender, WHO
stage at enrollment, CD4 cell count at the beginning of each
period, change in CD4 cell count in the first 4 months on
treatment, and whether the subject was censored for death or
LTFU in the period. In all models, the dependent variable was
TABLE 1. Input Unit Costs ($US)
Antiretroviral regimens*
Stavudine + lamivudine + efavirenz 31.88
Zidovudine + lamivudine + nevirapine 19.85
Zidovudine + didanosine + lopinavir/ritonavir 77.60
Monitoring and safety tests
CD4+ T-cell count 9.32




Tertiary teaching hospital 393.92
Secondary district hospital 154.39
Dedicated tuberculosis hospital 55.09
Primary care clinic visit‡ 75.53
*Cost of 28 days of treatment.
†Average 28-day period; costs varied by month and type of treatment.
‡Excludes patient-specific costs.
§Outpatient hospital visits were weighted at 26.5% of this cost.
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the natural logarithm of costs. The primary outcome measure
used was total cost per PYO. This is preferable to total cost per
patient observed because it takes into account the intensity
with which resources were consumed. The per-patient measure
was used as a secondary outcome. Statistical analyses were
performed using STATA 9.2 (Stata Corporation, College
Station, TX). Differences between regression coefficients were
tested using a joint Wald x2 test. All statistical tests were
2-sided at a = 0.05.
RESULTS
Demographic and clinical characteristics of the sample
are shown in Table 2. Just less than three quarters (72%) of
the patients were female, and most (79%) were younger than
40 years of age. Most enrollees had late-stage HIV at pro-
gram entry, with almost half (44%) having a previous
AIDS-defining illness and more than half (58%) having a
CD4 count of less than 100 cells/mL. After 16 weeks on the
program, surviving patients had a median rise in CD4 count
of 97 cells/mL, and after 48 weeks on the program, two
thirds (66%) of patients had CD4 cell counts greater than
200 cells/mL. Most (78%) censoring events were attributable
to death. For analytic purposes, all censoring events were
assumed to be homogeneous and presented as a single group.
Total length of follow-up was 25.2 patient-years in the Pre-
ART period, 164.5 patient-years in Year One, and 88.6 patient-
years in Year Two. During Year One, 5 patients moved from first-
line to second-line therapy; during Year Two, a further 4 did so.
The mean number of hospital outpatient visits (exclud-
ing the HCTC) per patient in the cohort was 0.26 Pre-ART,
0.77 in Year One, and 1.05 in Year Two; the mean number of
inpatient days was 3.04 Pre-ART, 3.73 in Year One, and 4.04
in Year Two. The mean number of hospital outpatient visits per
PYO fell from 2.15 Pre-ART to 0.98 in Year One and 0.87 in
Year Two; the mean number of inpatient days fell more sharply
from 25.52 Pre-ART to 4.75 in Year One and 3.35 in Year Two.
The cost of providing treatment and care, to all patients
and to those who were not censored, in each period is shown in
Table 3. Total costs were $404 per patient between enrollment
and ART commencement; the cost per patient for those who
died in this period ($976) was more than twice this figure. Cost
per PYO fell from $2502 in Year One to $1372 in Year Two.
Censored patients in the Year One period cost an average of
$16,645 per PYO, almost 5 times the average for that period.
Per patient, this figure was $21,810. Censored patients in Year
Two cost 4% less per PYO than the average for the period.
Figure 1 illustrates the division of costs in each period.
In the Pre-ART period, one quarter (25%) of all health care
costs were attributable to primary care visits to the HCTC, and
almost all other costs (69%) were attributable to hospital-based
care. In the Year One period, the cost of primary care and
hospital care fell as a proportion of total health care costs, to
16% and 49%, respectively. The cost of providing ART
amounted to 31% of total costs, with medicines accounting for
59% of these costs and monitoring tests for the remaining
41%. In the Year Two period, the absolute cost of ART fell
slightly, with higher medicine costs being offset by lower
monitoring test costs, but rose as a proportion of total health
care costs to 55%. The proportion of costs attributable to
primary care visits changed little but fell by 37% in absolute
terms. The cost of hospital-based care fell rapidly, by 73% in
absolute terms and by 50% in proportional terms. The cost of
censored patients in the Pre-ART and Year One periods (not
shown) comprised predominantly hospital care costs (88% and
85%, respectively), which were far higher in absolute and
percentage terms than for other patients.







Days of follow-up, median (IQR) 30 (28 to 49) 336 (336 to 336) 224 (112 to 336)
WHO clinical stage
1 or 2 22 21 16
3 94 93 60
4 93 86 56
CD4 cell count (cells/mL) At baseline At baseline At 48 weeks
,100 122 116 4
101–200 71 68 41
201–350 16 16 60
.350 0 0 27
16-week CD4 cell count rise,
median (IQR) [n = 181] 97 (49 to 153)
Censoring events
Death 10 20 2
LTFU 7 1
Transfer out 1
Changes to second-line ART 5 4
Age, median (IQR) in years 33 (29 to 38) 33 (29 to 38) 33 (29 to 38)
Male 58 54 30
Figures are counts unless otherwise stated. One patient began ART without entering the Pre-ART period.
350 q 2007 Lippincott Williams & Wilkins
Harling and Wood J Acquir Immune Defic Syndr ! Volume 45, Number 3, July 1, 2007
JOBNAME: joa 45#3 2007 PAGE: 3 OUTPUT: Wednesday May 23 00:19:15 2007
tsp/joa/139508/QAI200723










Results of the multivariate regression analysis are
presented in Table 4. In the Pre-ART period, patients in
WHO stage 1 or 2 cost one fifth as much per PYO as those with
an AIDS diagnosis, whereas those in WHO stage 3 cost 61%
as much per PYO as those in stage 4 (see Table 4, upper panel).
These differences were jointly significant. In contrast, a
patient’s baseline CD4 cell count, age, and gender were not
significantly associated with health care costs. Costs per PYO
for patients who were censored for death in the Pre-ART
period were 7 times higher than for other patients. The odds
ratio for censored patients dropped to 2.02 when the dependent
variable was changed to cost per patient (see Table 4, lower
panel), but all other coefficients remained roughly similar to
those for cost per PYO.
In the first year on ART, significant predictors of health
care costs continued to be WHO stage at program entry and
censoring, although the odds ratios were closer to the null than
in the Pre-ART period in both cases. The effect of a patient’s
baseline CD4 cell count continued to be nonsignificant. The
change in CD4 cell count between baseline and week 16 on
ART, however, was a significant predictor of costs, with each
50-cell/mL increase being associated with a 12% decrease in
cost per PYO. Furthermore, men had a 25% lower cost per
PYO after adjusting for all other variables, although this
difference was not significant. Once again, the cost per patient
analysis found similar results for all explanatory variables with
the exception of censored patients, who nevertheless had
significantly higher total costs than other members of the
sample. The results for Year One shown in Table 4 do not
include 19 individuals who did not have a week 16 CD4 cell
count because of having been censored (15 deaths, 3 LTFU,
and 1 transfer out). A regression containing all 200
observations and excluding week 16 CD4 cell count change
as an explanatory variable (not shown) found similar results.
In the Year Two period, predictors of health care changed.
Patients with a baseline WHO stage of 1, 2, or 3 still had lower
TABLE 3. Breakdown of Average Treatment Costs ($US) of Patients Enrolled in the HCTC Program by Time and Cost Component













No. patients 211 201 200 172 132 129
Antiretrovirals
Medicine 454.41 457.53 488.85 490.65
Monitoring tests 320.26 309.29 269.79 269.65
Primary care clinic
Overheads 8.60 8.55 28.15 26.82 17.61 17.66
Personnel 69.29 68.92 226.85 216.15 141.91 142.35
Medicines (not antiretroviral) 24.63 25.13 109.76 91.89 67.84 68.41
Tests and procedures 4.12 3.64 19.38 19.00 3.71 3.75
Adherence counseling 3.24 3.28 27.37 27.37 27.35 27.37
Hospital
Overheads 107.47 95.19 447.96 277.32 98.04 97.86
Personnel 147.40 132.04 585.15 356.12 125.45 124.92
Medicines (not antiretroviral) 5.21 5.00 60.67 49.32 2.52 2.51
Tests and procedures 9.98 8.67 119.39 92.26 103.96 104.53
Primary tuberculosis treatment 24.00 25.20 102.19 96.69 25.15 25.40
Total cost per patient 403.93 375.62
Total cost per PYO 2501.55 2019.77 1372.19 1375.06
*Costs are totals per patient.
†Costs are totals per PYO in the period.
Intention to treat includes all eligible patients beginning a period of observation; on program excludes those censored during the period.
FIGURE 1. Monthly cost ($US) of care by time period. TB
indicates tuberculosis.
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costs per PYO than those with an AIDS diagnosis but not
significantly so. Furthermore, censored patients no longer had
significantly higher costs per PYO. Instead, an individual’s
CD4 cell count at week 48 was a significant predictor, with
each 50-cell/mL increment being associated with a 5% lower
cost per PYO. Men cost 32% less per PYO than women.
Model checking using deviance residuals suggested that
1 patient, who had consumed a large proportion of all tertiary
inpatient services, might have had a significant influence on
the results in the Pre-ARTand Year One periods. Dropping this
observation from the regressions attenuated the coefficient
on CD4 cell count rise in the Year One regression to 0.97 (95%
confidence interval [CI]: 0.91 to 1.04) but did not significantly
affect any other results.
DISCUSSION
The patients seen in this study were of similar age and
clinical features as those seen in other early public sector ART
cohorts in sub-Saharan Africa.29–31 This analysis found that the
average cost per patient-year for those enrolled in an ART
program fell rapidly from the immediate Pre-ART period to
the first 48 weeks on treatment and then fell by almost 50%
over the following 64 weeks. It further found that predictors of
cost shifted from WHO stage at program entry to CD4 cell
count change in the first 16 weeks on treatment, and then
current CD4 cell count at 48 weeks on ART.
The strengths of this study include the comprehensive
data collection process, which included all persons enrolled at
the clinic studied, and all care received by these patients at
public health care facilities during the follow-up period.
Because the clinical inclusion criteria at this facility were the
same as those used in the national treatment program and the
WHO’s treatment criteria recommendations, it is likely that
the health care cost patterns observed here are representative of
those elsewhere in the country, and possibly Africa as a whole.
There were 2 important limitations to the study. First,
the costing of the tertiary hospital included all costs at the
institution, despite it being an academic institution. The
inclusion of these nonclinical costs may have skewed the data.
Concerns on this front are allayed by a sensitivity analysis
where per diem personnel costs were reduced by 45% to reflect
staff costs calculated in a microcosting study conducted in
1999/2000 that excluded academic components, adjusted for
inflation to 2004.32 This adjustment reduced the per diem cost
of a visit to the tertiary hospital by 21%, but reduced the
annualized cost of care by far less: 6.7% in the Pre-ART
period, 6.7% in Year One, and 3.0% in Year Two.
Second, this study may be limited by the relatively small
sample size. In particular, only 25 years of Pre-ART follow-up
were available for analysis. The results may thus have been
influenced by a few outlying large values, although the model
specification reduced this concern in multivariate modeling.
Nevertheless, the influence of a single observation was
TABLE 4. Regressions of Health Care Costs for Patients Enrolled in an ART Program
Pre-ART Year One Year Two
Dependent variable: cost per PYO
WHO stage 1 and 2 0.21 (0.07 to 0.63) 0.49 (0.24 to 1.00) 0.74 (0.50 to 1.09)
WHO stage 3 0.61 (0.30 to 1.20) 0.62 (0.39 to 0.97) 0.89 (0.69 to 1.15)
WHO stage 4 1.00 (reference) 1.00 (reference) 1.00 (reference)
CD4 count baseline 0.98 (0.74 to 1.28) 0.91 (0.77 to 1.08)
CD4 count rise at week 16 0.88 (0.78 to 1.00)
CD4 count week 48 0.95 (0.91 to 0.98)
Death, LTFU, transfer out 7.93 (1.90 to 33.0) 5.73 (2.05 to 16.0) 1.12 (0.49 to 2.53)
Age 0.98 (0.94 to 1.03) 0.99 (0.96 to 1.02) 1.01 (0.99 to 1.02)
Male 0.99 (0.46 to 2.13) 0.75 (0.45 to 1.25) 0.68 (0.51 to 0.91)
Joint x2 test (P value): all WHO stages = 1 7.95 (0.02) 5.89 (0.05) 2.47 (0.29)
Dependent variable: cost per patient
WHO stage 1 and 2 0.17 (0.05 to 0.63) 0.49 (0.24 to 0.97) 0.61 (0.35 to 1.08)
WHO stage 3 0.59 (0.24 to 1.41) 0.60 (0.39 to 0.94) 0.77 (0.53 to 1.13)
WHO stage 4 1.00 (reference) 1.00 (reference) 1.00 (reference)
CD4 count baseline 0.90 (0.66 to 1.22) 0.91 (0.77 to 1.07)
CD4 count rise at week 16 0.88 (0.79 to 1.00)
CD4 count week 48 0.94 (0.89 to 0.99)
Death, LTFU, transfer out 2.02 (0.37 to 10.9) 2.77 (1.07 to 7.20) 0.36 (0.11 to 1.20)
Age 1.01 (0.96 to 1.06) 0.99 (0.96 to 1.02) 1.02 (0.99 to 1.04)
Male 0.88 (0.34 to 2.30) 0.72 (0.44 to 1.18) 0.73 (0.48 to 1.12)
Joint x2 test (P value): all WHO stages = 1 6.98 (0.03) 6.76 (0.03) 3.49 (0.17)
Observations (n) 209 181 132
All figures are odds ratios (95% CIs), except where noted otherwise.
Odds ratios for CD4 counts are for 50-cell increments.
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sufficient to attenuate the result seen for CD4 cell change by
75%, and although there is no theoretic justification for this
patient’s exclusion from the sample, this finding reinforces the
preliminary nature of these cost data.
Total average annualized costs in this population,
particularly in the Pre-ART and Year One periods, are higher
than those previously reported in the South African public
sector, although they are lower than private sector program
annual costs (Table 5). Part of this disparity may be attributable
to this study’s focus on patients initiating treatment rather than
on total on-ART lifetime costs: costs were far lower for the
Year Two period than for Year One. High pre- and early on-
ART morbidity is likely to make direct comparisons between
average lifetime costs and the Pre-ART and Year One costs in
this study unreasonable, particularly given the short period of
Pre-ART follow-up (median = 30 days).
The high average cost of care suggests that at least part
of the gap is attributable to higher resource consumption in this
population than in other public sector settings. Contributing
factors may include the relatively high cost of the HCTC
compared with other primary care clinics21 or a differential
pattern of service utilization. Utilization patterns may differ
because of the availability of services or of variation in health
need. The high cost of the HCTC reflects its high ratio of
doctors to nurses relative to comparable public sector sites in
the Western Cape.36 This ratio arose early in the program’s life,
when it was one of only a handful of public sector ART clinics
in country, and is now falling. The ratio may reflect the heavy
use of privately funded adherence counselors, who perform
many of the roles traditionally played by nursing staff in South
Africa.17 Given these observations, further data are needed to
evaluate fully which level of costs is most representative of the
South African public ART program.
One cost factor that has changed rapidly in recent years
is the cost of antiretrovirals themselves. A recent review of
published sources on ART costs in Africa found annual drug
costs that ranged between $278 and $1540.11 The levels
reported in this study (range: $454–$491) are similar to those
of other South African studies although higher than those seen
elsewhere in Africa. In line with other studies from South
Africa, these drug costs are lower in absolute and relative
terms than those seen in higher income settings.
Predictive factors seen in the multivariate models are
similar to those observed elsewhere and reflect predictors of
mortality seen on ART. The importance of WHO stage has
been noted in past cost models in various settings.9,10,13,14 This
study adds nuance to this result, however, finding that after
1 year on treatment, baseline WHO stage ceased to be predic-
tive of such costs. This is in line with evidence that the impor-
tance of a historic AIDS-defining illness in predicting death
decreases dramatically after 6 months on treatment and is not
significant after 3 years.37 After 12 months on ART, difference
in CD4 cell count becomes the strongest clinical predictor of
health care costs, as has been seen elsewhere.7,9
In addition to WHO stage, in the Year One period, the
change in CD4 cell count by 16 weeks was a significant
predictor of health care demand in this population. This
reflects the importance of CD4 cell count response in the early
months of treatment previously reported for mortality at this
site.38 The result in the current study, however, is independent
of mortality, because death is adjusted for in the model. Also,
those dying in the first 4 months on treatment are not included
in the Year One analysis shown because they cannot have
a week 16 CD4 cell count result. This suggests that the effect
of low response to ART is to increase mortality and morbidity,
although the fragility of this result to the inclusion of a single
observation must make this finding a cautious one that would
benefit from further investigation.
In the Year One and Year Two periods, being male was
associ ted with reduced health care expenditures, significantly
so by Year Two. An analysis of the differences in categories of
cost (not shown) found the most important difference in
resource use to be at the primary care level, where men made
one third fewer unscheduled annual clinic visits than women
on average. This difference was, however, not statistically
significant.
Some effects seen in past studies were not observed in
this setting. Although age is a traditional risk factor for general
mortality and morbidity, such an association is not seen in this
population. This is likely to reflect the narrow range of ages
covered in this population, with 50% falling between 29 and
39 years old and only 4 individuals being more than 50 years
old. In Mexico, variation in health care demand arose from
differences in supply-side factors such as income and access
TABLE 5. Comparison of Estimates of Average Costs of ART Provision in South Africa
First Author Treatment Setting Population Treated Cost/Patient/Year Costs Excluded
Churchyard33 Private Employees and dependents $2287–$2761 Maybe inpatient and OI care
Cowlin34 Private Insured individuals $2173 Unclear
Badri13 Public hospital-based clinic Clinical trial patients $1513
Deghaye12 Public hospital-based clinic Health care professionals $1031 Inpatient and OI care First-line
ART only
Martinson35 Nongovernmental primary clinic Public sector patients $1322 Inpatient care
Cleary15 Nongovernmental primary clinic Public sector patients $1023
Harling Public primary clinic Public sector patients
$2502 (Year One)
$1372 (Year Two)
Base year for costs, degree of discounting, and items included in costing vary.
OI indicates opportunistic infection.
Adapted from Rosen et al.11
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to services.10 This study is not able to speak to such matters,
because the population seen here was economically and
socially homogeneous, coming from a single district and
having almost uniformly no earned income.
This study is among the first to analyze cost data for
patients initiating ART in Africa. It shows a 31% decrease in
cost per patient-year in the first year of ART provision com-
pared with the immediate pretreatment period. It also shows
another 45% fall in cost per patient-year between the first
and second years of ART. This study suggests that factors
predictive of costs change from clinical stage early in the
treatment process to CD4 cell count after 12 months on treat-
ment. These findings reinforce the importance of beginning
ART before AIDS diagnosis in reducing the short-term burden
of HIVon health care systems in countries with a high burden
of HIV and limited resources to deal with it.
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Scaling Up Antiretroviral Therapy in South Africa:
The Impact of Speed on Survival
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Background. Only 33% of eligible human immunodeficiency virus (HIV)–infected patients in South Africa
receive antiretroviral therapy (ART). We sought to estimate the impact of alternative ART scale-up scenarios on
patient outcomes from 2007–2012.
Methods. Using a simulation model of HIV infection with South African data, we projected HIV-associated
mortality with and without effective ART for an adult cohort in n ed of therapy (2007) and for adults who became
eligible for treatment (2008 –2012). We compared 5 scale-up scenarios: (1) zero growth, with a total of 100,000 new
treatment slots; (2) constant growth, with 600,000; (3) moderate growth, with 2.1 million; (4) rapid growth, with 2.4
million); and (5) full capacity, with 3.2 million.
Results. Our projections showed that by 2011, the rapid growth scenario fully met the South African need for
ART; by 2012, the moderate scenario met 97% of the need, but the zero and constant growth scenarios met only 28%
and 52% of the need, respectively. The latter scenarios resulted in 364,000 and 831,000 people alive and on ART in
2012. From 2007 to 2012, cumulative deaths in South Africa ranged from 2.5 million under the zero growth scenario
to 1.2 million under the rapid growth scenario.
Conclusions. Alternative ART scale-up scenarios in South Africa will lead to differences in the death rate that
amount to more than 1.2 million deaths by 2012. More rapid scale-up remains critically important.
South Africa has one of the largest burdens of HIV dis-
ease in the world, with an estimated 4.9 – 6.1 million
people infected and a reported prevalence of 18.8% in
adults 15– 49 years old [1]. In 2007, the World Health
Organization (WHO) and the Joint United Nations Pro-
gramme on HIV/AIDS (UNAIDS) estimated that
1,000,000 people in South Africa required antiretroviral
therapy (ART) [2]. The number of patients with access
to ART is steadily increasing, largely as a result of fund-
ing from the South African government itself, as well as
strategic assistance from the US President’s Emergency
Plan for AIDS Relief (PEPFAR) and the Global Fund to
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Fight AIDS, Tuberculosis and Malaria (GFATM) [3–5]. Treat-
ment efforts have been accompanied by a national AIDS plan for
drug distribution, creation of a more comprehensive health care
infrastructure, and establishment of treatment guidelines [6].
Even with these remarkable expansions in capacity, however, the
enormity of the epidemic continues to overwhelm the treatment
systems; by the end of 2006, ART was reaching fewer than 33% of
eligible patients in South Africa [7].
For development of health policy, it is useful to quantify the
potential consequences of disease outcomes under different
treatment and practice scenarios [8]. To this end, our objective
was to project alternative ART rollout scenarios over the next
several years in South Africa. The goals were to forecast the num-
ber of lives lost while awaiting needed therapy, to estimate the
number of people both in and out of care, and to project when
and whether HIV treatment needs would be fully met. These
estimates can be used to inform decisions regarding the life-
saving value of alternative treatment expansion scenarios in
South Africa, as well as in other developing countries.
METHODS
Analytic Framework
We conduct this analysis in 4 steps. First, we parameterized a
detailed computer-based simulation model of HIV disease with
data from South Africa. Second, we conducted a series of analy-
ses that assessed the outcomes associated with different ART
strategies in selected cohorts of patients. Outcomes included
mean CD4 count and HIV RNA levels of the surviving cohort
over time, as well as AIDS-related and non–AIDS-related deaths
each year. Treatment strategies included no ART and ART that
used 2 lines of therapy (“line” here refers to the modeled number
of sequential ART regimens available). Each strategy included
co-trimoxazole prophylaxis in all scenarios, provided according
to WHO guidelines [9]. Cohorts were selected to reflect the fact
that in 2007 (the year of the most up-to-date WHO estimates)
[2], patients who met ART eligibility criteria were distributed
across HIV disease stages, as well as the fact that in subsequent
years, patients who were initially in earlier disease stages progress
to meet ART criteria. Third, we used the information generated
from the model simulations to assess outcomes associated with
different scenarios intended to represent potential population-
based strategies for ART scale-up (table 1). Outcomes were ex-
pressed as number of people alive and on ART, as well as deaths,
between 2007–2012. Finally, in sensitivity analyses, we examined
the effect of changes in the CD4 count distribution of the cohorts
modeled, the number and efficacy of available ART regimens
[10, 11], and the availability of CD4 count monitoring [12].
CEPAC-International Model and Parameterization
The model. The CEPAC-International Model is a computer-
based simulation model of the natural history of HIV infection
in different settings; it has been used to estimate the clinical and
economic consequences of different strategies for opportunistic
infection prophylaxis and ART [13, 14]. We provide a focused
description here; further model details have been described else-
where (see the Appendix, which is available only in the electronic
version) [13, 14]. Disease progression was portrayed as a se-
quence of monthly transitions between health states defined to
capture key elements of disease and prognosis. Health states re-
flected chronic HIV infection, acute illness related to HIV (e.g.,
opportunistic infection), or death. Health states were stratified
by HIV RNA level (30,000 copies/mL; 10,001–30,000 copies/
mL; 3,001–10,000 copies/mL; 501–3,000 copies/mL and 500
copies/mL), which informs the monthly rate of decline in CD4
count. In turn, CD4 count (50 cells/L, 51–200 cells/L, 201–
350 cells/L, 351–500 cells/L, and 500 cells/L) informs the
monthly risk of opportunistic infection and death (table 2).
Clinical decisions, such as the initiation of ART, were based on
clinical findings and, when available, CD4 count and HIV RNA
results. Patients on effective ART experience monthly increases
in CD4 count, reducing their risk of opportunistic infections and
death. After virologic failure, CD4 counts decline, with a con-
comitant increase in the risk of opportunistic infections. Patients
who remain on ART despite virologic failure continue to have
some reduction in risk of opportunistic infections and mortality
Table 1. Alternative scale-up scenarios for antiretroviral therapy analyzed in the study.
Scale-up scenario Description New treatment slots available in year (t1)
Zero growth There are no new treatment slotsa New slots(t1)  0
Constant growth A fixed number of new slots open each year New slots(t1)  new slots(t)
Moderate growth Each year, 100,000 additional new slots open,
compared with the prior year
New slots(t1)  new slots(t)  100,000
Rapid growth Each year, the number of new slots doubles,
compared with the prior year
New slots(t1)  min ([2  new slots(t)],
patients in need(t1))b
Full capacity Each year, there are slots available to treat
everyone in need
New slots(t1)  Patients in need(t1) existing
slots freed up by deaths(t)
a This reflects newly available treatment slots for antiretroviral therapy (ART) and does not reflect treatment slots that became
available due to deaths of patients who received ART in the previous year.
b The no. of new slots is equal to whichever of these 2 values is smaller.










Table 2. Model input parameters for a simulation of scale-up of antiretroviral therapy
(ART) in South Africa.
Variable Estimate Reference
Monthly decline in CD4 count, mean, cells/L [15]
30,000 HIV RNA, copies/mL 6.4
10,001–30,000 HIV RNA, copies/mL 5.4
3,001–10,000 HIV RNA, copies/mL 4.6
501–3000 HIV RNA, copies/mL 3.7
500 HIV RNA, copies/mL 3.0







Monthly risk of mild opportunistic infectionsa, % [16]
Pneumocystis jiroveci pneumonia 0.00–0.12
Fungal 0.59–3.51
Other 2.51–3.11
Efficacy of co-trimoxazole, percent reduction
in monthly risk of infection
Mild bacterial infection 48.8 [14]




Mild fungal infectionsb 46.4
Rates of virologic suppression at 48 weeks, %
NNRTI  2 NRTI 84 [17, 18]
PI  2 NRTI (recycled NRTIs) 71 [19]
2007 prevalent cohort Model derived
CD4 counts, cells/L, mean  SD 92  49
Initial distribution of viral load, percentage of patients
30,000 HIV RNA copies/mL 67
10,001–30,000 HIV RNA copies/mL 19
3,001–10,000 HIV RNA copies/mL 9
501–3,000 HIV RNA copies/mL 3
500 HIV RNA copies/mL 2
2008–2012 incident cohorts Model derived
CD4 count, mean  SD, cells/L 210  50
Initial distribution of viral load, percentage of patients
30,000 HIV RNA copies/mL 71
10,001–30,000 HIV RNA copies/mL 18
3,001–10,000 HIV RNA copies/mL 8
501–3,000 HIV RNA copies/mL 2
500 HIV RNA copies/mL 1
NOTE. NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase
inhibitor; PI, protease inhibitor.
a Risk is stratified by CD4 cell count; in nearly all cases, monthly risk increased with decreasing CD4
count. The following 5 severe opportunistic infections were considered late stage and were used to
trigger initiation of antiretroviral therapy: severe fungal infections, isosporiasis, cerebral toxoplasmosis,
non-tuberculous mycobacteriosis, and other severe illnesses.











independent of CD4 count [20], compared with patients who do
not continue therapy. The model specified the most prevalent
opportunistic infections in South Africa and divided them into 8
severe and 3 mild categories (table 2).
Model input parameters. Model input data are summa-
rized in table 2 [14 –19, 22]. Model results for both the treated
and untreated cohorts were validated with current HIV-related
death rates in South Africa [21, 22]. Data on the monthly risk of
opportunistic infection were derived from a Cape Town cohort
of 2,080 patients followed up longitudinally since 1984 [16, 23–
25]. They were stratified by CD4 count, and the highest risk of
opportunistic infection occurred in the lower strata [16, 23–25].
Co-trimoxazole is effective in preventing several of these oppor-
tunistic infections (e.g., Pneumocystis jiroveci pneumonia [for-
merly Pneumocystis carinii pneumonia], toxoplasmosis, and
some bacterial infections), though it may also increase the risk of
mild fungal infections [14].
A first-line, nonnucleoside reverse transcriptase inhibitor–
based regimen (in combination with 2 nucleoside reverse trans-
criptase inhibitors [NRTIs]) had a 48-week HIV RNA suppres-
sion rate of 84%, with a mean CD4 count increase of 184 cells/L
[17, 18]. Upon observed clinical or immunologic failure of the
first-line regimen, the efficacy of a second-line regimen, if avail-
able, presumed the addition of a ritonavir-boosted protease in-
hibitor. This second-line regimen provided a 48-week HIV RNA
suppression rate of 71% and a corresponding CD4 count in-
crease of 151 cells/L [19].
Cohort Descriptions
We distinguished patients who required therapy in 2007 (hereafter,
the “prevalent cohort”) from those who would need therapy in the
period from 2008–2012 (hereafter, the “incident cohort”). The out-
comes of both cohorts were examined for both the ART and “no
ART” strategies. We defined patients in need of ART as those who
met the current South African criteria that define ART eligibility,
regardless of whether the patient had been identified as having HIV
infection [26, 27]. These criteria include WHO Stage 4 AIDS-
defining illness and/or symptomatic disease with a CD4 count
200 cells/L [26, 27]. In the base case, there is no prioritization for
ART; that is, among those eligible, patients are randomly chosen for
ART and are not given preference based on CD4 count, degree of
“AIDS sickness,” or time waiting for ART.
Patients in need of therapy in 2007. We began the time
horizon with the most recent WHO estimates (2007), when
there were an estimated 1,000,000 patients in South Africa in
need of therapy [2]. To approximate the distribution of stage of
illness for these patients, we assumed that the South Africa epi-
demic was in a steady state and that the number of incident cases
each year remained the same over the 10-year period prior to
ART rollout (1997–2006). As noted above, we refer to this co-
hort as the prevalent cohort.
Patients who require therapy in the future (2008 –
2012). Patients become newly eligible for therapy each year
from 2008 –2012. This reflects the fact that incident cases of HIV
will occur, and that existing patients with early infection will
progress to a point at which they are eligible for ART. Approxi-
mately 5.51 million people are estimated to be living with HIV/
AIDS in South Africa [2, 28]. With a mean 10-year progression
from HIV infection to AIDS [29], we estimated that 10% of
those 5.51 million infected people (or 551,000 people) would be
newly in need of therapy in each year. As noted above, we refer to
this group as the incident cohort.
Derivation of initial mean CD4 counts of the cohorts. The
mean CD4 count of the prevalent and incident cohorts were ob-
tained from the CEPAC-International Model. The incident cohort
was derived first. The characteristics of the incident cohort, which
becomes eligible for ART in yearly cycles, are obtained by tracking
the course of HIV disease for a relatively healthy starting cohort
(CD4 count, mean  SD, 534  100 cells/L) that received only
co-trimoxazole prophylaxis [30]. The model records and averages
the clinical characteristics of patients (e.g., CD4 count, HIV RNA
levels, and opportunistic infection history) as they reach the criteria
for ART eligibility (CD4  200 cells/L or severe opportunistic
infection). The resulting incident cohort had a mean (SD) CD4
count of 210 ( 50) cells/L.
The prevalent cohort was a heterogeneous distribution of pa-
tients who had been in need of ART for varying amounts of time.
The characteristics of the prevalent cohort were obtained by sim-
ulating and tracking the course of HIV disease for an incident
cohort as described above (CD4 count, mean  SD, 210  50
cells/L) that receives co-trimoxazole prophylaxis only [14].
Thus, the 1997 cohort was followed for 10 years, whereas the
2006 cohort was followed for 1 year. We then calculated a
weighted average of CD4 count and HIV RNA distribution on
the basis of the population distribution of all patients who were
alive at the end of the 10-year period. The patients alive at the
beginning of the ART rollout period consisted mostly of the
cohort that had become eligible in 2006 (44% of the patients
alive at beginning of the rollout period), whereas patients who
had reached the eligibility criteria in 1997 but were not treated
constituted less than 0.01% of those still alive in 2007. The re-
sulting cohort (i.e., the prevalent cohort) had a mean (SD)
CD4 count of 92 ( 49) cells/L.
Scenarios Examined
We examined 5 population-based strategies of ART scale-up
based, in part, on projections made by the Actuarial Society of
South Africa, the South African Joint Task Force, and the WHO
[6, 28, 31]. These scenarios (table 1) range from a situation in
which no new treatment funds are allocated (zero growth) to a
situation in which a rapid and aggressive scale-up program is
initiated (rapid growth) [32, 33]. We consider the full capacity
scale-up program only for purposes of comparison.










Using WHO surveillance data and model-generated mortality
rates, we projected the number of deaths under each scenario.
Each year, mortality was calculated to include deaths that oc-
curred among patients who needed, but had not yet received,
ART, in addition to deaths that occurred—albeit later and at a
slower rate—among patients who received ART. For patients
who died while receiving ART, we assumed that their treatment
slots (which reflected unused medications and human re-
sources) would be available for other patients in the following
year. In each scenario, the total deaths and total life years of
survival were tallied and reported from 2007–2012.
RESULTS
Survival Rates
Assessment of model performance. To ensure that model-
based death rates were appropriate for long-term projections, we
compared them to reported survival trends in South Africa, both
for patients who received ART and those who did not. At each
yearly time point, model-based estimates were within 10% of
reported survival (see the Appendix, which is available only in
the electronic version) [21].
Projected survival with and without ART for both
cohorts. Patients who entered the model in the prevalent co-
hort (2007; mean CD4 count, 92 cells/L) and received ART in
that year had 1- and 5-year projected survival rates of 94% and
70%, respectively. If they did not receive ART, these patients had
markedly reduced survival rates of 55% at 1 year and 1% at 5
years. For patients in the comparatively healthier incident co-
hort (2008 –2012, mean CD4 count, 210 cells/L) who received
ART as recommended without delay, 1- and 5-year survival rates
were 94% and 72%, respectively. If the patients did not receive
ART, the corresponding 1- and 5-year survival rates for the in-
cident cohort were 79% and 4%.
Number of Patients Who Received ART for Each Scenario
For each scale-up scenario, we examined the number of people alive
and on ART at the end of each year, comparing the current study to
published South African projections (figure 1). By 2012, if all pa-
tients received ART in the year that they first met eligibility criteria
(full capacity), 2.9 million people would be alive and receiving treat-
ment in 2012. The rapid-growth scenario results in 2.5 million peo-
ple receiving treatment, compared to 2.2 million in the moderate-
growth scenario, 831,000 in the constant-growth scenario, and
364,000 in the zero-growth scenario.
Figure 2 illustrates the percentage of patients alive and eligible
each year who received ART. All of the patients who needed ART
had access by 2011 in the rapid-growth scenario; the moderate-
growth scenario met 97% of treatment need by 2012. In 2012, the
constant-growth scenario met only 52% of the treatment need; the
zero-growth scenario—with no new treatment slots available after
2007—met just 28% of the treatment need by 2012 (figure 2).
Mortality Projections for Each Scenario
The number of deaths projected to occur before patients started
ART and while patients were receiving ART were also calculated
for each of the scenarios (figure 3). The total number of deaths
increases over time in the zero-growth scenario due to a yearly
influx of patients who require treatment (the incident cohort)
without the provision of any new treatment resources. The
rapid-growth scenario results in notably fewer deaths than all the
other scenarios (except full capacity, which is provided for pur-
poses of comparison). The increase in deaths under the rapid-
growth scenario in 2010 –2012 reflects patients who received
Figure 1. No. of patients alive and on antiretroviral therapy (ART) at the end of each year, according to scale-up scenario (dashed and dotted lines),
compared with previously published South African projections (solid lines). The constant growth scenario modeled in the study best approximates the
projections of the Actuarial Society of South Africa (ASSA), whereas the moderate growth scenario best approximates the projections of the South
African Joint Task Team on HIV Care in the Public Sector [6, 28, 31].









wnART during earlier years of their illness but who subsequently
failed ART, and who die several years after treatment initiation.
Table 3 summarizes outcomes associated with the nearly 3.8 mil-
lion patients eligible for therapy in the time horizon considered. The
total number of deaths over 6 years ranged from 2.5 million under
the zero-growth scenario to 1.2 million under the rapid-growth sce-
nario. Compared with the zero-growth scenario, the constant-
growth and moderate-growth scenarios averted 305,000 and
1,000,000 more deaths through 2012, respectively.
In a sensitivity analysis, we examined the assumption that pa-
tients in need of ART are prioritized on the basis of the length of
time they have been eligible for therapy (table 3). For example, in
this prioritized scenario, the whole 2007 prevalent cohort would
be treated before anyone in the 2008 incident cohort received
therapy. This sort of prioritization, on average, treats the sickest
patients (i.e., those with the lowest CD4 counts) first. For each
scenario, prioritization led to fewer deaths over the 6-year time
horizon, compared with the base case analysis. Comparison of
each scenario with its nonprioritized counterpart showed be-
tween 17,000 (zero-growth scenario) and 87,000 (moderate-
growth scenario) fewer deaths over 6 years.
We also examined the availability of only 1 line of ART (rather
than 2 successive lines), changes in the efficacy of second-line
therapy, the availability of 3 successive lines of ART, and a sce-
Figure 2. Percentage of patients eligible and alive who received antiretroviral therapy, for each modeled scenario. The rapid-growth scenario met
100% of need by 2011, and the moderate-growth scenario met 97% of need by 2012. The constant-growth scenario remained relatively unchanged and
met 52% of need by 2012. The percentage of need met in the zero-growth scenario declined steadily to 28% in 2012.
Figure 3. Annual projected no. of deaths through 2012, stratified by scale-up scenario and year. All scale-up scenarios (except full capacity) involved
the same number of treatment slots in 2007, and all scenarios included the availability of 2 successive lines of therapy. The estimated number of deaths
each year for those awaiting antiretroviral therapy (ART) and those receiving ART were calculated for each scale-up scenario by use of mortality rates
generated from model output. Annual mortality rates for both the prevalent and incident cohorts were stratified by treatment status (awaiting ART or
receiving ART) and length of time awaiting therapy.










nario in which no CD4 count monitoring was available. Com-
pared with scenarios in which there were no CD4 tests available,
the availability of CD4 testing resulted in 102,000 –986,000 fewer
deaths over 6 years. For each scenario, more deaths occurred
when there were 2 lines of therapy and no CD4 monitoring avail-
able, compared with only 1 line of therapy and CD4 monitoring.
Finally, varying the assumption regarding the efficacy of ART in
preventing severe opportunistic infections, independent of CD4
count, produced quantitative changes in the survival rate but
had no material impact on the qualitative findings.
DISCUSSION
We used a model-based analysis and South African data to project
the average impact of alternative ART strategies over the next 5
years. We applied these strategies to different cohorts, which were
intended to be representative of patients who were eligible for ART
in 2007, patients who will be eligible for ART from 2008–2012, and
patients who have been waiting for ART for varying periods of time.
We aggregated the results of these cohorts to create a comparative
analysis of population-based scenarios for ART scale-up.
The findings suggest that the potential loss of life associated with
the failure to provide ART to all who need it, in South Africa alone,
is enormous. A scenario that maintains current treatment capacity
with no addition of treatment resources over the long term (zero
growth) will result in over 1.2 million more deaths in South Af-
rica—a country with a population of 48 million people [34]—by
2012, compared with a scenario that provides the resources to en-
sure universal access to ART by 2011 (rapid growth). The current
projected time line for ART scale-up in South Africa (2.1 million
receiving treatment by 2012, or a moderate-growth scenario) will
likely result in nearly 1.5 million deaths through 2012, over 200,000
more than would be seen with rapid growth [35].
Table 3. Outcomes for patients eligible for antiretroviral therapy (ART), according to alternative scale-up
scenarios for ART in South Africa, 2007–2012.
Analysis, scenario
Dead, no. of patients Alive, no. of patients
Awaiting ART On ART Total Awaiting ART On ART Total
Base case
Zero growth 2,294,000 171,000 2,465,000 926,000 364,000 1,290,000
Constant growth 1,896,000 264,000 2,160,000 764,000 831,000 1,595,000
Moderate growth 978,000 471,000 1,449,000 64,000 2,242,000 2,306,000
Rapid growth 681,000 551,000 1,232,000 0 2,523,000 2,523,000
Full capacity 0 823,000 823,000 0 2,932,000 2,932,000
Sensitivity analyses
Prioritization
Zero growth 2,268,000 180,000 2,448,000 946,000 361,000 1,307,000
Constant growth 1,800,000 286,000 2,086,000 845,000 824,000 1,669,000
Moderate growth 888,000 474,000 1,362,000 152,000 2,241,000 2,393,000
Rapid growth 610,000 564,000 1,174,000 0 2,581,000 2,581,000
Full capacity 0 823,000 823,000 0 2,932,000 2,932,000
1 line of ART
Zero growth 2,264,000 229,000 2,493,000 910,000 352,000 1,262,000
Constant growth 1,861,000 344,000 2,205,000 740,000 810,000 1,550,000
Moderate growth 943,000 590,000 1,533,000 23,000 2,200,000 2,222,000
Rapid growth 672,000 681,000 1,353,000 0 2,402,000 2,402,000
Full capacity 0 1,024,000 1,024,000 0 2,731,000 2,731,000
3 sequential ART regimens
Zero growth 2,297,000 162,000 2,459,000 929,000 367,000 1,296,000
Constant growth 1,899,000 253,000 2,152,000 767,000 836,000 1,603,000
Moderate growth 981,000 458,000 1,439,000 68,000 2,248,000 2,316,000
Rapid growth 681,000 537,000 1,219,000 0 2,536,000 2,536,000
Full capacity 0 796,000 796,000 0 2,959,000 2,959,000
No CD4 monitoring
Zero growth 2,027,000 541,000 2,568,000 862,000 325,000 1,187,000
Constant growth 1,539,000 897,000 2,436,000 611,000 708,000 1,319,000
Moderate growth 673,000 1,565,000 2,237,000 0 1,518,000 1,518,000
Rapid growth 566,000 1,652,000 2,218,000 0 1,537,000 1,537,000
Full capacity 0 2,101,000 2,101,000 0 1,654,000 1,654,000










ART guidelines are generally country-specific and vary widely
[36]. Some countries, for example, Malawi, do not recommend
CD4 count monitoring, and ART initiation is based on WHO
stage-3 or stage-4 disease, or CD4 count, if available [37]. Pa-
tients are now being enrolled in trials to examine the long-term
impact of clinical monitoring versus laboratory monitoring
while on ART, because earlier reports from programs that used
clinical guidelines alone suggest substantial survival benefits,
even without CD4 count monitoring [12]. These reports are
consistent with the results reported here, however, without ac-
cess to CD4 monitoring, the number of deaths through 2012
may increase by as many as 986,000, compared with similar
scale-up scenarios in which CD4 monitoring is available. In-
deed, these results emphasize that the addition of any ART reg-
imen will greatly improve survival; however, they also highlight
that the benefits of ART will be maximized with the addition of
CD4 counts, as is current South Africa policy.
This analysis has several limitations. It does not compare differ-
ent strategies for the operational delivery of ART (an essential com-
ponent to effective scale-up), nor does it include unintended nega-
tive consequences of ART. Importantly, we also do not discuss the
opportunity costs of investment in expanded ART. One South Af-
rican projection estimates that full HIV treatment coverage by
2010—including the costs of antiretroviral drugs, nutritional sup-
port, and non-antiretroviral drugs—will cost 16.9–21.4 billion
Rand in South Africa (US$2.54–3.22 billion) [38]. Although we
have not addressed societal trade-offs in this paper, this analysis
offers a quantitative assessment of the opportunity cost—in lives
lost—of failing to make these investments in HIV care.
Beyond economic requirements, other complicated infra-
structure issues cannot be overlooked and must play a role in any
ART implementation. These include facilities, personnel, equip-
ment, and political will. A goal of rapid scale-up must also be
accompanied by a commitment to adequate monitoring of ther-
apy, to avoid depletions of stock and interruptions in drug de-
livery, and to ensure patient adherence so that drug resistance
does not occur. Recent findings on the role of extensively drug-
resistant tuberculosis (XDR-TB) suggest that the implementa-
tion of a large-scale ART program in South Africa will require
improvements in tuberculosis control programs as well, to max-
imize the survival benefits conferred by ART [39]. The rising
prevalence of drug-resistant strains of tuberculosis, coupled
with the high mortality rate among HIV-infected patients with
XDR-TB, risks considerably undermining the benefits of ART in
South Africa [39]. Infrastructure improvements for the care of
individuals with HIV infection and tuberculosis are particularly
important, given the possibility that XDR-TB may be transmit-
ted in healthcare settings, thus putting HIV patients who seek
medical care at greater risk of infection with this virulent tuber-
culosis strain [39].
As with all model-based analyses, data were derived from
multiple sources, which contributes to some uncertainty in the
model projections. In most cases, data are specifically from
South Africa. However, when South African data were unavail-
able, we used the closest appropriate surrogate data. To ensure
that the model outcomes adequately reflect the South African
context, we provided validation from the South African natural
history and treatment literature. The estimates of mean CD4
count in the population were made under the assumption of an
HIV epidemic in steady state. We have addressed this assump-
tion via sensitivity analyses, examining the parameters that
might be most influential in the overall results. The analysis of
prioritization made ART available first to those who had been
waiting longest. On average, this meant prioritizing those with
the lowest CD4 count (mean CD4 count when receiving ART
after a wait of 1 year was 139 cells/L, compared with a CD4
count of 210 cells/L for those who received ART immediately),
though this might not be true in every case.
Though the goal is ambitious, ART scale-up efforts to date have
been impressive. The number of people receiving ART in low-
income and middle-income countries worldwide increased more
than five fold between 2001 and 2005, from 240,000 to 1.3 million
[1]. This level of achievement was previously thought to be impos-
sible. Deliberate, purposeful, and expedient scale-up—together
with careful analysis of the outcomes associated with different pro-
grammatic approaches—will make the difference in saving hun-
dreds of thousands, or millions, of lives.
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This appendix is intended to provide methodological details to
supplement the article’s description of methods. We also include
here some additional model output and results.
METHODS
Defining the Cohorts for the CEPAC-International
Simulations
We defined several cohorts for the model simulations. The first
were the validation cohorts (treated and untreated), which were
defined to compare output from the model to endpoints and
outcomes reported in the literature. Next, we defined a prevalent
cohort, intended to model the distribution of patients who
needed therapy in 2007. Finally, we defined an incident cohort to
represent the distribution of newly-eligible patients who will re-
quire therapy in the future (2008 –2012).
Validation Cohorts
The validation cohorts were intended to reflect a previously pub-
lished cohort and are used to illustrate the fact that model out-
comes and survival are representative of findings that have been
reported in the South African setting [21, 22]. As noted in the
literature, the untreated cohort has a mean (SD) CD4 count of
273 ( 231) cells/L, and the treated cohort has a mean (SD)
CD4 count of 259 ( 153) cells/L (table A1) [21]. These mean
CD4 counts were used as model input parameters to assess
whether model output reflected the survival rates seen in the
reported cohorts. Badri et al. [21] report that 50% of patients
who received co-trimoxazole alone (reflective of the untreated
cohort) survived for 30 months, and 90% of patients who re-
ceived ART were alive at 36 months. Model-based estimates re-
port median survival times of 31.5 months on co-trimoxazole
prophylaxis alone, and 82.3% of patients who received ART
were alive at 36 months. As noted in the Results section, model-
based estimates reflected reported survival within 10%.
Survival and Mortality
Because the baseline characteristics of patients in the prevalent
cohort and the incident cohort differed, survival data were de-
rived separately for each cohort. Furthermore, survival data were
derived separately for patient populations awaiting ART (who
received only co-trimoxazole prophylaxis) and receiving ART.
Patients awaiting ART. We obtained the probabilities of
survival for patients awaiting ART by simulating the course of
HIV disease with co-trimoxazole prophylaxis only, using the
CEPAC International model [14]. Yearly probabilities of sur-
vival (conditional on survival to the beginning of the year) were
computed by dividing the number of patients alive at the end of
the given calendar year by the number alive at the end of the
previous year. This was done to reflect a patient’s probability of
surviving through the year, given that the patient was alive at the
Table A1. Validation cohort characteristics.
Variable Estimate Reference
CD4 count, mean SD, cells/L [21]
Treated 259  153
Untreated 273  231
Initial HIV RNA level, copies/mLa





a Data are percentage of patients in the validation cohort with a
given HIV RNA level.
Table A2. CD4 count and probability of death for patients
awaiting antiretroviral therapy (ART), according to cohort and















1 year 139 38 21.08 44.53
2 years 79 12 33.34 57.90
3 years 38 3 47.74 63.17
4 years 17 1 57.73 64.20
5 years 9 1 61.67 64.66
6 years 6 0 62.69 64.68
Table A3. Yearly probability of death for patients who received


















1 6.15 5.09 6.51 8.53 9.97 10.74
2 5.13 4.67 5.07 5.77 6.36
3 5.10 5.94 6.87 7.83




1 5.86 8.67 10.63 11.10 11.20 11.26
2 4.89 5.69 6.62 7.18 7.39
3 6.59 7.82 8.80 9.48











wnbeginning of the year. The yearly probabilities of death were defined
as the complement of the corresponding yearly probability of sur-
vival, as shown in table A2. The first column (“wait before initiating
ART”) indicates the number of years that patients had been await-
ing ART (since the start of the analysis in 2007).
Patients receiving ART. We obtained the probabilities of
survival for patients receiving ART by simulating the course of
HIV disease using the CEPAC-International model [13]. Be-
cause baseline clinical characteristics differed between the prev-
alent and incident cohorts, mortality rates were derived sepa-
rately for each cohort. Furthermore, because the baseline clinical
characteristics of patients who received ART depended on the
duration of time spent awaiting ART, several sets of yearly mor-
tality rates were derived (table A3).
We obtained the baseline characteristics of patients who had
awaited ART for varying durations of time (0 –5 years) by sim-
ulating the course of disease for patients in the prevalent and
incident cohorts while receiving co-trimoxazole prophylaxis
only, and recording population characteristics at the end of ev-
ery year (table A2).
We then simulated the course of disease while receiving ART
for each distinct patient population described above, as shown in
table A3. The first column indicates the patients’ cohort and the
number of years that patients had been receiving ART since the
initiation of the analysis in 2007. Columns 2 through 7 list the
probabilities of death for each patient population, depending on
the number of calendar years they waited for treatment.
RESULTS
Figure A1 illustrates the population alive, as a percentage of the
total population eligible for ART in each year. As an additional
551,000 patients become eligible for ART each year (the incident
cohort), the cumulative percentage of patients alive depends on
the speed of treatment scale-up. The change in the slope (from
downward to upward) in the rapid-growth and moderate-
growth curves reflects improved survival rates over time, com-
pared with the increasing total denominator of patients in need
(an additional 551,000 patients yearly). By 2012, the rapid-
growth and moderate-growth scenarios result in 67% and 61%
of the population alive, respectively, compared with the cumu-
lative eligible number (3,755,000). The constant-growth and
zero-growth scenarios result in worse cumulative survival rates,
with 42% and 34% of the population alive, respectively.
Figure A1. Percentage of total patients eligible for antiretroviral therapy (ART) (both those awaiting and those receiving ART) who were alive by
year, for each modeled scenario. The cumulative total of all eligible patients is noted below the graph, by year. The changing denominator and rapid
increase in access to ART account for the change in slope of the moderate-growth and rapid-growth curves. Nonprioritized cases are indicated with
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A B S T R A C T
Background
The provision of highly active antiretroviral therapy (HAART) in resource-limited settings
follows a public health approach, which is characterised by a limited number of regimens and
the standardisation of clinical and laboratory monitoring. In industrialized countries doctors
prescribe from the full range of available antiretroviral drugs, supported by resistance testing
and frequent laboratory monitoring. We compared virologic response, changes to first-line
regimens, and mortality in HIV-infected patients starting HAART in South Africa and
Switzerland.
Methods and Findings
We analysed data from the Swiss HIV Cohort Study and two HAART programmes in
townships of Cape Town, South Africa. We included treatment-naı̈ve patients aged 16 y or
older who had started treatment with at least three drugs since 2001, and excluded
intravenous drug users. Data from a total of 2,348 patients from South Africa and 1,016 patients
from the Swiss HIV Cohort Study were analysed. Median baseline CD4þ T cell counts were 80
cells/ll in South Africa and 204 cells/ll in Switzerland. In South Africa, patients started with one
of four first-line regimens, which was subsequently changed in 514 patients (22%). In
Switzerland, 36 first-line regimens were used initially, and these were changed in 539 patients
(53%). In most patients HIV-1 RNA was suppressed to 500 copies/ml or less within one year:
96% (95% confidence interval [CI] 95%–97%) in South Africa and 96% (94%–97%) in
Switzerland, and 26% (22%–29%) and 27% (24%–31%), respectively, developed viral rebound
within two years. Mortality was higher in South Africa than in Switzerland during the first
months of HAART: adjusted hazard ratios were 5.90 (95% CI 1.81–19.2) during months 1–3 and
1.77 (0.90–3.50) during months 4–24.
Conclusions
Compared to the highly individualised approach in Switzerland, programmatic HAART in
South Africa resulted in similar virologic outcomes, with relatively few changes to initial
regimens. Further innovation and resources are required in South Africa to both achieve more
timely access to HAART and improve the prognosis of patients who start HAART with advanced
disease.
The Editors’ Summary of this article follows the references.












The introduction of highly active antiretroviral combina-
tion therapy (HAART) since 1996 has substantially improved
the prognosis of HIV-infected patients in industrialized
countries [1]. Only few drugs were available initially, but
today over 20 approved antiretroviral drugs from four drug
classes are available, including nucleoside reverse transcrip-
tase inhibitors (NRTIs), non-nucleoside reverse transcriptase
inhibitors (NNRTIs), protease inhibitors (PIs), and fusion
inhibitors. In industrialized countries doctors prescribe from
the full range of available antiretroviral drugs. Resistance
testing and frequent monitoring of CD4 cell counts and viral
load are used to individually tailor drug regimens.
In contrast, based on the experience of treating tuber-
culosis, the World Health Organization (WHO) has developed
a public-health approach to providing HAART in resource-
limited settings. This approach takes the realities of weak
health systems into account, including the level of training of
health-care workers, the high patient burden, limited avail-
ability of drugs, and the experience of pilot programmes [2,3].
Key characteristics of this public-health approach include the
standardisation of first-line and second-line regimens, sim-
plified clinical decision-making, and standardised clinical and
laboratory monitoring [3]. The choice of regimens in these
programs is determined primarily by cost and ease of
administration and can include drugs that are no longer
widely used in industrialized countries. Viral load monitoring
is not considered essential, and individual drug resistance
testing is generally not available. A survey of national
guidelines developed by 43 low- and middle-income countries
showed that the public-health approach to antiretroviral
therapy has been widely adopted in these countries [4]. An
estimated 2 million people living with HIV/AIDS were
receiving treatment in low- and middle-income countries by
December 2006, representing 28% of the estimated 7.1
million people in urgent need of treatment at that t me [5].
We compared the public-health and individual approach to
HAART by analysing virologic response, changes to first-line
regimens, and mortality in patients starting HAART in
Switzerland and two townships in Cape Town, South Africa.
Methods
We analysed data from the Khayelitsha and Gugulethu
HAART programmes in the Republic of South Africa, which
are part of the International Epidemiological Databases to
Evaluate AIDS in Southern Africa (IeDEA-SA), and made
comparisons with the Swiss HIV Cohort Study (SHCS).
Khayelitsha and Gugulethu Cohorts, Cape Town, South
Africa
Khayelitsha and Gugulethu are townships located within
the Cape Town metropolitan area with estimated populations
of 400,000 and 300,000 people, respectively. Khayelitsha had,
in 1999, the first routine government-run programme for the
prevention of mother-to-child transmission of HIV in South
Africa. Antiretroviral treatment has been available since 2001
at three government clinics providing HIV care, supported by
Médecins Sans Frontières. In Gugulethu the Usaphu Luwethu
(‘‘Our Family Clinic’’) antiretroviral treatment programme
was initiated by the Desmond Tutu HIV Centre in September
2002. Ten primary-care HIV clinics form the patient referral
base.
Enrolment into treatment programmes follows the South
African government’s Department of Health national guide-
lines, which are based on the 2002 WHO recommendations
[6]. Individuals are eligible for treatment if they are in WHO
stage 4 (with the exception of extrapulmonary tuberculosis,
which is a stage 4–defining illness but not a criterion for
starting therapy in the Western Cape) or have a CD4 count
below 200 cells/ll. Data are collected prospectively using
structured records completed at each consultation, including
information on WHO stage-defining illnesses [7].
In Khayelitsha, viral load assessments are performed
routinely before starting HAART, after 3 mo, and then every
6 mo. In Gugulethu viral load is assessed before starting
HAART and every 4-mo thereafter. Plasma viral load was
measured using a branch DNA hybridization technique
(Bayer HIV-1 RNA 3.0 assay, Leverkusen, Germany) or nucleic
acid sequence-based amplification (Nuclisens EasyQ assay,
bioMérieux, Boxtel, The Netherlands). In South Africa,
provincial and national guidelines recommend switching
drug regimens after two consecutive viral loads above 5,000
copies/ml, but patients were not necessarily switched when
they fulfilled these criteria.
All treatment, clinic consultations, and laboratory work are
free of charge. In both sites patients receive counselling and
adherence support. Patients on HAART who miss appoint-
ments are contacted where possible, and if required, traced
through home visits. More details on the Khayelitsha and
Gugulethu cohorts are given elsewhere [8,9].
Swiss HIV Cohort Study
Set up in 1988, the Swiss HIV Cohort Study is a national
prospective cohort study of HIV-infected patients followed
up at outpatient departments of five University hospitals
(Basel, Bern, Geneva, Lausanne, and Zurich) and two
Cantonal hospitals (Lugano and St. Gallen) in Switzerland.
A comparison with official AIDS notifications and deaths
indicated that about 70% of all patients living with AIDS in
Switzerland participate in the study [10].
Data collection and study procedures are standardised.
Detailed information on demographics, mode of HIV
acquisition, risk behaviours, clinical events, laboratory re-
sults, and treatments is collected at registration and then at
intervals of 6 mo. HIV-1 RNA (Roche Amplicor HIV-1
Monitor assay), CD4 counts, and other laboratory parameters
are measured at least every 3 mo. Clinical AIDS diagnoses
(Centers for Disease Control and Prevention [CDC] stage C)
are recorded by the treating physicians on the basis of the
1993 CDC criteria [11]. The decision to change therapy was
informed by the International AIDS Society-USA guidelines.
All services, including antiretroviral therapy and laboratory
testing, are covered by compulsory health insurance. More
details on the SHCS are given elsewhere [12,13].
Eligibility Criteria and Definitions
The same eligibility criteria were applied to patients in
Switzerland and South Africa. All treatment-naı̈ve patients
who started HAART at any point since 2001 (the year when
HAART became available in the two South African sites), had
at least one day of follow-up, and were aged 16 y or older
were included. Patients from Switzerland who acquired HIV
PLoS Medicine | www.plosmedicine.org July 2008 | Volume 5 | Issue 7 | e1480002










through intravenous drug use were excluded from the
analysis because they are a group that is not represented in
the South African cohorts. In the South African cohorts HIV
transmission information is not routinely recorded, but most
patients were infected through heterosexual contacts.
HAART was defined as a combination of at least three
antiretroviral drugs. The type of regimen was defined as PI-
based (two NRTIs and one PI), NNRTI-based (two NRTIs and
one NNRTI), and other. Boosted PIs are counted as one drug.
The stage of disease was classified as less advanced (CDC stage
A/B, WHO stage I/II) or advanced (CDC stage C, WHO stage
III/IV).
Ethical Approval and Laboratory Quality Assurance
The local ethics committees of all seven study sites that
participate in the SHCS approved the study, and written
informed consent was obtained from all participants. Data
collection in the townships Khayelitsha and Gugulethu, South
Africa, as well as participation of these studies in the
Antiretroviral Treatment in Lower Income Countries Col-
laboration (ART-LINC) collaboration of IeDEA, were ap-
proved by the ethics committee of the University of Cape
Town, which did not require informed consent. All labo-
ratories involved in South Africa and Switzerland participate
in quality assurance programmes.
Endpoints
The following endpoints were considered: time to first
treatment change (overall and by reason for change),
virologic suppression (defined as HIV-1 RNA 500 copies/
ml), viral rebound (defined as HIV-1 RNA above 500 copies/
ml) after having achieved viral suppression, CD4 response,
and death from all causes. Viral rebound is usually defined as
two consecutive values above a given threshold. In our
analysis we used a single value, as the measurement frequency
differed between settings. In a sensitivity analysis we used two
consecutive values above 500 copies/ml. The threshold of 500
copies/ml was chosen because assays of different sensitivities
were used during the study period. Regimen change was
defined as any change to the treatment regimen, including
interruption and discontinuation, but excluding dosage
adjustments. The treating physician indicated the reason
for regimen changes, and these reasons were classified as
failure (virologic, immunologic, or clinical), toxicity, and
other. Specific definitions of reasons for regimen change,
including, for example, lactic acidosis, were not standardised
across sites. The severity of toxicities was not assessed.
Finally, we determined the proportion of initial regimens
that complied with the national South African guidelines or,
in the case of Switzerland, the International AIDS Society–
USA guidelines current at the time of starting HAART.
Statistical Analysis
We used an ‘‘intent-to-continue-treatment’’ approach and
thus ignored changes to treatment, including treatment
interruptions and terminations for virological endpoints
and death. Time was measured from the start of HAART or
from the first viral load measurement of 500 copies/ml or
below to the time the outcome occurred, the time of the last
follow-up visit, or 2 y after baseline, whichever came first. A
patient was considered lost to follow-up if the time between
the last visit of the patient and the closing date of the cohort
was longer than 1 y. Only patients who potentially had 1 y of
follow-up were included in the analysis of loss from follow-
up.
We used Kaplan–Meier graphs and Cox proportional
hazard models (for mortality and first treatment change)
and logistic regression (for viral response and viral rebound)
to estimate hazard ratios (HRs) and odds ratios (ORs) of
endpoints occurring, in comparing the two South African
cohorts with the Swiss cohort. For mortality, a separate model
was fitted for the first 3 mo after starting HAART (the period
with the highest mortality [14]) and for months 4–24. Since
background mortality differs between the two settings, we
compared expected mortality rates in Switzerland and South
Africa. We obtained estimates of non-HIV-related back-
ground mortality by sex and age group from the Global
Burden of Disease project [15,16], and used these rates to
calculate expected numbers of deaths in the two South
African cohorts. Similarly, we used rates available from the
Swiss Federal Statistical Office to calculate expected deaths
for the Swiss cohort.
For viral response the first viral load measurement within
6–12 mo after baseline was classified into 500 copies/ml
(virologic suppression) or .500 copies/ml. We used logistic
regression instead of a time-to-event approach, because the
frequency and timing of viral load measurements differed
between the two settings. Analyses were adjusted for baseline
CD4 count, HIV-1 viral load, stage of disease, sex, and age.
We calculated the rate of changing the first treatment
regimen by reason of change and time periods (1–3 mo, 4–6
mo, 7–12 mo, and 13–24 mo) by dividing the number of
patients developing the event by the number of person-years
at risk. We used Poisson regression to calculate confidence
intervals (CIs) for rates. Cause-specific cumulative incidences
were calculated applying a competing risk approach [17,18].
We used competing risk Cox regression as described by Lunn
and McNeil [19] to jointly analyze treatment change due to
failure, intolerance, and other reasons. This analysis was
adjusted for the same variables as above.
All analyses were performed using Stata version 9.2. Results
are presented as Kaplan–Meier probabilities, rates per 100
person-years, and HRs or ORs, with 95% CIs.
Results
Patient characteristics
A total of 3,364 patients—2,348 from Khayelitsha and
Gugulethu and 1,016 from the Swiss HIV Cohort Study—were
observed for 2,362 and 1,564 person-years, respectively. The
median observation time (taking censoring after 2 y into
account) was 0.7 y (interquartile range [IQR] 0.3–1.3 y) for
Gugulethu, 1.0 years (0.5–1.5 y) for Khayelitsha and 2.0 y (1.1–
2.0 y) for the Swiss cohort. Table 1 shows the characteristics of
patients at the time of treatment initiation. The patients in
the South African cohorts were younger, more likely to be
female, and in more advanced stages of the infection: the
median baseline CD4 count was 80 cells/ll compared to 204
cells/ll in the Swiss cohort, and 2,126 (90.6%) and 188
(18.5%), respectively, were in CDC stage C or WHO stage III/
IV. In South Africa the number of patients starting HAART
almost doubled every year from 79 in 2001 to 509 in 2003,
whereas in Switzerland the number of patients starting
HAART remained fairly constant since 2001.
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In Khayelitsha and Gugulethu over 95% of patients were
treated with one of four NNRTI-based first-line regimens
whereas in Switzerland 36 different regimens were used
(Table 1). The most commonly used regimens in South Africa
were stavudine/lamivudine (d4T/3TC) in combination with
efavirenz (EFV) (39.1%) or nevirapine (NVP) (33.2%). In
Switzerland the most frequent regimens were zidovudine/
lamivudine (AZT/3TC) in combination with either EFV (n ¼
304, 29.9%) or boosted lopinavir (LPV) (n ¼ 202, 19.9%) or
nelfinavir (NFV) (n ¼ 99, 9.7%). Stavudine (d4T) was used in
35 patients (3.4%) only. In South Africa 2,339 (99.6%) of
patients started with a regimen that was in accordance with
guidelines, compared to 966 (95.1%) of patients in Switzer-
land. In Switzerland 45 patients (4.5%) received regimens that
may have been chosen because of primary resistance or as
part of a study, and five patients (0.5%) received regimens
that clearly violated guidelines.
Changes to First-Line Regimens
Changes to the initial regimen during the first 2 y of
HAART were considerably more frequent in Switzerland
than in South Africa: 539 patients (53.1%) compared to 514
patients (21.9%) experienced at least one change during the
first 2 y of HAART. Substitutions of one drug were the most
frequent change both in Switzerland (274, 50.8%) and South
Africa (328, 63.8%). Figure 1 shows rates of any type of
change during months 1–3, 4–6, 7–12, and 13–24 along with
the estimated cumulative probability of change, by reason for
changing regimens: toxicity, failure, or other reasons. The
cumulative probability of change at 2 y due to toxicity was
23.8% (95% CI 21.0%–26.7%) in Switzerland compared to
11.7% (95% CI 10.0%–13.5%) in Khayelitsha and Gugulethu.
In contrast, the probability of changes due to failure was
similar in Switzerland and South Africa: 5.1% (95% CI 3.7%–
6.8%) and 3.9% (2.5%–5.6%), respectively. In patients who
were switched for failure, the median log10 HIV viral load
values at the time of treatment switch due to failure was 4.4
log10 copies/ml in South Africa (n¼31) and 3.4 log10 copies/ml
in Switzerland (n ¼ 39) (p , 0.001 for difference). In South
Africa all patients who switched for failure had detectable
viral loads, whereas in Switzerland ten patients (29%) had
viral loads 500 copies/ml. An estimated 30.9% (95% CI
27.7%–34.1%) of patients had changed regimens for other
reasons in Switzerland compared to 14.1% (12.1%–16.3%) in
South Africa.
In both settings toxicity was the dominant reason for
treatment change in the first 3 mo, but rates were consid-
erably higher in Switzerland than in South Africa: 53 per 100
person-years (95% CI 44–63) compared to 21 per 100 person-
years (17–25). Other reasons dominated from month 4
onwards, again with higher rates of change in Switzerland.
Treatment failure as reason for drug changes was rare in both
settings. Table 2 compares reasons for regimen change in
more detail. For toxicity the most notable difference relates
to elevated lactate levels and lactic acidosis: in Khayelitsha
and Gugulethu 32 (13.4%) of all regimen changes due to
toxicities were due to lactic acidosis (associated with d4T in
31 patients). In the Swiss study no patient changed the initial
regimen due to elevated lactate levels. Treatment changes due
to abdominal and gastrointestinal toxicity, including liver
toxicity, were more common in Switzerland than in South
Table 1. Baseline Characteristics of Patients Starting HAART in Khayelitsha and Gugulethu, South Africa and the Swiss HIV Cohort Study
Category Subcategory South African Cohorts Swiss HIV Cohort
Patients, n — 2,348 1,016
Females, n (%) 1,663 (71%) 333 (33%)
Age, y, median (IQR) — 32.7 (28.5–38.2) 38.3 (31.7–46.1)
CD4 cell count, cells/ll, median (IQR) — 80 (30–138) 204 (122–291)
CD4 cell count, number missing (%) — 123 (5.2%) 50 (4.9%)
HIV-1 viral load, log10 copies/ml, median (IQR) — 5.1 (4.6–5.5) 5.0 (4.5–5.5)
HIV-1 viral load, number missing (%) — 288 (12.3%) 53 (5.2%)
Clinical stage: CDC stage C, WHO stage III/IV, n (%) — 2,126 (90.6%) 188 (18.5%)
Duration of follow-up (years)a, median (IQR) — 0.9 (0.5–1.5) 2.0 (1.1–2.0)
Number of patients starting HAART in year, n (%) 2001 79 (3.4%) 179 (17.6%)
2002 246 (10.5%) 204 (20.1%)
2003 509 (21.7%) 185 (18.2%)
2004–2006b 1,514 (64.5%) 448 (44.1%)
Initial HAART regimen, n (%) 2 NRTIs þ 1 NNRTI 2,339 (99.7%) 470 (46.3%)
2 NRTIs þ 1 PI 9 (0.4%) 449 (44.2%)
Other 0 97 (9.6%)
Four most commonly used initial HAART regimens, n (%) 3TC D4T EFV 918 (39.1%) —
3TC D4T NVP 780 (33.2%) —
3TC AZT EFV 425 (18.1%) —
3TC AZT NVP 216 (9.2%) —
3TC AZT EFV — 304 (29.9%)
3TC AZT LPV/r — 202 (19.9%)
3TC AZT NFV — 99 (9.7%)
3TC TNV EFV — 65 (6.4%)
Initial HAART regimens used to treat 95% of patients, n — 4 36
Patients using initial HAART regimens recommended by guidelines, % — 95.1 99.6
aCensored after 2 y.
bRecruitment not completed for the years 2005/06.
doi:10.1371/journal.pmed.0050148.t001
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Africa. Changes due to other reasons were also more frequent
in Switzerland. The predominant other reasons for changing
first-line regimens in South Africa were pregnancy and
tuberculosis. In Switzerland changes due to patient requests
were common.
Virologic Response, Rebound, CD4 Response, and
Mortality
The frequency of HIV-1 RNA measurements differed in the
two settings (Figure 2). The median time to the first HIV-1
RNA determination was 3.1 mo (interquartile range [IQR]
2.8–3.7 mo) in Khayelitsha and Gugulethu compared to 1.0
mo (0.7–1.5 mo) in the Swiss study. During follow-up HIV-1
RNA was measured at regular time intervals in South Africa
(median 3.9 mo, IQR 3.2–6.0 mo) whereas in Switzerland the
time intervals were not well defined (2.9 mo, 1.9–3.4 mo). A
similar picture was evident for CD4 counts (unpublished
data). Kaplan-Meier plots show that in both settings most
patients suppressed HIV-1 RNA to 500 copies/ml or less
(Figure 3, top graph) within one year: 96.0% (95% CI 95.1%–
96.9%) of patients in the townships and 95.5% (94.0%–
96.7%) in the Swiss cohort. The proportion of patients with
viral load values 500 copies/ml at different time points was
around 90% up to 2 y in both Switzerland and South Africa.
Among the 2,644 patients who suppressed viral replication
to 500 copies/ml (1,716 in South Africa and 928 in
Switzerland), the probability of a viral rebound at 2 y after
suppression was 25.5% (95% CI 22.1%–29.3%) in South
Africa and 27.1% (23.9%–30.7%) in Switzerland (Figure 3,
middle graph). When analyses were repeated with two
consecutive measurements above 500 copies/ml, the rate of
viral rebound was slightly higher in Switzerland than in South
Africa, which is expected considering the higher measure-
ment frequency in Switzerland. During the 2 y the median
CD4 count increased from 80 cells/ll at baseline (IQR 30–138)
to 372 cells/ll (260–497) in South Africa and from 204 cells/ll
(122–291) to 449 (310–607) in Switzerland. Patients starting
HAART with lower CD4 cell counts tended to have lower
values throughout the study period, both in South Africa and
Switzerland.
Mortality was substantially higher in South Africa than in
Switzerland during the first months of HAART (Figure 3,
bottom graph). Cumulative mortality at 6 mo was 8.6% (95%
CI 7.5%–9.8%) and 0.9% (0.5%–1.8%), respectively. The
proportion of patients lost to follow-up was similar: by 1 y,
3.5% (95% CI 2.5%–4.7%) of patients in Khayelitsha and
Gugulethu and 3.2% (2.2%–4.7%) of patients in the Swiss
cohort were lost to follow-up.
Univariable and Multivariable Analyses
The results from univariable and multivariable logistic and
Cox models comparing the South African cohorts with the
Swiss cohort are presented in Table 3. For the three
endpoints change from first-line regimen, virologic response
and viral rebound, adjusting the models for sex and age, CD4
cell count, HIV-1 RNA, and stage of disease at baseline had
only modest effects on HRs and ORs. The adjusted HRs
comparing South Africa with Switzerland for treatment
change due to failure, intolerance, and other reasons were
0.25 (95% CI 0.12–0.50), 0.44 (0.32–0.60), and 0.30 (0.22–0.40)
respectively, but there was little evidence for a difference in
virologic response and viral rebound (Table 3). In contrast,
HRs for the mortality endpoints were attenuated consider-
ably in multivariable analysis: the adjusted HRs were 5.90
(95% CI 1.81–19.21) during months 1–3 and 1.77 (0.90–3.50)
during months 4–24. The expected non-HIV-related mortal-
ity rate was 28.1 per 10,000 person-years in the South African
cohorts compared to 13.3 in the Swiss cohort, for a rate ratio
of 2.11 (95% CI 1.10–4.06).
Discussion
This comparative study of patients starting HAART in
South Africa and Switzerland found that the initial virologic
response was similar, despite profound differences in patient
Figure 1. Rates and Kaplan-Meier Plots of First Treatment Change Due to
Toxicity, Failure, and Other Reasons in Khayelitsha and Gugulethu, South
Africa and the Swiss HIV Cohort Study
Dots indicate rates during months 1–3, 4–6, 7–12, and 13–24 with 95%
CIs; lines indicate the estimated proportion of patients changing their
first-line regimen. ‘‘Other reasons’’ (bottom graph) include mainly
treatment changes due to tuberculosis and pregnancy in South Africa
and changes due to patients’ wishes or physicians’ decisions in
Switzerland.
doi:10.1371/journal.pmed.0050148.g001
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characteristics and the approach to antiretroviral therapy,
and different viral strains causing the epidemics in the two
countries. Compared to South Africa, about twice as many
changes to the treatment regimen were recorded in Switzer-
land during the first two years. Mortality was higher in South
Africa than in Switzerland, particularly during the first three
months of HAART.
Public Health and Individualised Approaches to HAART
In South Africa, where the prevalence of HIV-1 subtype C
infection in the general population is estimated at 19%, the
Department of Health published detailed treatment guide-
lines for adults and children in 2004 [6], with the objective of
providing access to all patients in need. All patients start a
regimen consisting of a recommended NRTI backbone and
either EFV or NVP. In December 2006, an estimated
1,000,000 people in South Africa needed HAART, and
325,000 were receiving it [5]. In contrast, in Switzerland the
prevalence of HIV-1 is below 1% and mainly of subtype B,
HAART is covered by the compulsory basic health insurance
package, and access is therefore universal. Care is highly
individualised and delivered by specialists in HIV medicine.
The choice of the initial regimen is influenced by several
factors, including convenience, viral resistance to treatment,
potential side effects, and physician and patient preferences.
In both countries the provision of HAART has been found to
be cost-effective from a health services and societal perspec-
tive [20–22].
Antiretroviral Anarchy?
There has been concern that unregulated use of antire-
troviral drugs, interruptions in drug supplies, and the lack of
monitoring of treatment response in sub-Saharan Africa
might lead to ‘‘antiretroviral anarchy’’ and the emergence of
viral resistance [23]. For example, in Abidjan, Côte d’Ivoire,
39 (57%) of 68 patients who had relied on friends or relatives
in Europe or the United States for antiretroviral drugs before
a HAART programme was established had mutations in their
Table 2. Reasons for Change of the First HAART Regimen in the First Two Years of Treatment in Khayelitsha and Gugulethu, South
Africa and the Swiss HIV Cohort Study
Reason Details South African Cohorts (n ¼ 514) Swiss Cohort (n ¼ 539)
Patients, n (%) Patients, n (%)
Toxicity Any 238 (46.3%) 220 (40.8%)
Peripheral neuropathy 46 (8.9%) 53 (9.8%)
Gastrointestinal, including liver 37 (7.2%) 64 (11.9%)
Haematological 36 (7.0%) 20 (3.7%)
Lactic acidosis 32 (6.2%) 0 (0%)
Hypersensitivitya 30 (5.8%) 34 (6.3%)
Lipodystrophy 6 (1.2%) 12 (2.2%)
Dislipidaemia 4 (0.8%) 5 (0.9%)
Nephrological 0 (0%) 7 (1.3%)
Not specified 47 (9.1%) 25 (4.6%)
Failure Virologic, immunologic, or clinical 31 (6.0%) 39 (7.2%)
Other —b 244 (47.5%) 257 (47.7%)
Unknown — 1 (0.2%) 23 (4.3%)
aAny type of hypersensitivity in Switzerland, rash in South Africa.
bIn South Africa ‘‘other’’ reasons mainly included contraindications related to tuberculosis or pregnancy (167 patients); in Switzerland physician decisions (including contraindications,
changes in guidelines, etc.; 107 patients) and patient requests (85 patients).
doi:10.1371/journal.pmed.0050148.t002
Figure 2. Frequency of Viral Load Measurements in Khayelitsha and
Gugulethu, South Africa and the Swiss HIV Cohort Study
The frequency was standardized to the total number of measurements in
each setting.
doi:10.1371/journal.pmed.0050148.g002
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virus associated with resistance to at least one drug [24].
Similar data were reported from Libreville, Gabon [25]. The
development of resistance is closely linked to incomplete
adherence to therapy, and several studies have shown that
good adherence can be achieved in resource-limited settings
[26–28]. The overall virologic response observed in this study
suggests that adherence was good in the two South African
townships (the delay in reaching viral load values below 500
copies/ml in South Africa is probably explained by the less-
frequent viral load determinations in the township cohorts
compared to Switzerland). Therefore, our results indicate
that antiretroviral anarchy has been prevented in township
ART programmes in South Africa.
In industrialized settings, a substantial proportion of new
infections now involve strains resistant to one or more drugs
[29]. Viral resistance is rare in South Africa at present [30],
but is bound to increase in the future. WHO monitors drug
resistance at sentinel sites in South Africa and elsewhere [3].
The use of single-dose NVP to prevent mother-to-child
transmission of HIV may increase resistance levels, but the
implications for treatment are a matter of debate and the
subject of ongoing studies [31].
Considering the large number of first-line regimens used in
Switzerland, and the high rate of changes to these regimens,
one might argue that antiretroviral anarchy may in fact be
more prevalent in Switzerland than in South Africa. However,
we found that 95% of patients used regimens that were in
accordance with the International AIDS Society–USA guide-
lines in place during this period. Few regimens violated the
current guidelines. Nevertheless, a more standardised ap-
proach to the choice of the first-line regimen and monitoring
of viral load could probably reduce costs in Switzerland
without compromising the effectiveness of HAART.
Treatment Changes
Treatment changes that were reported to be due to toxicity
in the first 3 mo of treatment were more frequent in
Switzerland than in South Africa, despite the fact that in
Switzerland more drugs, and more drugs with a more
favourable adverse effects profile, are available. The type of
toxicities leading to treatment changes were fairly similar in
the two settings, with the exception of symptomatic hyper-
lactataemia or lactic acidosis, which was recorded in 32
patients in South Africa but not observed in Switzerland. This
difference is not surprising in light of the widespread use of
stavudine in South Africa but not in Switzerland. In South
Africa few patients switched because of lipodystrophy,
despite the widespread use of stavudine, possibly because
follow-up was relatively short. Indeed, a previous analysis of
the Khayelitsha and Gugulethu cohorts showed that drug
substitutions due to lipodystrophy occurred mainly after the
first year of treatment [32]. We stress that our analysis was
restricted to treatment changes attributed to toxicities: we
did not assess the overall incidence of toxicities nor the
severity of adverse events.
Early Mortality
Patients in South Africa started therapy with much more
pronounced immunodeficiency than did those in Switzer-
land, reflecting the large number of patients in great need of
treatment during the scale-up of HAART in South Africa. In
line with a previous collaborative analysis [14], the higher
mortality in the South African townships was probably only
partly explained by lower CD4 cell counts and more advanced
clinical stage at treatment initiation. It seems likely that
specific comorbidities, including invasive bacterial and fungal
infections, are important in this context. For example, an
Figure 3. Kaplan Meier Plots of Virologic Response, Viral Rebound, and
Mortality in Khayelitsha and Gugulethu, South Africa and the Swiss HIV
Cohort Study
Viral rebound is defined as having a HIV-1 RNA .500 copies/ml after a
viral load 500 copies/ml.
doi:10.1371/journal.pmed.0050148.g003
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wnearlier analysis of the Gugulethu data showed that six (27%)
of the 22 deaths that occurred during the first 3 mo were due
to cryptococcal disease, with a clinical course suggestive of
immune reconstitution disease [33].
Unfortunately, causes of death are not recorded system-
atically in the South African cohorts. A study from rural
Uganda showed that a positive serum cryptococcal antigen
was associated with substantially increased early mortality
(adjusted relative risk 6.6; 95% CI 1.9–12.6) [34]. The
corresponding relative risk for active tuberculosis was 4.4
(95% CI 1.2–15.4) [34]. Clinical trials in South Africa and
elsewhere will help identify strategies to reduce mortality,
including, for example, trials of HAART initiation in HIV–TB
coinfected patients [35] and isoniazid preventive therapy in
patients receiving HAART [36]. Limited access to diagnostic
tests, procedures, and drugs to diagnose and treat opportun-
istic illnesses, including access to intensive care, may also have
contributed to the higher mortality in the South African
townships.
After the first few months of HAART, mortality was low in
both the South African and Swiss cohorts. The higher
mortality in South Africa during this period probably reflects
a higher (non-HIV-related) background mortality in South
Africa. This interpretation is supported by our comparison of
mortality in Switzerland with non-HIV-related mortality in
South Africa. South African national HAART programme
still bases its treatment guidelines on the 2002 WHO
guidelines, which recommend HAART only for patients with
WHO stage IV disease or a CD4 cell count of less than 200
cells/ll [37]. These recommendations were revised in 2003
and now state that in patients with WHO stage III disease,
treatment should be considered when the CD4 count is below
350 cells/ll and initiated before the CD4 count drops to below
200 cells/ll [38]. Recent analyses from Cape Town showed
high mortality before HAART is started or before a formal
AIDS diagnosis is made [39–41]. Taken together, there is
strong evidence that public health strategies to increase
access in South Africa should be further promoted. A recent
analysis of the Swiss cohort showed that in Switzerland, late
presentation is the reason for late initiation of HAART: once
the diagnosis is made, uptake of HAART is fast [42].
Strengths and Limitations of the Study
All patients in this study were treatment-naı̈ve at the start
of HAART, and results are therefore not affected by previous
antiretroviral therapy.
The two South African township programmes were part of
the first public HAART programmes in Southern Africa and
are typical of many sites involved in the scale-up of HAART
in this region. Scale-up is reflected in the rapid increase in
the number of patients starting therapy during the study
period. Our study did not, however, include the private sector
in South Africa, and no comparison has been made between
the overall quality of medical care to support HAART and
HIV disease management that is likely to have an important
impact on mortality. The SHCS was one of the first HIV
cohort studies worldwide [12], and it includes all major HIV
outpatient clinics as well as a number of large private
practices. It is estimated that about 40% of all patients with
HIV and about 70% of patients with AIDS are included [10].
A limitation of our study is that although the reasons for
changes in therapy were assessed prospectively, this was not
done using the same, standardised instrument and definitions
in South Africa and Switzerland. The attribution of the causes
for treatment change is further complicated by the fact that
causes are not independent: a patient might want to change
therapy due to side effects, or side effects can cause problems
with adherence, which then leads to treatment failure.
The rate of loss to follow-up was low: in both settings
patients who missed appointments were contacted and, if
required, traced. However, follow-up information for the
South African sites is limited due to the continuous scale-up:
i.e., the majority of patients were registered only recently and
were thus followed only over a short period of time. These
patients will, by definition, not be lost to follow-up.
Continued follow-up of patients in South Africa is needed
to allow comparisons of treatment responses over longer
periods of time.
Table 3. Unadjusted and Adjusted HRs and ORs for Study Endpoints, Comparing Khayelitsha and Gugulethu, South Africa, with the
Swiss HIV Cohort Study
Study Endpoints Number of Patients, South
Africa/Switzerland





or ORs (95% CI)
p-Value
First treatment changed 1,972/959 514/539 — — — —
First treatment change
due to failure
— 31/39 0.33 (0.20–0.53) ,0.001 0.25 (0.12–0.50) ,0.001
First treatment change
due to intolerance
— 238/220 0.43 (0.36–0.52) ,0.001 0.44 (0.32–0.60) ,0.001
First treatment change
due to other reasons
— 244/257 0.37 (0.31–0.45) ,0.001 0.30 (0.22–0.40) ,0.001
Viral suppressionb 1,175/810 1,074/735 1.09 (0.79–1.48) 0.61 1.14 (0.67–1.93) 0.63
Viral rebound 862/783 74/52 1.32 (0.91–1.91) 0.14 1.26 (0.68–2.31) 0.46
Mortality (months 1–3) 1,972/959 118/4 14.60 (5.39–39.54) ,0.001 5.90 (1.81–19.21) 0.003
Mortality (months 4–24) 1,823/912 85/23 2.61 (1.64–4.15) ,0.001 1.77 (0.90–3.50) 0.10
HRs are given for mortality and treatment change, ORs for initial viral response and viral rebound. The difference in the number of patients included in these analyses compared to the
total number of patients shown in Table 1 is explained by missing values in key variables.
aAnalyses were adjusted for sex, age, baseline CD4 cell count, baseline HIV viral load and stage of disease.
bHIV-1 RNA 500 copies/ml.
doi:10.1371/journal.pmed.0050148.t003
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A public-health approach to HAART provision using a
limited repertoire of drugs and relatively few viral load
measurements resulted in virologic treatment outcomes in
townships in South Africa that were similar to outcomes in
Switzerland. Our study also shows that many patients would
benefit from earlier initiation of therapy, particularly in
South Africa.
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Speck, P. Taffé, A. Telenti, A. Trkola, P. Vernazza, R. Weber, S. Yerly.
Author contributions. OK, ME, and AB designed the study. CO,
RW, HF, GvC, and AB collected data for the study and enrolled
patients. OK wrote the first draft of the paper, which was
subsequently revised by CO and ME. All authors contributed to the
final version of the paper. CO collected and entered all the data from
the South African Gugulethu site. ME, MWGB, BL, and AB advised on
the statistical analyses, which were done by OK. GvC represents the
Khayelitsha cohort collaboration team, which includes staff from
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Editors’ Summary
Background. Acquired immunodeficiency syndrome (AIDS) has killed
more than 25 million people since the first reported case in 1981, and
more than 30 million people are now infected with the human
immunodeficiency virus (HIV), which causes AIDS. HIV destroys immune
system cells (including CD4 cells, a type of lymphocyte), leaving infected
individuals susceptible to other infections. Early in the AIDS epidemic,
most HIV-infected people died within 10 years of becoming infected.
Then, in 1996, highly active antiretroviral therapy (HAART)—a combina-
tion of several antiretroviral drugs—was developed. Now, in resource-
rich countries, clinicians provide individually tailored care for HIV-
infected people by prescribing combinations of antiretroviral drugs
chosen from more than 20 approved medicines. The approach to
treatment of HIV in developed countries typically also includes frequent
monitoring of the amount of virus in patients’ blood (viral load), viral
resistance testing (to see whether any viruses are resistant to specific
antiretroviral drugs), and regular CD4 cell counts (an indication of
immune-system health). Since the implementation of these interven-
tions, the health and life expectancy of people with HIV has improved
dramatically in these countries.
Why Was This Study Done? The history of HIV care in resource-poor
countries has been very different. Initially, these countries could not
afford to provide HAART for their populations. In 2003, however,
governments, international agencies, and funding bodies began to
implement plans to increase HAART coverage in developing countries.
By December 2006, more than a quarter of the HIV-infected people in
low- and middle-income countries who urgently needed treatment were
receiving HAART. However, instead of individualized treatment, HAART
programs in developing countries follow a public-health approach
developed by the World Health Organization. That is, drug regimens,
clinical decision-making, and clinical and laboratory monitoring are all
standardized. This public-health approach takes into account the realities
of under-resourced health systems, but is it as effective as the
individualized approach? The researchers addressed this question by
comparing virologic responses (the effect of treatment on the viral load),
changes to first-line (initial) therapy, and deaths in patients receiving
HAART in South Africa (public-health approach) and in Switzerland
(individualized approach).
What Did the Researchers Do and Find? The researchers analyzed data
collected since 2001 from more than 2,000 patients enrolled in HAART
programs in two townships (Gugulethu and Khayelitsha) in Cape Town,
South Africa, and from more than 1,000 patients enrolled in the Swiss HIV
Cohort Study, a nationwide study of HIV-infected people. The patients in
South Africa, who had a lower starting CD4 cell count and were more
likely to have advanced AIDS than the patients in Switzerland, started
their treatment for HIV infection with one of four first-line therapies, and
about a quarter changed to a second-line therapy during the study. By
contrast, 36 first-line regimens were used in Switzerland and half the
patients changed to a different regimen. Despite these differences, the
viral load was greatly reduced within a year in virtually all the patients
and viral rebound (an increased viral load after a low measurement)
developed within 2 years in a quarter of the patients in both countries.
However, more patients died in South Africa than in Switzerland,
particularly during the first 3 months of therapy.
What Do These Findings Mean? These findings suggest that the public-
health approach to HAART practiced in South Africa is as effective in
terms of virologic outcomes as the individualized approach practiced in
Switzerland. This is reassuring because it suggests that ‘‘antiretroviral
anarchy’’ (the unregulated use of antiretroviral drugs, interruptions in
drug supplies, and the lack of treatment monitoring), which is likely to
lead to the emergence of viral resistance, is not happening in South
Africa as some experts feared it might. Thus, these findings support the
continued rollout of the public-health approach to HAART in resource-
poor countries. Conversely, they also suggest that a more standardized
approach to HAART could be taken in Switzerland (and in other
industrialized countries) without compromising its effectiveness. Finally,
the higher mortality in South Africa than in Switzerland, which partly
reflects the many patients in South Africa in desperate need of HAART
and their more advanced disease at the start of therapy, suggests that
HIV-infected patients in South Africa and in other resource-limited
countries would benefit from earlier initiation of therapy.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050148.
 The World Health Organization provides information about universal
access to HIV treatment (in several languages) and on its
recommendations for a public-health approach to antiretroviral
therapy for HIV infection
 More details on the Swiss HIV Cohort Study and on the studies in
Gugulethu and Khayelitsha are available
 Information is available from the US National Institute of Allergy and
Infectious Diseases on HIV infection and AIDS
 HIV InSite has comprehensive information on all aspects of HIV/AIDS,
including detailed information about antiretroviral therapy and links to
treatment guidelines for various countries
 Information is available from Avert, an international AIDS charity, on
HIV and AIDS around the world and on providing AIDS drug treatment
for millions
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Olivia Keiser, Catherine Orrell, Matthias Egger, Robin Wood, Martin W. G. Brinkhof, Hansjakob Furrer, Gilles van Cutsem, 
Bruno Ledergerber, Andrew Boulle, for the Swiss HIV Cohort Study (SHCS) and the International Epidemiologic Databases to 
Evaluate AIDS in Southern Africa (IeDEA-SA)
Correction for:
Keiser O, Orrell C, Egger M, Wood R, Brinkhof MWG, et al. (2008) Public-health and individual approaches to antiretroviral 
therapy: Township South Africa and Switzerland compared. PLoS Med 5(7): e148. doi:10.1371/journal.pmed.0050148
The Table 1 originally published with this manuscript stated that 95.1% of the patients from South Africa used regimens 
recommended by guidelines, compared to 99.6% in the Swiss cohort. This is incorrect: the figures have been reversed. As the 
article text makes clear, 95.1% of the Swiss patients used regimens recommended by guidelines, compared to 99.6% in the 
South African cohorts.
A corrected version of Table 1 is published here.
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Received: August 13, 2008; Accepted: August 13, 2008; Published: September 30, 2008.
Copyright: © 2008 Keiser et al. This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited.
Table 1. Baseline Characteristics of Patients Starting HAART in Khayelitsha and Gugulethu, South Africa and the Swiss HIV 
Cohort Study
Category Subcategory South African Cohorts Swiss HIV Cohort
Patients, n — 2,348 1,016
Females, n (%) 1,663 (71%) 333 (33%)
Age, y, median (IQR) — 32.7 (28.5–38.2) 38.3 (31.7–46.1)
CD4 cell count, cells/µl, median (IQR) — 80 (30–138) 204 (122–291) 
CD4 cell count, number missing (%) — 123 (5.2%) 50 (4.9%)
HIV-1 viral load, log
10
 copies/ml, median (IQR) — 5.1 (4.6–5.5) 5.0 (4.5–5.5) 
HIV-1 viral load, number missing (%) — 288 (12.3%) 53 (5.2%)
Clinical stage: CDC stage C, WHO stage III/IV, n (%) — 2,126 (90.6%) 188 (18.5%)
Duration of follow-up (years)a, median (IQR) — 0.9 (0.5–1.5) 2.0 (1.1–2.0)
Number of patients starting HAART in year, n (%) 2001 79 (3.4%) 179 (17.6%)
2002 246 (10.5%) 204 (20.1%)
2003 509 (21.7%) 185 (18.2%)
2004–2006b 1,514 (64.5%) 448 (44.1%)
Initial HAART regimen, n (%) 2 NRTIs + 1 NNRTI 2,339 (99.7%) 470 (46.3%)
2 NRTIs + 1 PI 9 (0.4%) 449 (44.2%)
Other 0 97 (9.6%)
Four most commonly used initial HAART regimens, n (%) 3TC D4T EFV 918 (39.1%) —
3TC D4T NVP 780 (33.2%) —
3TC AZT EFV 425 (18.1%) —
3TC AZT NVP 216 (9.2%) —
3TC AZT EFV — 304 (29.9%)
3TC AZT LPV/r — 202 (19.9%)
3TC AZT NFV — 99 (9.7%)
3TC TNV EFV — 65 (6.4%)
Initial HAART regimens used to treat 95% of patients, n — 4 36
Patients using initial HAART regimens recommended by 
guidelines, %
— 99.6 95.1
aCensored after 2 y.











EPIDEMIOLOGY AND SOCIAL SCIENCE
Expanding Antiretroviral Options in Resource-Limited
Settings—A Cost-Effectiveness Analysis
Eran Bendavid, MD,*† Robin Wood, MD,‡ David A. Katzenstein, MD,†
Ahmed M. Bayoumi, MD, MSc,§k and Douglas K. Owens, MD, MS*¶
Background: Current World Health Organization (WHO) guide-
lines for treatment of HIV in resource-limited settings call for 2
antiretroviral regimens. The effectiveness and cost-effectiveness of
increasing the number of antiretroviral regimens is unknown.
Methods: Using a simulation model, we compared the survival and
costs of current WHO regimens with two 3-regimen strategies:
an initial regimen of 3 nucleoside reverse transcriptase inhibitors
followed by the WHO regimens and the WHO regimens followed by
a regimen with a second-generation boosted protease inhibitor (2bPI).
We evaluated monitoring with CD4 counts only and with both CD4
counts and viral load. We used cost and effectiveness data from Cape
Town and tested all assumptions in sensitivity analyses.
Results: Over the lifetime of the cohort, 25.6% of individuals failed
both WHO regimens by virologic criteria. However, when patients
were monitored using CD4 counts alone, only 6.5% were prescribed
additional highly active antiretroviral therapy due to missed and
delayed detection of failure. The life expectancy gain for individuals
who took a 2bPI was 6.7–8.9 months, depending on the monitoring
strategy. When CD4 alone was available, adding a regimen with
a 2bPI was associated with an incremental cost-effectiveness ratio of
$2581 per year of life gained, and when viral load was available, the
ratio was $6519 per year of life gained. Strategies with triple–
nucleoside reverse transcriptase inhibitor regimens in initial therapy
were dominated. Results were sensitive to the price of 2bPIs.
Conclusions: About 1 in 4 individuals who start highly active
antiretroviral therapy in sub-Saharan Africa will fail currently
recommended regimens. At current prices, adding a regimen with
a 2bPI is cost effective for South Africa and other middle-income
countries by WHO standards.
(J Acquir Immune Defic Syndr 2009;00:000–000)
INTRODUCTION
Africa is home to more than 20 million HIV-infected
individuals, two thirds of all new infections, and three quarters
of all HIV-related deaths.1 By the end of 2007, more than
2 million people have initiated highly active antiretroviral
therapy (HAART) in sub-Saharan Africa and access to
treatment continues to expand.2 However, HIV treatment in
publicly funded programs in sub-Saharan Africa is restricted
to 2 regimens.3,4 The World Health Organization (WHO)
provides no guidelines beyond second-line therapy, and
individuals who fail or cannot tolerate first-line and second-
line regimens do not have access to further antiretroviral
treatment options.4 In contrast, 6 different classes of anti-
retrovirals are available in developed countries yielding
multiple possible regimens for patients who fail initial
therapy.5–7 The growing experience with treatment of drug-
resistant infections may make new regimens in resource-
limited settings feasible.8
The first-line HAART regimen recommended for low-
income and middle-income countries includes a backbone of
2 nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs)
with a nonnucleoside reverse transcriptase inhibitor (NNRTI),
either nevirapine or efavirenz. The second-line regimen includes
2 similar but not identical NRTIs with a boosted protease
inhibitor (bPI) such as lopinavir/ritonavir.4 Previous studies
evaluated the effectiveness and cost-effectiveness of 2-regimen
strategies for Africa,9,10 but to date, no evaluation of strategies
employing additional HAART regimens has been done. We
evaluated strategies where the current treatment guidelines are
expanded to 3 lines of treatment. In addition, we examine the
relationship of treatment monitoring to antiretroviral strategies.
Recent studies examined the role of monitoring for the current
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2-regimen strategies,11,12 but the importance of monitoring
when using an expanded range of HAART regimens has not
been studied. As experience with HAART continues to expand
in Africa, additional treatment options are needed. This work
will help in planning for the next phase of antiretroviral therapy
options in sub-Saharan Africa.
METHODS
Overview
We developed a mathematical simulation model of the
clinical course of HIV-infected individuals who present to care
in South Africa (see Supplementary Appendix for more
details). We compared the effectiveness and costs of 3
alternative HAART strategies: (1) the World Health Organ-
ization’s (WHO) 2-regimen strategy, (2) a triple-NRTI regimen
followed by the WHO regimens, and (3) the WHO regimens
followed by a second-generation bPI–based regimen. We only
examined regimens that are as easy to administer as the
currently available regimens used in sub-Saharan Africa: oral
regimens, simple dosing, and little or no requirement for
refrigeration (Table 1). We followed each person’s health in
1-month increments, though clinical and laboratory data were
only available to the patient’s clinician during routinely
scheduled clinic visits, or sooner for acute events.
Treatment and Monitoring Strategies
We evaluated 3 HAART strategies, 1 with 2 lines of
treatment and 2 with 3 lines (Table 1). The 2-line WHO
strategy (a) included a regimen with 2 NRTIs plus an NNRTI
followed by a regimen with a different combination of NRTIs
and a bPI.4 The second strategy (b) started with a triple-NRTI
regimen followed by 2 regimens similar to the WHO strategy,
and the third strategy (C) consisted of the WHO sequence
followed by a regimen containing a second-generation bPI.
Strategies B and C are realistic in resource-limited
settings for clinical and practical reasons. Triple-NRTI
regimen hold several advantages as initial therapy in
resource-limited regions: they are inexpensive, have relatively
low pill burden, avoid important drug interactions, and spare
both NNRTIs and PIs, thus maintaining the effectiveness of
both drug classes for subsequent regimens. Although initial
therapy with triple-NRTI regimens have higher failure rates
than initial therapy with NNRTI or bPI, triple-NRTI regimens
have been studied in both clinical and cohort trials in
Africa.20,24,25 A third-line regimen with a second-generation
bPI is also reasonable, especially after failure of a regimen
with first-generation bPI. Easy dosing, side-effect profile
comparable to first-generation bPIs, increasing clinical
experience, and decreasing costs make this regimen a real
possibility for sub-Saharan Africa.23,26
The data on rates of failure were taken from cohort and
clinical trials (Table 1). Previous estimates of failure rates vary
widely based on the clinical setting, definition of failure,
existing or new drug resistance mutations, and multiple
determinants of adherence, including pill burden, funding
source for antiretrovirals, and adherence counseling.27–31 Most
of the available data on treatment failure come from trials
which enrolled individuals with HIV subtype B, a rare clade
in southern Africa. However, there is no evidence that
antiretroviral activity is significantly altered in non–subtype B
viruses that predominate in southern Africa.32 For the base
case estimates, we used data from South Africa, followed by
data from other sub-Saharan cohort studies, and non-African
trials where no other data were available (Table 2). Due to the
uncertainty in the estimates, we varied the rates of virologic
failure broadly to examine how uncertainty changes the
effectiveness and cost-effectiveness of the strategies.
We tested strategies where CD4 counts alone or in
combination with viral load were available for patient
monitoring. Viral load monitoring is relatively expensive
and rarely available in Africa, although there is interest in
increasing viral load capacity with the scale-up on HAART as
it is the most direct virologic measure of treatment failure.49
TABLE 1. Antiretroviral Regimen Strategies
Regimen
Suppressed
at 1 yr Range Sources
Strategy A: current WHO guidelines
Regimen 1: 2 NRTIs + NNRTI (based on AZT + 3TC + NVP or EFV) 85 60–90 Boulle et al,13 Orrell et al,14 Calmy15
Regimen 2: 2 NRTIs + PI/r (based on TDF + 3TC + LPV/r) 70 50–80 De Mendoza et al,16 Kaufmann et al,17
Robbins et al18
Strategy B: initial triple-NRTI regimen
Regimen 1: 3 NRTIs (based on AZT + 3TC + ABC) 60 40–70 Staszewski et al,19 DART,20 Srikantiah et al21
Regimen 2: 2 NRTIs + NNRTI (based on TDF + 3TC + NVP or EFV) 80 50–90 Gulick et al22
Regimen 3: 2 NRTIs + PI/r (based on TDF + 3TC + LPV/r) 70 50–80 De Mendoza et al,16 Kaufmann et al,17
Robbins et al18
Strategy C: third regimen with second-generation PI
Regimen 1: 2 NRTIs + NNRTI (based on AZT + 3TC + NVP or EFV) 85 60–90 Boulle et al,13 Orrell et al,14 Calmy15
Regimen 2: 2 NRTIs + PI/r (based on TDF + 3TC + LPV/r) 70 50–80 De Mendoza et al,16 Kaufmann et al,17
Robbins et al18
Regimen 3: 2 NRTIs + second-generation PI/r (based on TDF + 3TC + DNV/r) 60 30–75 Madruga et al23
3TC, lamivudine; ABC, abacavir; AZT, zidovudine; DNV/r, ritonavir-boosted darunavir; EFV, efavirenz; LPV/r, ritonavir-boosted lopinavir; NVP, nevirapine; PI/r, ritonavir-boosted
protease inhibitor; TDF, tenofovir.
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TABLE 2. Estimates for Model Variables
Variable Base Case Range Source
Demographic variables
Age at presentation (mean 6 SD) 33 6 9 — Holmes et al,33 Badri et al34
Male 60% 50%–70% Holmes et al,33 et al,35
Orrell et al30
CD4 at presentation, cells/mL (mean 6 SD) 307 6 227 Holmes et al,33 Badri et al34
Viral load at presentation, log copies/mL (mean 6 SD) 5.0 6 0.8 Badri et al36
Disease progression variables
Decline in CD4 (cells/mL /mo), viral load .105 Holmes et al,33 Mellors et al,37
Rodriguez et al,38 Ledergerber39
Baseline CD4 .500 cells/mL 5.9 650%
Baseline CD4 351–500 cells/mL 3.8 650%
Baseline CD4 201–350 cells/mL 2.6 650%
Baseline CD4 ,200 cells/mL 2.0 650%
Decline in CD4 (cells/mL/mo), viral load 103–105 Holmes et al,33 Mellors et al,37
Rodriguez et al,38 Ledergerber39
Baseline CD4 .500 cells/mL 3.9 650%
Baseline CD4 351–500 cells/mL 2.6 650%
Baseline CD4 201–350 cells/mL 1.7 650%
Baseline CD4 ,200 cells/mL 1.3 650%
Monthly probability of developing severe opportunistic





.350 cells/mL Holmes et al33
Oral candidiasis 3.50 2.04 1.26 0.57
Chronic diarrhea 2.00 0.49 0.18 0.00
Esophageal candidiasis 1.46 0.34 0.09 0.06
Wasting syndrome 1.29 0.23 0.02 0.00
Severe bacterial 1.15 0.04 0.03 0.00
Pulmonary TB 1.15 0.71 0.47 0.11
Extrapulmonary TB 0.98 0.47 0.18 0.05
PCP 0.67 0.05 0.02 0.00
CMV 0.52 0.07 0.02 0.00
Cryptococcal meningitis 0.52 0.05 0.00 0.00











Risk of virologic failure Table 1
Harm from discontinuation of a
nonsuppressive regimen
Deeks et al40
Drop in CD4, cells/mL 128
Rise in viral load set point, log copies/mL 0.8
Risk of regimen change or discontinuation
due to toxicity, %/mo
AZT + 3TC + ABC 0.3 0.1–0.5 DART,20 Munderi and DART41
AZT + 3TC + NVP or EFV 0.5 0.3–0.7 Orrell et al,14 Boulle et al13
TDF + 3TC + LPV/r 0.3 0.1–0.5 Amoroso,42 Calmy15
TDF + 3TC + DNV/r 0.5 0.3–0.7 Madruga et al,23 Clotet et al26
Utilization and cost variables
Annual inpatient cost (US $2007) Badri et al,43 Govender et al,44
Cleary et al,45 Thomas et al46
(continued on next page)
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Failure was defined as 2 successive measurements above 1000
copies per microliter.14 When CD4 counts only were available,
a decline to half the highest measured CD4 count after an
initial response was considered failure and prompted a regimen
change.4 Although the WHO currently recommends treatment
initiation at 200 cells per microliter, recent evidence and
ongoing trials are favoring earlier treatment initiation; thus in
our model, treatment was initiated at a CD4 threshold of 200–
350 cells per microliter.53,54
Disease Progression
The disease model is described in the Supplementary
Appendix and elsewhere.11 The principal determinants of short
term mortality were the CD4 counts and development of
severe opportunistic diseases.35 The CD4 counts changed
according to HAART regimen, duration of treatment, CD4 at
the start of treatment, age, viral load, and opportunistic
diseases (Table 2). We modeled the incidence of AIDS-
defining opportunistic diseases based on clinical experience
in Cape Town and estimated their contribution to mortality,
utilization of resources, and costs separately.33,43
Costs and Benefits
We included all direct costs of HIV care: inpatient,
outpatient, HAART, and monitoring costs. Inpatient and
outpatient costs were derived from costing studies in Cape
Town, and costs of HAARTwere taken from published sources
and estimated at the lowest available price in US $2007.
Second-generation bPI are rarely available in South Africa,
and we used expected prices for low-income and middle-
income countries.48 We measured the cost-effectiveness as the
ratio of the incremental costs to the incremental benefits of
each strategy compared with the next least cost-effective
strategy in US $2007 per year of life gained. We adopted
a societal perspective, although some indirect costs were
excluded as we assumed that they would be equivalent
between strategies. We discounted all costs and benefits at
3% annually.
Sensitivity Analysis
In sensitivity analysis, we varied the rates of virologic
failure to reflect uncertainty in published estimates. We also
varied several important cost parameters that are expected to
change. Specifically, bPIs are likely to become less
expensive due to entry of additional drugs and continued
price negotiations; and viral load monitoring is increasingly
affordable due to cheaper technologies, durable measure-
ment devices, and improving infrastructure.55 We performed
a probabilistic sensitivity analysis where we specified
distributions for model parameters and employed a Monte
Carlo simulation to sample from these distributions. We
used the results to calculate confidence intervals (CIs)
around our incremental cost-effectiveness ratio estimates.56
Additional details on the distributions used is in the
Supplementary Appendix.
RESULTS
We estimate that over the lifetime of the cohort, 25.6%
of individuals would experience virologic failure of WHO’s
TABLE 2. (continued ) Estimates for Model Variables
Variable Base Case Range Source
No AIDS on HAART 255 230–282
AIDS on HAART 483 386–596
No AIDS off HAART 887 839–939
AIDS off HAART 3632 3304–3985
Annual outpatient cost Badri et al,43 Govender et al,44
Cleary et al45
No AIDS on HAART 316 305–328
AIDS on HAART 276 248–308
No AIDS off HAART 158 149–203
AIDS off HAART 240 207–277
Annual cost of HAART regimens (US $2007) Medicines Sans Frontiers,47,48
Badri et al43
3 NRTIs (based on AZT + 3TC + ABC) 548
2 NRTIs + NNRTI (based on AZT + 3TC
+ NVP or EFV)
199
2 NRTIs + PI/r (based on TDF + 3TC
+ LPV/r)
737
2 NRTIs + second-generation PI/r (based on
TDF + 3TC + DNV/r)
1,332
Cost of CD4 test (US $2007) 15 10–25 Badri,43 Zijenah et al50
Cost of viral load test (US $2007) 45 15–75 Rouet and Rouzioux,51
Calmy et al52
3TC, lamivudine; ABC, abacavir; AZT, zidovudine; DNV/r, ritonavir-boosted darunavir; EFV, efavirenz; LPV/r, ritonavir-boosted lopinavir; NVP, nevirapine; PI/r, ritonavir-boosted
protease inhibitor; TDF, tenofovir.
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first-line and second-line regimens. All individuals with
virologic failure who remained in care were detected where
viral load monitoring was available. However, where CD4
monitoring alone was available, treatment failure based on
immunologic criteria was detected in only 6.5% of the cohort.
Monitoring individuals with CD4 counts alone led to lower
rates of detecting treatment failure primarily due to the
insensitivity of immunologic criteria for detecting virologic
failure.57 In addition, monitoring CD4 counts only was
associated with a delay of 16.1 months on average in detecting
failure. This, in turn, was associated with higher rates of
mortality (Table 3) and decreasing the opportunities for
detecting treatment failure.
HAART Strategies With CD4 Monitoring
Where CD4 alone was used to monitor treatment
success, the base strategy (a) was associated with a discounted
life expectancy of 78.7 months and lifetime costs of $6299
from the time of presentation to care. In comparison, the
strategy with a triple NRTI as initial therapy (b) was
dominated; that is, it decreased life expectancy and increased
costs (Fig. 1). The strategy where a second-generation bPI was
used as a third regimen (c) was associated with an increase in
life expectancy of 18 discounted days and an increase in
lifetime costs of $124, an incremental cost effectiveness ratio
of $2581 per year of life gained (95% CI 2044 to 3006, using
probabilistic sensitivity analysis). Only 6.5% of the population
were placed on third-line HAART in strategy C, but the life
expectancy of individuals who utilized additional HAART
in that strategy was, on average, 8.9 discounted (14.9
undiscounted) months longer than the equivalent population
in the WHO strategy (A). The gains in life expectancy were
associated with an overall reduction in the incidence of severe
opportunistic diseases (Table 3).
HAART Strategies With Viral Load Monitoring
When viral load monitoring was available, the WHO
strategy was associated with a discounted life expectancy of
81.0 months and a lifetime cost of $7645. Compared with the
WHO strategy, adding a regimen with a second-generation bPI
(c) was associated with a gain in life expectancy of 1.6 months
and additional $881 in lifetime costs, an incremental cost-
effectiveness ratio of $6519 per year of life gained (95% CI
5673 to 8129). The cost of HAART alone was $873 higher in
strategy C compared with the WHO strategy. Strategy C was
associated with a lower incidence of severe opportunistic
diseases, 9.7 per 100 patient-years, compared with 10.9 per
100 patient-years in the WHO strategy. With viral load
monitoring, 25.6% of individuals were eligible for third-line
treatment under strategy C. The life expectancy of those who
were placed on a second-generation bPI was 10.4 undis-
counted months longer than the equivalent population in the
WHO strategy. Strategy B was dominated by extended
dominance. That is, it was more costly and less effective than




Rates of failure vary widely based on the HAART
regimen, geography, clinical setting (eg,. trial or cohort) and
individual treatment history. For that reason, we varied the
rates of virologic suppression to reflect a broad range of
uncertainty. Decreasing the rates of virologic failure from
highest to lowest was associated with an average increase in
life expectancy of 5.6 months across all strategies (range 4.9–
6.1 months). Decreasing rates of virologic failure were also
associated with a less attractive incremental cost-effectiveness
ratio of additional HAART regimens. With viral load
monitoring, the incremental cost effectiveness ratio of strategy
C compared with the WHO strategy varied from $12,098 to
$5178 per life-year gained as the rate of virologic failure varied
from lowest to highest rate. Thus, the value adding an effective
third-line HAART regimen is greatest where rates of failure are
relatively high (Fig. 2).
Cost Implications
We varied several cost parameters to examine the
implications as drug and diagnostic technologies are in-
creasingly affordable. Specifically, we varied the costs of
second-generation bPIs and the cost of viral load testing.








Rate of ODs (per 100
Patient-Years)†
Incremental Cost-Effectiveness
Ratio ($/Year of Life Gained)
CD4 counts only available
A 78.7 6299 NA 11.7 —
B 76.1 6892 18.1 12.8 Dominated†
C 79.3 6423 6.5 10.9 2581
Viral loads available
A 81.0 7645 NA 10.9 —
B 81.1 8006 30.3 11.3 Dominated by extended dominance†
C 82.6 8526 25.6 9.7 6519
ODs, opportunistic diseases.
*The letter refers to the strategies listed in Table 1(A, 2 regimens; B, 3 regimens with triple NRTI as initial therapy; and C, 3 regimens with second-generation PI).
†Dominated strategies had at least 1 other strategy that was more effective and less costly than the dominated strategy. Extended dominance means that some blend of 2 strategies was
more effective and less costly than the dominated strategy.
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When the annual cost of a second-generation bPI dropped
below $540, strategy C with CD4 count monitoring dominated
the WHO strategy. That is, it saved costs and improved
outcomes relative to the WHO strategy. Reducing the cost of
viral load monitoring from $75 to $15 per test decreased the
incremental cost-effectiveness ratio of adding a second-
generation bPI to $5427 per life-year gained. Figure 2 shows
the effect of reducing the cost of viral load monitoring on the
incremental cost-effectiveness ratio of strategy C compared
with the WHO strategy.
Probabilistic Sensitivity Analysis
In probabilistic sensitivity analysis, we examined the
joint effect of parameter uncertainty. The analysis was repeated
1000 times, and we used the results to obtain CIs for our
estimates. Our 95% confidence bounds for the portion of the
population who had virologic failure to WHO’s first and
second line were 23.4% to 28.8%. In our analysis, the strategy
where a triple NRTI was used in initial regimen with CD4
count monitoring was dominated in 88% of the scenarios, we
simulated and it never dominated the WHO strategy.
DISCUSSION
We analyzed the benefits, costs, and cost-effectiveness
of adding HAART regimens for resource-limited settings
using data from South Africa. We show that adding an
effective third antiretroviral regimen could provide substantial
benefits for those who fail first-line and second-line therapy.
Our estimates suggest that individuals who fail both existing
regimens may gain between 6.7 and 8.9 months of life with
third-line HAART. Although at most a quarter of the infected
population could derive benefit from an effective third line, we
estimate that that is sufficient to improve the average life
expectancy of the entire infected population by 0.6–1.6
months, depending on the monitoring technology. Our
estimates of the need for additional regimens, which suggest
that the current recommended regimens will provide adequate
lifelong benefits for about three quarters of the infected
population on HAART, are consistent with recent evidence
showing low rates of failure in low-income countries.58
The WHO and World Bank suggest that interventions
with an incremental cost-effectiveness ratio less than 3 times
the gross domestic product (GDP) per capita represent good
value.59,60 By that criteria, adding a third-line regimen based
on a second-generation bPI to the existing WHO regimens
should be acceptable in South Africa. Although the in-
cremental cost-effectiveness ratio is higher with viral load
monitoring (due to higher HAART and monitoring costs),
adding a third regimen may be acceptable in countries with an
annual per capita GDP above $2000. Further reductions in the
price of second-generation bPIs will improve the cost-
effectiveness of adding a third regimen and may be cost
saving below $540 per year.
Our analysis, however, suggests that adding a less
efficacious first-line regimen may worsen outcomes where viral
load monitoring is not available. When methods for timing of
regimen change are associated with a significant delay, such as
when using CD4 counts, adding an initial regimen with rates of
failure higher than subsequent regimens may lead to worse
FIGURE 1. Health and cost outcomes of alternative HAART
regimens. Life expectancy and lifetime costs of alternative
HAART strategies. Letters correspond to strategies in Table 1.
(A, 2 regimens; B, 3 regimens with triple NRTI as initial therapy;
C, 3 regimens with second-generation bPI). Monitoring
strategy is represented as either CD4 counts only (CD4) or
CD4 and viral loads (VL). Strategy B is strictly dominated when
only CD4 counts are available (it is more costly and less
effective than other strategies) and dominated by extended
dominance when viral loads are available (it is more costly and
less effective than some combination of A and C). Solid lines
connect the cost-effective strategies within a given monitoring
strategy and the dotted lines connect the cost-effective
strategies regardless of monitoring strategy.
FIGURE 2. Effect of failure rates and viral load cost on cost-
effectiveness of a third-HAART regimen. The incremental cost-
effectiveness ratio of strategy C compared with the WHO
strategy with viral load monitoring as a function of rates of
failure and price of viral load monitoring. With lower rates of
failure, fewer people require advanced HAART regimens, and
the incremental benefits of those regimens diminishes, making
the incremental cost-effectiveness ratio higher. The incremen-
tal cost-effectiveness ratio depends on the per test cost of viral
load monitoring.
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outcomes. Although preserving drug classes has intuitive
appeal, the delay in diagnosis of treatment failure without viral
load monitoring led to additional opportunistic diseases and
higher mortality in our study. Even when viral load monitoring
is available, we estimate that the cost-effectiveness of adding an
initial triple-NRTI regimen is not as cost effective as adding
a second-generation bPI as a third regimen.
We also show the importance of preventing virologic
failure in improving patient outcomes. The variability in the
rates of failure reported in the literature may be attributed
to clinical practices and behavioral factors. Taking HAART
regularly is directly related to maintaining virologic suppres-
sion, and our study suggests that HAART outcomes improve
substantially with lower rates of failure. We find that the
relative value of additional HAART regimens is highest where
the rates of failure are also high.
Use of CD4 counts to determine when to initiate
HAART in resource-limited settings improves life expectancy
substantially and may reduce costs.11 Here we highlight
several important roles which viral load monitoring plays. It is
the preferred method for timing regimen change: it is more
accurate than using CD4 counts for determining treatment
failure and leads to a significantly shorter lag in diagnosis and
fewer opportunistic diseases. The findings in our analysis
dovetail with increasing evidence about the inaccuracy of
using CD4 count monitoring alone for determining treatment
failure.57,61 In addition, the benefits of viral load monitoring
are greater with more complex treatment options. However,
substantial expenditures, lack of infrastructure, and shortage
of skilled labor needed for viral load monitoring may continue
to be a barrier in many places.
Our model has several important limitations. We
estimate rates of virologic failure and medication toxicities
from clinical trials and cohort trials. Most of those were done
in sub-Saharan Africa on non–HIV subtype B, but where no
estimates were available from our region of interest, we used
data from developed countries. In addition, available data on
the effectiveness of sequential regimens is sparse, and our
estimates are partly based on conditional predictions. We also
do not account for rates of loss to follow-up, which some
suggest may be lower where diagnostic monitoring and
medical care is more extensive. Finally, it is also possible that
the pathways to resistance of non–HIV subtype B may differ
from reported experience. For all these reasons, we vary the
rates of failure across a wide range and indicate the limitations
of our estimates.
As access to HIV treatment continues to expand across
sub-Saharan Africa, where over 20 million are infected and
thousands are started on treatment weekly, the number of
people who will fail the existing regimens will continue to
increase. We suggest that offering additional effective
regimens provide substantial benefits to individuals who fail
existing therapies, is cost effective in many parts of southern
Africa where CD4 count monitoring is available, and may be
cost saving with substantial price reductions of second-
generation bPIs. Our analysis also shows that reducing
treatment failure is an effective way to minimize the need
for additional regimens and maximize the benefits of the
regimens that are currently available.
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Abstract
Background: The new 2010 World Health Organization (WHO) HIV treatment guidelines recommend earlier antiretroviral
therapy (ART) initiation (CD4,350 cells/ml instead of CD4,200 cells/ml), multiple sequential ART regimens, and replacement
of first-line stavudine with tenofovir. This paper considers what to do first in resource-limited settings where immediate
implementation of all of the WHO recommendations is not feasible.
Methods and Findings: We use a mathematical model and local input data to project clinical and economic outcomes in a
South African HIV-infected cohort (mean age = 32.8 y, mean CD4 = 375/ml). For the reference strategy, we assume that all
patients initiate stavudine-based ART with WHO stage III/IV disease and receive one line of ART (stavudine/WHO/one-line).
We rank—in survival, cost-effectiveness, and equity terms—all 12 possible combinations of the following: (1) stavudine
replacement with tenofovir, (2) ART initiation (by WHO stage, CD4,200 cells/ml, or CD4,350 cells/ml), and (3) one or two
regimens, or lines, of available ART. Projected life expectancy for the reference strategy is 99.0 mo. Considering each of the
guideline components separately, 5-y survival is maximized with ART initiation at CD4,350 cells/ml (stavudine/,350/ml/
one-line, 87% survival) compared with stavudine/WHO/two-lines (66%) and tenofovir/WHO/one-line (66%). The greatest life
expectancies are achieved via the following stepwise programmatic additions: stavudine/,350/ml/one-line (124.3 mo),
stavudine/,350/ml/two-lines (177.6 mo), and tenofovir/,350/ml/two-lines (193.6 mo). Three program combinations are
economically efficient: stavudine/,350/ml/one-line (cost-effectiveness ratio, US$610/years of life saved [YLS]), tenofovir/
,350/ml/one-line (US$1,140/YLS), and tenofovir/,350/ml/two-lines (US$2,370/YLS).
Conclusions: In settings where immediate implementation of all of the new WHO treatment guidelines is not feasible, ART
initiation at CD4,350 cells/ml provides the greatest short- and long-term survival advantage and is highly cost-effective.
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The 2006 World Health Organization (WHO) guidelines on
antiretroviral therapy (ART) established a worldwide standard of
care for patients with HIV infection [1]. Since this publication,
new evidence has emerged on how to treat patients infected with
HIV, and this evidence formed the basis for the WHO 2010 ART
guidelines update [2]. These revisions aim to better align global
standards with those already adopted in well-resourced countries
[3,4]. Specifically, revised guidelines recommend an increased
number of sequential ART regimens, routinely available CD4
count monitoring, earlier ART initiation thresholds
(CD4,350 cells/ml versus CD4,200 cells/ml), and replacement
of stavudine with the less-toxic drug tenofovir.
As WHO expands treatment recommendations, many countries
in resource-limited settings still struggle to implement 2006
guidelines [5]. In Malawi, for example, most HIV disease is
monitored clinically; CD4 count monitoring is limited to pregnant
women and children [6,7]. In South Africa, ART is available to
only 22%–36% of those reported to be in need [8]. In settings
confronted with numerous new recommendations, not all of which
are immediately feasible, the relevant policy question is: What to do
first? Should countries begin by replacing stavudine with tenofovir
or by making CD4 count monitoring universally available? To
assist policy makers in this prioritization process, we use a model-
based analysis with data from South Africa to project the clinical
and economic outcomes of alternative stepwise implementation
scenarios toward the 2010 WHO ART guidelines.
Methods
Analytic Overview
The Cost Effectiveness of AIDS Complications (CEPAC)–
International model is a Monte Carlo simulation model of the
natural history and treatment of HIV disease (see Text S1 for
model details) [9–11]. We populate the model with South African
clinical and resource utilization data to project survival and costs
under alternative guideline prioritization scenarios. We use a ‘‘no
ART’’ scenario for comparison and assume that baseline care
(designated the ‘‘reference strategy’’) is a one-line stavudine-
containing regimen, initiated at WHO stage III or IV disease,
without CD4 count monitoring capacity. We then examine every
feasible sequence of the following implementation elements: (1)
widespread CD4 count monitoring capacity, allowing for ART
initiation at CD4,200 cells/ml (and biannual monitoring), (2)
earlier ART initiation, at CD4,350 cells/ml (assumes CD4 count
availability), (3) an available second-line ART regimen upon first-
line failure, and (4) replacement of stavudine with tenofovir in the
first-line regimen. To refer to these strategies, we use the
following nomenclature: nucleoside analog in first line/ART
initiation criterion/number of regimens [e.g., stavudine/,200/
ml/two-lines]). The combined implementation elements result in
twelve possible strategies, in addition to no ART (Figures 1 and
S1). We examine the short- and long-term survival benefits and
cost-effectiveness of each stepwise, incremental policy change
from the reference strategy to full 2010 guideline implementation.
We also evaluate the cost and survival impact of imposing an
additional ‘‘equity’’ constraint—i.e., that all members of the
cohort at any given time are provided the same treatment
program. Finally, we use sensitivity analyses to examine the
efficacy and cost input parameters necessary to change the
conclusions.
When reporting clinical outcomes alone (per-person life
expectancy), we provide undiscounted results. When clinical and
economic results are used to create cost-effectiveness ratios, we
adhere to established convention in discounting both at 3% per
annum [12]; cost-effectiveness ratios are reported in US dollars
per year of life saved (dollars/YLS) (See Text S1 for details). We
conduct an ‘‘incremental’’ assessment of economic costs and
health benefits, as recommended by the US Panel on Cost-
Effectiveness in Health and Medicine [12]. Cost and health
outcomes are estimated for all 12 strategies (as well as no ART).
These are then ranked in order of increasing cost. After
eliminating all ‘‘dominated’’ strategies (i.e., strategies that both
cost more and confer fewer benefits than any combination of other
strategies), we compute the ratio of incremental costs to
incremental benefits for each strategy, comparing it to its next-
least-costly, non-dominated alternative [12].
Costs are converted to 2008 US dollars using the South African
gross domestic product deflators and the 2008 mean exchange rate
between the South African rand and the US dollar (8.23 rand = US$1)
[13,14]. Guided by the recommendations of the WHO Commission
on Macroeconomics and Health, we consider interventions to be cost-
effective in a given country if their cost-effectiveness ratio is less than 3
times the national per capita gross domestic product (South African
2008 gross domestic product = US$5,700) [14].
The CEPAC-International Model
The CEPAC-International model simulates the progression of
disease in a hypothetical cohort of patients infected with HIV as a
sequence of monthly transitions between health states. Health states
are defined to be clinically and economically representative of the
disease course and are stratified by current CD4 count, current HIV
RNA level, and history of opportunistic disease. A graphical
representation of a patient trace in South Africa is presented in
Figure S2, illustrating CD4 cell count, HIV RNA, and clinical
events, including tuberculosis, over a hypothetical patient’s lifetime.
We are careful to distinguish in the model ‘‘actual’’ CD4 cell count
and HIV RNA—i.e., the underlying immunologic and virologic
state, regardless of whether they are measured by a laboratory test—
from ‘‘observed’’ CD4 cell count and HIV RNA—that which is
measured by a test and upon which clinical decisions can be made.
Actual CD4 cell count determines the frequency of opportunistic
diseases, while ART influences actual HIV RNA levels and CD4
cell counts. Health states therefore reflect the underlying disease
process, and clinical decisions (ART initiation or switch) are based
on observed factors such as presentation with an opportunistic
disease, or CD4 count, if monitoring is available. Reflecting
standards of care in most sub-Saharan African nations, HIV RNA
monitoring is assumed to be unavailable [1]. Patients are followed
from entry into HIV care through death.
In strategies without available CD4 monitoring, decisions
regarding ART initiation and switching are made based upon
observation of any of the following severe opportunistic diseases
representative of WHO stage III/IV disease: severe bacterial
infection, severe fungal infection, tuberculosis, toxoplasmosis,
nontuberculous mycobacteriosis, Pneumocystis jiroveci pneumonia,
or other WHO stage IV defining diseases. Two mild oppor-
tunistic diseases (fungal and other) result in resource utilization
but no changes in the ART decision-making process. Patients
die in the model from an acute event (e.g., an opportunistic
disease or a drug-related toxicity), from chronic HIV disease, or
at South African age- and sex-adjusted background mortality
rates [15].
The frequency of clinical and laboratory assessments in the
model is user-defined. For this analysis, we have chosen clinical
assessments to occur every 3 mo; in strategies where CD4 counts
are available, they are modeled as being performed biannually.
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ART is initiated when one of two criteria is met: falling below a
defined CD4 count threshold or the development of WHO III/IV
disease (i.e., severe opportunistic disease). Effective ART in the
model results in actual virologic suppression (independent of
gender), a CD4 count increase, and a CD4-independent reduction
in risk of opportunistic diseases and chronic AIDS death [16–19].
Because HIV RNA monitoring is unavailable, virologic failure on
an antiretroviral regimen is itself not detected. However, the
impact of virologic failure is ultimately observed when it manifests
with immunologic dysfunction through either a documented
opportunistic disease or a CD4 decline that is revealed by
laboratory testing. Six months after ART initiation, observed
treatment failure is defined as meeting any one of the following
three criteria: the development of a severe opportunistic disease,
observation of a 50% decline from peak on-treatment CD4 count,
or observation of two consecutive CD4 counts below 100 cells/ml
[1]. Upon observed treatment failure, ART is switched if a
subsequent regimen is available or, if not, the failed regimen is
continued until death to maintain its modest decreases in the rates
of opportunistic disease and death [17,18]. For the purposes of this
analysis, we assume no treatment interruptions.
Stavudine- or tenofovir-related toxicity occurs with a one-time
probability, distributed over time since drug initiation. Depending
on the nature of the toxicity, toxicity results in a one-time cost
and/or a duration of costs spanning the time of increased need for
care. Certain types of toxicity—including lactic acidosis, lipody-
stropy, neuropathy, and nephrotoxicity—also result in a single
drug switch to zidovudine.
Evaluating Uncertainty
To converge on stable model output, we run a simulated cohort
of 1 million patients infected with HIV. Because the cohort size
can be varied in the simulation—i.e., we might also simulate 2
million or 5 million patients—95% confidence intervals and
standard deviations (SDs) do not adequately capture uncertainty in
simulation modeling. Instead, we adhere to the guidance of the US
Panel on Cost-Effectiveness in Health and Medicine for reporting
uncertainty in deterministic methods [12]. We use univariate
sensitivity analysis to examine the impact of variation in individual
input parameters. Having identified those variables that exert the
greatest influence on our conclusions, we then turn to multivariate
sensitivity analyses to examine the impact of simultaneous
variation in multiple parameters. This approach results in a large
variety of univariate and multivariate sensitivity analyses. We
report those instances in which variation of an underlying
parameter value has material impact on the findings and
conclusions. A more comprehensive description of relevant
sensitivity analyses is provided in Texts S2 and S3.
Figure 1. Clinical and policy decisions yield 12 implementation strategies. Clinical and policy decisions result in 12 possible implementation
strategies. These strategies are listed in Text S1. Squares represent decision points. The reference strategy is bolded. d4t, stavudine; TDF, tenofovir.
doi:10.1371/journal.pmed.1000382.g001
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Data sources for individual input parameters are referenced in
Table 1 and in Text S1.
Cohort characteristics. We define an ART-naı̈ve cohort of
patients with HIV in South Africa, with mean age 32.8 y [20]. We
intentionally choose an initial cohort with a relatively high mean
CD4 cell count of 375 cells/ml (SD, 25 cells/ml). A cohort with a
lower mean CD4 cell count would not clearly demonstrate the
benefits of an ART initiation threshold of CD4,350 cells/ml, as
illustrated in sensitivity analyses (Text S2). Over 40% of the cohort
has HIV RNA.100,000 copies/ml (Table 1) [21]. In the model,
this ART-naı̈ve cohort is then subject to the policies of ART
initiation and drug availability as indicated by each of the 12
strategies. In the absence of ART, the model tracks the patients’
natural history of disease for use in comparing the incremental
clinical benefits and costs. Figure S3 illustrates the internal
validation of South African data used to derive critical model input
parameters such as monthly mortality and opportunistic disease
incidence rates, stratified by CD4 count.
Opportunistic disease prophylaxis and ART efficacy. All
patients at model entry are provided co-trimoxazole prophylaxis,
conferring protection against mild and severe bacterial infections,
P. jiroveci̧ and toxoplasmosis [22,23]. We assume a non-nucleoside
reverse transcriptase inhibitor–based ART regimen that includes
stavudine. This regimen results in a 24-wk virologic suppression
rate of 75% with a mean 48-wk CD4 count rise of 136 cells/ml
among those with suppression [19]. The monthly probability of
virologic failure after 24 wk is 0.02. When stavudine is replaced
with tenofovir in first-line regimens, in the absence of reliable
efficacy data for a tenofovir-based regimen in resource-limited
settings, we use a virologic suppression rate of 85% at 24 wk, as
reported in clinical trials [24,25]. Despite the improved rates of
virologic suppression, we want to maintain conservative
assumptions with regard to CD4 benefit among those
suppressed, so we use the same benefit (136 cells/ml) as that used
for the stavudine-based regimen [19]. From these studies, the
monthly probability of failure of tenofovir-based ART after 24 wk
is 0.01 [24,25].
When second-line ART is available, it is a lopinavir/ritonavir-
based regimen with a 24-wk suppressive efficacy of 78%, a
resultant CD4 count increase of 151 cells/ml, and a 0.03 monthly
probability of virologic failure after 24 wk [16]. In sensitivity
analyses, we examine the impact of improved efficacy of first-line
ART associated with the use of tenofovir and the impact of
alternative second-line ART efficacies (Text S3).
Costs. We consider HIV-associated direct medical costs,
including inpatient days, outpatient visits, medication costs, and
laboratory tests, when available (Table 1). Direct non-medical
costs and indirect costs are excluded. Costs attributable to
inpatient hospitalization resulting from an opportunistic infection
are calculated as the mean cost of each inpatient day multiplied by
the mean length of stay for any given opportunistic disease.
Outpatient care costs include the mean cost of each visit, inclusive
of standard laboratory tests and procedures. Routine care costs are
stratified by CD4 cell count to account for the increased frequency
of visits that may be attributable to lower CD4 cell counts
(Table 1). The stavudine-based first-line regimen costs US$100 per
person-year (stavudine component = US$36), and the tenofovir-
based regimen costs US$204 per person-year (tenofovir
component = US$135) [26]; all other first-line regimen costs
are identical. Second-line ART regimens, when available, cost
US$669 per person-year [26]; CD4 count tests cost US$25 each
[27,28]. Tenofovir, second-line ART, and CD4 monitoring costs
are each varied in sensitivity analyses.
Results
Prioritization by Survival Benefits (Undiscounted)
An untreated HIV-infected South African cohort starting with a
mean CD4 count of 375 cells/ml (SD, 25 cells/ml) has a mean
undiscounted life expectancy of 47.9 mo. A single-line stavudine-
based ART regimen, initiated on development of WHO stage III/
IV disease (‘‘reference strategy’’; stavudine/WHO/one-line) in-
creases life expectancy to 99.0 mo. Table 2 provides the projected
5-y survival and life expectancies of alternative stepwise progressions
toward the 2010 WHO recommendations. Compared to stavu-
dine/WHO/one-line (step 1), 5-y survival is largest (87% survival)
with the addition of CD4 count availability and ART initiation at
CD4,350 cells/ml (stavudine/,350/ml/one-line). In this initial
step, tenofovir/WHO/one-line (66%), stavudine/,200/ml/one-
line (80%), or stavudine/WHO/two-lines (66%) each yield lower
projected short-term survival. Considering each of the guideline
components, stavudine/,350/ml/one-line also produces the great-
est anticipated life expectancy increase, D25.3 mo. With stavudine/
,350/ml/one-line (step 2), adding a second-line regimen results in
the next largest life expectancy increase (stavudine/,350/ml/two-
lines, D53.3 mo). The final step replaces stavudine with tenofovir
(tenofovir/,350/ml/two-lines, D16.0 mo, step 3), resulting in a
comprehensive strategy concordant with the 2010 WHO guidelines,
a 5-y survival of 91%, and a projected life expectancy of 193.6 mo
(Table 2).
Model-generated survival curves are provided for no ART, the
reference strat gy, and the three steps in Table 2, which act
stepwise to maximize life expectancy (Figure 2). Marked
differences in early survival are attributable to earlier ART
initiation thresholds; differences in survival later in the disease
course are associated with second-line ART availability.
Prioritization by Cost-Effectiveness
Incremental cost-effectiveness analysis (Table 3) reveals three
non-dominated strategies (i.e., strategies that attain a given survival
level by the least costly means): (1) stavudine/,350/ml/one-line
(US$610/YLS), (2) tenofovir/,350/ml/one-line (US$1,140/YLS),
and (3) tenofovir/,350/ml/two-lines (US$2,370/YLS). All other
strategies are ‘‘dominated’’—i.e., they are more expensive and
confer less survival benefit than some other combination of
strategies. Figure 3 (upper panel) maps the 13 strategies on a
discounted cost and life expectancy plane. The line connecting the
non-dominated strategies designates the ‘‘efficient frontier,’’ which
represents both the least expensive way to attain a given survival and
the maximum achievable survival for any given cost [12].
Thus, a country with a current stavudine/WHO/one-line
policy (Figure 3, lower panel) could switch to a tenofovir/,350/
ml/one-line policy (open arrow) and thereby simultaneously
decrease projected per-person lifetime costs and improve survival.
Similarly, a country with a stavudine/,200/ml/one-line policy
could decrease per-person costs and also improve outcomes by
changing to a stavudine/,350/ml/one-line policy (solid arrow-
head). Countries with a stavudine/,200/ml/two-lines policy
would require increased per-person expenditures to achieve the
survival benefits associated with tenofovir/,350/ml/two-lines, as
suggested in the revised WHO guidelines (dotted arrow).
Evaluating the Cost of Equity
Of the three efficient programs (Table 3; Figure 3), tenofovir/
,350/ml/one-line has a projected per-person lifetime cost of
US$6,870, and tenofovir/,350/ml/two-lines has a projected
lifetime cost of US$12,820. An HIV program budget that allows
for a per-person cost between US$6,870 and US$12,820 might be
Prioritizing HIV Care










Table 1. Model input parameters for analysis of the 2010 WHO ART guidelines.
Variable Estimate Reference
Initial cohort characteristics
Age, mean years 6 SD 32.869.2 [20]
Male (%) 54.6 [20]
Distribution of initial CD4, mean cells/ml (SD) 375 (25) Assumption







Natural history of disease











P. jiroveci pneumonia 0.00–0.12
Other severe opportunistic infections 0.25–2.57
Monthly risk of mild opportunistic diseases (%)a [20]
Fungal 0.59–3.51
Other 2.51–3.10
Efficacy of co-trimoxazole (% reduction in probability of infection)
Severe bacteria 49.8 [22,23]
Mild fungal infections 246.4b [22,23]
Toxoplasmosis 83.2 [22,23]
P. jiroveci pneumonia 97.3 [22,23]
Other WHO stage IV defining diseases 17.9 [22]
Efficacy of ART (range examined)
First line: stavudine-based regimen [19]
HIV RNA suppression 75% at 24 wk
CD4 count increase 136 cells/ml at 48 wk
Probability of later failure (monthly, after 24 wk) 0.02c (0.01–0.02)
First line: tenofovir-based regimen
HIV RNA suppression 85% at 24 wk (85%–95%) [24]
CD4 count increase 136 cells/ml at 48 wk [19]
Probability of later failure (monthly, after 24 wk) 0.01d (0.005–0.01) [24]
Second line: lopinavir/ritonavir-based regimen [16]
HIV RNA suppression 78% at 24 wk (40%–88%)
CD4 count increase 151 cells/ml at 48 wk
Probability of later failure (monthly, after 24 wk) 0.03e (0.01–0.06)
Toxicity (one-time probability [%])
Stavudine-based regimen (range examined)
Severe lactic acidosis 1.7 (1.7–3.4) [36]
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achieved in several ways; two are illustrative. The first would be to
proportionately divide the cohort between two of the programs
along the efficient frontier, so that part of the cohort receives
tenofovir/,350/ml/one-line and the rest receives tenofovir/
,350/ml/two-lines. An alternative would be to provide everyone
in the cohort a third program—one that lies below the efficient
frontier. The opportunity cost (e.g., the anticipated net loss in
discounted life expectancy associated with an alternative strategy
choice) of any non-efficient strategy may be quantified by
measuring its vertical distance from the efficient frontier. To
illustrate this opportunity cost, we take an arbitrary affordability
threshold of US$11,500 per person. In the example of a program
that can afford no more than US$11,500 per person (stavudine/
,200/ml/two-lines; Figure 3, lower panel), the opportunity cost of
uniformity in care (‘‘equity’’) is 14.5 mo per person of survival
(shown by the bracket in Figure 3, lower panel).
Sensitivity Analyses
Clinical parameters. In sensitivity analyses, we examine
changes in clinical input data required to alter the stepwise
Variable Estimate Reference
Lipodystrophy 1.3 (1.3–2.6) [36]
Neuropathy 2.6 (2.6–5.2) [36]
Tenofovir-based regimen (range examined)
Nephrotoxicity 1.6 (1.6–3.2) [37,38]
Anemia 0.4 (0.4–0.8) [24]
Discount rate 3% [12]
Costs (2008 US dollars) (range examined)
Co-trimoxazole prophylaxis (monthly) 1.03 [23]
Stavudine-based first-line ART (monthly) 8.33 [26]
Tenofovir-based first-line ART (monthly) 17.00 (10.00–17.00) [26]
Lopinavir/ritonavir second-line ART (monthly) 55.75 (8.36–55.75) [26]
Routine care (range by CD4, monthly)a 9.99–131.23 [20,39,40]
Inpatient hospital care, per day 224.25 [39]
Outpatient hospital care, per visit 10.87 [39]
CD4 count test US$25 (25–75) [27,28,41]
‘‘Range examined’’ indicates that we examined both extreme and intermediate values within the specified ranges.
aRange indicated by CD4 count; details by CD4 strata are presented in the Text S1.
bThe percent monthly risk of mild fungal infections is increased by 46.4% in the presence of co-trimoxazole [22].
cProjected using published 24-wk data [19].
dEstimated from published 24- and 48-wk data [24].
eEstimated from published 24- and 48-wk data [16].
doi:10.1371/journal.pmed.1000382.t001
Table 1. Cont.
Table 2. Projected life expectancies associated with alternative choices in the stepwise progression toward full implementation of








Step 1: begin with stavudine/WHO/one-line (reference strategy) (four options) 65 99.0 —
(1) Switch from stavudine to tenofovir, or 66 112.9 13.9
(2) Add CD4 monitoring capacity, initiate ART at CD4,200 cells/ml, or 80 115.6 16.6
(3) Add second-line ART regimen, or 66 121.4 22.4
(4) Add CD4 monitoring capacity, initiate ART at CD4,350 cells/ml 87 124.3 25.3
Step 2: begin with stavudine/,350/ml/one-line (two options) 87 124.3 —
(1) Switch from stavudine to tenofovir, or 89 144.8 20.5
(2) Add second-line ART regimen 91 177.6 53.3
Step 3: begin with stavudine/,350/ml/two-lines (one remaining option) 91 177.6 —
(1) Switch from stavudine to tenofovir 91 193.6 16.0
We use the following nomenclature to define the strategies: nucleoside analog used in first line/ART initiation criterion/number of available regimens. All strategies with
initiation criteria indicated by a CD4 count threshold assume availability of CD4 count monitoring. For each step, the option that maximizes survival is shown in bold.
aChange relative to the program selected in the previous step.
doi:10.1371/journal.pmed.1000382.t002
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ordering of program additions. Modest reductions in the mean
CD4 count of the cohort (to 250 cells/ml) show decreased clinical
benefits to earlier ART initiation but no substantial changes in
cost-effectiveness. When the mean CD4 count of the cohort is less
than 100 cells/ml, the benefits of a policy change to earlier ART
initiation are largely irrelevant (Text S2). This is because the
majority of the cohort is already ART-eligible regardless of the
initiation criterion (WHO stage III/IV disease, CD4,200 cells/
ml, or CD4,350 cells/ml). Although CD4 monitoring still
improves cohort survival compared to clinically based ART
initiation, in populations with mean CD4 counts far below the
policy-relevant ART initiation criteria, the addition of a second-
line regimen becomes the most clinically beneficial intervention.
For the anticipated life expectancy benefits of tenofovir/WHO/
one-line to exceed those expected with stavudine/,350/ml/one-
line, replacement of stavudine with tenofovir would have to
increase the 24-wk suppressive efficacy from 85% to 95% and
simultaneously decrease the monthly probability of later virologic
failure by 50% (from 0.01 to 0.005) (Text S3) [24]. Second-line
ART maintains its position in the stepwise order (step 2) as long as
its 24-wk viral suppression rate remains between 40% and 88%,
even with a 3-fold increase in the rate of late failure when efficacy
decreased to 40% (Text S3). Increasing stavudine toxicity by 2-fold
alters life expectancy estimates by less than 1 mo and does not
change the recommended stepwise additions (Text S3). Similarly,
changes in the gender distribution of the cohort have little impact
on the results (Text S3).
Cost parameters. Holding efficacy constant, results are very
sensitive to the price of tenofovir; a decrease in the cost of tenofovir
from US$135 to US$51 per person per year would make tenofovir
both more effective and less costly than stavudine. Results are less
sensitive to the costs of second-line regimens (15% of base case)
and CD4 monitoring (three times base case), neither of which
produced meaningful changes in cost-effectiveness results (Text
S2). In two-way sensitivity analyses, where the cost of tenofovir is
decreased and its efficacy increased, tenofovir/,350/ml/one-line
dominates stavudine/,350/ml/one-line when the tenofovir
regimen costs are US$153 annually (75% of the base case) and
its 24-wk suppressive efficacy is 90% (5% increase from the base
case).
Additional sensitivity analyses. Further sensitivity analyses
are detailed in the Texts S2 and S3. In Text S2, we present the 1-
through 5-y survival rates for all 12 strategies examined, as well as
the survival curves of the stepwise strategies selected on a 5-y,
rather than a 10-y, horizon (Figure S4). Text S2 also provides the
details of analyses under conditions of alternative mean CD4
counts for the cohort and alternative costs of both second-line
regimens and CD4 monitoring. Further analyses (Text S3) offer
Figure 2. Model-projected survival curves. Model-projected survival curves (undiscounted) of the reference strategy (stavudine/WHO/one-line)
and the three strategies projected to maximize life expectancy in stepwise progression toward the 2010 WHO guidelines (see Results and Table 2 for
details). Curves highlighting outcomes over the next 5 y are provided in Figure S4. The 20-y horizon is presented here, not to imply that HIV
treatment will remain unchanged over this time horizon, but rather to demonstrate when different interventions will have meaningful survival
impacts. Median survival increases from 90 mo with stavudine/WHO/one-line (reference strategy) to 121 mo with the addition of CD4 monitoring
and ART initiation at CD4,350 cells/ml (stavudine/,350/ml/one-line, step 1) to 177 mo with the addition of a second-line ART regimen (stavudine/
,350/ml/two-lines, step 2). A subsequent switch from stavudine to tenofovir results in a comparatively modest survival advantage, with a median
survival increase to 196 mo (tenofovir/,350/ml/two-lines, step 3). The survival curve of step 3 represents what might be expected when all the 2010
WHO treatment guidelines are fully implemented.
doi:10.1371/journal.pmed.1000382.g002
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additional comprehensive analytic variations in cohort gender
distributions, ART initiation criteria, first- and second-line ART
efficacies, stavudine-related toxicities, and costs. Within plausible
ranges, these sensitivity analyses, other than those reported above,
had little impact on clinical- or policy-relevant results.
Discussion
The new 2010 WHO ART guidelines aim to promote public
health interventions that ‘‘secure the greatest likelihood of survival
and quality of life for the greatest number’’ of individuals with
HIV. The reported guiding principles in the revision process
include: (1) do no harm, (2) ensure access and equity, (3) promote
quality and efficiency, and (4) ensure sustainability. Motivated by
these tenets, the new guidelines recommend a single CD4-based
ART initiation criterion for all populations, a switch from
stavudine to tenofovir, and universally available second-line
regimens [2]. We find that in settings where immediate
implementation of all of the new WHO treatment guidelines is
currently not feasible, ART initiation at CD4,350 cells/ml
provides the greatest short- and long-term survival advantage
and is very cost-effective. In countries that are already initiating
stavudine at CD4,350 cells/ml and have access to CD4
monitoring, switching from stavudine to tenofovir increases
survival and is also cost-effective. Access to second-line ART
provides more clinical benefit than access to tenofovir but at
substantially greater costs.
The additional outlays implied by the new guidelines stand in
stark contrast to the resource-constrained reality encountered on
the ground. Many countries are still striving to meet goals set by
the now-superseded 2006 guidelines. The WHO estimates the
current ART coverage rate across low- and middle-income
countries to be 42% [5,29]. Meanwhile, the new guidelines
recommend access to CD4 count monitoring, call for treatment of
almost double the 3–5 million people already requiring treatment
based on the previous guidelines [30], and suggest replacement of
the most widely used antiretroviral drug with one that costs nearly
US$100 per patient-year more [26]. In most resource-limited
settings, the relevant policy questions are: What is feasible now? and
What to do first?
Based on projected short- and long-term survival and cost-
effectiveness results, we identify three critical messages. First,
countries with very limited resources and still only one line of ART
available should focus first on access to CD4 count monitoring and
ART initiation at CD4,350 cells/ml. These should be implemented
before switching from stavudine to tenofovir and prior to providing
second-line ART. Although advising to use stavudine in the first-line
regimen—with its inherent toxicities—may be seen as conflicting
with the primary WHO principle ‘‘first, do no harm,’’ the switch from
stavudine to tenofovir is the recommendation that provides the least
overall increase in survival, according to the results presented here.
Initiating stavudine-based ART at CD4,350 cells/ml, compared
with clinically based ART initiation, provides immediate and
substantial short-term survival benefits, yields the greatest life
expectancy compared to other guideline components, and is cost-
effective by international standards. In cases where most patients
present to care with CD4 counts far below the ART initiation
threshold (e.g., CD4,100 cells/ml), a policy of earlier ART initiation
is neutral at worst—both in terms of cost and clinical outcomes—as it
serves only to increase life expectancy among patients with less
advanced disease.
Second, countries with currently one line of ART available but
more resources should ensure access to CD4 count monitoring
with ART initiation at CD4,350 cells/ml and then switch from
stavudine to tenofovir, before making second-line ART available.
Indeed, some countries have already responded to the 2010 WHO
guidelines and have made plans to phase out stavudine [31].
Reductions in the price of tenofovir could resolve the ongoing
debate surrounding the role for stavudine in resource-limited
settings. At an annual cost of US$51, tenofovir would be both less
costly and more effective than stavudine.
Table 3. Life expectancy, costs, and incremental cost-effectiveness ratios of the 12 possible stepwise combinations (and no ART)






No ART 2,540 44.9 (47.9)
Stavudine/,350/ml/one-line (step 1) 5,550 104.3 (124.3) 610
Stavudine/,200/ml/one-line 5,740 97.3 (115.6) Dominatedb
Tenofovir/,350/ml/one-line 6,870 118.3 (144.8) 1,140
Tenofovir/,200/ml/one-line 6,930 109.9 (133.9) Dominatedb
Stavudine/WHO/one-line (reference strategy) 7,440 84.5 (99.0) Dominatedb
Tenofovir/WHO/one-line 8,400 93.9 (112.9) Dominatedb
Stavudine/WHO/two-lines 10,140 98.8 (121.4) Dominatedb
Tenofovir/WHO/two-lines 10,640 105.0 (131.2) Dominatedb
Stavudine/,200/ml/two-lines 11,460 127.0 (161.3) Dominatedc
Tenofovir/,200/ml/two-lines 11,930 135.3 (175.5) Dominatedc
Stavudine/,350/ml/two-lines (step 2) 12,270 138.7 (177.6) Dominatedc
Tenofovir/,350/ml/two-lines (step 3) 12,820 148.4 (193.6) 2,370
The reference strategy and the strategies selected in the stepwise progression in Table 2 are shown in bold.
aWe use the following nomenclature to define the strategies: nucleoside analog used in first line/ART initiation criterion/number of available regimens. All strategies
with initiation criteria indicated by a CD4 count threshold assume availability of CD4 count monitoring; WHO indicates WHO stage III/IV disease.
bStrongly dominated (more expensive but confer less clinical benefit than some other strategy) [12].
cWeakly dominated (more expensive but confer less clinical benefit than some combination of other strategies) [12].
doi:10.1371/journal.pmed.1000382.t003
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Figure 3. Clinical and economic outcomes of each of the scale-up interventions. The clinical and economic outcomes of all combinations of
scale-up interventions are examined. The efficient frontier (marked by the line) connects the non-dominated strategies in the cost-effectiveness
plane. Strategies below and to the right of the efficient frontier are those that are either strongly or weakly dominated by other options (see
Methods). As illustrated in the upper panel, strategies based on clinical criteria (WHO stage III/IV) alone fall far below the efficient frontier (lower right
oval), indicating their relatively high cost for the comparative benefit gained. Strategies in the upper left oval are those representing CD4 monitoring
and one line of ART. Strategies incorporating a second-line regimen (upper right oval) all confer large survival benefits but at increased costs. The
lower panel examines potential country situations. For instance, a country with a current stavudine/WHO/one-line policy could switch to a tenofovir/
,350/ml/one-line policy (open arrow) and both decrease projected per-person lifetime costs and improve survival. A country with a stavudine/,200/
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Third, in countries with sufficient budgets to provide second-
line ART, it is neither effective nor cost-effective to maintain
stavudine in first-line regimens. Second-line ART may offer
additional efficiencies by decreasing the prevalence of resistant
virus and leaving future drug regimen options available.
Once countries have the capacity to provide early ART
initiation, tenofovir, and second-line regimens, there will be
additional clinical and policy questions. Policy makers will be
addressing what to do upon second-line failure; optimal third-line
regimens will be in question. Expanded ART regimen availability
leads to clinical need for timely ART switches and forces the issue
of HIV RNA laboratory availability. Finally, timely ART initiation
is currently limited by late presentation to care [32,33].
Concurrent with scaling up to achieve the 2010 WHO ART
guidelines, there should be a concerted effort to achieve the 2007
WHO HIV screening guidelines [34]; without earlier case
detection, a policy of ART initiation at CD4,350 cells/ml will
never be effectively realized.
It is important to highlight that full and immediate implemen-
tation of the comprehensive set of new guidelines is cost-effective
by South African standards. But, while it is helpful to critically
examine the survival and economic efficiency of alternative
programmatic choices, ‘‘cost-effective’’ does not mean ‘‘afford-
able.’’ In the setting of clear budget constraints, the question of
affordability may conflict with the political imperative that all
persons receive the same care package. In this case, prioritization
of equity over efficiency decreases mean life expectancy—
sometimes by more than 1 y per person—for the same healthcare
expenditure (Figure 3, lower panel).
This analysis has several limitations. We report results from a
cohort of HIV-infected individuals initiating ART. Although we
believe the overall results would be consistent, this analysis does
not specifically address ART programs with patients already in
alternative stages of care, including some on first-line regimens,
some on second-line regimens, and some who have previously
accumulated drug-related toxicities. Such diversity within a cohort
would require more individualized analyses. Additionally, a full
budget impact analysis would be required to examine the number
of patients in need of care, and to project the implications of each
component of the WHO recommendation on program budgets
over alternative time horizons.
Despite its limitations, this analysis represents the only
systematic, scientific effort we are aware of that marshals the
evidence base in support of implementing the WHO guidelines.
The most unfortunate outcome upon release of the revised WHO
guidelines would be either their complete dismissal on cost
grounds alone, or the execution of more expensive—though easier
to implement—interventions that offer less overall health benefit
than other interventions.
In cases where the simultaneous implementation of all
components of the 2010 WHO ART guidelines is beyond the
reach of programs or countries, important prioritization questions
emerge. This analysis suggests that CD4 count monitoring and
ART initiation at CD4,350 cells/ml are the critical initial
priorities. Replacing stavudine with tenofovir would further
increase survival and would also be cost-effective. Adding a
second-line ART regimen would provide large survival benefits,
but with substantial increases in the necessary budgets.
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Background. Since 1981, acquired immunodeficiency
syndrome (AIDS) has killed more than 25 million people,
and about 33 million people (30 million of them in low- and
middle-income countries) are now infected with the human
immunodeficiency virus (HIV), which causes AIDS. HIV
destroys immune system cells (including CD4 cells, a type
of lymphocyte), leaving infected individuals susceptible to
other infections (so-called opportunistic infections). Early in
the AIDS epidemic, most people with HIV died within 10
years of infection. Then, in 1996, highly active antiretroviral
therapy (ART)—a combination of several powerful
antiretroviral drugs—was developed. Now, in resource-rich
countries, clinicians care for people with HIV by prescribing
ART regimens tailored to each individual’s needs. They also
regularly measure the amount of virus in their patients’
blood, test for antiretroviral-resistant viruses, and monitor
the health of their patients’ immune systems through regular
CD4 cell counts. As a result, the life expectancy of patients
with HIV in developed countries has dramatically improved.
Why Was This Study Done? Initially, resource-limited
countries could not afford to provide ART for their
populations, and the life expectancy of HIV-positive people
remained low. Now, through the concerted efforts of
governments, the World Health Organization (WHO), and
other international agencies, more than a third of the people
in low- and middle-income countries who need ART are
receiving it. However, many without access are still in need
of ART, and ART programs in developing countries follow a
public-health approach rather than an individualized
approach. That is, drug regimens, clinical decision-making,
and disease monitoring are all standardized and follow
recommendations in the 2006 WHO ART guidelines. This year
(2010), these guidelines were revised. The guidelines now
recommend the following: earlier ART initiation—when the
CD4 count falls below 350/ml of blood, instead of below 200/
ml as in the 2006 guidelines; the provision of sequential ART
regimens instead of a single regimen; and the replacement
of the antiretroviral drug stavudine with tenofovir, a less
toxic but more expensive drug, in first-line ART regimens.
However, many resource-limited countries are still struggling
to implement the 2006 guidelines, so which of these new
recommendations should be prioritized? Here, the
researchers use a mathematical model to address this
question.
What Did the Researchers Do and Find? The Cost
Effectiveness of AIDS Complications (CEPAC)–International
model simulates the natural history and treatment of HIV
disease. The researchers entered South African clinical and cost
data for HIV treatment into this model and then used it to
project survival and costs in a hypothetical group of South
African HIV-positive patients under alternative guideline
prioritization scenarios. The reference strategy for the
simulations (denoted as ‘‘stavudine/WHO/one-line’’) assumed
that patients (with a mean CD4 count of 375/ml) began a single
stavudine-based ART regimen when they developed WHO
stage III/IV HIV disease (i.e., when patients develop multiple
opportunistic infections such as tuberculosis and pneumonia).
When the new guideline recommendations were considered
separately, ART initiation at CD4,350/ml (stavudine/,350/ml/
one-line) maximized five-year survival. Stepwise adjustment
from the reference strategy (which had a life expectancy 99.0
months) through strategies of stavudine/,350/ml/one-line (a
projected life expectancy of 124.3 months), stavudine/,350/ml/
two-lines (177.6 months), and tenofovir/,350/ml/two-lines
(193.6 months) produced the greatest improvements in life
expectancy. Finally, strategies of stavudine/,350/ml/one-line,
tenofovir/,350/ml/one-line, and tenofovir/,350ml/two-lines
produced incremental cost-effectiveness ratios of US$610,
US$1,140, and US$2,370 per year of life saved, respectively.
What Do These Findings Mean? As with all mathematical
models, the accuracy of these findings are dependent on the
assumptions included in the model and on the data
populating it. Nevertheless, these findings suggest that,
where resources are limited and immediate implementation
of all the new WHO recommendations is impossible, ART
initiation at a CD4 count of less than 350/ml would provide
the greatest survival advantage and would be very cost-
effective. In countries that are already initiating ART at this
threshold and that have access to CD4 monitoring, a switch
from stavudine to tenofovir would further increase survival
and would also be cost-effective. Finally, although access to
a second-line ART regimen would provide more clinical
benefits than access to tenofovir, the cost of this change in
strategy would be substantially greater. Importantly, these
findings should help policy makers adjust their ART program
strategies to maximize their clinical benefits and cost
effectiveness.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000382.
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on HIV/AIDS in South Africa and on HIV/AIDS
treatment and care (in English and Spanish)
N WHO provides information about universal access to AIDS
treatment (in English, French, and Spanish); its 2010 ART
guidelines can be downloaded
N More information on the CEPAC model is available
Prioritizing HIV Care










Early mortality among adults accessing a community-
based antiretroviral service in South Africa:
implications for programme design
Stephen D. Lawna,c, Landon Myera,b,d, Catherine Orrella,
Linda-Gail Bekkera and Robin Wooda
Objectives: To determine rates, risk factors and causes of death among patients
accessing a community-based antiretroviral treatment (ART) programme both prior
to and following initiation of treatment.
Methods: All in-programme deaths were ascertained between September 2002 and
March 2005 among treatment-naive patients enrolled into a prospective community-
based ART cohort in Cape Town, South Africa.
Results: Of 712 patients (median CD4 cell count, 94 cells/ml), 578 (81%) started triple
ART a median of 29 days after enrolment. 68 (9.5%) patients died during 563 person-
years of observation. The high pretreatment mortality rate of 35.6 deaths/100 person-
years [95% confidence interval (CI), 23.0–55.1) decreased to 2.5/100 person-years
(95% CI, 0.9–6.6) at 1 year among those who received ART. However, within the first
90 days from enrolment, 29 of 44 (66%) deaths occurred among patients awaiting ART;
these would not be identified by an on-treatment analysis. Multivariate analysis showed
that risk of death (both pre-treatment and on-treatment) was independently associated
with baseline CD4 cell count and World Health Organization (WHO) clinical stage;
stage 4 disease was the strongest risk factor. Major attributed causes of death were
wasting syndrome, tuberculosis, acute bacterial infections, malignancy and immune
reconstitution disease.
Conclusions: Most early in-programme deaths occurred among patients with advanced
immunodeficiency but who had not yet started ART. Programme evaluation using on-
treatment analyses greatly underestimated early mortality. This mortality would be
reduced by minimizing unnecessary in-programme delays in treatment initiation and by
starting ART before development of WHO stage 4 disease.
 2005 Lippincott Williams & Wilkins
AIDS 2005, 19:2141–2148
Keywords: HIV, AIDS, ART, antiretroviral, mortality, cohort, Africa
Introduction
While there is ample evidence that use of antiretroviral
treatment (ART) dramatically improves the prognosis of
individuals with HIV infection [1–4], the vast majority
of those requiring ART in sub-Saharan Africa and
other resource-limited settings do not have access to this
treatment. To address these inequities in treatment
availability, a number of initiatives have been developed
to expand ART access [5]. The collective goal of these
initiatives under the umbrella of the World Health
Organization (WHO) is to provide ART to 3 million
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people by the end of 2005 [5]. While progress towards this
goal is being achieved, it was estimated that just 310 000
(< 8%) of the 4 million patients aged 15–49 years in sub-
Saharan Africa who needed treatment were receiving it
by the end of 2004 [6].
The huge number of patients requiring treatment presents
a formidable logistical challenge. Despite increasing
allocation of resources to expand access to ART in
resource-limited settings, little is known about how best
to deliver treatment services. It is becoming increasingly
clear that the impact of ART services at a population level
will primarily be determined not by issues of drug efficacy
[7] but rather by programmatic issues of treatment
availability, accessibility and delivery [8]. Data from exis-
ting ART programmes are urgently required to identify
approaches to optimize outcomes. Previous studies indi-
cate that the first-year mortality from the time of initia-
tion of ART is broadly similar among cohorts receiving
ART in low- and high-income countries [9–14]. The
current study examines not only mortality during
treatment but also that occurring in the interval between
eligible individuals being enrolled into the ART pro-
gramme and the actual initiation of ART. Identification
of risk factors and stratification of mortality data
according to enrolment characteristics has also permitted




The ART service described here is based at the
Gugulethu Community Health Centre in Nyanga
district, Cape Town [15]. This peri-urban district is
home to a predominantly African population of over
300 000, the vast majority of whom live in conditions of
low socioeconomic status. In 2003, the antenatal HIV
seroprevalence was 28%. Ten primary care HIV clinics
form the patient referral base and enrolment into the
ART programme follows the Department of Health’s
national guidelines [16], which are based on the WHO
recommendations (2002) [17]. These criteria include
those with a prior AIDS diagnosis (WHO stage 4 disease)
or a blood CD4 cell count < 200 cells/ml.
Following referral to the ART service, the standard
schedule of visits was as follows: screening visit (week 0),
blood tests for plasma HIV load and blood CD4
lymphocyte count (week 2), treatment initiation (week
4) and treatment follow up (weeks 8, 12 and 20, and
16-weekly thereafter). At the screening visit, a treatment
readiness evaluation was completed and a 4-week
supply of co-trimoxazole was dispensed, with pill counts
at 14 and 28 days to assess adherence. Patients were
assessed by a doctor for symptomatic HIV-associated
disease.
At the screening visit, patients were also allocated a
therapeutic counsellor living in the same community
whose role was to use clinic and home visits to provide
ongoing counselling and adherence support. These coun-
sellors provided weekly updates to the multidisciplinary
team about the status of patients, including information
regarding those who failed to attend follow up appoin-
tments [16]. The treatment readiness status of patients was
reviewed each week until either treatment was started or
the patient was permanently deferred or had died.
Potential reasons for temporary deferral of treatment
included current investigation of an intercurrent oppor-
tunistic infection, lack of patient readiness or a failure to
attend follow-up appointments. Reasons for permanent
deferral of patients either before or after commencing
treatment included decision to access treatment else-
where, recurrent failure to attend follow up clinic
appointments, relocation out of area and psychosocial
reasons such as denial of HIV infection status.
First-line ART comprised stavudine, lamivudine plus a
non-nucleoside reverse transcriptase inhibitor (efavirenz
or nevirapine). The second-line regimen for those failing
the first-line treatment comprised lopinavir/ritonavir,
zidovudine and didanosine. Treatment adherence and
viral load suppression < 400 copies/ml in this cohort
both exceed 90% at 1 year [18]. All treatment was free of
charge and there were no interruptions in drug supply. All
patients with CD4 cell counts < 200 cells/ml received
daily co-trimoxazole prophylaxis; dapsone was used as an
alternative. In addition to the scheduled clinic appoint-
ments, patients had open access to the clinic for medical
problems. Patients requiring in-patient care were referred
to a 200-bed secondary hospital nearby.
Data sources
Structured clinical records were maintained on all patients
screened on entry to the ART programme and this
information was transferred on a weekly basis to a
database. Where blood CD4 cell counts and viral load
measurements from the week 2 visit were missing, the
results of tests done at the local referring centre within the
3 months prior to the screening visit were used where
available.
Information regarding deaths of patients within the care
of the ART clinic was obtained from the local secondary
and tertiary care hospitals, hospital mortality review
meetings and postmortem examinations. The most likely
attributable cause of death of each patient was assigned
based on all the available information after detailed review
by two specialists in infectious diseases and HIV medicine.
Data analysis
Data were analysed using STATA version 8 (College
Station, Texas, USA). Wilcoxon rank sum and Fisher’s
exact tests were used to compare medians and pro-
portions, respectively. For the main analysis, person-time










was calculated from the date of initial screening by the
service until the earliest of the following dates: (a)
permanent deferral from the ART service; (b) death, or
(c) date of data censorship (March 2005) for those alive
and still enrolled into the programme. Stratified analyses
were used to compare mortality rates by 90-day intervals
after enrolment into the programme, WHO stage,
baseline CD4 cell count, and for person-time while
receiving and or not receiving ART. Additional analyses
were restricted to individuals receiving ART, using
person-time calculated from the date of ART initiation
until death, permanent deferral or censorship of the
dataset. Kaplan–Meier analyses with log rank tests were
used to examine the effect of patient characteristics on
survival probabilities. All rates are reported per 100 per-
son-years and all statistical tests were two sided at
a ¼ 0.05.
Multivariate analyses modelled the association between
mortality rate, treatment status (based on person-time in
the programme while receiving or not receiving ART),
WHO clinical stage and CD4 cell count at screening, and
the age and gender of the participants. To account for
intraindividual correlations (on and off treatment) a
population-average log-linear model was used with an
exchangeable working correlation structure and sand-
wich (robust) estimators. The results are presented as
mortality rate ratios with corresponding 95% confidence
intervals (CI).
Results
Enrolment and follow up
Between September 2002 and February 2005, 758
individuals were referred for ART. Of these, the
following were excluded from the study analysis: patients
< 18 years of age (n ¼ 16); those transferred into the
ART service having previously initiated treatment
elsewhere (n ¼ 6) and those ineligible for ARTaccording
to programme criteria (n ¼ 24). The remaining 712
subjects were included in this analysis. Of these, 527
(74%) were female and the median age was 33 years
[interquartile range (IQR), 28.5–38]. Baseline blood
CD4 lymphocyte counts and plasma viral load measure-
ments were available for 675 (95%) and 647 (91%) of
subjects, respectively. The median blood CD4 lympho-
cyte count was 94 cells/ml; the numbers of patients with
CD4 cell counts < 50, 51–100, 101–150 and
> 151 cells/ml were 187 (28%), 163 (24%), 152 (23%)
and 173 (26%), respectively. The median plasma viral load
was 72 349 copies/ml (IQR, 30 721–191 000). Disease
was categorized as WHO clinical stage 1 for 63 subjects
(9%), stage 2 for 78 (11%), stage 3 for 354 (50%) and stage
4 for 215 (30%); data were not recorded for two subjects
(0.3%).
After screening, 578 patients (81%) started ART. The
median interval between screening and initiation of
treatment was 29 days: 75% of patients started treatment
within 6 weeks (42 days) and 96% within 3 months (90
days). The length of this interval was not associated with
blood CD4 cell count or viral load. A total of 563 person-
years of observation accrued during follow-up, of which
488 person-years were during ART, and the median
period of observation during treatment was 284 days
(IQR, 124–510) with a maximum of 925 days (2.5 years).
Twenty-two treated patients (4%) were lost to follow up
through transfer to another programme (n ¼ 3) or failure
to attend follow-up appointments (n ¼ 19; 3%).
Among 134 patients (19%) who did not receive ART, the
most frequent reasons for this were death, decision to
access treatment elsewhere, failure to attend follow up
clinic appointments, moving out of the area and
psychosocial reasons such as denial of HIV infection
status. The median period of observation for these
patients was 28 days (IQR, 19–50; maximum, 125 days).
The total untreated patient time was 75 person-years and
was made up of that for patients who did not receive ART
as well as that for patients who subsequently received
ART.
Death rates
Sixty eight (9.5%) patients died following enrolment into
the programme, with an all-cause mortality rate of
12.1 deaths/100 person-years (95% CI, 9.5–15.3)
(Table 1). The baseline pretreatment mortality rate
(during the first 30 days of entry to the programme) was
very high (35.6 deaths/100 person-years; 95% CI, 23.0–
55.1) but the overall rate decreased markedly during
follow up (Table 1). Forty-four (65%) of the deaths
occurred within the first 90 days from enrolment. Among
those who received ART, the mortality rate during the
first month of treatment (17.5 deaths/100 person-years,
95% CI, 8.8–35.0) was 2.03-fold (95% CI, 0.93–5.79)
lower than the baseline rate. The mortality rate continued
to decrease during ART, and after 6–9 months the rate
was 13.2-fold lower than the baseline rate. The survival
probability among treated patients at 1 year was 0.929
(Fig. 1). Deaths among patients who did not start ART
was very high (Fig. 2; Table 1) and 31 patients (5.4% of
enrolled patients) died before they were able to start ART.
Most importantly, among the 44 patients who died within
3 months of enrolment, 29 (66%) were not receiving
ARTand would have been excluded from data evaluating
the programme by an on-treatment analysis.
Risk factors for mortality
It was hypothesized that the very high early mortality rate
was primarily related to enrolment of patients with very
advanced immunodeficiency; therefore, the relationship
was examined between survival probability and baseline
WHO clinical stage of disease or the blood CD4 cell
count. Among those who received ART, no deaths










occurred among those with stage 1 or 2 disease; in
contrast, patients with stage 3 and stage 4 disease had an
incrementally greater risk of death (Fig. 3a). Increasing
risk of death was also significantly associated with
decreasing baseline CD4 cell count (Fig. 3b). Similar
significant associations were seen among those who did
not receive ART (data not shown). Among all patients
enrolled into the programme, the median blood CD4 cell
count of those who died was lower than that of those who
survived (54 versus 98 cells/ml; P < 0.001). Furthermore,
patients who died were more likely to have stage 4 disease
than those who did not die (37/68 [54%] versus 178/644
[28%]; P < 0.0001).
Kaplan–Meier survival curves for all patients enrolled
into the programme show that stage 4 disease and baseline
blood CD4 cell count 50 cells/ml were both associated
with a substantially lower survival probability compared
with other patients (Fig. 3c,d). Among the 44 deaths that
occurred within the first 3 months of the programme, 35
(66%) had stage 4 disease and 22 (50%) had blood CD4
cell counts < 50 cells/ml. Overall, patients with stage 4
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Fig. 1. Kaplan–Meier curve for patients who received anti-
retroviral treatment showing probability of survival from
initiation of treatment.
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Fig. 2. The effect of receiving antiretroviral therapy.
Kaplan–Meier curves for patients who did (ART) or did not
(No ART) receive treatment, showing the probability of sur-
vival from entry to the programme. The median interval
between enrolment and treatment initiation is indicated by
a double vertical line at 29 days.
Table 1. Distribution of deaths by 90–day intervals.
Interval (days)
Among all patients (from screening)
Person-time on ART (from start of treat-
ment) Person-time not on ART (from screening)
Deaths Person-days Rate (95% CI)a Deaths Person-days Rate (95% CI)a Deaths Person-days Rate (95% CI)a
1–90 44 53 919 29.8 (22.2–40.0) 24 45223 19.4 (13.0–28.9) 29 26122 40.5 (28.2–58.3)
91–180 11 38 555 10.4 (5.8–18.8) 6 35110 6.2 (2.8–13.9) 2 777 94.0 (23.5–375.7)
181–270 7 30 699 8.3 (4.0–17.5) 2 27472 2.7 (0.7–10.6) – 28 –
271–360 2 23 672 3.1 (0.8–12.3) 1 20486 1.8 (0.3–12.7) – – –
> 360 4 58 612 2.5 (0.9–6.6) 4 49873 2.9 (1.1–7.8) – – –
Total 68 205 457 12.1 (9.5–15.3) 37 178164 7.6 (5.5–10.5) 31 26927 41.5 (29.2–59.8)
ART, antiretroviral therapy; CI, confidence interval.










disease and/or blood CD4 cell counts < 50 cells/ml
accounted for 80% of the deaths within 3 months of
programme entry. In contrast, patients with CD4 cells
counts > 150 cells/ml had a low risk of death (Fig. 3d).
Having adjusted for the effects of treatment, multivariate
analysis showed that the mortality rate was not inde-
pendently associated with age or sex but was associated
with disease stage and blood CD4 cell count. Compared
with patients with stages 1 and 2 disease, those with stage
3 disease and stage 4 disease had mortality rate ratios
of 3.44 (95% CI, 0.80–14.85) and 5.93-fold (95% CI,
1.36–25.89), respectively. Similarly, the mortality rate
ratio comparing those with CD4 cell counts < 50 and
> 50 cells/ml was 3.34 (95% CI, 1.31–8.50).
Cause of death
Likely causes were identified for 61 of the 68 (89.7%)
deaths. Postmortem examinations were carried out for six
patients. Almost two-thirds of deaths were attributable to
wasting syndrome, tuberculosis, acute bacterial infections
and malignancy (Table 2). ART was associated with a
smaller proportion of deaths from acute respiratory
infections even though antibiotic prophylaxis was
received by all patients both before and during ART.
Of particular note, six cases of microbiologically proven
cryptococcal meningitis occurred, all among patients
within the initial weeks of ART. Of these, four were
receiving secondary prophylaxis with fluconazole. The
temporal association between initiation of ART and
development of fulminant cryptococcal meningitis
strongly implicated immune reconstitution disease as a
cause for this presentation. Three other deaths among
patients receiving ARTwere also thought to be related to
immune reconstitution disease, including two associated
with tuberculosis and one with Kaposi’s sarcoma. Of
these, two were diagnosed by postmortem examination.
Overall, immune reconstitution disease was thought to
have contributed to 9 of the 37 (24%) deaths during ART.
Among three drug-related deaths (Table 2), two were
among patients receiving ART: one patient developed
nevirapine-induced skin rash complicated by septicaemia
and another receiving nucleoside analogue reverse
transcriptase inhibitors developed laboratory-confirmed
lactic acidosis.
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Fig. 3. The effect of disease stage on survival in the programme. (a,b) Survival in patients who received antiretroviral treatment;
Kaplan–Meier plots showing the probability of survival from initiation of treatment stratified by baseline World Health
Organization stage (a) and blood CD4 lymphocyte count (b). (c,d) Survival for all patients enrolled into the programme;
Kaplan–Meier plots showing the probability of survival from enrolment stratified by baseline WHO stage (c) and blood CD4 cell











This study defined mortality rates among patients
accessing a community-based public sector ART
programme in South Africa and who were eligible for
treatment under the WHO 2002 guidelines [17]. This is
the first study in a resource-limited setting to report not
only mortality rates among patients during ART but also
rates in the interval between enrolment into the
programme and the actual start of treatment. Our data
highlight substantial ‘unseen’ in-programme mortality
that occurs within the interval between enrolment into
the programme and initiation of ART, providing
important additional insights beyond those provided by
previous studies reported from sub-Saharan Africa [9–
14]. Furthermore, we identified causes of death among
the majority of patients and were able to determine the
mortality risk associated with differing levels of baseline
immunodeficiency, thereby providing an evaluation of
ART enrolment criteria. These analyses were made
possible by rigorous prospective data collection. Use of
community-based therapeutic counsellors allocated to
every patient greatly enhanced the data completeness and
assignment of outcomes for patients who failed to attend
follow up appointments. Since triple-drug ART and
prophylactic co-trimoxazole were provided free of charge
to all patients, data were not limited by a variable standard
of care based upon the financial resources of the patients.
The baseline death rate among patients enrolled into the
programme was extremely high. Following development
of AIDS, the median survival of untreated patients in
South Africa and rural Uganda is just 9–10 months
[19,20] compared with around 2 years in high-income
countries prior to the advent of ART [21–23]. A
collaborative analysis of datasets from cohorts receiving
ART in northern and southern hemisphere countries also
shows that early on-treatment mortality rates among
patients with advanced baseline immunodeficiency were
much higher in low-income countries than in high-
income countries despite similar virological and
immunological responses to treatment [24].
A substantial reduction in mortality associated with ART
was evident within the first months of treatment and the
probability of survival on treatment at 1 year was high
(0.929). However, our most important finding was that
66% of the patients who died within 90 days of enrolment
to the programme were not yet receiving ART. The
interval from enrolment to starting treatment in this study
(median, 29 days; 75th centile, 42) was short compared
with the minimum of 4 months lead-in time at a similar
community-based antiretroviral programme in South
Africa [9] and is likely to compare favourably with many
programmes in the region. The pretreatment interval in
this programme permitted clinical assessment, blood
testing, patient attendance at a structured education
programme, arrangement of a home assessment by the
therapeutic counsellor, assessment of treatment compli-
ance using co-trimoxazole pill counts and procurement of
drug. Thorough preparation of patients for treatment in
this way has been associated with very high treatment
compliance rates and excellent virological response rates
[18,25].
An important implication of this study is that careful
consideration needs to be given to the design of
community-based ART programmes for low-income
countries. Although it cannot be concluded from the data
here, minimization of the in-programme pretreatment
interval may well decrease mortality in this and other
programmes. However, a balance needs to be established
between minimizing the pretreatment interval (poten-
tially reducing early mortality risk) and allowing adequate
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Table 2. Causes of in-programme deaths.
Cause of death
Deaths [No. (%)]
All patients (n ¼ 68) Patients receiving ART (n ¼ 37) Patients not receiving ART (n ¼ 31)
Wasting syndrome 13 (19.1) 5 (13.5) 8 (25.8)
Acute infection
Acute respiratory infection 7 (10.3) 1 (2.7) 6 (19.4)
Acute gastroenteritis 4 (5.9) 2 (5.4) 2 (6.5)
Systemic sepsis 2 (2.9) 2 (5.4) 0 (0)
Tuberculosis 10 (14.7) 5 (13.5) 5 (16.1)
Malignancy
Kaposi’s sarcoma 7 (10.3) 4 (10.8) 3 (9.7)
Lymphoma 1 (1.5) 1 (2.7) 0 (0)
Cryptococcal meningitis 6 (8.8) 6 (16.2) 0 (0)c
Chronic respiratory disease (non TB) 5 (7.4) 4 (10.8) 1 (2.3)
Drug adverse effects 3 (4.4) 2 (5.4) 1 (3.2)
Miscellaneous 4 (5.9) 3 (8.1) 1 (3.2)
Unknown 6 (8.8) 2 (5.4) 4 (12.9)
P ¼ 0.230;
P ¼ 0.041;










time to prepare patients for treatment (promoting high
rates of treatment adherence and reducing long-term
mortality rates). A system might also be employed
whereby patients at highest risk of death are ‘fast-tracked’
onto treatment; such patients might include those with
stage 4 disease, a blood CD4 lymphocyte count
< 50 cells/ml or an AIDS-defining illness associated with
a particularly poor prognosis, such as wasting syndrome
[26,27]. Data from other ART services in resource-
limited settings may help to identify optimal strategies. A
further implication of these data is that failure to record
in-programme pretreatment deaths may have resulted in
survival bias in previous reports, leading to an over-
estimation of survival benefits among those with
advanced immunodeficiency. Overestimation of the
benefits of ART among such patients may unwittingly
tend to skew priorities away from treating patients at an
earlier stage of disease.
The extremely high mortality in the first 30 days from
enrolment suggests that many patients enrolling into the
programme had disease that was too far advanced at entry.
This is clearly supported by the finding that risk of death
was very strongly associated with baseline blood CD4 cell
count and WHO clinical stage of disease. Indeed, 80% of
deaths within the first 3 months from enrolment were
among those with stage 4 disease or a baseline blood CD4
cell count of< 50 cells/ml. The South African ARTroll-
out programme currently employs the WHO 2002
guidelines, recommending treatment for those with a
clinical criterion of stage 4 disease or a laboratory
criterion of a CD4 cell count < 200 cells/ml. We found
that in-programme mortality among those with CD4 cell
counts > 151 cells/ml was low (Fig. 3d), suggesting that
initiation of ART among patients with CD4 cells counts
of 150–200 cells/ml would be an acceptable target range
for initiating treatment based on mortality outcomes. In
contrast, however, the in-programme mortality rate
among those with stage 4 disease was unacceptably high
(Fig. 3c). Once patients developed stage 4 disease, the
mortality rate is already so high that the inevitable delays
inherent in accessing care, diagnosis, referral to an ART
programme, preparation for treatment and actually
initiating ART result in an unacceptable mortality rate,
of the order of 7% per month [19]. Based on these data,
the clinical criterion for initiating ART should be when
patients first develop symptomatic (stage 3) disease.
Tuberculosis is the most frequent manifestation of WHO
stage 3 disease in the region and the tuberculosis
treatment programmes could provide a key point of
access to the ART programme. Therefore, recommend-
ing treatment for all patients with symptomatic (stage 3
and stage 4) disease and those whose CD4 cell counts
< 200 cells/ml may reduce mortality. In the face of
resource limitations, such a policy would avoid the even
greater expansion of patient numbers requiring treatment
that would result from recommendations to treat patients
with CD4 cell counts < 350 cells/ml as is practice in
high-income countries.
Cause-specific mortality data for HIV-infected individ-
uals living in sub-Saharan Africa are lacking. Postmortem
studies of selected in-patient deaths in Côte D’Ivoire and
Botswana found that the predominant causes were
tuberculosis, bacterial pneumonia and cerebral toxoplas-
mosis [28,29]. Active tuberculosis was also detected by
postmortem examinations among nearly one half of
patients dying with HIV wasting syndrome in West Africa
[30]. In our cohort, in which prophylaxis with co-
trimoxazole (or dapsone) was universally prescribed, 68%
of deaths among patients not receiving HAART were
associated with wasting syndrome, tuberculosis and acute
bacterial infections. The most striking difference in
mortality pattern, comparing those who did and did not
receive ART, was that the six deaths from cryptococcal
meningitis all occurred among patients within the first
few weeks of ART, strongly suggesting immune
reconstitution disease as a possible cause [31]. Overall
immune reconstitution disease was thought likely to have
contributed to over 20% of deaths within the first 3
months of ART. This is typically a complication of
patients with advanced immunosuppression at the time
ART is started and this phenomenon provides another
argument favouring treatment of patients earlier in the
course of disease.
In summary, this analysis found that most early in-
programme deaths occurred among patients with advan-
ced immunodeficiency who had not yet initiated ART. If
this observation is shared by other programmes, then
previously published programme evaluations using on-
treatment analyses may have greatly underestimated early
in-programme mortality. Unnecessary in-programme
delays in treatment initiation should be minimized. In
addition, we suggest that that the programmatic
application of the WHO 2002 treatment guidelines is
associated with an unacceptably high mortality rate in this
setting. Strategies to reduce early mortality should include
treatment of all patients with symptomatic (stage 3 and
stage 4) disease.
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The increasingly widespread use of highly active
antiretroviral therapy (HAART) since 1996 has
substantially improved the prognosis of HIV-infected
patients who have access to these drugs.1-3 In resource-
poor settings in Africa, Asia, and South America, where
90% of people with HIV/AIDS live, access to HAART is
limited. With falling prices of proprietary drugs, the
increasing availability of generic formulations and the
launch of initiatives by international agencies, including
the World Health Organization’s (WHO’s) “3 by 5”
programme (to get 3 million HIV patients on
antiretrovirals by 2005), the Global Fund to fight AIDS,
Tuberculosis and Malaria, and the US President’s
Emergency Plan for AIDS Relief (PEPFAR), this situation
is changing. The WHO estimates that as of June, 2005,
about 1 million people were receiving HAART, although
this number still only represents 15% of the estimated 6.5
million people in urgent need of antiretroviral therapy in
low-income and middle-income countries.4
Several factors could limit the effectiveness of HAART
in resource-poor settings. Interruptions in supply at the
programme level or patients’ limited financial resources
might compromise adherence and treatment efficacy.
The high prevalence of co-infections, notably with
tuberculosis and other bacterial diseases might also
affect prognosis.5-7 Here we report on the Antiretroviral
Therapy in Lower Income Countries (ART-LINC)
collaboration, a network of treatment programmes in
Africa, Asia, and South America.8 Our objective was to
compare early mortality and immunological and
virological response in patients starting HAART in these
settings with outcomes in patients participating in a
similar collaboration of cohort studies in high-income
countries, the ART Cohort Collaboration (ART-CC).1
Methods
Participants
Treatment programmes in low-income countries were
identified by searching published scientific reports,
including abstracts from recent conferences, and by
consulting with colleagues. Site assessments were done
with a standardised questionnaire. Programmes that
collected prospective data on patient characteristics and
outcomes were eligible for inclusion in ART-LINC.
23 treatment programmes were approached, 19 agreed
to participate, and 18 of these [A:?correct] contributed
data to this analysis. 
Information obtained for patients included
sociodemographic data, date of starting HAART, and,
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Mortality of HIV-1 patients in the first year of antiretroviral
therapy: comparison between low-income and high-income
countries 
The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups 
Summary
Background Highly active antiretroviral therapy (HAART) is being scaled up in developing countries. We compared
baseline characteristics and outcomes during the first year of HAART between HIV-1 patients in low-income and
high-income settings. 
Methods 18 HAART programmes in Africa, Asia, and South America (low-income settings) and 12 HIV cohort
studies from Europe and North America (high-income settings) provided data on 4810 and 22 217, respectively,
treatment-naïve adult patients starting HAART. All patients from high-income settings and 2725 (57%) patients
from low-income settings were actively followed-up and included in survival analyses.
Findings Compared with high-income countries, patients starting HAART in low-income settings had lower CD4
cell counts (median 108 cells/L vs 234 cells/L), were more likely to be female (51% vs 25%), and more likely to
start treatment with a non-nucleoside reverse transcriptase inhibitor (NNRTI) (70% vs 23%). At 6 months, the
median number of CD4 cells gained (106 cells/L vs 103 cells/L) and the percentage of patients reaching HIV-1
RNA levels lower than 500 copies/mL (76% vs 77%) were similar. Mortality was greater in low-income settings (124
deaths during 2236 person-years of follow-up) than in high-income settings (414 deaths during 20 532 person-years).
The adjusted hazard ratio (HR) of mortality comparing low-income with high-income settings fell from 4.3 (95% CI
[A: ?ok] 1.6–11.8) during the first month to 1.5 (0.7–3.0) during months 7–12. The provision of treatment free of
charge in low-income settings was associated with lower mortality (adjusted HR 0.23; 95% CI 0.08–0.61). 
Interpretation Patients starting HAART in resource-poor settings have increased mortality rates in the first months
on therapy, compared with those in developed countries. Timely diagnosis and assessment of treatment eligibility,











where available, CD4 cell counts and HIV-1 RNA levels at
baseline and during follow-up. Type of regimen was
defined as protease inhibitor-based (one protease inhibitor
and two nucleoside reverse transcriptase inhibitors
[NRTIs], including ritonavir-boosted regimens), non-
nucleoside reverse transcriptase inhibitors [NNRTI] based
(one NNRTI and two NRTIs), or other combinations
(including triple NRTI regimens and any other regimen
containing a minimum of three drugs). Programme
characteristics were also recorded, including the use of
generic drugs, virological monitoring, costs to patients,
tracing of patients who had been lost to follow-up, and
other services, including voluntary counselling and
testing, and tuberculosis clinics. We defined routine
monitoring of virological response as at least one viral load
measurement between 3 and 9 months after starting
HAART, in at least 50% of patients. 
The ART-CC is a collaboration of cohort studies and
clinical databases from North America and Europe,
established in 2001 to estimate prognosis in treatment-
naïve HIV-infected patients initiating HAART.
Eligibility criteria and methods have been reported
elsewhere.1;9 We included all patients in each of the two
collaborations who had not previously received
antiretroviral therapy, were aged 16 years or older, with
known date of starting HAART and a documented
baseline CD4 count. The stage of disease was classified
as either less advanced (CDC stage A/B, WHO stage
I/II) or more advanced (CDC stage C, WHO stage
III/IV). The selection of patients and extraction of data
was done at the participating centres. Anonymous data
were pooled and analysed centrally. At all sites,
institutional review boards had approved the collection
of data. We use the terms low-income and high-income
settings for the treatment programmes participating in
the ART-LINC and ART-CC collaborations, respectively.
Outcomes
The primary endpoint was mortality from all causes in
the first year after starting HAART. Changes in CD4 cell
counts in the first 6 months, and the proportion of
patients with viral load less than 500 copies/mL at
6 months were secondary endpoints. Measurements
closest to 6 months after starting HAART, within 3 to 9
months, were used in these analyses. We used an
intent-to-continue treatment approach, and ignored
changes to treatment, treatment interruptions and
terminations. Time was measured from the start of
HAART and ended at the earliest of: the date of death;
the date of the last follow-up visit; or month 12 after
starting HAART. A patient was judged to be lost to
follow-up if the last visit was recorded during the first
year after starting HAART and the patient had at least 1
year of additional potential follow-up until the closing
date of the database. The closing date was defined for
each cohort as the date of the most recent follow-up
recorded in the database.
Statistical analysis
In ART-LINC, disease stage at the time of starting
treatment was not available for all patients. Stage of
disease is strongly associated with other variables—in
particular, CD4 cell count. We therefore created multiple
datasets in which disease stage was entered on the basis
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Country Free access Use of Routine virological Voluntary counselling Tuberculosis clinic n (%) Active Proportion lost  
to treatment generic drugs testing and testing on site follow-up to follow-up
Programme
North Africa
Morocco ART cohort Morocco Yes No Yes No Yes 300 (6%) Yes xx (4%)
Southern Africa
Gaborone Independent Botswana No No Yes Yes No 209 (4%) Yes Xx (6%)
Lighthouse Malawi No Yes No Yes No 1056 (22%) No XX (31%)
CTAC South Africa Yes No Yes Yes No 305 (6%) Yes Xx (15%)
Khayelitsha South Africa Yes Yes Yes Yes Yes 278 (6%) Yes 0%
OPERA South Africa Yes No Yes Yes No 53 (1%) Yes 0%
East Africa
Nsambya Uganda No Yes No Yes Yes 236 (5%) Yes XX (44%)
GATP Kampala Uganda No Yes Yes No No 74 (2%) Yes 0%
Eldoret Kenya Yes Yes No Yes Yes 663 (14%) Yes XX (14%)
Central and west Africa
Parvy Cameroon Yes Yes Yes Yes Yes 115 (2%) Yes XX (44%)
COTRAME Côte d’Ivoire Yes No No Yes Yes 131 (3%) Yes 0%
Nigeria HAART Nigeria No Yes No Yes Yes 102 (2%) Yes 0%
ISAARV Senegal Yes Yes Yes Yes Yes 146 (3%) Yes XX (11%)
HIMS Various Yes Yes No Yes No 81 (2%) Yes 0%
South America
Rio de Janeiro HIV Brazil Yes Yes Yes No Yes 429 (9%) No XX (8%
SobrHIV Brazil Yes Yes Yes Yes Yes 496 (10%) No XX (6%)
Asia
YRG Care India No Yes No Yes Yes 104 (2%) No XX (8%)
HIV-NAT Thailand Yes Yes No No No 32 (<1%) Yes 0%
Table 1: Characteristics of antiretroviral treatment programmes in ART-LINC
[A: For HIV-NAT, please
provide the exact
percentage. Please add in
numbers where I have
indicated XX]
[A: Pls spell out












of whether the patient died, which cohort the were in,
CD4 count, age, sex, and type of HAART regimen,
accounting appropriately for uncertainties in both
indices and observation [A: please clarify what this
means].10,11 Analyses were run on each of 20 datasets,
including the input values, and the results combined
with Rubin’s rules.11 We used random-effects Weibull
regression models to estimate mortality hazard ratios
accounting for heterogeneity between treatment
programmes.12,13 Models included both individual level
(age, sex, baseline CD4 cell count, type of initial regimen,
and stage of disease) and programme level characteristics
(free of charge treatment, use of generic drugs, routine
monitoring of virological response, tuberculosis clinic on
site, and intensity of efforts to trace patients). We used a
parametric bootstrap procedure with 300 bootstrap
replications to derive confidence intervals for cumulative
hazards at months 6 and 12. Finally, we compared
mortality between low-income and high-income settings,
adjusting for differences in age, sex, baseline CD4 cell
count, type of initial regimen, and stage of disease. We
used Stata software (version 9) for analyses. Results are
presented as estimates of the probability of death,
mortality rates, and hazard ratios (HRs) with 95% CIs.
Role of the funding source
The sponsors of the study had role in study design; the
collection, analysis, or interpretation of data; the writing
of the report; or the decision to submit the paper for
publication.
Results
The ART-LINC dataset has 6498 treatment-naïve patients
with a known date of starting HAART and at least one
follow-up; 4810 (74%) patients also had a CD4 count at
baseline, and were thus included in the analysis.
Compared with treatment-naïve patients starting
HAART without an immunological assessment, those
with a documented baseline CD4 count were less likely to
be male and more likely to be treated in publicly funded
centres or programmes offering free care.8 The
characteristics of the programmes contributing data to
the present analysis are shown in Table 1. Eligibility
criteria for initiating HAART were generally advanced
immunodeficiency or clinical disease. Six programmes
were publicly funded through government and the
remaining were run by non-governmental organisations
or private doctors. All programmes included CD4 cell
count monitoring, with measurements planned every
4–6 months. Routine monitoring of virological response
was done in 10 programmes. 14 treatment programmes
actively followed-up patients with telephone calls (often
to mobile phones), letters, or home visits. 12 clinics
provided free access to treatment. Costs to patients in the
remaining six clinics varied from $8–198 per month for
drugs, $15–33.50 per CD4 count, and $30–100 per viral
load measurement. The number of patients included in
this analysis ranged from 32 to 1056 patients, the
proportion lost to follow-up from 0% to 44%.
The characteristics of the 12 cohorts from high-income
countries (ART-CC) have been described elsewhere.1
The database includes information on 22 217 patients
who were followed-up in nine cohorts from Western
Europe (including the multicentre EuroSIDA18 study),
two from Canada, and one from the USA. The cohorts
and number of patients included in ART-CC are: French
Hospital Database on HIV14 (n=9167), AIDS Therapy
Evaluation project Netherlands15 (2720), Italian Cohort of
Antiretroviral-Naïve Patients16 (2203), Swiss HIV Cohort
Study17 (2141), EuroSIDA18 (1144), Frankfurt cohort19
(1031), Collaborations in HIV Outcomes Research US
(CHORUS)20 (981), Köln/Bonn Cohort21 (759), Aquitaine
Cohort22 (649), Royal Free Hospital Cohort23 (647),
British Columbia Centre for Excellence in HIV/AIDS2
(507), and South Alberta Clinic24 (268). All cohorts
follow-up patients actively with telephone or postal
reminders, or both. Recording of deaths in ART-CC can
be assumed to be near complete: in two cohorts, deaths
are routinely ascertained from the national mortality
register, and mortality rates in these two cohorts are
similar to that in the others. 
Patients from low-income countries were more likely
to be female and more likely to start HAART with a
NNRTI-based regimen (table 2). The proportion of
participants who were women ranged from 29% in India
to 79% at a site in South Africa; corresponding
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Low-income settings (n=4810) High-income settings (n=22217)
n (%)* Deaths n (%)* Deaths
Age (years)
16–29 1013 (21%) 33 4125 (19%) 42
30–39 2188 (45%) 80 10421 (47%) 161
40–49 1177 (24%) 36 5043 (23%) 108
50 432 (9%) 16 2628 (12%) 103
Median (IQR) 36 (30–42) .. 36 (31–43) ..
Sex
Female 2461 (51%) 86 5486 (25%) 79
Male 2349 (49%) 79 16731 (75%) 335
Baseline CD4 (cells/L)
25 917 (19%) 66 2081 (9%) 113
25–49 557 (12%) 25 1350 (6%) 58
50–99 805 (17%) 30 2181 (10%) 52
100–199 1217 (25%) 30 4038 (18%) 87
200–349 940 (20%) 10 6018 (27%) 66
350 374 (8%) 4 6549 (30%) 38
Median (IQR) 108 (37–210) .. 234 (98–380) ..
Clinical stage
CDC stage A/B, WHO stage I/II 867 (18%) 13 17142 (77%) 154
CDC stage C, WHO stage III/IV 1733 (36%) 97 5075 (23%) 260
Unknown 2210 (46%) 55 0 (0%) ..
Initial antiretroviral regimen
NNRTI-based 3391 (70%) 120 5125 (23%) 71
Protease inhibitor-based 900 (19%) 30 13783 (62%) 276
Unknown or other combination 519 (11%) 15 3309 (15%) 67
*Data are n (%) unless otherwise indicated.
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proportions in high-income countries ranged from 9%
(CHORUS, USA) to 31% (Swiss HIV Cohort Study). In
patients from low-income settings, the median CD4 cell
count at the time of starting HAART was 108 cells/L
(IQR 37–210) compared with 234 cells/L (98–380) in
patients from Europe and North America. Information
on clinical stage was available for 2660 (54%) patients
from low-income settings and for all patients from high-
income settings. The route of infection was recorded in
few patients in low-income countries, but most are
assumed to have been infected through heterosexual
intercourse. Conversely, in high-income cohorts, sex
between men was the highest risk factor (8777 patients,
40%), followed by heterosexual sex (7910, 36%) and
intravenous drug use (3553, 16%). 
In low-income settings, 2725 (57%) patients were
treated in programmes with active follow-up procedures
and 3029 (63%) had free access to HAART. Webtables 1
and 2 compare the characteristics of patients treated in
programmes with active and passive follow-up, and
those in programmes free of charge and those that were
not free. 727 (15%) and 1104 patients (5%) were lost to
follow-up during the first year of therapy in low-income
and high-income settings, respectively. In low-income
settings, loss to follow-up was 12% (331 of 2725) in
programmes with active follow-up and 19% (396 of
2085) in programmes with passive follow-up; loss to
follow-up occurred after a median of 5.8 months (IQR
2.5–7.7) and 3.4 months (1.4–6.9), respectively. In
treatment programmes with active follow–up, those lost
to follow-up and those followed-up at 1 year had similar
baseline CD4 cell counts (median 115 cells/L and 123
cells/L), whereas patients lost to follow-up in
programmes with no active follow-up procedures had
considerably lower CD4 cell counts than those followed-
up (median 64 cells/L and 123 cells/L). Webtable 3
compares the characteristics of patients lost to follow-up
in both active and passive follow–up programmes. 
After 6 months of treatment, CD4 and HIV-1 RNA
measurements were available for 2789 (57%) and 2003
(48%) patients,respectively, in low-income settings, and
in 19 560 (88%) and 19 164 (86%) in high-income
settings. In low-income settings, patients with CD4
counts and viral load measurements at 6 months started
HAART 1–2 years earlier, had higher CD4 cell counts at
baseline, and were more likely to be treated in a
programme providing free access to HAART than
patients with no measurements. The median number of
CD4 cells gained was 106 cells/L (IQR 43–180) in low-
income countries and 103 cells/L (32–192) in high-
income, countries. 1527 (76%) in low-income settings
and 14825 (77%) in high-income countries had HIV-1
RNA levels lower than 500 copies/mL at 6 months. 
At 1 year, mortality was estimated at 6.4% (95% CI
5.1–7.7) in low-income programmes with active follow-
up (based on 124 deaths and 2236 person-years of follow-
up), 2.3% (1.5–3.2) in low-income programmes with
passive follow-up (41 deaths and 1508 person-years
follow-up), and 1.8% (1.5–2.2) in programmes from
high-income countries (414 deaths and 20 532 person-
years follow-up) (figure 1). Treatment programmes with
passive follow-up were excluded from subsequent
analyses.
Baseline CD4 cell count was strongly prognostic both in
low-income and high-income settings: the lower the
baseline CD4 cell count, the higher the probability of
death (table 3). Older age and more advanced clinical
4 www.thelancet.com Vol 367   Month xx, 2006 
Hazard ratio (95% CI)
Low-income settings (n=2725) High-income settings (n=22217)
Age (years)
16–29 1 1
30–39 1·12  (0·70–1·81) 1·16 (0·82–1·64)
40–49 1·09  (0·62–1·94) 1·47 (1·02–2·11)
50 1·53  (0·74–3·18) 2·57 (1·78–3·71)
Sex
Male 1 1
Female 0·84  (0·58–1·22) 0·85  (0·66–1·09)
Baseline CD4 (cells/L)
25 1 1
25–49 0·77 (0·46–1·28) 0·83 (0·61–1·15)
50–99 0·54  (0·32–0·90) 0·55 (0·40–0·77)
100–199 0·37  (0·22–0·64) 0·67 (0·50–0·90)
200–349 0·14  (0·06–0·35) 0·44 (0·32–0·62)
350 0·34  (0·12–1·01) 0·26 (0·17–0·39)
Clinical stage*
CDC stage A/B, WHO stage I/II 1 1
CDC stage C, WHO stage III/IV 2·02 (1·02–4·02) 3·75 (2·96–4·74)
Initial regimen
Two NRTIsone NNRTI 1 1
Two NRTIsone protease inhibitor 1·35 (0·76–2·40) 1·00 (0·77–1·31)
Unknown or other combination 1·13 (0·54–2·35) 1·17 (0·83–1·64)
*Entered for only 649 patients from low-income settings. 
Table 3: Hazard ratios of progression to death in HAART programmes in low-income and 
high-income countries
[A: The hazard ratio is
much highere here for
CD4 count =350
compared with 200-349




























Figure 1: Estimated cumulative probability of death in HAART programmes
in low-income and high-income countries










stage were also associated with increased mortality.
Among patients actively followed up, after imputation of
missing information, an estimated 1608 patients (59.0%)
had more advanced disease, whereas 504 patients (18.5%)
had less advanced disease with a CD4 cell count above 200
cells/L. There was little evidence for differences in
progression rates between men and women or between
patients starting HAART with different regimens.
In low-income settings, mortality was substantially
higher in the first months after starting HAART than in
later months. Mortality rates per 1000 person-years was
147 (95% CI 105–207) during month 1, 106 (71–160) in
month 2, 51 (33–77) in months 3–4, 51 (33–79) in
months 5–6, and 27 (19–40) in months 7–12  (figure 2).
This trend was also noted in high-income settings, with
mortality falling from 24 (21–27) during the first 6
months to 16 (14–19) during months 7–12. 97 (78%) of
124 deaths in low-income settings and 255 (62%) of 414
deaths in high-income countries happenedin the first 6
months [A: ?rewording ok]. Figure 2 shows crude and
adjusted hazard ratios, comparing mortality in low-
income countries to that in high-income settings, by
time period after starting HAART. Adjusted hazard
ratios fell from 4.31 (95% CI 1.57–11.81) during the first
month on HAART to 1.48 (0.73–3.01) during the second
half of the first year on HAART.
We assessed whether characteristics of treatment
programmes in low-income settings affected outcome
(table 4). In multivariable analysis, free access to
treatment (with no costs to patients) was associated with
lower mortality, whereas higher mortality was seen in
programmes that included a tuberculosis clinic. There
was little evidence for an association between mortality
during the first year and the use of generic drugs or the
routine monitoring of virological response. 
Discussion
Mortality rates of HIV-infected patients from low-
income settings in Africa, South America, and Asia fell
substantially within the first few months of HAART, and
approached those seen in Western Europe and North
America after 4–6 months. Patients in low-income
settings started treatment with considerably more
advanced immunodeficiency than those from
industrialised countries, but virological and
immunological response to HAART were similar in
both settings, a finding that tallies with results from a
recent collaborative analysis of treatment sites in the
Asia and Pacific region,26 a meta-analysis of the
literature,27 and reports from single centres.28-30
This systematic comparison of outcomes of HAART
between low-income and high-income countries was
done in treatment-naïve patients only, and results are
therefore not confounded by previous antiretroviral
therapy. Patients were enrolled in many different
settings, which should reflect the experience with
HAART in these regions. A substantial proportion of
patients from low-income settings had to be excluded,
and the data from low-income settings may thus be less
generalisable than those from Europe and North
America. Our study was restricted to adults, and results
might not be applicable to infants and children.
Information on AIDS events before starting treatment
was missing for some patients in low-income settings.
The statistical methods that we used to deal with this
make use of the fact that previous AIDS events are
strongly associated with measured factors at initiation,
in particular, the CD4 cell count, while allowing
appropriately for the additional uncertainty due to the
missing data.10,11
Loss to follow-up is an important issue in treatment
programmes in low-income settings. Ascertainment of
deaths was clearly incomplete in ART-LINC clinics where
no specific attempts were made to trace patients,
confirming the results of a study from Côte d’Ivoire.31
These sites were excluded from survival analyses. In
treatment programmes that actively followed-up patients,
Articles
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Hazard ratio (95% CI)
Unadjusted Adjusted
Free access to treatment
No 1 1
Yes 0·45 (0·13–1·54) 0·25 (0·08–0·78)
Use of generic drugs
No 1 1
Yes 1·78 (0·52–6·13) 1·40 (0·45–4·39)
Routine monitoring of virological response
No 1 1
Yes 1·43 (0·42–4·90) 2·28 (0·76–6·79)
Tuberculosis clinic on site
No 1 1
Yes 2·42 (0·71–8·28) 3·76 (1·01–14·02)
Table 4: Associations between HAART programme characteristics in



















Months from starting HAART
Figure 2: Comparison of mortality in the months after starting HAART in
low-income and high-income settings
Shaded areas represent the periods for which hazard ratios were calculated.











individuals lost to follow-up and those followed-up had
similar baseline CD4 cell counts: those lost to follow-up
were therefore probably not a selected group of patients
with worse prognosis. All patients were started on
HAART, which was documented for several months in
most patients later lost to follow-up. This means that
many will have survived the initial months, which have
high mortality rates. Finally, our censoring strategy was
conservative: follow-up was censored at the last visit.
Clearly, some patients lost to follow-up will have died
during the first year. In the worst-case scenario, if those
lost to follow-up had the same prognosis as untreated
patients, their baseline CD4 cell count (115 cells/L)
would mean that 25–50% died within 1 year.32 This would
increase mortality from 6.4% to as high as 15% [A: ?is
this what you meant]. A study33 of 910 adult treatment-
naïve patients from Port-au-Prince, Haiti, reported that
13% died during the first year and 8% were lost to follow-
up. This difference could suggest under-ascertainment of
deaths in ART-LINC. Alternatively, the higher mortality
in Port-au-Prince could be due to the more stringent
criteria for initiating antiretroviral therapy (clinical AIDS
or a CD4 cell count below 200 cells/L). In ART-LINC, a
substantial proportion of patients were free of AIDS at
baseline, with a CD4 cell count above 200 cells/L.
Notably, in both the Haitian study and ART-LINC about
80% of deaths occurred during the first 6 months.   
The higher mortality in low-income countries during
the first months of treatment compared with those in
Europe and North America was only partly explained by
the lower CD4 cell counts and more advanced clinical
stage. Co-morbidities that are present in many patients
starting HAART in resource-poor settings, including
tuberculosis and invasive bacterial and fungal infections,
might have increased mortality,34 considering that access
to prophylaxis, diagnostic facilities, and effective treatment
for opportunistic infections is often limited. Immune
reconstitution disease, an adverse consequence of
restoration of pathogen-specific immune responses might
also be a problem, particularly for tuberculosis.35 Advanced
immunodeficiency is associated with subclinical and
disseminated infections, with high mycobacterial antigen
load, and rapid improvement of restoration of immune
function during HAART.6,35 Inflammatory reactions occur
in about one-third of co-infected patients receiving both
HAART and tuberculosis treatment,35,36 and might have
contributed to the higher mortality we noted for sites with
dedicated tuberculosis clinics. 
However, even in the first months of HAART,
mortality was lower than previously noted in untreated
patients, suggesting an early beneficial effect of HAART.
For example, compared with a mortality rate of 147 per
1000 person-years in the first month after treatment
initiation in ART-LINC, mortality was 264 per 1000
person-years in the Cape Town AIDS Cohort37 of 974
patients not treated with HAART, 353 per 1000 person-
years in 746 untreated patients from the Gambia,38 and
231 per 1000 person-years in a prospective study of 201
untreated Ugandan patients.39
Mortality was increased in programmes that charged
fees. The World Bank, the International Monetary Fund,
and other agencies have been criticised for promoting
the privatisation of health services and private financing
of health services through user fees.40,41 Whitehead and
colleagues42 have argued that market-oriented policies
can result in untreated morbidity, reduced and more
unequal access to care, further impoverishment of those
who are already poor, and can promote the irrational[A:
?do you mean ‘inappropriate’ rather than ‘irrational’] use
of drugs. For example, treatment might have been
stopped when money ran out: payments for
antiretrovirals during the initial phase of therapy do not
mean that households have the ability to pay for
extended periods of time. In these settings, treatment
might also be more likely to be interrupted and resumed
upon clinical deterioration, which could promote viral
resistance to drugs. Our results extend those from a
systematic review and meta-analysis,27 which recorded
that provision of HAART free of charge to the patient
was associated with an increased probability of achieving
and maintaining suppression of viral replication.
Although we acknowledge that other aspects of the
delivery of care could have confounded associations,
there must be concern that the “inverse equity
hypothesis”, which stipulates that health inequities will
get worse as effective new public health interventions
initially reach those of higher socioeconomic status and
only later the poor, could be borne out in the case of
HAART in some resource-poor settings.43,44
In many of the countries included in our study, access
to potent antiretrovirals continue to be limited. For
example, the WHO estimates that as of June, 2005, the
percentage of people in need of antiretroviral therapy
who received HAART was 4–8% in Nigeria, 4–9% in
India, 10–17%% in Côte d’Ivoire, 10–14% in South
Africa, 11–14% in Malawi, 12–17% in Kenya, 11–19% in
Cameroon, and 35–43% in Uganda.4 Thailand,
Botswana, and Brazil are providing treatment to half or
more of people living with HIV/AIDS that need it,
consistent with the WHO “3 by 5” target.4 Clearly, the
global health emergency that was declared by the United
Nations General Assembly in 2001 continues. 
Effective antiretroviral therapy is feasible in low-
income settings, but, compared with industrialised
countries, mortality is high in the first months.
Eligibility for antiretroviral treatment and the need for
treatment of tuberculosis should be determined earlier,
and HAART should be started before serious co-
morbidities develop. The scalingup of HAART should
therefore be accompanied by an expansion of voluntary
counselling and testing services, and by efforts to reduce
the stigma and adverse social effects associated with a
positive HIV test, which might encourage more people
at risk of HIV to seek testing [A: ?ok]. 
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Determinants of Mortality and Nondeath Losses
from an Antiretroviral Treatment Service in South
Africa: Implications for Program Evaluation
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Background. The scale-up of antiretroviral treatment (ART) services in resource-limited settings requires a
programmatic model to deliver care to large numbers of people. Understanding the determinants of key outcome
measures—including death and nondeath losses—would assist in program evaluation and development.
Methods. Between September 2002 and August 2005, all in-program (pretreatment and on-treatment) deaths
and nondeath losses were prospectively ascertained among treatment-naive adults ( ) who were enrolledn p 1235
in a community-based ART program in South Africa.
Results. At study censorship, 927 patients had initiated ART after a median of 34 days after enrollment in the
program. One hundred twenty-one (9.8%) patients died. Mortality rates were 33.3 (95% CI, 25.5–43.0), 19.1 (95%
CI, 14.4–25.2), and 2.9 (95% CI, 1.8–4.8) deaths/100 person-years in the pretreatment interval, during the first 4
months of ART (early deaths), and after 4 months of ART (late deaths), respectively. Pretreatment and early
treatment deaths together accounted for 87% of deaths, and were independently associated with advanced im-
munodeficiency at enrollment. Late deaths were comparatively few and were only associated with the response to
ART at 4 months. Nondeath program losses (loss to follow-up, 2.3%; transfer-out, 1.9%; relocation, 0.7%) were
not associated with immune status and were evenly distributed during the study period.
Conclusions. Loss to follow-up and late mortality rates were low, reflecting good cohort retention and treatment
response. However, the extremely high pretreatment and early mortality rates indicate that patients are enrolling
in ART programs with far too advanced immunodeficiency. Causes of late access to the ART program, such as
delays in health care access, health system delays, or inappropriate treatment criteria, need to be addressed.
Although sub-Saharan Africa is home to just 10% of
the world’s population, more than 60% of the world’s
HIV-infected people live there; in 2005 alone, an esti-
mated 2.4 million people in the region died of HIV/
AIDS [1]. As one component of a strategy to address
this devastating epidemic, access to antiretroviral treat-
ment (ART) is now being rapidly expanded within the
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region. In June 2005, it was estimated that 6.5 million
people urgently required treatment in resource-limited
settings. In view of the enormous scale of this inter-
vention, a simplified programmatic approach has been
adopted to facilitate delivery of treatment [2–4]. The
efficacy of ART, as reflected by virological and im-
munological responses, is similar among patients
treated in high-income countries and patients treated
in resource-limited countries [5, 6]. The impact of ART
programs in low-income countries is, therefore, un-
likely to be related to questions of drug efficacy, but
rather to health system issues and program effectiveness
[7]. Parameters with which to evaluate the effectiveness
of programs need to be identified. Tuberculosis treat-
ment programs provide a useful model of how evalu-
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longitudinal program assessments and comparisons [8]. Similar
principals might usefully be applied to ART programs.
Two key goals of ART programs are to prevent mortality and
to retain people within the program, receiving treatment in the
long term. In this study, we describe mortality occurring (1)
in the short interval between program enrollment and initiation
of ART (the pretreatment interval), (2) during early ART (0–
4 months), and (3) during late ART (4 months to 3 years). We
also characterized nondeath losses. We have accurately quan-
tified these different losses during the first 3 years of a com-
munity-based ART program in South Africa. We identified the
temporal distribution and determinants of these different out-
comes, which have thereby provided important insights into
program performance.
SUBJECTS AND METHODS
ART. The ART service described here is based at the Gugu-
lethu Community Health Centre in Cape Town and has pre-
viously been described in detail [9–11]. This district has a pre-
dominantly African population of 1300,000, the vast majority
of whom live in conditions of low socioeconomic status. In
2003, the antenatal HIV seroprevalence was 28%. Patients are
referred to the ART program from primary care HIV clinics.
Treatment criteria are based on the World Health Organiza-
tion’s (WHO’s) 2002 recommendations [3], which include a
prior AIDS diagnosis (WHO stage 4 disease) or a blood CD4
cell count !200 cells/mL.
The time between enrollment of a patient in the service and
initiation of ART is ∼1 month, to permit thorough evaluation
of patients and preparation for treatment as described previ-
ously [9–11]. Assignment of each patient to a community-based
therapeutic counselor facilitates this preparation and provides
an efficient system for determining outcomes for all patients,
including tracing those who do not attend follow-up appoint-
ments. A proportion of patients do not initiate treatment in
this service for a variety of reasons other than death; such
individuals are deferred from the program, and follow-up is
censored at this time-point. However, all individuals contrib-
uted to the pretreatment person-time of observation, regardless
of whether they subsequently received ART.
First-line ART consisted of stavudine and lamivudine plus a
nonnucleoside reverse transcriptase inhibitor (efavirenz or ne-
virapine). The second-line regimen for those for whom first-
line treatment failed was composed of lopinavir/ritonavir, zi-
dovudine, and didanosine. All treatment was provided free of
charge. Treatment adherence and viral load suppression at a
level of !400 copies/mL in this cohort both exceeded 90% at
1 year [10–12]. All patients with CD4 counts !200 cells/mL
received prophylaxis with daily trimethoprim-sulfamethoxazole
or dapsone as an alternative. In addition to scheduled clinic
appointments at 4, 8, and 16 weeks and once every 16 weeks
thereafter, patients had open access to the clinic for medical
problems.
Definitions. ”Permanent deferrals” were patients who did
not receive ART for a reason other than pretreatment death
and who were subsequently excluded from the program. “Pre-
treatment deaths” were those that occurred among patients who
had enrolled into the program but who had not yet initiated
ART. “Early on-treatment deaths” were those that occurred
during the first 4 months of ART, and “late on-treatment
deaths” were those that occurred after 4 months of ART. “Trans-
fers-out” were patients whose care was transferred to another
ART program. “Relocations” were patients who moved to an-
other location but who were not referred to an ART service in
the new area. “Losses to follow-up” were patients receiving ART
who were 14 weeks late for a scheduled clinic or pharmacy
visit and who were neither transfers-out nor relocations. “Non-
death losses” were the sum total of transfers-out, relocations,
and losses to follow-up.
Data sources. Structured clinical records were maintained
for all patients screened on entry to the ART program. This
information was transferred to a computer database on a weekly
basis. Data were analyzed from the start of the program in
September 2002 until data censorship in August 2005. This
study was approved by the Research Ethics Committee of the
University of Cape Town, and all patients who were enrolled
gave written, informed consent.
Data analysis. Data were analysed using Stata, version 9.0
(StataCorp). Wilcoxon rank-sum and Fisher’s exact tests were
used to compare medians and proportions, respectively. In sep-
arate analyses, we calculated rates of mortality and other out-
comes from either program enrollment (the date of initial
screening by the service) or from ART initiation. Person-time
was censored at the end of August 2005 for individuals who
were alive and who had been retained by the service. Product-
limit analyses were used to calculate the instantaneous hazard
of death or other losses through time among individuals re-
ceiving ART; we plotted smoothed hazard-function estimators
using weighted kernel-density estimates based on an Epane-
chnikov function [13]. In other product-limit analyses, log-
rank tests were used to examine the effect of baseline WHO
clinical stage and category of CD4 cell count on survival prob-
abilities. All statistical tests are 2-sided at a p .05.
Multivariate analysis employed proportional hazard models
to examine determinants of mortality among individuals re-
ceiving ART. Separate models were developed to examine fac-
tors associated with early mortality, late mortality, and all
deaths. In separate models, baseline CD4 cell count was mod-
eled as both a continuous variable (per 50-cell/mL change in
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Figure 1. Flow diagram showing the outcomes of patients included in
the analysis ( ) at the time that data were censored. ART, an-n p 1235
tiretroviral therapy.
threshold effects. Covariates were included in the model if they
demonstrated an appreciable association with the relative haz-
ard of mortality, or if their removal affected associations in-
volving other covariates. Model diagnostics and the propor-
tional hazards assumption were examined using Schoenfield
and scaled Schoenfield residuals [14].
RESULTS
Cohort and follow-up. During the period of September 2002
through August 2005, 1340 patients enrolled in the program.
Those who were not naive to ART ( ) and those !15n p 53
years of age at enrollment ( ) were excluded. Amongn p 52
1235 patients who remained in the analysis, the median age
was 33 years (interquartile range [IQR], 28–38 years), and 882
patients (71%) were female. Baseline plasma viral load and
blood CD4 cell counts were available for 1086 and 1120 pa-
tients, respectively. The median plasma viral load was 4.81 log10
copies/mL (IQR, 4.42–5.23 log10 copies/mL), and the median
blood CD4 cell count was 100 cells/mL (IQR, 47–160 cells/mL).
Most patients (79%) had symptomatic disease, and 644 (52%)
and 332 (27%) had WHO stage 3 and 4 disease, respectively.
Nine hundred twenty-seven patients (75%) received ART
during the study period, and 117 (9.5%) were preparing for
treatment at the time the study was censored (figure 1). The
median time between enrollment in the program and initiation
of treatment was 34 days (IQR, 28–50 days). Over the course
of the study, 170 person-years of observation were accrued in
the pretreatment interval, and 808 person-years were accrued
during treatment.
Numbers and characteristics of deaths and nondeath losses.
One hundred thirty-five (9.5%) patients were deferred from
the service before initiation of ART (figure 1) for a variety of
reasons, including decision to access treatment elsewhere, fail-
ure to attend follow-up clinic appointments, movement out of
the area, or for psychosocial reasons. Among total deaths
( ), 56 (46%) occurred in the pretreatment interval, 49n p 121
(40%) were early on-treatment deaths, and 16 (13%) were late
on-treatment deaths. The death rate was high in the pretreat-
ment interval (33.3 deaths/100 person-years; 95% CI, 25.5–
43.0 deaths/100 person-years) but decreased during the first 4
months of ART (19.1 deaths/100 person-years; 95% CI, 14.4–
25.2 deaths/100 person-years), and was lower still beyond 4
months ART (2.9 deaths/100 person-years; 95% CI, 1.8–4.8
deaths/100 person-years). After 1 year of ART, the mortality
rate was just 1.3 deaths/100 person-years (95% CI 0.4–3.9
deaths/100 person-years).
Among those who initiated ART ( ), 110 patientsn p 927
(11.9%) were lost from the program (figure 1). Among these,
death was the most common reason, accounting for 65 (7.0%)
of losses, whereas 45 (4.9%) were due to other causes. These
nondeath losses were due to tra sfer-out (18 [1.9%]), reloca-
tion (6 [0.7%]), and loss to follow-up (21 [2.3%]).
We compared the characteristics of patients who were lost
from the program due to death with those who were lost due
to other reasons or who continued to receive treatment when
the data was censored (table 1). In univariate analyses, those
who died in the pretreatment interval or during early ART were
more likely to have a prior AIDS diagnosis, a baseline CD4 cell
count !100 cells/mL, and a baseline plasma viral load 1105
copies/mL, compared with those who remained in the program.
Those who died after 4 months of ART (late deaths) were also
more likely to have a baseline CD4 cell count !100 cells/mL,
although this association did not persist in the multivariate
analysis (see below). In contrast, nondeath losses were not as-
sociated with baseline immunodeficiency. Kaplan-Meier anal-
yses confirmed that the probability of in-program death was
strongly associated with WHO stage of disease and baseline
CD4 cell count (figure 2).
Temporal distribution of program losses. The risk of loss
from the program changed markedly during follow-up of pa-
tients receiving ART (figure 3A). Risk of death had 3 distinct
phases: an initially high—but steeply decreasing—risk during
the initial months of ART, followed by a moderate risk of death
up to ∼1 year, and a very low risk of death after 1 year (figure
3B). In contrast, the risk of program loss due to other causes
was relatively constant (figure 3C). After ∼1 year of ART, risk
of nondeath losses to the program exceeded losses due to death.
Multivariate analysis for risk of death during ART.
In multivariate analysis to predict the relative hazards of death
during ART, death was significantly associated with baseline
CD4 cell count and WHO clinical stage, but not with age, sex,
or baseline viral load. However, risk factors for early deaths
versus late deaths differed markedly (table 2). Early on-treat-
ment deaths were associated with advanced WHO clinical stage,
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Figure 2. Kaplan-Meier plots showing survival of patients from entry
into the program stratified by World Health Organization (WHO) clinical
stage (A) and baseline blood CD4 cell count (B). These reveal that risk
of death early in the program was strongly associated with the baseline
degree of immunodeficiency at enrollment.
Table 1. Baseline characteristics of patients who either remained in the program, died, or were






program lossesPretreatment Early Late
No. of patients 817 56 49 16 45
Female sex 601 (74) 37 (66) 25 (49) 12 (75) 32 (71)
Age, median years (IQR) 33 (28–38) 32 (28–40) 34 (28–39) 35 (32–41) 31 (27–35)
Prior AIDS diagnosis 207 (25) 30 (54)a 29 (59)a 7 (44) 12 (27)
CD4 count !100 cells/mL 410 (50) 35 (63)a 40 (82)a 13 (81)b 27 (60)
Viral load 1105 copies/mL 301 (37) 19 (59)b 26 (54)b 9 (56) 21 (47)
NOTE. Data are no. (%) of patients, unless otherwise indicated. Statistical comparisons were made between char-
acteristics of those who were retained in the program, compared with the characteristics of those who were lost to
the program. IQR, interquartile range.
a .P ! .05
b .P ! .001
In contrast, late on-treatment deaths were only independently
associated with the response to ART at 4 months, as reflected
by blood CD4 cell count and viral load. Although the number
of late deaths was small (data were available for 12 of 16 deaths),
this association with CD4 cell count was statistically highly
significant, and the trend towards an association with viral load
approached statistical significance.
CD4 cell count increases and risk of loss to program.
We examined how on-treatment program losses (death and
nondeath) were associated with CD4 cell counts at baseline and
after 4 months of ART. Although the median CD4 cell increases
among patients retained in the cohort (99 cells/mL; IQR, 49–
162 cells/mL) were similar to those among nondeath losses (83
cells/mL; IQR, 49–133 cells/mL), those who subsequently died
had much smaller CD4 cell count increases (44 cells/mL; IQR,
5–83 cells/mL). The vast majority of deaths occurred among
individuals who had a baseline CD4 cell count !100 cells/mL
and a CD4 cell count !200 cells/mL at 4 months (figure 4A).
In contrast, nondeath losses were not associated with the CD4
cell count distribution (figure 4B).
DISCUSSION
In this study we carefully quantified mortality and nondeath
losses in a community-based ART program in South Africa and
identified the temporal distribution and risk factors associated
with these losses. We defined pretreatment, early and late ART
mortality, and nondeath losses as useful outcome measures of
ART programs. Loss to follow-up and late mortality rates were
low, reflecting excellent cohort retention and treatment re-
sponse in this program. In contrast, however, pretreatment and
early mortality rates were very high: this finding very strongly
suggests that patients were enrolling with far too advanced
immunodeficiency. To reduce in-program mortality, the causes
of late program entry need to be addressed.
On-treatment mortality rates were similar to or better than
those previously reported from resource-limited settings [15–
19]. Although previous studies have not reported mortality
occurring within the program prior to actual initiation of ART,
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Figure 3. Smoothed hazard estimates for total losses to program (A),
death (B), and nondeath losses to program (C; i.e., transfers-out, relo-
cations, and losses to follow-up). Risk of mortality was initially high but
decreased steeply, and there were very few deaths after 400 days of
ART. Risk of nondeath losses was relatively consistent during follow-up.
ART, antiretroviral therapy
Table 2. Results of separate Cox’s models predicting relative
hazards of early deaths ( ) and late deaths ( ) aftern p 49 n p 12
initiation of antiretroviral therapy (ART).
Variable Early deaths Late deathsa
Ageb 1.01 (0.97–1.05) 1.07 (0.99–1.14)
Sex
Female 1.00 1.00
Male 2.00 (1.10–3.62) 0.58 (0.16–2.03)
WHO stage
1, 2, or 3 1.00 1.00
4 2.78 (1.52–5.09) 1.71 (0.50–5.82)
Baseline CD4 countc 0.62 (0.47–0.83) 0.98 (0.58–1.65)
CD4 count at 4 months … 0.42 (0.25–0.73)
Baseline viral load
105 log10 copies/mL 1.00 1.00
1105 log10 copies/mL 1.37 (0.77–4.44) 1.24 (0.36–4.28)
Viral load at 4 months
!50 copies/mL … 1.00
50 copies/mL … 3.17 (0.94–10.71)
NOTE. Data are hazard ratio (95% CI). WHO, World Health Organization.
a Complete data available for 12 of 16 patients.
b Analyzed as a continuous variable.
c Analyzed in 50-cell/mL increments.
deaths occur during this pretreatment interval [9]. The pre-
treatment interval in the present analysis (median, 34 days) is
shorter than reported elsewhere [15] but permitted careful eval-
uation, investigation, and treatment of opportunistic infections,
as well as thorough preparation of patients for ART. We believe
this preparation is key to the very high adherence rates and
excellent virological and immunological outcomes observed in
this program [10, 11]. Within this service, clinicians were able
to “fast-track” patients who had the most advanced immu-
nodeficiency; however, shortening the pretreatment interval for
all patients may not necessarily reduce early mortality and may
actually compromise long-term outcomes.
The present analysis shows that, after 3 years of this program,
deaths in the pretreatment interval contributed 146% of total
program mortality and therefore represent a very important out-
come measure. This mortality is likely to reflect a far greater
burden of mortality that is actually occurring prior to program
entry. Those who died in the first 4 months of treatment (early
deaths) shared the same baseline characteristics and risk factors
as those who died in the pretreatment interval (tables 1 and 2);
together, deaths in these 2 intervals constituted 87% of total
program mortality. The strong association of these deaths of
patients who had advanced immunodeficiency at baseline clearly
indicates that many of these patients had advanced disease that
could not be salvaged by ART, despite the active management
in many patients of concurrent infections. One-half of the pa-
tients enrolling into this program had a baseline CD4 cell count
!100 cells/mL. Kaplan-Meier survival analyses revealed that early
mortality was high among patients with WHO stage 3 and stage
4 disease (i.e., symptomatic disease) and patients with baseline
CD4 cell counts !100 cells/mL (figure 2).
The reasons why patients typically enter this and other pro-
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Figure 4. Scatter plots of baseline CD4 cell count against CD4 cell count at the 16-week follow-up time-point. On these plots, individual patients
(dark squares) who either died (A; data available for 12 of 16 patients) or were lost to the program for other reasons (B; ) after 4 months ofn p 22
antiretroviral therapy (ART) are indicated. Deaths—but not nondeath losses—occurred among individuals with advanced baseline immunodeficiency
and persisting immunodeficiency after 16 weeks of ART.
need to be identified. Possible reasons include (1) barriers to
voluntary counseling and testing and to access to health care,
(2) lack of routine blood CD4 cell count testing for patients
with new HIV diagnoses, (3) health system delays in referral
patients to ART clinics, (4) waiting times to enter programs,
and (5) criteria for initiation of ART that only include patients
with advanced disease. How to best promote early access of
ART-eligible patients to treatment programs is a central chal-
lenge facing the scale-up of these programs in resource-limited
settings [20]. Moreover, the South African national ART pro-
gram uses the WHO 2002 ART guidelines, which restricts treat-
ment to patients with stage 4 disease or CD4 cell counts !200
cells/mL [3]. The revised WHO 2003 guidelines for resource-
limited settings recommend earlier treatment [4], and the use
of these may help to lower mortality. Moves to earlier initiation
of treatment are supported by a collaborative analysis of da-
tasets that reveal that mortality rates in ART programs in re-
source-limited settings are higher than those in high-income
countries [5].
In contrast to early deaths, mortality after 4 months of ART
(late death) was independent of baseline immune status but
was strongly associated with the response to ART, as reflected
by the absolute blood CD4 cell count and viral load at 4 months.
As such, the late mortality rate reflected therapeutic success,
including drug regimen efficacy and tolerability as well as pa-
tient adherence to treatment. After the first year of ART, mor-
tality rate was very low—approaching 1% per year—and the
risk of loss to program due to nondeath causes exceeded those
due to death (figure 3). Thus, the effectiveness of programs
beyond 1 year is likely to relate to issues of long-term patient
retention rather than death. As patients remain healthy on long-
term medication, their motivation to continue treatment in the
longer term may diminish [21]. It remains unknown whether
an increasing rate of treatment failure and a secondary increase
in the death rate may occur with longer follow-up.
Among ART programs in sub-Saharan Africa, rates of non-
death program losses range from !5% [15, 17] to 150% [22].
When patients are termed “lost to follow-up” simply on the
basis of persistent failure to attend clinic appointments, it is
possible that some may in fact have died without detection by
the ART program. The true mortality rate among patients re-
ceiving ART may, therefore, often be underestimated. However,
in this analysis, the use of community-based therapeutic coun-
selors that were allocated to each patient enhanced the data
completeness and assessment of outcomes for patients who
failed to attend follow-up appointments.
Nondeath program losses in this setting were heterogeneous
in nature. Patients who moved out of the area accounted for
22% of total on-treatment program losses. As opposed to those
transferred to another ART program, the care of some patients
(here termed “relocations”) was not transferred, often because
of lack of provision of ART services in other areas. Because the
number of patients who are physically well and who are re-
ceiving long-term medication is increasing, the number of pa-
tients moving out of an area for social or economic reasons
may continue to increase. This finding emphasizes the impor-
tance of systems within national ART programs that can ensure
continuity of care for highly mobile populations of young
adults. Losses to follow-up in this treatment service were low,
likely as a result of dedicated community-based counsellors
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In summary, high pretreatment and early on-treatment mor-
tality rates in this program reflected very advanced immuno-
deficiency. The reasons for patients’ late access to the program
urgently need to be identified. It is likely that these early in-
program deaths reflect a far greater burden of mortality within
the health system and in the community that is occurring “up
stream” of the ART program. However, this study found that,
once patients have initiated ART and survived the initial few
months of treatment, the risk of death or loss to the program
thereafter was very low. Evaluation of these various outcome
measures provides important means of assessment for ART
programs, which thereby facilitates development of optimum
models of care in resource-limited settings.
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Early antiretroviral therapy mortality in resource-limited settings:
what can we do about it?
Linda-Gail Bekkera,b, Matthias Eggerc and Robin Wooda
Purpose of review
Highly active antiretroviral therapy has markedly reduced
HIV morbidity and mortality in industrialized countries.
Expanded access to the 6.5million individuals in immediate
need of antiretroviral therapy using a public-health-systems
approach is now promulgated as an international policy. An
approximate 1.6million individuals have already accessed
antiretroviral therapy within programs in resource-poor
settings.
Recent findings
Early studies from these treatment programs confirm similar
virologic and immunologic responses to antiretroviral
therapy as were observed earlier in industrialized settings.
While medium-term reductions in morbidity and mortality
also parallel those reported from Europe and North
America, of particular concern is the observation that
mortality immediately after starting antiretroviral therapy in
resource-poor settings is several-fold higher than that of
similar patients initiating antiretroviral therapy in
industrialized settings.
Summary
This earlymortality ismultifactorial and is both a reflection of a
very high preantiretroviral therapy mortality and a variety of
factors such as comorbid conditions, late presentation,
immune restoration disease, together with limited treatment
and diagnostic options. Causes ofmortality immediately prior
to and during early antiretroviral therapy are reviewed and
strategies to reduce mortality are identified and discussed.
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Introduction
The increasingly widespread use of highly active anti-
retroviral therapy (ART) since 1996 has substantially
improved the prognosis of HIV-infected patients [1–3]
and an estimated 3million years of life have been saved as
a result of access to ART in the USA alone [4!!].
Since the launch of the ‘3 by 5’ initiative of the WHO in
December 2003, 1.6million individuals had accessed
ART worldwide by the middle of 2006 [5]. A substantial
number of deaths have been averted in low and middle-
income countries as a result of widened access to HIV
treatment [6]. Only 24% of those in need have received
ART, however, and there remain an estimated 6.5million
people in urgent need of ART [5].
ART is now considered an integral part of the compre-
hensive approach to HIV prevention, care and support [7]
and there is a global commitment to universal access to
ART for all who need it by the end of 2010 [8].
The public-health delivery of ART focuses on maximiz-
ing survival at the population level through standardized
sequencing of limited drug regimens, delivered bymeans
of simplified approaches and supported by clinical and
basic laboratory monitoring. ART delivery has been
expandedmassively in Zambia andMalawi using a public
health approach [9,10]. While virologic and immunologic
responses to ART are comparable in poor and rich-
resourced settings [11!!,12], mortality in the first month
after initiating ART is over four-fold higher in resource-
poor countries [11!!,13]. With the scaling up of treatment
in low and middle-income countries, there is opportunity
to better understand causes of mortality and an oppor-
tunity to reassess and optimize program strategies. We
review published data that describe patterns of mortality
and identify possible strategies to reduce early mortality
in low-income ART programs.
Causes of mortality before antiretroviral
therapy
The primary rationale for an ART program is to decrease
general-population HIV morbidity and mortality. Since
the beginning of the ART era, antiretrovirals (ARVs)
have been recognized in industrialized settings to
decrease the incidence of new AIDS-related conditions
[1–3] but it is only recently that ART has been recog-











such as cardiovascular disease and non-AIDS-related neo-
plasms which occur at higher CD4 cell counts [14!!]. In
resource-poor settings, significant mortality also occurs at
higher CD4 cell counts. In a South African cohort [15!]
followed before access to ART, 50% of deaths occurred
before confirmation of an AIDS diagnosis. Rates of death
and progression to AIDS for those with CD4 cell counts
between 200 and 350 cells/ml were also higher than those
reported in European cohorts [15!]. Following develop-
ment ofAIDS, themedian survival of untreated patients in
South Africa and rural Uganda is just 9–10months [16,17]
compared with around 2 years in high-income countries
prior to the advent of ART [18–20].
Currently, the majority of patients access ART in sub-
Saharan Africa with low CD4 cell counts and advanced
clinical stage [9,10,11!!,12,13]. Inevitable delays in acces-
sing and initiating ART result in significant programma-
tic mortality [13]. The major causes of mortality in early
and advanced HIV infection for both industrialized and
resource-poor settings are shown in Table 1.
Differences between antiretroviral therapy
programs in industrialized and resource-poor
settings
Some of the differences in ART programs in well and less
well resourced settings are summarized in Table 2.
The scaling-up of antiretroviral therapy in resource-poor
settings has utilized a public-health approach [7,21].
WHO guidelines make provision for two treatment regi-
mens: an initial nonnucleoside reverse transcriptase
enzyme inhibitor (NNRTI)-based regimen followed
by a protease inhibitor-based regimen. The public
health approach is very different from the practice in
Europe and North America, where individualized
therapy has led to utilization of a much greater array
of ART combinations. An analysis conducted between
2003 and 2005 showed that 47 and 59 regimens were
used to treat 90% of patients in Western Europe and the
USA, respectively. In contrast, in Africa and Asia, only
three regimens were used to treat 90% of patients [22].
Fifty-five percent of the world’s population is rural,
whereas, in industrialized countries, approximately
75% are urbanized. The HIV epidemic mirrors this
distribution and is predominantly urban in North Amer-
ica and Europe and both rural and urban in resource-poor
settings [23]. Approximately 1.0–1.2million persons are
estimated to be living with HIV in the USA, of whom
25% are unaware of their infection and likely to have
transmitted their infection unknowingly [24,25]. In sub-
Saharan Africa, 24.5million individuals are living with
HIV [26], but fewer than 10% are aware of their HIV
status [27].
Despite global efforts to expand ART access as of
December 2005, fewer than 80% of individuals in need
of ART were receiving ART. Coverage in Europe and
North America was between 75 and 100%, whereas in
many countries of sub-Saharan Africa, coverage in 2005
was less than 10% of need [28].
The WHO guidelines [21] for scaling up ART in
resource-poor settings were first published in 2002 and
recommended initiation of ART for those with AIDS or a
CD4 count of less than 200 cells/ml or an AIDS diagnosis.
More recent revisions have allowed for earlier treatment
of those with non-AIDS symptoms and CD4 cell counts
of less than 350 cells/ml [7]. North American andEuropean
guidelines recommend therapy for all symptomatic indi-
viduals and those with CD4 cell counts of less than
350 cells/ml [29,30].
Virologic monitoring of ART is frequently not available
in resource-poor settings because of high cost and lack of
appropriate infrastructure and, when available, is less
frequently performed than in industrialized settings
[22,31].
Causes of mortality on antiretroviral therapy:
mortality during early antiretroviral therapy
The efficacy of ART as measured by viral suppression
appears similar in resource-rich and resource-poor set-
tings [11!!,12,32–37], but early deaths on ART are more
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PCP, MAI, CMV, KS Wasting syndrome
Lower respiratory
tract infections
CMV, cytomegalovirus; KS, Kaposi’s sarcoma; MAI, Mycobacterium
avium intracellulare; PCP, Pneumocystis carinii pneumonia.
Table 2 Characteristics of antiretroviral therapy programmes in
industrialized and resource-poor settings
Industrialized settings Resource-poor settings
Individualized management Public-health approach
HIV epidemic predominantly urban HIV epidemic urban and rural
Clinic-based treatment Clinic and community-based
treatment
High proportion aware of
HIV status
Low proportion aware of
HIV status
High ART coverage 24% of patients in need of ART
on ART
Guidelines for early ART initiation Guidelines for late ART initiation
Wide choice of ART options Limited number of ART regimens













frequent in resource-poor settings [11!!,13]. Early deaths
occur predominantly in those with advanced disease,
with risk factors for death being CD4 counts of less than
100 cells/ml, a prior AIDS diagnosis and older age
[11!!,13]. The higher mortality in low-income countries
during the first months of treatment compared with those
in Europe and North America is only partly explained by
the lower CD4 cell counts and more advanced clinical
stage [11!!,13]. The mortality occurring immediately
after starting ART appears to reflect the high mortality
preceding commencement of ART. Comorbidities that
are present in many patients starting ART in resource-
poor settings, including tuberculosis and invasive bac-
terial and fungal infections, may increase mortality,
particularly as access to prophylaxis, diagnostic facilities
and effective treatment is often limited. In a Cape Town
study [13], almost two-thirds of deaths in the first few
weeks of ART were attributable to wasting syndrome,
tuberculosis, acute bacterial infections and malignancy,
and immune restoration disease was implicated in 24% of
deaths. Although death rates rapidly decrease from those
prior to commencement of ART, approximately 66% of
ART program deaths occur in the first 4months of
therapy. After 4–6months of ART, mortality rates
approach those seen in Western Europe and North
America [11!!,12,38].
Mortality on established antiretroviral therapy
Mortality during established ART is predominantly due
to a continuing but lower frequency of HIV-related
events which occur predominantly in those who do not
adhere to therapy or who have blunted CD4-count
responses [39!] together with infrequent toxicities associ-
ated with therapy [40]. Life-threatening drug-related
adverse events can occur early (e.g. hypersensitivity
reactions to nevirapine or abacavir) or after several
months (e.g. lactic acidosis with d4T). In a Cape Town
ART program [13], two ARV-related deaths were
reported during 488 patient-years of follow-up, due to
a nevirapine-related Stevens Johnson syndrome and sta-
vudine-related lactic acidosis.
Access to less toxic NRTIs would provide additional
options to clinicians and patients, but these agents are
more expensive or have limited availability in many
resource-limited settings [41,42].
Strategies to reduce early antiretroviral
therapy mortality
A number of potential contributors to early mortality exist
and these are summarized in Table 3.
Guidelines for the initiation of antiretroviral therapy
Early HIV mortality is high in resource-poor settings
because of increased exposure to parasitic infections such
as malaria, increased exposure to tuberculosis and gastro-
intestinal parasitic infections as a result of poor water
supply and sanitation [43]. In advanced HIV infection, an
AIDS diagnosis in resource-poor settings is associated
with markedly lower survival than in industrialized set-
tings [44–51]. The risk–benefit analysis of ART com-
pared with no ART would justify early initiation of ART
in resource-poor settings in which there is an increased
exposure of immune-compromised individuals to patho-
genic organisms [43].
Increased access to voluntary counseling and testing
In the USA, where 1–1.2million are HIV-infected,
approximately 25% are unaware of their HIV serostatus
and are unable to access the benefits of ARV therapy
[26,27]. In contrast, in sub-Saharan Africa, where
24.5million are HIV-infected, 90% are unaware of their
HIV serostatus and therefore do not seek ARV treatment
[52]. Currently, individuals in sub-Saharan Africa access
therapy after development of serious opportunistic
infections rather than because of an awareness of HIV
infection. Earlier access to ARV therapy will only be
possible if a larger proportion of the HIV-infected popu-
lation is informed of their status as a result of Voluntary
Counseling and Testing (VCT). In order to increase
uptake of VCT, Botswana has initiated routine HIV
testing in all healthcare facilities (opt-out strategy)
[53] and South Africa has introduced provider-initiated
HIV testing in the 2007–2011 strategic plan for HIV
and AIDS.
Increased CD4 testing
Either a CD4 cell count of less than 200 cells/ml or the
presence of an opportunistic illness can define an AIDS
diagnosis in the expanded Centers for Disease Control
(CDC) definition of AIDS [54]. The prognosis of a CD4
cell count of 200 cells/ml and AIDS is very different,
however. The median survival of an individual in South
348 Complications of HIV therapy
Table 3 Possible interventions to reduce mortality before antiretroviral therapy initiation and in early and established antiretroviral
therapy
Pre-ART Early ART Established ART
ART initiation guidelines Early ART initiation Community access to free ART
Increased voluntary counseling and testing Access to free ART Adherence support
Increased access to CD4 testing Prophylaxis of opportunistic disease Active case follow-up
Minimize health-system delays Management protocols for immune
restoration disease











Africa with an AIDS diagnosis is 6–12months, whereas
the median survival from a CD4 cell count of 200 cells/ml
is 18–24months [55]. If patients in sub-Saharan Africa
could access therapy when their CD4 count had declined
to a count of 200 cells/ml, rather than when an AIDS
condition had been diagnosed, then mortality could be
markedly reduced both before ART and during early
ART periods. Wider access to CD4-cell monitoring is
therefore needed, particularly for those presenting to
healthcare facilities with nonAIDS conditions, such as
at VCT, family planning and maternity services, sexually
transmitted infection clinics and tuberculosis diagnostic
and treatment facilities. Knowledge of the CD4 cell
count also promotes the initiation of prophylaxis against
opportunistic disease, with subsequent improved survival
[35,56].
Reducing health-system delay
In sub-Saharan Africa, 90% of HIV-infected individuals
are unaware of their HIV serostatus [52] and many enter
medical care with symptoms and signs of advanced HIV
infection or with a diagnosis of an opportunistic infection.
A diagnosis of AIDS, however, already indicates that the
threshold for ART eligibility has already been crossed
and the median survival of such patients is only 6–
12months [55]. Therefore, each subsequent month’s
delay in accessing ART after presenting to the health
system with AIDS is associated with a 4–8% mortality.
Delayed referral may be due to ‘therapeutic nihilism’ of
health workers who have worked in healthcare settings in
which extraordinarily high AIDS mortality has been
accepted as normal [57]. ART is frequently only available
at a limited number of sites [58] and referrals across
fragmented health systems also may result in further
delays [36]. Facilities dispensing ARVs have also been
subject to rapid expansion and are frequently logistically
constrained, resulting in long waiting lists of several
months to receive ART [32]. All of the delays due to
referral, health system and waiting list contribute to both
pre-ART mortality and late initiation of ART. To date,
published studies of the effectiveness of ART in
resource-poor settings have concentrated on morbidity
and mortality after the initiation of ART and the high
mortality associated with delay in accessing ART has
remained largely unrecognized [13].
Optimizing antiretroviral therapy programs
In-program mortality may be seriously underestimated in
ART treatment programs which have not allocated
resources for active follow-up of patients, as high loss
to follow-up rates may hide true on-treatment mortality
[11!!]. Reporting systems incorporating active follow-up
of patients allow more accurate measurement of program
performance together with the early identification of
those for whom the program is failing.
In the developing world, many HIV-infected patients
are poor and are subject to other survival needs which
compete with the need for accessing medical care. An
across-program analysis [11!!] of heterogeneous ART
programs in the southern hemisphere has identified that
the requirement to make a financial copayment for
drugs, medical services or investigations was associated
with a two-fold increase in ART mortality. The pro-
vision of free ART within medical programs is therefore
likely to reduce on-treatment mortality. There may be
other costs for accessing care, however, particularly in
rural areas in which costs of transport are high [11!!].
Innovative models of successful community delivery of
ART have been developed in the poorest of settings
[59,60].
Adherence to treatment has been a neglected area of
many medical interventions. Adherence to treatment,
however, has been a strong and continuing focus of the
public-health approach to expanded access to ART
[7,61]. Despite initial skepticism that necessary levels
of adherence could be achieved in resource-poor popu-
lations [62], there have been many studies [63–66] from
ART programs documenting high levels of adherence
and viral suppression rates matching those achieved in
developed-world settings. A relative shortage of nurses
and doctors has encouraged the innovative use of non-
medically qualified community members for treatment
support within programs. In rural Haiti, community
‘accompagnateurs’ have been used to deliver ART
[59]; in urban South Africa, relatives and friends have
been used as ‘treatment buddies’ [66] and HIV-infected
individuals trained as ‘therapeutic counselors’ [60,65].
Use of these and other innovative adherence strategies
will continue to be necessary to address the continuing
challenge of maintaining high levels of adherence,
particularly as programs continue to scale up.
Increased access to ART has followed the marked
reduction in ARV drug prices. While program effective-
ness is increased by improved adherence, program costs
are still driven by the price of first-line regimens [42,67].
Consequently, many programs utilize ARVs because of
their cheapness with adverse toxicity profiles which may
result in on-treatment deaths [68–70]. A need for access
to cheaper and less toxic drugs therefore continues.
Patients currently access ART programs in sub-Saharan
Africa when CD4 cell counts are low [12,65,66] and
coinfections are frequent [71]. Delays due to diagnosis
and treatment of coinfections result in postponed
initiation of ART and contribute to very high mortality
rates [72,73]. The very high mortality of coinfected
patients may be reduced by earlier initiation of ART
[66] but such a policy is associated with increased rates of
immune restoration disease (IRD) [74]. IRD may be










mild, resulting in local discomfort from enlarged per-
ipheral tuberculous nodes, or may be life-threatening
with central nervous system involvement of tuberculo-
sis or cryptococcal infections [75,76]. The high fre-
quency of IRD together with its potentially lethal
complications reinforce the need for standardized man-
agement protocols for both treatment and prevention of
severe IRD.
Conclusion
The HIV epidemic has spread by exploiting the frailties
and weaknesses of human social behavior; similarly, high
morbidity and mortality have exposed weaknesses and
inequalities of healthcare systems. The scale of the HIV
epidemic in resource-poor settings has necessitated a
public-health approach to the expanded access of ART
and a critical analysis of health systems. While virologic
and immunologic responses achieved by this approach
are similar to those reported in industrialized settings,
mortality early after starting ART is very high. This
mortality is primarily due to a high pre-ART morbidity
compounded by advanced immune suppression at the
time of accessing ART. IRD and drug toxicities may add
to this already high mortality. Early ART program deaths
may be reduced by implementation of measures which
encourage earlier access to care for HIV-infected indi-
viduals in resource-poor settings.
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Abidjan, Côte d’Ivoire. AIDS 2003; 17 (Suppl 3):S5–S15.
36 Tassie JM, Szumilin E, Calmy A, Goemaere E. Highly active antiretroviral
therapy in resource-poor settings: the experience of Médecins sans
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EDITORIAL REVIEW
Early mortality among adults accessing antiretroviral
treatment programmes in sub-Saharan Africa
Stephen D. Lawna,b, Anthony D. Harriesb,c,d, Xavier Anglarete,f,
Landon Myerg,h and Robin Wooda
Two-thirds of the world’s HIV-infected people live in sub-Saharan Africa, and more than
1.5 million of them die annually. As access to antiretroviral treatment has expanded
within the region; early pessimism concerning the delivery of antiretroviral treatment
using a large-scale public health approach has, at least in the short term, proved to be
broadly unfounded. Immunological and virological responses to ART are similar to
responses in patients treated in high-income countries. Despite this, however, early
mortality rates in sub-Saharan Africa are very high; between 8 and 26% of patients die in
the first year of antiretroviral treatment, with most deaths occurring in the first few
months. Patients typically access antiretroviral treatment with advanced symptomatic
disease, and mortality is strongly associated with baseline CD4 cell count less than
50 cells/ml and WHO stage 4 disease (AIDS). Although data are limited, leading causes
of death appear to be tuberculosis, acute sepsis, cryptococcal meningitis, malignancy
and wasting syndrome. Mortality rates are likely to depend not only on the care
delivered by antiretroviral treatment programmes, but more fundamentally on how
advanced disease is at programme enrolment and the quality of preceding healthcare.
In addition to improving delivery of antiretroviral treatment and providing it free of
charge to the patient, strategies to reduce mortality must include earlier diagnosis of HIV
infection, strengthening of longitudinal HIV care and timely initiation of antiretroviral
treatment. Health systems delays in antiretroviral treatment initiation must be mini-
mized, especially in patients who present with advanced immunodeficiency.
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Introduction
Development of highly active antiretroviral treatment
(ART) in the mid-1990s revolutionized the care of
HIV-infected patients and led to marked reductions in
HIV-associated morbidity and mortality in many
industrialized countries [1–3]. Over 10 years later, access
to ART remains limited in sub-Saharan Africa and other
resource-constrained settings where the need is greatest.
Although only 10% of the world’s population live in sub-
Saharan Africa, the region is nevertheless home to around
two-thirds of the world’s HIV-infected people [4]. In
2007, an estimated 22.5 million adults and children in the
region were living with HIV/AIDS and 1.6 million died,
representing 76% of global AIDS deaths [4]. Great
progress has been made in providing access to ART
in sub-Saharan Africa; by April 2007, approximately
1.3 million people were receiving ART – some 28% of
the 4.8 million people estimated to be in need [5].
However, in addition to much needed HIV prevention
measures, ongoing expansion of capacity to effectively
deliver ART long-term to large numbers of people is
urgently required.
Early pessimism concerning effective delivery of ARTon
a large scale using a simplified public health approach has
largely proven unfounded, at least in the short term. For
example, ART access has been rapidly expanded on a
massive scale in Lusaka, Zambia, in Abidjan, Cote
D’Ivoire, and on a country-wide scale in Malawi with
good early clinical outcomes [6–8]. High levels of
treatment compliance and virological suppression have
been achieved in both hospital-based and community-
based programmes [9–11]. Meta-analyses of da a from
treatment cohorts have found that the efficacy of ART, as
reflected by rates of viral load suppression and CD4 cell
count recovery, is similar among patients treated in high-
income and resource-limited settings [12,13]. ART has
been demonstrated to be a cost-effective intervention in
resource-poor settings [14–16]. Furthermore, ART was
estimated to have averted 250 000–350 000 deaths in low
and middle-income countries in 2005 alone [17].
Despite these positive findings, data from the region
suggest that early mortality rates among adults in ART
programmes are high [12], contributing to substantial
losses in overall patient retention [18]. The ART–lower
income country (ART-LINC) collaboration compared
outcomes from 18 ART programmes in lower income
settings (predominantly in Africa) with those in 12 HIV
cohort studies from Europe and North America [12].
This analysis found that early mortality following
initiation of ARTwas several-fold higher among patients
in resource-limited settings compared to that of patients
treated in high-income settings, even after adjusting for
baseline immunodeficiency [12]. High mortality rates in
individual cohorts in sub-Saharan Africa have also been
reported on. To gain a greater understanding of this
problem, we review the mortality rates, temporal
distribution, risk factors and causes of death among
adult patients accessing ART programmes in sub-Saharan
Africa and consider possible strategies to address this.
Search strategy and selection criteria
We searched English-language publications in MED-
LINE, using the terms ‘antiretroviral’, ‘Highly Active
Anti-Retroviral Therapy (HAART)’, ‘ART’, ‘Africa’,
‘mortality’, ‘death’. Searches were completed up to
December 2007 to identify published reports from
observational ART cohorts in sub-Saharan Africa; those
reporting on survival proportions over time and those
describing the spectrum of causes of death were selected.
Additional articles were identified from references in
published papers and abstracts from major international
AIDS conferences in the preceding 12 months. For
cohorts with multiple presentations of mortality data from
different time periods, the most recent report was used.
Data from controlled clinical trials were not included in
the assessment of mortality rates as these data are unlikely
to be generalizable to the scale-up of ART services in the
general population. Summary estimates of the hazard
ratios for the association of early mortality with CD4 cell
count and with advanced WHO stage was conducted
using a random-effects model [19].
Rates and temporal distribution of
mortality
Data from 18 published cohort studies containing 39 536
patients treated in countries in west, east and southern
Africa are summarized in Table 1 [20]. Patients were
mainly receiving public sector treatment. Twelve of the
cohorts were based in urban settings and six were rural.
The median baseline CD4 cell count in these studies
ranged between 43 and 147 cells/ml, and the median
duration of follow-up ranged between 3 and 46 months.
The vast majority of these patients were ART-naive,
and most initiated triple-drug therapy that incorporated
two nucleoside analogues and a nonnucleoside reverse
transcriptase inhibitor.
Using product-limit methods, the 12-month survival
proportion in patients who were not lost to follow-up
ranged between 0.74 and 0.92, with the greatest burden
of mortality occurring during the initial months of
ART (Table 1). Heterogeneity in outcomes between
programmes may reflect differences in both baseline
patient characteristics and programme characteristics
[21]. Survival proportions were reported at both 12
and 24 months of follow-up in nine studies and these










Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
showed that mortality accruing in the second year of ART
was much less than that in the first (Table 1).
Longitudinal changes in mortality rates were calculated
in some studies [21–24]. In a South African cohort, the
rate in the first 4 months of ART was 19.1 deaths/100
person-years (100PYs), decreasing to 2.9 deaths/100PYs
beyond 4 months and 1.3 deaths/100PYs beyond 1 year
[23]. A similar pattern of mortality was observed in
another South African cohort [10], and in both studies,
rates of viral load suppression of less than 400 copies/ml
were high (>93% and >89%) [10,23]. In other studies,
however, substantial mortality accrued between 12 and
24 months of follow-up [24,25]. Mortality rates in a
cohort in Senegal, for example, were 12.5, 6.6 and 4.5
deaths/100PYs in the first, second and third years of
treatment, respectively [24]. The higher mortality rates
beyond the first year of ART in these studies might be
explained by lower rates of virological suppression and
associated poor immunological recovery, for example
[24,26].
In all 18 cohorts (Table 1), the mortality proportions at
12 months of follow-up (range 8–26%) exceeded the
ART–LINC summary mortality estimate of 6.4% [95%
confidence interval (CI), 5.1–7.7] [12]. The ART–
LINC estimate was derived from 4810 patients receiving
ART between 2001 and 2004 in resource-limited settings
and included 3449 patients in sub-Saharan Africa. Since
then, there has been a more than 10-fold increase in the
number of patients receiving ART in the region whose
outcomes have been published. The current literature
included in this review suggests that further updated
collaborative analyses might show a substantially higher
early-mortality rate than initially derived from the
original ART–LINC cohorts.
Reliability of mortality data
There may be a tendency for mortality rates in the
published literature to be lower than those observed in
most large-scale ART programmes that have not
published their data because of selective reporting from
well run ART programmes in urban settings with more
intensive service delivery and fewer resource constraints.
The quality of mortality data is unclear in some reports;
mortality is likely to be underestimated to a degree by
most cohorts due to misclassification of unascertained
patient deaths as losses to follow-up. The greater the loss
to follow-up rate the greater the potential for
misclassifications. Rates of loss to follow-up differed
greatly between studies, ranging between 2 and 24%
(Table 1), and unrecorded mortality among these
patients may only be detected by intensive active
follow-up [12,27–29]. The efficacy of active follow-
up may vary considerably between cohorts and details
concerning the intensity of patient tracing are infre-
quently reported.
Analysis of the characteristics of losses to follow-up may
provide insights into the reliability of programme
mortality data. ART cohorts in South African and Cote
D’Ivoire with good ascertainment of outcomes found
that, whereas most deaths occurred in the first months of
ART in patients with the lowest baseline CD4 cell
counts, losses to follow-up were evenly distributed over
time and were not associated with CD4 cell counts
[8,23]. Thus, if a programme reports a high loss to follow-
up rate in the first months of ART among patients with
the lowest baseline CD4 cell counts, this may be
suggestive of high rates of unascertained deaths in this
period.
In-programme mortality prior to starting
anti-retroviral therapy
Very high mortality rates recorded during the initial
months of ART may reflect a high mortality rate among
individuals who are eligible for ART but have yet to start
treatment. This includes individuals enrolled in care who
are waiting treatment as well as those elsewhere in the
healthcare system awaiting referral to HIV treatment
services.
Two cohorts in South Africa have reported on deaths
occurring in the interval between enrolment of patients
into the ART programme and initiation of treatment
[22,23,30]. In the Cape Town study, this interval of
approximately 30 days permitted thorough investigation
and treatment of coinfections and preparation of patients
for ART, the mortality rate in this interval was very high
(approximately 30 deaths/100PYs). Deaths occurring in
this short period accounted for 67% of deaths within
the first 3 months from programme enrolment [22].
Similarly, in the Free State cohort, 87% of deaths
occurred among patients prior to ART initiation [30].
Thus, it is likely that even short delays in ART initiation
are associated with considerable pretreatment mortality
risk. Delays in patient referral, waiting lists for ART
initiation and time taken to prepare patients to start
life-long treatment are likely to contribute to overall
mortality risk.
Such delays and associated mortality are not typically
reported by cohorts and so the optimum period for
preparation for ART is therefore unclear. How to balance
the need for thorough preparation of patients for life-long
therapy with the high risk of death among individuals
waiting to start therapy requires urgent research attention.
Clearly, flexibility in timing is needed as many patients
with advanced immunodeficiency need therapy urgently.
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Risk factors for mortality
Of the cohorts summarized in Table 1, low baseline CD4
cell count was a strong risk factor for early mortality in all
those with available data. The summary hazard ratio for
the association between CD4 count of less than 50 cells/
ml (versus CD4 >50 cells/ml) was 2.5 (95% CI, 1.9–3.2)
in studies with data presented in this format
[10,11,22,25,26,31,32]. A graded association with CD4
cell count was reported in some studies [6,12,23,33]
(Fig. 1a) but baseline viral load was not found to be an
independent risk factor in any of them.
Symptomatic disease (WHO stages 3 and 4) was
associated with mortality in some [6,8,12,22,34] but
not all [11,22] studies (Fig. 1b), possibly reflecting
differences in the accuracy of clinical staging or
homogeneity of cohorts with respect to this variable.
WHO stage 4 disease, however, was found to be a strong
predictor of mortality in all studies reporting on this
[6,22,23,25,31,35–39]. In three studies comparing
patients with WHO stage 4 disease at baseline with
those with WHO stages 1–3, WHO stage 4 was
associated with more than a doubling in the hazard of
death (summary hazard ratio, 2.2; 95% CI, 1.5–3.2)
[10,21,31].
Low body mass index [6,8,24,25,35,37,38,40] and
anaemia [6,8,25,38,40,41] were independently associated
with mortality in some studies. Anaemia may be
associated with a variety of conditions such as extra-
pulmonary tuberculosis (TB), gastrointestinal Kaposi’s
sarcoma and severe malnutrition or may reflect the direct
effects of advanced HIVon haematopoiesis. Male sex was
associated with poorer survival in six studies [6,8,10,23,
25,39]; the reasons for this are unknown, but could relate
to differences in health-seeking behaviour or poorer
treatment adherence among men [42].
In contrast to data from high-income settings [2],
increasing age was associated with higher mortality risk
in only one cohort [8]. The lack of an association may
reflect the younger and narrower age distribution of
patients receiving ART in Africa. Alternatively, this may
simply reflect the relatively short duration of follow-up in
these studies since immunological recovery during the
first 4 months of treatment is not age-dependent whereas
long-term recovery is [43–45].
Patients with TB at enrolment to ART programmes have
a high mortality risk [46,47], and yet, paradoxically, TB
and TB disease activity have not been found to be
independent risk factors for mortality during ART
[6,37,48]. Many deaths, however, may occur before ART
is initiated [48,49], and also much of the true burden of
disease may remain unascertained [50]. In contrast to TB,
detection of cryptococcal antigen in serum was an
independent predictor of early mortality in a rural cohort
in Uganda [51].
Although the type of ARTregimen and healthcare facility
(primary versus secondary) have not been found to be
associated with mortality [8,12,24–26], programmes in
which patients were required to pay for medication were
associated with a four-fold greater mortality risk [12].
This concurs with the findings of a meta-analysis of
treatment outcomes in resource-poor settings; due to
limitations in finances, patients who had to pay part or all
the cost of therapy had an approximately 30% lower
probability of having an undetectable viral load at 6 and
12 months compared with patients whose medication was
supplied free of charge [13]. In keeping with this, ART
adherence has been found to be predictive of mortality
[40,42].
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Fig. 1. Kaplan–Meier plot showing survival proportion over
21 months among patients (n U 1235) from the time of
entering a community-based antiretroviral treatment pro-
gramme in South Africa. The period covered includes the
interval between programme enrolment and ART initiation –
a median of 33 days. The survival proportions are shown
according to baseline CD4 cell count and baseline WHO
clinical stage. The graphs show the strong unadjusted associ-
ation between CD4 cell count, WHO clinical stage and
mortality risk in the first year of ART and the low mortality
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Risk factors for mortality may alter during the course of
ART. Whereas mortality during the first 4 months of
treatment in one cohort was associated with patient
characteristics at baseline, mortality beyond this time
point was only associated with the updated absolute CD4
cell count at 4 months and with failure of viral load
suppression [23]. These data suggest that the key long-
term determinant of mortality is the response to ART as
also suggested by more recent findings from Abidjan [35].
Causes of death
Five observational cohort studies from a range of
countries in sub-Saharan Africa report on the spectrum
of causes of early deaths [22,24,37,40,52]. The most
important causes of death reported include TB, acute
sepsis, cryptococcal meningitis, malignancies (especially
Kaposi’s sarcoma) and chronic diarrhoea or wasting
syndrome.
Diagnostic facilities are limited in many settings,
especially for rural cohorts, and no identifiable cause
could be identified in a proportion of deaths. No
systematic post-mortem studies of deaths during ART
have been reported and the overall data are therefore
limited. Deaths in the first few weeks of ARTare likely to
be caused by conditions that are either preexisting at
programme enrolment or new conditions arising in the
context of persisting immunodeficiency. In one study,
causes of death during the first 4 months of ART were
found to reflect those occurring just prior to ART with
the addition of deaths due to immune recons itution
disease associated with cryptococcal meningitis and
TB [22].
TB was among the two leading causes of death in four of
the five cohorts, accounting for up to 21% of deaths
[22,24,40,52]. However, TB is likely to be an under-
reported cause of death. Post-mortem studies in the pre-
ART period have found that up to 54% of untreated
patients dying from AIDS in Africa have evidence of
occult disseminated TB [53,54], and that this may be a
common underlying cause of ‘slim disease’ [55].
Although wasting syndrome (defined as wasting with
unexplained fever or chronic diarrhoea or both) was
specifically reported as an important cause of death
among in only one cohort [22], this may have been more
common as ‘chronic diarrhoea’ was also reported as a
common cause [37], and wasting was a common risk
factor for mortality in many cohorts (see earlier).
The contribution of TB immune reconstitution disease to
mortality has yet to emerge fully [56]. Although most
cases appear to be self-limiting, a minority are severe, and
deaths have been reported from cohorts in South Africa
and Thailand [57,58]. However, background mortality
rates were also very high among TB patients who did not
develop this complication, and neither of the studies
found immune reconstitution disease to be associated
with a significantly excess mortality risk. Larger
prospective studies are needed to clarify this issue.
Cryptococcal meningitis was among the two leading
causes of mortality in four of the five cohorts
[22,24,40,52], accounting for up to 20% of deaths.
Many of the deaths from cryptococcal disease in a South
African cohort were attributed to immune reconstitution
disease [59] and this was a more common cause of death
than TB immune reconstitution disease [22]. Many
patients developing this complication have previously
been treated for cryptococcal meningitis with fluconazole
monotherapy [22,59,60]. Although this is the standard of
care throughout much of Africa, fluconazole is a
fungistatic drug with far less efficacy than amphotericin
in clearing the organism from cerebrospinal fluid (CSF)
and especially so in the context of fluconazole resistance
[61]. Persistence of cryptococci or cryptococcal antigen
in the CSF is likely to predispose patients to immune
reconstitution disease, which has a high mortality risk
[59,60,62,63].
Kaposi’s sarcoma and other malignancies were among
the three leading causes of death in three of the five
cohorts [22,37,52], accounting for up to 14% of deaths.
Acute sepsis was another important cause identified in
some cohorts despite widespread use of trimethoprim-
sulphamethoxazole (cotrimoxazole) [22,40]. Acute res-
piratory disease, acute gastroenteritis or systemic sepsis
with no identifiable focus were the most common forms
of sepsis and collectively sepsis accounted for up to 19% of
deaths. Pneumocystis jiroveci pneumonia was reported in up
to 9% of deaths in two Ugandan studies [40,52] but the
basis for these diagnoses is not clear.
Microbiological causes of death from acute bacterial
infections have not been reported. In studies of acute
sepsis during cotrimoxazole prophylaxis in Abidjan,
Cote D’Ivoire [32,64–66], the predominant pathogens
were nontyphoidal salmonella, Escherichia coli, Shigella
spp. and Streptococcus pneumoniae. Although high rates of
cotrimoxazole resistance among nontyphoidal salmo-
nellae and pneumococcal isolates have been reported in
Uganda and Malawi [67,68], prophylaxis with this drug is
still effective in reducing mortality in both countries
[68,69].
The most widely used regimens in Africa include
stavudine (d4T) and nevirapine, which have the potential
for serious toxicities that include hepatotoxicity, Stevens–
Johnson syndrome and lactic acidosis [70,71]. However,
drug toxicity does not appear to be a major cause of early
mortality. Among 226 deaths reported by four cohorts,
seven (3.1%) were attributed to ART toxicity
[10,22,24,52]. These were comparatively well resourced
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programmes with access to biochemical laboratory
monitoring; mortality rates may be higher where
monitoring is not possible. Analysis of the temporal
distribution of drug substitutions due to toxicity shows
that nevirapine and zidovudine toxicity occur during
the first few months of ART, whereas d4T-associated
lactic acidosis occurs cumulatively from around 6 months
onwards [72,73]. Thus, the contribution of drug
toxicity to overall mortality may change over time
and may proportionately increase as the risk of oppor-
tunistic infections diminishes after the first 6 months
of ART.
Deaths associated with nevirapine-induced hepatotoxi-
city have been reported from South Africa when used
concurrently with rifampicin [70], but more data from
large cohorts are needed to quantify the risk during
concurrent TB treatment. In contrast, efavirenz is very
well tolerated [65], and simultaneous use of rifampicin
and efavirenz in cohorts in South Africa has not been
associated with mortality [48,74].
Strategies to reduce mortality
Early mortality rates are strongly associated with the
degree of immunodeficiency in patients at the time they
enrol into ART programmes. Strategies to reduce
mortality must therefore focus not only on delivery of
care within ART programmes but more fundamentally
they must promote early HIV diagnosis and improved
pre-ART HIV care.
(1) Early HIV diagnosis and longitudinal HIV care pre-
ART
(a) Promote HIV testing and early diagnosis.
(b) Strengthen long-term HIV care services for patients
prior to ART eligibility.
(c) Optimize prevention, screening and treatment of
opportunistic infections.
(d) Provide longitudinal clinical and CD4 cell count
monitoring to facilitate timely initiation of ART.
(e) Minimize health system delays in ART initiation.
(2) Delivery of ART
(a) Provide ART without charge to the patient.
(b) Use updated WHO guidelines for ART eligibility.
(c) Develop locally effective ART adherence strategies.
(d) Use ART regimens with lower toxicity.
(e) Opportunistic infections
(i) Cotrimoxazole prophylaxis during ART.
(ii) Optimize screening for TB at ART pro-
gramme entry.
(iii) Optimize diagnosis and management of TB
immune reconstitution disease.
(iv) Prevent nosocomial transmission of TB.
(v) Consider concurrent isoniazid preventive
therapy (IPT) during ART to reduce long-
term TB incidence (trial data awaited).
(vi) Optimise prevention, diagnosis and treatment
of cryptococcal meningitis and immune
reconstitution disease.
(f) Use of laboratory monitoring
(i) Laboratory monitoring for drug toxicity.
(ii) Define appropriate strategies for monitoring
response to ART.
Early HIV diagnosis and longitudinal HIV care
Patients entering ART programmes in sub-Saharan
Africa have typically had their HIV diagnosis made
following presentation to the health services with
advanced symptomatic disease. Such patients have a high
mortality risk in the period leading up to ART as well as
during early ART (Fig. 2). Provision of accessible and
user-friendly services for serial voluntary counselling and
testing (VCT) and CD4 cell count estimation is vital to
promote early HIV diagnosis and assessment of ART
eligibility. Early diagnosis and initiation of appropriate
longitudinal care would probably be associated with
much lower mortality risk in the period leading up to
ARTas well as during the initial months of ART (Fig. 2).




















Late HIV diagnosis and no
pre-ART HIV care




Fig. 2. Hypothetical graph showing relative mortality risk
(95% confidence interval) among patients accessing anti-
retroviral treatment with late HIV diagnoses and advanced
symptomatic disease (diamonds) compared to patients
whose HIV was diagnosed early and who received appro-
priate longitudinal HIV care and timely referral for antire-
troviral treatment (squares). Mortality risk is shown broken
down into 3 periods: pre-ART (the interval between enrol-
ment in the ART programme and the time ART is started), early
ART (first 4 months of ART) and late ART (beyond 4 months of
ART). ART, antiretroviral treatment. Data on patients with late
diagnoses are based on [23] and data from patients with early
diagnoses and care are hypothetical, being based approxi-
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Similar to the management of many chronic diseases in
Africa, longitudinal care from the time of HIV diagnosis
until requirement for ART is often poor. Thus, even
those patients who are diagnosed with relatively early
HIV infection are often lost to medical care only to later
re-enter medical services with advanced disease. Longi-
tudinal care must be strengthened and should include
screening for and treatment of opportunistic infections,
initiation of cotrimoxazole prophylaxis, isoniazid pre-
ventive therapy (IPT), reproductive healthcare, and serial
CD4 cell count assessment until eligibility for ART is
reached. This will require strengthening of HIV care
services and more widespread availability of CD4 cell
count measurement.
Prevention, screening and management of opportunistic
infections are needed throughout the HIV care pathway.
Cotrimoxazole prophylaxis should be initiated after
HIV diagnosis and continued during ART [75], as this is
associated with additional gains in life expectancy
[16,76]. Isoniazid preventive therapy (IPT) is an
underused intervention in Africa [77]. Key obstacles
include the difficulty of excluding active TB in patients
with moderate or advanced immunodeficiency.
IPT would therefore be more easily used among pa-
tients with less advanced disease, and yet, adherence
to treatment among such patients and the infra-
structure to efficiently deliver and monitor IPT remain
a challenge.
Delivery of anti-retroviral therapy
National ART programme criteria for ART eligibility
require ongoing re-evaluation. Initial WHO guidelines
(2002) for resource-poor settings recommended treat-
ment only for those with stage 4 disease or a CD4 cell
count of less than 200 cells/ml [78]. These were modified
in 2003 [79] and 2006 [80], bringing them closer to
guidelines for high-income settings. However, some
national programmes had earlier retained more restrictive
eligibility criteria. For example, South Africa’s national
programme has retained the 2002 WHO recommen-
dations despite the fact that under these guidelines much
of HIV-associated morbidity and mortality occurs prior to
eligibility for ART [81,82]. Studies on when to initiate
ART in resource-limited settings are needed. There are
currently two trials that aim to address this issue in Cote




As soon as patients are identified as being eligible for
ART, prompt referral for ART should be made. Where
possible, waiting lists for ART should be minimized and
those with highest risk might be prioritized [22,24].
Supply of medication free of charge to the patient is a key
issue [12,13]. While some international agencies advocate
the privatization of health services and private financing
of health services through user fees, this is very unrealistic
for most patients living in resource-limited settings who
require life-long ART.
The use of regimens in Africa with higher toxicity than
those used in the West is due to their low cost and the
availability of fixed dose combination formulations.
Although provision of treatment to the millions of
people living with HIV/AIDS who do not yet have
treatment access should be the priority, implementation
of less toxic regimens is nevertheless desirable.
Although laboratory monitoring and use of point-of-care
lactic acid meters may help detect and manage drug
adverse effects, no data yet exist to indicate that provision
of such monitoring reduces mortality risk. This issue is
being studied in the Development of AntiRetroviral
Therapy in Africa trial (DART, http://www.ctu.mrc.
ac.uk/dart/summary.asp). Braitstein et al. [12] found no
impact of viral load monitoring on mortality in the first
year of ART. However, any benefits are only likely to
occur during long-term treatment rather than during the
first year.
Effective strategies to screen for active TB at entry to
ART programmes need to be developed, including
detection of the high prevalence of both clinical and sub-
clinical disease [46,47,83,84]. Prompt initiation of TB
treatment may reduce patient mortality and reduce risks
of nosocomial TB transmission. The optimal timing for
initiation of ART among TB patients remains unknown
and randomized controlled trials of early versus delayed
initiation of ART is currently underway [85]. Similar to
data from the UK [86,87], observational data from South
Africa strongly suggest that expedited initiation of
treatment is needed among those with baseline CD4
cell count of less than 100 cells/ml in this setting in view of
their exceptionally high mortality rate while awaiting
ART [88,89].
Randomized controlled trials are needed to define both
the optimal management of moderate and severe TB
immune reconstitution disease [56] and to assess the
efficacy of concurrent isoniazid prophylaxis in reducing
the high rates of TB that persist during ART [46,90]. In
addition, the utility of pre-ART screening for and
management of asymptomatic cryptococcal antigenaemia
has yet to be defined [51]. Provision of a better standard of
care for cryptococcal meningitis using amphotericin
might be considered in settings with adequate facilities to
administer this drug safely. Guidelines for the prevention,
diagnosis and management of cryptococcal immune
reconstitution disease are also needed.
Despite early reports that treatment adherence does not
pose a major barrier to treatment success in sub-Saharan
Africa [91], more recent research suggests that overall
adherence rates and retention on ART in sub-Saharan
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Africa are quite variable and often poor [18,92].
Adherence is predictive of mortality [42] and develop-
ment of locally appropriate strategies to promote
adherence are central to the success of ART programmes.
Research is also needed to determine which cadre of
health-care professional is needed to deliver ART
effectively with good outcomes.
Conclusion
High early mortality within ART programmes in sub-
Saharan Africa has emerged as a key challenge. Between 8
and 26% of patients die in the first year of ART and key
issues surrounding this problem are summarized as
follows:
(1) Although virological and immunological responses to
ART are similar in patients living in high-income and
resource-limited countries, early mortality rates are
much higher.
(2) Most deaths occur in the first few months of ART.
(3) A high loss to follow-up rate may conceal true
mortality rates.
(4) High mortality rates during early ART also reflect high
mortality rates in the period preceding ART.
(5) Key risk factors for early mortality include low CD4 cell
count, advanced clinical stage of disease, and the need
for patients to pay for treatment.
(6) Early deaths largely reflect the spectrum of causes of
death prior to ART initiation plus immune reconstitu-
tion disease.
(7) Common causes of death are TB, acute sepsis,
cryptococcal meningitis malignancies and wasting
syndrome.
(8) Drug adverse effects are a relatively minor cause of early
mortality.
(9) Strategies to reduce early mortality include promotion
of early HIV diagnosis, strengthening of the patient care
pathway pre-ART, timely initiation of ART, provision
of ART free of charge to the patient, adherence support,
and optimal prevention, screening and management of
opportunistic infections.
Early death rates threaten the credibility of ART delivery
among communities accessing such therapy and among
health workers who are responsible for providing this
care. Although many factors are likely to contribute to
this mortality, an over-riding issue is that patients typically
present for ART once they have developed advanced
symptomatic disease. Much may be done within ART
services to potentially reduce this mortality by providing
medication free of charge, implementing effective
screening, treatment and prevention of opportunistic
infections, reinforcing treatment adherence and using
regimens with low toxicity. However, despite optimizing
ART delivery, a proportion of early deaths among
patients with very advanced disease are not likely to be
preventable. Thus, a more fundamental issue and the
greater challenge is the need for early HIV diagnosis and
provision of appropriate longitudinal HIV care prior to
ART eligibility.
Acknowledgements
S.D.L is funded by the Wellcome Trust, London, UK,
with grant 074641/Z/04/Z. R.W. is funded in part by
the National Institutes of Health, USA, RO1 grant
(A1058736-01A1) and a CIPRA grant 1U19AI53217-
01. X.A. is funded in part by the ANRS (Agence
nationale de recherches sur le SIDA et les hépatites virales,
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Changing mortality risk associated with CD4 cell
response to antiretroviral therapy in South Africa
Stephen D. Lawna,b, Francesca Littlec, Linda-Gail Bekkera,
Richard Kaplana, Elizabeth Campbela, Catherine Orrella
and Robin Wooda
Objective: To determine the relationship between mortality risk and the CD4 cell
response to antiretroviral therapy (ART).
Design: Observational community-based ART cohort in South Africa.
Methods: CD4 cell counts were measured 4 monthly, and deaths were prospectively
ascertained. Cumulative person-time accrued within a range of updated CD4 cell count
strata (CD4 cell-strata) was calculated and used to derive CD4 cell-stratified mortality
rates.
Results: Patients (2423) (median baseline CD4 cell count of 105 cells/ml) were observed
for up to 5 years of ART. One hundred and ninety-seven patients died during 3155 person-
years of observation. In multivariate analysis, mortality rate ratios associated with 0–49,
50–99, 100–199, 200–299, 300–399, 400–499 and at least 500 cells/ml updated CD4
cell-strata were 11.6, 4.9, 2.6, 1.7, 1.5, 1.4 and 1.0, respectively. Analysis of CD4 cell
count recovery permitted calculations of person-time accrued within these CD4 cell-
strata. Despite rapid immune recovery, highmortality in the first year ofARTwas related to
the large proportion of person-time accrued within CD4 cell-strata less than 200 cells/ml.
Moreover, patients with baseline CD4 cell counts less than 100 cells/ml had much higher
cumulative mortality estimates at 1 and 4 years (11.6 and 16.7%) compared with those of
patients with baseline counts of at least 100 cells/ml (5.2 and 9.5%) largely because of
greater cumulative person-time at CD4 cell counts less than 200 cells/ml.
Conclusion: Updated CD4 cell counts are the variable most strongly associated with
mortality risk during ART. High cumulative mortality risk is associated with person-time
accrued at low CD4 cell counts. National HIV programmes in resource-limited settings
should be designed to minimize the time patients spend with CD4 cell counts less than
200 cells/ml both before and during ART.
 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
AIDS 2009, 23:335–342
Keywords: Africa, antiretroviral, antiretroviral therapy, CD4, death, HIV,
immune reconstitution, immune recovery, mortality
Introduction
The countries of sub-Saharan Africa have been hit hardest
by the HIV/AIDS epidemic with an estimated 22.5
million adults and children living with the infection in
2007 [1]. Of these, 1.6 million died, representing 76% of
global AIDS deaths that year. Expansion of access to
antiretroviral therapy (ART) in recent years, however, has
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offered hope of averting hundreds of thousands of deaths
[2]. By April 2007, approximately 1.3 million people in the
region were receiving treatment [3], and early pessimism
concerning effective delivery of ARTon a large scale using
a simplified public health approach has largely proven
unfounded. However, early mortality risk is much higher
among patients treated in resource-limited settings
compared with those treated in high-income countries
[4,5].
Between 8 and 26% of patients receiving ART in sub-
Saharan Africa die within the first year of treatment, with
most deaths occurring in the first few months [4]. Baseline
patient characteristics independently associated with early
mortality include low CD4 cell count, advanced World
Health Organization (WHO) clinical stage of disease, low
body mass index, anaemia and male sex. In many
programmes in Africa, median baseline CD4 cell counts
are low (approximately 100–150 cells/ml) [4,6–11], and
this has been highlighted as a key problem [4].
Although most existing studies from sub-Saharan Africa
have examined short-term mortality outcomes and their
association with baseline patient characteristics [4], some
data suggest that risks of morbidity and mortality change
according to the response to ART [11–13]. Data are now
needed on longer term outcomes and, in particular, how
mortality risk changes in association with CD4 cell count
recovery. We hypothesized that even in those with rapid
immune recovery, many patients with advanced immu-
nodeficiency at baseline accrue considerable time with low
CD4 cell counts, resulting in a high cumulative mortality
risk. To examine these issues, we analysed prospectively
collected data from patients with up to 5 years of follow-up
in a large ART cohort in Cape Town, South Africa.
Methods
Antiretroviral treatment service
The ART service established in Gugulethu township in
Cape Town in 2002 has previously been described in detail
[6,12–14]. The district has a predominantly African
population of over 300 000, the vast majority of whom live
in conditions of low socioeconomic status. Ambulatory
patients eligible for ARTare referred to this service from a
series of other primary care clinics in the township. During
this study, the median time between enrolment of a patient
in the service and initiation of ART was approximately 1
month. This permitted thorough preparation of patients
for ART and screening and management of opportunistic
infections and other comorbidities. The vast majority of
patients with tuberculosis (TB) in this service have received
at least 1 month of TB treatment prior to ART [15].
National ART guidelines were based on the WHO 2002
recommendations [16], providing treatment for those
with a prior AIDS diagnosis (WHO stage 4 disease) or a
blood CD4 cell count of less than 200 cells/ml. First-line
ART comprised stavudine, lamivudine and a nonnucleo-
side reverse transcriptase inhibitor (predominantly efavir-
enz) and was supplied free of charge to patients.
Treatment compliance was high, and the virological
failure rate is approximately only 2% of patients per year
[17]. All patients routinely received prophylaxis with
trimethoprim-sulphamethoxazole both before and during
ART.
Data collection
Blood CD4 cell count and plasma viral load measurements
were done routinely at baseline and 4 monthly during ART
within accredited laboratories. Detailed structured clinical
and laboratory records were maintained for every patient
visit from the time of enrolment in the programme. Data
were transferred on a weekly basis to an electronic database.
Patients requiring in-patient care were referred to a nearby
200-bed secondary hospital. Information on in-patient
care was gained from discharge letters, hospital and
laboratory records and postmortem examinations.
Additional deaths and losses to follow-up were ascertained
by active community-based follow-up by peer counsellors
as previously described [13]. Patients were classified as lost
to follow-up if they did not attend the clinic for a
consultation or to collect medication for a period of 12
weeks. Collection of data on this study population for
research purposes was approved by the Research Ethics
Committee of the University of Cape Town; all patients
enrolled gave written informed consent.
Data analysis
Data were analysed using STATA (StataCorp LP, College
Station, Texas, USA). Data from all patients who initiated
ART within the programme between September 2002
and June 2007 were included. Person-time of observation
was accrued from the date of enrolment in the
programme until either occurrence of death, loss to
follow-up, transfer to another ART programme or
censoring of observation in September 2007.
Person-time on ART was subdivided into 4-month
intervals, each of which was defined by the CD4 cell
count measurement at the start of the interval. In the
event of missing CD4 cell data from the start of
the interval (<5% of all intervals), we used the mean
of the CD4 cell values immediately before and after the
interval. Intervals were categorized into CD4 cell count
strata (CD4cell-strata): 0–49, 50–99, 100–199, 200–
299, 300–399, 400–499 and at least 500 cells/ml. Total
person-time accrued within each of these CD4 cell-strata
during follow-up was calculated.
Overall mortality rates and rates within CD4 cell-strata
were calculated. Kaplan–Meier (product-limit) analyses
were used to estimate cumulative mortality risk both in
the overall cohort and stratified by baseline CD4 cell
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count. We estimated the association between baseline risk
factors, updated CD4 cell counts and viral load and the
incidence of mortality using univariate and multivariate-
mixed effect Poisson regression models.
The relationship between CD4 cell counts and duration
of ART was illustrated using lowest smooth curves
obtained from a series of locally weighted regressions with
bandwidth of 0.8. Poisson base confidence intervals (CI)
were calculated for per person-year incidence rates and
binomial exact CIs for cumulative mortality rates. In
other analyses, Wilcoxon rank-sum tests were used to
compare medians, and all statistical tests are two-sided at
alpha value of 0.05.
Results
Cohort characteristics and follow-up
During the study period, 2878 patients were enrolled in
the programme. At the time data were censored, 2423
(84%) patients had started ART, and their baseline
characteristics showed that most had advanced immu-
nodeficiency (Table 1). Of 455 patients who did not
receive ART, 298 (10%) had been deferred from the
programme (due to ineligibility for ART, treatment
refusal or loss to follow-up), 52 (2%) were currently
preparing to start treatment and 105 (4%) had died before
starting ART.
Individuals were followed up for up to 5 years, and a total
of 3155 person-years of follow-up accrued during ART.
With cohort expansion over time, the numbers of
patients alive and receiving treatment after 1, 2, 3 and
4 years of treatment were 1426, 681, 262 and 104,
respectively. Of those who started ART, 1856 (77%) were
still alive and receiving treatment at data censorship, 232
(10%) had been lost to follow-up, 143 (6%) had been
transferred out to another ART service and 192 (8%)
had died. Those who died had low CD4 cell counts;
at baseline, a median CD4 cell count of 78 cells/ml
[interquartile range (IQR) 25–171; range 1–966)] at the
time of death (Table 1). The proportions of patients with
viral load suppression of less than 400 copies/ml at 12, 24,
36 and 48 months of ART were 90.5, 90.3, 93.3 and
90.5%, respectively. One-third of those who died had an
undetectable viral load just prior to death (Table 1).
Mortality rates and cumulative mortality
estimates
The mortality rate during the 1-month period prior to
starting ART was very high [26.6 deaths/100 person-
years; 95% CI 21.8–32.3]. The rate during months 0–4
of ARTwas also high (16.3 deaths/100 person-years; 95%
CI 13.3–19.7) but decreased steeply thereafter, reaching a
rate of 4.4 (2.8–6.4) deaths/100 person-years during
8–12 months of treatment. Mortality rates in the second,
third and fourth years of ART were 2.6 (1.6–3.9), 0.7
(0.2–1.6) and 0.4 (0.1–1.6) deaths/100 person-years,
respectively.
Cumulative mortality estimates over 48 months of ART
were derived using Kaplan–Meier analyses (Fig. 1a). The
mortality estimate at 12 months (8.4%) was approximately
two-thirds of the overall estimate at 48 months (13.2%).
Cumulative mortality at 48 months in patients with
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Table 1. Characteristics of the patients starting antiretroviral treatment and of the patients who subsequently died during treatment.
Patient characteristics Patients starting ART (n¼2423) Survivors (n¼2231) Deaths (n¼192)
Median (IQR) age 33 (28–39) 32 (28–38) 36 (30–43)
Female patients 1624 (67) 1512 (68) 112 (58)
Baseline CD4 cells (cells/ml)
Median (IQR) 101 (48–157) 104 (52–159) 57 (16–111)
0–49 618 (21) 531 (24) 87 (45)
50–99 574 (20) 531 (24) 43 (22)
100–149 549 (19) 516 (23) 33 (17)
150–200 423 (17) 406 (18) 17 (9)
200 259 (11) 247 (11) 12 (6)
Baseline log viral load
5.0 log copies/ml 1052 (43) 946 (42) 106 (55)
WHO stage
1 and 2 575 (24) 560 (25) 15 (8)
3 1395 (53) 1300 (58) 95 (50)
4 552 (23) 470 (21) 82 (43)
Updated CD4 cell count prior to death (cells/ml)
Median (IQR) – – 78 (25–171)
0–99 – – 107 (56)
100–199 – – 45 (23)
200 – – 40 (21)
Updated viral load prior to death
400 copies/ml – – 128 (67)
Months ART at time of death
Median (IQR) – – 7.8 (3.3–22.8)
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baseline CD4 cell counts less than 100 cells/ml was
approximately double that of patients with counts more
than 100 cells/ml (P< 0.001) (Fig. 1b).
To permit comparison with data from other cohorts,
mortality estimates after 48 months of ART were also
determined for subgroups of patients. For those with
WHO stages 1–3 and baseline CD4 cell counts of more
than 100 cells/ml or less than 100 cells/ml, estimates were
6.3 and 12.6%, respectively. For those with WHO stage 4
disease and baseline CD4 cell counts of more than
100 cells/ml or less than 100 cells/ml, estimates were 20.1
and 24.8%, respectively.
Mortality rates and CD4 cell response to
antiretroviral therapy
We next examined how mortality rates changed in
relation to the CD4 cell response to ART. We categorized
person-time of observation according to the CD4 cell
count at the start of each 4-month follow-up interval. We
then calculated cumulative person-time accrued within a
series of CD4 cell-strata and used these as denominators
to calculate mortality rates stratified by updated CD4 cell
counts. The relationship between updated CD4 cell
counts and mortality rates was extremely strong (Fig. 2).
Risk factors for mortality during antiretroviral
therapy
We examined crude and adjusted associations between
mortality and patient baseline characteristics and updated
viral load and CD4 cell counts. In crude analyses, older
age, male sex, WHO stage 4 disease, updated CD4 cell
counts and detectable updated viral load measurements
were all significantly associated with mortality risk
(Table 2). With the exception of male sex, each of these
variables remained significantly associated in the multi-
variate model. However, updated CD4 cell counts were
the variable most strongly associated with death. Those
CD4 cell-strata lying below a threshold of 200 cells/ml
were each associated with a more than two-fold greater
adjusted mortality risk compared with the more than
500 cells/ml CD4 cell-stratum. Above a threshold of
200 cells/ml, small cumulative reductions in mortality
rates occurred as CD4 cell counts increased further, but
these differences did not reach statistical significance.
In another model, we excluded the first 4 months of
observation during ART, so that baseline CD4 cell counts
could be included as a separate variable in addition to
updated CD4 cell counts. In this model, updated but not
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Fig. 1. Kaplan–Meier plots showing cumulative mortality
risk over 48 months. (a) Cumulative mortality estimates for
the whole cohort at 12 and 48 months of ART were 8.4 and
13.2%, respectively. (b) Cumulative mortality estimates at 12
and 48 months from enrolment were 11.6 and 16.7%,
respectively, in those with baseline CD4 cell counts of less
than 100 cells/ml ( ) compared with 5.2 and 9.5% in
those with baseline counts more than 100 cells/ml ( ).
Fig. 2. Graph showing the mortality rates (95% confidence
interval, deaths/100 person-years) according to updated
CD4 cell counts during antiretroviral therapy. CD4 cell counts
(cells/ml) were measured at baseline and 4 monthly during
ART. Follow-up time intervals were defined by the CD4 cell
count at the start of each interval and categorized into one of
six different CD4 cell count strata. Cumulative person-time
accruing within these strata was determined and used to derive
the CD4 cell-stratum-specific mortality rates. Unadjusted
mortality rates during person-time accrued within the 0–49,
50–99, 100–199, 200–299, 300–399, 400–499 and at least
500 cells/ml CD4 cell-strata were 38.6 (30.3–48.6), 12.8 (8.9–
17.9), 5.4 (3.9–7.2), 2.7 (1.6–4.1), 2.0 (1.0–3.6), 2.0 (0.7–4.3)
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baseline CD4 cell counts were significantly associated
with mortality risk. Together, these models indicate that
the absolute CD4 cell count at any given time point is a
key determinant of mortality risk.
CD4 cell count recovery during antiretroviral
therapy
We next examined how the overall distribution of CD4
cell counts in the cohort changed over time. Figure 3
shows changes in the proportions of patients with CD4
cell counts lying below a series of thresholds during ART.
The proportion of patients with a CD4 cell count less
than 100 cells/ml decreased rapidly from 41% at baseline,
reaching a plateau of approximately 2% after 12–
18 months of ART. The proportion of patients with a
CD4 cell count of less than 200 cells/ml also decreased
from 89% at baseline and reached a plateau of
approximately 10% of patients after 24–36 months of
ART. Conversely, the proportion of patients with CD4
cell counts of more than 500 cells/ml steadily increased
from 0% at baseline to approximately 50% after 48 months
(Fig. 3). The slope of the 500 cells/ml contour indicates
substantial immune recovery was ongoing after 4 years
of treatment.
Cumulative person-time within low CD4
cell-strata and mortality risk
Having established the relationship between mortality
risk and updated CD4 cell counts and having charac-
terized CD4 cell recovery over time, we reasoned that
mortality rates in the overall cohort would be strongly
related to the cumulative person-time accrued within low
CD4 cell-strata. For each sequential year of ART, we
calculated the proportions of total person-time that were
accrued within different CD4 cell-strata. During years 1,
2, 3 and 4 of ART, the proportions of person-time
accrued at CD4 cell counts less than 100 cells/ml were
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Table 2. Risk factors for mortality among patients (n U 2423) receiving antiretroviral therapy.
Patient characteristics
Crude association Multivariate model
IRR 95% CI P-value IRR 95% CI P-value
Age 1.03 1.02–1.05 <0.001 1.04 1.02–1.05 <0.001
Male sex 1.72 1.29–2.29 <0.001 1.10 0.82–1.49 0.524
WHO stage
1–3 1 1
4 2.31 1.73–3.08 <0.001 2.28 1.70–3.07 <0.001
Cohort enrolment year
1 1 1
2 0.59 0.25–1.39 0.227 0.58 0.25–1.36 0.211
3 0.86 0.41–1.81 0.689 0.82 0.39–1.75 0.615
4 1.38 0.69–2.76 0.360 1.06 0.52–2.16 0.862
5 2.26 1.12–4.55 0.022 1.27 0.62–2.61 0.513
Updated CD4 cell count (cells/ml)
>500 1 1
400–499 1.59 0.45–5.63 0.460 1.41 0.40–5.01 0.597
300–399 1.60 0.50–5.11 0.425 1.45 0.45–4.64 0.533
200–299 2.16 0.74–6.34 0.158 1.66 0.56–4.91 0.358
100–199 4.37 1.57–12.17 0.005 2.59 0.90–7.42 0.076
50–99 10.44 3.71–29.43 <0.001 4.93 1.66–14.70 0.004
0–49 31.46 11.50–86.08 <0.001 11.63 3.95–34.29 <0.001
Updated viral load (copies/ml)
<400 1
>400 5.76 4.24–7.81 <0.001 2.06 1.37–3.09 <0.001
Age included as a continuous variable. CI, confidence interval; IRR, incidence rate ratio.
Fig. 3. Graph showing smoothed changes in distribution of
CD4 cell counts in the cohort over time during 48 months
of antiretroviral therapy. The proportions (percentage) of
patients with CD4 cell counts lying below thresholds of
100, 200, 300, 400, 500, 600, 700, 800, 900 and
1000 cells/ml are shown. The proportions of patients with
CD4 cell counts less than 100 and 200 cells/ml decreased
steeply over the 1st and 2nd years of ART, respectively. The
proportion of patients with CD4 cell counts more than
500 cells/ml steadily increased throughout follow-up, indicat-
ing ongoing immune recovery. Median CD4 cell counts at 0,
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26, 4, 1 and 1%, respectively, and the proportions of
person-time accrued at CD4 cell counts less than
200 cells/ml were 63, 25, 12 and 8%, respectively. These
observations provide insight into the very high mortality
rates in the first year of ART, which rapidly decreased to
long-term rates that were much lower.
Baseline CD4 cell counts were strongly predictive of the
cumulative person-time accrued within the lowest CD4
cell-strata. Those with the lowest baseline counts
(<100 cells/ml) accrued 28 and 53% of person-time with
CD4 cell counts of less than 100 and 200 cells/ml,
respectively, compared with 1 and 28% of person-time for
those with higher baseline counts (>100 cells/ml). Thus,
patients with lower baseline CD4 cell counts had a much
higher cumulative mortality risk (Fig. 1b).
Discussion
In this analysis, we examined the relationship between
mortality risk and CD4 cell counts measured at baseline
and 4 monthly during ART (updated CD4 cell counts) in
a large cohort. Mortality risk decreased markedly in
association with ART-induced CD4 cell recovery, but
patients remained at substantially greater mortality risk
during person-time accrued at CD4 cell counts below a
threshold of 200 cells/ml. Compared with patients with
the highest updated CD4 cell counts, patients with
updated CD4 cell counts of less than 200 cells/ml had a
more than two-fold greater adjusted mortality risk and
those with updated counts of less than 50 cells/ml had a
more than 10-fold greater adjusted mortality risk.
Cumulative person-time accrued within CD4 cell-strata
lying below 200 cells/ml explains both the high mortality
observed during the first year of ART and the high long-
term cumulative mortality risk among those with the
lowest baseline CD4 cell counts. Early HIV diagnosis and
timely initiation of ART before CD4 cell counts fall
200 cells/ml are required.
Despite virological suppression rates of more than 90% and
excellent CD4 cell count recovery in this cohort (Fig. 3),
cumulative mortality estimates after 48 months of ART
were far greater than those observed in ART cohorts in
high-income countries [18,19]. Similarly aged patients in
the Dutch AIDS Therapy Evaluation Project (ATHENA)
cohort, for example, who have sexually acquired HIVand
baseline CD4 cell counts of less than 100 cells/ml have 5-
year cumulative mortality estimates of 8% (AIDS patients)
or 4% (non-AIDS patients) [18]. These compare to 4-year
estimates of 24.8 and 12.6%, respectively, among similarly
stratified patients in our cohort. Corresponding estimates
from the ATHENA cohort for patients with baseline CD4
cell counts of 100–200 cells/ml were 4% (AIDS patients)
and 2% (non-AIDS patients) compared with estimates of
20.1 and 6.3% in our cohort. These findings indicate that
long-term cumulative mortality estimates are over three-
fold higher in our cohort.
Our data extend the findings of the Antiretroviral
Treatment in Lower Income Countries (ART-LINC)
collaboration, which reported that after adjustment for
baseline patient characteristics, mortality risk in the first
year of ART was higher among patients treated in
resource-limited settings compared with those treated in
high-income settings despite similar immunological and
virological responses to treatment [5,20]. Reasons
underlying this have yet to be defined but may include
differences in the spectrum of opportunistic pathogens
and access to healthcare. The most common causes of
early deaths in our cohort are TB, acute sepsis,
cryptococcal meningitis, wasting syndrome and Kaposi’s
sarcoma [6,15,21]. Immune reconstitution disease has
been speculated to contribute to early mortality in this
setting, and our experience is that cryptococcal disease
rather than TB is more important in this regard [6,22].
Existing studies from both high-income and resource-
limited settings have largely focused on the relationship
between mortality risk and baseline patient characteristics
[4,6–11,13,18,19]. We extended these findings, showing
that mortality risk changed markedly in relationship with
CD4 cell count recovery during ART (Fig. 2) and that
the bsolute CD4 cell count at any given time point was
the key determinant of mortality risk. However, above a
threshold of 200 cells/ml, further increments in CD4 cell
counts were associated with only minor additional
reductions in mortality rates that did not reach statistical
significance in this analysis.
Immune recovery in this cohort compares very favour-
ably with that observed in ART cohorts in high-income
countries [23]. The proportion of patients with CD4 cell
counts less than 200 cells/ml decreased steeply to reach a
plateau of approximately 10% after 24–36 months of
ART (Fig. 3). In the long term, the minority of patients
with updated counts less than 200 cells/ml contributed
disproportionately to overall mortality rates, and this
proportion may be an important factor underlying
differences in mortality rates between cohorts. Such
patients may have immunological nonresponse (approxi-
mately 10% of this cohort at 48 weeks [24]) or primary or
secondary virological failure. A detectable viral load
during follow-up was also an independent risk factor for
death, highlighting the importance of maintaining
virological suppression.
The slope of the 500 cells/ml CD4 cell count contour in
Fig. 3 indicates that substantial immune recovery was
ongoing after 48 months of ART. However, as mortality
risk varied relatively little above a CD4 cell count
threshold of 200 cells/ml, the steadily increasing pro-
portion of patients with counts more than 500 cells/ml is
unlikely to impact overall mortality rates substantially.
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This may be more important, however, with regard to
reducing risk of morbidity due, for example, to TB,
which persists at high rates during ART in this setting
[25].
Cumulative mortality risk was strongly related to the
proportions of person-time accrued within different CD4
cell-strata. During the first year of ART, the proportions
of person-time accrued within CD4 cell-strata lying
below 200 cells/ml were large, and the mortality that
accrued within this period was correspondingly high.
Beyond 1 year of treatment, these proportions rapidly
decreased, accounting for much lower mortality rates
thereafter.
In multivariate analyses, mortality risk at any given time
point was associated with updated CD4 cell count rather
than the baseline value. Lower baseline counts were,
however, predictive of greater proportions of person-time
accrued within low CD4 cell-strata with high mortality
risk. Thus, cumulative mortality estimates at 48 months
were much higher among patients with baseline CD4 cell
counts less than 100 cells/ml compared with those with
higher baseline counts (Fig. 1b). Median baseline CD4
cell counts are low in most ART programmes in sub-
Saharan Africa, and so many patients remain at high
mortality risk for considerable periods.
These data indicate that patients should start ART before
their CD4 cell counts fall below 200 cells/ml, though this
only occurs in a small minority of patients in Africa at
present. Earlier initiation of ART will require early HIV
diagnosis and strengthening of longitudinal HIV care,
with serial assessments of CD4 cell counts and clinical
status to trigger initiation of ART at an appropriate time
point. Eligibility criteria for ART in national programmes
in the region need to be reconsidered. The policy in
South Africa, for example, restricts ART to patients with
WHO stage 4 disease (AIDS) or a CD4 cell count less
than 200 cells/ml [26], which is not in keeping with
current WHO guidelines [27]. Thus, current South
African policy restricts the potential survival benefits that
could be derived from ART.
Strengths of this study include the completeness of data,
with less than 5% of CD4 cell count data-points missing,
good ascertainment of outcomes and a low loss to follow-
up rate. Previous data indicate that inadvertent misclassi-
fication of deaths as losses to follow-up in this cohort is
infrequent [13]. This analysis is novel with inclusion of
updated CD4 cell counts and viral load measurements as
time-dependent covariates. A much larger cohort would
be needed to detect any significant differences in mortality
risk in higher CD4 cell-strata, however. Baseline
characteristics of patients were typical of those accessing
ART in other public sector programmes across sub-
Saharan Africa. However, mortality and loss to follow-up
rates were lower than those observed in many other
programmes, and absolute CD4 cell-stratified mortality
rates may not be representative of all programmes [4,28].
In summary, long-term cumulative mortality estimates
in this South African cohort were approximately three-
fold higher than those in cohorts in high-income
countries despite excellent immunological and virologi-
cal responses to ART. Mortality risk during ART was
strongly associated with updated CD4 cell counts, and
overall mortality was related to the proportions of person-
time accrued within low CD4 cell-strata. Person-time
accrued at CD4 cell counts less than 200 cells/ml must
be minimized before and during ART. National HIV
programmes should take measures to promote early
diagnosis of HIV and initiation of ART before CD4 cell
counts fall below 200 cells/ml.
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Usefulness of total lymphocyte count in monitoring
highly active antiretroviral therapy in resource-limited
settings
Motasim Badri and Robin Wood
Objective: To assess the usefulness of total lymphocyte count (TLC) for monitoring
HIV-infected patients receiving highly active antiretroviral therapy.
Design: Observational cohort study.
Methods: Correlation between difference (˜) from baseline at week 4, 8, 12 and 48 in
TLC, CD4 cell count and viral load was determined in patients initiating HAART in
phase III clinical trials between 1995 and 2001 at the HIV Clinical Research Unit,
Somerset Hospital, Cape Town.
Results: The study included 266 patients. At weeks 4, 8, 12 and 48, median increase
in TLC was 30, 52, 139 and 219 cells 3 106/l, median increase in CD4 cell count was
8, 48, 88, and 145 cells 3 106/l, and median decrease in viral load was 1.6, 2.2,
2.5 and 2.7 log10 copies/ml, respectively. The correlation between all pairs of
˜TLC and ˜CD4 cell counts was significant (r, 0.61; P, 0.0001), but between ˜TLC
and ˜ viral load it was not (r, 0.014; P ¼ 0.73). However, the correlation between
median viral load reduction and median increase in both ˜CD4 cell count (r, 0.96;
P , 0.0001) and ˜TLC (r, 0.89; P, 0.0001) was significant. The slope of ˜CD4 cell
count was [52.493 + 0.14(˜TLC)]. Sensitivity and specificity of an increase or de-
crease from baseline in TLC for similar trend in CD4 cell count during follow-up were
83.4% and 87.3% respectively.
Conclusion: TLC correlated well with changes in CD4 cell count and at a group level
with viral load changes. TLC may have a role in inexpensive monitoring of the
immunological response to highly active antiretroviral therapy in a resource-con-
strained setting. & 2003 Lippincott Williams & Wilkins
AIDS 2003, 17:541–545
Keywords: HIV, total lymphocyte count, CD4 T lymphocyte count, viral load,
HAART
Introduction
The survival benefits of highly active antiretroviral
therapy (HAART) are well documented. However,
owing to high cost, few in the developing countries
currently have access to antiretroviral therapy (ART).
Recent initiatives of the World Health Organization
(WHO) for scaling up ART in resource-limited set-
tings [1] will result in an increasing number of HIV-
infected patients accessing ART. In well-resourced
settings, commencement of ART is based predomi-
nantly on the presence of HIV-related symptoms and
CD4 cell count. Laboratory capacity to measure CD4
cell count is limited in many areas with high HIV
seroprevalence. The WHO has proposed a TLC of
, 1200 3 106/l as a substitute indication for initiating
ART in resource-limited settings [1]. TLC is an
inexpensive and useful marker for disease staging and
predicting progression to AIDS or death in HIV-
infected patients [2]. A high correlation between TLC
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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and CD4 cell count both in asymptomatic and sympto-
matic HIV-infected patients has been observed [3].
Restoration and/or preservation of immunological
function together with suppression of plasma viraemia
are important goals of ART. Capacity to monitor
plasma viral load is very limited in resource-constrained
settings. Use of TLC as a surrogate for other expensive
markers, such as the CD4 cell count or viral load,
would result in substantial reduction in cost associated
with managing HIV-infected patients.
We conducted an observational study to determine
whether changes over time in CD4 cell count and
plasma HIV RNA could be monitored by changes in
TLC in a cohort of indigent patients accessing
HAART through participation in phase III randomized
clinical trials in a public healthcare facility in Cape
Town, South Africa between 1995 and 2001.
Methods
This prospective observational study was conducted in
the New Somerset Hospital HIV clinic, University of
Cape Town; a major public health care facility dedi-
cated for HIV-infected patients in Cape Town. This
clinic provides care for patients referred from a wide
range of primary healthcare facilities in Cape Town.
Subjects were recruited into the study from the on-
going clinical trials in the hospital, which have been
described in detail elsewhere [4]. In brief, patients . 16
years were recruited into the 12 trials conducted in the
hospital between 1995 and 2001. Entry viral load and
CD4 cell count requirements varied between studies.
Patients were excluded if they presented with acute
opportunistic infection, significant laboratory abnorm-
alities, and active substance abuse or if they were
treated with immune-modulating or systemic che-
motherapeutic agents. Pregnant or lactating females
were also excluded. All patients received at least three
antiretroviral drugs: a non-nucleoside reverse transcrip-
tase inhibitor with two nucleoside analogues; or three
nucleoside analogues; or a protease inhibitor with two
nucleoside analogues. Follow-up was repeated at 2–3-
month intervals, or more frequently if clinically in-
dicated. Total lymphocyte count (TLC), CD4 cell
count and plasma HIV RNA were measured prospec-
tively approximately every month. Plasma HIV RNA
was determined by reverse transcriptase–polymerase
chain reaction (Roche Amplicor HIV-1 RNA PCR
assay version 1.5, Roche, Branchberg, New Jersey,
USA), CD4 cell count by flow cytometry (Coulter,
Hialeah, Florida, USA) and TLC by automated blood
counter (CPICS, Hialeah, Florida, USA) on the same
day the blood sample was obtained.
As all three parameters were non-normally distributed,
when tested for normality using the Shapiro–Wilks’ W
test, association between all pairs of TLC, CD4 cell
count and plasma HIV RNA was determined using
Spearman’s partial rank order correlation. Median
change difference (˜) in baseline TLC, CD4 cell count
and viral load at weeks 4, 8, 12 and 48 were assessed
using the Friedman ANOVA non-parametric test.
Changes in CD4 cell count and plasma HIV RNA
relative to TLC was determined using the slope of the
correlation’s scatter graph. Sensitivity and specificity of
the absolute change (i.e., the absolute increase/de-
crease) in CD4 cell count and TLC from baseline at
the different time points during follow-up (i.e., every 4
weeks) as well as for TLC , 1250 3 106/l and CD4
cell count , 200 3 106/l were calculated. The choice
of a TLC , 1250 3 106/l as surrogate for a CD4 cell
count , 200 3 106/l was based on the significant
correlation observed previously in patients presenting
to our clinic [2]. All analyses were carried out using
STATISTICA software (release 6.6,Tulsa, Oklahoma,
USA).
Results
The study population consisted of 266 patients receiv-
ing HAART. At screening, 155 failed to meet entry
requirements. Mean age of patients was 34.5 years (SD,
9 years). 115 (44%) patients were female and 122 (46%)
presented with WHO clinical stage 3 or 4 at their
initial clinic visit. At inclusion, median CD4 cell count
was 254 3 106/l [inter-quartile range (IQR), 140–
364 3 106/l], median TLC was 1480 3 106/l (IQR,
1100–1830 3 106/l) and mean (log10) plasma HIV
RNA was 5.4 copies/ml.
At weeks 4, 8, 12 and 48, median increase in TLC
(3 106/l) was 30, 52, 139 and 219, respectively.
Median increase in CD4 cell count (3 106/l) was 8,
48, 88, and 145, respectively and median decrease in
plasma HIV RNA (log10 copies/ml) was 1.6, 2.2,
2.5 and 2.7, respectively. Median increase from
baseline in TLC (P , 0.0001) and CD4 cell count
(P , 0.0001), as well as median decrease in plasma
HIV RNA (P , 0.0001) was significant (Fig. 1).
A significant correlation was observed between all pairs
of ˜TLC and ˜CD4 cell count (r, 0.61; P , 0.01;
Fig. 2a). The correlation between all pairs of ˜ viral
load (VL) and ˜CD4 cell count was significant (r,
0.26; P , 0.0001; Fig. 2c), but between all the pairs
of ˜VL and ˜TLC it was not (r, 0.01; P ¼ 0.73;
Fig. 2b). However when the ˜TLC was log-trans-
formed, the correlation reached significance (r, 0.011;
P ¼ 0.03; data not shown). The slope of ˜VL and
˜CD4 cell count relative to ˜TLC was [2.02 
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.










0.00003(˜TLC)] and [52.5 + 0.14(˜TLC)] respec-
tively, and the slope of ˜VL relative to ˜CD4 cell
count was [1.84 – 0.004(˜CD4 cell count)].
Reduction in the median plasma HIV RNA at weeks 4,
8, 12 and 48 correlated well with median increase in
both ˜CD4 cell count (r, 0.96; P , 0.0001; Fig. 2f)
and ˜TLC (r, 0.89; P , 0.0001; Fig. 2e). The correla-
tion between median increase in ˜CD4 cell count and
˜TLC was also significant (r, 0.98; P , 0.0001; Fig.
2d). The correlation between all the pairs (P ¼ 0.004)
and median increase (P , 0.0001) in ˜VL and ˜CD4
cell count were significantly greater than that between
˜VL and ˜TLC. The slope of median ˜VL and ˜CD4
cell count relative to ˜TLC was [1.071  0.005(˜
TLC)] and [0.07 + 0.67(˜TLC)] respectively, and the
slope of median ˜VL relative to CD4 cell count was
[1.69 – 0.008(˜CD4 cell count)] (Fig. 2).
Sensitivity and specificity of an increase or decrease in
TLC for a similar trend in CD4 cell count were 83.4%
[95% confidence interval (CI), 81.5–85.1] and 87.3%
(95% CI, 83.6–90.4), respectively. To validate our
results, we calculated the sensitivity and specificity for
the categorical values of the change from baseline in
TLC of , 1250 3 106/l and CD4 cell count of
, 200 3 106/l which were 99.4% (95% CI, 98.8–
99.7) and 92.8% (95% CI, 89.6–95.1), respectively.
Discussion
This study evaluated the usefulness of TLC in monitor-
ing patients initiating HAART by quantifying the
association between improvement in TLC, CD4 cell
count and plasma HIV RNA following use of
HAART. Our findings indicate that TLC can be used
as a reasonable surrogate for CD4 cell count. Although
the association between change in TLC and plasma
HIV RNA is weak at the individual level, TLC can be
used to monitor plasma HIV RNA at the group level.
In addition to the proposed use of TLC for initiating
ART in resource-limited settings in the recent WHO
guidelines [1], TLC may have a role in inexpensive
monitoring of the immunologic response to HAART.
Given the significant correlation and the relatively high
sensitivity and specificity rates, in clinical practice TLC
can aid health care providers in monitoring the im-
munologic response to HAART using the slope of the
correlation ˜CD4 cell count [52.493 + 0.14(˜ TLC)].
For example, an increase from baseline of 1 3 106/l in
TLC is equivalent to an increase of 192.5 3 106/l CD4
cell count.
Recent ART strategies are based on the objective of
reducing plasma HIV RNA to below the detection
limits of assays in order to stop or reverse the
pathogenic process. Although usefulness of TLC as a















































































































Fig. 1. Median change in TLC (a), CD4 cell count (b) and HIV RNA (c) at weeks 4, 8, 12, and 48.










surrogate for CD4 cell count have been studied
previously, our study is the first to assess the association
between changes over time in these two parameters
and the plasma HIV RNA in patients receiving
HAART. In a study from the UK, Beck et al. observed
a high correlation (r, 0.76) between TLC and CD4 cell
count [3]. The correlation in their study was consis-
tently significant in asymptomatic patients (r, 0.64),
symptomatic non-AIDS HIV-infected patients (r, 0.72)
and AIDS patients (r, 0.73). Studies by Lai [5], Fournier
et al. [6] and Pulido et al. [7] have also demonstrated
significant correlation between TLC and CD4 cell
count, particularly in patients with CD4 cell count
, 200 3 106/l. In addition, in a cohort of non-
HAART users in Cape Town, Post et al. have demon-
strated that TLC , 1250 3 106/l and CD4 count
, 200 3 106/l predict similar progression to AIDS and
mortality [2].
For HAART interventions to be cost-effective, target-
ing and timing are of utmost importance. More
recently, the WHO proposed the use of a TLC of
1200 3 106/l as a substitute indication for ART treat-
ment in resource-limited setting for CD4 cell count
, 200 3 106/l [1]. Our sensitivity and specificity ana-
lyses suggest that a TLC of 1250 3 106/l is a reasonable
surrogate for evaluating the outcome of HAART in
patients failing to achieve immunologic reconstitution
to a CD4 cell count of 200 3 106/l. Our sensitivity
estimate concur with recent study by Flanigan et al.
from India (80%) [8].
The exclusion criteria for patients entering HAART
trials were protocol-determined but may have intro-
duced bias. The major causes for exclusion were acute
opportunistic infection and significant laboratory ab-
normalities as substance abuse among our patients is
minimal. Initiation of HAART at the same time as
treatment for acute opportunistic infections results in
high pill-burdens and added potential for adverse drug
interactions. In addition, acute opportunistic infection
may cause transient lymphopaenia [9]. However, de-
spite these exclusions, 46% of the patients included in
this study presented with WHO stage 3 or 4, indicating
that our cohort represents patients with wide spectrum
of immune suppression.
In conclusion, our findings indicate that in addition to its
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r  0.98, P  0.0001
Fig. 2. Correlation between (a) change in TLC and CD4 cell count, (b) change in TLC and HIV RNA, (c) change in CD4 cell
count and HIV RNA, (d) median change in TLC and CD4 cell count, (e) median change in TLC and HIV RNA, and (f) median
change in CD4 cell count and HIV RNA.










use for initiating HAART, as proposed by the recent
WHO guidelines, TLC can also be used as an inexpen-
sive surrogate for monitoring the immunolgical response
to HAART in resource-limited settings. This data is of
particular relevance to sub-Saharan Africa where the
laboratory infrastructure to perform CD4 cell and viral
load measurement is frequently not available and current
international initiatives for facilitating access to ART is
increasing the number of patients requiring monitoring.
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Abstract
Background: Viral load monitoring is not available for the vast majority of patients receiving
antiretroviral therapy in resource-limited settings. However, the practical utility of CD4 cell count
measurements as an alternative monitoring strategy has not been rigorously assessed.
Methods: In this study, we used a novel modelling approach that accounted for all CD4 cell count
and VL values measured during follow-up from the first date that VL suppression was achieved. We
determined the associations between CD4 counts (absolute values and changes during ART), VL
measurements and risk of virological failure (VL > 1,000 copies/ml) following initial VL suppression
in 330 patients in South Africa. CD4 count changes were modelled both as the difference from
baseline (ΔCD4 count) and the difference between consecutive values (CD4 count slope) using all
3-monthly CD4 count measurements during follow-up.
Results: During 7093.2 patient-months of observation 3756 paired CD4 count and VL
measurements were made. In patients who developed virological failure (n = 179), VL correlated
significantly with absolute CD4 counts (r = - 0.08, P = 0.003), ΔCD4 counts (r = - 0.11, P < 0.01),
and most strongly with CD4 count slopes (r = - 0.30, P < 0.001). However, the distributions of the
absolute CD4 counts, ΔCD4 counts and CD4 count slopes at the time of virological failure did not
differ significantly from the corresponding distributions in those without virological failure (P = 0.99,
P = 0.92 and P = 0.75, respectively). Moreover, in a receiver operating characteristic (ROC) curve,
the association between a negative CD4 count slope and virological failure was poor (area under
the curve = 0.59; sensitivity = 53.0%; specificity = 63.6%; positive predictive value = 10.9%).
Conclusion: CD4 count changes correlated significantly with VL at group level but had very
limited utility in identifying virological failure in individual patients. CD4 count is an inadequate
alternative to VL measurement for early detection of virological failure.
Background
Access to antiretroviral therapy (ART) is expanding in low-
and middle-income countries with over 2 million people
receiving treatment by December 2006, representing 28%
of the 7.1 million estimated to be in need [1]. Recent stud-
ies from sub-Saharan Africa have shown that ART is a cost-
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effective public health intervention [2-4]. Over 1.3 mil-
lion people in the region were receiving ART by December
2006 and yet more than 3.5 million further individuals
remained untreated [1]. To date, early pessimism that ART
could not be effectively delivered on a large scale in the
region using a simplified public health approach has
proven largely unfounded. However, lack of laboratory
monitoring to identify patients failing treatment and
requiring a switch in treatment regimen remains a critical
issue.
Plasma viral load (VL) monitoring, the gold standard used
in high-income countries for diagnosing virological fail-
ure, is not available in many resource-limited settings.
Currently a single World Health Organisation (WHO)-
recommended second-line regimen is the only therapeu-
tic option available for HIV-infected patients in sub-Saha-
ran Africa who develop virological failure during their
first-line regimen [5]. Although these regimens are offered
free of charge in the national ART programme in some
countries, no further treatment options are typically avail-
able in the public sector thereafter. Sensitive and specific
means for timely identification of treatment failure are
therefore greatly needed to maximize the benefits of these
limited drug options.
Routine VL monitoring in resource-limited settings
requires significant infrastructure and expertise and
remains prohibitively expensive in most settings. Other
low-cost means of detecting virological failure must there-
fore be considered. Colebunders and colleagues, for
example, proposed an algorithm based on clinical and
treatment history and inexpensive laboratory indices such
as haemoglobin level and total lymphocyte count [6].
However, when evaluated in a South African cohort, the
sensitivity and specificity of the algorithm were unaccept-
ably low [7]. WHO has recommended use of CD4 cell
count measurements and clinical outcomes for monitor-
ing ART in the absence of VL [5]. However, the clinical and
CD4 cell count changes that are able to predict virological
failure have not been identified.
When considering the utility of CD4 cell counts as a sur-
rogate for virological failure, the critical issue is whether
the variability in CD4 cell count measurements ade-
quately reflects the variability in viral load. A number of
previous observations suggest that this may be limited.
Firstly, in a study of untreated patients in the USA, higher
VLs were associated with greater rates of CD4 cell decline
at a group level, but had minimal value for predicting the
rate of CD4 cell decline in individual patients; only
4%–6% of the variability in CD4 cell losses could be
explained by plasma VL [8]. Secondly, it is well recognised
that a significant proportion of patients receiving ART
have discrepant virological and immunological
responses. Blood CD4 cell counts fail to increase in
5%–50% of patients receiving ART despite prolonged
undetectable plasma VL. Conversely, marked increases in
CD4 cell counts are observed in some patients despite
incomplete virological suppression [9-14]. Thirdly, in a
study from Botswana, initial blood CD4 cell count
increases only had moderate discriminative ability for
identifying those patients who successfully achieved VL
suppression after starting ART [15]. Collectively these
existing data suggest that CD4 cell counts have limited
capacity to explain the variability of VL measurements at
an individual level both in treated and untreated patients.
A number of studies have previously examined factors
associated with virological treatment failure in high-
income settings [16-23]. However, the practical utility of
CD4 cell count measurements as a substitute for viral load
monitoring has not been specifically assessed using rigor-
ous analyses. Data relevant to ART programmes in
resource-limited settings are especially needed. We there-
fore conducted an analysis of longitudinal data from the
Cape Town AIDS Cohort (CTAC) in South Africa in which
CD4 cell counts and VL measurements are routinely meas-
ured every three months. Using all data points measured
during follow-up, we determined the association between
VL measurements, risk of virological failure and CD4 cell
counts analysed as either absolute values, changes from
baseline (ΔCD4 count) or the difference between consec-
utive values (CD4 cell count slope). We were thereby able
to assess the utility of CD4 cell counts to predict virologi-
cal failure in a resource-limited setting.
Methods
Setting and study population
The Cape Town AIDS Cohort (CTAC) has been described
in detail previously [24]. In brief, ART-naïve patients were
referred to the cohort from a wide range of primary health
care facilities in Cape Town to the adult HIV clinics affili-
ated with the University of Cape Town (UCT). Patients
accessed ART through participation in multicentre phase
III clinical trials at the New Somerset Hospital and the
Desmond Tutu HIV Research Centre at UCT between
1996 and 2006. Participants gave informed consent and
clinical trials protocols were approved by the UCT Clinical
Research Ethics Committee. Enrolment criteria differed
between the various trials but collectively encompassed
patients with a wide spectrum of baseline blood CD4 cell
counts, viral load and clinical stages. All patients received
a minimum of three antiretroviral drugs: a non-nucleo-
side reverse transcriptase inhibitor and two nucleoside
analogues; three nucleoside analogues; or a protease
inhibitor with two nucleoside analogues.
Viral load was determined by reverse transcriptase-










BMC Infectious Diseases 2008, 8:89 http://www.biomedcentral.com/1471-2334/8/89
Page 3 of 8
(page number not for citation purposes)
Systems, Branchburg, New Jersey, USA) and CD4 counts
were measured by flow cytometry (Beckman Coulter®,
Miami, Florida, USA). Blood CD4 cell counts and plasma
VL were measured every 2–3 months when patients were
routinely reviewed. Clinical stage of disease was assessed
using WHO criteria. Demographic data were recorded and
the socioeconomic status of each patient was defined
using the Cape Metropolitan Council suburbs composite
index, which has been described previously [24].
Statistical analyses
In all analyses conducted in this study, virological sup-
pression was defined by a VL of < 400 HIV RNA copies/ml
following initiation of ART. The baseline CD4 cell count
was that measured at the time that virological suppression
was first achieved. Virological failure was defined as the
first episode of viral load ≥ 1,000 HIV RNA copies/ml fol-
lowing previous successful VL suppression, confirmed by
a second consecutive measurement. To investigate sensi-
tivity thresholds, we also explored in separate analyses VL
thresholds of > 400 and of > 10,000 HIV RNA copies/ml.
Changes in CD4 cell count were reported in two ways:
ΔCD4 was defined as the change in CD4 cell count from
the baseline value and the CD4 count slope was defined
as the difference between consecutive CD4 cell count
measurements as determined by subtraction of the former
value from the latter value.
Determinants of virological failure
The Wilcoxon matched pairs test was used to compare
continuous variables and the χ2 test for comparison of cat-
egorical variables. The Kaplan-Meier method was used to
estimate the virological failure-free proportion. Cox pro-
portional hazard regression models were fitted to identify
factors associated with the likelihood of virological fail-
ure, using the SAS phreg procedure (SAS software version
8.2, SAS, Cary, NC, USA). In this analysis virological fail-
ure-free survival was defined as the time from the date of
first virological suppression to when viral load was con-
firmed to reach > 1,000 copies/ml, death or last known
clinic visit. Risk factors considered in the analysis were
prevalent AIDS (prior to, or at the date of a first viral load
< 400 HIV RNA copies/ml) and incident AIDS (occurring
subsequent to the date of a first viral load < 400 HIV RNA
copies/ml), socio-demographic variables (including age,
socioeconomic status and gender), baseline CD4 cell
count and follow-up CD4 cell count (categorized a priori
as a < 100 or ≥ 100 cells/μl increase at any time-point dur-
ing follow-up). Follow-up CD4 cell count measurements
were modelled as a time varying covariate. At each time-
point in the modelling process, the CD4 cell count value
considered was the value recorded at that specific time-
point, if available. Otherwise, the most recent recorded
value (within 2–3 months) was considered. Variables sig-
nificantly associated with the likelihood of occurrence of
virological failure in univariate models (P < 0.05) were
considered for inclusion in a multivariate model.
Association between CD4 count and viral load failure
Different strategies were employed to comprehensively
assess the strength of the association between treatment-
induced changes in CD4 cell count and virological failure.
Firstly, for patients who failed virologically, we fitted three
separate scatter-plots of all VL measurements (log10 cop-
ies/ml) done during follow-up and either the concurrently
measured absolute CD4 counts, ΔCD4 count values or
CD4 count slopes at each time-point. In these analyses the
strength of association was assessed by calculating Pear-
son correlation coefficients.
For patients who developed virological failure, we next
compared the distributions of CD4 cell values, ΔCD4
counts and CD4 cell slopes measured at the time of failure
with the distributions of all data points from patients who
did not develop virological failure. All CD4 cell count and
viral load values included in these analyses were concur-
rently measured during follow-up. Data were included
from the date of first viral load suppression until the date
of development of virological failure or the date of last
CD4 count measurement for those who did not fail viro-
logically.
We next determined the association between the CD4 cell
count slope and virological failure using a receiver operat-
ing characteristic (ROC) curve. The area under the ROC
curve was assessed with the use of the C statistic. Sensitiv-
ity, specificity, positive predictive value, negative predic-
tive value estimates were calculated, with 95% confidence
interval (CI), using Clopper-Pearson exact method or
Fleiss approximation as appropriate.
Results
Virological failure during follow-up
Of 360 patients who started ART during the study period,
330 (91.7%) achieved initial viral load suppression dur-
ing follow-up and were therefore included in the analyses
of virological failure. All treatment regimens incorporated
at least 3 drugs; the numbers of patients receiving regi-
mens based on triple nucleosides, a non-nucleoside
reverse transcriptase inhibitor or a protease inhibitor were
51 (15%), 115 (35%) and 164 (50%), respectively.
Patients were followed for a median of 24.7 patient-
months (IQR, 4.7–51.6) of observation. During this time,
15 (4.5%) patients died.
Overall, a total of 3756 paired CD4 cell count and VL
measurements were made during 7093.2 patient-months
of observation. 179 (54.2%) patients developed virologi-
cal failure with an incidence of 30.3 (95%CI 26.2–34.2)
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maintained in the remaining 151 (45.8%) patients. Kap-
lan-Meier analysis showed that risk of virological failure
decreased with increasing duration of follow-up (Figure
1A). The median time to development of failure was 24.7
months.
Determinants of virological failure
The baseline clinical and socio-demographic characteris-
tics are reported in Table 1. Groups of patients who did or
did not develop virological failure were both composed of
young adults with similar distributions of gender, socioe-
conomic status, and baseline CD4 cell count and clinical
stage of disease. All had sexually acquired disease.
In univariate Cox proportional hazards regression mod-
els, none of the variables examined was significantly asso-
ciated with the likelihood of virological failure (Table 1).
These variables included follow-up CD4 cell count (Wald
test P = 0.32), baseline CD4 cell count (Wald test P =
0.46), baseline WHO stage (Wald test P = 0.50), incident
AIDS (Wald test P = 0.22), age (Wald test P = 0.09), gender
(Wald test P = 0.63), and socio-economic status (Wald test
P = 0.53). The lack of association with baseline CD4 cell
count was further confirmed using a stratified Kaplan-
Meier plot (Figure 1B).
In view of the lack of significant associations between
patient characteristics and virological failure, multivariate
analysis was not done. Collectively these data showed that
development of virological failure was not associated with
baseline patient characteristics, follow-up CD4 cell counts
or the development of new AIDS-defining illnesses. In
separate analyses, use of VL thresholds of > 400 and of >
10,000 HIV RNA copies/ml produced the same outcomes.
CD4 cell count changes and virological failure
We next examined in greater detail the associations
between all viral load and CD4 cell count values meas-
ured concurrently during follow-up. Correlations between
VL and absolute CD4 count, ΔCD4 cell counts and CD4
cell slopes were calculated for those patients who devel-
oped virological failure (Figure 2A–C). Significant correla-
tions were observed between log10 VL and both absolute
CD4 cell count values (r = - 0.08, P < 0.01), ΔCD4 cell
count (r = - 0.11, P < 0.01), and most strongly with CD4
count slope (r = - 0.30, P < 0.001). This suggests that the
(A) Kaplan-Meier probabilities of virologic failure-free pro-portionFigure 1
(A) Kaplan-Meier probabilities of virologic failure-
free proportion. The numbers of patients followed up for 
0, 12, 24, 36, 48 and 60 months were 330, 180, 123, 82, 39 
and 26, respectively. (B) Kaplan-Meier probabilities of failure-
free survival stratified by baseline CD4 cell count quartile 
range (median = 327; IQR = 205–435 cells/ul).
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Table 1: Baseline demographic and clinical characteristics of the cohort studied (N = 330 patients).
Characteristic Not failed (n = 151) Failed (n = 179) P-value
Gender
Male 84(56) 93(52) 0.51
Female 67(44) 86(48)
Age [median years(IQR)] 34(29–40) 32(27–38) 0.15
Socioeconomic status
High status 68(45) 88(49) 0.45
Low status 83(55) 91(51)
Baseline CD4 cell count (cells/μl)
Median (IQR) 331(193–467) 323(208–431) 0.74
< 200 40(27) 38(21) 0.28
200–350 41(27) 62(35)
> 350 70(46) 79(44)
WHO stage
Stage 1&2 74(49) 83(46) 0.82
Stage 3 59(39) 71(40)
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CD4 count slope at a given time-point would be the
strongest indicator of the likelihood of virological failure.
CD4 cell counts measured at the time of virological failure
were also compared with the distribution of all CD4 cell
count measurements obtained from patients who did not
develop failure (Figure 2D–F). These analyses showed that
the distributions of absolute CD4 counts, ΔCD4 counts
and CD4 count slopes did not significantly differ compar-
ing values during virological failure to values during viral
load suppression (P = 0.99, P = 0.92 and P = 0.75, respec-
tively).
Since CD4 slopes were the parameter most strongly asso-
ciated with log10 VL among those who developed virolog-
ical failure, we fitted a receiver operating characteristic
curve (ROC) using data from all the patients to examine
this association further (Figure 3). This analysis showed
that the predictive value of CD4 cell slope for virological
failure was poor. The area under the ROC curve was 0.59
and the sensitivity, specificity, positive predictive and neg-
ative predictive values were all low (Figure 3).
CD4 cell counts among patients who did not achieve 
virological suppression
Virological suppression was not achieved by 30 (8.3%) of
the total of 360 patients treated in this cohort during fol-
low-up and were therefore not included in the above anal-
yses. Separate analysis of data from these patients showed
that a significant correlation was similarly observed
Scatter plots of (A) absolute CD4 cell count, (B) ΔCD4 cell count (change in CD4 count from baseline) and (C) CD4 cell count slope (difference between consecutive CD4 count measureme ts) and corresponding viral load valu s (log10 copies/ml) meas-ured in atients who d veloped viro ogical failureFigure 2
Scatter plots of (A) absolute CD4 cell count, (B) ΔCD4 cell count (change in CD4 count from baseline) and (C) 
CD4 cell count slope (difference between consecutive CD4 count measurements) and corresponding viral load 
values (log10 copies/ml) measured in patients who developed virological failure. Distributions of (D) absolute CD4 
counts, (E) ΔCD4 counts and (F) CD4 count slopes of patients (n = 179) at the time of virological failure (dashed lines) com-
pared to the distribution of measurements of all patients (n = 330) at all time-points when viral load remained suppressed 
(solid lines).
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between all measurements of absolute CD4 counts and
the corresponding log10 VL measurements (r = - 0.25, P <
0.0001) (Fig 4A). However, the distributions of the ΔCD4
counts and CD4 count slopes in this group did not differ
significantly from those observed among the 151 patients
who achieved and maintained virological suppression
during follow-up (P = 0.87 and P = 0.25 respectively) (Fig
4B–C). This showed that CD4 cell counts were also a poor
correlate of viral load among patients who did not achieve
viral load suppression.
Discussion
Early detection of virological failure is important for opti-
mal management of HIV-infected patients receiving ART.
Patients who continue to receive a failing regimen are at
risk of immunological failure, morbidity and death.
Moreover, accumulation of multiple antiretroviral drug
resistance mutations may compromise the response to
future drugs and fuel the spread of primary drug resistance
within communities. Since VL monitoring is not available
in most resource-limited settings, we investigated the util-
ity of CD4 cell count measurements for predicting viro-
logical failure in a cohort of South African patients.
Baseline absolute CD4 cell counts as well as clinical and
socio-demographic characteristics were not predictive of
virological failure. Analyses of longitudinal data from
those who developed virological failure revealed that
absolute CD4 cell counts and CD4 cell count changes
(ΔCD4 cell counts and CD4 cell count slopes) were signif-
icantly correlated with viral load measurements at a group
level. However, subsequent analysis showed that none of
these methods of analysing CD4 cell counts could be used
to identify individual patients at the time they developed
Receiver Operating Characteristic (ROC) curve assessing the association between a negative CD4 cell count lope (ie a falling CD4 count) and virological failure (area der the curve = 0.59)Figure 3
Receiver Operating Characteristic (ROC) curve 
assessing the association between a negative CD4 
cell count slope (ie a falling CD4 count) and virologi-

































Virological failureNegative CD4 cell count slope
Scatter plot of the absolute CD4 count (cells/μl) and corresponding HIV RNA viral load (log10 copies/ml) for the subset of patients (n = 30) who did not ever achiev  viro ogical suppression during ART (A)Figure 4
Scatter plot of the absolute CD4 count (cells/μl) and corresponding HIV RNA viral load (log10 copies/ml) for 
the subset of patients (n = 30) who did not ever achieve virological suppression during ART (A). The distribu-
tions of ΔCD4 counts (B) and CD4 cell count slopes (C) of this group are compared with that of patients who achieved and 
maintained virological suppression throughout the study period (n = 151).
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virological failure. Since the distributions of CD4 cell
counts and CD4 cell count changes among those with
virological failure did not differ significantly from those of
patients who maintained virological suppression, these
could not be used to provide a clinically useful means for
individual patient assessment for virological failure.
A unique feature of our study is that we used a novel mod-
elling approach that accounted for all CD4 cell count and
VL values measured during follow-up from the first date
that VL suppression was achieved. Some previous studies
have modelled the difference between the CD4 cell counts
measured at initiation of treatment and at a single arbi-
trary point during ART defined a priori. Other studies
assessing factors associated with virological failure did not
account for all CD4 cell count measurements performed
during follow-up [15-23]. Neither of these approaches
fully evaluates CD4 cell count dynamics during ART,
increasing the potential for misclassification bias. Our
analytic approach also differs in that we modelled virolog-
ical failure as the end-point of interest rather than virolog-
ical treatment success as reported elsewhere. We used a VL
> 1,000 copies/ml to define treatment failure consistent
with local protocols. However, the same outcomes were
obtained using thresholds of > 400 and > 10,000 copies/
ml, which is consistent with previous data from this set-
ting [25].
Baseline CD4 cell count was not predictive of virological
failure in this ART-naïve population. However, in patients
who developed virological failure, absolute CD4 cell
count measurements, ΔCD4 cell counts and CD4 cell
count slopes during ART each correlated significantly with
VL measurements taken at the same time-points. Of these
three parameters, the CD4 cell count slope was the most
strongly correlated. This indicates that the rate of increase
or decrease of CD4 cell count at a given time-point was the
parameter that was most strongly associated with current
VL. However, the distributions of ΔCD4 cell count and
CD4 cell count slope values were very broad even among
patients who maintained virological suppression. This
suggests that considerable fluctuations in CD4 cell counts
occur among patients despite sustained virological con-
trol. When these distributions were compared with the
distributions of data from patients who had current viro-
logical failure, they almost completely overlapped. This
demonstrated that absolute CD4 cell counts and CD4 cell
count changes could not be used to identify patients who
have developed virological failure. These findings were
further corroborated by the observation that the distribu-
tions of CD4 cell count changes in the 30 patients who
never achieved virological suppression were also broadly
overlapping with the distributions of data from those who
maintained virological suppression.
To investigate these associations further, we focussed on
the use of CD4 cell count slopes since this was the param-
eter most strongly associated with VL at a group level.
However, ROC curve analysis confirmed that use of CD4
slopes provided very poor test characteristics for predict-
ing virological failure. The specificity and sensitivity of a
negative CD4 cell count slope was low, showing that this
parameter was not of practical utility in this clinical set-
ting. Furthermore, the data show that a negative CD4 cell
count slope could not even be used as a screen to identify
those at high risk of virological failure as a means of
rationing scarce viral load monitoring resources.
A strength of this study is that patients were closely fol-
lowed in a multicentre clinical trials unit with strict proto-
cols for regular clinical and laboratory monitoring every
2–3 months, leading to reliable identification of virologi-
cal failure. As soon as a VL > 1,000 copies/ml was first
detected, confirmatory viral load testing was done. The
cohort characteristics were diverse and so the data are not
only relevant to those with advanced immunodeficiency.
Despite differing cohort characteristics, follow-up proce-
dures and analytic approaches, our data are consistent
with and extend previous studies that have found a poor
association between CD4 cell counts and the develop-
ment of virological failure [8,15].
We acknowledge the limitations of this study. An impor-
tant potential limitation is that all patients studied were
ART-naïve. Therefore these findings may not be generalis-
able to treatment-experienced patients. Our patients par-
ticipated in international multicentre clinical trials. Their
experience may differ from that of patients accessing treat-
ment in a community-based setting. We do not have good
assessments of treatment compliance although the mech-
anism underlying virological failure is unlikely to affect
the relationship between CD4 cell counts and viral load.
Despite a limited cohort size, follow-up in this study was
prolonged, a substantial proportion developed virological
failure and the number of paired CD4 cell counts and VL
measurements was large.
Conclusion
In conclusion, we have shown that although changes in
CD4 cell count correlated significantly with VL at a group
level, they had very poor predictive value when being used
to assess individual patients. Thus, CD4 cell count meas-
urements cannot be used as a substitute for virological
failure monitoring. Rigorous cost benefit analyses are
required to further evaluate use of VL monitoring in this
setting. Furthermore, there is a great need for develop-
ment of simplified techniques to measure VL and for
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Nevirapine to prevent 
HIV transmission via 
breastfeeding
We, the co-principal investigator 
from India on the study of 6-week 
extended-dose nevirapine (July 26, 
p 300)1 and co-workers, are at variance 
with the way the paper has been 
presented and interpreted. The study 
team has concealed crucial parts of 
the fi ndings under complex statistical 
analysis and disguising adjustments.
First, the simple conclusion is that 
nevirapine given to infants for 6 weeks 
did not signifi cantly reduce HIV trans-
mission, compared with single-dose 
nevirapine, at the primary endpoint 
of 6 months. This end point was deter-
mined before the study began and was 
based on the fact that nevirapine given 
for the baby’s fi rst 6 weeks (when HIV 
transmission via breast feeding is very 
high) would last for another 10–14 days 
owing to its long half life, and that it 
takes between 10 days and 4 months 
for the baby to become PCR positive 
after entry of the virus.2 Therefore 
the fact that PCR positivity was lower 
at 6 weeks of age in the extended-
treatment group than in the single-
dose group does not refl ect the eff ect 
of 6 weeks of treatment at all.
Second, about 40% of infants in both 
groups had grade III or IV side-eff ects 
(rashes, neutro penia, or elevated 
amino trans ferases). The study team 
has not shown the duration of neutro-
penia, which could have varied with 
single-dose and 6-week regimens. One 
can imagine the clinical con sequences 
of prolonged neutro penia.
Third, the study team has analysed all 
“intention to treat cases (modifi ed)”. 
However, if one wants to study the 
effi  cacy of a drug, one should analyse 
the per-protocol population. The 
intention-to-treat population is more 
relevant for safety studies. Use of the 
per-protocol population for effi  cacy 
analysis has been questioned since 
some patients might discontinue a 
drug if they do not feel better and 
would thus get eliminated, skewing 
the results. But this subjective factor 
is not relevant to the present study, 
where the primary endpoint is 
objective—ie, becoming HIV positive. 
If both intention-to-treat and per-
proto col populations had been studied 
together and both gave identi cal 
results, confi dence in the trial would 
have increased.
Finally, the study team conclude 
that nevirapine ought to be given 
for longer than 6 weeks. This recom-
mendation is inappropriate, since the 
risk of trans mission via breastmilk is 
highest in the early weeks of life and 
falls as age advances.3,4 It is wrong that 
a drug which has not shown signifi cant 
benefi t and which has serious toxic 
eff ects in 38·4% of babies should be 
tried for longer and at a time when the 
risk of transmission has decreased. No 
drugs might be required at all, or some 
other strategy such as weaning foods 
might help.
It might be more prudent to follow 
WHO/UNICEF guidelines for devel oped 
countries and to make formula feed-
ing safe, sustainable, acceptable, and 
aff ord able for mothers in developing 
coun tries. The cost, training, and man-
power involved in giving 6 weeks 
of ne irapine to such women could 
be better used to educate them and 
supply milk substitutes in a hygienic 
form, thus bringing them in line with 
the developed world.
MAP was the principal investigator in India. PMB is a 
laboratory director and had a vital role nearly 
throughout the trial. NAK was part of the study team 
and did pharmacokinetic studies on nevirapine. We 
declare that we have no confl ict of interest.
*Mrudula A Phadke, P M Bulakh, 
N A Kshirsagar
drmapaa@yahoo.com
Maharshtra University of Health Sciences, Nashik, 
India (MAP, NAK); B J Medical College & Sassoon 
Hospital, Pune, India (MAP, PMB); and Seth G S 
Medical College & K E M Hospital, Mumbai, India 
(NAK)
1 Six Week Extended-Dose Nevirapine (SWEN) 
Study Team. Extended-dose nevirapine to 
6 weeks of age for infants to prevent HIV 
transmission via breastfeeding in Ethiopia, 
India, and Uganda: an analysis of 
three randomised controlled trials. Lancet 
2008; 372: 300–13.
2 Yogev R, Chadwick EG. Acquired 
immunodefi ciency syndrome. In: Nelson WE, 
ed. Textbook of pediatrics, 17th edn. St Louis: 
W B Saunders, 2004: 1113.
3 Miotti PG, Taha TE, Kumwenda NI, et al. 
HIV transmission through breastfeeding: 
a study in Malawi. JAMA 1999; 282: 744–49.
4 Nduati R, John G, Mbori-Ngacha D, et al. Eff ect 
of breastfeeding and formula feeding on 
transmission of HIV-1: a randomized clinical 
trial. JAMA 2000; 283: 1167–74.
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Monitoring of 
antiretroviral therapy in 
low-resource settings
Using a computer simulation model, 
Andrew Phillips and colleagues 
(April 26, p 1443)1 assessed the cost-
eff ec tiveness of three strategies for 
monitoring patients on antiretro viral 
therapy (ART) in resource-limited 
settings: viral load, CD4 cell count, or 
clinical events. We agree that lack of 
access to laboratory monitoring should 
not hinder expansion of ART access. 
However, we are concerned that the 
eff ectiveness of viral load monitoring 
might have been underestimated and 
that national policy makers might 
use these data to dismiss the use 
of laboratory monitoring strategies 
al together.
Poor treatment adherence is the 
most common reason for virological 
failure and, although potentially 
reversible, Phillips and colleagues 
make the assump tion that all pa tients 
with a single viral load of greater than 
400 copies per mL should switch to 
second-line ART. We have previously 
reported from a South African 
programme2 that three-quarters of 
patients whose viral load in creases to 
more than 400 copies per mL during 
ART subsequently achieve virological 
suppression after imple mentation of a 
targeted ART ad herence inter vention. 
As a result, only 2% of patients per 
year in this programme develop 
persisting viro logical failure requiring 
second-line ART.2
Thus, instead of triggering high rates 
of switching to second-line therapy, 
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used to promote adherence, there-
by retaining patients on fi rst-line 
therapy and minimising drug costs. 
Addi tionally, viral load monitoring 
might indirectly enhance retention 
of patients by identifying those with 
poor adherence who are in turn at risk 
of loss to follow-up.3
Finally, viral load measurements 
are valuable for monitoring and evalu-
ation, permitting strengthening of 
ART programmes. In conclusion, viral 
load monitoring has far greater use 
than as a simple trigger for second-line 
therapy. 
We declare that we have no confl ict of interest.
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LGB, RW); Clinical Research Unit, Department of 
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1 Phillips AN, Pillay D, Miners AH, Bennett DE, 
Gilks CF, Lundgren JD. Outcomes from 
monitoring of patients on antiretroviral 
therapy in resource-limited settings with viral 
load, CD4 cell count, or clinical observation 
alone: a computer simulation model. Lancet 
2008; 371: 1443–51.
2 Orrell C, Harling G, Lawn SD, et al. 
Conservation of fi rst-line antiretroviral 
treatment regimen where therapeutic options 
are limited. Antivir Ther 2007; 12: 83–88.
3 Lawn SD, Kaplan R, Wood R, Bekker LG. 
Promoting retention in care: an eff ective 
model in an antiretroviral treatment service in 
South Africa. Clin Infect Dis 2007; 45: 803.
Recent international debate has 
focused on the need for CD4 count 
monitoring, viral load testing, or 
both, for HIV treatment in resource 
limited-settings. Andrew Phillips and 
colleagues address this question using 
a computer simulation model,1 and 
conclude that the “benefi ts of viral 
load or CD4 cell count monitoring over 
clinical monitoring alone are modest.”
We have concerns with the main 
results in table 4 and the methods 
that underlie them. First, Phillips 
and colleagues do not eliminate 
“weak ly dominated” strategies—ie, 
strategies that are more expensive and 
incrementally less cost-eff ective than 
more expensive strategies—which 
is a crucial step in cost-eff ectiveness 
analysis.2,3 They calculate the incre-
mental cost-eff ectiveness ratio of 
the viral load monitoring strategy by 
erroneously comparing it with a weakly 
dominated strategy—CD4 decline 
from peak. Had they eliminated the 
weakly dominated strategies, the fi nal 
results would be as shown in our table.
Second, the incremental cost-eff ec-
tive ness ratio for viral load moni toring, 
when calculated correctly (US$3494 
per life-year gained), should be com-
pared with an external standard (eg, 
3× the per-capita gross domestic 
product4). Reporting it as “not the 
most cost-eff ective” does not allow a 
policy maker to compare its value with 
any “willingness to pay” threshold.
When calculated correctly, the 
results also suggest that all CD4 
monitoring strategies are weakly 
dominated by clinical monitoring 
strategies. These results are at odds 
with our published work5 which 
fi nds that CD4 monitor ing is cost-
eff ective in Côte d’Ivoire com pared 
with clinical monitoring alone. This 
fi nding calls into question whether 
the value of CD4 monitoring has 
been underestimated and, there-
fore, whether the incremental value 
of viral load monitoring has been 
overestimated by comparison.
We declare that we have no confl ict of interest.
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1 Phillips AN, Pillay D, Miners AH, Bennett DE, 
Gilks CF, Lundgren JD. Outcomes from 
monitoring of patients on antiretroviral 
therapy in resource-limited settings with viral 
load, CD4 cell count, or clinical observation 
alone: a computer simulation model. Lancet 
2008; 371: 1443–51.
2 National Institute for Clinical Excellence. 
Guide to the methods of technology appraisal. 
London: National Institute for Clinical 
Excellence, 2004.
3 Weinstein MC. Decision rules for incremental 
cost-eff ectiveness analysis. In: Jones A, ed. 
Elgar companion to health economics. 
Cheltenham: Edward Elgar Publishing, 2006.
4 Commission on Macroeconomics and 
Health. Macroeconomics and health: 
investing in health for economic 
development. Geneva: World Health 
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Cost-eff ectiveness of HIV treatment in resource-
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N Engl J Med 2006; 355: 1141–53.
In their Article on the outcomes of 
monitoring HIV-infected individuals 
by use of clinical observation, CD4 
counts, or viral load,1 Andrew Phillips 
and col leagues claim that expanding 
access to treat ment should proceed 
without attention to diagnostic 
monitoring, since outcomes are 
only trivially worse with obser va tion 
alone. This is an inter esting analysis, 
but it ignores the true benefi t of CD4 
monitoring: deter mining the timing 
of treatment initiation.
Outcomes for individuals who start 
treatment in Africa are substantially 
worse than in developed countries, 
especially in the fi rst year after treat-
ment initiation.2 There are two main 
factors that drive this gap: higher 
incidence of opportunistic infections, 
especially tuberculosis, and a lower 
CD4 count at treatment initiation. 
Waiting until the CD4 drops to the 
levels Phillips and colleagues assumed 
is avoidable and changing. CD4 counts 
at treatment initiation have been rising 
Life-years Costs (US$) Cost per life-year 
gained (US$)
Viral load >500 copies per mL 10·56 4055 3494
New WHO 3/4 event 10·22 2867 2662
Multiple WHO 3 events/new WHO stage 4 event 10·01 2308 927
New WHO stage 4 event 9·75 2067 ..
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Background: This study aimed to evaluate HIV type-1 
(HIV-1) drug resistance pretreatment and in those fail-
ing first-line non-nucleoside reverse transcriptase 
inhibitor (NNRTI)-based antiretroviral therapy (ART) in 
South Africa.
Methods: This was an observational cohort. Genotypic 
resistance testing was performed on treatment-naive 
individuals and those failing first-line ART (confirmed 
HIV-1 RNA >1,000 copies/ml) from public sector clin-
ics in Cape Town (2002–2007). Resistance profiles and 
mutations relative to timing of known virological failure 
were examined.
Results: In total, 230 patients (120 treatment-naive and 
110 with virological failure) were included: 98% had 
clade C virus. Among treatment-naive patients, preva-
lence of primary resistance was 2.5% (95% confidence 
interval 0.0–5.3). Three patients had one significant 
reverse transcriptase mutation: K65R, Y181C and G190A. 
Among treatment-experienced patients, 95 (86%) indi-
viduals had therapy-limiting NNRTI mutations, includ-
ing K103N (55%), V106M (31%) and Y181C (9%). The 
M184V mutation was the most common mutation, found 
in 86 (78%) patients. In total, 10 (9%) patients  had the 
K65R mutation. More individuals tended to develop thy-
midine analogue mutations when sampling occurred after 
6 months of detected therapy failure (10/31 [32%] indi-
viduals) compared with those who had genotyping before 
6 months (15/79 [19%] patients; P=0.246).
Conclusions: Prevalence of primary resistance in a sample 
of ART-naive clade C HIV-1-infected individuals in South 
Africa was low during the study period. Patients failing 
first-line ART most often developed resistance to NNRTIs 
and nucleoside reverse transcriptase inhibitors, the two 
drug classes used in first-line therapy. Viral load monitor-
ing in this setting is crucial and individual genotypes in 
those failing first-line therapy should be considered.
More than 3 million individuals now have access to 
antiretroviral therapy (ART) in low- and middle-income 
countries (LMIC) [1]. Delivery of ART on this scale 
has required utilization of a public health approach in 
which standardized, rather than individualized, regi-
mens are prescribed to very large numbers of HIV type-1 
(HIV-1 )-infected individuals [2]. At present, the major-
ity of individuals in these countries are initiating first-
line therapy with a non-nucleoside reverse transcriptase 
inhibitor (NNRTI) and two nucleoside reverse tran-
scriptase inhibitors (NRTIs) [3]. In addition to those 
receiving ART for treatment, many women receive nevi-
rapine (NVP) and/or zidovudine (AZT) for prevention 
of mother-to-child HIV-1 transmission (PMTCT) [4].
Second-line ART, based on a boosted protease 
inhibitor with two NRTIs, is several-fold more expen-
sive than the first-line regimens [1]. Although the pro-
portion of patients receiving second-line therapy is 
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presently estimated to be 4%, this is increasing by 3% 
per annum [5]. In LMIC the decision of when to change 
to a second-line regimen is frequently delayed, as it is 
often based on clinical or immunological criteria in 
the absence of viral load measurement [3,6]. Rational 
choice of the NRTI component of second-line therapy 
should be based on patterns of resistance developed 
during first-line therapy [7].
Much concern was expressed during the initial phase 
of expanded access to ART that ‘antiretroviral anarchy 
and viral mayhem’ might follow the widespread use of 
ART in LMIC [8]. However, despite the large scale of 
PMTCT and ART rollout, there has been little pub-
lished data detailing resistance either prior to or within 
large scale ART programmes. The effect of the wide-
spread use of single-dose NVP for PMTCT on primary 
resistance patterns of those entering ART programmes 
has not yet been widely characterized [9].
Furthermore, most data on viral mutations develop-
ing in patients on ART are from industrialized coun-
tries where  HIV-1 subtype B is prevalent, whereas viral 
subtypes in LMIC are frequently non-B, and non-B sub-
types might have different pathways to viral resistance 
[10–12]. Data on resistance patterns in both treatment-
naive and treatment-exposed clade C subtype are lim-
ited [13–21]. Our objective was to describe the resist-
ance genotype patterns in both ART-naive individuals 
and in those with first virological breakthrough while 
on first-line NNRTI therapy in the public sector ART 




Staff at the Desmond Tutu HIV Centre in Cape Town, 
South Africa, drew 30 samples per annum for geno-
typing from treatment-naive HIV-1-positive individuals 
between 2003 and 2006, resulting in 120 samples avail-
able for the current analysis. These individuals were 
from two periurban resource-poor communities in Cape 
Town. HIV-1-infected individuals attending HIV clinics 
at either of the two sites were asked to donate a sample 
on a first-come first-serve basis beginning in April each 
year until 30 samples had been collected. None of these 
individuals had been exposed to any ART, including 
PMTCT, at the time of sampling.
Treatment-experienced samples
All samples were from individuals failing first-line ther-
apy in public sector ART clinics in the greater Cape Town 
area between 2002 and 2007. Eight clinics provided 
samples. HIV-1-positive individuals in these clinics could 
access ART if they had a CD4+ T-cell count <200 cells/
µl or with WHO stage 4 clinical disease. First-line ART 
consisted of stavudine (d4T) and lamivudine (3TC), with 
an NNRTI (efavirenz or NVP) [6]. Pregnant women who 
did not yet qualify for ART were commenced on AZT at 
34 weeks and given a single dose of NVP in early labour 
[4]. For this study, virological breakthrough was defined 
as the first time a viral load was noted to be >1,000 cop-
ies/ml while on ART, and virological failure was defined 
as two consecutive viral loads >1,000 copies/ml.
Laboratory testing
Viral load and CD4+ T-cell counts were monitored 4- to 
6-monthly according to local protocol [4,6]. Viral load 
assays were done using the branch DNA hybridization 
technique (Bayer HIV-1 RNA 3.0 assay). Genotypic anal-
yses of the reverse transcriptase and protease sequences 
of HIV-1 DNA were completed using either the Trugene® 
HIV-1 (Bayer Healthcare, Leverkusen, Germany) or Gen-
eSeq™ (Monogram Biosciences, South San Francisco, 
CA, USA). The International AIDS Society (IAS)–USA 
list of mutations was used to determine which muta-
tions might be related to drug resistance [22]. Mutations 
noted in the IAS–USA listing that were not noted in this 
data group were not listed in the results. The Stanford 
University HIV Resistance Database Genotypic Resist-
ance Interpretation Algorithm was used to determine the 
possible drug resistance patterns per genotype [23].
The majority of samples were sourced from the Han-
nan Crusaid Treatment Centre (Cape Town, South 
Africa); this cohort has been described previously 
[13–15]. Excess plasma from the 4-monthly scheduled 
visits was frozen and stored. All individuals who reached 
a viral load of >1,000 copies/ml and who had an avail-
able stored plasma sample at the time of confirmation 
of virological failure were analysed for HIV-1 genotype. 
The dates of treatment initiation, first observed viro-
logical breakthrough (>1,000 copies/ml) and confirma-
tion of virological breakthrough (the date of the sample 
used for genotype analysis) were recorded.
Other samples were sourced from other ART sites in 
the Western Cape. Clinicians were asked to refer patients 
with a previously noted viral load of >1,000 copies/ml 
on first-line therapy to the study site for one-off geno-
type sampling. The dates of treatment initiation, first 
virological breakthrough (>1,000 copies/ml) and con-
firmation of virological breakthrough were recorded.
Demographic data (age, gender and disease stage) 
were recorded for all individuals with genotype results, 
as was viral load and CD4+ T-cell count at the time of 
genotypic sampling. Mutations considered related to 
the function of the HIV-1 reverse transcriptase and pro-
tease enzymes were recorded.
Statistical analyses
Demographic and baseline data were described using 
medians and proportions as appropriate. Baseline 
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characteristics described by interval data were com-
pared using non-parametric statistics for data not 
normally distributed. The 95% confidence intervals 
(CIs) around resistance mutation prevalence were 
constructed using the normal approximation of the 
binomial distribution. Among patients failing ART, 
we examined the association between timing of geno-
typing and resistance profile.
Results
Treatment-naive patient samples
Samples from 120 ART-naive HIV-1-infected individu-
als were included in the current analysis (Table 1). The 
median age of the cohort was 31 years (interquartile 
range [IQR] 25–38) and 63% were women. The median 
CD4+ T-cell count at the time of sampling was 262 cells/
µl (IQR 149–405) and the median viral load was 4.88 
log10 copies/ml (IQR 4.29– 5.23). In total, 117 (98%) 
samples were clade C; the other 3 samples were clade 
B and were known to be collected from men who have 
sex with men [24].
The individual genotype results for the treatment-na-
ive sample group are shown in Table 2 (Figure S1 in the 
Additional file). There was very little variation in the 
reverse transcriptase gene. One individual (0.8%) had 
a K65R mutation, denoting probable reduced sensitiv-
ity to tenofovir and abacavir, and three (2.5%) had the 
V118I mutation. Despite this cohort having no prior 
NNRTI exposure, there were two (1.7%) individuals 
with single NNRTI mutations, one Y181C and one 
G190A. In contrast to the reverse transcriptase, in the 
protease inhibitor region there were a number of muta-
tions that occurred frequently, although these were not 
expected to cause drug resistance. The most frequent 
protease mutations were L89I/M (89%), H69K (88%), 
L63P (52%) and M36I (87%). In addition, >10% had 
mutations at loci 20 (17%), 74 (10%) and 77 (18%).
Treatment-experienced patient samples
In total, 119 individuals attending the Hannan Crusaid 
Treatment Centre between September 2002 and Decem-
ber 2007, who were taking first-line therapy, experienced 
virological breakthrough. Six individuals who had failed a 
protease-inhibitor-based first-line regimen were excluded 
from the analysis. Stored samples were not available for 
34 individuals and genotype results were obtained for the 
remaining 79 individuals. Samples from an additional 
31 individuals with the same failure criteria were received 
from seven other public sector antiretroviral clinics bring-
ing the total number of genotypes available from indi-
viduals failing first-line therapy to 110.
The demographics of the treatment-experienced 
group were similar to that of the treatment-naive 
cohort. Their median age was 32 years (IQR 28–35) 
and 70% were women. The median CD4+ T-cell count 
was significantly lower than in the treatment-naive 
group, at 192 cells/µl (IQR 128–288; P=0.003) and the 
median log viral load at time of sampling was signifi-
cantly lower at 4.02 log10 copies/ml (IQR 3.61–4.76; 
P<0.001). The median time from treatment start date to 
initial detected virological breakthrough (>1,000 cop-
ies/ml) was 271 days (IQR 177–525), and that from 
first detected virological breakthrough to the time of 
confirmation and sampling for genotype was 97 days 
(IQR 31–195). Overall, 79 (72%) people had their 
repeat sample within 180 days of their initial raised 
viral load and 39 (28%) people after 180 days.
There were many more reverse transcriptase muta-
tions in the treatment- experienced samples than in the 
Characteristic Treatment-naive Virological failure P-value
Total samples, n (%) 120 (100) 110 (100) –
Mean age, years (IQR) 31 (25–38) 32 (28–35) 0.535
Female gender, n (%) 75 (63) 77 (70) 0.588
Median CD4+ T-cell count, cells/µl (IQR) 262 (149–405) 192 (122–283) 0.003
Median viral load, log10 copies/ml (IQR) 4.88 (4.29–5.43) 4.02 (3.61–4.76) <0.001
HIV-1 clade C, n (%) 117 (98) 56 (97)a  0.966
HIV-1 clade B, n (%) 3 (2) 2 (3)a  1.00
Treatment regimen   
d4T+3TC+EFV, n (%) – 78 (67.2) –
d4T+3TC+NVP, n (%) – 18 (15.5) –
AZT+3TC+EFV, n (%) – 7 (6.0) –
AZT+3TC+NVP, n (%) – 6 (5.2) –
Table 1. Demographic characteristics and laboratory results for treatment-naive and first virological failure groups in a sample 
from Cape Town, South Africa
The viral load and CD4+ T-cell count presented for the first-time virological failure group are those at the time of second consecutive viral load >1,000 copies/ml, a 
median of 97 days from initial viral load >1,000 copies/ml. aOf 58 available. AZT, zidovudine; EFV, efavirenz; HIV-1, HIV type-1; IQR, interquartile range; d4T, stavudine; 
NVP, nevirapine; 3TC, lamivudine.
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treatment-naive samples (Table 3 and Figure S2 in the 
Additional file): 91 (83%) individuals had ≥1 muta-
tions limiting susceptibility of NRTIs and 97 (88%) 
individuals had ≥1 therapy-limiting NNRTI mutations. 
The M184V, conferring resistance to 3TC and emtric-
itabine (FTC), was the most common single mutation 
(n=86 [78%]) and emerged rapidly in failure (Figure 
1A). According to the genotypic resistance interpreta-
tion algorithm four (4.0%) more people were likely to 
have intermediate resistance to 3TC and FTC because 
of the presence of K65R (Table 4) [23]. Seven (6.4%) 
of the samples had no reverse transcriptase mutations.
A total of 10 (9.0%) individuals, all taking d4T, had 
developed the K65R mutation, limiting future use of 
didanosine (ddI), tenofovir and abacavir, without hav-
ing had exposure to any of these medications (Table 4). 
In this group, those with the K65R did not have a sig-
nificantly higher mean viral load than those without 
[25]. Six (5.5%) individuals had both the K65R and 
the M184V mutations.
 NRTI mutations NNRTI mutations PI mutations
Ref Loci AA n (%) Ref Loci AA n (%) Ref Loci AA n (%)
K 65 R 1 (0.8) Y 181 CY 1 (0.8) L 10 IVF 6 (5.0)
V 118 I 3 (2.5) G 190 ACE 1 (0.8) G 16 E 2 (1.6)
– – – – – – – – K 20 RT 20 (16.6)
– – – –  – – – – M 36 I 104 (86.7)
– – – – – – – – M 46 I 1 (0.8)
– – – – – – – – I 47 IV 1 (0.8)
– – – – – – – – I 50 V 1 (0.8)
– – – – – – – – I 54 V 1 (0.8)
– – – – – – – – L 63 HLPSTV 62 (51.7)
– – – – – – – – H 69 K 108 (90)
– – – – – – – – A 71 ATV 3 (2.5)
– – – – – – – – G 73 S 3 (2.5)
– – – – – – – – T 74 S 12 (10)
– – – – – – – – V 77 I 22 (18.3)
– – – – – – – – LV 82 AF 1 (0.8)
– – – – – – – – L 89 IM 107 (89.2)
Table 2. Genotype results in a sample of ART-naive patients in Cape Town, South Africa 
Overall n=120. Prevalence of wild-type virus was 114 (95%). Mutations noted in the International AIDS Society–USA listing that were not noted in this group are not 
listed here. AA, amino acid; ART, antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PI, 
protease inhibitor; Ref, reference.
Table 3. Genotype results in a sample of patients with virological failure to first-line ART in Cape Town, South Africa
Overall n=110. Mutations noted in the International AIDS Society-USA listing that were not noted in this group are not listed here. Text in bold indicates thymidine 
analogue mutations (TAMs). Prevalence of wild-type virus was 7 (6.4%). AA, amino acid; ART, antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor; 
NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; Ref, reference.
 NRTI mutations NNRTI mutations PI mutations
Ref Loci AA n (%) Ref Loci AA n (%) Ref Loci AA n (%)
M 41 ML 1 (0.9) A 98 G 4 (3.6) L 10 IVF 7 (6.4)
K 65 R 10 (9.0) L 100 I 2 (1.8) I 13 V 8 (7.3)
D 67 N 14 (13) K 101 EP 18 (16) G 16 E 9 (8.1)
T 69 DN 2 (1.8) K 103 N 60 (55) K 20 RT 30 (27)
K 70 KR 4 (3.6) V 106 M 34 (31) D 30 N 1 (0.9)
L 74 L/I/V 1 (0.9) V 108 IV 13 (12) L 33 FV 2 (1.8)
V 75 IM 3 (2.7) E 138 A 2 (1.8) M 36 I 95 (86)
V 118 I 2 (2.7) V 179 DV 6 (5.5) L 63 HLPSTV 66 (60)
M 184 V 86 (78) Y 181 CY 11 (10) H 69 K 103 (94)
T 215 FSY 9 (8.1) Y 188 HL 9 (8.1) G 73 S 1 (0.9)
K 219 EQ 5 (4.5) G 190 ACE 22 (20) T 74 S 14 (13)
K 238 T 2 (1.8) P 225 H 15 (14) V 77 I 17 (15)
– – – – F 227 L 7 (6.4) LV 82 AF 1 (0.9)
  M 230 L 8 (7.3) L 89 IM 90 (82)
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Overall, 25 (23%) individuals had a total of 33 
thymidine analogue mutations (TAMs). Those with 
TAMs had a median viral load of 4.32 log10 copies/
ml (IQR 3.47–4.71) compared with a median of 4.01 
log10 copies/ml (IQR 3.47–4.71) in those without 
TAMS at the time of genotype sampling (P=0.896) 
[26]. Only five (4.5%) individuals had ≥1 (TAM). 
Figure 2 describes the proportion of those with non-
TAM resistance that had also developed TAMs in the 
reverse transcriptase gene. There were relatively few 
individuals with resistance to either 3TC, that is, indi-
viduals presenting with the M184V mutation (n=6 
[5.4%]), or NNRTIs (n=20 [18%]) alone. These indi-
viduals also had few TAMs, and no sample had ≥1 
TAM. Over two-thirds (n=75 [68%]) of individuals 
had a combination of 3TC and NNRTI resistance. Of 
these, 21 (28%) had TAMs and it was only in these 
samples that 2 or 3 TAMs were noted.
More TAMs were noted in those individuals who 
had failure confirmed >180 days after initial virologi-
cal breakthrough (Figure 1B). A total of 17 TAMs 
were noted in 15/79 (19%) individuals whose geno-
type was completed within 6 months, compared with 
16 TAMs noted in 10/31 (32%) individuals whose 
genotype was completed after 6 months (P=0.246). 
Multivariate logistic regression modelling of factors 
associated with acquiring a TAM demonstrated that 
for every 20 unit increase in CD4+ T-cell count at 
time of genotyping, the reduction in risk of develop-
ing TAMs was 9% (odds ratio 0.91, CI 0.83–0.99; 
P=0.035). Age, gender, time from failure to sample, 
viral load and NRTI used did not affect the acquisi-
tion of TAMs. There was no significant difference in 
the number of TAMs generated by the specific thymi-
dine analogue taken, whether AZT (4/13 [31%] indi-
viduals) or d4T (28/97 [29%] individuals; P=0.917). 
Susceptibility to AZT and d4T remained high in this 
group (Table 4).
Development of NNRTI resistance occurred rapidly 
and these mutations were the most common noted in 
this group (Figure 1C). A total of 70/79 (88%) individ-
uals whose genotype was completed within 6 months 
[AU: Please 



























































The proportion of individuals with either (A) the M184V mutation (B) thymidine analogue mutations (TAMs) or (C) non-nucleoside reverse transcriptase inhibitor 
mutations by time between initial virological breakthrough (first viral load >1,000 copies/ml) and failure (at the time of the second consecutive viral load >1,000 
copies/ml). Individuals were divided as those whose genotype (taken at the time of virological failure) was completed on or before 180 days (n=79) from breakthrough 
or after 180 days (n=31). None of the differences were significant, although a trend toward more TAMs with more time on failing therapy was noted.
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had NNRTI mutations, compared with  27/31 (87%) 
individuals whose genotype was completed after 6 
months (P=0.956). In total, 97 (88%) individuals 
had ≥1 therapy-limiting NNRTI mutations (Table 3), 
including K103N (55%), V106M (31%) and Y181C 
(10%), and probable drug susceptibility according 
to the genotypic interpretation algorithm was poor 
(Table 4) [23]. In total, 31 (28%) individuals had 1 
NNRTI mutation, 46 (42%) had 2 NNRTI mutations, 
16 (15%) had 3 NNRTI mutations and 3 (3%) sam-
ples had as many as 4 NNRTI mutations. One (0.9%) 
individual had 6 NNRTI mutations. The Y181C muta-
tion emerged more frequently in those failing NVP 
(8/25 [32%]) than efavirenz (3/85 [3.5%]; P=0.0004). 
There was no significant difference in the emergence 
of K103N whether NVP (9/25 [36%]) or efavirenz 
(51/85 [60%]) was taken (P=0.229) [27]. There was no 
significant difference in the emergence of V106M by 
drug. This mutation was seen in 8/25 (32%) people on 
NVP and 26/85 (31%) people on efavirenz (P=0.923). 
The ratio of V106M/K103N in patients failing EFV 
therapy was 0.5.
The protease gene had similar mutations to those 
noted in the treatment-naive population. The median 
number of mutations was four (IQR 3–5). The most 
frequent protease mutations remained M36I (86%), 
L63P (60%), H69K (94%) and L89I/M (82%), similar 
to the consensus sequence noted for clade C (differing 
amino acids compared with clade B subtypes at posi-
tions M361, R41K, H69K and L89M) [26]. As in the 
treatment-naive cohort, >10% had mutations at loci 
20 (27%), 74 (13%) and 77 (15%). According to the 
genotypic resistance algorithm, those with mutations at 
point 74 (n=14 [13%]) had possible low-level resistance 
to nelfinavir (Table 4) [23]. Two (1.8%) individuals 
with mutations at point 33 had possible low-level resist-
ance to fosamprenavir and tipranavir, and one (0.9%) 
individual had multiple protease inhibitor resistance 
because of mutations at positions 73 and 82 (Table 4).
Discussion
With increasing access to ART in LMIC, increased num-
bers of patients are failing first-line therapy and thus 
being switched to second-line therapy [15]. In higher 
   Possible low- Low-level Intermediate High
ART Susceptible, n (%) level resistance, n (%) resistance, n (%) resistance, n (%) resistance, n (%)
Lamivudine/emtricitabine 22 (20) – – 4 (4.0) 86 (78)
Abacavir 20 (18) 55 (50) 15 (14) 20 (18) –
Zidovudine 98 (89) 1 (1.0) 6 (5.5) 3 (2.7) 2 (1.8)
Stavudine 87 (79) 6 (5.5) 12 (11) 5 (4.5) –
Didanosine 76 (69) 9 (8.1) 9 (8.1) 14 (13) 2 (1.8)
Tenofovir 97 (88) 1 (1.0) 4 (3.6) 8 (7.3) –
Efavirenz 10 (9.0) 2 (1.8) – 13 (12) 85 (77)
Nevirapine 10 (9.0) 2 (1.8) 1 (1.0) 4 (4.0) 93 (85)
Etravirine 10 (9.0) 15 (14) 49 (45) 32 (29) 4 (4.0)
Protease inhibitors 93 (84) 16 (15)a 1 (1.0)b – –
Table 4. Expected resistance patterns according to the Stanford University HIV Resistance Database genotypic resistance 
interpretation algorithm in a sample of patients with virological failure to first-line ART in Cape Town, South Africa 
Overall n=110. aFourteen individuals with possible low-level resistance to nelfinavir alone; two with possible low-level resistance to fosamprenavir and tipranavir. bOne 



























Figure 2. Association between non-TAM resistance and 
development of TAMs in the reverse transcriptase gene
aLamivudine (3TC) resistance, non-nucleoside reverse transcriptase inhibitor 
(NNRTI) resistance or both. TAM, thymidine analogue mutation.
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income countries, both the choice of initial therapy and 
switch to second-line therapy are done with the use 
of individual genotypes [7]. In LMIC, a public health 
approach with more limited first- and second-line treat-
ment options has been used. In this setting, it is crucial 
to understand the evolution of resistance patterns, and 
whether the current treatment regimens are adequate.
The majority of virus in this South African sample, 
in both treatment-naive and  treatment-experienced 
patients, was clade C [24]. In both the treatment-naive 
and treatment-experienced group there were a number 
of mutations in the protease enzyme, possibly indicat-
ing divergence from clade B virus. The effect of these 
mutations on viral drug susceptibility is uncertain, but 
many, including L10I/V, K20R, M36I, L63P, A71V/T 
and V77I, are not expected to cause major drug resist-
ance [28]. These mutations are similar to those noted 
in other African clade C virus and clade C consen-
sus sequences [16–18,29]. Other mutations that are 
more likely to affect future use of a protease inhibitor, 
including D30N, M46I, I47V, I50V and V82A/F, were 
present, but in a minority of individuals, with only a 
single mutation noted per individual. The effect of such 
single mutations on the use of lopinavir in second-line 
therapy is not clear in our population.
There were very few mutations noted in the reverse 
transcriptase enzyme in the treatment-naive group. The 
two mutations that are likely to reduce susceptibility 
to NRTIs if transmitted, T215C and M41L, were not 
seen in either the treatment-naive or treatment-experi-
enced groups [28]. The multiplicity of NNRTI muta-
tions seen in the treatment-experienced group make 
NNRTI resistance the most likely to be transmitted in 
our population. Although the K103N mutation, which 
is expected to have the greatest effect on the use of 
NNRTIs, was not seen in the treatment-naive samples, 
there were two (1.6%) individuals each with a single 
mutation (Y181C and G190E) that would have some 
effect on NNRTI susceptibility. Although the currently 
recommended treatment regimens for first-line therapy 
remain appropriate, ongoing surveillance of NNRTI-
resistant virus remains important [3,6].
The samples in the treatment-experienced group 
were taken from 110 individuals failing initial NNRTI 
therapy in the South African public sector. Previous 
data have shown that the rate of confirmed virologi-
cal failure in this cohort was 5.6% at 32 months [15]. 
Adherence is monitored by tablet count in all public 
sector clinics in South Africa and any viral load increase 
should initiate a stepped-up adherence package includ-
ing counsellor-driven re-education sessions, more regu-
lar clinic visits with emphasis on the use of a pill-box 
as a reminder system, as well as a home visit to assess 
living circumstances where the resources are avail-
able for this service [15]. Overall, 75% of those with 
an initial viral load breakthrough of >1,000 copies/ml 
again achieved suppression after structured adherence 
interventions [15]. For those in whom failure was con-
firmed with a second specimen >1,000 copies/ml, the 
median time from treatment commencement to noting 
initial virological breakthrough was 9 months.
The focus on adherence might explain the relatively 
small number of individuals with virological failure who 
did not have a significant drug-resistant mutation. Only 
seven (6.4%) individuals had wild-type virus at geno-
type, a smaller proportion than seen in the DART study 
(10%) [20]. Most of these individuals with confirmed 
failure had resistance mutations, which would exclude 
use of two of the antiretrovirals used in first-line regi-
mens, that is, 3TC (83%; a similar proportion to that 
seen in the DART study of 70% [20], and the NNRTIs 
(86%). Resistance to both NNRTIs and 3TC (M184V) 
develops rapidly after initial virological breakthrough.
Resistance to the third drug in the regimen, the thymi-
dine analogue, occurred more slowly. Although 23% of 
the group had ≥1 AM, relatively few had two or three 
TAMs and the majority of individuals remained sus-
ceptible to both AZT and d4T. A trend towards TAM 
accumulation with prolonged time on failing therapy 
was noted, but was non-significant. People with lower 
CD4+ T-cell counts at the time of genotyping were also 
more likely to have acquired a TAM, perhaps indica-
tive of a longer time on failing therapy than noted here, 
because of the length of time between viral loads in this 
cohort. Thymidine analogues (AZT, ddI and lopinavir/
ritonavir) are currently recycled in second-line therapy 
in South Africa, so TAM accumulation might reduce 
the efficacy of this therapy. However, if failure is iden-
tified before acquisition of TAMs, second-line therapy 
might remain more efficacious.
The increased presence (9%) of the K65R mutation 
in the treatment- experienced samples was unexpected, 
given the absence of abacavir or tenofovir in the South 
African treatment regimens. There is emerging evidence 
that non-subtype B virus might have a propensity to 
develop the K65R more readily compared with subtype 
B [10,25,26]. Doualla-Bell et al. [10] noted that d4T 
also selected for K65R in subtype C virus in Botswana, 
and that the mutation developed within 3 months of 
tenofovir therapy, unlike in subtype B where the K65R 
tends to emerge slowly in a small proportion of indi-
viduals on tenofovir. It is also possible that 3TC might 
select for the K65R mutation as recently described 
[22]. With the registration of tenofovir in South Africa 
in 2007, there is a push for the widespread use of this 
agent to replace d4T, initially in those experiencing 
adverse effects, but with the view to broad-spectrum 
first-line use. The likely rapid emergence of resistance 
to tenofovir in clade C virus should be of concern for 
treatment programmes, as the presence of this mutation 
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reduces susceptibility to all NRTIs except AZT, and 
thus would limit the choice of NRTIs for second-line 
therapy [30].
A limitation of this study is the 4–6 month window 
between viral load samples in the South African anti-
retroviral programme. Some individuals might have 
failed within weeks of their last suppressed viral load 
and others within days of their first raised viral load. 
Time from first virological breakthrough to time of 
genotype might therefore be an underestimate.
Resistance to the reverse transcriptase enzyme after 
exposure to NNRTI-containing first-line therapy fol-
lows a pattern that is predictable and similar to that of 
clade B: initial resistance to antiretrovirals that require 
a single point mutation, followed by slower develop-
ment of resistance to drugs with a higher genetic barrier 
to resistance, such as the thymidine analogues.
Had second-line treatment been commenced within 
6 months of initial virological breakthrough in the treat-
ment-experienced group in this study, the likelihood of 
accumulating TAMs might have been reduced, with a 
potential increase in the efficacy of the recycled thymi-
dine analogue in second-line therapy. Identification of 
and rapid response to virological failure is thus impor-
tant to maintain the full benefit of second-line therapy. 
This would suggest clinical value to regular viral load 
testing to identify virological failure soon after it occurs, 
in contrast to a recently published model [31]. Because 
of the unexpected emergence of the K65R mutation in 
a substantial proportion of the cohort, tenofovir should 
be introduced cautiously with careful assessment of its 
effect on the emergence of resistance.
This study suggests that at present it is not crucial, 
in the context of the South African National ART pro-
gramme, to have routine access to genotypes at base-
line, as the vast majority of treatment-naive samples 
continue to be wild type. By contrast, the development 
of extensive resistance in those failing first-line therapy 
suggests that viral load monitoring is crucial and there 
could be a role for individual genotypes in those fail-
ing first-line therapy, particularly if second-line therapy 
is likely to be compromised by resistance to first-line 
therapy. Increased availability of low-cost assays for 
identifying resistance in patients in South Africa would 
be clinically valuable.
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Abstract
Background: The impact of highly active antiretroviral therapy (HAART) on health-related quality of life has
been widely researched in the developed world, but there are few data from sub-Saharan Africa, where the vast
majority of HIV-infected individuals live. This study examined health-related quality of life among HIV-positive
individuals initiating HAART in Cape Town, South Africa, and explored the impact of HAART-related drug
toxicities on quality of life.
Methods: Health-related quality of life was assessed using a standardised questionnaire, the Medical Outcomes
Survey Short Form 36. Physical health summary scores and mental health summary scores were compared pre-
HAART and at regular intervals during the first 48 weeks of HAART. The relationships between socio-
demographic, baseline and on-treatment variables and decline in health-related quality of life, as well as the impact
of drug toxicities on quality of life, were assessed in unadjusted bivariate and adjusted multivariate analyses.
Results: Two hundred and ninety-five patients were enrolled into the study. There was a significant increase in
health-related quality of life during the first 48 weeks on HAART. The median physical health summary score
increased from 45 to 53 units (p < 0.001) and median mental health summary score increased from 45 to 50 units
(p < 0.001).
The bulk of this increase occurred during the first 16 weeks. Overall, 23% of participants experienced a decline
in their physical health summary score, while 34% showed a decline in the mental health summary score. Average
drops in median physical and mental health summary scores were 8.4 units (SD 9.31) and 9.9 (SD 11.4) units
respectively. Participants with drug toxicity had lower physical health summary scores than participants without
drug toxicity at all time points. However, only three participants with toxicity (27%) reported an actual decline in
health-related quality of life by week 48. Drug toxicities had little impact on mental health summary scores.
Conclusion: These results confirm the health-related quality of life benefits of HAART. While the majority of
patients experienced a significant improvement in health-related quality of life on HAART, up to a third of patients
reported declines in this quality of life. This was largely related to better baseline clinical state. HAART-related
drug toxicities did not have a significant impact on health-related quality of life during the first year of HAART,
which supports the ongoing use of the current national first-line regimen.
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Background
By December 2006, an estimated 39.5 million people
worldwide were living with HIV and a further 2.9 million
people had died due to AIDS. The bulk of infections (63%
of the global burden) occurred in sub-Saharan Africa,
where 24.7 million people were reported to be HIV
infected [1]. In South Africa alone, 5.4 million people
were estimated to be infected with HIV by the middle of
2006 and 600 000 were thought to have AIDS [2].
Prior to 2004, people infected with HIV in South Africa
who were unable to access life-saving antiretroviral (ARV)
therapy progressed to AIDS and died of their disease. The
rollout of highly active antiretroviral therapy (HAART)
through national and provincial programmes has dramat-
ically altered this experience.
By late 2008, an estimated 549 700 HIV-positive individ-
uals were receiving HAART in South Africa [3]. With
increasing numbers of HIV-positive individuals being
enrolled onto HAART and increasing survival among
these patients, there is a growing need to understand the
impact of HAART use on the quality of lives of HIV-
infected individuals [4-8].
There is a sizeable body of research on the impact of
HAART on health-related quality of life (HRQoL) in the
developed world. Most recent cohort studies in the USA
and Europe have shown no significant change in HRQoL
within the first two years of HAART [9-11], although one
study showed an increase in mental quality of life only
[12], and two showed a decrease in physical quality of life
[13,14].
Table 1: Demographic, baseline and on-treatment characteristics of female and male patients with any health-related quality of life 
data
Variable Total Female Male P-value
Number 295 219 76 -
Age (years) (mean, (SD) 34 (7) 33 (7) 38 (6) <0.001
WHO stage 3 & 4
(n,(%))
254 (86) 184 (86) 70 (92) 0.079


























































Change in CD4 count cells/mm3
(mean, (SD))
178 (130) 184 (136) 159 (107) 0.152
Change in viral load
log copies/ml
(mean, (SD))
-2.96 (0.91) -2.91 (0.95) -3.11 (0.75) 0.107
Drug toxicity
(n, (%))
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In contrast, the 2NN study, which compared the efficacy
and safety of three non-nucleoside reverse transcriptase
inhibitor (NNRTI)-containing regimens (nevirapine, efa-
virenz, and nevirapine plus efavirenz in combination with
stavudine and lamivudine) showed an overall improve-
ment in HRQoL over 48 weeks [15].
To date, only four studies have addressed the impact of
HAART on HRQoL in developing countries [16-19].
Wouters et al [16] and Louwagie et al [17] assessed the
impact of HAART on HRQoL in cross-sectional surveys,
and showed a significant association between HAART and
improved physical and emotional health. Unfortunately,
the cross-sectional nature of these two studies and the lim-
ited time that participants were on HAART (six months or
less) restrict the inferences that can be drawn from these
studies.
Only the studies by Stangl et al [18] and Jelsma et al [19]
assessed longitudinal changes in HRQoL associated with
HAART use. Both reported a significant improvement in
HRQoL over 12 months of HAART, with the bulk of this
improvement occurring within the first three months on
treatment.
Internationally, there is concern about the impact of
HAART-related toxicity on HRQoL. In fact, it has been
suggested that studies that consider only mortality out-
comes ignore treatment-related morbidity and may actu-
ally overestimate the benefits of HAART [20].
These international concerns are echoed in South Africa
and other developing countries, where national first-line
regimens tend to be NNRTI-based and incorporate drugs
such as stavudine, which has been shown to be the reason
for up to 75% of drug switches for toxicity within the first
three years of first-line HAART [21]. In South Africa, there
is an ongoing debate about whether or not the side-effect
profile of HAART may adversely affect the HRQoL of HIV-
positive individuals.
More data about the impact of HAART and HAART-
related toxicities on HRQoL are required in developing
countries to inform programme and policy decisions
about HAART roll-out strategies in order to maximise the
quality of life of HIV-infected individuals.
Methods
Study population
This cohort study examined the HRQoL reported by HIV-
positive individuals pre-HAART and at regular intervals
during their first year of receiving HAART at the Hannan
Crusaid Treatment Centre between September 2002 and
March 2005. As per the national ARV guidelines, adult
patients who had World Health Organization (WHO)
Stage 4 disease and/or a CD4+ T cell count of <200 cells/
mm3 were commenced on first-line ARVs [22]. The major-
ity of patients (99.6%) initiated on-treatment were ARV-
naïve.
The Hannan Crusaid Treatment Centre is a community-
based ARV clinic that was initiated in September 2002 as
a joint venture between the Western Cape Department of
Health, Desmond Tutu HIV Foundation and Crusaid, a
UK-based non-governmental organization that raises
funds to support people living with HIV/AIDS. The clinic
was one of the first ARV rollout sites in the Western Cape
Province of South Africa. It is situated alongside the pri-
mary community health care centre and boasts a multidis-
ciplinary team of medical doctors, clinical nurse
practitioners, clinic nurses, Sizophila adherence counsel-
lors and a pharmacist.
Table 2: Median scores for the eight health concepts pre-HAART and at week 16, 32 and 48 on HAART (n = 147)
Pre-HAART Week 16 Week 32 Week 48
Physical function 85 95 100 100
Physical role 50 100 100 100
Bodily pain 61 84 74 84
General health 54 77 77 72
Vitality 55 75 80 85
Social function 75 100 100 100
Emotional role 50 99 99 99
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The clinic followed a programmatic approach to ARV care
with a standard first-line and second-line regimen. In
keeping with WHO recommendations, the first-line regi-
men was NNRTI-based and the second was protease
inhibitor-based [23].
Adults commenced on the first-line regimen (efavirenz or
nevirapine plus stavudine and lamivudine) were reviewed
at four, eight and 16 weeks, and thereafter every four
months by a medical doctor. At these scheduled visits,
patients were assessed clinically, virologically and immu-
nologically. Patients who discontinued their first-line reg-
imen – either due to virological failure or for toxicity
reasons – were worked up for the second-line regimen
(lopinavir/ritonavir, didanosine and zidovudine). Nucle-
oside reverse transcriptase inhibitor (NRTI) substitutions
were made within regimen 1 or 2 for NRTI-associated tox-
icities.
Study procedures
At the screening visit, HIV-positive individuals met with
the clinic nurse, who completed a demographic informa-
tion sheet. Blood was drawn for viral load, CD4 cell count
and safety blood testing (including a full blood count and
liver function tests) at the screening visit and at all subse-
quent scheduled visits prior to the patient seeing the med-
ical doctor.
The adherence counsellors were trained in the administra-
tion of the HRQoL instrument. The quality of life question-
naire was administered at each of the following scheduled
visits: screening, baseline, week 16, week 32, week 48 and
week 64. Although HRQoL data continued to be collected
at scheduled visits following week 64, this study focused on
quality of life only during the first year of ARVs.
HRQoL data were intended to be collected on all patients
at all scheduled visits within the first year. This, however,
was not always possible. Reasons for incomplete HRQoL
data were: death, loss to follow up, transfer out, and
patients leaving the clinic without the questionnaire being
administered. The analysis only included those patients
with HRQoL data available at all time points during the
first year on HAART.
The University of Cape Town Research Ethics Committee
approved all research activities involving antiretroviral
service delivery and patient outcomes at the site. Patients
signed a research consent form at the screening visit, indi-
cating their willingness to take part in this research study.
Study measures
Quality of life
Health-related quality of life was assessed using a stand-
ardised questionnaire, the Medical Outcomes Survey
Short Form 36 (MOS-SF36). The instrument uses 36 items
to assess eight health concepts: (1) physical functioning;
(2) role limitations because of physical health problems;
(3) bodily pain; (4) social functioning; (5) general mental
health; (6) role limitations because of emotional prob-
lems; (7) vitality; and (8) general health perceptions [24].
The MOS-SF36 questionnaire has been widely used in
studies of quality of life in HIV-positive patients in both
developed and developing countries, and has performed
well in all of these settings [11,12,14,25-28]. The instru-
ment has also undergone validity and reliability testing in
a multiracial South African population and was able to
differentiate between HIV-infected and non-infected indi-
viduals [28]. Population values exist for several countries,
Change in median physical health summary score and median mental health summary score over the fi st 48 weeks of HAARTFigur 1
Change in median physical health summary score 
and median mental health summary score over the 
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including South Africa. The English version of the instru-
ment was used, with standard Xhosa explanations given
by the counsellors for difficult concepts.
Quality of life data were entered using a custom-designed Epi
Info™ template to ensure high data quality. On completion
of data entry for each questionnaire, scores for the eight
health components were automatically generated according
to standard scoring algorithms. Data were then transferred
into a Microsoft Excel spreadsheet where health component
scores were transformed into the physical health summary
(PHS) and mental health summary (MHS) scores using
standardised factor analysis-based weights.
Missing questionnaire items were estimated using a standard
scoring algorithm that estimates missing values [24]. Scores
for screening and baseline were combined to form an aver-
age pre-HAART score. For those participants whose week 48
scores were not available, week 64 scores were used to
replace missing data. This replacement of scores was deemed
acceptable as data analysis demonstrated no significant dif-
ference between overall week 48 and week 64 scores.
Socio-demographic and clinical information
Demographic information was collected using standard
paperwork. Patients were staged according to WHO clini-
cal criteria by the medical doctor at their screening visit.
The Toga Laboratory performed viral load and CD4 cell
count testing. Viral load testing made use of the branch
DNA hybridisation technique (Versant™ HIV-1 RNA 3.0
branched chain DNA assay, Bayer HealthCare,
Leverkusen, Germany) and CD4+ T cell counts were meas-
ured by flow cytometry (FACSCount™, Becton Dickinson,
Franklin Lakes, NJ, USA).
Change in physical health summary score and mental health summary score over the first 48 weeks of HAART for 15 random participa tsFigur 2
Change in physical health summary score and mental health summary score over the first 48 weeks of HAART 










Journal of the International AIDS Society 2009, 12:5 http://www.jiasociety.org/content/12/1/5
Page 6 of 13
(page number not for citation purposes)
Table 3: Factors associated with negative physical health summary score at week 48
Variable Univariate model Multivariate model 1 Multivariate model 2
Odds ratio, 95% CI
(P-value)
Odds ratio, 95% CI
(P-value)
Odds ratio, 95% CI
(P-value)
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Week 48 CD4 count cells/mm3
(<250 = 0, ≥ 250 = 1)
0.63, (0.29; 1.37)
0.245
Week 48 CD4 count cells/mm3 <200 1
200–350 0.62, (0.25; 1.51)
0.29
350–500 0.67, (0.22; 2.07)
0.483
≥ 500 0.42, (0.08; 2.21)
0.309
Week 48 viral load copies/ml
(<50 = 0, ≥ 50 = 1)
0.96, (0.37; 2.48)
0.935
Week 48 viral load copies/ml <50 1
50–399 0.39, (0.08; 1.79)
0.224
400–4999 1.10, (0.11; 11.00)
0.936
≥ 5000 3.30, (0.77; 14.07)
0.107
Week 48 log viral load
log copies/ml
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Drug toxicities were detected by the medical doctor at
both scheduled and unscheduled clinical visits through
clinical questioning, examination and safety blood draws
(including a full blood count, liver function tests, amylase
and lactate levels as requested). Drug toxicities were
defined as any adverse event thought by the clinician to be
HAART-related and that required a change in antiretrovi-
ral therapy. Drug changes could either be a NRTI substitu-
tion or a change from NNRTI to a protease inhibitor.
Statistical analysis
The cohort was initially described using means, medians
and proportions, as appropriate. Changes in HRQoL pre-
HAART and at week 16, 32 and 48 were compared using
the Wilcoxon Rank Sum Test. Crude associations were first
examined using Fisher's Exact, Chi Squared and Wilcoxon
Rank Sum tests, as appropriate.
Negative HRQoL was defined as a decrease in PHS or MHS
scores between pre-HAART and week 48. Univariate rela-
tionships were then explored between the outcome varia-
bles – negative PHS and negative MHS – and each
explanatory variable. Multivariate analyses made use of
logistic regression models to examine the adjusted associ-
ation between negative HRQoL and various socio-demo-
graphic, baseline and on-treatment explanatory variables
as appropriate.
Multivariate analysis started with a full model (Model 1)
and explanatory variables were removed in a stepwise
manner until the final model (Model 2) was selected. All
final logistic regression models were checked against
model assumptions. Outliers and potentially influential
observations were identified and examined to ensure that
model results were not being unduly influenced by a
small number of non-representative observations. Models
were rerun with selected observations excluded.
All statistical analyses were performed using Intercooled
Stata Version 8.2 (Stata Corporation, College Station,
Texas, USA). All statistical tests are two-sided at alpha =
0.05.
Results
Of the 295 patients with any HRQoL data, 292 (99%) had
baseline data, 271 (92%) had week 16 data, 233 (79%)
had week 32 data, and 179 (61%) had week 48 data.
Complete HRQoL data, obtained pre-treatment and at
every scheduled on-treatment visit, were available for 147
patients.
Demographic, baseline and on-treatment characteristic
Table 1 describes the demographic and baseline character-
istics of the 295 patients with any HRQoL data. The aver-
age age of the cohort was 34 years (standard deviation: 4)
and 74% of patients were female (n = 219). Eighty-six per-
cent of patients (n = 370) had WHO Stage 3 and 4 disease.
The median baseline CD4 count was 88 cells/mm3 (inter
quartile range: 44, 154) and median baseline log viral
load was 4.9 (inter quartile range: 4.5, 5.3). Men were
older and had more advanced disease than women. The
majority of drug toxicities (90.9%) occurred in women
with only one drug change made due to toxicity among
men. There were no differences in demographic and base-
line characteristics between patients with complete
HRQoL data (n = 147) and those with incomplete data (n
= 148).
Health-related quality of life data
The median scores for the eight health concepts pre-treat-
ment and at regular intervals on-treatment are described
in Table 2. The scores all demonstrated an increase in
HRQoL between pre-HAART and week 48, with the great-
est increase occurring at week 16 (p < 0.001).
Week 48 log viral load
log copies/ml
<1.69 1
1.69–2.59 0.58, (0.16; 2.14)
0.414
2.60–3.69 1.10, (0.11; 11.00)
0.936
≥ 3.69 2.47, (0.51; 11.74)
0.225
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Table 4: Factors associated with negative mental health summary score at week 48




Odds ratio, 95% CI
(P-value)
Odds ratio, 95% CI
(P-value)
Odds ratio, 95% CI
(P-value)
Age (continuous) 1.01, (0.96; 1.06)
0.767
Age
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Week 48 CD4 count cells/mm3
(<250 = 0, >250 = 1)
1.67, (0.83; 3.37)
0.151
Week 48 CD4 count cells/mm3 <200 1
200–350 5.18, (1.92; 13.96)
0.001
350–500 2.39, (0.72; 7.91)
0.155
>500 2.52, (0.58; 10.88)
0.216
Week 48 viral load copies/ml
(<50 = 0, >50 = 1)
1.30, (0.57; 2.94)
0.535
Week 48 viral load copies/ml <50 1
50–399 0.95, (0.33; 2.69)
0.919
400–4999 2.05, (0.28; 15.14)
0.481
>5000 2.05, (0.49; 8.66)
0.327
Week 48 viral load
log copies/ml
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The physical health summary and mental health sum-
mary scores also showed an improvement in HRQoL over
time (Figure 1). There was a significant increase in both
summary scores between pre-HAART and week 16. The
median PHS score increased from 45 to 53 units (p <
0.001) and the median MHS score increased from 45 to
51 units (p < 0.001). These increases were then main-
tained through weeks 32 and 48.
However, not all participants experienced a linear increase
in HRQoL. Using a random sample of 15 participants, it
was evident that while the bulk of participants experi-
enced a gradual improvement in HRQoL, others experi-
enced a worsening of HRQoL (Figure 2). While the
average change in PHS score between pre-HAART and
week 48 was an increase of seven units (standard devia-
tion: 11.9), 23% of participants experienced a decrease in
PHS score during this period. The average drop in PHS
score among these participants was 8.4 units (standard
deviation: 9.31).
Similarly, while MHS score increased by an average of 3.3
units (standard deviation: 11.4) between pre-HAART and
week 48, 34% of participants experienced a decline in
MHS score. The average drop in MHS score among these
participants was 9.9 units (standard deviation: 5.92).
Factors associated with negative change in quality of life
Baseline log viral load, pre-HAART PHS score, change in
CD4 count and change in log viral load were all strongly
associated with a negative PHS in the univariate analyses
(Table 3).
In the multivariate regression model, pre-HAART PHS
score and baseline log viral load were the strongest predic-
tors of negative PHS at week 48. Participants with a higher
pre-HAART HRQoL score were more likely to report neg-
ative PHS (OR1.15; 95% CI 1.08, 1.23; p < 0.001),
whereas participants with a higher baseline log viral load
(>5.0 log) were less likely to report negative PHS than par-
ticipants with a lower baseline log viral load (≤ 5.0 log)
(OR 0.22; 95% CI 0.08, 0.60; p = 0.003).
Age was also predictive of negative PHS. Older partici-
pants (above 34 years of age) were more likely to report
negative PHS than younger participants (OR 1.07; 95% CI
1.01, 1.14, 0.085; p = 0.029). Neither gender nor any of
the week 48 variables were associated with negative PHS.
Baseline CD4 count, baseline log viral load, pre-HAART
MHS score and change in log viral load were all associated
with negative MHS in the univariate models (Table 4). In
the multivariate regression model, pre-HAART MHS score
was the strongest predictor of negative MHS at 48 weeks.
Participants with higher pre-HAART HRQoL scores were
more likely to report negative MHS than participants with
lower pre-HAART MHS scores (OR 1.09; 95% CI 1.04,
1.15; p = 0.001).
Baseline CD4 count and baseline log viral load remained
weakly associated with the outcome. Participants with
lower baseline CD4 count (≤ 50 cells/mm3) were less
likely to experience negative MHS than participants with
higher baseline CD4 count (>50 cells/mm3) (OR 0.41;
95% CI 0.16, 1.09; p = 0.075). Participants with a higher
baseline log viral load (>5.0 log) were less likely to expe-
rience negative MHS than participants with lower baseline
log viral load (≤ 5.0 log) (OR 0.50; 95% CI 0.23, 1.09; p
= 0.081). Gender and the week 48 variables were not pre-
dictive of negative MHS at 48 weeks.
Drug toxicities and quality of life
Eleven participants experienced drug-related toxicities
during the first 48 weeks of HAART. Ninety-one percent
(n = 10) of these toxicities occurred in women, with 50%
(n = 5) of these being due to lactic acidosis. Participants
experiencing drug toxicities had similar demographic and
baseline characteristics to the overall cohort.
Week 48 viral load
log copies/ml
<1.69 1
1.69–2.59 0.88, (0.31; 2.47)
0.808
2.60–3.69 2.05, (0.28; 15.14)
0.481
>3.69 2.74, (0.58; 12.85)
0.202
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Table 5 describes the types of drug toxicities that occurred
during the first year of HAART. Efavirenz hypersensitivity
reactions were the cause of drug toxicities within the first
16 weeks of HAART. Between weeks 16 and 32, peripheral
neuropathies were the main reason for drug changes. Ele-
vated transaminases and hyperlactatemia were the main
causes of drug toxicities between weeks 32 and 48 of
HAART.
One patient experienced an efavirenz hypersensitivity
reaction between weeks 32 and 48. This was due to the
fact that the patient was switched to efavirenz at this time.
The bulk (64%) of toxicities occurred during the week 32
to 48 interval and were mostly elevated transaminases and
hyperlactataemia related to stavudine use.
The 11 participants who experienced drug toxicity during
the first 48 weeks of HAART achieved lower PHS scores at
all time points than the 281 participants who did not have
toxicity. While these differences were not statistically sig-
nificant pre-HAART and at weeks 16 and 32, they did
become significant at week 48. The median PHS score at
week 48 was 50 for participants with drug toxicity, com-
pared to 53 for participants without drug toxicity (p =
0.0053) (Table 6).
Drug toxicities did not appear to have a significant impact
on median MHS scores over the first 48 weeks of HAART.
The 11 participants with drug toxicity had a lower median
MHS score pre-HAART than the 281 participants without
drug toxicity, but this difference was not statistically sig-
nificant (42 versus 45, p = 0.1793). There was no impact
of baseline mental health status on the reporting of toxic-
ities. At weeks 16, 32 and 48, participants with drug toxic-
ity reported higher median MHS scores than those
without toxicity. Again, these differences were not statisti-
cally significant (Table 6).
Examining the associations between drug toxicity and
negative HRQoL, it was noted that only three (27%) of all
drug toxicities occurred among participants who reported
negative PHS and that these toxicities occurred during the
week 32 to 48 treatment interval. No drug toxicities
occurred among participants who reported negative MHS.
Discussion
This study reported a significant increase in HRQoL dur-
ing the first 48 weeks on HAART, with the bulk of this
increase occurring during the first 16 weeks on treatment.
Improvement in HRQoL occurred across all core domains
assessed, as well as the physical health summary and men-
tal health summary.
This study therefore supports the findings of Stangl et al
[18] and Jelsma et al [19] who both reported an increase
in HRQoL within the first three months of therapy in sim-
ilar patient populations. The dramatic increase in HRQoL
during the first few weeks of HAART occurred over the
time period when patients usually experience the most
significant gains in health. The greatest decrease in viral
load happens within the first few weeks of treatment and
mortality and morbidity rates begin to fall after just a
month on HAART [29,30].
There have been few analyses dealing with declines in PHS
and MHS scores. In fact, negative HRQoL is often over-
shadowed by the overwhelming positive impact of
HAART on HRQoL, and is therefore not reported. This
research showed that although there was a general
improvement in HRQoL on HAART, up to a third of par-
ticipants experienced a decline in HRQoL during the first
48 weeks of HAART. Twenty-three percent of participants
reported a drop in PHS score and 34% reported a drop in
MHS score.
The most significant predictors of negative PHS and MHS
were baseline HRQoL score, baseline log viral load and
baseline CD4 count. The association between higher base-
line HRQoL score and negative HRQoL could have been
due to the fact that patients with higher baseline scores
had less room for improvement and were therefore more
likely to regress to the mean.
Table 5: Description of drug toxicities occurring during the first year of HAART
Description Week 0–16 Week 16–32 Week 32–48 Total
Any toxicity 2 2 7 11
EFV hypersensitivity reaction 2 *** 1 3
Peripheral neuropathy *** 2 *** 2
Elevated transaminases *** *** 1 1
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Baseline log viral load was strongly associated with nega-
tive PHS. Participants with higher baseline log viral loads
were less likely to report negative PHS than participants
with lower baseline log viral loads. Similarly, baseline log
viral load and baseline CD4 count were associated with
negative MHS. Participants with higher baseline log viral
loads or lower baseline CD4 counts were less likely to
report negative MHS than participants with lower baseline
log viral loads or higher baseline CD4 counts.
Participants with more advanced disease, characterised by
higher baseline viral loads and lower baseline CD4
counts, were less likely to report a decline in HRQoL than
those with earlier disease. So it was the relatively well
patients entering into the programme who were at greatest
risk of experiencing negative HRQoL. These associations
could be explained by the negative impact of symptoms
on HRQoL [10-12]. Patients with more advanced disease
are more likely to have a greater number or intensity of
symptoms than patients with less advanced disease pre-
HAART [10], but once on HAART, these symptoms
improve [11,12].
Although there is great concern about the impact of drug
toxicities on HRQoL, few studies have directly assessed
this association. In the developed world, symptoms have
been shown to impact negatively on both physical and
mental HRQoL [10,31]. However, the nature of the symp-
toms and whether they were attributed to the disease
process or to HAART was not clear.
In the developing world, Jelsma et al [19] concluded that
possible side effects of HAART had a negligible impact on
HRQoL. This conclusion was based on the overall increase
in HRQoL demonstrated for the cohort and did not spe-
cifically address those patients who experienced a decline
in HRQoL.
Few drug toxicities were recorded during the first 48 weeks
on HAART. While participants who experienced drug tox-
icity had lower PHS scores than participants without a
drug toxicity at all time points (most notably during the
32 to 48 week treatment interval), only three (27%) par-
ticipants with toxicity reported an actual decline in physi-
cal HRQoL between pre-HAART and week 48.
Drug toxicities, especially those related to stavudine use,
may have a negative impact on physical HRQoL at the
time of the toxicity. They do not, however, reduce overall
gains in HRQoL. Drug toxicities had little impact on men-
tal HRQoL.
The greatest strength of this study is its longitudinal
design. This allowed the assessment of the associations
between various socio-demographic and clinical factors
and HRQoL, and allowed for inferences to be made about
causal relationships.
Limitations to the study included possible selection bias
and information bias related to the use of the MOS-SF36
instrument. The loss of up to 50% of patients, who had
incomplete HRQoL data, from the final analysis may have
resulted in a selection bias towards the healthier section of
the cohort. However, as there were no significant differ-
ences in demographic, baseline and on-treatment charac-
teristics between patients with incomplete and complete
Table 6: Median physical health summary and median mental health summary scores and drug toxicity
N Pre-HAART Week 16 Week 32 Week 48
Median PHS
Drug toxicity 11 39 51 52 50
No drug toxicity 281 44 52 53 53
p-value 0.854 0.225 0.390 0.005
Median MHS
Drug toxicity 11 42 51 51 52
No drug toxicity 281 45 50 49 48
p-value 0.179 0.539 0.326 0.912
Median PHS and median MHS pre-HAART and at week 16, 32 and 48 in patients with any drug toxicity at any time in the first year compared to 
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HRQoL data, it is unlikely that this was the case. This did
impact on the number of patients available for analysis
though, and may have limited the ability of the study to
detect significant associations.
The MOS-SF36 instrument is a generic HRQoL measure
and, like all generic instruments, may not be sensitive
enough to measure the more specific aspects of HRQoL
impacted on by the HIV disease process. This could lead
to either an underestimation or overestimation of HRQoL
scores and, more important, to a change in HRQoL scores,
thereby under-reporting or over-reporting the actual
impact of HAART on HRQoL.
The MOS-SF36 instrument is also prone to ceiling effects,
where substantial numbers of patients get the highest pos-
sible score for a domain. This would have made it difficult
for the instrument to pick up changes in HRQoL at the
upper end of the scale, and may have been a problem with
increasing time on treatment. Ceiling effects could have
lead to the underestimation of HRQoL gains.
This study reported on HRQoL during the first 48 weeks
of HAART only. As HAART-related drug toxicities, espe-
cially those related to stavudine, increase with length of
time on HAART [21], this study may have under-reported
the impact of drug toxicities on gains in HRQoL.
Furthermore, this study only considered drug toxicities
that were severe enough to prompt a change in antiretro-
viral therapy. Less severe toxicities that may also have
impacted negatively on HRQoL were not reported on.
This could have led to an underestimation of the true neg-
ative impact of drug toxicities on HRQoL.
Conclusion
This study confirmed the overwhelmingly positive
HRQoL benefits of HAART in a community ARV clinic in
South Africa. HRQoL improved significantly during the
first 48 weeks of HAART, with the bulk of improvement
occurring during the first 16 weeks of treatment.
Up to a third of patients experienced a decline in HRQoL
on HAART. This was largely related to the patient's base-
line clinical state. HAART-related drug toxicities did not
have a significant impact on HRQoL during the first year
of HAART, supporting the ongoing use of the current
national first-line regimen.
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Nurse versus doctor management of HIV-infected patients 
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Summary
Background Expanded access to combination antiretroviral therapy (ART) in resource-poor settings is dependent on 
task shifting from doctors to other health-care providers. We compared outcomes of nurse versus doctor management 
of ART care for HIV-infected patients.
Methods This randomised non-inferiority trial was undertaken at two South African primary-care clinics. HIV-positive 
individuals with a CD4 cell count of less than 350 cells per µL or WHO stage 3 or 4 disease were randomly assigned 
to nurse-monitored or doctor-monitored ART care. Patients were randomly assigned by stratifi ed permuted block 
randomisation, and neither the patients nor those analysing the data were masked to assignment. The primary 
objective was a composite endpoint of treatment-limiting events, incorporating mortality, viral failure, treatment-
limiting toxic eff ects, and adherence to visit schedule. Analysis was by intention to treat. Non-inferiority of the nurse 
versus doctor group for cumulative treatment failure was prespecifi ed as an upper 95% CI for the hazard ratio that 
was less than 1·40. This study is registered with ClinicalTrials.gov, number NCT00255840.
Findings 408 patients were assigned to doctor-monitored ART care and 404 to nurse-monitored ART care; all 
participants were analysed. 371 (46%) patients reached an endpoint of treatment failure: 192 (48%) in the nurse group 
and 179 (44%) in the doctor group. The hazard ratio for composite failure was 1·09 (95% CI 0·89–1·33), which was 
within the limits for non-inferiority. After a median follow-up of 120 weeks (IQR 60–144), deaths (ten vs 11), virological 
failures (44 vs 39), toxicity failures (68 vs 66), and programme losses (70 vs 63) were similar in nurse and doctor 
groups, respectively.
Interpretation Nurse-monitored ART is non-inferior to doctor-monitored therapy. Findings from this study lend 
support to task shifting to appropriately trained nurses for monitoring of ART.
Funding National Institutes of Health; United States Agency for International Development; National Institute of 
Allergy and Infectious Diseases.
Introduction
Combination drug therapy has had a remarkable eff ect 
on the reduction of AIDS-related morbidity and 
mortality.1 In industrialised countries, antiretroviral 
management is administered by specialist physicians 
who prescribe from the full range of available 
antiretroviral drugs, supported by frequent laboratory 
monitoring including resistance testing.2 Finding from 
several studies in industrialised settings have shown 
that outpatients have better outcomes when cared for by 
a physician with HIV expertise than do those without 
such a physician, including quality of care and survival,3–7 
which could be an indicator of the complexities of HIV 
infection and its management.2 By contrast with the 
small epidemic in resource-rich countries, there are 
22·4 million people living with HIV in sub-Saharan 
Africa,8 with an estimated 3·8 million in urgent need of 
treatment.9 Globally, there is a shortage of 4·3 million 
health workers (doctors, midwives, nurses, and support 
workers);9 in South Africa there are only 17·4 medical 
practitioners per 100 000 people, who are largely 
concentrated in urban areas.10,11
By contrast with the individualised approach to HIV 
care in developed countries, WHO has proposed a public 
health approach to antiretroviral therapy (ART) to enable 
scaling up of access to treatment for large numbers of 
HIV-positive adults and children in developing countries.12 
An approach using standardised simplifi ed treatment 
protocols and decentralised service delivery was developed 
to enable lower level health-care workers to deliver care.13 
Models of care have investigated task shifting to clinical 
offi  cers14 and a combination of nurses and community 
workers;15 however, nurse-led models of antiretroviral 
delivery have been one of the most widely implemented 
models of HIV care in poor-resourced African settings.15–18 
Findings from a trial have shown that work-site treatment 
of hypertension by specially trained nurses led to 
signifi cantly improved blood pressure control and drug 
adherence.19 So far no randomised prospective study has 
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monitored ART. The HIV/AIDS strategic plan of South 
Africa, a middle-income country with the world’s largest 
national ART programme, envisions increasing reliance 
on nurses for monitoring of ART.20 With increasing 
deployment of nurses for HIV care, operational research 
is urgently needed to establish whether nurse-led models 
of care are safe and eff ective.
We therefore compared outcomes of nurse versus 
doctor management of doctor-initiated ART care for HIV-
infected patients. 
Methods
Study design and population
This prospective, unblinded, randomised controlled study 
was a community-based ART strategy trial done as part of 
the Comprehensive International Program for Research in 
AIDS in South Africa (CIPRA-SA).21 The trial was 
undertaken between Feb 25, 2005, and Jan 20, 2009, at two 
primary health-care sites in South African townships: 
Masiphumelele in Cape Town and Soweto in Johannesburg. 
The CIPRA-SA study compared two treatment monitoring 
strategies. Participants were allocated to receive either their 
primary care from doctors (hereafter referred to as doctor 
group) or from primary health-care nurses (hereafter 
referred to as nurse group). The standard-care strategy 
(doctor group) was consistent with the routine management 
of patients in the current South African ART programme, 
which is based on treatment initiated and monitored by a 
doctor.13 The experimental nurse monitoring strategy used 
doctor-initiated ART monitored by primary health-care 
nurses. To ensure that all procedures and overall study 
management conformed to the national guidelines,22 and 
National Institutes of Health guidelines for research on 
human patients,23 a clinical safety team was established 
consisting of clinicians with experience of research.
The eligible study population consisted of adults with 
HIV-1 infection who had received less than 6 weeks of 
ART, aged older than 16 years, with a CD4 cell count less 
than 350 cells per µL or a previous AIDS-defi ning illness,24 
and not in the fi rst trimester of pregnancy. Women who 
had received short-course ART for prevention of mother-
to-child transmission were not excluded. Screening 
laboratory investigations for renal function, liver enzymes, 
and haematology had to be less than grade 3 by the 
National Institutes of Health Division of AIDS toxicity 
grading scale.25 An active opportunistic infection was 
exclusionary if the patient’s treatment status was not 
considered stable (ie, treatment for <7 days) or in the case 
of tuberculosis if treatment had been for less than 8 weeks 
(amended in October, 2005, to <2 weeks of tuberculosis 
treatment). Other exclusion criteria were concomitant 
treatment with systemic myelosuppressive, neurotoxic, 
pancreatotoxic, hepato toxic, or cytotoxic treatment within 
30 days of randomisation; acute hepatitis; intractable 
diarrhoea (lasting >6 weeks); bilateral peripheral 
neuropathy of grade 2 or higher; and drug or alcohol 
misuse that was considered by the investigator to 
potentially interfere with study compliance.
The study was approved at the institutional review 
boards of the University of Cape Town and University of 
the Witwatersrand, and written informed consent was 
obtained from all participants before the start of study 
procedures.
Randomisation and masking
The clinical safety team was responsible for the 
recruitment of participants including consent, screening 
processes, start of therapy, and provision of ongoing 
consultation support by telephone to study nurses and 
doctors. Participants were randomly assigned in a ratio 
of 1:1 within sites. Randomisation lists were generated 
centrally with a stratifi ed permuted block randomisation 
(with blocks of six). The strata corresponded to the 
diff erent study sites. The allocation codes for a particular 
site were sealed in sequentially numbered envelopes, 
refl ecting their order on the randomisation list, and 
distributed to the site. At randomisation, the site 
pharmacist unsealed the sequential envelope to reveal 
the randomisation code and participant randomisation 
number. Neither the participant nor those analysing the 
data were masked to the assignment.
Procedures
At each site the experimental group (nurse) used two 
experienced primary health-care nurses. Primary health-
care nurses are a nationally registered cadre of nurses 
who have undergone 1 additional year of clinical training 
in primary health care. The control group (doctor) 
consisted of two doctors (medical offi  cers with no 
previous HIV-care experience) at each site. Primary-care 
providers who had little or no previous experience with 
ART were selected for both groups of the study. Each new 
917 assessed for eligibility 
105 excluded
         89 did not meet inclusion 
                criteria
         16 refused to participate
812 randomised
408 allocated to nurse group
10 lost to follow-up
53 discontinued intervention
14 lost to follow-up
56 discontinued intervention
408 analysed 404 analysed 
404 allocated to doctor group
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clinician (nurse or doctor) received similar structured 
didactic and clinical training in HIV and the use of ART 
from the clinical safety team. To limit contamination 
between randomised groups, work activity and 
monitoring schedules were separated with routine visits 
scheduled on diff erent days of the week, although at least 
one clinician was available to undertake unscheduled 
visits in the other group of the study. Whenever possible 
the participant saw the same clinician within the 
treatment group. Both groups were supported by a clinic 
nurse who ensured that the participant saw the correct 
clinician, did routine clinic procedures, and scheduled 
further patient visits; and by a team of lay community 
counsellors who were trained in treatment adherence 
counselling. A pharmacist oversaw ordering and 
dispensing of antiretroviral drugs at each site.
The primary study outcome was a composite endpoint 
of possible treatment-limiting events that could occur on 
fi rst-line ART. The composite endpoint was chosen to 
represent both biological measures of treatment safety, 
effi  cacy, and disease progression, and measures of patient 
dissatisfaction with the treatment strategy. These outcomes 
were: all-cause mortality, loss to follow-up, virological 
failure, toxicity failure, withdrawn consent, defaulting 
clinic schedule, and HIV-disease progression. Virological 
failure was defi ned as either a decline of less than 1·5 log10 
in viral load from baseline to 12 weeks of treatment (early 
failure), or two consecutive viral loads 4 weeks apart of 
more than 1000 copies per mL (late failure).
Toxicity failure was defi ned as grades 3 and 4 adverse 
events or other events needing treatment interruption for 
more than 42 days.25 However, single-drug substitution as 
a result of drug-related toxic eff ects was not regarded as 
failure if treatment was interrupted for less than 42 days.
Patients who missed three consecutive study visits and 
were not able to be contacted by the study team were 
defi ned as lost to follow-up. Defaulting clinic schedule 
was defi ned as missing three or more consecutive 
scheduled clinic appointments with a study visit window 
of 7 days, but patients were able to be traced. Disease 
progression was defi ned by new AIDS-defi ning clinical 
events, as classifi ed in the revised case defi nition of the 
Centers for Disease Control and Prevention (CDC).24 
Tuberculosis is hyperendemic in South Africa and 
therefore pulmonary tuberculosis was not included in 
the composite endpoint but was analysed separately.
Throughout the study, a data monitoring team reviewed 
data from all study visits to identify any default or loss to 
follow-up. An endpoint review committee reviewed all 
events classifi ed as death and toxicity failure to ascertain 
whether the correct assignment to study regimen and 
procedure were undertaken. An independent data and 
safety monitoring board reviewed the safety and effi  cacy 
of the CIPRA-SA study every 6 months.
ART was provided and specifi ed by the South African 
Department of Health. Regimens initially prescribed by 
the clinical safety team26 included a nucleoside backbone 
of stavudine and lamivudine, with a choice of efavirenz, 
nevirapine, or lopinavir plus ritonavir. The initial dose of 
stavudine was 40 mg daily for individuals weighing more 
than 60 kg, which was reduced to 30 mg for all patients 
from mid-2007 in line with WHO recommendations.27 
Efavirenz was the preferred non-nucleoside for men and 
women not wishing to become pregnant and willing to 
maintain both barrier and hormonal contraception 
throughout the study. Women of childbearing potential 
were prescribed nevirapine if their CD4+ lymphocyte 
count was less than 250 cells per µL, or lopinavir plus 
ritonavir if their count was 250 cells per µL or greater. 
Pregnant women, who were allowed to enrol after their 
fi rst trimester, were prescribed either nelfi navir or 
lopinavir plus ritonavir.
After consenting and randomisation by the clinical 
safety team, the primary-care provider of the assigned 
group undertook responsibility for treatment initiation, 
adherence counselling, and follow-up visits. Patients were 
scheduled for study visits at baseline and then at weeks 2, 
Nurse group (N=404) Doctor group (N=408)
Women 297 (73·5%) 276 (67·7%)
Age (years) 32·3 (28·0–36·6) 32·2 (28·0–37·4)
BMI (kg/m2) 23·5 (21·3–27·6) 23·5 (20·4–26·8)
CDC classifi cation  
Class A 160 (39·6%) 141 (34·6%)
Class B  111 (27·5%) 118 (28·9%)
Class C  133 (32·9%) 149 (36·5%)
CD4 cell count (cells per μL) 
<200 260 (64·4%) 257 (63·0%)
200–350 119 (29·5%) 131 (32·1%)
>350–500 23 (5·7%) 18 (4·4%)
>500 2 (0·5%) 2 (0·5%)
Median (IQR) 165 (105–235) 164 (110–225)
Viral load (copies per mL)
≤100 000 181 (44·8%) 170 (41·7%)
>100 000 223 (55·2%) 238 (58·3%)
Log10 viral load 4·99 (0·75) 5·09 (0·73)
Baseline regimen prescribed
Stavudine, lamivudine, efavirenz 293 (72·5%) 304 (74·5%)
Stavudine, lamivudine, nevirapine 72 (17·8%) 81 (19·9%)
Stavudine, lamivudine, lopinavir/ ritonavir* 35 (8·7%) 20 (4·9%)
Stavudine, lamivudine, nelfi navir* 4 (1%) 3 (0·7%)
Previous exposure to antiretrovirals†
Single-dose nevirapine 81 (20%) 86 (21·1%)
Zidovudine 2 (0·5%) 4 (1·0%)
Nevirapine, zidovudine 14 (3·5%) 15 (3·7%)
Triple-drug therapy 1 (0·2%) 0 (0%)
Data are number (%), median (IQR), or mean (SD). BMI=body-mass index. CDC=Centers for Disease Control and 
Prevention. *Regimens containing protease inhibitors were prescribed to pregnant women or women of childbearing 
potential with CD4 count greater than 250 cells per µL who were unable or unwilling to use both a barrier 
contraceptive and a progesterone contraceptive. These women could not receive a regimen containing either 
nevirapine or efavirenz. †Previous exposure to antiretroviral therapy for prevention of transmission, either from 
mother-to-child or in postsexual exposure. Prophylaxis was allowed by the protocol for up to 6 weeks of treatment. 











4 www.thelancet.com   Published online June 16, 2010   DOI:10.1016/S0140-6736(10)60894-X
4, 8, and 12, and every 12 weeks thereafter. Clinical records 
were maintained by the primary-care providers in each 
group. Study coordinators at each site extracted relevant 
study data into case report forms, which were relayed to a 
central database with Datafax (Clinical DataFax Systems, 
Hamilton, ON, Canada).
Statistical analysis
The sample size was calculated based on an 18-month 
accrual and 96 weeks’ follow-up with 80% power and α of 
0·05. Non-inferiority of the nurse group compared with 
the doctor group for cumulative treatment failure was 
prespecifi ed as an upper 95% confi dence limit for the 
hazard ratio (HR) that was less than 1·40. An initial sample 
size of 850 participants accounted for potential clustering 
of multiple enrolled participants within households. 
Because we did not record signifi cant household clustering, 
enrolment was able to be discontinued after 812 patients 
with no compromise of pre-established study power.
Baseline diff erences in randomisation groups were 
described with simple proportions for categorical variables 
and means and SDs for continuous variables. The primary 
analysis was an intention-to-treat analysis of any treatment 
failure with use of Cox proportional hazards regression. 
Diff erences in specifi c reasons for treatment failure (eg, 
lost to follow-up, toxicity, death, etc) were compared by 
treatment group with HRs and 95% CIs. Diff erences in 
time to failure used Kaplan-Meier analyses. Group 
comparisons with the log-rank statistic were regarded as 
signifi cant if p values were less than 0·05.
This study is registered with ClinicalTrials.gov, number 
NCT00255840.
Role of the funding source
Staff  of the major sponsor of the study, the Division of 
AIDS (DAIDS) of the National Institutes of Allergy and 
Infectious Diseases, at the US National Institutes of 
Health, contributed to study design, data interpretation, 
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Figure 2: Kaplan-Meier curves of time to cumulative treatment failure (A) and of time to specifi c reasons for treatment failure (B–D) by study group
(A) Kaplan-Meier curve showing the composite endpoint of cumulative treatment failure. The primary health-care nurse group of the study was non-inferior to the doctor group (log-rank p=0·42). 
(B) Time to virological failure stratifi ed by treatment group (log-rank p=0·53). (C) Time to toxicity failure stratifi ed by treatment group (log-rank p=0·47). (D) Time to loss to follow-up stratifi ed by 
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and review of the fi nal report. The corresponding author 
had full access to all the data generated by the study and 
shared fi nal responsibility for publication of the 
manuscript with IS.
Results
Figure 1 shows the trial profi le. 917 participants were 
screened for study enrolment, of whom 828 met eligibility 
criteria and 812 consented and were randomly assigned. 
Of the 89 patients excluded from the study, 32 did not 
meet the ART initiation criteria, 22 had acute medical 
conditions, 18 were considered unsuitable by investigators 
or did not return, eight had laboratory results out of 
eligible range, and nine were unable to take oral drugs or 
were receiving excluded drugs. 804 (99%) study 
participants were black African and 573 (70%) were 
women. 408 individuals were randomly assigned to the 
nurse group and 404 to the doctor group. The median 
follow-up was 120 weeks (IQR 60–144), with no diff erence 
between the nurse and doctor groups (median 
119 weeks [IQR 61–143] vs 120 weeks [58–144]). The follow-
up period was 815·7 patient-years for the nurse group 
and 830·9 patient-years for the doctor group.
Table 1 shows baseline characteristics together with 
previous antiretroviral exposure and initial regimens. 
The study cohort had a median age of 32 years and had 
advanced HIV disease, as manifested by 282 (35%) of 
812 patients having a previous CDC AIDS-defi ning event, 
viral loads greater than 100 000 copies per mL, and low 
median CD4 cell count (table 1). Patients in the nurse 
group were slightly more likely to be women and have 
CDC stage A disease than were those in the doctor group, 
but diff erences were small and not signifi cant (table 1). 
Despite the slight preponderance of women in the nurse 
group, previous exposure to antiretroviral prophylaxis as 
part of mother-to-child prophylaxis was evenly distributed 
between study groups (table 1).
Most patients started with non-nucleoside-based 
therapy together with a nucleoside backbone of stavudine 
and lamivudine (table 1), in accordance with the prevailing 
South African national treatment guidelines.
The primary endpoint of cumulative treatment failure 
was reached by 371 (46%) patients after 1647 patient-
years of follow-up (192 [48%] in the nurse group and 
179 [44%] in the doctor group). With proportional 
hazards regression we recorded a 9% increased risk of 
failure in the nurse group (HR 1·09, 95% CI 0·89–1·33). 
The HR and 95% CI lie below the predefi ned study 
criterion for inferiority of 1·40. The time to composite 
failure estimated by Kaplan-Meier analysis was similar 
for each group (fi gure 2).
Figure 3 shows the HRs for individual treatment failure 
parameters of the composite endpoint. Deaths 
contributed 6% of the total events, viral failure 22%, 
toxicity failure 36%, and failure from protocol-defi ned 
loss to follow-up failure 36% (fi gure 3). The subcategories 
of the composite endpoint HRs were all closely distributed 
to 1·00 (95% CI 0·92–1·15). We recorded no signifi cant 
diff erences between study groups for Kaplan-Meier 
estimates of time to death, viral failure, toxicity failure, 
and loss to follow-up (fi gure 2).
21 deaths, ten in the nurse group and 11 in the doctor 
group, were included in the analysis. One further death in 
the doctor group was not included in the analysis because 
the participant had met a protocol-defi ned endpoint of 
toxicity failure before the death occurred. All deaths were 
reviewed by a masked endpoint review committee to 
assign the cause of death as study related, treatment 
related, disease related, or non-study related. Two deaths 
in the doctor group were assessed as due to lactic acidosis, 
and two deaths in the nurse group were considered to be 
non-study and non-HIV related. None of the participants 
met the protocol-defi ned criteria for disease progression.
Immune response was not a component of the primary 
endpoint; however, median increases in CD4 cell count 
from baseline were 155 cells (IQR 119–193) in the nurse 
group and 158 cells (125–169) in the doctor group at 
1 year, and 239 cells (217–290) and 220 cells (174–274), 
respectively, at 2 years. Cumulative treatment failure was 
not aff ected signifi cantly by either baseline CD4 cell 
count less than 200 cells per µL nor viral load more than 
100 000 copies per mL (data not shown).
Table 2 shows grades 3 and 4 toxic eff ects that occurred 
during the study. The most frequent laboratory 
abnormalities were anaemia and neutropenia, raised 
lactate, and abnormal hepatic enzymes. The high 
frequency of hyperlactataemia resulted in a data safety 
monitoring board recommendation in 2007, for 
additional training and management of raised lactate. 
Cumulative failure
All virological failure
   Early virological failure*
   Late virological failure†
Toxicity failure
All loss‡
   Withdrew consent
   Default clinic schedule






























































Figure 3: Cumulative treatment failure (primary endpoint) and accompanying reasons by study group
The two groups of the study were compared with a composite endpoint or cumulative treatment failure. The 
composite consisted of each of the reasons listed below. *Early virological failure was defi ned as a decline of less 
than 1·5 log10 in viral load from baseline to 12 weeks of treatment. †Late virological failure was defi ned as two 
consecutive viral loads 4 weeks apart of more than 1000 copies per mL. ‡All loss was defi ned as: (1) withdrawal of 
consent, when the patient withdrew from participating in the study (in most cases a transfer away from the site to 
another location and clinic); (2) defaulting clinic schedule (a protocol-defi ned measure of adherence to the clinic 
schedule), for which any participant who missed three consecutive visits was considered to be defaulting; and 
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Grades 3 and 4 and dose-limiting toxic eff ects were 
more commonly reported in the doctor group than in 
the nurse group (incidence rate 1·31, 95% CI 1·14–1·49). 
However, a retrospective review by the CIPRA clinical 
safety team of all laboratory investigations undertaken 
throughout the study was consistent with the equal 
distribution of laboratory-defi ned adverse events 
between groups (data not shown). For clinical HIV-
related (incidence rate ratio 0·32, 95% CI 0·16–0·65) 
and non-HIV-related neurological events (0·39, 
0·14–1·10) doctors were more likely than were nurses 
to make a grade 3 or 4 neurological diagnosis.
Discussion
This study reports the fi ndings of a prospective, 
randomised, controlled study comparing nurse-
managed versus doctor-managed ART. A composite 
endpoint indicative of multiple aspects of ART delivery 
showed that nurse monitored therapy was not inferior 
to doctor monitored therapy. These fi ndings lend 
support to observational data from other treatment 
programmes reporting successful use of task shifting 
in HIV care in both resource-limited (South Africa, 
Rwanda, and Lesotho)28–31 and resource-rich (UK) 
countries,32,33 and for other disease management.34
Expansion of ART services is urgently needed in 
resource-poor countries to achieve universal access 
targets by 2010,35 and further expansion will be needed 
with the start of universal testing and treating strategies.36 
We noted no diff erence in mortality, viral failure, or 
immune recovery between the study groups. This study 
therefore lends supports to the strategy of task shifting, 
and suggests that HIV management by nurses can be 
safe and eff ective, probably even for those starting therapy 
with advanced HIV infection, although further studies 
with longer follow-up might be needed in this subgroup.
Although both study strategies successfully managed 
drug-related toxic eff ects, fi ndings from this study do 
draw attention to a high frequency of lipomorphological 
changes and lactate increases associated with use of 
regimens including stavudine. WHO and South African 
guidelines have moved away from reliance on 
stavudine;37,38 however, this drug remains widely used in 
resource-poor HIV therapy programmes.12 In our study 
the overall frequency of drug-related toxic eff ects seemed 
to be lower than earlier reports of stavudine-based 
toxicities, which resulted in drug substitutions in excess 
of 20% after 3 years.39 The dose reduction of stavudine to 
30 mg after the fi rst year of the study, which was in line 
with WHO recommendations,27 might have reduced 
drug-limiting toxic eff ects. However, two of the study 
deaths were attributable to hyperlactataemia—a 
recognised complication of stavudine use.
Randomised controlled studies are frequently regarded 
as the gold standard on which treatment policies should 
be based. However, there might be some caveats in 
Nurse group Doctor group IRR (95% CI)
Event in 815·74 
person-years
Rate per 100 person-
years (95% CI)
Event in 830·88 
person-years
Rate per 100 person-
years (95% CI)
Laboratory events
Haematology 62 7·6 (5·9–9·6) 106 12·7 (10·6–15·2) 0·60 (0·44–0·82)
Biochemistry 1 0·1 (0·0–0·6) 2 0·2 (0·0–0·8) 0·51 (0·05–5·62)
Liver 44 5·4 (4·0–7·1) 72 8·7 (6·9–10·7) 0·62 (0·43–0·91)
Hyperlactataemia 80 9·8 (7·9–12·0) 87 10·5 (8·5–12·7) 0·94 (0·69–1·27)
Pancreatic 4 0·5 (0·2–1·2) 4 0·5 (0·1–1·2) 1·02 (0·25–4·07)
Renal 3 0·4 (0·0–0·1) 1 0·1 (0·0–0·6) 3·06 (0·32–29·4)
Drug-related rash 4 0·5 (0·2–1·2) 5 0·6 (0·2–1·3) 0·81 (0·22–3·03)
Clinical HIV events
Tuberculosis 28 3·4 (2·3–4·9) 31 3·7 (2·6–5·2) 0·92 (0·55–1·53)
Cervical dysplasia 1 0·1 (0·0–0·6) 4 0·5 (0·1–1·2) 0·25 (0·03–2·28)
Neurological 10 1·2 (0·6–2·2) 32 3·9 (2·7–5·3) 0·32 (0·16–0·65)
Intestinal 8 1·0 (0·5–1·9) 7 0·8 (0·4–1·7) 1·16 (0·42–3·21)
Skin 1 0·1 (0·0–0·6) 2 0·2 (0·0–0·8) 0·51 (0·05–5·62)
Lipodystrophy, lipoatrophy 45 5·5 (4·1–7·2) 51 6·1 (4·7–7·9) 0·90 (0·60–1·34)
Miscellaneous 23 2·8 (1·9–4·1) 23 2·8 (1·8–4·1) 1·02 (0·57–1·82)
Clinical non-HIV events 
CNS 5 0·6 (0·2–1·4) 13 1·6 (0·9–2·6) 0·39 (0·14–1·10)
Obstetric/gynaecology 10 1·2 (0·6–2·2) 7 0·8 (0·4–1·7) 1·46 (0·55–3·82)
Miscellaneous 34 4·2 (2·9–5·7) 37 4·5 (3·2–6·0) 0·94 (0·59–1·49)
The nurse group had 815·74 total person-years and the doctor group 830·88 person-years. Active reporting of adverse events was undertaken by the primary-care-giving 
nurse or doctor, and the study team undertook a retrospective review of all laboratory adverse events of grade 3 or greater. IRR=incidence rate ratio. 
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application of trial fi ndings to non-study settings and 
other populations. The study did not necessarily replicate 
the typical conditions under which therapy is delivered in 
resource-poor settings. For example, in addition to 
structured training in the use of ART, all clinical staff  in 
the study received protocol-specifi c training in the 
conduct of ethical research including Good Clinical 
Practice, received didactic clinical management, and had 
access to ongoing telephonic clinical support if needed. 
However, widespread task shifting will need increased 
training, a redefi nition of scope of practice for nurses, 
and a clinical support structure. The study results also 
cannot be generalised to settings where multiple fi rst-
line ART options might be used to individualise patient 
treatment, which in turn might reduce dose-limiting 
treatment toxic eff ects.
A strength of our study was that it was undertaken in 
busy primary-care clinics located in South African 
communities with a high burden of HIV, where large-
scale task shifting will be needed. The cadre of nurses 
used in our study, primary-care nurses, are the staff 
whose role as clinician is being increasingly used in HIV 
and other specialties, such as tuberculosis in the South 
African health-care system. To restrict so-called 
contamination between the groups of the study, scheduled 
visits were booked for diff erent days of the week once 
participants were randomly assigned. A weakness of the 
study is the limited time during which participants were 
on-study. The divergence of the groups might have 
continued over time, and the chance of noting divergence 
might have been limited by only 2 years of follow-up.
The study showed a high overall composite endpoint 
rate in both nurse and doctor groups. A stringent 
defi nition of treatment strategy failure included the 
traditional virological failure (10–11%), dose-limiting 
toxic eff ects (16–17% with stavudine regimens), death 
(3%), and all clinic losses (15–17%) that tra slate to failure 
of the treatment strategy to maintain patients on ART. 
These rates are similar to other studies despite our use of 
a more stringent defi nition of study loss, and use of a 
stavudine-based ART regimen with stringent criteria for 
hyperlactataemia and clinical toxic eff ects.40 We noted a 
high rate of loss to follow-up in this study, but again this 
rate was similar to other studies in resource-constrained 
settings.40 The future of large-scale antiretroviral 
programmes make it important to understand how this 
loss evolves over time. We noted some small diff erences 
in diagnosis of some grade 3 or 4 laboratory adverse 
events and some clinical diagnoses, which could have 
aff ected wider roll-out of nurse-based ART care. These 
diff erences could be addressed by more focused training 
on monitoring of laboratory data, and by implementation 
of simple algorithms of when further neurological work-
up by a doctor is necessary.
The study design did not address nurse-initiated ART 
because the prescription of licensed drugs in South 
Africa is restricted to doctors. Implementation of nurse-
initiated therapy would therefore need additional changes 
to the existing legislation. However, the new national 
HIV strategic plan does envisage initiation of therapy by 
doctors together with wide-scale task shifting to nurses 
for ongoing patient management.20
In conclusion, primary health-care nurses were non-
inferior to doctors in monitoring of fi rst-line ART in a 
public health ART programme in South Africa. The 
results of this study lend support to the expanded access 
to treatment with use of models of task shifting in 
primary health care.
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Abstract
Objective—To investigate antiretroviral treatment (ART) interruption in a long-term treatment
cohort in South Africa.
Methods—All adults accessing ART between 2004 and 2009 were included in this analysis.
Defaulting was defined as having stopped all ART drugs for more than 30 days. Treatment
interrupters were patients who defaulted and returned to care during the study, whereas loss to
follow-up was defined as defaulting and not returning to care. Kaplan-Meier estimates and Possion
regression models were used to analyze rates and determinants of defaulting therapy and of
treatment resumption.
Results—Overall rate of defaulting treatment was 12.8/100 person years (95% CI 11.4-14.4).
Risk factors for defaulting were male gender, high baseline CD4 count, recency of ART initiation
and time on ART. The probability of resuming therapy within 3 years of defaulting therapy was
Correspondence Katharina Kranzer Desmond Tutu HIV Centre Institute of Infectious Disease and Molecular Medicine Faculty of
Health Sciences University of Cape Town Anzio Road, Observatory 7925Cape Town, South Africa Tel +27 828781226 Fax +27
216506963 katharina.kranzer@lshtm.ac.uk.
Role of the authors
KK designed the study, collected the data, and wrote the paper with input from NF, JL, JZ, CO, SDL and RW. KK designed and did
the statistical analyses with input from JL and NF. JZ and CO oversaw the field site and RW was responsible for research
infrastructure. All authors contributed to and approved the final version of the paper.
Conflict of Interest Statement
No conflicts of interest to declare.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing
this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it
is published in its final citable form. Please note that during the production process errors may be discovered which could affect the
content, and all legal disclaimers that apply to the journal pertain.
UKPMC Funders Group
Author Manuscript
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2011 May 1.
Published in final edited form as:




























42% (event rate=21.4/100 person-years). Factors associated with restarting treatment were female
gender, older age, and time since defaulting.
Conclusion—Defaulting treatment need not be an irreversible event. Interventions to increase
retention in care should target men, less immunocompromised patients and patients during the first
6 months of treatment. Resumption of treatment is most likely within the first year of interrupting
therapy.
Keywords
HIV; antiretroviral; unstructured treatment interruption; loss to follow-up; Africa
Introduction
Access to antiretroviral therapy (ART) has improved substantially in resource-limited
settings in Africa, Asia and South America where 90% of people with HIV/AIDS reside.
According to World Health Organization (WHO) estimates, more than four million people
with HIV/AIDS in low and middle income countries had initiated treatment by the end of
2008.1 Despite this success, ensuring that patients remain in care over time remains one of
the major challenges in resource-limited settings. Much attention has been paid to patient
adherence2-5, loss to follow-up, and mortality in ART programs in resource-limited settings.
6-9 A systematic review of 33 patient cohorts from 13 African countries reported that only
between 46 and 85% of patients remained in care at two years.8
The realization that a substantial proportion of patients reported as lost to follow-up may
have died has led to concern that there may be significant biases in program outcome reports
of survival.10 Another potential source of bias is the fact that a proportion of patients may
only transiently default, returning to care at a later stage. Such unstructured treatment
interruption has been reported to occur in around 20% of patients in industrialized settings.
11-14 The proportion of patients who transiently interrupt treatment in resource-limited
settings is largely unreported.
Treatment interruptions, planned or otherwise, have been found to increase the risk of
opportunistic infection and death15-17, with viral load increase and associated CD4 decline
most pronounced in the first two months.16, 18-20 Interruptions raise similar concerns with
respect to drug resistance and increased mortality as sub-optimal adherence.11, 15, 21-23
However, few studies have addressed the issue of unstructured treatment interruptions in
resource-limited settings. The aim of this study was to investigate the frequency and risk
factors of defaulting treatment and identify factors associated with subsequent return to care
in a long-term treatment cohort in South Africa.
Methods
Study site and data collection
The study was based in a peri-urban township in the greater area of Cape Town, with a
population of approximately 15,000 people and an estimated adult HIV prevalence of 23%
in 2005.24 The community is served by a single public-sector primary care clinic which
provides ART free of charge.
ART provision began in 2004. From 2005 to 2009 ART services were partly provided
according to the Antiretroviral Treatment Protocol of the Western Cape and partly through a
study funded by the National Institutes of Health (NIH). Patients enrolled in the NIH-funded
study could access ART with a CD4 count below 350 cells/ l or WHO stage 3 disease as
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compared to 200 cells/ l or WHO stage 4 disease in the provincial program. The NIH-
funded study completed enrollment in 2007 after which all patients were treated in the
provincial ART program.
Initial evaluation for ART eligibility included medical history, physical examination and
CD4 cell count. A follow-up appointment was scheduled one to two weeks later when the
laboratory results were reviewed and ART eligibility was determined. Patients eligible for
ART underwent three adherence counseling sessions before starting treatment.
The initial follow-up schedule for those starting ART included one visit two weeks after
ART initiation, followed by monthly visits until month three. Patients who were stable on
ART and did not experience any adherence problems were thereafter seen every three
months. Three attempts were made to contact patients who had missed appointments.
All patients aged ᚣ15 years accessing ART in the primary health care clinic between 01
March 2004 and 31 December 2009 were included in the analysis.
Sociodemographic and clinical data at baseline and laboratory data were collected
prospectively using a standardized data form. All laboratory tests were performed by the
National Health Laboratory Services in Cape Town.
Definitions
Patients defaulting treatment were defined as those who had not presented at the pharmacy
for ART refills for more than 30 days. This category included patients who subsequently
returned to care and restarted ART (treatment interrupters) and patients who had not
returned to care at the time of censoring (loss to follow-up) (figure 1).
Treatment interruption was defined as a patient-initiated episode of more than 30 days of
stopping ART (same definition as defaulting) but who subsequently resumed treatment
(figure 1).
Patients lost to follow-up were those who stopped ART for more than 30 days and had not
returned to care at the time of censoring (figure 1).
Study design
In-programme data on death, transfers outs and loss to follow-up were collected
prospectively. Death on ART was defined as any death within three months of drug refill. If
the exact date of death was not recorded it was estimated to be the 15th of the month
following the last clinic appointment.
Patients who had stopped ART for more than 30 days and resumed therapy were identified
using the pharmacy dispensing data. The electronic pharmacy dispensing system records
each time medication is dispensed to a patient. Treatment interruption was verified through
folder reviews.
The first endpoint was the time from ART initiation to the first time at which all drugs were
stopped for a period of at least 30 days (default). Follow-up of patients on continuous
therapy was censored at the date of death, date of transfer, or study end (31 December
2009).
The second endpoint was treatment resumption, defined as the time from defaulting
treatment for the first time to the time of restarting ART. Follow-up of patients for whom
therapy was not resumed was censored at the date of death, date of transfer, date of
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migration, or study end. For a proportion of these patients (48%) vital status, date of death,
date of transfer and date of migration was determined by home visits.
Statistical analysis
All analyses were carried out using Stata version 10.0 (Stata Corp. LP, College Station, TX,
United States of America). Frequency tables were produced for all categorical baseline
characteristics. For continuous baseline characteristics the median and interquartile ranges
were reported. Standard survival analysis methods, including Kaplan-Meier estimates and
Poisson regression models were used to analyze the rate and determinants of defaulting
therapy and of treatment resumption after defaulting treatment for the first time. The
proportional hazards assumption for potential interaction between each variable and time
was tested using the likelihood ratio test. A univariate Poisson regression model was used to
determine risk for time-to-event outcomes for each exposure variable. Multivariate models
were built through backwards elimination. Sensitivity analyses were conducted excluding
individuals with unascertained vital status. All reported p values are exact and 2-tailed, and
for each analysis p<0.05 was considered significant.
Ethical approval
The study was approved by the University of Cape Town Ethics Committee and the London
School of Hygiene and Tropical Medicine Ethics Committee. Written informed consent was
obtained from all patients at enrolment.
Results
Patient characteristics
A total of 1154 patients were included in the an lysis (table 1) and the median time of
follow-up was 1.45 years (IQR: 0.48-3.24). The majority of patients were young women
(65.2%) and residents in the township (95.5%). Prior to treatment initiation the majority of
patients were in WHO clinical stage 3 (51.1%) and 4 (25.1%) and median CD4 count was
122 cells/ l (IQR: 54-190). The number of patients initiating ART per year doubled from
137 in 2004 to 279 in 2006 and declined thereafter.
A total of 291 patients defaulted treatment at least once (figure 1). Among these, 96 resumed
therapy (treatment interruption) while 195 did not resume therapy during follow-up (lost to
follow-up). Of the 96 individuals resuming therapy, 75 individuals had one episode of
treatment interruption, 19 had two and 2 had three. The median time patients failed to
receive ART was 228 days (IQR: 126-409) during the first episode of treatment default and
194 days (IQR 121-278) during the second episode. Thirty five patients who had stopped
treatment underwent re-screening that included clinical assessment, laboratory tests and
adherence counseling and yet did not resume therapy during the period of the study.
Subsequent analyses investigated first episode of treatment interruption by analyzing the
time to stopping treatment for the first time and resuming therapy thereafter (non-shaded
cells in figure 1).
Factors associated with the probability of defaulting treatment
The overall rate of treatment default for the first time was 12.8/100 person years (PYs) (95%
CI 11.4-14.4). The Kaplan-Meier estimate of the probability of defaulting treatment for at
least 30 days was 14.9% (95% CI 12.7-17.4) by 1 year, 25.6% (95% CI 22.7-28.8) by 2
years and 41.0% (95% CI 37.0-45.3) by 5 years from ART initiation (figure 2).
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Factors associated with increased risk of defaulting therapy in univariate analysis were male
gender, higher baseline CD4 count, recency of ART initiation and shorter duration on ART
(table 2). Defaulting rate was highest in the first six months of ART (18.2/100 PYs, 95% CI
14.7-22.5) but decreased thereafter and had more than halved after two years (8.8/100 PYs,
95% CI 7.0-11.0).
Gender, baseline CD4 count, time on ART, and date of initiation remained significantly
associated with defaulting in the multivariate model. Men were 1.51 (95% CI 1.18-1.93)
times more likely to default treatment compared to women, as were those patients with a
higher baseline CD4 count. The adjusted hazard of defaulting treatment increased by 1.30
(95% CI 1.17-1.44) for each calendar year. Patients on treatment for more than 2 years had a
lower hazard of 0.69 (95% CI 0.48-0.98) of defaulting compared to patients during the first
6 months of treatment. Similar results were found in a sensitivity analysis that excluded
individuals whose vital status could not be ascertained.
Factors associated with the probability of resuming therapy
A total of 291 patients defaulted treatment at least once. The overall rate of treatment
resumption after defaulting treatment for the first time was 21.4/100 PYs (95% CI
17.5-26.2) (figure 3). The Kaplan-Meier cumulative estimate of the probability of treatment
resumption was 26.7% (95% CI 21.7-32.7) in the first year, 37.1% (95% CI 31.1-43.9) in
the second year and 42.1% (95% CI 35.2-49.7%) in the third year after stopping treatment.
In univariate analysis a greater likelihood of resuming ART was associated with older age
and shorter time since defaulting (table 3); gender, residency, calendar year of defaulting
and CD4 count nearest to the time of defaulting was not associated with resuming treatment.
In multivariate analysis men were less likely to resume treatment compared to women (IRR
0.67, 95% CI 0.43-1.04, p=0.07); whereas patients >30 years old were more likely to restart
treatment (IRR 1.80, 95% CI 1.13-2.89). The likelihood of resuming treatment decreased
significantly beyond one year of defaulting treatment (IRR 0.40, 95% CI 0.25-0.63).
Of the 96 patients resuming therapy, 86 had a CD4 count measurement while receiving
therapy and before the treatment interruption; the majority of these (80) responded to ART
with an increase in CD4. Patients who resumed therapy were found to have a median CD4
count (150.5 cells/ l, IQR: 73-266) comparable to their baseline CD4 count prior to
initiating therapy (138.5 cells/ l, IQR: 73-188). The median time between the measurement
of CD4 count and resuming therapy was 13 days (IQR 0-28 days).
Excluding individuals with unascertained vital status revealed similar results with regards to
parameter estimates, but the association with male gender became non-significant (HR 0.81,
95% CI 0.52-1.26, p=0.35).
Discussion
To our knowledge, this is the first study from sub-Saharan Africa to report on unstructured
treatment interruptions in a routine programme setting. Our analysis shows that treatment
interruption is a common phenomenon. The probability of ART defaulters to resume therapy
within 3 years was 42%. Most ART cohorts report on loss to follow-up defined as not
attending the clinic for more than 3 months,8 and assume that loss to follow-up is an
irreversible event. Our study shows that patients who fulfil the widely used definition of loss
to follow-up at one time point might resume therapy later. In this cohort, the median
duration of the first treatment interruption was 7.5 months.
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The median CD4 count of those resuming therapy was similar to their initial CD4 count
prior to starting treatment, which underscores the potentially negative impact of interruption
leading to a reversal in immunological recovery made while on treatment. Data from
industrialised settings suggest that treatment interruption has detrimental effects on CD4
count, viral load suppression, and clinical progression.11, 12, 19 Programmes that report
patient attrition and the number of patients in care will not account for the potential that up
to 14% of patients in care have interrupted treatment at least once.
We were able to determine risk factors for defaulting ART and factors associated with
resuming therapy. Male gender, high baseline CD4 count, recency of ART initiation and the
first 6 months of treatment were associated with a higher risk of defaulting. Treatment
resumption was more likely in women, patients more than 30 years old and within the first
year of stopping therapy.
Our finding that men were at higher risk of defaulting treatment and less likely to resume
treatment is consistent with studies showing that HIV-infected men are less likely to access
treatment25, 26, have an increased risk for loss to follow-up in the pre-treatment period27,
present with more advanced stages of HIV disease28 and have a higher mortality risk on
ART.2, 9, 29-33 Strategies to diagnose HIV in men earlier and to link and to retain them in
care might include: i) extending clinic hours into evenings and weekends, ii) training male
health care staff and counsellors, iii) offering additional adherence sessions to men and iv)
initiating male support groups.
Individuals initiating treatment in more recent years were more likely to default, suggesting
that programmatic factors might influence retention in care. A study including data from 15
treatment cohorts from Africa, Asia and South America showed that early patient losses
were increasingly common when programs were scaled up.6 Increasing cohort size in an
environment of scarce human resources for health has been suggested to influence both the
scale-up capacity and the long-term retention in ART programs.34 In the study clinic
resources and staffing were further reduced when enrolment for the NIH-funded study
finished in 2007. In contrast, year of defaulting was not associated with resumption of
treatment, suggesting that patient tracing was less influenced by cohort size (although this
would vary according to tracing procedures).
Treatment defaulting wa  more likely in patients with less advanced immunodeficiency at
baseline. This may be explained by the fact that individuals who default treatment and stay
alive do so because they feel better on treatment, a phenomenon that has been reported by
other studies.35 This finding is particularly important in view of the 2009 WHO guidelines
recommending ART initiation at CD4 counts below 350 cells/ l36 and when considering
initiation of ART regardless of CD4 count as proposed in the ‘test and treat’ strategy.37
Initiating ART at the time of HIV diagnosis will result in increased numbers of relatively
immunocompetent individuals on ART who may have a higher risk of defaulting treatment.
Specific interventions aimed at these individuals need to be developed to ensure optimal
retention in care.
This study has several limitations. First, ascertainment of vital status for treatment defaulters
was incomplete, which may have led to a misclassification of deaths as defaulters. However,
sensitivity analysis excluding individuals with unascertained vital status did not influence
our overall findings. Second, resumption of therapy was not ascertained in patients who
moved to other communities, possibly resulting in underestimation of treatment resumption.
Third, the clinical and immunological consequences of treatment interruption were not
analysed due to lack of laboratory data, in particular the lack of capacity to perform routine
viral load, and the small number of individuals resuming therapy. However it has been
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shown in industrialised settings that treatment interruption impacts negatively on CD4
count, viral load suppression and clinical progression.11, 12, 19
We consider that the main finding of this study that a considerable proportion of treatment
defaulters return to care is likely to be generalisable to similar settings. Nevertheless, risk
factors for defaulting and resuming therapy might differ with regards to eligibility criteria
and resources available for patient tracing.
A strength of this study is that the relatively large sample size and follow up time. This
allows for an assessment of risk factors for defaulting and treatment interruption that in turn
allows for several proposals to be made to limit defaulting and treatment interruption in
similar programme settings. In particular, interventions to keep patients in care should be
targeted at men, patients with higher CD4 counts and during the first 6 months of ART.
Moreover, the finding that the probability of resuming therapy was highest in the first year
following treatment defaulting suggests that efforts to bring patients back into care might be
most successful early into defaulting treatment.
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Figure 1. Flow chart of patients in care, first time defaulters and treatment interrupters
1 Defaulting treatment was defined as having stopped all ART drugs for more than 30 days.
This category included patients who subsequently returned to care and restarted ART
(treatment interrupters) and patients who had not returned to care at the time of censoring
(loss to follow-up).
2 Loss to follow-up was defined as stopping ART for more than 30 days and not returning to
care at the time of censoring.
3 Treatment interruption was defined as a patient-initiated episode of more than 30 days of
stopping ART and subsequently resuming treatment.
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Kaplan Meier plot showing the probability of not defaulting antiretroviral therapy (ART)
from the time of initiating ART up to the end of the 5th year of treatment
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Kaplan Meier plot showing the probability of resuming antiretroviral therapy (ART) from
the time of defaulting therapy up to 3 years after defaulting treatment
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Table 1
Baseline characteristics of patients (n=1154) who enrolled in the ART programme between 2004 and 2009




Age (years) 31.9 (27.3; 37.5)
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Abstract
Background: Antiretroviral therapy (ART) has been scaled-up rapidly in Africa. Programme reports typically focus on loss to
follow-up and mortality among patients receiving ART. However, little is known about linkage and retention in care of
individuals prior to starting ART.
Methodology: Data on adult residents from a periurban community in Cape Town were collected at a primary care clinic
and hospital. HIV testing registers, CD4 count results provided by the National Health Laboratory System and ART registers
were linked. A random sample (n = 885) was drawn from adults testing HIV positive through antenatal care, sexual
transmitted disease and voluntary testing and counseling services between January 2004 and March 2009. All adults
(n = 103) testing HIV positive through TB services during the same time period were also included in the study. Linkage to
HIV care was defined as attending for a CD4 count measurement within 6 months of HIV diagnosis. Linkage to ART care was
defined as initiating ART within 6 months of HIV diagnosis in individuals with a CD4 c unt #200 cells/ml taken within 6
months of HIV diagnosis.
Findings: Only 62.6% of individuals attended for a CD4 count measurement within 6 months of testing HIV positive.
Individuals testing through sexually transmitted infection services had the best (84.1%) and individuals testing on their own
initiative (53.5%) the worst linkage to HIV care. One third of individuals with timely CD4 counts were eligible for ART and
66.7% of those were successfully linked to ART care. Linkage to ART care was highest among antenatal care clients. Among
individuals not yet eligible for ART only 46.3% had a repeat CD4 count. Linkage to HIV care improved in patients tested in
more recent calendar period.
Conclusion: Linkage to HIV and ART care was low in this poor peri-urban community despite free services available within
close proximity. More efforts are needed to link VCT scale-up to subsequent care.
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Introduction
South Africa is home to one-sixth of the world’s population
living with HIV and has the largest antiretroviral therapy (ART)
programme in the world [1,2]. ART roll out began nationally in
late 2003 and by the middle of 2008, 568,000 adults and children
were receiving ART. This translated into around 40% of eligible
adults receiving ART in 2008 [3], although the latest guidelines
recommend earlier initiation for certain patients, thus increasing
the numbers eligible for ART and widening the treatment gap [4].
In an effort to increase access to prevention and care, South
Africa launched an ambitious national campaign in April 2010
aiming to test 15 million people for HIV and to reach 1.5 million
people with ART by June 2011. Increased HIV testing may
impact on risk behavior in the short-term [5]. However, there is
also a need to ensure that those who need treatment are linked to
the appropriate services while those not eligible for treatment are
monitored and started on ART when appropriate. A study from
Durban, South Africa, reported that almost two-thirds of newly
diagnosed patients accessing care in a semi-private hospital were
lost to care between HIV diagnosis and getting a CD4 count, and
another one in five patients were lost between CD4 testing and
ART initiation [6,7]. Another study from South Africa found that
only 45% of eligible patients started ART in a public sector ART
project in Free State. Mortality and TB incidence in patients
failing to initiate ART was more than 2 times higher compared to
patients initiating ART [8].
The impact of ART on mortality, morbidity, TB incidence
[9,10] and HIV transmission [11] at a population level depends on
ART coverage. ART coverage defined as the number of patients










receiving ART at a point in time, divided by the number needing
treatment is determined by timely HIV diagnosis and effective
linkage to ART. This study investigates linkage to HIV and ART
care using a random sample of individuals testing HIV positive
either provided-initiated (through antenatal care (ANC), tubercu-
losis (TB), sexually transmitted infection (STI) services) or client-
initiated (through voluntary counseling and testing (VCT) services)
in a peri-urban township in the Western Cape Province in South
Africa. Linkage to care was defined first as attending for a CD4
count measurement within 6 months of a positive HIV test and
second as the proportion of eligible individuals starting ART
within 6 months of their HIV diagnosis.
Methods
Setting
The study was based in a peri-urban township in the greater
area of Cape Town, with a population of approximately 15,000
people and a measured adult HIV prevalence of 23% in 2005
[12]. The community is served by a single public-sector primary
care clinic, which provides outpatient care including ART free of
charge. A nearby hospital (5 km away) provides all secondary care
for the population, including inpatient and antenatal services. The
hospital also provides ART for some HIV-infected individuals
from the community.
HIV testing, CD4 count measurements and ART services
Client-initiated HIV testing services have been available to all
individuals accessing either the local clinic or the hospital since
2001. Clients who tested on their own initiative are referred to as
having tested through VCT services. Provider-initiated testing was
routinely provided to any patient accessing TB services whose HIV
status was unknown. This was extended to all pregnant females
accessing the hospital or clinic in 2002 and patients accessing STI
services in 2007. All testing required signed consent. All CD4 count
tests were free for patients and performed by the centrally located
National Health Laboratory Services (NHLS) in Cape Town.
ART provision at the primary health care clinic and hospital
began in 2004.
Linkage to HIV and ART care
Linkage to HIV care was defined as attending for a CD4 count
measurement within 6 months of HIV diagnosis. We did not
ascertain if individuals actually received their CD4 counts.
Linkage to ART care was defined as initiating ART within 6
months of HIV diagnosis in individuals with a CD4 count #200
cells/ml taken within 6 months of HIV diagnosis. Having a repeat
CD4 count was defined as having had a repeated CD4 count in
individuals not yet eligible for ART (CD4 count .200 cells/ml)
and tested before 2009.
Data collection
We collected data from 3 sources. First, the primary care clinic
and hospital HIV testing registers provided all data on HIV infected,
adult community residents ($18 years) diagnosed between January
2004 and March 2009. Data at the primary health care clinic were
missing for the period from February 2008 to August 2008. For each
test encounter recorded in the registers, we retrieved data on client
identification variables (first name, surname, date of birth, and
medical record number); place of residence; sex; test acceptance; test
result and service. For HIV infected individuals who tested more
than once, the earliest positive HIV test was considered. Second,
data on CD4 counts performed at either the primary care clinic or
the hospital in the period from 2004 to October 2009 were obtained
from NHLS. The date of CD4 count was the date the client provided
blood. Third, data from residents who initiated ART care at the
primary health care clinic or hospital were obtained from electronic
ART registers at the clinic and hospital.
These three databases were merged on first name, surname,
medical record number and date of birth. In cases where
identifiers did not match completely two researchers (PG and
KK) independently confirmed that records in different databases
were from the same individual. Concordance between the two
researchers was 97%. Cases where the two researchers disagreed
were discussed until consensus was reached. For all subsequent
analysis data was stripped of all personal identifiers.
Ethics
Written informed consent was obtained from all individuals
initiated on ART and screened for ART. Individuals testing for
HIV are routinely entered into the HIV testing register. Informed
consent was not obtained from HIV positive individuals not
linking to care, as this was a retrospective study and individuals
were not actively follow-up. Data collection and analysis was
approved by the University of Cape Town Ethics Committee and
Partners Human Subjects Institutional Review Board and the
London School of Hygiene and Tropical Medicine.
Statistical analysis
A random sample (n = 885) of adults testing HIV positive
through ANC, STI and VCT services between January 2004 and
March 2009 was selected for this analysis. All adults testing
positive through TB services were included in this analysis to
ensure an adequate sample size in this group.
All analyses were carried out using Stata version 11 (Stata Corp.
LP, College Station, TX, United States of America). Proportions
were calculated stratified by service. Total proportions were
calculated taking the different sampling proportions into account.
Risk ratios investigating associations between age, sex, calendar
period and timely linkage to HIV care, CD4 count #200 cells/ml
and repeated CD4 counts were estimated for each service. Risk
ratios were calculated using a log binominal model [13].
Results
HIV testing and HIV prevalence
A total of 8515 records of HIV tests were available for adult
members of the community. The majority of individuals tested
through VCT (n = 5345, 62.8%) services (Table 1). The overall
HIV prevalence among those tested was 23.5% with the highest
prevalence among patients tested through TB (37.9%) and VCT
services (24.9%) (x2 test, p,0.01). The median age of individuals
tested was 26 (interquartile range (IQR), 22–32) and 67.9% were
women. HIV prevalence was 21.6% in men and 24.4% in women.
A total of 2002 clients tested HIV positive. Their median age
was 28 years (IQR, 24–33) and the majority were women (70.3%).
The proportion of women testing HIV positive was 100% in ANC,
66.2% in STI, 38.8% in TB and 66.4% in VCT clients. 1330
(66.4%) individuals tested HIV positive through VCT, 332
(16.6%) through ANC, 237 (11.8%) through STI and 103
(5.1%) through TB services.
Linkage to HIV and ART care
Linkage to HIV and ART care was assessed in a random
sample of 47% of individuals testing HIV positive through ANC,
STI and VCT services and 100% of individuals testing through
TB services: 150 tested through ANC, 113 through STI, 662
through VCT and 103 through TB services. Only 62.6% (95%CI
Linkage to HIV and ART Care










59.6–65.5) of clients attended for a CD4 count measurement
within 6 months of testing HIV positive (Table 2) and 26.3%
(95%CI 23.5–29.0) did not have any recorded CD4 count test.
The proportion of individuals attending for a CD4 count
measurement within 6 months was highest among individuals
tested through ANC (81.3%) and STI (84.1%) services and lowest
among those who learnt of their status via VCT (53.5%) (Table 2).
Among individuals with a CD4 count measurement within 6
months, 34.1% (95%CI 30.4–37.7) were eligible for ART according
the South African Department of Health criteria (CD4 count #200
cells/ml) at the time of the study (Table 2). Low CD4 counts were
more prevalent among individuals tested through TB (54.9%) and
VCT services (42.6%). In individuals attending for a CD4 count
measurement within 6 months the median time between HIV test
and CD4 count measurement was: 2 days (IQR 2–6) for ANC, 3
days (IQR 2–4) for STI, 3 days (IQR 2–5) for TB and 2 days (IQR
2–4) for VCT clients. Overall 4.3% of clients attended for a CD4
test at the same day as the HIV test. The majority of clients attended
for CD4 count testing within 1 week (84.9%), 14.2% within 8 days
and 3 months and only 0.9% within 3 and 6 months.
In individuals with a delayed first CD4 count measurements, the
mean time between HIV diagnosis and first CD4 count was 490
days (IQR 345–769). Among patients with delayed first CD4
count measurements, 33.2% (95%CI 24.3–42.1) had a CD4 count
#200 cells/ml and 26.2% (95%CI 17.8–34.8)243.2) had a CD4
count of 201–350 cells/ml.
Only 66.7% (95% CI 60.2–73.1) of eligible individuals with a
timely CD4 count accessed ART care within 6 months of HIV
testing (Table 2). Linkage to ART care was highest among
individuals tested through ANC services (72.2%). Among
individuals not yet eligible for ART only 46.3% (95%CI 41.4–
51.1) ever had a repeat CD4 count. Median time between the first
and the second CD4 count was 236 days.
Figure 1 summarizes the number of people tested through
different services and the numbers linking to HIV and ART care
by service using the proportions estimated from the random
sample.
Table 1. Number (%) of individuals who tested for HIV and










Tested N (%) 1525 (17.9) 1370 (16.1) 275 (3.2) 5345 (62.8) 8515 (100)
Positives N (%) 332 (16.6) 237 (11.8) 103 (5.1) 1330 (66.4) 2002 (100)
HIV Prevalence 21.8% 17.3% 37.5% 24.9% 23.5%
All HIV testing records available for the period from January 2004 until March
2009 from adult patients were included in this analysis.
ANC = antenatal care, STI = sexual transmitted infections, TB = tuberculosis,
VCT = voluntary counseling and testing.
doi:10.1371/journal.pone.0013801.t001
Table 2. Percentage of individuals linking to HIV care (as defined by attending for a CD4 cell count measurement), distribution of
CD4 count measurements, percentage of patients subsequently initiating ART and percentage of clients non-eligible for ART
returning for a repeat CD4 count.
Variables
ANC (n = 150)
% (N)
STI (n = 113)
% (N)
TB (n = 103)
% (N)




First CD4 count after HIV test #6 months 81.3 (122) 84.1 (95) 68.9 (71) 53.5 (333) 62.6 (59.6–65.5)
.6 months 2.0 (3) 2.7 (3) 13.6 (14) 14.8 (92) 11.1 (9.2–13.1)
None 16.7 (25) 13.3 (15) 17.5 (18) 31.7 (197) 26.3 (23.5–29.0)
First CD4 count within 6months of HIV test #200 cells/ml 14.8 (18) 22.1 (21) 54.9 (39) 42.3 (141) 34.1 (30.4–37.7)
201–350 cells/ml 24.6 (30) 32.6 (31) 23.9 (17) 23.7 (79) 25.3 (21.8–28.8)
.351 cells/ml 60.7 (74) 45.3 (43) 21.1 (15) 33.9 (113) 40.6 (36.8–44.4)
ART initiation within 6 months of HIV test in
eligible individuals with timely first CD4 count
Yes 72.2 (13) 52.4 (11) 71.8 (28) 67.4 (95) 66.7 (60.2–73.1)
No 27.8 (5) 47.6 (10) 28.2 (11) 32.6 (46) 33.3 (26.9–39.*)
Repeat CD4 count in individuals with a first CD4
count .200 cells/ml
Yes 48.5 (47) 57.6 (38) 34.5 (10) 42.3 (96) 46.3 (41.4–51.1)
No 51.5 (50) 42.4 (28) 65.5 (19) 57.7 (131) 53.7 (48.9–58.6)
ANC = antenatal care, STI = sexual transmitted infections, TB = tuberculosis, VCT = voluntary counseling and testing.
doi:10.1371/journal.pone.0013801.t002
Figure 1. Number of clients testing HIV+, with timely CD4
counts, eligible for ART and initiating ART estimated using
proportions from table 2. ART = antiretroviral therapy, ANC = ante-
natal care, STI = sexual transmitted infections, TB = tuberculosis,
VCT = voluntary counseling and testing.
doi:10.1371/journal.pone.0013801.g001
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Predictors of low CD4 count, linkage to HIV, and
repeated CD4 counts
Risk ratios investigating predictors for linkage to HIV care
showed that linkage to care in TB (RR 1.67, 95%CI 1.27–2.21)
and VCT (RR 1.60, 95%CI 1.40–1.84) clients was more likely in
2007–2009 compared to 2004–2006 (table 3). This was not the
case for ANC (RR 0.97) clients who were slightly less likely to link
to HIV care if tested more recently (table 3). Linkage to ART care
could only be assessed in VCT clients due to the small sample size
in the other groups. Neither age (RR 0.85, 95%CI 0.67–1.09) nor
sex (RR 1.03, 95% CI 0.81–1.31) nor year of testing (RR 1.02,
95% CI 0.81–1.30) predicted linkage to HIV care in VCT clients.
The risk of having CD4 count measurement #200 cells/ml was
higher in individuals aged more than 30 years regardless which
service they tested through (table 4). Repeated CD4 counts were
1.3 times more likely in individuals more than 30 years of age, but
this result only reached significance in the VCT clients (RR 1.25,
95% CI 1.00–1.55).
Discussion
This study evaluated the proportion of individuals linking to
HIV care in a public sector service in Cape Town, South Africa.
Only 63% of patients attended for a CD4 count measurement
within 6 months of diagnosis. Although a substantial proportion of
patients had CD4 counts #200 cells/ml (34%) and were therefore
eligible for ART according to South African guidelines [14], only
67% of these started ART within 6 months. Among those who did
have a timely CD4 count but were not yet eligible for ART, only
46% returned for a repeat CD4 count after a median time of 8
months. Individuals testing through ANC services had better
linkage to HIV and ART care and higher CD4 counts at time of
HIV diagnosis compared to individuals accessing the other
services.
HIV is a chronic disease and comprehensive HIV care needs to
be provided within a continuum of care [15]. ART is just one of
the components of HIV care and care of individuals not yet
requiring ART is equally important [16]. The continuum of HIV
care starts when an individual is diagnosed with HIV. ART
eligibility should be assessed when individuals are newly diagnosed
and in regular (6 monthly) intervals thereafter. Individuals not yet
eligible for ART should receive comprehensive HIV care
including cotrimoxazole, isoniazid preventive therapy, screening
for TB and cervical cancer, contraceptive advice, counseling and
social support until they become eligible for ART. Following
initiation of ART individuals needs to be supported within the
same framework to ensure good adherence and retention in care.
We identified a number of important issues in our study. First,
people who tested on their own initiative were least likely to have a
timely CD4 count measurement done, underscoring the need to
ensure that scale up of VCT programmes will be accompanied by
clear plans to ensure that those who test positive go on to receive
appropriate care. Second, almost a third (28%) of eligible patients
with TB did not receive ART despite recommendations in favour
of concomitant treatment since 2003 [17], and ART being
associated with a 64–95% reduction in mortality in such patients
[10,18,19,20]. This underscores the importance of integrating
HIV and TB services [21].
Table 3. Factors associated with linkage to HIV care (attending for a CD4 count measurement within 6 months of HIV diagnosis)
stratified by service.
Variables ANC STI TB VCT
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Female NA 1 1 1
Male NA 0.93 (0.79–1.09) 1.01 (0.82–1.25) 1.10 (1.01–1.33)
Age,30 years 1 1 1 1
Age$30 years 0.97 (0.90–1.04) 1.17 (1.01–1.35) 1.07 (0.84–1.35) 1.16 (0.96–1.26)
Tested in 2004–2006 1 NA 1 1
Tested in 2007–2009 0.87 (0.74–0.99) NA 1.67 (1.27–2.21) 1.60 (1.40–1.84)
ANC = antenatal care, STI = sexual transmitted infections, TB = tuberculosis, VCT = voluntary counseling and testing.
NA = not applicaple.
doi:10.1371/journal.pone.0013801.t003
Table 4. Factors associated with having a CD4 count #200 cells/ml within 6 months of HIV diagnosis.
Variables ANC STI Tb VCT
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Female NA 1 1 1
Male NA 0.82 (0.36–1.86) 0.97 (0.62–1.50) 1.27 (0.99–1.63)
Age,30 years 1 1 1 1
Age$30 years 2.42 (1.03–5.68) 2.00 (0.92–4.35) 1.10 (0.68–1.78) 1.40 (1.07–1.82)
Tested in 2004–2006 1 NA 1 1
Tested in 2007–2009 1.32 (0.57–3.08) NA 1.18 (0.75–1.85) 0.94 (0.74–1.19)
ANC = antenatal care, STI = sexual transmitted infections, TB = tuberculosis, VCT = voluntary counseling and testing.
doi:10.1371/journal.pone.0013801.t004
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This study shows that men and younger adults fail to access
health services efficiently. Only 30% of clients tested for HIV were
men. This is consistent with studies showing that HIV-infected
men are less likely to access treatment [22,23], present with more
advanced stages of HIV disease [24] and have a higher mortality
risk during ART [25,26,27,28,29,30,31,32]. Repeated CD4
counts were less likely in individuals under 30 years of age as
also reported elsewhere[33].
It is important to note that less than half of patients whose first
CD4 count was above the ART eligibility threshold came back for
a repeat test. One way of improving ART uptake, and thus reduce
mortality among patients who are otherwise lost to care, might be
to change the CD4 threshold to 350 cell/ml in line with the latest
World Health Organization recommendations [34].
Our overall finding that 33% of patients eligible for ART were
lost to care is consistent with several reports from elsewhere in
southern Africa. In a programme report from South Africa, only
55% of patients had a CD4 count measurement within 8 weeks of
HIV diagnosis and 81% of eligible patients were on ART at 3
months follow-up [6,7]. Out of 2483 patients eligible for ART in
Uganda 637 (26%) did not start ART; a third of these patients
died before ART initiation and another quarter were alive but not
taking ART [25]. In Mozambique only 57% of patients testing
HIV positive entered HIV care and 31% of patients eligible for
ART started ART within 3 months [35].
In our study only 63% of patients testing positive for HIV
attended for a CD4 count measurement within 6 months. These
outcomes are worse than those recently reported by a public-sector
clinic in Johannesburg where 84.6% of patients who tested positive
for HIV had a CD4 count measurement. The majority of these
patients did not return for their CD4 result within 12 weeks [36].
Data from the same clinic in Johannesburg showed that among
patients not yet eligible for ART only 26% returned for a
scheduled pre-ART medical visit within one year compared to
43% of our patients not yet eligible for ART returning for a repeat
CD4 count [37].
Substantial improvement in linkage to HIV care for TB and
VCT patients was observed in more recent years in this study and
yet this was not accompanied by improvements in linkage to ART.
Failure of linkage to HIV and ART services translates into
incomplete ART coverage at population level, seriously under-
mining the potential for reductions in mortality, morbidity, TB
incidence and HIV transmission.
The study has several strengths and limitations. Strengths
include that the study was conducted in a routine clinical program
where CD4 count testing and ART were provided free. Thus, the
results should be generalisable to similar settings. The study was
conducted over a prolonged period with increasing ART
availability. Among the limitations is the fact that patients might
have been misclassified as failing to link to care if they accessed
care with a service provider other than the primary health care
clinic or hospital. Thus, linkage to care might be underestimated.
However the nearest other ART site is more than 10 km away,
and residents of this poor community are unlikely to have sought
care in such a distant ART site unless they had moved away.
Second, we did not assess if patients who had a CD4 count
measurement actually returned to receive the result. Thirdly, we
did not investigate reasons for not linking to care. Studies that have
ascertained outcomes among patients lost to care have reported
that up to a third of patients who failed to initiate ART had died
[7,8,25]. Time cut-offs for linkage to care for both timely CD4
count and ART initiation are somewhat arbitrary. When no time
cut-offs were used 75.3% (95% CI 70.3–80.3) of eligible
individuals who had a CD4 count at some point during the study
period eventually initiated ART.
In conclusion, while considerable attention has been paid to loss
to follow-up and mortality among patients receiving ART
[32,38,39,40], data on losses at earlier stages of the care pathway
are scarce. As our study shows, a focus only on outcomes of those
patients fortunate enough to initiate treatment fails to account for
a substantial number of patients who are eligible for ART but do
not receive it or not yet eligible but fail to reappear. Pre-ART
defaulting should be encouraged in programme reporting.
Programme adaptation to ensure retention in care between testing
and ART should consider point of care CD4 count testing at time
of HIV diagnosis as well as provision of integrated TB and HIV.
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wnBackground: Large-scale programmes increasing
access to highly active antiretroviral therapy (HAART)
are being implemented in sub-Saharan Africa.
However, cost-effectiveness of initiating treatment at
different CD4 count thresholds has not been explored
in resource-poor settings.
Methods: A cost-effectiveness analysis was conducted
from a public health perspective using primary treat-
ment outcomes, healthcare utilisation and cost data (Jan
2004 local prices; US$1=7.6 Rands) derived from the
Cape Town AIDS Cohort. A Markov state-transition
model was developed to estimate life-expectancy, life-
time costs, quality-adjusted life-years (QALYs), cost per
life-year and QALY gained for initiating HAART at three
CD4 cell count thresholds (<200/µl, 200–350/µl and
>350/µl), including the no antiretroviral therapy (No-
ART) alternative. Each treatment option was compared
with the next most effective undominated option.
Results: Mean life-expectancy was 6.2, 18.8, 21.0 and
23.3 years; discounted (8%) QALYs were 3.1, 6.2, 
6.7 and 7.4; and discounted lifetime costs were
US$5,250, US$5,434, US$5,740, US$6,588 for No-
ART, and therapy initiation at <200/µl, 200–350/µl
and >350/µl scenarios respectively. Clinical benefits
increased significantly with early therapy initiation.
Initiating therapy at <200/µl had an incremental 
cost-effectiveness ratio (ICER) of US$54 per QALY
versus No-ART, 200–350/µl had an ICER of US$616
versus therapy initiation at <200/µl, and >350/µl 
had an ICER of US$1,137 versus therapy initiation at
200–350/µl. ICERs were sensitive to HAART cost.
Conclusions: HAART is reasonably cost-effective for
HIV-infected patients in South Africa, and most
effective if initiated when CD4 count >200/µl.
Deferring treatment to <200/µl would reduce the
aggregate cost of treatment, but this should be
balanced against the significant clinical benefits 
associated with early therapy.
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The recognition of toxicities associated with long-
term use of highly active antiretroviral therapy
(HAART) resulted in a pendulum shift in expert
opinion from an initial ‘hit-early hit-hard’ strategy to
a more conservative strategy of deferring treatment to
CD4 count <200 cells/µl [1,2]. However the case for
earlier treatment is being re-examined [3]. Current
guidelines recommend initiating therapy at a variety
of CD4 cell count thresholds: <200/µl, <350/µl or
>350/µl for patients with high plasma HIV RNA
count [4–8]. The CD4 count threshold for therapy
initiation is an important determinant of both clinical
benefit and cost-effectiveness of HAART [1–3, 9–15],
which is of particular relevance to sub-Saharan
Africa, where resources are scarce and the burden of
disease is large.
In sub-Saharan Africa the spectrum of opportunistic
infections differs from that reported in industrialized
countries [16–19]. Mycobacterium avium complex,
cytomegalovirus infection and toxoplasmosis are less
frequently diagnosed. Bacterial diseases are common
and can occur at early stages of immune suppression
[16–19]. Cryptococcal disease is a common cause of
death [16,18], and tuberculosis, the most frequent
opportunistic infection, is associated with accelerated
course of HIV infection [20]. However, the rarity of
Introduction
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these diagnoses could be related to limited diagnostic
resources or that patients die of commoner illnesses
prior to onset of Mycobacterium avium complex or
cytomegalovirus infection. Therefore, the clinical bene-
fits of HAART and consequently the cost-effectiveness
of therapy initiation demonstrated in industrialized
countries may not be generalizable to populations in
sub-Saharan Africa. In this study, we assessed the
impact of initiating therapy at CD4 >350/µl;
200–350/µl or <200/µl on healthcare utilization, life-




This analysis was based on the Cape Town AIDS
Cohort study (CTAC). Methods of recruiting patients
to the cohort are described elsewhere [21]. In brief,
CTAC was one of the largest sub-Saharan African
HIV cohorts, and is composed of patients referred
from a wide range of primary health care facilities in
Cape Town to the adult HIV clinics affiliated to the
University of Cape Town from 1992 to 2005. Patients
of this cohort are likely to represent urban popula-
tions that would seek care in the proposed rollout of
antiretroviral therapy (ART) in South Africa. During
the period of this study, ART was not available in the
public sector, and CTAC patients accessed ART
through international multicentre Phase III clinical
trials [22–26], which were conducted between 1996
and 2005, and were approved by the University of
Cape Town Research Ethics Committee.
The objectives of this study were to estimate
utilization and cost of HIV healthcare, and to assess
the cost-effectiveness of initiating HAART at different
CD4 cell count thresholds and a no antiretroviral
therapy alternative (No-ART). The first objective
provides primary input data for the second, a
modelled cost-effectiveness analysis.
Healthcare utilization and cost
Costing was undertaken from a public health systems
perspective. Healthcare utilization was extracted from
hospital records. The mean number (and 95% CI) of
inpatient days and outpatient visits per patient-year
was calculated for each CD4 count category. Unit
costs were obtained from a costing study of HIV
healthcare conducted locally in 2000 [27]. In this
study, costs relating to usage of medicines, including
treatment and prophylaxis for opportunistic infec-
tions and other non-ART drugs dispensed to the
patients during the course of care, and medical tests
and procedures were assessed by extracting data from
outpatient and inpatient medical records using the
micro-costing methods [28]. Consultancy, doctor,
nursing and capital costs were allocated using step-
down accounting methods [29]. These costs were
adjusted to 2004 prices using the South African
Consumer Price Index, excluding mortgage bonds
[30]. Hospital overheads and hotel costs were recal-
culated from 2003/2004 expenditure data, again
using step-down accounting methods. Estimates were
converted to US dollars (US$1=7.6 Rands) [31]. The
cost per inpatient day and outpatient visit was
US$182 and US$28 respectively, which is similar to
estimates from another analysis conducted in
South Africa [32].
A variety of ART drugs were used in the clinical
trials. HAART was defined as a non-nucleoside reverse
transcriptase inhibitor or protease inhibitor together
with two nucleoside analogues or three nucleoside
analogues. However, we considered costs for two ART
regimens currently recommended in the South African
public sector [33]: first-line regimen of stavudine,
lamivudine and efavirenz or nevirapine, and for those
virologically failing, a second-line regimen of zidovu-
dine, didanosine and lopinavir/ritonavir. The relative
proportion of patients on efavirenz versus nevirapine
was derived from a community pilot project [32]. ART
drugs costs were based on the official public sector
tender prices [Channing L, personal communication,
2004]. Viral load test was measured every 6 months if
viral load were <400 or between 400–5,000 copies/µl,
or every 3 months if >5,000 copies/µl, as per national
guidelines. Viral load costs were obtained from the
National Health Laboratory Service.
Cost-effectiveness analysis
Model description. Cost-effectiveness analyses were
conducted using a Monte Carlo simulated Markov
state-transition model. The model included seven
health states defined by three CD4 cell count cate-
gories (<200/µl, 200–350/µl and >350/µl), which
were further stratified according to WHO Non-Aids
(WHO stage 1, 2 or 3) and AIDS (WHO stage 4)
clinical stages, and death. The treeAge Software
(Williamstown, MA, USA) was used to develop the
model. To increase the precision of estimates, a 
cohort of 10,000 patients with sociodemographic
characteristics similar to CTAC patients (Table 1) 
was followed through the model over a sequence of 
1 month cycles. The model was run over a 50 
year period, such that greater than 95% of the cohort
was dead when the run of the model terminated. 
The model structure is presented in Figure 1.
In the HAART alternative, the effectiveness of
treatment was modelled as a rate of progression to
higher CD4 cell count strata, whereas the outcome of
M Badri et al.
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the No-ART alternative was modelled as a rate of
progression to a lower CD4 cell count strata, taking
into account the clinical WHO stage of each patient,
with death as the absorbing state in both alternatives.
Progression rates were calculated as the number of
events occurring over a 1 month period and were
expressed as transition probabilities using a binomial
distribution. The model incorporated all possible path-
ways of moving from one CD4 strata to another,
including the transition probabilities of switching from
first-line to second-line HAART therapy, or discontin-
uing therapy due to toxicity, withdrawal of consent or
loss to follow-up. Other trial-related reasons for stop-
ping HAART, such as pregnancy were excluded from
the probability of discontinuing therapy. Non-HIV
related mortality was captured using the South African
life-tables [34], adjusted for age, gender and socio-
economic status. Patients with an AIDS diagnosis were
assumed to begin therapy immediately irrespective of
CD4 level.
The model assigned healthcare utilization, cost esti-
mates and quality of life weights to the respective
health states. The cost-effectiveness ratio was calcu-
lated as the incremental cost per life year and per
quality-adjusted life-year (QALY) gained, comparing
each option with the next most effective, after ruling
out options with higher cost and lower effectiveness 
Antiviral Therapy 11:1 65
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Table 1. Baseline demographic and clinical characteristics of
the highly active antiretroviral therapy group (n=332) and
the no-antiretroviral therapy group (n=1284)
Characteristic HAART No-ART P-value*
n (%) n (%)
Age 0.60
<32 years 151 (45.5) 672 (52.3)
≥32 years 147 (54.5) 612 (47.7)
Gender 0.03
Male 182 (54.8) 616 (48)
Female 150 (45.2) 668 (52)
Socioeconomic status <0.0001
High 161 (45.5) 428 (33.3)
Low 171 (51.5) 856 (66.7)
WHO stage 0.12
Stage 1 & 2 169 (50.9) 667 (51.9)
Stage 3 121 (36.5) 407 (31.7)
Stage 4 42 (12.6) 210 (16.4)
CD4 cell count 0.003
<200/µL 126 (38) 529 (41.2)
200–350/µl 116 (35) 331 (25.8)
>350/µl 90 (27) 424 (33)
Viral load
Mean (log10 copies/µl) 5.0 -
































Figure 1. A state transition diagram representing the CD4 cell count and WHO clinical stage based Markov model for No-anti-
retroval therapy and highly active antiretroviral therapy states 
Patients dropping out of the highly active antiretroviral therapy (HAART) group will have the same transition probability as the respective no-antiretroviral therapy
(No-ART) group from the date they stop treatment (DTP).  HAART patients discontinuing first-line therapy (for reasons other than toxicity, with drawing consent or
loss to follow-up) will switch to second line therapy (SLT; see Table 3). 
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(simple dominance) or those with higher incremental
cost-effectiveness ratios (ICER) relative to more effec-
tive options (extended dominance), as recommended by
the USA Public Health Service Expert Panel on Cost-
effectiveness in Health and Medicine [35]. Future costs
and benefits were discounted at an annual rate of 8%,
which is widely used in South Africa, and is based on
the return on long-term government bonds [36].
Health-related quality of life data. Health-related quality
of life data were derived from two local studies. The
first assessed the impact of HIV infection on quality of
life [37], and the second evaluated changes in quality of
life attributable to HAART [38]. Both studies used the
Medical Outcomes Survey Short Form (SF-36). These
data were converted to SF-6D; a simplified health state
classification based on selected items from SF-36. SF-6D
health states were converted into QALYs using United
Kingdom general population standard gamble valua-
tions from a survey undertaken by Brazier et al. [39].
Sensitivity analysis. The robustness of results were
assessed in probabilistic and one-way sensitivity
analyses. The probabilistic analyses were undertaken to
reflect, in the results of the model, the uncertainty asso-
ciated with parameters, as recommended by the
National Institute for Clinical Excellence [40]. This
involved constructing triangular distribution based on
95% CI for healthcare utilization, and binomial distri-
butions for transition probabilities. The impact of these
parameter uncertainties was propagated through 
the model by means of second-order Monte Carlo sim-
ulation. This involved running the model 10,000 
times using randomly selected values from input distri-
butions in order to derive probability distributions for
model outputs [41]. One-way sensitivity analyses
included a no second-line HAART scenario, ART price
reductions, reduced No-ART healthcare costs, and 
0% and 3% discounting of costs and benefits. 
Further uncertainties typical to HAART cost-effective-
ness analyses, including overall durability of ART
regimens, costs and outcomes after treatment failure
[9–11] were also examined. In addition, we have 
extensively explored whether differential efficacy
would impact on our cost-effectiveness rankings. This
was done by increasing the probability of failing firs
line,and increasing the probability of dying and 
discontinuing therapy while on second-line.
Results
Study sample
The demographic and baseline clinical characteristics
of the study cohort (332 HAART and 1,284 No-ART
patients) are described in Table 1. In the HAART
group, 48 patients (incidence density rate [IDR]=2.59
per 100 patient-years [PYS]; 95%CI 1.91–3.44)
discontinued treatment permanently due to toxicity,
withdrawal of consent or loss to follow up, and 51
patients (IDR=2.76 per 100 PYS; 95%CI 2.05–3.63)
switched to second-line or salvage therapy. In the No-
ART group 295 patients died compared with 34
patients in the HAART group. Death events occured in
HAART patients with CD4 cell count of >350/µl
(IDR=0.40 per 100 PYS, 95%CI 0.08–1.18) or 200-
350/µl (IDR=1.18 per 100 PYS, 95%CI 0.38–2.75),
were significantly less than in those with <200/µl
(IDR=3.94 per 100 PYS, 95%CI 2.57–5.77); P-value
<0.05 and <0.001 respectively. The transition probabil-
ities from one health state to another for the two
groups are summarized in Table 2.
Healthcare utilization and cost
Across all health states, inpatient days were signifi-
cantly lower in the HAART group compared with the
No-ART group. Inpatient and outpatient use was
higher in patients with advanced immune suppression
and clinical disease (Table 3). The annual cost of first-
line and second-line regimens was US$322 and US$840
respectively, and monitoring viral load cost was US$79.
The monthly total cost of healthcare increased from
US$463 in No-ART patients with CD4 cell counts
>350/µl and no AIDS to US$3,434 in those with
<200/µl and AIDS. A similar trend was observed in
HAART patients (Table 3).
Cost-effectiveness analysis
The undiscounted mean life-expectancy was 6.2 years
for No-ART patients compared with 18.8, 21 and 23.3
years for HAART patients initiating therapy with CD4
cell count of <200/µl, 200–350/µl and 351–500/µl
respectively. Similar trends were observed for QALYs
(Table 4).
The No-ART discounted QALYs were 3.1, 6.2, 6.7
and 7.4 for No-ART and patients starting HAART at
CD4 cell count <200/µl, 200–350/µl and >350/µl
respectively. Initiating therapy at <200/µl had an ICER
of US$54 per QALY versus No-ART, initiating therapy
at 200–350/µl had an ICER of US$616 versus <200/µl,
and >350/µl had an ICER of US$1,137 versus therapy
initiation at 200–350/µl. ICERs were sensitive to
HAART cost. Compared with other therapy initiation
scenarios, starting with >350/µl was the most effective
option but the most costly, owing to higher projected
life expectancy (Table 4).
Sensitivity analysis
Confidence intervals presented in Table 4 indicate the
impact of parameter uncertainty on cost-effectiveness
results (propagated through the model via probabilistic
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sensitivity analysis). One-way sensitivity analyses indi-
cated that results were not sensitive to cost and
outcome after treatment failure, to cost reductions in
No-ART health states, to discount rate variations, to
increased failure rates of first-line therapy and to
reduced efficacy of second-line therapy.
Results were sensitive to HAART price. Figure 2
shows the impact of decreased HAART prices on the
cost-effectiveness of therapy. At 40% price reduction,
HAART therapy initiation will be cost-saving relative
to No-ART at all CD4 cell count thresholds (Figure 2).
Similarly, initiating therapy at <200/µl and 200–350/µl
was cost-saving relative to No-ART if patients were
assumed to receive first-line therapy only.
Discussion
This is the first study from sub-Saharan Africa to assess
the cost-effectiveness of initiating HAART at different
CD4 cell count thresholds in ART-naive individuals.
Hospitalization increased with advancing immune
suppression, but was significantly reduced in patients
receiving HAART. Due to higher life-expectancy, total
lifetime costs in the HAART group exceeded that of
the No-ART alternative. Initiating therapy at
200–350/µl and above 350/µl was more effective, but
requires more resources than deferring therapy to
CD4 cell count <200/µl.
Due to paucity of studies, cost-effectiveness has not
been routinely used in South Africa to inform public
health resource allocation policy, and it is not possible to
compare the ICERs in this study with other healthcare
interventions. However, the Commission on
Macroeconomics and Health has suggested that inter-
ventions that have an ICER that is less than per capita
gross domestic product (US$ 3,089 in 2003 in South
Africa) could be considered to be very cost-effective [42].
Since the ICER estimates in this study are much lower
than this threshold, all therapy initiation scenarios could
be considered cost-effective by this criterion.
Our findings concur with reports from industrialized
countries where initiation of therapy at CD4 cell counts
higher than 200/µl impacted favourably on clinical
progression [2,10,13,14,15,43]. A recent review
concluded that earlier initiation of HAART could be
associated with better immune improvement, less drug-
related toxicity, and reduced HIV transmission [2]. In a
study with extended follow-up, risk of disease progres-
sion was increased, even with durable virological
suppression, when initiating HAART at CD4 cell
counts <200/µl, compared with 200–350/µl or >350/µl
Antiviral Therapy 11:1 69
































Figure 2. The impact of HAART price on the cost-effectiveness
of different strategies of iniating HAART
Table 4. Cost-effectiveness of different treatment options for HIV-infected patients
Effectiveness ICER (incremental cost/incremental effect)
Treatment option Total lifetime costs Life years QALY Life years QALY
Discounted (8%)
No-ART 5,250 (4,953–5,577) 4.5 (4.3–4.7) 3.1 (3.0–3.3) N/A N/A
CD4 <200 cells/µl 5,434 (4,976–5,907) 8.2 (7.6–8.7) 6.2 (5.8–6.7) 46 (-240–166) 54 (-115–197)
CD4 200–350 cells/µl 5,740 (5,365–6,122) 8.7 (8.2–9.2) 6.7 (6.3–7.1) 577 (440–668) 616 (444–733)
CD4 >350 cells/µl 6,588 (6,272–6,893) 9.3 (8.9–9.7) 7.4 (7.1–7.8) 1,263 (1,069–2,209) 1,137 (1,011–1,317)
Undiscounted
No-ART 7,877 (7,315–8,472) 6.2 (5.8–6.6) 4.3 (4.0–4.6) N/A N/A
CD4 <200 cells/µl 14,230 (11,984–16,817) 18.8 (16.3–21.7) 14.6 (12.5–16.9) 499 (405–583) 611 (491–719)
CD4 200–350 cells/µl 15,880 (13,927–18,005) 21.0 (18.7–23.4) 16.4 (14.5–18.4) 766 (676–829) 915 (787–996)
CD4 >350 cells/µl 18,505 (16,745–20,347) 23.3 (21.2–25.6) 18.5 (16.8–20.4) 1,148 (971–1,635) 1,236 (1,110–1,468)
Costs and effects are per patient. ICER, incremental cost-effective ratio; N/A, not applicable; No-ART, no anti retroviral therapy; QALY, quality adjusted life years.
A-C represent 0%, 20% and 40% highly active antiretroviral therapy (HAART)
price reductions respectively. 1–3 represent CD4 cell count of <200/µl,
200–350/µl and >350µl respevtively. Points lying below no-antiretroviral
therapy (No-ART) indicate cost saving options (absolute dominance). Points
above No-ART indicate more effective but more costly options of HAART; the
incremental cost effectiveness ratio is represented by the slope of the lines
joining the points. QALY, quality-adjusted life year.










[43]. In previous analyses performed in our cohort,
early therapy initiation was associated with reduced
incidence of tuberculosis [21], AIDS and death
compared with deferring treatment to <200/µl [44].
Life-expectancy on HAART in this study ranged
between 18.8 and 23.3 years compared with 31.1 years
reported in patients of similar age in a large European
HIV cohort study [45]. Both studies involved extrap-
olation beyond follow-up, without restricting efficacy
of treatment as conservatively assumed in other
studies [9–11].
This study has several limitations. The treated arm
included participants in clinical trials. Management of
these patients may not reflect the standard or intensity
of care provided for patients not participating in clin-
ical trials. In addition, patients participating in the
HAART clinical trials were not randomly select from
the whole cohort, but were those patients who met
inclusion criteria. Due to the limited availability of
drugs in these trials, patients were invited to participate
on a first-come, first-served basis. Therefore, it is diffi-
cult to exclude the possibility of some selection bias in
recruiting patients into the clinical trial or to ensure
that characteristics of patients in the two groups
studied were strictly similar. However, outcomes for
these patients were not dissimilar from those reported
in large developed country cohort analyses [46]. The
design of our model also accounted for the most
measurable clinical and immunological confounding
factors. Starting therapy at a wider range of CD4 cell
counts in this cohort than is recommended, in the
South African ART rollout programme, allowed us to
assess the cost-effectiveness of the initiation of therapy
under different scenarios. Because the sample size of
the treated group was relatively small, we used one-
way and probabilistic sensitivity analysis of 10,000
simulated patients to approximate lifetime estimates,
and to ensure that uncertainty relating to data sources
and methodological choices was accounted for.
Healthcare cost estimates in this study are compa-
rable to a recent community-based South African study
by Cleary et al. [32], but higher than reported in other
African countries [47]. Viral load measurement was not
available for the No-ART group therefore we were
unable to adjust for the level of HIV RNA on disease
progression. However, it has been shown that CD4 cell
count is a better predictor of disease progression than
viral load [12]. We did not assess the cost implications
of our findings for the South African HAART rollout
programme because at present no data exist on the
distribution of HIV-infected patients by CD4 cell
count for the country. This study was conducted from
a public healthcare perspective. The societal perspec-
tive would capture added indirect costs or benefits
associated with HAART, such as productivity gains
and opportunity costs associated with seeking care,
which could potentially further improve the cost-
effectiveness of HAART [11]. However, valuing
productivity gains in a largely unemployed population
is fraught with ethical problems [48]. Furthermore,
these data do not currently exist. Costs of the No-
ART option reflect a level of urban access to health-
care that may not be available in remote areas of
South Africa. However, HAART initiation ICERs
were not sensitive to reductions in No-ART costs, and
‘do-nothing’ was not considered a reasonable policy
alternative. Moreover, the rollout is intended to start
from settings where infrastructure currently exists,
which would predominantly be urban.
Our findings indicate that HAART is a cost-effective
public health intervention in South Africa. The decision
of when to start therapy is complex and should carefully
balance reducing costs while maximizing the population
benefits of treatment within existing operational limita-
tions. The aggregate cost of starting HAART at CD4
cell counts >200/µl may be higher than deferring treat-
ment to <200/µl, but due to the high rates of untreated
disease progression at CD4 cells above 200/µl in sub-
Saharan Africa, countries with less binding resource
constraints should consider earlier therapy initiation to
take adv ntage of additional clinical benefits.
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Abstract
Background: Patients accessing antiretroviral treatment (ART) programmes in sub-Saharan
Africa frequently have very advanced immunodeficiency. Previous data suggest that such patients
may have diminished capacity for CD4 cell count recovery.
Methods: Rates of CD4 cell increase were determined over 48 weeks among ART-naïve
individuals (n = 596) commencing ART in a South African community-based ART programme.
Results: The CD4 cell count increased from a median of 97 cells/µl at baseline to 261 cells/µl at
48 weeks and the proportion of patients with a CD4 cell count <100 cells/µl decreased from 51%
at baseline to just 4% at 48 weeks. A rapid first phase of recovery (0–16 weeks, median rate = 25.5
cells/µl/month) was followed by a slower second phase (16–48 weeks, median rate = 7.7 cells/µl/
month). Compared to patients with higher baseline counts, multivariate analysis showed that those
with baseline CD4 counts <50 cells/µl had similar rates of phase 1 CD4 cell recovery (P = 0.42),
greater rates of phase 2 recovery (P = 0.007) and a lower risk of immunological non-response (P
= 0.016). Among those that achieved a CD4 cell count >500 cells/µl at 48 weeks, 19% had baseline
CD4 cell counts <50 cells/µl. However, the proportion of these patients that attained a CD4 count
200 cells/µl at 48 weeks was lower than those with higher baseline CD4 cell counts.
Conclusion: Patients in this cohort with baseline CD4 cell counts <50 cells/µl have equivalent or
greater capacity for immunological recovery during 48 weeks of ART compared to those with
higher baseline CD4 cell counts. However, their CD4 counts remain <200 cells/µl for a longer
period, potentially increasing their risk of morbidity and mortality in the first year of ART.
Background
The World Health Organisation (WHO) estimated that in
June 2005 4.7 million people living in sub-Saharan Africa
were in urgent need of antiretroviral treatment (ART) [1].
Despite formidable logistical hurdles, the number of indi-
viduals able to access this treatment in the region is
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expanding. One of the programmatic challenges facing
ART services in sub-Saharan Africa is that many HIV-
infected patients only access healthcare once they have
developed advanced symptomatic disease [2] and this
delay may be further compounded by health-systems
delays. The median CD4 cell count among those enrolling
in ART programmes is often under 100 cells/µl even
where programmes have been well established for several
years [3-5].
Patients enrolling into ART programmes with very low
CD4 cell counts have heightened risk of morbidity and
mortality both before and during the initial months of
ART [5-8]. Moreover, advanced pre-treatment immunode-
ficiency is also reported to be associated with diminished
capacity for restoration of CD4 cell counts and CD4 cell
functional responses during ART [9-14]. This raises the
concern that many patients entering ART programmes in
sub-Saharan Africa may have limited potential for
immune recovery. Although previous studies from sub-
Saharan Africa have reported overall CD4 cell count
responses [3,15,16], there are no published data from the
region regarding rates of CD4 cell recovery and rates of
immunological non-response to ART among patients
with CD4 cell <50 cells/µl.
In this study we have examined determinants of CD4 cell
count recovery among patients accessing a community-
based antiretroviral programme in South Africa. We focus
on the hypothesis that advanced pre-treatment immuno-
deficiency diminishes the capacity for CD4 cell count
recovery during ART as determined by rates of CD4 cell
count increase and risk of immunological non-response.
Methods
Study population
We studied patients accessing ART at the Gugulethu Com-
munity Health Centre, Cape Town, South Africa [5]. The
vast majority of patients receiving treatment at this clinic
live in conditions of low socioeconomic status and HIV
transmission is predominantly heterosexual. The South
African national ART programme guidelines are based on
the World Health Organisation (WHO) 2002 recommen-
dations [17], with criteria for ART including those with a
prior AIDS diagnosis (WHO stage 4 disease) or a blood
CD4 cell count <200 cells/µl.
The first-line ART regimen was comprised of stavudine,
lamivudine plus a non-nucleoside reverse transcriptase
inhibitor (efavirenz or nevirapine). The second-line regi-
men for those failing first-line treatment was comprised of
lopinavir/ritonavir, zidovudine and didanosine. Treat-
ment adherence exceeds 90% at one year [18]. All treat-
ment was free of charge and there were no interruptions
in drug supply. All patients with CD4 counts <200 cells/µl
received daily cotrimoxazole prophylaxis; dapsone was
used as an alternative.
Data collection
Plasma HIV-1 load was measured at baseline and 4
monthly during treatment using Versant™ HIV-1 RNA 3.0
branched chain DNA assay (Bayer HealthCare,
Leverkusen, Germany) with a lower limit of detection of
50 RNA copies/ml. Blood CD4 cell counts were measured
at the same time-points by flow cytometry using FACS-
Count™ (Becton Dickinson Inc., Franklin Lakes, NJ, USA).
These assays were all performed in a single nationally
accredited laboratory which has rigorous quality assur-
ance procedures.
Structured clinical and laboratory records were main-
tained on all patients screened on entry to the ART pro-
gramme and this information was transferred on a weekly
basis to a computer database. Data were analysed from
the start of the programme in September 2002 until data
censorship in August 2005. All treatment-naive patients
aged over 15 years and with at least a 16-week follow-up
time point were included in the analysis. Study of these
patients was in compliance with the Declaration of Hel-
sinki and was approved by the Research Ethics Committee
of the University of Cape Town; all patients enrolled gave
written informed consent.
Data analysis
Data were analysed using Stata version 9.0 (College Sta-
tion, Texas, USA). We calculated absolute responses in
CD4 cell counts during three intervals (from baseline to
16 weeks of ART, 16 to 32 weeks, and 32 to 48 weeks), as
well as rates of CD4 cell increase (cells/µl/month) during
each interval. The first interval was used as an estimate of
the initial (phase 1) response to ART. The CD4 cell count
responses observed during the latter two intervals (16 to
32 and 32 to 48 weeks after treatment initiation) were
very similar, and were combined into a single measure of
the second phase of CD4 cell responses (phase 2).
We further evaluated CD4 cell responses in the following
ways: i) whether patients failed to attain an absolute CD4
cell count increase from baseline of at least 50 cells/µl at
48 weeks (defined as immunological non-response); ii)
whether patients achieved an absolute CD4 count of 200
cells/µl at the 48 week visit; iii) and whether patients had
achieved an absolute CD4 cell count of 500 cells/µl at 48
weeks (super-responders).
In bivariate analyses, medians were compared using Wil-
coxon rank-sum and sign-rank tests; proportions were
compared using chi-square tests. All statistical tests were
two-sided at alpha = 0.05. Separate multiple linear regres-
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rates of CD4 cell count increase per month during the first
and second phases. Baseline CD4 cell counts were catego-
rised as follows: <50, 50–99, 100–149 and >150 cells/µl.
Multiple logistic regression was used to assess factors asso-
ciated with the binary outcomes of a CD4 cell increase of
≥ 50 cells/µl and ≥ 100 cells/µl during the 48 weeks of
ART, as well as achieving an absolute CD4 cell count of ≥
200 cells/µl during follow-up. Variables were included in
multivariate models if they demonstrated a persistent
association with the outcome of interest, or if their
removal affected appreciably associations involving other
variables [19].
Results
Baseline characteristics and follow-up
Of 698 individuals who commenced ART between Sep-
tember 2002 and April 2005, 596 (85%) had completed a
16-week follow-up visit at the time of data censorship, 34
(5%) were awaiting this appointment, 48 (7%) had died
and 20 (3%) were either transferred out or were lost to fol-
low-up. Of the 596 individuals who met the inclusion cri-
teria for the study, 580 (97%) remained within the
programme at study censorship, 11 (2%) died and 7 (1%)
were lost from the programme.
At baseline the median age was 32 years (IQR, 28–38) and
75% were female. The median plasma viral load was 4.88
log10 RNA copies/ml (IQR, 4.50–5.27) and 58% of
patients had a viral load >100,000 copies/ml. The median
blood CD4 cell count was 97 cells/µl (IQR, 50–153) and
the proportions of patients with CD4 cell counts within
the ranges <50, 50–99, 100–149 and ≥ 150 cells/µl were
25%, 26%, 23% and 26%, respectively. Eighty per cent of
patients had symptomatic disease, with 53% and 27% of
patients having WHO stages 3 and 4 disease, respectively.
During follow-up, only 7 (1%) patients switched to the
second-line drug regimen.
Virological and CD4 cell responses to ART
Virological responses to treatment were excellent with
viral load suppressed <400 copies/ml in ≥ 94% of patients
at each of the follow-up time-points (Table 1). As a result,
the frequency distribution of blood CD4 cell counts
within the cohort shifted markedly from baseline over 48
weeks of treatment (Fig. 1). Whereas the proportion of
individuals with CD4 cell counts <100 cells/µl was 51% at
baseline, this proportion decreased to only 4% by week 48
of treatment. The median CD4 cell count increased almost
3-fold from baseline, reaching 261 cells/µl after 48 weeks
ART (Table 1).
The rate of CD4 cell count increase in the first 16 week
period greatly exceeded the rates in both the 16–32 week
and 32–48 week intervals, but the rates did not differ
comparing the latter two intervals. Thus, the pattern of
CD4 cell count increase was divided into 2 phases: a ra–
pid phase 1 (0–16 weeks; median = 25.5 cells/µl/month)
and a slower phase 2 (16–48 weeks; median = 7.7 cells/µl/
month).
Baseline characteristics and rates of CD4 cell count change
in phase 1 and phase 2 did not differ when comparing the
results of analyses of all eligible patients with those
restricted to subjects who had data for every time-point (n
= 292); this was also the case for all subsequent stratified
analyses. Use of data from the larger cohort (n = 596) was
therefore validated.
Effect of baseline CD4 cell count on rates of CD4 cell 
increases
Rates of phase 1 CD4 cell increase were similar across all
CD4 cell count strata (Figure 2). Subsequent multivariate
analysis found that baseline plasma viral load was the sin-
gle factor independently associated with phase 1 CD4 cell
recovery (Table 2). This association was strong; among
Graphs showing the frequency distribution of absolute blood CD4 cell counts (a) at bas line (n = 596) and ( ) after 48 weeks (n = 311) of antiretroviral eatme tFigure 1
Graphs showing the frequency distribution of absolute blood 
CD4 cell counts (a) at baseline (n = 596) and (b) after 48 
weeks (n = 311) of antiretroviral treatment. Smoothed 
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those with a baseline viral load <5 log10 copies/ml the
phase 1 CD4 cell slope was 21.3 cells/µl/month compared
to 31.0 cells/µl/month among those with baseline viral
load of >5 log10 copies/ml (P < 0.001).
Contrary to our initial hypothesis, the rate of phase 2 CD4
cell increase was greater among those with a baseline CD4
cell count <50 cells/µl compared to those with higher
baseline counts (Figure 2). This association was highly sig-
nificant in multivariate analysis (Table 2). The rate of
phase 2 CD4 cell increase was also greater among younger
compared to older patients (Figure 3). Multivariate analy-
sis confirmed that both low baseline CD4 cell count and
younger age were the only baseline characteristics that
were significantly associated with higher rates of phase 2
CD4 cell recovery (Table 2).
In the multivariate model predicting rates of phase 2 CD4
cell increase, factors associated with the response to ART
during the first 16 weeks were also included. A lower rate
of phase 1 CD4 cell increase and full suppression of viral
load at 16 weeks were both strongly associated with
greater rate of phase 2 CD4 cell increase. Viral load sup-
pression <400 copies/ml at 16 weeks was associated with
a subsequent rate of CD4 cell increase of 6.8 cells/µl/
month compared to 0.7 cells/µl/month among those
whose viral load remained >400 copies/ml (P < 0.001).
Baseline CD4 cell count and risk of immunological non-
response
We next examined whether baseline CD4 cell count was a
risk factor associated with immunological non-response
(defined as a CD4 cell increase of <50 cells/µl at 48
weeks). Among those followed to 48 weeks (n = 311), the
blood CD4 cell count increased by <50 cells/µl among 30
(9.7%) patients; of these, the viral load was suppressed
<50 copies/ml among 22 patients, representing a treat-
ment discordance rate of 7%. Contrary to our initial
hypothesis, low baseline CD4 cell counts were not associ-
ated with increased risk of immunological non-response.
Table 1: Changes in blood CD4 cell counts and plasma viral load during ART.
Baseline Week 16 Week 32 Week 48
No. of patients 596 596 404 311
Virological Response
Median VL 75,858 <50 <50 <50
Number (%) patients wilh VL ≥ 400 585 (98) 31 (5) 26 (6) 18(6)
Number (%) patients with VL ≥ 50 591 (99) 117 (20) 74 (18) 54 (17)
CD4 Cell Count Response
Median (IQR) CD4 cell count (cells/µl) 97 (50–153) 199 (140,314) 226 (162, 314) 261 (193, 363)
Median (IQR) CD4 cell slope in preceding interval (cells/µl/month) - 25.5 (12.7, 42.9) 7.5 (-4.6, 19.8) 7.9 (-3.0, 20.0)
VL = viral load (copies/ml)
Table 2: Multiple linear regression models estimating the average change in CD4 cell count per month (CD4 slope). Separate models 
analyse the first (0 – 16 weeks) and second (16 – 48 weeks) phases of immune recovery during ART.
Phase 1 (0–16 weeks) CD4 slope (n = 596) Phase 2 (16–48 weeks) CD4 slope (n = 311)1
Mean (95% CI) P value Mean (95% CI) P value
Age (years) <30 1.0 1.0
30–39 -2,27 (-6.71,2.17) 0.32 -2.18 (-5.98, 1.63) 0.26
>40 -2.17 (-7.87, 3.54) 0.46 -7.31 (-12.11, -2. 50) 0.003
Sex Female 1.0 1.0
Male -3.60 (-8.22, 1.02) 0.13 -0.94 (-4.98, 3.10) 0.65
Baseline CD4 coimt (cells/µl) >150 1.0 1.0
100–149 3.85 (-1.63, 9.33) 0,17 -2.17 (-7.09, 2.76) 0.39
50–99 3.53 (-1.84, 8.91) 0.20 0.93 (-4.22, 6.08) 0.72
<50 2.34 (-3.31, 7.98) 0.42 8.55 (2.39, 14.71) 0.007
WHO clinical stage 1 & 2 1.0 1.0
3 1.79 (-3.33, 6.91) 0.49 -0.70 (-5.40, 4.00) 0.77
4 0.55 (-5.39, 6.49) 0.86 -1.76 (-6.93, 3.41) 0.50
Baseline viral load (copies/ml) <5 log10 1.0 1.0
>5 log10 11.14 (7.10, 15.18) <0.001 2.21 (-1.37, 5.80) 0.23
1 The Phase 2 model included as covariates all variables shown, as well the phase 1 CD4 cell slope, the CD4 cell count at 16 weeks and the viral load 










BMC Infectious Diseases 2006, 6:59 http://www.biomedcentral.com/1471-2334/6/59
Page 5 of 8
(page number not for citation purposes)
Among patients with baseline CD4 cell counts of <50, 50–
99, 100–149 and 150 cells/µl, the proportions of patients
who were immunological non-responders were 5%, 4%,
11% and 19%, respectively. Furthermore, in multivariate
analyses, an increment of <50 cells/µl was independently
associated with higher baseline CD4 cell count as well as
older age, lower baseline viral load, and a viral load >400
copies/ml at any follow-up time-point (Table 3).
Baseline CD4 cell count and failure to attain a CD4 cell 
count of ≥ 200 cells/µl
We next determined factors associated with failure to
attain an absolute CD4 cell count of 200 cells/µl at 48
weeks. Although patients with a baseline CD4 cell count
<50 cells/µl had similar rates of phase 1 CD4 cell recovery
and greater rates of phase 2 CD4 cell recovery compared
to those with higher baseline counts, such patients never-
theless had a reduced likelihood of attaining a CD4 cell
count of 200 cells/µl at 48 weeks (Table 3). The propor-
tions of patients with baseline CD4 cell counts of <50,
50–99, 100–149 and 150 cells/µl who failed to attain a
CD4 cell count of 200 cells/µl at 48 weeks were 49%,
35%, 18%, and 9%, respectively. Failure to attain 200
cells/µl was also significantly associated with older age,
lower baseline plasma viral load, and a viral load >400
copies/ml at any follow-up time-point (Table 3).
Super-responders
Of 311 patients studied out to 48 weeks, 21 (6.8%)
achieved an absolute CD4 cell count of >500 cells/µl.
These super-responders were principally characterised by
age <40 years and by all having follow-up viral loads per-
sistently suppressed <50 copies/ml and a CD4 cell count
of 150 cells/µl after 16 weeks of ART. This group of
patients had a wide distribution of baseline CD4 cell
counts, and included among them were 4 (19%) who had
baseline CD4 cell counts of <50 cells/µl. Thus, a low base-
line CD4 cell count did not preclude patients from having
an excellent immunological response.
Discussion
To our knowledge this is the first analysis to examine the
determinants of CD4 cell count recovery among patients
receiving ART in resource limited settings. These data indi-
cate that those with baseline CD4 cell counts <50 cells/µl
had similar rates of phase 1 CD4 recovery (0–16 weeks)
and greater rates of phase 2 recovery (16–48 weeks) com-
pared to rates among those with higher baseline CD4 cell
counts. Moreover, those with the lowest baseline counts
Graph showing the median CD4 cell counts at baseline and during ART stra ified by geFigure 3
Graph showing the median CD4 cell counts at baseline and 
during ART stratified by age. Below the graph, the median 
(IQR) rates of CD4 cell increase (cells/µl/month) are given 





























Patient age (years) Phase 1 Phase 2
(0-16 weeks) (16-48 weeks)
<30 26.8 (12.7, 43.3) 8.4 (1.1, 20.4)
30-39 24.8 (11.8, 43.0) 6.6 (-1.2, 16.9)
≥40 23.3 (13.1, 38.0) 4.8 (-1.4, 10.6)1
Graph showing the median CD4 cell counts at baseline and during ART stra ified by baseline CD4 cell countFigure 2
Graph showing the median CD4 cell counts at baseline and 
during ART stratified by baseline CD4 cell count. Below the 
graph, the median (IQR) rates of CD4 cell increase (cells/µl/
month) are given for phase 1 (0 – 16 weeks) and phase 2 





























Baseline CD4 cell count (cells/µl) Phase 1 Phase 2 
(0-16 weeks) (16-48 weeks)
≥150 21.9 (9.3, 42.9) 5.1 (-3.0, 15.5)
100-149 24.5 (13.4, 44.2) 5.3 (-2.1, 13.5)
50-99 26.0 (11.4, 42.9) 6.8 (-0.2, 14.6)
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were least likely to be immunological non-responders to
ART. Despite these observations, those with baseline CD4
cell counts <50 cells/µl were nevertheless least likely to
attain a CD4 cell count 200 cells/µl at 48 weeks. Taken
together, these results suggest that although patients with
very low baseline CD4 cell counts retain capacity for sim-
ilar or slightly greater rates of CD4 cell count recovery
compared to those with higher counts, they are neverthe-
less likely to require a longer period of time to attain a
CD4 cell count threshold of 200 cells/µl. Thus, a pro-
longed period below a 'safe' CD4 cell count threshold
rather than a diminished rate of immunological recovery
is likely to underlie the high rates of morbidity and mor-
tality observed among those with advanced disease during
the early months of ART [4,5,8].
The findings of this analysis are strengthened by the rela-
tively homogeneous study population receiving treatment
at a single facility using standardised clinical protocols.
Patients were all ART-naïve and received a standard triple-
drug regimen with uniform follow-up time points. Qual-
ity-assured laboratory assays were all performed in a sin-
gle nationally accredited laboratory. In contrast, previous
studies of the determinants of CD4 cell count recovery
have examined heterogeneous study populations in mul-
tiple centres and used diverse treatment regimens. Moreo-
ver, these studies included many patients with prior ART
exposure [20-22] and some included only those who
maintained suppression of plasma HIV load [9,23,24].
Our patient population was treated under the government
ART roll-out programme and data are therefore likely to
be generalisable to other ART programmes in sub-Saharan
Africa. Our study is limited to analysis of CD4 cell recov-
ery during the first year of ART and long-term outcomes
and their sustainability remain to be determined. Moreo-
ver, in the present analysis we have examined recovery of
CD4 cell counts but not CD4 cell functional responses.
The immunological response to ART among those with
low CD4 cell counts was excellent with the proportion of
patients with a CD4 cell count <100 cells/µl decreasing
from 51% at baseline to just 4% at 48 weeks. However,
our most important finding was that in multivariate anal-
ysis baseline CD4 cell counts <50 cells/µl were independ-
ently associated with similar rates of phase 1 CD4 cell
recovery and greater rates of phase 2 CD4 cell recovery
compared to individuals with higher baseline CD4 cell
counts. This has not been clearly highlighted in previous
publications from Europe and North America although
comparison of our data with previous studies is difficult
in view of differing cohort compositions. However, this
overall observation is consistent with the findings of Ben-
nett et al.[21], and Le Moing et al. showed a similar but
non-significant trend when comparing patients with base-
line CD4 cell counts <200 cells/µl with those with higher
counts [20]. Kaufmann et al. found that CD4 cell increases
in the first year of ART were similar comparing those with
baseline counts <100 cells/µl with those with counts 100–
199 cells/µl [22].
Survival bias could potentially have affected our findings.
We have previously shown in this cohort that patients
with the lowest baseline CD4 cell counts had a higher risk
of death [5] and immunological non-responders or poor
Table 3: Results of logistic regression models predicting overall change in blood CD4 cell count during ART. Responses are defined as 
either (i) the risk of immunological non-response (an increase of <50 cells/µl) or (ii) failure to attain an absolute CD4 cell count of ≥ 200 
cells/µl after 48 weeks ART.
Risk of immumological non-respouse at 48 
weeks
Risk of failure to attain CD4 cell count of ≥ 
200 cells/µl at 48 weeks
OR (95% CI) P value OR (95% CI) P value
Age (years) <30 1.0 1.0
30–39 3.15 (1.09, 9.15) 0.035 1.34 (0.66, 2.72) 0.41
>40 3.88 (1.13, 13.39) 0.032 3.52 (1.55, 7.99) 0.003
Sex Female 1.0
Male 0.42 (0.13, 1.39) 0.16 1.73 (0.90, 3.35) 0.10
Baseline CD4 count >150 1.0 1.0
100–149 0.63 (0.23, 1.72) 0.37 2.49 (0.89, 6.96) 0.08
50–99 0.18 (0.05 0.70) 0.013 5.97 (2.29, 15.58) <0.001
<50 0.18 (0.05, 0.72) 0.016 12.11 (4.43, 33.14) <0.001
WHO clinical stage 1 & 2 1.0 1.0
3 1.12 (0.37, 3.40) 0.84 1.32 (0.54, 3.26) 0.54
4 2.11 (0.63, 7.03) 0.22 1.19 (0.45, 3.17) 0.72
Baseline viral load <5 log10 1.0 1.0
>5 log10 0.21 (0.07, 0.66) 0.008 0.47 (0.26, 0.86) 0.014
Follow-up viral load <400 all visits 1.0 1.0
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responders may have a greater mortality risk, leading to a
survivor effect. However, we were careful to ensure that
rates of CD4 cell recovery in the CD4 cell strata did not
differ when comparing analyses of the whole cohort with
those for whom data points were available at every time-
point. Secondly, WHO clinical stage of disease is the
strongest predictor of death in this cohort [5] and yet this
variable was not associated with CD4 cell responses.
Thirdly, the majority of deaths occurred in the first few
weeks of ART among those whose disease was simply too
far advanced; such deaths probably do not reflect a lack of
immunological response to ART. Finally, we have previ-
ously reported that over 20% of early deaths in this cohort
are due to immune reconstitution disease [5,25]; such
deaths typically occur among those with low baseline
CD4 cell counts and good CD4 cell recovery. These deaths
would tend to cause exactly the opposite bias. Thus,
although an important consideration, we do not think
that survival bias had an overall dominant effect.
We have previously shown that low baseline CD4 count at
entry to an ART programme was associated with increased
risks of tuberculosis and of mortality during the first year
of ART [5,8]. Results from the present study suggest that
these increased risks are likely to reflect an increased
period of time required for such patients to achieve a 'safe'
level of immune function rather than reflecting impaired
rates of immune recovery and this is consistent with the
findings of a study from Spain with longer term follow-up
[11]. More recently we have found that risk of mortality
and risk of incident tuberculosis is strongly associated
with the current CD4 cell count during ART rather than
the baseline count (unpublished data). Thus, if patients
with profound baseline CD4 lymphocytopenia survive
the initial few months of treatment and achieve full viral
load suppression, then high rates of immune recovery are
likely to result in a better prognosis that might have been
anticipated.
Rates of phase 1 and phase 2 CD4 cell increase were sim-
ilar in magnitude to those previously reported from high-
income countries [9,20]. The rapid phase 1 CD4 cell
recovery was strongly associated with baseline viral load
as described previously [20,21]; patients with viral loads
>105 log10 copies/ml had 11-fold greater CD4 count
increases than those with lower viral loads. Immune dys-
regulation and immune cell activation promote sequestra-
tion of CD4+CD45Ro+ memory T cells in lymphoid tissue;
suppression of viral replication then triggers rapid redistri-
bution of this cell pool and a reduction in apoptotic cell
death during the initial weeks of ART [26,27]. A positive
correlation between the plasma viral load and the degree
of cell sequestration may provide a possible mechanism
underlying the observation that those with the highest
viral loads have the greatest initial CD4 cell increment.
The fact that patients with profound CD4 lymphocytope-
nia have good immunological recovery during ART is
likely to be important in the pathogenesis of immune
reconstitution disease associated with Mycobacterium
tuberculosis[28], Cryptococcus neoformans[25] that is fre-
quently observed in this patient population.
Greater phase 2 CD4 cell recovery was strongly associated
with age as reported elsewhere [9,24]. Sustained suppres-
sion of viral replication is also critical to second phase
recovery [20,21] and we confirmed that viral load at 16
weeks was a strong independent predictor of subsequent
immunological recovery. Ten per cent of patients were
immunological non-responders (CD4 cell increment <50
cells/µl at 48 weeks) and 7% of patients had discordant
responses, having immunological non-response despite a
fully suppressed viral load. These rates are much lower
than those reported in previous series from industrialised
countries [14,29], possibly because our study only
included antiretroviral-naïve patients, rates of HIV pri-
mary drug resistance in this setting are likely to be low,
and because rates of treatment adherence in our cohort
are very high. However, those with CD4 cell counts <50
cells/µl were least likely to be immunological non-
responders. Moreover, 19% of 'super-responders' had
baseline CD4 cell counts <50 cells/µl, indicating that a
very low baseline CD4 cell count does not preclude an
excellent CD4 cell count response to ART.
Conclusion
Patients with the lowest CD4 counts in this setting do not
have diminished capacity for immune recovery. Although
patients with low baseline CD4 counts have increased risk
of acute morbidity and mortality, if such patients survive
the initial months of ART and fully suppress the viral load,
their chances of immunological recovery are good during
the first year. Future studies are required to determine the
long-term prospects for immune recovery among patients
treated in ART programmes in sub-Saharan Africa.
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Major Clinical Outcomes in Antiretroviral Therapy
(ART)–Naive Participants and in Those Not
Receiving ART at Baseline in the SMART Study
The Strategies for Management of Antiretroviral Therapy (SMART) Study Groupa
(See the editorial commentary by Hughes and Ribaudo, on pages 1084 – 6.)
Background. The SMART study randomized 5472 human immunodeficiency virus (HIV)–infected patients with
CD4 cell counts 350 cells/L to intermittent antiretroviral therapy (ART; the drug conservation [DC] group)
versus continuous ART (the viral supression [VS] group). In the DC group, participants started ART when the CD4
cell count was 250 cells/L. Clinical outcomes in participants not receiving ART at entry inform the early use of
ART.
Methods. Patients who were either ART naive (n  249) or who had not been receiving ART for 6 months
(n  228) were analyzed. The following clinical outcomes were assessed: (i) opportunistic disease (OD) or death
from any cause (OD/death); (ii) OD (fatal or nonfatal); (iii) serious non-AIDS events (cardiovascular, renal, and
hepatic disease plus non–AIDS-defining cancers) and non-OD deaths; and (iv) the composite of outcomes (ii) and
(iii).
Results. A total of 477 participants (228 in the DC group and 249 in the VS group) were followed (mean, 18
months). For outcome (iv), 21 and 6 events occurred in the DC (7 in ART-naive participants and 14 in those who had
not received ART for 6 months) and VS (2 in ART-naive participants and 4 in those who had not received ART for
6 months) groups, respectively. Hazard ratios for DC vs. VS by outcome category were as follows: outcome (i), 3.47
(95% confidence interval [CI], 1.26 –9.56; P  .02); outcome (ii), 3.26 (95% CI, 1.04 –10.25; P  .04); outcome (iii),
7.02 (95% CI, 1.57–31.38; P  .01); and outcome (iv), 4.19 (95% CI, 1.69 –10.39; P  .002).
Conclusions. Initiation of ART at CD4 cell counts 350 cells/L compared with 250 cells/L may reduce
both OD and serious non-AIDS events. These findings require validation in a large, randomized clinical trial.
Trial registration. ClinicalTrials.gov identifier: NCT00027352.
The most recent randomized clinical trial that addressed
the question of when to start antiretroviral therapy
(ART) for the treatment of HIV disease was the Con-
corde study [1]. Since then, despite enormous advances
afforded through the development of antiretroviral
drugs and the use of combination regimens, there has
been no randomized study to address this critically im-
portant issue. The absence of randomized data in both
the developed and developing world has required anti-
retroviral treatment guidelines to rely on the interpreta-
tion of nonrandomized studies and expert opinions [2,
3]. Current recommendations for the initiation of ART
are conservative because of the uncertainty about the
risk-benefit ratio associated with earlier ART use at
higher CD4 cell counts. These include toxicities, cost-
effectiveness, quality of life issues, adherence, and drug
resistance. At present, the initiation of ART is recom-
mended for asymptomatic patients with CD4 cell
counts between 201 and 350 cells/L or, in developing/
resource-poor countries, when the CD4 cell count has
declined to 200 cells/L.
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Data from cohort studies indicate that the risk of AIDS de-
creases with increasing CD4 cell counts but nevertheless per-
sists at CD4 cell counts 500 cells/L [4]. Furthermore, at any
given CD4 cell count, the risk of AIDS appears to be lower in
patients treated with ART than in those who are not [5], and the
risk of AIDS or death declines with the start of therapy, even
among those with high CD4 cell counts at initiation, compared
with that in patients not receiving ART [6, 7]. Importantly, co-
hort studies also indicate that risks of serious non–AIDS-related
diseases, including cardiovascular, renal, and hepatic conditions
and non-AIDS malignancies, are less common at higher CD4
cell counts [8 –13]. Data from the SMART study are consistent
with these observations insofar as the rates of AIDS and serious
non-AIDS events were significantly higher in participants ran-
domized to the intermittent ART group than in those random-
ized to the continuous ART group [14].
Here, we report the major clinical outcomes for a subgroup of
participants enrolled in SMART who were either ART naive or
who had not been receiving ART for 6 months before random-
ization. This subgroup provides a randomized comparison be-
tween early ART at a CD4 cell count of 350 cells/L versus
deferred ART until the CD4 count declines to 250 cells/L.
Subgroup analyses for major clinical outcome according to ART
history were proposed a priori. However, the analyses presented
here are post hoc. Thus, we regard our results as hypothesis
generating.
METHODS
Participants. Participants were included if they were random-
ized in the SMART study and were either ART naive or satisfied
the following eligibility criteria for having been previously
treated but not receiving ART for a minimum of 6 months be-
fore randomization (hereafter, “not receiving ART”): (1) were
not receiving ART at the time of randomization in SMART; (2)
had at least 1 plasma HIV RNA assessment during the 6 months
before randomization; and (3) all plasma HIV RNA levels in the
6 months before randomization were 10,000 copies/mL. We
excluded patients who had not been receiving ART for 6
months before randomization to avoid the possible short-term
effects of ceasing ART (e.g., the steeper decline in CD4 cell
count). The principal eligibility criterion for the SMART study
was a CD4 cell count of 350 cells/L. Other eligibility criteria
for SMART are described elsewhere [14].
Randomization. Participants were randomly allocated in
equal proportions to 1 of 2 treatment strategies: continuous ART
(the viral supression [VS] group) and intermittent ART (the
drug conservation [DC] group). For the present analyses, this
randomization corresponded to the immediate (re)initiation of
ART after randomization at CD4 cell counts 350 cells/L
(the VS group) versus the deferred (re)initiation of ART when
either the CD4 cell count declined to 250 cells/L, the CD4
cell percentage declined to 15%, or symptoms of HIV disease
developed (the DC group).
Assessments. Before randomization, participants’ ART and
medical history were obtained along with nadir and baseline
CD4 cell counts and plasma HIV RNA levels. Routine visits
occurred at 1 and 2 months, every 2 months thereafter for the
first year, and every 4 months in subsequent years. Visits in-
cluded clinical assessments, and samples were obtained for mea-
surement of CD4 cell count and plasma HIV RNA level. At
baseline and annually, a 12-lead electrocardiogram was ob-
tained, and data were electronically transmitted to a central
reading facility for assessment of silent myocardial infarc-
tion [15].
End-point definitions. Definitions for the primary end
point of opportunistic disease (OD) or death from any cause
(OD/death) and the major secondary composite end point of
cardiovascular-, renal-, and hepatic-disease events are given in
the online-only appendix of the primary-results article [14]. In
the present report, 4 major clinical outcomes are considered: (i)
the SMART primary end point (OD/death); (ii) OD (fatal or
nonfatal); (iii) serious non-AIDS events (cardiovascular, renal,
and hepatic disease plus non–AIDS-defining cancers [excluding
nonmelanoma skin cancers] and deaths from non-OD causes);
and (iv) the composite of outcomes (ii) and (iii). In the end-
point categories (ii) and (iii), deaths due to OD and all causes
except OD are counted. Thus, the composite of (ii) and (iii) can
be viewed as major morbidity (OD and non-OD) or all-cause
mortality. As previously reported, an end-point review commit-
tee, blinded to treatment group, reviewed all major nonfatal
clinical events [14]. The end-point review committee also clas-
sified the underlying cause of death using the system of the Cod-
ing of Death in HIV Project [16]. Grade 4 adverse events were
defined as potentially life-threatening symptomatic events ac-
cording to the Division of AIDS common toxicity table.
Statistical analysis. All analyses were intention to treat.
Data through 11 January 2006 were reported. On that date, fol-
lowing the recommendations of an independent data and safety
monitoring board, all participants in the DC group were advised
to (re)initiate ART. Thus, time-to-event analyses are censored at
the earliest of the date of death, the lost to follow-up date, or 11
January 2006.
The time from randomization to first event was compared
between the DC and VS groups by use of Kaplan-Meier plots for
each event category. For patients reporting multiple events in a
single outcome category, only the first event was included. For
patients reporting multiple events in different outcome catego-
ries, each first event in each category was included. The hazard
ratio for DC vs. VS— hereafter, HR(DC/VS)—was estimated by
fitting a Cox model with a single binary indicator for treatment
group overall and separately in ART-naive and ART-
experienced participants. Differences between these 2 groups
were assessed by including an interaction term in the Cox model.










Randomization protects these comparisons between treatment
groups from confounding.
Person-years at specific CD4 cell counts were counted ac-
cording to the most recently measured or time-updated value
(latest CD4 cell count), and rates per 100 person-years for the
composite outcome were determined for DC and VS partici-
pants. Randomization does not protect these comparisons be-
tween treatment groups from confounding.
Throughout, P values refer to 2-sided tests. Because the sub-
group and the serious non-AIDS outcomes considered in this
report were not prespecified, we recommend cautious interpre-
tation of P values.
RESULTS
Patient population. A total of 477 participants (8.7%) in the
SMART study were either ART naive (n  249) or had not been
receiving ART for 6 months before randomization (n  228)
and are included in these analyses. The relationship of these par-
ticipants to the total SMART cohort is summarized in figure 1.
Table 1 shows the baseline characteristics of the 228 and 249
participants who were respectively randomized into the DC and
VS groups. Treatment groups were well balanced for all baseline
characteristics. One-hundred eighteen participants (52%) and
131 participants (53%) were ART naive in the DC and VS
groups, respectively. The median baseline CD4 cell count and
plasma HIV RNA level for the cohort were 447 cells/L and 4.5
log10 copies/mL. The median nadir CD4 cell count was 361
cells/L.
The median duration of ART exposure in previously treated
participants was 4 years. Approximately 75% had used an HIV
protease inhibitor (PI), for a median duration of 2.5 years.
Approximately 50% had used a nonnucleoside reverse-
transcriptase inhibitor (NNRTI), for a median duration of 2.5
years. All previously treated participants had used a nucleoside
reverse-transcriptase inhibitor (NRTI).
In the VS group, (re)initiation of ART comprising NRTIs in
combination with NNRTIs, NRTIs in combination with a PI,
and NRTIs alone was reported for 134 (56%), 73 (31%), and 31
(13%) participants, respectively.
There were modest differences in baseline characteristics be-
tween participants who were ART naive and those who were
experienced. ART-naive participants were on average 3 years
younger, less likely to be current smokers, less likely to be taking
blood-pressure-lowering or lipid-lowering therapy, and had
slightly lower serum triglyceride levels. They were also less likely
to be coinfected with either hepatitis B or C virus and less likely
to have had a prior AIDS-defining illness.
The mean period of follow-up was 18 months (median, 15
months). Eleven (4 DC and 7 VS) participants were lost to
follow-up.
Exposure to ART. DC and VS participants received ART for
18% and 89% of the follow-up time, respectively. In the DC
group, 68 participants (30%) (re)initiated ART, 25 of whom
were ART naive (21% of the ART-naive participants) and 43 of
whom were ART experienced (39% of the ART-experienced
participants). Reasons for (re)initiation of ART included CD4
cell count decline to 250 cells/L (38 participants [56% of
those who (re)initiated ART]); CD4 cell percentage decline to
15% (28 participants [41%]); symptoms of HIV disease or
development of OD (14 participants [21%]), with 4 participants
developing an OD event; and nonprotocol reasons (14 partici-
pants [21%]). Of these 68 participants, 30 (44%) initiated ART
at a CD4 cell count 250 cells/L. Kaplan-Meier estimates for
DC participants (re)initiating ART were 11%, 25%, 39%, 45%,
47%, and 55% at 6, 12, 18, 24, 30, and 36 months, respectively. In
the DC group, participants (re)initiated ART at a median CD4
cell count of 236 cells/L (interquartile range [IQR], 183–310
cells/L); those who were ART naive initiated ART at median of
245 cells/L (IQR, 192–338 cells/L), versus 225 cells/L (IQR,
180 –307 cells/L) among ART-experienced participants. In
comparison, 238 participants (96%) in the VS group (re)initi-
ated ART at study entry, at a CD4 cell count 200 cells/L
higher; 189 (79%) had a CD4 cell count between 350 and 549
cells/L, and 49 (21%) had a CD4 cell count 550 cells/L.
In the DC group, 68 (30%) of 228 participants started ART,
and 27 (12%) subsequently interrupted ART. The majority of
Figure 1. Selection of the analyzed cohort (antiretroviral therapy [ART]
naive or not receiving ART for 6 months) from the overall population of
SMART participants. DC, drug conservation; VS, viral supression.










follow-up time was accrued before the first (re)initiation of
ART: 236 person-years (79%) accrued from study entry to first
(re)initiation of ART, 39 person-years (13%) from (re)initiation
of ART to discontinuation, and 25 person-years (8%) after dis-
continuation of ART. During this 8% of follow-up time, 3 par-
ticipants in the DC group experienced an OD event, a serious
non-AIDS event, or died.
CD4 cell count and plasma HIV RNA outcomes. Reflecting
the differing ART exposures, there were substantial differences in
CD4 cell counts and plasma HIV RNA levels over time between
the DC and VS groups. Figure 2 shows time curves for CD4 cell
count and plasma HIV RNA level for each treatment group. The
CD4 cell count was, on average, 148 cells/L lower in DC than VS
participants. The proportions of participants with plasma HIV
Table 1. Overall baseline characteristics and those for patients who were antiretroviral therapy (ART) naive or who had not received
ART for 6 months (no ART) before randomization in the SMART study.
Characteristic















Age, median, years 40 41 41 39 43 41 39 42 41 (35–47)
Female 20.3 22.7 21.5 27.5 32.2 29.7 24.1 27.6 25.8
Race/ethnicity
Black 32.2 39.1 35.5 35.9 39.0 37.3 34.1 39.0 36.4
White 54.2 48.2 51.3 45.8 48.3 47.0 49.8 48.3 49.1
Other 13.6 12.7 13.2 18.3 12.7 15.7 16.1 12.7 14.5
Mode of infection
Same sex contact 55.1 53.6 54.4 48.1 53.4 50.6 51.4 53.5 52.4
Opposite sex contact 44.9 45.5 45.2 52.7 42.4 47.8 49.0 43.9 46.5
Injection drug use 6.8 18.2 12.3 7.6 11.9 9.6 7.2 14.9 10.9
Other or unknown 6.8 7.3 7.0 12.2 11.0 11.6 9.6 9.2 9.4
Body mass
Weight, median, kg 76.7 73.9 75.3 76.7 78.0 77.1 76.7 75.5 76.2 (67.5–87.6)
BMI, median 25.1 24.8 24.9 25.6 25.8 25.8 25.2 25.4 25.3 (22.7–28.8)
CD4 cell count, median,
cells/L
Nadir 371 339 358 378 347 365 376 341 361 (300–422)
Baseline 441 458 452 432 447 435 437 452 447 (385–536)
Baseline plasma HIV RNA
level, median, log10
copies/mL 4.6 4.7 4.6 4.3 4.6 4.5 4.4 4.6 4.5 (4.1–4.9)
Prior AIDS 5.9 14.5 10.1 7.6 16.1 11.6 6.8 15.4 10.9
Current smoker 44.9 51.8 48.2 42.7 50.0 46.2 43.8 50.9 47.2
Diabetes 5.9 6.4 6.1 3.8 5.9 4.8 4.8 6.1 5.5
Prior cardiovascular disease 2.5 0.9 1.8 1.5 4.2 2.8 2.0 2.6 2.3
Blood-pressure-lowering
drugs 7.6 20.9 14.0 16.8 17.8 17.3 12.4 19.3 15.7
Lipid-lowering drugs 5.9 6.4 6.1 3.8 7.6 5.6 4.8 7.0 5.9
Lipid levels, median, mg/dL
Total cholesterol 163 163 163 164 171 166 164 164 164 (142–193)
HDL cholesterol 35 36 36 38 33 36 36 35 36 (29–45)
LDL cholesterol 98 94 96 100 99 100 99 96 97 (78–123)
Triglyceride 120 126 124 121 144 132 121 135 128 (87–192)
ART history
ART naive 100.0 0.0 51.8 100.0 0.0 52.6 100.0 0.0 52.2
PI experienced 0.0 75.5 36.4 0.0 69.5 32.9 0.0 72.4 34.6
NNRTI experienced 0.0 47.3 22.8 0.0 55.9 26.5 0.0 51.8 24.7
Coinfection
Hepatitis B virus 0.9 4.6 2.7 1.6 5.2 3.3 1.2 4.9 3.0
Hepatitis C virus 8.5 24.5 16.2 13.0 16.9 14.9 10.8 20.6 15.5
NOTE. Data are percentage of participants, unless otherwise indicated. BMI, body mass index; DC, drug conservation; HDL, high-density lipoprotein; IQR,
interquartile range; LDL, low-density lipoprotein; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; VS, viral supression.










RNA levels 400 copies/mL at 12 and 24 months were 10% and
25% in the DC group and 59% and 56% in the VS group.
Clinical outcomes. Fifteen participants in the DC group
and 5 in the VS group experienced OD/death (HR, 3.5 [95%
confidence interval {CI}, 1.3–9.6) (figures 3 and 4A). The corre-
sponding HR(DC/VS) for OD and for serious non-AIDS events
was 3.3 (95% CI, 1.0 –10.3) and 7.0 (95% CI, 1.6 –31.4), respec-
tively (figures 3, 4B, and 4C). There was relatively little overlap in
Figure 2. Mean change from baseline CD4 cell count (A) and percentage of patients with plasma HIV RNA levels 400 copies/mL (B) during
follow-up. The solid red lines indicate participants in the drug conservation (DC) group, and the dashed blue lines indicate participants in the viral
supression (VS) group. Vertical bars represent  2 standard errors.
Figure 3. Hazard ratios (HRs) for clinical outcomes among the overall cohort and among those who were either antiretroviral therapy (ART) naive
or not receiving ART at baseline. Horizontal lines represent the 95% confidence interval for each HR. The P value for interaction compares event rates
within each category for ART-naive and ART-experienced participants. DC, drug conservation; VS, viral supression.










OD and serious non-AIDS events (table 2); 21 participants in the
DC group and 6 in the VS group experienced at least 1 of these
(the composite end point) (figures 3 and 4D). The HR for the
composite outcome was 4.2 (95% CI, 1.7–10.4). The excess risk
(DC minus VS) was 5.4 events/100 person-years (95% CI, 3.4 –
7.4). The cumulative percentage developing the composite
end point by 12, 24, and 36 months were 8%, 13%, and 18%
for DC participants and 2%, 4%, and 4% for VS participants
(figure 4D).
For the composite end point, HRs were 4.6 (95% CI, 1.0 –
22.2) for the ART-naive participants and 3.7 (95% CI, 1.2–11.2)
for the ART-experienced participants (P  .84 for difference in
these HRs). In participants excluded from this cohort (see figure
1), HRs for the composite end point were 1.3 (95% CI, 0.6 –3.2)
for experienced participants not receiving ART at entry (200 DC
and 199 VS participants) and 2.0 (95% CI, 1.5–2.6) for partici-
pants receiving ART at entry (2292 DC and 2304 VS partici-
pants) (P  .27 for the difference in HRs between these 4 sub-
groups). In the entire SMART study, there were 270 participants
with a composite end point (180 DC and 90 VS participants),
with a corresponding HR of 2.1 (95% CI, 1.6 –2.7).
Table 3 summarizes the composite outcome by treatment
group and proximal CD4 cell count. Event rates were higher
during the time when participants experienced lower CD4 cell
counts. Per design, participants in the DC group, relative to
those in the VS group, spent substantially longer periods of time
with CD4 cell counts in the 350 cells/L stratum (28% vs.
11% of the time) and substantially less time with CD4 cell
counts in the 500 cells/L stratum (32% vs. 61% of the time).
The majority of events in the DC group (57%) occurred at prox-
imal CD4 cell counts 350 cells/L. Nine (75%) of 12 events in
the DC group (1 OD and 8 serious non-AIDS events) that oc-
curred at CD4 cell counts 350 cells/L happened before the
(re)initiation of ART. Table 3 also summarizes the composite
outcome in the subgroup of participants without prior AIDS and
without a prior non–AIDS-defining illness, for which the
HR(DC/VS) was 6.0 (95% CI, 1.7–20.8) and 7.5 (95% CI, 2.2–
25.4), respectively. Although event rates were similar or reduced
compared with the overall cohort, the HR(DC/VS) did not de-
crease after excluding participants with these prior events.
We investigated whether differences in nadir CD4 cell
counts might have affected the distribution of clinical events.
The data in table 1 indicate that median nadir CD4 cell counts
were not substantially different for the ART-naive or previously
treated participants between treatment groups. The differences
between ART-experienced and ART-naive participants with re-
spect to median baseline CD4 cell count (437 and 376 cells/L,
respectively) and median nadir CD4 cell count (452 and 341
cells/L, respectively) participants were not appreciable. The
HR(DC/VS) for our primary outcome was unaffected in analy-
ses that did or did not adjust for nadir CD4 cell count (HR of
3.7 in both analyses).
Grade 4 events were experienced by 25 DC participants and 18
VS participants. The HR(DC/VS) was 1.6 (95% CI, 0.9 –3.0).
Figure 4. Kaplan-Meier time curves for cumulative probability of opportunistic disease (OD) and death (A), OD alone (B), serious non-AIDS events
and non-OD death (C), and the composite of OD and serious non-AIDS events, which includes all-cause death (D). The solid red lines indicate events
in participants in the drug conservation (DC) group, and the dashed blue lines indicate events in participants in the viral supression (VS) group.






























1 Herpes zoster Yes No 479 498 400
2 Herpes zoster Yes Yes 600 456 41,400
3 Oesophageal candidiasis Yes No 696 696 244,000
4 Oesophageal candidiasis No Yes 448 404 5210
5 Tuberculosis No No 393 221 534,279
6 Oesophageal candidiasis No Yes 387 342 41,846
7 Oesophageal candidiasis No No 408 254 34,700
7 Mycobacterium avium complex No No 408 338 130,000
7 Herpes simplex No No 408 48 17,600
7 Death due to OD No No 408 48 17,600
8 Kaposi sarcoma No No 368 288 750,000
9 Tuberculosis No No 458 337 720,000
10 Lymphoma No No 801 362 668,000
10 Death due to NHL No No 801 307 50
11 Pneumocystis jirovecii pneumonia No No 400 310 388,394
VS group
12 Tuberculosis Yes Yes 399 80 515,705
13 Death due to OD (bacterial pneumonia) No No 588 426 81,375
14 Oesophageal candidiasis No Yes 518 296 30,400
14 Bacterial pneumonia No Yes 518 533 90,700
15 Kaposi sarcoma No Yes 586 428 2228
Serious non-AIDS events
DC group
16 Hepatic cirrhosis Yes Yes 627 463 8800
17 End-stage renal disease Yes No 379 233 109,000
18 Death due to CVD Yes No 492 415 154,000
19 Myocardial infarction Yes No 390 330 4370
19 Coronary artery disease surgery Yes No 390 330 4370
20 Death due to CVD No Yes 376 248 265,100
21 Silent myocardial infarction No No 1271 1132 1140
5 Myocardial infarction No No 393 324 124,390
5 Silent myocardial infarction No No 393 212 401,672
5 Coronary artery disease surgery No No 393 212 401,672
6 Death due to digestive system disease No Yes 387 620 16,271
22 Accidental death No No 1224 488 10,037
23 Death due to renal disease No No 483 615 75
24 Hepatic cirrhosis No Yes 459 467 25,176
25 Non-AIDS cancer No No 610 407 134,000
25 Myocardial infarction No No 610 377 240,000
VS group
26 Hepatic cirrhosis Yes No 701 423 388
27 Death due to non-AIDS cancer No No 577 251 26,542
NOTE. Seven patients had multiple events. Statistical analyses included only the first occurrence of the given end point. Clinical events shown in
boldface are those diagnosed in patients known to be receiving antiretroviral therapy (ART). CVD, cardiovascular disease; DC, drug conservation; NHL,











The randomization in the SMART study for this patient subset
directly compared the early use of ART (at 350 CD4 cells/L)
versus the deferred use of ART (at 250 CD4 cells/L). To our
knowledge, the data presented here represent the first substan-
tive evidence from a randomized trial to inform this critical issue
in HIV medicine since 1994 [1]. During follow-up, there was
substantially lower exposure to ART in the deferred treatment
group (DC). The deferred use of ART was consistent with the
protocol in the majority of participants; although the DC strat-
egy included discontinuation of ART when the CD4 cell count
increased to 350 cells/L, 92% of accrued follow-up was in
participants who were either not receiving ART or taking ART
for the first time after randomization. In the early ART group
(VS), most participants (re)initiated ART with CD4 cell counts
between 350 and 549 cells/L. We combined data from partici-
pants who were ART naive and those who had not been receiving
ART for at least 6 months before randomization. Had we been
more conservative and included only participants who had not
been receiving ART for 12 months before randomization, we
would have reduced the overall number of composite events
from 27 (21 in DC and 6 in VS participants) to 23 (17 in DC and
6 in VS participants). The calculated HR(DC/VS) would still
have indicated a significant benefit for the VS strategy (HR, 3.1
[95% CI, 1.2– 7.9]).
The results suggest that morbidity and mortality associated with
HIV is probably higher than previously thought for patients with
earlier stages of HIV disease. In DC participants, the rates of OD and
serious non-AIDS events were similar. The risk of a composite out-
come was 4-fold higher in DC participants than in VS partici-
pants. The data indicate that the risk of such events is reduced by
early versus deferred use of ART (the absolute risk of an OD or
serious non-AIDS event in DC versus VS participants was 7.0 vs.
1.6/100 person-years). This difference in absolute risk, if confirmed
in a larger trial, is important. Treatment guidelines for the initiation
of ART are conservative because the risk of AIDS (OD in our cate-
gories) at high CD4 cell counts is relatively low and because ART-
related toxicities (and other factors) have been assumed to out-
weigh any likely ART-related benefits. Our data suggest that early
ART use may result in substantial reductions in serious non-AIDS
events. Relative to the DC group, 289 additional person-years of
ART prevented 20 serious clinical events in the VS group. Hence,
prevention of 1 event requires 14 extra person-years of ART. When
assessed for AIDS events alone, prevention of 1 event requires 42
extra person-years of ART.
The occurrence of AIDS at higher than expected CD4 cell
counts has been described previously [7, 17]. There are fewer
Table 3. Clinical events (composite end point), by treatment group and proximal CD4 cell count.
Patient category,
proximal CD4 cell count
DC group VS group
HR(DC/VS) 95% CI
Person-
yearsa (%) Eventsb Ratec
Person-
yearsa (%) Eventsb Ratec
All participants
250 cells/L 19 (6.4) 3 (2) 16.0 10 (2.6) 1 10.5
250–349 cells/L 65 (21.7) 6 (3) 9.3 30 (7.9) 2 6.7
350–499 cells/L 118 (39.5) 9 (7) 7.6 108 (28.8) 3 2.8
500 cells/L 98 (32.4) 3 (2) 3.1 230 (60.7) 0 0.0
Overall 300 (100) 21 (14) 7.0 378 (100) 6 1.6 4.2 1.7–10.4
Those without prior AIDS
250 cells/L 16 (5.9) 2 (2) 12.8 8 (2.4) 0 0.0
250–349 cells/L 58 (21.6) 5 (2) 8.6 26 (7.7) 1 3.9
350–499 cells/L 107 (39.8) 5 (4) 4.7 95 (28.1) 2 2.1
500 cells/L 88 (32.7) 3 (2) 3.4 209 (61.8) 0 0.0
Overall 269 (100) 15 (10) 5.6 338 (100) 3 0.9 6.0 1.7–20.8
Those without a prior
non–AIDS-defining illness
250 cells/L 17 (5.9) 3 (2) 18.2 9 (2.5) 1 10.9
250–349 cells/L 63 (22.0) 5 (2) 8.0 28 (7.9) 1 3.6
350–499 cells/L 116 (40.4) 8 (6) 6.9 103 (29.1) 1 1.0
500 cells/L 92 (31.7) 3 (2) 3.3 214 (60.5) 0 0.0
Overall 288 (100) 19 (12) 6.6 354 (100) 3 0.8 7.5 2.2–25.4
NOTE. CI, confidence interval; DC, drug conservation; HR(DC/VS), hazard ratio for DC group vs. VS group; VS, viral supression.
a Time spent in the CD4 cell count category (censored at event).
b First events only. Values in parentheses indicate the no. of events that occurred before the (re)initiation of antiretroviral therapy.
c Per 100 person-years.










data linking CD4 cell counts and the risk of non–AIDS-related
morbidity and mortality. Some non-AIDS conditions appear to
be linked to progressive immunodeficiency [8, 9, 18]. In the
SMART study, lower CD4 cell counts and higher plasma HIV-
RNA levels explain much of the excess risk in DC compared with
VS participants for non-OD death as well as OD [18]. The data
presented here for SMART participants not receiving ART are
consistent with these observations.
Mechanistically, it appears to be unlikely that a common
pathway for all non-AIDS events exists. Furthermore, the risk
and/or the benefit of ART for reducing non-AIDS diseases is not
clear. For example, PI therapy has been associated with an in-
creased risk of myocardial infarction [19, 20]. On the other
hand, continuous ART in SMART was associated with better
cardiovascular outcomes than ART interruption [14]. It is pos-
sible that untreated HIV disease supports a range of inflamma-
tory responses that, particularly over long periods, set the scene
for atherosclerosis in individuals with additional risk factors for
poor cardiovascular outcomes. The increased risk of cardiovas-
cular disease in patients with systemic lupus erythematosus is
similar in this regard [21, 22]. In addition, in SMART, changes in
lipids appear to explain some of the increased risk of cardiovas-
cular disease in the DC compared with the VS group [23]. The
pathogenesis of hepatic and renal disease along with non-AIDS
cancer is less clear. These equivocal and perhaps controversial
issues further highlight the need for a careful evaluation of risks
and benefits of early treatment with ART [24]. Furthermore,
they reinforce the importance of studies with systematically col-
lected clinical end points matched with appropriate biological
samples as a key feature of trial design for HIV infection [25].
There are limitations to our findings. First, we did not pre-
specify the patient subgroup or composite outcome of OD and
serious non-AIDS events in the original SMART analysis plan.
Thus, our findings generate new hypotheses that equire confir-
mation. Predefined components of our composite outcome
have been reported for all SMART participants [14, 26]. For each
end point, there is an excess risk in the DC compared with the VS
group. The higher risk in DC compared with VS participants for
this composite outcome is not limited to those in this small sub-
group. The HR(DC/VS) for the composite of OD and serious
non-AIDS events is 1 for each of the 4 cohorts classified by
baseline ART use and is and significantly 1 for all SMART
participants. Second, although the CIs around the HR estimates
are wide as a result of the small number of composite events
(n  27), they are qualitatively similar to the reliably estimated
2-fold difference in risk for the overall SMART study. Third, we
included a small number of participants who had prior AIDS-
defining illnesses (23 DC and 29 VS participants). However,
analyses that excluded these participants were consistent with
the present results (table 3). Finally, in SMART we did not for-
mally collect information on treatment-limiting toxicities that
did not attain the severity to qualify as a grade 4 adverse events.
During the period of observation, there were 3 DC participants
(1%) and 24 VS participants (10%) who ceased ART with toxic-
ities being the reason cited. During follow-up, there were 25 and
18 grade 4 events in the DC and VS groups, respectively.
These data indicate that the absolute risk of serious non-AIDS
events in untreated patients is greater than the risk of AIDS at
high CD4 cell counts. They reveal that risk reductions for AIDS
associated with the earlier use of ART appear to be greater than
previously estimated. Furthermore, the data suggest that re-
duced risk for serious non-AIDS outcomes arising from the early
use of ART might substantially outweigh any increased risk of
serious non-AIDS outcomes associated with the use of ART. We
believe the data presented here provide a strong clinical rationale
for the design and conduct of a randomized trial to estimate
precisely the risks and benefits of the initiation of ART before the
CD4 cell count declines to 350 cells/L for the treatment of
chronic HIV disease.
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When to Start Antiretroviral Therapy in Resource-Limited Settings
Rochelle P. Walensky, MD, MPH; Lindsey L. Wolf, SB; Robin Wood, FCP, MMed, DTM&H; Mariam O. Fofana, AB;
Kenneth A. Freedberg, MD, MSc; Neil A. Martinson, MBBCh, MPH; A. David Paltiel, PhD; Xavier Anglaret, MD, PhD;
Milton C. Weinstein, PhD; and Elena Losina, PhD, for the CEPAC-International Investigators*
Background: The results of international clinical trials that are as-
sessing when to initiate antiretroviral therapy (ART) will not be
available for several years.
Objective: To inform HIV treatment decisions about the optimal
CD4 threshold at which to initiate ART in South Africa while await-
ing the results of these trials.
Design: Cost-effectiveness analysis by using a computer simulation
model of HIV disease.
Data Sources: Published data from randomized trials and observa-
tional cohorts in South Africa.
Target Population: HIV-infected patients in South Africa.
Time Horizon: 5-year and lifetime.
Perspective: Modified societal.
Intervention: No treatment, ART initiated at a CD4 count less than
0.250  109 cells/L, and ART initiated at a CD4 count less than
0.350  109 cells/L.
Outcome Measures: Morbidity, mortality, life expectancy, medical
costs, and cost-effectiveness.
Results of Base-Case Analysis: If 10% to 100% of HIV-infected
patients are identified and linked to care, a CD4 count threshold for
ART initiation of 0.350  109 cells/L would reduce severe oppor-
tunistic diseases by 22 000 to 221 000 and deaths by 25 000 to
253 000 during the next 5 years compared with ART initiation at
0.250  109 cells/L; cost increases would range from $142 million
(10%) to $1.4 billion (100%). Either ART initiation strategy would
increase long-term survival by at least 7.9 years, with a mean
per-person life expectancy of 3.8 years with no ART and 12.5 years
with an initiation threshold of 0.350  109 cells/L. Compared with
an initiation threshold of 0.250  109 cells/L, a threshold of
0.350  109 cells/L has an incremental cost-effectiveness ratio of
$1200 per year of life saved.
Results of Sensitivity Analysis: Initiating ART at a CD4 count less
than 0.350  109 cells/L would remain cost-effective over the next
5 years even if the probability that the trial would demonstrate the
superiority of earlier therapy is as low as 17%.
Limitation: This model does not consider the possible benefits of
initiating ART at a CD4 count greater than 0.350  109 cells/L or
of reduced HIV transmission.
Conclusion: Earlier initiation of ART in South Africa will probably
reduce morbidity and mortality, improve long-term survival, and be
cost-effective. While awaiting trial results, treatment guidelines
should be liberalized to allow initiation at CD4 counts less than
0.350  109 cells/L, earlier than is currently recommended.
Primary Funding Source: National Institute of Allergy and Infec-
tious Diseases and the Doris Duke Charitable Foundation.
Ann Intern Med. 2009;151:157-166. www.annals.org
For author affiliations, see end of text.
* For a list of the CEPAC-International investigators, see Appendix 1 (available
at www.annals.org).
Recent data from cohort studies and mathematicalmodels in the developed world suggest that treat-
ment outcomes of HIV-infected patients improve when
antiretroviral therapy (ART) is initiated at CD4 counts
less than 0.350  109 cells/L or even 0.500  109
cells/L (1– 4). The question of when to start ART in
HIV-infected patients is even more critical in resource-
limited settings, in the context of higher rates of mor-
tality and opportunistic diseases—including tuberculo-
sis and other severe bacterial infections—at CD4 counts
greater than 0.200  109 cells/L (5). At CD4 counts
between 0.200 and 0.350  109 cells/L, the rates of
such opportunistic diseases in South Africa may be 10-
fold higher than those seen in the United States (5, 6).
Several international clinical trials, including one in
South Africa, are currently enrolling patients. These tri-
als will explicitly address the clinical benefits of earlier
ART initiation (at CD4 counts 0.350  109 cells/L
or 0.500  109 cells/L) compared with the current
World Health Organization (WHO) standard of care
(stage 3 or 4 disease or when CD4 counts decrease to
0.200  109 cells/L) (7–9).
Although clinical trials may provide insight into the
optimal timing of ART in resource-limited settings, they
can only address short-term outcomes and will not be
available to inform practice for several years (8, 9). Our
objective is to inform crucial decisions now, until these
trials are reported, by using a model-based analysis to ex-
amine treatment strategies with different ART initiation
thresholds in South Africa.
See also:
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Using a computer-based model of HIV disease, we
examined the policy decision regarding when to initiate
ART in South Africa. We considered 3 strategies for in-
terim treatment until the results of the ART initiation tri-
als are available: no treatment (for comparison purposes),
initiate ART at a CD4 count less than 0.250  109 cells/L
(or severe opportunistic disease) (7), and initiate ART at a
CD4 count less than 0.350  109 cells/L (or severe oppor-
tunistic disease). We initiated cotrimoxazole prophylaxis at
a CD4 count less than 0.500  109 cells/L in all strategies,
in accordance with WHO recommendations (10). We ex-
amined the effect of this decision over both short-term
(5-year) and lifetime horizons. We emphasize that all of
these strategies would involve acting optimally on the re-
sults of the trials once they are available in 5 years.
To report on cost-effectiveness, we adopted a modified
societal perspective, considering only direct, HIV-associated
use of medical resources. We reported all costs in 2006
U.S. dollars by using country-specific gross domestic prod-
uct (GDP) deflators and the 2006 mean exchange rate
between the South African rand and the U.S. dollar (6.8
rand  1 U.S. dollar) (11, 12). We discounted all costs
and life expectancies at 3% per year (13). The WHO
guidelines designate health interventions as cost-effective if
the cost per quality-adjusted life-year is less than 3 times
the country’s per-capita GDP, and very cost-effective if the
cost per quality-adjusted life-year is less than the country’s
per-capita GDP (14, 15). Although our analysis computes
cost-effectiveness ratios in terms of years of life saved (YLS)
(rather than quality-adjusted life-years), these thresholds
provide general guidance. As a reference point, we com-
pared the results with South Africa’s 2006 per-capita GDP
(U.S. $5400) (11).
Projections Over the Next 5 Years
We first examined the policy over the next 5 years to
inform decisions regarding whether it would be best to
consider therapy at a CD4 count threshold of 0.350  109
cells/L rather than 0.250  109 cells/L while waiting for
the clinical trial results. We did this in 2 steps. First, we
projected the number of South African patients who would
require ART over the 5-year time horizon and their antic-
ipated short-term clinical outcomes (defined as deaths and
opportunistic diseases) and costs under alternative ART
initiation scenarios. To do so, we used model-based meth-
ods, similar to those previously described (16), to examine
how many HIV-infected persons in South Africa would be
eligible for ART at a CD4 count threshold of 0.350  109
cells/L versus 0.250  109 cells/L over the 5-year time ho-
rizon. This estimate assumes steady HIV incidence over
the next 5 years and accounts for HIV- and non–HIV-
related deaths that occur before reaching the 0.350  109
cells/L threshold.
By combining data from the WHO and the Presi-
dent’s Emergency Plan for AIDS Relief, we estimated the
proportion of HIV-infected persons who were identified
and linked to care in South Africa (Appendix 2, available
at www.annals.org) (17, 18). We estimated the effect if
10% (the proportion estimated to be receiving ART), 30%
(the estimate of those receiving either ART or other, gen-
eral President’s Emergency Plan for AIDS Relief services),
or 100% (as an upper bound) of patients were linked to care.
Finally, we assumed that a clinical trial will provide
perfect information in 5 years about whether using an
ART initiation threshold of 0.350  109 cells/L is more
efficacious than the current standard of care and developed
a decision criterion under which it would be cost-effective
(3  GDP) to invoke a policy of initiation at a CD4
count threshold of 0.350  109 cells/L now while awaiting
clinical trial results. This criterion included a threshold
value for the probability that the trials will demonstrate the
superiority of starting ART at CD4 counts less than
0.350  109 cells/L.
Developing a Decision Criterion
To develop a decision criterion for earlier ART initia-
tion now, we examined 2 potential policy scenarios (ART
initiation at CD4 counts 0.350  109 cells/L vs.
0.250  109 cells/L) over the next 5 years and their as-
sociated clinical and economic outcomes (Figure 1). These
outcomes excluded any long-term benefits, detriments, or
costs potentially associated with either decision beyond the
5-year horizon. Although the calculated outcomes included
ART-related toxicities, they also excluded any excess tox-
Context
Rapid control of HIV infection is especially important in
resource-limited countries with high rates of opportunistic
infections. Therapy initiation guidelines would be useful
for South African physicians while awaiting the results of
ongoing trials of different CD4 count thresholds for ther-
apy initiation.
Content
The investigators used a computer simulation of HIV dis-
ease to perform a cost-effectiveness analysis of 3 options:
no treatment and thresholds of 0.250 and 0.350  109
cells/L. Compared with a threshold of 0.250  109 cells/L,
starting at 0.350  109 cells/L was highly cost-effective,
even when the probability that a trial would show its
superiority was as low as 17%.
Implication
Earlier antiretroviral therapy will probably prove to be
superior in South Africa.
—The Editors
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icity that might be associated with earlier ART beyond
the 5-year horizon. If ART is initiated at a CD4 count
less than 0.350  109 cells/L, the trial may demonstrate
in 5 years that a 0.350  109 cells/L initiation threshold
provides a benefit (probability P) or that it produces
equivalent outcomes to a 0.250  109 cells/L threshold
(probability 1  P). In the latter case, the associated
costs of a 0.350  109 cells/L initiation threshold in-
clude not only those of earlier initiation but also the
HIV medical costs accrued because of the additional
deaths ($536 each) and opportunistic diseases (ranging
from $105 to $1006 each) anticipated with using a
CD4 count threshold of 0.250  109 cells/L compared
with those anticipated with using 0.350  109 cells/L
(19). If ART is initiated at a CD4 count less than
0.250  109 cells/L over the next 5 years, clinical out-
comes and costs would be those derived for the short-
term strategy of initiating ART at CD4 counts less than
0.250  109 cells/L. Averaging out the simple tree in
Figure 1, we created the decision rule under which it
would be economically efficient to set the initiation
threshold at 0.350  109 cells/L now. We defined this
decision rule by examining alternative values for P and
using the cost-effectiveness willingness-to-pay threshold
of 3 times GDP ($16 200/YLS).
Lifetime Projections
After projecting 5-year outcomes, we then projected
and compared the per-person life expectancy and mean
lifetime HIV treatment costs for patients at CD4 count
thresholds for ART initiation of 0.350  109 cells/L and
0.250  109 cells/L. We used these outcomes to produce
incremental cost-effectiveness ratios; we used sensitivity
analyses to examine the effect of key input parameters on
the cost-effectiveness results.
CEPAC International Model
The CEPAC (Cost-Effectiveness of Preventing AIDS
Complications) International model is a state-transition
model of HIV disease in resource-limited settings, with data
derived for several country-specific analyses, including South
Africa (16, 20, 21). In brief, a cohort of hypothetical patients
pass one at a time through health states, in monthly cycles,
from entry into HIV care until death. Health states are de-
fined to be both clinically and economically relevant and are
stratified by current CD4 count, current HIV RNA level, and
history of opportunistic disease. Opportunistic diseases are
categorized into the following groups on the basis of cause,
severity, and similarities in prophylaxis and treatment: mild or
severe bacterial infections, mild or severe fungal infections,
tuberculosis, toxoplasmosis, nontuberculous mycobacteriosis,
Pneumocystis jiroveci pneumonia, and other mild and severe
Figure 1. Decision tree that outlines ART strategy options over the next 5 years while trial results are pending.
Conduct trial
Start ART at CD4 count
<0.350  109 cells/L over 
next 5 y until trial complete
Conduct trial
Start ART at CD4 count




with ART at CD4 count
<0.350  109 cells/L
Projected deaths and
opportunistic diseases
with ART at CD4 count
<0.250  109 cells/L
Projected deaths and
opportunistic diseases
with ART at CD4 count
<0.250  109 cells/L
Clinical
Outcomes
Projected cost of care
with ART at CD4 count 
<0.350  109 cells/L
Projected cost of care 
with ART at CD4 count
<0.350  109 cells/L




<0.250  109 cells/L vs.
ART at <0.350  109 cells/L
Projected cost of care 
with ART at CD4 count
<0.250  109 cells/L
Costs
+
Branch A: Trial confirms that starting
at CD4 count <0.350  109 cells/L
improves outcomes (P)
Branch B: Trial confirms that starting
at CD4 count <0.350  109 cells/L or
<0.250  109 cells/L produces
equal outcomes (1 – P)
The payoffs in terms of both clinical outcomes and costs are delineated to the right of the tree. The probability P represents the chance that the
forthcoming trials studying ART initiation will demonstrate a clinical benefit of ART initiation at a CD4 count threshold of 0.350  109 cells/L. Using
a cost-effectiveness willingness-to-pay threshold of 3 times the per-capita gross domestic product of South Africa ($16,200/year of life saved), the tree
suggests that initiating ART at CD4 counts less than 0.350  109 cells/L now would be optimal for values of P such that $16 200  {[P  costs (left
branch)]  [(1  P)  costs (middle branch)] – [costs (right branch)]}  {[P  outcomes (left branch)]  [(1  P)  outcomes (middle branch)] –
[outcomes (right branch)]}. As described in the Results section, values of P greater than 0.17 satisfy this decision rule. ART  antiretroviral therapy.
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diseases (5). Deaths in the model occur from acute opportu-
nistic events (within 30 days of the event), chronic AIDS (not
within 30 days of an opportunistic disease), or non–HIV-
related causes (22).
Effective ART in the model functions to suppress HIV
RNA level and increase CD4 count (23, 24). Beyond the
beneficial effect of increased CD4 count on opportunistic
diseases and chronic HIV-related death (5), ART results
in an additional reduction in opportunistic diseases and
chronic HIV-related death, as investigators in Côte
d’Ivoire and the United States recently reported (25, 26).
Clinical assessments are assumed to occur every 3 months
and CD4 and HIV RNA testing every 6 months while
receiving therapy, consistent with South African recom-
mendations (27). In accordance with the current standard
of care, the model uses 2 sequential lines of ART; the
second line is initiated when observed CD4 count de-
creases by 30% from its peak observed on-treatment level
or when a severe opportunistic disease is observed at least 6
months after initiation of therapy (27). In accordance with
current treatment guidelines, the second regimen for each
patient is continued until death (7, 28).
Input Parameters
Trial-Eligible Patients
For the short-term projections, we developed a hypo-
thetical cohort of HIV-infected patients who had the ap-
propriate clinical attributes (Table 1). We defined both a
prevalent HIV-infected cohort (to indicate those currently
infected) and an incident HIV-infected cohort (to indicate
those who will become infected and trial-eligible during
the 5-year horizon) (see Appendix 2, available at www.
annals.org). We used previously described methods (16) to
estimate the characteristics (CD4 count and viral load dis-
tribution) of the prevalent cohort in South Africa that
might be eligible now at a CD4 count threshold for ART
initiation of 0.350  109 cells/L. The mean CD4 count
was 0.321  109 cells/L (SD, 0.146) for the prevalent co-
hort; 21% of patients in this cohort would be eligible
for ART initiation at a threshold of 0.350  109 cells/L
versus 0.250  109 cells/L. We also used projections from
the Actuarial Society of South Africa to forecast the number
of incident HIV infections anticipated over the 5-year trial
horizon (29). The incident cohort had a mean CD4 count
of 0.534  109 cells/L (SD, 0.164). In the first year after
incident infection, 15% of patients in this cohort would be
eligible for ART initiation at a threshold of 0.350  109
cells/L versus 0.250  109 cells/L.
Because the CD4 counts and HIV RNA distributions
of patients in the prevalent cohort and the incident cohorts
differ, we derived survival data separately for each cohort.
Using the CEPAC International model, we initialized the
prevalent and incident cohorts to create a composite pic-
ture of the CD4 and HIV RNA distribution of each co-
hort, given their duration of infection (16). We projected





Mean age (SD), y 32.8 (9) 5
Men, % 55 5
Mean CD4 count (SD),  109 cells/L
5-year projections for prevalent cohort 0.321 (0.146) 16
5-year projections for incident cohort 0.534 (0.164) 16
Long-term projections 0.375 (0.10) Assumption
HIV RNA distribution, % 28
100 000 copies/mL 42.5
30 001–100 000 copies/mL 28.3
10 001–30 000 copies/mL 17.9
3001–10 000 copies/mL 7.8
501–3000 copies/mL 2.3
500 copies/mL 1.2
Natural history of disease
Monthly CD4 count decrease,  109
cells/L
30
30 000 copies/mL 6.4
10 001–30 000 copies/mL 5.4
3001–10 000 copies/mL 4.6
501–3000 copies/mL 3.7
500 copies/mL 3.0








Pneumocystis jiroveci pneumonia 0.00–0.12
Other World Heath Organization stage
4–defining diseases
0.25–2.57





Monthly risk for HIV-related death, %* 5
With no history of opportunistic disease 0.09–3.33
With history of opportunistic disease 0.29–7.94
Efficacy of antiretroviral therapy†
First-line therapy‡ 84% 23
Second-line therapy§ 71% 24
Efficacy of cotrimoxazole, %
Bacterial, severe 49.8 31, 32
Toxoplasmosis 83.3 31, 32
Pneumocystis jiroveci pneumonia 97.3 20
Costs, $¶
First-line ART‡, monthly 24 36
Second-line ART§, monthly 47 36
Cotrimoxazole, monthly 1 34
Routine care, monthly** 10–129 5, 19, 33
Inpatient hospital care, per day 221 19
Outpatient clinic care, per visit 11 19
CD4 count, per test 10 35
HIV RNA, per test 49 35
ART  antiretroviral therapy.
* Range by CD4 count. Risk for opportunistic disease varies by CD4 stratum,
divided into 0.050  109 cells/L, 0.051–0.200  109 cells/L, 0.201–0.350 
109 cells/L, 0.351–0.500  109 cells/L, and 0.500  109 cells/L.
† HIV RNA suppression rate at 48 weeks.
‡ Nonnucleoside reverse transcriptase inhibitor–based regimen.
§ Protease inhibitor–based regimen.
 Reduction in probability of occurrence.
¶ In 2006 U.S. dollars.
** Range by CD4 count.
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the survival for HIV-infected patients who did not receive
ART (for the no ART comparison) and those who began
receiving ART at counts less than 0.350  109 cells/L and
less than 0.250  109 cells/L (16). We calculated annual
probabilities of survival (conditional on survival to the be-
ginning of the year) by dividing the number of HIV-
infected patients who were alive at the end of a given cal-
endar year by the number who were alive at the end of the
previous year. This reflects a patient’s probability of surviv-
ing through the year, given that the patient was alive at the
beginning of the year.
Cohort Characteristics
For the long-term projections, the simulated cohort
was designed to resemble the characteristics of HIV-
infected persons in South Africa. Clinical and demographic
characteristics were based on data from the Cape Town
AIDS Cohort (5). In the absence of specific data from
South Africa, we obtained rates of CD4 count decrease,
stratified by baseline HIV RNA level, from the Multicenter
AIDS Cohort Study in the United States (Table 1) (30).
We assumed that patients who entered the model were
initiating HIV care and had a mean age of 32.8 years. For
the long-term projections, we used a mean baseline CD4
count of 0.375  109 cells/L to simulate enrollment crite-
ria for the ART initiation trials; 42.5% of patients had
baseline HIV RNA levels greater than 100 000 copies/mL
(Table 1).
Opportunistic Disease Prophylaxis and Efficacy of
Antiretroviral Therapy
In the absence of reported data from South Africa,
we derived the efficacy of cotrimoxazole prophylaxis in
our model from clinical trials in Côte d’Ivoire (31, 32).
In Côte d’Ivoire, cotrimoxazole confers protection against
bacterial infections, P. jiroveci pneumonia, isospora and
malaria, and toxoplasmosis; isospora infection and malaria
are not reported in the South African data (Table 1) (20).
We assumed that 2 sequential antiretroviral regimens would
be available. First-line therapy was a nonnucleoside reverse
transcriptase inhibitor–based regimen with which a re-
ported 84% of patients experienced HIV RNA suppression
at 48 weeks (mean CD4 count increase, 0.184  109
cells/L [interquartile range, 0.108 to 0.271  109 cells/L])
(23). Patients for whom the first-line regimen failed re-
ceived a protease inhibitor–based second-line regimen. In
this regimen, we incorporated the need for recycled nu-
cleoside reverse transcriptase inhibitors, with a published
estimate of 71% of patients experiencing HIV RNA
suppression at 48 weeks (mean CD4 count increase,
0.151  109 cells/L [interquartile range, 0.105 to
0.239  109 cells/L]) (24).
Costs
We considered HIV-associated direct medical resource
use, including inpatient days, outpatient visits, laboratory
tests, and medication costs (19, 33–37). We excluded di-
rect nonmedical costs and indirect costs (such as patient
time and lost wages). We used a utilization analysis and
unit costing approach to derive health care use from the
Cape Town AIDS cohort (5, 19, 33). We derived costs on
the basis of the number of inpatient hospital days and
outpatient clinic visits associated with each type of oppor-
tunistic disease, or each month of routine HIV care in the
absence of opportunistic disease, and the number of days
and visits during the month of death.
Role of the Funding Source
The study was funded by the National Institute of
Allergy and Infectious Diseases and the Doris Duke Foun-
dation. The funding sources had no input in the study
design, analysis and interpretation of data, writing of the
report, or decision to submit for publication.
Table 2. Clinical and Economic Outcomes of Both ART Initiation Strategies Over the Next 5 Years
Scenario and ART Initiation Criteria Opportunistic Diseases, n Deaths, n Discounted
Costs, $
At 10% HIV case identification and linkage to care
CD4 count 0.350  109 cells/L or opportunistic disease 1 599 859 1 664 458 9 974 640 200
CD4 count 0.250  109 cells/L or opportunistic disease 1 621 969 1 689 739 9 832 663 100
Difference* (22 110) (25 281) 141 977 100
At 30% HIV case identification and linkage to care
CD4 count 0.350  109 cells/L or opportunistic disease 1 406 618 1 348 856 10 436 784 100
CD4 count 0.250  109 cells/L or opportunistic disease 1 472 947 1 424 699 10 010 852 800
Difference* (66 329) (75 843) 425 931 300
At 100% HIV case identification and linkage to care
CD4 count 0.350  109 cells/L or opportunistic disease 730 272 244 249 12 054 287 800
CD4 count 0.250  109 cells/L or opportunistic disease 951 370 497 059 10 634 516 900
Difference* (221 097) (252 810) 1 419 770 900
* Results at CD4 count threshold of 0.350  109 cells/L  results at 0.250  109 cells/L. Data in parentheses denote fewer opportunistic diseases and deaths with ART
initiation at 0.350  109 cells/L. ART  antiretroviral therapy.
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Outcomes Projected Over a 5-Year Horizon
We estimated that 4.7 million HIV-infected persons
in South Africa would become eligible to start ART if the
CD4 count threshold is 0.350  109 cells/L instead of
0.250  109 cells/L over a 5-year time horizon. Among
such persons, 1.2 million are eligible now, 1.6 million will
be eligible over the next year, and 1.9 million will become
eligible over the ensuing 3 years.
For our assumptions that 10%, 30%, and 100% of
these 4.7 million persons are identified and linked to care,
we projected the opportunistic diseases, deaths, and costs
over the next 5 years of alternative ART strategies while
awaiting results of the ART initiation trials (Table 2). At
the conservative HIV identification and linkage to care
estimate of 10%, a CD4 count threshold of 0.350  109
cells/L for ART initiation would result in fewer total cases
of opportunistic disease (1 599 900 vs. 1 622 000) and
fewer total deaths (1 664 500 vs. 1 689 700) than a thresh-
old of 0.250  109 cells/L. A threshold of 0.350  109
cells/L would also lead to a discounted $142 million cost
increase over the next 5 years, which reflects the additional
treatment costs (offset in part by the reduced incidence of
opportunistic diseases). At the maximum estimate (100%
identification and linkage to care), 221 000 cases of oppor-
tunistic disease and 253 000 deaths could be averted. In
this situation, the additional costs of using a threshold of
0.350  109 cells/L would exceed $1.4 billion. Figure 2
provides results for the clinical and economic effect if be-
tween 10% and 100% of HIV-infected, eligible patients
are identified and present for care. Clinical and cost results
move together—the fewer patients identified, the fewer
deaths and opportunistic diseases are averted and the lower
the added total costs of an earlier ART initiation strategy.
Decision Criteria
We then examined the probability that the data from
the forthcoming trials would provide enough statistical ev-
idence that a CD4 count threshold for ART initiation of
0.350  109 cells/L is superior to a 0.250  109 cells/L
threshold—which would confirm the model-based results.
If this is certain (100% probability), the incremental cost-
effectiveness of a threshold of 0.350  109 cells/L com-
pared with 0.250  109 cells/L is $2400/YLS, considering
only the costs and benefits over the next 5 years. If the
probability that the trials show a benefit to a threshold of
0.350  109 cells/L decrease to 10%, the incremental cost-
effectiveness over the next 5 years would increase to
$27 100/YLS. Using the established WHO cost-effectiveness
guideline, a policy option to initiate ART at CD4 counts
less than 0.350  109 cells/L should be used over the next
5 years if the probability that the trial will confirm model-
based results is 17% or greater (Figure 3). In sensitivity
analyses, we varied the composite increase in deaths asso-
Figure 2. Model-based projections over the next 5 years for
strategies of ART initiation at CD4 count thresholds of






















HIV Diagnosed and Linked to Care, %
Opportunistic diseases, ART at CD4 count <0.250  109 cells/L
Opportunistic diseases, ART at CD4 count <0.350  109 cells/L
Deaths, ART at CD4 count <0.250  109 cells/L
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Squares indicate total deaths and circles indicate total opportunistic dis-
eases for the 2 strategies (left vertical axis). The bars indicate excess total
costs of initiating ART at a threshold of 0.350  109 cells/L compared
with 0.250  109 cells/L over a 5-year horizon (right vertical axis). The
horizontal axis represents results at varying proportions of HIV cases
identified and linked to care in the population. ART  antiretroviral
therapy.
Figure 3. Incremental cost-effectiveness of ART at CD4
count thresholds of 0.350  109 cells/L versus 0.250  109
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P represents the probability that the trial will confirm model-based re-
sults indicating a benefit of earlier therapy (see Methods and Figure 1).
The incremental cost-effectiveness is provided for the 5-year time hori-
zon. The height of the bar provides the cost-effectiveness ratio of an
initiation threshold of 0.350  109 cells/L versus 0.250  109 cells/L
for alternative values of P; bars that remain below the horizontal solid
line (3  GDP) are considered to be cost-effective and those that re-
main below the horizontal dotted line (1  GDP) are considered to
be very cost-effective. ART  antiretroviral therapy; GDP  gross
domestic product in South Africa (U.S. $5400); YLS  year of life saved.
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ciated with an ART initiation threshold of 0.250  109
cells/L versus 0.350  109 cells/L from 2-fold more deaths
(base case) to 1.5-fold more deaths. The decreased benefits
of the 0.350  109 cells/L threshold can simulate situa-
tions in which earlier therapy is less effective on an indi-
vidual level than the model projects or linkage to care is
lower at a threshold of 0.350  109 cells/L than at
0.250  109 cells/L because of the absence of clinical trial
data. Under such a scenario, a policy option to initiate
ART at CD4 counts less than 0.350  109 cells/L should
be used over the next 5 years if the probability that the trial
will confirm model-based results is 28% or greater (Appen-
dix Figure, available at www.annals.org).
Lifetime Projections
When we projected long-term outcomes for a cohort
with a mean CD4 count of 0.375  109 cells/L, the no-
treatment strategy resulted in a mean survival of 3.83 years
(4.11 undiscounted), compared with 11.71 years (15.23
undiscounted) at a CD4 count threshold for ART initia-
tion of 0.250  109 cells/L and 12.48 years (16.27 undis-
counted) at a threshold of 0.350  109 cells/L (Table 3).
The survival curves that corresponded to ART initiation
thresholds of 0.350  109 cells/L a d 0.250  109 cells/L
diverged within about 1 year, after which time they became
essentially parallel, when nearly all patients had initiated
ART at a threshold of 0.250  109 cells/L; by year 3,
initiation at CD4 counts less than 0.350  109 cells/L
maintained a consistent 6% absolute advantage in the pro-
portion of the cohort alive through year 10 (Figure 4).
Per-person lifetime direct costs were lowest with no ART
($3930) (Table 3). Lifetime costs increased to $12 730 per
person at an initiation threshold of 0.250  109 cells/L
and $13 620 at 0.350  109 cells/L. The incremental cost-
effectiveness ratio was $1100/YLS at a CD4 count thresh-
old of 0.250  109 cells/L compared with no treatment
and $1200/YLS at a threshold of 0.350  109 cells/L com-
pared with 0.250  109 cells/L (Table 3).
Sensitivity Analyses on Lifetime Projections
Because the long-term results consistently favored a
CD4 count threshold for ART initiation of 0.350  109
cells/L, we designed the sensitivity analyses to bias against
earlier initiation. Specifically, we examined large decre-
ments in second-line antiretroviral efficacy in the earlier
therapy strategies. Second-line efficacy would have to be
fewer than 39% of patients achieving HIV RNA suppres-
sion at 48 weeks—a 32% relative decrease from the base
case—to match the projected survival rate from using a
threshold of 0.250  109 cells/L. To examine the effect of
pill fatigue and failed retention in care (38, 39), we also
considered higher rates of discontinuation of care. We as-
sumed that some patients who started ART at CD4 counts
less than 0.350  109 cells/L discontinued ART at the
time they would have started receiving second-line regi-
mens, thereby only realizing the benefits of first-line ther-
apy (although they still received prophylaxis and treatment
for opportunistic diseases). More than 19% of patients
who received ART at a threshold of 0.350  109 cells/L at
the time of treatment failure would need to discontinue
treatment to decrease survival to that associated with a
threshold of 0.250  109 cells/L. Finally, when we in-
cluded a hypothetical third-line antiretroviral regimen, sur-
vival and costs increased for both ART treatment strategies.
The incremental cost-effectiveness of using a threshold of
0.350  109 cells/L was largely unchanged from that of
using 0.250  109 cells/L ($1000/YLS). Appendix 2
(available at www.annals.org) provides detailed results of
these and other analyses.
DISCUSSION
Although the forthcoming trials in South Africa and
other resource-limited settings should yield important in-
formation in the next 5 to 10 years, our analysis suggests
that, until trial data are available, a CD4 count threshold
of 0.350  109 cells/L for initiating ART would probably
yield better clinical outcomes than a lower threshold. The
magnitude of such benefits multiply with increased rates of
HIV identification and linkage to care. A threshold of
0.350  109 cells/L is also expected to be highly cost-
effective in the interim. Many of the clinical benefits of
starting earlier occur beyond the 5-year time horizon of the
trial (manifested in increased life expectancy). Even so, our
results suggest that a threshold of 0.350  109 cells/L re-









No treatment 3930 3.83 (4.11) –
Initiating ART at CD4 counts 0.250 
109 cells/L or opportunistic disease
12 730 11.71 (15.23) 1100
Initiating ART at CD4 counts 0.350 
109 cells/L or opportunistic disease
13 620 12.48 (16.27) 1200
ART  antiretroviral therapy; YLS  year of life saved.
* Discounted at 3% per year.
† Incremental cost-effectiveness ratios are calculated compared with the next less costly strategy. Because of rounding, the incremental cost-effectiveness ratios may not match
exactly the ratios of lifetime costs and projected survival reported in the table.
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mains cost-effective if the probability is 17% or greater that
the forthcoming trials will demonstrate improved clinical
outcomes with starting ART earlier.
When ART is initiated according to current treatment
guidelines, we found that an ART initiation threshold of
0.250  109 cells/L is very cost-effective in the long term
for HIV infection in South Africa, with a ratio of $1100/
YLS (7); for a threshold of 0.350  109 cells/L, the cost-
effectiveness ratio is $1200/YLS. That these ratios are sim-
ilar suggests that if HIV treatment is worth initiating, early
initiation provides similar value to later treatment. We spe-
cifically designed sensitivity analyses to see how these re-
sults might change and found that very high rates of drug
resistance and pill fatigue would be required to make ear-
lier therapy not cost-effective. Because our results depend
heavily on the frequency of opportunistic diseases at higher
CD4 counts, morbidity rates should be assessed carefully at
high CD4 counts; initiation of therapy at a greater CD4
count threshold than 0.350  109 cells/L may be justified
in South Africa.
Conducting the current trials remains critically impor-
tant in informing the question of when to start ART.
Evidence-based guidelines continue to maintain that ran-
domized, controlled trials are the gold standard for devel-
oping policy; modeling analyses are still considered lower
levels of evidence (40, 41). As such, randomized trials will
probably be used as the benchmark evidence for HIV treat-
ment throughout the world. Meanwhile, our model-based
analysis suggests that opening up the option to start ART
earlier in the disease course would probably improve clin-
ical outcomes, at least until trial results are available. Our
results suggest that 25 000 lives may be at stake; waiting 5
years for trial results could be costly in human terms.
Despite findings that a CD4 count threshold for ART
initiation of 0.350  109 cells/L may be beneficial, a study
on patient characteristics at presentation to care in South
Africa suggests that a discussion of earlier versus deferred
ART initiation may not be germane at present; in that
study, the mean CD4 count of patients who started ART
was only 0.096  109 cells/L (42). However, wider imple-
mentation of the WHO guidelines for using HIV testing
technologies (43) and improved HIV screening and linkage
to care should result in the identification of more patients
who are eligible for earlier therapy initiation (7). Decisions
need to be made on how best to optimize their care, and
efforts to identify them must continue if a policy of earlier
therapy is to have a meaningful effect. Our analysis dem-
onstrates that a CD4 count threshold of 0.350  109
cells/L is highly effective and confers similar value to a
threshold of 0.250  109 cells/L.
However, an ART initiation threshold of 0.350  109
cells/L may not be optimal in some cases, such as when
treatment capacity is limited—as is currently the case in
many places (16). In such settings, prioritization—whether
ART should be provided on a first-come, first-served basis
or on a CD4 count–based policy—is already problematic
(44). With inadequate treatment capacity, increasing the
treatment initiation threshold for all patients to a CD4
count of 0.350  109 cells/L, without prioritization for the
sickest patients, could result in more deaths in the near
term, even if earlier therapy is associated with long-term
benefits. Thus, guidelines that move toward ART initia-
tion at higher CD4 counts should be implemented only in
settings with adequate capacity to treat all of those who are
eligible and at highest risk.
Our study has limitations. First, this analysis does not
represent an assessment of the estimated value of perfect
information, which would examine whether the trial is
worth doing. Because trials are already enrolling, we ad-
dress the question of the optimal clinical strategy while
awaiting the results of those trials. Second, we incorporated
input data from multiple sources. Although they were uni-
formly derived, not all data are from similar cohorts in
South Africa. Sensitivity analyses demonstrate that within
reasonable reported ranges, our major conclusions are
robust to these data estimates. Third, implementation
of ART strategies by CD4 threshold in international
settings—where CD4 testing is not universally available—
may require investments in infrastructure. Fourth, our
model does not account for the potential benefits of ART,
unrelated to opportunistic diseases, that might be attribut-
able to treatment at CD4 thresholds higher than the cur-
rent standard of care (45). We also do not capture any
additional benefits in preventing HIV transmission that
earlier ART may confer because of viral load reduction
(46). To the extent that these benefits occur, earlier therapy
would be even more advantageous. Finally, earlier therapy
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The annual mortality hazard 2 years after entry into care was 0.01 for a
threshold of 0.350  109 cells/L, 0.05 for 0.250  109 cells/L, and 0.06
for no ART. Two years after entry into care, the composite annual
hazard of severe opportunistic disease, tuberculosis, or death was 0.06 for
a threshold of 0.350  109 cells/L, 0.16 for 0.250  109 cells/L, and
0.17 for no ART (data not shown). ART  antiretroviral therapy.
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may have other additional benefits in African countries
that have higher rates of malaria and bacterial diseases than
those documented in South Africa (5, 31).
Ongoing randomized trials are studying the question
of when to initiate ART in resource-limited settings. As
these trials continue to enroll and accrue follow-up toward
the primary outcomes, decisions must be made now re-
garding the optimal ART initiation policy in these settings.
While we await trial results in settings of adequate treat-
ment capacity, this study demonstrates that it is probably
both effective and cost-effective to liberalize the opportu-
nity for ART to be initiated at a CD4 count threshold of
0.350  109 cells/L in South Africa.
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APPENDIX 2: TECHNICAL APPENDIX
We offer this technical appendix to provide supplementary
data to reviewers regarding requested model input parameters
and further sensitivity analyses.
Methods
Appendix Table 1 provides the calculations we used to
project the number of persons eligible, by year, for the treatment
decision of ART initiation at a CD4 count threshold of
0.350  109 cells/L versus 0.250  109 cells/L.
Appendix Table 2 provides estimates of HIV-infected per-
sons who were identified and linked to care in 3 countries. These
estimates are obtained in part from WHO country-specific re-
ports on the number of persons living with HIV/AIDS (17) and
from the President’s Emergency Plan for AIDS Relief reports on
the number of HIV-infected persons who received care and sup-
port in fiscal year 2008 as well as those who received ART (18).
Appendix Table 3 provides the monthly risk for opportu-
nistic diseases, stratified by the CD4 cell counts used in the
model (Table 1 provides a summary of these data).
Results
Sensitivity Analysis of Trial Projections
Table 2 indicates an approximate 2-fold increase in total
deaths at a CD4 count threshold for ART initiation of
0.250  109 cells/L compared with 0.350  109 cells/L over a
5-year horizon. Because this 2-fold estimate results from model
output, many degrees of freedom within the model inform this
estimate, including rates of opportunistic diseases, deaths associ-
ated with those events, ART efficacy, and AIDS-related mortality
itself.
We examined the composite death rates of model output
from the 2 ART strategies, diminishing the benefit of a CD4
count threshold for ART initiation of 0.350  109 cells/L from
2.0 to 1.1. For example, if the initial death rate in year 1 was 0.03
when using a threshold of 0.350  109 cells/L and 0.07 when
using 0.250  109 cells/L, then our sensitivity analysis for a ben-
efit of 1.5 examined a new death rate for year 1 of 0.05 for a
threshold of 0.350  109 cells/L ([(0.07  0.03)  0.5] 
0.03). For each sensitivity analysis, we determined this adjusted
death rate in every year of the 5-year horizon. We used a similar
approach with our estimates of opportunistic diseases (decreasing
the benefit of a 0.350  109 cells/L threshold by half) and used
detailed model output to adjust the effect this would have on
costs. For increasing benefits of a threshold of 0.350  109
cells/L (ranging from 1.0 [no benefit] to 2.0 [our results]), the










Appendix Figure provides alternative values for P that meet the
following 2 criteria: the trial demonstrates superiority of an ART
initiation threshold of 0.350  109 cells/L and the cost-
effectiveness ratio (over 5 years) is less than $16 200/YLS
(3  GDP). The solid arrow indicates the threshold P value of
17%; at a value of 1.5 (half the benefit that our model suggests
for a threshold of 0.350  109 cells/L), the value for P is 28%,
indicated by the hollow arrow.
Sensitivity Analyses on Lifetime Projections
Because the results of the lifetime analyses consistently fa-
vored earlier therapy, we designed sensitivity analyses to bias
against earlier initiation. Specifically, we examined large decre-
ments in second-line antiretroviral efficacy in the 0.350  109
cells/L strategies; presumed poorer downstream adherence in the
0.350  109 cells/L strategies; and included a third-line anti-
retroviral regimen, which potentially decreased the survival ben-
efit of initiating ART at 0.350  109 cells/L.
Efficacy and Cost of Antiretroviral Therapy
First-line therapy efficacy varied from 79% to 94% of pa-
tients achieving HIV RNA suppression at 48 weeks (base case,
84%), with minimal effect on the life expectancy and cost-
effectiveness ratios of ART initiation at 0.350  109 cells/L com-
pared with 0.250  109 cells/L (Appendix Table 4). Assuming
that a third line of available antiretrovirals (at the same cost and
efficacy as the second-line regimen) increased survival and costs in
both the 0.350  109 cells/L and 0.250  109 cells/L strategies, the
incremental cost-effectiveness of earlier therapy improved to $1100/
YLS compared with deferred therapy. Changes in the cost of anti-
retroviral drugs from 50% to 200% of the base case altered the
cost-effectiveness ratio of earlier compared with deferred therapy
from $800 to 2400/YLS (Appendix Table 4).
Discontinuation of Antiretroviral Therapy
To examine the effect of pill fatigue and failed retention in
care, we considered increasing rates of discontinuation of care.
Specifically, we assumed that some patients discontinued anti-
retroviral therapy at the time they would have started receiving a
different regimen, thereby only realizing the benefits of first-line
therapy (although they still received prophylaxis and treatment
for opportunistic diseases). More than 19% of patients who re-
ceived therapy at a CD4 count threshold of 0.350  109 cells/L
would need to discontinue treatment to decrease survival to that
associated with deferred therapy. We also considered discontinu-
ation of antiretroviral therapy at thresholds of 0.350 and
0.250  109 cells/L. If the rate of discontinuation at a threshold
of 0.250  109 cells/L was similar to that at 0.350  109 cells/L,
the benefits of earlier therapy diminished as the rates of discon-
tinuation increased; for example, the increase in life expectancy
associated with a threshold of 0.350  109 cells/L compared
with 0.250  109 cells/L was 0.8 year with no discontinuation,
0.7 year with 20% discontinuation, and 0.5 year with 50% dis-
continuation.




Year Persons With CD4 Count
Between 0.250 and 0.350 
109 cells/L
Proportion Persons, n
5 628 474 (2008)† 2008 0.210 1 176 271
2009 0.263 1 480 606
2010 0.124 699 602
2011 0.066 373 664
2012 0.030 166 853
497 756 (2009)‡ 2009 0.153 76 343
2010 0.157 78 094
2011 0.161 80 298
2012 0.136 67 834
492 244 (2010)‡ 2010 0.153 75 498
2011 0.157 77 229
2012 0.161 79 409
488 186 (2011)‡ 2011 0.153 74 875
2012 0.157 76 592
485 346 (2012)‡ 2012 0.153 74 440
* Using methods described here and in reference 16.
† Prevalent cases.
‡ Incident cases.
Appendix Table 2. Estimates of HIV-Infected Persons
Identified and Linked to Care in 3 African Countries*
Country Persons Estimated






South Africa 5 200 000 1 852 700 (34) 549 700 (10)
Côte d’Ivoire 605 000 103 200 (17) 50 500 (8)
Uganda 615 000 392 100 (63) 145 000 (24)
ART  antiretroviral therapy.
* We use the midpoint of the estimated range of cases from the World Health
Organization to calculate percentages. The denominator is the estimated number
of persons living with HIV/AIDS.










Appendix Table 3. Monthly Risk for Opportunistic Diseases, by CD4 Count













Severe opportunistic disease, %
Bacterial 0.71 0.30 0.13 0.08
Fungal 2.22 0.42 0.10 0.02
Tuberculosis 1.96 1.14 0.67 0.21
Toxoplasmosis 0.06 0.02 0.00 0.00
Nontuberculous mycobacteriosis 0.30 0.03 0.00 0.01
Pneumocystis jiroveci pneumonia 0.12 0.02 0.00 0.01
Other World Health Organization stage 4–defining diseases 2.57 0.68 0.30 0.25
Mild opportunistic disease, %
Fungal 3.51 2.05 1.28 0.59
Other 3.06 2.70 3.11 2.51
Appendix Table 4. Selected Sensitivity Analyses and Results for the Projected Cost-Effectiveness of Earlier ART Initiation




Base case – 12.48 1200
Efficacy of first-line ART 79%–94% achieving virologic suppression at
48 wk
12.17–12.63 1200–1100
Number of ART regimens available 1–3 lines 10.89–13.89 1100‡–1100‡
Cost of ART 0.5–2.0  base-case value (first-line monthly
cost range, $12–$48; second-line monthly
cost range, $24–$94)
– 800‡–2400
ART switching rule “Only switch at opportunistic disease event” to
“switch at opportunistic disease event or
50% decrease in peak CD4 count”
12.47–12.47 1200–1200
ART stopping rule “Stop at opportunistic disease event or 90%
decrease in peak CD4 count” to “never
stop”
10.68–12.48 500‡–1200
CD4-independent effect of ART on
death and opportunistic diseases
No effect 8.96 1100
ART  antiretroviral therapy; YLS  year of life saved.
* Discounted.
† Unless otherwise noted, incremental cost-effectiveness ratios are reported for initiating ART at CD4 counts 0.350  109 cells/L versus 0.250  109 cells/L.
‡ We report the incremental cost-effectiveness ratio for initiating ART at CD4 counts 350  109 cells/L compared with no treatment because we excluded all strategies
that were dominated when we calculated cost-effectiveness ratios.










Appendix Figure. Sensitivity analysis on the benefit of ART at
















Relative Risk for Death With 
ART at <0.250  109 cells/L vs. ART at <0.350  109 cells/L









Results from the model suggested a 2-fold decrease in the death rate with
ART initiation at a CD4 count 0.350  109 cells/L. The vertical axis
shows the threshold P value at which the trial will demonstrate a benefit
of ART initiation at 0.350  109 cells/L and that also meets the
cost-effectiveness threshold criterion of $16 200 (3 times the gross
domestic product of South Africa). The solid arrow indicates the 17%
threshold discussed in the article; the open arrow indicates the results if
the benefit of ART initiation at 0.350  109 cells/L were half (1.5) of
what the model projected. ART  antiretroviral therapy.
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Initiating patients on antiretroviral therapy at CD4
cell counts above 200 cells/ml is associated with
improved treatment outcomes in South Africa
Matthew P. Foxa,b,c,d, Ian M. Sannec, Francesca Conradiec,
Jennifer Zeineckere, Catherine Orrelle, Prudence Ivec,
Mohammed Rassoolc, Marjorie Dehlingerf, Charles van der Horstg,
James McIntyreh and Robin Woode
Objectives: To compare treatment outcomes by starting CD4 cell counts using data
from the Comprehensive International Program of Research on AIDS-South Africa trial.
Design: An observational cohort study.
Methods: Patients presenting to primary care clinics with CD4 cell counts below
350 cells/ml were randomized to either doctor or nurse-managed HIV care and followed
for at least 2 years after antiretroviral therapy (ART) initiation. Clinical and laboratory
outcomes were compared by baseline CD4 cell counts.
Results: Eight hundred and twelve patients were followed for a median of 27.5 months
and 36% initiated ART with a CD4 cell count above 200 cells/ml. Although 10% of
patients failed virologically, the risk was nearly double among those with a CD4 cell
count of 200 cells/ml or less vs. above 200 cells/ml (12.2 vs. 6.8%). Twenty-one deaths
occurred, with a five-fold increased risk for the low CD4 cell count group (3.7 vs. 0.7%).
After adjustment, those with a CD4 cell count of 200 cells/ml had twice the risk of death/
virologic failure [hazard ratio 1.9; 95% confidence interval (CI), 1.1–3.3] and twice the
risk of incident tuberculosis (hazard ratio 1.90; 95% CI, 0.89–4.04) as those above
200 cells/ml. Those with either a CD4 cell count of 200 cells/ml or less (hazard ratio 2.1;
95% CI, 1.2–3.8) or a WHO IV condition (hazard ratio 2.9; 95% CI, 0.93–8.8) alone
had a two-to-three-fold increased risk of death/virologic failure vs. those with neither,
but those with both conditions had a four-fold increased risk (hazard ratio 3.9; 95% CI,
1.9–8.1). We observed some decreased loss to follow-up among those initiating ART at
less than 200 cells/ml (hazard ratio 0.79; 95% CI, 0.50–1.25).
Conclusion: Patients initiating ART with higher CD4 cell counts had reduced mortality,
tuberculosis and less virologic failure than those initiated at lower CD4 cell counts. Our
data support increasing CD4 cell count eligibility criteria for ART initiation.
 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
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Introduction
With the increase in global funding for HIV/AIDS, the
developing world has seen unprecedented access to
lifesaving antiretroviral therapy (ART) over the past
5 years. Funds mandated toward rapidly scaling up access
to ART have been successfully targeted and nearly four
million people are now on ART [1]. When large-scale
treatment programs began, in most cases, treatment was
limited to patients with advanced disease. The ideal time
to initiate ART is currently unknown [2]. Although
guidelines for resource-rich environments currently
recommend ART initiation at CD4 cell counts below
350 cells/ml [3,4], developing country guidelines recom-
mended initiating ARTat CD4 cell counts of 200 cells/ml
or less in the absence of clinical disease until November
2009 when the WHO recommended initiating treatment
at CD4 cell counts below 350 cells/ml [5,6]. As new
evidence from resource-rich environments has accumu-
lated, showing that starting ART at higher CD4 cell
counts is associated with better treatment outcomes [7–
9], programs in resource-limited settings, given limited
resources, must make difficult choices about whether
or not to raise initiating CD4 cell count thresholds to
higher levels.
The debate about when to initiate treatment is difficult as
ART is a lifelong treatment that has significant cost and
can have significant side effects. On an individual level,
decisions about when to initiate therapy must balance the
potential medical benefits of initiating at higher CD4 cell
counts [10] and reductions in HIV transmission [11] with
the risk of toxicity and the costs associated with longer
time on treatment. On a public health level, a decision
about when to initiate ART must balance not only any
expected population-level benefits of initiating treatment
at higher CD4 cell counts with the cost implications of
potentially increased demand for treatment if treatment
thresholds are raised but also any possible cost savings
associated with earlier treatment, including reduced
hospitalization and treatment of opportunistic infections
[12]. The first step toward rationalizing decisions on
when to initiate ART is to assess, using data from
resource-limited settings, the likely treatment benefits
that can be expected.
Recent evidence from the developed world suggests that
starting ART at CD4 cell counts below 350 cells/ml
improves treatment outcomes and decreases mortality
compared with waiting until the CD4 cell count drops
below 200 cells/ml [13–17], and the benefits may
even begin when initiating at CD4 cell counts above
350 cells/ml [13], yet limited evidence from the devel-
oping world exists to inform policy [18]. To date, only
one study from a developing country has attempted to
randomize patients to initiate ART at CD4 cell counts
below 350 cells/ml compared with waiting until the CD4
cell count drops below 200 cells/ml. An interim analysis
of the Comprehensive International Program of Research
on AIDS (CIPRA)-Haiti trial [19,20] found that initiat-
ing ART at CD4 cell counts below 200 cells/ml was
associated with a four-fold increased risk of mortality and
a two-fold increased risk of incident tuberculosis (TB)
compared with starting at a CD4 cell count between 200
and 350 cells/ml.
The recent changes in WHO guidelines have yet to be
adopted globally [21]. In order to support decision-making
around when to initiate ART, we assessed the association
between treatment outcomes and starting ART at higher
CD4 cell counts using data collected as part of the
Comprehensive International Program of Research on
AIDS-South Africa (CIPRA-SA) randomized trial com-
paring nurse-monitored antiretroviral treatment with
doctor-monitored treatment in South Africa [22].
Methods
Study design
The data for this study were collected as part of the
CIPRA-SA trial, an unblinded, prospective, randomized
controlled trial comparing nurse vs. doctor-monitored
HIV care and demonstrated equivalence of the two
monitoring strategies for treatment failure over 2 years
[hazard ratio 1.09; 95% confidence interval (CI), 0.89–
1.33] [22]. The study enrolled 812 HIV-positive ART-
naive patients of at least 16 years of age with a CD4 cell
count of 350 cells/ml or less or prior AIDS-defining
illness [Centers for Disease Control and Prevention
(CDC) category B/C] at one of two sites in South Africa
(Soweto, Johannesburg and Masiphumelele, Cape Town).
All patients were managed under South African National
Guidelines for HIV treatment and were given standard
ARTregimens consisting of lamivudine given with either
zidovudine or stavudine and either efavirenz or nevira-
pine [5]. A protease inhibitor-based regimen was used
in a limited number of cases (N¼ 62) for women of
childbearing potential with a CD4 cell count above
350 cells/ml. Patients were randomized 1 : 1 to have their
HIV care monitored by either a nurse or a clinical officer
and were followed for a minimum of 96 weeks. Details of
the CIPRA-SA trial can be found elsewhere [22].
Patient follow-up and data collection
Patients were seen at baseline and then returned for
follow-up visits at weeks 0, 2, 4, 9, 12 and then every
12 weeks. At each visit, patients had a clinical exami-
nation, symptom screening for TB and a blood draw for
laboratory testing, including CD4 cell count, viral load,
hematology and biochemistry.
Although current guidelines in South Africa allow for
initiation of ART for patients with CD4 cell counts of
200 cells/ml or less or WHO Stage IV condition [5], and
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because the CIPRA-SA study enrolled patients with a
CD4 cell count of 350 cells/ml or less, we conducted a
prospective cohort study assessing differences in treatment
failure among those initiating ART at a CD4 cell count
above 200 cells/ml and those initiating at 200 cells/ml
or less.
Definition of study variables
The primary exposure was CD4 cell count above 200 vs.
200 cells/ml or less at ART initiation. CD4 cell count was
measured at randomization in the main CIPRA-SA study
and was assessed using CD4þ flow cytometry (Flow-
Count Fluorospheres; Beckman Coulter-Immunotech,
Marseille, France).
We assessed the relation between starting CD4 cell count
and three indicators of program failure: treatment failure
(an indicator of death or failure to achieve or maintain
viral suppression), incident TB and program failures
(indicated by patients who leave care). Virologic failure
was defined as either failure to reach a 1.5 log10 drop in
viral load by 12 weeks on treatment or two consecutive
viral loads of more than 1000 copies/ml within 1 month
of each other after 24 weeks on treatment. We defined
loss to follow-up (LTFU) as missing three or more
consecutive study visits (in the main study shown as
LTFU and defaulting clinic schedule); we did not include
patients who voluntarily withdrew from the study, as
these patients could remain in care just not on the study
protocol.
To determine whether there were any association
between toxicity-related outcomes and initiating treat-
ment at higher CD4 cell counts, we examined the relation
between initiating CD4 cell count and treatment-related
toxicities. Details of the toxicities that occurred are given
elsewhere [22] but included any toxicity which required
discontinuation of the study regimen, with a resulting
treatment interruption of more than 6 weeks.
For all analyses, person-time accrued from initiation of
treatment to the date of the earliest of experiencing
a treatment outcome (defined above), completion of
48 months of treatment, becoming LTFU (except in
analyses in which LTFU was the outcome) or date of
closing the dataset (20 January 2009).
All patients in the CIPRA-SA trial signed informed
consent forms. The CIPRA-SA trial was approved by the
Institutional Review Boards (IRB) of the University of
the Witwatersrand and the University of Cape Town. The
Boston University IRB gave approval for analysis of the
data in a de-identified manner.
Statistical methods
We compared differences between study groups by
stratifying our data by baseline CD4 cell count group. We
looked for crude associations between baseline predictors
and treatment outcomes and compared groups using
relative risks (RRs) and 95% CIs. We explored the
relation between initiating CD4 cell count and treatment
failure by describing the rate of treatment failure using
crude Kaplan–Meier curves. We used Cox proportional
hazards regression to model the relation between CD4
cell count at ART initiation and treatment failure. All
models were adjusted for age, sex (stratified at baseline
into men, pregnant women and nonpregnant women),
study site and randomization group. We did not include
postbaseline measures, as these may be influenced by
baseline CD4 cell count. We looked for a dose response
between higher CD4 cell count and treatment outcomes
by fitting a model with finer categorizations of baseline
CD4 cell count. Finally, we looked for interactions
between CD4 cell count and other markers of immu-




Baseline characteristics of the 812 patients enrolled in the
CIPRA-SA cohort stratified by baseline CD4 cell counts
group are shown in Table 1. Patients were followed for a
median of 27.5 months (interquartile range 13.8–33.1),
with no differences by study group. As expected based on
randomization, roughly half of those in each CD4 cell
count group had nurse-monitored and half had doctor-
monitored ART care. Median age was 32 years and more
than two of three were women with no differences
by CD4 cell count group. Prior ART use (typically
for prevention of mother-to-child transmission) was
balanced between CD4 cell count groups. Those in the
low CD4 cell counts group were more likely to have
nevirapine in their baseline regimen than efavirenz,
whereas those in the higher CD4 cell counts group were
more likely to have lopinavir–ritonavir.
Five hundred eighteen patients (64%) fell into the low
CD4 cell counts group (200 cells/ml), whereas the
remaining 294 patients (36%) were in the high CD4 cell
count group (>200 cells/ml). Those in the low CD4 cell
count group were more immunosuppressed at baseline as
indicated by viral loads of at least 100 000 copies/ml (RR,
1.67; 95%CI, 1.43–1.95), WHO stage IV (RR, 2.32;
95% CI, 1.62–3.33) or CDC C (RR, 1.42; 95% CI,
1.16–1.73). Few patients had extremely low or high CD4
cell count; only 16% (85/518) of those in the low CD4
cell count group had a CD4 cell count below 50 cells/ml
and only 16% (46/294) of those in the high CD4 cell
counts group had a CD4 cell counts above 350 cells/ml.
Death and virologic failure
Treatment outcomes by CD4 cell count group are shown
in Table 2. There were 21 deaths in the study (2.6%);










Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
CE: Swati; QAD/202293; Total nos of Pages: 10;
QAD 202293
however, in crude analyses, those with a baseline CD4 cell
count of 200 cells/ml or less had a five-fold increased risk
vs. those above 200 cells/ml (RR, 5.4; 95% CI, 1.3–
23.0). Virologic failure occurred in 10% of the cohort,
with the majority (84%) of these virologic failures based
on two consecutive viral loads of above 1000 copies/ml
and not based on failure to achieve a 1.5 log10 drop in viral
load from baseline by 12 weeks (16%, 13/83). Those
with a CD4 cell count of 200 cells/ml or less at baseline
had nearly twice the crude risk of virologic failure as
those above 200 cells/ml (RR, 1.79; 95% CI 1.10–2.90).
The Kaplan–Meier curve of death or virologic failure
presented in Fig. 1(a) shows that the difference between
the two groups in death and virologic failure emerges
mainly between 6 and 24 months on treatment.
Table 3 shows three different crude and adjusted models
of the relation between baseline CD4 cell counts and
virologic failure or death. We present three separate
models that are identical except that they use different
categorizations of CD4 cell count (models 1 and 2) or
include an interaction between baseline WHO stage and
CD4 cell count (model 3). Model 1, which uses the CD4
categories used previously (200 vs. >200 cells/ml),
shows that after adjusting for age, sex and pregnancy, site,
treatment arm and other indicators of immunosuppres-
sion, those with a baseline CD4 cell count of 200 cells/ml
or less had twice the risk of virologic failure or death
(hazard ratio, 1.94; 95% CI, 1.14–3.30). Having a
baseline WHO stage IV (hazard ratio, 1.98; 95% CI,
1.18–3.33), a viral load above 100 000 vs. below
4 AIDS 2010, Vol 24 No 00
Table 1. Differences in baseline characteristics by baseline CD4 cell count group among 812 patients enrolled in the Comprehensive
International Program of Research on AIDS-South Africa trial at two sites in South Africa.
Baseline CD4 cell count (cells/ml )
Variable 200 (N¼518) >200 (N¼294) Relative risk (95% CI)
Follow-up [months, median (IQR)] 27.5 (13.4–33.1) 27.5 (13.8–33.0)
Site
Johannesburg 299 (57.7%) 150 (51.0%) Reference
Cape Town 219 (42.3%) 144 (49.0%) 0.86 (0.74–1.01)
Study group
Primary healthcare nurse 260 (50.2%) 144 (49.0%) Reference
Medical officer 258 (49.8%) 150 (51.0%) 0.98 (0.85–1.12)
Sex
Male 155 (29.9%) 84 (28.6%) Reference
Female 363 (70.1%) 210 (71.4%) 0.98 (0.90–1.08)
Age at baseline, median (IQR) 32 (28.1–37.3) 32.5 (27.8–36.7)
Race
Black/African 515 (99.4%) 289 (98.3%) Reference
Mixed race 3 (0.6%) 5 (1.7%) 0.34 (0.08–1.41)
Baseline ART regimen
d4T–3TC–EFV 370 (71.4%) 227 (77.2%) Reference
d4T–3TC–NVP 119 (23.0%) 34 (11.6%) 1.87 (1.32–2.65)
d4T–3TC–LPVr 25 (4.8%) 30 (10.2%) 0.54 (0.33–0.90)
d4T–3TC–NLF 4 (0.8%) 3 (1.0%) 0.82 (0.19–3.63)
Prior ART exposure
None 390 (75.3%) 219 (74.5%) Reference
sdNVP 113 (21.8%) 54 (18.4%) 1.14 (0.85–1.52)
ZDV mono 2 (0.4%) 4 (1.4%) 0.28 (0.05–1.54)
NVP/ZDV 13 (2.5%) 16 (5.4%) 0.47 (0.23–0.97)
ART 0 (0%) 1 (0.3%)
WHO stage at baseline
1 71 (13.8%) 80 (28.0%) Reference
2 154 (29.8%) 96 (33.6%) 1.25 (1.07–1.47)
3 197 (38.2%) 84 (29.4%) 1.44 (1.22–1.69)
4 94 (18.2%) 26 (9.1%) 2.32 (1.62–3.33)
CDC category
A 177 (34.2%) 124 (42.2%) Reference
B 135 (26.1%) 94 (32.0%) 1.00 (0.82–1.22)
C 206 (39.8%) 76 (25.9%) 1.42 (1.16–1.73)
CD4 cell count at baseline, median (IQR) 123 (77–159) 254.5 (224–308)
Baseline hemoglobin, median (IQR) 11.7 (10.3–13.1) 12.4 (11.4–13.5)
BMI at baseline, median (IQR) 23.1 (20.5–26.6) 24.1 (21.3–28.4)
Baseline viral load
<100 000 174 (33.6%) 177 (60.2%) Reference
100 000 344 (66.4%) 117 (39.8%) 1.67 (1.43–1.95)
Viral load at baseline (1000), median (IQR) 201.5 (64.8–525.0) 66.9 (20.9–188.0)
3TC, lamivudine; ART, antiretroviral therapy; CI, confidence interval; CIPRA-SA, Comprehensive International Program of Research on AIDS-
South Africa; d4T, stavudine; EFV, efavirenz; IQR, interquartile range; LPVr, lopinavir–ritonavir; NLF, nelfinavir; NVP, nevirapine; sdNVP, single-
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10 000 copies/ml (hazard ratio, 2.05; 95% CI, 0.71–5.89)
and having a nelfinavir-based regimen (hazard ratio, 4.27;
95% CI, 1.17–15.6) were also predictive of virologic
failure or death independent of CD4 cell counts.
In Model 2, we looked for a CD4 cell count dose
response between decreasing baseline CD4 cell count and
risk of death or virologic failure by stratifying baseline
CD4 cell count into finer categories (0–99, 100–199,
200–299, and 300 cells/ml). After adjustment, we
found those with a CD4 cell count between 100 and
199 cells/ml and those with a CD4 cell count below
100 cells/ml had a roughly three-fold increased risk of
death or virologic failure as those with at least 300 cells/ml
(CD4 cell count <100 vs. >300 cells/ml; hazard ratio,
3.08; 95% CI, 0.92–10.4 and CD4 cell count 100–199
vs. >300 cells/ml, hazard ratio, 3.23; 95% CI, 0.99–
10.6 cells/ml), whereas those with a CD4 cell count of
ART outcomes initiating at CD4 cell count >200 vs. <– 200 Fox et al. 5
Table 2. Reasons for antiretroviral therapy treatment failure stratified by baseline CD4 cell count group among 812 patients enrolled in the
Comprehensive International Program of Research on AIDS-South Africa trial at two sites in South Africa.
Baseline CD4 cell count group
200, N¼518 >200, N¼294 Total, N¼812 Relative risk (95% CI)
Outcome
Death 19/518 (3.7%) 2/294 (0.7%) 21 (2.6%) 5.39 (1.26–22.0)
Virologic failure 63/518 (12.2%) 20/294 (6.8%) 83 (10.2%) 1.79 (1.10–2.90)
1.5 log dropa 8/518 (1.5%) 5/294 (1.7%) 13 (1.6%) 0.91 (0.30–2.75)
2 Viral load >1000b 55/518 (10.6%) 15/294 (5.1%) 70 (8.6%) 2.08 (1.20–3.62)
Incident tuberculosis 41/518 (8.0%) 9/294 (3.1%) 50 (6.2%) 2.59 (1.27–5.24)
Other study outcomes
Toxicity failure 81/518 (15.6%) 53/294 (18.0%) 134 (16.5%) 0.87 (0.63–1.19)
LTFU 52/518 (10.0%) 42/294 (14.3%) 94 (11.6%) 0.70 (0.48–1.03)
Default clinic schedule 40/518 (7.7%) 30/294 (10.2%) 70 (8.6%) 0.76 (0.48–1.19)
LTFU 12/518 (2.3%) 12/294 (4.1%) 24 (3%) 0.57 (0.26–1.25)
CI, confidence interval; CIPRA-SA, Comprehensive International Program of Research on AIDS-South Africa; LTFU, loss to follow-up.
aFailure to achieve a 1.5 log10 drop in viral load from baseline at 12 weeks on treatment.



























CD4 > 200 293
































CD4 > 200 293



































CD4 > 200 293






























CD4 > 200 293

















CD4 > 200 CD4 < 200
CD4 > 200 CD4 < 200 CD4 > 200 CD4 < 200
Fig. 1. Kaplan–Meier analysis. Time to (a) death or virologic failure, (b) tuberculosis, (c) LTFU and (d) toxicity by baseline CD4 cell
count group among 812 patients enrolled in the CIPRA-SA trial at two sites in South Africa. Note that y-axis goes from 0 to 0.5.
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200–299 cells/ml had twice the risk (hazard ratio, 2.00;
95% CI, 1.19–3.37). Thus, higher baseline CD4 cell
count does appear to be associated with lower risk of
virologic failure and death.
We also looked for interactions between the baseline
CD4 cell count group and other markers of immuno-
suppression. Model 3 shows the results of a regression
model that includes the only significant interaction
we identified, that between baseline CD4 cell count
(200 vs. >200 cells/ml) and baseline WHO Stage IV.
Compared with the reference group of those with a
baseline CD4 cell count above 200 cells/ml and no WHO
Stage IV condition, those with either a WHO Stage IV
condition alone or a CD4 cell count of 200 cells/ml or less
alone had a two-to-three-fold increased risk of death or
virologic failure (hazard ratio, 2.87; 95% CI, 0.93–8.83
and hazard ratio, 2.14; 95% CI, 1.20–3.81, respectively).
However, those with both a WHO Stage IV condition
and a CD4 cell count of 200 cells/ml or less at baseline had
a four-fold increased risk of death or virologic failure vs.
those with neither condition (hazard ratio, 3.91; 95% CI,
1.88–8.14).
Tuberculosis
Overall about 6% of all patients in the study developed
incident TB over the course of follow-up with sub-
stantially more of it occurring among those initiated on
ART at CD4 cell counts of 200 cells/ml or less than
among those initiated above 200 cells/ml (8.0 vs. 3.1%;
RR, 2.6; 95% CI, 1.3–5.2) (Table 2). In a Kaplan–Meier
analysis (Fig. 1c), we note that the majority of the
difference between the two groups emerged within the
first 24 months on treatment. In Table 4, we present two
separate models of incident TB that are identical except
that they use different categorizations of CD4 cell count
(Models 1 uses200 vs.>200 cells/ml, whereas Model 2
uses<50, 50–199 and200 cells/ml). After adjusting for
site, treatment group, age, sex, use of a protease inhibitor-
based regimen, baseline viral load, WHO stage and BMI,
using proportional hazards regression, we found that
those initiated on ARTat CD4 cell counts of 200 cells/ml
were twice as likely to develop TB compared with those
initiated above 200 cells/ml (hazard ratio, 1.9; 95% CI,
0.89–4.0) (Table 4, Model 1). When we further stratified
the lowest CD4 cell counts group into those above and
below 50 cells/ml (Model 2), we found that those with a
CD4 cell count below 50 vs. above 200 cells/ml were at
strongly increased risk of incident TB (hazard ratio, 3.4;
95% CI, 1.4–8.5), whereas those with 50–200 vs. above
200 cells/ml were at lower increased risk (hazard ratio,
1.60; 95% CI, 0.73–3.5) (Table 4).
Loss to follow-up
Nearly 12% of the cohort were LTFU and LTFU was
more common among those with a baseline CD4 cell
count above 200 than 200 cells/ml or less (14.3 vs.
10.2%)(Table 2). After adjusting for age, sex, baseline
WHO stage, viral load, use of a protease inhibitor,
treatment arm and site (data not shown), we found a small
decreased risk of being LTFU among those initiated on
ART with lower CD4 cell counts (200 cells/ml) vs.
those initiated at higher CD4 cell counts (>200 cells/ml)
(hazard ratio, 0.79; 95% CI, 0.50–1.25). Figure 1(b)
shows that the difference between the groups emerges
only after 24 months, the minimum potential follow-up
time for the cohort. Those with a baseline WHO stage IV
condition also had an increased risk of LTFU (hazard
ratio, 1.61; 95% CI 0.93–2.79) (data not shown).
Toxicities
Toxicity endpoints were experienced by about 17%
of the entire cohort (Table 2). We observed small
differences in rates of toxicities between CD4 count
ART outcomes initiating at CD4 cell count >200 vs. <– 200 Fox et al. 7
Table 4. Crude and adjusted hazard ratios of incident tuberculosis among 812 patients enrolled in the Comprehensive International Program of
Research on AIDS-South Africa trial at two sites in South Africa.
Model 1a Model 2a
Predictor of death or viral load failure Crude HR (95% CI) Adjusted HR (95% CI) Crude HR (95% CI) Adjusted HR (95% CI)
Age at baseline (continuous) 1.02 (0.98–1.06) 1.02 (0.98–1.06) 1.02 (0.98–1.06) 1.02 (0.98–1.06)
BMI at baseline (continuous) 0.90 (0.84–0.97) 0.91 (0.84–0.99) 0.90 (0.84–0.97) 0.91 (0.84–0.99)
Women 0.71 (0.40–1.26) 1.30 (0.66–2.55) 0.71 (0.40–1.26) 1.29 (0.65–2.54)
Johannesburg vs. Cape Town 0.58 (0.33–1.02) 0.60 (0.32–1.12) 0.58 (0.33–1.02) 0.69 (0.36–1.32)
Nurse vs. doctor 0.92 (0.53–1.60) 1.06 (0.59–1.89) 0.92 (0.53–1.60) 1.03 (0.58–1.84)
Regimen with a protease inhibitora 0.54 (0.13–2.22) 0.93 (0.21–4.04) 0.54 (0.13–2.22) 0.98 (0.22–4.27)
WHO stage IV vs. III/II/I 2.09 (1.09–4.00) 1.27 (0.63–2.56) 2.09 (1.09–4.00) 1.12 (0.55–2.29)
Viral load >100 000 vs. <10 000 2.37 (0.73–7.66) 1.23 (0.36–4.22) 2.37 (0.73–7.66) 1.18 (0.34–4.07)
Viral load 10 000–100 000 vs. <10 000 0.65 (0.17–2.51) 0.53 (0.13–2.08) 0.65 (0.17–2.51) 0.50 (0.13–1.97)
CD4 cell count 200 vs. >200, cells/ml 2.64 (1.28–5.43) 1.90 (0.89–4.04)
CD4 cell count 0–49 vs. 200, cells/ml 5.95 (2.57–13.8) 3.39 (1.35–8.51)
CD4 cell count 50–199 vs. 200, cells/ml 2.05 (0.96–4.36) 1.60 (0.73–3.51)
CI, confidence interval, CIPRA-SA, Comprehensive International Program of Research on AIDS-South Africa; HR, hazard ratio.
aCrude models are adjusted for each predictor by itself, whereas adjusted models are adjusted for all other variables in the model. All adjusted
models included regimen, age, sex, site, randomization group, baseline viral load, WHO stage and BMI. Model 1 included a dichotomous
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groups slightly favoring those with baseline CD4 cell
counts of 200 cells/ml or less vs. above 200 cells/ml (15.6
vs. 18.0%) (Fig. 1d). After adjusting for age, sex, baseline
WHO stage, viral load, treatment regimen, treatment arm
and site, women (hazard ratio, 1.95; 95% CI, 1.17–3.24),
those who with a BMI above 30 vs. 18.5–30 kg/m2
(hazard ratio, 2.17; 95% CI, 1.41–3.34) or a baseline
WHO stage IV condition (hazard ratio, 1.91; 95% CI,
1.15–3.18) were at increased risk of toxicity failure, but
we found little difference between CD4 cell count groups
(hazard ratio, 0.78; 95% CI, 0.53–1.16) (data not shown).
Use of lopinavir–ritonavir vs. efavirenz-based regimens
decreased the risk of toxicity (hazard ratio, 0.40; 95% CI,
0.16–1.02). Nevirapine use was associated with increased
risk of toxicity vs. efavirenz-based regimens in unadjusted
analyses (hazard ratio, 1.46; 95% CI, 0.99–2.16), but the
association disappeared after adjustment (hazard ratio,
1.01; 95% CI, 0.63–1.61).
Discussion
The results of analyses of the CIPRA-SA trial data show a
clearly increased risk of death or virologic failure
associated with initiating ART at lower CD4 cell counts.
We found that those who started ARTat CD4 cell counts
of 200 cells/ml or less had roughly twice the risk of death
or virologic failure as those initiated at CD4 cell counts
above 200 cells/ml (hazard ratio, 1.94; 95% CI, 1.14–
3.30) and twice the risk of developing incident TB
(hazard ratio, 1.90; 95% CI, 0.89–4.04). These findings
are in line with numerous observational studies [23–27]
from resource-limited settings showing low baseline CD4
cell count is a major predictor of death and LTFU.
Recently, an interim analysis of the CIPRA-HT001 trial
in Haiti showed a nearly four-fold increased risk of death
among those starting ARTwith a CD4 cell count of 200
vs. 200–350 cells/ml [19], very similar to our five-fold
increased risk (RR, 5.4; 95% CI, 1.3–23.0) [19]. Thus, a
body of evidence is beginning to emerge, showing the
benefits of earlier treatment initiation in resource-limited
settings. This, along with a recent analysis by Lawn et al.
[28] showing that the longer a patient maintains a CD4
cell count of below 100 cells/ml, the higher the risk of
death suggests that starting patients at higher CD4 cell
counts may allow them to maintain their CD4 cell counts
above the point at which they are at increased risk of
death.
Our findings are also consistent with data from resource-
rich environments. Observational data have shown that
higher CD4 cell counts are associated with lower risk of
death [7,9]. More recently, Kitahata et al. [13] have shown
that patients initiating ART at CD4 cell counts above
500 cells/ml had substantially reduced risk of mortality vs.
those below 500 cells/ml. Although our data cannot be
used to comment on CD4 cell counts above 350 cells/ml,
our finding of decreased mortality and virologic failure
risk associated with having a starting CD4 cell count
above 300 cells/ml is suggestive of a dose response with
increasing baseline CD4 cell count associated with better
outcomes.
Although we found a substantial association between
earlier ART initiation and better treatment outcomes we
also found a slightly increased risk of being LTFU among
those with higher baseline CD4 cell counts, which could
potentially offset some of the benefits of initiating
treatment earlier. However, we urge caution in inter-
preting these results. Under ideal conditions, assessing
the effectiveness of initiating ART at higher CD4 cell
counts would come from randomizing patients to either
immediate initiation of ART when the CD4 cell count
falls below 350 cells/ml or follow patients and delay
ART until the CD4 cell count falls below 200 cells/ml
[14,29]. In both arms, patients would be followed from
the time of their first CD4 cell count below 350 cells/ml.
In our study, patients were initiated onto ART at
enrollment as long as their CD4 cell count was below
350 cells/ml, so we do not have any follow-up time to
approximate what happens to patients in the time their
CD4 cell count is between 200 and 350 cells/ml;
however, we anticipate some deaths and LTFU occur in
this time. Although methods exist to adjust for this lead-
time bias [30], they require pre-ART data, which we did
not have.
The current analysis has several strengths. The data were
from a large prospective randomized trial with excellent
follow-up data at standardized intervals, which allowed
the assessment of the impact of starting treatment at
higher CD4 cell counts. Although the data were from a
randomized trial of another intervention, because the
trial showed no differences between randomization
groups (i.e. nurse vs. doctor-monitored care) and because
adjustment for randomization group had no impact on
our current results, there is little evidence that the primary
intervention had any impact on our findings.
Still, the current analysis should be considered in light of
several limitations. First, as noted above, we did not have
the ideal comparison group to assess death and virologic
failure (i.e. a group followed from a CD4 cell count of
350 cells/ml until 200 cells/ml and then initiated on
ART). Thus, any deaths occurring between 350 and
200 cells/ml would not be included in our analysis. As we
are missing deaths in the high CD4 cell count group, this
analysis may underestimate the treatment benefits of
starting at higher CD4 cell counts. Thus, our estimates
cannot be considered the true causal effect of starting
treatment at higher CD4 cell counts. Second, as the data
came from a randomized trial with conservative defi-
nitions of toxicity, many patients who were treatment
failures for toxicity might have otherwise continued on
treatment under usual practice conditions. This could
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have biased our toxicity results toward the null and
prevented us from observing a true difference between
the groups if one existed. Third, in our analysis of LTFU,
we were not able to determine the final outcomes of
patients lost and, therefore, we cannot say whether
patients left care because they were feeling well nor
could we determine how many of them have since died.
Finally, as the data were from a trial, the study popu-
lation may have been healthier than the general clinic
population.
Conclusion
We found that patients initiated on standard first-line
South African ART regimens were at increased risk of
death and virologic failure if initiated at CD4 cell counts
below 200 cells/ml compared with those initiated above
200 cells/ml. This is consistent with findings from
developed areas that have shown that the benefits of
starting at earlier CD4 cell counts outweigh the risks of
toxicity and long-term adherence. Although the cost
implications are unknown, national and international
guidelines on the topic of when to initiate ART should
consider our findings when deciding on whether to
increase initiating CD4 cell count thresholds. If thresholds
are increased, then substantial efforts will need to be made
to move patients into care earlier in their disease
progression in order to obtain the maximum benefit
from ART.
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Optimum time to start antiretroviral therapy during
HIV-associated opportunistic infections
Stephen D. Lawna,b, M. Estée Törökc and Robin Wooda
Introduction
Remarkable progress has beenmade over the past 15 years
in the treatment of HIV infection such that average
additional life expectancy of young adults initiating anti-
retroviral therapy (ART) in high-income countries is esti-
mated to be in the region of 50 years [1]. However,
mortality remains unacceptably high among those patients
who present to ART services with advanced immunode-
ficiency and serious opportunistic infections and especially
in resource-limited settings [2–4]. It is as yet unclear when
patients should start ART during the treatment for their
opportunistic infections to minimize this mortality risk. In
this paper, we discuss the rationale for either early or
deferred initiation of ART. We review insights provided
by observational cohort studies and the key evidence that
is now emerging from randomized controlled trials.
Rationale for early or late initiation of
antiretroviral therapy
The rationale for either early or deferred initiation of
ART is defined by a range of potential factors (Table 1).
Early ART halts progressive immunodeficiency and rapid
immune recovery may reduce the risks of further oppor-
tunistic infections and mortality. It may also promote
more rapid immune clearance of the opportunistic infec-
tions and reduce the risk of relapse [5]. Moreover, for
some infections such as cryptosporidiosis, microsporidio-
sis and progressive multifocal leucoencephalopathy,
ART represents the most important component of treat-
ment and should therefore not be delayed at all.
For other serious opportunistic infections such as tuber-
culosis (TB) and cryptococcal meningitis, however, there
are several adverse consequences associated with early
initiation of ART, which may favour delaying treatment
(Table 1). The high pill burden with overlapping regi-
mens may reduce treatment tolerability and undermine
adherence. In addition, there may be pharmacokinetic
drug–drug interactions and cotoxicities. An important
example of this is the concurrent use of rifampicin-con-
taining TB treatment and ART regimens containing
either non-nucleoside reverse transcriptase inhibitors
(NNRTIs) or protease inhibitors [6,7]. Moreover, in
patients who develop suspected adverse reactions to
aThe Desmond Tutu HIV Centre, Institute of Infectious
Disease and Molecular Medicine, Faculty of Health
Sciences, University of Cape Town, Cape Town, South
Africa, bClinical Research Unit, Department of
Infectious and Tropical Diseases, London School of
Hygiene and Tropical Medicine, London, UK and
cDepartment of Infectious Diseases, Cambridge
University Hospitals NHS Foundation Trust,
Cambridge, UK
Correspondence to Stephen D. Lawn, Desmond Tutu
HIV Centre, Institute of Infectious Disease and
Molecular Medicine, Faculty of Health Sciences,
University of Cape Town, Anzio Road, Observatory
7925, Cape Town, South Africa
Tel: +27 21 650 6970; fax: +27 21 650 6963;
e-mail: stevelawn@yahoo.co.uk
Current Opinion in Infectious Diseases 2011,
24:34–42
Purpose of review
We review recently published literature concerning the optimum time to start
antiretroviral therapy (ART) in patients with HIV-associated opportunistic infections.
Recent findings
In addition to data from observational studies, results from six randomized controlled
clinical trials were available by July 2010. The collective findings of these trials were that
patients with CD4 cell counts less than 200cells/ml who start ART within the first 2
weeks of treatment for opportunistic infections including Pneumocystis jirovecii
pneumonia, serious bacterial infections or pulmonary tuberculosis have lower mortality
when compared to patients starting ART at later time-points. Moreover, patients with
pulmonary tuberculosis and CD4 counts of 200–500cells/ml who started ART during
tuberculosis (TB) treatment had improved survival compared to those who deferred
ART until after the end of treatment. In contrast, in two separate studies, immediate ART
conferred no survival benefit in patients with TB meningitis and was associated with
substantially higher mortality risk in patients with cryptococcal meningitis.
Summary
Initiation of ART during the first 2 weeks of treatment for serious opportunistic infections
has been shown to be associated with improved survival with the exception of patients
with tuberculous meningitis and cryptococcal meningitis. Further clinical trials are
ongoing.
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drugs, identifying the cause is more complex when
multiple drugs are started simultaneously.
Paradoxical immune reconstitution disease (IRD; also
known as immune reconstitution inflammatory syndrome
or IRIS) and its consequences is one of the most import-
ant considerations and is frequently cited as a key reason
for treatment deferral. This complication arises as an
inflammatory response to residual microbial antigen
during rapid immune recovery [8,9]. The risk of IRD
is therefore higher the earlier ART is started [10,11]. A
particular concern is that IRD associated with opportu-
nistic infections involving the central nervous system
(CNS) may be associated with higher mortality risk than
that associated with IRD occurring outside the CNS [12].
Thus, the optimal timing of ART depends on a number
of important competing risks. For many years this has
been associated with considerable clinical uncertainty
and yet data from many observational studies and a
number of controlled clinical trials are now available.
Observational studies
Studies from South Africa have highlighted the high
mortality risk of adults and children waiting to start
ART [13–15]; even short delays of a few weeks may
be associated with substantial mortality risk. Mortality
risk before and during ART are higher for patients
initiating treatment in resource-limited settings [16]. In
sub-Saharan Africa, for example, between 8 and 26% of
patients die in the first year of ART [4]. A high proportion
of these deaths occur in the first 3 months of ART and
mortality risk in this period is several-fold higher than
that of patients treated in high-income settings even after
adjustment for the degree of immunodeficiency and
other baseline patient characteristics [3]. Deferral of
ART may therefore be associated with greater risks for
patients treated in sub-Saharan Africa and the optimum
timing for ART initiation during opportunistic infections
may differ between settings [17].
In patients with HIV-associated TB, there was concern
that poor tolerability of concurrent treatment regimens
and reduced plasma concentrations of NNRTIs and
protease inhibitors due to induction of hepatic metab-
olism by rifampicin would undermine virological out-
comes [6,7]. However, excellent virological outcomes
have subsequently been reported, regardless of whether
patients were treated using a simplified public health
approach in resource-limited settings or with highly indi-
vidualized treatment in high-income settings [18–20].
Similarly, despite fears of cotoxicity from concurrent use
of ART and TB treatment, treatment-limiting toxicity is
not common in cohorts receiving NNRTI-based ART
[21–23].
Perhaps the greatest concern among those favouring
deferred initiation of ART in patients with TB was that
of IRD [8]. A small proportion of patients with TB IRD
die, and yet this risk has to be understood from the
perspective that those who are most likely to develop this
complication are the very patients who have the highest
pre-existing mortality risk [8]. A recent systematic review
andmeta-analysis reported a pooled incidence estimate of
TB IRD of 15.7% [95% confidence interval (CI) 9.7–24.5]
among patients receiving overlapping TB treatment and
ART [24!]. Of those developing this complication, 3.2%
(0.7–9.2) died [24!], indicating that approximately 1 in 200
(0.5%) patients receiving concurrent TB treatment and
ART die from (or with) this complication.
The optimal timing of ART initiation may depend on the
opportunistic infection and its anatomical location. IRD
involving the CNS, for example, is generally more severe
and associated with higher mortality risk [12]. A meta-
analysis of studies of patients with cryptococcal menin-
gitis starting ART found a pooled incidence of IRD of
19.5% (95% CI 6.7–44.8) and of these patients 20.8%
(5.0–52.7) died [24!]. Thus, approximately 1 in 25
patients starting ART during treatment for cryptococcal
meningitis died of immune reconstitution disease. In a
South African study of 23 patients with paradoxical TB
IRD involving the CNS, 87% required hospital admis-
sion, 91% received corticosteroids and 13% died during
the 6-month follow-up period [25!]. Thus, early ART
initiation in patients with CNS opportunistic infections
may be associated with adverse overall outcomes.
Researchers have attempted to delineate the optimal
timing of ART from observational cohorts of patients
with TB. A retrospective analysis of 1003 Thai patients
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Table 1 Potential advantages and disadvantages of starting antiretroviral therapy early in the course of treatment for serious
opportunistic infections
Potential advantages of early initiation of ART Potential disadvantages of early initiation of ART (overlapping treatment)
Prevent progressive immunodeficiency High pill burden
More rapid immune recovery Cotoxicity
More rapid resolution of OI Pharmacokinetic drug interactions
Rapid reduction in mortality risk Immune reconstitution disease
Prevention of further OIs and other morbidity More difficult to identify drug causing toxicity










demonstrated that patients with HIV-associated TB who
delayed ART for at least 6 months after TB diagnosis had
a higher mortality rate than those who initiated ART less
than 6 months after TB diagnosis (hazard ratio 2.65, 95%
CI 1.15–6.10) [26]. Velasco and colleagues [27!] in Spain
studied 313 adult patients with HIV-associated TB who
received overlapping therapy. Groups of patients who
started ART either within the first 2 months of TB
treatment or after completing at least 3 months of TB
treatment had similar median baseline CD4 cell counts
but the adjusted hazards of death among those starting
ART within 2 months of TB treatment was 0.37 (95% CI
0.17–0.66). A major weakness in this analysis, however, is
that it did not account for patients who died before
starting ART nor for biases inherent in ART allocation.
Observational data have also been derived from an
analysis of a large paediatric cohort of children with
HIV-associated TB (n" 573) in South Africa [28!].
Mortality risk was calculated stratified according to the
timing of ART during TB treatment. The authors report
a statistically nonsignificant trend in results; delay in
ART for more than 60 days compared to less than
60 days was associated with hazard of death of 1.32
(95% CI 0.55–3.16) and a hazard of viral suppression
of 0.84 (95% CI 0.61–1.15). Such analyses remain fun-
damentally flawed even after adjustment for baseline
immunodeficiency and other characteristics. The timing
of ART initiation is a clinically based decision and so
sicker patients with more advanced immunosuppression
(and higher mortality risk) are much more likely to start
ART early in the course of TB treatment. How this
decision is made cannot be fully adjusted for in obser-
vational data, which therefore remain confounded by
indication.
Randomized controlled trials
Observational studies have proven useful in defining the
competing risks inherent in the clinical decision making,
informing early versions of treatment guidelines and
shaping the subsequent design of controlled clinical
trials. Well conducted randomized clinical trials are,
however, needed to provide definitive data to underpin
public health policy. By July 2010, data were available
from five randomized controlled trials (RCTs) in which
mortality was included in the primary outcome
[29!!,30,31!!,32!!,33]. These studies enrolled patients
with a range of opportunistic infections in different
geographical settings (Table 2) and below we discuss
each of these in turn.
A sixth study was a pilot study in Tanzania that assessed
the impact of delayed versus early initiation of a triple-
nucleoside regimen on adverse events including IRD in
patients (n" 70) being treated for TB [34!]. Both early
and late ART initiation was well tolerated and no IRD
events were diagnosed.
Acute opportunistic infections excluding tuberculosis
The AIDS Clinical Trials Group (ACTG) study A5164
was the first randomized controlled trial to be reported
and enrolled most of its participants in the USA (Table 2)
[29!!]. Patients had very advanced immunodeficiency
(median CD4 cell count, 29 cells/ml) and a range of
opportunistic infections, excluding TB. A majority
(63%) had Pneumocystis jirovecii pneumonia (excluding
severe disease), with the other most frequent opportu-
nistic infections being bacterial infections, cryptococcosis
and toxoplasmosis (Table 2). Patients were randomized
to start ART within the first 14 days of opportunistic
infection treatment (median 12 days) or to start ART after
completion of opportunistic infection treatment (median
45 days; IQR 41–55) and were followed up for 48 weeks.
The primary end-point was a composite three-level
ordered categorical variable that included death, pro-
gression to AIDS and virological response. A trend
favouring earlier treatment, however, was not statistically
significant. Because virological responses at 48 weeks in
the two groups were equivalent, inclusion of virological
suppression within the composite primary end-point
effectively ’diluted’ the observed differences in the
important clinical outcomes. The simpler (and perhaps
more appropriate) secondary end-point of death or pro-
gression to AIDS was strongly associated with the timing
of ART (Fig. 1). The early arm had fewer patients with
progression to AIDS or death compared to the late arm
(14.2 versus 24.1%; odds ratio" 0.51, 95% CI 0.27–0.94).
Early ART was also strongly associated with a shorter
time to achieving a CD4 cell count greater than 50 cells/
ml (4.0 versus 8.6 weeks, P< 0.001) and no increase in
adverse events or immune reconstitution disease.
These data therefore provided important evidence to
support early initiation of ART in patients presenting
with acute AIDS-related opportunistic infections or
severe bacterial infections with the exclusion of TB.
There were, however, an insufficient number of patients
with cryptococcal meningitis to inform management of
this condition although there was a very strong trend
towards lower progression to AIDS or death in those
receiving early treatment.
Pulmonary tuberculosis in South Africa
In an open-label, randomized controlled trial in Durban,
South Africa (the ‘SAPIT’ trial), HIV-infected patients
with sputum smear-positive pulmonary TB were
assigned to start ART within the first 4 weeks of the
intensive phase of TB treatment (early integrated arm),
within the first 4 weeks of the continuation phase (late
integrated arm) or within 4 weeks of completing TB






























Table 2 Summary of data available from randomized controlled trials to date
Study
Study name/acronym











282 Acute AIDS-related OIs or
severe bacterial infections
excluding TB (63% PCP,
12% bacterial infections,
12% cryptococcal disease,
5% toxoplasmosis, 8% other)
Early arm: started ART within
14 days of starting treatment
for OI (median"12 days)
Deferred ART: started ART





No difference in primary
composite end-point.
But early ART associated
with low risk of progression
to AIDS or death (OR"0.51,
95% CI 0.27–0.94) and






South Africa 642 Smear positive pulmonary TB
and CD4 cell counts
<500 cells/ml
Early: 2 ‘integrated’ arms started
ART with first 3 months of TB
treatment
Late: the deferred group started
ART within 1 month of the





The hazard of death in the early
‘integrated’ groups was 0.44
(95% CI 0.25–0.79) overall,
0.54 (0.30–0.98) in those
with CD4 counts #200 cells/ml
and 0.16 (0.03–0.79) in those





Cambodia 661 Smear positive pulmonary or
extrapulmonary TB and CD4
cell counts <200 cells/ml
Early arm: within 2 weeks
Late arm: after 2 months
Early: 25 (11–56)
Late: 25 (10–55)




NCT00433719 Vietnam 253 Tuberculous meningitis Immediate ART versus ART
deferred for 2 months
Early: 39 (18–116)
Late: 43.5 (16–84)
Hazard of death in immediate arm








The hazard of death in the early
arm was 2.85 (95% CI 1.1–7.23)
Late arm: after 10 weeks
of treatment with fluconazole










treatment (sequential arm) [31!!]. Patients with diag-
noses of new or recurrent TB and with CD4 cell counts
less than 500 cells/ml were included. The primary out-
come was all-cause mortality (Table 2).
Following an interim analysis by the data safety and
monitoring board, the sequential arm of the study was
halted due to a high mortality rate. This initial report
from the study compared the outcomes of patients in the
two integrated arms combined with those of patients in
the sequential arm [31!!]. Overall, the hazard of death in
the integrated arms was 0.44 (95% CI 0.25–0.79). For
those with CD4 cell counts 200 or less or 200–500 cells/
ml, the hazards of death were 0.54 (0.30–0.98) and 0.16
(0.03–0.79), respectively. Thus, delay of ART initiation
until after the completion of TB treatment was associated
with significantly higher mortality risk for all patients
regardless of CD4 cell count stratum.
Study limitations included the enrolment only of patients
with smear-positive pulmonary TB. Smear-negative and
extrapulmonary TB are more frequent forms of disease at
lower CD4 cell counts and are associated with higher
mortality risk. The study was open-label and clinical
judgement took precedence over the protocol-defined
timing of ART, potentially undermining baseline random-
ization during follow-up. There were 36 withdrawals from
the study and 41 patients were lost to follow-up, repre-
senting a total of 12% of patients enrolled.
This study has drawn criticism with regard to the
inclusion of patients with CD4 cell counts less than
200 cells/ml into the sequential arm in which ART was
deferred by upto 7 months for new TB cases and upto
9 months for retreatment TB cases [35,36]. It was pre-
dictable that such patients would have higher mortality
and it is difficult to justify that equipoise existed when
the study was designed in 2005. It was known that such
patients had high case fatality rates of 16–35% during
6 months of TB treatment [37] and that ART substan-
tially reducedmortality risk [38,39].Moreover, a systema-
tic review of TB IRD in 2005 found not a single case that
resulted in death [8] and there were no data to indicate
drug cotoxicity resulted in appreciable mortality.
Notwithstanding this ethical concern, these data provide
important evidence that all TB patients with CD4 cell
counts in the range 0–500 cells/ml should receive con-
current (integrated) TB treatment and ART. The key
remaining question is the optimal timing of ART during
the initial 2–3 months of TB treatment.
Pulmonary tuberculosis in Cambodia
More recent data provided by an open label RCT con-
ducted inCambodia (the ‘CAMELIA’ trial) have provided
more precise data for the optimum timing of ART in TB
patients with CD4 cell counts less than 200 cells/ml (Table
2) [33]. Eligible patients (n" 661) were ART-naive adults
with newly diagnosed smear-positive pulmonary or extra-
pulmonary TB. ART initiation after 2 and 8 weeks of TB
treatment were compared. Follow-up was for a minimum
of 1 year (mean, 2 years). The primary outcomewas death.
The mortality rate in the early arm was 8.3 deaths/100
person-years (95% CI 6.4–10.7) compared to 13.8 deaths/
100 person-years (11.2–16.9) in the late arm (P" 0.002).
IRD events were twice as frequent in the early arm (33
versus 15%) and, although there were five IRD deaths in
the early arm compared to one IRD death in the late arm,
this did not off-set the benefits of early ART. In adjusted
analyses, the hazards of death in the late arm was 1.52
(1.12–2.05; P" 0.007) and early treatment was associated
with a 35% lower mortality. Kaplan–Meier analyses
showed that the survival benefit gradually accrued during
long-term follow-up and was not a short-term effect. This
was not related to long-term differences in the immuno-
logical and virological response to ART and the reasons
for this remain unclear.
The benefit observed is entirely consistent with the data
from Zolopa et al. [29!!] as discussed above. However, it
should be noted that in both these studies, patients had
very advanced immunodeficiency and further data from
patients with less advanced disease and from a range of
settings are required.
Tuberculous meningitis in Vietnam
HIV-associated TB meningitis (Fig. 2) has a devastating
prognosis, with a mortality of 67% and median time to
38 HIV infection and AIDS
Figure 1 Graph showing the probability of survival without
death or development of an AIDS-defining illness in the
randomized controlled trial comparing antiretroviral therapy
initiation within 14 days of starting treatment for acute oppor-
tunistic infections (excluding tuberculosis) versus delayed anti-
retroviral therapy until after completion of the opportunistic
infection
P = 0.02





























death of 20 days reported from the cohort patients with-
out ART availability in Vietnam [40]. The risks and
benefits of early versus delayed ART are unknown and
may differ from those in patients with other forms of TB.
A randomized double-blind placebo-controlled trial of
patients with HIV-associated TB meningitis (n" 253)
has now been completed in Vietnam [30] (Table 2).
The proportions with grade I, grade II and grade III
meningitis were 32, 38 and 29%, respectively, and the
median CD4 cell counts in the early and late arms were
39 and 44 cells/ml. Patients received a 9-month TB treat-
ment that contained rifampicin throughout. Either efa-
virenz-based ART (immediate arm) or placebo (deferred
arm) were started at the same time as TB treatment and
all patients subsequently received open label ART from
2 months. Adjunctive corticosteroids tapered over 6–8
weeks and cotrimoxazole were also standard of care for all
patients. Mortality at 9 months was the primary outcome.
Mortality was high at 9 months. Kaplan–Meier survival
proportions were just 35.2 and 40.3% in the immediate
and deferred arms, respectively. Compared to the
deferred arm, immediate ART was not significantly
associated with mortality (hazard ratio 1.12; 95% CI
0.81–1.55; P" 0.50) or the time to new AIDS events
or death (hazard ratio 1.16; 95% CI 0.87–1.55; P" 0.31).
The dominant independent predictor of mortality was
the TB meningitis grade.
Grade III or IV adverse events were observed in both
immediate and deferred arms during the course of the
study (90 versus 89%), but these were more common
during the first 2 months in the immediate arm (86 versus
75%, respectively; P" 0.04). Secondary end-points of
immunological and virological responses to ART were,
as expected, more rapid with immediate treatment. Over-
all, these data do not support immediate initiation of
ART in patients with TB meningitis. Further data are
needed from other settings.
Cryptococcal meningitis in Zimbabwe
Cryptococcal meningitis remains a major cause of HIV-
associated morbidity. Mortality rates of 10–25% are
reported from high-income settings but may be consider-
ably higher in resource-limited settings [41]. Little, how-
ever, is known about the optimal timing of ART. A
randomized open-label clinical trial conducted in Zim-
babwe compared initiation of ART within the first 72 h of
antifungal treatment with initiation after 10 weeks [32!!].
All patients presented with their first episode of crypto-
coccal meningitis and were ART-naive. They were trea-
ted with oral fluconazole (800mg once daily) and nevira-
pine-based ART and followed up for 3 years. The trial
was discontinued prematurely after an interim analysis by
the data safety and monitoring board found a significantly
higher mortality in the early treatment arm.
The baseline characteristics of the two groups were
adequately matched. However, the 3-year mortality in
the early and deferred arms was 88 versus 54% (P" 0.006)
and median survival in the two arms was 28 and 637 days,
respectively (P" 0.031). In adjusted analyses, early ART
was associated with an almost three-fold greater mortality
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Figure 2 Saggital and transverse T1-weighted MRI scans
Saggital (a) and transverse (b) T1-weighted cranial MRI scans showing

























Table 3 Summary of ongoing trials examining timing of antiretroviral initiation in HIV-associated tuberculosis (TB)
Trial and sponsor
Setting and sample
size Type of tuberculosis
CD4 count
at entry





SAPIT (follow-up of arms
1 and 2): A study
to compare three existing
time points for









Arm 1: ART within first
4 weeks
Arm 2: ART within 4 weeks
of completion of intensive
phase
18 months All cause mortality and
progression to
AIDS-defining illness
TB-HAART: An evaluation of
the impact of
early initiation of HAART
on TB treatment










Arm 1: ART initiation at
2 weeks
Arm 2: placebo for 6 months
followed by ART
24 months Composite endpoint
of TB treatment




ACTG A5221: Immediate versus









Confirmed or probable TB <200 Tenofovir, emtricitabine,
efavirenz
Arm 1: ART initiation at
2 weeks
Arm 2: ART initiation at
8 to 12 weeks
48 weeks Survival without
progression to AIDS








Arm 1: immediate ART
for 6 months
Arm 2: ART delayed
until CD4 count
<250 cells/mm3
2 years CD4 count decline and
progression to AIDS










Arm 1: ART initiation after
4 weeks
Arm 2: ART initiation after
12 weeks
144 weeks Composite endpoint of
death rate,
hospitalization








Mexico; N"160 Active pulmonary TB <200 Tenofovir, emtricitabine,
efavirenz
Arm 1: immediate ART
Arm 2: ART initiation after
2 months
96 weeks Signs and symptoms
of active tuberculosis;
mycobacterial load in
body fluids or affected
tissues










risk (adjusted hazard ratio 2.85; 95% CI 1.1–7.23). A large
majority of deaths occurred in the first 2 weeks after
diagnosis and almost all occurred within 4 weeks. Causes
of death were ascribed using clinical observation and
were primarily thought to be due to complications of
cryptococcal meningitis.
The data show that under the circumstances studied,
early ART was very strongly associated with higher
mortality risk. However, a number of factors need to
be considered when interpreting these data [42]. ‘Early
ART’ was given very early indeed (<72 h) and ‘late ART’
was given very late (>10 weeks). Many clinicians would
perhaps not intuitively choose either of these timings for
treating their patients. Patients received high-dose oral
fluconazole (a fungistatic drug) for their cryptococcosis as
this is the standard of care in most African countries. Use
of amphotericin, a fungicidal drug, is thought to clear
cryptococcal antigen from the CNSmore rapidly [41] and
may therefore be associated with a lower risk of IRD,
which was potentially a key factor driving mortality in the
early arm. Patients were also under routine care of local
hospital physicians rather than the study team and did not
have protocol-driven monitoring and interventions to
reduce intracranial pressure, a very important component
of the management of this condition. There was neither
clinical case definition nor management plan for crypto-
coccal IRD – a likely important cause of raised intracranial
pressure andmortality [43].Thus, the excessmortality risk
associatedwith early ARTmight have been diminishedby
amphotericin use and appropriate management of raised
intracranial pressure. Future studies will need to address
alternative ART timing strategies, different antifungal
regimens, management of raised intracranial pressure
and use of adjunctive corticosteroids.
Current WHO guidelines
The WHO guidelines (2002) for the use of ART in
adolescents and adults have been sequentially revised
in 2003 and 2006 and most recently in 2010 [44!]. Data
from early observational studies and later RCTs have
resulted in a gradual shift in the guidelines towards earlier
initiation of ART in those with TB. The most recent
guidelines recommend that all patients with HIV-associ-
ated TB should start ART regardless of the CD4 cell
count and this should be done as soon as possible within
the first 8 weeks of TB treatment [44!]. Although the data
from the CAMELIA trial emerged after publication of
these guidelines, the data are nevertheless entirely sup-
portive of the recommended timing [33]. No specific
recommendations were made regarding the management
of TB meningitis, however, but the currently available
data [30] do not show an adverse impact of early treat-
ment on survival as discussed above. No recommen-
dations either were given in the current WHO guidelines
regarding the timing of ART during treatment of other
serious acute opportunistic infections. Future guidance
will be particularly important with regard to the manage-
ment of cryptococcal meningitis.
Ongoing clinical trials
A number of ongoing RCTs also aim to address the
optimum time to start ART in TB patients (Table 3).
These studies are being conducted in a wide range of
geographical locations and include patients with differing
degrees of immunodeficiency. A variety of study primary
outcomes include survival, disease progression, TB treat-
ment outcomes and drug toxicity. However, none of
these studies includes participants under the age of
13 years and thus a critical need exists for studies in
children. A further RCT (NCT01075152) was also
funded in 2010 to investigate the optimal timing of
ART in patients receiving amphotericin treatment for
cryptococcal meningitis at three sites in Uganda and
South Africa (D. Boulware, personal communication).
Conclusion
Great progress has recently been made in defining the
optimum timing of ART in patients with serious oppor-
tunistic infections. The overall conclusion from the accu-
mulated data is that early ART (within the first 2 weeks)
is associated with lower mortality for patients with P.
jirovecii pneumonia, serious bacterial infections and pul-
monary TB compared to treatment at later time points.
However, RCTs have shown that immediate ART con-
ferred no survival benefit in patients with TB meningitis
in Vietnam and was associated with substantially higher
mortality risk in patients receiving fluconazole for cryp-
tococcal meningitis in Zimbabwe. In both these con-
ditions, further data are required to determine the opti-
mum management strategies.
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Pulmonary tuberculosis in HIV infection: radiographic appearance is related 
to CD4 ÷ T-lymphocyte count 
F. A. Post*, R. Wood*. G. P. Pillay t 
*Department of Medicine, UCT Medical School, {Department of Radiology, Somerset Hospital, Cape Town, South 
Africa 
S U M M A R Y. Setting: An adult HIV outpatient clinic in Cape Town, South Africa. 
Objective: To investigate the relationship between the radiographic appearance of pulmonary tuberculosis 
(PTB) in HIV infected patients and CD4 ÷ T-lymphocyte count. 
Design: Pretreatment  radiographs of 150 patients with newly diagnosed PTB were reviewed. CD4 ÷ T- 
lymphocyte count was used as a marker  of HIV disease progression. 
Results: Upper zone infiltrate typical of PTB reactivation was present in 18 patients. This pattern was associ- 
ated with early HIV infection (mean CD4 ÷ T-cell count 389) and had 78% positive predictive value for identify- 
ing patients with > 200 CD4 ÷ T-lymphocytes/gL. Pleural effusion was present in 32 patients and occurred over 
a wide intermediate range of CD4 ÷ T-cell counts (mean 185). Lower or midzone infiltrates, adenopathy, inter- 
stitial pat tern or normal radiograph occurred in 136 patients and were associated with advanced HIV disease 
(mean CD4 ÷ T-cell count 105). These patterns had 84%, 89 %, 89 % and 100 % positive predictive value, respec- 
tively, for identifying patients with < 200 CD4 ÷ T-cells/gL 
Conclusion: Pulmonary tuberculosis in African HIV-positive patients presents with a spectrum of radiographic 
abnormalities, and specific patterns are predictive of stage of HIV disease progression. In patients dually 
infected with HIV and PTB, chest radiographs are a useful adjunct to clinical staging. 
R E S U M E. Cadre: Dispensaire ambulatoire pour  des adultes VIH+ h Cape Town, Afrique du Sud. 
Objet: Evaluer la relation entre l 'aspect radiographique de la tuberculose pulmonaire (PTB) et le nombre de 
lymphocytes T CD4+ chez des malades VIH+. 
Schema: Les radiographies pr6-traitement de 150 malades atteints d 'une PTB nouvellement diagnostiqu6e ont 
~t~ ~valu~es. Le comptage des lymphocytes T CD4+ a ~t~ utilis~ comme marqueur  de l'~volution de la maladie 
VIH. 
R~sultats: Un infiltrat des territoires sup6rieurs typique d 'une r6activation de PTB 6tait pr6sent chez 18 des 
malades. Cette caract6ristique 6tait associ6e h une infection VIH pr6coce (num6ration moyenne des cellules T 
CD4+: 389) et avait une valeur positive pr6dictive de 78% dans l 'identification des malades avec > 200 
lymphocytes T CD4+/~tL. Un 6panchement pleural 6tait observ6 chez 32 malades et survenait pour une large 
6chelle interm6diaire de num6ration des cellules-T CD4+ (moyen 185). Des infiltrats des territoires inf6rieurs 
ou moyens, des ad6nopathies, des profils interstitiels ou des radiographies normales sont survenus chez 136 
malades, en association avec une maladie VIH avanc6e (num6ration moyenne des cellules-T CD4+: 105). Ces 
profils avaient une valeur positive pr6dictive respectivement de 84%, 89%, 89% et 100% dans l 'identification 
de malades avec < 200 cellules-T CD4+/ktL. 
Conclusion: La tuberculose pulmonaire chez des malades africains VIH+ se pr6sente avec une gamme 
d'anomalies radiographiques; certaines images sont pr6dictives d 'un  stade de l'6volution de la maladie VIH. 
Chez des malades avec une double infection VIH/PTB, la radiographie thoracique repr6sente une adjonction 
utile h la classification du stade clinique. 
R E S U M E N. Marco de referencia: Dispensario para  adultos VIH + en Ciudad del Cabo, Africa del Sur. 
Correspondence to: Dr Robin Wood, Department of Medicine, UCT 
Medical School, Observatory 7925, South Africa. 
Paper received 12 January 1995. Final version accepted 24 March 
1995. 
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Objetivo: Evaluar la relaci6n entre el aspecto radiognifico de la tuberculosis pulmonar (PTB) y el recuento de 
linfocitos T CD4+ en los pacientes infectados con VIH. 
M(todo: Se revisaron las radiografias pre-tratamiento de 150 pacientes con PTB recientemente diagnosticada. 
Se utiliz6 el recuento de linfocitos T CD4+ como marcador de la evoluci6n de la enfermedad VIH. 
Resultados: En 18 enfermos se constat6 una zona infiltrada apical, tipica de una reactivaci6n de una PTB. Esta 
caracteristica estaba asociada a una infecci6n VIH precoz (recuento promedio de linfocitos T CD4+ : 389) y 
tenla un valor predictivo positivo de 78% para identificar pacientes con > 200 linfocitos T CD4+/gl. En 32 
pacientes se observ6 un derrame pleural, el cual se presentaba en un amplio grado intermedio de recuento de 
linfocitos T CD4+ (promedio : 185). En 136 pacientes se observ6 un infiltrado en las zonas bajas o intermedias, 
adenopatias, sombras de tipo intersticial o radiografias normales,  caracteristicas que estaban asociadas a una 
enfermedad VIH avanzada (recuento de linfocitos CD4+ promedio : 105). Estos tipos de im~igenes tenian un 
valor predictivo positivo para identificar pacientes con < 200 linfocitos T CD4+/~tl, de 84%, 89%, 89%, y 100% 
respectivamente. 
Conclusi6n: La tuberculosis pulmonar en los pacientes africanos VIH+ se presenta con un espectro de 
anormalidades radiogr~ificas; ciertas im~igenes especificas son predictivas del estado de evoluci6n de la 
enfermedad VIH. En los enfermos con doble infecci6n VIH/PTB, la radiografla de t6rax representa un auxiliar 
fitil para la evaluaci6n del estado clinico. 
I N T R O D U C T I O N  
The interaction between the human immunodeficiency 
virus (HIV) epidemic and pulmonary tuberculosis (PTB) 
has been recognised in both the developed and develop- 
ing world. In sub-Saharan Africa, HIV seroprevalence 
of up to 67% has been reported among patients with 
newly diagnosed PTB.~,2 The World Health Organisation 
(WHO) included PTB as one of the HIV clinical stage 3 
criteria 3 and more recently it has been proposed that 
PTB should be an acquired immunodeficiency syndrome 
(AIDS) defining diagnosis. 4 In African HIV-infected 
patients, however, PTB was found to be a poor marker 
of stage of disease. In areas of high PTB prevalence, 
individuals may be HIV seropositive and develop PTB 
without significant immunosuppression. 5 
Patients dually infected with HIV and PTB frequently 
present with chest radiographic abnormalities that differ 
from those of PTB in HIV-negative individuals. 6-~° This 
study, conducted in an area with a high PTB prevalence 
of 1134/100 00011 and an estimated 2.5% HIV seropre- 
valence, 12 investigated the relationship between various 
radiographic patterns and CD4 ÷ Tqymphocyte counts. 
METHODS 
Medical records of adults attending Somerset Hospital 
HIV outpatient clinic in Cape Town, South Africa, from 
1989-1994 were examined. Pretreatment chest radio- 
graphs of 150 patients (103 M, 47 F, mean age 33, range 
17-75) in whom PTB was diagnosed were reviewed. 
These radiographs and those of 100 consecutive HIV 
clinic attendees without respiratory symptoms were 
reported on by a radiologist and categorized in a blinded 
fashion by 2 physicians independently. In case of dis- 
parity, the radiologist reviewed the films and was the 
final arbiter. 
Radiographs with infiltrates localized predominantly 
in the upper lobes or apical segment of the lower lobes 
with or without cavitation were categorized as typical of 
reactivation (post-primary) PTB. In addition, radiographs 
were screened for the presence of pleural effusions, 
mediastinal and hilar adenopathy, lobar or segmental 
parenchymal infiltrates, and reticulo-nodular or miliary 
pattern. Fibro-cystic changes and pleural scarring were 
considered evidence of previous PTB. Patients without 
typical reactivation pattern could be included in more 
than one category. 
A PTB diagnosis was confirmed on sputum in 104 
patients (smear only n = 40, smear and culture n = 42, 
sputum culture with negative smear n = 22). Pleural 
fluid adenosine deaminase (ADA) and pleural culture/ 
histology (n = 8), effusion ADA only (n = 9), lymph-node 
histology (n = 12), blood culture (n = 3) or clinical and 
radiographic response (n = 14) to 4-drug antituberculosis 
medication (Isoniazid, Rifampicin, Ethambutol and 
Pyrazinamide) suggested active PTB. Smear-positive 
sputum was not routinely cultured. In accordance with 
WHO recommendations, 13 HIV seropositivity was con- 
firmed by a combination of four positive ELISA assays 
on two separate blood samples. CD4 ÷ T-lymphocyte 
counts were determined by flow cytometry. 
Statistical analysis 
Sensitivity, specificity and positive predictive values 
were calculated with standard formulae. 14 CD4 ÷ T- 
lymphocyte counts were expressed as means _+ standard 
deviation (SD). CD4 + T-cell counts associated with 
various radiographic patterns were compared by T test. 
A two-sided level of significance of 0.05 was used to 
reject null hypotheses. 
RESULTS 
The distribution of chest radiographic patterns of PTB 
in 150 HIV-positive patients and the mean CD4 + 
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520 Tubercle and Lung Disease 
A TYPICAL 
n = 1 8  
B PLEURAL EFFUSION 
n =  32 
C ATYPICAL INFILTRATE 
n = 5 1  
D RETICULO- NODULAR 
n =  29 
E ADENOPATHY 
n =  46 
389 
700 600 500 400 300 200 100 0 
CD 4+T - Lymphocyte count (x 106/L) 
Figure---CD4 ÷ T-Lymphocyte counts associated with PTB radiographic patterns in 150 HIV positive 
patients. CD4 + T-cell numbers are shown as mean +SD. Pattern A is defined by upper zone infiltrate with or 
without cavitation and pattern C by parenchymal infiltrate in mid or lower zone. Pattern A is associated with 
early HIV disease and pattems C, D, and E with advanced HIV infection. Patients may be included in one 
or more of categories B-E. 
T-lymphocyte count (±SD) associated with each pattern 
is shown in the Figure. Patients with pleural effusions 
had a significantly lower mean CD4 ÷ T-lymphocyte 
count when compared to those with radiographs typical 
of  reactivation PTB (P < 0.01). Adenopathy, lower or 
midzone parenchymal infiltrates and diffuse reticulo- 
nodular or miliary pattern were associated with signifi- 
cantly lower mean CD4 ÷ T-cell counts than either 
pleural effusions (P < 0.05) or typical reactivation pattern 
(P < 0.01). 
Radiographs with typical upper zone infiltrates with 
or without cavitation had 96% specificity and 78% posi- 
tive predictive value for identifying subjects with > 200 
CD4 ÷ T-lymphocytes/gL. Cavitation occurred exclu- 
sively within upper zone infiltrates. Three patients had a 
normal chest radiograph, were sputum smear positive 
and had CD4 + T-lymphocyte counts < 200/gL. The 
specificity and positive predictive values for the atypical 
radiographic patterns for identifying patients with < 200 
CD4 ÷ T-lymphocytes/gL are shown in the Table. Apical 
fibrocystic disease and pleural scarring, representing 
prior PTB, had no predictive value for HIV stage of  
disease (data not shown) and occurred in 12% of both 
the patient and the control population. 
Table: The specificity and positive predictive value of atypical PTB 
radiographic patterns for identifying HIV positive patients with < 200 
CD4 ÷ T-cells/I.tL 
Radiographic pattern Specificity Positive 
predictive value 
Normal radiograph (n = 3) 100% 100% 
Reticulo-nodular (n = 36) 88% 89% 
Adenopathy (n = 46) 85% 89% 
Lower/midzone (n = 51) 76% 84% 
Infiltrate 
Mycobacterial culture of  sputum and pleural effusion 
was performed in 71 patients. Mycobacterium tuberculo- 
sis was the pathogen cultured in 94% (64 of  68 patients), 
three cultures lost viability or became contaminated. 
Atypical mycobacteria (M. kansasii, M. xenopi and two 
undefined non-tuberculous mycobacteria) were isolated 
from sputum of four patients who had < 200 CD4 ÷ T- 
cells/gL. These patients were excluded from analysis. 
Sputum smear or culture positivity occurred in 73% of 
PTB patients with reticulo-nodular or miliary pattern. Of 
100 HIV-positive PTB-negative controls, 75% had a 
normal chest radiograph, 12% showed evidence of  pre- 
vious PTB, 7% had parenchymal infiltrates and 6% a 
reticulo-nodular pattern. Hilar or mediastinal adenopatby 
was not present in these PTB negative patients and was 
thus not a feature of  the persistent generalized lympha- 
denopathy of  HIV infection. 
D I S C U S S I O N  
This study documented that PTB occurred at all stages 
of  HIV infection, and that there was a spectrum of chest 
radiographic presentation related to HIV stage of  disease. 
In southern Africa, latent M. tuberculosis infection has 
been reported to be present in the majority of  adults, 1,2,a5 
and HIV seronegative adults typically develop reactiva- 
tion PTB with post-primary infiltrates and cavitation. 1°,15 
This pattern in our HIV-positive patients was associated 
with early HIV disease as manifested by relatively 
preserved CD4 ÷ T-cell counts. Pleural effusion, although 
regarded as a marker of  early clinical HIV disease, 16,17 
occurred throughout an intermediate range of lymphocyte 
counts and its presence was less helpful for prediction of  
HIV stage of  disease. 
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In advanced HIV disease, both PTB reactivation and 
reinfection radiographically resemble primary tuber- 
culosis, with features such as adenopathy and interstitial 
or non-cavitating parenchymal infiltrates. 16,~7,18 These 
radiographic abnormalities occurred in our patient popu- 
lation despite historic or radiographic evidence of prior 
reactivation PTB. In contrast to miliary PTB in HIV- 
negative patients, ~9 HIV-positive patients with reticulo- 
nodular and miliary pattern have multi-bacillary PTB 1 
confirmed in our patients by frequent sputum smear and 
culture positivity. In agreement with previous reports, 
adenopathy was the best predictor of low CD4 ÷ T- 
lymphocyte count, t7,2° A histopathological spectrum of 
M. tuberculosis infection in HIV disease analogous to 
that seen in M. leprae infection has been described. ~ 
This study reports a radiographic spectrum of pulmonary 
tuberculosis related to stage of HIV disease. In early 
HIV disease, a preserved cell mediated response results 
in paucibacillary PTB with apical fibrosis and cavita- 
tion. In advanced HIV infection, patients present with 
normal chest radiographs, interstitial patterns or aden- 
opathy and advanced immunosuppression results in high 
bacterial load. The latter as radiographic appearances of 
PTB could be regarded as AIDS-defining criteria in our 
HIV-positive patients. 
Although outpatient records were reviewed, patients 
had often required hospital admission or been referred 
from the community. The sample of patients might there- 
fore be a reasonable representation of HIV-associated 
tuberculosis in our area. Tuberculosis in early HIV 
disease might have been under-represented, as specific 
abnormalities prompting HIV testing are often absent 
during early HIV infection. HIV serology is extremely 
sensitive, 2~ and the multiple ELISA essays performed 
on our patients should ensure a high specificity. Conse- 
quently, the chance of false HIV seropositivity in our 
patients should be minimal. 
In sub-Saharan Africa, PTB is the commonest 
opportunistic infection in HIV disease and CD4 ÷ T- 
lymphocyte counts are frequently unobtainable. In this 
setting, radiographic criteria are a useful adjunct to 
clinical HIV disease staging. Prospective studies, how- 
ever, will be required to confirm these findings in other 
population groups. 
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SCIENTIFIC LETTERS
To the Editor: Arecent letter in the Journal1 suggested that
ultrasound of the abdomen might be an appropriate way to
diagnose tuberculosis (TB) when sputum smears are repeatedly
negative for TB and in febrile patients known or suspected to
be HIV-positive. The authors describe ultrasound findings they
regard as pathognomonic of TB but do not give the number of
scans performed or the yield of helpful scans. We have
presented such an analysis with regard to microbiological
investigations for TB,2 and provide data for abdominal
ultrasound.
In our case series of 141 consecutive HIV-positive patients
with proven TB, seen between October 1994 and September
1996 at Somerset Hospital, Cape Town, 35 (25%) had an
abdominal ultrasound. This high figure relates in part to a
concurrent study at Somerset Hospital of abdominal pain in
HIV-infected patients.3 TB was found to be the leading cause of
abdominal pain and our study focused on the diagnostic
approach to TB, leading to overlap. However, while ultrasound
was performed in 12 of 17 patients with TB and abdominal
pain, the majority of scans were performed to look for disease
processes other than TB that might have contributed to pyrexia.
As an aside, all scans were normal or reflected the likely
presence of TB — indicating that the use of ultrasound to
exclude concomitant non-tuberculous pathology was not
warranted.
To investigate whether ultrasound can be an appropriate tool
in the diagnosis of TB we applied our previously published
diagnostic algorithm to the 35 patients with ultrasound scans
(Fig. 1, Table I). This approach is compatible with that of Emby
and Hunter1 who only advocate use of ultrasound if initial
microbiological investigations are negative. The algorithm we
originally published has been modified here by adding
ultrasound of the abdomen as the diagnostic investigation of
choice in patients with negative sputum smears who do not
have pleural effusion or who are negative on lymph node
biopsy.
Scans were classified as normal, reporting intra-abdominal
lymphadenopathy, or abnormalities of the liver or spleen
according to the radiologist’s report. When a pericardial
effusion was suspected on clinical grounds the request form for
the abdominal scan also recorded the need to examine the
heart in the manner suggested by Emby and Hunter. In 2 of the
10 patients with intra-abdominal lymphadenopathy the
radiologist examined the heart and both scans demonstrated a
pericardial effusion, confirming the clinical assessment. Of the
9 patients with other abdominal abnormalities 2 requests for
ultrasonographic assessment of the heart yielded 2 further
pericardial effusions. However, owing to the directed nature of
these assessments we cannot comment on whether all
abdominal scans should be accompanied by an assessment of
the heart, as implied by Emby and Hunter. Many
radiographers might be reluctant to assess patients in this way
routinely.
Table I shows for each category of abdominal scan the
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Ultrasound for the diagnosis of HIV-associated tuberculosis
Fig. 1. Diagnostic algorithm for HIV-infected patients with











    
  

















Table I. Eligiblity for scan had algorithm been followed in




Normal denopathy liver or spleen
(N = 16) (N = 10) (N = 9)
Patient eligible (N)
Diagnosed on 
urine culture 1 - -
Diagnosed on
sputum culture - 1 1
Diagnosed on
liver biopsy - - 1
Patient ineligible (N)
Not anaemic
(Hb > 11.0 g/dl) 2 - -
Sputum smear
positive 3 2 5
Peripheral nodes
suitable for biopsy 10 7 1













number of patients for whom the scan was appropriate or not
in terms of the diagnostic algorithm. It can be seen that the
number of scans could have been reduced to 6. Two of the 16
negative scans could have been avoided if a policy was in force
of only scanning patients with anaemia (a surrogate marker of
dissemination).  
In conclusion, there is a limited role for ultrasound in the
diagnosis of TB. However, at a time of crisis in academic and
rural medicine in South Africa, calls for use of existing
investigations in new ways should be qualified by careful cost-
benefit analysis. We should also point out that our study was
performed in an HIV-positive population at very high risk of
TB.4 Experience elsewhere may differ, possibly resulting in
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To the Editor: In 1908 Leishman and Donovan 1 described the
protozoan Lesishmania donovani in splenic tissue. Almost a
century later leishmaniasis has emerged in new regions and
new settings.1 Recent interest in the disease has been prompted
by recognition of cases in returning US Gulf War veterans and
people with HIV infection.2 We describe a case of visceral
leishmaniasis diagnosed on bone marrow aspirate in a patient
presenting to a tertiary hospital in KwaZulu-Natal.
A 42-year-old Mozambican national, who works as a marine
merchant, was referred from a local hospital with fever,
hepatosplenomegaly and pancytopenia. He had a 6-month
history of gradual weight loss of approximately 10 kg with
intermittent fever and rigors. He was treated for hepatic
tuberculosis in a Mozambican hospital. A liver biopsy was not
done before commencement of antituberculosis therapy and
the patient did not improve after completion of this treatment.
He had been treated for malaria several years previously
while living in Mozambique. He travelled to Brazil, Argentina,
Italy and Portugal between 1995 and 1998.
On examination, the patient was febrile (39.8°C). He was
pale and had no lymphadenopathy. He had a hepatomegaly
that extended 10 cm below the costal margin and a 3 cm
splenomegaly.
The full blood count showed haemoglobin 8 g/dl
(normochromic, normocytic anaemia), platelets 132 ! 109/l and
white blood cell count 1.8 ! 109/l. Liver function tests revealed
a hyperglobulinaemia. He had an erythrocyte sedimentation
rate (ESR) of 113 mm/h, and his urea and electrolytes were
normal. HIV and hepatitis screens were negative. The chest
radiograph was normal. Ultrasound of the abdomen detected
no additional abnormalities. A bone marrow aspirate and
trephine were done in the first instance to investigate the
pancytopenia. A liver biopsy was scheduled, but this was
deferred when the results of the bone marrow aspirate and
trephine were received. Fig. 1 is a photomicrograph of the
marrow aspirate showing the characteristic intracellular
amastigotes of leishmaniasis.This was confirmed on the
trephine biopsy.
The patient was treated with intravenous amphotericin B 
(60 mg/kg/day) for 20 days. Renal impairment and
thrombophlebitis complicated his therapy. The renal function
improved when amphotericin B was stopped. At 3 months
after treatment the hepatosplenomegaly had resolved and a
repeat bone marrow aspirate was normal.
Discussion
This case highlights the importance of considering exotic
diseases associated with common clinical presentations, given
June 2003, Vol. 93, No. 6  SAMJ
Massive hepatomegaly due to visceral leishmaniasis
Fig. 1. Bone marrow aspirate — Gram stain showing intracellular ‘dot-like’
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Abstract
Background: Interferon-gamma (IFN-γ) ELISPOT assays incorporating Mycobacterium tuberculosis-
specific antigens are useful in the diagnosis of tuberculosis (TB) or latent infection. However, their
utility in patients with advanced HIV is unknown. We studied determinants of ELISPOT responses
among patients with advanced HIV infection (but without active TB) living in a South African
community with very high TB notification rates.
Methods: IFN-γ responses to ESAT-6 and CFP-10 in overnight ELISPOT assays and in 7-day whole
blood assays (WBA) were compared in HIV-infected patients (HIV+, n = 40) and healthy HIV-
negative controls (HIV-, n = 30) without active TB. Tuberculin skin tests (TSTs) were also done.
Results: ELISPOTs, WBAs and TSTs were each positive in >70% of HIV- controls, reflecting very
high community exposure to M. tuberculosis. Among HIV+ patients, quantitative WBA responses
and TSTs (but not the proportion of positive ELISPOT responses) were significantly impaired in
those with CD4 cell counts <100 cells/µl compared to those with higher counts. In contrast,
ELISPOT responses (but not WBA or TST) were strongly related to history of TB treatment; a
much lower proportion of HIV+ patients who had recently completed treatment for TB (n = 19)
had positive responses compared to those who had not been treated (11% versus 62%,
respectively; P < 0.001). Multivariate analysis confirmed that ELISPOT responses had a strong
inverse association with a history of recent TB treatment (adjusted OR = 0.06, 95%CI = 0.10–0.40,
P < 0.01) and that they were independent of CD4 cell count and viral load. Among HIV+ individuals
who had not received TB treatment both the magnitude and proportion of positive ELISPOT
responses (but not TST or WBA) were similar to those of HIV-negative controls.
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Conclusion: The proportion of positive ELISPOT responses in patients with advanced HIV
infection was independent of CD4 cell count but had a strong inverse association with history of
TB treatment. This concurs with the previously documented low TB risk among patients in this
cohort with a history of recent treatment for TB. These data suggest ELISPOT assays may be useful
for patient assessment and as an immuno-epidemiological research tool among patients with
advanced HIV and warrant larger scale prospective evaluation.
Background
The HIV-associated tuberculosis (TB) epidemic in sub-
Saharan Africa is fuelling a global increase in TB incidence
of 1% per year [1]. TB incidence rates in southern Africa
have reached almost unprecedented levels [2] and much
of this disease remains undetected in the community [3].
This escalating epidemic led to the declaration by the
World Health Organisation in 2005 of "a regional emer-
gency requiring urgent and extraordinary actions" [4].
However, most existing tools with which to confront the
TB epidemic are blunt, especially those used for diagnosis
of Mycobacterium tuberculosis infection and disease in HIV-
infected patients.
Recent developments of immune-based assays to detect
Mycobacterium tuberculosis infection are a significant
advance [5]. ESAT-6 and CFP-10 are two proteins encoded
by the RD1 genomic segment of M. tuberculosis, which is
absent from all BCG strains and the vast majority of envi-
ronmental mycobacteria [6-8]. As a result, enzyme-linked
immunospot (ELISPOT) assays that detect interferon-
gamma (IFN-γ) release in response to these antigens dif-
ferentiate between M. tuberculosis infection and immune
sensitisation by BCG vaccination or exposure to environ-
mental mycobacteria. In outbreaks of TB in the UK, ELIS-
POT responses among contacts showed better correlation
with the degree of exposure than tuberculin skin tests
(TSTs) [9,10]. Among HIV-negative patients with culture-
positive TB, ELISPOT assays have a sensitivity of approxi-
mately 80–90% [11-13]. Moreover, increasing evidence
suggests that ELISPOT responses in human and bovine
models correlate with mycobacterial load during antitu-
berculosis treatment [13-18].
At present, very few studies have examined the utility of
ELISPOT assays in HIV-infected individuals. In a study
from Zambia, ELISPOT responses to ESAT-6 or CFP-10
were positive in 90% (n = 39) of HIV-infected patients
with sputum smear-positive pulmonary TB [19]. Also,
when used in the diagnosis of TB in South African chil-
dren, the sensitivity of the assay was not significantly
impaired by HIV coinfection [12]. More recently the assay
was found to be relatively unimpaired in the detection of
either latent M. tuberculosis infection or active TB in
patients with moderately advanced HIV infection [20,21].
However, responses in those with advanced HIV have not
previously been reported.
The aim of the present study was to identify determinants
of ELISPOT responses among patients with advanced HIV
infection (but not active TB) living in a South African
community with very high TB incidence. Overnight IFN-γ
ELISPOT assay responses were assessed among a group of
HIV-infected patients enrolling in an antiretroviral treat-
ment service and were compared with responses in a
group of healthy controls living in the same community.
To provide greater insight, these responses were compared
to 7-day whole blood assays (WBA) of IFN-γ release and
TSTs.
Methods
HIV-infected (HIV+) patients were recruited to the study
at the antiretroviral treatment clinic based at the Gugu-
lethu Community Health Centre in Cape Town. The study
cohort and clinic have previously been described in detail
[22-25]. The district has a predominantly African popula-
tion of over 300,000, the vast majority of whom live in
conditions of low socioeconomic status. In 2003 the ante-
natal HIV seroprevalence was 28% and the annual TB
notification rate exceeded 1,000/100,000 [26]. Patients
were referred to the ART programme for evaluation for eli-
gibility for antiretroviral treatment under national guide-
lines.
Consecutive HIV+ patients were recruited to the study
before starting antiretroviral treatment. Non-pregnant
adults between the ages of 18 and 50 years, who were not
currently receiving antituberculosis treatment nor had evi-
dence of active TB were eligible. Details of previous med-
ical history were obtained from the referral letter and were
cross-checked with the patient. Patients were clinically
characterised and carefully evaluated for TB. Available
investigations for TB included sputum smear microscopy
and liquid culture (MGIT, Becton Dickinson, Sparks, Mar-
yland, USA), chest radiology, and fine needle aspiration
of lymphadenopathy for cytology and culture. Nebulised
sputum induction was accessible when required. Patients
with active TB diagnosed at baseline were excluded as
were those who subsequently developed TB within 4
months of the recruitment date since they may have had
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antituberculosis treatment nationally uses a 6-month
rifampicin-containing regimen and primary and second-
ary isoniazid prophylaxis is not recommended by the
national TB control programme.
Healthy HIV- control patients aged 18–50 years were
recruited from the same community. These individuals
were part of a prospective cohort being studied in prepa-
ration for phase III HIV vaccine trials. Consecutive indi-
viduals with two negative HIV tests three months apart
who remained asymptomatic and had no previous history
of TB or other significant morbidity were enrolled.
At a single clinic visit venous blood was taken and TSTs
were done using 2 TU purified protein derivative (PPD)
RT23 (Statens Serum Institut, Copenhagen, Denmark) on
the volar aspect of the forearm. TSTs were read by a single
health care worker experienced in the technique, measur-
ing the diameter of induration at 48–72 hours using calli-
pers. Plasma HIV-1 load was measured using Versant™
HIV-1 RNA 3.0 branched chain DNA assay (Bayer Health-
Care, Leverkusen, Germany) and blood CD4 cell counts
were measured by flow cytometry using FACSCount™
(Becton Dickinson Inc., Franklin Lakes, NJ, USA). All sub-
jects studied gave written informed consent. The study
was approved by the Research Ethics Committee of the
University of Cape Town and conformed to the declara-
tion of Helsinki.
ELISPOT assays
Peripheral blood mononuclear cells (PBMCs) were sepa-
rated from heparinized venous blood by Ficoll-Paque cen-
trifugation. A commercially available IFN-γ ELISPOT kit
containing a pre-coated 96-well plate was used (Mabtech,
Stockhom, Sweden). Paired wells with 250,000 cells/well
were stimulated with anti-CD3 antibody at 100 ng/ml
(positive control, Mabtech), were left unstimulated (neg-
ative control) or contained the following antigens each at
5 µg/ml final concentration: PPD RT49 (Statens Serum
Institut) or recombinant ESAT-6 and CFP-10 (Lionex,
Braunschweig, Germany). After incubation for 18 hours,
plates were developed according to the manufacturer's
protocol. Plates were read on an Immunospot Series 3B
Analyzer (Cellular Technology, Cleveland, OH, USA) and
were retained for visual inspection in the case of anomaly.
Low level spot counts in unstimulated negative control
wells were subtracted from the test well results. The mean
number of spot-forming units (SFU) in paired wells was
multiplied by 4 to provide SFU/106 PBMC. Counts of ≥ 20
SFU/106 PBMC that were at least ≥ 2-fold greater than
background counts were predefined as positive responses.
Using this cut-off, this assay produces very similar results
to other commercially available and 'in-house' assays per-
formed in the same laboratory [20,21].
Whole blood assays
Whole blood assays were done using a methodology sim-
ilar to that described previously [27,28]. Heparinized
whole blood was diluted 5-fold using RPMI 1640 supple-
mented with penicillin, streptomycin and 2 mM L-
glutamine and was plated into 96-well plates in the pres-
ence of antigen or mitogen or left unstimulated. Phyto-
haemagglutinin (PHA, Sigma, St. Louis, MS, USA), PPD
RT49, and recombinant ESAT-6 and CFP-10 were all used
at a final concentration of 5 µg/ml. Any small residual
traces of endotoxin in antigen preparations were neutral-
ised using 10 µg/ml polymyxin B sulphate (Sigma) as ver-
ified in pilot experiments. Day 7 supernatants were
harvested following incubation at 37°C. All assays were
piloted and conditions, antigen concentrations and time-
points were optimised using patient and control samples.
IFN-γ responses to recombina t ESAT-6 were equivalent
when compared with those generated using a sample of
recombinant antigen from Statens Serum Institut, Copen-
hagen.
Concentrations of IFN-γ were determined in paired sam-
ples of supernatant using an ELISA with a standard curve
that ranged from 10,000 pg/ml to 41 pg/ml and using pre-
viously described methodology [28,29]. Background con-
centrations of IFN-γ were subtracted from sample results,
which were then categorised as positive if ≥2-fold higher
that the lower limit of detection of the assay. Negative
control values falling below the lower limit of detection
were assigned half the value of the lowest standard.
All laboratory assays were done blinded to the status of
the patients.
Data analysis
χ2, Fisher's exact and Mann-Whitney U tests were used to
compare proportions and medians as appropriate. Assay
responses were evaluated as continuous (quantitative)
variables and as categorical variables (positive or negative
responses) according to the thresholds stated above. Asso-
ciations between patient characteristics and positive ELIS-
POT and WBAs were examined using univariate analyses
and multiple logistic regression models. CD4 cell count,
plasma viral load and history of previous TB were
included in the multivariate models a priori; age and sex
were included if there was a trend towards an association
(p < 0.10). SAS version 8.2 (SAS, Cary, North Carolina,
USA) and Prism version 4.0 (GraphPad Software, San
Diego, CA, USA) software were used for data analysis.
Results
Patient characteristics
A total of 77 subjects were recruited; 7 were excluded due
to failed ELISPOT assays (n = 4; no positive control
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ble TB (n = 3). Eleven individuals invited to participate
declined (predominantly due to transportation difficul-
ties). Among those included in the analysis, 40 were HIV+
patients being evaluated for antiretroviral treatment; these
had baseline characteristics (Table 1) which were similar
to those described in previous reports of this treatment
cohort [22-24]. None of the patients had serious co-mor-
bidity (such as lymphoma, Kaposi's sarcoma requiring
cytotoxic chemotherapy or diabetes mellitus) that might
have affected T cell assays. CD4 cell counts showed that
immunodeficiency was advanced in most patients; 48%
had a history of completed treatment for TB within the
preceding 3 years (Table 1) consistent with previous find-
ings [22]. The median period since completion of TB treat-
ment was 4 months (IQR, 2–13 months). HIV- controls
(n = 30) had similar age and sex distribution as HIV+
patients (Table 1).
A large proportion (58%) of the HIV+ patients had cuta-
neous anergy to PPD (Table 1) and TSTs reactions >10
mm occurred in a significantly lower proportion of HIV+
patients than HIV- controls (43% versus 77%, P < 0.05).
TST responses were significantly associated with CD4 cell
count; the proportion of patients with a TST response >10
mm was much lower among those with CD4 cell counts
<100 cells/µl (n = 17) compared to those with CD4 cell
counts >100 cells/µl (n = 23) (16% versus 56%, respec-
tively; P < 0.05). In contrast, TST responses were not sig-
nificantly associated with history of TB treatment (P =
0.2).
ELISPOT and WBA results
In all 70 subjects included in the analysis the positive con-
trol stimuli produced measurable responses in ELISPOT
assays and WBAs. The magnitude of responses to all stim-
uli were significantly lower among HIV+ patients com-
pared to HIV- controls (Table 2). However, in contrast to
TSTs, the magnitude of these responses in HIV+ patients
was not significantly associated with CD4 cell count using
either assay. Instead IFN-γ responses, especially ELISPOT
results, were strongly associated with history of previous
TB treatment; responses among treated patients were
lower than those who had no history of treatment (Table
2).
We next calculated the proportions of patients with assay
responses categorised as positive according to the prede-
fined thresholds (Figure 1). In general, greater propor-
tions of 7-day WBA responses were positive compared to
the overnight ELISPOT assay. Furthermore, the propor-
tions of positive responses were typically greater using
PPD compared to RD1 antigens.
Positive responses to RD1 antigens were detected in 70%
of healthy HIV- controls using the ELISPOT assay and in a
significantly greater proportion using the 7-day WBAs
(93%; P < 0.05) (Figure 1). Positive responses to PPD
were also observed in very high proportions of HIV- con-
trols using both assays (Figure 1). Similar to the quantita-
tive responses (Table 2), the proportions of positive
ELISPOT responses in HIV+ patients were also very
strongly associated with previous history of TB treatment
(Figure 1). Compared to those who had not previously
received TB treatment, treated patients had a 5.6-fold
lower proportion of positive ELISPOT responses to RD1
antigens (P < 0.01) and a 2.4-fold lower proportion of
positive ELISPOT responses to PPD (P = 0.02) (Figure 1).
In marked contrast, WBA responses in HIV+ patients did
Table 1: Characteristics of HIV-negative controls (HIV-) and HIV-infected patients (HIV+)
Characteristic HIV- controls HIV+ patients
All With history of TB With no history of TB
Number 30 40 19 21
Median age (years) 28 31 30 32
Female 23 (77) 32 (80) 13 (68) 19 (90)
CD4 count (cells/µL)
Median (IQR) - 114 (72–246) 98 (44–160) 117 (77–267)
Distribution
0–99 - 17 (43) 10 (53) 7 (33)
100–199 - 10 (25) 5 (26) 5 (24)
≥200 - 13 (32) 4 (21) 9 (43)
Median viral load 5.0 (4.5–5.3) 5.0 (4.6–5.4) 4.9 (4.4–5.3)
TST (mm)
0 6 (20) 23 (58) 13 (68) 10 (48)
1–9 1 (3) 0 (0) 0 (0) 0 (0)
≥100 23 (77) 17 (43) 6 (32) 11 (52)
Unless otherwise stated, values show numbers (%) of patients.
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not show a significant inverse association with history of
TB treatment (P > 0.25 for each comparison) (Figure 1).
Thus, there was a clear dissociation between ELISPOT
responses and WBA responses in those who had previ-
ously been treated for TB (Figure 1).
We next examined the effect of CD4 cell count on the pro-
portion of positive assay responses by comparing the
results of those with CD4 cell counts <100 cells/µl (n =
17) with those of patients with CD4 cell counts >100
cells/µl (n = 23). There was no significant difference
between these groups using the WBA (82% vs 61%,
respectively; P = 0.18) although there was a non-signifi-
cant trend towards an association using the ELISPOT assay
(24% vs 52%, respectively; P = 0.10). Importantly, how-
ever, history of TB treatment is confounded as a variable
by CD4 cell count in this cohort [22] (Table 1). Thus, we
next analysed ELISPOT responses stratified by both CD4
cell count and history of TB treatment. This clearly
showed that responses were strongly associated with his-
tory of TB treatment but not with CD4 cell count (Figure
2).
To confirm these findings we next did multivariate analy-
sis to identify factors independently associated with posi-
tive ELISPOT responses to RD1 antigens (Table 3). This
showed that ELISPOT responses were not significantly
associated with CD4 cell count or viral load but that there
was a highly significant independent association with his-
tory of TB treatment.
Responses in HIV+ patients with no history of TB 
treatment
Results thus far indicated that HIV+ patients who did not
have a history of recent TB treatment were much more
likely to have positive ELISPOT responses to RD1 antigens
than those who had been treated. We reasoned that while
treated patients were likely to have cleared any viable
mycobacteria, untreated patients would have a similar risk
of latent M. tuberculosis as HIV- controls. We therefore
compared IFN-γ responses in HIV- controls and the sub-
group of HIV+ patients with o history of TB treatment.
There was indeed no significant difference between these
groups in quantitative ELISPOT responses to PPD, ESAT-6
and CFP-10 (P > 0.1 for all comparisons) whereas quanti-
tative WBA responses were much lower in the HIV+ sub-
group (P < 0.01 for all stimuli) (Table 2). Moreover, the
proportion of positive ELISPOT responses did not signifi-
cantly differ between the HIV- and the untreated HIV+
subgroup (P = 0.55) (Figure 2).
Table 2: Quantitative interferon-γ (IFN-γ) responses to anti-CD3 (positive control) and mycobacterial antigens as assessed by 





Anti-CD3 PPD ESAT-6 CFP-10 PHA PPD ESAT-6 CFP-10




61 (26–214) 24 (7–199) 30 (6–89) >10,000 >10,000 4820 3678




21 (2–53) 7 (2–46) 6 (0–39) 3991 799 355 96












8 (2–49) 2 (1–17) 1 (1–10) 2550 1034 528 125
P value 0.93 0.42 0.19 0.12 0.13 0.89 0.14 0.12
HIV+ no 
previous TB 
Rxd (n = 19)
476 (269–
2299)
34 (3–147) 22 (2–80) 36 (1–80) 6938 1529 495 179
HIV+ 
previous TB 
Rx (n = 21)
1020 (400–
1844)
6 (2–42) 5 (0–14) 0 (0–6) 2749 313 65 20
P value 0.70 0.085 0.044 0.028 0.10 0.115 0.220 0.038
aELISPOT responses expressed as median (interquartile range) spot-forming units/106 peripheral blood mononuclear cells.
bWBA responses expressed as median values in pg/mL.
cCD4 cell count in cells/µL.
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Discussion
This study conducted in a setting with very high TB bur-
den is, to our knowledge, the first to assess the utility of
ELISPOT responses to M. tuberculosis-specific antigens
among HIV-infected patients with advanced immunodefi-
ciency. To provide further insight into the determinants of
such responses, we compared the overnight ELISPOT
assay (which assesses rapid effector memory T cell
responses [18,30,31] with a 7-day IFN-γ WBA (which
reflects central memory T cell responses [32]. We found
that both assays were able to detect IFN-γ responses to
ESAT-6 and CFP-10 in a substantial proportion of HIV+
patients despite the low median CD4 cell count of 114
cells/µl. The proportion of positive ELISPOT responses
was independent of CD4 cell count in stratified and mul-
tivariate analyses (Table 2, Figure 2); instead responses
were strongly associated with history of TB treatment (Fig-
ures 1 and 2; Tables 2 and 3). Almost half the HIV+
patients had completed treatment for TB a median of 4
months earlier, resulting in likely clearance of the burden
of viable mycobacterial infection; this was reflected by a
low proportion of positive ELISPOT responses in these
patients but persistence of a high proportion of positive
Proportion of positive ELISPOT IFN-γ responses to M. tuber-cul sis-specific antigens (ESAT-6 and/or CFP-10) among HIV- ontrols ( = 30) compared to HIV+ patients (n = 40) s rati-fied by CD4 ell cou t >100 cells/µl (n = 23) or <10  cells/µl(n = 17) a d accordi g to hist ry of rec nt TB treatment (n = 19) or no hist ry of suc  tr atment (n = 2 )Figure 2
Proportion of positive ELISPOT IFN-γ responses to M. tuber-
culosis-specific antigens (ESAT-6 and/or CFP-10) among HIV- 
controls (n = 30) compared to HIV+ patients (n = 40) strati-
fied by CD4 cell count >100 cells/µl (n = 23) or <100 cells/µl 
(n = 17) and according to history of recent TB treatment (n 











































Table 3: Multivariate analysis of factors associated with positive IFN-γ ELISPOT responses to ESAT-6 or CFP-10 in HIV+ patients (n = 
40)
Variable Crude OR P value Adjusted OR P value
Age <31 years 1.00 - -
>31 years 0.58 (0.16–2.12) 0.41 - -
Sex Male 1.00 - -
Female 5.44 (0.60–49.56) 0.13 - -
CD4 count >100 1.00 1.00
(cells/µL) <100 0.34 (0.08–1.34) 0.12 0.58 (0.11–3.16) 0.53
Log viral load <5.0 1.00
(copies/mL) >5.0 0.39 (0.10–1.49) 0.17 0.30 (0.05–1.69) 0.17
History of TB No 1.00
Yes 0.07 (0.01–0.40) <0.01 0.06 (0.10–0.40) <0.01
OR = odds ratio
Proportion of positive IFN-γ ELISPOT responses and 7-day IFN-γ whole blo d assay (WBA) responses to ESAT-6 and/or CFP-10 (RD1) an purified protein derivative (PPD) amongHIV  controls (n = 30) and HIV+ pati nts (n = 40) subdividedint  th se with (n = 19) or without (n = 21) a history of pre-vious tub rcul si reatment (TB Rx)Figure 1
Proportion of positive IFN-γ ELISPOT responses and 7-day 
IFN-γ whole blood assay (WBA) responses to ESAT-6 and/or 
CFP-10 (RD1) and purified protein derivative (PPD) among 
HIV- controls (n = 30) and HIV+ patients (n = 40) subdivided 
into those with (n = 19) or without (n = 21) a history of pre-
vious tuberculosis treatment (TB Rx). ELISPOT assay 
responses in HIV+ patients were strongly associated with 
history of TB treatment. *In HIV+ patients who had previ-
ously received TB treatment, the proportions of positive 
responses to RD1 and PPD antigens were significantly lower 
using the ELISPOT assay than the WBA (P < 0.05 for each 
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WBA (memory) responses. In contrast, ELISPOT
responses in HIV+ patients with no history of TB treat-
ment did not significantly differ from those of HIV- con-
trols. Collectively, these observations suggest the ELISPOT
assay provides data that are clinically and immuno-epide-
miologically informative in patients with advanced HIV.
Antigen stimulation in 7-day WBA permits T cells to dif-
ferentiate and proliferate, leading to amplification of IFN-
γ responses. Similar to lymphocyte proliferation assays,
WBAs thereby provide an assessment of memory
responses to antigens encountered at any time past or
present. In contrast, the overnight ELISPOT assay detects
rapid effector memory cells; such cells are thought to have
recently encountered antigen from viable organisms in
vivo and can rapidly release IFN-γ when re-exposed to anti-
gen in vitro [18,30,31]. Thus, ELISPOT responses appear to
be more strongly associated with current antigen load
rather than with past antigen exposure [13-18]. These facts
provide a logical rationale for the very strong inverse asso-
ciation between ELISPOT responses (but not 7-day WBA
responses) and history of recent TB treatment in HIV+
patients.
The HIV- control group was recruited in the same commu-
nity and had similar demographic characteristics as the
HIV+ group and so were likely to have similar prior expo-
sure to M. tuberculosis. Retention within an HIV-negative
cohort for ≥3 months provided the opportunity to pro-
spectively verify that these patients were free of both TB
and HIV. Positive WBA responses to mycobacterial anti-
gens were detected among a very high proportion of HIV-
controls, which is consistent with extremely high rates of
previous exposure to M. tuberculosis in this community.
Similar to a study in a neighbouring community in Cape
Town [20], TSTs ≥ 10 mm and ELISPOT responses to RD1
antigens were positive in 70% and 77% of HIV- controls,
respectively, consistent with high rates of latent M. tuber-
culosis infection.
The HIV+ group was drawn from a very well-characterised
cohort of patients enrolling for antiretroviral treatment in
which risk factors for TB have been established [22]. An
important finding previously reported was that patients
who had completed successful TB treatment within the
preceding 2 years had an approximately 5-fold lower risk
of active TB compared to those who had not [22]. The
ELISPOT results in this study strongly concur with this
observation. We suggest that successful TB treatment
would have cleared viable mycobacterial infection, result-
ing in low risk of reactivation TB and negative ELISPOT
responses due to absence of antigen. An alternative
hypothesis to explain the ELISPOT data would be that
those who had previously had TB developed lasting sup-
pression of IFN-γ responses to RD1 antigens, although the
WBA data do not support this.
Our findings are consistent with previous studies showing
that HIV infection does not appear to substantially under-
mine ELISPOT responses in patients with either active TB
[12,19,21] or latent M. tuberculosis infection [19-21]. In
two separate studies, Rangaka et al. found that assay
responses to RD1 antigens were not significantly impaired
in two cohorts of patients with latent infection and mod-
erate HIV-associated immunodeficiency (both median
CD4 cell counts of 392 cells/µl and 464 cells/µl) [20,21].
Our data extend this observation to patients with
advanced immunodeficiency (median CD4 cell count =
114 cells/µl). Although we found no impact of CD4 cell
count on the proportion of positive responses, there was
a trend towards overall quantitative ELISPOT responses
being reduced in those with CD4 cell counts <100 cells/µl
and the study lacks the statistical power to adequately
assess this.
The normalised input of peripheral mononuclear cells
used in ELISPOT assays may, in part, explain why this
assay appears to retain utility among patients with low
CD4 cell counts. This also might explain why studies
using a commercially available data overnight IFN-γ
whole blood assay (QuantiFERON-TB Gold, Cellestis,
Melbourne, Australia) in which the cell input is not nor-
malised have found that responses do not appear to be
greatly affected in HIV-infected patients with moderate
immunodeficiency but that there was a high rate of inde-
terminate results among those with advanced immunode-
ficiency [20,33,34]. It cannot be assumed that only CD4 T
cell responses are measured by these assays as other IFN-
γ-secreting PBMC subsets such as CD8 T cells and NK cells
may also be detected. Future immunophenotypic studies
would be useful in this regard.
A high proportion of HIV+ patients had anergic TSTs, con-
firming the known limited utility of this test in advanced
HIV. Moreover, both TST responses and quantitative WBA
responses to mycobacterial antigens were very strongly
associated with CD4 cell count, contrasting with the ELIS-
POT assay. A potential reason for this is that both TST and
WBA responses depend on interleukin-2-mediated T cell
proliferation, which is markedly inhibited by HIV infec-
tion [35,36]. In contrast, the overnight ELISPOT assay
detects terminally differentiated effector cells [18,30] and
is therefore independent of T cell proliferation.
This study has certain limitations. Case control studies
may be subject to selection bias. However, the characteris-
tics of the HIV+ group were representative of those previ-
ously described in this cohort [22] and HIV- controls had
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were enrolled within the community rather than at health
facilities. The assays used are research tools and are not
directly comparable with commercially available IFN-γ-
release assays currently used in clinical practice. Although
the group of HIV+ patients with a history of TB treatment
was heterogeneous with regard to the time since comple-
tion of TB treatment, we have previously found that such
patients have a substantially lower risk of TB [22]. Thus,
history of previous TB treatment was included as a key var-
iable within the analyses. This study, however, was not
designed to specifically evaluate the impact of TB treat-
ment on ELISPOT responses and the data should not be
over-interpreted in this regard. Common to all such stud-
ies, the sensitivity of the ELISPOT assay in diagnosis of M.
tuberculosis infection in this population cannot be defini-
tively evaluated in the absence of a gold standard. The
study included few HIV-infected patients with high CD4
cell counts and this may have limited the ability to fully
evaluate the effect of CD4 cell count on ELISPOT
responses. However, our findings are consistent with
other published data [20,21]. The number of patients
studied was limited, but in view of the very high rates of
TB exposure in this community and very strong statistical
associations observed, the aims of the study were never-
theless achieved.
Conclusion
This study provides evidence that the IFN-γ ELISPOT assay
retains utility among patients with advanced HIV infec-
tion as suggested by the following key observations: (i)
the proportion of positive responses was not associated
with CD4 cell count in stratified and multivariate analy-
ses; (ii) responses were strongly related to hi tory of TB
treatment – a known key factor associated with TB risk in
this patient population; (iii) responses in HIV+ patients
who had not been treated for TB in the past were similar
to those of HIV- controls. Collectively these data indicate
that the ELISPOT assay provides data that are informative
in patients with advanced HIV and is therefore likely to be
useful for patient assessment and as an immuno-epidemi-
ological tool. These data provide an important basis for
the justification of future large scale evaluation of the
assay in prospective cohort studies of patients with
advanced HIV.
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THE CHALLENGES OF HIV TO TB CONTROL
The HIV epidemic in South Africa has been associated with a 
similar increase in TB case load as reported in other sub-
Saharan countries. The incidence of TB has increased markedly
among HIV-infected individuals, with a proportional increase
in smear-negative pulmonary disease, extrapulmonary
involvement, frequent atypical clinical presentations, an
increased mortality and a strong association with multidrug
and extreme drug-resistant TB. The impact of HIV on a TB clinic
is illustrated by the changes in TB notification data from a
Cape Town peri-urban township over the last 10 years as HIV
adult seroprevalence has increased from 8% in 1996 to 23% in
2005.6 During this period TB incidence rates have increased
4.75-fold from 400/100 000 in 1996 to 190 000/100 000 in
2005, with the highest increase occurring in 20 - 40-year-
olds.6 In 2005 the overall TB notification rate was 5.4-fold
higher among HIV-positive individuals (5 140/100 000) than
HIV-negative individuals (953/100 000) (Table I). Smear-
negative disease notification was 8-fold higher among HIV-
positive individuals (1 891/100 000) than HIV-negative
individuals (238/100 000). Despite a plateauing of HIV
seroprevalence, TB notifications have continued to increase.6
THE CHALLENGES OF TB IN AN ART PROGRAMME
The diagnosis of TB is particularly challenging in 
patients accessing antiretroviral therapy (ART) when their HIV
infection is advanced. The Hannan Crusaid clinic was the first
It is estimated that 2 billion of the world's population are latently infected with Mycobacterium tuberculosis (Mtb) with a
resultant 8 - 9 million cases of active tuberculosis (TB) and 1.6 million deaths annually.1 The tools used for diagnosis of TB have
remained largely unchanged since the 1880s when sputum microscopy, Mtb culture on solid media, tuberculin skin testing and
chest radiology were initially developed. In 1991 the World Health Assembly set targets to be reached in 2005 for 70% case
finding of smear-positive TB, which represents 6 million cases to be identified per annum.2 A second target was that 80%
(5 million) of those identified cases should complete anti-TB treatment.2 Subsequently the millennium development goals of
2000 set a target of halving the prevalence of TB disease from 300/100 000 to 150/100 000 and deaths from 30/100 000 to
15/100 000 by 2015.3 While progress toward these targets was being made in countries with established market economies
there was a quadrupling of TB incidence between 1990 and 2005 in most African countries. In 2005 the World Health
Organization Regional Committee for Africa declared tuberculosis an emergency for the African region.4
In South Africa in 2005 the WHO estimated that of 284 592 TB cases 270 360 were notified to the national TB control
programme, representing a somewhat ambitious reported case finding proportion of 95%.5 The proportion treated under the
directly observed treatment (DOTS) programme is 94%, and HIV prevalence among notified cases was 58% (97.5% confidence
interval (CI) 49 - 65%). South Africa is a middle-income country and is relatively well provided with 143 laboratories
performing sputum smears, and 18 culture laboratories also capable of performing drug sensitivity testing.5 Multidrug
resistance (MDR) in new TB cases varies between provinces from 0.9% to 3.6%, while MDR is higher amongst retreatment
cases, with prevalence rates varying between 1.8% to 13.7% in different provincial surveys.
TB Total adult HIV-positive HIV-negative HIV+ve/HIV
type population adults adults -ve ratio
(PTB) 1 931 5 140 953 5.4
Smear-positive 
PTB 1307 3 248 715 4.5
Smear-negative 
PTB 624 1 891 238 7.9
PTB = pulmonary tuberculosis.
TABLE I. ADULT PULMONARY TB NOTIFICATION RATES PER










dedicated public sector ART facility in South Africa and
currently provides treatment to 3 000 patients. Eighty-nine per
cent of those accessing ART have symptomatic HIV disease
(WHO clinical stage 3 and 4) with a median CD4 cell count of
95 cells/µl. More than 50% have a history of prior completed
TB treatment, 15% are on current TB treatment, 11% are
diagnosed with previously undiagnosed TB, and a further 10%
develop new incident TB after initiation of ART.7 Multivariate
analysis identified risk factors for development of incident TB
to be WHO stage 3 and 4 disease (relative risk (RR) 5.9, 95%
CI 3.2 - 10.9 and 8.9 95% CI 4.6 - 17.3 respectively), baseline
CD4 cell count (RR 1.41, 95% CI 1.2 - 3.1 for each 50 CD4 cell
count decline) and baseline viral load (RR 1.4, 95% CI 1.1 - 1.8).
A  history of completed TB treatment within the previous 2
years was associated with significant protection against
incident TB (RR 0.21, 95% CI 0.2 - 0.7).
THE CHALLENGE OF HIV/TB IN A COMMUNITY
The high case finding proportion (close to 100%)2 reported for
the South African TB control programme is based on an
estimate of the TB burden. The programme is based on passive
case finding together with directly observed therapy of those
cases identified. Active case finding enables a direct
assessment of TB burden and can identify differing case
finding proportions for either HIV-negative or HIV-positive
individuals. Active TB case finding and HIV testing of a
randomly selected sample of 762 individuals living in
Masiphumelele, a periurban township outside Cape Town, was
performed in 2005 and identified 23% of adults to be
seropositive for HIV, 11 individuals with prevalent treated TB
and a further 12 individuals with previously unrecognised
smear-positive (N = 6) and culture-positive (N = 6) pulmonary
TB.8 Both HIV infection and a history of recent incarceration
were strongly associated with TB. The TB prevalence among
HIV-infected individuals was 7.6%, of which 4.4% was smear
positive disease. The case finding proportion for HIV-negative
individuals (ratio of prevalence of treated to prevalence of
treated and untreated with smear-positive disease) was 67%
(95% CI 41 - 100), while that for HIV-positive individuals with
smear-positive disease was 37% (95% CI 25 - 53) (Table II). In
this community, with a single TB clinic providing care to the
whole community, the TB control programme appeared to
perform less well for those with HIV infection than for those
who were HIV negative. 
THE CHALLENGE OF MULTI- AND EXTREMELY 
DRUG-RESISTANT TB
In 2005 an outbreak of extremely drug-resistant TB (XDR)
was recognised in Tugela Ferry, situated in a rural area of
northern KwaZulu-Natal. A report of the first 53 cases was
published in 2006.9 The epidemic was recognised in
predominantly HIV-positive individuals and was characterised
by an extremely high early mortality rate. Over 50% of cases of
XDR died within 30 days of presentation. Eighty per cent of the
identified cases had positive sputum smears and 25% had
evidence of extrapulmonary involvement. Analysis of risk
factors for XDR identified that 55% had no history of prior
treatment for TB, indicating that these cases had primary
rather than acquired resistance. Only 15% had a history of
treatment default or failure. The one factor which was of
concern was that 67% gave a history of admission to the local
health facility, raising the concern that nosocomial
transmission may have played a significant role in the
epidemic. XDR cases have continued to be recognised, and 266
cases have been confirmed of which 264 were HIV-positive.
This epidemic illustrates the potential problems associated
with integration of HIV and TB programmes and the increasing
need for rapid diagnosis of initial TB infection in both HIV-
positive and negative individuals and recognition of early
treatment failure and development of resistance within a
treatment programme.
CURRENT TB DIAGNOSTICS
Current TB diagnostics, TB skin testing (TST), sputum smear and
culture and radiology have remained the mainstay of TB
diagnostics since 1882. TST has been used to support the
diagnosis of TB in populations where TB infection is low. In
South Africa a positive TST can be used to support the
diagnosis in paediatric TB but is of limited use in adult
diagnosis. TST is however still  a useful tool for epidemiological
studies of the annual risk of infection in children but by
adulthood the majority of South Africans have been exposed
to TB. In industrialised countries the TST identifies a minority
of individuals who are at increased risk of disease progression,
to whom diagnostic and preventive resources can be targeted.
In contrast, in South Africa the majority of adults have already
been exposed to TB and in those with advanced HIV infection,
who are at highest risk of disease progression, the test has low
sensitivity with up to 50% false negatives. 
Sputum smear microscopy has high specificity in high TB
prevalence settings. Sputum microscopy has been the
mainstay of TB control programmes as it is able to identify the
most infectious cases. The test is relatively inexpensive and
widely available. Despite its wide availability in the field it is
dependent on highly motivated technicians. The overall
sensitivity for identifying TB infection is 35 - 70%, but the
sensitivity in HIV-infected cases can be as low as 20%.
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HIV-positive HIV-negative
adults adults
Prevalence of treated 1 563 352
smear-positive PTB (1 108 - 2 138) (233 - 507)
Prevalence of treated 4 400 527
and untreated smear- (3 619 - 5 299) (280 - 711)
positive PTB
Case finding 0.37 0.67
proportion (0.25 - 0.53) (0.41 - 1.0)
PTB = pulmonary tuberculosis.
TABLE II. PREVALENCE OF TREATED AND UNTREATED
SMEAR-POSITIVE PULMONARY TB WITH ACTIVE CASE
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Diagnosis of TB with a chest X-ray is fast, convenient and has
high sensitivity in HIV-negative individuals. In HIV infection
the radiological findings of active TB disease decrease with the
level of immune suppression, resulting in low sensitivity in
advanced disease.10 The occurrence of opportunistic diseases
that can also mimic the radiological changes of TB results in
lowered specificity in AIDS cases. The combination of relative
expense, restricted availability and low sensitivity and
specificity in HIV infection limits the role of radiology for TB
control in the high HIV prevalence setting.
Mtb culture is sensitive and specific for pulmonary TB in both
HIV-positive and HIV-negative individuals. Solid media culture,
however, is limited by the prolonged time required for positive
and negative results, which can be delayed for 6 - 8 weeks.
Culture of sputum has low sensitivity for extrapulmonary TB,
which occurs more commonly in HIV-infection. TB culture also
requires a high level of laboratory bio-safety, which
consequently restricts its availability to sophisticated
centralised reference laboratories.  
NEW TECHNOLOGIES
Serological diagnosis of TB is a relatively simple and 
inexpensive technology which could be a potentially attractive
strategy for paediatric and adult extrapulmonary TB diagnosis.
A large number of commercially marketed antibody detection
tests are available. In 2005 the WHO performed an evaluation
of available TB rapid diagnostic antibody tests. Nineteen of 27
invited manufacturers agreed to submit their products for
evaluation against a panel of known specimens. The
evaluation study found that the performance of antibody tests
varied widely with high ‘lot to lot’ and ‘reader to reader’
variability. The specificity was less than 80% in the majority of
products. Those tests with higher sensitivity lacked specificity
and detected fewer than 40% of TB cases. The conclusion of
the study was that none of the antibody assays performed
well enough to replace microscopy.11
Liporabinomannan (LAM) is a component of Mtb cell walls,
which is excreted unchanged in urine. A quantitative enzyme-
linked immunoassay (ELISA) has been used to demonstrate a
correlation between urinary LAM concentrations and the level
of Mtb organism load in the sputum of pulmonary TB cases.12
Urinary LAM concentrations may therefore be a reflection of
infecting Mtb organism load, able to diagnose TB in both HIV-
positive and HIV-negative individuals. The quantitative
thresholds of urinary LAM for diagnosis and sensitivity, and
specificity for identifying pulmonary and extra-pulmonary TB,
are still to be defined. The LAM ELISA format is suited for
peripheral laboratory use; however, a simpler ‘tube format’ test
has also been shown to be robust and does not require a cold
chain. A dipstick format of the test is under development,
which could possibly prove be the first TB diagnostic suitable
for use in ‘point of care’ clinics.
Cytokine detection assays are based on the observation that
lymphocytes with immunological memory produce interferon-
gamma (INF-) when re-exposed to a specific antigenic
challenge. Two commercially available assays have been
developed; the QuantiFERON®-TB GOLD, which uses whole
blood as its substrate, and the T-SPOT TB assay, which uses
isolated peripheral blood mononuclear cells. Both assays use
Mtb specific antigens and therefore should not be subject to
cross-reactions due to exposure to other environmental
mycobacteria or exposure to the M. bovis strain used for BCG
vaccination. The performance criteria of these tests for
identifying latently infected individuals in published studies is
in the range of 0.75 - 0.95 for sensitivity and 0.9 - 1.0 for
specificity; however, the sensitivity in HIV-infected individuals
may be reduced.13 The advantage of INF- assays over TST, of
a single visit with a result not subject to observer error, is
offset by the requirement of venepuncture, the cost and the
need for laboratory infrastructure. Although cytokine assays
appear to be more sophisticated and sensitive versions of the
TST, these tests may be measuring differing aspects of the
immune responses to Mtb infection. INF- secretion by cells
incubated with mycobacterial antigens over a week may
reflect long-term immunological memory, while the shorter 3-
day incubation may reflect more recent immunological
memory. We have shown that the 3-day INF- secretion from
PBMCs co-incubated with Mtb antigens is similar in both HIV-
negative and HIV-positive controls, but the secretion from
cells of those with a history of recent TB treatment was
significantly lower than controls (Lawn et al in press).
CULTURE TECHNIQUES
Culture of Mtb remains the gold standard for both diagnosis 
and drug sensitivity testing. The characteristics of culture and
media and growth detection are shown in Fig. 1. Culture in
liquid media is faster, with results available as soon as 7 days
compared with 42 - 56 days’ required growth on solid media.
A variety of growth detection methodologies have been
utilised. Early detection of growth may be based on
mycobacterial metabolism, identification of microscopic
colonies or macroscopic plaques on secondary organisms. The
BACTEC 460-TB® commercial assay incorporates a radioactive
marker in the liquid media which is detected when growth
occurs. A more recent development, the BACTEC MGIT 960®
assay, utilises a plastic tube containing a broth with a
fluorescence quenching-based oxygen sensor. Consumption
of oxygen by growth of Mtb produces fluorescence when
illuminated by a UV lamp. The non-commercial microscopic
optical detection system (MODS) uses an inverted microscope
to detect characteristic tangles of developing Mtb colonies in
96 well pates. The FAST-plaque™ assay identifies viable
organisms which have been infected with bacteriophages by
the development of macroscopically visible plaques on a lawn
of fast growing M. smegmatis.14
Drug sensitivity testing (DST) conventionally takes 4 - 6 weeks
after confirmation of primary detection on solid media, a
process which takes 6 - 8 weeks. Liquid culture media can
incorporate antibiotics at the time of initial inoculation, with
the inference than surviving organisms are phenotypically
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can therefore be available within the same time frame as
mycobacterial diagnosis.
NUCLEIC ACID AMPLIFICATION TESTS
Nucleic acid amplification (NAA) is a rapidly evolving
improvement in the detection and identification of Mtb which
requires strong laboratory capacity and good quality control
procedures and is relatively expensive. Bacterial or ribosomal
RNA transcribed into DNA is amplified, followed by an
appropriate reading system using a signal generating probe.
The inclusion of internal positive controls reduces the
incidence of false negatives, and use of a single tube format
can reduce potential for contamination. NAA tests can be used
for tuberculosis diagnosis but cannot be used for evaluation of
patients receiving therapy as the technology cannot
distinguish between live and dead organisms. The outstanding
feature of NAA tests is that a positive result together with a
high degree of specificity can be achieved within hours.
NAA tests usually have high specificity but variable sensitivity,
so a positive test is good evidence of infection but a negative
test is less informative. It is considered that current NAA tests
cannot replace microscopy or culture, are unsuitable for
smear-negative disease, and should be used only in
conjunction with these tests and clinical data.15,16 Drug
resistance can be identified by identifying sequences in the
rpoB and katG genes which encode for rifampicin and
isoniazid resistance or by hybridisation of this region with
specific DNA probes. Recent advances in NAA technology
include the ability to amplify directly from clinical samples,
isothermal amplification of DNA and improved amplification
product detection.
The AMPLICOR® MTB test can give a result within 6 - 7 hours
and is a US Federal Drug Administration (FDA) approved test
for confirming smear-positive pulmonary TB LAMP (loop
mediated isothermal amplification) is able to amplify TB DNA
directly from clinical samples and does not require a
thermocycling device, and a positive result, confirmed by a
colour reaction visible with the naked eye, can be achieved
within 2 hours. With further development a version of the
LAMP test may be suitable for use in peripheral laboratories. A
commercial assay (Hain Lifesciences) allows a specific Mtb
diagnosis together with detection of rifampicin and isoniazid
resistance achieved by PCR amplification of the 16S-23S
ribosomal DNA spacer region followed by hybridisation of the
amplified DNA product with specific oligonucleotide probes.
The probes are immobilised as parallel lines on membrane strip
however the test format is suited to reference laboratories
rather than lower resourced peripheral laboratories.
DIAGNOSTIC PIPELINE
There is now more interest and financial investment in the 
development of new TB diagnostics than has occurred over
the prior decades (Fig. 2). The development pipeline is active;
however, most of the immediate advances in diagnosis and
drug sensitivity testing will be applicable only to the reference
laboratory.17 Advances in peripheral laboratory capacity are
2 - 5 years away and are characterised by improved micro-
scopy techniques and development of simplified nucleic acid
amplification methodologies. There is little immediate hope of
improved ‘point of care’ TB diagnostics, where the need is
greatest. The time frame for new tests in the peripheral clinic
is 3 - 7 years and is dependent on formulating simplified
antigen and antibody testing such as dipstick tests. The role of
newer diagnostics with potential to address the spectrum of
clinical scenarios posed by TB and HIV infection are shown in
Table III. 
CONCLUSIONS
The HIV epidemic has reversed the advances made in global 
TB control. The increase in smear-negative disease has
exposed the inadequacies of existing diagnostics which have
remained essentially unchanged since the 1890s. HIV infection
has been associated with decreased sensitivity of all present
diagnostic modalities of TST, sputum microscopy, TB culture
and radiology. Active community case finding indicates that
the present diagnostic algorithm used in the national TB
control programme fails to identify a large proportion of HIV-
associated tuberculosis. There is therefore an urgent need for
4
Clinical scenario Potentially useful tests
TB infection
HIV negative TST, INF- whole blood assays
HIV positive TST,  INF- isolated PBMC assays
TB disease
Smear positive Direct smear, rapid Mtb culture, 
phage, NAT,
Smear negative Rapid Mtb culture, urinary LAM
TB treatment failure Rapid Mtb culture with DST 
Drug sensitivity testing Rapid Mtb culture, phage assay, 
NAAT, hybridisation assays
TABLE III. TESTS WITH POTENTIAL TO ADDRESS DIFFERENT
CLINICAL SCENARIOS
Culture
• More sensitive than direct sputum smear, requires between 5
and 100 organisms/ml v. 5 000 - 10 000 for positive smear
• Allows species identification and concomitant drug sensitivity
testing (DST)
Media
• Solid media requires 6 - 8 weeks for confirmed diagnosis and
further 4 - 6 weeks for DST
• Liquid culture is faster with results of diagnosis and DST as
soon as 7 days
Growth detection methods
• Radioactivity-BACTEC 460-TB®
• Fluorescence-BACTEC MGIT 960®
• Phage-based tests- FASTPlaque TB-RIF™
• Inverted microscopy-MODS
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point of care tests with increased sensitivity for screening of
HIV-positive individuals.
The association of HIV-infection with MDR and XDR has also
driven the need for tests which can be used to recognise early
treatment failure and rapid identification of drug resistance.
The rapid progression of TB in HIV-infect d individuals
together with increased mortality has also emphasised a need
for much faster identification of infection and failure of
therapy. The development of rapid liquid culture assays and
NAA assays offer significant advances over conventional solid
media culture and drug sensitivity testing.   
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Importance of full disclosure of all
medicalcondftions
To the Editor: We appeal to all medical practitioners to
assist the insurance industry by completing the medical
documents for insurance purposes fully, providing the
company with accurate details and dates of all the
applicant's medical conditions. An absence of accurate
detailed information leads to increased costs by requiring
further investigation to establish the severity of the
condition.
As a general principle, the industry relies on full and
accurate disclosure by the client of all relevant medical
information so that the application can be underwritten fairly
and equitably. The contract of assurance is one of good
faith, which imposes a duty of full disclosure on the client. It
is important that the client and the sales intermediary
understand the consequences of material non-disclosure on
the contract of assurance. Material non-disclosure will result
in the contract's being voided or offered wrth a loading.
The insurance industry would greatly appreciate the
assistance of the medical profession in achieving better
levels of disclosure. I would like to record the industry's
gratitude for the services that the medical profession
provides to the insurance industry.
t K Lockyer
Memt:Jer: LOA Medical and Undftrwriting SliJnding CommitT!!f!
Ufe OHices' Association of South Africa
5th Floor, Norwich on St George's
SI George's Mall
Cape Town
'Discriminatory' advertising in the SAMJ
To the Editor: The April edition of the SAMJ included an
advertisement for doctors for 'men's clinics' in different
centres in the country. When I contacted Mr Nic Goslar to
enquire about these positions I was told finnly that they
were not interested in women doctors,GlSthese clinics were
for men with sexual problems. When I pointed out that it
was no longer permissible to discriminate on the grounds of
gender Mr Goslar laughed, admittedly' rather uncomfortably.






Mr Goslar replies: Thank you for bringing this matter to
my attention. I hope that I have not offended Or Farham by
implying that the positions are only open to male doctors. I
would like to point out, for the benefit of Or Farham, that our
group of clinics is in no way associated with the SAMJ, and
that the SAMJ has never, as far as we are aware, condoned
discriminatory recruitment.
It can't be done!
To the Editor: I wonder how many of us read Adam Smith's
letter1 and really took heed of its contents. How many of us
reflected on the paragraph in which he quoted John Ruskin:
'the common law of business balance prohibits paying a
little and getting a lot - it can't be done'.
The so-called 'full MASA rate' for medical practitioners
was determined by the MASA in consuttation with financial
experts. It is not a fee determined to create wealth. The
MASA fee ensures a reasonable return for the financial
outlay of a practice and for the work and involvement with
all its ethical and legal implications, and, most importantly,
ensures that the medical professional can provide for his or
her retirement years. Ask any 55-year-old doctor if he will be
able to retire in 5 - 10 years' time. It will almost certainly be
impossible! AI1y company director, on the other hand, is
comfortably looking forward to his pension and retirement
package.
Remember that the doctor who retires from practice does
not have an asset to provide for the retirement years. I often
tell my patients that my practice is a 'depreciating asset'.
The goodwill is myself. It leaves when I ieave, and my
equipment is worth a pittance on the open market. The
doctor needs to have secured a reasonable nest-egg, which
cannot be done while desperately trying to make ends meet
on a month-ta-month basis. Stop fooling yourself with the
Scale of Benefits fee. In order to survive financially you
would need to create volume, and in the medical context
this means over-servicing, or packing extra patients into
your day (which is in any case impossible for certain
specialists, such as anaesthetists). You cannot practise
honest and decent medicine at these rates - it just can't be
done.
Peter Desmarais
Suite 208, PdrldiJJ'\ds Medical Centra
Overport
Durban
1. Smith AJ. 'Fabled service' in medical private practice (lener). S AIr Med J 1997;
87: 174-175.
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Patients who can't afford to pay - time
for a code of ethics
To the Editor. Is it not time for private pro"viders to introduce
a code of ethics for dealing with patients who cannot afford
to pay for their health services? Options for collaboration
between the public and the private sector are being tossed
back and forth, and mechanisms for regulating the private
sector are on the table. But these processes take time, and
it is surely better for the private sector to moderate its own
activities than to wait for government intervention.
My concern arises out of a number of experiences -
erther first-hand or described to me - in which private
health providers appear to have acted unethically, or at least
against the best interests of patients who could not afford to
pay for their health care.
As interns. one saw numerous patients who had been
turned out of private hospitals once their medical aid cover
had run out.
I remember tending to a street vendor whose femoral
artery had been transected by a stray bullet in an anned
robbery in the centre of Durban. We were inadvertently taken
to a private hospital, where it was established that she could
not afford to pay for the surgery. Precious time ticked by
while we attempted to secure transport and a public sector
destination which would undertake the limb-saving surgery.
Another incident was related to me by a perplexed and
troubled mother, who could not understand why her son,
seriously injured in a car accident, had been transferred 80
km for radiological procedures and treatment when these
were available in a nearby state hospital. It tumed out that
the services were offered by private proViders, and were
available only to private sector patients over weekends.
After being shuttled between hospitals and waiting over 18
hours, the young man was finally admitted to intensive care
in a public hospital. He died 4 days later of adun respiratory
distress syndrome. Did the delay in treatment contribute to
his death?
I was told about the transfer of a medically unstable
patient from a private hospital to a public hospital at
2 o'clock in the morning because he. 'would have incurred a
whole day's extra fees if he had stayed till morning'.
These are jus! a few of the disconcerting incidents of
which I am personally aware. people'S lives and limbs are
being jeopardised because they cannot afford to pay for
heatth care, particularly when, in an emergency, fate delivers
them to the door of a private doctor 0< hospital.
Arguably, there are constitutional imperatives which would
require private doctors to treat people in an emergency,
regardless of their ability to pay. But surely more compelling
are ethical considerations? At the moment rt would seem
that for some private providers, money is the only factor
determining emergency management of the poor.
tt seems to me that a code of ethics is urgently needed for
the management of patients who can't afford to pay. This
code should address at least: (I) emergency management of
patients with life- or limb-threatening injuries; fi/) procedures
for transfer from private to public health services; and (iil)
care for chronic or long-term patients who have exhausted
their medical aid cover.
There is general agreement that greater co-operation
between the public and private sectors is needed if human
resources for .health are to be.used more optimally. A private
sector code of ethics for managing patients wh.o cannot
allon:t to pay would be a good place to start.
David Harrison




Trace elements and osteoporosis
To the Editor: Wynchank and Saltman' suggest that trace
elements may be of importance in the treatment and
prevention of osteoporosis. Osteoporosis is muttifactorial in
origin, although the primary cause in postmenopausal women
is oestrogen lack. Dietary supplementation with calcium,
vitamin D and possibly trace elements and other factors may
have a 'permissive' role in the prevention aPKI treatment of
osteoporosis, particularly in older subjects.2 Many dietary
factors have been claimed to have an effect on bone mass,
including the trace minerals zinc, copper and manganese, as
well as boron and silicon and also vitamins ~, 8 12, C and K.3
Saltman and Strauss' compared the effect of dietary
supplementation with: (I) calcium alone; (it) trace elements
alone; (iil) calcium and trace elements combi~ed; and (iv) a
placebo on bone mineral density (BMD) in four groups of
postmenopausal women. The BMD fell in all the groups
except those grven calcium and trace elements combined.
Oestrogen was only given to 35% of the women and the
authors state that the groups were balanced in respect of the
number of subjel;ls receiving oestrogen therapy. According to
the authors the oestrogen users neither k>st nor gained
significant quantities of bone. No iflformation, however, was
given about the non-users of oestrogen who, in all probability,
experienced a signilicantlall in BMD. n is possible that trace
elements may have a 'permissive' function, similar to that of
calcium, in the prevention and trea!!TIent of osteoporosis in
postmenopausal women. Much research, however, would be
required to elucidate the role of supplementation with the
different elements, particularly in different women with
different dietary intakes. Trace elements are fairly ubiquitous
and many calcium prepaiations used for dietary
supplementation contain them in varying quantrties. There is
no evidence that elements such as zinc, copper and
manganese, when taken in trace quantities, do any harm; in
the manufacture of calcium preparations it may be easier, and
less costly, to retain rather than remove such elements. The
inclusion of trace elements in calcium supplements may not
be undesirable, though more evidence is reqUired to
determine their importance in bone maintenance. Oestrogen
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in clinical coding ;:;
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common descrip'tions and \'ariant medical
term's into standard dia'gnosis (ICD·10)
and procedure (ePT) codes, using its
versatile lo!'kup-techaiques.
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useful data that 'will benefit your organisation
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in South Africa.
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HIV infection is not associated with an
increased rate of drug-resistant
tuberculosis
To the Editor: Concern has been raised about an increased
prevalence of primary and acquired tuberculosis drug
resistance among HIV-positive patients_' No drug resistance
data stratified for HIV status are available for the Western
Cape, the region wrth the highest TB prevalence and
incidence rates in South Africa.2
All 385 patients with newly diagnosed tuberculosis
admitted to Somerset Hospital, Cape Town, from November
1994 until October 1996 were prospectively evaluated, An
HIV test resu~ was obtained in 90% (347 of 385); 50
patients were previously known to be HIV-positive. Of the
297 patients with TB and prior unknown HIV status, 115
(39%) tested positive for HIV-l, The prevaience of HIV
infection was significantly higher in black patients than in
coloured patients with TB (53% v, 37%, P < Om), being
42%, 54% and 80% in patients with pulmonary TB,
tuberculous pleural effusion and extra-pulmonary TB,
respectively. Tuberculosis in these hospitalised patients was
associated with advanced HIV infection (median CD4 T-<:ell
count 65/~1 for pulmonary or extra-pulmonary 13 and 172/~1
for pleural TB),
Mycobacterial culture and drug sensitivities were available
for 99 of 165 HIV-positive and 115 of 182 HIV-negative
patients. All HIV-negative pafients were infected with
Mycobacterium tuberculosis, whereas 6 HIV-positive
patients (6.1 %) had atypical mycobacterial species isolated.
Sensitivity patterns of M_ tuberculosis were as follows:
HIV-positive HIV-negative
MTB fUlly sensitive 88 (94,6%) 107 (93,0%)
MTB INH-resistant 1 (1 :0%) 4 (3.5%)
MTB rifampicin-resistant 1 (1,0%) 1 (0.9%)
MTB mUltidrug-resistant 3 (2,9%) 3 (2,6%)
Acquired M_ tuberculosis drug resistance was present in 1
of 5 HIV-positive and 6 of 8 HIV-negative patients. White
male homosexuals (N = 8) accounted for 2 of 3 multidrug-
resistant HIV-positive cases and 3 of 6 atypical
mycobacterial infections.
In the Western Cape, therefore, HIV infection is highly
prevalent in hospitalised patients with tuberculosis. In the
black and coloured populations, HIV infection was not
associated with an increased prevalence of (multi-) drug-
resistant tuberculosis. This is in keeping with recent surveys
in Malawi and Cote d'lvoire, which found TB drug resistance
to be unrelated to HIV statusY Our data support the current
practice, which is to treat tuberculosis with a standard drug




University of Cape Town
1. Frieden TR, Sterling T, Pabloz-Mendez A, Kilburn JO. Cauthen GM, Dooley SW.
The emef'9eoce of drug-resistanl tuberculosis in New York City. N Engl J Med
1993: 328; 521-526.
2. Report o' the revIew of tuberculosis control programme 01 South Africa.
Epidemiological Comments 1996: 23(1): 2-19.
3. Glynn JR, JenkJn, PA, Fine JM. et al. Pattl!'l'ns of initial and acqUired
antituben;ulosis drug resistance in Karonga District. Malawi. Larn::et 1995; 345:
907-910_
4. Braun MM, Kilburn JO. Smithwick RW. et al. HIV infection atld primary resislatlCe
to antituberculosis drugs in Abidjan. Cote d'hloire. AIDS 1992: 6: 1327~1330.
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Our peripheral hospitals - crisis or
opportunity?
To the Editor: We are in dire need of a vision for our future.
The crisis in our peripheral hospitals must not be allowed to
translate into failure of our health service.
We need a system that will consolidate the individual
departments at each hospital. This includes an adequate
number of full-time consultants, who will co-ordinate in-
house teaching and CME for MOs, interns and nursing staff,
evaluate effectiveness of casualties, wards and OPDs, and
run programmes to maintain and improve standards
generally.
This high profile of our senior staff will help boost staff
morale and stop that sinking feeling!
To achieve this, we need a commitment from the health
authorities to provide the posts, and from our universities to
provide specialists trained to fulfil this unique role. We need
imaginative restructuring of medical education to provide
doctors to suit our country's needs at this stage of our
history, rather than to provide other Western countries with a
constant supply of South African doctors. Universities
should perhaps be rewarded by a pro rata subsidy for every
graduate who stays on in South Africa, on a year-ta-year
basis; or should be persuaded to rotate a small proportion
of their senior registrars or junior consultants through
peripheral hospitals via a roster to give these hospitals some
extra consuttant cover.
There are many departments of community health around
the country that would be only too Willing to tackle this
challenge. Why are they not being used?
We need dialogue. We need an exchange of ideas. We
need lateral thinking. This is our window of opportunity -





To the Editor: 'Where there is o vision, the people perish.'
How tragically these words ring true when one works in a
large, understaffed regional hospital desperately trying to
meet the challenge of providing a full regional service.
We applaud the commitment of the government and
provincial health authorities to make improved health
services available to all South Africans, and acknowledge
many of the steps taken towards this. However, I believe
that they are failing to see one vital fact; that in order to
create strong regional specialist units, we must attract senior
clinicians with vision for the department, the hospital and
the region. Attract strong heads of department, who are
willing to commit themelves for several years, and good
juniors will arrive. Build up regional hospital departments,
and district hospitals will be supported.
With regard to the government's proposals regarding
longer training requirements for South African doctors and
de-recognition of British medical training for registration in
this country, we must realise that we will never build solid
foundations for our hospitals using junior doctors who are
here temporarily and by force. Who is to support and teach
them?
I work in a regional paediatrics department which from
1994 to 1996 had no leadership whatsoever. Doctors
changed by the month, there was very little after-hours
cover, and only one of us had any paediatric qualification -
a DCH (not mine!). Through word of mouth, and personal
contacts overseas, we have in 1 year grown to a department
of three doctors with an MRCP (Paed) (UK), three with a
DCH (SA), one with part 1 of the MRCp, and a further two
with a long-term interest in paediatrics. I believe that, largely
due to our energetic leader, our service has improved
significantly. But, barring two of us, we are all from the UK!
The other two are also not South African. What are we going
to do in a few months when most of this team has left to
continue structured careers in the UK? Who will take over
the challenge and the vision? In 2 years we managed to get
only one South African specialist to visit and advise us.
To those who make decisions - we desperately need
conditions of service that will draw experienced local
clinicians with a long-term vision to the regional services.






Medical Council's proposed new
categories of registration
To the Editor. Thank you for the editorial in the April
edition of the SAMJ.' As a concerned medical practitioner
working in a rural hospital I would like clarification from the
Medical Council on the current moratorium on the
registration of foreign doctors and the proposed new
registration of medical practitioners in this country. Having
studied proposed new registration...categories, I am very
concerned about ~ow we are going to staff our hospital in
the future.
Mosvold Hospital is a 250-bed hospital situated in deep
rural Kwalulu-Natal. It serves a population of 110 000
people who live in scattered homesteads and eke out a
living from subsistence farming, which is supplemented by
income generated by migrant labourers and pension
payouts.
The hospital (currentiy staffed by 6 medical officers) has
an active primary health care service and supervises 5
residential clinics, a mobile clinic service, an under-5 mother
and child service and 138 community health workers who
each take responsibility for approximately 100 homesteads.
Doctors visit the clinics on a weekly basis to see problem
patients and to provide CME to the nursing staff.
Between January 1990 and May 1992 there were five
medical officers at the hospitaL Three of these doctors were
South African and the other two were British. Sinca May
1992 we have been unable to attract any South African
doctors to Mosvold Hospital, despite a number of adverts
in the SAMJ. The hospital has been kept going by short-
term visits from British doctors who stay anywhere from
3 months to 18 months. Currently there are seven doctors at
the hospital - two South Africans and the other five from
Volume 87 No. 7 July 1997 SAMJ
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The transition to more comprehensive
clinical recording is one of the many
changes that South African healthcare
organisations are having to make. The
advent of managed care and technological
changes in patient treatment demand a
more accurate and sophisticated
under.;randin2 of the healthcare business.
In the days of fee for services, managers
were principally concerned with revenue
management and the type of patient
treated was nor as imponanr as the
consumables that they utilised. As
healthcare contracting shifts to per diem
and COSt per case, managers now have to
transition to expense management and
must invoke a higher understanding of
the actual business.
Refined and accurate clinical coding is
cenrral to knowin2 one's business.
Procedure coding; which is all that's
needed for fee for service billing, is
inadequate for per diem or per case billing
or for management information. Funders
and providers, with few exceptions. have
over-empbasised the new CPT procedure
c':Xiing system and ignore, at their peril,
the need for both dia2tlostic as well as
procedure classifications to be able to
under.;tand their patient profiles.
The table illustrates how these two codes
can be powerful in combination but
potentially dangerous in isolation.
Providers or funders basing their long
term exposure on procedures or diagnoses
alone face the risk of over-simplifying
the enormous effects of complications.
Providers, being the most at risk under
fee per case reimbursement. can face
serious financial pressure.
Funders. on the orner hand, cannot work
with undefined margins of error and need
equally to under.;rand how patient profiles
vary between plans. regions and facilities.
Healthcare manager.; have basically had
an easy job. The survivor.; will be those
that adjust to the realisation that more
data and more infonnation are required
for their business, not just more services
rendered. The introduction of managed
care into the South African healthcare
arena does not mean that a "win/win"
environment cannot be achieved.
However, unless there is an understanding
of the true picture of business being
generated, decisions will be made seeing
only a pan of the picture.
Clinical Condition A"e Length of Sta~· A"'e Cost per Case (Cdn S) Variance
Bronchitis
\\ith complicatioolcomorbidi~' 7.] 54 ]80
DO comolica.lionfcomorbidin' •. \ S 2 979 47~
Major in[eSdna1IrectaJ. procedure
...ith complic:Ltionlcomorbidi~' IV S 11 :SS]
DO cornolicarionfcomortlidin' 9.] S 7 79:5 .9«
l.aparolom)'
with complicationlmmortlidil)' 8.9 S 7 991
110 comDlicationft:omorbidit'; 6.5 S:5 2S6 51'X
Hip replacement
with complicationlcomorbidil)' ItS S 16723
no complicationlcomorbidir. 9.4 S l.l. 293 \71<
Urinary neoplasm
with complicationlcomorbidil)' 7.6 55169
no cornplicaIionlcomorbidin' J.3 52264 128'ii-
Providers and payers must work together
in order to achieve the most efficient and
effective healthcare delivery system.
Value Health Services offers a series of
non-partisan services and products aimed
at implementing and utilising the new
coding systems scientifically and to the
benefit of health care in South Africa in
2eneral.
: .. u ..... ,. " .. ,,,, ~
Britain; without the support that we get from these British
doctors, we would be unable to continue to run the
hospital.
The current proposed registration makes Ft compulsory for
every doctor who has not qUalified in South Africa to write
an examination before being able to practise in this country.
While I agree with the sentiment of the document and agree
that it is essential that the Council ensure that doctors
practising in this country are competent to do so, I feel that
this proposed registration may well end up forcing hospitals
such as Mosvold to close because we are no longer able to
recruit medical staff to assist with the running of the
hospital. The (mainly) junior staff that we have had from the
UK have been competent and have quickly adapted to local
conditions. Many of them would not have come to South
Africa if they had been compelied to write an entrance
examination.
I would urge those responsible for drafting such
recommendations to consider carefully the implications of
these recommendations for institutions such as Mosvold
Hospital. Furthermore, should these recommendations be
accepted, Council should be willing to take responsibiiity
upon themselves to help find suitable doctors for institutions






t. Ncayiyana DJ. Medical CouncWs forkec tongue (Mlni-edItotlal). S AIr Med J
1997; 87: 387.
DOTS - are we over-optimistic?
To the Editor: An article in a recent issue of the SAMJ 1
reports the World Health Organisation's claim that 'as the
resu~ of its OOTS (Directly Observed Treatment Short-
course) the global TB epidemic is levelling off for the first
time in several decades'. In addition, in the press release to
which this article presumably refers,2 Or Hiroshi Nakajima,
Director-General of the WHO, states: 'DOTS is the biggest
health breakthrough of this decade in terms of lives we will
be able to save', and Dr Kochi, Director of the WHO Global
TB Programme says: 'This is the single most important
development in the fight against humanity's oldest and most
deadly infectious disease since Robert Koch discovered the
TB bacillus in 1882'.
These are strong statements, which one would assume
are informed by firm evidence. Surprisingly, this is not the
case. We have just completed the first edition of a
systematic review of trials that examined specific strategies
to promote patient adherence to tuberculosis treatment.3 We
included trials that were randomised or pseudo-randomised,
tested interventions aimed at improving adherence to
curative or preventive therapy for tuberculosis, and
contained at least one outcome measure of adherence_ We
used a comPrehensive search strategy and five studies met
the prespecified inclusion criteria. Several interventions, e.g.
reminder letters to clinic defaulters, assistance of patients by
lay health workers, monetary incentives and increased
supervision of clinic staff, seemed to be of benefit. None of
the completed trials examined DOTS, although we identified
two trials in progress that are randomising the specific
SAMJ Volumt 87 No. 7 July 1997
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strategy of observing ingestion of medication. Results of
these studies will be included in Mure editions of the review
as they become available.
The enthusiasm for DOTS is based on the results of non-
randomised, often poorly controlled research. We are
concerned that selection biases inherent in these stUdies
may have led to over-optimistic estimates of the effect of
DOTS. In addition, as we have mentioned elsewhere, co-
interventions could potentially explain the supposed benefits
of DOTS.< DOTS is a specific strategy whereby the patient
swallows medication under the direct supervision of a third
person. DOTS programmes, on the other hand, usually
consist of substantial effort and investment to improve
tuberculosis services, such as better service access,
improved drug supplies, patient incentives, defaulter tracing
and outreach activities. These parallel interventions, rather
than DOTS per se, may account for the beneficial effects
being attributed to DOTS. The risk associated with the
rather simplistic statements from the WHO is that countries
may alter their current administrative systems for managing
tuberculosis to DOTS without the accompanying parallel
interventions and investment. It is therefore our opinion that
the recent WHO claims are premature and potentially
counterproductive. Carefully designed randomised trials will
help provide a more informed policy.
J Vo/mink





UvetpOOl School of TroPIcal Medicine
University of Uverpool
UK
1. TB levelling off (lzlIldaba). S AIr Med J 1997; 87: 576.
2. Work:! Health Organl~tlOn.Breakthrough in TB control announced by tl'le Wood
Health Organisauon. Press Release WH0I23. 19 March 1997.
3. Volmink J, Garrtef" P. Promoting adherence to tuberculosis ueatment. In: Garner P,
Gelband H, OIliaro P, Salinas R. Volrmnk J, Wilkinson D. eds. Infectious diseases
module of the Codlrane D.uabilSe of Systematic ReViews (updated 15 April
1997). The Cochtane lIbrat)'. Oxfam: Update Software, 1997.
4. Volmink J. Garner P. Directly Observed therapy. Lancer 1997; 349: 1399-4000.
Bestuurde gesondheidsorg - wie gaan
die wenners wees?
Aan die Redakteur: Die mening5 wat dr. KrOger1 oar die
invloed van bestuurde gesondheidsorg en die kwessie van
uitkontraktering en prof~ionele fooie onlang5 uitgespreek
het, is tiperend van die verlore stryd wat die
privaatpraktiserende gel ,~esheer in Suid-Afrika die dTgelope
3 dekades veer. Sy menings en voorstelle is niks nuut nie.
Inteendeel, ek het aI meer as 13 jaar gelede dieselfde
argumente gevoer en voorstelle gemaak2.3 wat geen reaksie
van enige kollega of organisasie uitgelok het nie. .
Geneeshere kon nog nooit as 'n verenigde front
saamstaan nie en noudat die stryd teen die geldbeherende
groot besighede verloor is, bly net die vertroeteling van 'n
edel geneesheer-pasient verhouding en mediese versorging
waarop die professie trots is en waarvoor die pasient
dankbaar is, oar. Die dae van hoe finansiele vergoeding en
leefwyse in 'n land wat wemel'van armoede is heel
waarskynlik verby en ons salons maar moet staal om as
werknemers van privaat gesondheidsorgfinansierders of die
owerhede ons professie te beoefen. Die gans wat vir die
afgelope 30 jaar die goue eiers getrou gele het, is oud en
afgeleef en word vervang deur 'n roofvoel wat die kuns het
om sy verswakte prooi met dodelike akkuraatheid af te
maai.
Miskien is die nasionale gesondheidsversekeringsplan van
die regering tog nie so 'n slegte plan nie, Net jammer die
privaatpraktiserende geneeshere het nie die geleentheid
benut om 'n leidende rol daarin te speel nie. Dit kon 'n
deurslaggewende faktor vir die toekoms gewees het!




1. KrUger CM. 6estuurde gesondheidsorg - ....le gaan die ....enners ....ees? (Bnelj.
S AIr Med J 1997: 87: 332.
2. Erasmus RJE. Die ver$legtende posrSIe van die algemene praktlSyn f6net).
S AIr Med J 1983; 64: 967.
3. Erasmus RJE. Hanterinq van die voordeleSkaal (Brie!). S AIr Med J 1985: 68; 365.
Evaluation of community radio as a
medium for health messages
To the Editor: Community radio is a neWly developing
sector. Very little empirical audience-based research
assessing its impact has been conducted. However, more
and more organisations are giving this attention. The
National Progressive Primary Health Care Network's Media
and Training Centre (MTC), together with Radio Zibonele,
have started a multifaceted research programme combining
quantitative, qualitative and participatory methodology. We
therefore took special interest in the letter by Bardwell et al. 1
The following comments are based on careful scrutiny of the
full research report, in conjunction with the abbreviated
version published.
The stUdy was conducted by four undergraduate medical
students as part of their Community Health module. It was
conducted within a praxis framework, meaning that it was
conducted congruently with the values of the sector and
that results are fed back in a way that contributes
constructively to sector building, and deserves support and
special mention on these grounds. However, the project
lacked sound methodological guidance. We have several
points of critique, given in summary here (a full document is
aVailable).
The project is characterised by an over-generalised title,
inadequately reflecting the research question. (If you take
the title at face value, you have to concede that the research
design renders ll1e stUdy internally invalid.) Initially ll1e study
is introduced as 'a survey'. Yet, jf it claims to be a survey, no
claims of either internal or external Validity can be made.
Later on it becomes clear that a case control design was
implemented - the easier design option in the context of
the complexities of the research question. The
consequences of the lack of control over all variables
(especially extraneous variables) inherent in this design,
have not been taken into account in either techniques used
or the interpretation and presentation of findings, resulting in
uncritical over-interpretation. The most fundamental point of
critique, however, relates to an inadequate measuring
Volum~ Si No. i July 199i SAMJ
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Interest: R92L93 "o/u q J
Balance: R23. 05
Interest: R944,98 25/05/96 1debt. Close fi e.
Balance: write off as bad
Action: Address unknown
Remarks:
DON'T LOSE PATIENTS OVER UNPAID BILLS
Do YOU HAVE THE TIME TO CHASE UP BAO OEBTS?
WITH THE PRESSURES OF YOUR PRACTICE, YOU
PROBABLY DON'T.
WHY SPEND HOURS SENDING OUT PAYMENT
DEMANDS, WHEN SNYMAN & VENNOTE'S SPECIAL-
IST NEGOTIATORS CAN COLLECT WHAT IS OUE WITH
SPEED ANO EFFICIENCY? YET SO TACTFULLY THAT
YOUR DEFAULTING PATIENTS WON'T NOTICE ANY
DISCOMFORT!
WE ENSURE THAT THE MEASURES WE EMPLOY
REFLECT THE ETHICS AND INTEGRITY OF YOUR
OWN PROFESSION. RE-SCHEDULING DEBTS IF
NECESSARY, REHABILITATING DEBTORS WHERE
POSSIBLE AND PRESERVING GOOD RELATIONSHIPS.
OUR TRACK RECORD SPEAKS FOR ITSELF.
BUT IF WE FAIL TO COLLECT YOU DON'T PAY.
SNYMAN
MORE AND MORE MEDICAL PRACTITIONERS ARE
USING SNYMAN & VENNOTE TO SOLVE THEIR CRED-
IT PROBLEMS AND UNCLOG THEIR CASH FLOW -
WHILE MAINTAINING CONTROL OF THEIR ACCOUNTS.
SOMETIMES IT MAKES SENSE TO CALL IN A SPE-
CIALIST. SNYMAN & VENNOTE HAS 100 OFFICES
COUNTRYWIDE. PHONE OUR CLIENT SERVICE NOW
TOLLFREE ON 0800 117 224 (SOUTH AFRICA);
0926461 224228 (NAMIBIA).
• FAST, INTEGRATED COLLECTION SERVICE
(NO COLLECTION, NO CHARGE)
• UNIQUE CREDIT BUREAU PROVIDING
POSITIVE AND NEGATIVE PROFILES
• INNOVATIVE SOLUTIONS TO SPECIFIC
P-ROBLEMS
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instrument: the measurement of both 'attitude' and
'practices' fails in terms of construct validity and content
validfty; measurement of 'listenership to Radio Zibonele' is
crude and unreliable. The backbone of the study therefore
falls short of acceptable methodological standards,
rendering all conclusions invalid and unreliable.
The only measure of association that warrants attention is
the one between 'knowledge' and 'presenting with gastro'.
The other 'noteworthy trends in the data' and 'striking
consistency of results' are unfounded. All references to
measures of association between 'Iistenership to Radio
Zibonele heafth programmes' and 'knowledge', 'attitude'
and 'practices' remain unsubstantiated. Unfortunately, even
the reported positive impact of community radio on
knowledge of the community is invalid in the context of the
study.
Where does this leave us as far as researching community
radio is concerned? After 4 years of MTC's involvement in
community radio in South Africa, we have ample 'everyday'
experiences confirming its positive impact on primary health
care and community development. Despite this, there is a
strong need to conduct research as a formalised, systematic
process that investigates these everyday experiences in an
objective, reliable and valid manner. The mere commitment
to conducting research (within a praxis framework) is not
enough, however; it needs to be backed up by quality
output. The whole sector (researchers and users of research
- especially community radio stations) is responsible for
ensuring that this happens. Researchers need to be held
accountable for their methodology and reporting, and users
of research need to become informed enough to ask critical
questions. For this to happen, research needs to be a
demystified, transparent process for everybody - a starting




Media and Training Centre
National Progressive Primary Health Care Networil:
Cape Town
1. Bardwell H. Burrows C, Ford P, Mclntosh C, London L Evaluation of community
radio as a mltdium for health messages (Lener). S Afr Mea J 1997; 87: 338.
Effective asthma control- time for
physician and pharmacist to join forces
To the Editor: We have seen a concerted and successful
effort by the National Asll,ma Education Programme (NAEP)
to increase both doctor and patient awareness of asthma.
However, the greatest challenge facing asthma care-givers is
not lack of patient awareness, but a pervasive non-
compliance that occurs universalty with inhaled 'preventer'
medication.
For optimal asthma control, prolonged and consistent
anti-inflammatory therapy is reqUired even in the absence of
symptoms. To achieve consistent medication usage, doctors
will actively have to enrol the assistance of the community
pharmacist. Use of the phannacist as a medication
supervisor and an asthma educator will greatly improve
adherence to inhaler medication regimens.
Physicians tend to assume that their 'obedient' patients
will automatically comply, and greatly overestimate
adherence to medication regimens. Studies' show that only
about 50% of patients take their medication in the dosages
prescribed. The reasons for this are varied and complex,
and numerous efforts to improve patient compliance have
been disappointing. Unless community pharmacists are
actively encouraged to play a greater supervisory role,
asthma prevention programmes are doomed to fail. Even the
Royal Pharmaceutical Society considers the SUbject of non-
adherence a priority issue and has recommended that the
term 'compliance' be substituted with the less autocratic
term 'concordance'. It hopes that this will lead to a greater
spirit of negotiation and co-operation between care-giver
and patient.2
A recent study' in the USA on compliance with regard to
long-term inhaled corticosteroids in asthma showed that
despite patients having a good understanding of the
inflammatory nature of asthma and diligently filling in diary
cards, non-adherence was extremely high. In the study,
95.4% of patients claimed to be taking their inhalers on a
regUlar twice-daily basis, while actual use, determined by an
electronic monitor, was only 58.4%. An interesting
observation was that the more poorly controlled asthma
sufferers who required 'rescue' oral steroids or
hospitalisation had even worse compliance data, In this sub-
group, only 13.7% took their inhaled corticosteroids
regularly as prescribed. This study has far-reaching
implications when one considers the financial impact of
wasted medication, unnecessary hospitalisation for
exacerbations, and worsening long-term morbidity due to
uncontrolled illness.
It is imperative that physicians and pharmacists bury old
animosities and work together as 'educators', so as to
increase the awareness of non-eompliance and find ways of
combating it vi~ mutual co-operation.
Adrian Morris
A1lervr Clinic
Red Cross War Memorial Children's Hospital
Cape Town
1. Haynes RB. Taylor DW, Sacken CL Compliance in HeQJfh Cllre. Baltimore: Johns
Hopkins University Pr"s, 1979.
2. Royal Pharmaceutical Society of Great Britain. From Compliance ra
Concordance: TowarcJs Sharea GOllls in Medicine Taifing. London: RPS, 1997,
3. Milgrom H, Bender B, Ackerson L. Bowry P. Smith B, Rand C. Non-eompliance
and treatment failure in children with asthma. J Allergy Clin ImmunoJ 1997; 98 (6,
pan 1): 1051·1057.
Migrancy and HIV/STDs in South Africa -
a rural perspective
To the Editor. Williarns and Carnpbell' raise the important
issue of the role of migration in the spread of HIVlSTDs in
their discussion of a proposed intervention around a mining
centre near Johannesburg. Recognising that an intervention
aimed soiely at mineworkers would be futile, they argue that
interventions must be targeted not only at mineworkers 'but
also at members of the broader communities surrounding
the goldmines, in which mineworkers live out their social
and sexual lives while they are away from home'.
This represents an important strategy, but could go
further. The vast majority of mineworkers are migrant
Volume 87 No.7 July 1997 SAMJ
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labourers from rural areas. Interventions must therefore also
be aimed at rural partners of migrants who themselves may
be at increased risk for HIVlSTD infection because their
partners are migrants.
The link between migration and HIVlSTQ has been
documented in the few studies that have been done.2~
These studies suggest that 'migration of poor, rural and
young sexually active individuals to urban ar~ __ . played a
prominent role in the dissemination of HIV globally'.~ In
South Africa, the system of migrant labour has been shown
anecdotally to exacerbate the spread of tuberculosis,7 HIVS
and other STDs.9 However, with few exceptions, all these
studies have examined the relationship between HIVlSTO
and migration from the perspective of urban migrants at
their workplace. Consequently, they fail to document the
impact of - and implications for - migrants' ·return to rural
areas.
To that end, we are currently studying;the social and
epidemiological consequences of migratio~at the
household level in the Hlabisa district of Kwazulu-Natal.
Fonnative research has been underway since May 1996 and
is aimed at understanding the patterns of migration into and
out of the district, knowledge and awareness of Hlv/STDs,
local health beliefs and health-seeking behaviours, and
patterns' of sexual networking. A variety of qualitative
research methods are being used, including the
establishment of more than 20 key-informant households
which are serving as long-term case studies, ongoing work
with school students who are keeping daily logs of the
composition of their households, observations at local taxi
ranks, and interviews with traditional healers. The second
phase of the research, due to begin in June 1997, will be a
cross-sectional study aimed attesting the hypothesis that
migrants and their rural partners are at increased risk for
contracting HIV/STDs compared with non-migrants and their
partners.
Our preliminary research suggests that nearly two-thirds
of households in the district include a male who is a migrant.
While nearly one-third of male migrants from Hlabisa work in
the Johannesburg area.. 48% work in towns scattered along
the northern Natal coastline (within a 2-hour drive of Hlabisa)
and 18% are in Durban (a 3'h-hour drive from Hlabisa).
These findings challenge the s1ereolype that migration is
generally long-distance and long-temn.
Our research also challenges the commonly held
assumption that it is only men who migrate. While we have
not yet measured the prevalence of migration among
women, we do know that women who migrate tend to stay
much closer to home than their male counterparts do. Of the
women migrants we have identified, none works in
Johannesburg and the majority work within a 1 - 2-hour
drive from Hlabisa
Patterns of migration in South Africa did not simply arise
by chance. On the contrary, a myriad of laws under
apartheid prohibtted black South Africans from settling
permanently in 'whrtes-onty' areas. Migration patterns in
South Africa, although incompletely documented, tend to be
'oscillatory' or circular, with migrant men and women
maintaining close links to their rural homesteads. These
pattems, however, are clearly in flux and these changes may
bring with them important implications for the spread - and
control - of HIV-STDs. In the past, for example, migrants
who went from Hlabisa to work in Johannesburg could
return home only ohee a year. Now, however, with the lifting
of restrictive laws, improvements in the transportation
systems and more flexible work contracts, men from Hlabisa
working in Johannesburg are able to return home much
more often - on average about once every 2 - 3 months.
One impact of this change in migration patterns may well be
that rural partners are more frequently exposed to potential
infections, and are therefore more likely to be infected with
HIV and other SIDs.
The work that Williams and Campbell and their colleagues
propose around the goldmines is important indeed. At the
same time, there is a need to understand migration from
both ends of the sPl'!'trum. Appropriate HIVlSTD treatment
and prevention programmes must be targeted to migrants -
both at their place ·of work and at home. They must also be
targeted to rural partners of migrants rt the epidemic is to be
curtailed.
Funding for this research has been provided by the South
African Medical Research Council and the Fogarty International
Centre, NIH.
Marlc Lurie
South African Medical Research Council and






South African Meaical Research Council
1. Williams B. Campbell C. Mines. migrancy and HIV in South Africa - managing
the epidemic. S Air Med J 1996; 88: 1249-1251.
2. Anarfi JK. ~JluaJity. migratlon and AlDS In Ghana - il soclo-behaviooraJ Sl\ldy.
Health Transition Review 1993; 3; 45-67.
3. Decosas J. Kane F. Anarli JK. Sodji KDR, Wagner H. Migration and AIDS. Lancet
1995; 346: 826-828.
4. Ouinn T. Population migration and spread of types 1 and 2 human
immunodeficiency virus. Proc NarJ Acad Sci USA 1994; 91: 2407·2414.
5. Pison G. Le Guenno 6, Lagarde E. En~ C, Seck C. Seasonal migration: a risk
faC"lOl'" for HI'.' in rural SenegaL J Acquir Immune Defic Syndr 1993; 6: 196-200.
6. Nunn A, Wagnet H·U, Kamali A. Kengeya-Kayondo J. Mulder D. Migration and
HIV-l seropl'"evalence In il rural Ugandan population. AIDS 1995; 9; 503-506.
7. Packard RM. White Plague, 8Jack Labor. TubMcu/osis and the Political Economy
of Health and Disease in South AfriCa. 8er1teley. Calif: University of Calrtornia
Press. 1989.
8. Jochelson K. MOthlbell M. Leger J-P. Human immunodeficiency YlfUS and migrant
labor in South Africa. Int J Health SMv 1991; 21 (1); 157-173.
9. Hunt C_ Migrant labor and sexually transmitted disease: AlDS in Africa.. J Health
Sce 8ehav 1989; 30: 353-313.
Sarafina Ill?
To the Editor: As an intern, I would like to share some of
my objections and those of my colleagues to the proposed
plan of community service. When we embarked on a career
in medicine we did not enter into any contract with the
Department of Health or Dr Zuma with regard to our
conscription.
It enrages us that we have neither been consulted nor
given the opportunity to voice our opinions_ Is it not arrogant
and misinformed to presume that individuals enter the
medical fraternity purely for altruistic reasons?
Another of the many unaddressed issues is why one
profession is being targeted. Why not force accountants to
SAMJ Volume 87 No.7 July 1997
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do government audits, lawyers to provide legal aid, and
engineers to develop our rural infrastructure?
The transparency of the pseudonym 'vocational training'
has been revealed, and it is obvious that it is the antithesis
of an incentive-driven voluntary scheme. To justify this,
suddenly our competence and that of our teachers (many of
them internationally recognised in their fields) are being
questioned. Why, then, are we considered competent for
employment in First-World countries?
The Department of Health's shortsightedness is borne out
by the following unaddressed issues: (I) how can supervisory
posts be created overnight in satellite hospitals when
academic institutions are reeling from the current critical
shortage of teaching staff?; and (iJ) why not make family
practice a specialty rather than force demotivated doctors
into areas of medicine which hold no interest for them?
In this new era of democracy and constitutional rights, I
find IT highly contradictory and, ironically, reminiscent of the
previous regime. The vocational training scheme is violation
of an individual's right to equality, right against forced labour,
and right to choose one's place of residence and one's
profession.
Leaders in this country should be held accountable for
their decisions. Young doctors would willingly stay and serve
their country, but it would seem that Or Zuma plans to drive





Abortion objectors - rights and
responsibilities
To the Editor: The Choice of Termination of Pregnancy Act
passed recently in Parliament has brought with it some major
logistic problems, particularly as a result of doctors and
nurses at many hospitals having moral objections to being
involved. These objections range from not wanting to have
anything to do with women requesting abortion to agreeing to
all but the handling of the manual vacuum aspirator
themselves. Many, if not most, objections are based on
reluctance to take or participate in the taking of an innocent
baby's life. Often, however, zeal for the cause may result in
avoidance of careful history-taking, failure to do a full and
dignified examination, and sloppy handling of the patient.
This is inexcusable and may be medicolegally negligent. I
have on one occasion found that a woman requesting an
abortion was not pregnant, and another had an ectopic
gestation. I do not object to confirming the presence of a
normal pregnancy and declaring the woman medically fit,
even if she would have been assessed at any antenatal
booking clinic by a qualified midwife had she wished to keep
her pregnancy. Preliminary evaluation of these women should
really be performed at an antenatal clinic.
To avoid the problems of directive counselling it is
probably a good idea for the waiting rooms of
gynaecological OPOs to have clearly and simply explained
options and alternatives in the appropriate languages for
women before they are seen and examined by staff. They
may then be able to enquire further in an informed manner.
The practitioner who objects has every right to refuse to
write up or administer misoprostol to induce an abortion and
it is prudent for medical superintendents to organise
presigned scripts or willing practitioners to oversee its use.
I think it is indefensible for a doctor or nurse with
objections to refuse to see a patient arriving at hospital with a
threatened, inevitable or incomplete abortion, even in the
knowledge that an abortion had been procured. Certainly
once the baby has been delivered. retained products
constitute a grave risk to the mother's future health and
fertility. Refusal to attend to her would surely be medicolegally
CUlpable. If the objectors feel that the method by which she
aborted constitutes grounds for refusal to treat, then the
corollary exists that they must refuse to see injured drunk
drivers or attempted suicides. However, agreement to see
these patients on an emergency basis ensures that what
would previously have been regarded as an 'emergency' has
now become 'routine' work and thus forces staff who object
strongly to participate in abortion work to keep the system
running. This is stressful and highly unsatisfactory for the staff
and should motivate administrators to designate separate
staff and facilities for fetocidal purposes.
Some doctors and nurses attempt to stigmatise and even
persecute colleagues who are prepared to do abortions and
run the risk of allowing their differences of opinion to spill
over into interpersonal relationships, which affects co-
operation on other work. This only polarises the profession
and generates more heat than light. The fact of the matter is
that abortionists and objectors exist, are employed in the
same institutions and will not resign their jobs. A clear
statement of one's moral position does not mean a calt to
arms. The need to co-operate fully to provide the vast
remainder of O&G responsibilities is critical and should not
be threatened by this divisive issue. To expect one willing
member to futfil routine duties plus deal with the abortion
load is grossly unfair and may be construed as mere
avoidance of work.
With the passing of the new legislation, rights have been
afforded many women without the means to accede to
them. Uttle if any attempt was made to assess the
Willingness of current medical staff to fulfil the requirements
of the new Act. If the current impasse is not broken by
means of creative co-operation, the stalemate may threaten
the very survival of our fragile medical network to the
eventual detriment of all.
rf the government does not take the issue of





Diagnostic disagreement with malaria
diagnosis in Mpumalanga
To the Editor: Durrheim et al. 1 describe disagreement
following the examination of blood smears for malaria. The
specimens were examined successively at four different
laboratories. Experience has shown that repeated
Volume i No. 7 luly 1997 SA-MJ
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examination and cleaning result in loss of material and
fading of the stain. Specimens received at one of the
laboratories were in this category. When parasitaemia is at a
low level, detection may be problematic and may only take
place at a subsequent examination. No informat;on on
parasite levels was given. A further confounding factor is the
differing quality and condition of microscopes in use. The
laboratory results given are unsatisfactory and require further
investigation, especially those of laboratory 2 when
compared with the other three.
A quality assurance service has been operational for
several years in the Northern Province involving the
confirmation of positives and re-examination of at least 10%
of negatives undertaken at a separate laboratory. Apart from
a few instances where faulty equipment or microscopist
stress has been responsible, 99.4% of results have been
confirmed during the past 2 years. Training involves an initial
course using a defined syllabUS, regular refresher courses
for all microscopists and recall for further training of those
microscopists who give discrepant reports.
To ensure uniformity when laboratories are compared, it
would be preferable to make multiple specimens from each
patient or for specimens to be protected by sealed cover
glasses. Parasite counts should be made by all participating
laboratories. Confirmation of diagnosis with a PCR!
molecular-based test for parasite presence and species
should be undertaken and used for comparison.
C FHansford
C M van Vuuren
Malaria Co-ordinating Centre
T~neen. Northern Province
1. Ourrheim ON. Seeker PJ, Brink A. Diagnostic disagreement - the·lessons learnt
from malaria diagnosis in Mpumalanga. S Air Med J 1997; 87; 609-611.
(A response to this letter by Durrheim et al. arrived too late
for inclusion in this issue of SAMJ. It will be published in
August.)
Impact of antimicrobial resistance and
antibiotic choice on the outcome of
pneumococcal meningitis
To the Editor: I noted with interest the paper on the
epidemiology of post-neonatal bacterial meningitis in Cape
Town children.1 An important observation of the study,
highlighted in the text and the abstract, is the poor outcome
of pneumococcal meningitis relative to meningococcal or
haemophilus meningitis_ Of the 10 deaths in the study, all
occurred among children with pneumococcal meningitis. The
case fatality rate of 38% (10/26) is not unusual in series of
patients with pneumococcal meningitis. For example, the
case fatality rate among 84 children with pneumococcal
meningitis at Baragwanath Hospital from 1989 to 1991 was
32%." While the authors identified young age as a risk factor
for severe disease or death among children with haemophilus
and meningococcal disease, they were unable to find such an
association for pneumococcal meningitis. In our study at
Baragwanath Hospital," the outcome of pneumococcal
meningitis was poor, since relatively penicillin-resistant strains
were common and treatment commenced with penicillin
and/or chloramphenicol. Hussey et al. 1 give no data on the
susceptibility of the pneumococci they isolated, and no data
are presented on the antibacterial agents used to treat
meningitis dUring their study. It would be interesting to know
whether the excess mortality from pneumococcal meningitis
they reported was due at least in part to the presence of
resistant strains, and whether this mortality could be reduced
by the use of third-generation cephalosporins such as
cefotaxime or ceftriaxone for empirical management.
KPKlugman
MAC Pneumococcal Diseases Research Unit
South African Institute 101" Medical Research and
University of the Witwalersrand
Johannesburg
1. Hussey G, Schaaf H, Hanslo D, et al. Epidemiology of post-neonatal bacterial
meningitis in Cape Town children. S Afr Med J 1997; 87; 51-56.
2. Friedland IR, KlU9man KP. Failure of chloramphenicol therapy in penicillin-
resistant pneumococcal menin9itiS. Lancet 1992: 339':: 405-408.
Drs Hussey and Hanslo reply: We thank Professor
KJugman for drawing attention to the association between a
poor outcome of pneumococcal meningitis and occurrence of
peniciJJin-resistant strains. Our study focused on the
epidemiology of post-neonatal bacterial meningitis, and was
not designed t address antimicrobial therapy or the
resistance patterns of the causative organisms. The limited
available data were used to determine the presence of any
risk factors. We cannot therefore confirm an association
between mortality and penicillin resistance_ During the study
period the empirical antimicrobial treatment of presumed
bacterial meningitis was a combination of penicillin and
chloramphenicol. However, third-generation cephalosporins
were frequently used, especially in situations where
pneumococci were seen on Gram stains of cerebrospinal fluid.
Subsequent to this epidemiological study, a further one
was undertaken to investigate the antimicrobial resistance
patterns of pneumococcal isolates (G Hussey -
unpublished data). Three of 26 strains from CSF (11.5%)
were found to be resistant to penicillin (two with
intermediate resistance and one fully resistant). The mortality
rate in this cohort of children was 27%. The number of
patients was too small to determine any clear association
between mortality and penicillin resista[1ce. The rate of
penicillin resistance in blood culture isolates was 24/88
(27.3%), with 22 of these showing intermediate resistance.
In the light of the emerging resistance of pneumococci to
penicillin and the reported association between mortality
and penicillin resistance, our current antibiotic policy for the
treatment of pneumococcal meningitis is a third-generation
cephalosporin.
Lamotrigine and serious skin reactions
To the Editor: The Medicines Control Council has been
alerted to the potential for serious skin reactions with the
use of lamotrigine. Paediatric patients are at special risk.
Lamotrigine is an anti-epileptic drug indicated as
monotherapy or add-on treatment for partial eQilepsy, with
or without secondary generalised tonic-clonic seizures, and
in primary generalised tonic-elonic seizures in adults.
Lamolrigine should be used in children aged 2 - 12 years as
add-on treatment for partial epilepsy (with or without
secondary generalised tonic-elonic seizures) that is not
satisfactorily controlled with other anti-epileptic medicines.
Volume 87 No.7 fuly 1997 SAMJ
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Lamotrigine is known to cause skin rashes in approximately
5 - 10% of adult patients and 17% of children. This usually
happens, but not always, within the first 6 - 8 weeks of
therapy. The concomitant use of sodium valproate increases
the incidence of skin reactions to 21 % in adutts and 34% in
children (Glaxo-Wellcome - unpublished data, 1994).
Serious skin reactions, such as Stevens-Johnson
syndrome and toxic epidermal necrolysis, occur in 1 in every
1 000 adult patients, and in approximately 1 in 300 to 1 in
100 children.1 In addITion to age, the risk of rash is also
strongly associated with: ~) high initial doses of lamotrigine,
which exceed the recommended dose escalation of
lamotrigine; and Q1) concomitant use of sodium valproate,
which doubles the half-life of lamotrigine.2
A further concern is a hypersensitivity reaction to
Jamotrigine associated with variable symptoms, including
fever, lymphadenopathy, facial oedema, haematological and
hepatic abnormalities that may progress to disseminated
intravascular coagulation and multi-organ failure. This
syndrome mayor may not be associated with a rash.'
Based on this information, the following recommendations
have been included in the product labelling:
1. Lamotrigine remains indicated as add-on treatment in
children for partial epilepsy not adequately controlled with
other anti-epileptic medicines. The safety and efficacy of
lamotrigine as monotherapy in children under 12 years of
age have not been established, and there are serious
misgivings about safety in this age group.
2. The dosage instructions in the package insert should
be strictly followed, especially when used in combination
therapy with valproate where one-tenth to one-fifth of the
normal dose is recommended. The initial dose and
subsequent dose escalation should not be exceeded.
3. In children, the initial presentation of a rash may.
erroneously be attributed to the usual childhood diseases.
Physicians should exercise a high index of suspicion in a1l
patients (adutts and children) who present with a rash,
lymphadenopathy and/or fever, especially during the first 3
months of therapy with lamotrigine. Patients developing this
adverse effect should be promptly evaluated and lamotngine
withdrawn immediately unless the symptoms are clearly
found not to be drug-related.
4. Patients should be advised to see their doctor
immediately if they develop a skin rash or fever.
Doctors are encouraged to report these adverse drug
reactions to the National Adverse Drug Event Monitoring
Centre.
UshmaMehta
National Adv~ DnJg Event MOf"'- n9 Cenrre
Medicines Conrrol CouncIl
Cape Town
1. Glax.o Wellcome. A risk-benefit assessment of lamorrigine (Lamictal) and serious
skin reaction in children. 24 March 1997 (In-house publication).
2. Yuen AWC. Land G. Weatherty BC. Peck AW. Sodium valproate aCutely inhibits
'amotiigine metaboll$ltl. Br J Clin Pharmaco/1992: 33: 511·513,
Private immunisation - the agony is
worse than the injection
To the Editor: Much work has been done in South Africa on
hepatitis 8, especially with regard to its incidence and
relation to cancer of the Jiver. Although a vaccine.has been
available for a long time, only health workers have been
routinely immunised. The carrier rate is about 14.5% in rural
Kwazulu-Natal and half that in the rest of South Africa.
Since 1995, hepatitis B has been included in the staMory
immunisation of infants at well-baby clinics. Since this has
left a large proportion of schoolchildren unimmunised, it was
feH: that a private scheme for immunising schoolchildren
could be launched.
What a Pandora's box of trouble this has opened!
Resistance was experienced from local health authorities,
who fett that it might be unethical; this ultimately required
state approval. Then a complaint was laid with the Interim
Medical and Dental Council that the Pharmacy Act was being
violated (even though all the doctors on the scheme were
registered, 2 as paediatricians and all as dispensing doctors).
Many general practitioners on school boards said that it was
going to take away their practice (few, if any, had in fact
immunised their own children). Headmasters and
headmistresses said that the children should go to their own
family doctor or health clinic, and all showed woeful
ignorance of the disease, and a great naivety with regard to
the children at school. Parents, of course, had never heard of
the disease and taking their children to a clinic or doctor was
therefore out of the question. Even getting the names of
schools and t,heir principals proved to be a great hurdle, let
alone travelling to the schools, or getting sufficient co-
operation to use a room or hand out literature for the parents.
Getting supplies of vaccine has also been a major problem
because of price fluctuation. Sudden increases in price of
more than 25% between the first and the third injection have
caused immense administrative problems, and the companies
concerned have a 'take it or leave it' attitude.
Surely, somewhere along the line, there should be more
co-operation with regard to what is an advancement of
universal immunisation?
It was also painfully obvious that there is still a great need
for knowledge and publicity in preventing a potentia/ly fatal
disease and for the manufacturers of the vaccine to keep
prices down to levels that would make private




Overtime for hospital doctors in the
Eastern Cape
To the Editor: The working conditions of doctors in
provincial service in the Port Elizabeth metropole are totally
unacceptable for a number of reasons, one of which is the
refusal of senior hospital management to adopt a reasonable
approach to doctors' working hours.
Management seems to be incapable of accepting the fact
that these doctors are working long and arduous hours -
well beyond the required 56 hours per week without extra
remuneration, despite the fact that they are supposed to be
paid for all overtime worked. The provincial government has
in fact been given the funds to pay this overtime, but it is
refusing to do so.
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In July 1996 I was told that overtime worked would be
paid for, and I subsequently agreed to work beyond the
required 56 hours. In October it became obvious that the
overtime worked was not going to be paid. I subsequently
withdrew my services for work beyond 56 hours.
I wrote a letter to the superintendent of the hospital
concerned and was infonned that despite an average of 6.5
hours extra overtime per week over a period of 25 weeks,
management had decided that overtime would only be paid
after 70 hours worked and so I did not qualify. This decision
was based on the wilful misinterpretation of a Medigram
(August 1996) stating that overtime should be capped at 70
hours.
In consultation with Mr Peter Brewer of MASA it has been
decided to pursue this matter further, hopefully to a
satisfactory conclusion.
I feel that it is time for the doctors of the Eastern Cape to
make a stand for what is right and just, not only in our own
interests but in the interests of the patients we serve.
I urge all doctors who have overtime owing to them as
from 1 July 1996 to: (I) write to their superintendents
requesting that they be paid for the overtime owing; (if)
attach duty rosters and time sheets to prove their claim; and
(iil) write to Mr Peter Brewer of the MASA requesting that he
attend to the matter if the overtime payment is refused - if




POrt Elizabeth. E Cape
Dietary management of diabetes mellitus
To the Editor: An extract from an Association for Dietetics in
Southern Africa (ADSA) Position Statement on dietary
management of diabetes mellitus was used in the Diabetes
Mellitus Clinical Guidelines published as part 3 of the April
1997 SAMJ (pp. 493-512).
Unfortunately the compilers of the Guidelines did not
acknowledge all those who were involved in the compilation
of the ADSA Position Statement, namely A Badenhorst
(Convenor), J Badham, R Blaauw, A Dannhauser, W du Toit,
C Herbert, J Johnson, E Menssink, C Peberdy, N Silvis,
M Slabber, P Wilson and R Wilson.
Because the ADSA document used by the compilers of
the Guidelines was not the final version, the Guidelines
contain two further errors.
Under the heading 'Carbohydrates' (p. 504), the second
sentence should read: 'The daily consumption of a diet high
in complex carbohydrates and ideally containing
approximately 3 9 dietary fibre (non-starch polysaccharides)
per 1 000 kJ, is recommended.'
Under the heading 'Sweeteners' (also p. 504), the final
sentence should read: 'More research is needed to identify
the effects of long-term use of non-nutritive sweeteners in
humans. especially pregnant and lactating women.'
The full ADSA Position Statement will be published in a
future 'Clinical Nutrition' issue of the SAMJ.
Penny Love
~eCommrrret!!: Publicarions
AssociatIOn lor DietetiCS <n South Africa
Taylepiece
The Doctour's Tayle
Whan thatte Marche wyth hys shoures pissynge doun
Thatte brynge swich floddes to every parte of toun
Ther cam oon Zuma, a learned doctour of phisik
In al thyss world ne was there noon she lik
She wot the reason for thyss contree's jeopardye
And nameth AIDS the roote cause of thyss maladye
And whatte AIDS engendred, and its discomfiture
She was a verray parfit praktisour
She vowyd thyss dreddfol pestylaunce to cure
For alle thyss contree's populaycioun - eyven Beer.
For God pardee, the cure was wel wythin her kenne
For in her praktyse hadde she met an actynge gentlemanne
To maketh musiekalles was hys wane
For he was Fredde Aystayre's owene sane
We! koude he dressyth maydens in tyte gymmslyps
Wych hydeth nat theyre rounded bottoums nor theyre hyps.
To Woodstokke hadde he been on pilgrimage
And kenned the virtuye of artystik budgette large
Ngema was thyss actynge manne y-klept
And forteen millyon randes dyd he gretefutlie axept.
Thyss musiekaHe, eftsoons, was oonlie partlie new -
And twas the reason he y-klept it '5arafina two'.
For tho a musiekalle wyth trobbles is bisette
Thyss forteen millyon kept him cleerly oat of dette.
The learned doctour Zuma natheless hath nat been praysed
And opposicioun membres mayde her soore amayzed
Wyth jaJous cryes for lye detectour tests
(Wych sheweth opposicioun spekers are Iyke pests).
God wot, the messauge of thyss musiekalle is cleer:
'Forsaketh nakyd screwynge threo-oot the yeyre
And tho ye be a lustfoll and a Iikerous boy
Tis ofte tymes sayffer to do the toyi-toyi.
And tho ye fynde it grete/y combersom
If screw ye must, thanne use con rubberysed condom!
Douglas Tobias
Durban
This item appeared in the April 7996 Natal Inland Branch
newsletter and we thank the Editor, Or Rod Inglis, for
permission to reprint it.
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PROPRIETARY NAME AND DOSAGE FORM;
COZAAR* COMP Tablets
COMPosmON
Each CDZAAA COMP tablet CllIIIains 50 mg losartan potassIUm and 12.5 mg hydrochlorothiazide.
COZAAR COMP coolains 424 Ill\! (0,108 mEQ) ()/ potassium
PHARMACOLOGICAL CLASSIACATION
A7.1 ,3 Other hypolensives
PHARMACOLOGICAL ACTION
COZAAR COMP (losartan potassium-hydrochlorothiazide) combines an angiotensin 11 recepi()f {lyjJe AT1} antagonist
arK! a diufelic, hydrochlorothiazide.
Lasartan
Angiotensin 11. a potent vasoconstrlttor. is ltIe prImary aclrve hormone ot the renin-angiOlensm system. and a major
derermirnrn 01 tile paih~iology of hypertension. Angiotensin If bmds 10 me AT1receptor found in many tISSUeS (e,g,.
vascular smooi!l muscle, adrenal g!arld, kidneys. and !he heart) and elitits several ~Gr1an1 biologicaJ acIlOrIS, includ-
ing vasotlJnstricrion and liJe release of aldosreIOne Angillloosin 11 also stimulates smoofh muscle cell proliferation.
Losarian is a syn!heIic. orally actrve compound wtuch blllos selectively to the AT1 receptOI BoIh fosartan and its
pharmacologfcafly iUive carboxylic <K:id metabolite (E-3174) block the actions of angiotensm 11, regardless of the SOtJrce
of synthesis
Losanan binds seIf£liVEly to liJ;; AT1 recevlor and does not bind to or block other hormone receptors or ion channels
important in cardiOYclSCllfal regulation. Furthermore. losartan does not mhlbil ACE {kimrnse 11), the enzyme !ha!
degrades bradykinin, Consequemly....iects not directly rel<iied III blocking tile AT11ecep!0r. slld1 as the polentiation 01
bradykjnin-med~ed ettecls or liJe geflEfiI\Ioo 01 oede'na are IIOl associated withlosartan.
Hydroclllorofhiazide
Themechanism ot me anlihype;tensive elled: oIthiatides is unkn()\l/n. Thiatides do nOl usually a1tect normal blood pres-
sure.
Hydrodlforottliazide is adiurelic and antrhypetlensive agent I1 affects the dis!a! fenaltub\llar mechaIlism 01 electrolyte
reabsorptiort Hyorochlorothtande increases excretion 01 sodium and chloride in approlimalety equivalefl\ amO\!nts.
Nalriuresis may be~ied by sorre loss of potassium. magnesium and bicarOOnaie.
Aftel olilf use diUl€SIS begins within 2 hours, peaks 10 aboUl4 haulS and Iasls abouI6to 12 hllUrs.
Losartan Potassium-Hydrochlorothiazide
l()S<lljan and hytlrodlloro!tliazide are additive in their antihypertensive efficacy
Losartan
Absorption
Following mal administration, tosanan undergoes first-pass meiabolism. forming an CiClive carboxylic acid rnetabolite
and ore iRiidive metibolnes. ThE systemic blOavi!ilailility 01 fosartan tablelS is approximately 33 %. Mean peak
COOCfnuations oIlosartall and IlS active merabolile are readiel:l in 1hour and in 3 -4 Murs, fespectlvely. There was no
clinically slgnilicam erred (Ill the plasma CllfICOOtraOOO pmfile of losartan whefl COlAAR COMP was administered with
a stIndal'dized meal.
Distribution
Bolh Iosarran and its active meta/)Qlite arez 99 % bouml 10 pfasma prO/erns. prilffilily albumin. The volume 01 dislri-
bUion oIlosarGn is 34 lilers. S.'udies in rals indlCale that losartm CfI>SSeS tile blood-bmin barrier poorly. if at all.
Metabolism
Aboul14 %oIlOtraveOOIlSly- or orally-admimSlered dose 01 losanan is converted 10 its a::iIve metabofite.
Elimination
Plasma cIear.!I1ce ut losartan and its active met;boIire is about 000 mVmin and 50 mVmin, respecllYely. Renal clearance
of losart3n and its il:live metabolile is about 74 mljmjn and 26 ml/min. respectively When losartan potassitJlTl is ad-
ministered orally. aboiJl4 % ollbe dose is excreied unchallged in !he urine, and aboul6 % ot ItJe dose is excreted in
!he urine as:Dive rooabolile Tre pharmaco~inelics of losartall and its active merabolite are linear with olilllosartall
potaSSium doses up to 200 mg.
Fol!O"iog maf admlOiSlration. plasma coocefllralions of klsartan and rts active melabohte decline polyexponenliaify With
a terminal haJf-lite 01 about 2 hoU/s and 6 - 9 hours. Iespectrlely
Both biliary and urinaryexcreiion CO!1lnbule to the elimination of losartan alld its mElaboliies. Following an oral dose of
14G-fabelfed losartan in man. about 35 % of radioacriyity rs recovered in the unrf and 58 %in !he faeces
FoJlllYling oral admrnislJation in patients with mjJd 10 moderaiealcoholic cirrhosis oIliJe liver. plasma concentrations 01
!osarIan and its actIve IT'tIaboIite were, lespeaiw!y, 5-fo1d and 1.T-lold greater ttB1 those seen in young male volun-
"'"Neill1er kIsarIan nor !he melabolite can be removed lly haemodialysis.
HYDROCHLOROTHIAZIDE
When plasma levels t!al'e D?en loHoVow lor alleast 24 hoolS, ltte plasma halt-file has beffl observed 10 vary belween
5,6aml 14,8 hours. HydrochlmothiaZlde is nat melaboltred bul is efimrnaled rapidly lly!he ~idney. Al leasl 61 %01 the
oral dose is eliminated undlanged Wllhin 24 ~oOOrs Hydrochlolothiazide crOSSES the placema bul not the blood-rn-am
""'0
LOSARTAN POTASSiUM-HYDROCHLOROTHIAZlOE
In a pharrnacokineoc inieraclion study. hydrochlorothiazide 12.5 mg did not alter the pharmacokrneucs ollosartan 50
fOg and via! versa.
INDICATIONS
COZAAR COMP is rndiCaled tm the t1eatmerll of hyperierlsJon in patients esiablished OIl ideflticaJ doses 0I1tJe individual
""" CONTRA-INDfCATIONS
COlAAR COMP is corrtril-lI1dicaled in paHenlS who are hypersensitl~ 10 any componem of thiS ploducl
Because of the h)'drochlorOlhlazide component this product is contra-indica:ed in patienlS with anuri~ or hypersensI-
tivity 10 llIher sulfonamlde-tlerrved drugs.
Pregnancy
When pregnancy is detected, COZAAR CllMP should be discnnlinued as saon as possible. Nollo !le
used in pregnancy as teratogenicit) lIas Oilen shown in experimemal animals.
Thiazides cross tile placental bailie' and appeal r rt! o'ood fne rOUU!1€ 1IS€ IJI dlureilCS in ot!lerwis" IJealthy creg-
nanl women rs noIrecorrrnende<i and exposes ~~_JIEf ar.o toe!US to unllfCfSSary ha.-ard Includ,rrg teetal or'leOll<:lal
j;;undia:. inlOmbocy!opaenia and possibly othi;r "t!verSi: reactions 'Nhlch have occurreo II1ltle adult. DiUIe!rcs do nor
prevent oevelopment ot toxaer11la 01 pregnarlCY ~a!l\efe is no satistaclory evidence that they are useful In the trearmenl
of toxaemia.
Worren of childbwlllg age shoufd ensure adequaie conlracepoon
Paediatric Use
SafelY and eifil3:)' in childrell has noI been established
Lactation
OOSAGE AND OlRECTIONS FOR USE
The uswl dose of COZAAR COI.1P is one tablet once dallY Fm OO1Ients will) do !l(!t respond aaeQuately 10 COlAAR
COMP 50 rrlP'12.5 mg. the dosage may be mcreased to t,vo tablets once daily More Ihan two talJlets daily are nol
recorMIefIlled. The frn);l!IlU11 antihypertensive eiIW IS anamell wilhn fhree 'Nee!ls alier mrtiauon 01 therapy
COlAAA COMP shoold not be Illitiated in patiaJts ..oo are intravascularly volume-deplered (e.g., those treated Volth
niglHiose diuretics)
CDZAAR COMP IS not rceomrneOOed for paients With sevefe renal ImpaIrment or for patients with hepatic impaJrlnent
(see SPfCIAL PRECAUTIONS).
No inrtial dosage adjUSlmfnllS !I!teSSarY /01 elderly palients
COlMR COMP may be administered with otter antihypertensIVe agents, panicularty calcium d1ar.w blockfrs and
B-blocifrs.
COZAAf! COMP may be adnuruSlefed WIth or witnout food
·F.egt5lefed Traaemarll of 1:.1 liJ Pm de Ne!'wrs and Company, WllmrngtOll, Delaware USA.
Copyr~ MERCK & GO, INe 1993
SlOE EFFECTS AND SPECIAL PRECAUTIONS
Side Effects
In coll!lolled clinical trlals Im essenlial hypffiension. dizziness and aslheIliaJ!al:igue were observed in patients lreate
wifh COZAAA COMP.
LosartlR potassium
In conlrolled clinical trials tor eswltial hypenension. dizziness, orthoSL1lic hypote!1Sion. readache and rash. Vo'ere sid
ellects reponed.
Other mr-se experiences 1lla1 have occurred 'Mri!l losartarl are:
Body as a Whole: Abdominal pain, asl!lenialtaligue, c~ pain, oedemaIsv.'flling
Canliavascular: Palpilanon.ladlytardia
Digestive: Diarrhoea d'fSPEPsia. nausea
MUSl:Uloskeletal: Back pain. muscle cramps
NervousJPsychialril:: Dizziness. headad1e. i!lSOOV1ia
Respiratory: COUgh, nasal congestion. pharyngitiS, sinus disorder. upper respiratory inlection
laboralory Test Findings
In controlled clinical trials, hyperkalaemia (serum potassium:> 5,5 mEqIL) occurred m1,5 %01 ~IS. but in lhes
trials. discontinuation of COZAAR COMP due to hyperkalaania was nat necessary. Efevahons of al2nil'lE amino lrare:
ferase (AlT) have occurred tlUt usuaJfy resolved ~n diSClllltinualion of therapy.
Hydrachlorathiazide
Olher side cllects that have occurred with hydrodllorot!Jiazide are:
Gastroinrestinal sysrem: anorex.ia gastric Irritation, nausea. I'llmiling. cramping, dfar!hoea, consiipation, jaun
dice (intrahepatic choleslalic laundice). pancreatitis. sialadenitis.
Central nervous syslem:vertigo, paresthesias. headache. xanthopsia.
Haemalologic: leukopenia. agranulocyiosis.ltnomllocylopaenia. aplasiic anaemia, hemolytic anaemia.
Cilrdiovascular: h)ilOlensioIL including orthostatic tt,polension (fl\o.')' be aggraYaied by alcohol. barbiturates. naJ
rotics or antihypertensiVE drugs).
Hypersensitivity:pulPUra. pholosensitivity. rash. urticaria. necrolizing angiitis (vascufitis) (cutaneous vasculitis
levEl', respiratory distress including pne!Jmonilis and pulmonary oedema, ~ylactic reactions.
Metabolic: hyperglycaemia, glycosuria, hyperuricaemia, electrolyte imbalance.
Renal: renal oystunction. ImerstiliaJ nephritis. renal lailure.
Other: muscle spasm. WEi!kness, restlessness. transl~nt tlIooed vision
Labor3lnry Test Findings
In controlled dinicallrials with COZAAR CaMP, hyperkalaemia (serum potassium:> 5.5 mEWl) occurred in 0,7 %(
patients, but in these trlafs, discontinuation of COZAAfl COMP due 10 hyperkalaemia was nO! r.ecessary. Elevations (
alanine arnillO lr.3nsferastl (ALT) have occurred bu1 usually resolved upon disconhnuation oll!lerapy
SP£CIAl PRECAUTIONS
Hepatic and renal impairment
COZAAR COMP is not recorrunencled tOI patients with hepa!rc impairmenl or severe renal impairment (see DOSAG
AND DIRECTIONS FOR USE).
Hypotension and electrolyteftluid imbalance
In patients who are intravascularly ~olume-<lepleted (e.g.. lOOse treated with high-dose diuretics), symptOmaIH: hypoten
sion may llCCUl. ThesecondilioflS should becorrederi prim to adminisir2lion 01 COZAAR CDMP, or a tov.'er starting dos
Should be used (see DOSAGE AND DIRECTIONS FOR USE). Periodic determination 01 serum electrolytes shoul
be pertonnro ai appropnaie inlervals as in any pai~t receiVing diuretics.
Other mediCllion Ihill affect the renrn-angiotensin syslem may increase blood uleaand serum creatinine in patients wit
bilaleral renal arL"ry stenosis or stenosis 01 the artery 10 a solitary kidney. While nol conlinned. !his potEntially may OCCI.
with angiotensm 11 receplor anlagonists.
Metabolie and endoerine efh!cts
Thiazide ttmpy may Impail gtocose toleraoce. Dosage adjusiment of antidiabetic agenlS, including insulin. may b
requirro (see INTERACTIONS).
Thrazides may decrease (JI'inary c:alcium axcreiion and may cause intermttlem and siigtrt ele<.'alion 01 serum caJciUlT
Marked hypercalcaemia may be evidence 01 hidden hyperparathyroidism. Thiazides should be disconrinued belore caJ
rying out lests tor parath)'roid turv;lion.
Increases in cholesterol alld triglyceride levels may be associated with thiazide diuretic therapy. Thiazide therapy ma
precipitate hyperuricaemia and/or gOL~ in certain pa!jents. Because losartan decleases uric acid. losartan in combino
lion with hydrochlorofhiazide attffiWies the diU/ehc-indLced hyperurfcaemia.
""'"in patients receiving thiazicles, sensilivity reactions may occur with or 'f;ithoul a history of allergy or bronchial aslhmi
Exawtation or activalioo of systemic lupus erylhemaloStiS has be€fl reported with the use oIlbiarides.
INTERACTIONS wmt OTHER MEDICAMENTS
Losartan Potassium
No medicaiion interactions 01 clinical significance have been idenlified. Compounds whir;h hiIve besJ studied in c1ini
ClI pharmacokinetic trials ioclude hydrochlorothiazide, digoxin. v.artarin. cimetidine and phenobarbital.
Hydrochlorothiazide
When admimstered COOCUlrentfy tile lollowing medication may imeraa willl thiazide diurerics:
Alcohol. barbiwrares, or narcotics: potenliatill/l 01 orthOSlatic hypoiension may occur.
Antidiabetic medication (oral agents and inSUlin): dosage adjusbnenl 01 the antidiabetic drug may be required.
Other iIJ1tihypertensive mediCJtion: additive effect or polaJtii!lion.
CholeSt'/ramine and co!estipol resins: absorption ot tl1drochfolOthiwde is [mpaired in ine presence 01 anioni
ex..rflange resins. Single doses 01 eliher r;holestyrarnillE or cofeslipol resins bind the hydrochlorothiazide and reduce ~
absorption from the gastrointestinaJ tract lly up to 85 and 43 percent. respectively. COZMR CaMP should reefore b
administered one hour befme the inlake of the !€SIn
Corticosteroids. ACTH: intensili~ electrolyte deplellOO, parnctdarfy hypokalma
Pressor amines (e.g. norepinephrine):possible decreased response to pressor amiOes ll\JI nO! sull"crenl ro precfud
their use.
SkeletJl muscle re!axilnts. nondepotarizing (e.g. tubocurarine): possibfe increased rES\.'ilflSrveness 10 tile muse!
relaxatlt
Lithium: shOllld no! generally be given v.ith diU/aies. D1uraic agenlS reduce the renal clearance ut liltlium and add
high risk of lithium 10XlClIy Reler io the package rnsen fOllithium p;epar;rtions before use of such pleparations wil
COlAAR CaMP
Non-steroida! anti-inflammatory medication: In some pallents, me adminrstralion 01 a non---slelOidal anti-intlam
maIory il\;enl can reducs the diuretic. natriuretIC. and antihypertemive elleds 01 foop. potassillTl-Spafing and thiazid
diuretiCS
Effects on ability 10 drive and use machines
There is no data to SUgqeslthat COlAAR COMP aifecis the ability to drive and use machines.
KNOWN SYMFTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TllEATMEHT
Losartan Polassium
Slgnilicantly le!nality ',m obselved in mice and rats a1tel oral ministration 011(({1 rngIKg (3OOJ mg/m') and 200
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on a quest for recognition for traditional healers.
Interview
A 'traditional' traditional healer:
Philip Kubukeli
'It was the call of my ancestors,' says traditional healer
Philip Sobanku Kubukeli, from Khayelitsha in the Western
Cape, explaining how he came to this vocation. 'I had
some symptoms which I could not understand, and my
mother, who was a traditional healer, said they indicated
that I was being called.'
And that call, which occurred when the Transkei-born
and bred Kubukeli was in
Standard 5, was to have a
profound effect on his life, if for
nothing else than curtailing his
education. But now, more than
40 years on from that time, its
power is no less strong as he
devotes his energies largely to
the quest for the recognition
and respect for the profession
that he believes it surely
deserves.
Softly-spoken, Kubukeli
explains that traditional healing
is an inheritance and that in
this tradition, he did his training
as a healer under his mother,
while at the same time
completing his Junior
Certificate. Subsequently he
was sent to Lesotho for further
training for 2 years with an
'elder' healer, under whom he
qualified in 1962.
Such training essentially
involves three components, he says. These are the spiritual
training for diagnosis - 'you don't touch the patient but
look at them and eventually the spirits of the ancestors will
tell you from what the patient is suffering and the cause of
it'; the dance, which 'encourages the spirits to come'; and
a knowledge of the traditional medicinal plants, which
occur throughout the country.
Kubukeli estimates that there may be up to 35 000
traditional healers in South Africa and possibly as many as
150 different healers' associations, and of these he says
the Westem Cape Traditional Healers and Herbalist
Association, of which he is President, is both the largest -
with some 1 500 members - as well as the most
democratic, including all different types of healers.
But it is in such fragmentation that problems lie, he
argues, and traditional healers are 'suffering'. They often
feel left out in the cold by other medical practitioners and
by government, and there is an increasing number of
'charlatans' who are practicing as healers. Further, these
charlatans are putting traditional medicinal plants under
threat by over-collecting them - in some cases, he says, in
amounts of up to a hundred bags a week .:. and 'they are
ultimately going to collect all the plants and there will be
nothing left for future generations'.
The solution, Kubukeli believes, lies in the recognition by
government of traditional healers and with this some form
of control such as registration, and as a first step he has
initiated discussions with a number of associations with a
view to forming an umbrella body to 'help meet the
objectives of all healers'. However, so far there has been
only limited support from other associations, although he
feels this may be due, in part at least, to a lack of
understanding of the role of such a body.
He has also had some discussions with Western Cape
MEC for Health and Social Services, Ebrahim Rasool, on
the role of traditional healers and the formation of an
umbrella body, but not as yet at national level. But, he
says, 'I think Or Zuma will be very understanding and I am
trying to contact her.'
Nevertheless, Kubukeli feels
that the gap between
traditional healing and western
medicine is narrowing and that
efforts are being made by the
two parties to work together.
And this is something he tries
to encourage, he says, pointing
out that he himself is involved
in a referral scheme where
people with cancer or TB are
referred on.
However, an issue that is of
concern to traditional healers is
the ownership of their
knowledge and the fear that it
may be 'stolen', he notes,
adding that his view is that this
should be 'input' to TRAMEO
(the traditional medicines
research unit at UC1) and
certain other bodies. Indeed he
himself has supported the
establishment of the unit,
which will investigate the scientific basis of traditional
healing, and says 'the chiefs of TRAMEO have assured that
our knowledge will be secure and won't reach other hands
without our consent.'
Kubukeli believes that traditional healers have an
important role to play in the health care system and that
their numbers will grow in the future. And by way of
example, he says that there are already some 200 white
healers when formerly there were none.
In the meantime he is also getting involved in other
projects to take traditional healing into the Mure, such as
the drafting of a traditional medicines formulary with
TRAMED and the cultivation of traditional medicinal plants
in collaboration with organisations such as the Western
Cape Nature Conservation department and the National
Botanical Institute.
And, Kubukeli says: 'When we are recognised, we will
then know we are working for the government and our
people.'
Jonathan Spencer Jones
SA.~1J Volumt 7 Xo.7 July J997
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Survival of human immunodeficiency 
virus-infected persons with 
pulmonary tuberculosis 
We have described the radiological features of 150 
HIV-1 infected patients presenting with pulmonary tu-
berculosis to a Cape Town HIV clinic between 1989 
and 1994.1 All patients had confirmed tuberculosis 
and received rifampicin-based short course chemo-
therapy (6 months RHZ for initial cases, 6 months 
RHZE for relapse cases). Treatment was both super-
vised (5 days per week) and self-administered (weekly 
supply of medication). Subsequent follow-up of this 
cohort demonstrated an overall mortality rate of 
411100 person years. However, different radiological 
presentations of pulmonary tuberculosis were associ-
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Number of patients at risk 
Time (months) 0 6 12 18 24 
Typical 18 15 10 6 5 
Effusion 32 19 14 12 10 
Atypical 100 52 27 14 10 
Figure Kaplan-Meier estimated survival of HIV-infected patients 
with pulmonary tuberculosis, stratified by radiographic appear-
ance. Typical presentation includes infiltrates limited to the upper 
lobes or apical segments of lower lobes. Effusion denotes pleural 
effusion. Atypical pattern includes lower and mid zone infiltrates, 
adenopathy and/or interstitial infiltrates. Survival is significantly 
impaired in those patients presenting with pleural effusion or 
atypical patterns (Iogrank test P < 0001). 
ated with highly significant (logrank test P < 0.001) 
differences of Kaplan-Meier proportional survival 
(Figure). The total lymphocyte count was also found 
to be a major predictor of survival. Sixty-one percent 
of patients presented with lymphopaenia of <12501 
J..I.L, 39% had a total lymphocyte count >12501 J..I.L. 
Lymphopaenic patients had a significantly higher mor-
tality rate than those patients with a normal total 
lymphocyte count (65 vs 21100 person years, X2 test 
P < 0.001). 
The 2-year mortality rate of patients with HIV-l in-
fection and pulmonary tuberculosis described by 
Kassim et aJ.2 was considerably lower (20.3/100 per-
son years) than that reported by Small et al. 3 and our-
selves. Each of these studies used rifampicin-based 
chemotherapy, but the different mortality rates could 
be explained on the basis of differences in study popu-
lation. The CD4 lymphocyte count has been found to 
be a major determinant of mortality,4 but is frequently 
unavailable in resource-poor countries. In contrast, 
chest radiographs and total lymphocyte counts are 
widely available and were powerful prognostic mark-
ers of mortality in our patients with HIV-l related pul-
monary tuberculosis. These variables have such a strong 
impact on mortality that they should be reported and 
controlled for in comparative studies of response to 
tuberculosis chemotherapy in HIV-infected individuals. 
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Pulmonary clofazimine crystals 
in two patients with the acquired 
immunodeficiency syndrome 
Mycobacterium avium complex (MAC) infections are 
frequent manifestations of the acquired immuno-
deficiency syndrome (AIDS).l They require combina-
tion therapy, often including a treatment used in lep-
rosy, clofazimine. We report two cases of pulmonary 
crystals associated with clofazimine. 
Case 1 
A 31-year-old male patient with human immunodefi-
ciency virus (HIV) infection known since 1988 received 
from November 1993 a combination of ethambutol 
1 g q.d., clarithromycin 500 mg b.i.d. and clofazimine 
100 mg b.i.d. for MAC bacteremia. Fever and hypox-
emia improved until February 1994, when the patient 
was admitted for cough and dyspnea. Chest radio-
graph was unremarkable, and laboratory tests were 
similar to those observed the previous visit. Examina-
tion of bronchoalveolar lavage (BAL) revealed numer-
ous red needle-shaped crystals in macrophages, evoca-
tive of clofazimine (Figure). Culture later yielded 
Haemophilus in[iuenzae. Spirometric examination re-
vealed ;1 mixed ventilatory defect of moderate sever-
ity. Despite interruption of clofazimine, symptoms 
persisted. Spirometry performed 15 days later showed 
no improvement. 
Case 2 
A 34-year-old man with HIV infection known since 
1987 received from March 1994 a combination of 
ethambutol 800 mg q.d., clarithromycin 500 mg 
b.i.d. and clofazimine 100 b.i.d. for MAC bacteremia. 
He was admitted in June 1994 for cough with puru-
lent discharge and dyspnea. Chest radiograph showed 
an alveolar infiltrate of the left lower lobe. BAL exam-
ination revealed sparse macrophage crystals evocative 
of clofazimine. Culture yielded meticillin-resistant 
Staphylococcus aureus. Therapy was instituted with 
Figure Bronchoalveolar lavage specimen demonstrating nu-
merous needle-like crystals (Giemsa, x 400). 
vancomycin and fusidic acid concomitantly with clo-
fazimine. Pulmonary symptoms resolved in 7 days 
and did not recur in a 5-month follow-up. 
In neither case was MAC isolated from blood or 
BAL culture at admission. 
Discussion 
Clofazimine is a lipid soluble molecule which concen-
trates in the cells of the reticula-endothelial system 
and macrophages. 2 High drug concentrations in the 
lungs and skin have been demonstrated. 2 Discolora-
tion and crystal formation appear proportional to 
duration of therapy. Clofazimine is used in AIDS-
associated MAC infection. l Three cases of clofazimine-
associated pulmonary crystal in patients with AIDS 
have been published. 3-5 In two cases, clofazimine was 
pursued4,,'i without deleterious effects on pulmonary 
function. In the other3 it was discontinued, although 
it is unclear whether symptoms were due to clofazi-
mine or to MAC resistance to this drug. In our first 
patient, symptoms persisted despite interruption of 
clofazimine. In our second patient, pulmonary symp-
toms were clearly related to S. aureus pneumonia. The 
evolution, in our report, does not seem clofazimine-
related. The appearance of crystals is probably only 
related to the duration of clofazimine therapy, and 
should therefore not prompt therapy interruption. 
The population of patients with MAC is expected to 
grow. The number of patients receiving clofazimine 
will probably increase even if clofazimine efficacy is 
decreased. These patients often present with pulmo-
nary symptoms. Clinicians need to be aware of this 
complication and seek it with non-invasive methods 
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langue frans:aise;' October 27-28, 1994, LiIle, France. 
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Levofloxacin in the treatment of 
drug-resistant tuberculosis 
A 69-year-old male patient presented to the chest 
clinic under the administration of the Department of 
Health at the end of October 1994 with cough and 
haemoptysis, Chest radiograph revealed bilateral up-
per lobe cavitary lesions, and sputum microscopy 
showed presence of acid-fast bacilli. Thus active pul-
monary tuberculosis was diagnosed. He had previ-
ously been treated for pulmonary tuberculosis in 
China in 1978 with streptomycin, isoniazid and rifam-
picin. The drug dosages used and compliance could 
not, however, be ascertained. In November 1994 the 
patient was started on a combination of kanamycin, 
isoniazid, rifampicin, ethambutol and pyrazinamide, 
given under full supervision. However the pretreat-
ment sputum culture subsequently yielded Mycobac-
terium tuberculosis resistant to rifampicin, ethambutol 
streptomycin, kanamycin and amikacin, but suscep-
tible to isoniazid, pyrazinamide, ofloxacin, ethion-
amide, and cycloserine. The patient was referred for 
treatment of his drug-resistant tuberculosis (DR-TB) 
in May 1995. He was started on isoniazid 300 mg, 
ofloxacin 600 mg, pyrazinamide 1.5 gm and also eth-
ionamide 750 mg, all on daily basis. Cycloserine 750 
mg once daily was added after one week of treatment. 
After receiving all drugs for four weeks the patient 
developed severe giddiness, followed by a generalized 
seizure. Serum ofloxacin was found to be 7.30 mg/L. 
Based on previous experience we felt that the patient's 
neurological reactions were due to the co-administration 
of ofloxacin and cycloserine. 1 Cycloserine was with-
drawn, but the patient still complained of giddiness 
and unsteady gait. The peak serum ofloxacin level 2 
weeks after the seizure episode, while the patient was 
still on ofloxacin 600 mg daily, was 9.74 mg/L. Oflox-
acin was reduced to 500 mg daily in late June 1995, 
but the neurological symptoms did not improve. Be-
cause levofloxacin is more active in vitro against M. 
tuberculosis than ofloxacin (MIC90s of ~ 0.5 - 1 
mg/L versus 1-2 mg/L2,.3), we substituted levofloxa-
cin at a lower dose on the premise that this might les-
sen the risk of neurological reactions but preserve ther-
apeutic efficacy. The patient was started on 
levofloxacin 300 mg, isoniazid 300 mg, pyrazinamide 
1.5 g and ethionamide 750 mg, all once daily, at the 
beginning of September 1995. One week after switch-
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ing from ofloxacin to levofloxacin his condition im-
proved, with giddiness and unsteady gait subsiding al-
most completely. Subsequently, isoniazid was also 
withdrawn because the sputum culture of June 1995 
also showed resistance to isoniazid. In October 1995 
he was discharged, free from any neurological symp-
toms, on directly observed therapy with levofloxacin, 
ethionamide and pyrazinamide. Sputum cultures col-
lected in July, August, September and October 1995, 
as well as those from March, May and July 1996, 
were all negative. The chest radiographs were also 
stable. As closure of cavities had not occurred by July 
1996, the treatment was continued for a total of 18 
months. 
This case suggests the potential utility of levoflox-
acin in the face of adverse neurological reactions to 
ofloxacin. Levofloxacin, more active than ofloxacin 
against M. tuberculosis both in vitro and in vivo,2--4 
might be used for treatment of DR-TB at lower doses 
than ofloxacin. This could reduce the risk of neuro-
toxicity and other adverse reactions. However, more 
clinical data need to be accrued before levofloxacin 
can firmly be recommended as a preferred drug over 
ofloxacin. 
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Short-course chemoprophylaxis 
evaluated in gold miners with 
chronic silicosis 
In the paper entitled 'Short-course chemoprophylaxis 
with rifampicin, isoniazid and pyrazinamide for tu-
berculosis evaluated in gold miners with chronic sili-
cosis: a double-blind placebo controlled trial' by R L 
Cowie (Tubercle Lung Dis 1996; 77: 239-243), the 
author concludes that the regimen failed to prevent tu-







































standing the findings in two recent reports [3, 4], in most cases itCutaneous Miliary Tuberculosis in the AIDS Era
would be more appropriate to use procedures with documented high
diagnostic yield, e.g., lymph node biopsy [5], than to perform a skinSIR —A recent review of cutaneous miliary tuberculosis in the
biopsy. Isolated instances of positive skin biopsy specimens mustAIDS era [1] emphasized the importance of having a high index
be weighed against the large number of negative skin biopsy speci-of suspicion for this condition in HIV-positive patients with skin
mens if the recommendations of Libraty and Byrd are followed.lesions and advanced immunodeficiency. However, the authors
were able to identify only five such cases in the literature, in
addition to the case they reported. In a prospective study, ongo- Christopher P. Hudson, Robin Wood,
ing since October 1994, we have identified only one case of and Elizabeth A. O’Keefe
cutaneous tuberculosis among nearly 400 patients with biopsy- Departments of Medicine, University of Cape Town and Somerset
Hospital, Green Point, Cape Town, South Africaconfirmed or culture-confirmed tuberculosis; 47% of these pa-
tients were HIV-positive. In view of the rarity of cutaneous
tuberculosis and the fact that skin biopsy is not usually necessary
References
to make a diagnosis of disseminated tuberculosis, we believe
that skin biopsy should be performed primarily to exclude other 1. Libraty DH, Byrd TF. Cutaneous miliary tuberculosis in the AIDS era: case
report and review. Clin Infect Dis 1996;23:706–10.causes of skin conditions in patients with advanced HIV disease,
2. Shafer RW, Kim D, Weiss J, Quale J. Extrapulmonary tuberculosis inas the following case report illustrates.
patients with HIV. Medicine (Baltimore) 1991;70:384–97.A 48-year-old HIV-infected heterosexual man who had no
3. Franca IE, Borges F, Mansinho K, et al. Cutaneous mycobacteriosis inhistory of use of illegal substances but who had received treat-
AIDS patients [abstract WcB 3357]. In: Program and abstracts of thement for two previous episodes of tuberculosis presented with
11th International Conference on AIDS (Vancouver). 1996.
chronic pathogen-negative diarrhea, colicky abdominal pain, 4. Oliva SM, Redini L, Santucho E, et al. Cutaneous tuberculosis in AIDS
weight loss, fever, and dark maculopapular lesions on his hands. [abstract TuB 2364]. In: Program and abstracts of the 11th International
The CD4 cell count was 3 1 106/L, and a chest roentgenogram Conference on AIDS (Vancouver). 1996.
showed fibrocystic changes in the right upper lobe and possible 5. Bem C, Patil PS, Elliot AM, Namaambo KM, Bharucha H, Porter JDH.
mediastinal adenopathy. The value of wide-needle aspiration in the diagnosis of tuberculous
lymphadenitis in Africa. AIDS 1993;7:1221–4.An ultrasonogram of the abdomen showed adenopathy in the
epigastrium. No sputum was obtained, but a blood culture for
mycobacteria with use of the radiometric system (BACTEC; Bec- Reprints or correspondence: Dr. Christopher P. Hudson, Department of Med-
ton Dickinson, Sparks, MD) was negative. Examination of a duo- icine, Medical School, Observatory 7925, Cape Town, South Africa.
denal biopsy specimen obtained by endoscopy revealed cryp- Clinical Infectious Diseases 1997;25:1484
tosporidia. One of the skin lesions was biopsied to exclude ￿ 1997 by The University of Chicago. All rights reserved.
1058–4838/97/2506–0040$03.00Kaposi’s sarcoma, and the specimen was sent for a routine myco-
bacterial culture. A diagnosis of disseminated tuberculosis was
made on the basis of the patient’s clinical presentation and the
Cutaneous Miliary Tuberculosis in a Patient Infected
presence of adenopathy; he was discharged and received antituber-
with Human Immunodeficiency Virusculous therapy as an outpatient. Mycobacterium tuberculosis was
cultured from the skin biopsy specimen 2 weeks later.
While cutaneous manifestations are common in the HIV-positive SIR—Libraty and Byrd [1] recently described a case of cutaneous
miliary tuberculosis in an HIV-positive patient and reviewed thepopulation in Cape Town, South Africa, few lesions are biopsied,
so we may have missed other cases of cutaneous miliary tuberculo- published cases of cutaneous miliary tuberculosis among patients
with AIDS [1]. The authors claimed that only six cases (includingsis. However, as was true for our patient, the diagnosis of dissemin-
ated tuberculosis is usually evident on clinical grounds; cultures are their own case) have been reported so far. However, they did
not mention two cases of cutaneous miliary tuberculosis due toperformed to confirm the diagnosis and to exclude drug resistance.
Although the positive culture of the skin biopsy specimen con- multidrug-resistant Mycobacterium tuberculosis in patients with
AIDS, which we described previously [2]. Since the publicationfirmed the diagnosis for our patient, the result was unexpected; if
the result had been negative, treatment would have been continued. of our report in October 1995, we have diagnosed a further case
of cutaneous miliary tuberculosis, also known as tuberculosis cutisSimilarly, in the case reported by Libraty and Byrd, the patient’s
risk factors and presentation, apart from the short history of symp- miliaris disseminata (TCMD).
A 38-year-old man with an 8-year history of intravenous drugtoms, were suggestive of disseminated tuberculosis. Further, the
positive culture result for the skin biopsy specimen became avail- abuse who was receiving methadone maintenance therapy pre-
sented with a 1-week history of high fever (temperature, 40￿C),able after acid-fast bacilli had been seen on examination of bron-
choalveolar lavage fluid and bone marrow biopsy specimens. chills, a nonproductive cough, epigastric pain, and dysphagia. He
had been aware of his HIV seropositivity for 3 months. He wasIn conclusion, our own experience and that of other investigators
[2] is that an HIV-related diagnosis of extrapulmonary tuberculosis not receiving any antiretroviral therapy or prophylaxis for Pneumo-
cystis carinii pneumonia.can usually be made without performing a skin biopsy. Notwith-
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The SAMJ and editorial independence
To the Editor: It was with a sense of pleasure and
vindication that I read the June issue of the SAMJ dealing
with the MASA's submission to the TRC, and I congratulate
the Editor on at last publishing the letters received by the
SAMJ at the time of the Biko affair. I leave it to others better
qualified than I am to decide how best the MASA can
continue to shake off the legacy of its dubious past and plan
for the future as a major guardian of the conscience of the
profession. However, I feel that I must at this juncture put
forward a strong plea for editorial independence of the
SAMJ from its MASA proprietors, a process already started,
but one which needs to be clearly recognised as a crucial
issue if the mistakes of the past are never to be repeated.
When I joined the SAMJ in 1983 as Assistant Editor, the
Editor was firmly under the control of the MASA hierarchy,
and was not allowed to print anything remotely controversial
without reference to either the Secretary-General or the
Chairman of Federal Council. At the time I considered this to
be a wholly unsatisfactory state of affairs, and one which
could only lead to the SAMJ's never being able to function
as the voice of the whole South African medical profession,
and not just that of the MASA's current masters.
When I became Editor in 1987, I tried to move the SAMJ
in the direction of editorial independence - a process akin
to walking on eggs, but which, I believe, worked, or at least
started to. In this I was greatly inspired by the example of
the BMJ, which made its bid for editorial independence from
the BMA when Hugh Clegg was Editor. At a time when the
BMA was rather sycophantically wooing the Royal Colleges,
Clegg wrote an editorial entitled 'The gold-headed cane'
which fired a torpedo into the whole process. At the
subsequent meeting of the BMA Council, a motion was put
to fire him, but, to its everlasting credit, the Council gave
Clegg its support in the interests of free speech. The New
England Journal of Medicine also has a proUd record of
editorial independence, and Arnold Relman, the previous
editor, wrote that never, throughout its whole existence, had
the Massachusetts Medical Society attempted to interfere
with editorial decisions. This is probably one of the major
reasons for its great reputation.
Both the MASA and the SAMJ have come a long way in
the past 10 years, but the issue of editorial independence
needs to be recognised as a vital ingredient in their mutual
relationship. Like the stripes of a zebra, both belong
together, but to confuse their functions can only lead to a
monotonous and ineffectual shade of gray. As Stephen Lock
once wrote in the BMJ, nobody wants to publish in a journal
which is a constrained parish magazine.
Nick Lee
Emeritus Eajror. SAMJ
Promoting HIV vaccine research and
development in southern Africa
To the Editor: In a recent editoriaP we proposed that a
working group be established to promote HIV vaccine
research in Africa. In follow-up, we wish to report on a
workshop held in Cape Town on 13 March 1997 as part of
the 3rd IUIS African Immunology Conference concerning
promotion of HIV vaccine development and research in
Africa. The workshop brought together more than 50 AIDS
researchers from 9 African countries (Tanzania, South Africa,
Zimbabwe, Nigeria, Kenya, Uganda, Mozambique, Ethiopia
and Cameroon) as well as from Europe and the USA to
present data and discuss ideas on what else is needed to
accelerate the development and evaluation of HIV vaccine(s)
for use on the African continent. Representatives from three
international organisations with the mandate for promotion
of HIV vaccine research, the HIV Network for Prevention
Trials (HIVNET, a USA National Institutes of Health Program).
the International AIDS Vaccine Initiative (IAVI) and the Joint
United Nations Programme on HIV/AIDS (UNAIDS) also
participated. While the workshop focused predominantly on
basic science, other issues relating to ethics, conduct of
field trials and advocacy and lobbying for vaccine
development were touched upon to highlight some of the
gaps in knowledge that currently exist. Of a total of more
than 24 million people living with HIVlAIDS in the world, 18.5
million are sub-Saharan Africans2 and more than 2 million
are South Africans (R Swanevelder, Department of Health,
South Africa - personal communication). The continued
spread of HIV makes development of vaccines an
increasingly important part of current prevention strategies.
Most candidate HIV-l vaccines to date are based on the
genetic subtype B of HIV-l. However, the HIV-l sUbtypes
prevalent in Africa are mostly from subtypes other than B,
namely A, 0 and E in west, east and central Africa and C in
southern Africa. At present the immunological significance of
this genetic variation is not clear. Preliminary data presented
at the workshop suggest limited cross-reactivity of
neutralising antibodies directed to different HIV-l sUbtypes.
On the other hand. cell-mediated immune responses against
different HIV antigens seem to be more cross-reactive.
Overall. this emphasises the need to obtain additional
information on the possible protective efficacy of
experimental vaccines in populations infected with different
HIV-l sUbtypes. Further laboratory-based research and
efficacy trials are needed to obtain such information. In
preparation for future HIV vaccine trials in Africa. it is
importa,t to build and strengthen capacity for laboratory,
clinical, epidemiological and social-behavioural vaccine-
related research, including the establishment and follow-up
of well-characterised cohorts of HIV-l seronegative
SAM, Volume 87 No.8 August 1997 1015 I
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volunteers. (Epidemiological research capacity building has
already been initiated in South Africa through the Fogarty
International HIVlAJDS Research and Training Program.
Since its inception in 1993, eight South African
epidemiologists have been trained at master's level at
Columbia University, New York (Grant Two-0231).)
Vaccine research in humans should adhere to the strictest
possible code of ethics to ensure that volunteers are willing
to participate freely in trials, that they will not be subjected
to unnecessary riSks (medical or social), and that individuals
and populations will benefit from the resutts of the research.
It is clear that the issues are many and complex. The need
for rapid exchange of information and for a working group to
guide informed decision-making is obvious.
The authors are keen to initiate such a group in South
Africa, with membership open to anyone interested. To
initiate the process of facilitating channels of communication
between AIDS researchers in southern Africa, and their
colleagues elsewhere, it was proposed that a web site and
electronic mailing list be created for the analysis and
subsequent dissemination of infonnation. This will address
vaccine development and other HIV research issues relevant
to Africa, and will be effected by the South African National
Bio-informatics Institute at the University of the Western
Cape. Any person wishing to participate or provide
information can contact the following people: Elna van der
Ryst (gnvrevdr@med.uovs.ac.za), Win Hide
(winhide@techno.sanbLac.za), Quarraisha Abdool Karim
(sakarim@hoopoo.mrc.ac.za) or Carolyn Williamson
(cwilliam@medmicro.uct.ac.za). This activity will be co-
ordinated with the HIV vaccine trials network t.ding
established by UNAIDS and with the IAVI.
Elna van der Ryst
Oepartmenl of Medical Virology
Univef'Sity of Ihe Orange Free State
Bloemfontein
Clive Gray
Center for AIDS Research





University at Cape Town
Lynn Morris
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1. Morris L Van det Ryst E, Gray C. WilHamson C. Shouk:l South Africa be preparing
for HIV·, vaccine efficacy trials? S Air Med J 1997: 81: 285·290.
2. Ouinn T. HIV·l: an international perspective. Paper presented at a work$hop on
emerging and re-emerging infectious diseases. Pretoria. 21 April 1997.
Diagnostic disagreement - the lessons
leamt from malaria diagnosis in
Mpumalanga
To the Editor: Hansford and Van Vuuren1 should be
commended for implementing a training and quality
assurance programme for microscopists, as recommended
in our article.2 However if, as they assert, repeated
examination with loss of material and fading was the
principal explanatory variable for our finding of malaria
diagnostic disagreement, the positivity rate Would be
expected to decline at consecutive laboratories. However,
no such trend was found. Consecutive examination by the
first, second, third and fourth examining laboratories
recorded 8.3%, 45.8%, 6.3% and 20.8% positive blood
smears, respectively (x'_ = 0.0, df = 1, P > 0.5).
The focus on laboratory 2 is unfounded, as our statistical
analysis demonstrated very poor concordance between all
of the six possible laboratory pairs.3
Although the polymerase chain reaction promises to
provide a gold standard for malaria diagnosis in the future,
its ability to detect SUb-microscopic parasite burdens could
complicate inter-laboratory comparison further.
The object of the present investigation was to explore the
quality of microscopy of routine field blood smears. We
agree that blood smear preparation by busy clinics is often
inadequate, thus complicating microscopy. We therefore
recommend that where cost-effective valid alternatives for
rapid malaria diagnosis are available, these should replace




Mpumalanga Department of Health
Communicable Disease Conuol
Nelspruit. Mpwnalanga
1. Hansford CF, Van Vuurert CM. Diagnostic disagreement with malaria diagnosis in
Mpumalanga (Lener1_ S Aft Med J 1997: 87; 9t0-912.
2. Ountleim ON. Becker PJ. Brink A.. Diagnostic disagreemenl - the It!$$Ons learnt
~ malana diagnosis in Mpuma/anga. S Air Med J 1997: 87: 609-611.
3. Kirkwood ER. Essentiafs of Medica} StatiStics. Oxford: 8lackwlllfl Scientific
Publications, 1988: 102-104.
Conscious sedation in children
To the Editor: The publication of the conscious sedation
clinical guidelines! by the MASA Conscious Sedation
Working Group is commendable. However, it has failed in its
objective of global application in that the focus is narrow
particularly with regard to conscious sedation in Children: It
is unfortunate that nef1:her the Association of Paediatrics nor
the Association of Paediatric Surgeons was invited to
contribute.
Conscious sedation in children may be indicated for a
variety of procedures other than those mentioned in the
l
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guidelines, Le. diagnostic imaging (eT, MRI) or endoscopy.
These include lumbar punctures, bone marrow biopsies,
suturing of lacerations, reducing fractures, dressing changes
(particularfy for burns), chest tube placement or removal,
echocardiography or cardiac catheterisation, to mention but
a few, and involve every discipline_ Indeed even blood
sampling can be extremely traumatic for a child and may
require sedation. Each of the above procedures will require a
varying degree of sedation depending on the age, health
and character of the child, the parents' views and the
attitude and character of the 'sedationist' (sic).
The glib remark that children require a 'deeper degree of
sedation' and that 'before embarking on repeat doses' or
additional sedatives an 'anaesthesiologist should be
consulted' is dangerous. Deeply sedated children can easily
move to a state of general anaesthesia depending on
individual response, route of drug administration and degree
of stimulation. Paediatrics-trained individuals capable of
monitoring and resuscitating a neonate, infant, toddler or
child should be in attendance both during and after the
procedure. Appropriate equipment for that particular child's
age group should be available prior to initiation of the
sedation, particularly in institutions where children are not
often treated. Conscious sedation in children should not be
undertaken lightly. Despite adherence to the guidelines for
paediatric patients by various interest groups,'-~ which the
authors recommend as essential reading, conscious
sedation carries significant morbidity and mortality,6.7
particularly when opiates are used.s
A sedation treatment plan should be formulated to handle
any eventuality prior to, during and after the procedure -
with an anaesthesiologist or someone equally capable on
standby if the situation so dictates. Psychological support
techniques (CUddling, parental support when appropriate,
warm blankets, a gentle reassuring voice, hypnosis) are








1. MASA Conscious Sedation Working Group. Conscious sedation clinical
guidelines_ S AIr Med J 1997; 87: 484-492_
2. Guidelines lor monitoring and management 01 paediatric patients during and after
sedation for diagnostic and therapeutic procedures. Pediarrics 1992; 89: 1110-
1114.
3. Guidelines for the elective use 01 pharmacologic conscious sedation and deep
sedation in pediatric dental patients. Pediatr Dent 1993; 15: 291-30l.
4. Cote C. Sedation for the pediatric patient. A review. Pediarr Clin Nonh Am 1994;
.1: 31-58.
5. Sacchetti A. Schalermeyer A, Gerardi M. er al. Pediatric analgesia and Se<lat,on
Ann Emerg Med 1994; 23: 237·250.
6. Vade A. Sukhani R. Dolenga M. Habisohn-Schuck C. er al. Chloral hydrate
Sedation of children undergoin9 CT and MA imaging: Safety as judged by AAP
Guidelines. AJR 1995; 165: 905-908.
1. Terndrop TE. Cantor AM. Madden CM. Intramuscular meperidine. promethazine
and chlorpromazine: analysis 01 use and complicalions in 481 pedialric
Ilme/yency department patients. Ann Emerg Med 1989; 18: 528-533.
8. Yaster M, Nichols DG. Oeshpande JK. Wetlel FiC. Midazolam·fentanyl sedation in
Children: case report of respiratory arrest. Pediatrics 1990; 86: 463-461.
Professor 0 Morrell, Or E Barker and Ms V J Pinkney-
Atkinson reply: We thank Professors Bosenberg and Hadley
for their contribution and comments. First, it is common
knowledge that conscious sedation in children is a far more
risky undertaking than in adults and should not be
undertaken by anyone inexperienced in paediatric
pharmacology. We agree that children require special
management during conscious sedation and the lack of this
information in the guideline is apparent. Participants at
conscious sedation workshops repeatedly request more
information on paediatric patients.
Second, the conscious sedation clinical guideline
development process made adequate provision for wide
consultation. The South African Association of Paediatrics
and the South African Association of Paediatric Surgeons
were invited to comment in a letter sent to them on 22
November 1996. Neither organisation returned the
endorsement/comment form. Only the Radiological Society
of South Africa made reference to children in its comments.
Individuals were invited to comment on the guideline via the
MASA Medigram publication of 9 November 1996. Some 50
doctors responded and asked for the draft guideline.
The following steps have been taken:
1. The existing conscious sedation clinical guideline will
be publicised and labelled as pertaining to 'adults only'.
2. A separate evidence-based paediatric conscious
sedation clinical guideline will be developed before the end
of 1997. It is hoped that Professors Bosenberg and Hadley
will be key participants in this process, as will other
experienced practitioners. Discussions to this effect are
already under way. Further details will be published in
Medigram.
Reconciliation and justice
To the Editor: I returned from a 22-year exile to help build
the new South Africa and have faced considerable
disappointment in the last 3 years. Being excluded from
posts I applied for because of being an elderly white man
without ANC endorsement was acceptable as evidence of
transformation. Working in a health service which continues
to ignore the needs of the rural and dispossessed has been
a very sore point, but the health service will continue to be
pressurised to get its priorities right.
My biggest concern has been the lack of interest in this
process of reconciliation by the medical profession and the
previously privileged public. The handful of activists of the
past remain a concerned handful while the voices of the
previously compromised, who now apologise for the past,
sound very hollow and insincere. No sacrifices are being
made to atone for being a beneficiary of apartheid, and no
one that I know of has volunteered to do community
service in deprived areas. Even our Health Minister is too
timid to demand such conscription from the pre-1990
graduates and prefers to tackle inexperienced and innocent
young doctors.
I did not seek reconciliation. My own resistance to
apartheid (of course, these days we all fought apartheid)
was on a small scale which reaped massive punishments.
My career was damaged by dismissals from two hospitals
as a houseman. When I asked the MASA for help, they
suggested I emigrate to the USA_ Only one of my
professors, Ossie Heyns, gave me any sort of support. I
worked as a mine medical officer until I was arrested in July
1964 and my pregnant wife was evicted a week later. I was
I
I
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Population HIV% 8eroprevalence (HIVGP)
In a defined population. the proportion of tuberculosis cases that are HIV-positive
(HIV,.) is given by the ratio of cases of HIV-positive tuberculosis to the total number of
cases. (Wheffl HIV", is the proportion of HlV infection in tuberculosis cases, TB is the
tuberculosis incidence rate and HIVGP is the HIV seroprevaJence in the general .
population_
(HIV"" x TB;< AA)
HIV,. = ~(HC;;IV"~'-'CCT;;B;-'-;R"R;CI;' (TB x (l-HIV""j.





Fig. 1. Plots of HIV prevalence in tuberculosis versus general
population HIV seroprevalence are shown for three groups at
differing AAs for the development of active tuberculosis-
Hlabisa patients with an RR of S, Cape Town patients with an RR
of 16 and AIDS patients exposed during a tuberculosis outbreak
with an RR of 30.
in jail when my beloved father died and I was not allowed to
attend his funeral. My son was born when I was in jail and I
was never allowed to touch him until my release when he
was nearly 2 years old. I was banned and even the
University of the Witwatersrand would not give me a job at
Alexandra Clinic in 1966. The Minister of Justice (sic!) denied
me the right to study for my Diploma in Public Health at Wits
- and even just to go to the library to read journals! I finally
left for Edinburgh on an exit permit in 1968, painfully leaving
my stepson behind to go to boarding school.
Who can make up for these things? Hundreds of
thousands of such things occurred to tens of thousands of
people. Millions experienced daily humiliations. Will we ever
hear about them? The answer has to be 'no'. And the
expressions of regret from the innocent beneficiaries of
apartheid are very faint, even in the humane medical
profession.
Real transformation remains on the horiz~n. Doctors can
contribute to the process by regarding themselves as
Africans and giving their loyalty to Africa, rather than to their
pockets. This is the spirit that will create the much-vaunted
'rainbow nation' that does not yet exist.
Costa Gazi




















To the Editor: Wilkinson and Davies recently described the
changing epidemiology and clinical features of t.uberculosis
in a rural Kwazulu-Natal hospital and related this to a rapid
increase in HIV seroprevalence in antenatal clinics in the
region.' We have also noted an increase in tuberculosis
cases at Somerset Hospital, Cape Town, where 21 % of
admissions of black patients to the general medical wards
are now for tuberculosis. Atypical clinical and radiological
presentations have also become more common.2.3
Some comment is needed on the authors' estimate of the
proportion of tuberculosis cases attributable to HIV infection.
The authors estimated the attributable fraction (AF) of
tuberculosis due to HIV infection using the relative risk (RR)
of HIV infection in patients with tuberculosis compared with
antenatal women. Ideally, the RR used in the calculation of
AF should have been the ratio of incidence of tuberculosis in
a cohort with or without HIV infection. Given the difficulty in
obtaining such data, the RR for tuberculosis in HIV infection
can be derived from the relationship beween HIVm, the
proportion of HIV infection in tuberculosis, and HIVGP , the
general population's HIV seroprevalence. Using this
relationship (Fig. 1) and assuming that HIV prevalence in
antenatal clinics (HIV....~) is equivalent to HIVc;p, the calculated
RR for tuberculosis in the HIV-positive population in
Kwazulu-Natal is 8.5, somewhat higher than the quoted
4.14.
Although it is generally assumed that the RR for
tuberculosis in HIV-positive people is constant in different
settings, this is unlikely, firstly because of the variation of
risk of reactivation with immune status of the individual and
hence the stage of the epidemic in the population and,
secondly, because of the varying risk of transmission of
tuberculosis from and to HIV-infected adults, depending on
behavioural and socio-economic factors. At Somerset
Hospital, a new diagnosis of HIV infection was made in
45% (Cl 32 - 58%) of black women admitted with
tuberculosis in 1995 - 1996. During this period, the antenatal
HIV prevalence for this population group was 4.7%
(Cl 2.5 - 6.9%). Fig. 1 shows a plot of HIVrn versus HIVGP for
Kwazulu-Natal with an AA of 8, for Cape Town where the
RR obtained using the formula is 16 and for AIDS patients
with an RR of 30, calculated during a tuberculosis outbreak. 4
The Cape Town analysis was limited to black females
between the ages of 14 and 49 years with a new diagnosis
of tuberculosis, for whom the HIVAN should best approximate
the HIVGP • Patients with prior known HIV-positive status
were excluded from the analysis to avoid referral bias from
local HIV clinics. It should be noted that all curves show an
initial steep slope which moderates with increasing
seroprevalence. This non-linear relationship illustrates why
tuberculosis patients act as a sentinel group for HIV early in
the epidemic, all the more so if the RR for tuberculosis in
HIV-positive patients is high. The initial steepness of the
curves, however, should caution us that inaccuracies in
HIVc;p will be reflected as large changes in RR calculated with
the formula, especially when HIVGP is < 20%. Calculation of
attributable risk further amplifies any inaccuracies in the
measured RA inherent in this type of analysis.
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B r e w e
Both the tuberculosis incidence rate and the RR
associated with HIV.infection in Kwazulu-Natal are similar to
other reports from Africa.5 In contrast the high RR of the
Cape Town urban black population may indicate a
significant amount of horizontal transmission. Combined
with a background tuberculosis incidence rate that is already
the highest in Africa, we can expect an increase in HIV-
related tuberculosis in Cape Town that is unprecedented in
the global HIV epidemic to date.
Finally, we would like to emphasise the point made by
Wilkinson and Oavies, that national notifications have not
increased in recent years.6 The lack of culture facilities in
most areas of South Africa, the high rate of smear-negative
cases and the atypical presentation in advanced HIV
infection are probable causes of underreporting. However, it
must also be questioned whether the widespread
underreporting is a manifestation of the crisis of morale and
manpower in our health care system. Studies such as that of
Wilkinson and Davies complement routine notification, but
should not be a substitute for it. Population attributable
fraction and RR may be considered abstruse, but accurate
measurement of these parameters is important for projection
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To the Editor: I read with great interest the paper by
Wilkinson and Davies1describing the increasing burden of
HIV-related tuberculosis. The importance of their message is
beyond any doubt. I would like to add two points. Firstly, the
authors seem to be unaware of my previous report,2 which,
as far as I am aware, is the first study on the impact of the
HIV epidemic on tuberculosis in rural South Africa. Of much
more importance, however, is the fact that both surveys12
point in the same direction.
Directly observed therapy (DOT) was started at Emmaus
Hospital, Bergville District, Kwazulu-Natal, in 1987.:J
A survey from 1987 throu9h 31 July 1995, showed a 3.7-fold
caseload increase, Le. in excess of Hlabisa's. Smear
positivity rate was much higher - 91 % without known or
suspected HIV and 64% with HIV. The HIV status was tested
in consenting patients in whom, on a clinical basis, there
was a suspicion of their being immunodepressed. They
represented 11.2% of all tuberculosis patients enrolled for
DOT between 1 August 1994 and 31 July 1995. The
proportion of HIV seropositivity was 71.4%, Le. in excess of
55% at Hlabisa in 1995. The overall mortality rate increased
over the years from 3% in 1987 to 11 % during the last year
of the survey. The overall tuberculosis reactivation rate was
13.7%; the estimated prevalence of drug resistance was
6%. (No figures concerning same are reported from
Hlabisa.) The RR of HIV infection with tuberculosis was 5.1;
the attributable fraction where tuberculosis was attributable
to HIV was 0.80. At Hlabisa the latter two values were 4.14
and 0.76, respectively.
In conclusion, the similarities between both reports are
striking, and confirm the magnitude of the problem of HIV-
related tuberculosis in rural South Africa. I also agree with





1. Wilkinson O. Davies GR. The increasing burden of tuberculosis in rural South
Africa - impact of the HIV epidemic. S Afr Med J 1997: 81: 447-450.
Van Bogaert U. Treatment of tuberculosis in developing countfles. Lancet 1995;
346: 1099-1100
3. Weslaway MS. Conradie PW, Remmers L. Supervised out-pallem treatment for
tuberculosis: evaluation of a South Afncan treatment programme. Tubercle 1991;
12: 140-145.
Or Wilkinson replies: We are grateful for the interest in
our work shown by your correspondents. We did not quote
Van Bogaert's work as the results are probably biased and
should be interpreted cautiously. If HIV testing is limited to
patients in whom immunosuppression is suspected,
reported HIV seroprevalence will most probably be high.
Indeed only 11.2% of patients seem to have been tested: it
is therefore not possible to draw conclusions about the HIV
status of other patients, and further analysis should be
undertaken cautiously. We have previously reported the data
requested.'
The formulas used by Wood and Hudson are not
referenced and we are not sure that all their assumptions
hold. However, we did state in our paper that our estimate of
the population attributable risk percentage was probably
conservative and we gave reasons and justification for this.
We need to be cautious about draWing broad assumptions
from referral settings, as it is very difficult to be sure what
the source population really is and how unbiased patient
selection is. It is not clear what criteria are used for
admitting patients with suspected tuberculosis to Somerset
Hospital. It is also not clear if there are substantial
differences in tuberculosis transmission rates between
Cape Town and KwaZulu-Natal. In a large community-based
study of the molecular epidemiology of tuberculosis
transmission2we showed that approximately 45% of new
cases of smear-positive tuberculosis were probably recently
transmitted, which is a higher proportion than that shown by
Warren et al. in Cape Town? We await with interest
unbiased, population-based data from Cape Town that
document accurately the extent of the impact of HIV
infection on tuberculosis.
1. WHkinson D, p,llay M. Davles GR, Srurm AW. ReSistance !o antltuberculosis
drugs In rural South Afnea: rates. pauerns. risks, and transmiSSion dynam,cs.
Trans R Soc Trap Med Hyg 1996; 90: 692-695_
2. WHk,nson O. Pillay M. Lombard C. Davles GR, Sturm AW. Molecular epidemiology
and tr2'lSmlSSlon dynamics of Mycobacterium tuberculosis in rural Africa: results
from a large, population-based study. Trap Med Inr Healrh 1997 (in press).
3. Warren R. Hauman J, 8eyers N. el al. Unexpectedly high strain diversity of
Mycobacrenum tuberculosis In a high-incidence community. S Afr Med J 1996;
86; <t5~49.
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* DNA was amplifiable in HHV8-negative specimens (see text).

































Serological surveys based on an immunofluorescence
assay (IFA) detecting an HHV8 latent antigen have shown
that the prevalence of HHV8 varied from about 1.4% in
British and American blood donors to 80 - 100% in AIDS-KS
and classic KS patients. '4-16 In Ugandan H1V-negative
individuals, depending on the assay, HHV8 seroprevalence
rates ranged from 35% to 53%. In the pre-AIDS era, KS
showed a marked difference in geographical distribution in
Africa, being commoner in the tropics than in the north or
south,17 and if HHV8 is the cause of this tumour one would
expect the seroprevalence rates in the different countries to
reflect this. It would be important to measure the
seroprevalence of HHV8 in South African populations of
varying HIV risks to inform projections about the increasing
incidence of KS in the country and to look at risk factors
facilitating its transmission. We are currently conducting
transmission and serological studies in South Africa to
address some of these questions.
This study was approved by the University of the
Witwatersrand Ethics Committee and funded by the Freddy
Mercury Trust Fund and the Institute of Cancer Research,
London. The National Cancer Registry is funded by the
Department of Health, the Cancer Association of South Africa






National Cance.r Registry and
Department 01 Anatomical Pathology
School 01 Pathology
South African Institute for Medical Research and
UniverSIty ot the Witwatersrand
Johannesburg
Occurrence of human herpes virus 8 in
Kaposi's sarcoma and other tumours in
South Africa
To the Editor. Kaposi's sarcoma (KS) is becoming the
commonest tumour in populations with high seroprevalence
rates of HIV. 1 In Uganda 48% of cancers in males and 20%
of those in females are now KS, compared with less than
2% 20 years ago. 1 Increases in the incidence of KS
attributed to the HIV epidemic have also been noted in
Zimbabwe" and in Zambia.3 No increases in the incidence of
KS have been reported by the South African National
Cancer Registry (NCR) up to 1991, but anecdotal
unpublished data from the NCR suggest that KS is now
seen more frequently. In a recent study in South Africa, the
relative risk (odds) of an HIV infected person's developing
KS was about 60.<
The non-random distribution of KS in HIV-infected
individuals in the West (i.e. common in homosexual men, but
uncommon in patients with haemophilia or intravenous drug
users) has suggested that a sexually transmitted agent could
be involved in the pathogenesis.5 Recently, sequences of a
new gammaherpesvirus, designated Kaposi's sarcoma-
associated herpesvirus (KSHV) or human herpesvirus 8
(HHV8), were identified in AIDS-KS biopsies, and have since
been found in all epidemiological forms of KS (classic,
endemic and post-transplant).&B
We used the polymerase chain reaction (PCR) to test for
the presence of HHV8 DNA in South African paraffin wax-
embedded tissues from 10 KS (5 HIV-positive and 5 HIV-
negative) and 70 non-KS tumour specimens. Specimens
were retrieved from the South African Institute of Medical
Research (Department of Anatomical Pathology) archives.
DNA was extracted from 10 IJm tissue for PCR for HHV8 as
previously described.9 PCR products (233 bp) were
electrophoresed and visualised on a 3% agarose gel stained
with ethidium bromide.
HHV8 was initially detected in 8 of 10 KS biopsy
specimens (80%) and in 4 of 70 non-KS tissues (5.7%)
(Table I). We tested the quality of DNA in the 2 HHV8-
negative KS specimens using PCR to amplify human
pyruvate dehydrogenase (HPD). This was negative,
indicating that this DNA was not adequate for PCR. All of 8
KS biopsy specimens were therefore positive for HHV8.
Assuming that the 70 non-KS tumours are an adequate
unmatched control group, the relative odds of the
association between HHV8 and KS was 251.2 (95%
confidence interval 12.4 - 5 084.9) (;C' = 49.0,
P ~ 0.001).
In this study of South African samples we confirm the
findings of others that HHV8 DNA is present in HIV-positive
and negative cases of KS, but seldom detectable in other
tumours or tissues.&13 This indicates that either HHV8 is
specifically associated with KS or HHV8 is a passenger virus
('opportunist') in KS tissue because the virus, or the cell
type harbouring HHV8, preferentially replicates in the
cytokine-rich micro-environment of KS. First-generation
serological assays, however, suggest that HHV8 is not
ubiquitous, but predominantly present in those at risk for
developing KS.''<'-lfi These early serological studies therefore
support a causative role for the new virus in KS
pathogenesis.
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Evaluating community radio as a medium
for health messages in Alexandra
To the Editor: Uke any evaluations of media-based health
messages that compare 'exposed' (readers, listeners or
viewers) and 'unexposed' (non-readers, non-listeners or
non-viewers) individuals, Bardwell et ai.'s' evaluation of
Radio Zibonele as a medium for health messages relied on
three inherent assumptions: (1) that exposure to additional
sources of health information was the same for 'exposed'
and. 'unexposed' groups; (it) that these groups were
comparable in terms of educational and soda-economic
characteristics that influence access to health information;
and (iit) that the initial health knowledge of each group was
the same. The limited validity of all three assumptions
became apparent during an evaluation of Soul City's
'Healing Hearts' programme which was broadcast on
A1exandra's community radio station, A1ex FM, from October
1995 to January 1996. This 60-part series, which included a
weekly phone-in discussion programme, covered a variety of
topics including pregnancy, child care, breast-feeding and
immunisation. Interviews with 250 women resident in
Alexandra (81 listeners and 169 non-listeners), conducted 8
weeks after the broadcasts ended, revealed that significantly
more of those who listened to 'Healing Hearts' had
previously watched television broadcasts of Soul City
(61.7% of listeners v. 43.2% of non-listeners; X2 = 7.52,
df = 1, P = 0.006), and that listeners were significantly more
likely to have seen the booklet that accompanied Soul City
(63.0%) than non-listeners (40.8%; X' = 10.75, df = 1,
P = 0.001). In view of the greater impact of health
campaigns that use multiple exposures in different media
('rnultimedia').2 it was surprising that these listeners did not
select a higher percentage of correct answers in a 20-item
questionnaire based on topics covered by the 'Healing
Hearts' series (listeners: SO 76.7 ± 17_5%; non-listeners: SO
77.2 ± 16.0%). However, because the programme was
targeted at low-income women, aged 15 - 45 years,2 it is
possible that there were pre-existing differences in health
knowledge between listeners and non-listeners. If, for
example, the listeners had poorer initial health knowledge
than non-listeners, then the comparable questionnaire
scores achieved after listening to 'Healing Hearts' might
actually reflect a relative improvement in the health
knowledge of listeners. In fact, the broadcasts of 'Healing
Hearts' on Alex FM were successful in reaching a
disproportionate number of 25 - 44-year-old women
(X' ~ 17.3, df =2, P =< 0.001), although significantly fewer
listeners lived in informal dwellings (51.9%) than non-
listeners (66.3%; X' = 4.82, df = 1, P = 0.006). In view of
these fundamental sociodemographic differences between
listeners and non-listeners, it is surprising that there were no
differences in health questionnaire scores between the two
groups and it is possible that exposure to 'Healing Hearts'
(and other Soul City media) had improved the (previously
poorer) health knowledge of listeners,
Indeed, because a large number of listeners said that they
enjoyed listening to 'Healing Hearts', and discussed its
content with other people, it is clear that the broadcasts on
A1ex FM were successful in raising interest and awareness,
both of which are important steps towards improving health
behaviour.3 Unfortunately, a variety of social and economic
factors often limit the impact of interest and awareness on
behaviour,4 even when these subsequently lead to changes
in knowledge and attitude. This might explain why Bardwell
et al.' found a weaker relationship between maternal
listenership and infant gastro-enteritis than between
maternal listenership and 'good attitude'. Low-income
mothers, such as those from Khayelitsha in their study, may
be unable to implement health media messages,~ even when
these messages are effective at improving their attitude and
knowledge,' For this reason it is perhaps naive to believe
that media health campaigns always have a direct impact on
health behaviour, although they can help to influence
attitudes, knowledge and awareness, without which changes





Institute of Urban Primary Health Care
Alexandra Health Centre and Univl!fsity Clinic
Johannesburg
1. Bardwell H, Burrows 0, Ford P, MClntosh C, London L Evaluation of community
radio as a medium for health messages. S AIr Med J 1997; 87: 338-339.
2. Institute of Urban Primary Health Care. 'Let the Sky be to the Limit' - Soul City
Evaluation Reporr. Johannesburg: IUPHC, 1995.
3. Downie AS, Fyfe C, Tannahill A. Health Promotion Models and Values. Oxford:
Oxford University Press, 1990.
4. Kimati VP. Who is ignorant? Aural mothers who feed their well-nourished children
or the nutrition experts? The Tanzania story. J Trap Paediarr 1986; 32: 130-136.
5. Huskisson JM. Feulback S, A profile of the soclo-demographic background of
children admitted with acute diarrhoea to the Red Cross Children's Hospital,
Cape Town. Curationis 1995; 18: 3.1-36.
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Cost-effective on-site screening for
anaemia in pregnancy
To the Editor: We read the article on 'Cost-effective on-site
screening for anaemia in pregnancy in primary care clinics"
with interest. Even in developed countries, bedside testing is
an important adjunct to laboratory-based diagnostic testing.:.'
Where laboratory-based testing presents logistical problems,
bedside testing is obviously more important.
The low specificity (81 %; 95% confidence interval
77 - 85%) and poor positive predictive value (37%; 95%
Cl 29 - 47%) of the copper sUlphate test as described by
Wilkinson and Sach is of concern. When we evaluated the
feasibility of the copper sulphate method to screen for
anaemia in pregnancy,3 we found a specificity of 95% (95%
Cl 88 - 98%) and positive predictive value of 80% (95%
Cl 56 - 93%). (In a Jamaican study a positive and negative
predictive value of 100% was found!4) Why the difference?
The poor specificity might have been caused by technical
factors. If a copper sulphate solution with a higher specific
gravity (SG) is used, the test should be more specific.
possibly at the expense of sensitivity. Were other SGAEs
investigated, or was the SG that we presented originally
used5 without further testing? Technical problems, such as
temperature fluctuations, might also be more prevalent in a
mobile clinic. Anyone interested in evaluating or
implementing the copper sulphate test is encouraged to
read the original articles on the subject.6.7 These articles
provide an exhaustive reference to technical causes of
possible inaccuracies.
Another issue is the accuracy of the Sysmex analyser that
was used as a 'gold standard'. How often and with what
precision was the Sysmex analyser calibrated? Did the delay
in performing the laboratory-based haemoglobin assay lead
to inaccuracies?
Obviously, the human factor could also have played a
part. The mental shift from the traditionaliy used
haemoglobinometer estimation towards the copper sulphate
solution is not always easy. A hand-held haemoglobinometer
compensates for a lack of accuracy by providing the illusion
of precision, whereas the copper sulphate test only provides
a qualitative answer. Obviously,' different copper sulphate
solutions could be used to provide a semi-quantitive test.:!
When implementing the copper sulphate test in the
antenatal clinic of Kalafong Hospital, we also found
inaccuracies that were related to staff who were uncertain
of the meaning of the symbols ">' and '<'. The staff now
record the result as 'above 10' or 'below 10', and not as
'> 10' or '< 10'.
This said, we would like to congratulate the authors on
their drive towards bedside testing in antenatal clinics.
They correctly remark that 'on-site testing ... offers the





Oepanment of Obstetrics and Gynaecology
University of Pretoria and
Kalatong Hospital
Pretoria
:-"ilki.nson 0, Sach ME. Cost-effective on-site screening for anaemia in pregnancy
10 pnmary care clinics. S Afr Med J 1997: 87: 463-465.
2. Hobbs R. Near patient testing in primary care (Editorial). BMJ 1995: 312.: 263.
3. Plstonus LR, Funk M, Pattinson RC, Howanh GR. Screening for anemia in
pregnancy with copper sutfate densitometry.lnt J Gynecol Obstet 1996: 52: 33-36.
4. Stone JE, Simmons WK, Jutsum PJ, Gurney JM. An evaluation of methodS of
screenin9 for anaemia Bull World Health Organ 1984; 623: 115-120.
5. Pislorius LA, Funk M, Paninson RC. Howarth GA. Screening for anaemia in
pregnancy with copper sulphate densitometry. In: Proceedings of the t4th
Co.nference of Priorities in Perinatal Care in South Africa, 1995: 134-138.
6. Phlflips AA, Van Slyke DO, Hamilton PS, Dole VP, Emerson K, Archibald RM.
Measurement of specific gravities for whole blood and plasma by standard
copper sulfate solutions. J Bioi Chem 1950; 183: 305-330.
7. Van Slyke DD, Phillips RA, Dole VP, Hamihon PS, Archibald RM, PlalDn J.
i:~~~~~~on of hemoglobin from blood specific gravities. J Bioi Chem 1950; 183:
Or Wilkinson replies: We are grateful for the interest in
our work shown by Pistorius et al. We agree with the
possible reasons given for the small differences in specificity
and positive predictive value in our two studies. These
observations affirm the importance of different groups'
testing the same procedure in different settings, before
reaching a firm conclusion about the utility of any
intervention. Positive predictive value is strongly influenced
by the prevalence of the condition being screened for. The
Sysmex analyser was calibrated according to normal
laboratory practice. In a pilot study we observed no
difference between haemoglobin estimations made on the
same sample between 0 and 72 hours after venepuncture,
but thereafter estimation became highly variable; all
specimens were therefore tested within 48 hours.
Growth, feeding practices and infections
in black infants
To the Editor: The recent article on growth, feeding
practices and infections in black infants by Delport et al.'
highlights the confusion surrounding the use of National
Centre tor Health Statistics (NCHS) reference charts to
assess the growth of children. Throughout the article these
charts are described as 'standards' instead of 'references'.
These charts were designed as references, for comparative
purposes using samples or groups, and this use has been
recommended by the World Health Organisation.2 Indeed,
Delport et al.' quite correctly emphasise that 'a distinction
must be made between the concept of a reference and that
of a standard or target'. However, their continued
description of these references as 'standards', even though
they use them appropriately as references, only perpetuates
the conceptual confusion between these charts.
Delport et al.' also make the case for a local or national
South African reference chart, as I have done on a previous
occasion in this journal.J While abundant data are now
available to create such a reference for South African urban
and rural children, the eventual publication of such
references is unlikely without a major shift in understanding
and attitude by the paediatric community. The shift in
understanding must be towards the realisation that
references reflect the situation as it is, not necessarily as it
should be. The attitudinal shift must be away from assuming
that anyone who promotes the development of a national
reference chart is advocating that the growth of South
African children is good and that future interventions will not
improve their growth, and thus health, status. 4 It is, of
1024 Volume 87 No. 8 August 1997 SAMJ
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course, understandable that during the apartheid era
support for a chart that might be interpreted as indicating
optimal growth, when in fact the growth of South African
children was far from optimal, was thought to be
misdirected. However, we are now in a post-apartheid era
and such a national chart can only increase the sensitivity
with which we can assess the growth of South African
children.
The interpretation that the growth of breast-fed infants
coincided with 'greater-than-average' growth performance
with regard to weight gain must be viewed against the
current debate as to the appropriateness of the NCHS
references. Numerous studies of both breast-fed and bottle-
fed infants5-11 have highlighted the fact that samples in both
developed and developing countries demonstrate an
apparent acceleration in weight for age between birth and
6 months followed by a deceleration between 6 and 12
months. It is now internationally recognised that this so-
called 'growth faltering' between 6 and 12 months is in fact
a result of inadequacy of the NCHS reference data for the
first 2 years of life.S.'2.13 That recognition has led to the WHO
establishing a protocol for an international growth study in
which participating mothers will exclusively breast-feed their
offspring for 4 - 6 months, in accordance with WHO
recommendations. The data resulting from these studies will
be used to create truly 'international' growth references free
from the current inadequacies of the NCHS charts.
Finally, I am concerned that Delport et al.' perpetuate the
notion that height-far-age Z-scores less than the NCHS
nonns are 'probably due to a genetic influence'. It has been
established unequivocally that differences in height for age
are almost exclusively environmental in origin." Delport et
al_' describe their sample as being from 'urban or rural
economically disadvantaged communities', which are
characterised by poor maternal nutrition and health care in
addition to deprived socio-economic circumstances and
morbidity impacting on the infant postnatally. In such
situations low height for age is the result of maternal and
infant deprivation and is not the result of 'genetic influence'.
Indeed, the genetic control of human growth does not begin
to demonstrate its influence until well after the first year of
life and during the first year environmental factors are of far
greater importance in detennining growth status. '5 To raise
the spectre of a genetic difference in growth potential
between groups of children in South Africa not only ignores
the empirical evidence but also takes us back to a time in
the recent history of this country when 'genetic differences'
were used as a basis for discriminatory legislation.
Noel Cameron
Human Growth Research Programme
Department of Anatomical Sciences
Univl!fSity of the Witwatersrand
Johannesburg
1. Delport SO, Seeker PJ. Bergh A. Growth, feeding practices and infections in
black infants. S Afr Med J 1997; 87: 57-61.
2. Waterlow JC. Buzina R, KeJler W, Lane JM, Nichaman MZ, Tanner JM. The
presentation and use 01 height and weight data lor comparing the nutritional
status of groups of children under the age of 10 years. Bull World Healrh Organ
1977; 55: 489-498.
3. Cameran N_ StandardS for human growth: their constf\lction and use. S AIr Med
J 1986; 70: 422-425.
4. Kibble MA, Leary PM, Walker ARP. Standards for human growth. S Afr Med J
1986; 70: 777-778.
5. DeltWyler KA. Fishman C. Infant feeding practices and growth. Annu Rev Anrtlrop
1992; 21: 171-204.
6. Ahn CH, MacLean WC. Growth of the exclusively breast·fed infant. Am J Clln
Nurr 1980; 33: 183-192.
1. Chandra RK. Physical growth of exclusively breast-fed infants. Nutr Res 1982: 2:
275~276.
8. Garza C, Stuff J. Bune N. Growth of the breast-fed inlant. In: Goldman AS,
Atkinson SA. Hanson LA, eds. Human Lactation. New York: Plenum, 1989: 109-
12t.
9. Kim l. Pollin E. Differences in the panern of weight growth of nutritionally at-risk
and well-nouriShed infants. Am J Clin Nutr 1987; 46: 31-35.
10. Rowland MGM, Paul AA. Whitehead RG. Lactation and infant nutrition. Br Med
BUll 1981: 31: 11-82.
11 ·Whitehead RG, Paul AA. Infant growth and human milk requirements: a fresh
approach. Lancet 1981; 2: 161~163.
12 Gorstein J, Sullivan K, Vip R. et al. Issues in the assessment of nutritional status
using anthropometry. Bull World Health Organ 1994; 72: 273-283
13. WHO Working Group on Infant Growth. An Evaluation of Infanr Growth. Geneva:
World Health Organisation Nutrition Unit. 1994
14 Mattorell A, Habicht J~P. Growth in early childhood in developing countries. In:
Falkner F. Tanner JM. ads. Human Growth: A Comprehensive Treatise. Vol. 3. 2nd
ed. New Vorll: Plenum. 241-262.
15. Tanner JM. Growth at Adolescence. Oxford: Slackwell Scientific Publications.
1962.
Dr Delport replies: Professor Cameron's constructive
criticism is appreciated and accepted. His reiteration of the
inadequacies of the NCHS reference data for the first 2
years of life is particularly relevant.
Geographical differences in infant feeding
patterns in disadvantaged communities
To the Editor. The feeding patterns for infants born at
Kalafong Hospital in Pretoria described by Delport et al. '
provide an interesting comparison to the patterns observed
in the Birth to Ten study among 1 267 children from similar
disadvantaged communities in greater Soweto.~ When these
children were 6 and 12 months old, interviews with their
principal caregiver provided data on infant feeding patterns
similar to those described by Delport et al., I including
information on the duration of breast-feeding and the age at
which non-breast-milk, cereal/porridge, maize meal and
protein-rich supplementary foods (eggs, fish and/or meat)
were introduced. In comparison with the infants studied by
Delport et al.,' those from greater Soweto received very
different diets (Tables I and 11). Although a similar proportion
(around 95%) of mothers in both studies breast-fed their
infants for at least 1 month, from 6 months onwards
significantly fewer of the mothers from greater Soweto
continued to breast-feed. Not surprisingly, significantly more
of these mothers made use of non-breast-milk feeds and
significantly fewer were exclusively breast-feeding at 1, 3
and 6 months compared with mothers from the outskirts of
Pretoria (Table I).
These geographical differences in infant feeding patterns
illustrate how environmental and/or socio-economic
differences influence infant diets even among similar,
disadvantaged communities. To some extent these
differences may reflect the socio-economic and/or social
consequences of urbanisation, as 13.4% of the infants in
Delport et al. 'SI study were from a 'rural setting' while those
from greater Soweto lived in established urban and peri-
urban communities, Indeed, within the Birth to Ten stUdy as
a whole these mothers displayed the longest duration of
breast-feeding, white those living in inner-city communities
in central Johannesburg breast-fed on average for less than
4 months_3
The longer duration of breast-feeding among mothers
from Delport et al.'s' study was accompanied by the use of
SAMJ Volume 87 No, 8 August 1997 1025
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Table I. A comparison of milk intake among Birth to Ten infants from greater Sowet02 and those from the outskirts of Pretoria examined
by Oelport et al.'









Soweto east and west
Exclusively breast-milk
Greater Pretoria




































supplementary feeds comprising significantly less cereal and
protein-rich foods, and significantly more maize meal, than
the supplementary foods received by infants from greater
Soweto (fable 11). Mthimkhulu~ described similar differences
in the types of supplementary foods received by Birth to Ten
infants from greater Soweto: those who were still being
breast-fed at 6 months were significantly less likely to
receive cereals (P < 0.05) or eggs (P < 0.01), and infants
who were still breast-feeding at 12 months were significantly
more likely to receive maize meal as a supplementary food
use of more appropriate, nutrient-dense supplementary
foods.
G TH Ellison
Institute of Urban Primary Health Care
Alexandra Health Centre and University Clinic
Johannesburg
L Wagstaff
Department of PaediatriCS and Child Health
University of the Witwatersrand
Johannesburg
Table 11. A comparison of supplementary foods received at 6
months by Birth to Ten infants from Oiepmeadow and Soweto, and
those from the outskirts of Pretoria examined by Oelport et al.'
Percentage of infants receiving
CereaV Maize Eggs!
porridge meal meat
(P < 0.05) than those who had stopped breast-feeding.
These results suggest that prolonged breast-feeding is often
associated with a supplementary diet that contains little
protein and little energy-dense food. Despite the
acknowledged benefits of continuing to breast-feed for up
to 2 years,s the association between prolonged breast-
feeding (" 1 year) and a poor supplementary diet among
mothers from disadvantaged communities might partly
explain why a number of studies,6 including Birth to Ten/
have found an association between prolonged breast-
feeding and suboptimal growth. Similary, this might partly
explain why the children examined by Delport et al. l
displayed relatively poor growth after 6 months of age when
supplementary feeds play an increasingly important role in
infant growth and development.s Interventions aimed at
improving the growth of these children after 6 months of age
should seek to protect breast-feeding while encouraging the
Significantly different from greater Soweto:
• Po:: 0.05.
"'Po:: 0.01.
..... P 0:: 0.001.
Greater Soweto








Human Growth Research Programme
Department of Anatomical Sciences




Urbanisation and Health Programme
Medical Research Council
University of the Witwatersrand
Johannesburg
1. Delport SO, Beeker PJ, Bergh A. Growth, feeding practices and infections in
black infants. S Afr Med J 1997; 87: 57-61 .
2. Wagstaff L, De Wet T, Anderson A. Infant feeding: Birth to Ten. Urbanisation
Health Newslerrer 1993; 18: 9-13.
3. EJlison GTH, Wagstaff L, De Wet T. Sociodemographic differences in infant
feeding practices amongst children from Johannesburg and Soweto enrolled in
South Africa's Birth to Ten study. Proc Nutf Soc 1997 (in press).
4. MlhimkhUlU DC. The impact of weaning food quality on the nutrition of children in
Soweto. Unpublished thesis, University of Greenwich, London. 1996.
5. UNICEF. Strategy for Improved Nuuition of Children and Women in Developing
Countries. New York: UNICEF. 1992.
6. Victora GC, Vaughan JP, Martines JC, et al. Is prolonged breast-feeding
associated with malnutrition? Am J CUn Nutr 1984; 39: 307-314.
7 EJlison GTH, Cameron N, Wagstaff L, et al. Weight gain during the first year of
the Birth to Ten study. The interaction between morbidity and infant feeding
patterns. Ann Hum 810/1996; 23: 180.
Erratum
In the letter by Stein ef al. entitled 'The Tnuth and
Reconciliation Commission and post-traumatic stress
disorder', which appeared on p. 763 of the June SAMJ, the
names of two of the authors were misspelled. The correct
spellings are Annarnarie Schmidt and Alfred Allan.
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Tuberculous pleural effusions in
HIV-positive patients
Non-reactive, multi-bacillary tuberculosis is associ-
ated with severe immune suppression and advanced
HIV infection.1 The small study by Trajman et al. (Int
J Tuberc Lung Dis 1997; 1: 498–501) reporting on
the histological parameters of pleural tuberculosis in
HIV positive patients suggested that most HIV-positive
patients with pleural TB have a preserved immune
response resulting in pauci-bacillary TB with well
formed granuloma. These results are in contrast with
previous reports.2,3
We performed a prospective study of all patients
(n ! 74) with tuberculous pleural effusion admitted
to Somerset Hospital, Cape Town, South Africa, dur-
ing 1995 and 1996. Pleural histology was reviewed
by a pathologist and classified as reactive (well
formed granulomas), hypo-reactive (poorly formed
granulomas) or non-reactive (no true granulomas),
and scored for the number of acid fast bacilli ("1 or
#1 per high powered field).2
HIV status was available for 66 patients. The HIV
prevalence rate was 55%, which was higher than the
42% HIV prevalence of patients admitted with pul-
monary TB during the same period. The median CD4
count in the HIV positive patients with pleural TB
was 177/$L (range 4–760).
Adenosine deaminase (ADA) levels, suggestive of
tuberculous aetiology if present in high concentration
in the effusion,4 were similar for HIV-positive and
HIV-negative patients, irrespective of CD4 count
(Table). Yield of pleural culture for Mycobacterium
tuberculosis tended to be increased in patients with
advanced immune suppression. Histological evalua-
tion revealed that hypo-reactive pattern occurred in
all groups, and multi-bacillary TB was unusual, even
in patients with low CD4 counts (Table).
Tuberculous pleural effusions in HIV-infected
patients are associated with moderately advanced HIV
disease, as evidenced by CD4 count5 and survival pat-
tern.6 In agreement with the findings of Trajman et al.,
histological grade and number of acid-fast bacilli on
pleural biopsy were similar for HIV-negative and
-positive patients. It is suggested that TB pleural effu-
sions in HIV-positive patients occur prior to the onset




University of Cape Town
South Africa
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Severe arthropathy with ofloxacin in
two cases of MDR tuberculosis
The 4-quinolone group of drugs is now being used
extensively for various infections, including tubercu-
losis, due to their efficacy and very few side effects.
In immature animals they are reported to have pro-
duced arthropathy of weight-bearing joints.1 Peflox-
acin and other 4-quinolone derivatives are reported
to produce arthropathy, tendinitis and tendon rup-
ture in humans,2–4 but there are no reports so far
regarding arthropathy attributed to ofloxacin. This















14/26 (54%) 7/15 (47%) 12/16 (75%)†
Histology
Reactive 13/18 (72%) 6/14 (43%) 4/8 (50%)†
Hypo-reactive 5/18 (28%) 8/14 (57%) 4/8 (50%)†
Acid-fast bacilli
on biopsy
"1/hpf 16/17 (94%) 9/9 (100%) 6/7 (86%)†
#1/hpf 1/17 (6%) 0/9 1/7 (14%)†
*adenosine deaminase.
†P # 0.05 for comparison HIV&, HIV% CD4 # 200 and HIV % CD4 " 200.
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losis as a second-line drug, along with other drugs such
as pyrazinamide, which is known to produce arthrop-
athy due to hyoperuricemia.5 When arthropathy devel-
ops in such situations, it is difficult to attribute it to
either pyrazinamide or ofloxacin, hence it is essential
to distinguish pyrazinamide-induced arthropathy from
the ofloxacin-induced condition.
We report our experience of similar situations
when two patients with MDR tuberculosis developed
arthropathy after receiving ofloxacin with other anti-
tuberculosis drugs in the course of therapy. Case I: A
30-year-old female south Indian doctor attended our
OPD with cervical lymphadenitis. Biopsy of the gland
suggested tuberculosis etiology. She had taken anti-
tuberculosis treatment (ATT) with 2 months of etham-
butol (E) 800 mg, INH (H) 300 mg, rifampicin (R)
450 mg and pyrazinamide (Z) 1500 mg OD, followed
by 4 months of INH 300 mg and rifampicin 450 mg
OD (2EHRZ/4HR) irregularly before attending our
OPD. Since the patient gave a history of irregular
ATT, she was started on a regimen of 2SHRZ %
ofloxacin (Ofl) 200 mg BD, clarithromycin (CL) 500
mg OD and cycloserine (C) 250 mg BD with 10 HRE
and ofloxocin. [Regimen-1, 2 SHERZ % Ofl % C%
CL and 10 HRE % Ofl] Her biochemical parameters,
including serum uric acid level, were normal. The
patient noticed swelling and joint pain with severe
tenderness and local rise of temperature around both
knees and ankle joints after 5 days of treatment.
There was also tenderness on the plantar aspect of the
right foot which was aggravated by the movements
of the toes. With these features, a clinical diagnosis of
arthritis of the ankle and knee, with tendinitis of the
right foot was made. X-rays of both joints were nor-
mal. Since pyrazinamide is known to produce hyper-
uricemia and arthritis,5 it was withdrawn and the
serum uric level was analysed. The patient was con-
tinued with other drugs along with anti-inflammatory
drugs. [Regimen-II, SHER % Ofl % CL, C). There was
no improvement in her condition after 1 week of
treatment; on the contrary, she became completely
bedridden. Her uric acid level was 4 mg/dl, within the
normal limits. Since 4-quinolones are reported to pro-
duce arthropathy, ofloxacin was withdrawn (Regi-
men-III, SHERZ % C % CL) and within 4 days there
was a dramatic improvement in her condition. In
order to confirm whether ofloxacin had actually pro-
duced arthropathy or not, the drug was reintroduced
at the same dosage, along with other drugs (i.e., Reg-
imen I was given). The patient again developed arth-
ropathy within 2 days thus confirming ofloxacin as
the offending drug. Ofloxacin was withdrawn from
the regimen and the patient continued on other drugs.
She was followed up for one year on 2SHERZ % C %
CL and 10 HRE (Regimen III). The pain and swelling
in the knees and ankle joints completely subsided. X-
ray of the joints was normal, but she continued to
have pain in the right foot, probably due to tendinitis,
for a long time after the withdrawal of ofloxacin. Her
lymph nodes completely regressed after one year of
treatment.
Case II: A 35-year-old south Indian nurse had
developed tuberculous adenitis and had taken regular
ATT with INH, rifampicin and ethambutol for one
year, but the gland did not regress and repeat biopsy
suggested TB adenitis. The culture from the gland
yielded MDR tuberculosis. The patient was put on 2
EHRZ % ethionomide 500 mg (ET) OD, ofloxacin
(Ofl) 200 mg BD, and cycloserine 250 mg (C) BD.
Her blood count, lives function tests (LFT) and uric
acid level were normal before the start of treatment.
On the 6th day of treatment she developed severe
pain in the knee joints. Her uric acid level was again
normal. Pyrizinamide was withdrawn but there was
no improvement, then ofloxacin was withdrawn and
patient had a dramatic relief from the pain. Treat-
ment was continued with the other drugs along with
pyrazinamide, and the patient had no further symp-
toms of joint pain. Her lymph glands completely
regressed.
Quinolones as a group, and pefloxacin in particu-
lar, are known to produce cartilage toxicity in ani-
mals and human beings.3 So it is reasonable to specu-
late that ofloxacin, being a quinolone, could have
caused cartilage toxicity and arthropathy. It is diffi-
cult to ascertain whether or not synovial inflamma-
tion was the cause of arthropathy, as there was no
effusion in our patient. The presence of tendinitis in
case No. 1 raises a number of questions. Was there
any drug binding to the macromolecules in the joints
and tendons, inciting inflammatory reaction? Was it
due to chronic inflammatory reaction in the tendon
that the patient experienced tendinitis even long after
withdrawal of the drug? If so, the long term effects of
ofloxacin treatment, which is given particularly in
MDR tuberculosis, needs to be analysed in case con-
trol studies. Ofloxacin in normal therapeutic doses is
usually eliminated completely within 24 to 36 hours.
Hence the renal mechanism does not appear to be the
cause of its toxicity when given alone; however when
it is given along with other drugs such as cycloserine
in the treatment of MDR tuberculosis, there may be
an impairment of glomerular clearance of ofloxacin,
leading to elevated serum levels causing toxicity. This
aspect needs to be studied further in assays of serum
ofloxacin levels during the course of MDR tuberculo-
sis treatment.
Pyrazinamide-induced arthropathy should be dis-
tinguished from that of ofloxacin, as both drugs are
given concomitantly to treat MDR tuberculosis. Pyra-
zinamide produces arthropathy by inducing hyper-
uricemia. The urate crystals are usually precipitated
in synovial fluid and induce inflammatory reaction.
The diagnosis is usually made by detecting high serum
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The role of MDR tuberculosis in producing oflox-
ocin-induced arthropathy, and ethnic differences in its
interreaction with other drugs, need to be studied fur-
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DOTS and beyond: towards a holistic approach 
to the conquest of tuberculosis
The excellent, thought-provoking editorial by John
Grange1 on this subject brings out many points of
great relevance to the management of tuberculosis,
especially in the developing countries. The World
Health Organization (WHO)2 has been campaigning
in strong terms that Directly Observed Treatment,
Short-course (DOTS) is the most important ‘break-
through’ in the treatment of tuberculosis that has
been achieved in recent times. WHO3 has stated that
DOTS ‘is the name for a comprehensive strategy by
which health workers counsel and observe their
patients swallowing each dose of a powerful combi-
nation of medicines and the health services monitor
the patients’ progress until each is cured.’ For success-
ful outcome of the DOTS strategy,3 WHO has high-
lighted five essential elements: prompt diagnosis,
direct observation of the ingestion of the drugs,
proper record keeping, adequate and constant supply
of the drugs and the necessary funding to implement
this program. In no unambiguous terms, it has
stressed that ‘political and financial commitment and
a dependable drug supply are essential parts of the
DOTS strategy’.
It is clear, as has been pointed out by Grange,1 that
the DOTS philosophy rests solely on the premise that
the patient is totally responsible for the failure of che-
motherapy. This assumption is not completely correct
in the vast majority of situations prevailing in the de-
veloping countries,4 though it may be more applicable
in developed countries. In fact Banerji5 has estimated
that the patient’s role in the failure of chemotherapy in
developing countries due to noncompliance can con-
stitute less than 10% of the total causes. The non-
compliant patient in the US, as has been excellently
described by Reichman,6 typically fits into the picture
demanding DOT. On the other hand, the behaviour
of the non-compliant patient in developing countries
is quite frequently not because of his innate nature or
irresponsible conduct of non-co-operation, but as an
unfortunate consequence of the drug delivery and
treatment systems, which, as Grange1 has pointed
out, have many shortcomings. The typical non-com-
pliant patient in such countries, as was described by
Pamra7 some years ago, is the one who is forced to ig-
nore or, at the most, give a lower priority to his tuber-
culosis treatment, than to his other demanding re-
sponsibilities—job, wages and even food and shelter.
As Grange1 and Gangadharam8 have mentioned,
many, if not all, of the so-called non-compliant pa-
tients in developing countries would be compliant, if
a proper drug delivery system were functioning. For
instance, if the clinics are made to operate to suit the
convenience of the patients, with minimum turn-
around time, and, more importantly, if there is an un-
interrupted supply of all the prescribed drugs, there
should definitely be an excellent compliance on the
part of the patients in these countries.
Even when the drugs are provided, and the dispen-
saries are scheduled to operate under conditions
which are most suitable for the vast majority of pa-
tients, as suggested by Grange1 and Pamra,7 there is
another unrecognised serious problem of corruption.8
In many countries, such malpractices are prevalent.
Even though the drugs are purchased by the hospital
pharmacies, they are channelled through corrupt
practices to ‘black market’ dispensaries. DOT can
correct this only when the infrastructure itself is fully
competent and honest. Besides proper procurement
of all the drugs, a problem which Grange1 has alluded
to, proper and honest distribution should be ensured.
As has been mentioned earlier,8 every member in the
hierarchy of drug delivery—directors, doctors, nurses,
pharmacists and field workers—should be conscien-
tiously devoted to his or her assigned duties. Only
then will any method, be it DOT or another method
of drug delivery, function properly and produce the
expected results. What we need in many developing
countries is DOD (Directly Observed Doctors) as
Olle-Goig9 has indicated, or more appropriately,
DOP (Directly Observed Program or Directly Ob-
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Based on all these, it is correct to state, as Grange1
implied, that DOT or DOTS is not a universal recipe
for controlling tuberculosis. Iseman et al.10 have
stated that it is a procedure which cannot be ignored.
Their recommendations are perhaps applicable to
countries like the US, where the patient is mostly to be
blamed, and funds and administrative machinery are
available to the best possible extent. The application
of DOT has indeed ‘turned the tide’ in an otherwise
trying situation as existed in New York.11 On the
other hand, whenever the availability of necessary
funds and facilities, particularly adequate supply of
drugs, are wanting, less than optimal results will be
obtained as has been cautioned by Riechman.12
Finally, it is worth emphasizing another important
fact which was unfortunately missed by Grange.1
DOT or DOTS was born more than 34 years ago in
Madras, India.13 In fact, the picture of a nurse directly
observing a patient taking the pills, a DOT scenario,
which the WHO has put in one of its pamphlets,14 is
from that original classical Madras study.13
P. R. J. Gangadharam, Ph.D.
Professor of Medicine
Microbiology and Pathology
Director of Mycobacteriology Research
University of Illinois at Chicago
College of Medicine
808 S. Wood Street, Room #868, M/C 735
Chicago, IL 60612
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Editor’s note
Professor Gangadharam correctly points out several issues which
confound the DOTS strategy. However, his assessment of drug-tak-
ing behavior in patients in developing countries may be overly opti-
mistic. Study after study documents substantial nonadherence with
diverse treatments in persons from all racial, ethnic, national, eco-
nomic, social and educational groups. Much as we anticipate cer-
tain patterns of clinical manifestations with Mycobacterium tuber-
culosis, so might we regard nonadherence as a predictable attribute
of Homo sapiens.
Registration and treatment of patients with 
smear-positive pulmonary tuberculosis
Quarterly reports from district tuberculosis (TB)
officers on case-finding and treatment outcome are an
essential component of the monitoring system of a
National Tuberculosis Control Programme. It is rec-
ommended by the International Union against Tuber-
culosis and Lung Disease (IUATLD) that all patients
recorded as smear-positive in the laboratory register
be compared with the list of patients commenced on
treatment in the TB register, to ensure that no patients
identified in the laboratory go without treatment.1 It
is further recommended by the World Health Organi-
zation that smear-positive patients in the laboratory
register who have never appeared for registration or
treatment must be registered in the TB register and
should be classified as treatment interrupted (default-
ers) in the treatment outcome.2
In practice, these recommendations are often not
followed, at least in Malawi, which is said to have a
well-functioning TB Control Programme. Although
the laboratory register is compared with the TB regis-
ter during routine supervisory visits, quarterly reports
are based solely on assessment of the TB registers. We
decided to 1) document the proportion of smear-pos-
itive TB patients in the laboratory register who do not
appear in the TB register and the possible reasons,
and 2) the length of time between laboratory diagno-
sis and commencement of treatment of smear-positive
patients during country-wide visits in 1997.
There are 43 central, district or mission hospitals
in Malawi that perform sputum smear microscopy
for acid-fast bacilli in PTB suspects and which then
register smear-positive PTB patients for treatment.
During the first 6 months of 1997, 41 hospitals (3
central, 22 district and 16 mission) were visited by the
TB Programme Management Group, and TB officers
were requested to record, during the next 6 months,
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tory sputum register as smear-positive, and 2)
whether these smear-positive patients had been regis-
tered in the hospital TB register and commenced on
short-course chemotherapy. The dates of these entries
and activities were noted. If patients were not regis-
tered in the TB register, TB officers were asked to find
out wherever possible what had happened.
Data on 3482 smear-positive PTB patients in labo-
ratory registers from 41 hospitals were collected over
a mean period of 5.4 months (range 2–8 months);
2980 (86%) patients were registered in the TB regis-
ter. The length of time between diagnosis in the labo-
ratory register and commencement of treatment was
documented for 2975 patients; it was 7 days or less in
2534 (85%) patients, 8–14 days in 311 (10%)
patients, 15–21 days in 76 (3%) patients and 22–88
days in 54 (2%) patients. 502 (14%) patients were
not registered in the TB register. Of 595 patients with
smear-positive PTB in the three central hospitals, 236
(40%) were not registered (range 34%–44%). Of 991
patients with smear-positive PTB in the 16 mission
hospitals, 107 (11%) were not registered (range 0–
36%). Of 1896 smear-positive PTB patients in the 22
district hospitals, 159 were not registered (range 0–
17%). The reasons for non-registration in all 41 hos-
pitals are shown in the Table.
This study shows that 86% of patients in the lab-
oratory register were registered and placed on anti-
tuberculosis treatment, and that in 85% of registered
patients the time between laboratory diagnosis and
start of treatment was one week or less. Although we
did not document reasons for the delays in starting
treatment, this is often because of patients submit-
ting sputum specimens at health centres and the
logistic difficulties encountered in getting results
back to the patient and getting the patient to report
at the hospital for registration and treatment. A sig-
nificant proportion (14%) of smear-positive PTB
patients failed to be registered in the hospital at
which the sputum smear diagnosis was made. The
proportion of failed registrations was particularly
high in the three central hospitals; this is disappoint-
ing, given that a reasonably successful cough register
system was set up in one of the central hospitals in
1995.3 In one quarter of all patients there was a doc-
umented reason for failed registration such as early
death or registration and treatment at another dis-
trict in the country. Although in the majority of
patients the reasons were not known, we suspect that
many registration failures can be explained by rea-
sons documented in the Table.
As a result of this study and other operational
research studies focusing on diagnostic issues and
treatment outcomes, we have started two initiatives
to understand and to try and reduce the problem.
First, all TB officers will be required on a regular basis
to check the laboratory register and indicate in writ-
ing, against all smear-positive patients, the manage-
ment outcome (i.e., either the TB treatment registra-
tion number or another outcome such as death/
transfer to another district). This will be monitored
every quarter by regional TB officers using a struc-
tured check list, and we have set a target for the
National TB Programme that 95% of smear-positive
PTB patients will be registered and placed on treat-
ment. Second, in each region there is now a quarterly
meeting of TB officers so that they can compare and
share their information on transfer out and default
rates; we hope that this type of peer-review will con-
tribute to improved performance. The aspect of TB
control is of importance because at present Malawi is
under-reporting both its true smear-positive TB case
rate and its true default rate.
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Table Resasons for smear-positive PTB patients in the 
laboratory register not being registered in the hospital
TB register
Reasons for not being registered n (%)
Died before registration 40 (8%)
Registered and treated in another district in Malawi 27 (5%)
Absconded and not traced 20 (4%)
Transferred to another district in Malawi: registration
and treatment status unknown 18 (4%)
Transferred to Mozambique: registration and
treatment status unknown 5 (1%)
Discharged from hospital before smear results known
and not traced 4 (1%)
Refused to be treated* 2
Reason unknown 386 (77%)
Total 502
*One of these patients believed he had been bewitched and left to seek the
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Tuberculin PPD RT23 is stable:
quality control data cannot be denied
We have read the rebuttal1 of Dr. Kim and his col-
leagues to our counterpoint paper “Tuberculin PPD
RT23: still going strong”2 with interest, and have
noted their arguments that RT23 was indeed used in
most of the surveys and that BCG vaccination may
not have changed tuberculin reactivity in TB patients.
However, the rebuttal does not deal adequately
with the quality control data in our paper. It is stated
that “quality control in animal models is not possible
with low doses such as 1 T U directly and it is very
true that the smaller the dose, the greater the varia-
tion in potency.” This statement is clearly wrong.
RT23 dilutions prepared at Statens Serum Institut are
controlled according to the European Pharmaco-
poeia,3 which describes a potency assay for 1 and 2
T U dilutions. This monograph further requires that
the observed potency must be in the interval 80–
125% of the stated potency and that “The fiducial
limits (P = 0.95) of error are not less than 64% and
not more than 156% of the stated potency.” These
requirements to the precision of the potency determi-
nation of 1 and 2 T U dilutions are precisely the same
as for more concentrated dilutions of tuberculin.
The rebuttal therefore does not present any argu-
ments for the statement1 that “The SSI cannot claim
that there was no potency change with the quality
control data observed in guinea pigs.” Indeed, the
data given in Figures 1, 2 and 3 of the counterpoint
paper2 do not give any indications of a potency loss of
RT23. Finally, we wish to emphasise the point given
in our paper2 that if the decline in tuberculin reactiv-
ity seen in Korean TB patients should be explained by
a loss of potency of RT23, it can be calculated that
RT23 should have lost more than 90% of its activity
in the period 1965–1995! This fact, which is not com-
mented on in the rebuttal of Dr. Kim and colleagues,
is clearly incompatible with both the quality control
data in guinea pigs as well as with the recent clinical
study in Mexico showing equivalent reactivity of 2
T U of RT23 and 5 T U of Tubersol.2
Kaare Hasløv
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colleagues (Oct 2, p 1159)1 report data
from 344 febrile inpatients in Malawi
and Thailand who had mycobacterial
blood cultures and HIV testing in
addition to routine care. Their findings
confirm those of a study from Abidjan,
Côte d’Ivoire,2 in which all patients
with mycobacteraemia had advanced
HIV infection, as indicated by a mean
CD4-cell count of 49/L and mortality
of 80%. However, whether scarce
resources should be used for expensive
investigations on patients with a poor
outcome is debatable.
We are concerned that McDonald
and colleagues’ study promotes the
increased use of mycobacterial cultures
when much cheaper tests—ie, repeat
sputum smears and wide-needle
aspirate of lymph nodes—would
suffice. We have done a study of 141
consecutive HIV-positive inpatients
with confirmed tuberculosis to assess
yield and timeliness of results.3 Blood
culture was by far the least cost-
effective diagnostic approach, whereas
the most cost-effective was lymph-
node aspirate. Results of 16 of 19
positive blood cultures were returned
after the diagnosis had been made by
other means. Our findings are in
keeping with those of others.4
It should also be noted that many
sick patients find it difficult to produce
sputum on the day of admission and
on-the-spot samples have a lower yield
than those collected overnight. In our
series only 17 (31%) of 54 patients
diagnosed on sputum smear were
identified on the day of admission.
Unrecognised tuberculosis may
therefore be an artifact created by
McDonald and colleagues’ case
definition.
Finally, a search for unrecognised
Mycobacterium tuberculosis would be
best done by sputum culture (higher
yield and lower unit cost). Use of
blood cultures would be rational if the
original intention were to look for
unrecognised M avium-intracellulare.
No cases seem to have been found, in
accord with other findings.5
*Christopher P Hudson, Gary M aartens,
Robin Wood
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Sir—Clifford McDonald and
colleagues1 report that 10% of febrile
adults admitted to hospitals in Malawi
and Thailand had mycobacteraemia at
the time of admission. However, the
conclusions drawn from this study
have surprised some of us working in
Malawi. The data from Malawi are
presented as though these patients
with unrecognised M tuberculosis
bacteraemia would not have been
correctly diagnosed during their
hospital stay.
The constellation of chronic fever,
cough, or weight loss (not including
oral thrush), picked out by the
investigators as predicting myco-
bacteraemia, would routinely trigger
clinicians in Malawi to investigate for
tuberculosis with sputum-smear
microscopy and radiography.2
Unfortunately, the investigators give
no follow-up data on the outcome of
the patients, many of whom may have
been correctly diagnosed and treated
during their admission. In Malawi,
these patients are likely to have been
started on tuberculosis treatment
before the results of blood cultures
became available. How often did the
results of blood cultures in McDonald
and colleagues’ study influence
patient management?
The researchers raise concerns
about the nosocomial risk posed by
the admission of undiagnosed
tuberculosis cases to medical wards,
especially where rates of HIV infection
are high. However, that they chose to
use mycobacteraemia in febrile
patients to argue that blood cultures
are required to identify infectious
cases, and therefore to reduce the risk
of nosocomial transmission, is
surprising. Surely the cause of
concern should be the 113 (33%) of
343 patients who had chronic cough
in addition to fever, and who may
have been expectorating viable
mycobacteria in their sputum.
We collected blood samples from
113 patients with chronic cough with
axillary temperatures greater than
37·4ºC. Tuberculosis was confirmed
in 55 patients (48·5%): 33 were
sputum smear positive and 22 were
smear negative but culture positive.
11 patients had tuberculosis isolated
from blood cultures (ten had M
tuberculosis and one had atypical
mycobacteria). All patients with
mycobacteraemia were HIV positive.
Eight of these patients had acid-fast
bacilli detected in their sputum. The
remaining three patients had chest
radiographs consistent with
pulmonary tuberculosis, and were
started on tuberculosis therapy before
the results of blood cultures were
known. Pulmonary tuberculosis was
confirmed by sputum smear or culture
in a further 44 patients for whom
blood-culture samples were negative.
Blood culture did not contribute to
management of patients in any of these
cases, and sputum-smear microscopy
rapidly identified patients constituting
the greatest nosocomial risk.
We suggest that a better strategy for
preventing nosocomial transmission
would be rapid (same-day) acid-fast
bacilli smear microscopy for patients
admitted with chronic cough.
*Nicola J Hargreaves, Sam Phiri,
John Kwanjana, Daniel S Nyangulu,
S B S quire
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Diagnosing HIV-associated tuberculosis: reducing costs
and diagnostic delay
C. P. Hudson,* R. Wood,† G. Maartens*
S U M M A R Y
* Department of Medicine, University of Cape Town, Cape Town, † Somerset Hospital, Green Point, South Africa
SETTING: University-affiliated hospital in South Africa.
OBJECTIVE:  To assess the time to diagnosis and the yield
and laboratory cost of diagnostic procedures in human
immunodeficiency virus (HIV) associated tuberculosis.
DESIGN: Cohort study.
PATIENTS: Adult HIV-infected patients with newly-
diagnosed tuberculosis admitted over a 2-year period.
RESULTS:  A total of 141 admissions fulfilled the case
definition. Sputum smear yield (43% overall) correlated
strongly with chest radiograph appearance but not with
CD4! lymphocyte count. Sputum smear yield was
approximately 40% per sample sent, resulting in a high
cumulative yield when " three samples were sent. Smear
of sputum or wide needle lymph node aspirates were the
most cost-effective diagnostic methods. Significant diag-
nostic delay occurred in sputum smear-negative patients.
Most patients with sputum smear-negative tuberculosis
had either pleural effusions or lymphadenopathy. Lymph
node biopsy had a high diagnostic yield even in patients
with symmetrical nodes, but was under-utilised in this
group. There was unnecessary expenditure on cultures,
with many patients having several positive cultures.
CONCLUSION: Repeated sputum smear examination
produces a high cumulative yield in HIV-associated
tuberculosis. Considerable savings in laboratory utilisa-
tion and bed occupancy would have been made if a
streamlined diagnostic approach with greater use of
lymph node aspirate and early pleural or lymph node
biopsy had been followed.
KEYWORDS: HIV infection; tuberculosis diagnosis; spu-
tum smear; needle aspirate; South Africa.
TUBERCULOSIS IS the leading cause of mortality
and morbidity in human immunodeficiency virus
(HIV) infected patients in Africa and Asia.1–4 In both
developing5 and industrialised6 nations, delayed or
missed diagnoses of tuberculosis have important ad-
verse consequences including nosocomial transmission,
death, and wasted bed occupancy.5,6 Sputum smear is
the preferred method of rapid diagnosis of tuberculosis
due to its low cost. However, most7–9 but not all10,11
studies of HIV-infected patients with tuberculosis have
found a higher rate of smear-negative sputum.
The aims of the present study were to investigate
the clinical correlates of smear-negative sputum in
HIV-infected in-patients with tuberculosis, to assess
recent recommendations to reduce the number of spu-
tum smears from three to two per patient-episode,12 to
examine resource utilisation in cases where sputum
is smear-negative, and to propose a cost-effective ap-
proach to rapid diagnosis.
METHODS
The study was conducted in an urban university-
affiliated hospital providing general in-patient ser-
vices over the period October 1994 to September
1996. During this period all patients with suspected
tuberculosis were offered HIV testing and 88%
accepted. During the study period the policy was to
send at least one sputum specimen for mycobacterial
culture for all HIV seropositive admissions. Myco-
bacterial culture was encouraged on biopsy material
as well as other specimens. Discharge summaries of
patients treated for tuberculosis were collected pro-
spectively and cross-checked against the laboratory
database and monthly records of HIV-positive admis-
sions compiled by the hospital infection control nurse
to ensure that all patients with proven or empirically
treated tuberculosis were identified. Radiological and
clinical data were abstracted from the medical records
and the laboratory database was used to identify
investigations for tuberculosis.
The case definition for tuberculosis required one of
the following three criteria: 1) culture of Mycobacte-
rium tuberculosis from any site; 2) an anatomical
diagnosis of tuberculosis at necropsy; 3) the presence
of acid-fast bacilli (AFB) on a smear or granulomas
on histology with subsequent response to treatment.
Patients who defaulted from treatment and presented
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with early relapse were excluded. Sputum smear-
negative tuberculosis was defined as negative smear on
all sputum samples sent, irrespective of the number of
specimens sent. Smears of sputum and aspirates from
lymph nodes were examined using the fluorochrome
method except when urgent processing was requested,
in which case Ziehl-Neelsen staining was done.
Mycobacterial cultures were performed with a radio-
metric system (BACTECTM). Laboratory cost data
were obtained from the March 1996 unit costs sup-
plied by the laboratory. The unit costs include
reagents, staff and other costs.
Fisher’s exact test and #2 with Yate’s continuity
correction were used for comparison of proportions
as appropriate. The Kruskall-Wallis test was used for
comparison of means.
RESULTS
During the review period there were 415 medical
admissions of HIV-infected patients, of whom 179
were treated for tuberculosis. Mycobacterial culture
of sputum was requested for 51/69 patients with res-
piratory conditions other than tuberculosis, and for
157/179 patients treated for tuberculosis. Of 149
admissions that fulfilled the case definition of tuber-
culosis, eight patients who had defaulted and pre-
sented with early relapses were excluded as the diag-
nosis was already available, leaving 141 admissions
in 131 patients (10 patients had recurrent tuberculo-
sis). HIV was acquired by heterosexual transmission
in 122/131 (93%) patients and by homosexual trans-
mission in the remainder. There were 91 Africans, 30
Coloureds (a mixed race community) and 10 Cauca-
sians. CD4! lymphocyte counts were done within a
month of admission in 103 patients (median count
83/$l, interquartile range 37–207). In the 141 admis-
sions the diagnosis was confirmed by culture of M.
tuberculosis in 109 (77%), a treatment response
coupled with AFB on histology or sputum smear in
21, granulomas on histology together with a treat-
ment response in six, and on necropsy in five.
Diagnostic yield of sputum
Sputum smear was positive in 60 admissions (43%),
negative in 49 and sputum could not be obtained in
32. Sputum smear was more likely to be positive if the
clinical presentation suggested pulmonary involve-
ment (cough, chest pain or focal chest signs): 59/124
(48%) had clinical evidence of pulmonary involve-
ment compared with 1/17 (6%) who did not (P %
0.01). Detailed description of the chest radiograph
was available for 91 of the 124 patients with clinical
evidence of pulmonary involvement—the radiographic
appearance correlated with the yield of sputum smear
(Table 1). The yield of sputum smear was not related
to the CD4! lymphocyte count: 35/68 (51%) with
pulmonary symptoms and a CD4! lymphocyte count
%200/$l were smear-positive compared with 10/25
(40%) with higher counts (odds ratio 1.59, 95% con-
fidence interval 0.57–4.48, P & 0.45).
In view of recommendations to reduce the number
of sputum smears,12 we examined the yield of smears
of consecutive sputum specimens. Sputum smear
yield was not significantly different for consecutive
samples (45/109 [41%] for the first, 20/61 [33%] for
the second, 12/32 [38%] for the third and 8/18 [44%]
for the fourth; #2 for linear trend 0.027, P & 0.868).
The incremental yield from repeating the smear on
those patients negative on preceding smears was 8/39
for a second, 4/21 for a third and 3/12 for a fourth
specimen. The yield of smear on first sputum was 17/29
(59%) in patients able to produce a sample on the day
of admission compared to 22/65 (34%) when sputum
was obtained after day one (P & 0.04).
The yield of culture of the first sputum sample was
25/34 (74%) on smear-negative patients and 37/43
(86%) on smear-positive patients (P & 0.28). Thirty-
three patients had two sputum samples cultured with
a similar yield (26/33 and 28/33), but five patients
who were negative on the first specimen were positive
on the second.
Resource utilisation
To reflect clinical decision-making, time to diagnosis
was assessed for admissions where the diagnosis was
based on specimens obtained during admission, i.e.,
excluding necropsy diagnoses (five patients) and diag-
noses made on specimens sent from the clinic prior to
admission (8 patients). Mean time to diagnosis was
13 days when sputum was smear-negative or the
patient could not produce sputum, compared to 2
days for smear-positive tuberculosis (P % 0.01). Of
smear-negative admissions, mean time to diagnosis
was 11 days for patients who had a biopsy compared
to 20 days for patients who did not (P & 0.01). For
smear-negative admissions with a biopsy diagnosis,
mean time to diagnosis was 3 days in patients under-
going pleural biopsy compared to 7 days for patients
undergoing biopsies of other tissues (P & 0.04).
In patients with smear-negative sputum or no spu-
tum, wide needle aspirate and/or biopsy was per-
formed in 13/43 (30%) with symmetrical lymph node
enlargement compared to 13/17 (76%) with lymph
Table 1 Chest radiographic appearance and yield of sputum 










Pleural effusion 11 1 (8)
Normal 12 5 (29)
Nodular infiltrate 22 14 (39)
Consolidation 7 15 (68)
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nodes noted to be asymmetric in size (P % 0.01).
Patients with negative aspirate went on to biopsy only
when the nodes were noted to be asymmetric. This
difference in use of investigations occurred despite no
difference in yield: 6/7 biopsies of symmetrical node
enlargement were positive compared to 8/10 for biop-
sies of asymmetrical nodes, and the corresponding
figures for aspirates were 3/7 and 5/9.
Table 2 displays for each investigation the diagnos-
tic yield and cost per diagnosis. Due to the large num-
bers of positive results obtained after a previous pos-
itive result, diagnostic yield is shown both as number
of positive results and number of occasions when the
positive result was the first evidence of tuberculosis.
Cost per diagnosis is calculated as total cost (number
of investigations multiplied by the March 1996 unit
costs) divided by the number of occasions when the
positive result was the first evidence of tuberculosis.
One diagnosis was made on culture of a skin biopsy13
but, as this was the only investigation of this type, it is
excluded from Table 2 along with five cases diag-
nosed at autopsy and eight on samples sent prior to
admission.
Given the high cost per diagnosis of many investi-
gations and frequent delay in obtaining diagnoses, we
modelled laboratory utilisation using the diagnostic
yield data from the 127 admissions in Table 2. Spu-
tum smear-negative patients fell into three groups—
those with pleural effusions, those with lymph nodes
'1 cm and those with neither. Investigations for
patients with pleural effusions could be limited to his-
tology of pleural biopsy followed by trial of therapy
pending results of pleural fluid culture. The labora-
tory cost for the 22 patients with pleural effusion
would have decreased from US$1015 to US$570
(44% reduction), but three patients would have been
empirically treated instead of confirmed as tuberculo-
sis. Investigations for patients with lymph nodes '1 cm
can be limited to wide-needle aspirate followed by
excision biopsy if the aspirate smear is negative. The
laboratory cost for the 40 sputum smear-negative
patients with nodes '1 cm would have decreased
from US$1615 to US$445 (72% reduction), but four
patients (10%) would have required further investi-
gations to confirm the diagnosis of tuberculosis. Only
10 patients were smear-negative or unable to produce
sputum and had neither effusion nor nodes '1 cm.
DISCUSSION
Tuberculosis in patients co-infected with HIV is asso-
ciated with more extra-pulmonary disease and, as
immunity declines, more non-cavitating pulmonary
tuberculosis.14 This presents diagnostic difficulties as
sputum is often unobtainable or smear-negative. This
is reflected in the present study, where 23% of patients
were unable to produce sputum and the overall yield
of sputum smear was 43%. As we have shown, nega-
tive sputum smears are associated with diagnostic
delays. The most important resource used in the diag-
nosis of tuberculosis is bed occupancy, and the time to
diagnosis is critical.15 A more rapid diagnosis would
also reduce morbidity and mortality in HIV-infected
patients.6
The yield of sputum smear in our study was
approximately 40% per sample sent. We believe this
is an accurate reflection of HIV-associated tuberculo-
sis in in-patients, as a large number of sputum sam-
ples were assessed and the diagnosis of tuberculosis
was unlikely to be missed in our extensively investi-
gated cohort. The incremental yield of sputum smear
depends on the yield per sample sent. If this is 80%,
then '95% of cases who are sputum-smear positive
will be detected on two smears (80% positive on the
first smear and 80% positive on the remaining
20%—i.e., 96%). This was the finding of an out-
patient study in Tanzania of patients of unknown
HIV status.12 That study has influenced policy to the
extent that the South African National Tuberculosis
Programme requires only two sputum samples be sent
from clinics. In our in-patient HIV cohort with a spu-
tum smear yield of 40% per sample sent, six speci-
mens would need to be sent in order to detect '95%
of cases. However, it would waste bed occupancy to
wait for six sputum samples before embarking on
other tests. With a yield of 40% per sample, three
smears will detect almost 80% of cases—it would
thus be reasonable to proceed to invasive diagnostic
Table 2 Laboratory cost per diagnosis (calculated as the total 
cost for each investigation divided by the number of occasions 










Smear 85/220 (39) 54 $9
Culture 116/142 (82) 17 $78
Lymph node
Aspirate 8/16 (50) 8 $5
Biopsy 14/17 (82) 13 $20
Pleura
Histology 15/21 (71) 15 $20
Culture 6/9 (67) 1 $82
Pleural fluid
Smear 2/20 (10) 2 $26
Culture 12/20 (60) 4 $45
Bone marrow
Histology 5/19 (26) 3 $103
Culture 6/16 (38) 2 $67
Urine
Smear 1/26 (4) 1 $67
Culture 11/26 (42) 3 $74
Liver
Histology 3/4 (75) 1 $112*
Blood
Culture 19/45 (42) 3 $267
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tests after three negative sputum smears. Further
smears can still be sent, but the additional yield will
be progressively lower and no more than six in total
should be sent.
The observed lack of relation of CD4! lympho-
cyte count to sputum smear result is in keeping with
one previous study by Smith et al.11 but contrasts
with another by Jones et al.,16 and requires further
study. This was a surprising finding given that there
was a good correlation of the CD4! lymphocyte
count with the chest radiographic appearance, which,
as we have previously shown, correlates well with the
CD4! lymphocyte count.14
Based on our finding that most patients with spu-
tum smear-negative tuberculosis have either pleural
effusions or lymphadenopathy, we suggest a stream-
lined diagnostic approach which would result in con-
siderable savings in laboratory utilisation and bed
occupancy (Figure). Early pleural biopsy and aspira-
tion should be done in patients with pleural effusions.
The combined yield of these two procedures is very
high. Most clinicians would be comfortable continu-
ing anti-tuberculosis treatment even if histology and
cultures are negative if there is a satisfactory response.
Lymphadenopathy is significantly associated with
tuberculosis in HIV-infected patients presenting with
respiratory disease.17 Lymph node aspirates have a
high yield in HIV-associated tuberculosis.18,19 and were
under-utilised in our cohort. This was the most cost-
effective diagnostic test. Our finding that lymph node
biopsy was often diagnostic even when the nodes were
symmetrically enlarged, in contrast with tuberculous
lymphadenitis in HIV seronegative patients, is in agree-
ment with a large central African study performed by
Bem.20 Provided that the clinical picture suggests
tuberculosis, clinicians should not hesitate to biopsy
nodes that are symmetrically enlarged. Despite the
aggressive approach to diagnosis in our patients, three
patients died without treatment and without investiga-
tion, all with symmetrical lymph node enlargement.
Patients who are sputum smear-negative and have
neither effusion nor lymph nodes (only 8% in this
study), together with those with a negative lymph
node biopsy, could have a trial of therapy pending
culture results if the clinical picture is strongly sugges-
tive of tuberculosis. The specimen with the highest
culture yield in our study was sputum, whilst urine,
blood and bone marrow had a similar yield. Culture of
bone marrow aspirate or blood should be performed
wherever atypical mycobacteria are common.21,22
The yield of the two investigations is similar, but the
bone marrow trephine biopsy provides an opportu-
nity to make a rapid diagnosis if granulomas or AFB
are found (26% yield in the present study). Blood cul-
ture was an expensive diagnostic test in our study
largely because it was slow and other cultures were
often positive first. In addition, a reasonable yield of
blood cultures can only be assured by case selection
on CD4! lymphocyte count (modest yield with
counts 100–200 ( 106/l and high yield with counts
under 100),16 adding to expense. Urine culture is
valuable even in the absence of pyuria.23 Sending two
or three specimens for mycobacterial culture prior to
a trial of therapy should be sufficient—reducing the
number of specimens cultured has been identified by
others as an important area for cost savings.24
Figure Proposed diagnostic algorithm for HIV-infected patients with suspected tuberculosis.
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We believe that our findings are relevant to settings
with different resource constraints from ours. In more
resource-rich settings, more cultures could be sent
and procedures such as bronchoscopy could be used.
We obtained diagnostic confirmation of tuberculosis
without resorting to bronchoscopy (which was diffi-
cult to arrange during the study period); this is in
keeping with the finding of Daley et al. that bronchos-
copy is of little value in areas where tuberculosis is
endemic.25 In more resource-poor settings, where myco-
bacterial cultures are often unavailable, the early use of
lymph node aspirate followed by biopsy or pleural
aspirate and biopsy would yield the diagnosis in most
cases. In resource-poor settings algorithms for empir-
ical treatment based on symptoms can be used for the
remaining cases.17
Acknowledgements
We are indebted to staff at the South African Institute of Medical
Research, Green Point, Cape Town for their assistance in providing
data on tuberculosis investigations and their cost.
References
1 Lucas S B, Hounnou A, Peacock C, et al. The mortality and
pathology of HIV infection in a West African city. AIDS 1993;
7: 1569–1579.
2 Tembo G, Friesan H, Asiimwe-Okiror G, et al. Bed occupancy
due to HIV/AIDS in an urban hospital medical ward in
Uganda. AIDS 1994; 8: 1169–1171.
3 Maartens G, Wood R, O’Keefe E, Byrne C. Independent ep-
idemics of heterosexual and homosexual HIV infection in
South Africa—survival differences. Q J Med 1997: 449–
454.
4 Kitayaporn D, Tansuphaswadikul S, Lohsomboon P, et al. Sur-
vival of AIDS patients in the emerging epidemic in Bangkok,
Thailand. J AIDS Hum Retrovirol 1996; 11: 77–82.
5 Harries A D, Kamenya A, Namarika D, et al. Delays in diag-
nosis and treatment of smear-positive tuberculosis and the in-
cidence of tuberculosis in hospital nurses in Blantyre, Malawi.
Trans Roy Soc Trop Med Hyg 1997; 91: 15–17.
6 Kramer F, Modilevsky T, Waliany A, et al. Delayed diagnosis of
tuberculosis in patients with HIV. Am J Med 1990; 89: 451–456.
7 Klein N C, Duncanson F, Lenox T, et al. Use of mycobacterial
smears in the diagnosis of pulmonary tuberculosis in AIDS/
ARC patients. Chest 1989; 95: 1190–1192.
8 Elliott A M, Namaambo K, Allen B, et al. Negative sputum
smear results in HIV! patients with pulmonary tuberculosis in
Lusaka, Zambia. Tubercle Lung Dis 1993; 74: 191–194.
9 Long R, Scalcini M, Manfreda J, Baptiste M, Hershfield E. The
impact of HIV on the usefulness of sputum smears for the diag-
nosis of tuberculosis. Am J Public Health 1991; 81: 1326–1328.
10 Houston S, Ray S, Mahari M, et al. The association of tuber-
culosis and HIV infection in Harare, Zimbabwe. Tubercle
Lung Dis 1994; 75: 220–226.
11 Smith R L, Yew K, Berkowitz K, Aranda C. Factors affecting
the yield of acid-fast sputum smears in patients with HIV and
tuberculosis. Chest 1994; 106: 684–686.
12 Ipuge Y A I, Rieder H, Enarson D. The yield of acid-fast
bacilli from serial smears in routine microscopy laboratories
in rural Tanzania. Trans Roy Soc Trop Med Hyg 1996; 90:
258–261.
13 Hudson C P, Wood R, O’Keefe E. Cutaneous miliary tuber-
culosis in the AIDS era. Clin Infect Dis 1997; 25: 1484.
14 Post F A, Wood R, Pillay G P. Chest radiographic appearance
of pulmonary tuberculosis relates to the degree of HIV immu-
nosuppression. Tubercle Lung Dis 1995; 76: 518–521.
15 Harmon J C, Roche J. Development of a research-based proto-
col to rule out tuberculosis. Am J Infect Control 1995; 23:
329–336.
16 Jones B, Young S, Antoniskis D, Davidson P, Kramer F, Barnes
P. Relationship of the manifestations of tuberculosis to CD4
count in patients with HIV. Am Rev Respir Dis 1993; 148:
1292–1297.
17 Samb B, Henzel D, Daley C L, et al. Methods for diagnosing
tuberculosis among in-patients in Eastern Africa whose spu-
tum smears are negative. Int J Tuberc Lung Dis 1997; 1: 25–30.
18 Bem C, Patil P, Elliott A, et al. The value of wide-needle aspi-
ration in the diagnosis of tuberculous lymphadenitis in Africa.
AIDS 1993; 7: 1221–1225.
19 Pithie A D, Chicksen B. Fine-needle extrathoracic lymphnode
aspiration in HIV-associated sputum-negative tuberculosis.
Lancet 1992; 340: 1504–1505.
20 Bem C. Human immunodeficiency virus-positive tuberculous
lymphadenitis in Central Africa: clinical presentation of 157
cases. Int J Tuberc Lung Dis 1997; 1: 215–219.
21 Northfelt D W, Mayer A, Kaplan L, et al. The usefulness of di-
agnostic bone marrow examination in patients with HIV. J
Acquir Immune Defic Syndr 1991; 4: 659–666.
22 Modilevsky T, Sattler F, Barnes P. Mycobacterial disease in
patients with HIV. Arch Intern Med 1989; 149: 2201–2205.
23 Shafer R W, Kim D, Weiss J, Quale J. Extrapulmonary tuber-
culosis in patients with HIV. Medicine 1991; 70: 384–397.
24 Soo Hoo G W, Palmer D, Sopher R. Reducing tuberculosis de-
tection costs. Chest 1984; 86: 860–862.
25 Daley C L, Mugusi F, Chen L, et al. Pulmonary complications
of HIV in Tanzania. Am J Respir Crit Care Med 1996; 154:
105–110.
R É S U M É
CADRE : Hôpital d’Afrique du Sud affilié à l’Université.
OBJECTIF : Déterminer la durée nécessaire au diagnostic,
le rendement et le coût en laboratoire des procédés
de diagnostic dans la tuberculose associée au virus de
l’immunodéficience humaine (VIH).
SCHÉMA : Etude de cohorte.
PATIENTS : Sujets adultes infectés par le VIH et admis au
cours d’une période de deux ans pour une tuberculose
récemment diagnostiquée.
RÉSULTATS : 141 admissions ont répondu à la définition
des cas. Le rendement du frottis d’expectoration (glo-
balement 43%) est en étroite collaboration avec l’aspect
du cliché thoracique, mais non avec les décomptes de
lymphocytes CD4!. Le rendement du frottis d’expecto-
ration fut d’environ 40% par échantillon, ce qui entraîne
un rendement cumulatif élevé de l’envoi de trois échan-
tillons ou davantage. Les méthodes de diagnostic dont le
rapport coût-efficacité est le meilleur sont le frottis
d’expectoration ou la ponction-aspiration ganglionnaire
au moyen d’une grosse aiguille. Un délai significatif de
diagnostic existe chez les patients dont l’expectoration
est négative à la bacilloscopie. La plupart des patients
atteints d’une tuberculose à bacilloscopie négative dans
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raux, soit d’adénopathies. La biopsie ganglionnaire a un
rendement diagnostic élevé même chez les patients dont
les adénopathies sont symétriques, mais elle a été sous-
utilisée dans cette étude. L’on a fait des dépenses inutiles
pour des cultures chez beaucoup de patients dont plu-
sieurs cultures se sont avérées positives.
CONCLUSION : La répétition de frottis d’expectoration
entraîne un rendement cumulatif élevé dans les tubercu-
loses associées au VIH. D’importantes économies en
matière d’utilisation du laboratoire et d’occupation des
lits auraient pu être faites si une approche de diagnostic
rationnelle avait été suivie, faisant appel aux ponctions
ganglionnaires et aux biopsies pleurales ou ganglion-
naires précoces.
R E S U M E N
MARCO DE REFERENCIA : Hospital afiliado a la Univer-
sidad de Sud África.
OBJETIVO : Evaluar el tiempo de diagnóstico, el ren-
dimiento y el costo de laboratorio de los métodos de
diagnóstico en la tuberculosis asociada con VIH.
MÉTODO : Estudio de cohorte.
PACIENTES : Pacientes adultos infectados por el VIH con
tuberculosis reciente, hospitalizados en un período de
dos años.
RESULTADOS : En total, 141 pacientes hospitalizados
cumplieron los requisitos del objetivo. El rendimiento
del examen de esputos (43% del total) se relacionaba
fuertemente con las imágenes radiográficas pero no con
el recuento sérico de linfocitos TCD4. El rendimiento
del examen de esputo fue aproximadamente del 40%
por cada muestra enviada y aumentó fuertemente con el
envío de "3 muestras. El examen de esputos o la aspi-
ración con aguja de los ganglios fueron los métodos de
más alto rendimiento costo-beneficio. Existió una demora
diagnóstica significativa en los pacientes con esputo ne-
gativo. La mayoría de los pacientes con tuberculosis y
esputo negativo tenían una pleuresía o adenopatías. La
biopsia ganglionar tuvo un gran rendimiento aún en
pacientes con ganglios simétricos, pero fue poco uti-
lizada en este grupo. Existió un gasto innecesario con los
cultivos.
CONCLUSIÓN : Los análisis repetidos de esputos pro-
ducen un alto rendimiento acumulativo en la tuberculo-
sis asociada al SIDA. Se hubieran logrado ahorros con-
siderables en el uso del laboratorio y ocupación de las
camas si se hubiera recurrido más a la aspiración gangli-











Risk Factors for Developing Tuberculosis in HIV-1–Infected
Adults From Communities With a Low or Very High Incidence
of Tuberculosis
*Robin Wood, *Gary Maartens, and †Carl J. Lombard
*Department of Medicine, University of Cape Town, Cape Town; †*Centre for Epidemiological Research in South Africa,
Medical Research Council, Cape Town, South Africa
Objective: To estimate the incidence rate of tuberculosis in HIV-1–infected adults
resident in a region with a high tuberculosis prevalence and to identify clinical and
laboratory parameters associated with increased risk of developing tuberculosis.
Methods: Adult patients going to the University of Cape Town HIV clinics between
January 1986 and May 1996. The following variables were assessed for the risk of
developing tuberculosis: ethnicity, employment and education status, World Health
Organization (WHO) clinical stage, erythrocyte sedimentation rate (ESR), CD4+
count, and total lymphocyte count. Tuberculin skin test data were not available.
Results: There were 198 prevalent and 144 incident cases of tuberculosis in the
cohort of 1206 patients. The incidence rate of tuberculosis risk was 10.4/100 person
years. WHO clinical stages 3 and 4 (risk ratio [RR], 3.4; 95% confidence interval [CI],
1.8–6.4), ESR >75 mm/hour (RR, 3.5; CI, 1.8–6.5) and being a member of a high-
prevalence tuberculosis community (RR, 2.5; CI, 1.2–5.1) were independently asso-
ciated with the risk of developing tuberculosis.
Conclusions: HIV-infected adults in Cape Town are at high risk of developing
tuberculosis irrespective of tuberculin skin testing. The risk increases markedly with
HIV disease progression. Patients at extremely high risk can be identified on the basis
of demographic and clinical features. Such individuals would be suitable for targeted
tuberculosis prophylaxis.
Key Words: HIV-1—Tuberculosis, epidemiology—South Africa—CD4 lympho-
cytes—Erythrocyte sedimentation rate.
An estimated 1.7 billion people, many of whom live in
sub-Saharan Africa, are latently infected withMycobac-
terium tuberculosis(1). The spread of the HIV epidemic
in Africa has resulted in large numbers of dually infected
individuals and increasing tuberculosis (TB) incidence
rates in sub-Saharan African countries (2,3).
TB has been a disease the diagnosis of which has
required physicians to notify government authorities in
South Africa since 1921, with the highest such notifica-
tion rates being reported in Cape Town and the Western
Cape region. Before onset of the present heterosexual
HIV epidemic, this region had one of the highest re-
ported TB incidence rates in the world, at 670/100,000
per annum (4,5). The four main communities of the
Western Cape in descending order of population size are
“coloured” (a term used in South Africa to describe a
mixed race group in South Africa and used here with that
spelling to denote this particular group within the South
African context the paper describes), African, white, and
Asian. TB rates in the coloured and African communities
are extremely high, while rates in whites and Asians are
similar to those found in industrialized countries (4,5).
During the period of this study, adult HIV seropreva-
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lence increased rapidly, initially in the homosexual popu-
lation (almost exclusively white and coloured patients)
and subsequently in the heterosexual population (pre-
dominantly African) (6). An unlinked anonymous ante-
natal survey in 1994 estimated adult HIV seroprevalence
in the region to be 1.18% (7). Adult HIV seroprevalence
is increasing most rapidly in the growing periurban in-
formal settlements of Cape Town, where antenatal HIV
seroprevalence reached 7% in 1995 (Professor Moodie,
personal communication, 1996). The increasing HIV epi-
demic in a population with such a high TB prevalence
poses a major challenge to the existing TB control pro-
gram. TB prophylaxis of dually infected individuals has
recently been shown to be effective in Africa (8), but this
is difficult to implement because of the large numbers of
patients at risk and operational difficulties (9).
The aim of this study was to estimate the incidence
rate of TB in HIV-infected adults from communities with
both low and extremely high prevalence of TB, and to
assess prognostic markers that would allow identification
of patients at particularly high risk. Such groups may be
suitable for targeted TB prophylaxis.
METHODS
The study population consisted of adult patients going to the HIV
outpatient clinics of Somerest and Groote Schuur hospitals, Cape
Town, between January 1986 and May 1996. Both hospitals are teach-
ing institutions of the University of Cape Town and were the only
public sector HIV clinics in the region for most of the study period;
thus there could be no significant referral bias. The same protocols
were used at both clinics and there was partial sharing of clinical staff.
HIV-1 infection was confirmed by two enzyme-linked immunosorbent
assays (ELISAs) on two nonsimultaneous blood samples. Patients were
evaluated according to their clinical condition: those with early disease
were seen at 3- to 6-month intervals, while advanced patients were seen
monthly or more frequently if necessary.
Patients were clinically staged at each visit, using the World Health
Organization (WHO) clinical staging system (10). In this system, clini-
cal stages 1 and 2 represent early disease, stage 3 is similar to the
AIDS-related complex, and stage 4 is AIDS. The performance scale (a
symptom score) was not used for staging purposes. WHO clinical
staging was done retrospectively before December 1991 by two inde-
pendent observers with good interobserver agreement (k 4 0.91) and
prospectively after that date. Patients presenting with TB at initial visit
were excluded from subsequent cumulative risk analysis. TB was di-
agnosed by passive case-finding. The case definitions for TB were:
definite culture ofM. tuberculosisor autopsy diagnosis, probable smear
positive or granulomata on histology (with or without caseation or
smear positivity), and possible clinical response to drug therapy (short-
course rifampicin-based regimens). Cases diagnosed by clinical re-
sponse alone were only included after careful review (by Wood); ra-
diologic response was required for patients with abnormal chest radio-
graphs. Patients diagnosed in this way typically presented with
intrathoracic adenopathy or exudative lymphocytic pleural effusions
with negative cultures. Pulmonary TB was defined as a pulmonary
infiltrate, or sputum smear or culture positivity, or a pleural effusion.
Extrapulmonary TB was defined as disease not confined to pleura or
lung and included disease affecting other intrathoracic structures such
as mediastinal lymphadenopathy. Isoniazid prophylaxis was not rou-
tinely prescribed during the study period.
TB-free survival of patients (excluding TB prevalent cases) was
assessed by Kaplan-Meier analysis. Patients were censored at last visit
date and at death. The predictive value of ethnic group, employment
status, highest education level, gender, WHO clinical stage 1 to 4, CD4
T-cell count, total lymphocyte count, and erythrocyte sedimentation
rate (ESR) for subsequent TB-free survival was further investigated by
Cox-proportional hazards modeling using a stepwise selection proce-
dure (PHEG procedure, SAS software, SAS, Cary, NC, U.S.A.). Trans-
formations were used for CD4 and lymphocyte counts (logarithmic)
and ESR (square root).
RESULTS
The patient cohort consisted of 1206 adults infected
with HIV-1. There were 342 cases of TB (198 prevalent
and 144 incident cases): 38% definite, 48% probable,
and 14% possible. Pulmonary TB was present in 66%
and extrapulmonary in 34%. CD4+ T-lymphocyte counts
at the time of TB diagnosis were available for 195 pa-
tients and ranged from 1 to 823 cells/ml with a median of
113 cells/ml. The median CD4+ T-lymphocyte count at
time of pulmonary TB diagnosis was 159 cells/ml and for
extrapulmonary TB it was 90 cells/ml. Sixty five percent
of all TB and 85% of extrapulmonary TB occurred in
patients with less than 200 CD4+ T-lymphocyte/ml.
Demographic data for the 1,008 patients who did not
have TB at initial visit is shown in Table 1. There were
TABLE 1. Demographic characteristics of the 1008 patients who






















Mean ESR (mm/hour) 44 ± 41
Percentages do not always sum to 100 due to rounding
WHO, World Health Organization of the United Nations; ESR,
erythrocyte sedimentation rate; SD, standard deviation.
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1391 total person years of observation, 232 (23%) died,
and 313 (31%) were lost to follow up (defined as not
having been seen by physicians at the clinics for >12
months). The incidence rate of TB was 10.4/100 person-
years. The incidence rate of TB by race for patients with
both early and late HIV disease together with the risk
ratios compared with those found in the general popula-
tion of Cape Town (11) are shown in Table 2.
Ethnic grouping was a strong confounder of TB-free
survival and was included in all subsequent modeling.
TB-free survival did not differ significantly between Af-
rican and coloured patients (p4 .10) who were then
combined for further analysis as the high-prevalence TB
community. Similarly, there were no significant differ-
ences in TB-free survival between WHO clinical stages
1 and 2 (p 4 .69) and clinical stages 3 and 4 (p 4 .62),
so that these categories were also combined for further
analysis. There was a significantly higher (p < .001) risk
of developing TB in advanced (WHO stages 3 and 4)
versus early (WHO stages 1 and 2) HIV disease for both
high and low prevalence TB communities (Fig. 1).
WHO clinical stage was the most predictive variable
for the development of TB with ESR second, CD4+ T-
lymphocyte count third, and total lymphocyte count
fourth. Of 520 patients with complete information on all
the variables at first visit, 54 (11%) developed TB with
censored data from 466 (89%) of patients. Exploratory
analysis of TB events versus ESR revealed that the in-
cidence was stable <75 mm/hour but increased at higher
values. The predicted TB-free survival in clinical stage
3/4 patients with ESR <75 mm/hour was similar to the
survival profile of clinical stage 1/2 patients with ESR
>75 mm/hour. ESR >75 mm/hour remained strongly pre-
dictive of the subsequent development of TB after ex-
cluding patients who developed active TB within 3
months of measuring ESR (risk ratio [RR], 3.62; 95%
confidence interval [CI], 1.57–8.37).
Cox-proportional hazard modeling, demonstrated that
only ethnic group, clinical staging, and ESR contributed
significant independent information to the modeling of
TB-free survival. We found no differences in these find-
ings when data were analyzed separately for the periods
before and after December 1991 to assess the effect of
retrospectively assigning WHO clinical staging, but the
risk of developing TB was higher after December 1991
as a result of the increasing proportion of patients from
high-prevalence TB communities. CD4+ lymphocyte
count was not significantly associated with the risk of
developing TB after adjustment (RR, 1.6; 95% CI, 0.9–
2.7). Employment status and education level were not
independently associated with TB-free survival. The es-
timated risk ratios of a final multiple Cox regression
model using WHO clinical stage (3 and 4), ESR (>74
mm/hour), and high-prevalence TB community with
male gender as a control are shown in Table 3.
DISCUSSION
The high incidence rate (IR) of TB reported in this
study is the result of the development of an HIV epi-
demic in a population with one of the highest TB preva-
lence rates in the world. The overall TB IR in the Cape
Town HIV-infected population is similar to that reported
in defined high-risk HIV cohorts, such as intravenous
drug users in Madrid at 9.1/100 person-years (12), New
York at 9.8/100 person-years (13), and patients in Haiti
at 7.5/100 person-years (14). The RR for TB associated
with HIV infection in African and coloured patients with
WHO stage 1 and 2 disease is similar to that reported for
HIV-positive individuals elsewhere in Africa. HIV-
associated RRs of 4.7, 8.3, and 10 have been reported
from the Ivory Coast (15), Tanzania (16), and Zaire (17),
respectively. The high prevalence of TB in coloured and
African communities is a reflection of their poor socio-
economic circumstances (5). Socioeconomic indicators
available for analysis in the study were relatively crude
and did not include measures defining crowding or total
household income. Although the highest IRs were in Af-
rican and coloured patients, it is of interest that the high-
est RR were recorded in white patients. One possible
TABLE 2. Race-specific tuberculosis incidence rates for HIV-infected people stratified by World Health
Organization (WHO) clinical stage
Race
Tuberculosis incidence/100 person years (95% CI) Risk ratioa
WHO 1 and 2 WHO 3 and 4 WHO 1 and 2 WHO 3 and 4
White 3.5 (1.8–5.2) 7.6 (4–11.1) 140 304
Coloured 5.0 (2.7–7.3) 31.8 (19.9–43.6) 10.1 64.4
African 8.7 (5.3–12.1) 68.5 (52.7–84.3) 10.3 81.5
a Risk ratios were calculated using the general Cape Town, South Africa, population incidence (11); HIV
incidence rate (per 100 person years)/population incidence (per 100,000 per year (10−3).
Data is not shown for Asians due to their small numbers.
CI, 95% confidence intervals.
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FIG. 1. Infected patients with
World Health Organization stage
1/2 or stage 3/4 disease from (A)
low-prevalence (white and Asian)
and (B) high-prevalence (African
and coloured) tuberculosis commu-
nities. Risk of tuberculosis was sig-
nificantly higher in those with ad-
vanced HIV disease (p < .001).
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explanation for this is that white patients could have been
exposed toM. tuberculosisin our clinic waiting areas.
A major finding of this study was that the risk of
developing TB increased markedly with advancing HIV
disease. The resultant IRs in WHO stage 3 and 4 disease
exceeded the reported prevalence of positive tuberculin
skin reactivity in these communities (18), which may
reflect a high rate of acquisition of new TB infections in
patients without prior exposure. A weakness of the pres-
ent study is the absence of tuberculin skin test data. The
predictive value of tuberculin skin testing, however, is
limited in a population such as that of Cape Town with
a high immunization rate with bacille Calmette-Guérin
(5). Furthermore, anergy is likely to be common in pa-
tients with WHO stage 3 and 4 disease whose annual risk
of TB, in African and coloured patients, exceeded 30%
in the present study. We have found Mantoux induration
of >5 mm in only 24% of African and coloured patients
with WHO stage 3 and 4 disease in an ongoing isoniazid
prophylaxis study.
Although previous studies in Africa have shown a
strong association between HIV infection and TB, they
have not demonstrated a marked increase in TB inci-
dence with HIV disease progression. Two studies from
Central and West Africa have reported higher CD4+ T-
lymphocyte counts of patients with TB and HIV-
infection than in the present study (19,20). However,
both studies were limited to sputum smear–positive pul-
monary TB and would have underdiagnosed extrapulmo-
nary TB as well as the more atypical pulmonary presen-
tations associated with advanced immune suppression
(21). In contrast, autopsy studies from Zaire and the Coˆte
d’Ivoire showed evidence of disseminated TB in 41%
and 54% of AIDS patients, respectively (22,23) with a
median CD4+ T-lymphocyte counts of 88 cells/ml in the
Zaire study (22). The facilities for histology and TB cul-
ture available in our hospitals may have increased case
finding, because radiographic presentation of pulmonary
TB in our HIV-infected patients is frequently atypical
(21) and 52% of cases provided a negative result on
sputum smear. A recent prospective multicenter U.S. co-
hort study (24) found the risk of developing TB was
significantly higher in patients with a CD4+ T-
lymphocyte count <200 cells/ml.
The finding that WHO clinical staging was a more
powerful prognostic risk factor for TB than the CD4+
T-lymphocyte count is of particular importance in Af-
rica, where flow cytometry and CD4+ T-lymphocyte
counts are not generally available. The association of
high ESR with increased subsequent progression to TB
parallels the observation that ESR is a predictor of mor-
tality in HIV infection (25,26).
Prophylaxis has been shown to effectively reduce TB
in tuberculin skin test–positive HIV-infected patients in
Haiti (14) and Uganda (8). Tuberculin skin testing is
operationally difficult in resource-poor settings (9) and,
as already indicated, there is a high rate of anergy in
patients with advanced disease who are at highest risk.
Furthermore, the duration of benefit after TB prophylaxis
is short-lived (27,28). Life-long or repeated TB prophy-
laxis has been suggested, but this would cause major
operational problems. However, life-long prophylaxis
may be feasible for patients with advanced HIV infection
in high-prevalence TB communities because their sur-
vival is limited (access to antiretroviral therapy is limited
in most areas where TB is highly prevalent). Cohorts of
HIV-infected patients at very high risk for TB can be
identified by simple clinical HIV staging. Our data indi-
cate that the risk is high irrespective of tuberculin skin
test status. Patients with advanced HIV disease have ei-
ther been excluded from trials of TB preventive therapy
(8,14) or were only a small proportion of the study popu-
lation (28), thus indicating the need for further studies in
these patients.
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ClI 'IClANS SOCIID AIDS REVIEW
DOES ANTIRETROVIRAL THERAPY
HAVE A ROLE TO PLAY IN THE
CONTROL OF TUBERCULOSIS IN
SOUTH AFRICA?
Tuberculosis is the most common opportunistic infection
occurring in HIV infection in Africa.! This is especially so in
South Africa, where one of the worst TB epidemics in the
world, with disease rates more than double those observed in
other developing countries and up to 60 times higher than
those currently seen in the USA or Western Europe, is raging.
There is great variation among the South African provinces,
and the worst hit is the Western Cape, with incidence rates of
approximately 600/100 000 reported in 1996. These numbers
have been projected to increase considerably with the HIV
epidemic unless effective control is achieved, and will result in
an estimated 3.5 million new cases of TB by 2005 and a
staggering 90 000 deaths - all due to a treatable and fully
curable illness2 (Fig. 1).
804 in 1997 to 957 in the first quarter of 2000.' We have learnt
many lessons from the Hlabisa area in KwaZulu-Natal, where
the extremely high HIV rates have had an adverse impact on
TB and the TB programme in the district.' The current strategy
of the national TB control programme, based on positive
sputum smears, passive surveillance and emphasis on
improving treatment completion rates, is failing to control this
HIV-driven TB epidemic.
IMPACT OF HIV ON THE INDIVIDUAL WITH
TB
Patients infected with HIV are at increased risk of both
reactivation and new-infection TB, particularly as their
immunity declines with advancing HIV infection. In a large
group of patients with advanced HIV from a high TB
prevalence area in Cape Town the median time to development
of TB was 20 months (with incidence rates of 31.8 - 68.5/100
per year of follow-up)' (Fig. 2). In addition, we know that the
diagnosis of TB has serious survival implications for these
patients. It has been shown in HIV-infected patients in Cape
Town that a diagnosis of TB was associated with an increased
risk of death at all CD4+ T-cell counts." Tuberculosis results in
an increase in HIV replication and elevated viral loads months
after the TB is diagnosed and the patient otherwise appears to
be responding favourably to TB treatment.7"




--. WHO Silage 1&2
...
j
R.Wood, <I al. AIDS 2000; 23:75·80





CUrrent t=1d tcriinued , ',,,,,,,
,







1994 95 96 97 98 99 2000 01 02 03 04 2005
Fig. 1. Predicted tuberculosis incidence rates/lOO 000 papulation at
current rates of increase and modelling to show what can be achieved
if the HNITB epidemic were controlled.
IMPACT OF HIV ON THE TB EPIDEMIC
It is clear that this epidemic must have a severe public health
impact as numbers of cases of HIV-associated TB increase and
overwhelm TB programmes and primary care health services.
For example, TB incidence rates per 100 000 population in a
high-prevalence reporting district in Cape Town increased from
August 2001, Vol. 91, No. 8 SAMJ
Fig. 2. Kaplan-Meier plots of tuberculosis-free survival for HIV-
infected patients with WHO stage 1 and 2 or 3 and 4 from high-
prevalence (black and coloured) tuberculosis communities. Risk was
significantly higher in advanced HN disease (P < 0.001).
It is dear that if we are to prevent this morbidity and
mortality on an individual as well as a community basis some
new and specific strategies need to be considered. While
increased resources should certainly go into further improving
and strengthening TB programmes, it has been shown through
mathematical modelling that this will be insufficient on its
. own." Strategies such as active case-finding, recommended by
the World Health Organisation in their report on the global
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HIV/ AIDS epidemic in June 2000,1° as well as INH prophylaxis
in HIV-infected individuals, are modalities that will not be
discussed further here. A further strategy on which little has
been written is the use of antiretroviral therapy (ART) to
reduce the incidence and impact of tuberculosis.
IMPACT OF ART ON TB EPIDEMICS IN THE
WORLD
ART has been shown to reduce the incidence of TB in HIV-
positive patients in developed countries. In Italy it has been
noted that there has been a decline in cases of TB following the
introduction of highly active ART (HAART).1l In a large cohort
of HIV patients from 11 US cities where the TB incidence was 5
cases/1 000 years, the risk of TB was much lower among those
taking HAART (relative risk (RR) 0.2, 95% confidence interval
0.1 - 0.5) than among those not prescribed HAART .12 Owing to
lack of access to HAART in developing countries where TB
rates are considerably higher, the efficacy of ART in preventing
TB in these settings has not been established. Recent data from
Cape Town have just become available, and the following very
encouraging findings have been reported.13
In this study, 378 patients on antiretroviral therapy attending
a University of Cape Town HIV clinic from 1996 to 2001 were
compared with 562 similar control patients not on ART and
attending the same clinic from 1992 to 1996. The patients had
advanced disease. Those treated had median baseline CD4 T-
cell counts of 244 and median log'O viral loads of 5.4, and 40%
of patients were at World Health Organisation clinical stages 3
or 4. Adherence to ART in this group was remarkably high -
92% at 48 weeks.
Using a strict case definition of tuberculosis, TB incidence
was 9.9/100 per year in the untreated control group and
decreased to 2.1/100 per year in the triple therapy group,
despite similar background TB rates in the population over
both periods.
With Cox proportional hazards modelling adjusting for age,
clinical stage, baseline CD4 level and ethnicity, the adjusted RR
for dual (some patients had been on two antiretroviral agents
only) and triple therapy was 0.28 and 0.11 respectively, which
was highly significant (Fig. 3).
Predictive variables in the triple therapy arm were baseline
CD4+ T-eell count of less than 200 (adjusted RR 2.6) and
clinical stages 3 and 4 (adjusted RR 2.7), while for each log
increase in baseline viral load the adjusted RR increased by 3.1.
Reduced adherence to antiretroviral therapy « 90% of tablets
taken over the study period) was strongly associated with
development of tuberculosis in these patients (adjusted RR
122).
These data show that antiretroviral therapy significantly
decreases the incidence rate of tuberculosis, even in a setting
where TB rates are among the highest in the world, and may be
a powerful strategy for the control of HIV-associated
tuberculosis even when programmes and health services are
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Fig. 3. Adjusted relative risk for developing tuberculosis in an HIV-
Injected Cape Town cohort on dual or triple antiretToviral agents
compared with those not on antiretroviral treatment.
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Summary
Background Studies of the effect of highly active
antiretroviral therapy (HAART) on the risk of HIV-1-
associated tuberculosis have had variable results. We set
out to determine the effect of HAART on the risk of
tuberculosis in South Africa.
Methods We compared the risk of tuberculosis in 264
patients who received HAART in phase III clinical trials and
a prospective cohort of 770 non-HAART patients who were
attending Somerset Hospital adult HIV clinic, University of
Cape Town, between 1992 and 2001. Poisson regression
models were fitted to determine risk of tuberculosis;
patients were stratified by CD4 count, WHO clinical stage,
and socioeconomic status.
Findings HAART was associated with a lower incidence of
tuberculosis (2·4 vs 9·7 cases per 100 patient-years,
adjusted rate ratio 0·19 [95% CI 0·09–0·38]; p0·0001).
This finding was apparent across all strata of
socioeconomic status, baseline WHO stage, and CD4
count, except in patients with CD4 counts of more than
350 cells/L. The number of tuberculosis cases averted by
HAART was greatest in patients with WHO stage 3 or 4
(18·8 averted cases per 100 patient-years, adjusted rate
ratio 0·22 [0·09–0·41]; p=0·03) and in those with CD4
counts of less than 200 cells/L (14·2 averted cases per 
100 patient-years, adjusted rate ratio 0·18 [0·07–0·47];
p0·0001).
Interpretation HAART reduced the incidence of HIV-1-
associated tuberculosis by more than 80% (95% CI 62–91)
in an area endemic with tuberculosis and HIV-1. The
protective effect of HAART was greatest in symptomatic
patients and those with advanced immune suppression.
Lancet 2002; 359: 2059–64
Introduction
More than 70% of the 36·1 million HIV-1-infected
individuals worldwide live in sub-Saharan Africa, and 
a high proportion of these are co-infected with
tuberculosis.1,2 An accelerated course of HIV-1 infection
after the onset of tuberculosis has been reported in many
studies.3–6
Tuberculosis is the leading cause of morbidity 
and mortality among HIV-1-infected patients in 
sub-Saharan Africa.7–9 Unlike other HIV-1-related
opportunistic infections, tuberculosis occurs at all levels
of CD4 count,9–11 is infectious, and its prevention is a
major public-health priority.
Tuberculosis control programmes based on passive
case finding and treatment of sputum-smear-positive
disease by short-courses of directly observed chemo-
therapy (DOTS) have been successful in developed
countries. However, these strategies have failed to
achieve similar success in countries with high burdens 
of HIV-1 inf ction.12,13 Consequently, WHO has
formulated a strategic framework aimed at functional
integration of control programmes for tuberculosis and
HIV/AIDS.14
The survival benefits associated with highly active
antiretroviral therapy (HAART) are well documented;
however, studies assessing the effect of HAART on
tuberculosis have shown variable results. Although some
studies have shown that HAART can reduce the risk of
tuberculosis by more than 80%,15–17 others have reported
no significant reduction.18,19 No similar studies have been
done in sub-Saharan Africa because only a tiny minority
of the population presently has access to HAART. The
UN has mobilised the Great Global Alliance to facilitate
increased access to antiretroviral therapy in resource-
limited settings.20
We did an observational study to compare the risk of
tuberculosis in indigent cohorts of HIV-1-infected
patients without access to HAART and in those
receiving this treatment through participation in phase
III randomised trials at a public health-care facility in
Cape Town, South Africa.
Methods
Patients
New Somerset Hospital HIV Clinic, University of Cape
Town, South Africa, is a major public health-care
facility dedicated to HIV-1-infected patients in Cape
Town. It was established in 1986, and serves largely
indigent patients who are referred to the clinic from a
wide range of primary health-care facilities in Cape
Town. Antiretroviral therapy is not available in the
public sector in South Africa, and patients access
HAART through participation in clinical trials. Patients
who expressed interest in joining the ongoing HAART
clinical trials at the hospital were invited to participate
on a first-come first-served basis. The desired sample
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sizes were achieved in all the clinical trials. All studies
were fully recruited. Participants gave informed consent,
and protocols were approved by the University of Cape
Town Clinical Research Ethics Committee.
Inclusion criteria common to all 12 HAART clinical
trials carried out between 1995 and 2001, from which the
treated cohort of this study was accrued, were: age at least
16 years; a minimum baseline plasma HIV-1 RNA
concentration of 1000–5000 copies/mL (5000–30 000
copies/mL range in one study); and a CD4 count of more
than 50 cells/L (one trial), more than 100 cells/L (three
trials), more than 200 cells/L (two trials), less than 
200 cells/L (one trial), and less than 350 cells/L (one
trial). The remaining four had no CD4 restrictions.
Exclusion criteria were: acute opportunistic infection,
significant laboratory abnormalities, current evidence of
active substance abuse, pregnancy or lactation, and
treatment with immune-modulating or systemic chemo-
therapeutic agents. All patients received at least 
three antiretroviral drugs: a non-nucleoside reverse
transcriptase inhibitor with two nucleoside analogues,
three nucleoside analogues, or a protease inhibitor 
with two nucleoside analogues. Follow-up was every 
2–3 months, or more frequently if clinically indicated. At
each visit, the attending health-care personnel recorded
clinical, immunological, and virological information.
Patients who presented to the clinic between 1992 and
2000, and who were not participating in the clinical trials,
were included in the study as a comparison group. In 
this cohort, patients were followed up every 3–6 months, or
more frequently if clinically indicated. CD4 count was
measured about every 6 months by flow cytometry. Owing
to resource constraints, viral-load measurements were not
available in public health-care facilities, and therefore were
not analysed in this group. HIV-1 infection was confirmed
by ELISA or western blot on two blood specimens. At each
visit, the patient’s disease was staged by use of WHO
clinical criteria,21 and laboratory data were recorded.
Patients who were taking antiretroviral monotherapy or
dual therapy were excluded from this study.
To account for variability in socioeconomic
circumstances in the two cohorts, the Cape Metropolitan
Council suburbs composite index was used.22 This index
is based on household income (proportion of households
earning less than US$1500 per year), education level
(proportion of adults with less than 8 years of schooling),
unemployment status (unemployed adults who are
actively seeking work as a proportion of all adults), welfare
status (proportion of household heads who are single
women with three or more children), and overcrowding
status (households with more than 1·5 people per
habitable room). In this composite index, a score of more
than 28·5 correlated well (r=0·7) with poor living
conditions,22 and therefore patients were categorised into
low or high socioeconomic status by means of this cut-off.
Further uniform exclusion criteria were applied to both
cohorts. Patients were excluded if they presented with
tuberculosis at their initial clinic visit, if the diagnosis of
tuberculosis did not fulfil the case definition, or if they
had used prophylactic isoniazid 6 months before
presentation or at any time during follow-up. The
tuberculosis case definition in this study was either
“definite” (culture of Mycobacterium tuberculosis or an
autopsy diagnosis of active tuberculosis) or “probable”
(presence of acid-fast bacilli or a histological finding of
caseating granulomata).
Statistical analysis
Differences in proportions were compared by 2 test, and
differences in means by Student’s t test. Time to
tuberculosis was calculated as the time from the initial
clinic visit to the date of confirmed diagnosis. Tuberculosis
incidence was defined as the number of new episodes
occurring in each group per 100 patient-years of follow-up.
The analysis was further stratified by the baseline CD4
count, WHO clinical stage, and socioeconomic status.
Number of tuberculosis cases averted by HAART was
calculated with the adjusted rate ratio estimates of the
Poisson multivariate regression analyses described later,
and was reported with 95% CI (calculated by Poisson
distribution). The choice of Poisson regression was based
on the small frequency of tuberculosis events in the
HAART cohort. All tests were two-sided and a p value of
0·05 was regarded as significant.
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HAART Non-HAART Adjusted risk ratio p Adjusted number of 
Number of cases Patient- Incidence* Number of cases Patient- Incidence* (95%CI) cases averted (95% CI)
of tuberculosis years of tuberculosis years
Overall 9 375·1 2·4 82 848·2 9·7 0·19 (0·09–0·38) <0·0001 7·3 (4·7–9·8)
CD4 count (cells/L)
<200 5 148 3·4 41 235 17·5 0·18 (0·07–0·47) <0·0001 14·2 (9·7–19·7)
200–350 2 121·2 1·7 27 225 12·0 0·12 (0·03–0·53) <0·0001 10·6 (6·8–15·9)
>350 2 100·1 2·0 14 388·3 3·6 0·36 (0·1–1·74) 0·78 2·3 (1·1–4·4)
WHO stage
1 or 2 1 219 0·5 36 657·4 5·5 0·08 (0·01–0·57) 0·01 5·1 (3·45–7·1)
3 or 4 8 172·75 4·6 46 190·8 24·1 0·22 (0·09–0·41) 0·03 18·8 (13·2–26·1)
Socioeconomic status
Low 6 166·21 3·6 65 514·34 10·9 0·21 (0·09–0·49) <0·0001 8·6 (6·2–11·5)
High 3 208·89 1·44 17 333·86 5·09 0·17 (0·05–0·57) <0·0001 4·2 (2·3–7·0)
HAART=highly active antiretroviral therapy. *Per 100 patient-years.
Table 2: Tuberculosis incidence and cases averted, stratified by baseline CD4 count, WHO stage, and socioeconomic status
HAART Non-HAART p
(n=264) (n=770)
Mean (SD) age (years) 34·5 (9) 32·9 (9) 0·51
Number of women 115 (44%) 497 (65%) <0·0001
Number with WHO stage 3 or 4 122 (46%) 227 (29%) <0·0001
CD4 T-lymphocyte count 
(cells/L)
Median (IQR) 254 (140–364) 303 (159–468) 0·01*
<200 102 (38%) 233 (32%) 0·08
200–350 90 (35%) 189 (26%) 0·01
>350 72 (27%) 310 (42%) <0·0001
NA .. 38 (5%) ..
Mean viral load (log10 5·4 NA
[copies/L])
Number with low socio- 120 (46%) 454 (59%) 0·0003
economic status
HAART=highly active antiretroviral therapy. NA=not available. *Median test.
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The Kaplan-Meier technique and the generalised 
log-rank test were used to construct and compare 
the tuberculosis-free survival probabilities curves of the two
groups. Tuberculosis-free survival was defined as the time
from inclusion to the date of tuberculosis diagnosis, to
death from any cause, or to the last follow-up visit. Patients
who were switched over from the non-HAART to the
HAART cohort contributed survival time to both cohorts:
for the non-HAART cohort from their initial clinic visit to
the date they started HAART, and to the HAART cohort
from date of starting HAART until the date of tuberculosis
diagnosis, death, or the last follow-up visit. To compare
survival in the two cohorts by baseline immunological and
clinical status, the Kaplan-Meier analysis was further
stratified by baseline CD4 count (<200, 200–350, and
>350 cells/L) and WHO clinical stage (1 or 2, 3 or 4).
Univariate and multivariate Poisson regression models
were fitted to determine risk of tuberculosis, which was
expressed as a rate ratio. Sex, socioeconomic status,
baseline age, year of presentation, CD4 count, and
clinical WHO stage were considered for inclusion into
the multivariate analysis as potential confounding
variables if they were significantly associated with the
risk of tuberculosis in the univariate analyses. Age 
was modelled as a categorical variable (less or greater
than the mean age of the patient’s cohort). Female sex
and WHO stage 1 or 2 were modelled as baseline risk 
for sex and clinical WHO stage. To validate our results,
we did further analyses on the subsets of patients 
with baseline WHO stage 1 or 2, and stage 3 or 4
separately. CD4 count was tested for normality using the
Shapiro-Wilks’ W test and was later log-transformed
when found to be non-normally distributed. EpiInfo
(version 6.0; CDC, Atlanta, GA, USA), STATISTICA
(release 6.6, Tulsa, KA, USA), and STATA 
(version 6.0, College Station, TX, USA) software were
used for data analysis.
Role of the funding source
The funding source had no role in the data collection,
analysis, or interpretation, or the decision to submit the
study for publication.
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Results
1085 patients in the non-HAART cohort and 270 patients
in the HAART cohort were studied. 315 patients were
excluded from the non-HAART cohort: 79 were on
antiretroviral monotherapy or dual therapy, isoniazid
prophylaxis, or both; 222 presented with tuberculosis at
their initial clinic visit; and 14 incident cases received
tuberculosis chemotherapy but did not meet the
tuberculosis case definition. The remaining 770 patients
were included in the analysis. Of the 270 patients recruited
in the HAART trials, two patients who presented with
tuberculosis at their initial clinic visit, and four who started
tuberculosis chemotherapy but did not meet tuberculosis
case definition were excluded from the study. The
remaining 264 patients included in the analysis received
HAART. 40 patients who started off in the non-HAART
cohort switched to the HAART cohort.
The baseline demographic and clinical characteristics of
both cohorts are shown in table 1. Mean age in the two
groups did not differ significantly, but the proportion of
women in the non-HAART cohort was significantly higher
than in HAART cohort, probably due to the systematic
exclusion of pregnant or lactating women in the HAART
cohort. At baseline, the HAART cohort had more clinical
advanced HIV-1 disease and lower CD4 counts than the
non-HAART cohort. Baseline CD4 count was not available
for 38 patients in the non-HAART cohort.
Mean follow-up in the HAART cohort was significantly
greater than in the non-HAART cohort (16·8 months [SD
8·3] vs 13·2 months [15·5]). During follow-up, nine cases of
tuberculosis (four probable and five definite) were reported
in the HAART cohort compared with 82 cases (48 probable
and 34 definite) in the non-HAART cohort (unadjusted
rate ratio 0·15 [95% CI 0·08–0·32]; p0·0001, table 2).
The rate ratio remained significant when patients were
stratified by baseline WHO stage or CD4 count, except in
the stratum of patients with CD4 count of more than 
350 cells/L. The greatest number of tuberculosis cases
averted by HAART was in the subset of patients with
baseline WHO stage 3 or 4 (table 2).
A similar trend to that reported in the above stratified
incidence analysis was seen in the tuberculosis-free survival
proportions in the stratified Kaplan-Meier analysis of the
two cohorts shown in the figure. Overall median
tuberculosis-free survival in the HAART cohort was
significantly greater than that of the non-HAART cohort,
and across all strata of WHO stages and CD4 counts, but
not in the stratum of more than 350 CD4 cells/L.
We did a separate analysis to ascertain the outcome of
the 38 patients with missing baseline CD4 count in the
non-HAART group. The proportion of tuberculosis
cases occurring in this group (five of 38 [13%]) was not
significantly different from that of patients in the non-
HAART cohort for whom baseline values were available
(82 of 770 [11%]; p=0·8). Tuberculosis-free survival
was also similar in the two groups (p=0·42).
Poisson multivariate regression analysis revealed that,
after controlling simultaneously for baseline differences,
HAART conferred an independent protective benefit
against risk of tuberculosis (table 3). Other predictors of
tuberculosis were WHO stage 3 or 4, low socioeconomic
status, and baseline CD4 count (table 3). In the
univariate analyses, sex (female, rate ratio 1·45 [95% CI
0·93–2·28]; p=0·07) and age (greater or less than mean
age, 0·78 [0·51–1·20]; p=0·09), and year of presentation
(0·99 [0·91–1·08]; p=0·87) were not significantly
associated with the risk of tuberculosis and were thus
not included in the multivariate analysis.
In a separate subset, an independent and consistent
protective benefit of HAART was seen in multivariate
analyses of patients with baseline WHO stage 1 or 2 or
stage 3 or 4 (table 3). The adjusted risk of tuberculosis
associated with CD4 count (log10 baseline) was
significant in the multivariate analysis of patients 
with baseline WHO stage 1 or 2, but not in patients 
with baseline WHO stage 3 or 4. Conversely, low
socioeconomic status was associated with increased risk
of tuberculosis in the subset analysis of WHO stage 3 or
4 but not of WHO stage 1 or 2 (table 3).
Discussion
We have shown a substantial reduction in tuberculosis
incidence attributable to HAART in HIV-1-infected
individuals in sub-Saharan Africa. This study differs
from previous reports because the high frequency of
tuberculosis in our cohort allowed quantification of the
protective effect of HAART at the different stages of
HIV-1 disease. The effect of HAART was significant
across all the baseline immunological, clinical, and
socioeconomic variables in our cohort, except in
patients with CD4 counts of more than 350 cells/L.
The greatest number of tuberculosis cases averted by
HAART was in patients with baseline WHO clinical
stage 3 or 4 and those with CD4 counts of less than 
200 cells/L.
The overall tuberculosis risk reduction estimate of
81% (95% CI 62–91) associated with use of HAART 
in this study is similar to that reported in two studies
from the USA and Italy (80% and 92%, respectively).16,17
Brodt and colleagues18 found no significant tuberculosis
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Rate ratio (95% CI)
Univariate p Multivariate p
analysis analysis
General cohort
HAART 0·25 (0·13–0·50) 0·0001 0·19 (0·09–0·38) <0·0001
CD4 count (log10 baseline) 0·45 (0·11–0·62) <0·0001 0·67 (0·47–0·99) 0·03
WHO stage (3 or 4) 3·48 (1·17–5·29) <0·0001 4·28 (2·64–6·95) <0·0001
Low socioeconomic status 1·67 (1·02–2·59) 0·02 1·59 (1·01–2·50) <0·0001
WHO stage 1 and 2
HAART 0·10 (0·01–0·74) 0·02 0·07 (0·009–0·55) 0·01
CD4 count (log10 baseline) 0·28 (0·13–0·59) 0·001 0·18 (0·08–0·43) <0·0001
Low socioeconomic status 1·56 (0·77–3·16) 0·22 1·39 (0·69–2·84) 0·35
WHO stage 3 and 4
HAART 0·19 (0·09–0·42) <0·0001 0·21 (0·10–0·46) 0·039
CD4 count (log10 baseline) 0·89 (0·56–1·45) 0·66 0·89 (0·57–1·42) 0·65
Low socioeconomic status 2·17 (1·23–3·81) 0·008 1·83 (1·03–3·24) 0·03
HAART=highly active antiretroviral therapy.
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reduction during a 5-year period in which HAART 
use in a German cohort increased from 5·7% to 87·3%.
Moreover, although there was a tendency towards a
lower risk of tuberculosis with HAART use in a study by
Santoro-Lopes and colleagues from Brazil,19 the
adjusted estimate was not significant. However, only 41
individuals received HAART in that study.
The number of tuberculosis cases averted is a function
of both risk reduction due to HAART and tuberculosis
incidence. The overall tuberculosis incidences in the
studies from the USA and Italy were low (0·5 and 0·79
per 100 patient-years, respectively);16,17 rates were higher
in the studies by Brodt and colleagues (2·1 per 100
patient-years)18 and Santoro-Lopes and colleagues (8·4
per 100 patient-years)19 because only patients with
advanced HIV-1 disease (CD4 counts <200 cells/L
and <15%, respectively) were enrolled. Although the
overall tuberculosis incidence in our study was 7·4 per
100 patient-years, patients with CD4 counts of less than
200 cells/L had a tuberculosis incidence of 12 per 100
patient-years, which is a substantially higher rate than
those reported in these studies.
Owing to current international funding initiatives 
and decreasing cost, access to HAART is expected to
increase in resource-constrained countries. Our results
are of particular relevance to the recently proposed
WHO guidelines for the scaling up of antiretroviral 
therapy in resource-limited settings. These guidelines
recommend starting antiretroviral therapy in adult and
adolescent HIV-1-infected patients with WHO stage 4
disease or a CD4 count of 200 cells or fewer per L.20 In
the light of these recommendations, our analyses suggest
that starting HAART in these two groups will result 
in prevention of 14–20 cases of tuberculosis per 
100 patient-years of treatment. However, tuberculosis
incidence remained high in these groups and in
individuals with CD4 counts of between 200 and 
350 cells/L, despite the substantial numbers of
tuberculosis cases averted by HAART.
Initiation of HAART in patients with CD4 counts of
less than 350 cells/L will have large cost implications,
particularly in resource-constrained settings. Therefore,
tuberculosis preventive therapy, which has been
reported to reduce the risk of tuberculosis in HIV-1-
infected patients with a tuberculin-positive skin test
(PPD) by more than 40%,23,24 might be a more attractive
alternative for reducing risk of tuberculosis in patients
with CD4 counts between 200 and 350 cells/L.
In multivariate analysis, low socioeconomic status was
independently associated with increased risk of
tuberculosis in the general cohort and in patients with
baseline WHO stage 3 or 4, but not in those with baseline
WHO stage 1 or 2. 56% of our cohort were socially
deprived and lived in areas characterised by high rates of
tuberculosis infection and poor living conditions. These
factors, compounded with advanced HIV-1 disease,
resulted in extremely high tuberculosis rates.
Our study has some limitations. Tuberculosis
prophylaxis of PPD-positive individuals was not part of
the national tuberculosis control programme during the
study period, and PPD test results were not available in
our cohort. Latent tuberculosis infection is, however,
prevalent in our local population. In more than 900
antiretroviral-therapy-naive patients with confirmed 
HIV-1 infection at a voluntary counselling centre in
Cape Town, PPD positivity was 55%.25 We have
adjusted in our multivariate analysis for factors known
to be associated with overt tuberculosis disease in our
setting.26
The observational design of our study is a further
limitation, but because of the recognised survival
benefits of HAART, a randomised placebo-controlled
trial in patients with advanced HIV-1-disease at high
risk of tuberculosis would not be ethically justifiable.
The two cohorts in our study were largely self-selected
and the HAART cohort was under trial-determined
conditions with fairly intense follow-up that might lead
to greater opportunity to diagnose tuberculosis.
Unmeasured factors such as viral load, which was not
available for the non-HAART cohort, could account for
some of the higher tuberculosis incidence in this group.
The two cohorts were not strictly contemporaneous, but
year of presentation was not a significant factor for the
risk of tuberculosis in our analysis. Data on baseline
CD4 count were not available for 38 patients in the non-
HAART cohort. However, survival and tuberculosis
incidence in this group was not different from that of
patients in whom baseline CD4 counts were available.
The median follow-up in our cohort was limited;
however, the number of tuberculosis events was higher
than that reported in all previous studies.
In conclusion, our study has quantified the added
benefit of tuberculosis reduction that would result from
expanded access to HAART, as proposed by WHO, in a
setting of high tuberculosis and HIV-1 prevalence. 
The decrease in tuberculosis incidence with HAART was
substantial, but immune-compromised and symptomatic
individuals were still at unacceptably high risk of
developing active tuberculosis. Tuberculosis preventive
therapy remains an important strategy for patients with
early HIV-1 disease. However, because social deprivation
was shown to be a significant risk factor for tuberculosis in
this group, medical interventions cannot be separated
from the need for social improvement. Our findings
suggest that HIV-1 control is required for effective
tuberculosis control, and that HAART can have a critical
role in addressing the therapeutic nihilism surrounding
the HIV-1 and tuberculosis co-epidemic in South Africa
and other African countries.
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How effectively does HAART restore immune
responses to Mycobacterium tuberculosis?
Implications for tuberculosis control
Stephen D. Lawna,b, Linda-Gail Bekkera and Robin Wooda
Use of highly active antiretroviral treatment (HAART) has had a major impact on
HIV-associated morbidity and mortality in industrialized countries. Access to HAART is
now expanding in low-income countries where tuberculosis (TB) is the most important
opportunistic disease. The incidence of TB has been fuelled by the HIV epidemic and in
many countries with high HIV prevalence current TB control measures are failing.
HAART reduces the incidence of TB in treated cohorts by approximately 80% and
therefore potentially has an important role in TB control in such countries. However,
despite the huge beneficial effect of HAART, rates of TB among treated patients
nevertheless remain persistently higher than among HIV-negative individuals. This
observation raises the important question as to whether immune responses to
Mycobacterium tuberculosis (MTB) are completely or only partially restored during
HAART. Current data suggest that full restoration of circulating CD4 cell numbers
occurs only among a minority of patients and that, even among these, phenotypic
abnormalities and functional defects in lymphocyte subsets often persist. Suboptimal
restoration of MTB-specific immune responses may greatly reduce the extent to which
HAART is able to contribute to TB contr l at the community level because patients
receiving HAART live much longer and yet would maintain a chronically heightened
risk of TB.  2005 Lippincott Williams & Wilkins
AIDS 2005, 19:000–000
Keywords: HIV, Mycobacterium tuberculosis, tuberculosis, antiretroviral,
HAART, immune reconstitution
Introduction
Since the mid 1990s, use of highly active antiretroviral
treatment (HAART) has been associated with a dramatic
decline in HIV-associated morbidity and mortality in
many high-income countries [1–3]. Suppression of viral
replication permits both quantitative and functional
reconstitution of the immune system [4–6]. Primary
and secondary prophylaxis for opportunistic pathogens
such as cytomegalovirus, Pneumocystis jirovecii, Mycobac-
terium avium complex (MAC), Toxoplasma gondii and
Cryptococcus neoformans can be discontinued as functional
host responses to these organisms are gradually restored
[7–10]. The risk of recurrence of these opportunistic
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infections is generally very low once blood CD4 cell
counts have reached stable levels > 200  106 cells/l [7].
Thus, substantial clinical benefit is achieved without full
restoration of circulating CD4 cell numbers. It remains
unclear, however, whether long-term viral suppression by
HAART can effect complete quantitative and functional
restoration of the immune system. Moreover, the optimal
timing for initiation of HAART to preserve capacity for
restoration remains to be determined.
The extent of immune restoration has important
implications for the pattern of opportunistic infections
occurring during HAART. Partial immune restoration
may be sufficient to prevent disease from low virulence
opportunistic pathogens such as disseminated MAC that
develops exclusively in patients with profound immu-
nodeficiency. However, more virulent pathogens such
as M. tuberculosis (MTB) cause disease across the full
spectrum of HIV-associated immunodeficiency [11]
and restoration of MTB-specific functional immune
responses that is only partial will result in a persistently
heightened risk of tuberculosis (TB). The differential
impact of HAART on host responses to pathogens has
contributed to major changes in disease epidemiology
in the HAART era. For example, TB is now the most
frequent HIV-associated mycobacteriosis in Europe
whereas the incidence of disseminated MAC was twice
that of TB in the pre-HAART era [12].
Access to HAART is expanding in many low-income
countries where the spectrum of opportunistic infections
differs from that in high-income countries [13]. It is
not yet clear how HAART will impact this burden of
HIV-associated disease. TB is the opportunistic infection
of prime importance and is the leading cause of morbidity
and mortality among HIV-infected patients living in
sub-Saharan Africa [14,15]. An estimated 31% of cases
and 39% of TB deaths are attributable to HIV [16] and
case series indicate that up to 80% of patients with TB are
co-infected with HIV. In some townships in Cape Town,
South Africa, HIV prevalence rates among antenatal
women are approximately 30% and the incidence of
TB in these communities has increased to around
1400/100 000 per year (unpublished data). Among
HIV-infected patients with World Health Organization
(WHO) stage 3 and 4 disease in Cape Town, the
incidence of TB is extremely high with 24.1 cases per
100 patient-years [17].
The existing TB control strategy of case-finding and
directly observed treatment of sputum smear-positive
patients using short-course antituberculosis treatment
is not proving adequate in countries with a high burden
of HIV [18,19]. WHO has therefore formulated a
strategic framework aimed at functional integration
of control programmes for TB and HIV/AIDS [20].
HAART is one element within this framework.
However, whether widespread use of HAARTwill prove
an effective tool in TB control at the community level is
not yet known.
The extent to which HAART will have an effect on TB
control will be determined, in part, by the rate and extent
to which functional immune responses to MTB are
restored. Epidemiological, clinical and laboratory data
all provide evidence that HAART restores host responses
to MTB. These data include: (i) reductions in incidence
of TB; (ii) alterations in the clinicopathological features of
the disease; (iii) changes in skin test responses to purified
protein derivative (PPD); and (iv) laboratory data show-
ing improvements in functional responses of circulating
lymphocytes. However, data are also emerging that
suggest that immune restoration during HAART is
incomplete and that an ongoing heightened risk of TB
persists during long-term treatment. The magnitude of
this risk is likely to reflect time-dependent changes in host
immune function. Here we review these data and discuss
the potential of HAART in TB control.
Impact of HAART on the incidence of TB
With one exception [21], studies conducted in countries
with low [12,22–24] or high [17,25] prevalence of TB
have shown that HAART is associated with substantial
reductions in risk of TB in the order of 70–90% among
HIV-infected cohorts (Table 1). In Cape Town, South
Africa, this impact was significant across all the baseline
immunological, clinical and socioeconomic variables,
except for patients with blood CD4 cell counts
>350  106 cells/l [17]. The greatest number of TB
cases averted by HAART was in patients with baseline
WHO clinical stage 3 and 4 and those with CD4 cell
counts of <200  106 cells/l (Fig. 1). These studies
suggest that expanding access to HAART may have a
beneficial impact on TB control in high prevalence
countries.
However, emerging data also suggest that although TB
rates in treated cohorts decrease following initiation of
HAART, rates remain persistently higher than among
HIV-negative individuals. This observation has been
made in countries with a low and high burden of TB.
Among the Swiss cohort, in which the median pre-
HAART CD4 cell count was 188  106 cells/l, an
elevated though diminishing rate of TB was observed for
at least the first 6 months of HAART [22]. Certainly a lag
time exists between the initiation of HAART and the
restoration of sufficient levels of anti-mycobacterial
immune function that are able to exert a protective
effect. High but diminishing rates of TB after commence-
ment of HAART are likely to reflect time-dependent
reductions in residual immunodeficiency, the duration
and extent of which may well depend on the nadir CD4
cell count. Immune reconstitution disease (IRD) may also










contribute to TB incidence in the initial months of
HAART (see below); active but subclinical TB among
profoundly immunodeficient patients may manifest as
host immune responses are restored [26,27].
An increased rate of TB during HAART is not simply a
short-term phenomenon. An observational study in Italy
of HIV-associated TB in the era of HAART described
factors associated with 271 cases incident cases [28]. Of
these, 30.3% were receiving HAART prior to TB
diagnosis and this treatment had been prescribed for a
median of 27 months. The median blood CD4 cell count
at diagnosis of TB (220  106 cells/l) was significantly
greater than the level pre-HAART (80  106 cells/l) and
was also significantly greater than the median CD4 cell
count of HIV-infected patients who developed TB but
were not receiving HAART (109  106 cells/l). This
finding suggests that substantial restoration of CD4 cell
numbers had occurred among the majority of patients
receiving HAART by the time TB was diagnosed.
Similar observations are also being reported from the
developing world. TB was the most common oppor-
tunistic infection in a cohort of patients with advanced
immunosuppression receiving HAART in Thailand [29].
Among patients with WHO stage 3 and 4 disease in Cape
Town, South Africa, the incidence of TB during
HAART was 4.6 cases/100 patient-years; this is appro-
ximately 10-fold greater than the incidence among
HIV-negative individuals in the same community [17].
A pilot community-based antiretroviral project in Cape
Town reported high rates of TB during the first year of
HAART [30]. Our current observations at the same site
are that among patients referred for HAART, appro-
ximately 5% have active TB on pre-HAART screening
and a further 10% of patients develop TB after initia-
tion of HAART during the first year of follow up
(unpublished data) despite excellent treatment com-
pliance [31]. Thus, although TB rates are markedly
reduced by HAART, TB still represents a substantial
burden of disease during this treatment, especially in
communities with high TB prevalence.
Impact of HAART on the manifestations of
TB
Clinical and radiological presentation
The impact of HIV on the clinicopathological features
of TB is well documented [32,33]. HIV-associated
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Fig. 1. The incidence of TB [cases per 100 person-years (py)]
among cohorts of HIV-infected patients in Cape Town, South
Africa who were or were not receiving antiretroviral treat-
ment (ART). Data are stratified by blood CD4 cell count
( 106 cells/l) and WHO clinical stage of disease (Adapted
from Badri et al. 2002 [17]).
Table 1. The impact of HAART on the incidence of tuberculosis (TB) in cohort studies.
Study Country Study population Outcome
Studies in countries with high TB incidence
Badri et al. 2002 [17] South Africa Prospective case-control cohort
study (264 receiving HAART,
700 non-HAART), 1992–2001
Adjusted rate ratio for TB was 0.19 (95% CI, 0.09–0.38)
among those receiving HAART
Santoro-Lopes et al.
2002 [25]
Brazil Prospective cohort (n ¼ 255),
1991–1998
Relative hazard of TB among those receiving triple-therapy
was 0.19 (95% CI, 0.03–1.09) compared to those
receiving monotherapy or no treatment
Studies in countries with low TB incidence
Brodt et al. 1997 [21] Germany Prospective cohort of homosexual
men (n ¼ 1003), 1992–1996
No change in TB incidence during HAART despite
major reductions in other opportunistic infections
Girardi et al. 2000 [23] Italy Multicentre prospective cohort
(n ¼ 1360), 1995–1996
Relative hazard of TB among those receiving HAART
was 0.08 (95% CI, 0.01–0.88), compared to those
not receiving HAART
Jones et al. 2000 [24] USA Multicentre prospective
cohort study 1996–1998
Relative risk of TB among persons receiving HAART
was 0.2 (95% CI, 0.1–0.5) compared to those not
receiving HAART
Kirk et al. 2000 [12] 17 European
countries
EuroSIDA multicentre
prospective cohort (n > 7000)
TB incidence decreased from 1.8 cases/100 py to
0.3 cases/100 py during HAART.










immunodeficiency results in an increased frequency of
cutaneous anergy to PPD and increased rates of
extrapulmonary and disseminated disease [32,34]. Radio-
graphic appearances of pulmonary TB in patients with
HIV-1 coinfection are more frequently atypical, reflecting
impaired tissue inflammatory responses to infection
[35,36]. All-cause mortality is also greatly increased
and is directly related to the degree of immunodeficiency
[37]. However, as might be expected, HAART modifies
the clinicopathological features of TB as immune
function is restored. HAART increases the frequency
of the typical post-primary radiographic pattern of
pulmonary TB (Fig. 2) [38,39], rates of PPD skin test
conversion (Fig. 3) are higher [40,41] and patient survival
is increased [38]. The frequency of extrapulmonary
disease might also be expected to decrease among
patients receiving HAART, but the single study examin-
ing this possibility was not of sufficient size for full
evaluation [38].
Immune reconstitution disease
The most striking evidence of restoration of functional
immune responses to MTB is that provided by reports
of IRD, also known as the immune reconstitution
inflammatory syndrome. IRD is an adverse consequence
of restoration of immune responses during the initial
months of HAART [26,27]. Previously subclinical
infections are ‘unmasked’ or pre-existing partially treated
opportunistic infections clinically deteriorate as immu-
nopathological host inflammatory responses are ‘switched
on’ during HAART. IRD associated with HAART was
originally described in patients with MAC infection and
who were receiving zidovudine monotherapy [41].
Presentation with IRD was temporally associated with
development of positive PPD skin test responses (Fig. 3)
among patients with previous cutaneous anergy, provid-
ing evidence of restoration of delayed type hypersensi-
tivity (DTH) responses.
IRD associated with MTB was not reported until after
the development of HAART [42]. Among 86 published
cases of TB-associated IRD, the median duration of
HAART prior to development of IRD was just 4 weeks,
illustrating the extraordinary rapidity with which
HAART reverses HIV-associated paresis of immune
responses to MTB [26]. Among these cases, the median
blood CD4 cell count increased from a pre-treatment
nadir of 5  106 cells/l [interquartile range (IQR),
26 106 103  106 cells/l] to 205  106 cells/l (IQR,
110 106 298  106 cells/l) at the time of IRD diag-
nosis. Typically the plasma viral load is markedly reduced
by the time of IRD onset, reaching the lower limit of
detection in approximately half the patients. Some
patients develop IRD associated with TB within 2
weeks of initiating HAART, even prior to an increase in
CD4 cell count. This finding is likely to reflect the rapid
restoration of functional immune responses that accom-
panies rapid reductions in viral load.
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Fig. 2. Chest radiograph of an HIV-infected patient with
pulmonary TB during HAART. Despite previously advanced
immunodeficiency, restoration of immune function during
HAART may lead to an increased frequency of typical
post-primary apical cavitating disease as shown in this patient
at the right lung apex (arrow).
Fig. 3. Conversion of a DTH skin test response to tuberculin
from anergic to positive may reflect restoration of cell-
mediated immune responses to M. tuberculosis and may also
accompany immune reconstitution disease associated with
this organism. (Photograph courtesy of Division of Tubercu-
losis Elimination, National Center for HIV, STD and TB











MTB-associated IRD most commonly presents with
fever, lymphadenopathy or worsening respiratory symp-
toms. A wide spectrum of other manifestations include
development of pleural effusions, ascites, hepatospleno-
megaly [43], psoas abscesses [44], intra-abdominal
abscesses [45], epididymo-orchitis [43], central nervous
system lesions [46], skin lesions [42], acute renal failure
[47] and hypercalcaemia [48]. These observations indicate
that HAARTrapidly restores anti-mycobacterial immune
function in diverse anatomical compartments and suggests
that HAART permits recruitment and proliferation of
effector cells at those sites. Rapid reversal of immune
function may trigger severe immunopathology in patients
with subclinical or partially treated TB. Life-threatening
clinical manifestations include acute respiratory failure
from widespread pulmonary alveolitis [49,50] and
major airway obstruction due to rapidly expanding
intra-thoracic lymph nodes (Fig. 4) [51]. Systemic
corticosteroid treatment plays a key role in the control
of severe manifestations.
Histopathological examination of tissues involved in IRD
associated with mycobacteria may show suppuration and
a degree of necrotizing inflammation that is unusual in the
context of profoundly immunocompromised patients
[52–54]. It is likely that the rapidity with which immune
responses are restored and the lack of compensating
immunoregulatory mechanisms result in the uncontrolled
tissue-damaging responses that characterize IRD. Further
indirect evidence that HAART restores the ability to
form physiologically functioning granulomas (Fig. 5) is
provided by reports of hypercalcaemia during mycobac-
terial IRD [48,55]. Hypercalcaemia is a well-recognized
complication of mycobacterial infection, arising as a
result of production of 1,25-dihydroxycholecalciferol in
functional granulomas [56]. Elevated serum levels of
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Fig. 4. Immune reconstitution disease associated with M. tuberculosis. (a) Chest radiograph of an HIV-infected patient showing
right paratracheal lymphadenopathy (arrow) and a reticulonodular infiltrate due to M. tuberculosis infection. (b) After 2 months of
anti-TB therapy and HAART, the patient presented with stridor. A repeat chest radiograph shows massive right paratracheal
adenopathy (arrow) displacing and compressing the trachea, minor right hilar adenopathy and a nodular infiltrate in the right mid-
zone. (c) Computed tomography shows enlarged lymph nodes in the right paratracheal region (arrows) causing displacement and










1,25-dihydroxycholecalciferol and hypercalcaemia dur-
ing mycobacterial IRD is therefore likely to reflect
restoration of the ability to form physiologically func-
tioning granulomas [48].
Mechanisms and extent of immune
recovery during HAART
The development of HAART using combinations of
reverse transcriptase and protease inhibitors in 1995
marked the dawn of a new era in HIV management. For
the first time, robust suppression of plasma viral load was
associated with substantial immune restoration [4–6].
HAARTusually leads to a>90% reduction in plasma viral
load within the first weeks of treatment [57]. Three
principal laboratory parameters provide evidence of sub-
sequent immune recovery during HAART: (i) quantita-
tive restoration of immune cells; (ii) normalization of cell
phenotype; and (iii) recovery of immune cell function.
Here, we initially consider immune recovery in general
and later review the data that specifically relate to
immunity to MTB.
Changes in CD4 cell counts
The CD4 cell count increases that accompany the viral
load reductions occur in two principal stages. A rapid
increase in the number of circulating CD4 cell
lymphocytes within 1–2 weeks of starting HAART
and continuing over the first 2–3 months largely
represents a redistribution of activated CD45Ro memory
cells previously sequestered in lymphoid tissue, and a
generalized reduction in apoptotic cell death [4,5]. This
initial increase coincides with the period within which
manifestations of IRD are most frequently observed.
A slower second phase of CD4 cell expansion persists over
subsequent months and may continue for years. This
observation represents expansion of naive CD45RA cells
as thymic function is restored and results in the long-term
sustained rise in CD4 cell count. This sustained increase
in CD45RA cells correlates with the magnitude of viral
load suppression and its stability over time [5].
After 2–4 years of HAART, mean or median increases in
CD4 cell counts are approximately 200–400  106 cells/l
[58–62]. The increases predominantly occur in the first
1 or 2 years with comparatively smaller gains thereafter. In
a multicentre study of 314 HIV-infected homosexual men
in the USA, blood CD4 cell counts were observed to
plateau between 2 and 3.5 years of HAART [63]. In a
prospective cohort of 237 HAART-naive patients, with a
baseline median CD4 cell count of 175  106 cells/l and
viral suppression maintained for more than 1 year, more
sustained CD4 lymphocyte increases were observed
during HAART [61]. After an initial rapid increase in
median CD4 cell count of 97.2  106 cells/l in the first
month, the rate of CD4 cell increase sequentially
diminished thereafter, with rates of 175  106 cells/l/
month from year 1 to year 2 and an estimated rate of
5.4  106 cells/l/month at year 2. A more recently
published study with 6 years follow-up of 20 selected
patients found that CD4 cell counts continued to rise,
albeit slowly, during years 3–6 of HAART [64].
While viral suppression is a key determinant of long-term
CD4 cell recovery [62], the nadir CD4 cell count at the
time HAART is started may also be an important factor.
CD4 cell repletion in both blood and lymphoid
compartments occurred during the first year of HAART
among patients with early disease and baseline CD4 cell
counts > 400  106 cells/l [65]. In contrast, CD4 cell
numbers had not normalized after nearly 3 years of follow
up among patients with severely depleted CD4 cell
counts at initiation of treatment [66]. A more recently
published study of a small group of patients, however,
showed that CD4 cell rises may continue for up to 6 years
despite severe pre-treatment CD4 cell depletion [64].
Kaufmann et al. found that older age and lower nadir CD4
cell counts were both predictive of a poorer CD4 cell
recovery [59] and these factors may be related to persistent
impairment of thymic function [67]. The extent of CD4
cell recovery may also be related to low-level viraemia and
pro-viral DNA levels [68]. It can be concluded that
responses to HAART fall within a spectrum. Some
patients have little or no rise in CD4 cell counts despite
complete viral suppression [69,70]; others may have CD4
cell counts that plateau at suboptimal levels [63] and a
proportion have persistent CD4 cell increases over many
years [64].
Changes in CD4 cell phenotype
The phenotype of circulating T lymphocytes in HIV-
infected patients reflects immune competence. Numbers
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Fig. 5. Haematoxylin and eosin stained tissue section show-
ing a florid granulomatous host response to M. tuberculosis.
As immune responses recover during HAART, the ability to
form granulomas is restored. (Photomicrograph courtesy of
the Division of Anatomical Pathology, Faculty of Health










of studies show that circulating CD4 and CD8
lymphocyte subsets are only partially restored in the first
year of HAART [4,71,72]; as with total CD4 cell counts,
however, changes in these subsets may continue for many
years [64]. Although expression of the cellular activation
markers, HLA-DR and CD38, by CD4 and CD8
lymphocytes decreases substantially during the first year of
HAART, these populations remain abnormally activated
for up to 6 years of HAART [60,64]. Furthermore, the
number of circulating CD4 and CD8 lymphocytes that
express CD28, a co-stimulatory molecule important in
T-cell responses to antigen, do not increase to normal
levels during long-term HAART even among those
who normalize their CD4 cell counts [73]. Additionally,
HLA-DR and CD38 expression by CD8 lymphocytes
remain elevated among patients starting HAART with
advanced disease. Overall, among patients with virologi-
cal suppression, the likelihood of phenotypic normaliza-
tion of circulating lymphocytes diminishes the lower the
nadir CD4 cell count [73].
Changes in CD4 cell function
In addition to demonstrating quantitative cellular
restoration and improvements in immune cell phenotype,
a number of studies has also described improvements in
immune function during HAART [4,60,72–74]. In
general, in vitro T-cell proliferative responses to recall
antigens and mitogens improve during treatment
[4,60,72] and cytokine responses shift from a predomi-
nantly type 2 to a type 1 pattern, with increases in
interferon (IFN)-g and interleukin (IL)-2 production
[75–77]. Later increases in circulating CD45RA naive
lymphocytes are associated with reversal of HIV-
associated defects in the T-cell receptor (TCR) repertoire
[78,79] and restoration of immune responses to neoanti-
gens [74]. DTH responses to antigens assessed by skin
testing also improve and correlate with the magnitude of
viral load reduction [80].
It is clear, however, that long-term functional deficits
persist during HAART. Imbalances in cytokine profile
and TCR repertoire disruptions persist for at least
1 year of treatment [77,79] and antibody responses to
vaccines, such as pneumococcal vaccine, remain
suboptimal during long-term treatment [81]. Lange
et al. conducted a detailed assessment of functional
T-cell responses among patients who had a wide spectrum
of nadir blood CD4 cell counts, good virological
responses and normalized CD4 cell counts on long-
term HAART [82]. Antibody responses to immuniz-
ations, lymphocyte proliferation in vitro and DTH
responses to vaccine antigens were evaluated. Despite
normal CD4 cell counts, functional immune responses
remained impaired and the degree of impairment was
directly related to the nadir but not current CD4 cell
count [73].
Restoration of MTB-specific immune
responses during HAART
Few studies examine restoration of anti-mycobacterial
and MTB-specific immune responses. Among a cohort of
patients with a history of disseminated MAC infection,
proliferation of peripheral blood mononuclear cells
(PBMC) in response to MAC antigen in vitro showed
stimulation indices of 3 among 46% of patients prior to
HAART and among 77% of patients after 6 months
of HAART [83]. There was no further increase in
the proportion of patients with positive responses at
12 months and the proportion of positive responders was
similar to that among HIV-negative control subjects.
Similar data are reported by Wendland et al. [80]. Res-
toration of proliferative responses to MAC and M. xenopi
during the first 6 months of HAART is temporally
associated with development of IRD [84].
Proliferation of PBMC stimulated in vitro with PPD is also
enhanced during receipt of HAART; the proportion of
positive responders increases steeply during the first
6 months [4,72,80] and is sustained at 12 months [72]. Li
et al. showed that not just the proportion of responders
but also the magnitude of cell proliferation increases
markedly [72]. In a prospective cohort of 10 patients
followed up at 2-monthly intervals over 1 year, Schluger
et al. found that PBMC stimulated with the laboratory
strain MTB H37Ra also produced a steadily increasing
amount of IFN-g [85]. However, responses at 1 year were
markedly less than those among HIV-negative control
groups with either positive or negative PPD skin test
responses. Furthermore, production of IL-2 and IL-12
increased minimally.
Hsieh et al. prospectively studied 13 patients during
HAART for 1 year, using expression of the lymphocyte
activation marker CD69 following in vitro stimulation of
PBMC with PPD as a correlate of MTB-specific immune
responses [86]. In a majority of patients, the percentage of
CD4 cells and CD8 cells responding to PPD increased
during the first year of HAART. However, although
substantial increases in CD4 cell count were observed
in all patients, a small group of patients failed to restore
these responses after 1 year of HAART. These patients
were more likely to have nadir CD4 cell counts of
<50  106 cells/l compared to those who had good
restoration of responses [86]. This suggests that delaying
initiation of HAART in chronic HIV infection may lead
to long-term impairment of functional immune responses
to MTB.
Quantitative restoration of MTB-specific IFN-g-secret-
ing cells during HAART has not been investigated.
Hengel et al. described a single patient with disseminated
MTB infection and HIV infection who started anti-
tuberculosis treatment and HAART concurrently [87].
The proportion of peripheral blood MTB-specific CD4










cells staining positively for IFN-g increased from 8.6%
on day 11 to 33% on day 95 of treatment. To what extent
this remarkable expansion of MTB-specific T cells
represented an effect of HAART or an effect of anti-
tuberculosis treatment is unknown. Studies are needed to
determine the extent to which MTB-specific T cell
clones are restored during HAART.
HAART as a TB control strategy
Although finding and curing active TB cases remains the
principal intervention for TB control in high HIV
prevalence settings [88] it is nevertheless failing [18,19]. A
multifaceted approach is therefore required [20]. The
extent to which HAART will play a role within such a
framework has yet to be determined and will depend on:
(i) the efficacy of HAART in preventing TB; (ii) the
population coverage; and (iii) the extent to which
HAART prolongs life. It seems likely that if HAART is
unable to completely restore MTB-specific immune
responses and thereby reverse the risk of TB to levels
present prior to acquisition of HIV infection, then the
overall improvement in patient prognosis will result in an
expanding survivor cohort with a chronically heightened
susceptibility to TB. Thus, when considering the effect
on TB control, the huge short-term benefit of HAART
in reducing TB risk for the treated individual is unlikely
to be reflected at the community level in the long term.
Williams and Dye (2003) modelled the potential impact
of HAARTon TB incidence, combining data on rates of
CD4 cell decline during HIV infection, relative incidence
of TB at different CD4 cell counts and the known impact
of HAARTon TB incidence [89]. They calculated that if
HAART were given to patients with CD4 cell counts
< 200  106 cells/l with complete coverage and perfect
compliance; the cumulative incidence of TB would be
decreased by just 22% over 20 years. Conversely, to reduce
TB incidence by 50% over 20 years with 85% effective
coverage, use of HAART would have to be greatly exp-
anded to include patients with CD4 cell counts < 500 
106 cells/l–an unrealistic proposition [89]. The small
long-term impact of HAART on TB incidence is
explained by the fact that HAART reduces the risk of
TB but also extends life expectancy markedly. Thus,
HAART-treated individuals develop TB at a lower rate
but over a longer period of time.
The modelling data of Williams and Dye is based upon
several assumptions. Calculations assume that HAART
restores functional responses to MTB to levels present in
the early stages of chronic HIV infection. However, at
present there are insufficient data to know whether this is
the case during long-term HAART. It is likely that there
are gradual time-dependent changes in immune function,
which are paralleled by time-dependent changes in
patient susceptibility to TB. The modelled predictions are
based on a 20-year time-scale whereas data on efficacy of
HAART in reducing TB incidence are derived from
studies with a much shorter duration of follow up. More-
over, the effect of HAARTon rates of TB transmission and
reinfection are not taken into account. Future data may
help to further validate these modelling calculations.
The extent to which HAART restores long-term
MTB-specific immune responses is critical and will be
a key determinant of the extent to which HAART is able
to contribute to TB control at the community level.
Strategies that optimize MTB-specific immune restora-
tion need to be explored. Current data indicate that early
initiation of HAART may promote more complete
immune restoration. Thus, in communities with high
TB burden, early initiation of HAART may have an
important long-term benefit in reducing TB rates.
Further adjunctive strategies might also be explored
to boost the restoration of MTB-specific immune res-
ponses. Such interventions might include use of
bacille Calmette–Guerin vaccination during HAART
or co-administration of cytokine therapy such as IL-2
[90]. Prophylaxis with isoniazid during HAART remains
an alternativ strategy.
The challenge of incident TB during
HAART
Since HAART fails to reduce the incidence of TB to
levels in HIV-negative individuals, a substantial rate of TB
persists during HAART. This fact presents a major
challenge to HAART programmes, especially in com-
munities with a high prevalence of TB. In Cape Town, for
example, our experience is that these problems are many-
fold: (i) TB is an ongoing substantial cause of morbidity
and mortality that consumes already over-stretched health
resources; (ii) development of TB despite HAART
undermines patient confidence in HAART; and (iii)
concurrent treatment with HAART and anti-TB drugs
presents difficulties associated with pill burden, patient
adherence to treatment, pharmacokinetic interactions
and overlapping toxicities [91]. An additional concern is
the potential for nosocomial transmission of TB at
HAART clinics; this is as yet unquantified. Thus, although
the clinical benefits of HAARTare undoubtedly huge, our
experience at a successful community-based HAART
project in Cape Town is that incident TB remains a major
challenge among treated patients.
Conclusions
HAART has a remarkable impact on HIV/AIDS-
associated morbidity and mortality and has greatly










extended the prognosis of people living with the virus.
We have reviewed how suppression of viral replication
permits gradual restoration of lymphocyte numbers,
phenotype and function over many years. The extent to
which CD4 cell counts are restored is variable. Current
data, however, show that even among those patients who
develop full numeric restoration of circulating CD4 cell
lymphocytes, phenotypic abnormalities and functional
defects persist. Persistent abnormalities are most likely
when immunodeficiency is more advanced at the time of
initiation of HAART (Table 2).
Long-term deficits in MTB-specific immune responses
are likely to be an important factor contributing to the
higher than expected incidence of TB among patients
receiving HAART. Suboptimal restoration of MTB-
specific immunity hinders the extent to which HAART
may play a role in TB control at the community level
since patients receiving HAART survive longer and yet
maintain a chronically heightened risk of TB. Thus,
although the benefit of HAART to the individual in
reducing TB risk is great, the impact at the community
level is much less. Current modelling analysis predicts
that HAART will have a more limited impact on TB
incidence than might have been anticipated (Table 2).
Future epidemiological studies need to more clearly
define the long-term incidence of TB during HAART
in prospective study cohorts in low-income countries.
The impact of HAART on TB epidemiology at the
community level should also be studied, using careful TB
surveillance to determine the effect on both the burden
of disease and patterns of TB transmission within the
community. The extent to which transmission of TB
occurs at antiretroviral clinics also needs to be assessed.
Laboratory studies should prospectively define the rate
and extent to which functional immune responses to TB
are restored during long-term HAART. This would
permit factors associated with suboptimal restoration to
be identified and strategies to augment MTB-specific
immune responses to be explored. The timing of initia-
tion of HAART may prove to be the most important
factor in this respect and early initiation of HAART
may lead to long-term benefits in TB risk reduction.
However, widespread early initiation of HAART in
low-income countries would be very costly in health
resources and detailed cost-benefit analyses are required.
Nevertheless, as access to HAART expands in low-
income countries and treatment recommendations are
established and refined, the long-term effect of HAART
on TB control needs to be carefully evaluated.
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Risk Factors for Tuberculosis among HIV-infected
Patients Receiving Antiretroviral Treatment
To the Editor :
Although tuberculosis (TB) incidence among HIV-infected co-
horts receiving highly active antiretroviral treatment (HAART)
is reduced by 70–90%, it remains substantially higher than among
HIV-noninfected patients (1, 2). Strategies to reduce the burden
ofTBduringHAARTare needed.We therefore readwith interest
the article by Seyler and colleagues, which reported risk factors
for TB among patients receiving HAART in Abidjan (3).
Using multivariate analysis, Seyler and colleagues found that
a past history of TB was the only significant risk factor for TB
during HAART (3). The 31 patients in the cohort with a past
history of TB had all been declared cured following 6 mo or
more of rifampicin-containing anti-TB treatment, and yet six
developed TB during HAART over a median of 26 mo observa-
tion. This represents an unusually high recurrence rate (4) even
without taking into account the major protective effect of
HAART. Of note, however, 33% of the incident cases were
smear- and culture-negative; potential misdiagnoses of active
TB among patients with symptomatic posttuberculous lung dis-
ease may have confounded past history of TB as a risk factor.
Advanced immunodeficiency might be expected to be associ-
ated with an ongoing increased risk of TB during HAART, at
least until a satisfactory degree of immune restoration has been
achieved. We have studied a large cohort in Cape Town (de-
scribed in Reference 2) that includes patients with a diverse
range of CD4 cell counts and clinical stages. Analysis reveals
that the ongoing risk of TB during HAART is much greater
among those with low nadir CD4 cell counts and advanced clini-
cal stage of disease; past history of TB is not a risk factor. The
disparities with the findings of Seyler and colleagues may reflect
differences in diagnostic criteria for TB and the fact that the
restricted enrollment criteria for the Abidjan cohort resulted in
inclusion of few patients with stage 1 or 2 disease or CD4 cell
counts greater than 200 cells/!l; the resulting cohort composition
diminishes the power to assess CD4 count and clinical stage as
risk factors. This is a problem common to analysis of data from
many cohorts receiving HAART in Africa where often only
those with advanced disease are treated.
If it is confirmed that the risk of TB during HAART is
associated with advanced pretreatment immunodeficiency, the
risk might be decreased by earlier initiation of HAART. In
addition, those patients with advanced immunodeficiency may
derive greatest benefit from adjunctive treatments such as isonia-
zid prophylaxis.
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From the Authors:
Lawn and colleagues raise a number of crucial points. However,
we disagree with them on most of these issues. They state that,
in our study, the rate of tuberculosis (TB) in patients with a past
history of TB (11.3/100 person-years) represents an “unusually
high recurrence rate.” In a recent report by Grant and coworkers
(1), the incidence of TB in non–HAART-treated South African
adults with a past history of TBwas estimated at 19.3/100 person-
years. In Grant and coworkers’ study, as in ours, the “rate of
TB in persons with a past history of TB” is not a “recurrence
rate” but the rate of TB after the date of study enrollment,
which was not the date of the end of the previous TB episode.
In our patients with a history of TB, the mean time since the
last TB episode was 2.8 yr. Including this time in the period at
risk would obviously have led to an estimate of recurrence rate
quite lower than the TB rate after enrollment.
In the study by Grant and coworkers, the rate of TB in
non–HAART-treated patients with no TB history was half that
of patients with TB history (1). We observed the same phenome-
non in patients on HAART. Lawn and colleagues report that
they did not, although they do not provide sufficient data to
allow us to comment on the strength and limits of their analysis.
We would be interested in seeing their data on TB incidence in
patients with and without TB history (even if not significantly
different in their sample), and in the procedures used to docu-
ment a TB history at study entry.
Documenting smear- and culture-negative (SCN) TB re-
quires standardized diagnosis criteria and systematic review by
an event documentation committee. Both conditions were ap-
plied in our study. In HIV-infected patients, SCN TB has long
been recognized as a frequent problem, even in industrialized
countries (2, 3). In reports from sub-Saharan settings, the per-
centage of SCN episodes which are diagnosed as “possible TB”
by experienced infectious diseases specialists is frequently high
(4). Where low rates are reported, one expects that patients with
SCN TB died before being diagnosed. SCN TB is frequently
extrapulmonary and found in patients with low CD4 count.
Therefore, SCN TB and culture-positive TB may be associated
with different risk factors. Contrary to Lawn and colleagues, we
don’t believe that SCN TB should be excluded from TB risk
factor studies.
Finally, we agree with Lawn and colleagues on one point:
studies performed in sub-Saharan Africa frequently include pa-
tients with low CD4 count. Some of them occasionally give
negative conclusions on patients with high CD4 count, despite
insufficient power (5). In our reduced sample of patients with
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Highly active antiretroviral therapy
(HAART) has revolutionized the care of
HIV-infected individuals, causing major
reductions in HIV-associated morbidity
and mortality. Once blood CD4+ cell
counts have reached stable levels of 1200
cells/mL, the risk of developing opportu-
nistic disease due to cytomegalovirus,
Pneumocystis jirovecii, Mycobacterium av-
ium complex (MAC), Toxoplasma gondii,
and Cryptococcus neoformans is generally
very low [1]. This reflects the fact that
partial restoration of the immune system
is sufficient to suppress these low-viru-
lence pathogens. In contrast, however, it
is emerging that patients receiving
HAART retain a chronically heightened
risk of disease due to other, more virulent
pathogens, such as tuberculosis (TB) and
invasive pneumococcal disease [2–4]. In
the case of TB, it might be hypothesized
that this observation might relate to the
coexistence of other risk factors for TB or
possibly to nosocomial TB exposure at
HIV treatment facilities. However, a prin-
cipal underlying cause is undoubtedly the
persistence of deficits in immune function
during treatment [5]. Because the risk of
TB is increased even among those with
minor degrees of HIV-associated immu-
nodeficiency, complete normalization of
immune function during HAART would
be required to reduce the risk of TB to
background levels. Increasing evidence,
however, shows that this goal is generally
not attainable. Even among patients who
have good responses to HAART, func-
tional immunological deficits usually per-
sist [5–7], including those specific to My-
cobacterium tuberculosis [5, 8, 9].
Despite limitations in the extent to
which TB-specific immunity may be re-
stored [5], HAART nevertheless has a ma-
jor impact on TB incidence in treated co-
horts. Studies conducted in both countries
with a high prevalence of TB and those
with a low prevalence of TB have shown
that HAART reduces the risk of TB by
70%–90% [3, 10–14]. The duration of fol-
low-up in these studies was limited, how-
ever; therefore, these results may not re-
flect the full beneficial effects to be derived
from HAART in the longer term.
The article by Girardi and colleagues
[15] in this issue of Clinical Infectious Dis-
eases reports the burden of TB during 3
years of HAART in cohorts in Europe and
North America. In high-income countries
in which TB prevalence is low, such a
study could only be achieved by collabo-
rative analysis of data sets from multiple
cohorts—a major strength of this article.
A key finding was that HAART resulted
in time-dependent reductions in TB in-
cidence throughout follow-up. Although
the greatest reduction was during the first
year of treatment, the rate continued to
decrease, with a ∼5-fold reduction be-
tween the first and third years (figure 1).
These changes are likely to reflect incre-
mental gains in CD4+ cell count and func-
tion, which are greatest during the first 1–
2 years of HAART, with only small
additional increases occurring thereafter
[16]. It remains an open question as to
whether TB incidence rates may decrease
further during long-term HAART and
whether background rates are ultimately
reached. In the study by Girardi and col-
leagues [15], the incidence at 3 years was
still several-fold higher than the rates in
the general population where these pa-
tients were treated. However, extrapola-
tion of these data (figure 1) would suggest
that any further decreases in TB incidence
beyond 3 years are likely to be small.
Moreover, it is actually impossible to de-
fine the background TB incidence rate for
these cohorts, because the individuals in-
cluded may differ from the general pop-
ulation in having other long-term risk fac-
tors for TB.
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Figure 1. Changes in tuberculosis (TB) incidence during 3 years of HAART with regression curve
fitted. TB incidence rate is expressed as number of cases per 1000 person-years of follow-up. Data
are adapted from the study by the Antiretroviral Therapy Cohort Collaboration [15].
ardi and colleagues [15] was particularly
high during the first 3 months of HAART.
Several different reasons may underlie the
presentation of cases during this interval:
1) many cases will have arisen at this time
because of residual immunodeficiency, 2)
intensive investigation of some patients
with symptomatic disease during prepa-
ration for HAART may have yielded re-
sults that only became positive after
HAART initiation, and 3) some cases of
previously subclinical disease may have
manifested as immune reconstitution dis-
ease [17], as has been reported by one of
the centers collaborating in this study [18].
A substantial weakness of the study by
Girardi and colleagues [15] was that pa-
tients with AIDS were excluded; such pa-
tients are the very individuals who have
the greatest risk of TB [3]. Thus, the TB
incidence rates reported in this study do
not reflect the overall burden of HIV-as-
sociated TB in these cohorts. Moreover,
because the extent of restoration of TB-
specific immunity during HAART is lim-
ited, particularly among those with AIDS
[5, 8], the long-term rates of TB among
such patients are likely to be higher than
those reported in this study.
Girardi and colleagues [15] identified
risk factors for TB during HAART using
multivariate analysis. The association of
TB risk with route of HIV acquisition is
likely to be attributable to the association
of this variable with country of origin or
social factors, which are also risk factors
for TB. Unfortunately, the ethnic origin of
patients was not recorded. The strongest
risk factor for AIDS-associated TB in Lon-
don is African origin [19], and this in-
creased risk is likely to persist during
HAART. Confirmation of this might per-
mit targeting of chemoprophylaxis to fur-
ther reduce TB incidence among such
high-risk groups.
Girardi and colleagues [15] also iden-
tified low baseline CD4+ cell count as an
independent risk factor for the develop-
ment of TB; in addition, risk of TB oc-
curring after 6 months of HAART was
associated, not only with baseline CD4+
cell count, but also with the CD4+ cell
count at 6 months after initiation of
HAART. With increasing duration of
HAART, it might be hypothesized that the
risk of TB would become more strongly
associated with current CD4+ cell count
and less strongly associated with baseline
CD4+ cell count. Alternatively, because
long-term failure of immune functional
recovery is particularly associated with ad-
vanced pretreatment immunodeficiency
[7, 8], it is possible that, among those with
advanced disease, a low baseline CD4+ cell
count may actually predetermine a long-
term increased risk of TB.
Access to HAART is now rapidly ex-
panding in low-income countries where
the prevalence of TB is high and TB is the
predominant cause of HIV-associated
morbidity and mortality [20]. In a cohort
based in a hospital out patient service in
Cape Town, South Africa, the TB inci-
dence was 24 cases per 1000 person-years
during a median of 16 months of follow-
up [3]; after 13 years of follow-up, this
rate was ∼10 cases per 1000 person-years
(unpublished data), which is ∼7-fold
higher than the rate found in the study by
Girardi and colleagues [15]. The burden
of TB during HAART is even greater
within a local community-based antiret-
roviral program in Gugulethu (near Cape
Town, South Africa), where the annual TB
incidence in the general community ex-
ceeds 1000 cases per 100,000 population
[21]. Among HIV-infected patients re-
ceiving HAART at that location, 10%–
15% develop TB during the first year of
HAART (unpublished data). This huge
burden of disease has great implications
in terms of morbidity, utilization of
health resources, and difficulties associated
with concurrent administration of both
HAART and antituberculosis treatment.
These difficulties relate to pill burden, pa-
tient adherence, pharmacokinetic inter-
actions, and overlapping drug toxicities.
The implications go further. Because
the TB incidence remains much higher
among patients receiving HAART than
among the general community, modelling
analysis suggests that good, effective cov-
erage with HAART may have relatively lit-
tle impact on the overall burden of TB in
communities in low-income countries
over a 20-year time span [22]. The reason
for this is that life expectancy is greatly
extended during HAART, and therefore,
although the risk of TB per unit time for
individuals receiving HAART is greatly re-
duced, the lifetime risk of disease may not
decrease [5, 22]. Background data for this
modelling analysis, however, were derived
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follow-up, and longer term studies of the
effect of HAART on incidence rates and
risk factors for TB in low-income coun-
tries are needed.
A recently published study from Abi-
djan found that past history of TB was the
sole risk factor for development of TB
during HAART [23]. This article, however,
has limitations related to the size of the
study population, the number of TB cases,
restricted cohort composition, and diag-
nostic criteria for TB, potentially con-
founding the findings [23, 24]. The study
by Girardi and colleagues [15] excluded
patients who received an AIDS diagnosis
before initiation of HAART, thereby ex-
cluding those with a past history of TB
and precluding examination of this vari-
able as a risk factor. However, our findings
in Cape Town, South Africa, agree with
those of Girardi and colleagues [15]. We
have found, in a prospective cohort study,
that risk of TB was strongly associated
with the pretreatment level of immuno-
deficiency, as reflected by the baseline
CD4+ cell count and clinical stage of dis-
ease (as defined by the World Health Or-
ganization); past history of TB was not a
risk factor [24]. Moreover, we also found
that the immunological response to
HAART was impaired among patients
who developed TB, compared with those
who remained free of TB (unpublished
data), suggesting that poor treatment re-
sponse was an important underlying
mechanism. Again, this agrees with the
findings of Girardi and colleagues [15].
Collectively, these data demonstrate
that during the first 3 years of HAART, in
both high- and low-income settings, risk
of TB is associated with the baseline level
of immunodeficiency. This has important
implications for the antiretroviral treat-
ment programs in low-income countries.
The median blood CD4+ cell count among
patients enrolling in our own community-
based antiretroviral program in Cape
Town is !100 cells/mL, as is typically the
case among programs elsewhere in sub-
Saharan Africa [25]. As a result of dimin-
ished capacity for immune recovery, ini-
tiation of HAART among patients with
advanced disease may result in an ex-
panding cohort of patients who remain
vulnerable to TB. This may undermine the
potential benefits of HAART in TB con-
trol, and barriers to earlier access to
HAART in these settings need to be
overcome.
In conclusion, despite major reductions
in TB incidence among individuals re-
ceiving HAART, TB risk remains elevated
among those receiving treatment in both
high- and low-income countries. This on-
going burden of disease has major impli-
cations for antiretroviral programs in low-
income countries and undermines the
potential for HAART to contribute to TB
control at the community level.
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Tuberculosis among HIV-infected patients receiving
HAART: long term incidence and risk factors
in a South African cohort
Stephen D. Lawna,b, Motasim Badria and Robin Wooda
Objectives: To determine the long-term incidence of tuberculosis (TB) and associated
risk factors among individuals receiving HAART in South Africa.
Design: Prospective cohort study.
Methods: Microbiologically or histologically confirmed incident TB was identified in a
hospital-based cohort of 346 patients receiving HAART between 1996 and 2005 in
Cape Town.
Results: The TB incidence density rate was 3.5/100 person-years in the first year and
significantly decreased during follow-up, reaching 1.01/100 person-years in the fifth year
(P ¼ 0.002 for trend). TB incidence during the study was highest among patients with
baseline CD4 cell counts < 100 cells/ml and those with World Health Organization
(WHO) clinical stage 3 or 4 disease (5.71 and 3.88/100 person-years, respectively). Risk
of TB was independently associated with CD4 cell count < 100 cells/ml (adjusted risk
ratio [ARR], 2.38; 95% confidence interval (CI), 1.01–5.60; P ¼ 0.04), WHO stage 3 or 4
disease (ARR, 3.60; 95% CI, 1.32–9.80; P ¼ 0.01) and age < 33 years (ARR, 2.86; 95%
CI, 1.29–6.34; P ¼ 0.01). Risk of TB was not independently associated with plasma viral
load, previous history of TB, low socioeconomic status or sex. Despite similar virological
responses to HAART, blood CD4 cell count increases were much smaller among patients
who developed TB than among those who remained free of TB.
Conclusions: Incidence of TB continues to decrease during the first 5 years of HAART
and so HAART may contribute more to TB control in low-income countries than was
previously estimated from short-term follow-up. Patients with advanced pretreatment
immunodeficiency had persistently increased risk of TB during HAART; this may reflect
limited capacity for immune restoration among such patients.
 2005 Lippincott Williams & Wilkins
AIDS 2005, 19:2109–2116
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Introduction
Use of HAART has dramatically decreased HIV-
associated morbidity and mortality in many high-income
countries since the mid 1990s [1–4]. Suppression of
viral replication permits both quantitative and functio-
nal reconstitution of the immune system [5,6]. As a
result, primary and secondary prophylaxis for many
opportunistic infections that occur among patients with
advanced immunodeficiency can subsequently be dis-
continued [7–10]. The risk of recurrence of these low
virulence opportunistic pathogens, including cytomega-
lovirus, Pneumocystis jirovecii, Mycobacterium avium com-
plex, Toxoplasma gondii and Cryptococcus neoformans is
generally very low once blood CD4 cell counts have
reached stable levels > 200 cells/ml [7].
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Studies conducted in countries with either low or high
TB prevalence have also shown that TB incidence is
reduced by 70–90% in HIV-infected cohorts receiving
HAART [11–16]. However, in contrast to low-virulence
pathogens, increasing evidence suggests that significant
rates of TB persist during HAART [16–18]. Therefore,
although the risk of TB is greatly diminished during
treatment, the risk nevertheless remains substantially
higher than that among individuals who do not have HIV.
This has important implications for the extent to which
HAART may assist in TB control in low-income
countries [19]. Modelling analysis suggests that good
effective coverage with HAART in such communities
may have relatively little impact on the overall burden of
TB over a 20-year timespan [20]. The reason for this is
that life expectancy is greatly extended during HAART
and so treated patients may develop TB at a lower rate but
over a much longer period of time [19,20]. However,
these existing analyses were based upon data from a
cohort with a short median duration of follow-up [16]
and the longer-term effect of HAART on TB incidence
rates remains undefined.
The existing TB control strategy of case-finding and
directly observed treatment of sputum smear-positive
patients using short-course antituberculosis treatment is
proving inadequate in countries with a high burden of
HIV [21,22]. The World Health Organization (WHO)
has, therefore, formulated a strategic framework aimed at
functional integration of control programmes for TB and
HIV/AIDS [23]. HAART is one element within this
framework but data are now needed to clarify the effect
that HAART will have on TB control. This study
determined TB incidence rates during HAART and
identified risk factors for TB in a treatment cohort




The study was based on the Cape Town AIDS Cohort,
which has been described in detail previously [16,24].
Patients were enrolled into this cohort from 1996
onwards when HAART was not available in the public
sector in South Africa. These patients, therefore, accessed
HAART through participation in multicentre phase III
clinical trials at the New Somerset Hospital and the
Desmond Tutu HIV Research Centre, University of
Cape Town. Participants gave informed consent and
clinical trials protocols were approved by the University of
Cape Town Clinical Research Ethics Committee.
Enrolment criteria for HAART differed between the
various trials but collectively encompassed patients with a
wide spectrum of baseline blood CD4 cell counts and
clinical stages [16]. Patients were clinically staged using
the WHO criteria. Demographic data were recorded,
including socioeconomic status according to the Cape
Metropolitan Council suburbs composite index, as des-
cribed previously [16]. At baseline and at each follow-up
time-point, patients were clinically assessed and sympto-
matic disease was investigated. All patients received at least
three antiretroviral drugs: a non-nucleoside reverse trans-
criptase inhibitor and two nucleoside reverse transcriptase
inhibitors; or three nucleoside reverse transcriptase in-
hibitors; or a protease inhibitor with two nucleoside
reverse transcriptase inhibitors. Patients were reviewed
routinely every 2–3 months or more frequently if cli-
nically indicated. Blood CD4 cell counts and plasma viral
load were measured every 2–3 months. Systematic
clinical records were maintained and were used to update
a prospective electronic database. Patients were excluded
from the analysis if they were receiving TB treatment
at enrolment.
Case definition for tuberculosis
TB was defined as either definite – culture of
Mycobacterium tuberculosis or a postmortem diagnosis of
active TB – or presumptive – acid-fast bacilli present in
sputum or tissue samples or caseating granulomata seen in
histological samples obtained from a patient with a clinical
presentation consistent with TB and who subsequently
responded to antituberculosis treatment.
Statistical analysis
Differences in proportions were compared by x2 test.
Intraindividual paired comparisons of median CD4 cell
counts and plasma HIV RNA concentrations were
carried out using the Wilcoxon signed rank test. The
Mann–Whitney U test was used to compare these values
between different groups of subjects. Trend analyses were
conducted using Cochrane–Armitage test for linear
trend. All tests were two sided and a P value of 0.05 was
considered significant.
TB incidence density rate (IDR) was defined as the
number of new episodes of TB occurring per
100 patient-years of observation. The analysis was further
stratified by the baseline HIV RNA viral load (< 5 or
 5 log10 copies/ml), CD4 cell count (< 100 or
 100 cells/ml), WHO clinical stage (stage 3 or 4 versus
1 or 2), socioeconomic status, previous history of TB, age
(above or at/below median age), and gender. Different
CD4 cell count categories were modelled, but a cut-off
of 100 cells/ml was used in the final analysis because
it was significantly associated with risk of TB in this
cohort.
Kaplan–Meier plots were used for TB-free survival
probabilities. TB-free survival was defined as the time
from enrolment to the date of TB diagnosis, death from
any cause or the last follow-up visit. TB-free survival was
stratified further by baseline immunological and clinical










status and was compared using the generalized log rank
test. Univariate and multivariate Cox proportional
hazards regression models were fitted to determine the
risk of TB, which was expressed as a rate ratio. Variables
were considered for inclusion into the multivariate model
if they were found associated with the risk of TB in the
univariate analyses at P < 0.15. Past history of TB was
included a priori in view of previously published findings
[17]. The assumption of proportional hazards was
examined by plotting the log[log(survival function)]
estimates against log time plots. When determining the
effect of response to HAARTon risk of TB, blood CD4
cell count and plasma viral load measurements made
within the 3 months prior to TB diagnoses were used.
PEPI version 4.0 (Sagebrush Press, Salt Lake City, Utah,
USA), STATISTICA release 6.6 (Tulsa, Texas, USA) and
SAS version 8.2 (SAS, Cary, North Carolina, USA)
software were used for data analysis.
Results
Patients and follow-up
Between 1996 and 2005, 363 patients received HAART.
At enrolment, 17 patients were receiving TB treatment
and were, therefore, excluded from the analysis. At
baseline, the remaining 346 patients had a median age of
33 years [interquartile range (IQR), 28–40], 190 (55%)
were male and 178 (51%) were of low socioeconomic
status. Their median blood CD4 cell count was 242 cells/
ml (IQR, 120–343); median plasma viral load was
4.9 log10 copies/ml (IQR, 4.4–5.5); 178 (51%) had
symptomatic disease (WHO clinical stages 3 or 4); and
47 (14%) had a previous episode of TB that had been
diagnosed a median of 13 months (IQR, 9–23) prior
to enrolment.
The median duration of follow-up was 40 months (IQR,
18–53; range, 0.78–104). During a total of 1108 person-
years of observation, 27 cases of TB were diagnosed. Of
these, 20 were presumptive and 7 definite; 22 were
pulmonary and 5 were extrapulmonary. Of 30 deaths
within the cohort, three (10%) were among those who
were diagnosed with TB.
TB incidence rates
All 27 episodes of TB occurred within the first 5 years of
follow-up and the overall TB IDR was 2.44/100 person-
years [95% confidence interval (CI), 1.61–3.54]. A
significant reduction in IDR was observed over the
5-year period, decreasing from 3.35/100 person-years in
the first year to 1.01/100 person-years in the fifth year
(Fig. 1). It was possible that this decrease resulted from a
changing cohort composition during follow-up. How-
ever, trend analysis revealed that the proportion of
patients remaining in the cohort from year to year did not
differ according the risk factors identified in subsequent
analysis: WHO clinical stage (P ¼ 0.41 for trend),
baseline CD4 cell count < 100 cells/ml (P ¼ 0.24 for
trend) and age (P ¼ 0.07 for trend).
Baseline characteristics and risk of tuberculosis
TB incidence rates were calculated for patients stratified
by baseline characteristics (Table 1). This analysis showed
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significantly higher incidence rates among those with the
following characteristics: age < 33 years (median age of
the cohort), nadir blood CD4 cell counts < 100 cells/ml,
baseline plasma viral load  5 log copies/ml and
symptomatic (WHO stage 3 and 4) disease at enrolment.
Incidence rates did not differ according to sex, socio-
economic status or previous history of TB.
The TB-free survival proportion for the total cohort over
the 5-year follow-up period was 0.88 (Fig. 2a). However,
the 5-year TB-free survival proportion was significantly
lower among patients with baseline CD4 cell count
< 100 cells/ml than in those with  100 cells/ml (81%
versus 92%; Fig. 2b). Similarly, the survival proportion
was lower among patients with baseline WHO stage 3 or
4 compared with those with WHO stage 1 or 2 (81%
versus 94%; Fig. 2c). The lowest 5-year TB-free survival
proportion was among patients with WHO stage 3 or 4
disease and who also had a CD4 cell count< 100 cells/ml
(Fig. 2d). Of the total TB episodes occurring among this
latter subgroup, 50% developed during the first 6 months
of HAART.
Cox regression analyses were used to analyse risk factors
for TB and showed that the risk of TB was independently
associated with a baseline CD4 cell count< 100 cells/ml,
WHO clinical stage 3 or 4 and age < 33 years (Table 2).
Past history of TB was included in the multivariate
analysis a priori and, although it was not associated with
risk of TB in the univariate analysis, there was a trend in
multivariate analysis towards a past history having a
protective effect against TB. A subanalysis assessing risk
factors associated with development of TB during the first
year of ART alone showed that the single variable
independently associated with risk of TB was a baseline
blood CD4 cell count < 100 cells/ml (adjusted risk ratio,
6.14; 95% CI, 1.44–26.01; P ¼ 0.01).
Tuberculosis and response to HAART
Having determined the effect of baseline patient
characteristics on risk of TB, a further analysis examined
whether the virological and immunological responses to
HAARTwere also associated with risk of TB. Among the
27 patients who developed TB, the median plasma viral
load at the time TB was diagnosed was 2.98 log10 copies/
ml (IQR, 2.60–4.16), which was significantly lower than
that at enrolment (5.38 log10 copies/ml; IQR, 4.69–
5.87) (P < 0.0001; Fig. 3a). Furthermore, the median
blood CD4 cell count at the time of TB diagnosis
(198 cells/ml; IQR, 79–397) was significantly higher
than at baseline (112 cells/ml; IQR, 58–253) (P ¼ 0.025)
(Fig. 3b). These data indicated that those who developed
TB had responded virologically and immunologically
to HAART at the time of TB diagnosis. However,
although the rates of viral load suppression did not differ
significantly between those patients who developed TB
and those who remained free of TB (Fig. 3c), the
immunological responses of the two groups differed
markedly. The median increase in blood CD4 cell count
among those who developed TB (74 cells/ml; IQR,
70–76) was significantly smaller than that of patients who
remained free of TB (248 cells/ml; IQR, 185–312)
(P ¼ 0.007; Fig. 3d). Therefore, TB developed among
patients whose immunological responses to HAART
were suboptimal.
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Table 1. Tuberculosis incidence density rate stratified by baseline sociodemographic and clinical characteristics.
Characteristics No. of patients Person-years No. with TB TB IDR (95% CI)a P valueb
Total Patients 346 1108.8 27 2.44 (1.61–3.54)
Age (years)
< 33c 162 475.5 18 3.79 (2.25–5.98)
 33 184 633.2 9 1.42 (0.65–2.70) < 0.01
Sex
Male 190 632.1 12 1.90 (0.98–3.31)
Female 156 476.7 15 3.15 (1.76–5.19) 0.19
Socioeconomic status
Low 178 650.6 17 3.03 (1.77–4.86)
High 168 548.2 10 1.82 (0.88–3.36) 0.36
Past history of TB
Yes 47 155.4 3 1.93 (0.39–5.64)
No 299 953.5 24 2.52 (1.61–3.74) 0.64
CD4 cell count (cells/ml)
 100 273 898.8 15 1.67 (0.93–2.75)
< 100 73 210.1 12 5.71 (2.95–9.96) < 0.0001
Viral load (log10 copies/ml)
< 5 199 633.1 10 1.58 (0.76–2.90)
 5 147 475.9 17 3.57 (2.14–5.72) 0.04
WHO clinical stage
Stage1 or 2 168 567.4 6 1.06 (0.39–2.30)
Stage3 or 4 178 541.4 21 3.88 (2.40–5.98) 0.003
TB, tuberculosis; IDR, incidence density rate (per 100 person-years); CI, confidence interval.
bObtained by x2 test for difference in TB IDR.











This study documented the incidence rates and risk
factors for TB in a South African cohort of patients
receiving HAART over a median duration of follow-up
of 40 months. Previous studies in low-income countries
have been of much shorter follow-up and have not
documented time-dependent changes in TB incidence
rates during HAART [15–17]. A further important
strength of this cohort is that broad enrolment criteria for





































































Fig. 2. Kaplan–Meier plots of tuberculosis (TB)-free survival proportion. (a) In the total cohort; (b) among patients stratified by
baseline CD4 cell count: - - -, > 100 cells/ml; –—, < 100 cells/ml); (c) among patients stratified by WHO clinical stage of disease:
- - -, - - -, WHO stage 1 or 2; –—, WHO stage 3 or 4; (d) among patients with baseline CD4 cell count < 100 cells/ml and WHO
stage 3 or 4 (–—) compared with the remainder of the cohort (- - -). P values from the log rank test are given.
Table 2. Cox regression analyses of predictors of tuberculosis in the whole cohort.
Variable
Univariate analysis Multivariate analysis
RR, (95% CI) P valuea ARR, (95% CI) P valuea
Age (years)
< 33b 2.23 (1.02–4.88) 0.04 2.86 (1.29–6.34) 0.01
 33 1 1
Past history of tuberculosis
Yes 0.76 (0.23–2.53) 0.66 0.31 (0.09–1.08) 0.07
No 1 1
CD4 cell count (cells/ml)
 100 1 1
< 100 3.50 (1.62–7.56) 0.001 2.38 (1.01–5.60) 0.04
Viral load (log10 copies/ml) 1.74 (1.03–2.94) 0.04 1.28 (0.72–2.29) 0.40
WHO clinical stage
Stage 1 or 2 1 1
Stage 3 or 4 3.72(1.50–9.26) 0.005 3.60 (1.32–9.82) 0.01
RR, rate ratio; ARR, adjusted rate ratio; CI, confidence interval.
aObtained by x2 test for difference in tuberculosis incidence density rate (per 100 person-years)










HAARTresulted in a cohort with diverse baseline patient
characteristics, including a wide spectrum of baseline
blood CD4 cell counts and WHO clinical stages of
disease. This increased the power of the analysis to
identify risk factors for TB. All diagnoses were supported
by microbiological or histological evidence, further
strengthening the data. However, the low event frequ-
ency beyond 5 years of follow-up prevented estimation of
TB incidence rates beyond this time-point, and a larger
cohort would be needed to examine this. Furthermore,
data from this hospital-based cohort may not reflect TB
incidence rates observed in community-based HAART
programmes.
We have previously reported from this same cohort that
HAART reduces the incidence of TB by approximately
80%; however, the mean duration of HAART in this
previous analysis was 16.8 months [16]. Data in the
present study showed an ongoing time-dependent
reduction in TB incidence, which was more than
three-fold lower in the third year of HAART compared
with the first year. These data have implications for
mathematical modelling calculations that assume that
HAART is likely to have limited impact on the TB
incidence at the community level in low-income
countries [20]. The previously reported TB incidence
rate in this cohort was 2.4/100 person-years over a mean
of 16.8 months receiving HAART [16]; however, the
present data show that the rate further decreased to
approximately 1.0/100 person-years after 5 years of
treatment. These new data suggest that the likely long-
term impact of HAARTon the community burden of TB
may be greater than previously estimated.
The decreases in TB incidence rates observed in this study
are likely to reflect time-dependent changes in TB-
specific immune function. The extent of immune
reconstitution resulting from HAART is greatest during
the first 2 years of treatment, with small further
increments in CD4 cell numbers occurring in the longer
term among some patients [19]. Such a pattern was
mirrored by the reductions TB incidence rates observed
in this study (Fig. 1). However, increasing evidence
suggests that long-term restoration of immune cell
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Fig. 3. Changes in plasma viral load (VL; log copies/ml) and blood CD4 cell counts (cells/ml) during HAART. Among patients
who developed tuberculosis (TB; n ¼ 27), median plasma VL at baseline was compared with that at the time TB was diagnosed (a),
and the blood CD4 cell count at baseline was compared with that at the time of TB diagnosis (b). Box and whisker plots show the
median (square), 25th and 75th centiles (box) and range (whiskers). (c) The percentage of patients with plasma VL suppressed to
< 400 copies/ml during follow-up comparing those who remained free of TB with those who developed TB. (d) The median











phenotype and function are limited, even among the
minority of patients whose blood CD4 cell counts
normalize [19,25,26]. From an immunological perspect-
ive, it is, therefore, unlikely that TB risk during long-term
HAARTwill return to the levels seen among individuals
who do not have HIV infection. An alternative explana-
tion for the reduction in TB incidence rates during
follow-up, the possibility that an element of survival bias
may have resulted from deaths during follow-up (n ¼ 30),
cannot be excluded. However, the majority of deaths
occurred early after initiation of treatment and could
not account for ongoing reduction in TB rates over
several years. Moreover, analysis of cohort composition
during follow-up did not reveal significant changes in
the proportion of patients who had identified risk factors
for TB.
We have shown in this study that age < 33 years (median
age of the cohort), baseline blood CD4 cell count
(< 100 cells/ml) and WHO clinical stages 3 and 4 were all
independently associated with a increased risk of TB. It is
unclear why younger age was a risk factor, but this may
possibly reflect behavioural differences that affect
exposure. In the analysis of baseline blood CD4 cell
count as a risk factor, categorization of patients using a
cut-off of 100 cells/ml represented the best-fit for
regression analyses but does not necessarily represent a
risk threshold. Risk factors for TB found in this study
contrast markedly with the findings of a study from West
Africa [17]. In this study, past history of TB was the only
risk factor for development of TB during HAART.
However, the study had design limitations related to the
size of the study population, the number of TB cases,
diagnostic criteria for TB and restricted cohort compo-
sition [27]. In settings with high TB incidence but low
rates of multidrug resistance, a 6-month course of
antituberculosis treatment containing rifampin might
rather be expected to confer a time-limited reduction in
TB risk among HIV-infected individuals, as was sugges-
ted by the trend seen in the multivariate analysis in the
present study.
Among HIV-infected individuals who are not receiving
HAART, risk of TB increases with increasing HIV-
associated immunodeficiency [28]. The data presented
here indicate that those with the most advanced pre-
treatment immunodeficiency (as shown by both blood
CD4 cell count and WHO clinical stage) retain the
highest risk of TB during HAART. This may reflect the
fact that the greater the degree of pre-HAART immuno-
deficiency, the more prolonged the period of treatment
required to restore immune function. Moreover,
advanced pretreatment immunodeficiency also limits
the extent to which immune function can be restored in
the long term [19,25,26,29]. Treatment criteria in some
national antiretroviral programmes in sub-Saharan Africa,
including South Africa, include only those with stage 4
disease and CD4 cell counts < 200 cells/ml (WHO 2002
recommendations [30]). Treatment according to these
recommendations may limit the extent to which long-
term TB-specific immune responses may be restored in
many patients. This, in turn, may restrict the potential
benefit of widespread use of HAART on TB control.
Our data show that TB developed among individuals
who were responding to HAART. However, a more
important finding was that median increases in blood
CD4 cell count were much smaller among those who
developed TB than in those who did not. Although
virological response rates were also lower among those
who developed TB, the difference was not statistically
different and did not provide an explanation for the major
difference in CD4 cell responses. Acute TB itself causes
a transient CD4 lymphocytopenia, which may in part
reverse during treatment [31]; however, this also would
not explain the major persistent CD4 cell count
difference between the two groups. The likeliest explana-
tion is that a proportion of HIV-infected patients,
especially those with low nadir CD4 cell counts, have
poor CD4 cell responses to HAART [32,33] that may
in some be related to lack of viral suppression. These
patients are likely to retain a chronically heightened risk
of TB.
Despite the major beneficial effects of HAART, TB
incidence rates in this cohort after 5 years of HAART
were still approximately 1000 cases per 100 000 popula-
tion every year. Further longer-term studies of larger
cohorts are needed to determine whether incidence rates
continue to decrease beyond 5 years of HAART. Adjunc-
tive strategies to reduce the risk of TB further should also
be explored. Such interventions might include ones that
boost immunological recovery during HAART, vaccina-
tion during HAART to increase TB-specific immunity
or use of isoniazid prophylaxis coadministered with
HAART. Such use of isoniazid within the South African
national antiretroviral programme would raise two im-
portant issues. First, stavudine is used within the first-line
regimen and concurrent use of isoniazid is likely to
increase the high rates of drug-induced neuropathy
[34]. Second, incidence rates of active TB during the
initial months of HAART in local community-based
programmes are extremely high [19], giving rise to the
possibility that significant numbers of patients with un-
diagnosed active TB might inadvertently receive isoniazid
monotherapy. Consequently, the practicalities and the
risk–benefits of such a strategy would have to be carefully
evaluated.
In summary, long-term HAART confers a greater
reduction in TB risk than previously reported and
HAART may, therefore, contribute more to TB control
in low-income countries than previously estimated. TB
risk is not only strongly associated with advanced baseline
immunodeficiency but also with suboptimal CD4 cell
count responses during HAART. Additional strategies to










reduce TB rates further during HAART need to
be explored.
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The countries of southern Africa are currently at the epicentre 
of the HIV pandemic, and as a consequence of this annual 
tuberculosis (TB) notification rates in these countries have 
increased 2- to 5-fold since 1990.1 An estimated 2.4 million new 
TB cases and 540 000 TB-related deaths occur in sub-Saharan 
Africa annually and this regional epidemic is fuelling a global 
increase in TB incidence of 1% per annum.1,2 In response to this 
HIV-associated TB epidemic the World Health Organization 
(WHO) Committee for Africa declared an African regional 
emergency mandating ‘urgent and extraordinary actions’.3 
   In South Africa some communities have among the highest 
TB incidence rates in the world, with annual TB notification 
rates in some townships in the Western Cape exceeding            
1 000/100 000 in 2003.4 We have more recently described a 
community with TB notification rates approaching 1 500/     
100 000 and rates of over 2 500/100 000 among those aged 
30 - 49 years.5 The majority of this disease burden is HIV-
associated, and even in townships where HIV prevalence rates 
are now stabilising, the sobering reality is that TB incidence 
rates are likely to continue to rise in these communities for 
a further number of years.2,5 This lag between the epidemics 
is because as the HIV epidemic in a community matures, the 
proportion of individuals with advanced immunodeficiency 
continues to increase after HIV prevalence has plateaued. Thus, 
although TB incidence has reached unprecedented levels in 
many communities heavily affected by HIV, further increases 
may occur for some years to come in the absence of further 
effective interventions.
   Although the WHO TB control strategy based on DOTS 
(directly observed treatment, short course) is central to TB 
control efforts globally, it has failed to contain the African TB 
epidemic. It is now clear that although the DOTS strategy is 
necessary, it is insufficient. Additional measures are needed in 
countries with high HIV prevalence. The WHO has therefore 
formulated a strategic framework aimed at functional 
integration of control programmes for TB and HIV/AIDS.6 
It is hoped that a combination of multiple interventions may 
provide a more concerted approach to these epidemics.
   Highly active antiretroviral treatment (HAART) potentially 
has a significant role to play within that strategic framework. 
Since HAART is associated with huge reductions in HIV-
associated morbidity and mortality,7,8 one might anticipate that, 
as access to HAART is scaled up in resource-limited settings, 
this might have a beneficial impact on TB control. In support 
of this sup osition, numbers of cohort studies from both high-
income and resource-limited settings have demonstrated that 
HAART reduces TB incidence by 70 - 90% during short-term 
follow-up.9 In a study in Cape Town this benefit was observed 
among patients with a broad range of baseline blood CD4 cell 
counts and WHO clinical stages of disease.10 Paradoxically, 
however, mathematical modelling calculations suggest that 
widespread use of HAART may have very limited impact on 
TB burden.11 Here we explore the reasons why. 
   The proven efficacy of HAART in reducing short-term risk of 
TB in a treatment cohort does not necessarily reflect the likely 
long-term impact of HAART as a TB control intervention at 




Antiretroviral treatment (ART) is extremely effective in 
reducing the risk of end stage opportunistic infections such 
as cryptococcal meningitis and pneumocystis pneumonia by 
increasing CD4 cell counts above a safe threshold level. In 
contrast, the risk of TB is increased even among patients with 
high CD4 cell counts and so a safe CD4 cell count threshold 
for minimising risk of TB does not exist. Moreover, although 
HAART substantially restores functional TB-specific immune 
responses, this is almost certainly incomplete in the long term.9 
This is likely to explain why TB incidence rates in the Cape 
Town AIDS cohort have remained elevated at 1  000/100 000/
year after 5 years of HAART.12 Furthermore, in a community-
based treatment cohort in Gugulethu, we estimate that the 




Dr Stephen D Lawn is Consultant Physician in Infectious 
Diseases and Tropical Medicine and a senior lecturer at the 
London School of Hygiene and Tropical Medicine. He is based 
in the Desmond Tutu HIV Centre at the Institute of Infectious 
Diseases and Molecular Medicine at the University of Cape Town, 
where his major research interest is HIV-associated tuberculosis.
   Professor Robin Wood is head of the Desmond Tutu HIV Centre. 
His research interests are antiretroviral treatment  and tuberculosis, 
and he has published widely in this field.
502
June 2006, Vol. 96, No. 6  SAMJ












remains more than 5-fold greater than the rate among non-
HIV-infected individuals living in the same community (S 
Lawn – unpublished data, 2006). Thus, although HAART is 
associated with a very substantial reduction in risk of TB, the 
effect is nevertheless suboptimal. 
Effective ART coverage
The effective coverage of HAART (reflecting both access and 
adherence to treatment) achieved in a community is obviously 
another important factor affecting the impact of HAART on 
TB control. Although high levels of adherence have been 
demonstrated to be achievable in South African communities,13 
national HAART coverage was estimated at just 10 - 14% in 
June 2005.14 Therefore, at present the low levels of coverage are 
unlikely to have much impact on TB rates at the national level. 
How early HAART is initiated
In high TB prevalence settings, the timing of HAART initiation 
may have a major impact on an individual’s lifetime risk of 
TB. If HAART is initiated late in the course of the disease, 
a significant proportion of HIV-infected individuals will 
have had TB before initiating HAART. For example, in a 
community-based ART service in Gugulethu, patients have a 
median baseline CD4 cell count of < 100 cells/μl;15 51% of them 
have had TB before programme entry, most of which was HIV-
associated (S Lawn – unpublished data, 2006). HAART would 
have to be commenced earlier in the course of disease to have a 
more significant impact on TB burden in these individuals.
   In South Africa utilisation of the WHO 2002    
recommendations16 in the national antiretroviral treatment 
guidelines17 restricts treatment in the public sector to those 
with an AIDS diagnosis or a CD4 cell count < 200 cells/μl. 
In contrast, many other countries in sub-Saharan Africa are 
using the revised 2003 guidelines,18 which recommend earlier 
initiation of therapy. One of the consequences of South African 
policy may be to limit the potential impact of ART on TB-
related morbidity and mortality as is suggested by previous 
mathematical modelling calculations.11  
Increased life expectancy
A further critical variable in determining the impact of HAART 
on TB control is the extent to which this treatment prolongs 
life. We have shown that HAART in Cape Town leads to a 
dramatic decrease in HIV-associated mortality.14 If patients do 
not die then they of course remain at risk of developing TB 
and adding to the community burden of disease. Therefore, 
if HAART were to reduce the annual risk of TB 10-fold, for 
example, and yet prolong life expectancy 10-fold, then there 
would be no net reduction in the individual’s lifetime risk of 
TB during HAART. If risk of TB were reduced 10-fold and life 
expectancy increased 15-fold, however, then lifetime risk of TB 
could paradoxically increase. 
   In conclusion, HIV is driving the current TB epidemic in 
South Africa and rates of HIV-associated TB may continue 
to increase even in communities where HIV prevalence has 
stabilised. HAART roll-out is unlikely to have a substantial 
beneficial impact on this TB epidemic in the foreseeable future 
because: (i) although TB risk reduction is substantial during 
HAART it is incomplete; (ii) patients typically initiate HAART 
with advanced immunodeficiency and this is associated with 
high risk of TB both before and during early HAART; (iii) 
community coverage with HAART is currently low; and (iv) 
life expectancy is increased by HAART, greatly extending 
the period during which patients may develop TB. Sentinel 
communities with good disease surveillance are needed to 
better understand the dynamics of the TB epidemic during 
HAART roll-out. Meanwhile, increased resources are needed 
to strengthen the South African HIV prevention and TB control 
programmes. Additional TB control strategies such as active 
TB case finding and use of isoniazid prophylaxis need to be 
evaluated and where appropriate implemented urgently.
   SDL is funded by the Wellcome Trust, London, UK.
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To the Editor—Breen et al. [1] reported
a retrospective analysis of virological re-
sponses to highly active antiretroviral
treatment (HAART) among patients in
London who were receiving concomitant
treatment for tuberculosis (TB). Despite
the potential for pharmacokinetic drug in-
teractions and the increased risk of treat-
ment interruptions due to drug intoler-
ance or cotoxicity, virological responses in
these patients were nevertheless similar to
those observed in control subjects who did
not have TB. This is an important finding.
The authors reasoned that “specialist care
provided by a team experienced in treating
both tuberculosis and HIV could over-
come the potential difficulties” (p. 1437)
in the concurrent management of these 2
infections. Moreover, the fact that the
group of patients with TB received 5 dif-
ferent drug regimens that contained 31
different drug combinations was perceived
by the authors as reflecting a need for
highly individualized care, which was po-
tentially responsible for the positive out-
comes. If highly individualized care deliv-
ered by specialists is required, then this
has great implications for the provision of
care to the huge number of patients with
TB receiving HAART in resource-limited
settings.
A majority of the global burden of HIV-
associated TB is in sub-Saharan Africa [2],
and rates in southern Africa have reached
almost unprecedented levels [3]. Access to
antiretroviral treatment in the region is
expanding, but it can only be delivered us-
ing a simplified public-health approach,
rather than individualized patient care. At
a community-based public-sector antiret-
roviral treatment program in Cape Town,
South Africa, which now treats 12000 pa-
tients, 25% of patients at entry to the pro-
gram are already receiving anti-TB treat-
ment or have active TB [4]. This burden
of TB presents a huge challenge for the
delivery of clinical care and has the po-
tential to undermine program outcomes.
However, similar to the findings of Breen
et al., we recently reported that concurrent
anti-TB treatment does not affect virolog-
ical or immunological responses [4]. HIV
loads were suppressed to !400 copies/mL
in 194% of patients at 16 and 48 weeks
whether the patients received concurrent
treatment containing rifampicin for TB or
not. HAART was delivered using a sim-
plified public-health approach, in accor-
dance with World Health Organization
guidelines [5], with a nonnucleoside re-
verse-transcriptase inhibitor (NNRTI)–
based first-line regimen. Thus, excellent
virological outcomes among antiretrovi-
ral-naive patients receiving anti-TB treat-
ment can be achieved on a large scale
without specialist care and using a single
standard HAART regimen.
The coadministration of rifampicin is
known to reduce plasma concentrations
of NNRTIs [6], which has led to debate
over the optimal doses of NNRTIs for pa-
tients receiving rifampicin. Breen et al. did
not report the doses used in patients who
received NNRTI-based regimens in their
study [1]. Studies in Thailand, however,
have shown that standard doses of efa-
virenz and nevirapine achieve adequate
plasma concentrations in most patients re-
ceiving rifampicin [7, 8]—when such pa-
tients were randomized to receive either
600 or 800 mg of efavirenz daily, equiv-
alent virological responses were observed
at 48 weeks [9]. Our data from South Af-
rica agree with these findings; excellent vi-
rological responses were achieved when a
standard daily dose of 600 mg of efavirenz
was used in patients receiving treatment
for TB [4].
A further critical issue for clinicians
treating patients with HIV-associated TB
is the decision of when to commence
HAART during anti-TB treatment. Al-
though early initiation might reduce risk
of HIV-associated morbidity or mortality,
this may increase the risks of immune re-
constitution disease, cotoxicity, and phar-
macokinetic interactions [6, 10]. However,
the data of Breen et al. and those from
our study in Cape Town indicate that no
improvement in immunological or viro-
logical outcomes is derived from delaying
HAART. These data therefore add weight
to the argument favoring the early initi-
ation of HAART.
In summary, excellent virological re-
sponses to HAART can be achieved among
patients receiving concurrent anti-TB treat-
ment using a standard dose efavirenz-
based regimen delivered by a simplified
public-health approach in resource-lim-
ited settings, without specialized care. The
fact that virological responses are not
undermined by the early initiation of
HAART during anti-TB treatment sup-
ports policies favoring the early initiation
of HAART.
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Reply to Lawn and Wood
To the Editor—We thank Lawn and Wood
for their interest in our data and for the
valuable information they provide regard-
ing the successful management of tuber-
culosis (TB) and HIV coinfection in an
antiretroviral program in Cape Town. De-
spite the 31 different drug combinations
used in our cohort, 62% of individuals
who received highly active antiretroviral
therapy (HAART) concurrently with anti-
TB therapy were prescribed a regimen that
contained a single nonnucleoside reverse-
transcriptase inhibitor (NNRTI), as is
most widely available in resource-poor
settings [1]. The large number of drug
combinations that we used partly reflects
the fact that, during the time period stud-
ied, the number of available antiretroviral
agents and their suggested effective com-
binations changed. In addition, 26% of
our patients were receiving HAART at the
time when they received their diagnosis of
TB, and a significant number had previ-
ously received antiretrovirals; it is these
individuals in particular whom we suggest
benefited from specialized care.
The dosing of NNRTIs administered
concomitantly with rifampicin is un-
doubtedly an important area that has yet
to be fully elucidated. In our cohort, we
followed national guidelines based on
published pharmacological data that sug-
gested using efavirenz 800 mg daily in in-
dividuals weighing 150 kg and 600 mg
daily in individuals weighing !50 kg [2,
3]. This produced excellent outcomes with
no observed increase in rates of adverse
events, compared with those in patients
receiving other HAART regimens [4]. For
reasons of practical ease and cost, it would
be beneficial to be able to use a 600-mg
dose in all cases, but this requires further
study in all ethnic groups.
We agree that the timing of HAART
initiation remains controversial and that
data that inform this decision are wel-
come. The data reported from our cohort
and that of Lawn and Wood certainly pro-
vide no reason to delay HAART, and we
observed no increase in treatment-limit-
ing adverse events according to whether
HAART was commenced within 2 months
of the TB diagnosis or later [4]. The risk
of paradoxical reactions does, however,
appear to be increased if HAART is started
early [5, 6]. We believe that the effect of
those variables that appear to be associated
with clinical outcome should be assessed
in a well-planned, prospective study.
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The Vaginal Flora of Healthy
Women Is Not Always
Dominated by Lactobacillus
Species
To the Editor—Marrazzo’s interesting ed-
itorial commentary [1] about the “enig-
matic ecological mystery” of bacterial vag-
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recent findings of several investigations
[2–5] that call into question some long-
held assumptions about this disorder. Her
essay begins with the pronouncement that
we have known for decades that the nor-
mal vagina is dominated by hydrogen per-
oxide–producing lactobacilli and then
follows this with the declaration that de-
creases in the numbers of lactobacilli have
been associated with a host of problems,
including BV, gonorrhea, HIV infection,
and cervicitis. However, several investi-
gations conducted using cultivation-in-
dependent methods have shown that a sig-
nificant proportion (!30%) of healthy
women lack appreciable numbers of Lac-
tobacillus species.
A critical problem in studies of the eti-
ology of BV is the diagnostic criteria used.
Although numerous studies have shown
that women with high numbers of Lac-
tobacillus species do not have BV, it is a
logical fallacy to conclude that women
whose vaginal communities have few or
no Lactobacillus species have BV. Formally,
this is termed a “fallacy of propositional
logic” (it is also known as “denial of the
antecedent”). Unfortunately, this fallacy is
the premise of the Nugent criteria [6] and
is a component of the Amsel criteria [7],
which are widely used for the diagnosis
of BV—for these criteria, the degree of
“healthiness” is assessed by scoring the
abundance of Lactobacillus species by
microscopic analysis of a Gram-stained
smear or wet mount prepared from a vag-
inal sample.
We postulate that, because of this logical
fallacy, BV is often misdiagnosed. This
could partly account for the reported high
incidence of so-called asymptomatic BV
in reproductive-age women [8] and could
also explain a proportion of BV treatment
failures and apparent recurrences of BV in
women. Acknowledgment that not all vag-
inal communities of healthy women are
dominated by Lactobacillus species would
also be in accordance with the observation
that the vaginal communities of postmen-
opausal women (not receiving hormone-
replacement therapy) often lack Lactoba-
cillus species, yet these individuals do not
exhibit other untoward symptoms.
We suspect that the causes of and cures
for BV will continue to be enigmatic until
it is recognized that, although “normal
and healthy” can be equated with high
numbers of lactobacilli, the converse—
“unhealthy” being equated with low num-
bers of or no lactobacilli—is not nec-
essarily true. We must be vigilant and
recognize that, for a significant proportion
of women, normal and healthy can also
occur in the absence of appreciable num-
bers of Lactobacillus species.
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Reply to Forney et al.
To the Editor—I could not agree more
with Forney et al.’s reminder [1] that our
understanding of what constitutes “nor-
mal” vaginal flora is incomplete and that
the criterion standard for diagnosing bac-
terial vaginosis (BV)—the Nugent criteria
[2]—may become tarnished as molecular
methodologies redefine the ecosystem of
the vaginal environment. In fact, my in-
tention—perhaps an overly subtle one—
in putting quotation marks around the
term “normal” in the first paragraph of
my editorial was to question what we cur-
rently believe contributes most to vaginal
health. Although the focus of my editorial
was on the natural history of BV as re-
ported by Bradshaw et al. [3], whose anal-
yses did not involve molecular analyses of
subjects’ vaginal flora, it is useful to re-
mind the Journal ’s readers of the recent
expansion of literature in this important
area, which has been extensively reviewed
elsewhere by Fredricks and myself [4]. As
these studies progress, it will be critical to
(1) determine whether the presence of
vaginal bacteria (including previously un-
defined bacteria in the Clostridiales order,
Atopobium vaginae, Eggerthella species,
and Megasphaera species) that are detected
more easily or solely by noncultivation
techniques is associated with women’s own
perceptions of abnormal vaginal symptoms
and with examination findings that are
suggestive of a disrupted vaginal environ-
ment; (2) perform the same analyses with
respect to detection of individual vaginal
Lactobacillus species; and (3) carefully as-
sess the relationship between molecular
profiles of vaginal bacteria and concur-
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as between these profiles and individual
components of the Amsel criteria [5].
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Short-term and long-term risk of tuberculosis
associated with CD4 cell recovery during
antiretroviral therapy in South Africa
Stephen D. Lawna,b, Landon Myerc,d, David Edwardsa,
Linda-Gail Bekkera and Robin Wooda
Objective: To determine the short-term and long-term risks of tuberculosis (TB)
associated with CD4 cell recovery during antiretroviral therapy (ART).
Design: Observational community-based ART cohort in South Africa.
Methods: TB incidence was determined among patients (n¼1480) receiving ART for
up to 4.5 years in a South African community-based service. Updated CD4 cell counts
were measured 4-monthly. Person-time accrued within a range of CD4 cell count strata
(CD4 cell strata) was calculated and used to derive CD4 cell-stratified TB rates. Factors
associated with incident TB were identified using Poisson regression models.
Results: Two hundred and three cases of TB were diagnosed during 2785 person-years
of observation (overall incidence, 7.3 cases/100 person-years). During person-time
accrued within CD4 cell strata 0–100, 101–200, 201–300, 301–400, 401–500
and more than 500 cells/ml unadjusted TB incidence rates were 16.8, 9.3, 5.5, 4.6,
4.2 and 1.5 cases/100 person-years, respectively (P<0.001). During early ART (first
4 months), adjusted TB rates among those with CD4 cell counts 0–200 cells/ml were
1.7-fold higher than during long-term ART (P¼0.026). Updated CD4 cell counts were
the only patient characteristic independently associated with long-term TB risk.
Conclusion: Updated CD4 cell counts were the dominant predictor of TB risk during
ART in this low-resource setting. Among those with baseline CD4 cell counts less than
200 cells/ml, the excess adjusted risk of TB during early ART was consistent with
‘unmasking’ of disease missed at baseline screening. TB incidence rates at CD4 cell
counts of 200–500 cells/ml remained high and adjunctive interventions are required. TB
prevention would be improved by ART policies that minimized the time patients spend
with CD4 cell counts below a threshold of 500 cells/ml.
 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
AIDS 2009, 23:000–000
Keywords: Africa, antiretroviral, CD4 cell, HIV, immune reconstitution,
resource-limited country, tuberculosis
Introduction
In recent years, access to antiretroviral therapy (ART) has
been rapidly scaled up in the countries of sub-Saharan
Africa, which have borne the brunt of the dual tuberculosis
(TB) and HIVepidemics. ART is associated with a 70–90%
decrease in TB incidence rates among treated individuals
[1–6] and is therefore a potentially important intervention
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to address the HIV-associated TB epidemic. Despite this,
however, studies from within the region have reported that
rates of TB during ART persist at levels much higher than
background rates [7–11].
This high burden of TB is a key challenge to ART
services in sub-Saharan Africa as this is a major cause of
morbidity and mortality and concurrent administration of
TB treatment and ART is problematic [9,11–13]. These
congregate clinical settings are also associated with
substantial risk of transmission of both drug-susceptible
and multidrug-resistant TB [14,15]. Furthermore, high
persisting rates of TB during treatment may substantially
undermine the potential for ART to effect TB control at
the population level [9,16,17].
Potential means to reduce this burden of TB might
include initiation of ART at higher CD4 cell counts [17]
and use of the interventions included within the World
Health Organization (WHO) ‘3Is policy’ [18]. However,
these approaches must be based on a clear understanding
of clinical epidemiology of TB during ART. How TB risk
changes over time in association with immune recovery
in the short-term and long-term has not been clearly
defined. Although some reports suggest that TB rates are
particularly high during the initial weeks of ART due to
immune-mediated ‘unmasking’ of subclinical disease
[19,20], this phenomenon has not previously been
quantified. Of particular importance, the CD4 cell count
threshold above which TB rates are minimized during
ART-induced immune recovery is not known. To address
these questions, we analysed data collected prospectively




The ART service in Gugulethu township in Cape Town
has been described previously [21,22]. The district has a
predominantly African population of over 300 000, the
vast majority of whom live in conditions of low
socioeconomic status. At the time of the study, the
antenatal HIV seroprevalence was approximately 30% and
the annual TB notification rate exceeded 1500/100 000.
National ART guidelines were based on WHO 2002
recommendations [23], providing free treatment for those
with a prior AIDS diagnosis (WHO stage 4 disease) or a
blood CD4 cell count less than 200 cells/ml. First-line
ART consisted of stavudine, lamivudine and a non-
nucleoside reverse transcriptase inhibitor (predominantly
efavirenz). Treatment compliance was high with over
90% of patients achieving viral load suppression less than
400 copies/ml [22] and with a virological failure rate of
approximately 2% of patients per year [24]. In keeping
with current national practice, patients receiving ART
did not receive isoniazid preventive therapy (IPT).
A TB screening questionnaire was used routinely at
baseline to identify symptomatic patients for TB
investigations, and during ART investigations for TB
were conducted when clinically indicated. Available tests
include sputum smear fluorescence microscopy, auto-
mated liquid culture of sputum (MGIT 960; Becton
Dickinson, Sparks, Maryland, USA), sputum induction,
chest radiology, abdominal ultrasonography and fine
needle lymph node aspiration for cytology. Microbiolo-
gical specimens were processed within nationally
accredited laboratories.
Blood CD4 cell counts (CD4 cell counts) and plasma
viral load measurements were done routinely at baseline
and 4-monthly during ART together with clinical
review. Patients had open access to the clinic in the event
of intercurrent illnesses. Detailed structured clinical and
laboratory records were maintained for every patient
visit. Data were transferred on a weekly basis to an
electronic database. Patients requiring hospital admission
were referred to a nearby 200-bed facility. Information
on in-patient care was gained from discharge letters,
hospital and laboratory records and post-mortem
examinations. Deaths and losses to follow-up were
ascertained by active community-based follow-up as
previously described [25].
Collection of data on this study population for research
purposes was approved by the Research Ethics Commit-
tee of the University of Cape Town and all patients
enrolled gave written informed consent.
Definitions
Incident TB was defined as the first new clinical episode
of TB diagnosed during ART for which the date of onset
of overt symptoms occurred after ART initiation; TB
episodes were dated according to symptom onset. The
terms ‘early’ and ‘short-term’ ART were used inter-
changeably and were defined as the first 4 months of
treatment. ‘Long-term’ ART was defined as treatment
beyond 4 months. The terms ‘updated CD4 cell count’
and ‘updated viral load’ were used to refer to follow-up
measurements during ART. TB diagnoses fulfilled
WHO criteria for smear-positive pulmonary TB,
smear-negative pulmonary TB or extrapulmonary TB
[26].
Data analysis
Data were analysed using STATA version 10.0 (College
Station, Texas, USA). Data from all patients who initiated
ART between September 2002 and March 2006 were
included. Person-time at risk of TB was accrued from the
date of starting ART until either occurrence of incident
TB, death, loss to follow-up, transfer to another ART
programme or censoring of observation in early 2007. All
person-time of observation accrued during treatment of
prevalent TB present at baseline and during treatment of
incident TB during ART was excluded.
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As CD4 cell count and viral load measurements were
routinely made every 4 months, person-time was
subdivided into 4-month intervals for analysis. Each
interval was defined by the CD4 cell count measurement at
the start of the interval; in the event of missing CD4 cell
count values (<5% of all intervals), we used the mean of the
two values immediately before and after the start of the
interval. These intervals were categorized into CD4 cell
count strata (CD4 cell strata) 0–100, 101–200, 201–300,
301–400, 401–500 and more than 500 cells/ml. Total
person-time accrued within each of the CD4 cell count
strata during follow-up of the cohort was calculated.
TB incidence rates in the overall cohort and within CD4
cell count strata were calculated and Kaplan–Meier
(product limit) calculations were used to estimate TB-free
survival. We compared TB incidence during early (0–
4 months) and long-term (>4 months) ART and the
incidence of TB within CD4 cell count strata using
Poisson regression; results are presented as incidence rate
ratios (IRRs) with 95% confidence intervals (CIs). In
these analyses, variances were adjusted for clustering of
person-time on individual patients using the Huber–
White sandwich (robust) estimator.
In other analyses, Fisher’s exact and Wilcoxon rank-sum
tests were used to compare proportions and medians,
respectively, and all statistical tests are two-sided at a value
of 0.05.
Results
Cohort characteristics and follow-up
During the study period, 2000 consecutive patients were
enrolled in the programme. Those aged less than 15 years
(n¼ 161) and those who were non-naive to ART (n¼ 85)
were excluded. At data censorship, 274 (15.6%) patients
had not received ART because they had died (n¼ 91,
5.2%), were alive and awaiting treatment (n¼ 3, 0.2%) or
had been deferred from the programme for a variety of
reasons (n¼ 180, 10.3%). ART was received by 1480
(84.4%) patients; these typically had advanced immuno-
deficiency and many had previous TB diagnoses
(Table 1).
Of those who received ART, 155 (10.5%) died during
treatment, 165 (11.2%) were lost to follow-up and 91
(6.1%) were transferred or moved out of area. The
remaining 1069 (72.2%) patients were alive and receiving
ART at the time data were censored. Patients were
followed up for a median of 2.1 years [interquartile range
(IQR), 1.5–2.7; range, 1.0–4.5 years]. Overall 2785
person-years of observation accrued during follow-up
with person-time during TB treatment excluded.
During ART, 203 patients developed TB and they had
broadly similar baseline characteristics as patients who did
not develop TB except that those developing incident TB
were less likely to have prevalent TB at baseline (Table 1).
In those in whom disease site was specified (n¼ 198), 147
(74%) had pulmonary and 51 (26%) had extrapulmonary
disease. Overall 64% of cases were microbiologically
confirmed. Kaplan–Meier estimates of TB-free survival
proportions at 1, 2 and 3 years were 0.89, 0.85 and
0.82, respectively.
Association between tuberculosis incidence rates
and CD4 cell counts
The overall TB incidence rate during follow-up was
7.28 cases/100 person-years (95%CI, 6.32–8.36). Rates in
the 1st, 2nd, 3rd, 4th and 5th years of the cohort were 12.5
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Table 1. Baseline characteristics of patients who initiated antiretroviral therapy and of those who did or did not develop tuberculosis during
treatment.
Total (n¼1480) Incident TB (n¼203) No incident TB (n¼1277)
Mean age (years) 34.0 33.2 34.1
Men 448 (30) 56 (28) 392 (31)
Baseline WHO stage 1 and 2 294 (20) 35 (17) 259 (20)
3 825 (56) 112 (55) 713 (56)
4 360 (24) 56 (28) 304 (24)
Baseline CD4 cell count
Median (IQR) 97 (47–155) 95 (46–143) 97 (47–155)
150 388 (27) 45 (23) 343 (28)
100–149 308 (22) 50 (25) 258 (21)
50–99 351 (25) 49 (25) 302 (25)
<50 375 (26) 54 (27) 321 (26)
Baseline viral load
Median (IQR) 4.84 (4.44–5.25) 4.86 (4.50–5.26) 4.85 (4.44–5.26)
5.0 570 (41) 92 (44) 478 (40)
<5.0 829 (58) 118 (56) 711 (60)
History of previous TB 686 (46) 116 (57) 570 (45)
TB treatment at baseline 448 (30) 32 (16) 416 (33)
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(10.6–14.7), 4.5 (3.2–6.1), 3.2 (1.8–5.5), 4.5 (1.8–9.2)
and 2.2 (0.1–12.5) cases/100 person-years, respectively.
To provide greater insight into changes in TB incidence
rates and the association with underlying immune
recovery, we next calculated TB rates stratified according
to updated CD4 cell counts categorized into 0–100,
101–200, 201–300, 301–400, 401–500 and more than
500 cells/ml CD4 cell count strata. A strong graded
association was observed with the highest TB rates during
person-time accrued within the less than 100 cells/ml
CD4 cell stratum and the lowest during person-time
accumulated within the more than 500 cells/ml CD4 cell
stratum (Fig. 1).
Poisson regression models were used to examine risk
factors for incident TB during long-term ART. A very
strong independent association between TB risk and
updated CD4 cell counts during ART was observed
(Table 2). The adjusted TB rate associated with the lowest
CD4 cell stratum was more than nine-fold higher than
the rate associated with the highest CD4 cell stratum. TB
risk was not, however, independently associated with
baseline patient characteristics, updated viral load
measurements or duration of ART, which was included
to control for any survival effect not reflected by updated
CD4 cell counts.
Excess tuberculosis rates during early
antiretroviral therapy
Thus far we have demonstrated that TB rates during ART
were very strongly associated with updated CD4 cell
counts. However, further analyses exploring the excep-
tionally high TB rates (18.8 cases/100 person-years;
95%CI, 15.2–23.3) during the first 4 months of ART
found that the rate of TB during this period was much
higher than that during long-term ART having adjusted
for relevant covariates.
Initial unadjusted analyses showed that within the 0–100
and 101–200 cells/ml CD4 cell strata, TB rates during
early ART were approximately double the rates during
long-term ART (Fig. 2). In contrast, within the 201–
300 cells/ml CD4 cell stratum, rates in two periods did
not significantly differ. This excess TB incidence rate
observed during early ART among those with CD4 cell
counts 0–200 cells/ml was found to be confined to the
first 4 months of treatment. After adjustment for
covariates, including viral load, absolute CD4 cell count
values, clustering and variable interval duration, the
incidence rate during early ART remained significantly
higher (adjusted IRR¼ 1.66; 95%CI, 1.06–2.59;
P¼ 0.026). Thus, the excess proportion of TB cases
presenting during early ARTwas 40% (95%CI, 6–61%).
High persisting tuberculosis rates during long-
term antiretroviral therapy
As the extent of CD4 cell count recovery was the
dominant association with long-term TB incidence rates,
we next examined how CD4 cell counts changed over
4 years of ART (Fig. 3). The proportion of patients with a
CD4 cell count less than 200 cells/ml decreased steeply
from 89% at baseline, reaching less than 10% of patients
beyond 128 weeks. Conversely, the proportion of patients
attaining a CD4 cell count more than 500 cells/ml steadily
increased, representing 48% of patients after 4 years
(Fig. 3).
We next reasoned that the overall rate of TB in the cohort
would be related to the proportions of person-time
accrued at different CD4 cell count levels. Despite
excellent CD4 cell count recovery resulting in a steadily
increasing proportion of patients achieving a CD4 cell
count more than 500 cells/ml, 88% of person-time was
nevertheless associated with CD4 cell strata below
500 cells/ml. Thus, in this analysis, only 12% of













































Rate per 100 PYO 
(95%CI)
≤ 100 59 352.0 16.76 (12.76-21.62)
101-200 65 701.2 9.27 (7.15-11.82)
201-300 38 693.7 5.48 (3.88-7.52)
301-400 23 499.1 4.61 (2.92-6.91)
401-500 13 307.1 4.23 (2.25-7.24)
> 500 5 334.2 1.50 (0.49-3.49)
Fig. 1. Graph of tuberculosis incidence rates (95% confi-
dence interval, cases/100 person-years) plotted against seri-
ally updated CD4 cell counts measured during total duration
(early and late) of antiretroviral therapy. CD4 cell counts
(cells/ml) were measured at baseline and 4-monthly during
antiretroviral therapy (ART). Tuberculosis (TB) incidence rates
are seen to decrease with increasing CD4 cell counts. Data
used to derive these rates are displayed in the table beneath.
Median CD4 cell counts within the 0–100, 101–200, 201–
300, 301–400, 401–500 and more than 500 CD4 cell strata
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person-time was associated with the lowest TB rates
achievable during ART (1.5 cases/100 person-years).
Impact of baseline CD4 cell counts on
person-time within low CD4 cell strata
We also hypothesized that patients with the lowest
baseline CD4 cell counts would accrue substantially more
person-time within the lowest CD4 cell strata and thereby
remain at high risk of TB for long periods. Indeed, during
long-term ART, those with baseline CD4 cell counts of
100 cells/ml or less accrued 40% of person-time with
CD4 cell counts in the range 0–200 cells/ml compared
with just 17% of person-time accrued by those whose
baseline counts were more than 100 cells/ml (P< 0.001).
Thus, patients with the lowest baseline counts remained at
high risk of TB for a longer period of time.
Discussion
In this analysis, we calculated TB incidence rates stratified
by serially updated CD4 cell counts during ART and
compared TB rates during early and long-term treatment.
Several key findings emerged. Among patients with CD4
cell counts less than 200 cells/ml, there was a 1.7-fold
excess adjusted TB rate during early ART compared with
rates during long-term treatment (P¼ 0.026). During
long-term ART, a very strong independent association
between TB rates and updated CD4 cell counts was
observed. At CD4 cell counts of 200–500 cells/ml, TB
incidence rates remained high but were significantly
lower at CD4 cell counts exceeding a threshold of
500 cells/ml. However, despite excellent immune recov-
ery, patients spent a large majority of time at CD4 cell
counts less than 500 cells/ml and overall TB rates in the
cohort were, therefore, high. These data substantially
extend the findings of previous studies [7–11], providing
important insights that will assist in the development of
approaches to address the challenge of HIV-associated
TB.
We suggest that the excess TB rates during early ART
among those with CD4 cell counts less than 200 cells/ml
may be due to ART-induced ‘unmasking’ of subclinical
TB that was present but unrecognized at baseline [20,27].
In patients who develop ‘unmasking’ TB, rapid immune
recovery is thought to trigger host inflammatory
responses and development of symptomatic disease
[20]. Although some overt cases of ‘unmasking TB’ have
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Table 2. Risk factors for incident tuberculosis during long-term antiretroviral therapy, excluding the first 4 months of treatment.
Crude association Multivariate model
Patient characteristics IRR 95%CI P IRR 95%CI P
Age 0.99 0.97–1.02 0.605 0.99 0.97–1.01 0.307
Sex 1.04 0.73–1.48 0.845 0.99 0.67–1.46 0.969
Previous TB diagnosis 1.23 0.87–1.75 0.240 1.29 0.85–1.96 0.239
Baseline WHO stage 1 and 2 1 1
3 1.06 0.68–1.64 0.800 1.07 0.63–1.83 0.797
4 1.19 0.73–1.92 0.488 1.21 0.66–2.21 0.533
Baseline CD4 cell count (cells/ml) >150 1 1
101–150 1.18 0.76–1.84 0.466 1.12 0.70–1.79 0.632
51–100 1.05 0.67–1.65 0.832 0.78 0.45–1.35 0.369
0–50 0.94 0.59–1.50 0.795 0.66 0.37–1.18 0.162
Baseline viral load (log copies/ml) 0.88 0.71–1.10 0.258 0.92 0.71–1.20 0.548
Cohort enrolment year 1 1 1
2 0.81 0.53–1.26 0.353 0.67 0.43–1.04 0.078
3 0.89 0.61–1.30 0.545 0.63 0.41–0.96 0.030
4 0.65 0.31–1.37 0.255 0.44 0.20–0.97 0.042
Duration of ART 5–12 months 1.0 1.0
13–24 months 0.52 0.35–0.76 0.001 0.66 0.42–1.03 0.069
>24 months 0.43 0.27–0.67 <0.001 0.62 0.34–1.12 0.116
Updated CD4 cell count (cells/ml) >500 1 1
401–500 2.82 1.01–7.90 0.048 3.59 1.17–11.03 0.025
301–400 3.08 1.18–8.09 0.022 3.78 1.30–11.01 0.015
201–300 3.65 1.43–9.30 0.007 4.13 1.45–11.81 0.008
101–200 4.86 1.93–12.26 0.001 5.42 1.79–16.47 0.003
0–100 7.39 2.74–19.92 <0.001 9.21 2.69–31.52 <0.001
Updated viral load (copies/ml) <400 1
>400 1.86 1.33–2.61 <0.001 1.29 0.88–1.87 0.192
Age and baseline viral load included as continuous variables. For baseline viral load, the IRR for a 1.0 log decrease in viral load is shown. ‘Previous
TB diagnosis’ includes all TB diagnoses established at any time prior to ART initiation. ‘Updated’ CD4 cell count and viral load values are the serial
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been described [19,20,28–31], this phenomenon lacks a
clear clinical case definition [27] and has not previously
been quantified.
Several lines of indirect evidence support our hypothesis.
First, high rates of subclinical, culture-proven TB have
been detected in patients enrolling for ART in this [32]
and in other HIV cohorts in Africa [33–36]. Immune
recovery in the first 4 months of ART in this cohort is
very rapid, even in those with low baseline CD4 cell
counts [37]. In keeping with ‘unmasking’ TB, excess rates
were restricted to those with baseline CD4 cell counts less
than 200 cells/ml and were confined to early ART
[19,20,27,28]. Further corroboration is derived from a
study of Ugandan children in whom a more than two-
fold increase in TB rates during the initial months of ART
was attributed to ‘unmasking’ TB [38].
These data suggest that ‘unmasking’ TB may account
for over one-third of TB cases presenting during the
initial months of ART in this setting. CIs around this
estimate are wide, however, and confirmatory studies are
required. Pre-ART investigations for TB were routinely
done only in those with suggestive symptoms or clinical
signs. These data suggest the potential need for routine
microbiological screening for TB at baseline in all
patients starting ART in this setting and this approach is
supported by the findings of a more recent study in this
cohort [32].
Although we have previously found that CD4 cell counts
were strongly associated with TB incidence rates during
ART [9], the present study used a novel analytic approach
to derive CD4 cell-stratified TB rates, yielding important
new insights. A steep risk gradient was observed between
the highest and lowest CD4 cell strata with a more than
9-fold difference in adjusted rates. We have used a similar
analytic approach to examine changing mortality risk in
this cohort [39]. Whereas mortality risk was found to be
largely minimized by the attainment of an updated CD4
cell count of more than 200 cells/ml, the present study
shows that a threshold of more than 500 cells/ml has to be
exceeded to minimize TB rates. Thus, eligibility criteria
for ART initiation that aim to minimize mortality risk are
not optimal for TB prevention.
Immune recovery in this cohort compared very favourably
with that observed in ART cohorts in high-income
countries [40]. Approximately half of the patients achieved
a CD4 cell count more than 500 cells/ml after 4 years of
ART (Fig. 3) and in these patients, TB rates (1.5 cases/100
person-years) remained approximately only two-fold
higher than the rate among HIV-seronegative adults in a
comparable neighbouring community (0.7 cases/100
person-years) [41]. However, despite excellent immune
recovery, the large majority of person-time in this cohort
accrued at CD4 cell counts less than 500 cells/ml, with TB
rates ranging between 4.2 and 16.8 cases/100 person-years.
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Fig. 2. CD4 cell-stratified tuberculosis incidence rates
during first 4 months of antiretroviral therapy (early anti-
retroviral therapy) and during person-time thereafter (late
antiretroviral therapy). Within each of the CD4 cell strata 0–
100, 101–200 and 201–300 cells/ml, tuberculosis (TB) inci-
dence rates during early antiretroviral therapy (ART) are
compared with rates during late ART [cases/100 person-years,
95% confidence interval (CI)]. Incidence rates and incidence
rate ratios (IRRs) for these CD4 cell strata are shown. Within
the two lowest strata (0–100 and 101–200 cells/ml), TB
incidence rates during early ART were approximately double
the rates during long-term ART in unadjusted analyses and
1.7-fold higher in adjusted analyses (P¼0.026).
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Fig. 3. Changes in CD4 cell counts during 4 years of anti-
retroviral therapy. The graph shows the changes in the
proportions (%) of patients with CD4 cell counts lying below
thresholds of 200, 500 and 1000 cells/ml with increasing
duration of antiretroviral therapy (ART). During the first year
of ART, the proportion of patients with a CD4 cell count less
than 200 cells/ml decreased steeply from 89% at baseline,
eventually accounting for less than 10% of patients. In con-
trast, the proportion of patients with CD4 cell counts more
than 500 cells/ml increased steadily over time reaching 48%
after 4 years. Only data from patients with at least two serial
measurements were included and the numbers of patients
represented at 0, 48, 96, 144 and 208 weeks were 1313,
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As a result, the overall TB incidence rate in the cohort was
high (7.3 cases/100 person-years), approximately 10-fold
higher than the rate in HIV-seronegative adults in these
communities [41].
Although this analysis only examined incident TB from
the time of ART initiation, other factors occurring just
prior to this may have influenced the findings. Many
patients enrolling in this cohort had recently completed
TB treatment, potentially conferring a relative protection
against further TB episodes [9]. Although all person-time
accrued during TB treatment was excluded from the
analysis, a similar protective effect may also have been
present during the period following TB treatment in the
many patients with TB diagnoses at baseline. These effects
may have reduced the unadjusted TB incidence rates
among those with the lowest baseline CD4 cell counts.
In multivariate analysis, baseline CD4 cell counts did not
have any predictive value for TB risk over and above that
provided by the current CD4 cell count at any given
time-point. This does not support the hypothesis that
lower baseline CD4 cell counts are associated with
increased risk of clinically significant persisting defects in
TB-specific immune function during long-term ART
[17]. Importantly, however, patients with low baseline
CD4 cell counts accrued much greater person-time
within low CD4 cell strata, thereby remaining at high TB
risk for longer periods. Thus, whereas current CD4 cell
counts are the key predictor of instantaneous TB risk,
baseline CD4 cell counts are key predictors of cumulative
long-term risk of TB during ART as was similarly found
for mortality [39].
Data from this study provide insight into the strategies
needed to reduce the long-term burden of incident TB.
Most fundamentally, the time that patients spend at low
CD4 cell counts less than 500 cells/ml needs to be
minimized. This requires both earlier HIV diagnosis and
initiation of ART at higher CD4 cell counts. Unfortu-
nately, the current South African national ART policy
restricts eligibility to those with AIDS or a CD4 cell
count of less than 200 cells/ml and therefore greatly
undermines the potential benefits of ART for TB
prevention. A change in this policy is needed to reduce
both high mortality rates [39] and to improve TB control.
Adjunctive TB prevention strategies such as the WHO
‘3Is policy’ [18] are also needed to reduce TB in ART
services. Within this policy, intensified case finding (ICF)
might be done not only at baseline but also serially (e.g.
6-monthly) during at least the first year of ARTwhen TB
rates are highest. This approach might particularly target
those with persistently low CD4 cell counts. Use of IPT
concurrently with ART is likely to reduce long-term TB
rates [42] but data from randomized controlled trials are
awaited [43]. However, initiation of IPTat the same time
as ART may be problematic because high rates of
subclinical active TB at baseline and ‘unmasking’ TB
during the first 4 months of ART may inadvertently lead
to many patients with active TB receiving isoniazid
monotherapy. In light of our findings, a logical approach
might be to consider initiating IPT after completion of
the first few months of ART.
Strengths of this study include good patient retention and
ascertainment of outcomes, frequent monitoring of CD4
cell counts and the novel analytic approach. Some person-
time may have been misclassified as CD4 cell counts
continuously change over time. Some TB disease may
have remained unascertained among those who died,
leading to underestimation of TB rates particularly in
those with the lowest CD4 cell counts. Not all TB cases
were proven by culture of Mycobacterium tuberculosis,
although the rates and proportions of pulmonary and
extrapulmonary disease reported are entirely consistent
with other data from this setting [6,8,9,41]. The multiple
lines of evidence for ‘unmasking’ TB during early ART
are indirect and yet provide a coherent and biologically
plausible explanation.
Baseline characteristics of the patients were typical of
patients in ART roll-out programmes across Africa, but
rates of loss to follow-up were comparatively low [44].
Such losses are not related to degree of immunodeficiency
in this cohort [25] and so we do not suspect they affected
the TB rates observed. The countries of southern Africa
are the areas of the world hit hardest by the TB and HIV
epidemics and the absolute TB rates recorded are likely to
be higher than those in other regions. Nevertheless, the
key relationship between TB risk and updated CD4 cell
counts is likely to be applicable in other settings.
In conclusion, low baseline CD4 cell counts and
‘unmasking’ of subclinical TB are likely to explain the
high burden of TB during the first 4 months of ART. This
may potentially be reduced by initiation of ARTat higher
baseline CD4 cell counts and more effective screening for
TB at baseline. The high long-term TB incidence is
strongly associated with the proportion of person-time at
CD4 cell counts less than 500 cells/ml and adjunctive TB
prevention interventions are undoubtedly needed.
However, the impact of ART on TB prevention in
low-resource settings would be greatly improved by ART
policies that minimize the time patients spend with CD4
cell counts less than 500 cells/ml.
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Tuberculosis-associated immune reconstitution
disease: incidence, risk factors and impact in an
antiretroviral treatment service in South Africa
Stephen D. Lawna,b, Landon Myerc,d, Linda-Gail Bekkera and
Robin Wooda
Objective: To determine the burden and impact of immune reconstitution disease
(IRD) associated with tuberculosis (TB) among patients initiating antiretroviral treatment
(ART) in sub-Saharan Africa.
Design: Retrospective analysis of a study cohort enrolled over 3 years within a
community-based ART service in South Africa.
Methods: Patients receiving treatment for TB at the time ART was initiated (n¼160)
were studied. Cases of TB-associated IRD during the first 4 months of ART were
ascertained.
Results: The median baseline CD4 cell count was 68 cells/ml [interquartile range (IQR),
29–133 cells/ml) and ART was initiated after a median of 105 days (IQR, 61–164 days)
from TB diagnosis. Although IRD was diagnosed in just 12% (n¼19) of patients overall,
IRD developed in 32% (n¼12) of those who started ART within 2 months of TB
diagnosis. Pulmonary involvement was observed in 84% (n¼16) and intra-abdominal
manifestations were also common (37%). Overall, 4% (n¼7) of the cohort required
secondary level health-care for IRD and two (1%) patients died. In multivariate analysis,
risk of IRD was strongly associated with early ART initiation and low baseline CD4 cell
count. Of patients with CD4 counts <50 cells/ml, the proportions who developed IRD
following initiation of ART within 0–30, 31–60, 61–90, 91–120 and >120 days of TB
diagnosis were 100%, 33%, 14%, 7% and 0%, respectively.
Conclusions: The risk of TB-associated IRD in this setting is very high for those with low
baseline CD4 cell counts initiating ART early in the course of antituberculosis treatment.
However, most cases were self-limiting; overall secondary health-care utilization and
mortality risk from IRD were low.  2007 Lippincott Williams & Wilkins
AIDS 2007, 21:335–341
Keywords: immune reconstitution disease, antiretroviral treatment,
tuberculosis, resource-limited country, Africa
Introduction
A majority of the global burden of HIV-associated
tuberculosis (TB) lies in sub-Saharan Africa [1] and rates
in southern Africa have reached almost unprecedented
levels [2]. Antiretroviral treatment (ART) is now
becoming more widely available in the region. However,
the fact that many patients accessing ART are already
receiving treatment for TB [3,4] presents a major
clinical challenge due to the complexities involved in
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the concurrent management of these two infections [5–
8]. In addition to high pill burden, drug co-toxicity and
pharmacokinetic drug interactions, TB-associated
immune reconstitution disease (IRD) has been reported
in up to 43% of patients in high-income countries
receiving concurrent treatment for these infections
[9,10].
Since the prevalence of TB among patients entering ART
programmes in sub-Saharan Africa is extremely high
[3,4], TB-IRD could greatly complicate the delivery of
ART in the region, causing substantial in-programme
morbidity and mortality and increasing the burden on
secondary health-care facilities. Moreover, the risks
associated with TB-IRD are important variables in the
debate over the optimal time for ART initiation in
patients with TB [7,8,10]. There are, however, no
existing published reports of the frequency and impact of
TB-IRD in ART programmes in sub-Saharan Africa.
Data concerning the burden of TB-IRD in ART
programmes in sub-Saharan Africa are clearly needed
to inform both clinicians and those involved in the
development of treatment guidelines for ART progra-
mmes. We have previously described a community-based
ART programme in Cape Town, reporting detailed
analyses of morbidity, mortality, immunological recovery
and overall programme outcomes [3,11–15]. Within this
service 25% of patients have prevalent TB at programme
entry, the majority of whom subsequently receive
overlapping antituberculosis treatment and ART [3].
Collection of detailed prospective data on this large
cohort over 3 years provided the opportunity to analyse
the burden of TB-IRD in this setting.
Methods
The ART service based at the Gugulethu Community
Health Centre in Cape Town was started in 2002 and has
previously been described in detail [11–13]. The district
has a predominantly African population of over 300 000,
the vast majority of whom live in conditions of low
socioeconomic status. In 2003 the antenatal HIV
seroprevalence was 28% and the TB notification rate
exceeded 1 000/100 000 [16]. Patients were referred from
primary care HIV clinics to theART programme. National
guidelines for use of ARTwere based on the WHO 2002
recommendations [17], which advise treatment for those
with a prior AIDS diagnosis (WHO stage 4 disease) or a
blood CD4 cell count < 200 cells/ml. First-line ART
comprised stavudine, lamivudine plus a non-nucleoside
reverse transcriptase inhibitor (predominantly efavirenz).
Treatment compliance rates were very high as reflected by
rates of viral load suppression < 400 copies/ml, which
exceeded 90% at all follow-up time-points over the first 3
years of the programme [11]. In addition to the minimum
schedule of clinic appointments at 4, 8, and 16 weeks,
patients with clinical problems such as concurrent TB were
reviewed more frequently. All patients had open access to
the clinic for medical problems during weekdays and
24-hour access to care by the nearby secondary hospital. All
care and medication was supplied free of charge to
the patients.
The high burden and diagnostic criteria for TB in this
programme have been described in detail [3]. Available
investigations for TB included sputum smear microscopy
and culture (MGIT, Becton Dickinson, Sparks, Mary-
land, USA), chest radiology, abdominal ultrasonography,
fine needle aspiration of lymphadenopathy for cytology
and culture and drug sensitivity testing of mycobacterial
isolates. Nebulized sputum induction was accessible when
required. Results of investigations for TB were cross-
checked with electronic records held by the National
Health Laboratory Service.
Detailed structured clinical and laboratory records were
maintained for every patient visit. Data were transferred on
a weekly basis to an electronic database. Patients requiring
in-patient care were referred to a nearby 200-bed
secondary hospital. Information on in-patient care was
gained from discharge letters, hospital and laboratory
records and post-mortem examinations. Deaths and losses
to follow-up were ascertained by active community-based
follow-up as described in detail previously [12,13].
Outcomes were determined for all patients. Attributable
causes of death were assigned based on all the available
information after detailed review by two specialists in
infectious diseases and HIV medicine.
Definitions
Patients with ‘prevalent TB’ included those receiving
antituberculosis treatment at entry to the ART pro-
gramme as well as patients with new TB diagnoses
established after enrolment in the programme but prior to
ART initiation. TB-IRD was diagnosed among patients
with prevalent TB who had an initial symptomatic
improvement during antituberculosis treatment followed
by deterioration of symptoms after initiation of ART,
which was not due to another opportunistic infection,
drug adverse effect, ineffective TB treatment or drug-
resistant TB [10].
Data analysis
All patients enrolled into the programme between
September 2002 and April 2005 were studied and the
period between ART initiation and the 4-month follow-
up appointment was studied. In analyses, Fisher’s exact and
Wilcoxon rank-sum tests were used to compare propor-
tions and medians, respectively. Multiple logistic regression
was used to examine the associations between IRD and
patient demographic and clinical characteristics. Regres-
sion diagnostics followed standard procedures [18]. All
P-values reported were two-sided at alpha¼ 0.05.
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Results
Patients and follow-up
A total of 756 ART-naive patients who enrolled during the
study period initiated ART. Their median age was 33 years
[interquartile range (IQR), 28–37 years] and 73% were
female. Antituberculosis treatment was being received at
the time of ART initiation by 160 (21%) patients. Those
with prevalent TB differed from those who were TB-free
in having a lower median CD4 cell count (68 cells/ml;
IQR, 29–133 cells/ml) versus 101 cells/ml (IQR, 52–
156 cells/ml; P< 0.001), a higher median viral load (4.96
versus 4.84 log RNA copies/ml; P¼ 0.003) and more
advanced WHO stages of disease (stages 3 and 4 among
62% and 38% versus 51% and 26%, respectively). Since
many patients had initiated antituberculosis treatment
prior to entering the programme whereas others had TB
diagnosed after enrolment, the duration of the interval
between TB diagnosis and ART initiation was very broad
(median 105 days; IQR, 61–164 days).
Of thepatientswithTB (n¼ 160), 142 (89%) were retained
on ART at the 4-month follow-up appointment. Of the
remaining patients, one (0.6%) was transferred-out at week
14,one (0.6%)was lost to follow-upatweek5, and16 (10%)
died. Overall a total of 60.1 person-years of observation
accrued during follow-up. Deaths were due to advanced
Kaposi’s sarcoma (n¼ 4), acute sepsis (n¼ 3), cryptococcal
immune reconstitutiondisease (n¼ 2), renal failure (n¼ 1),
and wasting syndrome with profuse chronic diarrhoea
(n¼ 2). Two patients died of TB without evidence of IRD:
one had very advanced hypoxic lung disease and the other
had activediseasedue toTBtreatmentdefault.Twopatients
died with TB-IRD as described below.
Cases of TB immune reconstitution disease
Among patientswith prevalentTB, a total of 19 (12%) were
diagnosed as having TB-IRD. Symptoms developed a
median of 2 weeks (IQR, 1.5–3.5 weeks) after initiation of
ARTand systemic as well as organ-specific symptoms were
present in all. IRD presented as an exacerbation of existing
disease manifestations alone in 10 patients with pulmonary
disease among the majority (n¼ 9) (Table 1). Seven further
patients with initial diagnoses of pulmonary TB developed
new disease manifestations at another anatomic site as well
as a concurrent exacerbation of respiratory disease in five
(Table 1). Two other patients with disseminated disease
developed IRD that culminated in death; both had
pulmonary, intra-abdominal and bone marrow involve-
ment. These two cases occurred early in the history of the
ART programme; since diagnoses were not established
ante-mortem, neither was managed as IRD.
Overall, intra-abdominal manifestations occurred in 7
(37%) IRD cases. Hepatomegally with elevated serum
concentrations of alkaline phosphatase and gamma-
glutamyl transferase but relatively normal serum concen-
trations of alanine transaminase were detected in four
patients (21%). IRD was self-limiting in the majority of
patients. Secondary level out-patient or in-patient care was
received by three and four patients, respectively, two
receivedoral corticosteroids andone required a laparotomy.
Risk factors for TB immune reconstitution
disease
Comparison of the characteristics of TB patients who
developed IRD (cases) with those who did not is shown
in Table 2. Cases had significantly lower baseline CD4 cell
counts and ARTwas initiated after a shorter interval from
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Table 1. Clinical manifestations of tuberculosis (TB)-associated
immune reconstitution disease (n U 19).
Exacerbation of existing disease manifestations (n¼10)
deterioration of pulmonary TB (n¼9)
deterioration of cervical lymphadenopathy (n¼1)
Development of new disease manifestations at another





tuberculous terminal ileitis with perforation and
peritonitis (n¼1)
cervical and intra-abdominal lymphadenopathy,
hepatomegally and splenic micro-abscesses (n¼1)
tuberculous arthropathy of left hallux (n¼1)
IRD resulting in death (n¼2)
death due to deterioration of disseminated TB with pulmonary,
intra-abdominal and bone marrow involvement
Table 2. Characteristics of patients with tuberculosis (TB) (n U 160)











Median age (years) 35 32 0.60




Patients in CD4 cell categories (cells/ml) [n (%)]
>150 0 26 (18)
100–149 2 (11) 28 (20)
50–99 5 (26) 42 (30)
<50 12 (63) 45 (32) 0.03
Median viral load (log copies/ml) 5.13 4.96 0.27
Extrapulmonary TB (%) 4 (21) 40 (28) 0.59
Time from TB diagnosis to ART (days)
Median 40 117 <0.001
Patients in time categories [n (%)]
>120 1 (5) 64 (45)
91–120 2 (11) 28 (20)
61–90 4 (21) 23 (16)
31–60 5 (26) 20 (14)
0–30 7 (37) 6 (4)
Follow-up at 4 months
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TB diagnosis. There was no significant correlation
between the baseline CD4 cell count and the delay
between TB diagnosis and ART (r, 0.09; P¼ 0.259).
Cases did not differ from those who remained IRD-free
with respect to other baseline characteristics or laboratory
results at 4 months’ follow-up (Table 2).
Among patients with baseline CD4 cell counts< 50, 50–
99, 100–149 and  150 cells/ml, IRD developed among
21%, 14%, 7% and 0%, respectively. Although only 12%
of patients overall developed TB-IRD, the proportion of
patients affected who commenced ARTwithin 2 months
of TB diagnosis was much higher (32%). Furthermore,
the risk of IRD for patients with low baseline CD4 cell
counts commencing ART early in the course of
antituberculosis treatment was especially high (Fig. 1).
Multivariate analysis that included all baseline character-
istics showed that increased odds of developing IRD was
significantly associated with lower baseline CD4 cell
counts but that the association with shorter delays from
TB diagnosis to ART initiation was particularly strong
(Table 3).
Discussion
The proportion of patients with HIV-associated TB
reported to develop IRD following initiation of ART in
high-income countries ranges between 11% and 43%
[9,19–22]. This wide variation is likely to reflect
differences in cohort characteristics, case definitions
and differences in the mean time interval between TB
diagnosis and ART initiation. Data from resource-limited
countries on TB-IRD is scarce; a rate of 8% was reported
from India [23] but a study from Tanzania reported no
cases at all [24]. This study from South Africa is the largest
series patients with overlapping ARTand antituberculosis
treatment yet reported. We found that overall 12% of TB
patients developed IRD. However, the low rate is likely to
reflect the fact that many patients were referred to the
ART programme having already completed several
months of antituberculosis treatment (median, 3.5
months) and so many were likely to be at low risk of
338 AIDS 2007, Vol 21 No 3
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Fig. 1. Graph showing the risk of TB-IRD among patients stratified by baseline CD4 cell count and by the interval between TB
diagnosis and initiation of ART (days). The proportion (%) of patients in each stratum who developed TB-IRD is displayed
graphically. The numbers of cases of TB-IRD together with the total number of patients in each stratum is displayed beneath the
graph.
Table 3. Multivariate analysis for risk factors for TB-associated
immune reconstitution disease (TB-IRD) among patients with
prevalent TB receiving antiretroviral treatment (ART) (n U 160).
RR of IRD 95% CI P
Age1 1.03 0.93–1.13 0.596
Sex
Female 1.00
Male 3.07 0.74–12.74 0.123
Baseline CD4 counta,b 0.983 0.970–0.997 0.018
Baseline viral loada 2.39 0.68–8.34 0.172
TB site
Pulmonary 1.00
Extrapulmonary 0.59 0.12–3.00 0.525
TB diagnosis to ART
delay (days)
>90 1.00
61–90 6.64 1.20–36.5 0.030
31–60 10.6 1.88–59.5 0.007
0–30 69.5 9.94–485.6 <0.001
aAnalysed as continuous variables and thus the relative risk (RR)
reflects the change in RR of TB-IRD associated with a 1-unit increase
in the independent variable.
bA decrease in CD4 cell count of 100 cells/ml is associated with a 5.3-
fold increase in the relative risk of developing IRD (P¼0.020). CI,
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IRD. Risk of TB-IRD was much higher among those
with early initiation of ART, affecting 32% of patients
initiating ARTwithin 2 months of TB diagnosis. The rate
among these patients, a more relevant comparison group,
is consistent with rates reported from high-income
countries [9,20–22].
Most previous reports of TB-IRD are from series of
patients attending referral hospitals [9,20,21,23]. In
contrast, this is the first report of TB-IRD from a
community-based ART programme in a resource-limited
setting. An important strength of this analysis is that all
patients within the programme receiving TB treatment at
the time of ART initiation were included and outcomes
for all patients are known except for one who was lost to
follow-up. Data collection was detailed and prospective;
access to unscheduled clinic visits when needed was good,
and all treatment was free of charge. As a result, data
completeness is likely to be high. All patients were ART-
naive and received a standard first-line ART regimen,
excluding these as potential variables affecting risk of
IRD. In common with most previous studies
[9,19,20,22,23], diagnoses of IRD were made retro-
spectively but were nevertheless based on systematically
collected prospective data. Although some cases of
TB-IRD have been reported to occur > 16 weeks of
ART [10], only one case occurred beyond 12 weeks and
so we restricted this analysis to the first 16 weeks of ART.
The retrospective study design may have missed some
very mild manifestations of TB-IRD but, because of
excellent cohort retention and close follow-up of cases, all
clinically relevant disease is likely to have been detected
and thus the impact of TB-IRD on this ART programme
should have been accurately assessed. The focus of this
study was on IRD presenting as clinical deterioration of
prevalent TB rather than ‘unmasking’ of new TB
presenting after ART initiation.
As the overall size of the cohort of TB patients was large,
we were able to perform multivariate analysis to identify
risk factors associated with development of IRD. As
reported previously, early initiation of ARTwas associated
with a higher risk of IRD [10,20,22]. However, in view
of the broad range of the intervals between TB diagnosis
and ART initiation, we were able to define this
relationship more clearly than has been done previously
(Fig. 1, Table 3). Risk of IRD was significantly increased
if ART was commenced within 3 months from TB
diagnosis but increased greatly when ART was initiated
within 1 month. However, as the numbers of patients and
cases within each time stratum are small, these data should
not be taken as precise estimates of risk of TB-IRD
within each stratum.
In addition to the timing of ART, we also found that
increased risk of IRD was also significantly associated
with lower baseline CD4 cell counts (Tables 2 and 3). A
similar trend has been observed in some [19,21] but not
other [9,20,23] studies. Compared to other studies, a
higher mean baseline CD4 count may explain the
unusually low rate of IRD in a study from India [23]. The
association of low CD4 cell count with increased risk of
IRD is plausible as those with the most advanced HIV-
associated immunodeficiency are likely to have higher
mycobacterial antigen load and greater impairment of
immune responses that may rapidly reverse during early
ART [25]. Some previous studies have also found
extrapulmonary TB to be associated with increased risk of
IRD [9,19,20]. However, in resource-limited settings,
patients with a diagnosis of pulmonary TB are often not
investigated further for evidence of asymptomatic
extrapulmonary involvement, probably resulting in
substantial under-diagnosis in those with advanced
immunodeficiency.
Existing studies do not show consensus on whether early
immunovirological responses to ART are risk factors for
IRD [9,20–22] although the largest of these studies did
find that risk was increased among those with a more
rapid fall in viral load [22]. In this cohort, rates of
virological suppression and immunological recovery were
exceptionally high but were not discriminatory as risk
factors for IRD. However, these measurements were
made at 16 weeks of ARTand not at the onset of IRD. In
view of the timing of these measurements, however, these
data strongly suggest that following development of IRD,
treatment compliance and responses to ART thereafter
were not undermined.
Manifestations of TB-IRD are diverse, but literature from
high-income countries [10] and from India [23] reported
cervical lymphadenitis much more frequently than was
observed in this study. This is likely to reflect true
differences in the spectrum of disease since cervical
adenitis is clinically readily apparent and is therefore
unlikely to have been missed. Respiratory manifestations
were most common but a high rate of intra-abdominal
disease was also observed, including frequent hepatic
involvement with elevation of serum concentrations of
bile cannalicular enzymes. Many patients initially treated
for pulmonary TB developed additional manifestations of
IRD at extrapulmonary sites, again reflecting likely initial
under-diagnosis of extrapulmonary involvement in
patients with pulmonary TB. In this study, two (1%)
TB patients died of IRD; both diagnoses were retro-
spective and neither was managed with either use of
corticosteroids or discontinuation of ART. This is an
important finding as a review of previous cases from high-
income countries revealed that although life-threatening
manifestations were reported there were no deaths [10].
This illustrates the importance of establishing clinical
diagnoses of TB-IRD and the need for access to
secondary level health care for some patients in this
setting. However, overall mortality associated with
TB-IRD in this cohort was low and the majority of
TB-IRD was self-limiting. Indeed, we have previously
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reported that cryptococcal IRD is a far more common
cause of death in this service [12,15].
IRD could potentially lead to a high rate of secondary
health-care utilization. However, just 4% of TB patients
were referred for either in-patient or out-patient
secondary care for this reason, representing approximately
1% of all patients in the cohort. This represents a very
small proportion of total secondary health-care utilization
by individuals accessing ART in this service, which was
received by approximately 16% of patients during the first
16 weeks of ART (Guy Harling, unpublished data).
The factors affecting the optimal timing for initiation of
ART in patients with HIV-associated TB are multiple. It
has recently been shown that active TB and antitubercu-
losis treatment during ART do not compromise immuno-
logical and virological responses to treatment in this [3] and
other cohorts [26,27], suggesting that pharmacokinetic and
compliance issues are not strong arguments for delaying
treatment [28]. Risk of IRD has also been raised as a factor
favouring delayed treatment initiation [6,8]. However, the
present study suggests that the overall mortality risk
associated with TB-IRD is small whereas we have
previously reported that even short delays in initiation
of ART are associated with a high mortality risk in this
cohort [12,13]. Taken together, these data would favour a
policyof earlier initiation of ARTamong TB patients. Our
data, however, indicate that such a policy would
substantially increase the proportion of patients at risk of
IRD. Diagnostic and management strategies for TB-IRD
in resource-limited settings must be developed, including
guidelines for use of corticosteroids. Moreover, the long
delays for many TB patients in this study to initiate ARTare
indicative of the lackof integration of TBand ART services
locally. These delays and the need for coordinated
management of patients with TB-IRD strongly support
moves to integrate such services.
In summary, the risk of TB-associated IRD in this setting
is very high for those with low baseline CD4 cell counts
and early initiation of ART. Although the contribution of
TB-IRD to secondary health-care utilization and
mortality risk in the whole cohort was small, any future
policy changes recommending early initiation of ART
among TB patients would be very likely to lead to an
increase in this burden of disease.
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Tuberculous meningitis occurring in HIV-infected 
individuals (HIV/TBM) exemplifies the dilemmas facing 
clinicians when addressing potentially preventable 
mortality. HIV/TBM has a devastating clinical impact with 
a median time from onset of symptoms to presentation 
of 10 days, 67% mortality and a median time to death 
of 20 days.3 Expert opinion on when to start HAART in 
HIV-infected patients with TB meningitis varied between 
2 weeks and 12 months after starting TB medications.4 
This uncertainty of expert opinion reflects the present 
lack of randomised clinical trial data with which to 
inform clinical management. A clinical trial specifically 
addressing immediate initiation versus deferring HAART 
(zidovudine/lamivudine/efavirenz) for 8 weeks has been 
conducted at two hospital sites in Ho Chi Minh city, 
Vietnam. Results of this study should become available in 
late 2008 or early 2009.5 A study demonstrating proof of 
the concept that earlier initiation of antiretroviral therapy 
may impact on mortality of HIV patients with active 
opportunistic infections (OIs) was recently presented.6 
The AIDS Clinical Trials Group study 5164 (ACTG 5164) 
was a randomised strategy trial of immediate versus 
delayed ART in the setting of acute OI. At the time of 
inclusion study subjects had pneumocystis pneumonia 
(63%), cryptococcal meningitis (13%), other acute 
pneumonic illnesses (10%) or multiple opportunistic 
infections (30%). Patients were randomised to immediate 
or delayed initiation of HAART, a median of 12 days or 
45 days after starting OI treatment, respectively. After 
48 weeks, deaths in the early treatment group were 
significantly lower with no difference in drug toxicities, 
adherence or hospitalisation. Somewhat counter-
intuitively, IRD was also less frequent in the earlier 
treatment group. The conclusion from this study was 
that in the absence of contraindications very early use 
of HAART should be considered in patients with acute 
OIs. However, it should be noted that TB cases were not 
included in this study population.
CONSIDERATIONS DETERMINING EARLIER VERSUS 
LATER INITIATION OF HAART
The decision when to initiate HAART after TB treatment 
is complex, involving a number of variables including 
treatment tolerance, drug co-toxicities, pharmacokinetic 
drug interactions and impact of polypharmacy on 
adherence (Fig. 1). However, of over-riding importance 
is the mortality associated with delays in ART initiation 
versus mortality associated with IRD when HAART is 
initiated early. The frequency of IRD in cohort studies 
describing co-infected patients varies markedly between 
8% and 43%.7,8 The mean interval to IRD after HAART 
initiation also varies widely (1 - 180 days) with most cases 
occurring within the first 28 days.7 However, cross-cohort 
comparisons are complicated by differing mortality in 
cohorts from high- and low-resourced settings and 
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has the highest TB notification rate of any country. The World Health Organization (WHO) estimated that in 2006 
South Africa had 303 114 incident TB cases; of these patients, 32% were tested for HIV and 53% were found to be 
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differing incidences of TB-associated IRD in TB patients 
starting HAART in different settings. Furthermore, 
while variable rates of IRD may represent differences 
between cohorts, analysis is complicated by variable 
ascertainment and lack of a standardised IRD definition. 
A consensus document with proposed definitions of 
IRD for use in resource-constrained settings may help 
address the problem of differing case definitions.8 IRD 
is characterised by worsening of systemic symptoms, 
transient enlargement of pre-existing lesions, onset of 
new lesions including lymphadenopathy, and worsening 
of radiographic changes. Life-threatening conditions 
are rare but include tracheal and bronchial obstruction, 
pulmonary adult respiratory distress syndrome (ARDS), 
central nervous system tuberculomas and cerebral 
oedema.7-13 The management of life-threatening IRD 
includes use of high-dose steroid therapy and may 
necessitate interruption of HAART, although there are 
no randomised controlled studies to inform policy. The 
precise pathological processes responsible for IRD are 
not clearly defined, but the condition is associated with 
an expansion of CD4 cells in the peripheral blood8,14 
and increased macrophage activity.15 Fig. 2 illustrates 
a proposal that clinical manifestations result from an 
interplay between cellular events and mycobacterial 
antigen load.16 The risk factors for development of IRD are 
predominantly a low CD4 cell count and a short interval 
between starting TB therapy and HAART initiation.9,13,17 
In a prospective Cape Town cohort, IRD occurred in 
100% and 70% of patients commencing HAART within 
30 days with CD4 counts of <50 cells/µl and 50 - 100 
cells/µl respectively13 (Fig. 3). Extrapulmonary TB and 
black ethnic group have been identified as additional 
risk factors for IRD.9 Severe TB-associated IRD therefore 
tends to develop in those patients who have a high 
mortality risk, manifested by low CD4 cell counts 
and a high mycobacterial burden associated with 
disseminated TB. Several studies reporting considerable 
morbidity associated with IRD have not shown an excess 
mortality.13,17-21 Similar findings were also reported in a 
South African cohort where 10.5% who developed TB-
IRD died; however, 9.9% of TB patients who did not 
develop IRD also died.9 Development of IRD and IRD-
associated mortality in these studies was therefore not 
associated with significant excess overall mortality.
Variations in IRD frequency and associated mortality 
indicate that the optimal timing of ART initiation may 
differ between settings. In lower income countries, 
the risk of mortality associated with delays in ART 
initiation is likely to outweigh the excess mortality of 
TB-associated IRD. The optimal timing of ART initiation 
may therefore be earlier in the course of TB treatment 
for patients in resource-limited settings compared with 
those in high-income settings. Current guidelines for the 
timing of HAART in patients with TB are shown in Table 
I.  All these guidelines reflect an increased urgency to 
commence HAART at lower CD4 cell counts with variable 
timing recommendations due to a lack of data from 
randomised controlled trials. This lack of informative 
data is clearly reflected in the recommendations of the 
International AIDS Society (IAS), USA.  Several guidelines 
focus on 8 weeks as a key time point in TB therapy when 
simplification of TB medications occurs. In South Africa 
schedule 1 TB therapy consists of an intensive four-
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drug therapy (isoniazid, rifampicin, pyrazinamide and 
ethambutol) which is reduced to two-drug maintenance 
(RIF/INH) after 8 weeks.22 The South African TB control 
programme promotes use of fixed-dose combination 
tablets which results in identical pill burdens before and 
after the 8-week treatment time point.  Rifampicin, the 
anti-TB agent with the greatest potential for drug-drug 
interactions with non-nucleoside and protease inhibitor 
antiretrovirals, is continued throughout the whole 6 
months of treatment. Similarly isoniazid, with a potential 
for peripheral neuropathy co-toxicity with stavudine, is 
also continued throughout TB therapy. The main co-
toxicity shared between TB and HAART is hepatotoxicity, 
and some staggering of initiation of the two treatment 
regimens may simplify clinical management of drug-
induced hepatitis. Although pyrazinamide, which is 
routinely discontinued after 8 weeks of TB treatment, 
may contribute somewhat to hepatic co-toxicity, it is 
unproven whether the optimal deferring time period is 
8 weeks,
STUDY DATA ADDRESSING WHEN TO START HAART
Randomised controlled trials addressing the optimal 
timing of ART initiation in patients with TB are awaited, 
but meanwhile data from observational cohorts and 
modelling studies may help inform policy. Cohort studies 
have reported a markedly variable impact of HAART on TB 
mortality.19,23-26 Three cohort studies describing outcomes 
in patients starting HAART at different time points after 
TB therapy reported at the International AIDS Society 
2008 Conference meeting in August 2008 highlight the 
difficulties in interpreting cohort data. A Brazilian clinic-
based cohort study of 662 patients found no significant 
difference in survival between patients starting HAART 
in the first 2 months, 2 - 6 months or more than 6 
months after commencement of TB treatment.24 In 
contrast, an Iranian study of 69 hospitalised patients 
showed significant increases in TB cure rate and survival 
in patients who started HAART within 2 weeks compared 
with 8 weeks of TB treatment.25 A third study, from 
Argentina, showed similar differences in TB cure rate and 
survival with early initiation of HAART.26 However, this 
last study also reported significant differences in baseline 
characteristics between the groups, demonstrating that 
cohort studies may be subject to considerable selection 
bias. A South African cohort study of the International 
Epidemiological Databases to Evaluate AIDS Group 
(IeDEA) retrospective analysis of 4 000 HIV/TB patients 
from multiple sites in the Free State and Cape Town 
will be completed and is planned for reporting during 
2009.27 
A decision analysis model, based on published cohort 
data, examined three treatment strategies in patients 
with AIDS and TB; early initiation of HAART (<2 months), 
deferred HAART (>2 months), and no HAART strategy.28 
The model indicated that earlier HAART could reduce 
mortality at 1 year by 30% and 80% compared with the 
deferred and no HAART strategies, respectively.
Several randomised controlled studies addressing 
the timing of HAART after starting TB treatment are 
currently enrolling.5,29-32 Of these ongoing studies only 
Year Organisation CD4 count Recommendations
2003 American Thoracic Society* CD4 <350 
CD4 >350




             Defer 4 - 8 wks
2004 WHO ‘Scaling up ART
in resource-limited settings’‡
CD4 <200  
CD4 200 - 350
CD4 >350
2 wks - 8 wks 
Start at 2mo.
Defer HAART





2 wks - 8 wks
8 wks
6 mo.
2006 IAS/USA panel¶                                           Individualise as there are no RCTs
2008 DHHS: Guidelines CD4 <100 
CD4 100 - 200





8 - 24 wks or defer
Guidelines available at: *http://www.thoracic.org; †htpp://www.cdc.gov/mmwr/; ‡http://www.doh.gov.za; §http:// www.iasusa.org/pub/; ¶http:// www.aidsinfo.nih.gov/
Guidelines/; Пhttp://www.who.int/3BYS/publications/documents/ARV_guidelines/en/
MMWR = ; WHO = World Health Organization; IAS =  ; DHHS = .
TAbLE I. CURRENT INTERNATIONAL AND SOUTH AFRICAN GUIDELINES FOR THE TIMING OF INITIATION OF 
HAART IN HIV-INFECTED pATIENTS ON Tb THERApY
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the Vietnamese TB meningitis study is expected to 
be able to report outcomes in the near future (Table 
II). The Cambodian Early versus Late Introduction of 
Antiretrovirals (CAMELIA), a large randomised open-
labelled study conducted in five sites in Cambodia, should 
be the first of these studies to report outcomes, some 
time during 2009 or 2010.29  Unexpectedly, preliminary 
data from the Starting Antiretroviral therapy in three 
Time Points in Tuberculosis (SAPIT) study conducted in 
KwaZulu-Natal became available in September 2008 
owing to the data safety and monitoring board (DSMB) 
discontinuing the third randomisation arm of the study 
because of a 55% increased  mortality in subjects 
deferring HAART for 6 - 8 months.31 
DISCUSSION
Determination of the optimal timing of initiation of ART 
in patients with TB is urgently needed in South Africa, 
where HIV/TB is extremely common and availability of 
HAART is rapidly expanding. HIV/TB case fatality rates 
are high and the optimal deferral time will therefore 
be determined predominantly by mortality rather 
than morbidity. Unfortunately the results of several 
randomised controlled trials addressing when to start 
HAART in TB, with a primary endpoint of survival, will 
not be available until 2009/2010. Meanwhile, preliminary 
data from the SAPIT study indicate that deferring 
treatment for 6 months is associated with significantly 
increased mortality.31 The Vietnamese study results of 
immediate initiation of HAART in TBM should become 
available in the next few months.5 The results of this 
study may not necessarily be generalisable to other 
forms of TB; however, any significant mortality benefit 
of immediate initiation of HAART will bolster support for 
earlier treatment in other severe forms of TB. 
The present status of information concerning the most 
important factors that may impact on the optimal timing 
of HAART in TB are shown in Fig. 4. Reduction of ongoing 
HIV-related mortality by HAART is counterbalanced by TB/
IRD-associated mortality and a clinical need to stagger 
the initiation of both treatments for ease of clinical 
management of co-toxicity. Those at highest risk of HIV 
progression also have the highest risk of co-toxicity and 
IRD. The ACTG 5164 study has demonstrated improved 
survival with very early initiation of HAART in patients 
co-infected with acute OIs.6 Treatment of TB requires 
prolonged treatment and is complicated by frequent 
occurrence of IRD. However, published reports indicate 
that while TB/IRD is a common cause of morbidity it is a 
less frequent cause of death.
Much interest has rightly focused on the optimal 
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income settings TB in HIV-infected patients is often only 
diagnosed after prolonged delay, and yet the mortality 
associated with even short delays in accessing HAART 
is unacceptably high. Furthermore, the potentially more 
important problem of delays in the care pathway has 
received little attention.
While the results of randomised controlled studies 
addressing the timing of initiation of HAART are eagerly 
awaited, the results may still not be generalisable to all 
types of TB, HIV progression, race and health systems. 
In the meantime it is important to recognise that time 
delays between the onset of TB symptoms and starting 
HAART in those eligible for HAART are associated with 
potentially preventable HIV-related mortality and that 
all delays should be minimised. 
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Tuberculosis (TB) is the most common opportunistic disease in HIV-
infected patients during the initial months of antiretroviral therapy
(ART) and presents a great challenge to ART programs in resource-
limited settings. The mechanisms underlying development of TB in
this period are complex. Some cases may represent progression of
undiagnosed subclinical disease present before starting ART, em-
phasizing the importance of careful screening strategies for TB. It
has been suggested that progression in such cases is due to immune
reconstitution disease—a phenomenon in which dysregulated res-
toration of pathogen-specific immune responses triggers the pre-
sentation of subclinical disease. However, whereas some cases have
exaggeratedor overtly inflammatory manifestations consistent with
existing case definitions for IRD, many others do not. Moreover,
since ART-induced immune recovery is a time-dependent process,
active TB may develop as a consequence of persisting immunodefi-
ciency. All these mechanisms are likely to be important, representing
a spectrum of complex interactions between mycobacterial burden
and changing host immune response. We propose that the potential
range of effects of ART includes (1) shortening of the time for sub-
clinical TB to become symptomatic (a phenomenon often referred to
as ‘‘unmasking’’), (2) increased rapidity of initial onset of TB symp-
toms, and (3) heightened intensity of clinical manifestations. We
suggest that theterm‘‘ART-associatedTB’’beusedtorefercollectively
to all cases of TB presenting during ART and that ‘‘immune reconsti-
tution disease’’ be used to refer to the subset of ART-associated TB
cases in which theeffectondisease severity results in exaggeratedand
overtly inflammatory disease.
Keywords: HIV; tuberculosis; antiretroviral; immune reconstitution;
IRIS
Since the mid-1990s, availability of antiretroviral therapy (ART)
has transformed the prognosis of HIV-infected people living in
high-income countries and more recently in resource-limited set-
tings (1, 2). Through suppression of HIV replication, ART permits
both quantitative and functional reconstitution of the immune
system (3, 4), thereby reducing the risk of new opportunistic
infections and neoplasia (1, 5). However, an appreciable (albeit
diminished) risk of opportunistic infection persists during ART,
especially during the first few months of treatment. Tuberculosis
(TB) is the most frequent of these both in high-income and
resource-limited settings (6–15).
Although heightened clinical vigilance may, in part, account
for increased ascertainment of cases of TB during the initial
months of ART, several different mechanisms may also underlie
the temporal distribution of cases. ART-induced immune recov-
ery occurs gradually over time and so active TB may develop in
some patients as a consequence of persisting immunodeficiency.
Conversely, restoration of pathogen-specific immune responses
during treatment may cause subclinical TB to manifest or be
‘‘unmasked’’ (16–19). Of these latter cases, there is debate as to
whether some or all of these should be termed ‘‘immune recon-
stitution disease’’ (IRD); clarity on this issue is needed.
The burden of TB during early ART is particularly great in
resource-limited settings where this presents a major challenge
in treatment programs (9). Management of these two diseases
requires concurrent use of two multidrug regimens, with associ-
ated high pill burden, overlapping toxicity, and pharmacokinetic
interactions (20). Furthermore, patients with incident TB during
ART have increased mortality risk and may be a source of TB
transmission within ART clinics (9, 21). Understanding the under-
lying mechanisms will facilitate development of preventive and
therapeutic strategies. In this article, we consider how ART-
induced immune recovery is likely to mediate a range of effects
on both the timing and manifestations of active TB.
BURDEN OF TB DURING EARLY
ANTIRETROVIRAL THERAPY
A number of reports have described the incidence of TB in
patients receiving ART in high-income countries (12–15). The
largest of these is a study of European and North American
cohorts that included over 17,000 patients with a median baseline
CD4 cell count of 280 cells/ml (12). The prevalence of TB at base-
line was not known but the incidence rate was 1.3 cases per 100
person-years during the first 3 months of ART (12). Beyond this
time point, the risk of TB decreased sharply (Figure 1A).
As might be expected, incidence rates of TB are substan-
tially higher in ART cohorts in sub-Saharan Africa and other
resource-limited settings (7, 9–11, 22). For example, in a com-
munity-based ART cohort in South Africa with a median base-
line CD4 cell count of 96 cells/ml, prevalent TB (disease either
newly diagnosed or in patients already receiving treatment) was
reported among 25% of all patients at baseline (9). Despite the
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high yield of prevalent TB detected during pre-ART screening
of all patients with suggestive symptoms, the rate of inc dent TB
in the first 3 months of ART was nevertheless extremely high at
23 cases per 100 person-years (Figure 1B). All cases had new
onset of symptoms after initiation of ART and therefore rep-
resented true incident disease. The risk of TB decreased steeply
during the first year of ART (Figure 1B) and was strongly asso-
ciated with improving immune status (9).
ROLE OF IMMUNODEFICIENCY
Patients accessing ART programs in resource-limited settings
typically have advanced immunodeficiency (2) and therefore
have very high TB incidence rates just before commencing
ART. An exceptionally high rate in excess of 50 cases per 100
person-years has been reported in African patients with World
Health Organization clinical stages 3 and 4 disease in the pre-
ART era, for example (23). In cohorts in which incidence rates
are so high, active but ‘‘subclinical’’ TB is likely to be present in
a proportion of patients at any given point in time. This could
either progress to symptomatic disease or remain undiagnosed
until death of the patient.
Post mortem studies of patients who died with HIV/AIDS
support the supposition that rates of subclinical TB are high in
Africans with advanced HIV infection; occult disseminated TB
has been detected in up 54% of cadavers (24, 25). Furthermore,
in studies in which HIV-infected patients in southern Africa were
actively screened for TB, high rates of culture-proven pulmonary
disease have been detected despite the absence of suggestive
symptoms (26–29). In the absence of a standard definition for
subclinical TB, the proportions reported by such studies will
therefore vary according to the criteria used. However, the fact
that the World Health Organization’s DOTS (directly observed
treatment, short course) strategy places greatest emphasis on inves-
tigation of symptomatic patients is problematic and most sub-
clinical disease is likely to remain undetected pre-ART.
The limited sensitivity of TB diagnostic tests when applied to
patients with advanced immunodeficiency further compounds
poor TB case-finding in patients preparing to start ART. Sputum
smear microscopy, for example, which is the mainstay of TB di-
agnosis in much of the developing world, typically detects less
than 50% of active pulmonary disease in those with HIV in-
fection (9, 27, 30). Thus, a proportion of the TB presenting during
early ART may simply reflect failure of diagnosis of suspected
cases before treatment initiation. This burden will vary between
settings according to the intensity of screening and diagnostic
facilities available.
We suggest that subclinical TB among patients entering
ART programs provides much of the reservoir of infection that
fuels the high rates of symptomatic TB presenting during early
ART. Because ART-induced immune recovery is time depen-
dent, some of these cases may progress to symptomatic disease
during early ART in the context of persisting immunodeficiency.
In addition, rates of latent Mycobacterium tuberculosis infec-
tion and new exogenous infection are also very high in high-
TB-prevalence settings (31, 32); these may also progress and
contribute to the burden of active disease during early ART.
ROLE OF IRD
Having discussed the role of immunodeficiency, we now con-
sider IRD as a further important potential mechanism in the
presentation of TB (33–35). IRD (also known as immune recon-
stitution inflammatory syndrome or IRIS) is believed to be
caused by dysregulated recovery of pathogen-specific immune
responses during the initial months of ART. This leads to de-
velopment of unusual and overtly inflammatory disease, most
commonly in association with chronic viral, mycobacterial, and
invasive fungal infections (33–36).
TB-associated IRD presents in two principal ways. The most
common form occurs in patients with TB receiving effective
treatment who subsequently start ART; ART-induced immune
recovery results in the deterioration of the clinical manifesta-
tions of TB. This has been reported to occur in 8 to 43% of
patients with TB starting ART (35, 37–42). In the context of this
review, however, the second form of TB IRD is the more
relevant. Here, recovery of host immune responses triggers the
clinical presentation or ‘‘unmasking’’ of previously subclinical
TB during the early months of ART (33–35). It seems likely that
these two types of IRD may be related phenomena, but
immunologic studies to support this assertion are lacking.
Reports of TB IRD causing presentation of TB after ART
initiation are relatively few (16, 18, 19, 43, 44), the clearest
example being that reported by Goldsack and colleagues (19).
In this report, a 41-year-old African with advanced HIV in
London commenced ART. Two weeks later, he presented again
with rapid-onset fever, breathlessness, and hypoxia. Although
his chest radiograph was normal before treatment, a repeat ra-
diograph revealed florid miliary shadowing that was microbio-
logically proven to be TB. The onset of this complication was
temporally associated with a rapid immunologic and virologic
response to ART. The patient developed adult respiratory dis-
tress syndrome, requiring mechanical ventilatory support, but
he subsequently had a good response to anti-TB drugs and ad-
junctive corticosteroid therapy. An appropriate diagnosis of TB
Figure 1. Graphs showing the high incidence of tuberculosis (TB)
during first 3 months of antiretroviral treatment (ART) and the sub-
sequent rapid decrease. Data are from (A) cohorts in low-TB-burden
countries in Europe and North America (data are from Reference 12)
and (B) a community-based ART program in Cape Town, South Africa,
where the burden of TB is very high (data are from Reference 9). Power











IRD was made, which is entirely consistent with similar cases
we have seen in South Africa.
Breen and colleagues in London, United Kingdom, described
a series of 19 cases of incident TB during ART and hypothesized
that the presentation of 13 of these cases may have been attrib-
utable to IRD (16). The rationale for this was largely based on
the temporal distribution of cases; 13 early-onset cases were
clustered within the first 4 months of ART and many of these had
a marked inflammatory response and systemic illness. Also, a
paradoxical reaction after initiation of anti-TB therapy was ob-
served in eight (62%) of the early cases compared with none of
the late-onset group (16).
In agreement with the report by Breen and colleagues,
workers in Uganda speculated that IRD was also the cause of
the large number of new cases of TB diagnosed during ART in
their setting (18). In a further report from the same country, all
cases of incident TB during the first year of ART were de-
scribed by the authors as being due to IRD (45). Park and
coworkers reported from South Korea that 82% of new TB
events occurring during the first year of ART (either new TB
cases or paradoxical reactions at a new disease site) were
attributable to IRD (17).
Evaluation of the role of IRD among cases of incident TB
during ART is hindered by the lack of a diagnostic test or
a clinical case definition specific to this condition. Importantly,
however, the existing literature indicates that, for a diagnosis of
IRD to be made, either the clinical manifestations and/or the
clinical course of disease should be atypical and be consistent
with an exaggerated, overtly inflammatory host response (34, 35,
46). Our own clinical experience gained during several studies of
TB during ART in South Africa (7, 9, 42), however, is that most
cases of TB diagnosed in the initial months of ART have typical
clinical presentations. Only a subset of such cases present with
unusual, overtly inflammatory manifestations that would be con-
sistent with a clear diagnosis of IRD. Moreover, in high-TB-
burden settings, it cannot be reasoned that the timing of onset of
TB during the first months of ART is particularly unusual. Thus,
in the context of the existing literature on IRD, it would appear
appropriate to use the term IRD to refer to some but not all cases
of incident TB during the initial months of ART.
HYPOTHESIS: A SPECTRUM OF EFFECTS OF IMMUNE
RECOVERY ON TB PRESENTATION
Thus far, we have considered contrasting reasons why TB may
present during early ART, with TB developing in the context of
persisting immunodeficiency or TB presenting as TB IRD. How-
ever, we suggest that these represent opposing ends of a spec-
trum of important effects of ART-induced immune recovery on
TB presentation.
Because immunopathologic host responses to M. tuberculosis
are central to the clinical presentation of TB, we suggest that
development of symptoms at a given anatomic site is a function
of two key parameters: the mycobacterial antigen burden and
the intensity and quality of the associated host inflammatory
response. It is the interrelationship between these that is likely
to determine the threshold for symptom onset and to affect the
timing and severity of cases of TB presenting during early ART.
The supposition that high mycobacterial load is a risk factor
for TB IRD is strongly suggested by two observations: first, the
risk of IRD is greater the earlier ART is started during anti-TB
therapy when the residual mycobacterial burden is high; second,
the risk of TB IRD is increased in those with disseminated TB
(35, 38, 42). Considerable improvements in immune function
occur during the initial weeks of ART in most ART-naive
patients living in resource-limited settings, even in those with
the lowest baseline CD4 cell counts (47–49). Thus, the potential
for cases of TB presenting in this period to be modified by
changes in immune function is substantial. We suggest that im-
mune recovery has three principal effects on the progression of
subclinical TB to symptomatic disease, namely the timing of
onset, the rapidity of initial symptom onset, and the overall in-
tensity of clinical manifestations.
Timing of Onset
In an HIV-infected patient with a certain level of immune func-
tion, symptoms of TB are likely to develop at a given anatomic
site once the mycobacterial burden that is sufficient to trigger
host inflammatory responses has been reached (Figure 2A). If
ART is initiated, however, TB-specific immune function in-
creases rapidly (49, 50), and this would have the effect of rapidly
lowering the threshold for symptom development (Figure 2B).
This process may be augmented by immune-mediated liberation
of mycobacterial antigen, further enhancing immune responses.
In patients with subclinical TB, this would cause TB to manifest
much sooner than would otherwise have occurred in the absence
of ART (Figure 2B). In effect, the initiation of ART may serve
as a therapeutic challenge that unmasks subclinical disease,
triggering the presentation of TB. This accelerated progression
Figure 2. (A) A hypothetical graph showing the rising burden of Myco-
bacterium tuberculosis over time at a given anatomic site in an HIV-infected
patient with advanced immunodeficiency (shown as a linear rise over
time for simplicity). Symptom onset occurs when the mycobacterial
load rises to a level at which the host inflammatory responses are trig-
gered (symptom threshold). With poor immune function, the symp-
tom threshold is reached at time t1. (B) If the patient were to have
started antiretroviral therapy (ART), tuberculosis-specific immune func-
tion would increase rapidly and the threshold for development of symp-
toms would correspondingly decrease. As a result, symptoms would
develop much earlier soon after the initiation of ART (time t2).










to symptomatic TB would result in the temporal clustering of
cases in the initial 3 months of ART as observed in Figure 1 and
in the report by Breen and colleagues (16).
Rapidity of Onset
In patients with advanced immunodeficiency, TB often has a
fairly insidious onset. In contrast, however, our clinical impres-
sion is that, in cases of TB presenting during the initial weeks of
ART, the initial onset of symptoms is often unusually rapid.
This is consistent with the speed with which antimycobacterial
immune responses recover during early ART (49, 50).
Intensity of Clinical Manifestations
When immune recovery causes unmasking of subclinical TB,
the severity of clinical manifestations at a given anatomic site is
likely to depend on the interrelationship between two main
variables: the mycobacterial antigen load and the rate, intensity,
and quality of immune recovery (Figure 3). In those in whom
immune function remains very poor, TB is likely to remain
subclinical despite an increasing mycobacterial load. Those
patients with an intermediate rate of immune recovery would
tend to develop clinical disease with a relatively ‘‘normal’’ pre-
sentation. In contrast, we propose that patients with dysregu-
lated immune recovery are the ones most likely to develop
unusual and severe manifestations that characterize IRD. This
would be most pronounced in those with a high mycobacterial
load (Figure 3). Within this model, therefore, only a proportion
of patients in whom ART causes the unmasking of TB in the
initial months of ART would fulfill existing case definitions for
IRD. With a disease that is as heterogeneous in its clinical pre-
sentation as TB, it will clearly be difficult to develop a robust
case definition for these cases.
CLINICAL AND PROGRAMMATIC IMPLICATIONS
The high early burden of TB during ART highlights the funda-
mental problem of how to efficiently screen for TB among
patients preparing for ART. The less adequate the pre-ART
screening processes, the greater the burden of TB is likely to be
after starting treatment. Optimal screening strategies need to be
defined; it is possible that all patients entering ART programs in
resource-limited settings should ideally undergo culture-based
screening for TB regardless of the presence or absence of symp-
toms. The major need to upgrade laboratory facilities and ex-
pand availability of culture-based diagnosis in resource-limited
settings has been recognized and more sensitive tools for TB
diagnosis at the point of care are desperately needed (30).
Although screening for TB among patients with advanced
HIV-associated immunodeficiency is difficult, ART may para-
doxically serve as a useful diagnostic tool, serving to unmask
occult disease. Research is needed to determine the relative
merits of delaying initiation of ART to permit full culture-based
investigation for TB versus starting ART without delay if there
is no initial evidence of TB. Because few of the cases of un-
masking TB have increased clinical severity and yet delays in
ART initiation may be associated with high mortality risk in this
setting (51), we would not advocate a strategy of deferring ART
while waiting for TB culture results in all patients.
Many in the field agree that management of those with
moderate or severe TB-associated IRD should include cortico-
steroids (33–35). Pending the results of a randomized controlled
trial in South Africa, however, the only evidence for this comes
from case reports and expert opinion. In view of the seemingly
normal clinical presentations of the large majority of cases of
unmasking TB presenting in the initial months of ART, how-
ever, it seems likely that most patients who develop TB during
early ART are unlikely to require adjunctive immunomodula-
tory therapy. On the basis of the same premise, there may be
little merit in a strategy of using corticosteroids as prophylaxis
against unmasking TB in high-TB-burden settings. Potential
benefits, if any, may well be restricted to a small minority of
patients and could be outweighed by adverse events (52).
Finally, it has been speculated that the unmasking of TB
during the early months of ART may contribute to the overall
burden of TB in resource-limited countries where ART is being
rolled out (16). This is of course true and is an inevitable conse-
quence of hundreds of thousands of lives being saved by ex-
panding access to ART. However, the longer term burden of
TB during ART (rather than that occurring in the initial months
of treatment) is much more important with regard to TB control
at the population level (9, 49, 53).
CONCLUSIONS AND SUGGESTED TERMINOLOGY
Using data and clinical experience from both low- and high-TB/
HIV-burden countries, we propose that a spectrum of mecha-
nisms underlies the development of TB during the first 3 months
of ART. Much of this disease is likely to represent progression
of subclinical TB that was present before ART initiation, either
due to persisting immunodeficiency or due to unmasking during
ART-induced immune recovery. The spectrum of effects of im-
mune recovery on TB presentations in this period may include
shortening of the time to development of symptoms (unmasking
TB), increasing the rapidity of the initial onset of symptoms
of TB, and increasing the intensity of clinical manifestations.
These effects are likely to depend on the antigen load and the
rate and intensity of immune recovery. Much remains to be
learned from studies of the immunologic mechanisms underly-
ing these phenomena.
Because it is presently not possible to clinically distinguish
the underlying disease mechanisms, we suggest that cases of TB
presenting during the initial months of immune recovery might
collectively be referred to as ‘‘ART-associated TB.’’ To refer to
Figure 3. Progression of subclinical disease to symptomatic tubercu-
losis (TB) during early antiretroviral therapy (ART). This hypothetical
conceptual diagram shows the interrelationship between Mycobacte-
rium tuberculosis antigen load, rate, and intensity of immune recovery
during early ART and the resulting clinical presentation of TB (plot area)
in patients with subclinical TB at the time of ART initiation. Most cases
of incident TB present with relatively ‘‘normal’’ clinical features, and TB
immune reconstitution disease (TB IRD) forms only a subset of incident
TB cases. TB IRD is most likely in patients with high antigen burden and
dysregulated immune recovery, leading to development of exagger-











the phenomenon whereby immune recovery triggers the presen-
tation of TB, we suggest the term ‘‘unmasking’’ disease be used.
Finally, in agreement with the existing literature, we suggest
that only the subset of patients with exaggerated and overtly
inflammatory manifestations of TB should be referred to as
IRD. To enable case definitions for unmasking TB and TB IRD
to be derived, further immunologic and clinical studies are
needed to better characterize these phenomena.
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Immune reconstitution inflammatory syndrome 
Stephen D Lawn i!~, Robin Wood a 
We read with interest Monika MUller and colleagues'l systematic review and meta-analysis of immune 
reconstitution inflammatory syndrome (IRIS) in the April, 2010, issue of The Lancet Infectious Diseases. 
Antiretroviral therapy (ART)-induced IRIS is a highly heterogeneous adverse effect arising in the initial months 
of treatment. The investigators should be congratulated for providing an important summary of IRIS 
frequency in patients with a range of HIV-associated diseases. 
On assessing the data for the Review, some studies seem to be extreme outliers with unusually low 
frequencies of IRIS, which is striking. For example, the study by Wan Beam Park and colleagues. from South 
Korea shows a rate of only 2% for tuberculosis-associated IRIS. Similarly, our studyl from Cape Town, South 
Africa, was reported as showing a rate of only 2% for cryptococcal-associated IRIS. Both of these results are 
well below the lower 95% credibility intervals of MUller and colleagues' meta-analysis. We are concerned that 
the data for ours and for Park and colleagues' study have been misinterpreted, and that two broad categories 
of IRIS, which should be considered as separate entities within such an analysis, have not been regarded. 
Paradoxical IRIS is used to describe IRIS among patients who are already receiving treatment for an 
opportunistic disease, and in whom immune recovery after subsequent initiation of ART triggers the clinical 
deterioration of that disease during the initial months of treatment. In contrast, unmasking IRIS is used to 
denote the clinical event in which opportunistic disease, which was not present at the time of ART initiation, 
becomes clinically manifest because of ART-induced immune recovery. Although risk of paradoxical IRIS is 
strongly related to the timing of ART during treatment for the opportunistic disease,1 the frequency of 
unmasking IRIS will vary with the prevalence of the opportunistic disease in any given setting, and with the 
efficiency of screening before ART .>, ~ Tuberculosis and cryptococcal disease can both be associated with 
either form of IRIS. Because the denominators that are used to calculate the frequencies of these two forms 
of IRIS are mutually exclusive, the calculation of pooled summary estimates from data that include both 
forms of IRIS makes little sense. We suspect that this explains why the results from Park and colleagues, and 
from our study, seem to be outliers in Mliller and colleagues' analysis, and we are concerned that this 
irregularity might have particularly undermined the summary estimate of the meta· analysis for the frequency 
of cryptococcal IRIS. 
In their meta-analysis of cryptococcallRIS, MUller and colleagues sourced data from six studies, five of which 
relate exclusively to the risk of paradoxical IRIS in patients with known cryptococcal disease before starting 
ART. In these five studies, 67 cases of IRIS were reported among 245 patients with a crude frequency of 
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described six cases of paradoxical-cryptococcallRIS among 18 patients with a pre-existing diagnosis of 
cryptococcal meningitis, giving a frequency of 33% (95% CI 16-56). This proportion is entirely consistent with 
the other five studies, and including these cases in this form would have been entirely appropriate. However, 
we also reported three cases of unmasking-cryptococcallRIS among the remaining cohort of 416 patients who 
did not have pre-existing cryptococcal disease. Unfortunately, Muller and colleagues have not distinguished 
between paradoxical and unmasking forms of disease, and simply reported an overall rate of 2% for 
cryptococcallRIS in the total cohort of 434 patients. The study therefore seems to be an extreme outlier 
within the data of the meta-analysis. Both the numerator and denominator, which we used to calculate the 
event frequency are entirely different to those obtained from the remaining five studies and, therefore, the 
meta-analysis summary estimate from the total of six studies is unfortunately flawed. The effect of this flaw 
will have been to underestimate the true frequency of paradoxical-cryptococcaIIRIS. 
A further consequence of the failure to distinguish between paradoxical and unmasking forms of IRIS is that 
the timing of ART in patients with tuberculosis or cryptococcal meningitis has not been considered. This 
factor is a crucial determinant of the risk of paradoxicailRIS1 and might partly explain the considerable 
heterogeneity in rates between studies. Clinicians can control this key variable, and thus it is the subject of 
several ongoing randomised trials. Notwithstanding these limitations, our own experience in this specialty is 
consistent with the important findings by MUller and colleagues that cryptococcallRIS is the form of IRIS most 
strongly associated with mortality.Z, § 
SOL is funded by the Wellcome Trust, London, UK. RW is partly funded by the National Institutes of Health 
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Impact of HIV Infection on the Epidemiology of
Tuberculosis in a Peri-Urban Community in South
Africa: The Need for Age-Specific Interventions
Stephen D. Lawn,1,3 Linda-Gail Bekker,1 Keren Middelkoop,1 Landon Myer,1,2 and Robin Wood1
1Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, and 2Infectious Diseases Epidemiology Unit, School
of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, South Africa; and 3Clinical Research Unit, Department
of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
(See the editorial commentary by Whalen on pages 1048–50)
Background. In August 2005, the World Health Organization declared the tuberculosis (TB) epidemic in Africa
to be a regional emergency. Current TB-control measures are failing, largely as a result of the human immuno-
deficiency virus (HIV) epidemic. Evaluation of additional control interventions requires detailed understanding
of the epidemiological relationship between these diseases at the community level.
Methods. We examined age- and sex-specific trends in TB notifications and their association with the prevalence
of HIV infection in a peri-urban township in South Africa during 1996–2004. Denominators for TB notifications
were derived from population census data. The local TB-control program used the World Health Organization
directly observed treatment, short-course (DOTS) strategy.
Results. TB notification rates increased 2.5-fold during the period, reaching a rate of 1468 cases per 100,000
persons in 2004 ( , by test for trend); the estimated population prevalence of HIV infection increasedP p .007
from 6% to 22% during the same period. After stabilization of prevalence of HIV infection, the TB notification
rate continued to increase steeply, indicating ongoing amplification of the TB epidemic. In 2004, at least 50% of
children aged 0–9 years who developed TB were HIV infected. Annual TB notification rates among adolescents
increased from 0 cases in 1996–1997 to 436 cases per 100,000 persons in 2003–2004, and these increases were
predominantly among female. However, 20–39-year-old persons were affected most, with TB notification rates
increasing from 706 to 2600 cases per 100,000 persons among subjects in their 30s. In contrast, TB rates among
persons aged 150 years did not change.
Conclusions. HIV infection is driving the TB epidemic in this population, and use of the DOTS strategy alone
is insufficient. TB notifications have reached unprecedented levels, and additional targeted, age-specific interventions
for control of TB and HIV infection in such populations are needed.
Annual tuberculosis (TB) incidence rates have increased
by 2- to 3-fold in many countries in sub-Saharan Africa
since 1990 [1]. The African continent, which contains
just 11% of world’s population, now accounts for 27%
of the global burden of TB and 30% of TB-related
deaths; an estimated 2.4 million new TB cases and
540,000 TB-related deaths occur in Africa annually [1].
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The World Health Organization (WHO) TB-control
strategy, which is based on the directly observed treat-
ment, short course (DOTS) strategy, has failed to con-
tain the African TB epidemic, primarily because of the
effects of the HIV epidemic in the region. In August
2005, the WHO Committee for Africa declared the TB
epidemic to be an African regional emergency [2].
Rapid escalation of the disease rate in the region is
undermining progress towards the Millennium Devel-
opment Goals for TB control and was deemed as man-
dating “urgent and extraordinary actions” [2].
An interaction between the HIV and TB epidemics
has been well established by demonstration of increased
TB case load in populations affected by HIV infection;
an increased prevalence of HIV infection among per-
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and progressively increasing risk of TB with advancing im-
munodeficiency [3–5]. The impact of HIV infection is accen-
tuated in populations with preexisting high TB case rates [5].
Moreover, the impact on TB notification rates may increase
during the course of a rapidly maturing HIV epidemic as the
proportion of patients with advanced immunodeficiency in-
creases [3]. Thus, the relationship between HIV and TB epi-
demics in a community is likely to evolve over time.
Existing data on the population-level interaction between the
TB and HIV epidemics in sub-Saharan Africa are derived largely
from national or regional data [5]. Such data are often incom-
plete and do not define the relationship within individual com-
munities bearing the brunt of disease. Insights into the dual
epidemic have also been derived from studies of rural districts
or unusual populations, such as gold miners [6–10]. However,
neither population is likely to reflect the situation in urban and
peri-urban communities.
We investigated epidemiological changes in TB notifications
and the prevalence of HIV infection during 1996–2004 in a
well-defined, peri-urban community in the Western Cape,
South Africa. The study objective was to document the epi-
demiological association of these 2 epidemics in a community
during a period in which the prevalence of HIV infection rap-
idly increased. Such information is needed to provide a sci-
entific basis for any modification of present TB-control
strategies.
METHODS
Study population. We studied a peri-urban township near
Cape Town, South Africa, which was established in 1992 and
has grown to its current population size of ∼13,000 people.
The township is home to an almost exclusively African pop-
ulation, and the majority of persons have low socioeconomic
status. Unemployment rates exceed 50%, and housing predom-
inately consists of closely aggregated, informal structures with
high levels of overcrowding. The township is geographically
clearly demarcated and constitutes a well-defined population
for research studies and community health interventions. This
research was approved by the Research Ethics Committee of
the University of Cape Town.
Health services. The study community is served by a single
government primary health care clinic with a dedicated TB
service. All patients with TB in the community are treated at
this facility. The program adhered to the South African National
TB Control Programme guidelines throughout the study period
and included the WHO DOTS strategy. DOTS coverage in this
community was complete, and cure rates for smear-positive
disease exceeded 80% in the district [11]. All sputum testing
was performed at the National Health Laboratory Services fa-
cilities in Cape Town.
Case definitions. Pulmonary sputum-positive TB was di-
agnosed on the basis at least 1 positive sputum culture of My-
cobacterium tuberculosis or 2 sputum smears containing acid-
fast bacilli in the context of a compatible clinical illness.
Pulmonary sputum-negative TB was diagnosed on the basis of
negative smears and cultures for M. tuberculosis in the context
of clinically and radiologically compatible illness of at least 3
weeks’ duration that did not respond to administration of sim-
ple antibiotic treatment but that responded to subsequent an-
tituberculosis treatment. Diagnosis of extrapulmonary TB was
based on a combination of clinical, radiological, and histo-
pathological findings, as well as a response to antituberculosis
treatment.
Data sources. Numbers of TB notifications, demographic
characteristics, history of previous TB, sputum microbiologic
test findings, and TB classification data were obtained from the
community TB clinic register. Demographic data for the com-
munity were derived from the 1996 South African national
census and from a household census performed in 2004 as part
of ongoing health research. Prenatal HIV prevalence data were
collected within the local Prevention of Mother to Child Trans-
mission program. The prevalence of HIV infection among pa-
tients who had TB diagnosed was obtained from the results of
voluntary counseling and testing routinely performed at the
TB clinic in 2004 and from re-treatment cases tested in 2003–
2004.
Estimates of the prevalence of HIV infection. Age-specific
estimates of the prevalence of HIV infection were made using
the Actuarial Society of South Africa 2002 demographic model
for the African population. This model estimates the prevalence
of HIV infection in South Africa using prenatal surveys and
demographic data. The assumptions and results of the model
have been described elsewhere [12, 13], and this model was
validated for use in this community using a cross-sectional
survey of 6% of the population in 2005.
Data analysis. Denominators for rate calculations were
based on extrapolations of 1996 and 2004 population census
data, assuming a linear trend in age- and sex-specific distri-
butions over the study period. TB notification rates, TB re-
treatment rates, and age- and sex-specific rates of TB were
calculated using the data from the TB register and population
census data. Ninety-five percent CIs for rates are based on
Poisson-distributed standard errors. Trend analyses were con-
ducted using Cuzick’s nonparametric test for trend [14].
Changes over time in the median age of subjects with TB di-
agnoses were compared using the Wilcoxon rank sum test. All
tests were 2-sided at .a p 0.05
RESULTS
TB notification rates and prevalence of HIV infection.
During 1996–2004, a total of 968 cases of TB were diagnosed.
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Figure 1. Annual numbers of tuberculosis (TB) notifications, stratified
by site of disease and sputum microbiologic test findings. Children with
diagnoses of primary TB were excluded.
Table 1. Tuberculosis (TB) notification rates and the prevalence of HIV infection in a peri-














1996 32 5518 580 3 6.3
1997 42 6429 653 21 8.9
1998 67 7339 913 7 11.6
1999 74 8250 897 20 14.2
2000 90 9161 982 17 16.5
2001 142 10,071 1410 15 18.4
2002 150 10,982 1366 18 19.9
2003 175 11,892 1472 22 21.1
2004 188 12,803 1468 24 21.9
a , by test for trend.P p .007
b , by test for trend.P p .073
study period, reaching 1468 cases per 100,000 persons in 2004
(table 1). Rates of TB re-treatment also increased to 120% of
notifications in 2003–2004.
The estimated prevalence of HIV infection in the community
increased from 6% to 22% (table 1). In 2004, among persons
aged 115 years, 98 (59%) of 166 persons who provided TB
notifications were HIV seropositive, whereas 30% were HIV
seronegative, and 11% had not been tested. On the basis of
these data, the TB notification rate among HIV-infected in-
dividuals was calculated to be 4381 cases per 100,000 persons
(95% CI, 3570–5313 cases per 100,000 persons), and the rate
among HIV-uninfected individuals was 656 cases per 100,000
persons (95% CI, 486–866 cases per 100,000 persons). Even if
persons who were not tested in 2004 were assumed to be HIV
seronegative, a statistically significant increase in TB notifica-
tion rates among HIV-uninfected individuals in this commu-
nity could not be demonstrated (data not shown). Among pa-
tients who underwent re-treatment, cure of the previous
episode of TB was microbiologically confirmed among 32 pa-
tients in 2003–2004. Of these 31 tested patients, 27 (87%) were
found to be HIV seropositive.
Spectrum of TB. Of the 968 TB cases diagnosed, 450
(46.5%) were pulmonary sputum positive, 247 (25.5%) were
pulmonary sputum negative, 140 (14.5%) involved extrapul-
monary disease (predominantly lymph node), and 108 (11.2%)
were primary disease among children. Sputum test results were
missing for 23 cases of pulmonary disease, representing 2.3%
of all TB notifications.
The spectrum of TB diagnoses changed over the course of
the study period (figure 1). The notification rate of sputum-
positive TB cases increased 1.9-fold, from 326 cases per 100,000
persons (95% CI, 181–471 cases per 100,000 persons) in 1996
to 617 cases per 100,000 persons (95% CI, 481–752 cases per
100,000 persons) in 2004 ( , by test for trend). However,P ! .01
increases in the rates of extrapulmonary and sputum-negative
pulmonary disease were proportionately greater, increasing 4.3-
fold from 167 cases per 100,000 persons (95% CI, 63.8–271.0
cases per 100,000 persons) in 1996 to 719 cases per 100,000
persons (95% CI, 572–865 cases per 100,000 persons) in 2004
( , by test for trend).P ! .01
TB among adults. Predominantly young people lived in
this community, with the modal age lying in the 20–29-year-
old age range; 88% of the population were !39 years of age.
Comparison of census data from 1996 with data obtained in
2004 showed that the age-sex composition of this population
had not changed significantly. Subsequent analysis of the age-
specific distribution of TB notifications during 1996–2004 re-
vealed a marked increase in the number of notifications among
20–39-year-old persons (figure 2A). This pattern was similar
to increases in the estimated age-specific prevalence of HIV
infection in this population during the same period (figure 2B).










Figure 2. A, Changes in the number of tuberculosis (TB) notifications, stratified by age, 1996–2004. B, Estimated numbers of HIV-infected individuals,
stratified by age, 1996–2004. C, Total number of TB notifications, stratified by age and sex, 1996–2004. Changes over time are predominantly seen
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Figure 3. Age-specific tuberculosis (TB) notification rates (95% CI) in 1996–1997, compared with rates in 2003–2004. Rates significantly increased
among 10–49-year-old persons, with the greatest rate increase among those aged 30–39 years.
escalating burden of TB were both concentrated among young
adults.
During 1996–2004, the median age of patients with TB (ex-
cluding those aged !10 years) decreased from 43 years to 32
years ( ). Additional comparison of age- and sex-specificP ! .001
notifications showed that the modal age group for patients
with TB was 20–29 years for women and 30–39 years for men
(figure 2C).
Although the distribution of age-specific TB notification
rates observed during 1996–1997 conformed to that observed
historically in this region [15], the distribution changed sub-
stantially over the study period. The highest TB notification
rates in 2003–2004 occurred among adults aged !50 years (fig-
ure 3), and the greatest increase in notification rates was among
persons aged 30–39 years, reaching 2600 cases per 100,000 per-
sons in 2004. However, no significant increase in rate occurred
among those aged 50 years.
TB among adolescents and children. TB was notified for
44 adolescents aged 10–19 years (31 of whom were female, and
13 of whom were male). Although no cases occurred in 1996–
1997, the TB notification rate among adolescents steadily in-
creased from 1998 onwards, particularly among female subjects
(figure 2A and 2C), to reach an average annual rate of 436
cases per 100,000 persons in 2003–2004 (figure 3). Of 11 TB
cases notified in 2004, 5 involved persons aged !16 years who
had not undergone HIV testing. Among the remaining 6 ad-
olescents tested, 3 were HIV seropositive.
The increase in TB notification rates among children aged
0–9 years was not statistically significant. However, 18 cases
were diagnosed in 2004, and of 13 children tested, 9 (50% of
total cases) were found to be HIV infected.
Temporal association between HIV and TB epidemics.
We next analyzed the rates of these 2 diseases among persons
aged 20–39 years in whom both epidemics were concentrated
(figure 4). Major increases in the prevalence of HIV infection
occurred before 2000, and yet a high rate of increase in the TB
notification rate continued thereafter. With data from 1996–
1997 used as baseline values, we calculated the increases in the
TB notification rate per unit increase in the prevalence of HIV
infection. For each 1.0% increase in the prevalence of HIV
infection, TB notification rates increased by 54.7 cases per
100,000 persons in 1998–1999 and by 80.6 cases per 100,000
persons in 2004. Thus, increases in the prevalence of HIV in-
fection were associated with ongoing amplification of the TB
epidemic several years later.
DISCUSSION
To our knowledge, this is the first community-based study from
sub-Saharan Africa to characterize in detail the epidemiological
associations over time between rapidly evolving epidemics of
TB and HIV infection. The 2.5-fold increase in overall TB
notification rates culminated in annual rates exceeding 1400
cases per 100,000 persons, ∼9-fold higher than the TB notifi-
cation rate for sub-Saharan Africa and 280-fold greater than
that for the United States [1]. A striking temporal association
between the evolving age-specific burdens of TB and HIV in-
fection was demonstrated. Despite the existence of a well-run
TB-control program, the DOTS strategy alone is failing to con-
trol TB in this population, and additional measures are urgently
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Figure 4. Changes in age-specific tuberculosis (TB) notification rates and the prevalence of HIV infection among persons aged 20–39 years, 1996–
2004. With data from 1996–1997 used as baseline values, increases in the TB notification rate per unit increase in the prevalence of HIV infection
are tabulated below the graph.
The strength of this study lies in fact that this clearly defined
community was well characterized by total-population census
surveys at the beginning and the end of the study period. This
permitted calculation of disease rates, taking into account the
changing demographic profile of the community. Moreover,
the community is served by a single health center, where all
patients with TB in this community are treated. Thus, data
completeness is likely to be high. Trends in TB incidence in
this community before the HIV epidemic are not known, and
we cannot exclude other factors in addition to HIV infection
that may have contributed to the increasing burden of TB.
However, TB notification rates in the Western Cape were rel-
atively stable in the 1980s, before the advent of the HIV epi-
demic in South Africa. Whether these data can be generalized
is unknown, and the findings may apply only to similar com-
munities with a high burden of TB and HIV infection.
Annual TB notification rates exceeding 1400 cases per
100,000 persons are almost unparalleled in the era of modern
antituberculosis treatment, except for rates reported among the
Inuit population of Northern Canada in the early 1960s [16].
Three key factors probably underlie the explosive TB epidemic
in this and similar communities: the high pre-existing TB no-
tification rate, the rapid increase in the prevalence of HIV in-
fection, and the population composition, in which 20–40-year-
old persons who bear the brunt of these 2 diseases are
disproportionately represented. The strongest factor pointing
towards HIV infection as the principal cause underlying the
increasing burden of TB was the temporal association between
the evolving age-specific burdens of the 2 epidemics (figure 2A
and 2B). Other factors corroborating this association were the
disproportionate increases in the rates of extrapulmonary and
pulmonary sputum-negative TB and the high prevalence of
HIV infection among patients with TB.
The epidemiology of TB in this community has changed
profoundly over a short period of time. Historically, TB no-
tification rates in this community have been highest among
persons 160 years of age [15]. However, in 2003–2004, the rates
were highest among persons aged 30–49 years (figure 3), in-
dicating a major shift in the burden of disease to individuals
in the economically productive age groups who also have the
most dependents. A particularly concerning finding was the
burden of TB among adolescents, especially girls, with TB rates
among 10–19-year-old adolescents reaching 436 cases per
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prevalence of HIV infection among adolescents aged 10–19
years in this community was 7% among male subjects and 11%
among female subjects in 2004 (unpublished data), indicating
that increases in the burden of TB in this age group were very
likely to be, at least in part, attributable to HIV infection.
The risk of TB increases with advancing immunodeficiency
[3, 4], so as the HIV epidemic in a community matures, the
burden of HIV-associated TB may be expected to increase, even
after the prevalence of HIV infection has stabilized. This is
likely to explain why the major increases in the prevalence of
HIV infection in this community occurred before 2000, yet TB
notification rates continued to increase steeply thereafter (figure
4). These data suggest that ongoing amplification of the TB
epidemic continues for several years as a result of earlier in-
creases in the prevalence of HIV infection.
Although increases in the number of notifications were more
pronounced for less infectious types of TB (i.e., pulmonary
sputum-negative and extrapulmonary TB), the number of no-
tifications of infectious, sputum-positive disease also increased
substantially (figure 1). The secondary impact of HIV-associ-
ated burden of sputum-positive TB in the general community
remains incompletely defined [7, 9, 17], but we were unable
to demonstrate a statistically significant increase in rates among
HIV-uninfected individuals. Moreover, TB notification rates
among persons aged 50 years, among whom the prevalence
of HIV infection is low, did not increase (figure 3). HIV-as-
sociated sputum-positive disease clearly does not cause a pro-
portionate increase in transmission within the general com-
munity. This is almost certainly related to the fact that
HIV-associated TB becomes symptomatic more quickly and is
diagnosed earlier than disease in HIV-uninfected individuals
[6], diminishing the period for potential transmis ion.
Although the DOTS strategy is central to the WHO policy
for TB control, the explosive increase in TB notifications in
this community and others like it show that the DOTS strategy
alone is not sufficient, and additional measures are required.
We suggest that these strategies may be targeted in various ways
on an age-specific basis among children, adolescents, those aged
20–49 years, and those aged 50 years. A substantial propor-
tion of children who developed TB in 2004 were HIV infected.
Thus, prevention of mother-to-child transmission services need
to be strengthened, and voluntary counseling and testing for
HIV in prenatal clinics and access to antiretroviral treatment
must be provided for HIV-infected pregnant women. Secondly,
administration of isoniazid prophylaxis to household contacts
of adults with TB needs to be more rigorously implemented.
The escalating burden of TB and HIV infection among ad-
olescents, among whom TB was previously rare, is of great
concern. Schools in this and similar communities across Africa
are extremely crowded and may provide a key site of TB trans-
mission. Moreover, in South Africa, the prevalence of HIV
infection is high among teachers [18], who may, therefore,
represent an important source of TB transmission. Therefore,
we suggest that TB and HIV diagnostic and prevention services
for adolescents and teachers should be introduced into schools.
Annual TB notification rates among persons aged 50 years
did not increase but remained ∼1800 cases per 100,000 persons
(figure 3). The major burden of disease in this age group was
among men who were unlikely to be HIV infected (figure 2B
and 2C). Because HIV-uninfected individuals with TB are more
infectious [19], this age group may represent a key source of
TB transmission and may be targeted by intensified case-
finding.
Most of the increasing burden of TB occurred among 20–
49-year-old persons. TB and HIV interventions need to be
rigorously implemented in health care facilities, and provision
of such services in workplaces may also facilitate access for this
age group. In this community, HIV infection is frequently di-
agnosed once individuals have presented with TB; strategies to
diagnose HIV infection before the development of TB are ur-
gently needed. This mandates intensification of voluntary coun-
seling and testing in prenatal, sexual health, and family-plan-
ning clinics and whenever individuals interface with the health
care system.
In addition to the DOTS strategy, antiretroviral therapy may
play an important adjunctive role in addressing this TB epi-
demic. Antiretroviral therapy reduces TB risk by 70%–90% in
treated cohorts over 1–2 years of follow-up [4, 20]. Voluntary
counseling and testing among patients with TB on an opt-out
basis may be accompanied by use of antiretroviral therapy
among all persons who are found to be HIV seropositive. The
majority of such patients here and elsewhere fall within the
eligibility criteria for antiretroviral therapy [21, 22]. This in-
tervention may reduce both the rate of new cases of TB, as
well as the high TB recurrence rate. However, there is concern
that, although antiretroviral therapy is very effective in reducing
an individual’s risk of developing TB per unit time, the lifetime
risk of disease may not decrease [20, 23]. Thus, the overall
burden of TB in the community may not substantially diminish,
despite good antiretroviral coverage. Other adjunctive inter-
ventions that may also be important include use of primary
and secondary isoniazid prophylaxis [24, 25].
In conclusion, we have carefully documented the differential
impact of HIV infection on TB notifications in age- and sex-
specific groups in this community. These data show that ad-
ditional interventions may need to be targeted in an age-specific
manner to address this regional emergency.
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Background: Although failure of tuberculosis (TB) control in sub-
Saharan Africa is attributed to the HIV epidemic, it is unclear why
the directly observed therapy short-course (DOTS) strategy is insuf-
ficient in this setting. We conducted a cross-sectional survey of
pulmonary TB (PTB) and HIV infection in a community of 13,000
with high HIV prevalence and high TB notification rate and a well-
functioning DOTS TB control program.
Methods: Active case finding for PTB was performed in 762 adults
using sputum microscopy and Mycobacterium tuberculosis culture,
testing for HIV, and a symptom and risk factor questionnaire. Survey
findings were correlated with notification data extracted from the
TB treatment register.
Results: Of those surveyed, 174 (23%) tested HIV positive, 11 (7
HIV positive) were receiving TB therapy, 6 (5 HIV positive) had
previously undiagnosed smear-positive PTB, and 6 (4 HIV positive)
had smear-negative/culture-positive PTB. Symptoms were not a
useful screen for PTB. Among HIV-positive and -negative individuals,
prevalence of notified smear-positive PTB was 1,563/100,000 and
352/100,000, undiagnosed smear-positive PTB prevalence was
2,837/100,000 and 175/100,000, and case-finding proportions were
37 and 67%, respectively. Estimated duration of infectiousness was
similar for HIV-positive and HIV-negative individuals. However, 87%
of total person-years of undiagnosed smear-positive TB in the com-
munity were among HIV-infected individuals.
Conclusions: PTB was identified in 9% of HIV-infected individuals,
with 5% being previously undiagnosed. Lack of symptoms sugges-
tive of PTB may contribute to low case-finding rates. DOTS strategy
based on passive case finding should be supplemented by active
case finding targeting HIV-infected individuals.
Keywords: African community; case finding; HIV infection; incidence
and prevalence; pulmonary tuberculosis
Present tuberculosis (TB) control strategies based on directly
observed therapy short-course (DOTS) strategy is insufficient
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
The complex interaction between the dual HIV and TB
epidemics at a community level is underreported.
What This Study Adds to the Field
Pulmonary tuberculosis is common in HIV-infected indi-
viduals. Specific active case finding strategies need to be
targeted at HIV-infected individuals.
to contain TB in sub-Saharan Africa, largely because of the
parallel epidemic of HIV in the region (1). An estimated 2.4
million new TB cases and 540,000 TB-related deaths now occur
in sub-Saharan Africa annually. Consequently, in August 2005,
the World Health Organization declared the epidemic in Africa
to be a regional emergency (2).
The DOTS strategy has been shown to be effective in many
settings, particularly where levels of HIV are relatively low (3–5).
However, the reasons for increasing TB rates where HIV is
prevalent have not been clearly defined. Failure of TB control
may in part be due to poor implementation of the DOTS strategy
because of lack of infrastructure or adequate resources (6). How-
ever, TB control may be less effective in communities with high
HIV prevalence because of alterations in patterns of transmis-
sion or disease presentation. By examining where DOTS has
been less successful (7), we may understand the reasons for the
breakdown in TB control efforts and suggest modifications and
improvement in current approaches and design new control
strategies.
The interactions between HIV and TB are complex; however,
understanding the interplay between these two epidemics is par-
ticularly important in countries of southern Africa, where HIV
has fueled an unprecedented increase in TB notification rates
(8). Because infectivity decreases rapidly after initiation of anti-
TB therapy (9), TB control is based on rapid identification and
treatment of infectious cases, thereby reducing the mean dura-
tion of infectiousness and the resultant number of secondary
infections (10). However, HIV may affect TB case finding due
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coinfections, which may mimic the symptoms of TB. HIV-medi-
ated immune deficiency also increases risk for development of
disease (17), and the vulnerable population increases during the
course of a maturing HIV epidemic as the proportion of those
with advanced immune deficiency increases (18, 19).
We have previously reported an increasing TB notification
rate in a community with high HIV and TB prevalence despite
implementation of a DOTS TB control program with good out-
come measures (20). In this population of approximately 13,000
individuals, data collected over 10 yr have shown a 2.5-fold
increase in TB notifications, to unprecedented levels exceeding
1,400 of 100,000, coincident with HIV prevalence in the commu-
nity increasing from 6 to 22% (20). In the present study, we
conducted a cross-sectional, population-based survey of both
HIV and TB prevalence to estimate the burden of undiagnosed
TB among HIV-infected people in this community. To avoid
selection bias, all individuals in the study sample were screened
for TB without any preselection on the basis of symptoms. In
conjunction with notification data, these data allow the estima-
tion of case-finding rates under the local DOTS program and
the population burden of undiagnosed TB disease. Some of the




The study community comprised 13,000 black African individuals living
mainly in shacks in a high-density residential area sited within well-
demarcated boundaries, where unemployment exceeds 50% (20). The
estimated mid-2005 adult population ( 14 yr) was derived from a
household survey performed in December 2004, adjusted for population
growth. There is a single public-sector primary care clinic, which incor-
porates voluntary HIV counseling and testing, and a TB clinic for the
diagnosis and management of TB in accordance with the South African
national TB control program protocols.
TB and HIV Prevalence Survey
Between February and June 2005, a total of 1,150 adults included in
the 2004 census were selected using simple random sampling. This
sample size was chosen to calculate an anticipated prevalence of TB
of 2.5%, with precision of 1.0%, and with corrections for anticipated
nonresponse (22). An initial home visit confirmed 971 of the selected
adults were living permanently on the identified plots, and these individ-
uals were invited to participate in the study. Of these, 762 adults (78%)
consented to participate in the study, 61 were unable to be contacted
after five home visits, and 148 declined to participate.
Participants were requested to bring an early-morning sputum sam-
ple to the study site. At the study visit, a second saline nebulized sputum
sample was collected and an oral transudate was taken for anonymous
linked HIV testing; HIV test results were available for 758 individuals
(two patients declined testing and two specimens were unsuitable for
analysis). Voluntary counseling, testing, and disclosure were offered to
all participants wishing to know their HIV status. HIV counseling, care,
treatment, and prevention services are run from the primary health
care clinic on site. A structured questionnaire investigating participant
demographic characteristics, TB symptoms (cough, loss of appetite,
weight loss, and night sweats), risk factors for TB (including housing,
alcohol, smoking, recreational drug use, incarceration, previous contact
with health services, time away from community, and employment
history), and risk factors for HIV infection (including number of sexual
partners and condom use) was completed. Questionnaires were admin-
istered in participants’ home language (predominantly isiXhosa) by
trained interviewers who used standardized isiXhosa phrasing for all
questions. All interviews took place in a private room within the clinic.
Draft questionnaires, including translated versions, were piloted before
the study began to ensure appropriate translation and participant com-
prehension. All participants gave written, informed consent. The study
received approval from the Research Ethics Committee of the Univer-
sity of Cape Town.
Case Definitions for TB Disease
TB definitions used for notification data were as defined by the South
African TB Control Program (23). Definitive prevalent smear-positive
TB was defined as a positive sputum smear confirmed with a second
positive smear or culture of Mycobacterium tuberculosis; and smear-
negative pulmonary TB (PTB) was defined by two positive cultures of
M. tuberculosis with confirmed identical spoligotype patterns.
TB Incidence and Treatment Outcomes
TB is a notifiable condition in South Africa, and each TB clinic is
required to maintain and report TB statistics, including patient demo-
graphics, TB diagnostic criteria, treatment regimen prescribed, results
of laboratory monitoring, voluntary HIV counseling and testing results,
and treatment completion and interruptions.
The adult TB case notification rate was determined as the number
of cases notified and initiating TB therapy during the 2005 calendar
year. Program performance criteria were extracted from the TB register
for all patients commencing therapy from 2002 to 2004.
Laboratory Procedures
Sputum smears were examined for acid-fast bacilli (AFB) using the
auramine O fluorescent stain. Mycobacterial growth indicator tubes
(Becton-Dickinson, Sparks, MD) were inoculated according to the man-
ufacturer’s instructions and incubated for 8 wk before being recorded
as negative. Positive cultures were screened for the presence of AFB
by Ziehl-Neelsen staining, and identified as M. tuberculosis complex
by inhibition of growth on p-nitrobenzoic acid. A polymerase chain
reaction assay specific for M. tuberculosis (24) was performed on those
cultures that had AFB visible on microscopy, but were contaminated
and could thus not be identified using the p-nitrobenzoic acid test. DNA
isolated from all M. tuberculosis cultures underwent spoligotyping.
An oral mucosal transudate for HIV testing was collected using the
OraSure (OraSure Technologies, Bethlehem, PA) oral fluid collection
device. The Vironostika Uni-Form II (bioMérieux, Marcy-l’Etoile,
France) HIV-1 and HIV-2 plus O ELISA test was used to test for
HIV-1 and HIV-2 antibodies.
Statistical Methods
Data were analyzed using Stata version 9.0 (StataCorp, College Station,
TX). Notification rates are based on the mid-2005 population estimates.
Median time receiving treatment in the TB program was calculated
from date of commencing treatment to date of completion, death, and
loss to follow-up, or transfer out of the program. Kaplan-Meier mortal-
ity proportions at 6 mo were estimated from the start of treatment to
death, treatment completion, loss to follow-up, or transfer. Because the
notification data come from routine service delivery where HIV testing
is optional, test results were available for only 81% of notified PTB
cases; for subsequent calculations, we made a conservative assumption
that the prevalence of HIV in notified PTB cases of unknown HIV
status was similar to the observed prevalence in notified cases with
HIV data available. The mean time that PTB cases spent in the commu-
nity before diagnosis and treatment (for both smear-positive disease
and all PTB) was estimated as the observed PTB prevalence divided
by the incidence of TB treatment (notification data). The time before
treatment was corrected for the excess mortality associated with HIV
infection in individuals with TB (as observed in the community DOTS
program between 2002 and 2004). In turn, the total person-time (i.e.,
the time that different types of PTB cases spent in the community
before diagnosis) is estimated as the product of the number of affected
individuals in the community and the mean time before diagnosis. Case-
finding proportions were calculated as the quotient of the prevalence
of treated PTB divided by the sum of the prevalence of treated and
the prevalence of untreated PTB. Exact 95% confidence intervals (CI)
are based on the hypergeometric distribution (25). We evaluated risk
factors for TB using Fisher’s exact tests, and Mann-Whitney U tests
were used to compare proportions and medians, respectively; all statisti-
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TABLE 1. 2005 ADULT PULMONARY TUBERCULOSIS TREATMENT NOTIFICATION RATES PER
100,000 PER ANNUM, CALCULATED FOR TOTAL ADULT POPULATION (n  10,408) AND
HIV-POSITIVE (n  2,432) AND HIV-NEGATIVE (n  7,976) POPULATIONS
Adult Population HIV-positive Adults HIV-negative Adults
(95% CI) (95% CI) (95% CI)
Pulmonary tuberculosis case notifications 1,931 (1,676–2,214) 5,140 (4,296–6,093) 953 (751–1,191)
Sputum smear–positive tuberculosis 1,307 (1,097–1,544) 3,248 (2,580–4,032) 715 (542–925)
Sputum smear–negative tuberculosis 625 (482–795) 1,891 (1,388–2,515) 238 (143–372)
Definition of abbreviation: CI  confidence interval.
HIV test results were available for only 81% of notified PTB cases; a conservative assumption has been made that the prevalence
of HIV in notified PTB cases of unknown HIV status is similar to the observed prevalence in notified cases with HIV data available.
RESULTS
TB Notifications 2005
The mid-2005 adult population was projected to be 10,408 with
an HIV seroprevalence of 23% using existing data (20). Thus,
approximately 8,000 HIV-negative and 2,400 HIV-infected indi-
viduals constituted the study population. A total of 259 TB cases
were notified in adults over the age of 14 yr and 201 (78%) of
these were categorized as PTB. The direct sputum smear–
positive and smear–negative adult PTB treatment notifications,
stratified by HIV status, are shown in Table 1. HIV testing was
performed in 81% of notified TB cases, with 66% testing positive.
The HIV-related odds ratio (OR) for smear-positive TB was 4.7
(95% CI, 3.3–6.7) and for smear-negative TB was 8.1 (95% CI,
4.7–14.7).
In the 2002–2004 performance criteria for the TB control
program among HIV-negative and HIV-positive individuals,
treatment completion was obtained in 84 and 73%, mortality in
3 and 13%, transfer out in 9 and 12%, and treatment interruption
occurred in 4 and 1%, respectively. The median length of TB
treatment was 178 d and the Kaplan-Meier estimations of mortality
among HIV-negative individuals were 4 and 5% at 6 mo for
smear-positive and smear-negative TB, respectively. The corre-
sponding mortality estimates for HIV-positive TB were 10.5 and
11% at 6 mo, respectively.
Prevalence Survey
Of the 762 participants in the community survey, 174 (23%)
tested HIV positive, confirming the modeled HIV prevalence
estimate. The survey sample also closely matched the predicted
2005 age, race, and sex distribution (data not shown). Among
study participants, 11 individuals with TB were currently notified
and receiving TB treatment. A further 12 previously undiag-
nosed definitive TB cases were identified: 6 smear-positive cases
TABLE 2. PREVALENCE SURVEY OF 762 RANDOMLY SELECTED ADULTS
Survey Sample HIV-positive Subjects HIV-negative Subjects
(n  762)* (n  174) (n  588)
Total pulmonary tuberculosis cases 23 (3.3) 16 (9.2) 7 (1.2)
Pulmonary tuberculosis cases on treatment 11 (1.4) 7 (4.0) 4 (0.7)
Newly identified
Pulmonary tuberculosis 12 (1.6) 9 (5.2) 3 (0.5)
New direct sputum smear–positive cases 6 (0.8) 5 (2.9) 1 (0.2)
New culture positive
New culture-positive smear-negative cases 6 (0.8) 4 (2.3) 2 (0.3)
Numbers (%) of identified treated cases of tuberculosis, previously undiagnosed pulmonary tuberculosis, previously undiagnosed
direct sputum smear–positive and Mycobacterium tuberculosis culture-positive/smear-negative cases stratified by HIV infection
status.
* Two patients refused HIV testing and two oral transudates were inadequate for testing. These four patients were all in the
non-TB category.
had either a second positive smear (n  1) or culture of
M. tuberculosis (n  5); and 6 smear-negative cases had positive
M. tuberculosis cultures obtained from two sputum specimens.
Spoligotyping of DNA from these cultures demonstrated six
distinct M. tuberculosis subtype patterns, with paired specimens
from each individual showing identical patterns.
The HIV status of previously and newly identified cases of
smear-negative and smear-positive TB is shown in Table 2. Of
the 12 previously undiagnosed TB cases, 9 (75%) tested positive
for HIV. Demographic characteristics of all participants with
and without TB are sh wn in Table 3, together with symptoms
and risk factors for TB. Prior imprisonment and HIV infection
were significantly associated with notified TB, and HIV infection
with previously undiagnosed TB. Cough, night sweats, loss of
appetite, and weight loss were absent among 67% of those with
previously undiagnosed TB. Two or more symptoms were pres-
ent in 25% of previously undiagnosed TB cases compared with
22% among the no-TB group (p  0.826).
Case-finding Proportions
In 2005, the point prevalence of adult PTB in the community
(2,517/100,000; 95% CI, 2,225–2,837) was calculated by addition
of notified case prevalence (notified incidence rate/median time
on treatment  942/100,000; 95% CI, 765–1146) and survey-
determined untreated TB prevalence (1,575/100,000; 95% CI,
816–2,735). Based on this point prevalence, the proportion of
cases identified and receiving TB treatment was only 37%. The
prevalence of newly diagnosed smear-positive PTB among HIV-
positive and -negative individuals was 2,837 of 100,000 and 175
of 100,000, respectively. Estimates of smear-positive PTB case-
finding proportions for HIV-positive and -negative individuals,
together with estimated time in the community before initiation
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TABLE 3. CHARACTERISTICS OF STUDY SAMPLE, OVERALL AND BY PREVALENT TUBERCULOSIS
INFECTION, AMONG 762 PARTICIPANTS
All Surveyed No TB Nonnotified TB Notified TB
(n  762) (n  739) (n  12) p Value (n  11) p Value
Demographics
Median age, yr 27 27 26.5 0.81 30 0.12
Median school grade completed 11 11 11.5 0.31 8 0.06
Presently employed 398 (52) 390 (53) 7 (58) 0.78 1 (9) 0.004
Median household income, South African rands 1,300 1,300 1,400 0.98 578 0.009
Median residence, yr 5 5 5 0.83 6 0.33
Time away from home in last 6 mo 209 (27) 204 (28) 2 (17) 0.53 3 (27) 0.99
Median residents in household 3 3 3 0.07 3 0.85
Median persons sleeping in same room 2 2 2 0.81 2 0.65
Symptoms
Cough 142 (19) 134 (18) 2 (17) 0.99 † —
Night sweats 130 (17) 121 (16) 1 (8) 0.70 † —
Loss of appetite 144 (19) 137 (19) 1 (8) 0.71 † —
Loss of weight 207 (27) 193 (26) 4 (33) 0.52 † —
Risk factors
Ever had TB in past 61 (8) 58 (8) 0 0.61 3 (27) 0.053
Alcohol intake in past 6 mo 324 (43) 313 (42) 5 (42) 0.99 6 (55) 0.54
Visited shebeen (bar) in past 6 mo 180 (24) 175 (24) 3 (25) 0.99 2 (18) 0.99
Smoked in past 6 mo 205 (27) 196 (27) 4 (33) 0.53 5 (45) 0.18
Recreational drugs in past 6 mo 29 (4) 28 (4) 0 0.99 1 (9) 0.35
Employment history
Past mining 43 (6) 41 (6) 1 (8) 0.50 1 (9) 0.47
Health care worker 21 (3) 20 (3) 0 0.99 1 (9) 0.27
Prison 11 (1) 8 (1) 1 (8) 0.14 2 (18) 0.008
HIV positive 174 (23)* 158 (22) 9 (75)  0.001 7 (64) 0.003
Definition of abbreviation: TB  tuberculosis.
All values are n (%) unless otherwise specified. p values are for comparing nonnotified TB (n  12) and notified TB (n  11)
against no-TB (n  739).
* Two patients refused HIV testing and two oral transudates were inadequate for testing. These four patients were all in the
non-TB category.
† Symptoms questionnaire results do not represent prediagnosis symptoms and have been excluded.
burden of disease, estimated as the product of the number of
affected individuals and the mean time before diagnosis and
treatment, is presented in Figure 1. HIV-infected individuals
were found to contribute 87% of the total person-years of undi-
agnosed disease.
DISCUSSION
This is the first population-based active case-finding survey of
HIV and TB in sub-Saharan Africa. The major finding of this
study was that, despite a well-run DOTS-based TB control pro-
gram, 63% of community adult cases with PTB remained unrec-
ognized to the TB treatment services. Among HIV-negative
individuals, passive case finding identified 67% of prevalent
smear-positive cases, which is close to the target of 70% sug-
TABLE 4. PREVALENCE PER 100,000 OF NOTIFIED, TREATED ADULT CASES WITH PULMONARY
TUBERCULOSIS AND UNTREATED CASES WITH PULMONARY TUBERCULOSIS IN THE
COMMUNITY, WITH ESTIMATED CASE-FINDING PROPORTION AND TIME IN YEARS BEFORE
INITIATION OF TREATMENT
Total Population HIV Positive Total Population HIV Negative
(95% CI) (95% CI)
Prevalence of treated PTB 2,508 (1,924–3,210) 464 (327–639)
Prevalence of total (treated and untreated) PTB 7,648 (6,623–8,777) 978 (774–1,219)
Case-finding proportion* 0.34 (0.26–0.46) 0.48 (0.32–0.70)
Estimated mean time (yr) of TB patients before treatment† 1.19 1.02
Definition of abbreviations: CI  confidence interval: PTB  pulmonary tuberculosis.
* Prevalence of treated PTB/prevalence of treated and untreated PTB.
† Mean time untreated  PTB prevalence/(PTB incidence  HIV mortality rate), where the HIV mortality rate is the excess
mortality associated with HIV infection in individuals notified with PTB 2002–2004.
gested for adequate DOTS implementation (26). In contrast,
among individuals with HIV infection, passive case finding only
identified 33% of those with smear-positive TB. Thus, our study
identified a huge unrecognized burden of TB in the community,
predominantly among HIV-infected people. In this group, un-
treated smear-positive and smear-negative/culture-positive
prevalence rates of TB were 2.9 and 2.3%, respectively. Among
those with sputum smear–positive TB, the mean time spent in
the community before accessing TB treatment was estimated to
be as long for HIV-positive as for HIV-negative individuals,
even after accounting for increased HIV mortality. HIV-infected
individuals accounted for 87% of total person-years of untreated
smear-positive TB before diagnosis and treatment. This finding
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TABLE 5. PREVALENCE PER 100,000 OF NOTIFIED, TREATED ADULT SPUTUM SMEAR–POSITIVE
CASES WITH PULMONARY TUBERCULOSIS AND UNTREATED SPUTUM SMEAR–POSITIVE
CASES WITH PULMONARY TUBERCULOSIS IN THE COMMUNITY, WITH ESTIMATED
CASE-FINDING PROPORTION AND TIME IN YEARS BEFORE INITIATION OF TREATMENT
HIV Positive, Smear Positive HIV Negative, Smear Positive
(95% CI) (95% CI)
Prevalence of treated PTB 1,563 (1,108–2,138) 352 (233–507)
Prevalence of total (treated and untreated) PTB 4,400 (3,619–5,299) 527 (380–711)
Case-finding proportion* 0.37 (025–0.53) 0.67 (0.41–1.0)
Estimated mean time (yr) of TB patients before treatment† 0.98 0.73
For definition of abbreviations, see Table 4.
* Prevalence of treated PTB/prevalence of treated and untreated PTB.
† Mean time untreated  PTB prevalence/(PTB incidence  HIV mortality rate), where the HIV mortality rate is the excess
mortality associated with HIV infection in individuals notified with PTB 2002–2004.
gold miners, which estimated mean duration of smear-positive
TB before diagnosis to be only 2 mo for HIV-positive miners
(15). In that study, HIV-positive miners attended an HIV clinic
and resulting ascertainment bias and use of isoniazid prophylaxis
may have lowered the rate of previously undiagnosed smear-
positive TB among the HIV-positive subjects (0.4%), resulting
in a low calculated mean TB duration before diagnosis. The
mean duration of infectiousness is a key determinant of the
dynamics of the TB epidemic. In our study, the combination of
high prevalence of untreated PTB among HIV-infected people,
together with a prolonged exposure time in the community, may
account for the lack of success of the DOTS program. However,
TB infectivity may be lower for HIV-infected compared with
HIV-uninfected individuals (27).
The study was performed in a community characterized by
high HIV prevalence and increasing TB notification rates (20),
and was sited within well-demarcated boundaries. There was a
single community health clinic, making it likely that diagnosis
and reporting of TB was uniform, thereby minimizing reporting
biases. The TB DOTS control program performance over the
3 yr immediately before the survey demonstrated reasonable
treatment completion rates but with a significant TB case fatality
rate, which was higher in HIV-infected patients and those with
smear-negative disease. The results of this survey reflect the
epidemiology of TB and HIV in this community before access
to highly active antiretroviral therapy (HAART) and without
use of isoniazid prophylaxis.
The population-based survey identified individuals from
whom M. tuberculosis was isolated but who did not perceive
Figure 1. Community burden of undiagnosed pulmonary
tuberculosis (PTB) by HIV and smear status. The closed
diamonds (HIV ve) and open diamonds (HIV ve) indicate
the estimated number of person-years, and the horizontal
lines the 95% confidence intervals around these estimates.
Estimated time before diagnosis is adjusted for increased
mortality (13/100 patient-years) for HIV-positive individuals.
themselves to have symptoms of PTB. These individuals would
therefore be less likely to present early to a TB control program.
Our finding of a large burden of undiagnosed TB in this popula-
tion is in contrast to a prior study in South Africa, which found
a modest burden of undiagnosed TB in a rural population. How-
ever, in that study, laboratory investigation of TB was limited
to only those with chronic cough and may therefore have under-
estimated the true TB burden (28).
Isolation of M. tuberculosis from asymptomatic individuals
may initially appear to be in conflict with the international stan-
dards of TB care, which emphasize the investigation for TB
among those with chronic cough (29). However, in a prospective
population-based survey in the United States, symptoms of pro-
longed cough and fever were found to be insensitive predictors
of TB (30). HIV infection has also been recognized to be a
major modifier of the clinical presentation of TB, such that TB
symptoms may be relatively minor (15, 16), atypical (11–13), or
subclinical in HIV coinfected individuals (14). Furthermore, post
mortem studies from Africa have reported TB as the cause of
death in 38 to 47% of HIV-infected individuals in whom the
diagnosis was suspected in only half while they were alive (31–
33). In this poor community in our study, cough, night sweats,
loss of appetite, and weight loss were reported frequently even
in the absence of TB.
This study also highlights the problem of applying diagnostic
tests developed primarily for clinic-based diagnosis to a popula-
tion-based survey. Demonstration of acid-fast organisms on di-
rect sputum smear lacks sensitivity (34) but has high specificity
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M. tuberculosis culture from sputum is sensitive but may be subject
to false-positive results due to laboratory cross-contamination (37,
38). The performance characteristics of these diagnostic tests are
of particular importance in population surveys. Limiting testing
only to those with symptoms may increase the positive predictive
value of TB tests; however, this strategy may miss a significant
proportion of TB cases (30). In our study, restricting the case
definition to those individuals with two positive laboratory re-
sults increased the specificity of diagnosis. Furthermore, false-
positive cultures due to laboratory cross-contamination were
very unlikely in our study because of the demonstration of multi-
ple M. tuberculosis spoligotypes and 100% concordance among
duplicate spoligotypes from each individual.
These data should be interpreted in light of several limita-
tions. Although TB events are frequent in this population, the
sample size was modest and therefore calculated prevalences
have relatively wide confidence intervals.
There is evidence that many black African communities in
this region have high degrees of mobility (39); however, time
spent away from the community was not correlated with TB
infection (either notified or nonnotified), suggesting that any
such bias would have a minimal impact on the results. The
response rate to the prevalence survey was not complete, al-
though this response rate (78%) was relatively high and there
were no differences in the distribution of age, sex, or race be-
tween our sample and the community based on population cen-
sus data. Furthermore, the HIV prevalence observed in our
sample (23%) was identical to modeling of the HIV epidemic
in this setting (20). In addition, because our TB notification data
come from routine service in which HIV testing is optional, HIV
test results were available for only 81% of the notified TB cases;
because we have assumed that the HIV prevalence among TB
cases whose HIV status is unknown is similar to that of known
individuals, these missing data are unlikely to affect our results
substantially. Last, the generalizabilty of our findings will be
dependent on the confirmation of our findings in other popula-
tions with very high HIV and TB burdens.
The results of this study have implications for individual man-
agement of HIV-infected individuals and the TB control pro-
gram. Active screening of known HIV-infected individuals for
TB, with induced sputum for sputum microscopy and culture,
is indicated in this setting, even in the absence of symptoms
suggestive of TB. Active screening for TB should precede initia-
tion of isoniazid prophylaxis to avoid monotherapy of active TB,
and screening based on symptoms may be inadequate. It will
need to be prospectively evaluated whether screening for TB at
entry to ART programs can identify the approximately 5% of
individuals who develop TB soon after initiation of ART (40).
TB control in this and similar communities will be dependent
on the ability of the health system to identify HIV infections.
Voluntary counseling and testing will need to be combined with
subsequent active screening for TB of those who test HIV
positive.
We have reported a large burden of HIV-associated undiag-
nosed TB in a community despite a well-functioning DOTS TB
control program. Further population-based prevalence studies
are required to confirm these findings in similar communities
where HIV/TB coinfection is common, but our data indicate
that such studies should not be limited to those with symptomatic
disease. The passive case-finding aspect of the DOTS program
performed inadequately for those with HIV infection and re-
sulted in lower case-finding proportions in HIV-infected com-
pared with HIV-uninfected individuals. The lack of symptoms
suggestive of PTB may in part have contributed to this failure.
Our data confirm that more intensive TB case finding in HIV-
infected individuals is required, as has been previously suggested
(21, 41–43).
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Cape Town, South Africa
Tuberculosis (TB) has proven to be difficult to control in regions with a high prevalence of human immu-
nodeficiency virus (HIV) infection. We previously described high prevalence of HIV infection among adults
(23%) and rapidly escalating TB notification rates in a peri-urban township, Site-M in Cape Town, South
Africa. The combination of delineated boundaries, a well-characterized population, centralized TB record
keeping, and high levels of HIV testing make this population uniquely suited for TB epidemiologic and
transmission studies. The driver of the HIV and TB coepidemic appears to be a high annual risk of Myco-
bacterium tuberculosis infection in this community. A high annual risk of M. tuberculosis infection may be
the result of unrecognized infections coupled with intense social interaction and crowding. New non–facility-
based interventions will be required, with emphasis on community-based case finding and contact tracing to
decrease the infective TB pool. There is a need for better understanding of the transmission dynamics of TB
and the intensity of social interactions, which have exacerbated an HIV and TB epidemic in this community
of hyperendemicity.
Tuberculosis (TB) remains a challenge to global public
health, is a major cause of mortality, and has proven
to be particularly difficult to control in regions with a
high prevalence of human immunodeficiency virus
(HIV) infection. An estimated 1.3 million deaths due
to TB occur annually among HIV-uninfected individ-
uals, and an additional 0.5 million deaths occur among
HIV-infected persons. Of the estimated global burden
of 9.3 million new TB cases in 2007, 1.37 million
(14.8%) were associated with HIV infection and ac-
counted for almost 25% of global AIDS-related mor-
tality [1].
Sub-Saharan Africa has borne the brunt of the HIV
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and TB coepidemics, accounting for 79% of the global
burden of HIV infection–associated TB cases in 2007.
The 9 countries of the southern African region with
hyperendemicity have TB case notification rates that
are much higher than those for the rest of the African
continent; these 9 countries have generalized HIV ep-
idemics and report a prevalence of HIV infection of
!50% among persons with newly diagnosed TB (Figure
1). In 2007, the estimated rate of TB case notifications
in Africa was 161 cases per 100,000 population; how-
ever, in this subregion of hyperendemicity, incidence
rates of TB in South Africa and Swaziland increased to
948 cases per 100,000 population and 1198 cases per
100,000 population, respectively, with 73% and 80% of
new TB cases, respectively, involving HIV coinfection.
The Millennium Development Goals for global TB
control are to halt and start to reverse the increasing
incidence of TB and to halve the 1990 prevalence and
death rates by 2015 [2]. In countries where TB is hy-
perendemic, such as South Africa and Swaziland,
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Figure 1. Estimated prevalence of HIV infection among persons with newly diagnosed cases of tuberculosis (TB), 2007. Reprinted with permission
from the World Health Organization [1].
is unlikely, because it would require a reversal of present TB
incidence trends and a 6-fold reduction in TB incidence during
the next 6 years.
Since the World Health Organization (WHO) declaration in
1993 that TB was a global emergency, the directly observed
therapy short-course (DOTS) strategy has been the key public
health intervention that has been widely used to affect global
TB control [3]. The strategy focuses on TB case management
of sputum smear–positive cases with use of short-course ri-
fampicin-containing chemotherapy. Case finding is passive and
facility based, with emphasis placed on case retention and the
achievement of a high cure rate. Although DOTS has been
effective in most regions of the world, contributing to the sus-
tained downward trend in global TB prevalence, it has been
comparatively ineffective in countries with a high prevalence
of HIV infection [1, 4–7]. During 2002–2004, the WHO and
the Stop-TB Partnership published guidelines [8], a strategic
framework [9], and an interim policy for TB and HIV infection
[10] to address the specific challenge of HIV infection–asso-
ciated TB. These interventions aim to reduce the burden of TB
in HIV-infected persons through use of TB prevention strat-
egies, including isoniazid preventive therapy (IPT), intensified
case finding, and infection control in conjunction with anti-
retroviral therapy (ART)—the so-called “3 I’s.”
However, mathematical modeling suggests that a combina-
tion of very high levels of ART coverage and early ART initi-
ation at high CD4 cell counts may be required to significantly
affect population TB control, especially in settings where TB
and HIV infection are hyperendemic [11]. Similarly, IPT is an
intervention that reduces the risk of active TB in already HIV-
infected individuals with latent TB infection rather than a pri-
mary strategy to control the public health burden of TB [12].
Although IPT is effective in decreasing the individual risk of
progression to TB [13], the modeled population impact of IPT
in areas of hyperendemicity is predicted to be small [14]. There-
fore, there is an urgent need to understand the epidemiological
factors driving the coepidemics in regions of hyperendemicity
to inform TB-control strategies.
LESSONS FROM EPIDEMIOLOGIC STUDIES IN
AN URBAN COMMUNITY WHERE TB IS
HYPERENDEMIC
Although the global burden of HIV infection–associated TB is
concentrated in the southern African subregion, there are large
differences in disease burden even in the subregion. Specific
subpopulations, such as South African mine workers, have been
well documented to have a high TB incidence, in part because
of the multiplicative effect of HIV infection and mine work–
associated pulmonary silicosis [15]. In addition, rapid growth
of urban areas is occurring in the context of generally declining
economic performance, and the growth of urban areas includes
huge numbers of persons with low-income status [16, 17]. It
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Figure 2. An aerial photograph of Site-M (in Cape Town, South Africa), with superimposed property boundaries outlined. The figure was created
using ArcGIS, version 9.2 (ESRI, 380 New York St, Redlands, CA 92373-8100).
57% of these persons live in slum conditions [18] where TB
and HIV burdens are greatest [19].
We previously described an epidemiologic study in South
Africa that found a high prevalence of HIV infection among
adults (23%) [5] and rapidly increasing TB notification rates
[20]. Specifically, annual TB notifications have now reached
2000 cases per 100,000 population in this peri-urban township
in Cape Town, designated by our study as “Site-M” [5, 20].
Regular household censuses have been performed that have
shown that the community has undergone rapid population
growth from 5000 residents in 1996 to 15,000 residents in 2008.
This population growth has occurred within well-circumscribed
boundaries (Figure 2). The community is socially deprived,
living in overcrowded, largely informal dwellings located on
demarcated plots serviced with water and sanitation. There is
a single health care facility that provides primary medical care
to community residents, and there is a primary and secondary
school. Increases in TB notification rate have occurred despite
a well-implemented national TB-control program based on the
WHO DOTS strategy [21] at the single community clinic that
manages all resident TB cases. Routine HIV testing (with con-
sent) of patients with incident TB was introduced in 2002. The
combination of delineated boundaries, a well-characterized
population, centralized TB record keeping, and high levels of
HIV testing make this population uniquely suited for studies
on TB epidemiology and transmission.
IMPACT OF HIV INFECTION ON TB CONTROL
Almost 2 decades ago, before the development of effective com-
bination ART, Styblo [6] reported that existing TB-control
strategies would be significantly undermined by HIV infection,
particularly in Africa. It was postulated that the impact of HIV
infection on the epidemiological situation of TB would depend
primarily on the following parameters: (1) the prevalence of
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Figure 3. The relationship between tuberculosis (TB) notification rates and seroprevalence of HIV infection in the South African population (diamonds)
and the population at Site-M (triangles), with exponential regression lines for South African data during 1990–2005 (R2, 0.8461) and for Site-M data
during 1996–2005 (R2, 0.9376).
general population aged 15–49 years, (3) the progression from
latent TB to active disease, (4) the level and trend in the annual
risk of (new) TB, and (5) the detection rate of new and relapse
cases of TB and cure rate among persons with smear-positive
cases.
Other more recently recognized factors include the obser-
vation that combination ART can significantly decrease TB in-
cidence [22] and the observation that TB incidence is very
dependent on current CD4 cell counts [23]. Taking these factors
into consideration, studies have focused on measuring the fol-
lowing likely drivers of increasing TB incidence in the study
community: prevalence of HIV infection, prevalence of un-
derlying latent TB, rates of progression from latent TB to active
TB, annual risk of TB, and case detection rates.
PREVALENCE OF HIV INFECTION
Since 1990, the South African Department of Health has per-
formed annual national surveys on the prevalence of HIV in-
fection among women attending antenatal services [24]. The
TB notification rates in South Africa from 1990 through 2005
[1] and the national antenatal seroprevalence of HIV infection
are shown in Figure 3 [24]. The corresponding adult TB no-
tification rates and prevalence of HIV infection among adults
at Site-M from 1996 through 2005 are also shown in Figure 3.
During the these periods, the seroprevalence of HIV infection
increased markedly, reaching levels of 30% and 23% among
national antenatal attendees and adults at Site-M, respectively.
TB notification rates have increased logarithmically for linear
increases in prevalence of HIV infection; an even stronger pos-
itive relationship was shown in the high-burden township. Pos-
sible explanations for this nonlinear relationship could include
changes in CD4 cell count distribution in the HIV-infected
population during the rapid-growth phase of the HIV epidemic
or increasing TB transmission between HIV-infected individ-
uals as the HIV epidemic grows rapidly.
AGE-SPECIFIC TB AND HIV INFECTION
Over the past decade the number of TB notifications has in-
creased markedly at Site-M, with the increased burden of TB
disease predominantly affecting persons aged 15–45 years (Fig-
ure 4A). The numbers of TB presentations at any age are a
function of the number of individuals in each age strata and
the TB rate specific to that age group. There have been sig-
nificant changes to age-specific TB rates over the past decade
that have been associated with increasing prevalence of HIV
infection (Figure 4B). TB rates appear to have increased in all
age groups; however, the most marked increases are among
persons aged 15–44 years, the age group most at risk of ac-
quisition of HIV infection.
POPULATION PREVALENCE OF TB
Prevalence of underlying latent TB at any age is influenced by
both the prevailing TB transmission rate and transmission rates
during the preceding years of life; therefore, prevalence of TB
increases with increasing age because of accumulated exposure.
The traditional way to measure latent TB is to measure reaction
to tuberculin antigens by tuberculin skin testing. Population
tuberculin skin testing surveys have been infrequently per-
formed in recent decades; however, a recent tuberculin skin
testing survey at Site-M township primary school reported TB
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Figure 4. A, Number of tuberculosis (TB) notifications, stratified by
age, at Site-M over two 4-year periods: 1996–1999 (diamonds) and 2004–
2007 (triangles). B, TB notification rates, stratified by age, at Site-M over
two 4-year periods: 1996–1999 (diamonds) and 2004–2007 (triangles).
the age of 15 years [25]. Moreover, prevalence of latent TB
appeared to continue to increase throughout adolescence. In
2006, the HIV-uninfected control population at a similar nearby
township in Cape Town had a TB prevalence of 77% by the
age of 28 years [26]. Other similar township populations in
Cape Town have also shown equally high prevalence of adult
TB infection [27].
RATE OF PROGRESSION TO ACTIVE TB
DISEASE
The temporal association between infection and risk of pro-
gression to active disease has been well recognized [28]. Pro-
gression to active disease is particularly rapid in children and
has been a marker of ongoing transmission; however, the re-
sultant TB disease is frequently sputum smear negative [29].
Childhood TB is conventionally reported internationally as a
!15 years smear positive rate [1]. In 2007, South Africa reported
a high smear positive childhood rate of 30 cases per 100,000
population. However, the high burden of childhood disease is
not adequately reflected by the !15 years smear positive rate.
In 2007, although the !15 year smear positive rate for Site-M
was 81 cases per 100,000 population, the TB notification rate
was 54 cases per 100,000 population among children !15 years
of age and reached 1390 cases per 100,000 population among
children !5 years of age.
There has been a marked change in the adult age of TB
disease presentation. During 1996–1997, a period of relatively
low prevalence of HIV infection, the incidence of TB increased
progressively with advancing age, with no case notifications for
adolescents (age, 10–19 years); however, TB notification rates
increasing steadily to 1700 cases per 100,000 population in the
fifth decade of life [5]. During 2003–2004, when the prevalence
of HIV infection among adults exceeded 20%, TB notifications
predominantly were for adolescents and young adults.
The estimated incidence of TB among HIV-uninfected and
HIV-infected adult community members in 2005 was 953 cases
per 100,000 population and 5140 cases per 100,000 population,
respectively [20], indicating a 5-fold increased risk among HIV-
infected individuals. As a consequence of these high TB inci-
dence rates, the lifetime cumulative risk of TB is extremely high
for both HIV-uninfected and HIV-infected individuals in this
community. The very high cumulative lifetime TB risk for HIV-
uninfected individuals is also much higher than the conven-
tional estimated lifetime risk of latent infection progressing to
TB disease of 10%–20% [30]. The increased lifetime risk may
result from increased rates of progression because of poor nu-
trition, exogenous reinfection, or exposure to a high initial
amount of infective TB [31]. The majority of individuals who
are coinfected with TB and HIV live in sub-Saharan Africa, an
area where hunger and malnutrition were already pressing con-
cerns before the onset of the HIV and TB epidemics.
LEVEL AND TREND OF ANNUAL RISK OF TB
Population density varies markedly among and within coun-
tries. Both the nature of the dwelling and crowding within the
dwelling will have an impact on the number of individuals
exposed to an infected person. Site-M has had an increasing
population density, reaching 15,700 persons/km2 in 2008. The
annual risk of TB among primary school children in 2008 was
estimated to be 3.8%–4.8% [25], which is unprecedented in
the current TB chemotherapeutic era. The annual risk of TB
is similar to that found in several large scale surveys performed
in western, eastern, and southern Africa from 1995 through
1960 [32]. In the prechemotherapy era, mean annual rates of
infection as high as 13% per annum were reported among
Parisian children in 1910 [33]. Lower rates of infection of 3%
per annum were recorded among children in post–World War
II Denmark [34].
A 77% prevalence of TB infection by age 28 years (during
a period of increasing TB notifications) would indicate a high
and ongoing mean risk of TB infection of 5.5% during an
individual’s preceding years of life. Childhood infection and
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with exposure to adult smear-positive TB in combined family
groups that are resident on each serviced plot [35].
In summary, the annual risk of TB in this community is
extremely high and appears to be maintained or to increase
throughout childhood and adolescence. Trends in the annual
risk of TB over time in any specific age group in this community
are less certain; however, there is little evidence for decreasing
transmission.
CASE DETECTION AND TREATMENT
Efficient case management of infective TB is the cornerstone
of the DOTS strategy [3], to which other supplementary control
strategies may be added [8–10]. The single TB facility in Site-
M implements DOTS-based, short-course, rifampicin-contain-
ing chemotherapy, administered in accordance with national
guidelines [36]. TB-associated mortality during 2002–2004, be-
fore availability of ART, among HIV-infected and HIV-unin-
fected persons with TB was 13% and 3%, respectively [20].
Treatment completion rates of persons surviving to 6 months
of age were 84% among HIV-infected persons and 86.6%
among HIV-uninfected persons [20]. In 2005, a cross-sectional
survey of a randomly selected subset of the general population
found that the existing facility-based smear-positive case find-
ing was higher for HIV-uninfected community members than
for HIV-infected community members (rates, 0.67 [95% con-
fidence interval, 0.25–0.53] and 0.37 [95% confidence interval,
0.41–1.0], respectively) [20].
TB TRANSMISSION PATTERNS
Over a 5-year period from 2001 through 2005, all acid-fast
bacilli–positive sputum samples obtained at the single clinic in
Site-M were cultured, and IS6110-based restriction fragment-
length polymorphism analysis [37] was performed [38]. A
broad diversity of !200 distinct circulating M. tuberculosis
strains were estimated to be circulating in this community—a
finding consistent with other studies in sub-Saharan Africa [39,
40]. This study also found an association between W-Beijing
family strains and HIV infection that may reflect ongoing trans-
mission of TB among HIV-infected persons. W-Beijing strains
have been associated with increased virulence [41] and the
development of multidrug resistance [42]. The high degree of
genotypic diversity in certain strains may indicate that they
either are endemic in this population or may be emerging and
diversifying in the community.
Another important finding was the high rate of strain clus-
tering. In this study, approximately half of the strains were
clustered, and there were close temporal associations, especially
among the paired clusters, supporting the likelihood that a
significant proportion of disease in the community is attrib-
utable to recent infections. No association was found between
HIV infection and clustering; therefore, new infections may be
occurring in both HIV-uninfected and HIV-infected patients.
DISCUSSION
This review has focused in detail on a specific, well-demarcated
population that is heavily burdened with the dual epidemics
of HIV infection and TB. Detailed analysis of the HIV and TB
epidemics in this community may reveal insight into the factors
driving the HIV and TB regional emergency in southern Africa.
The incidence of TB has increased logarithmically with growth
of the HIV epidemic and has been associated with a changed
age distribution, resulting in the TB burden transferring from
the elderly to young adults. The HIV epidemic appears to have
unmasked a previously unrecognized high prevalence of TB
and an unprecedented rate of TB in this crowded township.
Modeling studies suggest that a combination of interventions
will be required to regain TB control [12]. The present strategy
for global TB control remains the identification and effective
case management of infectious TB cases [33]. However, al-
though the facility-based program in this community appears
to have achieved standard targets for TB case management for
HIV-uninfected community members, the program has not had
an impact on the extremely high annual risk of TB.
Strategies to decrease progression from prior infection may
include ART and IPT. However, ART will need to be introduced
with high coverage and earlier in the course of HIV infection,
at higher CD4 cell counts, to significantly have an impact on
rates of TB in the population [12]. Although the effect of ART
is greater with continuing length of therapy [34], the benefits
of IPT for HIV-infected patients are time-limited, compared
with those for HIV-uninfected persons [14].
The underlying driver of the explosive HIV and TB coepi-
demic appears to be an extremely high annual risk of TB in
this community. A high annual risk of TB may be the result
of unrecognized infectious cases in the community and intense
social interaction and crowding. New interventions in addition
to the present clinic-based model of TB case management will
be required, with increased emphasis on active community-
based case finding and contact tracing to decrease the infective
TB pool. There is also an urgent need for better understanding
of the transmission dynamics of TB and intensity of social
interactions that have exacerbated the HIV and TB coepidemic
in this community of hyperendemicity.
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Rationale: In 2005, we reported high prevalence of untreated
pulmonary tuberculosis (TB) in a South African community. Preva-
lent untreated TB is the main source of transmission. In settings with
large burdens of human immunodeficiency virus (HIV) and TB,
highly active antiretroviral therapy (HAART) may contribute to TB
control.
Objectives: To assess the community-level impact of HAART on TB
prevalence, we repeated a community-based TB prevalence cross-
sectional survey in 2008 following HAART roll-out.
Methods: A random 10% adult population sample was identified
from the community. Participants provided two sputum specimens
for acid-fast bacilli microscopy and TB culture. Oral transudate
specimen was collected for anonymous HIV testing, linked to TB
diagnosis. An interviewer-administered, structured questionnaire
identified TB and HIV history and risk factors.
Measurements and Main Results: In the 2008 survey, 1,250 adults
participated (90% response rate); 306 (25%) tested HIV positive, of
which 60 (20%) were receiving HAART. A total of 20 TB cases were
identified (12 receiving TB treatment), representing a significant
decline in prevalence from 3.2 to 1.6% (P 5 0.02) between the
surveys. TB prevalence in participants not infected with HIV was
unchanged (P 5 0.90). The decline occurred among participants not
infected with HIV, decreasing from 9.2 to 3.6% in 2005 to 2008,
respectively (P 5 0.003). In participants infected with HIV, preva-
lenceof treatedTB declined from4 to 2.3% (P 5 0.06), and untreated
TB prevalence from 5.2 to 1.3% (P 5 0.02). The proportion of
untreated TB in patients receiving HAART decreased significantly,
from 22 to 0% (P , 0.001).
Conclusions: Prevalence of undiagnosed TB declined significantly
over a period of increasing HAART availability. The decline was
predominantly in individuals infected with HIV receiving HAART.
Keywords: tuberculosis; prevalence; human immunodeficiency virus;
antiretroviral therapy
Tuberculosis (TB) prevalence is the proportion of a population
with active TB disease, both treated (diagnosed) and untreated
(undiagnosed), at a given point in time. Patients with TB re-
ceiving TB chemotherapy are considered to be less infectious
(1), and it is this group of patients that is reflected in notification
data. Untreated or inadequately treated TB disease, in contrast,
is often unrecognized, and is the primary driver of transmission
in a population (1–4). Therefore, prevalence of untreated TB is
often considered a useful measure of this transmission factor.
One of the Stop TB Partnership targets is to reduce TB
prevalence by 50% from 1990 to 2015 (5). The World Health
Organization (WHO) has called for national surveys in high
burden countries, such as South Africa, to monitor progress
toward this target (5). However, evaluating population TB
prevalence is logistically challenging, and cross-sectional surveys
are costly due to the large sample sizes required, particularly in
low-prevalence settings (6). Moreover, surveys require well
trained staff and reliable laboratory services (6, 7), and, therefore,
few population surveys have been performed in resource-poor
settings (8–11). Reported surveys have often been limited to high-
risk groups, such as prisoners (12–14), miners (15), or patients
infected with human immunodeficiency virus (HIV) (16, 17).
Thus, due to the paucity of national data, TB prevalence reported
by the WHO for most countries is not measured directly, but is
an indirect estimate based on related parameters (18). In the
particular example of South Africa, prevalence data has been
estimated from TB incidence and trends in TB mortality (5).
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Prevalent untreated tuberculosis (TB) is the main source of
Mycobacterium tuberculosis. However, little data are avail-
able on the impact f highly active antiretroviral therapy
(HAART) on TB prevalence at a community level.
What This Study Adds to the Field
Our evidence suggests that the significant decline in un-
diagnosed TB prevalence is associated with the introduction
of a rapid and large-scale HAART program, particularly in
adults infected with human immunodeficiency virus. This
decline is due to the increased case finding in the HAART
program, and may also be a result of the impact of HAART-
associated immune recovery on the risk of TB.
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In South Africa, 73% of TB incidence is HIV related (5).
Highly active antiretroviral therapy (HAART) has been shown
to reduce TB incidence in treatment cohorts (19, 20), and,
therefore, wide-scale availability of HAART may play a role in
TB control. However, little data are available on the impact of
ART on TB prevalence—in particular, undiagnosed TB prev-
alence, at a community level.
In 2005, before the extensive roll-out of an ART program, we
performed a community-based TB prevalence cross-sectional
survey in a well defined, peri-urban township in South Africa. The
survey reported a 3% overall TB prevalence in this community,
and, in particular, a high rate of untreated, laboratory-confirmed
pulmonary TB (PTB) among individuals infected with HIV (21).
The residents of this community were of predominantly poor
socioeconomic status, with high unemployment rates and over-
crowded living conditions. The community had a high TB and
HIV burden (21, 22), and was serviced by a single primary
health care clinic. The clinic managed all patients with TB in
accordance with the National TB Control Guidelines (23),
which have not changed substantially since 2005. However,
since 2005, there has been a significant scale-up of the ART
program in this community, with ART coverage among in-
dividuals infected with HIV increasing from 5% in 2004 to
13% and 21% of the HIV-infected population in 2005 and
2008, respectively (24).
To assess the impact of a wide-scale HAART program on
TB prevalence in this community, we repeated the cross-
sectional survey in 2008, measuring both TB disease and HIV
infection. Some of the results of these studies have been
previously reported in the form of a conference abstract (25).
METHODS
This study was performed from June to December 2008, and the same
methodology as the 2005 survey was used (21). A house-to-house
enumeration of the community provided a database of 14,592 residents,
of whom 1,500 residents 15 years of age or older were randomly
selected for study participation (10% of the community).
All participants completed a structured questionnaire investigating
participant demographic characteristics, TB history, TB symptoms
(cough, night sweats, loss of appetite, and loss of weight), risk factors
for TB (including housing, alcohol use, smoking, recreational drug use,
prior incarceration, and employment history), and risk factors for HIV
(including number of sexual partners and condom use). Questionnaires
were interviewer administered in the participants’ home language. Two
sputum specimens were collected from each participant: an early-
morning sputum produced at home, and a second, induced sputum
collected at the site with saline nebulization. Both sputum speci-
mens were tested at the same laboratory for acid-fast bacilli (AFB)
by microscopy and for Mycobacterium tuberculosis (Mtb) growth
by culture. An oral transudate specimen was collected for anony-
mous HIV testing, with HIV results linked to TB diagnosis. The
study was approved by the Research Ethics Committee of the
University of Cape Town, and all participants provided written
informed consent.
Laboratory Procedures
Sputum specimen smears were examined for AFBs with an auramine-
O stain. Sputum sediments were cultured in the mycobacterial growth
indicator tubes automated system (Sparks, MD) and incubated for 6–8
weeks before being reported as negative. Positive cultures were
examined for the presence of AFB by Ziehl Neelsen staining, and
were identified as Mtb complex with a polymerase chain reaction assay.
The oral mucosal transudate specimen for HIV testing was collected
with the Orasure oral fluid collection device (Orasure Technologies,
Bethlehem, PA). The Vironostika Uni-Form II HIV-1 and HIV-2 plus
0 ELISA test (bioMérieux SA, Marcy l’Etoile, France) was used to test
for HIV-1 and HIV-2 antibodies.
Case Definitions
Following on the 2005 methodology, participants who reported on the
questionnaire that they were currently receiving TB treatment were
classified as ‘‘treated TB cases.’’ ‘‘Untreated TB cases’’ were defined as
participants’ without a prior known TB diagnosis, but with laboratory-
confirmed infection, as defined by two positive AFB smear results or two
positive Mtb culture results, or a positive AFB smear result confirmed by
a positive Mtb culture on separate specimens. All untreated TB cases
were referred to the local TB clinic for chemotherapy.
Statistical Analysis
Data were analyzed with STATA 10.0 (StataCorp, College Station, TX).
Bivariate analyses employed Student’s t, Wilcoxon’s rank sum, and
Chi-square tests, as appropriate. Multiple logistic regression models
were developed to examine changes in overall TB prevalence, as well
as treated and untreated TB prevalence between the two surveys, after
adjusting for variation in individual participant characteristics. These
models were weighted for the proportion of the population sampled in
each survey. Median CD4 counts were calculated for the total HAART
cohorts in 2005 and 2008, based on each HAART patients’ averaged
CD4 count recorded in the survey year. Annual median CD4 counts
were compared across the two years with Wilcoxon’s rank sum test.
Case-finding proportion was calculated as the proportion of prevalent
cases, overall and by HIV strata, that were reported as treated TB
cases. The 95% confidence intervals (CIs) were based on the Poisson
distribution, and all statistical tests were two-sided (at a 5 0.05).
RESULTS
Of the 1,500 residents selected for participation in the 2008
survey, home visits confirmed that 1,383 of these individuals
were still resident in the community, and eligible for the study.
Of these, 1,250 (90%) consented to enroll in the study, 121 (9%)
refused participation and 12 (1%) were not contacted after five
home visits. In the initial survey (2005), 762 (78%) of 971
randomly selected, eligible residents were enrolled in the study,
with a refusal rate of 15% (21). Demographic characteristics of
the two samples are shown in Table 1.
TABLE 1. CHARACTERISTICS OF TWO SURVEY SAMPLES
Characteristics 2005 Survey 2008 Survey
Community size (>15 yr old), n 9,935 11,958
Study sample, n 762 (15% refusal) 1,250 (9% refusal)
Demographics
Median age (IQR), yr 27 (22–35) 27 (22–33)
Male sex, n (%) 340 (45) 648 (52)
Median school grade completed (IQR) 10 (8–11) 10 (8–11)
Presently employed, n (%) 398 (52) 662 (53)
Median residence, yr (IQR) 5 (3–7) 5 (2–10)
Median residents in household (IQR) 3 (2–5) 3 (2–4)
Median persons sleeping in
same Room (IQR)
2 (2–3) 2 (1–3)
Risk factors, n (%)
Ever had TB in past 58 (8) 101 (8)
Alcohol intake in past 6 mo 324 (43) 408 (33)
Visited shebeen (bar) in past 6 mo 180 (24) 261 (21)
Smoked in past 6 mo 205 (27) 289 (23)
Recreational drugs in past 6 mo 29 (4) 54 (4)
Employment History, n (%)
Past mining 43 (6) 44 (4)
Health Care Worker 21 (3) 21 (2)
Prison in the past 6 mo 11 (1) 15 (1)
HIV positive (95% CI)* 174 (23; 20–26%) 306 (25; 22–27%)
HIV positive on HAART (% of HIV
infected; 95% CI)
9 (5; 2–10%) 60 (20; 15–25%)
Definition of abbreviations: CI 5 confidence interval; HAART 5 highly active
antiretroviral therapy; HIV 5 human immunodeficiency virus; IQR 5 Interquartile
range; TB 5 tuberculosis.
* In 2005, four participants declined HIV testing, and in 2008, 43 participants
declined HIV testing.










In 2005, overall, 23% (95% CI, 20–26%) of the participants
were HIV infected, and four participants (1%) declined HIV
testing (21). Of the 174 participants infected with HIV, 5% (95%
CI, 2–10%) were receiving HAART. In 2008, 43 participants
(3%) declined HIV testing; among those that were tested, 25%
(95% CI, 22–27%) were HIV infected (P 5 0.23), and, of these,
20% (95% CI, 14–23%) were receiving HAART.
Total Study Population TB prevalence
In 2008, 12 participants (1%) reported receiving TB treatment at
the time of study participation, and a further eight (0.6%)
untreated cases were identified. The prevalence results of the
2005 and 2008 surveys, overall and by HIV strata, are reported in
Table 2 and shown in Figure 1. The overall TB prevalence
(treated and untreated cases) declined significantly, from 3% in
2005 (21) to 1.6% in 2008 (P 5 0.04). When adjusted for age, sex,
HIV status, as well as demographic and risk profile characteristics
that differed between the two surveys, this reduction in preva-
lence remained significant (P 5 0.05), as shown in Table 3. The
reduction in prevalent treated TB (from 1.5 to 1.0%) was not
significant (adjusted P 5 0.34); however, the reduction in
prevalent untreated TB from 1.6 to 0.6% was significant, and
remained significant after adjustment as described previously
here (crude and adjusted P 5 0.05) (Table 3).
In 2005, 50% (n 5 6) of the untreated TB cases had smear-
positive PTB (21), whereas, in 2008, 13% (n 5 1) of the
untreated cases had smear-positive PTB (P 5 0.09).
In 2008, untreated TB was not associated with reported
cough (P 5 0.90), night sweats (P 5 0.35), loss of appetite (P 5
0.32), or loss of weight (P 5 0.22). This was in keeping with the
2005 survey findings (21).
Participants Not Infected with HIV
The total TB prevalence in participants not infected with HIV
remained unchanged between surveys (adjusted P 5 0.90), as
did the prevalence of both treated TB (adjusted P 5 0.90) and
untreated TB (adjusted P 5 0.69) in this group.
Participants Infected with HIV
The total TB prevalence dropped significantly in participants
infected with HIV, from 9.2 to 3.6% (adjusted P 5 0.013).
Although the decrease in treated TB prevalence was not
significant in this group (4.0% in 2005 versus 2.3% in 2008;
P 5 0.22 after adjustment for age, sex, HAART status, and
demographic and risk profile characteristics, as described pre-
viously here), the prevalence of untreated TB cases declined
significantly, from 5.2% in 2005 to 1.3% in 2008 (adjusted P 5
0.02). The multivariate logistic models for total TB prevalence
and untreated TB prevalence in participants infected with HIV
are reported in Table 4.
HAART
The distribution of treated and untreated TB cases by HAART
status in patients infected with HIV is shown in Table 2 (2005
TABLE 2. TUBERCULOSIS PREVALENCE SURVEY RESULTS, OVERALL AND BY HUMAN
IMMUNODEFICIENCY VIRUS AND ANTIRETROVIRAL THERAPY STATUS, 2005 AND 2008










Total TB cases 762 3.0 (23) 1.5 (11) 1.6 (12) 48
HIV-negative cases 584 1.2 (7) 0.7 (4) 0.5 (3) 57
HIV-positive cases 174 9.2 (16) 4.0 (7) 5.2 (9) 44
HIV-positive no ART 165 7.3 (12) 3.0 (5) 4.2 (7) 42
HIV-positive ART 9 44.4 (4) 22.2 (2) 22.2 (2) 50
2008
Total TB cases 1250 1.6 (20) 1.0 (12) 0.6 (8) 60
HIV-negative cases 901 1.0 (9) 0.6 (5) 0.4 (4) 56
HIV-positive cases 306 3.6 (11) 2.3 (7) 1.3 (4) 64
HIV-positive no ART 246 2.8 (7) 1.2 (3) 1.6 (4) 43
HIV-positive ART 60 6.7 (4) 6.7 (4) 0.0 (0) 100
Definition of abbreviations: ART 5 antiretroviral therapy; HIV 5 human immunodeficiency virus; TB 5 tuberculosis.
Figure 1. Prevalence of
treated and untreated
tuberculosis (TB) in the
(A) total study sample,




with HIV. *Adjusted for
age, sex, HIV status, ed-
ucation level, mean res-
idents in household,
reported alcohol use,
smoking, and history of
working in a mine; **ad-
justed for age, sex, edu-
cation level, mean residents in household, reported alcohol use, smoking, and history of working in a mine; †comparison of untreated TB in HIV-infected
population, adjusted for age, sex, education level, mean residents in household, reported alcohol use, smoking, and history of working in a mine;
††comparison of overall TB in HIV-infected population, adjusted for age, sex, education level, mean residents in household, reported alcohol use,
smoking, and history of working in a mine.









wnand 2008). The proportion of overall and untreated TB cases onHAART decreased significantly from 2005 to 2008 (P 5 0.01and P , 0.001, respectively). The median CD4 count for the
total HAART cohort in this community was 269 (interquartile
range, 177–350) in 2005, and 350 (interquartile range, 240–504)
in 2008 (P , 0.001).
Case-Finding Proportions
As shown in Table 2, the case-finding proportion by the TB
clinic in this community increased from 48% in 2005 to 60% in
2008. Case-finding proportions did not change significantly in
participants not infected with HIV (57 versus 56%). However,
in the HIV-infected population, case finding increased sub-
stantially, from 44 to 64%. Case finding increased for patients
on HAART, from 50% in 2005 to 100% in 2008.
DISCUSSION
To our knowledge, this is the first repeated c oss-sectional
prevalence survey following the large-scale availability of
HAART in a sub-Saharan Africa community. The study was
performed among randomly selected individuals in a well defined
community, with HIV and HAART data linked to TB results.
The main finding was that the prevalence of PTB in adults
declined significantly between 2005 and 2008, and this decline
was due to a nearly threefold decrease in TB prevalence in the
HIV-infected population(from 9.2 to 3.6%). In the HIV-infected
group, the decrease was predominantly due to a fourfold decline
in untreated TB. In patients infected with HIV on HAART, TB
prevalence dropped from 44 to 6.7%, and the largest decline was
also seen in untreated TB cases.
To explain these findings, we postulate that a widespread
HAART program can decrease prevalent TB in a community
through two mechanisms: increased TB active case finding, and
immune recovery associated with HAART.
Increased Case Finding in the HAART program
When patients entered the HAART program, they underwent
active screening for TB, based on the National and WHO policy
(26, 27). Screening for TB is based on symptom review. In
patients with symptoms suggestive of TB, sputum staining for
AFB and/or culture for Mtb growth is performed. The imple-
mentation of this policy is demonstrated by the increased
proportion of case finding in the HIV-infected population, from
2005 to 2008, whereas the case-finding proportion in the HIV-
uninfected population remained unchanged. This has resulted in
a significant decrease in the previously large burden of un-
diagnosed, untreated TB in patients infected with HIV reported
in the first survey. Furthermore, the decrease in untreated,
smear-positive TB cases was greater than the decrease in the
TABLE 3. MULTIVARIATE LOGISTIC MODEL FOR OVERALL, TREATED, AND UNTREATED TUBERCULOSIS
PREVALENCE IN THE TOTAL STUDY POPULATION
Total TB Prevalence Treated TB Prevalence Untreated TB Prevalence
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Survey year
2005 1 1 1
2008 0.53 (0.28–0.97) 0.05 0.66 (0.28–1.56) 0.34 0.39 (0.15–0.96) 0.05
Age, yr 1.01 (0.97–1.05) 0.61 1.03 (0.97–1.07) 0.19 0.98 (0.91–1.04) 0.48
Sex
Male 1 1 1
Female 0.88 (0.40–1.96) 0.75 0.71 (0.25–2.09) 0.52 1.08 (0.31–3.84) 0.90
Education, yr in school 0.99 (0.89–1.11) 0.92 0.90 (0.79–1.02) 0.11 1.26 (0.99–1.60) 0.06
No. of residents in household 1.08 (0.94–1.25) 0.29 1.17 (0.98–1.40) 0.09 1.00 (0.78–1.27) 0.98
Alcohol intake in past 6 mo 0.96 (0.46–1.97) 0.90 0.84 (0.31–2.31) 0.74 1.12 (0.40–3.12) 0.83
Smoked in past 6 mo 2.14 (0.94–4.90) 0.07 2.27 (0.74–6.90) 0.15 1.77 (0.49–6.40) 0.38
Past employment in mines 1.97 (0.62–6.30) 0.25 0.34 (0.04–3.03) 0.34 12.19 (2.48–59.92) 0.002
HIV status
HIV negative 1 1 1
HIV positive 6.42 (3.34–12.32) ,0.001 6.14 (2.55–14.80) ,0.001 6.48 (2.43–17.25) ,0.001
Definition of abbreviations: CI 5 confidence interval; HIV 5 human immunodeficiency virus; OR 5 odds ratio; TB 5 tuberculosis.
TABLE 4. MULTIVARIATE LOGISTIC MODEL FOR OVERALL AND UNTREATED TUBERCULOSIS
PREVALENCE IN THE HUMAN IMMUNODEFICIENCY VIRUS–INFECTED STUDY POPULATION
Total TB prevalence
OR (95% CI) P Value
Untreated TB prevalence
OR (95% CI) P Value
Survey year
2005 1 1
2008 0.35 (0.15–0.80) 0.01 0.20 (0.07–0.74) 0.02
Age (in years) 1.03 (0.98–1.09) 0.22 1.04 (0.96–1.14) 0.29
Sex
Male 1 1
Female 0.93 (0.31–2.83) 0.90 1.40 (0.23–8.45) 0.72
Education, yr in school 1.00 (0.87–1.16) 0.95 1.24 (0.92–1.67) 0.15
No. of residents in household 0.98 (0.79–1.23) 0.86 0.80 (0.55–1.17) 0.25
Alcohol intake in past 6 mo 1.01 (0.41–2.50) 0.99 1.80 (0.50–6.43) 0.37
Smoked in past 6 mo 1.26 (0.40–3.98) 0.70 1.57 (0.28–8.97) 0.61
Past employment in mines 2.81 (0.67–11.76) 0.16 7.44 (1.12–49.58) 0.04
Definition of abbreviations: CI 5 confidence interval; OR 5 odds ratio; TB 5 tuberculosis.










overall untreated TB prevalence, and this finding may suggest
that active case finding is removing the more infectious cases
(28, 29) from the community. It is therefore possible that part of
the decrease in TB prevalence may be due to a reduction in TB
transmission. Patients infected with HIV have a more rapid rate
of progression to TB disease after recent infection compared
with individuals not infected with HIV (30). As a result, any
benefit to the HIV-uninfected population accruing from de-
creased transmission may not be evident in the short interval
between these surveys. The impact of active-case finding on TB
prevalence is in keeping with results of mathematical models,
which have assessed the impact of intervention strategies on
population TB rates (31, 32).
Risk of Disease: Immune Recovery on HAART
Active case finding would transfer untreated TB cases into the
treated, notified group. However, rates of treated TB did not
increase in this population; in contrast, treated TB in participants
infected with HIV had declined between the two surveys. This
finding may reflect changes in the immune status of the HIV-
infected population related to high HAART coverage. It is well
documented that HAART, and the subsequent CD4 count
recovery, is associated with a substantial reduction in TB risk in
patients infected with HIV (19, 33–35). The rapid scale-up of the
ARV program in this community (with 20% of the HIV-infected
population receiving HAART in 2008) would have resulted
in a large treatment cohort, with an increasing mean CD4 count
(as found in treatment cohorts in similar settings [36]), and,
therefore, a decrease in risk of TB disease in patients infected
with HIV. Although the ART cohort had a higher mean CD4
count in 2008 compared with 2005, the median CD4 count in 2008
was still relatively low. Therefore, it is possible that the impact on
reduction of TB prevalence will continue to increase with ongoing
ART initiation and accumulative immune recovery.
Alternative Explanations for Study Findings
The decrease in TB prevalence in this community is unlikely to be
due to changes in the TB control program other than the active
case finding in HAART patients, nor to increased population
awareness of TB due to the surveys. This is supported by the
stable rates of treated and untreated TB in participants who are
HIV negative in this study, and furthermore, that overall TB
notification rates of participants who are HIV negative have
remained constant over the last decade (37). Similarly, TB-
associated mortality rates have declined in this community (data
not shown), particularly in patients infected with HIV, and, as
such, an increase in mortality is not likely to be responsible for
the decrease in TB prevalence. Emigration could result in a de-
creased prevalence of disease, but biennial censuses, performed
from 2002 to 2008, show that net immigration is greater than
emigration in this growing community, with a 12% increase in
population size between the two surveys. Furthermore, the same
TB control program laboratory services, with consistent pro-
tocols, were used for the microscopy, culture, and differentiation
of sputum specimens in both surveys.
It should be noted that the 2008 survey participants had a lower
TB risk profile compared with the participants in the 2005 survey.
However, after adjusting for these factors, the decrease in both
overall TB prevalence as well as untreated TB prevalence in
participants infected with HIV between the two surveys remained
statistically significant. HIV testing was accepted by 98% of the
participants (averaged across both surveys); however, HIV status
was available for all TB cases, both treated and untreated. This
relatively small community is typical of many recently urbanized
populations in South Africa, but there is a need for further
investigation to confirm our findings in other high HIV and TB
prevalence settings.
Undiagnosed TB prevalence is an important driver of TB
transmission (1–4). We have shown a significant decline in adult
TB prevalence—in particular, undiagnosed TB prevalence in
patients infected with HIV—associated with the introduction of
a rapid and large-scale HAART program in this community.
This decline appears to be due to the increased case finding in
the HAART program, and may also be a result of the impact of
HAART-associated immune recovery on TB risk. These find-
ings suggest that large-scale HAART programs may contribute
to TB control in high HIV prevalence settings.
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South African reports to the World Health Organization (WHO) 
indicate that its tuberculosis (TB) notifications have increased 
fivefold over the last 20 years; in 2008, South Africa (SA) had the 
third-highest TB burden, after India and China.1 SA and Swaziland 
now have the highest TB notification rates in the world, with about 
1% of their populations developing TB annually.1,2 SA was responsible 
for approximately 25% of the global burden of HIV-associated TB 
cases in 2007.2
While a worsening epidemic is revealed, data give little insight into 
understanding why TB control is failing. To better understand the 
epidemiology of TB control, the national and available community 
and city level data must be integrated; understanding this provides 
insights into the weaknesses of existing strategies and permits 
the development of additional rational interventions to regain TB 
control.
TB notifications
In 2007, 315 000 cases of TB were notified in South Africa – a 
rate of new and recurrent disease of 649 per 100 000 population.2 
Approximately 40% of nationally notified cases were tested for HIV 
infection, of which 73% were estimated to be positive, but this high 
prevalence may be affected by selection bias. The 2009 Cape Town 
(population 3.4 million) notification of 31 095 TB cases3 represents 
double the number of TB cases reported in the USA (population >300 
million people).2
Provider-initiated HIV testing in Cape Town TB clinics has 
increased to over 85%, allowing analysis of data stratified by age and 
HIV status, and providing a better understanding of the epidemiology 
of TB in a large urban population. Using denominators from the Cape 
Town population structure (Calle Hedberg, City of Cape Town and 
Stats SA) and TB notification data, age-specific TB notification rates 
stratified by HIV status were derived (Fig. 1). HIV-associated TB 
accounted for 44% of the total case burden. The peak TB notification 
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South Africa’s rate of tuberculosis (TB) has increased over the last 
20 years, to now having the third-highest TB burden in the world. 
The TB control programme has primarily focused on effective case 
management of passively presenting TB cases, and progress has been 
recorded towards international treatment targets. While outcomes 
for notified TB cases have improved, this strategy failed to contain 
the TB epidemic. South Africa has the highest per capita annual 
risk of TB disease of comparably sized countries globally, and its 
communities have extremely high TB transmission rates. The rates 
of TB infection of children and adolescents are now similar to those 
reported 100 years ago in Europe long before chemotherapy became 
available. High rates of HIV testing of TB patients in Cape Town 
allows analysis of TB notification data stratified by age, type of TB 
and HIV status, and a better understanding of TB epidemiology. 
TB infection prevalence data from Cape Town communities allow 
estimation of the prevailing force of TB infection and, together 
with TB notification and prevalence data, the effective number 
of secondary infections and case finding proportions can be 
estimated. This better understanding of the major drivers of the TB 
epidemic allows reasons to be identified for failure of the present 
strategy. New control strategies can also be identified, that must be 
accompanied by novel TB control targets.
S Afr Med J 2010;100:111-114. 
Tuberculosis control has failed in South Africa – time to 
reappraise strategy























Fig. 1. Tuberculosis notifications in 2009 for the City of Cape Town stratified by 5-year age 
groups and by provider-initiated HIV testing results. The demominators for age strata derived 
from National Department of Health/Health Information System Programme by disaggregating 
StatsSA district estimates (November 2009) using data from the `Small Area Layer` (StatsSA, 
2004). 
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rate was among young adults, exceeding 1 400 per 100 000 population 
(Fig. 1). Of those aged between 25 years and 45 years, 63% of TB 
cases were HIV-associated. Of particular concern is that about 1% 
of children <5 years old were notified as having TB. Since children 
rapidly progress from TB infection to TB disease, childhood TB 
disease indicates recent ongoing TB transmission.4,5 These data 
strongly indicate very high transmission rates in the community.
The cumulative lifetime risk of new and recurrent TB of HIV-
uninfected individuals living in Cape Town was calculated by 
cumulatively adding the annual incidence of each 5-year age grouping 
(Fig. 2). The denominators for these calculations are the total age 
strata populations. As the HIV-infected population is included in the 
denominator, the resultant rate estimations are conservative. With 
the status quo, 1 in 5 individuals resident in Cape Town who remain 
HIV-uninfected will be at risk for developing TB before reaching the 
age of 60 years. This modern lifetime risk is unprecedented and is 
approximately twice that for individuals acquiring TB infection in the 
UK in the 1950s.6 The cumulative risk of TB disease for those who 
become HIV-infected is considerably higher. Therefore our TB control 
strategies have failed, resulting in the highest reported global rates of 
TB disease in children and HIV-infected and uninfected adults.
TB infection
The epidemiological transitions relevant to the pathogenesis of TB 
from exposure to death or cure are outlined in Fig. 3. As with other 
infectious diseases, the key primary event is the initial acquisition 
of infection. While there have been no recent systematic attempts 
to measure TB infection rates in South Africa, data from Cape 
Town report extremely high prevalence rates of TB infection among 
children and adolescents.7-10
In 2005, the prevalence of a positive (>10 mm induration) 
tuberculin skin test (TST) among 7 457 primary school children 
(median age 8.6 years) was 37.4%.7 A TST survey in a Cape Town 
school in 2005 reported TB prevalence to be 26.2% in 5 - 8-year-
olds, increasing to 52.5% in 14 - 17-year-olds.8 The prevalence of TB 
infection increased from 20% at school entry to 52% at 15 years, and 
reached 75% at 25 years in another study including HIV-negative 
adolescents and adults.9 Note also that a further 8% of the population 
will have developed TB disease by the age of 25 years (Fig. 2) and they 
were excluded from the prevalence surveys. In 2 neighboring urban 
communities with low HIV prevalence, a high prevalence of TB 
infection in children (6 - 9 years) was reported.10 Transmission rates 
increased between 1998 and 2005 and remained among the highest 
(4.1 - 5.8% per annum) in the world.10
Collectively, these studies indicate an extremely high prevalence of 
TB infection in Cape Town acquired during childhood, and that high 
rates of acquisition of TB infection continue throughout adolescence 
and into young adulthood. These high rates of TB transmission 
predate the HIV epidemic and have not declined over the last decade. 
Together with increasing TB notification rates, these data clearly 
indicate a failure of TB control.
Force of TB infection
The force of infection is the proportion of TB-uninfected individuals 
newly infected per annum, and is principally determined by the 
prevalence of infectious TB cases and the effective number of 
secondary cases infected by each infectious case. A TB prevalence 
survey of a random sample of the general population was conducted 
in a Cape township in 2005. The prevalence of laboratory-proven 
TB among HIV-uninfected and infected adults was 0.47% and 5.2% 
respectively.11 After the community scale-up of antiretroviral therapy 
(ART), the prevalence of TB among the HIV-uninfected population 
did not change, but the prevalence among HIV-infected adults 
decreased from 5.2% to 1.3%.12
Cape Town studies estimated the force of TB infection to be 
between 4% and 8% per annum.7-10 In historical perspective, these 
values are similar to the force of infection estimated for the UK 
population in the early decades of the 20th century, which was long 
before TB chemotherapy was developed. In 1900 in the UK, the force 
of infection was 10% per annum, declining to 1% around 1950 and 
to <0.01% by 2000.13
Fig. 4 shows the relationship between increasing force of infection 
and the proportion of the population with primary TB infection 
and the proportion multiply exposed to TB infection. Effective TB 
control interventions that produced small reductions in the force of 
infection in Cape Town could produce large benefits in transmission 
reduction. Reduction of the force of infection to 1% would decrease 
the proportion of the population exposed to multiple TB exposures 
from over 50% to <0.5% (β1 in Fig. 3) and the proportion acquiring 
primary infection would decrease from 75% to <30% (α in Fig. 3).
Effective contact number
An effective TB contact is defined as a contact between an infectious 
pulmonary case and a susceptible individual, sufficient to result in 























Fig. 2. The accumulated life-time risk of being notified with new or relapsed tuberculosis 
calculated for HIV-negative individuals. Values are based on cumulative 2009 age-specific 
tuberculosis notification rates for Cape Town. 
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Fig. 3. An outline of tuberculosis transition states for a susceptible population from initial 
infecti n to disease and treatment outcome or death. The force of infection is shown as a 
functi n of prevalent untreated TB disease and determines the rate of primary TB infection () 
and the rate of multiple i fection exposures (1) of l tently infect d individuals. 2 is the 
progression rate from l tent to active disease,  the case-finding proportion,  the cure rate, and 
1 & 2 the off- and on-chemotherapy mortality rates respectively. 
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effective contact number) is determined by the ratio of the force of 
infection and the prevalence of infectious pulmonary TB cases. The 
ratio between a force of infection of 4 - 8% (4 000 - 8 000/100 000) 
TB infection rate and a prevalence of smear-positive pulmonary 
cases notified during 2009 in Cape Town of 370/100 000 indicates 
an effective contact number of between 11 and 22. Historically, the 
effective contact number in the UK declined from 22 in 1900, to 10 
in 1950 and to 1 in 1990.13
For long-term control of an epidemic, the effective contact 
number must be lower than the number of individuals who can be 
expected to produce a single new case of infectious pulmonary TB 
during a lifetime. As the lifetime risk in Cape Town of developing 
smear-positive pulmonary TB among HIV-negative residents is 
approximately 10%, the effective contact number must be reduced to 
<10 to achieve a reduction in the TB epidemic. Current interventions 
are not achieving this.
Impact of the HIV epidemic
The South African HIV epidemic has expanded markedly over 
20 years, and it was recognised early that TB was a major cause 
of morbidity and mortality.15,16 A pertinent question is the degree 
to which the HIV-associated TB epidemic has caused the failure 
to control TB or the manifestation of the failure to contain TB 
transmission. Although 44% of the total TB case load in Cape Town 
in 2009 was HIV-related, only 14.3% of smear-positive pulmonary 
disease was HIV-related. It therefore appears likely that the HIV 
epidemic disproportionately increases TB case load rather than TB 
transmission.
There is no strong evidence that HIV-associated immune 
suppression affects the acquisition of TB infection (α Fig. 3). Instead, 
HIV infection appears to be associated with a marked increase in 
risk of progression from latent infection to TB disease, following 
either a primary (β2 Fig. 3)17-19 or recurrent exposure (β1 Fig. 3).20,21 
Case-finding proportions (γ Fig. 3) were reduced in HIV-infected 
individuals (44%) compared with HIV-uninfected (57%) in a Cape 
Town township.7 However, the population case-finding proportion 
improved following introduction of an ART programme (64%).8 TB 
case fatality (μ1 and μ2 Fig. 3) is increased particularly in those with 
low CD4 cell counts.22 ART partially reverses immune suppression23 
and can reduce risk of TB progression after recent TB exposure (β1 
Fig. 3) and, together with isoniazid preventive therapy, can decrease 
the progression from latent to active disease (β2 Fig. 3).24 Active 
case-finding within ART programmes markedly improves TB case 
finding.12,25-28
Why is TB control failing?
Broad existing strategies for TB control are case-finding and 
treatment of active disease, treatment of latent TB infection, and 
vaccination with bacille Calmette-Guérin (BCG).25 Universal BCG 
vaccination of all infants protects against progression to miliary TB 
and TB meningitis but does not affect TB transmission.29 Treatment 
of latently infected individuals with isoniazid prophylaxis has not 
been widely implemented in either HIV-infected or uninfected 
populations in SA.2
The SA TB control strategy predominantly focuses on the 
quality of case management of patients passively presenting to TB 
clinics. Passive case-finding is detection of active TB disease among 
symptomatic patients presenting to medical services, and is promoted 
in developing countries as part of the WHO-recommended DOTS 
strategy.30,31 Consequently, the primary targets and reporting statistics 
of the SA TB control programme has been the proportion of 
TB cases which are effectively treated under DOTS with anti-TB 
chemotherapy.1,2 SA national DOTS coverage increased from 77% to 
100% and the treatment success rate from 61% to 74% between 2001 
and 2006.1,2 However, TB notifications doubled in the same period.1,2
The TB burden was decreasing in industrialised countries before 
effective chemotherapy was introduced, with reductions in the force 
of infection from approximately 10% to 1% in the early 20th century.13 
Introducing effective chemotherapy in the 1950s consolidated these 
trends in improved TB control. While effective TB case management 
is necessary in TB control, it was, however, predicted that it would 
be insufficient for TB control in scenarios such as South Africa 
with a high force of infection, high proportion of latently infected 
individuals and a generalised HIV epidemic.32 The DOTS strategy 
is insufficient in high HIV-burdened settings.33 In high transmission 
settings where effective contact numbers are high, lower case-finding 
rates and delays in diagnosis and initiation of chemotherapy result in 
ongoing transmission.
Development of a new TB control 
strategy
The benefits of improved case-finding depend on the prevailing 
epidemiology of TB transmission. In a setting with a force of 
infection <1.0, detecting a case of TB will mainly benefit that 
individual alone. In contrast, the benefit of early detection of a TB 
case where there is an effective contact number >10 will additionally 
prevent up to 10 secondary cases. The benefits of increased and 
earlier case-finding on TB transmission are therefore significantly 
amplified in high-transmission settings. Decreasing TB infection 
rates is fundamental to achieving the long-term aim of TB control 
of a steady decline of disease in successive generations. Reducing 
the high force of TB infection, especially in high-density townships, 
should therefore become a primary target for long-term TB control. 
Historical TB control measures using community-based interventions 
such as enhanced and intensified case-finding strategies must be 
re-explored in view of the additional benefits accruing for decreasing 
transmission.25,34,35
Reducing the time period of infectiousness also directly influences 
the prevalence of infectious TB. The period of infectiousness results 
from delays including health-seeking behaviour, diagnostic delays and 
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Fig. 4. The relationship between ‘force of tuberculosis infection’ and proportion of population 
acquiring primary TB infection and multiple infectious exposures. The prevalence of primary 
infection is defined as P1=[60x=0(1-exp(-Fx)]/61 and the prevalence of mul iple infection 
exposures is defined as P2=[60x=0(1-exp(-Fx)-(Fx)exp(-Fx)]/61 where F is force of  infection 
and x is age. 
 
Fig. 4. The relationship between ‘force of tuberculosis infection’ and proportion 
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case-finding can increase awareness of typical symptoms of TB disease, 
thereby improving health-seeking behaviour. Diagnostic delays can 
be reduced by using newer molecular diagnostic technologies, and 
improved health systems efficiencies can further decrease time to 
initiation of effective TB therapy.
High-risk communities should be specifically targeted, and age-
specific interventions are necessary to interrupt TB transmission 
to infants and young children, school-age children and adolescents, 
and both HIV-negative and positive adult populations. A change in 
priority focus from case management to TB transmission reduction 
should be accompanied by incorporating new outcome measures 
that reflect ongoing TB transmission at national and sentinel sites. 
A reduction in TB disease rates among young children, and a steady 
decrease in the number of latently infected children at school entry 
and subsequently, would reflect a decrease of TB transmission to 
children. TB control among adults would be reflected by a decrease in 
the proportion of recent infections, a decrease in the effective contact 
number, and eventually a decrease in lifetime risk of TB disease. In 
HIV-infected patients, full implementation of existing ART guidelines 
will reduce the pre-ART TB disease burden. The TB infection rates 
of patients on ART probably reflect the current force of TB infection. 
The effectiveness of 6-month isoniazid prophylaxis therapy (IPT) to 
reduce TB disease in already latently infected individuals is very likely 
undermined where the force of TB infection is high and consistent 
with southern African data indicating little or no lasting benefit after 
6 months IPT.36,37
Changing the emphasis from individual benefit to population 
benefit has parallels with the concept of using ART as prevention, 
which has been modelled as a potential strategy to control the HIV 
epidemic.38,39 This may have an additional effect on control of HIV-
associated TB.40 The HIV force of infection is the result of prevalent 
community levels of HIV load and sexual networking, which can be 
reduced by widespread HIV testing and initiation of ART. Similarly 
for the TB epidemic, the drivers of the high force of infection are 
population prevalence of infectious TB cases and the effective contact 
number. Reducing the high force of TB infection, especially in high-
density townships, should therefore become a primary target for 
long-term TB control.
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Antiretroviral Therapy and TB Notification Rates in a High
HIV Prevalence South African Community
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Background: Antiretroviral therapy (ART) has been proposed as
an intervention for reducing tuberculosis (TB) burdens in areas with
high HIV prevalence. However, little data is available on the impact of
ART on population-level TB.
Methods: Trends in adult TB case fatality and notifications were
assessed before and during increasing ART coverage in a well-
defined periurban community, from 1997 to 2008. Mean changes in
TB rates were measured using linear autoregression models. ART
coverage increased from 1% in 2003 to 5%, 13%, and 21% of
HIV-infected population in 2004, 2005, and 2008, respectively.
Results: From 1997 to end of 2004 TB notification rates increased
by an average of 187 cases/100,000/year (P , 0.001), reaching
a peak of 2536/100,000 in 2005. From 2005 to 2008, TB notification
rates declined by approximately 202 cases/100,000/year (P, 0.001).
TB rates were initially stable in HIV-uninfected individuals, but
declined moderately from 2005. TB rates declined in HIV-infected
adults from 6513/100,000 in 2005 to 4741/100,000 in 2008.
The predominant decline in TB notifications occurred among
HIV-infected patients receiving ART (1156 cases/100,000/year)
and was less marked in those not receiving ART (416cases/100,000/
year). Similarly, TB case fatality was constant for HIV-uninfected
individuals, but declined in HIV-infected individuals from 23% in
2002 to 8% in 2008 (P = 0.01).
Conclusions: In this community heavily affected by both HIV
and TB epidemics, rapid and high ART coverage was associated
with significant reductions in TB notifications and TB-associated
case fatality.
Key Words: antiretroviral, community, HIV, notification rates,
tuberculosis
(J Acquir Immune Defic Syndr 2011;56:263–269)
INTRODUCTION
The current World Health Organization (WHO)–
recommended TB control strategy is failing to control the
tuberculosis (TB) epidemic in high HIV prevalence countries,
and TB rates continue to escalate in countries such as South
Africa.1 The STOP TB Partnership has proposed adjunctive
strategies to address this problem, including the ‘‘Three I’s’’
strategy for reducing the burden of TB in HIV-infected
patients: intensified case finding, isoniazid preventative
therapy, and infection control.2 However, this strategy has
not been widely implemented to date. Due to the reduction in
TB risk in HIV-infected patients on highly active antiretroviral
therapy (HAART),3,4 HAART has also been proposed as an
adjunctive strategy for controlling the TB epidemic in low-
income and middle-income countries with generalized HIV
epidemics.5 This strategy has been more extensively imple-
mented, and through programs such as the ‘‘3 by 5’’ initiative,6
the President’s Emergency Plan for AIDS Relief (PEPFAR),7
and the Global Fund,8 there has been substantial progress in
patients’ access to HAART.9
However, the impact of HAART on TB rates at
a population level remains uncertain. Although incidence of
active TB disease in HIV-infected patients is reduced by
70%–90% by HAART,3,10 patients still have a 5–10 times
higher risk of TB disease 3 years into HAART treatment
compared with HIV-uninfected individuals.11,12 The combi-
nation of prolonged survival and residual increased risk of TB
incidence in HIV-infected patients on HAARTwill result in an
increased number of highly susceptible individuals in the
population. Therefore, even substantial population coverage
with HAART may have a limited impact on TB incidence
at a population-level. However, empirical data addressing
this issue are sparse, and most evidence comes from
mathematical modeling.13
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Despite the well-described TB benefits of HAART use
for HIV-infected individuals, there are no population-level
studies describing the impact of increased access to HAART
on community TB rates in areas with generalized HIV
epidemics. Therefore, we assessed the impact of increasing
antiretroviral provision on TB notification rates in a community
with high HIV prevalence.
METHODS
Study Community
The study took place in a well-defined South African
periurban township with a population of approximately 15,000
people and an HIV prevalence of 23% in 2005.14 The
community is served by a single primary care clinic that
follows the National TB control program guidelines,15 based
on WHO-recommended DOTS program. The clinic manages
all TB patients resident in the community, and the protocol for
diagnosis and management of TB patients did not change
significantly from 1997 to 2008. The main change to the
national TB protocol has been the addition, since 2004, of
active TB screening for patients initiating HAART. This
screening was based on sputum investigation and did not
include testing for latent TB infection. Isoniazid preventive
therapy has not been implemented in this community. Despite
an apparently well-functioning TB program,16 we have
previously reported escalating TB notification rates in this
community before rapid, high coverage HAART availability.17
HAART provision began in 2003 with patients in the
community accessing antiretroviral treatment at the local
clinic or local hospital, but the HAART program was only
scaled-up in 2005.
TB and HAART Data
TB notification data were obtained from the local TB
clinic from 1997 to 2008. HIV status, antiretroviral treatment
status, and CD4 count data were obtained from the TB register,
clinical folders, and clinic and hospital HAART databases.
Adults were defined as patients $15 years of age.
Population Model
Annual and age-specific TB rate calculations were based
on population denominators obtained from the 1996 South
African national census, and community household censuses
performed in 2002, 2004, 2006, and 2008. Linear population
growth was assumed between each census. Community HIV
prevalence from 1996 to 2004 was estimated using the
Actuarial Society of South Africa (ASSA) 2003 AIDS and
Demographic model for the African population.18,19 In 2005
and 2008, the Desmond Tutu HIV Centre performed two
community-based random cross-sectional HIV prevalence
surveys among adults $15 years of age in the study
community.14,20 When the ASSA 2003 model predictions
were compared with the 95% confidence intervals (CIs) from
the community surveys, the 2005 survey data14 matched the
model’s predictions for the HIV prevalence in the community.
However, the 2008 survey showed a shift toward higher HIV
prevalence among 30 to 45-year olds and particularly among
women. This is in keeping with the impact of antiretroviral
programs on community HIVepidemics, and the ASSA model
estimates for the study community HIV prevalence from 2005
to 2008 were adjusted based on the survey results. The number
of HIV-infected individuals derived from this model was used
as the denominator for calculation of TB rates among HIV-
infected population. Numbers of patients on HAART in each
year, derived from the antiretroviral program registers, were
used as denominators for TB notification rates on HAART.
HAART coverage was calculated as the proportion of the adult
HIV-infected population in the community receiving HAART
in each year.
HIV and TB Rates Calculations
All TB rates are reported as cases/100,000. HIV testing
was routinely offered to TB patients from 2002, and therefore,
HIV-associated rates were only available from that year. To
account for missing HIV test results, extreme case scenarios
for HIV-associated and non–HIV-associated TB rates were
calculated assuming 100% of patients with unknown HIV
status were HIV infected and HIV uninfected, respectively.
Analyses in HIV-infected and HIV-uninfected strata were
performed on patients with known HIV status.
Direct standardization method was used to calculate the
age-standardized annual TB rates for the population using the
1997 population age distribution as the reference population.
Similarly, using HIV-infected population as the reference
population, direct standardization was used to calculate
age-standardized rate ratio (RR) of TB in HIV-infected adults
off HAART versus adult patients on HAART. Mean changes
in TB rates and significance of trends before (pre-2005) and
after (post 2004) the implementation of a high coverage
HAART program were assessed using linear regression
models. An autoregressive model with a 1-year lag was used
to account for the autocorrelation of the data, and the impact
of HAART was examined through an interaction term. We
a priori chose 2005 as the first year of HAART availability, as
this was the first year that an appreciable number of patients
were receiving HAART. The median baseline CD4 counts of
patients initiating HAART in each year were calculated from
the most recent CD4 count in the 3 month period before
HAART initiation.
TB completion rates were calculated as proportion of TB
patients who completed TB treatment (TB treatment comple-
tion or cure), excluding those who were transferred out of the
community during the treatment course. Retreatment TB was
defined as a new TB diagnosis in a patient who had previously
completed TB treatment. All cause case fatality rates in TB
patients were calculated as proportion of TB patients who died
on TB treatment each year, excluding those who were
transferred out of the community during the treatment course.
Trend analysis for TB treatment completion rates and case
fatality rates were assessed using x2 test for trend.21
Data were analyzed using Stata Version 10.0
(Stata Corporation, College Station, TX). All statistical tests
were 2-sided at alpha = 0.05. This study analysis was
performed on register data, and ethics approval for the study
was obtained from the University of Cape Town Human
Research Ethics Committee.
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Over the 12-year study period, 1974 TB cases were
notified in the study community. Of these, 1741 were adult
cases, the median age of which was 32 years (interquartile
range: 26–40 years), and 45% were female. Overall, HIV
testing was performed in 77% of adult cases, of which
69% were HIV infected. From 2002, 87% of adult TB cases
were tested for HIV, of which, 70% were HIV infected. In
2003, 1% of the HIV-infected population was receiving
HAART. By end of 2005, this proportion had increased to
13%, and by the end of the study period, 21% of the estimated
HIV-infected population were receiving HAART (Fig. 1).
Adult TB Notification
Table 1 shows total adult TB notification, TB case
fatality, and TB treatment completion data over the study
period. From 1997 to end 2004, adult TB notification rates (per
100,000) increased by an average of 187 cases a year (95% CI:
143 to 232; P , 0.001). From 2005, the rate of adult cases
decreased by an average of 202 cases per year (95% CI:2233
to 2172; P , 0.001) (Fig. 1). The annual age standardized
rates confirmed these trends, with an increase in annual rate
from 1998 to 2005, followed by a decreasing trend to 2008
(Table 1). TB treatment completion rates averaged 80% over
the study period, with no significant change over the study
period (P = 0.88).
HIV-Infected and HIV-Uninfected
TB Notifications
Table 2 shows TB notification data for HIV-uninfected
patients and HIV-infected patients not on HAART and those
patients on HAART at time of TB diagnosis from 2002 to
2008. Adult TB rates in HIV-infected and HIV-uninfected TB
patients are shown in Figure 2A, including extreme case
scenarios for HIV-associated and non–HIV-associated TB
rates assuming 100% of patients with unknown HIV status
were HIV infected and HIV uninfected, respectively. TB rates
(per 100,000) in known HIV-uninfected patients did not
change substantially from 1997 to 2004 (with an average
annual increase of 49 cases; P = 0.65), but showed a modest
annual decline of 143 cases per year from 2005 (95% CI:
2195 to 291; P , 0.001). However, from 2002 to the end of
2004, overall TB rates in known HIV-infected adults increased
by an average of 432 cases per year (95% CI: 109 to 755;
P = 0.009), after which rates decreased significantly by 578
cases per year (95% CI: 2697 to 2459; P , 0.001). TB
treatment completion rates did not change significantly for
HIV-infected or HIV-uninfected patients from 2002 to 2008
(P = 0.21 and P = 0.43, respectively).
TB Notification and HAART
Figure 2B shows TB rates (per 100,000) in HIV-infected
patients stratified by HAART. TB rates in HIV-infected
patients not on HAART increased by an average of 362 cases
per year from 2002 to end 2004 (95% CI: 2264 to 988;
P = 0.26). From 2005, there was a significant average annual
decrease of 416 TB cases in HIV-infected patients not on
HAART (95% CI: 2526 to 2305; P , 0.001). TB rates in
HIV-infected patients on HAART decreased significantly by
an average of 1156 cases per year (95% CI:21191 to21120;
P , 0.001). After standardizing for age differences across
annual populations, HIV-infected patients not on HAART had
a lower rate of TB compared with HIV-infected patients on
HAART early in the HAART program (RR = 0.41 in 2004).
However, as the period of the HAART program increased, the
RR of TB in patients off HAART increased to nearly twice that
of the patients receiving HAART (RR = 1.98 in 2008).
Baseline CD4 Count
The number of HIV-infected patients initiating HAART
in each year is shown in Table 2. The median baseline CD4
counts in patients commencing HAART increased from 15
cells per microliter in 2003 to 86 cells per microliter in 2004,
129 cells per microliter in 2005, peaking at 153 cells per
microliter in 2006, and then stabilizing at 122 cells per
microliter in 2007, and 141 cells per microliter in 2008.
Retreatment TB
Overall retreatment TB rates (per 100,000) increased
significantly from 1997 to 2004, at an annual average increase
of 52 cases (95% CI: 35 to 71; P , 0.001), after which
retreatment rates stabilized (P = 0.59). Retreatment TB rates in
HIV-uninfected patients remained stable over the study period
(P = 0.53 from 2002 to end 2004 and P = 0.56 from 2005 to
end 2008). In HIV-infected patients not receiving HAART,
retreatment TB rates increased by an average of 157 cases per
year (95% CI: 95 to 219; P , 0.001) from 2002 to 2004, and
then decreased by an annual average of 67 cases (95%
CI: 2129 to 25; P = 0.03). Annual retreatment TB rates in
HIV-infected patients on HAART from 2004 to 2008
decreased significantly by an average of 824 cases/100,000
per year (95% CI: 21492 to 2156; P = 0.02) (Fig. 3).
TB Case Fatality
Overall case fatality during TB treatment decreased over
the study period (Fig. 4). Although TB case fatality rates
FIGURE 1. Adult TB notifications rates and antiretroviral coverage
in study community, from 1997 to 2008. *The P value for
autoregression model from 1997 to 2004. **The P value
for autoregression model from 2005 to 2008.
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remained relatively constant in HIV-uninfected individuals
(P = 0.81), TB case fatality dropped significantly in HIV-
infected patients from 13% in 2002 to 4% in 2008 (P = 0.001).
DISCUSSION
This community-based study from sub-Saharan Africa
demonstrated an association between the implementation of an
HAART program and TB notification rates. In this community,
TB notification and case fatality rates decreased with the rapid
and high coverage implementation of an HAART program.
TB is a major cause of mortality in HIV-infected patients
in sub-Saharan Africa.1,22 A key finding in this study is the
significant reduction in TB case fatality rates in HIV-infected
patients. The use of HAART has been associated with
a reduction in TB-associated mortality among individuals and
in treatment cohorts.23,24 In our study, the implementation of
a community HAART program was also associated with
a decrease in TB case fatality in HIV-infected patients.
In 2002, the case fatality rate in HIV-infected patients was 4
times greater than that of HIV-uninfected patients but had
decreased to the same rate as HIV-uninfected patients by 2008.
This suggests that HAART programs may greatly assist in
achieving the Stop TB Partnership goal to halve TB mortality
rates by 2015.
The decrease in TB notification rates in the study
community occurred against a background of increasing
national TB notification rates.1 TB rates in HIV-uninfected
patients were stable from 1997 to 2004, with HIV-associated
TB driving the escalating epidemic in the study population.
Although HIV-uninfected rates showed a decline from 2005,
the reduction in community TB notification rates in this study
was predominantly due to a decrease in TB rates in HIV-
infected patients and more specifically in patients receiving
HAART.
Although the HIV prevalence in this community was
relatively stable from 2002 to 2008, the TB notification rates in
HIV-infected patients continued to escalate until 2005. After
the rapid scale-up of HAART availability from 2005, the
TB rates in HIV-infected patients not on HAART stabilized
TABLE 1. Total Adult TB Notification and Age-Standardized TB Rates, and TB Case Fatality and Treatment Completion Rates in the




















1997 30 2 17 4695 639 Reference population 7 61
1998 46 1 32 5305 867 882 3 80
1999 61 1 53 5916 1031 1060 2 98
2000 72 7 47 6527 1103 1117 11 77
2001 112 9 75 7138 1569 1582 10 80
2002 131 9 94 7722 1696 1762 8 80
2003 160 17 122 8714 1836 1876 11 79
2004 177 17 125 9706 1824 1924 11 81
2005 252 20 176 9935 2536 2784 9 79
2006 231 15 170 10,165 2273 2386 7 78
2007 231 13 181 11,062 2088 2171 6 85
2008 238 10 163 11,958 1990 2183 5 81






























2002 39 70 0 22.5 1737 0 652 4030 0
2003 50 85 0 22.9 1993 11 744 4289 0
2004 52 100 8 23.0 2233 113 696 4697 7692
2005 81 130 20 23.2 2303 308 1,061 6458 6897
2006 52 121 27 25.5 2591 516 687 5762 5499
2007 50 126 25 26.0 2877 573 611 5408 4570
2008 52 129 21 26.5 3164 713 591 5193 3088
Patients of unknown HIV status excluded.
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and then decline moderately. However, there was a dramatic,
almost 3-fold decline in TB rates in those HIV-infected
patients on HAART. Of note is the high initial retreatment
TB rate in patients receiving HAART compared with those
patients not on HAART, followed by a substantial reduction in
retreatment TB in HIV-infected patients on HAART.
The levelling-off and subsequent decline of TB
notification rates in HIV-infected patients not on HAART
may be due to the removal of those with the highest TB risk
(lowest CD4 counts) from this group into the group on
HAART.4 This stabilizing of notification rates suggests that the
rate at which people are removed from the susceptible pool
approximates the rate at which HIV-infected patients not on
HAART are progressing into a high-risk state of immune
compromise. This finding suggested that the rate at which an
HAART program is implemented in a community might be an
important variable determining the impact of this intervention
on overall HIV-associated TB rates.
Although TB does occur at all CD4 strata, the highest
risk of TB in HIV-infected patients occurs at low CD4 counts
(,200 cells/mL).25,26 The South African National Antiretro-
viral program recommended initiating patients on HAART at
CD4 count ,200 cells per microliter or WHO clinical stage
IV.27 Patients initiating HAART have a high risk of TB in the
first months of treatment compared with later in treatment due
to the risks associated with low baseline CD4 counts and with
possible unmasking of subclinical TB.28–30 The overall
increase in median baseline CD4 count in our study reflects
that patients with more advanced disease were initiated onto
treatment in the early stages of the HAART program. With
increasing duration of the HAART program, the pool of
severely immune-compromised patients off treatment de-
creased, and patients were started on HAART at higher
baseline CD4 counts. However, despite the overall increase in
median baseline CD4 count, by 2008, the median CD4 count
at initiation of HAART was still well below 200 cells per
microliter and TB risk before HAART initiation remained
high, as evidenced by the nearly 2-fold higher standardized RR
in HIV-infected patients off HAART compared with those
patients on HAART in 2008.
HIV-infected patients off HAART accounted for 64% of
TB disease in 2008, and thus contribute a large portion of the
TB burden. By 2008, the HAART coverage in this community
was high, at approximately 90% of the estimated community
need as defined by the national HAART treatment guide-
lines.27,31 If similar coverage rates and impacts were achieved
nationally, a .20% reduction in TB rates might be attained.
But this impact could be more substantial if treatment was
initiated earlier in the HIV disease process, thus also reducing
FIGURE 2. TB rates in HIV-
uninfected and adult HIV-infected
patients (A) and HIV-infected pa-
tients receiving HAART and not
receiving HAART (B) in the study
community, from 2002 to 2008.
*The P value for autoregression
model from 2002 to 2004. **The P
value for autoregression model from
2005 to 2008. fThe P value for
autoregression model from 2004 to
2008.
FIGURE 3. Adult retreatment TB rates overall and by HIV and
HAART status, in the study community from 2002 to 2008.
FIGURE 4. Adult TB case fatality rate by HIV status, in the study
community from 2002 to 2008.
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TB burden before HAART initiation and during the early
months on HAART.
Prevalence of TB is a function of TB incidence and
period of infectivity in the community. Period of infectivity
can be decreased by earlier diagnosis and treatment of cases.
The key change to case-finding activities has been the
introduction of active case finding for TB in patients initiating
HAART. This practice may have resulted in a decrease in TB
prevalence, thus indirectly contributing to the decrease in
notifications over time. In addition, in 2005, a community-
based cross-sectional survey was performed in 10% of the
study community, investigating participants for active TB
disease. A sensitivity analysis, excluding those participants
diagnosed in that survey from the notification data, showed no
change in the study results, including the peak noted in 2005
(data not shown). Therefore, this survey does not seem to have
had a direct effect on the notification rates in this community.
The increased TB screening of HAART-eligible patients
associated with the scale-up of the HAART program in 2005
may explain the 2005 peak in notification rates. This increased
screening together with the survey may have increased
community awareness of TB, potentially contributing to the
moderate increase in TB notifications also noted in
HIV-uninfected patients.
Although there was a strong temporal association
between the decline in TB notification rates and the
implementation of an HAART program and there is sub-
stantive biological plausibility to support this association, it is
worth considering alternative explanations for the decrease
noted in TB notification rates. Improved TB treatment
completion rates may, for example, result in decreased
TB transmission, which could reduce TB incidence. However,
TB completion rates remained stable over the study period,
and this was consistent for both HIV-infected and HIV-
uninfected patients. Period of infectivity, and thus prevalence
could be decreased by increased TB-associated mortality;
however, TB case fatality has decreased.
There were no changes in the infection control policies
within the clinic over this period, and therefore, decreased
nosocomial TB transmission is unlikely to explain the study
findings. Although changing social conditions may also
impact TB transmission in communities, this community
has remained one of extremely poor socioeconomic status
since its establishment in 1994.
HIV testing uptake was not complete among TB patients
in this community. However, to explore the potential biasing
influence of those patients with unknown status, we performed
an extreme case scenario analysis. The result of this analysis
showed that our findings were robust and did not alter the
findings of the study. The population denominators were
derived from community census data with the assumption of
linear growth between censuses, and HIV-infected denomi-
nators were obtained from a mathematical model fitted to local
HIV data. Sensitivity analyses were run for models assuming
different trends of population growth and different assump-
tions for HIV prevalence. These analyses also did not show
substantive changes in study inferences. This community is
typical of many recently urbanized populations in South
Africa, but further investigations are needed to confirm the
generalizability of our findings in other high prevalence
settings.
This study was performed in a well-demarcated
community, with population data derived from frequent
community censuses. All residents receive their TB treatment
at a single clinic, and therefore, TB notification data is likely
to be a complete representation of TB notifications in the
community. Similarly residents obtained HAART from the
clinic or the local referral hospital and access to both these
databases ensured an accurate description of the HAART
program in this community. These analyses are dependent on
the fidelity of the relevant data records, and therefore, the
databases underwent a 10% quality control assessment.
In conclusion, against a background of increasing
TB notifications nationally, we have shown that a rapidly
implemented, high coverage HAART program can reduce the
TB notification rates and TB case fatality within a community
heavily affected by both HIV and TB epidemics. This
reduction in TB was due predominantly to the decrease in
TB rates in HIV-infected patients receiving HAART and may
be the result of both active TB screening and improved
immune function in these patients.
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Backround. Despite consistently meeting international performance targets for tuberculosis case detection and
treatment success, areas where tuberculosis is hyperendemic fail to achieve the predicted epidemiological impact. In
this article, we explore the anomalous relationship between defined performance targets and actual reduction in
tuberculosis transmission.
Methods. In areas where tuberculosis is endemic, poorly ventilated social gathering places such as shebeens
(informal alcohol drinking places), minibus taxis, and clinic waiting rooms are all potential transmission hot spots.
We modeled the transmission reduction achieved by removal of infectious persons in settings with different
tuberculosis prevalence rates to demonstrate the concept of transmission elasticity. We then applied this concept to
real-life data from a hyperendemic community in Cape Town, South Africa.
Results. In a hyperendemic area, reducing the number of infectious people by a given percentage results in
a smaller percentage decrease in the annual risk of infection (ARI) compared with a nonendemic area; for example,
removing 10% of infectious persons could result in as little as a 5% reduction in the ARI. With use of real-life data
and removal of 60% of infectious individuals with tuberculosis, as would be achieved by meeting current
performance targets of 70% case detection and 85% cure, the estimated ARI reduction is 50%.
Conclusions. The relationship between the number of infectious people removed and the decrease in ARI is
nonlinear. The concept of transmission elasticity has important implications for the formulation of universal
performance targets, since hyperendemic areas would require more stringent targets to achieve comparable
transmission reduction.
Tuberculosis is caused by Mycobacterium tuberculosis,
which spreads by aerosol transmission. Individuals with
active lung disease expel infectious droplets into the am-
bient air, where they remain suspended for a considerable
period in the absence of adequate ventilation. Progression
to disease is uncommon among immunocompetent
people following inhalation of an infectious droplet.
However, high levels of ongoing transmission and suffi-
cient numbers of vulnerable people sustain the epidemic
in areas where tuberculosis is endemic [1–3]. Molecular
epidemiology studies have established that in areas where
tuberculosis is endemic, disease results from recent in-
fection (primary or reinfection) in the majority of cases
[1–3]. This underscores the importance of reducing on-
going transmission in order to establish epidemic control.
The World Health Organization adopted the Directly
Observed Therapy Short course (DOTS) strategy to-
gether with specified performance targets in order to
control the tuberculosis epidemic. Despite curing mil-
lions of patients with tuberculosis and saving many lives,
the epidemiologic impact of this strategy has beenmixed
[4, 5]. The global tuberculosis incidence (number of
new cases identified each year) shows excessive vari-
ability, with the highest rates being recorded in sub-
Saharan Africa. Tuberculosis incidence rates in excess
of 1,500 cases per 100,000 people have been reported
in some hyperendemic communities. Mathematical
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models based on data from Western Europe predicted that
achieving 70% case detection and 85% cure rates would lead to
a decrease of tuberculosis incidence of up to 11% per year [5–7].
However, tuberculosis incidence failed to decrease as predicted
in many hyperendemic areas where the DOTS strategy has been
fully implemented and performance targets met [5, 8]. This
failure could be attributed to inaccurate calculation and/or re-
porting of estimates or to deficiencies in the mathematical
models used to define DOTS-related performance targets. Ap-
plying mathematical models in regions other than those from
which they were derived is questionable, since these models fail
to consider transmission dynamics that may be unique to hy-
perendemic areas. Typical models assume homogeneity; that is,
they assume that infectious people are uniformly distributed
over the whole population, but in reality tuberculosis cases are
heavily clustered within particular sections of the community. In
this article, we explore the potential nonlinearity between the
number of infectious tuberculosis cases removed (successfully
treated) and the decrease in ongoing tuberculosis transmission,
as a novel reason for unreliable predictions by standard models
when applied to hyperendemic areas.
Settings that are most conducive to transmission are crowded
and poorly ventilated households, workplaces, prisons, and
homeless shelters as well as shebeens (informal alcohol drinking
places), minibus taxis, clinic waiting rooms, community halls,
and churches [9–11]. For convenience, we use the term cohort to
mean a group of people who spend time together in such
a setting on a regular and frequent basis. For our purposes, the
cohort need not comprise the same people each time. Suscep-
tible people may be members of several cohorts; for example,
they may undertake a minibus taxi journey to work in the
morning (transport cohort), spend several hours at work (work
cohort), and then return home in the afternoon with a second
transport cohort. In hyperendemic areas around Cape Town,
South Africa, many unemployed people spend a great deal of
time socializing in shebeens [9, 10]. The essential attributes of
a cohort entail spending prolonged time on a regular basis with
a group of people, approximately fixed in number, in an en-
closed space with inadequate ventilation.
In any given cohort, infectious tuberculosis cases may be
present, in which case the cohort would become epidemiologi-
cally active. In hyperendemic areas, it is expected that, not in-
frequently, 2 or more concurrent infectious persons with
tuberculosis will form part of a single cohort (doublet cohort),
whereas this would be extremely unlikely in low-prevalence
areas, where only 1 infectious person would form part of a co-
hort (singlet cohort). Treating 10% of infectious people in a low-
prevalence setting will therefore cause, on average, nearly 10% of
the epidemiologically active cohorts to be deactivated so that
one can expect a 10% decrease in transmission. This will not be
the case in hyperendemic areas, where doublet or multiple
exposure cohorts will remain active since they are likely to lose
only 1 of the $2 infectious members. The expected decrease in
transmission will therefore be ,10%.
We utilized established transmission theory and real-life data
from a well-characterized community to quantify the above
considerations and show that in similar settings the relationship
between the number of infectious tuberculosis cases successfully
treated and the decrease in the annual risk of infection (ARI) is
indeed unequal. Thus, reducing the number of infectious people
by a given percentage results in a smaller percentage decrease in
the ARI than might otherwise be expected. This has important
implications for setting optimal performance targets for
tuberculosis control programs.
METHODS
To quantify the transmission reduction achieved by successfully
treating infectious tuberculosis cases, we have to estimate the
following: (1) the probability distribution of infectious people
among different cohorts, (2) the expected probability of trans-
mission events in cohorts containing variable numbers of in-
fectious people, and (3) for a given cohort, the risk of a
susceptible individual becoming infected or reinfected over the
course of 1 year, before and after a given percentage reduction in
the number of infectious people.
Probability Distribution of Infectious People Among Cohorts
The cohorts most conducive to transmission involve prolonged
socialization in crowded places with poor ventilation. Any of
these cohorts may be shared by 2 or more infectious people. In
general, we must find the distribution of infectious people
among these cohorts and estimate the proportion of cohorts (of
each type) that actually contain $2 infectious persons.
Suppose that in a community of M people there are N who
have infectious tuberculosis. The probability that any given
person in the population is infectious is given by q 5 N/M.
Assuming independence in the distribution of the infectious
people, the probability, Pk, that there are k infectious people in
a cohort where X people are present can be approximated by





As an example, we use data from a well-characterized hy-
perendemic community [12]. Figure 1 reflects the percentage of
cohorts likely to contain either 1 or 2 infectious tuberculosis
cases in this community, providing for different cohort sizes. For
example, with a tuberculosis prevalence of 1,600 cases per
100,000 people and cohort size 20, #4% of the cohorts will
contain 2 infectious people (doublet cohorts) and 24% will










contain only 1 (singlet:doublet ratio of 6:1). With larger cohort
sizes the relative number of doublet cohorts increases. The
number of cohorts containing $3 infectious people seems neg-
ligible (with M 5 15,000 the expected number of triplet cohorts
is .8), so we ignored this possibility in our model; triplet cohorts
may occur more frequently with exceptional case densities.
Transmission Risk Within a Cohort Containing a Given Number
of Infectious People
The circumstances conducive to tuberculosis transmission are
those of close confinement in poorly ventilated areas for pro-
longed periods. Being a member of an active cohort implies tu-
berculosis exposure and the possibility of acquiring infection. The
number of transmission events within each cohort can be esti-
mated using theWells-Riley equation [13–15] or the Gammaitoni
and Nucci model [16]. Under the conditions we are considering
here there is little difference in the predictions made by these










In this equation, C is the number of transmission events, S is
the number of susceptible people, k is the number of infectious
people in each cohort, T is the time of exposure, q is the in-
fectivity of the infectious people, p is the susceptible respiration
rate, and Q is the germ-free ventilation.
As an example, using typical data from our well-defined study
community [12], S 5 18 (for 2 infectious people in a cohort of
size 20), q5 1, T5 t3 D, where t5 1 h/d and D5 60 d is the
period of infectiousness, and P 5 14,400 L/d. Figure 2 reflects
the probability of transmission within cohorts, depending on the
number of infectious cases and various ventilation rates (Q). For
a Q value of 2 m3/h, the probability of transmission when 1
infectious person is present in a cohort is .46, whereas for 2
infectious people in a cohort, the probability is .71.
Transmission Reduction Resulting From Removal of Infectious
Cases
We assume passive case finding, in which cases emerge from the
community in a random way with equal chances of treatment
success. We calculate the proportional reduction in transmission
events after the removal, in a random manner, of a given pro-
portion of infectious cases as follows.
The expected annual risk of infection within a cohort is given
by the expected proportion of the year during which 1 infectious
person is present in the cohort multiplied by the probability of
transmission when 1 infectious person is present plus the similar
factor for 2 infectious people. This annual risk is therefore















The probability that 3 or more infectious people are present is
negligible and is therefore ignored.







We require the proportional effect on R when the number of
infectious people (ie, the prevalence) is reduced by a given
proportion. This corresponds exactly to the concept of price
elasticity of demand in economics, and we therefore find it
appropriate to use the prevalence elasticity of annual risk of








Applying equation (5) to equation (4) and using k 5 qX











where h 5 1 1 e2/ with / 5 pTq/Q as above.
Note that g 5 dR/dq $ q/R (equation [5]) is the limiting
value of DR/Dq $ q/R, where DR and Dq are (small) increments
Figure 1. Distribution of infectious people among community cohorts at various tuberculosis prevalence rates (cases per 100,000 people per year).






















that is, the percentage reduction in the ARI is approximately
g times the percentage reduction in the prevalence.
Transmission elasticity reflects the potential effectiveness of
attempts to reduce transmission by case detection and treatment.
In the ideal situation where g 5 1, the percentage reduction in
ARI is exactly equal to the percentage reduction in prevalence.
This is implicitly assumed in most mathematical models where
the law of mass action is applied to estimate the rate of trans-
mission (rate of transmission5 force of infection 3 number of
infectious people 3 number of susceptible people). We are
concerned here with the possibility of settings where g , 1. At
a low prevalence the elasticity is close to 1, but in hyperendemic
communities this may drop significantly below 1. With a value
of .6, the percentage reduction in transmission (ARI) will be
only 60% of the percentage reduction in prevalence, since ARI
reduction is g times the percentage reduction in prevalence.
RESULTS
Figure 3 shows variable rates of transmission reduction (trans-
mission elasticity) at different tuberculosis prevalences within
cohorts of size 20 and 40. Figure 3 and formula (6) show that
g/1 as k/0; that is, at low prevalences there is parity between
transmission reduction and the percentage reduction in preva-
lence. Transmission elasticity is demonstrated at high preva-
lences, where parity with the percentage reduction in prevalence
is no longer maintained. At a tuberculosis prevalence of 2,000
cases per 100,000 people the ratio (reflected on the y-axis) drops
to ,.5, which corresponds to a proportional reduction in ARI
that is less than half of the proportional reduction in tubercu-
losis prevalence.
In order to estimate the effect on the ARI within a community
where tuberculosis cases are successfully treated, it is necessary
to supply parameter values for formula (6). These parameter
values are specific to the community under consideration and
also vary from one cohort type to another. We consider 2
population components in order to accommodate variable ex-
posure risk. The high-risk component includes people who
spend a minimum of 1 h/d in the company of $20 people in
circumstances conducive to M. tuberculosis transmission. Ex-
amples of such conditions include shebeens, taxis, clinics, and
community halls; it is estimated that 39% of the study pop-
ulation would fall into this high-risk component (Robin Wood,
personal communication). Restriction fragment length poly-
morphism data suggest that the majority of transmission occurs
within this high-risk component where the tuberculosis preva-
lence is estimated to be .3,200 cases per 100,0000 people [12].
Household transmission is relatively less common than in low-
prevalence areas [12, 19], and household cohorts were excluded
from this analysis. For simplicity we assumed zero infection risk
in the low-risk component, which should result in more con-
servative estimates for the community as a whole.
We assigned the following typical values: q 5 1, T 5 t 3 D,
where t 5 1 is the minimum time expressed in hours per day
and D 5 60 d is the period of infectiousness, P 5 14,400 L/d,
andQ5 4m3/h (96,000 L/d) [12]. We then calculated the risk of
infection for the high-risk component using formula (4). The
risk for the remainder of the population is, as explained above,
assumed to be 0. The risk of infection for these 2 components
Figure 3. Proportional reduction in annual risk of infection compared
with tuberculosis (TB) prevalence within cohorts of different size (X5 20
or 40 people) and different daily exposure times (t 5 1 or 4 h). period of
infectiousness (D), 60 d [12]; susceptible respiration rate (p), 14,400 L/d;
ventilation rate (Q), 4 m3/h.
Figure 2. Estimated annual probability of transmission within a given
cohort, of size 20, depending on the number of infectious people in the
cohort and various ventilation rates (Q). daily exposure time (t), 1 h/d;
period of infectiousness (D), 60 d [12]; susceptible respiration rate (p),
14,400 L/d.










combined is then the weighted sum of these 2 risks with the
weightings given by the total proportions that each of these
groups form within the community as a whole, namely, 39%
and 61%. We now estimate the transmission elasticity in the
population as a whole by considering this weighted sum of the
risks.
To illustrate the result, we consider the effect on transmission,
in the community as a whole, of a 10% reduction in prevalence.
With the conservative assumptions made, a 10% case reduction
at a prevalence of 1,600 tuberculosis cases per 100,000 people,
estimated transmission would be reduced by 8.3% (Figure 4).
Given current performance targets (70% case detection and 85%
treatment completion), it is of interest to estimate what the
transmission impact would be if these targets were achieved and
60% (.7 3 .85 5 .595) of tuberculosis cases cured. Figure 5
demonstrates the variable ARI reductions achieved given dif-
ferent case densities (initial prevalence rates).
Several points should be noted:
1. The proportional reductions calculated are for the
infection rate, not the disease rate. However, the risk to
progress from infection to disease should remain constant in
the short term, and thus the proportional reduction in disease
rate will be similar. However, if the population profile changes
considerably over time (reducing overall vulnerability) then
correspondence may no longer apply. These factors should be
accounted for in mathematical models of the longer-term
epidemiological impact where, in the typical scenario, the state
variables are updated using successive time-step iterations.
These changing values imply a possible change in risk to
progress from infection to disease. The changes may be small at
each time step, but the cumulative effect could be substantial.
2. Our calculations reflect the direct impact on trans-
mission; they do not consider secondary or more dynamic
longer-term effects. When modeling longer-term impact,
various delays have to be factored in; delays that facilitate
ongoing transmission will only accentuate the elasticity effect.
3. In the present study we investigated the situation in
a particular high-prevalence community. However the
methods could be applied to low-burden settings as well,
where infectious people are heterogeneously distributed.
Within particular transmission hot spots such as prisons,
homeless shelters, or immigrant clusters, prevalences of .500
cases per 100,000 people would suggest that transmission
elasticity becomes relevant. If averaged over the entire low-
burden setting, the effect may not be observable.
DISCUSSION
In an environment where tuberculosis is hyperendemic, it is
likely that susceptible individuals may be simultaneously ex-
posed to .1 infectious person with tuberculosis. Previous
mathematical models failed to consider the potential impor-
tance of this transmission overlap, which has particular rele-
vance in hyperendemic communities. Reducing the tuberculosis
prevalence will reduce ongoing transmission, but our data
suggest that this reduction is highly variable (transmission
elasticity) depending on the initial prevalence rate and likeli-
hood of transmission overlap. Transmission elasticity may partly
explain why the transmission impact observed in some com-
munities that achieved and maintained global performance
targets failed to meet expectations. Although the effect seems
modest at an averaged population level, it is likely that trans-
mission elasticity is greatly enhanced within particular trans-
mission hot spots where high-risk individuals are likely to
congregate.
Only 2 avenues exist to gain control of the global tuberculosis
epidemic: (1) reduce host vulnerability at the population level
and/or (2) limit ongoing M. tuberculosis transmission. The
challenge is greatly increased by factors such as the coexistent
human immunodeficiency virus (HIV) infection epidemic,
Figure 4. Effect of a 10% reduction in tuberculosis (TB) prevalence on
annual infection risk within the total population at various tuberculosis
prevalence rates. The proportion of the community considered part of the
high-risk component is 39% [12].
Figure 5. Percentage decrease in annual risk of infection with a 60%
reduction in tuberculosis (TB) prevalence at different case densities
(initial prevalence rates).










drug-resistant tuberculosis, and the multiple social determinants
of tuberculosis [4, 5]. Our work focused exclusively on trans-
mission dynamics and the development of mathematical models
that are more robust and predictive in hyperendemic areas.
Although we utilized data from a particular setting, we believe
the underlying principles are generalizable and transmission
elasticity should be considered in future attempts to model tu-
berculosis epidemiology in hyperendemic settings. Simplified
models are likely to overestimate the epidemiological impact that
will be achieved in areas with significant transmission overlap, as
is likely to occur within transmission hot spots. A remaining
shortcoming of current transmission models is their failure to
consider the impact of diagnostic delay and transmission satu-
ration [20]. With delayed diagnosis, the transmission impact of
curative treatment is greatly reduced [21]. Current targets do not
reflect the importance of limiting diagnostic delay, which is es-
sential to reduce ongoing transmission.
Transmission elasticity demonstrates that any control policy is
likely to be less effective than predicted by currentmodels especially
in high-prevalence settings. Dowdy and Chaisson [22] showed
that once case detection rates stabilize at any constant level,80%,
no further reduction in tuberculosis incidence occurs. Adding the
transmission elasticity effect to this finding provides further sup-
port for efforts to optimize case detection and treatment success,
irrespective of whether existing targets have been met. Delays in
accurate diagnosis and institution of effective treatment erode the
effectiveness of target interventions, which has particular relevance
for the spread of drug-resistant tuberculosis [23, 24].
In conclusion, the incorporation of transmission elasticity in
future mathematical models supports the identification of more
stringent performance targets for global tuberculosis control.
Tuberculosis control programs should vigorously pursue im-
provements in case detection, reductions in diagnostic delay,
and reductions in time to effective treatment, particularly in
hyperendemic areas where transmission elasticity is likely to be
most relevant.
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M A J O R A R T I C L E
Rates of Tuberculosis Transmission to Children and
Adolescents in a Community with a High Prevalence
of HIV Infection among Adults
Keren Middelkoop,1,2 Linda-Gail Bekker,1,2 Landon Myer,3,5 Rodney Dawson,4 and Robin Wood1,2
1Desmond Tutu HIV Centre, Institute of Infectious Diseases & Molecular Medicine, 2Department of Medicine, and 3Infectious Diseases
Epidemiology Unit, School of Public Health & Family Medicine, University of Cape Town, and 4Centre for Tuberculosis Research Innovation,
University of Cape Town Lung Institute, Cape Town, South Africa; and 5Department of Epidemiology, Mailman School of Public Health, Columbia
University, New York, New York
(See the editorial commentary by Rieder on pages 356–7)
Background. Tuberculin skin test surveys are routinely used to test for tuberculosis (TB) infection in com-
munities, but there are few data from tuberculin skin test surveys from countries in which both TB and human
immunodeficiency virus (HIV) infection are prevalent.
Methods. We conducted a tuberculin skin test survey among 831 school-going children aged 5–17 years in a
community that was experiencing an increase in the prevalence of TB and HIV infection. Responses to purified
protein derivative RT23 were measured 3 days after the test was administered to determine tuberculin skin test
results.
Results. The prevalence of tuberculin skin test results positive for TB (i.e., an induration 10 mm in diameter
in response to the skin test) ranged from 26.2% among children aged 5–8 years to 52.5% among children aged
14–17 years. The overall annual risk of infection was 4.1% using a 10-mm cutoff and 2.0% using a 17.4-mm
cutoff. Annual risks of infection were constant across age groups. This is consistent with the finding that TB
incidence remained the same in children ( ) from 1999 through 2005, although total TB incidence andP p .48
adult TB (determined by sputum smear test) incidence increased in this community during the same period
( ).P ! .001
Conclusions. The annual risk of infection is high in the community. It appears that HIV infection–associated
TB is not a major influence on the annual risk of infection and that TB transmission from adults to children may
be associated with a subset of TB cases in the community. An improved understanding of TB transmission patterns
is urgently needed help the implementation of novel strategies for reducing the annual risk of infection in this
setting.
The directly observed therapy short-course strategies
that are currently recommended by the World Health
Organization are insufficient to contain the tuberculosis
(TB) epidemic in countries with a high prevalence of
HIV infection [1–3]. It is unclear how the HIV infec-
tion–related TB epidemics impact the children in af-
fected communities. The tuberculin skin test (TST) is
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an epidemiological tool to test for TB; because the prev-
alence of TB among young children may be interpreted
as incidence, data generated by TST surveys can be used
to calculate an annual risk of TB infection (ARTI).
Although limitations attributable to the methodological
weaknesses inherent in this technique are recognized
[4, 5], TST surveys are valuable for the detection of TB
in communities with low case-detection rates and for
assessing the impact of HIV infection on a TB epidemic
[6]. Additionally, TST surveys have an important role
in understanding the impact of both HIV infection and
TB epidemics on children.
In the prechemotherapy era, Styblo [7] described a
fixed relationship between ARTI and disease incidence
(based on sputum smear results positive for TB). This
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TB chemotherapy would alter any relationship between ARTI
and TB incidence [4, 5, 8, 9]. TB treatment increases survival
rates and reduces person-time of infectiousness in a commu-
nity, thereby reducing infection risk [4] and subsequently de-
creasing TB prevalence and incidence. However, these factors
are all dependent on the performance of the TB control pro-
gram [4, 5, 8], which may vary over time and between different
communities. The relationship between ARTI and TB incidence
may have been altered by the impact of the HIV epidemic on
TB. This change is postulated on the basis of the increase in
the number of TB cases with both positive and negative sputum
smear results in areas with a high prevalence of HIV infection
and the changes in the duration of infectiousness of HIV-in-
fected TB patients [4, 10]. However, there is conflicting evi-
dence regarding whether HIV-infected TB patients are as in-
fectious as non–HIV-infected TB patients [11–13].
There have been few studies regarding the impact of the HIV
epidemic on TB infection among children, and available find-
ings are mixed. One study from Tanzania reported a significant
decrease in ARTI among children aged 6–14 years for the period
1983–2003 [14] in the context of an increasing HIV epidemic
(HIV infection prevalence, 7%–11% [15]). This trend was re-
ported despite an increase in TB notification rates [14]. In 1994,
a study of Ugandan children reported a decrease in ARTI
among school-going children [16]. In contrast, research from
Kenya reported an increased ARTI during the period 1986–
1996, which was associated with an increasing TB epidemic in
areas with a high prevalence of HIV infection [17]. These sur-
veys have reported ARTIs ranging from 0.68% to 1.2% [14, 16,
17]; the variability in ARTI may be attributable to the differing
performance of TB control programs in the study communities.
There is little recent published tuberculin skin test data from
southern Africa, where the prevalence of HIV infection has
reached unprecedented levels [18].
We have previously reported on the growing TB epidemic
in a periurban township that is heavily affected by HIV infection
in Cape Town, South Africa. The prevalence of HIV infection
among adults in this community is 23% [19], and it is 10%
among adolescents aged 11–19 years [20]. The National TB
Control Program, which operates on the basis of World Health
Organization directly observed therapy short-course recom-
mendations, is well run, with treatment completion and cure
rates of patients with positive sputum smear results of ∼80%
[21] and case-finding rates of 67% among non–HIV-infected
patients with positive sputum smear results, but case-finding
rates are lower among HIV-infected patients with positive spu-
tum smear results [19]. However, local TB notification data
shows a rapid increase in TB notification rates among adults,
from 789 notifications per 100,000 population in 1996 to 11900
per 100,000 population in 2005, with the incidence rates of TB
with positive sputum smear results among adults increasing
from 326 per 100,000 population in 1996 to 1307 per 100,000
population in 2005 [3, 19]. A cross-sectional survey of TB
prevalence performed in 2005 showed an overall prevalence of
TB with positive sputum smear results of 1495 per 100,000
population, and 0.8% of these cases were untreated [19]. We
believe that, in this community that has an adequate TB control
program, the HIV epidemic is driving the increase in TB in-
cidence [3]. To better understand patterns in the transmission
of TB in this context, we assessed the prevalence of TB infection
among children aged 5–17 years in this setting of increasing
TB and HIV infection prevalence.
METHODS
The TST survey was performed on a sample of children at-
tending school in the community, which is comprised of
∼13,000 predominantly Xhosa-speaking individuals who live in
a very poor, high-density residential area. A cross-sectional sur-
vey was performed in 2 stages among school children attending
the local government primary school. Children were eligible if
they were a resident in the community and registered at the
local school. Children in grades 1–3 were enrolled in October
2006 and children in grades 5–7 were enrolled in October 2007.
Parental consent and assent from participants who were 16
years of age was obtained prior to enrollment. The survey was
performed on the school premises. Basic demographic infor-
mation was collected for each participant. All participants were
examined for the presence of a bacille CalmetteGuérin (BCG)
scar; the TST was performed for participants regardless of BCG
scar status. The World Health Organization–recommended
standard of 2 TU of purified protein derivative RT23 with
polysorbate 80 (Tween 80, Statens Seruminstitut) was admin-
istered intradermally to the volar surface of the left forearm by
a trained nurse.
The size of the reaction to the tuberculin was measured by
a trained reader at a second visit 3 days after the inoculation.
The presence or absence of a reaction was noted, and, where
present, the size of the induration was measured along per-
pendicular axes using standard calipers.
This study was approved by the University of Cape Town’s
Research Ethics Committee, and all procedures were in accor-
dance with the ethical standards of this committee and the
Declaration of Helsinki, 1975, as revised in 1983. All children
with a TST reaction induration 10 mm were recalled for
investigation for active TB, and children with signs or symp-
toms of active disease were referred to the local clinic for ad-
ditional management.
Data were analyzed using STATA, version 9.0 (StataCorp).
Results reported here were calculated as the mean of the 2
diameters of the TST reaction induration: a positive reaction
was defined at 10-mm and 17.4-mm cutoff points in separate
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Mean age, years 7.3 9.9 12.5 14.6 10.7
Sex
Male 115 (49) 122 (55) 110 (46) 87 (63) 434 (52) .01
Female 118 (51) 100 (45) 127 (54) 52 (37) 397 (48)
BCG scar status
BCG scar observable 30 (13) 66 (30)a 87 (37) 30 (22) 213 (25) !.001
No BCG scar observable 203 (87) 155 (70)a 150 (63) 109 (78) 617 (75)
NOTE. Data are no. (%) of patients, unless otherwise indicated. BCG, bacille Calmette Guérin.
a One participant’s BCG scar status was indeterminable because of burn scars ( ).n p 221
fection in clinical settings [22]; the 17.4-mm cutoff was deter-
mined as the mean induration size, excluding all nonreactive
individuals [23]. ARTI was calculated as follows:
1/mean age+0.5( )1  1  prevalence .
Because the age (in full years) of the patient at their most-
recent birthday was used, 0.5 was added to the mean age for
the calculation of ARTI [23]. The cohort was divided into
groups of participants aged 5–8 years, 9–11 years, 12–14 years,
and 15–17 years, and prevalence and ARTI were calculated
overall and for each age group. Bivariate analyses employed the
Student’s t test and Fisher’s exact test, as appropriate. Wilcoxon
rank-sum tests were used for the comparison of TST results
between different groups. Multiple logistic regression models
were developed to examine factors associated with positive TST
results. A x2 test for trend was used to assay for a trend between
age and ARTI, as well as for changes in TB notification rates
over the 5-year period. All statistical tests were 2-sided, with
.a p 0.05
The number of notified TB cases in children was obtained
from the TB register at the community TB clinic, and TB prev-
alence rates were calculated using the 1996 South African Na-
tional Census and the 2003, 2004, and 2006 house-to-house
census performed by the Desmond Tutu HIV Centre. Ratios
of TB prevalence and incidence of new TB infections were
calculated from the ARTI and from TB prevalence and inci-
dence data already published for this community [3, 19].
RESULTS
Of the 1060 children enrolled in the target grades at the primary
school, 1020 (96%) were eligible for study participation. Of the
40 children excluded from the study, 18 (45%) were ineligible
because they lived outside of the community, and 22 (55%)
were ineligible because they had dropped out of school during
the course of the year. Consent was obtained from the parents
of 837 (82%) of the eligible children. The parents of 44 children
(4%) refused consent and 137 children (13%) had incorrect
location information listed in the school register. We enrolled
832 children in the study (99% of children from whom consent
was obtained). The outstanding 5 children were not enrolled
because of persistent absenteeism. Tuberculin reaction was as-
sessed in all children who were inoculated, except 1, who re-
located before the reaction was assessed. Thus, this child was
excluded from the analysis ( ).n p 831
Table 1 shows the demographic characteristics of the study
cohort. Ages ranged from 5 to 17 years with a mean age of
10.7 years, and 52% of the participants were male. The majority
of the children (74%) did not have a BCG scar; 1 child’s BCG
scar status was unobservable because of burn scars on the upper
arm, and the child was thus excluded from analysis involving
BCG scar status. In the crude analysis, older children (children
of age greater than the mean) were more likely to have BCG
scars than were children aged less than the mean age (P !
)..001
The frequency distribution of reaction induration sizes for
positive TST results is presented in figure 1. There were no
significant differences between the mean reaction induration
sizes of participants who had BCG scars and the mean reaction
induration sizes of those who did not have scars (6.2 vs. 7.0
mm, ).P p .28
The cutoff point, determined by the mean induration size
excluding TST nonreactors, was 17.4 mm. Using the 10-mm
cutoff, 311 participants (37%) had a TST result positive for
TB; using the 17.4-mm cutoff, 171 participants (21%) had a
result positive for TB. At both the 10-mm and 17.4-mm cutoff
points, there was no significant difference in the defined TB
positivity by sex ( and , respectively) or BCGP p .97 P p .69
status ( and , respectively). In a logistic regres-P p .39 P p .08
sion model that predicted the relative odds of a positive TST
result, age was positively associated with a positive TST result
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Figure 1. Frequency distribution of positive tuberculin skin test reactions.
in age, 1.19; 95% CI, 1.12– 1.25; ) and the 17.4-mmP ! .001
cutoff (adjusted OR, 1.19; 95% CI, 1.12– 1.27; ).P ! .001
The total ARTI for this population was 4.1% using the 10-
mm cutoff and 2.0% using the 17.4-mm cutoff. The ARTI did
not differ significantly across the age quartiles for the 10-mm
or the 17.4-mm cutoff ( and , respectively).P p .50 P p .39
Tables 2 and 3 report TB prevalence and ARTI by age quartiles
for both cutoffs.
TB notification rates among children ranged from 456 no-
tifications per 100,000 population in 1999 to 395 per 100,000
population in 2005. Figure 2 shows the change in notification
rates of total cases of TB, cases of pulmonary TB with positive
sputum smear results in adults, and cases of TB in children in
this community for the period 1999–2005. The rate of total
cases of TB in the population and the rate of TB with positive
sputum smear results in adults has increased significantly over
this period ( for both, by test for trend). However, TBP ! .001
notification rates in children have not changed significantly
during the same period ( , by test for trend).P p .48
The ARTI of 4.1% indicates that there should be 4100 ex-
posures per 100,000 population each year. On the basis of the
incidence of new TB infections with positive sputum smear
results in 2005 (1459 cases per 100,000 population) [19], we
estimated that the ratio of TB incidence to new infections is
approximately 1:2.8. Because 0.8% of TB cases with positive
sputum smear results in the community are untreated [19], the
ratio of prevalence to new infections is estimated to be 1:5.
DISCUSSION
To our knowledge, this is the first study from southern Africa
reporting ARTI in the context of a rapidly growing epidemic
of TB and HIV. AR I is a measure of TB infection risk for
previously unexposed individuals. A fixed relationship between
the prevalence of TB (as a measure of ARTI) and the incidence
of TB with positive sputum smear results was proposed in the
prechemotherapy era [8], although this relationship has been
increasingly questioned [5]. It is recognized that chemotherapy,
TB case-finding, and the performance of the TB control pro-
gram also affect ARTI by modifying the person-time of infec-
tiousness in the community [4, 5, 8, 9]. The HIV epidemic has
a profound influence on the epidemiology of TB. However,
individuals who have TB who are coinfected with HIV may be
less likely to infect their close contacts than are non–HIV-
infected individuals who have TB [11, 12]. The relationship
between ARTI and HIV infection–associated TB at a population
level is therefore unclear. This study was performed in a well-
defined community with detailed information available re-
garding TB incidence and prevalence and TB control program
performance parameters, together with longitudinal data on
HIV and HIV-TB coinfection prevalence.
The main finding of the study is that, regardless of the cutoff
used for positivity, the ARTI observed in this study was mark-
edly higher than those documented in other sub-Saharan coun-
tries that were heavily affected by HIV infection (2.0% or 4.1%
in our study vs. 0.68%–1.2% in other studies [14, 16, 17]). The
prevalence of latent TB infection of 70%–83% among young,
non–HIV-infected adult controls from similar communities in
Cape Town is consistent with this high ARTI rate [24, 25]. With
no TST induration size results between 0–5 mm and little evi-
dence of the cross-reaction with environmental Mycobacterium
species that was present in other studies, the high prevalence
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Table 2. Tuberculosis prevalence and annual risk of tuberculosis infection (ARTI)














5–8 7.8 233 61 26.2 3.8
9–11 10.4 222 70 31.5 3.6
12–13 13.0 237 107 45.1 4.5
14–17 15.1 139 73 52.5 4.8
All 11.2 831 311 37.4 4.1
a The mean age reported here is the age used for the ARTI calculations and was determined by
adding 0.5 years to the mean age for the age category.
Table 3. Tuberculosis prevalence and annual risk of tuberculosis infection (ARTI)














5–8 7.8 233 25 10.7 1.4
9–11 10.4 222 39 17.6 1.8
12–13 13.0 237 71 30.0 2.7
14–17 15.1 139 36 25.9 2.0
All 11.2 831 171 20.6 2.0
a The mean age reported here is the age used for the ARTI calculations and was determined by
adding 0.5 years to the mean age for the age category.
assess ARTI by age strata, providing a measure of prevalence
over time. Surprisingly, we found that the ARTI remained con-
stant across the age range of 5–17 years, despite the fact that
children were being exposed to a rapidly escalating TB epi-
demic. This finding is additionally supported by the fact that
the TB notification rate among children !14 years of age re-
mained unchanged during the past 7 years; however, it should
be noted that, because TB case detection rates are low in this
community, there may be more cases of TB among children
than were detected by the TB control program.
We have shown previously that HIV infection is driving the
increasing TB epidemic, especially among adults aged 20–40
years in this community, an age group with the highest prev-
alence of HIV infection [3]. However, ARTI has remained stable
during a period when the prevalence of HIV infection among
adults has increased from 14% to 23% [3, 19]. In 2005, 170%
of patients with TB were also HIV infected, and TB notification
rates among HIV-infected patients were nearly 7-fold greater
than those among non–HIV-infected patients [3]. Therefore, it
appears that HIV infection–associated TB is not the major de-
terminant of the ARTI in this community. This would be con-
sistent with the findings from other studies of lower infectivity
of HIV-infected TB patients [11, 12]. It may also reflect that
children are not proportionately affected by the HIV epidemic,
because their predominant social contacts are peers, parents,
and teachers.
Despite a significant increase in the total number of pul-
monary TB cases and in the number of pulmonary TB cases
with positive sputum smear results among adults in this com-
munity during the past 5 years, the TB incidence among chil-
dren has remained stable. The ratio of ARTI to the number of
new TB cases with positive sputum smear results decreased
from 1:6 in 1999 to 1:3 in 2006. However, the more relevant
ratio between the ARTI and the cases of untreated TB with
positive sputum smear results was only 1:5 in 2005. These data
are based on a small study sample performed at a single school
in one community, and therefore, they may not be generalizable
to other regions.
Since 1960, the policy in South Africa has been to vaccinate
all infants with the BCG vaccine [26]. However, only 25% of
the children in this study had an observable BCG scar, although
BCG scarring may be variable [27, 28]. We also found no
difference in the distribution of TST results between those chil-
dren with and those children without BCG scars, and we there-
fore included all children in the analysis. This lack of correlation
between the presence of a BCG scar and a tuberculin reaction
has been shown in other studies [28–30].
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Figure 2. Changes in notification rates of total tuberculosis (TB) cases, cases of pumonary TB with positive sputum smear results in adults, and
cases of TB in children (aged !14 years) in the study community during the period 1999–2005.
because this might have adversely affected parental willingness
to consent to their child’s participation. Study participants were
born in the period 1990–2001, when the reported HIV infection
prevalence at antenatal clinics ranged from 0.7% to 24% [31].
This was prior to the introduction of the prevention-of-mother-
to-child-transmission program. With a transmission rate of
∼30%, we estimate that 0.2% of the older cohort and up to
7% of the younger children may have been infected with HIV
perinatally. However, considering the high early mortality rate
among HIV-infected children [32], it is probable that a max-
imum of 0.1%–4% of children in this study sample were HIV-
infected. This is a small percentage and is unlikely to have had
a large impact on the TB prevalence. However, any impact of
HIV infection on the prevalence of TB would have also been
offset by the skin test anergy caused by advanced HIV disease,
which results in false-negative TST reactions. Additionally, it is
possible that there is a bias among school attendees and that
non–school-attending children may have higher TB infection
rates; this may have resulted in an underestimation of the TB
prevalence.
An ARTI of 2.0%–4.1% would result in the majority of in-
dividuals being latently infected before reaching adulthood, and
would ensure the continued exposure of these individuals to
further TB infection. The combination of high latent infection
rates, repeated ongoing exposures, and an extremely high life-
time risk of HIV infection may go a long way towards explain-
ing the explosive epidemics of HIV infection and TB [3]. TB
control will require measures that are targeted at decreasing the
ARTI. The current TB control program implements a directly
observed therapy short-course policy and reports treatment
completion rates 180%. The finding rate of TB cases with pos-
itive sputum smear results in this community is below World
Health Organization targets and could be improved by active
case finding among both non–HIV-infected and HIV-infected
individuals. Preventative isoniazid therapy is not routinely used
for either TB control or HIV programs, and its role needs to
be explored. An antiretroviral treatment program has been in-
stituted, and 130% of HIV-infected individuals are receiving
therapy (data not shown). Although antiretroviral therapy will
likely decrease TB rates among HIV-infected individuals, the
findings of this study suggest that this measure is unlikely to
positively impact the ARTI. This is possibly because this mea-
sure may provide limited information about the epidemic
among population groups that are not primarily composed of
the participants’ parents and teachers. In this poor community,
the impact of social policies that are intended to improve hous-
ing and decrease crowding also cannot be ignored.
This study shows high ARTI rates among school-going chil-
dren in this setting of rapidly growing TB and HIV epidemics.
The ARTI observed was markedly higher than those published
for other sub-Saharan countries that are similarly affected by
HIV infection. The ARTI was constant across the age groups
studied, which indicates that the HIV infection–driven TB ep-
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Novel strategies for reducing the ARTI need to be considered,
and this study highlights the importance of improving the un-
derstanding of TB transmission in this setting.
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Abstract We present a simple mathematical model with six compartments for the
interaction between HIV and TB epidemics. Using data from a township near Cape
Town, South Africa, where the prevalence of HIV is above 20% and where the TB
notification rate is close to 2,000 per 100,000 per year, we estimate some of the model
parameters and study how various control measures might change the course of these
epidemics. Condom promotion, increased TB detection and TB preventive therapy
have a clear positive effect. The impact of antiretroviral therapy on the incidence of
HIV is unclear and depends on the extent to which it reduces sexual transmission.
However, our analysis suggests that it will greatly reduce the TB notification rate.
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1 Introduction
In South Africa, 5.5 million people are infected with the human immunodeficiency
virus (HIV), that is 12% of the country’s total population [66, p. 455]. Approximately
270,000 cases of active tuberculosis (TB) are notified each year [76, p. 137]. Among
adult cases of active TB, nearly 60% are HIV+ because coinfection with HIV and
Mycobacterium tuberculosis (MTB) increases greatly the probability of progressing
from latent to active TB.
Detailed studies of these epidemics in a township near Cape Town have been pub-
lished recently [35,75]. Estimates of the TB notification rate (based on the yearly
number of TB notifications, on two population censes conducted in 1996 and in 2004,
and assuming a linear population increase in between) and of the prevalence of HIV
(estimated using data from an antenatal clinic) are shown in Table 1.
For the year 2005, 259 TB cases were reported among adults (age≥ 15) [75]; 66%
of those who were tested for HIV were HIV+. The adult population was then estimated
to be 10,400 and the total population 13,000. So the TB notification rate in the whole
population was over 259/13, 000  1, 992 per 100,000 per year. Moreover, in a sample
population of 762 adults, 12 had undiagnosed TB (3 HIV− and 9 HIV+). Around 23%
(174/762) of the sample population was HIV+. More than 80% of smear-positive TB
cases receiving treatment were cured.
There have been many studies in the medical literature focusing on particular aspects
of the joint HIV–TB epidemics in this and other similar townships near Cape Town
[3,34,35,37–40,75]. In the present paper, we build a mathematical model to integrate
the data on TB and HIV in order to develop a better understanding of the epidemic. We
keep the model as simple as possible consistent with the available data and we do not
stratify the model by age. The main focus is on the impact of various control measures.
Given the extremely high levels of both HIV and TB in this setting, it is essential to
know what are the most effective control measures. Of particular importance is the fact
that a substantial project is being planned to control HIV and TB in this township. The
model may help the planning and design of the intervention. Furthermore, the model
and its predictions may provide a framework for evaluating the success or failure of
the intervention.
Section 2 reviews mathematical models that have previously been developed to
investigate joint epidemics of HIV and TB. Section 3 introduces the model we use,
which we have tried to keep as simple as possible. Section 4 analyzes some mathe-
matical properties of the model. Section 5 reviews parameter values in the medical
literature. Section 6 estimates several parameters using the data from the South African
Table 1 TB notifications per 100,000 per year and HIV prevalence (%)
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004
TB 580 653 913 897 982 1,410 1,366 1,472 1,468
HIV 6.3 8.9 11.6 14.2 16.5 18.4 19.9 21.1 21.9
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township. Section 7 contains bifurcation diagrams showing qualitatively and quanti-
tatively how the steady states of the model change for different sets of parameter val-
ues. This approach is needed since some parameters are known only approximately.
Section 8 investigates how various control measures might affect the HIV and TB epi-
demics with a focus on transient dynamics, since the convergence to a steady state takes
many decades. The main question is about the impact of antiretroviral therapy (ART)
on the TB notification rate, the answer to which is not obvious. Indeed, coinfected peo-
ple on ART have a risk of developing TB reduced by 80%, but their life expectancy
is also greatly increased. As their risk of developing TB is still several times higher
than for HIV− people, this may increase TB transmission. Our numerical results sug-
gest the contrary: ART could decrease considerably the TB notification rate even as it
increases the prevalence of HIV. This conclusion should be considered with caution
as there are uncertainties not only in parameter values but also in model formulation.
2 Review of HIV–TB epidemic models
Table 2 reviews HIV–TB epidemic models. The models have been of essentially two
different types: either computer simulation studies focusing on transient behavior of
realistic but complex models, or “mathematical” studies of simpler but less realistic
models focusing on steady states and their stability. These models have considered
the situation in sub-Saharan Africa, the USA, Russia, India, or in Brazilian prisons.
Some models tried to present a global view by considering all of the five WHO-
regions. Other models did not focus on any specific area. The compartments combined
a certain number of HIV-states (call it i) and a possibly different number of TB-states
(call it j). In such a case, one would expect the model to contain i × j compartments.
Some models have aggregated several compartments while others have added more
compartments to take into account specific interventions. This is why the number of
compartments is written as i × j ±k in Table 2. Some models took the form of a system
of ordinary differential equations (ODEs). Most others used discrete-time difference
equations. Finally, we mention the ongoing work of Lungu [43]. Several other models
have considered generically two diseases infecting a single population, but either they
did not include a separate compartment for coinfected people [47], or they did not
include a latent state [5], an important feature of TB.
All these models contain many unknown parameters but rely on little data. For
example, it seems that [14,15,32,57,70] were the only ones to fit their parameters by
using real time series of both HIV prevalence (AIDS cases in [70]) and TB notifications.
For the South African township under study, we have two extra pieces of information:
the percentage of HIV+ people among TB notifications and the prevalence of TB at one
time point. These two extra constraints should make our parameter estimations more
robust. Moreover, the township is certainly more homogeneous than whole countries
(the USA in [70], Kenya in [14,15], Zimbabwe in [32]) and less exceptional than a
female prison [57]. Besides, we have focused our attention on one of the simplest
models we could reasonably think of, with a minimum number of compartments and
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Table 2 Review of HIV–TB models
Year References Type of model, area studied, model structure and summary
1992 [4] Static model for sub-Saharan Africa with 2 × 2 − 2 = 2 compartments.
Affine relationship between TB incidence and HIV prevalence
[59] Simulation over 20 years for sub-Saharan Africa (details in [60]). Impact
of assumed HIV prevalence increase on TB incidence
1993 [31] Simulation over 10 years for Uganda with 2 × 4 = 8 compartments. TB
chemoprophylaxis more efficient than treatment
[44] Mathematical analysis of 16 ODEs. Numerical study of the stability of
steady states
1994 [60] Simulation over 20 years for sub-Saharan Africa and Canada structured
by age and time since HIV or MTB infection. Impact of assumed HIV
prevalence increase on TB incidence
1996 [8] Simulation over 10 years for the USA with 3×5−2 = 13 compartments,
3 age groups and drug-resistant TB. Combining TB prevention and
treatment necessary to reach current goals
1997 [70] Simulation over 25 years for the USA with 30 ODEs including homo-
sexuals, drug users and immigration. More data on HIV status of TB
cases needed
1998 [21] Simulation over 22 years for the whole World with age structure. Model
details no longer on journal website. Impact of WHO TB-strategy on
number of deaths
[51] Simulation over 32 years for the whole World with 2 × 19 = 38 ODEs.
Estimation of the size of the TB problem
2000 [17] Simulation over 30 years for the USA structured by age, sex, ethnicity
and location. 14 compartments in TB sub-model
2001 [55] Stochastic simulation over 2 years for the USA with 5 × 6 = 30 com-
partments. Size of TB outbreaks are very sensitive to TB treatment
rate
2002 [56] Mathematical analysis for Brazil of 3 × 3 − 1 = 8 ODEs. Bifurcation
diagram of steady states. TB transmission occurs in prisons
2003 [14] Simulation over 20 years for Kenya, Uganda and South Africa with
3 × 6 = 18 compartments. Improving TB detection and treatment
more efficient than other interventions
[57] Mathematical analysis for Brazil of 3 × 3 − 2 = 7 ODEs. Stability of
steady states
[58] Mathematical analysis of 3 ODES and of a stochastic spatial model for
South East Asia. HIV maybe unable to invade populations with high
TB burden
2004 [29] Simulation over 20 years for Uganda of 2 × 5 + 1 = 11 ODEs with
constant HIV prevalence and BCG vaccination. TB chemoprophylaxis
for HIV+ has a small impact on total TB burden
2005 [1] Simulation over 20 years for Russia with 3 × 18 = 54 compartments.
Impact of cure rates for drug-resistant TB on number of deaths
[72] Simulation over 40 years for India. Model details not shown. ART nec-
essary to reach Millennium Development Goals for TB
[15] Simulation over 20 years for Kenya with 2 × 6 = 12 compartments.
Improving TB detection and treatment more cost-effective than ART
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Table 2 continued
Year References Type of model, area studied, model structure and summary.
2006 [10] Simulation over 30 years for sub-Saharan Africa of 2 × 22 + 1 = 45
ODEs. TB chemoprophylaxis speeds up the emergence of drug
resistant TB
[20] Simulation until steady state for sub-Saharan Africa with 3 × 8 = 24
compartments. Impact of better TB diagnostic techniques compared
with other interventions
[32] Stochastic simulation over 70 years for Zimbabwe with 3 × 6 = 18
compartments. 10,000 people in households. Work in progress
2007 [2] Simulation over 10 years for Russia with 3 × 18 = 54 compartments as
in [1]. High ART coverage necessary with drug-resistant TB
2008 [63] Mathematical analysis of 4×4−1 = 15 ODEs with reinfection. Stability
of steady states. Backward bifurcation for TB
3 The model
The compartmental structure of our model combines two states for HIV (HIV− and
HIV+) with three states for TB (susceptible, latent TB and active TB as in [46,48,
64]). The notations for the resulting six compartments are shown in Table 3. The
subscript 1 always refers to HIV− people and the subscript 2 to HIV+ people. People
in compartments E1, E2, I1 and I2 are those infected with MTB.
The parameters of the model are shown in Table 4. The physiological parameters are
more or less the same for people throughout the world or at least for people living in sub-
Saharan Africa: the death rates µ1 and µ2, the TB parameters p1, p2, q1, q2, a1, a2, m1
and m2. On the contrary, the “social” parameters depend on the area under study, in par-
ticular on population density and living conditions (the transmission rates k1 and k2),
access to TB clinics (the detection rates γ1 and γ2), quality of treatment (ε1 and ε2),
sexual habits and local cofactors for the transmission of HIV such as other sexually
transmitted diseases and male circumcision (d), speed at which information on HIV
diffuses (λ) or epidemic history (t0). Estimates for most physiological parameters can
be found in the medical literature. All “social” parameters have to be estimated from
local data.
Table 3 The six compartments
of the model and some notations
S1 Number of HIV− people who are not infected with MTB
S2 Number of HIV+ people who are not infected with MTB
E1 Number of HIV− people with latent TB
E2 Number of HIV+ people with latent TB
I1 Number of HIV− people with active TB
I2 Number of HIV+ people with active TB
P Total population: P = S1 + E1 + I1 + S2 + E2 + I2
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Table 4 The 22 parameters of the model and some extra notations (subscript 1 for HIV− people, subscript
2 for HIV+ people)
B Birth rate
µ1, µ2 Death rate of people who do not have active TB
k1, k2 Maximum transmission rate of MTB
p1, p2 Proportion of new infections with fast progression to TB
q1, q2 Proportion of reinfections with fast progression to TB
a1, a2 Progression rate from latent TB to active TB
β1, β2 Recovery rate from active TB without treatment
γ1, γ2 Detection rate of active TB cases
ε1, ε2 Probability of successful treatment for detected active TB cases
m1, m2 Death rate for active TB cases
d Maximum transmission rate of HIV
λ Parameter representing behavior change
t0 Time of introduction of HIV
p′1, p′2 Proportion with slow progression to TB: p′1 = 1 − p1, p′2 = 1 − p2
b1, b2 Recovery rate from TB: b1 = β1 + γ1 ε1, b2 = β2 + γ2 ε2
f (H) Reduced transmission rate of HIV: f (H) = d e−λ H
The equations of our model are
d S1
dt
= B − S1 (k1 I1 + k2 I2)/P − µ1 S1 − f (H) H S1 , (1)
d E1
dt




= (p1 S1 + q1 E1)(k1 I1 + k2 I2)/P − (b1 + m1) I1 + a1 E1 − f (H) H I1 ,
(3)
for HIV− people and
d S2
dt
= −S2 (k1 I1 + k2 I2)/P − µ2 S2 + f (H) H S1 , (4)
d E2
dt




= (p2 S2 + q2 E2)(k1 I1 + k2 I2)/P − (b2 + m2)I2 + a2 E2 + f (H) H I1 ,
(6)
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Fig. 1 Flows between the compartments of the model. Here, i = (k1 I1 + k2 I2)/P and g(H) = f (H) H
Table 5 Correspondence between some medical vocabulary and the model
TB notification rate (γ1 I1 + γ2 I2)/P
MTB infection rate (k1 I1 + k2 I2)/P
“total” TB incidence rate T = a1 E1 + a2 E2
+ (p1S1 + p2 S2 + q1 E1 + q2 E2)(k1 I1 + k2 I2)/P
TB incidence rate T/P
MTB prevalence (E1 + I1 + E2 + I2)/P
TB prevalence (I1 + I2)/P
“Styblo’s ratio” 1,000×(TB incidence rate)/(MTB infection rate)
Endogenous reactivation (%) (a1 E1 + a2 E2)/T
Exogenous reinfection (%) (q1 E1 + q2 E2)(k1 I1 + k2 I2)/T/P
Primary disease (%) (p1S1 + p2 S2) (k1 I1 + k2 I2)/T/P
Table 5 shows the correspondence we will use between some medical vocabulary
and our model. The TB notification rate is the rate at which people in compartments
I1 and I2 are detected (only a fraction ε1 or ε2 of these really move back to the latent
compartments E1 and E2). The TB incidence rate is the rate at which people enter the
compartments I1 and I2 divided by the total population usually given “per 100,000
population per year”. The MTB infection rate (the continuous-time analogue of the
annual risk of infection) is the rate at which people in compartments S1 (resp. S2)
move to compartments E1 or I1 (resp. E2 or I2). MTB prevalence is the proportion of
the total population in compartments E1, I1, E2 or I2. TB prevalence is the proportion
of the total population in compartments I1 or I2. It includes active TB cases, i.e., either
undiagnosed TB cases or TB cases that have been detected but that are unsuccessfully
treated. We use the expression “Styblo’s ratio” to refer to the ratio between TB inci-
dence rate (any form of TB) and MTB infection rate (1,000×). In the literature, the
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TB notifications) and the corresponding value has often been assumed to be constant
and equal to 50 for HIV− populations. In other words, an infection rate of 1% per
year corresponds to an incidence rate of 50 smear-positive cases per 100,000 per year,
or about 100 cases (smear positive and smear-negative) per 100,000 per year. This
hypothesis is usually called “Styblo’s rule” [6]. However, as we will see in Table 7,
Styblo’s ratio can no longer be assumed to be the same in areas with a high prevalence
of HIV. This remark raises some doubts concerning the method used by Schulzer
et al. [59]. Endogenous reactivation is the contribution to the TB incidence coming
from compartments E1 or E2 at a constant rate a1 or a2, exogenous reinfection is the
contribution coming from compartments E1 or E2 at a rate depending on the number
of active TB cases I1 and I2. Primary disease is the contribution coming directly from
compartments S1 and S2 after infection.
A number of key points should be borne in mind:
• At time t0, we assume that one HIV+ person is introduced in an HIV-free steady
population where TB is endemic. We chose this first HIV case to be in state S2.
The formulas for S1, E1 and I1 at the endemic TB steady state will be given in
Sect. 4.1.
• Age and sex are not taken into account. In particular, the model cannot distinguish
different routes of transmission of HIV, such as sexual transmission and mother-
to-child transmission. We did not distinguish pulmonary from extra-pulmonary
TB, smear-positive (infectious) TB from smear-negative (non-infectious) TB in
order to reduce the number of compartments to a minimum.
• Drug-resistant TB is still very limited in the South African township under study.
The efficiency of BCG vaccination is also unclear. We have not included these
aspects in our model.
• In Eq. (1), the birth rate is assumed to be a constant independent of the number of
people who die of HIV and/or TB. Therefore, our model considers the evolution
of cohorts with a fixed size at birth. This is not unreasonable if we use only data
on the prevalence of HIV, i.e., the percentage of the population with HIV (not the
total number of HIV-infected people), and on the TB notification rate per 100,000
population per year (not the total number of TB notifications during 1 year). If we
assumed that deaths are replaced by new “immigrants”, we would have to specify
their TB and HIV status, something for which it is difficult to get any information.
If on the other hand we assumed that births are proportional to the population,
then a steady state analysis would become impossible. The demography of the
township is in fact quite complex. The population has grown considerably over the
past decade. The age pyramid is skewed with more young adults and few children
and old people. There are also population inflows and outflows.
• In Eqs. (1) and (4), we chose the “standard form” for TB infection and reinfection
as in [24,63,64], and not the “mass action” form used e.g. in [26,46,48]. With a
constant birth rate, the total population decreases as the HIV epidemic develops. If
we used the “mass action” form for TB transmission, the transmission rate would
also decrease and this would artificially slow down the TB epidemic.
• In Eqs. (1)–(3), we also chose the “standard form” for the transmission of HIV
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diseases. Following [73] and unlike [63], we assumed however, that the trans-
mission rate is an exponentially decreasing function of HIV prevalence to reflect
behavioral changes as HIV awareness develops in the HIV− population. Refer-
ence [73, Suppl.] showed that this special function gives a good fit to HIV infection
rate data from another survey in South Africa. It is essential to keep HIV prevalence
at realistic levels in a model with no heterogeneity in sexual behavior.
• All other terms are linear. In reality, the rate of progression to active TB is a function
of the time since infection, the rate being high during the first 1 or 2 years and
relatively low for the rest of one’s life [68]. Of course, it is possible to put this
into equations [25]. But to keep the number of parameters in the model as small
as possible, we have assumed as in [26,46,48,54,64] that a certain fraction of new
MTB infections develops active TB immediately, the rest entering a latent state
with a constant rate of progression to active TB. Similarly, a certain fraction of
reinfections is assumed to lead immediately to active TB as in [24,26,46,48,64].
The other reinfections are “lost” as these people are already latently infected.
• Notice how the equations model people that are unsuccessfully treated for TB. They
are counted in the TB notification rate γ1 I1 + γ2 I2, and induce lower recovery
rates b1 = β1 + γ1 ε1 and b2 = β2 + γ2 ε2 among active TB cases. But they are
not counted in a separate compartment.
4 Mathematical analysis
The disease-free steady state with no TB and no HIV is given by S01 = B/µ1 and
E1 = I1 = S2 = E2 = I2 = 0.
4.1 TB only
Background. The model with TB but no HIV consists only of three compartments
(S1, E1, I1) satisfying Eqs. (1)–(3) with I2 = 0, H = 0, and P = S1 + E1 + I1:
d S1
dt
= B − k1S1 I1/P − µ1S1 , (7)
d E1
dt
= (p′1 S1 − q1 E1) k1 I1/P − (a1 + µ1) E1 + b1 I1 , (8)
d I1
dt
= (p1 S1 + q1 E1) k1 I1/P − (b1 + m1) I1 + a1 E1 . (9)
These equations are up to notations the same as those considered by Singer and
Kirschner in [64, Sect. 3]. Building on one side on the earlier work by Feng et al. [24]
on a model with four compartments (one more compartment for recovered people)
including reinfection but no primary progression (see also the review in [9, Sect. 4.5])
and on the other side on the remarks made by Lipsitch and Murray [42] on the model
in [24], reference [64] aimed to show that for a model including all three routes to TB
(primary progression, reactivation, and reinfection), a backward bifurcation occurred
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realistic (as noticed in [42]). In our opinion, there are two weak points in the analysis
presented in [64, Sect. 3]. The first point is that, following the idea used in [42], realistic
parameters have to satisfy the inequality q1 ≤ p1, as latent TB tends to protect against
fast progression to active TB in case of reinfection [68]. This inequality did not appear
in [64]. The second weak point is that the threshold given in [64, Eq. (7)] is estimated
using Latin hypercube sampling of a set of parameter values. With such a method, the
conclusion reached is probable but not sure, and can depend on the choice of the set of
parameter values. We will show below that the backward bifurcation occurs when q1
is above a threshold q∗1 which is always bigger than p1. This proves that the backward
bifurcation does not occur for realistic parameter values. Finally, [64] did not show
the details of their analysis of the steady states, emphasizing only the conclusions. For
our study, we need the formula for the endemic steady state with TB only, as it serves
as the initial condition for the full model with both TB and HIV.
One should also mention here the work of Moghadas et al. [46,48] on a model
similar to Eqs. (7)–(9) but with “mass action” instead of “standard” incidence. Their
model also assumes implicitly that people who have recovered from TB are protected
for the rest of their life (they do not return to the latent state), a somewhat unrealistic
hypothesis. Formally, this corresponds to the case b1 = 0 in our model. Despite the
remarks made by Lipsitch and Murray [42], reference [48] claimed that this backward
bifurcation could occur for realistic parameter values. Notice, however, that the para-
meter values used in [48] for k1, p1, and the product k1q1 do not satisfy the inequality
q1 ≤ p1, so they seem to be unrealistic.
Recently, as a part of their analysis of an HIV–TB model, Sharomi et al. [63] studied
an extension of the TB-model with four compartments and reinfection introduced by
Feng et al. [24]. Again, much emphasis was put on backward bifurcation, which was
shown to occur if the ratio q1/p1 was above a certain threshold. But this threshold
may be bigger than 1 (it is hard to say if this is always so as the formulas for models
with four compartments are very complicated). And indeed, the authors chose the
unrealistic ratio q1/p1 = 3 (called ηr in [63]) to illustrate their results.
Analysis. Linearizing system (7)–(9) near the disease-free steady state, we obtain
d E1
dt
 k1 p′1 I1 − (a1 + µ1) E1 + b1 I1 ,
d I1
dt
 k1 p1 I1 − (b1 + m1) I1 + a1 E1 .






a1 + µ1 −b1
−a1 b1 + m1
)−1
,
which can easily be computed:
RTB0 =
k1(a1 + p1 µ1)











Modeling the joint epidemics of TB and HIV in a South African township
Because this formula does not depend on the reinfection parameter q1, it is the same
as [49, Eq. (10)]. When b1 = 0 and p1 = 0, it is the same as the formula given in
[24, Sect. 1]. A slightly more intuitive way of deriving (10) consists in writing that
RTB0 is the expected number of secondary infectious cases produced by one infectious
index case in an otherwise disease free population. This index case transmits MTB to
k1 people per unit of time and stays infectious on average 1/(b1 + m1) units of time.
Moreover, each new infected person will be immediately infectious with a probability
p1 and infectious only after reactivation with a probability (1 − p1) a1/(a1 + µ1).
Finally, the index case can become infectious again after recovering (possibly several
times), with a probability which is the product of b1/(b1 + µ1) and of a1/(a1 + µ1).
















gives indeed the same result as (10). Since the probability a1/(a1 +µ1) of developing
active TB by reactivation is small, a good approximation for RTB0 would be obtained
by replacing the infinite sum in (11) by its first term, which is equal to 1.
Let us look for an endemic TB steady state of the form (S∗1 , E∗1 , I ∗1 , 0, 0, 0) of
system (1)–(6) with S∗1 > 0, E∗1 > 0, and I ∗1 > 0, i.e., a nontrivial steady state
(S∗1 , E∗1 , I ∗1 ) of system (7)–(9). For convenience, let us introduce the following nota-
tions:
P∗ = S∗1 + E∗1 + I ∗1 , s∗1 = S∗1/P∗, e∗1 = E∗1/P∗, i∗1 = I ∗1 /P∗. (12)
After some tedious computations, one can show starting from Eqs. (7)–(9) that the












+ a1m1 + m1µ1 + µ1b1
q1k21
(1 − RTB0 ) = 0. (13)
Moreover, we have
e∗1 = i∗1






from which we can compute
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Quadratic equations similar to Eq. (13) were found in [24, Eq. (A.1)] and [46, Eq. (5.3)].
Set
k∗1 =
a1m1 + m1µ1 + µ1b1
a1 + p1µ1 . (16)
and
q∗1 =
a1 + b1 + (1 − p1) m1 + p1µ1




Because of (10), we have RTB0 = k1/k∗1 . So RTB0 < 1 when k1 < k∗1 , and RTB0 > 1
when k1 > k∗1 . Let us study the steady states of Eqs. (7)–(9) in the parameter space
(k1, q1). In the appendix, we show that:
• for q1 < q∗1 , system (7)–(9) has no endemic steady state when 0 < k1 < k∗1 , and
one endemic steady state when k1 > k∗1 (“transcritical bifurcation” as k1 increases
from 0 to +∞);
• for q1 > q∗1 , there exists another threshold k̂1(q1) < k∗1 , depending on q1, such that
system (7)–(9) has no endemic steady state when 0 < k1 < k̂1(q1), two endemic
steady states when k̂1(q1) < k1 < k∗1 , and one endemic steady state when k1 > k∗1
(“backward bifurcation”).
Notice that the first fraction in (17) is bigger than 1 and that the second fraction
is bigger than p1. So q∗1 is always bigger than p1. But realistic values for q1 are
necessarily less than p1, as already mentioned. This shows that the parameter region
with a backward bifurcation is a mathematical curiosity that does not occur in practice,
confirming the remarks in [42] and the conclusion suggested by [64]. Notice that
formula (17) for q∗1 could have been obtained in [64] if the expression (16) for k∗1 had
been inserted in the condition [64, Eq. (7)].
4.2 HIV only
When there is no TB, system (1)–(6) reduces to
d S1
dt
= B − µ1 S1 − f (H) H S1 , d S2
dt
= −µ2 S2 + f (H) H S1 (18)
with H = S2/(S1 + S2). Similar epidemic models with a contact rate depending
nonlinearly on the number of infected people have been studied for example in [30,
69]. A more complicated model for HIV transmission with a contact rate depending
nonlinearly on the prevalence was used in [73]. First, let us linearize the second
equation in (18) near the disease-free steady state S1 = S01 and S2 = 0:
d S2
dt
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Hence, the basic reproduction number for HIV is given by
RHIV0 = f (0)/µ2 .
It is easily shown using (18) that any endemic steady state with HIV but no TB has to
be given by
Ŝ1 = B (1 − Ĥ)
µ1(1 − Ĥ) + µ2 Ĥ
, Ŝ2 = B Ĥ
µ1 (1 − Ĥ) + µ2 Ĥ
,
where Ĥ is the steady state prevalence of HIV, Ŝ2/(Ŝ1 + Ŝ2), and is the solution of
the equation
(1 − Ĥ) f (Ĥ) = µ2 (19)
in the interval (0, 1). Notice that the left side of (19) is a decreasing function of Ĥ ,
taking the value f (0) = d when Ĥ = 0 and the value 0 when Ĥ = 1. So Eq. (19) has
no solution in (0, 1) if RHIV0 < 1 and exactly one solution in (0,1) if R
HIV
0 > 1.
4.3 HIV and TB
The endemic TB steady state can be invaded by HIV. Linearizing system (4)–(6) near
this steady state and using the notations introduced in (12), we obtain
d S2
dt
 −k1S2 i∗1 − µ2 S2 + f (0) s∗1 (S2 + E2 + I2) ,
d E2
dt
 k1 (p′2 S2 − q2 E2) i∗1 − (a2 + µ2) E2 + b2 I2 + f (0) e∗1 (S2 + E2 + I2) ,
d I2
dt
 k1 (p2 S2 + q2 E2) i∗1 − (b2 + m2) I2 + a2 E2 + f (0) i∗1 (S2 + E2 + I2) .
So the basic reproduction number rHIV0 for HIV when introduced in a population at
the TB endemic steady state (notice that rHIV0 is different from R
HIV
0 ) is the spectral











k1i∗1 + µ2 0 0
−k1 p′2 i∗1 k1q2 i∗1 + a2 + µ2 −b2





Notice that this matrix is of rank 1 so the spectral radius is equal to the trace. Hence,
one gets
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where τS2 , τE2 and τI2 are complex expressions with a simple interpretation. For
example, τS2 is the life expectation of a person from the moment he/she enters state S2
(in the linearized model). In particular, τS2 , τE2 and τI2 are all strictly less than 1/µ2




Not surprisingly, the expected number of secondary HIV-cases produced by an
“average” HIV+ person in a population with endemic TB is less then in a popula-
tion with no TB since active TB may shorten the life of such a person.
Similarly, the endemic steady state with HIV can be invaded by TB. Linearizing
Eqs. (2)–(3)–(5)–(6) near (Ŝ1, 0, 0, Ŝ2, 0, 0) and setting




 p′1ŝ1(k1 I1 + k2 I2) − (a1 + µ1) E1 + b1 I1 − f (Ĥ) Ĥ E1 ,
d I1
dt
 p1ŝ1(k1 I1 + k2 I2) − (b1 + m1) I1 + a1 E1 − f (Ĥ) Ĥ I1 ,
d E2
dt
 p′2ŝ2 (k1 I1 + k2 I2) − (a2 + µ2) E2 + b2 I2 + f (Ĥ) Ĥ E1 ,
d I2
dt
 p2ŝ2 (k1 I1 + k2 I2) − (b2 + m2)I2 + a2 E2 + f (Ĥ) Ĥ I1 .
So the basic reproduction number rTB0 for TB when introduced in a population at the




0 p′1k1ŝ1 0 p′1k2 ŝ1
0 p1k1ŝ1 0 p1k2 ŝ1
0 p′2 k1ŝ2 0 p′2k2 ŝ2








a1 + µ1 + f (Ĥ) Ĥ −b1 0 0
−a1 b1 + m1 + f (Ĥ) Ĥ 0 0
− f (Ĥ) Ĥ 0 a2 + µ2 −b2




Whether rTB0 is bigger or smaller than R
TB
0 seems to depend on the numerical values
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Assuming realistically that q1 ≤ p1 (so that there is no backward bifurcation for
the model with TB but no HIV), this linear stability analysis suggests the following
conjecture:
• when RHIV0 < 1 and RTB0 < 1, the disease-free steady state is a global attractor of
system (1)–(6);
• when RHIV0 > 1 and rTB0 < 1, the HIV-endemic steady state is a global attractor;
• when RTB0 > 1 and rHIV0 < 1, the TB-endemic steady state is a global attractor;• in all other cases, there is an endemic steady state with both HIV and TB, which
has to be computed numerically, and which is a global attractor.
Since RHIV0 > r
HIV
0 , the fourth case contains in fact only two subcases:
• RHIV0 > 1, rTB0 > 1, RTB0 > 1 and rHIV0 > 1. Both the HIV-endemic and the
TB-endemic steady states exist but they are saddle points.
• RHIV0 > 1, rTB0 > 1, and RTB0 < 1. The HIV-endemic steady state exists but it is a
saddle point. There is no TB-endemic steady state.
5 Parameter values fixed after reviewing the medical literature
5.1 Demographic parameters
Natural mortality was taken to be µ1 = 0.02 per year as e.g. in [10], corresponding
to a life expectancy equal to 1/µ1 = 50 years. This is a little pessimistic even for an
area where people live in severe poverty, such as the South African township we are
considering. The mortality was assumed to be 0.0064 per year in [31], 0.0081 per year
in [29], and 0.0167 per year in [56]. Notice that the mortalities in [29,31] correspond
to life expectancies which are much too high.
The birth rate B was chosen to attain a total population for the disease-free steady
state (S1 = B/µ1) of 10,000, the approximate size of the township [35]. This yields
B = 200 per year.
5.2 HIV parameters for people not infected with MTB
Mortality for HIV+ people was taken to be µ2 = 0.1 per year as is usually done (see
e.g. [10]) to get an average survival time of 10 years. This mortality was 0.13 per year
in [31] and in [29] (citing a study from Uganda [53]). Schulzer et al. [59] assumed a
fixed survival time of 10 years.
5.3 TB parameters for HIV− people
Parameters p1 and a1 modeling the progression to active TB. As already mentioned,
the rate of progression to active TB is a decreasing function of the time since infection.
Using data from the Netherlands for the period 1951–1970, Sutherland et al. [65]
estimated that men have a 5% annual risk of developing primary TB disease during
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after 5 years. For women, the numbers were 6 and 0.002%. Vynnycky and Fine [68]
did a similar study using data from England and Wales for the period 1953–1988.
For individuals over 20 years old, they estimated that the cumulative risk during the
first 5 years was about 14%, with a risk of approximately 8% during the first year, 3%
during the second, 1% during the third year. The risk of later reactivation was estimated
to be 0.03% per year. For individuals aged 0–10 and 15, the cumulative risks for the
first 5 years were 4 and 9% and the risks of reactivation close to 0 and 0.015% per
year, respectively. Notice that the cumulative risk during the first 5 years in [65] is
about 25%, considerably higher than the 14% from [68]. Our model does not include
the time since infection as a variable but assumes instead that a certain fraction of new
infections will develop TB immediately while the rest will enter a latent stage where
the rate of progression to active TB is constant. Following the more recent estimates
of Vynnycky and Fine [68], we will assume that p1 = 11% (the estimated cumulative
risk for the first 2 years) and a1 = 0.03% per year.
Given the natural mortality µ1 previously chosen, these parameter values corre-
spond to a probability a1/(a1 + µ1)  1.5% of progressing from latent to active TB
and to a total probability p1 + a1/(a1 + µ1)  12.5% of developing active TB after
MTB infection. Notice that it is not sure if parameter estimates of TB progression
from a study of British people are relevant for black Africans living in very different
conditions. More data is needed on this issue.
As a comparison, the percentage of HIV− people that progress rapidly to active
TB in previous mathematical models was assumed to be 5% in [59] (within 1 year; no
reference), 5% in [70] (after a short latent period of about 1 year; no reference), 5%
in [29] (immediate progression; no reference), 5% per year in [56] (constant risk; no
reference), 7% in [20] (immediate progression; citing [67]), 14% in [10] (after a short
latent period of about 1 year; citing [65] and other references), 14% in [32] (within
5 years; citing [65,68] and other references). The rate of reactivation was assumed
to be 0.01% per year in [10] (citing [68] and other references), 0.074% per year in
[29], 0.1% per year in [20], and 0.1% per year in [32] (after 5 years of infection, also
citing [68]). Both [59] and [70] used more complex models taking into account the
time since infection. Notice the disagreement concerning parameter values.
Infection versus reinfection: q1/p1. Sutherland et al. [65] estimated that a previous
MTB infection reduced the risk of disease after reinfection by 63% for HIV− males
and by 81% for HIV− females. Vynnycky and Fine [68] found a reduction of risk
by 16% among HIV− adolescents and by 41% among HIV− adults. In their model,
Cohen et al. [10] assumed a reduction of risk of 65% for HIV− people (citing [65,68]).
Dowdy et al. [20] assumed a reduction by 72% for HIV− people and people with early
stage HIV (citing [65]). The two previous studies seem to follow the results of [65]
rather than the more recent results of [68]. Here, we prefer using an average of the
values found in [68]. We assume that q1/p1 = 0.7, corresponding to a 30% risk
reduction for HIV− people.
Mortality m1 and natural recovery rate β1. Data on TB mortality without treatment
goes back to the era when no effective treatment was available, that is at the beginning











Modeling the joint epidemics of TB and HIV in a South African township
50%. This is the estimate mentioned in the review [50]. Another review [13, Table 1]
estimated that the mean duration of disease for untreated HIV− TB cases [1/(m1+β1)]
was approximately 2 years. These two estimates for 1/(m1 + β1) and m1/(m1 + β1)
correspond to m1 = 0.25 per year and β1 = 0.25 per year. These are the values that we
shall use for our model. Another model assumed 35% deaths after 1 year [31, p. 407].
In those models that considered different mortalities for infectious and non-infectious
untreated TB cases, the mortalities were 0.3 and 0.2 per year, respectively [10], or 35
and 10% after 1 year [20]. The rate at which untreated HIV− TB cases could return
to the latent state [β1] was assumed to be 0.2 per year in [10]. All these values are not
too far from the ones we have chosen.
5.4 Parameters involving both HIV and TB
The infectiousness ratio k2/k1. HIV+ TB cases are on average less infectious than
HIV− TB cases as extrapulmonary TB occurs more often among HIV+ people. Previ-
ous models have often split the compartments for active TB cases (whether HIV− or
HIV+) in two, with one sub-compartment for infectious TB and one sub-compartment
for non-infectious TB. The percentages of HIV− and HIV+ TB cases that are infec-
tious were 50 and 40% in [59], 57 and 50% in [29], 45 and 30% in [10]. In the present
model, we do not distinguish those TB cases that are infectious from those that are not
infectious. Instead, we use an average infectiousness k1 for all HIV− TB cases and an
average infectiousness k2 for all HIV+ TB cases. Given the structure of our model,
the difference in infectiousness can be taken into account by choosing an appropriate
value for the ratio k2/k1. Following the numerical values from [10], we assume that
k2/k1 = 30/45 = 2/3.
Progression rate a2 to active TB for HIV+ people. As for HIV− people, the rate of
progression from latent to active TB depends on the time since infection but also on
the stage of HIV infection. However, our model does not distinguish HIV stages, so
we will focus only on estimates that are averages over all stages. For HIV+ injecting
drug users in the USA, Selwyn et al. [61,62] found an average rate of progression
between 0.079 and 0.097 per year. In Cape Town, Badri et al. [3] found an average TB
incidence (including reactivation, fast progression, and reinfection) of 0.097 per year.
But the incidence of TB was as high as 0.24 per year among HIV+ people in WHO
stage 3 or 4 [3]. Following [61,62], we assume for the reactivation rate of our model
that a2 = 0.08 per year, an estimate which seems also compatible with the data from
[3]. Heymann [31] also used the estimate from [61,62] in his model. Other studies
used 0.0074 per year [29] (assuming a ten-fold increase compared to HIV− people),
0.05 per year [56], or 0.17 per year [10] (no reference). Schulzer et al. [59] used a
more complicated model distinguishing whether MTB infection occurred before or
after HIV infection. Notice again the disagreement concerning parameter values.
Infection versus reinfection: q2/p2. Data concerning reinfection in HIV+ people is
scarce. In the outbreak of TB studied by Di Perri et al. [19], none of four individuals that
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reduction of risk of 25% for HIV+ people [10, Suppl., Table 2] (no reference). Dowdy
et al. [20] assumed a reduction by 25% for people with AIDS (citing [14]). Here, we
will assume as in [10] that q2/p2 = 0.75. But more data is needed to confirm this
hypothesis. Recall that for HIV− people, we assumed that q1/p1 = 0.7.
Mortality m2 and natural recovery rate β2. The mortality of HIV+ TB cases [m2] was
assumed to be 0.325 per year in [29] (citing [23]) and 1.0 per year in [10] (citing [53])
for both infectious and non-infectious TB. The rate at which untreated HIV+ TB cases
could return to the latent state [β2] was 0.1 per year in [10]. For our model, we will
again use the data from [13, Table 1]: the mean duration of disease for untreated HIV+
TB cases [1/(m2 + β2)] was given as 0.5 year. In the same reference, the associated
case fatality ratio [m2/(m2 +β2)] was 81% for infectious TB (35% of cases) and 76%
for non-infectious TB (65% of cases): we use the weighted average, which is close
to 80%. These two estimations for 1/(m2 + β2) and m2/(m2 + β2) correspond to
m2 = 1.6 per year and β2 = 0.4 per year.
6 Estimation of the other parameters from the South African data
Proportions ε1 and ε2 of successful treatments. The proportion of successful treatments
is approximately 80% [75]. We take this value for ε1 and ε2.
Detection rates γ1 and γ2. [75] reported 259 TB notifications among adults (age≥ 15)
in 2005; 66% of those who were tested for HIV were HIV+. The adult population in
that year was estimated to be 10,400. Moreover, in a sample population of 762 adults,




1  34% × 259, I adult1  10, 400 × 3/762 , (22)
γ2 I
adult
2  66% × 259 , I adult2  10, 400 × 9/762 . (23)
This gives the estimates γ1  2.2 per year and γ2  1.4 per year. But notice that since
the ratios 3/762 and 9/762 are small, the uncertainty is large: the 95% binomial confi-
dence interval for the ratios 3/762 and 9/762 are (0.08%, 1.15%) and (0.54%, 2.23%),
respectively. Using Eqs. (22)–(23), the corresponding interval for γ1 is (0.74, 10.6)
per year, and the one for γ2 is (0.74, 3.0) per year. Corbett et al. [12] suggest that γ2
may be larger than γ1. For our model, we chose the lower bound of the confidence
interval for γ1 (γ1 = 0.74 per year) and the upper bound of the confidence interval for
γ2 (γ2 = 3.0 per year). One motivation was that recent unpublished data shows that
the MTB infection rate in the past few years has not increased so much. In our simu-
lations, we found that this was only possible with values of γ2 that are several times
higher than γ1. Indeed, the great increase in TB notifications has to be compensated
by a shorter infectious period to keep the MTB infection rate at a relatively low level.
With these choices, we obtain b1 = β1+γ1ε1  0.84 per year and b2 = β2+γ2ε2 
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and b2 were both equal to 0.3 per year, but case detection is probably not as good as
in the South African township under study here.
We notice also that the probabilities for TB to be detected are given by
γ1
m1 + β1 + γ1  60%,
γ2
m2 + β2 + γ2  60% .
Despite the high death rate m2, the detection probability for HIV+ TB cases is the
same as for HIV− because of the high value of γ2 used here. Recall that the target set
by the World Health Organization for case detection is 70%. The average durations of
disease are
1
b1 + m1  0.92 year ,
1
b2 + m2  0.23 year .
As a comparison, Corbett et al. [12] estimated the duration of (smear-positive) disease
before diagnosis to be 1.15 and 0.17 year for HIV− and HIV+ South African gold
miners, respectively.
MTB transmission rate k1. The average TB notification rate in the decade before 1995
in South Africa, i.e. before the rise of HIV prevalence, was about 200 per 100,000
per year (see [74] and [76, p. 184]). This is also a reasonable estimate for the town-
ship under study given the data from Table 1. In our model, the TB notification rate
when there is no HIV is γ1 i∗1 . Using Eq. (13) for i∗1 , it is possible to estimate the
only unknown parameter left: k1. We take k1 = 11.4 per year, which corresponds to
a TB notification rate of 203 per 100,000 per year. In the review [50], each HIV−
person with undiagnosed and untreated smear-positive TB was believed to cause
10 to 14 infections per year. If smear-positive cases make half of all cases, an “aver-
age” HIV− TB case would cause 5–7 infections per year. This range is consistent
with our estimate k1 = 11.4 per year for the maximum infection rate in a completely
susceptible population and with our estimate of nearly 1 year for the average duration
of disease 1/(b1 + m1). If for example x = 60% of the population is already infected
with MTB, one active TB case infects about x k1/(b1 + m1) susceptible people.
HIV parameters d, λ and t0. Summing the three equations (1)–(3) for HIV− people
and the three equations (4)–(6) for HIV+ people, setting X1 = S1 + E1 + I1 and
X2 = S2 + E2 + I2, and noticing that the prevalence of HIV is H = X2/(X1 + X2),
we obtain the system
d X1
dt
= B − µ1 X1 − f (H) H X1 + (µ1 − m1) I1 , (24)
d X2
dt
= −µ2 X2 + f (H) H X1 + (µ2 − m2) I2 . (25)
To get a first estimation of d , λ and t0, we neglect the terms involving I1 and I2 (active
TB cases form a very small proportion of the population). The resulting system involves
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X1(t0) = B/µ1 and X2(t0) = 1, a good fit to HIV prevalence data from Table 1 is
obtained with the parameters d = 0.7/year, λ = 5.9, and the year t0 = 1984 for the
beginning of the HIV epidemic. Three parameters are necessary and usually sufficient
to fit any set of increasing numbers resembling the logistic curve, as is the case here.
Recall that d, λ and t0 cannot be taken from studies of other areas.
The parameter p2 for fast progression to TB among HIV+ people. In 1989, Di Perri
et al. [19] studied an outbreak of TB among HIV+ people: after the index case,
eight people developed TB rapidly and six had a newly positive tuberculin skin test,
suggesting that 8/14  57% of newly infected HIV+ people develop primary TB
disease. In 1992, Daley et al. [16] studied a similar outbreak and found a proportion
equal to 11/15  73%. But it is possible that only large outbreaks are studied, and that
outbreaks with less cases of primary TB disease either are not noticed or are not a good
subject for publication. A similar bias would occur if we based our estimate for the
probability of fast progression to TB among HIV− people on reports of TB outbreaks
such as the one investigated in [33], during which 14 out of 41 newly infected people
(34%) developed primary disease. As a result, we prefer to let p2 vary in order to fit the
data concerning the TB notification rate from Table 4. For this purpose, we simulated
system (1)–(6) starting from the initial condition
S1(t0) = S∗1 , E1(t0) = E∗1 , I1(t0) = I ∗1 , S2(t0) = 1, E2(t0) = 0, I2(t0) = 0.
Notice at this point that all the parameters in Table 1 have already been fixed except
p2. A relatively good fit was obtained with p2 = 30% (plain line in Fig. 2a), i.e.,
nearly 3 times the value p1 for HIV− people. Notice that this value for p2 is still
lower than the ones obtained by studying TB outbreaks among HIV+ people [16,19].
Given the mortality µ2 previously chosen for HIV+ people, the estimates for a2 and
p2 correspond to a probability a2/(a2 +µ2)  44% of progressing slowly from latent
to active TB and to a probability p2 + a2/(a2 + µ2)  74% of developing active
TB after infection by MTB. As a comparison, the percentage of HIV+ people that
progress rapidly (either immediately or within 1 year) to active TB after infection by
MTB was assumed to be 20% in [29] (no reference), 42% in [59] (no reference), 67%
in [10] (citing [16]), and 100% in [70]. In models with a separate compartment for
AIDS such as [20], the percentage was assumed to be 7% for early stage HIV (the
same as for HIV− people) and 56% at the AIDS stage (citing [16,19]).
All the parameter values have now been fixed and are summarized in Table 6.
The percentage of HIV+ TB notifications. The dashed line in Fig. 2a shows the con-
tribution of HIV+ people to the TB notification rate, as given by the simulation of
the full model (1)–(6) with the parameters from Table 6. The curve passes close to
the only data point we have (66% HIV+ among TB notifications in 2005 [75]). This
suggests that our parameter estimates are not unreasonable.
Checking the hypothesis used to estimate the HIV parameters d, λ and t0. One can
check if neglecting the terms involving I1 and I2 in (24)–(25) was reasonable. Figure 2b
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TB notification rate (per 100,000 per year)

























MTB infection rate (per year)





Fig. 2 a Data and simulation curve for the TB notification rate. The dashed curve shows the contribution
of HIV+ people (only one data point). b Data and simulation curve for HIV prevalence. c Simulation curve
for the prevalence of active TB. The data point with 95% binomial CI corresponds to the prevalence of
undiagnosed TB among adults, which is higher than for the whole population. d MTB infection rate
Table 6 Numerical values for the parameters of the model
HIV− HIV+
Mortality µ1 0.02/year [10] µ2 0.1/year [10]
TB mortality m1 0.25/year [13] m2 1.6/year [13]
MTB infections k1 11.4/year Fit k2 k1 × 2/3 [10]
Fast route p1 11% [68] p2 30% Fit
Slow route a1 0.0003/year [68] a2 0.08/year [3,61,62]
Reinfection q1 0.7 p1 [68] q2 0.75 p2 [10]
Recovery β1 0.25/year [13] β2 0.4/year [13]
Detection γ1 0.74/year [12,75] γ2 3.0/year [12,75]
Treatment ε1 80% [75] ε2 80% [75]
Births B 200/year [35]
Contact rate d 0.7/year Fit
Prevention λ 5.9 Fit
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Table 6 still gives a reasonably good fit to the HIV data. Notice that the data point with
a 95% binomial confidence interval in Fig. 2b corresponds to the 23% HIV prevalence
(174/762) in the sample population taken in the year 2005 [75].
Other curves. Figure 2c shows the prevalence of undiagnosed TB computed by sim-
ulating the full model (1)–(6) with the parameters from Table 6. The data point with a
95% binomial confidence interval corresponds to the prevalence of undiagnosed TB
among adults (12/762), which should be higher than for the whole population. Hence,
Fig. 2c also suggests that our parameter estimates are not unreasonable. Finally, we
also show the MTB infection rate (Fig. 2d), for which data has been collected recently
but has not yet been published. Recall, however, that our choice for the TB detection
rates γ1 and γ2 was influenced by the knowledge that MTB infection rate had not risen
as steeply as the TB notification rate.
7 Sensitivity of steady states with respect to changes in parameter values
All the parameter having been fixed or estimated (Table 6), we look at the numerical
results following from the mathematical formulas of Sect. 4 for the steady states. First,
the disease-free steady state with no HIV and no TB is S01 = 10, 000. We also obtain
RTB0  1.3 , RHIV0  7.0 , rTB0  1.7 , rHIV0  5.8.
The estimate RTB0  1.3 is close to the range 0.6–1.2 mentioned in the review [50].
Using national HIV prevalence data from antenatal clinics, Williams et al. [71,73]
found a similar result for RHIV0 , namely 6.4 ± 1.6. Notice also that rTB0 > RTB0 : an
“average” person newly infected with MTB will produce more secondary cases if
introduced in a TB-free population where HIV is endemic than if introduced in a
completely disease-free population. This is mainly because this “average” person is
likely to be HIV+, so its probability of progressing to active TB and of infecting other
people is high (this depends on the numerical values of several parameters, including
a2, but not on the structure of the model). Finally, rHIV0 is less than R
HIV
0 as explained
in Sect. 4.3. In some sense, TB slows down the HIV epidemic.
In the following subsections, we study the sensitivity of the different steady states
with respect to the most important parameters of the model, namely those that enter
in the nonlinear terms of system (1)–(6): the TB transmission rates k1 and k2, the
reinfection parameters q1 and q2, and the parameters d and λ for HIV.
7.1 A global look at steady states in the (k1, d) parameter space
Figure 3 shows a bifurcation diagram of the steady states in the (k1, d) parameter
space using the numerical values from Table 6 except of course for k1 and d and
assuming that the ratio k2/k1 is fixed. The black dot near the 2,000 per 100,000
per year level curve for the TB notification rate corresponds to the values of k1 and
d in Table 6. The boundaries between the four domains of the bifurcation diagram






























Fig. 3 Bifurcation diagram in the (k1, d) phase plane and level curves of the steady state TB notification
rate (dashed lines, 500 stands for 500 per 100,000 per year) and of the steady state prevalence of HIV
(dotted lines)
equations RHIV0 = 1, rHIV0 = 1, RTB0 = 1 and rTB0 = 1 with respect to k1 and d. Since
RHIV0 does not depend on k1 and R
TB
0 does not depend on d, the line R
HIV
0 = 1 is
horizontal and the line RTB0 = 1 is vertical. The line rHIV0 = 1 separates “TB” from
“HIV+TB”. The line rTB0 = 1 separates “HIV” from “HIV+TB”.
Notice in Fig. 3 how the level curves for the TB notification rate are distorted as
they cross the line rHIV0 = 1 from the area labeled “TB” to the area labeled “HIV+TB”.
Notification rates near the “reinfection threshold” mentioned in Sect. 4.1 (for example
the 1,000 and 2,000 level curves), which seemed totally unrealistic in the absence of
HIV, occur now for smaller values of the transmission rate k1 if HIV prevalence is
high enough. With k1 = 11.4 per year as in Table 6, the steady state TB notification
rate increases from 200 to 2,000 per 100,000 per year as HIV prevalence increases
from 0 to about 25%.
7.2 The steady state with TB but no HIV
The steady state with TB but no HIV is shown in the left part of Table 7. This is the
steady state used as the initial condition in the simulations for the complete model with
both HIV and TB. Notice that “Styblo’s ratio” (for both smear-positive and smear-
negative cases) is about 100, the value commonly admitted for HIV− populations.
Figure 4 shows how the TB steady state changes if we let k1 and q1 vary. The level
curves of the steady state TB notification rate are also drawn. The black dot on the
200 per 100,000 per year level curve corresponds to the numerical values of k1 and
q1 in Table 6. A similar “hand-drawn” picture without the level curves appears in [24,
Fig. 3]. Some level curves cross each other in the zone of Fig. 4 with two positive
solutions. They are the projections on the plane of level curves on a three-dimensional
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Table 7 Characteristics of the
endemic steady state with TB
only (Sect. 4.1) and with TB and
HIV (Sect. 4.3)
TB only TB and HIV
Total population 9,695 4,161
Susceptible (HIV−) S1 3,904 1,112
Latent TB (HIV−) E1 5,764 2,029
Active TB (HIV−) I1 27 30
Susceptible (HIV+) S2 0 208
Latent TB (HIV+) E2 0 762
Active TB (HIV+) I2 0 20
HIV prevalence 0 24%
TB notification rate/100,000 per year 203 2,005
HIV+ TB notifications 0 74%
MTB prevalence 60% 68%
TB prevalence 0.27% 1.2%
MTB infection rate/year 3.1% 12%
TB incidence rate/100,000 per year 299 2,945
“Styblo’s ratio” 96 222
Reactivation (among TB cases) 6% 50%
Reinfection (among TB cases) 48% 32%


















Fig. 4 TB only. Number of positive steady solutions of (7)–(9) in the parameter space (k1, q1). There is
only one such solution to the right of the vertical line and either 0 or 2 to the left. The level curves of the
steady state TB notification rate (per 100,000 per year) are also shown (dashed lines). Some level curves
cross each other in the area with two solutions
Numerically, the threshold above which two positive steady states can exist is
q∗1  12.5%, while we have chosen q1 = 7.7%. The other threshold separating the
area where there are either 0 or 2 positive solutions from the area where there is
1 solution is k∗1  8.8 per year, while our estimate is k1 = 11.4 per year. The level

























Fig. 5 TB only. Level curves of the percentage of new TB cases due to reinfection in the parameter space
(k1, q1)
in q1. This means that our estimation in Sect. 6 of the parameter k1 (q1 being fixed)
should be considered with caution.
As noticed in [26,64] for a slightly different model, the dependence of the TB
notification rate with respect to q1 is even greater above a certain “reinfection thresh-
old” (see the remarks at the end of the appendix and [7,27] for a dispute over this
terminology). Notice for example how close the 2,000- and 10,000-level curves in
Fig. 4 are. However, notification rates close to 2,000 per 100,000 per year as in the
township under study here (with HIV) are already among the highest ever reported in
a community. So it seems unlikely that TB parameter values for a community without
HIV can be above the “reinfection threshold” as suggested in [26,64].
The percentage of new TB cases due to reinfection is shown as a function of k1
and q1 in Fig. 5. Notice that the vertical scale is not the same as in Fig. 4. A black dot
indicates the numerical values for k1 and q1 from Table 6 that correspond to 45% of
reinfection among new TB cases.
7.3 The steady state with HIV but no TB
In our model, the steady state with HIV but no TB is given by Ŝ1  3,450, Ŝ2  1,310,
and Ĥ  28%. The total equilibrium population with HIV is less than half of the
disease-free steady state S01 , because we consider cohorts of B births per year and not
the real total population with its inflows and outflows. The sensitivity of the steady state
prevalence of HIV with respect to variations in λ and d are shown in Fig. 6. The black
dot in the top right corner corresponds to the numerical values for λ and d from Table 6.
7.4 The steady state with both HIV and TB
The endemic steady state with both HIV and TB can be computed numerically. Its































Fig. 6 HIV only. Bifurcation diagram in (λ, d) parameter space and level curves of the steady state HIV
prevalence
been obtained if the simulations in Fig. 2 had been continued until reaching a steady
state. Compared to the endemic steady state with TB only (left part of Table 7), the TB
notification rate and the TB incidence have been multiplied by 10, the TB prevalence
and the MTB infection rate by 4. The prevalence of MTB has only slightly increased.
Reactivation has become the most important way of progression to active TB. The
sensitivity of the steady state with both HIV and TB with respect to variations in k1
or d was already shown in Fig. 3.
The question of whether the HIV-associated TB epidemic leads to an increased risk
of MTB infection in the population (and in particular among HIV− people) has been a
subject of discussion in the medical literature [22,38,74]. Egwaga et al. [22] found that
the risk of infection had decr ased between 1983 and 2003 in Tanzania among children
aged 6–14 years despite the increase of HIV-associated TB incidence in the population.
Similarly, Corbett et al. [11] did not find any increase in TB incidence among HIV−
South African gold miners. On the contrary, Lawn and Wood [38] noticed that in
the South African township under study here, the TB notification rate among HIV−
adolescents had dramatically increased in recent years, so the risk of infection must
have also increased. This is also what happens in our model: the MTB infection rate
is multiplied by 4 as HIV prevalence increases from 0 to a steady state at 24%.
8 Control measures
8.1 Increasing condom use
Notice from (20)–(21) that rHIV0 is proportional to f (0) = d (the maximum transmis-
sion rate of HIV) and that rTB0 is proportional to k1 (the maximum transmission rate
of TB), the ratio k2/k1 being fixed. So if d is divided by at least rHIV0 (the other para-
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TB notification rate (per 100,000 per year)














Fig. 7 Assuming that a sudden increase in condom use occurs in the year 2008 (the maximum transmission
rate d becomes d ′). The different curves correspond from top to bottom to d ′ = d, d ′ = d/2, d ′ = d/4,
d ′ = d/8 and d ′ = 0. a TB notification rate. b Prevalence of HIV
in the long run. Similarly, if k1 is divided by at least rTB0 , the new r
TB
0 will be less
than 1 and TB will disappear in the long run. In Fig. 3, starting from the black dot
representing the real situation, one can check that if k1 is divided by rTB0  1.7, we
move from the area labeled “HIV+TB” to the area with HIV only. If d is divided by
rHIV0  5.8, we move from the area “HIV+TB” to the area with TB only. To decrease
the parameter k1, living conditions should be changed. The parameter d decreases if
more condoms are used.
Figure 7 shows the impact of a sudden decrease of the HIV transmission rate d,
from an initial value d to a new value d ′, on the prevalence of HIV (Fig. 7b) and also
indirectly on the TB notification rate (Fig. 7a). The impact is obviously a monotonic
function of d ′, as one would expect. We can check on these simulations that HIV
disappears in the long run only if d ′ < d/rHIV0  d/5.8 (that is in the two simulations
d ′ = d/8 and d ′ = 0 but not when d ′ = d , d ′ = d/2 or d ′ = d/4). If so, the TB
notification rate returns finally to its level of the beginning of the 1980s, before HIV
was introduced. The asymptotic TB notification rate and prevalence of HIV can also
be read directly by looking at the level curves in Fig. 3, but the speed at which these
steady states are reached can only be seen in Fig. 7.
In the absence of intervention (Fig. 7, d ′ = d), notice in the simulation that the
peak for the prevalence of HIV occurs at about the same time as the peak for the
TB notification rate. This does not seem incompatible with the data from Kenya [15,
Fig. 1], which suggested a delay of several years between the rise of HIV and the
rise of TB. One reason for such a delay may be that active TB tends to appear with a
higher frequency in late stages of HIV infection. Notice, however, that the data from
the South African township does not show any clear delay. Our model with just two
compartments for HIV (HIV− and HIV+) could fit reasonably well the data for both
TB and HIV although it does not include any delay. The background environments
in the Kenyan study and in the South African township are probably quite different
since for similar levels of HIV prevalence, the TB notification rate in Kenya is only
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Fig. 8 Increasing the TB detection rate: a bifurcation diagram in the phase plane (1/γ1, 1/γ2) and level
curves of the TB incidence rate. b TB incidence rate as a function of time, assuming that a sudden increase
in the TB detection rate for HIV+ people occurs in the year 2008. The parameter γ2 is replaced from top
to bottom by γ2, 2γ2, 4γ2 or 8γ2
Finally, one should mention that large scale prevention campaigns promoting con-
dom use on television started at the end of the year 2006 in South Africa. In principle,
one might be able to get data concerning the number of condoms purchased by the
population of the township and check if behaviors have changed.
8.2 Increasing TB detection
Now we consider the possibility of increasing the TB detection rates γ1 and γ2 and
increasing the probabilities ε1 and ε2 of successful treatment. For the township, this
could be achieved by actively searching for TB cases instead of waiting for them
to come to the TB clinic. Notice that the four parameters above enter the system
of differential equations (1)–(6) only through the combination b1 = β1 + γ1 ε1 and
b2 = β2 + γ2 ε2. However, we have to be a little careful because γ1 and γ2 enter in
the expression of the TB notification rate (through γ1 I1 + γ2 I2). If γ1 or γ2 increase,
the steady state TB notification rate may increase and will start decreasing only if γ1
or γ2 are high enough. It is therefore not suitable to use the TB notification rate as a
measure of the severity of the situation when the detection rate changes. Instead, we
will use the TB incidence rate.
Figure 8a shows the bifurcation diagram and the level curves of the steady state
TB incidence rate in the parameter space (1/γ1, 1/γ2), using the numerical values
from Table 6 for the other parameters. Since γ1 and γ2 do not enter in the formula for
RHIV0 , the HIV-endemic steady state is always there. The question is: when can it be
invaded by TB? This is given by the equation rTB0 = 1, an implicit equation for γ1
and γ2 shown by the thick black line separating “HIV” from “HIV+TB” in the bottom
left corner of Fig. 8a. The values for γ1 and γ2 in Table 6 correspond to the black dot
shown in the figure.
Figure 8b shows the impact of a sudden increase in the TB detection rate γ2 for
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Fig. 9 Isoniazid preventive therapy for HIV+ people (decreasing a2): a bifurcation diagram in the phase
plane (a1, a2) and level curves of the steady state TB notification rate. b TB notification rate as a function
of time. Assumption: starting in 2008, a2 is replaced from top to bottom by a2, a2/2, a2/4, a2/8 or 0
do not show it. Of course, the TB incidence decreases monotonically as the detection
rate increases.
8.3 Isoniazid preventive therapy
This control measure reduces the parameter a1 if used for HIV− people and the para-
meter a2 if used for HIV+ people. These parameters do not enter in the formula for
RHIV0 , so HIV is always present and the question is whether TB can be stopped in the
presence of HIV: the threshold is given by rTB0 = 1 (the corresponding curve appears
in the bottom of Fig. 9a as the level set 0). The level curves of the TB notification rate
in the diagram (a1, a2) are almost horizontal (Fig. 9a). So preventive therapy used for
HIV+ people (reducing a2) has a much greater impact on the TB notification rate than
if used for HIV− people (reducing a1). The values for a1 and a2 in Table 6 correspond
to the black dot in Fig. 9a close to the 2,000 per 100,000 per year level curve.
Figure 9b shows the impact of a sudden decrease of the progression rate a2 for
HIV+ people due to isoniazid preventive therapy. Since this has almost no impact on
the curve for the prevalence of HIV, we do not show it. The steady state TB notification
rate decreases monotonically as a2 decreases.
8.4 ART
We consider now the possible impact of antiretroviral treatment (ART), more pre-
cisely, of highly active antiretroviral treatment (HAART). ART reduces viral load and
therefore also the transmission parameter d for HIV. But ART also increases the life
expectancy of HIV+ people by decreasing µ2 and m2 (of course not below the nat-
ural mortality µ1), a fact which increases the number of people living with HIV and
enhances further transmission of HIV. These two effects are antagonistic, so the impact
on HIV at the population level is not obvious and depends very much on how much
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TB notification rate (per 100,000 per year)















Fig. 10 ART. a TB notification rate as a function of time. b HIV prevalence as a function of time.
Assumption: 100% of HIV+ people are put on ART starting in 2008. The parameter µ2 is replaced by
µ2/2, the parameter m2 by m2/2, the parameter a2 by a2/5, while the parameter d is replaced either by d,
d/2, d/4, d/8, or 0 (from top to bottom). The dashed line shows the case without intervention
average rate a2 at which coinfected people develop active TB, though not to the same
level a1 as HIV− MTB-infected people [3,34,36,39], and even if “immune reconsti-
tution disease” may on the contrary increase a2 during the first few months of ART
treatment [41]. Again, the effect of ART on TB is not clear because HIV+ people
under ART live longer. Quantitatively, ART was shown in studies in South Africa
[3,36] and Brazil [45] to reduce a2 by 80% , i.e., to divide a2 by 5. With a2 = 0.08
per year without ART, this gives a2 = 0.016 per year under ART. This is still 50 times
higher than the parameter a1 = 0.0003 per year for HIV− people. Another report [37]
mentioned a risk 5 to 10 times higher after 3 years of ART compared to HIV− people.
We assume furthermore that:
• µ2 is divided by 2 under ART, giving µ2 = 0.05 per year instead of 0.1 per year,
still higher than the natural mortality µ1 = 0.02 per year; the new life expectancy
for HIV+ people under ART is 20 years;
• m2 is divided by 2 under ART (the new m2 is 0.8 per year, compared to m1 = 0.25
per year).
We determined what would happen under various assumptions for the HIV transmis-
sion parameter d (Fig. 10), assuming that 100% of HIV+ people are put immediately
on ART starting in 2008, independently of their CD4 cell count (a variable which is
not included in our model anyway). This hypothesis is of course quite optimistic and
would require the entire adult population of the township to be tested for HIV. Notice
also that in practice and in more realistic models, some factors may favour a delayed
initiation of ART [40]. With our choice of parameter values, we find a decrease for
the TB notification rate even in the extreme case where ART would have no influ-
ence on the parameter d (Fig. 10a, top plain curve), a case which would lead to an
increase in HIV prevalence (Fig. 10b, top plain curve). The cases where d ′ = d/2 and
d ′ = d/4 are probably more realistic, since we expect HIV transmission to decrease
if everybody knows his/her HIV status. In such cases (and assuming that the other
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d ′ = d/4 but not for d ′ = d/2 (Fig. 10b, second and third plain curves from the top).
So the future of HIV prevalence under ART is uncertain. But with a progression rate a2
reduced by 80% and a life expectancy 1/µ2 multiplied by 2, it seems that ART would
dramatically decrease the TB notification rate even though the new reactivation rate
for HIV+ people would still be several times higher than the one for HIV− people.
ART has become increasingly available in the township since 2006. But it is still
too early to understand what its impact on both the HIV and TB epidemics has really
been.
9 Conclusion
This work is a first attempt to model the simultaneous HIV and TB epidemics in a
township near Cape Town, South Africa, for which a considerable amount of data is
available. The main difficulty is due to the large number of parameters in the model,
which makes estimations and mathematical analysis a little difficult. Keeping this
number as small as possible, we have been able to provide a fairly complete picture
of the model with HIV or TB only.
Backward bifurcation for our model with TB only was shown to be impossible
under realistic parameter values because MTB infection provides a certain degree
of protection against a fast progression to active TB after reinfection (q1 ≤ p1). To
our knowledge, no TB model has ever been shown to exhibit backward bifurcation
under realistic parameter values despite all the emphasis put on this possibility in the
more mathematically oriented articles on TB [24,48,63]. On this point, we agree with
Lipsitch and Murray [42] and with Singer and Kirschner [64].
For the full model (1)–(6) with both HIV and TB, we analyzed the linear stability
of the endemic steady states with either TB or HIV. We conjectured that there was
still no backward bifurcation for (1)–(6) when q1 ≤ p1. Verifying this point can be
considered as an open mathematical problem. We used numerical methods to draw
bifurcation diagrams with level curves for HIV prevalence and TB notification rate.
The most interesting diagram is Fig. 3. It shows how for a fixed value of the TB
transmission rate k1, the steady state TB notification rate can increase from 200 to
2,000 per 100,000 per year as HIV prevalence increases from 0 to around 25%.
Gomes et al. [26–28] have emphasized the role of a “reinfection threshold” in
TB models without HIV. In [26, Fig. 3] or [28, Fig. 2], the “reinfection threshold”
occurred when approximately 1% of the population had active TB. In the South African
township, 12/762  1.6% of a sample population was found to have undiagnosed
active TB in 2005. This could suggest that there are indeed populations above the
“reinfection threshold”. However, one can wonder if populations with endemic TB but
with low HIV prevalence can really reach 1% prevalence of active TB. In other words,
one can wonder if such populations are not systematically below the “reinfection
threshold”, and if the “reinfection threshold” can still be used to explain problems in TB
epidemiology such as the inefficiency of BCG vaccination [26]. Even in populations
with high HIV prevalence, the “reinfection threshold” does not seem to play such an
important role. Table 7 suggests that the percentage of reinfection with HIV and TB
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Among the control measures studied, most have an obvious positive impact in
controlling the HIV or TB epidemics: this is the case for condom use, increased
TB detection and preventive treatment. The situation for ART is more complicated.
However, although the future for the prevalence of HIV is uncertain, it seems that a
generalized access to ART would lead to a significant decrease of the TB notification
rate. Indeed, ART has been shown both in South Africa and in Brazil to reduce the
progression rate from latent to active TB by about 80%, i.e., to divide it by a fac-
tor 5. If HIV+ people under ART live approximately 2 times longer than the average
10-year survival time of HIV+ people with no access to ART, then one could expect
the TB incidence to be multiplied by 0.4 = 2/5, i.e. to be reduced by 60%. This simple
argument may be wrong if ART increases the prevalence of HIV and indirectly the
incidence of TB. Our numerical results suggest that this is not so. Even in the worst
scenario we considered where HIV prevalence increased as a result of ART (top plain
curve in Fig. 10b), the TB notification rate decreased considerably (top plain curve in
Fig. 10a).
It is difficult to guess if the observations drawn from this model with parameters
adapted to this particular South African township are still valid for less crowded
areas with high HIV prevalence. One could try to use the same model and adapt the
parameters to data from such areas. Unfortunately, reliable data on both HIV and TB is
still rare. For example, HIV prevalence in Zimbabwe has probably not been estimated
as regularly as [32, Fig. 5] might suggest (J. Hargrove, personal communication).
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Appendix
Let us call i+1 and i
−
1 the two (possibly complex) roots of Eq. (13), which for conve-
nience we rewrite as
(
i∗1
)2 + c1 i∗1 + c0 = 0 . (26)
We are only interested in positive roots, which are the ones with a biological meaning.
The existence of positive roots depends in particular on the signs of c1 and c0. We
need to distinguish several cases:
• The case k1 > k∗1 . Since c0 < 0, it follows that i+1 × i−1 < 0. This case occurs
only if i+1 > 0 and i
−
1 < 0. So there is only one positive solution of (13).• The case where 0 < k1 < k∗1 and 0 < k1 < k̃1(q1), the new parameter k̃1(q1)
being defined by
k̃1(q1) = a1 + b1 + (1 − p1) m1 + p1µ1
q1
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In this case we have c1 > 0, so i
+
1 + i−1 < 0. But i+1 × i−1 > 0, so this case occurs
only if i+1 and i
−




1 are complex conjugates with a
negative real part. So there is no positive solution of (13). Notice that k̃1(q1) < k∗1
only when q1 > q∗1 , the definition (17) of q∗1 having been precisely chosen for this
purpose.
• The case where 0 < k1 < k∗1 and k1 > k̃1(q1) (which implies that q1 > q∗1 ). Let 
be the discriminant of (13). Let us emphasize its dependence on k1 by writing (k1)
while we keep q1 fixed. From (13), we see that (k1) is a quadratic polynomial with
respect to 1/k1, so the equation (k1) = 0 has at most two roots in the half-line
k1 > 0. Since (k1) = c21 −4 c0, since c1 = 0 when k1 = k̃1(q1) and c0 = 0 when
k1 = k∗1 , it follows that (̃k1(q1)) < 0 and (k∗1) > 0. So the equation (k1) = 0
has at least one root in the interval (̃k1(q1), k∗1), and it cannot have two roots since
the function k1 → (k1) has to change sign an odd number of times in this interval.
Call k̂1(q1) the unique root. Then (k1) < 0 for k̃1(q1) < k1 < k̂1(q1): in this
case, Eq. (13) has no real solution. For k̂1(q1) < k1 < k∗1 , we have (k1) > 0,
c0 = i+1 × i−1 > 0, and c1 = −(i+1 + i−1 ) < 0: in this case, Eq. (13) has two
positive solutions.
We still have to check that if (13) has a positive root i∗1 , then all the components of
the triplet (S∗1 , E∗1 , I ∗1 ) given by (14)–(15) are positive. For this purpose, it is enough
to show that s∗1 > 0 and e∗1 > 0. But adding (8) and (9), we find that s∗1 = (µ1e∗1 +
m1i∗1 )/(k1i∗1 ). So it is enough to show just that e∗1 > 0, i.e., i∗1 < 1 − m1/k1. Notice
first from (27) that if (13) has a positive root i∗1 , then k1 > m1 necessarily holds. Let
us call χ(i1) the quadratic polynomial on the left of (13), so that χ(i∗1 ) = 0. Simple
computations show that
χ(1 − m1/k1) = [b1 + (1 − p1) m1] (k1 − m1 + µ1)
q1k21
> 0 ,
χ ′(1 − m1/k1) = 1 − m1
k1
+ a1 + b1 + (1 − p1)m1 + p1µ1
q1k1
> 0 ,
which imply that i∗1 < 1 − m1/k1. Q.E.D.
Finally, let us add a short comment on the notion of “reinfection threshold” [7,26,27]
for our model in the case k1 > k∗1 (which is equivalent to RTB0 > 1 and also to c0 < 0).





c21 − 4 c0
]
/2 .
Consider the special case where 4|c0|/c21 is small. This case turns out to be satisfied
numerically in the whole area k1 > k∗1 of Fig. 4 except in a very narrow strip around
the curve c1 = 0, whose equation can be rewritten as
q1 = Q1(k1) = a1 + b1 + (1 − p1)m1 + p1µ1
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Then one can show that
i∗1 
{−c0/c1 if c1 > 0 ,
−c1 if c1 < 0 .
The approximation for c1 > 0 corresponds to neglecting the quadratic term in Eq. (26),
while the approximation for c1 < 0 corresponds to neglecting the constant term. Notice
that because 4|c0|/c21 was assumed to be small, the expression −c0/c1 is much smaller
than −c1. So the prevalence of TB is high when q1 > Q1(k1) and much smaller when
q1 < Q1(k1). But as pointed out in [7,27] for a slightly different model, the “reinfection
threshold” we have just obtained is not very well defined from a mathematical point
of view (a similar situation happens e.g. when defining the width of “boundary layers”
in physics).
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To explore the relationship between human immunodefi-
ciency virus (HIV) and Mycobacterium tuberculosis geno-
types, we performed IS6110-based restriction fragment–
length polymorphism analysis on M. tuberculosis culture
specimens from patients with smear-positive tuberculosis in
a periurban community in South Africa from 2001 through
2005. Among 151 isolates, 95 strains were identified within
26 families, with 54% clustering. HIV status was associated
with W-Beijing strains ( ) but not with clustering perP p .009
se. The high frequency of clustering suggests ongoing trans-
mission in both HIV-negative and HIV-positive individuals
in this community. The strong association between W-Beijing
and HIV infection may have important implications for tu-
berculosis control.
Tuberculosis remains a major cause of morbidity and mortality
worldwide and in Africa human immunodeficiency virus (HIV)
is fueling the epidemic [1]. South Africa, which bears 28% of
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the global burden of HIV-related tuberculosis, is undergoing
rapid urbanization [2], with immigrants to the cities concen-
trating in poor, crowded periurban townships where both HIV
prevalence and tuberculosis incidence rates are high [3]. We have
previously described high HIV prevalence in adults (23%) [4]
and rapidly escalating tuberculosis notification rates [3] in a
periurban township in Cape Town, South Africa. Despite a well-
implemented national tuberculosis control program (based on
the World Health Organization’s DOTS [directly observed ther-
apy, short course] strategy [5]), the number of tuberculosis cases
has escalated at the single community clinic that manages all of
this township’s resident patients with tuberculosis. This geo-
graphically well-defined community with ∼15,000 people of low
socioeconomic status living in overcrowded, largely informal
dwellings is ideally suited for tuberculosis transmission studies.
The advent of such molecular epidemiological tools as IS6110-
based restriction fragment–length polymorphism (RFLP) geno-
typic analysis of Mycobacterium tuberculosis has expanded our
ability to investigate and understand tuberculosis [6]. Different
M. tuberculosis strains have been associated with diverse levels of
virulence, immunological responses, epidemic potential, and
even drug resistance [6]. However, the relationship between spe-
cific host characteristics (such as HIV infection) and M. tuber-
culosis genotypes is poorly understood. To explore the association
between HIV infection and circulating M. tuberculosis strains, we
performed RFLP analysis of M. tuberculosis isolates cultured from
individuals with smear-positive pulmonary tuberculosis in the
above-mentioned study community from 2001 through 2005.
Methods. Sputum specimens from patients with acid-fast
bacilli smear–positive tuberculosis residing in the study com-
munity were collected for genotype analysis from 2001 through
2005. Sputum specimens were obtained from patients in ac-
cordance with National Tuberculosis Control Program guide-
lines [7] and were labeled as study specimens at the clinical site
for identification by laboratory personnel. The age, sex, details
of clinical diagnosis, clinical outcome, and HIV status of each
patient were collected from the clinic’s tuberculosis register and
patient folders. The study was approved by the ethics review
boards of the University of Cape Town and of the University of
Medicine and Dentistry of New Jersey (UMDNJ), and partici-
pants provided informed consent.
Sputum specimens were assessed for the presence of M. tu-
berculosis bacilli by means of fluorescent (auramine) micros-
copy. Isoniazid and rifampicin susceptibility testing was per-
formed on samples from retreatment patients and from patients
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Figure 1. Mycobacterium tuberculosis strains from the study community in a phylogenetic framework. RFLP, restriction fragment–length polymorphism;
SNP, single-nucleotide polymorphism.
months of treatment [7]. Susceptibility to rifampicin was tested
at a concentration of 1.0 mg/mL, and susceptibility to isoniazid
was tested at concentrations of 0.1 and 0.2 mg/mL on myco-
bacterial growth indicator tubes and on Middlebrook 7H11
agar, respectively. Sputum samples that tested positive for acid-
fast bacilli were cultured on Lowenstein-Jensen slants at the
Tuberculosis Laboratory at the Institute of Infectious Diseases
and Molecular Medicine at the University of Cape Town. Iso-
lates that tested positive for M. tuberculosis by culture were
inoculated in duplicate into 7H9 liquid medium supplement-
ed with oleic acid, albumin, dextrose, and catalase (OADC)
and 15% glycerol, then stored at 70C.
Frozen duplicate culture stock was shipped to the Pub-
lic Health Research Institute (PHRI) Tuberculosis Center at
UMDNJ. Culture stocks were subcultured on Lowenstein-
Jensen slants, and DNA was extracted from each isolate.
IS6110-based RFLP analysis was performed as described else-
where [8]. RFLP patterns were analyzed using Bio Image pat-
tern matching software (Bio Image). M. tuberculosis isolates
that had DNA fingerprints with an identical hybridization
banding pattern were considered to be the same strain and
assigned a strain code following a nomenclature system that
has been described elsewhere [9]. M. tuberculosis strains were
assigned to 1 of 9 (I–VIII and II.A) discrete synonymous single-
nucleotide polymorphism (SNP)–based phylogenetic lineages
(synonymous SNP clusters) that were inferred on the basis of
RFLP patterns and of previous analysis, reported elsewhere [6],
of M. tuberculosis clinical isolates at PHRI. In addition, strains
that exhibited similar IS6110 hybridization profiles (65% sim-
ilarity), suggesting common recent ancestry, were collectively
grouped into genotype families (eg, W-Beijing, CC, and BM)
[6]. Strain clusters were defined as 11 occurrence of a specific
strain during the study period. Strain patterns that were rep-
resented only once in the PHRI database and did not qualify
for a family assignment were considered unique and given a
default assignment (001).
Data were analyzed using Stata software (version 10.0; Sta-
taCorp). Bivariate analyses used the Student t, x2, and Fisher
exact tests, as appropriate. A Wilcoxon rank sum test was used
for comparison of median age between different groups. Pa-
tients’ ages were categorized by decade (15–19, 20–29, 30–39,
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Figure 2. Distribution of the clusters, by cluster size, date of diagnosis, human immunodeficiency virus (HIV) status, and Mycobacterium tuberculosis
strain family.
tribution of the 4 main M. tuberculosis families by age. A x2
test for trend was used to assess changes in strain distribution
over time.
Multiple logistic regression models were developed to ex-
amine factors associated with the dominant strain families and
with clustering of strains. The period between occurrences of
cases within clusters was calculated on the basis of the date of
tuberculosis diagnosis. The ArcMap (version 9.2; Esri) geo-
graphic information system was used to assess the spatial dis-
tribution of M. tuberculosis strains occurring in clusters during
the course of the study.
Results. Over the 5-year study period, 467 patients in the
study community were diagnosed with sputum smear–positive
pulmonary tuberculosis. The study laboratory received sputum
specimens from 282 patients (60% of smear-positive patients)
over this period. Of the 282 specimens received from these
patients, 53% ( ) were successfully cultured for RFLPn p 149
analysis, 22% ( ) lost viability during shipping or storage,n p 61
19% ( ) failed to culture M. tuberculosis, and 6% (n p 55 n p
) were contaminated. Two patients had dual infections with17
2 different strains, and therefore a total of 151 M. tuberculosis
isolates were included in this analysis.
No statistically significant differences were found between
patients with and those without RFLP data (including patients
for whom we did not receive specimens) in terms of age
( ), sex ( ), tuberculosis category (ie, new or re-P p .11 P p .63
treatment cases; ), test results for multidrug-resistantP p .22
(MDR) tuberculosis (resistant to at least isoniazid and rifam-
picin; ) or HIV status (among those tested; ).P p .15 P p .58
However, patients for whom we did not obtain RFLP data had
a higher death rate than did those for whom we did obtain
RFLP data ( ).P ! .001
The 149 patients with RFLP results ranged in age from 14
to 67 years (median age, 36 years), and 62% ( ) weren p 92
men. In total, 81% ( ) of the patients were tested forn p 121
HIV, and 54% ( ) of those 121 patients tested were in-n p 65
fected with HIV. Four of the 149 patients (3%) had confirmed
MDR tuberculosis. There were no tuberculosis-related deaths
in this cohort.
A total of 95 different M. tuberculosis strains were identified
(including 4 unique isolates), which are presented in a phy-
logenetic framework in Figure 1. Eight of the 9 recognized
synonymous SNP clusters [10] were present in the community.
The synonymous SNP cluster VI comprised 49% ( ) ofn p 74
the patients. Genetic variability within this group was high,
with 57 strains detected in 74 patients. The synonymous SNP
cluster II was the second largest group, with 26% ( ) ofn p 39
strains.
Twenty-six different M. tuberculosis genotype families were
identified; the 4 largest families were W-Beijing (accounting for
26% of all M. tuberculosis strains in the community), CC (25%),
AH (11%), and BM (7%). Bivariate analysis revealed no sta-
tistically significant association between the 4 dominant families
and sex ( ), age category ( ), tuberculosis categoryP p .56 P p .31
( ), or outcomes of tuberculosis treatment ( ).P p .73 P p .53
There was no change in the distribution of the main strain
families across the 5-year period of data collection ( ).P p .54
Multivariate analysis adjusting for age, sex, tuberculosis cat-
egory, and outcome yielded no association between HIV status
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{CI}, 0.48–3.17]), AH strain (OR, 0.68 [95% CI, 0.21–2.25]),
or BM strain (OR, 0.26 [95% CI, 0.04–1.49]). However, patients
with the W-Beijing strain were significantly more likely to be
HIV positive (OR, 3.65 [95% CI, 1.37–9.71]).
Of the patients with MDR tuberculosis, 2 were infected with
W-Beijing strains, 1 was infected with a CC strain, and 1 was
infected with an H strain. There was no statistical association
between MDR tuberculosis and strain ( ) or HIV statusP p .67
( ).P p .87
In this study, 54% ( ) of isolates occurred in strainn p 81
clusters ranging in size from 2 to 14 patients, with 27% of the
clustered strains occurring in pairs. Figure 2 demonstrates the
distribution of the clustered strains over time by HIV status.
In multivariate analysis, there was no association between clus-
tering and HIV status (OR, 1.20 [95% CI, 0.55–2.65]). Paired
clusters were diagnosed on average 157 days apart (!6 months),
compared with an average of 321 days (110 months) between
occurrences of cases in the larger clusters ( ). Smaller,P p .013
temporally associated clusters were noted within the larger clus-
ters of the W451 and AH strains. With the exception of 2 cases
in the AH cluster, none of the clustered cases occurred on the
same residential plot in the township studied.
Discussion. The key finding of this study is the association
between W-Beijing, one of the largest identified M. tuberculosis
strain families, and HIV infection. This association persisted
after controlling for a number of clinical factors and could be
due to either an increased pathogenicity or virulence of the
strain or an increased susceptibility of HIV-infected patients to
these strains. W-Beijing M. tuberculosis strains have shown
marked virulence in animal models of infection [6] and it has
been suggested that certain sublineages of W-Beijing may have
increased transmissibility and/or pathogenicity [11]. However,
to our knowledge this is the first population-based study to
show an association between W-Beijing and HIV infection.
Further study of the biology of the W-Beijing strains and of
their interaction with the HIV-infected host may help to explain
the increased susceptibility of HIV-infected patients to tuber-
culosis and may also indicate novel ways to either protect or
more effectively treat HIV-infected patients coinfected with M.
tuberculosis. Other studies have found W-Beijing strains to be
associated with MDR tuberculosis [12]. Therefore, the asso-
ciation with HIV-infected patients may have serious implica-
tions for the spread of MDR tuberculosis. The increased mor-
tality in those without RFLP analysis may reflect a lower sputum
retrieval rate at the local hospital, where tuberculosis was ini-
tially diagnosed in sicker patients.
This study has demonstrated a broad diversity of different
M. tuberculosis strains, consistent with findings of other studies
in sub-Saharan Africa [13, 14]. The high degree of genotypic
diversity within the CC strains (related to F11/LAM) [13] may
indicate that they are endemic in this population. The W-Bei-
jing family also shows a high degree of diversity (16 variants
in 39 patients), although to a lesser degree than the CC family,
suggesting that these strains may be emerging and diversifying
in the community. However, chromosomal location of IS6110
insertions may affect the movement of the insertion sequence
elements, and therefore genetic diversity as determined by
IS6110 RFLP may be independent of strain endemicity.
Another finding was the high rate of strain clustering. Clus-
tering is not necessarily synonymous with recent transmission;
evidence of geographical linkage, temporal association, and so-
cial contacts may be needed to support the suggestion of trans-
mission. IS6110 fingerprinting is one of the most discriminatory
typing techniques for isolates with 16 IS6110 bands (eg, CC
and W-Beijing), although it is less discriminatory for strains
with fewer bands (eg, AH) [6], and may underestimate sub-
clusters within the AH family. In this study approximately half
of the strains were clustered, and there were close temporal
associations, especially among the paired clusters. A proportion
of disease may therefore be due to new infections. Because no
association was found between HIV infection and clustering,
new infections may be occurring in both HIV-negative and
HIV-positive patients. Given the incomplete sampling of the
study population, we probably underestimated the number of
circulating strains, number of clusters, and sizes of clusters [15].
The spatial analysis demonstrated that temporally linked
clusters did not occur on the same residential plots, suggestive
of transmission outside of households. Temporally related clus-
tering was also identified within larger clusters, such as of the
W451 and AH strains. The strong temporal relationship of
tuberculosis in HIV-positive patients within the W451 strain
cluster (4 patients in 2003 and 6 patients in 2005) (Figure 2)
may reflect nosocomial transmission at the single community
clinic. Traditional epidemiological studies, including social in-
teraction studies, are required to further delineate transmission.
In conclusion, we have shown that a wide diversity of strains
exists in this periurban community in South Africa. Strain clus-
tering, suggestive of ongoing transmission, was common in both
HIV-positive and HIV-negative adults. The W-Beijing family was
associated with HIV infection, a new finding that requires con-
firmation and explanation.
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Childhood tuberculosis infection and disease: A spatial and 
temporal transmission analysis in a South African township 
Keren Middelkoop, Linda-Gail Bekker, Carl Morrow, Eugene Zwane, Robin Wood 
Tuberculosis (TB) is a leading cause of mortality and morbidity 
globally.  South Africa has the largest per capita TB burden in 
the world, and its TB notification rates are highest in crowded 
urban areas.1,2 Although DOTS programmes (directly observed 
therapy, short course) have reduced TB prevalence and death 
rates in many regions of the world, implementation has not  
significantly impacted on TB transmission and incidence 
in Africa.1 Adult TB disease comprises a combination of 
recent infections and reactivation of latent TB, and therefore 
represents both recent and past TB exposure. HIV co-infection 
increases the progression to disease of both recent and latent 
TB infection.3,4 In contrast, childhood infection is acquired 
predominantly from adults, as child-to-child transmission 
is uncommon,5 and young children with TB infection have 
a greater risk for progression to active disease than adults.6 
Infection and disease in young children are therefore a measure 
of recent TB transmission.
Country-specific TB rates in children are usually reported 
as smear-positive TB rates per 100 000 of the <15-year-old 
population.1 This may substantially underestimate the true 
child TB burden due in part to the low proportion of smear-
positive cases in children.7 Furthermore, childhood TB disease 
occurs most frequently in children <2 years, resulting in the 
numerator of disease for this small age group being diluted by 
the larger population denominator (0 - 14-year-olds). This may 
explain why, despite significant increases in overall TB rates in 
the Africa region, the reported rates of childhood TB disease for 
South Africa have remained relatively unchanged since 2002.1,8
We have previously reported a growing TB epidemic in a 
peri-urban township heavily affected by HIV in Cape Town, 
South Africa. Recently urbanised, overcrowded, consisting 
largely of informal dwellings and with a population of low 
socio-economic status, the township is a well-demarcated, 
geographically isolated community.  The HIV prevalence is 
23% among adults9 and 10% among adolescents aged 11 - 19 
years.10 The National TB Control Programme, based on WHO 
DOTS recommendations, appears to be functioning well at the 
community’s single clinic, with treatment completion and cure 
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Background. Tuberculosis (TB) remains a leading cause of 
mortality and morbidity in South Africa. While adult TB 
results from both recent and past infection, childhood TB 
results from recent infection and reflects ongoing transmission 
despite current TB control strategies.
Setting. A South African community with high rates of TB and 
HIV disease.
Outcomes. A Geographic Information System was used to 
spatially and temporally define the relationships between TB 
exposure, infection and disease in children <15 years of age 
with exposure to adult HIV-positive and HIV-negative TB 
disease on residential plots between 1997 and 2007.
Results. During the study period the annual adult TB 
notification rate increased from 629 to 2 106/100 000 and the 
rate in children aged <15 years ranged between 664/100 000 
and 1 044/100 000. The mean number of exposures to adult 
TB for TB-uninfected children, latently TB-infected children 
and TB cases were 5.1%, 5.4% and 33% per annum and the 
mean number of adult smear-positive cases per exposed child 
was 1.0, 1.6 and 1.9, respectively. Acquisition of TB infection 
was not associated with HIV status of the adult TB case to 
which the child was exposed, and 36% of child TB cases were 
diagnosed before the temporally closest adult case on their 
plot.
Conclusions. Childhood infection and disease were 
quantitatively linked to infectious adult TB prevalence in an 
immediate social network. Childhood infection should be 
monitored in high-burden settings as a marker of ongoing TB 
transmission. Improved knowledge of township childhood 
and adult social networks could also facilitate targeted active 
case finding, which may provide an adjunct to currently 
failing TB control strategies. 
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rates of sputum-positive cases of approximately 80%2 and case-
finding rates of 67% in HIV-negative smear-positive patients.9 
However, local TB notification data show a rapid escalation 
in TB notification rates in adults. In particular the incidence 
rate of smear-positive TB increased from 326/100 000 in 1996 
to 1 307/100 000 in 2005.11,9 During the same period childhood 
TB notification rates have increased, but less markedly. We 
also reported a remarkably high TB prevalence rate of 26% 
in children aged 5 - 8 years, and a mean annual risk of TB 
infection in children of 4.1%.12 
There are few data on TB exposure, infection and disease in 
children in a high TB and HIV disease burden setting. Adult 
TB notification data from this community and Geographic 
Information System (GIS) software were used to correlate the 
relationships between TB exposure, infection and disease in 
children with exposure to adult HIV-positive and HIV-negative 
TB disease on residential plots over time. The temporal 
association between adult cases and childhood disease was 
also explored.
Methods
The study community consists of a formal sector with 
demarcated, individually numbered serviced plots and 
an informal sector of shacks sharing communal services. 
Childhood TB disease cases from 1997 to 2007 were extracted 
from the community TB register. Childhood TB infection data 
were obtained from school-based tuberculin skin test (TST) 
surveys performed in the community in 2006 and 2007.12 
The analysis was restricted to residents in the formal sector 
(approximately 78% of the community) who use the assigned 
plot number as their address; 1 - 20 houses are built on a single 
plot (average of 4 houses/plot). All adult TB cases notified by 
the community TB clinic between 1997 and 2007 were cross-
referenced with both childhood TB cases and TST results from 
the school surveys. Children diagnosed with childhood TB 
disease during the study period were excluded from the TST 
database for this analysis. Adult TB cases were defined as 
patients ≥15 years of age and children as <15 years. Childhood 
TB infection was defined as an induration ≥10 mm in response 
to 2 units of purified protein derivative (PPD) administered 
intradermally.12 Demographic and clinical data including age, 
gender, TB clinical diagnosis and HIV status were collected 
from the TB register and clinic records. These studies were 
approved by the University of Cape Town’s Research Ethics 
Committee. 
Data were analysed using STATA 9.0 (StataCorp, College 
Station, Texas). Bivariate analyses employed Student’s t-
test, Wilcoxon’s sum rank test and the chi-square test, as 
appropriate. Rates of notified child disease were calculated 
using population denominators from community census 
data obtained in 1996, and biennially from 2002 to 2008 using 
linear interpolation. The time difference between adult and 
child cases was calculated based on the year of case diagnosis. 
Analysis of childhood TB cases initially included all adult TB 
exposures on the same residential plot, followed by an analysis 
of the adult TB exposure with the closest temporal link to each 
childhood TB case. Multiple logistic regression models were 
developed to determine characteristics of adult TB cases that 
were associated with positive TST results. As the age of the 
child was the only known factor associated with a positive 
TST result in the TST sample,12 logistic regression models 
assessing factors associated with TST positivity included this 
variable and models were adjusted for clustering effect on 
plots. TB case characteristics were included as binary exposures 
(any exposure to a TB case with a particular characteristic) 
and as counts of exposures to a TB case with a particular 
characteristic, per child. All statistical tests were 2-sided at 
α=0.05. Average annual exposure rates for disease, infection 
and non-infection were calculated by dividing the percentage 
exposed to adult disease by the median age of the group of 
interest.
The ArcMap 9.2 (Esri™) Geographic Information System 
was used to assess the spatial distribution of childhood TB 
disease, infection and exposure with linked adult cases in the 
community.
Results
The population childhood TB notification rate varied between 
315/100 000 and 1 105/100 000 over the study period, and 
adult TB rates increased from 629/100 000 to 2 106/100 000. 
Of the 1 708 notified TB cases 1 386 (81%) were resident in the 
formal sector. Of these 1 386 notifications 1 212 were adult and 
171 were childhood cases, with 3 cases excluded from analysis 
because no age was recorded. TB cases in the formal sector 
did not differ from those in the informal sector in terms of age 
(p=0.21), gender (p=0.83), site of TB disease (i.e. pulmonary v. 
extrapulmonary disease (EPTB); p=0.60), HIV status among 
those tested (p=0.58) and outcomes of TB treatment (p=0.16). 
However, TB cases from the formal sector were more likely 
to be transferred out of the community than those from the 
informal areas (11% v. 6% respectively, p=0.016). 
Childhood TB disease and exposure to adult TB at 
residence
The average annual rate of childhood TB disease in the 
formal sector of the community was 721/100 000 for all TB 
notifications and 65/100 000 for smear-positive TB. The median 
age of the 171 childhood TB cases was 2 years (interquartile 
range (IQR) 1 - 6 years), and 58% were female. In total 120 
(70%) of cases were classified as primary TB, with 28 cases 
(16%) of pulmonary TB (PTB) and 23 cases (13%) of EPTB. 
The HIV testing was performed in 52 children (33 positive, 
19 negative). Childhood TB cases occurred on 144 plots in the 
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Overall 113 (66%) of the childhood TB patients had one or 
more exposures to a notified adult TB case on their residential 
plot during their lifetime, with an annual exposure rate of 
33%. In 28% of cases a family name was shared with one of 
the adults notified on the plot. In total 105 children (61%) were 
exposed to adult PTB cases, 91 being exposed to a mean of 
1.9 smear-positive PTB cases and 40 to smear-negative PTB 
cases (53% of all child TB cases v. 23%, p<0.001). Fig. 1 shows 
the distribution of child TB cases and adult TB cases in the 
community. Children who were exposed to TB cases on their 
residential plot did not differ from those children not exposed 
in terms of age (p=0.23), gender (p=0.51) or HIV status (p=0.76). 
However, childhood TB cases not exposed on their residential 
plot were more likely to be retreatment TB cases than those 
exposed on the plot (12% v. 4%, p=0.03). 
A total of 47 (42%) adult cases occurred in the same year as 
the child cases, 25 (22%) occurred before the child case and 
41 (36%) occurred after the child case. When restricting the 
analysis to the adult TB case most closely linked temporally 
to each child case, the time interval between cases varied from 
3 years before the child TB case to 8 years after the child TB 
case (Fig. 2, a). The disease characteristics of the closest adult 
TB cases by time are shown in Table I.  The adult cases that 
occurred in the same year, before the child TB case and after 
the child case, did not differ from each other with respect to 
age (p=0.91), gender (p=0.55), HIV status (p=0.87) or treatment 
outcome (p=0.40). The time interval between diagnosis of all 
adult exposure cases and the child case ranged from 9 years 
before the diagnosis of the child TB case to 10 years after 
(median 1 year after child case; IQR 1 year before to 4 years 
after) (Fig. 2, b).  
Childhood TB infection and exposure to adult TB at 
residence
Of the 831 children analysed in the TST survey, 651 (78%) 
lived in the formal sector and 640 (77%) of these had not had 
childhood TB. The subset of 640 children used in this study 
did not differ from the total TST study sample in terms of age 
(p=0.95), gender (p=0.25), BCG status (p=1.00) or positive TST 
reaction (p=0.69).  
Of the 640 formal sector TST survey participants, 359 
(56%) had been exposed to an adult TB case on their plot, 
and the proportion exposed was significantly higher among 
TST-positive compared with TST-negative children (65 v. 
51%; p=0.001). The average annual exposure rate for children 
with infection was 5.4% per annum and for children without 
infection 5.1% per annum. Table II shows the distribution of 
type of adult TB case by TST result. 
Fig. 1. Distribution of childhood TB cases and of notified adult TB cases 
from 1997 to 2007 in the community.
Fig. 2. Distribution of time difference between all adult TB exposures 
and childhood TB case (2a) and distribution of time difference between 
temporally closest adult TB exposure and childhood TB case on the same 
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Fig. 3 (a and b) show the distribution of adult TB cases with 
TST-positive and TST-negative results, respectively. The odds 
of a positive TST result was 71% higher in those children 
exposed to any TB case on their plot (odds ratio (OR) 1.71; 
95% confidence interval (CI) 1.20 - 2.44), 88% higher in those 
exposed to PTB (OR 1.88, 95% CI 1.32 - 2.68), and 110% higher 
in those exposed to smear-positive PTB disease (OR 2.10, 95% 
CI 1.46 - 3.01) compared with no plot-based exposure to adult 
TB. Exposure to smear-negative TB was not associated with 
a positive TST result (OR 0.95, 95% CI 0.59 - 1.54), and this 
finding persisted after adjusting for HIV status of notified 
adult TB cases (OR 0.68, 95% CI 0.21 - 2.18).
Multiple exposures increased risk further, and the odds of a 
positive TST result increased by 60% for every additional 
exposure to a smear-positive PTB adult (OR 1.60, 95% CI 1.21 - 
2.11). The mean number of adult smear-positive exposures for 
TST-positive children was significantly higher than for TST-
negative children (1.6 v. 1.0, p<0.001).
Discussion
We have shown that children in this community have 
extremely high exposure to adult TB on their residential 
plot. The strongest association of childhood TB infection and 
disease was with adult cases of smear-positive PTB rather 
than smear-negative PTB or EPTB. There was no independent 
risk of infection associated with exposure to adults with HIV-
associated TB, in keeping with the previous finding in this 
community that child TB notification rates have not increased 
parallel with adult HIV/TB notification rates.12 It is therefore 
probable that the HIV epidemic may indirectly impact on 
childhood TB disease rates by increasing the burden of 
adult smear-positive TB cases in children’s immediate social 
network.11 
While TST surveys can assess rates of TB infection in 
children, our residential plot analysis was unique in allowing 
an assessment of annual rate of exposure to adult TB cases. 
The average annual exposure to adult TB case on residential 
plots was high for all children living on serviced plots in this 
community (5.1%), but was extremely high for children with 
TB disease (33% per annum). These exposure rates probably 
drive the high rates of child TB infection and disease in this 
community. By age of 6 years, at school entry, approximately 
Fig. 3. Distribution of TST positive (a) and TST negative (b) results and of 
adult TB cases from 1997 to 2007 in the community.
Table I. Temporal associations between childhood TB cases and exposure to temporally closest adult TB cases on the same 
residential plot
   Exposure to adult          Exposure to adult Exposure to adult smear-    Exposure to adult smear-
   TB case (N (%))         PTB case (N (%)) positive PTB case (N (%))    negative PTB case (N (%))
Child TB cases (N=171) 113 (66)          92 (53)  75 (44)      17 (10)
Adult TB case notified  72 (64)          60 (83)  48 (67)      10 (14)
before or in same year
as child case
Adult TB case notified  41 (36)          32 (78)  27 (66)      5 (12)
after child case
p-value*    <0.001          0.47   0.93      0.80
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26% of children are latently infected with TB12 and most 
adolescents are infected before sexual debut.12,10 The average 
annual TB notification rate for children under 15 years in this 
community was 721/100 000 and their smear-positive rates 
were nearly 3-fold higher than the South African national rates 
(83 v. 30/100 000).1 The very high rate of HIV-related TB in 
young adulthood may also result from the high proportion of 
young adolescents latently infected with TB.
The residential plots contain multiple households, which 
share communal water and sanitation services and constitute 
a geographically defined unit for social interaction between 
adults and children outside the immediate household. Family 
names differed between children and all their adult exposures 
in 72% of cases. 
This study was restricted to the formally serviced sector 
in which 78% of the community is resident. We could not 
define the geographical area of interaction between adults and 
children living in the informal sectors, and shack identifiers in 
this sector were not constant over the study period. For this 
analysis we also assumed that the children had all lived in 
the community since 1997 or from birth. Some children may 
have moved into the community subsequent to these dates; 
however, this would have decreased the strength of association 
between adult and child TB exposures and resulted in an 
under-estimation, rather than over-estimation, of the contact 
rate between adult and children with TB infection and disease. 
The majority of childhood TB disease (64%) was diagnosed 
in the same year or soon after an index adult TB case was 
notified to the TB control programme. However, over a 
third of child TB cases in this study were notified before the 
temporally closest notified adult case on their plot. Adult cases 
were diagnosed as much as 8 years after the childhood case of 
TB. These more temporally distant cases probably represent 
secondary or even tertiary cases due to ongoing adult-to-adult 
transmission. Potential explanations for this delayed adult 
presentation include a primary source that may have remained 
subclinical, who subsequently moved off the plot, or died 
before diagnosis. However, these data illustrate a significant 
prevalence of undetected and untreated adult TB on these 
plots. 
Molecular epidemiology from this community shows that 
adult-to-adult transmission occurs predominantly outside the 
residential plot.13 The use of molecular epidemiology among 
children is complicated by the low frequency of smear- and 
culture-negative disease. However, we have demonstrated that 
child TB infection and disease rates are strongly associated 
with exposure to adult TB within their restricted social 
environment as defined by their residential plot. The high rates 
of child TB infection and disease therefore indicate failure to 
control prevalent infectious adult cases. To reduce TB exposure, 
enhanced and active case finding (ACF) must be combined 
with the DOTS-based programme. The yield of ACF will vary 
in different settings. A random, community-based survey in 
this community showed that 0.1% of the adult population had 
undiagnosed smear-positive TB and an equal proportion had 
undiagnosed culture-positive TB, similar to the range of 0.1 - 
0.2% in case finding surveys in other developing countries.14,15 
We postulate that ACF targeted at residential plots, rather than 
only households, may have a higher yield than these cross-
sectional surveys and may decrease the prevalence of infectious 
cases, resulting in a lower rate of transmission to children. In 
addition to the TB case detection yield, efficacy of such a 
targeted intervention over time could be assessed through 
repeated TST surveys in children, to ascertain the impact on 
childhood infection rates.
In conclusion, TB transmission within households and close 
social networks is an important component of both childhood 
infection and disease in this community. Childhood TB is a 
sentinel of infectious adult prevalence and therefore childhood 
infection and disease rates need to be monitored in these 
high prevalence settings in order to ascertain the true burden 
of infection and disease. Targeted ACF, aimed at close social 
networks of child TB cases may be an appropriate intervention 
in this setting. 
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S E T T I N G :  Crowded townships of Cape Town, South 
A frica, where human immunodefi ciency virus (HIV) 
prevalence and tuberculosis (TB) notifi cation rates are 
among the highest in the world.
O B J E C T I V E S :  To determine age-specifi c prevalence rates 
of latent tuberculosis infection (LTBI) among HIV-
negative individuals, and the annual risk and force of in-
fection during childhood and adolescence. 
D E S I G N :  A cross-sectional survey using a standardised 
tuberculin skin test (TST) in HIV-negative individuals 
aged 5–40 years. A TST diameter of ⩾10 mm was de-
fi ned as indicative of LTBI. 
R E S U LT S :  Among 1061 individuals, only 4.7% had low-
grade TST responses of 1–9 mm. However, the propor-
tions of individuals with TST ⩾10 mm increased from 
28.0% in the 5–10 year age stratum to 88.0% in the 
31–35 year age stratum. The mean annual risk of infec-
tion was 3.9% up to 5 years of age. The estimated 
force of infection (the rate of acquisition of LTBI among 
the residual pool of non-infected individuals) increased 
throughout childhood to a maximum of 7.9% per year 
at age 15 years. 
C O N C L U S I O N S :  Extremely high rates of infection in 
childhood and adolescence result in very high LTBI prev-
alence rates in young adults who are most at risk of ac-
quiring HIV infection. This may be an important factor 
fuelling the high rates of HIV-associated TB in southern 
Africa.
K E Y  W O R D S :  TB infection; age; sex; Africa; TST
SOUTH AFRICAN tuberculosis (TB) notifi cations 
have increased six-fold over the last two decades, 
largely as a result of increasing human immunodefi -
ciency virus (HIV) prevalence.1 A total of 461 000 
new cases of TB in 2007 refl ected one of the highest 
national TB notifi cation rates in the world. The over-
all incidence rate was estimated at 948 per 100 000 
population, of which 73% were estimated to be co-
infected with HIV. South Africa alone accounted for 
approximately 25% of the global burden of HIV-
a ssociated TB.1 
Total TB notifi cations in Cape Town, a city of 
3.2 million people, reached 27 000 in 2006.2 The dis-
tribution of TB cases within this population, however, 
is very unequal, with unprecedentedly high burdens 
in the crowded and socially deprived African town-
ships. Here TB annual notifi cation rates were reported 
to exceed 1500/100 000 in 2006.3–5 Fuelled by high 
HIV prevalence, TB notifi cations are now most fre-
quent between the ages of 20 and 40 years.6
This marked deterioration of TB control in South 
Africa over the past two decades of increasing HIV 
prevalence has occurred despite reported progress to-
wards National TB Control Programme case man-
agement targets.1,7 Coverage using the World Health 
Organization (WHO) DOTS strategy is 100% and 
case detection rates have remained above target since 
2003.1 In the decade from 1996 to 2005, treatment 
default and treatment failure during treatment im-
proved respectively from 18.1% to 10.4% and from 
3.5% to 1.7%.8
In 1990, Karel Styblo, a leading protagonist of ef-
fective case management for TB control, postulated 
that ‘the impact of HIV infection on the epidemiolog-
ical situation of TB is so large that under some condi-
tions, the tools available at present for TB control 
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will fail to restrain the incidence of TB caused by HIV 
infection’.9 He further proposed that the impact of 
HIV infection would depend not only on the preva-
lence of HIV infection but also on the prevalence of 
latent TB infection (LTBI) and the annual risk of TB 
infection (ARTI) in the general population. However, 
although the HIV epidemic in South Africa has been 
carefully monitored by annual seroprevalence surveys 
among antenatal women and by household surveys,7,10 
few data describe the prevalence of LTBI or the ARTI 
in the general population. 
We therefore undertook a study to measure the 
prevalence of LTBI in the township populations of 
Cape Town. The tuberculin skin test (TST) has been 
the most widely used of all the immunological tests 
for estimation of prevalence, incidence and trend 
of Mycobacterium tuberculosis infection in popula-
tions, despite concerns about its sensitivity and speci-
fi city.11 We assessed TST responses among healthy 
HIV-negative residents of high-density townships aged 
between 5 and 40 years and used these to derive esti-
mates of the age-specifi c prevalence of LTBI. Further 
analyses estimated the ARTI in the study population 
and the force of TB infection (the rate of acquisition of 
TB infection among the residual pool of non-infected 
individuals). These data provide important insights 
into the explosive impact of the high rates of HIV ac-
quisition in young adults on TB control. 
METHODS 
Study population
TST responses were assessed in 1061 healthy indi-
viduals, including children and adolescents aged 5–
17 years (n = 832) and HIV-negative adults aged 
18–40 years (n = 229). Participants were residents of 
high-density predominantly black townships of Cape 
Town, where annual TB notifi cation rates in 2006 ex-
ceeded 1500/100 000.3–5 Children were all school at-
tendees, as described in a previous study,3 and healthy 
HIV-negative adults were recruited from a prospec-
tive cohort recruited for a Phase III HIV vaccine study 
(n = 60) or from HIV voluntary counselling and test-
ing centres (n = 169). Eligibility criteria included res-
idence within the study communities described above, 
age between 5 and 40 years, confi rmed HIV-negative 
(adults only), non-pregnant, no previous or currently 
suspected episodes of TB and no exposure to isonia-
zid preventive therapy or corticosteroids. 
These studies were approved by the University of 
Cape Town Research Ethics Committee.
Tuberculin skin testing
TST responses were assessed using the WHO-
r ecommended standard methodology.12 Two tuber-
culin units of purifi ed protein derivative (PPD) RT23 
(Statens Serum Institut, Copenhagen, Denmark) were 
administered intradermally to the volar surface of the 
left forearm. Induration was assessed between 48 h 
and 72 h after inoculation and the diameter was mea-
sured. Age and sex were also recorded for each par-
ticipant, as was bacille Calmette-Guérin (BCG) scar 
status in children.
Defi nition of latent TB infection
TST induration of ⩾10 mm at the inoculation site 
was considered indicative of LTBI.
Statistical analysis
‘R’ statistical software was used for analyses. The 
relationship between TST diameter and age was 
e xplored by regression analysis. A generalised non-
parametric logistic model13 was proposed to quantify 
the relationship between LTBI prevalence rate (as de-
fi ned by TST diameter ⩾10 mm) and age. We fi tted 
the model using the penalised regression spline ap-
proach.14 To evaluate sex differences, prevalence rates 
for female and male subjects were obtained separately 
using a generalised semi-parametric logistic model 
which was then fi tted to the data.15 The proportional 
rate of change in TB prevalence per year increase in 
age was estimated using the derivative of the preva-
lence rate with respect to the age of subjects. The an-
nual risk of infection was calculated as: 1 − (1 − 
prevalence)1/mean age+0.5. The force of infection was 
also calculated at specifi c ages for the pool of indi-
viduals who remained non-infected (annual change 
in prevalence/[1 − prevalence]).
RESULTS
TST diameters
TST responses were available from 1061 individuals, 
524 male and 537 female. Diameters of induration 
ranged between 0 and 35 mm, with a mode within 
the 16–20 mm stratum (Figure 1). No TST response 
was recorded in 535 individuals (50.4%), 1–5 mm in 
Figure 1 Frequency distribution of diameters of induration 
at 48–72 h after standardised TST in 1061 individuals aged 5–










408 The  International  Journal  of  Tuberculosis  and  Lung  Disease
8 individuals (0.8%), 5–9 mm in 41 individuals (3.9%) 
and ⩾10 mm in 477 (45%) individuals (Figure 1). 
To establish whether the magnitude of TST re-
sponses was associated with age, TST diameters re-
corded as ⩾1 mm were plotted against age (Figure 2). 
The linear regression line for these data approximated 
to a horizontal line, indicating no overall signifi cant 
relationship. Furthermore, as previously reported,3 
there was no signifi cant difference in mean TST di-
ameter among those aged 5–17 years when compar-
ing those who had observable BCG scars (n = 213) 
and those who did not (P = 0.28). 
Prevalence of LTBI
Using a TST diameter of ⩾10 mm to defi ne LTBI, the 
age-stratifi ed prevalence of infection for the total 
population and for male and female sub-populations 
was calculated (Table 1). LTBI prevalence increased 
steadily from 28.0% in the 5–10 years age stratum to 
a peak of 88.2% in the 31–35 years age stratum. 
To better demonstrate the quantitative relationship 
between LTBI prevalence and age, a non-parametric 
curve fi tting approach was used (Figure 3). The 
smoothed curve shows best fi t of the prevalence with 
increasing age together with 95% confi dence inter-
vals (95%CIs). This analysis was also used to derive 
estimates of the LTBI prevalence at specifi c ages 
(T able 2). This shows that LTBI was estimated to be 
present in approximately one third of 10-year-old 
children, one half of adolescents aged 15 years, two 
thirds of 20-year-olds and three quarters of 25-year-
olds (Table 2). 
LTBI prevalence among males and females
Estimates of LTBI prevalence were separately derived 
for male and female subjects (Figure 4). The differ-
ence in prevalence rates between the male and female 
subjects was greatest among the older study partici-
pants. The maximum estimated LTBI prevalence 
among males was at 33 years (85%) compared to 
Figure 2 Scatter plot of diameters of TST induration vs. age 
at time of performing test. Linear regression demonstrates no 
signifi cant relationship between size of TST response and age. 
TST = tuberculin skin test.
Table 1 Prevalence of positive TST diameter of induration 
(⩾10 mm) stratifi ed by age in township residents (n = 1061) 





















































TST = tuberculin skin test; CI = confi dence interval.
Figure 3 Relationship between the prevalence of TST diame-
ters of ⩾10 mm and age for 1061 subjects, using a generalised 
non-parametric logistic model.13 The 95% point-wise confi dence 
bands are also plotted. The prevalence rate reached a maximum 
of 82% at an age of 27.5 years. TST = tuberculin skin test.
Table 2 Estimated prevalence (95%CIs) of LTBI* at specifi c 
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* LTBI is defi ned as a tuberculin skin test diameter of induration ⩾10 mm. 
The estimated force of TB infection (the annual change in prevalence among 
the remaining non-infected pool of individuals = Δ prevalence / [1 − preva-
lence]) and the mean annual risk of infection for children aged 5–15 years 
are shown with 95%CIs. 
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29 years among females (78%). The decreasing trend 
in prevalence at ages >29 years was mainly due to 
changes in prevalence among females. However, the 
main sex effect (P = 0.22) and the age-sex interaction 
effect (P = 0.29) were not statistically signifi cant.
Rates of change in LTBI prevalence by age
Estimates of the change in LTBI prevalence rate per 
year increment in age were derived for males and fe-
males (Figure 5). The patterns of the curves were sim-
ilar for both groups. The rate of change in prevalence 
rate increased from 5 years of age and peaked at the 
age of 13 years. Maximum rates were 4.4% per year 
in males and 3.7% per year in females (Figure 5). Af-
ter age 13 years, the annual rate of change in LTBI 
prevalence decreased. 
Annual risk and force of infection
Further analyses estimated the ARTI among children 
aged 5, 10 and 15 years, showing a range of 3.9% to 
4.8% per year (Table 2). The force of infection was 
also calculated at specifi c ages for the pool of individ-
uals who remained non-infected (annual change in 
prevalence/[1 − prevalence]; Table 2). This parameter 
reached a peak of 7.9% (95%CI 2.5–13.2) per year 
among individuals aged 15 years and was negative 
above the age of 30 years. This analysis of force of in-
fection did not adjust for active TB disease (an exclu-
sion criterion from the cohort) or TB-associated 
mortality. 
DISCUSSION
We have shown rapidly increasing prevalence of TST 
responses in healthy HIV-negative township resi-
dents aged between 5 and 40 years. Using a cut-off of 
⩾10 mm diameter of induration as evidence of LTBI, 
we found that, by the age of school entry, almost a 
fi fth of children were already infected. By the aver-
age age of sexual debut at 15 years,16 50% of adoles-
cents in these communities were infected. By the age 
of 25 years, when HIV prevalence peaks in South Af-
rica,7 approximately 75% of individuals had evidence 
of LTBI. The rate of increase in the prevalence of 
LTBI was maximal at 13 years of age in both males 
and females. Between the ages of 5 and 15 years, the 
mean ARTI remained exceptionally high (range 3.9–
4.8%), while the force of infection (the risk of infec-
tion in the residual pool of non-infected individuals) 
was maximal, at 7.8%, at the age of 15 years.
The complexities and limitations of the TST have 
been extensively discussed elsewhere.11,12,17 Contro-
versies have included the choice of the antigen uti lised, 
the threshold for defi ning positivity and the perfor-
mance characteristics of the test in different settings. 
The tuberculin reagent employed in this study was 
standard WHO-recommended PPD RT23, which 
a llows comparison with other population surveys.18 
Non-specifi c sensitivity resulting from exposure to en-
vironmental mycobacteria impairs test performance 
in some populations,11 manifesting with a high pro-
portion of low-positive results. In our study popula-
tion, there was a relatively clear separation between 
negative and positive results; the mode of positive re-
sults was in the 16–20 mm diameter stratum and the 
proportion of low positive results was very small. 
Furthermore, diameter of induration was not directly 
associated with known confounders, such as presence 
of BCG scar or the age of participants. We therefore 
used the conventional cut-off for test positivity of 
⩾10 mm. 
Figure 4 Fitted prevalence rate vs. age for male (solid line) and 
female (dotted line) subjects, respectively, using the generalised 
non-parametric logistic model.13 The interaction term of age 
and sex was also considered in the model. The prevalence rate 
reached a maximum (points indicated) of 92% at age 31.5 years 
for male and the peak 84% at age 26.5 years for females.
Figure 5 The annual change in the prevalence of TST diame-
ters of ⩾10 mm vs. age for male (solid line) and females (dotted 
line) subjects are plotted using a generalised non-parametric 
logistic model.13 The change in the prevalence of TST responses 
⩾10 mm increased between age 5 and age 13 years, and 
reached a maximum at age 13 years in both groups. TST = 
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The relationship between prevalence of LTBI, age 
and sex is determined by the individual’s current and 
lifetime exposure to infection. While prevalence in 
children refl ects more recent transmission, prevalence 
in adults refl ects overall historical trends in transmis-
sion risk. It has been observed that, at low prevalence 
rates of LTBI, instability of TST reactions may lead to 
false interpretations of secular trends.19 However, the 
predictive value of TST responses is much greater 
when prevalence of infection is high.11 In our study 
population, TST performance characteristics appeared 
good and LTBI prevalence rates were exceptionally 
high. Furthermore, trends in sputum smear-positive 
TB notifi cations are very well documented, increas-
ing relentlessly over the last two decades in South Af-
rica and particularly in the study communities.1,6,20 
To explore the relationship between LTBI preva-
lence, age and sex, we fi tted a generalised non-
p arametric (i.e., no assumptions about the data distri-
bution) logistic model. The resultant ‘S’-shaped curve 
had strong similarities with age and sex prevalence 
curves from TST surveys performed over 50 years 
ago in urban and rural sites of Bechuanaland (Bo-
tswana), Ghana, Liberia, Nigeria, Sierra Leone and 
Swaziland.21 
Between 5 and 15 years of age, the curve is con-
cave upwards (Figure 3). This could be indicative of 
decreasing transmission in recent years22 but, in the 
known context of rapidly increasing TB notifi cations 
over the past two decades, this is much more likely to 
be indicative of increasing risk of infection with age.23 
The fi nding of maximal risk of acquisition in the mid-
teenage years may refl ect social mixing patterns and 
associated TB exposure in this age group.23,24 
From 15 to 30 years, the curve had an exponential 
form (Figure 3), compatible with either a steady or 
decreasing infection risk with age.23 From 30 years 
onwards, declining prevalence with age was more 
marked in females. Declining of immunological mem-
ory with age did not appear to be a signifi cant con-
tributor, as reaction size was not shown to diminish 
signifi cantly with age. Alternative explanations could 
include immigration from lower prevalence settings, 
survival from a period of lower TB transmission or 
preferential progression of individuals with TST pos-
itivity to TB disease, as a history of TB treatment was 
an exclusion criterion in adult participants. 
Larger TST studies, such as those performed be-
tween 1955 and 1960, included heterogeneous popu-
lations with very variable TB exposure rates.23 This 
study, which was modest in size (n = 1061), focused 
particularly on a population within a single city that 
has an extraordinary high burden of HIV and TB dis-
ease. The study population was not representative of 
the total community, as HIV-infected individuals and 
those who had already developed TB disease were ex-
cluded. We believe that the risk of TB infection and 
performance characteristics of TST in HIV-infected 
patients and patients with TB disease may be very dif-
ferent. The results are therefore only descriptive of 
those remaining free of both TB and HIV. The num-
ber of individuals aged >30 years was relatively small, 
leading to wide CIs around prevalence estimates in 
this age group. The differences between calculated 
and modelled prevalence estimates (Table 1 and Fig-
ure 3) were not statistically signifi cant.
The mean ARTI in children aged <5 years was ap-
proximately 4%, and while the more dynamic mea-
sure of force of infection at a specifi c age was similar 
at 5 years, it reached a peak of 7.9% at age 15 years. 
Such rates of TB infection, as reported elsewhere in 
Cape Town,25 are unprecedented in the modern post-
chemotherapy era. The calculation of force of infec-
tion takes into account both the prevailing rate of in-
fection as well as historical exposure, and may tend 
to underestimate the force of infection in the context 
of rapidly increasing TB notifi cation rates, as has oc-
curred in these communities. The high ARTI suggests 
that individuals may be recurrently exposed to M. tu-
berculosis. This may result in infection with multiple 
strains, and also potentially explains the observed high 
rates of TB recurrence in individuals receiving cura-
tive TB treatment.6
In summary, we have shown an extremely high rate 
of acquisition of LTBI in childhood and adolescence 
in poor African townships of Cape Town. The rates 
observed are as high as the highest rates observed in 
the WHO surveys conducted in African countries over 
50 years ago, in the era prior to modern multidrug 
TB treatment and TB control programmes.21 The com-
bination of high prevalence and force of infection in 
adolescence before the acquisition of HIV infection 
may be a key factor underlying the explosive HIV-
associated TB epidemic in South Africa. HIV preva-
lence among those aged 20–39 years in these commu-
nities reached 30% in 2002,6 and the current data 
suggest that approximately two thirds of these indi-
viduals were likely to have already been infected with 
M. tuberculosis infection prior to HIV acquisition. 
This may be an important factor fuelling high rates 
of HIV-associated TB in southern Africa.
The long-term aim of TB control is to lower infec-
tion rates in successive generations. Present facility-
based TB control is failing to reduce TB infection rates 
in children and adolescents in these communities. 
Systematic evaluation and reduction of infection rates 
in these high-burden communities of Southern Africa 
should be incorporated as a target of TB control. 
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R É S U M É
C O N T E X T E  :   Les faubourgs peuplés de Cape Town, 
A frique du Sud, où les taux de déclaration de la préva-
lence du virus de l’immunodéfi cience humaine (VIH) et de 
la tuberculose (TB) sont parmi les plus élevés du monde.
O B J E C T I F  :   Déterminer les taux de prévalence de l’in-
fection tuberculeuse latente (LTBI) spécifi ques pour l’âge 
parmi les individus séronégatifs pour le VIH et le risque 
annuel et la puissance de l’infection au cours de l’enfance 
et de l’adolescence.
S C H É M A  :   Enquête transversale utilisant un test tubercu-
linique standardisé (TST) chez les individus séronégatifs 
pour le VIH âgés de 5 à 40 ans. On a défi ni comme indi-
quant la LTBI un diamètre du TST ⩾ 10 mm.
R É S U LTAT S  :   Parmi 1061 individus, 4,7% seulement ont 
eu des réactions du TST de faible degré (1 à 9 mm). Toute-
fois, les proportions d’individus dont les diamètres de 
TST sont ⩾10 mm augmentent de 28% dans la classe 
d’âge de 5 à 10 ans jusqu’à 88% dans la classe d’âge de 
31 à 35 ans. Le risque annuel moyen d’infection est 
de 3,9% jusqu’à l’âge de 5 ans. La puissance estimée de 
l’infection (taux d’acquisition de la LTBI dans le réser-
voir ré siduel d’individus non-infectés) augmente pen-
dant l’en fance jusqu’à un maximum de 7,9% par an à 
l’âge de 15 ans. 
C O N C L U S I O N S  :   Les taux extrêmement élevés d’infection 
dans l’enfance et l’adolescence entraînent les taux très 
élevés de prévalence de la LTBI chez les jeunes adultes où 
le risque de l’infection VIH est maximal. Ceci peut être 
un facteur important qui nourrit les taux élevés de tu-
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M A R C O  D E  R E F E R E N C I A :   La prevalencia de infección 
por el virus de la inmunodefi ciencia humana (VIH) y las 
tasas de notifi cación de tuberculosis (TB) en las locali-
dades densamente pobladas de la Ciudad del Cabo en 
Sudáfrica, se encuentran entre las más altas del mundo.
O B J E T I V O S :   Determinar las tasas de prevalencia especí-
fi cas por edad de infección tuberculosa latente (LTBI) 
en las personas con examen serológico negativo para el 
VIH y evaluar el riesgo anual y la fuerza de la infección 
durante la niñez y la adolescencia. 
M É T O D O S :   Se llevó a cabo un estudio transversal apli-
cando la prueba cutánea de la tuberculina (TST) a per-
sonas entre los 5 y los 40 años de edad, con serología 
negativa para el VIH. Se escogió una reacción de diá-
metro ⩾10 mm como indicativo de LTBI. 
R E S U LTA D O S :   De las 1061 personas que participaron, 
solo 4,7% tuvieron reacciones menores a la TST (con 
diámetros de 1 mm a 9 mm). Sin embargo, la propor-
ción de personas con reacciones de diámetro ⩾10 mm 
aumentó de 28,0% en el grupo de 5 a 10 años de edad 
hasta 88,0% en el grupo de 31 a 35 años de edad. El 
riesgo anual de infección promedio fue 3,9% hasta los 
5 años de edad. La fuerza calculada de la infección (la 
tasa de contracción de la LTBI en un grupo residual de 
personas sin infección) aumentó durante la infancia, hasta 
un máximo de 7,9% por año a la edad de 15 años. 
C O N C L U S I O N E S :   Las tasas extremadamente altas de 
i nfección tuberculosa en la infancia y la adolescencia 
conllevan altas tasas de prevalencia de LTBI en los adul-
tos jóvenes, quienes presentan el mayor riesgo de con-
traer la infección por el VIH. Este puede ser un factor 
importante que alimenta las altas tasas de tuberculosis 
asociada con la infección por el VIH en Sudáfrica.
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M A J O R A R T I C L E
Tuberculosis Transmission to Young Children
in a South African Community: Modeling
Household and Community Infection Risks
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Stephen D. Lawn,1,2,4 and Linda-Gail Bekker1,2
1Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine, and 2Department of Medicine, University of Cape Town
Faculty of Health Sciences, and 3Department of Science and Technology/National Research Foundation Centre of Excellence in Epidemiological
Modeling and Analysis, University of Stellenbosch, Cape Town, South Africa; and 4Clinical Research Unit, Department of Infectious Diseases,
London School of Hygiene and Tropical Medicine, London, United Kingdom
Background. Tuberculosis transmission is determined by contact between infectious and susceptible individuals.
A recent study reported a 4% annual risk of child tuberculosis infection in a southern African township. A model
was used to explore the interactions between prevalence of adult tuberculosis infection, adult-to-child contacts,
and household ventilation, which could result in such a high annual risk of tuberculosis infection.
Methods. Number of residents per household and tuberculosis incidence were derived from a household census
and community tuberculosis registers. Using the Wells-Riley equation and probability analyses of contact between
infectious adults with tuberculosis and preschool children, we estimated the annual risk of tuberculosis infection
within and outside of the home.
Results. There was a mean of 2.2 adults per child-containing household with a 1.35% annual adult smear-
positive tuberculosis notification rate. The maximal household annual risk of tuberculosis infection was 3%, which
was primarily determined by the number of resident adults. Transmission risk outside the home increased with
increasing number of households visited. Transmission probabilities were sensitive to exposure time, ventilation,
and period of adult infectivity. The benefits of increased ventilation were greatest when the period of infectivity
was reduced. Similar reductions in household transmission could be achieved by increasing ventilation from 2 to
6 air changes/hour or by separating child and adult sleeping areas.
Conclusions. The annual risk of tuberculosis infection of preschool children predominantly results from in-
fectious residents in the home. However, even with limited social interactions, a substantial proportion of trans-
missions may occur from nonresident adults. The benefits of increased ventilation are maximized when the period
of infectivity is reduced by prompt treatment of source cases.
South Africa is now the country with the fifth highest
tuberculosis burden in the world, with high rates of
both adult and childhood (ages 0–15 years) tuberculosis
notifications [1]. The total number of tuberculosis no-
tifications in the South African city of Cape Town, with
3.2 million people, reached 27,000 in 2006 [2]. How-
ever, the distribution of tuberculosis cases within the
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city is very unequal, with unprecedented high burdens
in the crowded and socially deprived African townships.
In these townships, housing consists largely of informal
shack dwellings, in which the annual tuberculosis no-
tification rates exceed 1500 per 100,000 persons [3–5].
Whereas adult tuberculosis disease is caused by a com-
bination of reactivation of remote infection and rapid
progression of recent adult-to-adult transmission [6],
childhood disease reflects rapid progression from recent
adult-to-child transmission [7]. Childhood (ages 0–15
years) tuberculosis notification rates have been reported
to be 3.5 times the adult rate in specific highly burdened
Cape Town communities, where childhood tuberculosis
contributed 39% of the total tuberculosis case load [8].
Recent studies of childhood tuberculosis infection rates
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Table 1. Age Distribution of Residents in All Study Site Households, Households with Adults Residents Only, and Households with




















All households 6654 1051 1640 12,097 1.82 14,788 2.22
Households with only adults 4946 0 0 8148 1.65 8148 1.65
Households with children aged !15 years 1708 1051 1640 3949 2.31 6640 3.89
Households with children aged !5 years 918 1051 516 2083 2.27 3650 3.98
Figure 1. The proportions of households with preschool children (aged
!5 years) in which different numbers of adults are resident. A total of
2083 adults and 1051 preschool children were resident in 918 households.
Data were derived from a 2008 household survey performed at the study
site.
of tuberculosis infection as high as 4% per annum [9–11]. This
annual risk of tuberculosis infection is similar to reported values
from 60 years ago, before implementation of national tuber-
culosis control programs [12].
Childhood tuberculosis infection is quantitatively related to
exposure of susceptible children to adults who have sputum
smear–positive tuberculosis [13, 14]. The prevalence of infec-
tious adults is determined by the annual incidence rate of
smear-positive tuberculosis in adults and the mean time of
infectivity, the period between becoming infective and either
initiation of effective therapy or death. The prevalence of un-
treated tuberculosis is therefore primarily determined by the
effectiveness of the tuberculosis control program to identify,
diagnose, and effectively treat infective tuberculosis cases. The
risk of a possible transmission event is related to the number
of contacts a child has with infectious adults. The efficiency of
transmission, in turn, is determined by the infectiousness of
the source, the length of contact, and the environmental char-
acteristics at the site of a contact. Tuberculosis transmission
thus results from the interplay between social interactions, en-
vironmental factors, and the prevalence of infective adults. The
period of infectiousness (D) of adults is the only modeled pa-
rameter affected by the activities of the tuberculosis control
program.
We modeled tuberculosis transmission among preschool
children (aged 0–5 years), both in and outside of their primary
residence, using the distribution of resident adults per house-
hold and the prevalence of adult infectious tuberculosis. The
modeled transmission probabilities were adjusted for length of
exposure time and variable household ventilation characteris-
tics. We also explored decreased periods of adult infectivity and
increased household ventilation, which would be required to
achieve significant reductions in transmission.
METHODS
Study design. The study aim was to explore probabilities of
transmission from adults to preschool children within and out-
side of households in a South African township. The Wells-
Riley equation is a well-known transmission model that has
been used to describe airborne transmission probabilities of a
single enclosed room or space with defined ventilation [14].
The Wells-Riley equation, which has been applied to a wide
range of transmission scenarios [15–19], was used in combi-
nation with the distribution of adults per household and their
probability of being infectious, to explore adult-to-child tu-
berculosis transmission probabilities.
Study community. The study site used to provide data in-
puts to these modeling analyses is a periurban township (Site-
M) near Cape Town, South Africa, which was established in
1992 and has grown to a 2008 population of 14,788 people.
The township is home to an almost exclusively African pop-
ulation, the adult human immunodeficiency virus (HIV) prev-
alence in 2005 was 23%, and the majority of persons have low
socioeconomic status [3]. Unemployment exceeds 50%, and
housing predominately consists of closely aggregated, formal
and informal structures. The township has clearly demarcated
boundaries and constitutes a well-defined population for re-
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No. of tuberculosis notifications 1289 1158 45 86 670
Population years of exposure 67,747 53,056 9181 5510 53,056
Tuberculosis rate per 100,000
population (95% CI) 1909 (1799–2018) 2137 (1984–2339) 546 (346–546) 1522 (1419–1533) 1347 (1108–1437)
NOTE. CI, confidence interval.
Tuberculosis control program. The study community is
served by a single government primary health care clinic with
a dedicated tuberculosis service. All patients with tuberculosis
in the community are treated at this facility. The program ad-
hered to the South African National TB Control Program
guidelines and included the World Health Organization Directly
Observed Treatment Short Course (DOTS) strategy [20]. DOTS
coverage in this community was complete, and treatment com-
pletion rates for smear-positive disease exceeded 80% [13].
Adult pulmonary sputum-positive tuberculosis was diagnosed
on the basis of at least 1 sputum culture positive for Myco-
bacterium tuberculosis or 2 sputum smears containing acid-fast
bacilli in the context of a compatible clinical illness. Childhood
tuberculosis diagnosis was made with a scoring system using a
combination of clinical and radiological features [20]. A score
7 indicated a high likelihood of tuberculosis, using the fea-
tures length of illness (1–3), nutritional status (1–3), family
history of smear-positive disease (3), tuberculin skin test reac-
tivity (3), enlarged lymph nodes (3), abdominal mass (3), cen-
tral nervous signs (3), chest radiography (3), and spinal angling
(4). All sputum testing was performed at the National Health
Laboratory Services facilities in Cape Town.
Data sources. Tuberculosis definitions used for notification
data were as defined by the South African TB Control Program
[20]. Tuberculosis is a notifiable condition in South Africa, and
each tuberculosis clinic is required to maintain and report tu-
berculosis statistics. The numbers of tuberculosis notifications,
demographic characteristics, history of previous tuberculosis,
sputum microbiologic test findings, and tuberculosis classifi-
cation data were obtained from the community tuberculosis
clinic register. Tuberculosis program data were collected for the
years 2004–2008, to cover the period of potential tuberculosis
exposure for children aged 5 years in 2008. Demographic
data for the community were derived from household censuses
performed in 2004, 2006, and 2008 as part of an ongoing health
research program. This research was approved by the Research
Ethics Committee of the University of Cape Town.
Mathematical transmission model. The number of child-
hood tuberculosis infections (C) within a household with sus-
ceptible children (S) was assumed to be a function of the num-
ber of infectious adults (I), their infectivity (q), the time of
exposure (t), the susceptible respiration rate (p), and germ-free
ventilation (Q) as given by the Wells-Riley equation: C p
. The number of infectious adults at any time isIptq/QS(1  e )
given by the smear-positive incidence rate (M) and the period
of infectivity (D). The risk of contact with an infectious adult
is given by the Poisson distribution , whereI l(l/I!)e l p
is the expected number of infectious adults in a house-M ∗ A
hold with A adults. Prevalence was defined as .M/(365/D)
Modeled inputs. Germ-free ventilation (Q) was calculated
as air changes per hour (ACH) for a standard shack dwelling
with a volume of 30 m3. Three values of ACH were modeled:
2 ACH (poor ventilation), 6 ACH (moderate ventilation), and
12 ACH, which is recommended by the World Health Organ-
ization for an airborne precaution room [21]. Shacks with
closed windows and doors would have an ACH of 2. Shacks
with an open window (size, 0.25 ) facing the prevailing wind2M
and an open door on the leeward side would achieve 6 ACH
with low prevailing wind speeds of 4–5 km/h and 12 ACH with
winds of 8–10 km/h [22].
The rate of production of infectious tuberculosis quanta (q)
was modeled at a value of 1 infectious quantum per hour, which
is the mean measured value of smear-positive inpatients in a
tuberculosis ward [15]. Sensitivity analyses were performed for
values of q between 0.1 and 10 infectious quanta/h. The mean
respiratory rate of preschool children aged 0–5 years was es-
timated to be 225 L/h, which approximates a respiratory volume
of 150–200 mL/kg/min [23].
The period of diagnostic delay during which an adult may
be infective has been estimated in a systematic review to be
very variable but is frequently reported to be 60–90 days [24].
Since D may exceed the period of diagnostic delay and is the
primary modeled parameter influenced by the functioning of
the tuberculosis control program, it was allowed to take values
of 30, 60, 90, and 120 days in the model.
For modeling purposes, child time allocation within a 24-h
period was 12 h within the home, to allow interaction with
resident adults during the evening and night, including 8 h for
sleeping and 4 h for other family activities. Similar exposure
to nonresident adults can result from adults visiting the primary
home or from the child visiting other households. For modeling
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which tuberculosis transmission was assumed to be negligible,
and 9 h allocated equally between 1–3 additional households
with similar numbers of residents as in the primary residence.
RESULTS
Household Survey 2008
The total population of the study community in December
2008 was 14,788, of whom 12,097 were adolescents and adults
aged 115 years and 2691 were children aged !15 years, in-
cluding 1051 children aged !5 years. The total number of
households was 6654, of which 1708 contained children aged
!15 years and 918 contained children aged !5 years. The age
distribution of residents of households with adults only and
with both adults and children is shown in Table 1. Crowding
in child-containing households was twice as high as that in
adult-only households. Of the 918 households with children
aged !5 years, 800 contained a single child, 109 contained 2
children, and 9 contained 3 children aged !5 years. The median
number of adults in these households was 2.27 per household,
and only 28% of these households had 3 resident adults
(Figure 1).
Tuberculosis Notifications
From 2004 through 2008, 1289 cases of tuberculosis were no-
tified to the national tuberculosis control program, of which
90% occurred in adults and 10% occurred in children aged
15 years. Of the childhood tuberculosis cases, 66% occurred
in children aged !5 years (Table 2). The population increased
from 12,803 in 2004 to 14,788 in 2008, resulting in a total of
67,747 person-years of residence. The population growth was
restricted to adults, because the population of children aged !5
years remained relatively constant, with 1057 children in 2004
and 1051 children in 2008. A mean of 1.35% of the adult
population were identified as having sputum smear–positive
tuberculosis each year (Table 2).
Transmission from Resident Adults
Ventilation. The modeled impact of increasing the shack ven-
tilation on the probability of a child becoming infected with
tuberculosis is shown for 4 periods of adult infectivity (D p
, 60, 90, and 120 days) in Figure 2A. The maximal risk of30
tuberculosis transmission even under poor environmental ven-
tilation and a prolonged period of adult infectiousness reached
only 3%. This maximal condition was primarily determined by
the mean number of adults resident in the household and their
tuberculosis incidence rate. Transmission could be reduced by
a combination of high ventilation and a reduction of the in-
fectivity period. For example, a reduction of the risk of trans-
mission to 1.5% would require either 4, 8, or 12 ACH for D
values (period of infectiousness) of 30, 60, and 90 days, re-
spectively. Sensitivity analyses with low values of infectious
quanta ( ) were unable to reach significant transmissionq p 0.1
probabilities, and high values of infectious quanta ( )q p 10
reached probabilities 12.75% at all achievable values of D and
ACH.
Infective period. The modeled impact of increasing periods
of adult infectiousness (D) on the probability of a child aged
!5 years becoming tuberculosis infected is shown for 3 levels
of ventilation (2, 6, and 12 ACH) in Figure 2B. The benefits
of increased ventilation are greatest when D is low. Increasing
ventilation from 2 to 6 ACH reduces transmission to 2.5%
(16%), to 2.2% (25%), 1.8% (36%), and 1.1% (51%)
for D values of 120, 90, 60, and 30 days, respectively. Identical
reductions in transmission could be alternatively obtained by
reducing the child exposure time by 8 h per day. A reduction
in exposure time could be achieved by separation of child sleep-
ing areas from those of adults for an 8-h sleeping period. When
the modeled infective number of infectious quanta were low
( ), the transmission probabilities of transmission didq p 0.1
not reach 1%, and when the number of quanta were high
( ), the tuberculosis transmission probabilities rapidly be-q p 10
came maximal at 3% with minimal sensitivity to either in-
creased ventilation or shortened period of infectivity. The mod-
eled proportions of annual risk of tuberculosis infection due
to transmission from resident adults were 70% and 74% for
periods of infectivity of 60 and 90 days, respectively. Therefore,
we went on to explore additional transmission (26%–30%) that
might occur as a result of contact with other potentially in-
fective adults in addition to those residents in the home.
Transmission from Nonresident Adults
The probability of tuberculosis infection as a result of spending
75% of daytime indoors and visiting 1–3 households other than
the child’s home is shown for visited households with poor
ventilation (2 ACH) in Figure 3A. Increasing the number of
visited households increased the exposure to an additional 2.2
potentially infective adults per household, which resulted in
greatly increased probabilities of infection when D exceeded 30
days. When multiple poorly ventilated households were visited,
annual risks of tuberculosis infection exceeding 4%, 5.5%, and
6% could be achieved when D was 60, 90, and 120 days, re-
spectively. Sensitivity analyses of low infectious quanta (q p
) resulted in transmission risks !1%, and high infectious0.1
quanta ( ) resulted in rates of transmission that wereq p 10
directly related to the number of households visited for all
modeled values of D.
In contrast, the corresponding risks of infection when visiting
households with 6 ACH showed minimal increase in trans-
mission risk with increasing number of households visited. Un-










Tuberculosis Transmission to Children • CID 2010:51 (15 August) • 405
Figure 2. A, Effect of ventilation (air changes per hour [ACH]) and mean period of infectivity (delta) on the mean annual risk of tuberculosis infection
resulting from a child sleeping in a shack shared with adults. Values are plotted for mean periods of adult infectivity of 30, 60, 90, and 120 days.
B, Effect of period of infectivity (delta) and ventilation (ACH) on the mean annual risk of tuberculosis infection resulting from a child sleeping in a
shack shared with adults. Values are plotted for 2, 6, and 12 ACH. Note that the period of infectivity (delta) is the mean time from onset of infective
tuberculosis until initiation of effective antituberculosis chemotherapy. Modeled estimations are based on a potential nighttime exposure of 12 h, a
median of 2.2 adult residents per shack, a 1.35% annual risk for smear-positive tuberculosis, and a mean production of 1 infectious airborne quantum
of tuberculosis per hour during untreated smear-positive disease.
determinant of tuberculosis transmission risk. Sensitivity anal-
yses of low infectious quanta ( ) resulted in transmissionq p 0.1
risks of !0.4%, and high infectious quanta ( ) resultedq p 10
in rates of transmission of 6%–9% that were directly related
to number of households visited for all values of D.
DISCUSSION
These modeling analyses demonstrate that the high reported
rates of community tuberculosis transmission to children in
southern Africa [9–13] can be explained by the interplay be-
tween the prevalence of adult infectious tuberculosis, social
mixing between adults and children, and the prevailing do-
mestic ventilation characteristics.
The model in this study was based on the Wells-Riley equa-
tion, which has been used to examine airborne tuberculosis
disease transmission since the 1970s [14] in a wide variety of
medical and nonmedical settings and thus has been useful for
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Figure 3. Mean annual risk of tuberculosis infection for a child visiting 1–3 households other than his or her own residential household during the
day with ventilation of 2 air changes per hour (A) and 6 air changes per hour (B). Values are plotted for mean periods of adult tuberculosis infectivity
(delta) of 30, 60, 90, and 120 days. Note that the period of infectivity (delta) is the time from onset of infective tuberculosis until initiation of effective
antituberculosis chemotherapy. Modeled estimations are for a preschool child spending 75% of daytime indoors, a median of 2.2 resident adults per
visited shack, a 1.35% annual risk for smear-positive tuberculosis, and a mean production of 1 infectious airborne quantum of tuberculosis per hour
during untreated smear-positive disease.
real-life situations [15–19]. This study used a novel approach
of incorporating population data from a specific South African
township to populate the Well-Riley equation, to explore house-
hold and nonhousehold tuberculosis transmission to preschool
children.
Of particular interest, our model indicated that the potential
of the existing clinic-based tuberculosis control program to
reduce transmission to children is somewhat limited. Even re-
ductions in D (the period of infectiousness) to 30 days by active
case finding and rapid tuberculosis diagnosis would have sig-
nificant impact on transmission to children only when venti-
lation rates in households exceed 6 ACH. However, such high
ventilation rates for informal dwellings during the cold Cape
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Since similar reductions in tuberculosis transmission could be
achieved by separating child and adult sleeping areas, this might
be a more practicable stratagem.
Another major finding of our study was that a maximum of
75% of the total annual risk of infection could possibly be
explained by the interaction between a child and the limited
number of adults resident in a primary household. Preschool
children are susceptible to tuberculosis infection predominantly
because of exposure to infectious adults [6, 7]; therefore, the
main determinant of maximal transmission risk in either setting
was the number of adults to whom a child was exposed.
Our model also indicated that at least 25% of the risk of
infection resulted from exposure to nonresident adults. In well-
ventilated settings, transmission was related to D, rather than
to the number of households visited. In contrast to transmission
risks from adult household residents, transmission from non-
resident adults can be markedly influenced by the tuberculosis
control program’s ability to decrease D by active case finding.
In poorly ventilated nonresidence settings, transmission risks
increased markedly with increasing numbers of households vis-
ited. These analyses indicate that as children become more
socially mobile, the potential for transmission in poorly ven-
tilated nonhousehold settings might become the largest con-
tributor to total transmission risk. Indeed, we have reported
increasing tuberculosis infection rates throughout childhood in
this community, which peak at ∼8% at age 15 years [11].
The strength of this study was the availability of accurate
information specific to this community, including the annual
risk of tuberculosis infection, the number of adults and children
per household, and smear-positive tuberculosis notification
rates. A caveat is that some important parameters, such as D
and the numbers of infective quanta produced by adults with
tuberculosis disease, are difficult to measur directly, and es-
timates were derived from published data. Indeed, D may not
be identical to the period of diagnostic delay in published stud-
ies, and the incidence of smear-positive tuberculosis may only
approximate the smear-positive notification rate. The model
used the epidemiologic assumption that the tuberculosis epi-
demic was generalized, with equal mixing of infectivity and
contact risks. However, stochastic transmission events, such as
close nonhousehold contact with highly infectious individuals,
are not captured in this model. Despite these limitations, the
outputs from the model were robust and were compatible with
the previously observed annual risk of tuberculosis infection
in this and similar communities [9–11].
Our findings may give insight to why tuberculosis rates of
transmission in South Africa have remained very high despite
apparent improvement in case management by the tuberculosis
control program [1]. The conditions within crowded African
townships with high unemployment rates may have much in
common with the conditions present during the industrial rev-
olution of the 18th and 19th centuries, when tuberculosis bur-
dens were also extremely high. Children lived and worked side-
by-side with adults [25], but successive factory acts in the
United Kingdom and the United States reduced the childhood
exposure to adults in the workplace [26, 27]. Improvement in
housing and schooling also reduced the amount of close ex-
posures between children and adults. The crèche movement
further limited the frequency of contacts between young chil-
dren and potentially infectious adults [28] and may have the
potential to decrease nonhousehold transmission in crowded
townships. Reduction in household tuberculosis transmission
in poor informal housing will be difficult to achieve. However,
improvement of housing stock should particularly focus on
improved ventilation and separation of child from adult sleep-
ing areas.
These modeled analyses have identified social and environ-
mental factors that contribute to high rates of tuberculosis
transmission in this community. Social mixing patterns of pre-
school children result in tuberculosis transmission within the
extended family, rather than the nuclear family. Where tuber-
culosis is highly endemic, interruption of community tuber-
culosis transmission requires prompt treatment of source cases.
Tuberculosis control will therefore necessitate an increased fo-
cus on active case finding and a reduction in diagnostic delays.
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Abstract
Background: Understanding of the transmission dynamics of tuberculosis (TB) in high TB and HIV prevalent
settings is required in order to develop effective intervention strategies for TB control. However, there are little data
assessing incidence of TB infection in adolescents in these settings.
Methods: We performed a tuberculin skin test (TST) and HIV survey among secondary school learners in a high
HIV and TB prevalence community. TST responses to purified protein derivative RT23 were read after 3 days. HIV-
infection was assessed using Orasure® collection device and ELISA testing. The results of the HIV-uninfected
participants were combined with those from previous surveys among primary school learners in the same
community, and force of TB infection was calculated by age.
Results: The age of 820 secondary school participants ranged from 13 to 22 years. 159 participants had
participated in the primary school surveys. At a 10 mm cut-off, prevalence of TB infection among HIV-uninfected
and first time participants, was 54% (n = 334/620). HIV prevalence was 5% (n = 40/816). HIV infection was not
significantly associated with TST positivity (p = 0.07). In the combined survey dataset, TB prevalence was 45% (n =
645/1451), and was associated with increasing age and male gender. Force of infection increased with age, from
3% to 7.3% in adolescents ≥20 years of age.
Conclusions: We show a high force of infection among adolescents, positively associated with increasing age. We
postulate this is due to increased social contact with infectious TB cases. Control of the TB epidemic in this setting
will require reducing the force of infection.
Background
Tuberculosis (TB) remains a major cause of morbidity
and mortality in the world[1]. In order to develop effec-
tive intervention strategies for TB control, it is impor-
tant to understand TB transmission in high burden
settings. While there have been recent studies assessing
TB infection in young children[2-5], there are few data
assessing TB infection in older children and adolescents
in communities with high TB and HIV burdens[6].
Incidence of TB infection is a measure of current trans-
mission in a community. While repeated testing of
uninfected individuals over time is a conventional
method for determining incidence of a disease, this
methodology is both labour and time intensive, and is
further complicated by the boosting of the immune
response in immunology-based tests such as the tubercu-
lin skin test (TST)[7,8]. Therefore alternative approaches
for calculating incidence from prevalence data have been
developed. The annual risk of TB infection (ARTI), cal-
culated from TB infection prevalence data, is an averaged
measure of risk of TB infection over the lifetime of the
study participants[7,9]. The limitation of this measure is
that ARTI only provides an estimate of current transmis-
sion or incidence if calculated in very young participants.
In comparison, force of infection, defined as the propor-
tion of susceptible individuals that have become infected
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with Mycobacterium tuberculosis in a specified period,
can be calculated using changes in age-specific preva-
lence rates[10-12], and provides an estimate of recent
infection incidence across a wider age range.
This approach is a relatively new concept that has
been utilized to estimate incidence in diseases in which
true incidence is difficult or costly to measure, such as
glaucoma[13] and more recently, HIV[12,14]. The math-
ematical techniques utilized are based on the principle
that prevalence is a function of incidence and duration
of illness or infectivity[15]. This principle holds true
under the assumptions of disease stability. Data from
this community suggest that TB transmission has
remained relatively constant over the past decade, as
evidenced by the stable TB notification rates among
HIV-uninfected adults from 1997 to 2008[16], as well as
the stable childhood TB over the same time period[2].
We performed a TST survey among adolescents in a
high HIV and TB prevalence community to assess pre-
valence of TB infection and force of infection by age.
Methods
This study was the third in a series of cross-sectional
tuberculin skin testing surveys performed among
school-attending children in the study community. The
first two surveys were performed in the local primary
school in 2006 and 2007[2]. The survey reported in this
manuscript was performed in children attending second-
ary school in the study community in 2009. The same
methodology was used in all three surveys, with the
addition of HIV testing in the secondary school survey.
Children were eligible if they were resident in the com-
munity and registered at the local secondary school.
Parental consent, and assent from participants <18 years
of age, were obtained prior to enrolment. Adolescents
≥18 years of age provided written consent. Basic demo-
graphic information was collected and participants were
examined for the presence of a BCG scar. Participants
received the TST regardless of BCG scar status.
The WHO-recommended standard Mantoux test of
2TU of PPD (Purified Protein Derivative) RT23 with
Tween 80 (Statens Seruminstitut, Copenhagen) was
administered intradermally to the volar surface of the
left forearm by a trained nurse. The tuberculin reaction
size was read by a trained assessor three days following
the inoculation. The presence or absence of a reaction
was noted, and, where present, the size of the induration
was measured along perpendicular axes using standard
calipers. Participants also provided an oral transudate
specimen for HIV testing, using the Orasure® collection
device and Vironostika Uni-Form II HIV-1 and HIV-2
plus 0 ELISA test (bioMérieux SA, Marcy l’Etoile,
France). HIV results were anonymous but linked to TST
results and all adolescents were encouraged to have
separate voluntary counseling and testing at local facil-
ities. HIV testing was not performed in the primary
school surveys[2].
This study was approved by the University of Cape
Town’s Research Ethics Committee. All children with a
TST reaction ≥10 mm were recalled for investigation for
active tuberculosis and referred to the local clinic for
further management if appropriate.
Data were analyzed using STATA 9.0 (StataCorp, Col-
lege Station, Texas). Analysis was performed in two
parts: firstly on the secondary school dataset, excluding
HIV-infected individuals, and secondly on the secondary
school dataset combined with the primary school dataset,
excluding the HIV-infected individuals from the second-
ary school survey. Children who declined HIV testing
were considered to be HIV-uninfected for the purposes
of the TB analysis.
TST results were calculated as the mean of the two dia-
meters of the TST reaction: a positive reaction was defined
at 10 mm cut-off, based on clinical guidelines[17,18].
ARTI was calculated as 1-(1-prevalence)1/(mean age+0.5)[19].
As the age in full years at participants’ last birthday was
used, 0.5 was added to the mean age for the calculation of
ARTI[19]. The secondary school sample was divided into
age quartiles and TB prevalence and ARTI were calculated
overall and for each age group. Bivariate analyses
employed Student’s t-, Fisher’s exact and Wilcoxon sum
rank tests, as appropriate. Multiple logistic regression
models were developed to examine factors associated with
positive TST results.
HIV data secondary school participants
Univariate and multivariate logistic regression models
were developed to determine the demographic charac-
teristics associated with HIV, and to assess for an asso-
ciation between HIV and TB infection. In these models,
a TST reaction size of ≥5 mm was used as a positive
cut-off for TB infection in HIV-infected adolescents, in
keeping with clinical guidelines[17,18].
Subset of repeat TST participants
Overall, 159 students who had participated in the 2007
survey also took part in the secondary school survey,
resulting in repeat tuberculin testing of these partici-
pants. Repeated TST tests may be associated with boost-
ing of the immune response, complicating the
interpretation of the second TST reaction size[7,8]. We,
therefore, analyzed this subset of participants separately
from the rest of the cohort. In keeping with existing lit-
erature, we defined a true conversion to TST positivity
between the two surveys as a change from a negative
result (<10 mm) on original TST to a positive result
(≥10 mm) on the second test, with an absolute reaction
size increase of at least 6 mm[20-22]. Bivariate analyses
Middelkoop et al. BMC Infectious Diseases 2011, 11:156
http://www.biomedcentral.com/1471-2334/11/156










used Wilcoxon sum rank and Student’s t tests, as appro-
priate for comparison of participants with repeated TST
compared to first time participants in 2009. A multivari-
ate regression model was developed to compare reaction
sizes between the two groups. The McNemar test was
used for matched comparison of 2007 and 2009 TST
results.
Combined surveys database
In order to assess the effect of age on TB prevalence
and force of infection, we combined the primary and
secondary survey datasets, excluding HIV-infected parti-
cipants from 2009, as well as the second test in those
participants who had repeat tests in 2009. The partici-
pants were divided into age quartiles and TB prevalence
and ARTI were calculated overall and for each age
group.
Smoothed prevalence of TB infection by age was cal-
culated from predictive logistic regression models on
the combined primary and secondary school dataset,
overall and stratified by gender, excluding those who
tested HIV-infected in the secondary school. Force of
infection was calculated at specific ages for the pool of
individuals who remained uninfected [annual change in
prevalence/(1-prevalence)]. Trends in ARTI and force of
infection were assessed using Cox-Stuart test for trend
[23,24].
For all analysis, 95% confidence intervals (CI) were
based on the Poisson distribution and all statistical tests
were 2-sided at alpha = 0.05.
Results
Of the 959 children enrolled in the secondary school,
839 were eligible for study participation (87%). Ineligibil-
ity was due to residence outside of the community (n =
80) or having dropped out of school (n = 40). Consent/
assent was obtained for 820 children (98% of those eligi-
ble). Refusal by parent or learner accounted for 18 non-
consenters and 1 child was not consented due to absen-
teeism over the study period. All 820 consented students
were enrolled. Four of the children enrolled declined
tuberculin skin testing, and four children declined HIV
testing. Of the 816 children who underwent skin testing,
813 (99.6%) had the TST reaction read within 72-96
hours (Figure 1). No study-related adverse events were
noted in the three children assessed outside the window
period and these participants were excluded from the
analysis.
Table 1 shows the demographic characteristics of the
secondary school study cohort. Of the 813 participants
who completed TST testing, 159 had received tuberculin
skin testing in the 2007 survey in the community. These
participants were excluded from the main analysis and
their results are presented in a sub-analysis. Of the
remaining 654 children, all but three of the participants
underwent HIV testing. In total 34 participants of the
remaining participants tested HIV-infected, and were
excluded from the TB analysis (n = 620; Figure 1).
Among the 620 participants, ages ranged from 13 to
22 years, with a mean age of 17.5 years, and 59% of par-
ticipants were female. The majority of the children did
not have a BCG scar (87%); one child’s BCG scar status
was not recorded, and this participant was excluded
from analysis involving BCG scar status.
TST reaction sizes ranged from 0 to 30 mm (median
= 11.5 mm; IQR: 0-16.5 mm), and 222 children had a
TST result of 0 mm (36%). The frequency distribution
of reaction sizes >0 mm are presented in Figure 2.
There was no significant difference between the median
size of reactions in participants with BCG scars com-
pared to those without scars (11 vs 11.5 mm respec-
tively, p = 0.24).
At the 10 mm cut-off 334 participants (54%) had a
positive TST result. There was no significant difference
in the defined TB positivity by BCG scar status (p =
0.99). In a multivariate logistic regression model predict-
ing the relative odds of a positive TST result, age was
positively associated with a positive TST result (adjusted
odds ratio (OR) for a 1-year increase in age: 1.10, 95%
CI: 1.01 - 1.21; p = 0.03), as was male gender (adjusted
OR for female compared to male: 0.65, 95% CI: 0.47-
0.90; p = 0.01).
The overall ARTI for this sample was 4.2% (95% CI:
3.8-4.7%). Table 2 reports TB prevalence and ARTI
overall, and by age quartiles. The ARTI did not differ
significantly across the age quartiles (p = 0.75) or across
age by years from 14 to 21 years of age (p = 0.63).
Sub-analysis: HIV and TB infection
Of the 820 participants enrolled in the secondary school
survey, 816 (99.5%) consented to HIV testing. In total
40 (4.9%) participants tested HIV-positive. In a logistic
regression model, HIV infection was associated with
increasing age (OR: 1.3; 95% CI: 1.1-1.6; p = 0.001) and
female gender (OR: 2.3; 95% CI: 1.1-4.7; p = 0.03).
Among the 809 participants who underwent both TST
and HIV testing, 38 were HIV-infected, four of whom
had previous TST testing in 2007. The median TST
reaction size among HIV-infected participants (amongst
those who did not have repeat TST assessment; n = 34)
was smaller than that of HIV-uninfected participants (0
vs 11.5 mm; p = 0.08), and this difference was signifi-
cant when adjusted for age and gender (p = 0.04). Using
the revised cut-off of ≥5 mm, 15 (40%) HIV-infected
participants were TST positive. In a multivariate logistic
regression model adjusted for age and gender, HIV
infection was not significantly associated with TST posi-
tivity (OR = 0.53; 95% CI: 0.27-1.05; p = 0.07).
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Figure 1 Consort Diagram for Secondary School Cohort. * including the 3 participants who declined HIV testing
Table 1 Demographic characteristics of the secondary school sample.
First time TST participantsF Repeat TST participantsFF
HIV-uninfected HIV-infected Total HIV-uninfected HIV-infected Total
n = 617 n = 34 n = 654 n = 154 n = 4 n = 159
n (%) n (%) n (%) n (%) n (%) n (%)
Age: mean (range) 17.5 (13-22) 18.4 (15-22) 17.5 (13-22) 15.4 (13-19) 15.3 (14-17) 15.4 (13-19)
13-16 yrs 176 (29) 5 (15) 183 (28) 133 (86) 3 (75) 136 (86)
17 yrs 148 (24) 4 (12) 152 (23) 13 (8) 1 (25) 15 (9)
18 yrs 112 (18) 9 (26) 121 (19) 6 (4) 0 (0) 6 (4)
19-22 yrs 181 (29) 16 (47) 202 (30) 2 (1) 0 (0) 2 (1)
Gender: Male 255 (41) 9 (34) 266 (41) 81 (53) 2 (50) 84 (53)
BCG Scar present 80 (13) 6 (18) 86* (13) 32 (21) 0 (0) 32 (20)
TST positive 331 (54) 11 (32) 345 (53) 90 (58) 1 (25) 91 (57)
*n = 653: one participant’s BCG scar status was not recorded
F Three participants declined HIV testing
F F One participant declined HIV testing
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Sub-analysis: Repeated TST testing
In 2009, 159 students who had participated in the 2007
survey took part in the secondary school survey, four of
whom were HIV-infected. The mean reaction size in
2009 among participants with repeat tests was larger
compared to participants who tested for the first time
(15 vs 11.5 mm; p < 0.001), and this finding persisted
when adjusted for age and gender (p < 0.001). Overall,
TB prevalence did not differ between those that had a
repeat TST test and those participants who were testing
for the first time (58 vs 54%, p = 0.29).
Using a 10 mm cut-off for positivity, in 2007, 76 (48%)
of the 159 participants had a positive TST result; in
2009 91 (57%) tested TST positive. Overall, 19 of the 83
participants who were TST negative in 2007 tested posi-
tive in 2009 (p = 0.003), and four (5%) reverted to a
TST negative result. Using the definition outlined above,
18 of the 19 convertors had an increase in reaction size
of ≥6 mm and were therefore considered true new
infections with TB. These 18 participants, from the pool
of 83 susceptible children in 2007, equate to an inci-
dence of 22% over two years (95 CI: 13-32%), or an
annual incidence of infection of 11% ([18/83]/2).
Combined Primary and Secondary school database
In order to assess the effect of age on TB prevalence and
force of infection, we investigated combining the primary
and secondary school surveys. We compared the preva-
lence of TST positive results for the three cohorts in the
overlapping age ranges of 10 to 12 years and 14 to 16
years. The chi-squared test for comparison was not sig-
nificant (survey 1 and 2: p = 0.66; survey 2 and 3: p =
0.46), nor was survey year a significant risk factor in mul-
tivariate regression model for TST positivity (p = 0.23).
Therefore we combined these two datasets. In the pri-
mary school survey, TST readings were available for 831
of the 832 children enrolled. Therefore the combined
database, excluding the participants who tested HIV-
infected, was comprised of 1,451 participants.
Ages of the combined cohort ranged from 5 to 22 years,
with a mean age of 13.6 years (standard deviation = 4.1),
and 52% of participants were female. The majority of the
children did not have a BCG scar (80%); BCG scar status
was not available for two participants and they were there-
fore excluded from analysis involving BCG scar status.
TST reaction sizes ranged from 0 to 30 mm (mean =
8.0; median = 0 mm). Overall 728 (50%) of the participants
had no reaction to the TST. At the 10 mm cut-off 645
participants (45%) had a positive TST result (Table 3). TB
prevalence by age is presented in Figure 3. In a multivari-
ate logistic regression model a positive TST result was sig-
nificantly associated with age (adjusted OR for a 1-year
increase in age: 1.17, 95% CI: 1.10 - 1.25; p < 0.001) and
male gender (adjusted OR for female compared to male:
0.74, 95% CI: 0.60-0.92; p = 0.01). TST positivity was not
associated with BCG scar status (p = 0.40).
Table 4 reports the smoothed prevalence of TB infec-
tion by age, as predicted by our logistic regression
model. Also reported in Table 4 are the ARTI and force
of infection by age, calculated from the smoothed preva-
lence. The overall ARTI for this sample was 4.1% (95%
CI: 3.8-4.4%). The ARTI did not differ significantly
across age by years from 6 to 22 years of age (p = 0.15).
The force of infection increased with increasing age, and
this trend was significant (p = 0.01).
Discussion
This is one of the first studies to report TB infection
prevalence, ARTI and force of infection in adolescents
in a high TB and HIV prevalent setting.
Figure 2 Frequency distribution of TST reactions (>0 mm) in
HIV-uninfected participants in secondary school survey.
Table 2 Secondary school TB prevalence and ARTI by age
quartile for the 10 mm cut-off point (excluding HIV-



























TOTAL 18 620 334 53.9% 4.2%
(3.8-4.7%)
* The mean age reported here is the age used for the ARTI calculations, and
is based on the mean age for the age category+0.5 years, as described in the
methods section.
Note: Participants who declined HIV testing were presumed to be HIV-
uninfected and were included in the TB analysis
Middelkoop et al. BMC Infectious Diseases 2011, 11:156
http://www.biomedcentral.com/1471-2334/11/156










In this study we confirmed the high ARTI rate
reported in the primary school children[2], and show a
high force of infection. ARTI provides a measure of the
averaged risk of infection over the participants’ lifetime.
Therefore this measure pertains to the annual risk over
a period of up to 20 years, and consequently the ARTI
provides little information on the current transmission
within the study population.
Force of infection is a measure of recent transmission
and the high rates reported here are in keeping with the
substantial burden of TB prevalence[25] and notifica-
tions[26] in this community and in South Africa[1]. We
demonstrated that force of infection was positively asso-
ciated with increasing age. These findings are consistent
with those reported prior to the HIV epidemic[27], as
well as by more recent mathematical modeling[6]. The
advantage that this study had over the modeling paper
is that of greater numbers of older adolescent partici-
pants all recruited from the same community, and the
ability to show that the force of infection continues to
increase up to approximately 20 years of age. In adult-
hood force of infection becomes harder to measure due
to a reduced proportion of susceptible individuals, and
the inability to identify secondary infections.
Force of infection is a function of the probability of
an effective encounter with an infectious TB case, and
as such is a product of TB disease prevalence and mix-
ing patterns. We postulate that the association between
force of infection and age may be due to increasing
social mixing patterns, resulting from changing social
interactions associated with age. We have previously
shown that TB infection in primary school children is
associated with an adult TB case on their residential
plot[28], while TB transmission between adults is due
to social interactions off the residential plots[6]. Data
from Europe shows that number of social contacts
peak in adolescents[29], suggesting that the likelihood
of contact with infectious persons may also peak at
this time. The social interactions, and therefore risk of
TB infection, of mid-teens may more closely resemble
that of adults rather than younger children in the
community.
We have also shown a changing risk of TB infection
by gender: in the primary school surveys, gender was
not associated with TB infection[2], but in the secondary
school survey, male gender was associated with
increased TB infection. As males get older, their risk of
TB infection out-strips that of females of similar age,
and this is consistent with other reports in the literature
[9,21]. This increased risk may be due to a combination
of increased biological susceptibility, differing immuno-
logical responses or differences in socialization patterns
of male compared to female adolescents.
The lack of association between HIV and TB infection
is a key finding: adolescents infected with HIV did not
appear to be at higher risk for acquiring primary TB
infection. This is in keeping with findings reported from
lower HIV and TB prevalent settings[30,31], and consis-
tent with studies that suggest the establishment of TB
infection is mechanistic, as opposed to immune-based
[32]. However, adolescents are at increased risk of pro-
gression to TB disease in the first two years following TB
Table 3 TB prevalence and ARTI by age quartile for the
10 mm cut-off point for the three surveys combined







































TOTAL 14.1 1,451 645 44.5% 4.1%
(3.8-4.4%)
* The mean age reported here is the age used for the ARTI calculations, and
is based on the mean age for the age category+0.5 years, as described in the
methods section.
Note: Participants who declined HIV testing were presumed to be HIV-
uninfected and were included in the TB analysis
Figure 3 TB prevalence in combined dataset, by age (in years).
Note: This figure is based on the unadjusted data presented in
Table 3.
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infection[33], and the high infection rates in this commu-
nity place adolescents at substantial risk of TB disease.
The high incidence rate of TB infection in the subset of
participants tested 2 years apart, confirms the high force
of infection. However, due to the boosting of the immune
response with enhanced allergy noted with repeated
TSTs[8,34-38], the incident rate in this subset is higher
than the force of infection. This is highlighted by the lar-
ger median TST reaction sizes in participants with a
repeat test compared to first time participants. Similarly,
reduced and anergic responses to TST have been noted
in HIV-infected patients[39-42], as evidenced by the
smaller median reaction sizes in HIV-infected partici-
pants compared to HIV-uninfected participants. These
two scenarios highlight a limitation of using an immune-
based test for determining TB infection.
Only 20% of the children in this study had an observa-
ble BCG scar, despite the South African policy to vacci-
nate all infants with the BCG vaccine[43]. However
BCG scarring may be variable[38,44] and we found no
difference in the distribution of TST results between
those children with or without BCG scars.
In this study, only 1% of TST results were weakly
positive (1 to 5 mm), suggesting minimal cross reaction
with environmental mycobacteria[19]. Given the high
TB prevalence in the sample, the positive predictive
value of the TST is likely to be high.
HIV testing was not performed in the primary school
surveys. However, the Actuarial Society of South Africa
(ASSA) 2003 AIDS and Demographic model for the
African population[45,46] reports an HIV prevalence of
<4% in this age group. Therefore HIV is unlikely to
have substantially impacted TST readings in this group
and, given the anergic reactions to TST associated with
HIV[39-42], any impact of HIV is likely to result in an
underestimate of TB infection. We were able to exclude
HIV-infected children from the secondary school TB
analysis, thereby reducing the potential bias resulting
from dual infections.
This study had a very low refusal rate (<4% across all
three surveys), and as such volunteerism is unlikely to
have biased our results. However, it should be noted
that the school-attending children may not be represen-
tative of all the children in the community, in particular
with regards to risk of HIV infection[47,48]. However,
should either HIV or TB infection be higher among
non-school attending children, this would result in an
underestimation of the prevalence and force of TB
infection in this study.
The high force of infection in this community would
result in significant rates of primary and secondary TB
infection and, given the high HIV prevalence among
adults[6], and the considerable increased risk of progres-
sion to TB disease in HIV-infected individuals[30,49],
Table 4 Predicted prevalence, ARTI and force of infection by age in study cohort
Age Number of participants Predicted Prevalence*
(95% CI)
ARTI** Force of infection F
5 1 0.22 (0.17 - 0.27) 4.85
6 36 0.24 (0.19 - 0.29) 4.47 2.93
7 84 0.26 (0.22 - 0.30) 4.21 3.15
8 112 0.28 (0.24 - 0.32) 4.06 3.39
9 92 0.31 (0.27 - 0.34) 3.96 3.81
10 71 0.33 (0.29 - 0.36) 3.91 3.96
11 59 0.35 (0.32 - 0.39) 3.89 4.28
12 107 0.38 (0.35 - 0.41) 3.91 4.47
13 135 0.41 (0.38 - 0.43) 3.93 5.03
14 116 0.43 (0.41 - 0.46) 3.97 5.11
15 84 0.46 (0.44 - 0.49) 4.04 5.58
16 106 0.49 (0.46 - 0.52) 4.10 5.70
17 154 0.52 (0.48 - 0.55) 4.18 6.05
18 112 0.54 (0.51 - 0.58) 4.27 6.44
19 101 0.57 (0.53 - 0.61) 4.36 6.63
20 46 0.60 (0.55 - 0.64) 4.45 7.11
21 21 0.62 (0.58 - 0.67) 4.55 7.37
22 14 0.65 (0.60 - 0.70) 4.66 7.34
* Predictive logistic regression model: logit{P(Age)} = -1.82+0.111 age.
** The ARTI calculations are based on the mean age for the age category+0.5 years, as described in the methods section.
F Force of infection = annual change in prevalence/(1-prevalence)
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these findings could explain the substantial incidence of
TB disease in this setting. Control of the TB epidemic
requires an increasing proportion of non-infected indivi-
duals in a population, in other words, a decreased force
of infection[50]. In order to reduce the force of infec-
tion, National Tuberculosis Programmes need to
decrease the prevalence of infectious cases in the com-
munity. We have previously shown that a high coverage
antiretroviral treatment (ART) program will reduce TB
prevalence among HIV-infected participants, due to
both improved immune function and the active TB
case-finding among patients initiating ART[25]. Extend-
ing active case finding to HIV-uninfected residents may
substantially reduce the burden of infectious cases.
Social programs, such as improved housing, that impact
the environment in which individuals interact may also
lead to a reduction in the incidence of TB infection.
Conclusions
In conclusion, these data suggest a substantial force of
infection among adolescents, which is associated with
increasing age. This is most likely due to changing social
mixing patterns among adolescents, resulting in
increased contact with infectious TB cases. Studies into
social interaction patterns at different ages in this setting
may help to better understand this increasing risk of TB
infection. HIV infection was not associated with
increased risk of TB infection. However, the extremely
high force of infection, together with the high commu-
nity HIV prevalence, explains the overwhelming burden
of TB disease in this township. Control of the TB epi-
demic will require reducing the force of infection, and
further studies assessing intervention strategies such as
those suggested here are required.
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